PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bai, JR; Sui, JH; Zhu, RY; Tallarico, AS; Gennari, F; Zhang, DS; Marasco, WA				Bai, JR; Sui, JH; Zhu, RY; Tallarico, AS; Gennari, F; Zhang, DS; Marasco, WA			Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SCID-HU MOUSE; PHAGE DISPLAY TECHNOLOGY; IN-VITRO; ANTI-TAT; T-CELLS; P-TEFB; PROTEIN; RNA; MODEL	Human immunodeficiency virus, type 1 (HIV-1) replication requires the interaction of Tat protein with the human cyclinT1 (hCyclinT1) subunit of the positive transcription elongation factor (P-TEFb) complex, which then cooperatively binds to transactivation response element (TAR) RNA to transactivate HIV transcription. In this report, a non-immune human single-chain antibody (sFv) phage display library was used to isolate anti-hCyclinT1 sFvs that could disrupt hCyclinT1-Tat interactions. The N-terminal 272 residues of hCyclinT1, including the entire cyclin domains and the Tat-TAR recognition motif (TRM), that fully support Tat transactivation was used for panning, and of the five unique anti-hCyclinT1 sFvs that were obtained, three bound to the cyclin box domains and two bound to TRM. All sFvs could be expressed as intrabodies at high levels in transiently transfected 293T and in stable Jurkat and SupT1 transfectants and could specifically co-immuno-precipitate co-expressed hCyclinT1 in 293T cells with varying efficacy without disrupting hCyclinT1-Cdk9 interactions. In addition, two sFv clones (3R6-1 and 2R6-21) that mapped to the cyclin box domains markedly inhibited Tat-mediated transactivation in several transiently transfected cell lines without inhibiting basal transcription or inducing apoptosis. When HIV-1 challenge studies were performed on stable 3R6-1-expressing Jurkat T cells, near complete inhibition of viral replication was obtained at a low challenge dose, and 74-88% inhibition to HIV-1 replication was achieved at a high infection dose in SupT1 cells. These results provide proof-in-principle that anti-hCyclinT1 intrabodies can be designed to block HIV-1 replication without causing cellular toxicity, and as a result, they may be useful agents for "intracellular immunization"-based gene therapy strategies for HIV-1 infection/AIDS.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Marasco, WA (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JFB 824,44 Binney St, Boston, MA 02115 USA.		Zhu, Ren-Yuan/V-8966-2019; Yang, Fan/GYU-4249-2022	Zhu, Ren-Yuan/0000-0003-3091-7461; SUI, JIANHUA/0000-0002-1272-9662	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028785] Funding Source: NIH RePORTER; NCRR NIH HHS [5R01-RR14447] Funding Source: Medline; NIAID NIH HHS [2R01-AI28785] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI J, 2002, IN PRESS MOL THER; Bai JR, 2000, MOL THER, V1, P244, DOI 10.1006/mthe.2000.0038; Banda NK, 1998, J HEMATOTHER, V7, P319, DOI 10.1089/scd.1.1998.7.319; Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Brooks DG, 2002, J VIROL, V76, P1673, DOI 10.1128/JVI.76.4.1673-1681.2002; Brooks DG, 2001, NAT MED, V7, P459, DOI 10.1038/86531; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372; Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Jamieson B D, 1996, Semin Immunol, V8, P215, DOI 10.1006/smim.1996.0027; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; KORBER B, 1998, HIV SEQUENCE DATABAS; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Marasco WA, 1999, J IMMUNOL METHODS, V231, P223, DOI 10.1016/S0022-1759(99)00159-3; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Mhashilkar AM, 1997, J VIROL, V71, P6486, DOI 10.1128/JVI.71.9.6486-6494.1997; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; ZHOU C, 1994, GENE, V149, P33	37	63	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1433	1442		10.1074/jbc.M208297200	http://dx.doi.org/10.1074/jbc.M208297200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12401780	hybrid			2022-12-25	WOS:000180462200010
J	Burke, JR; Pattoli, MA; Gregor, KR; Brassil, PJ; MacMaster, JF; McIntyre, KW; Yang, XX; Iotzova, VS; Clarke, W; Strnad, J; Qiu, YP; Zusi, FC				Burke, JR; Pattoli, MA; Gregor, KR; Brassil, PJ; MacMaster, JF; McIntyre, KW; Yang, XX; Iotzova, VS; Clarke, W; Strnad, J; Qiu, YP; Zusi, FC			BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-ALPHA; ACTIVATION; BETA; PHOSPHORYLATION; COMPLEX; UBIQUITINATION; PROTEOLYSIS; SUBUNITS; EPSILON	The signal-inducible phosphorylation of serines 32 and 36 of IkappaBalpha is critical in regulating the subsequent ubiquitination and proteolysis of IkappaBalpha, which then releases NF-kappaB to promote gene transcription. The multi-subunit licB kinase responsible for this phosphorylation contains two catalytic subunits, termed licB kinase (IKK)-1 and IKK-2. BMS-345541 (4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline) was identified as a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50 = 0.3 muM, IKK-1 IC50 = 4 muM). The compound failed to inhibit a panel of 15 other kinases and selectively inhibited the stimulated phosphorylation Of IkappaBalpha in cells (IC50 = 4 muM) while failing to affect c-Jun and STAT3 phosphorylation, as well as mitogen-activated protein kinase-activated protein kinase 2 activation in cells. Consistent with the role of IKK/NF-kappaB in the regulation of cytokine transcription, BMS-345541 inhibited lipopolysaccharide-stimulated tumor necrosis factor a, interleukin-1beta, interleukin-8, and interleukin-6 in THP-1 cells with IC50 values in the 1- to 5-muM range. Although a Dixon plot of the inhibition of IKK-2 by BMS-345541 showed a non-linear relationship indicating non-Michaelis-Menten kinetic binding, the use of multiple inhibition analyses indicated that BMS-345541 binds in a mutually exclusive manner with respect to a peptide inhibitor corresponding to amino acids 26-42 of IkappaBalpha with Ser-32 and Ser-36 changed to aspartates and in a non-mutually exclusive manner with respect to ADP. The opposite results were obtained when studying the binding to IKK-1. A binding model is proposed in which BMS-345541 binds to similar allosteric sites on IKK-1 and IKK-2, which then affects the active sites of the subunits differently. BMS-345541 was also shown to have excellent pharmacokinetics in mice, and peroral administration showed the compound to dose-dependently inhibit the production of serum tumor necrosis factor a following intraperitoneal challenge with lipopolysaccharide. Thus, the compound is effective against NF-kappaB activation in mice and represents an important tool for investigating the role of IKK in disease models.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Immunol Inflammat & Pulm Drug Discovery, Princeton, NJ 08543 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Preclin Candidate Optimizat, Wallingford, CT 06492 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Wallingford, CT 06492 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Burke, JR (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Immunol Inflammat & Pulm Drug Discovery, POB 4000, Princeton, NJ 08543 USA.							Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bauerle PA, 1996, CELL, V87, P13; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Burke JR, 2002, BIOCHEM BIOPH RES CO, V293, P1508, DOI 10.1016/S0006-291X(02)00417-5; Burke JR, 1999, J BIOL CHEM, V274, P36146, DOI 10.1074/jbc.274.51.36146; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Ghezzi P, 2000, CYTOKINE, V12, P1205, DOI 10.1006/cyto.2000.0697; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SEGEL IH, 1975, ENZYME KINETICS, P474; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TREIBER HJ, 1994, Patent No. 4329970; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	432	459	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1450	1456		10.1074/jbc.M209677200	http://dx.doi.org/10.1074/jbc.M209677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12403772	hybrid			2022-12-25	WOS:000180462200012
J	Ellison, M; McIntosh, JM; Olivera, BM				Ellison, M; McIntosh, JM; Olivera, BM			alpha-conotoxins ImI and ImII - Similar alpha 7 nicotinic receptor antagonists act at different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; BINDING-SITES; PEPTIDE; VENOM; IDENTIFICATION; SELECTIVITY; SUBTYPES; TARGETS; LIGAND	A novel conotoxin, alpha-conotoxin Imll (alpha-CTx Imll), identified from Conus imperialis venom ducts, was chemically synthesized. A previously characterized C. imperialis conotoxin, alpha-conotoxin ImI (alpha-CTx ImI), is closely related; 9 of 12 amino acids are identical. Both alpha-CTx ImH and alpha-CTx ImI functionally inhibit heterologously expressed rat alpha7 nAChRs with similar IC50 values. Furthermore, the biological activities of intracranially applied alpha-CTx Iml and alpha-CTx ImH are similar over the same dosage range, and are consistent with a7 nAChR inhibition. However, unlike a-CTx ImI, a-CTx Imll was not able to block the binding of a-bungarotoxin to alpha7 nAChRs. alpha-Conotoxin ImI and alpha-bungarotoxin-binding sites have been well characterized as overlapping and located at the cleft between adjacent nAChR subunits. Because alpha-CTx Iml and alpha-CTx ImH share extensive sequence homology, the inability of alpha-CTx ImH to compete with alpha-BgTx is surprising. Furthermore, functional studies in oocytes indicate that there is no overlap between functional binding sites of alpha-CTx Iml and alpha-CTx Imll. Like alpha-CTx Iml, the block by alpha-CTx Imll is voltage-independent. Thus, alpha-CTx ImII represents a probe for a novel antagonist binding site, or microsite, on the alpha7 nAChR.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Ellison, M (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053631, R29MH053631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677, GM08537] Funding Source: Medline; NIMH NIH HHS [MH53631] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; Cooper ST, 1998, J NEUROCHEM, V70, P2585; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; McIntosh J M, 1999, Methods Enzymol, V294, P605; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; Pereira EFR, 1996, J PHARMACOL EXP THER, V278, P1472; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; Rakhilin S, 1999, J CELL BIOL, V146, P203; Rangwala F, 1997, J NEUROSCI, V17, P8201; Schoenfeld RA, 1999, THESIS U UTAH; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; Shon KJ, 1998, J NEUROSCI, V18, P4473; Whiteaker P, 1999, EUR J NEUROSCI, V11, P2689, DOI 10.1046/j.1460-9568.1999.00685.x; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	26	96	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					757	764		10.1074/jbc.M204565200	http://dx.doi.org/10.1074/jbc.M204565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12384509	hybrid			2022-12-25	WOS:000180321900011
J	Friday, RP; Pietropaolo, SL; Profozich, J; Trucco, M; Pietropaolo, M				Friday, RP; Pietropaolo, SL; Profozich, J; Trucco, M; Pietropaolo, M			Alternative core promoters regulate tissue-specific transcription from the autoimmune diabetes-related ICA1 (ICA69) gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-CELL ANTIGEN; DNA METHYLATION; T-CELL; HUMAN THYMUS; REPRESSES TRANSCRIPTION; EXPRESSION; CREB; ACTIVATION; AUTOANTIGEN; TOLERANCE	Islet cell autoantigen 69-kDa (ICA69), protein product of the human ICA1 gene, is one target of the immune processes defining the pathogenesis of Type 1 diabetes. We have characterized the genomic structure and functional promoters within the 5'-regulatory region of ICA1 5'-RNA ligase-mediated rapid amplification of cDNA ends evaluation of ICA1 transcripts expressed in human islets, testis, heart, and cultured neuroblastoma cells reveals that three 5'-untranslated region exons are variably expressed from the ICA1 gene in a tissue-specific manner. Surrounding the transcription initiation sites are motifs characteristic of non-TATA, non-CAAT, GC-rich promoters, including consensus Sp1/GC boxes, an initiator element, cAMP-responsive element-binding protein (CREB) sites, and clusters of other putative transcription factor sites within a genomic CpG island. Luciferase reporter constructs demonstrate that the first two ICA1 exon promoters reciprocally stimulate luciferase expression within islet- (RIN 1046-38 cells) and brain-derived (NMB7) cells in culture; the exon A promoter exhibits greater activity in islet cells, whereas the exon B promoter more efficiently activates transcription in neuronal cells. Mutation of a CREB site within the ICA1 exon B promoter significantly enhances transcriptional activity in both cell lines. Our basic understanding of expression from the functional core promoter elements of ICA1 is an important advance that will not only add to our knowledge of the ICA69 autoantigen but will also facilitate a rational approach to discover the function of ICA69 and to identify relevant ICA1 promoter polymorphisms and their potential associations with disease.	Univ Pittsburgh, Sch Med, Childrens Hosp, Div Immunogenet,Diabet Inst,Rangos Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pietropaolo, M (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp, Div Immunogenet,Diabet Inst,Rangos Res Ctr, 3460 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053456, R01DK056200] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56200, R01 DK53456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beohar N, 1998, J BIOL CHEM, V273, P9168, DOI 10.1074/jbc.273.15.9168; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; Carey M, 2000, TRANSCRIPTIONAL REGU; Carvalho AB, 1999, NATURE, V401, P344, DOI 10.1038/43827; CHAPLIN DD, 1992, CURRENT PROTOCOLS MO; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; Comeron JM, 2000, GENETICS, V156, P1175; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DellaFazia MA, 1997, FEBS LETT, V410, P22, DOI 10.1016/S0014-5793(97)00445-6; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DIBB NJ, 1993, FEBS LETT, V325, P135, DOI 10.1016/0014-5793(93)81429-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duret L, 2001, TRENDS GENET, V17, P172, DOI 10.1016/S0168-9525(01)02236-3; Egwuagu CE, 1997, J IMMUNOL, V159, P3109; GAEDIGK R, 1994, CYTOGENET CELL GENET, V66, P274, DOI 10.1159/000133711; Gaedigk R, 1996, GENOMICS, V38, P382, DOI 10.1006/geno.1996.0641; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GERMAN M, 2000, DIABETES MELLITUS FU, P11; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Hurst LD, 1999, TRENDS GENET, V15, P437, DOI 10.1016/S0168-9525(99)01832-6; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Karges W, 1997, DIABETES, V46, P1548, DOI 10.2337/diabetes.46.10.1548; Karges W, 1997, BBA-MOL BASIS DIS, V1360, P97, DOI 10.1016/S0925-4439(97)00002-1; Karges W, 1996, DIABETES, V45, P513, DOI 10.2337/diabetes.45.4.513; KENNEDY GC, 1995, NAT GENET, V9, P292; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMPASONA V, 1994, J AUTOIMMUN, V7, P665, DOI 10.1006/jaut.1994.1051; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lubbert M, 1999, LEUKEMIA, V13, P1420, DOI 10.1038/sj.leu.2401486; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; MARTIN S, 1995, DIABETOLOGIA, V38, P351, DOI 10.1007/s001250050292; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MIYAZAKI I, 1994, BBA-MOL BASIS DIS, V1227, P101, DOI 10.1016/0925-4439(94)90113-9; MIYAZAKI I, 1995, J IMMUNOL, V154, P1461; Newell-Price J, 2001, MOL ENDOCRINOL, V15, P338, DOI 10.1210/me.15.2.338; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; Persengiev SP, 1996, NEUROREPORT, V8, P227, DOI 10.1097/00001756-199612200-00046; Pfeifer K, 2000, AM J HUM GENET, V67, P777, DOI 10.1086/303101; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; Pietropaolo M, 2002, NAT IMMUNOL, V3, P335, DOI 10.1038/ni0402-335a; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Pugliese A, 2001, J CLIN INVEST, V107, P555, DOI 10.1172/JCI10860; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Roep BO, 1996, EUR J IMMUNOL, V26, P1285, DOI 10.1002/eji.1830260616; Roep BO, 1996, DIABETES, V45, P1147, DOI 10.2337/diabetes.45.9.1147; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schwab J, 2001, INT IMMUNOL, V13, P705, DOI 10.1093/intimm/13.5.705; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; SOLIMENA M, 2002, DIABETES METAB RE S4, V18, P32; Sospedra M, 1998, J IMMUNOL, V161, P5918; Stassi G, 1997, DIABETOLOGIA, V40, P120; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Werdelin O, 1998, SCAND J IMMUNOL, V47, P95; Winer S, 2000, J IMMUNOL, V165, P4086, DOI 10.4049/jimmunol.165.7.4086; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	67	14	14	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					853	863		10.1074/jbc.M210175200	http://dx.doi.org/10.1074/jbc.M210175200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409289	hybrid			2022-12-25	WOS:000180321900023
J	Buechter, DD; Paolella, DN; Leslie, BS; Brown, MS; Mehos, KA; Gruskin, EA				Buechter, DD; Paolella, DN; Leslie, BS; Brown, MS; Mehos, KA; Gruskin, EA			Co-translational incorporation of Trans-4-hydroxyproline into recombinant proteins in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; EXPANDED GENETIC-CODE; ESCHERICHIA-COLI; PROLINE TRANSPORT; TRIPLE-HELIX; AMINO-ACIDS; COLLAGEN; OSMOREGULATION; OSMOPROTECTANT; POLYPEPTIDES	Trans-4-hydroxyproline (Hyp) in eukaryotic proteins arises from post-translational modification of proline residues. Because the modification enzyme is not present in prokaryotes, no. natural means exists to incorporate Hyp into proteins synthesized in Escherichia coli. We show here that under appropriate culture conditions Hyp is incorporated co-translationally directly at proline codons in genes expressed in E. coli. The use of Hyp by E. coli protein synthesis machinery under typical culture conditions is not adequate to support protein synthesis; however, intracellular concentrations of Hyp sufficient to compensate for the poor use are achieved in media with hyperosmotic sodium chloride concentrations. Hyp incorporation was demonstrated in several recombinant proteins including human Type 1 collagen polypeptides. A fragment of the human collagen Type 1 (alpha1) polypeptide with global Hyp for Pro substitution forms a triple helix. Our results demonstrate a remarkable pliancy in the biosynthetic apparatus of bacteria that may be used more generally to incorporate novel amino acids into recombinant proteins.	US Surg Corp, Div Life Sci, N Haven, CT 06473 USA		Gruskin, EA (corresponding author), Acorda Therapuet Inc, 15 Skyline Dr, Hawthorne, NY 10532 USA.							Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Bhatnagar RS, 1996, CIRCULAR DICHROISM C, P183; Deming TJ, 1996, MACROMOLECULES, V29, P1442, DOI 10.1021/ma9510698; DEMING TJ, 1994, POLYM MAT SCI ENG P, V71, P673; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; Fersht A., 1985, ENZYME STRUCTURE MEC; FOWDEN L, 1963, NATURE, V199, P35, DOI 10.1038/199035a0; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; Glaasker E, 1996, J BACTERIOL, V178, P575, DOI 10.1128/jb.178.3.575-582.1996; GOWRISHANKAR J, 1986, J BACTERIOL, V166, P331, DOI 10.1128/jb.166.1.331-333.1986; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; HOGUE CWV, 1992, FEBS LETT, V310, P269, DOI 10.1016/0014-5793(92)81346-N; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kohrer C, 2001, P NATL ACAD SCI USA, V98, P14310, DOI 10.1073/pnas.251438898; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LANG K, 1990, J MOL BIOL, V212, P185, DOI 10.1016/0022-2836(90)90314-C; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.biophys.24.1.435; Miller J.H., 1972, EXPT MOL GENETICS; MILNER JL, 1987, J GEN MICROBIOL, V133, P1851; NEUMAN RE, 1950, J BIOL CHEM, V184, P299; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; PAPAS TS, 1970, J BIOL CHEM, V245, P1588; Rossi A, 1996, BIOCHEMISTRY-US, V35, P6048, DOI 10.1021/bi9518151; ROWLAND I, 1975, J BACTERIOL, V123, P871, DOI 10.1128/JB.123.3.871-877.1975; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WATANABE K, 1994, EUR J BIOCHEM, V226, P277, DOI 10.1111/j.1432-1033.1994.tb20051.x; WOOD JM, 1988, J MEMBRANE BIOL, V106, P183, DOI 10.1007/BF01872157; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YOSHIKAWA E, 1994, MACROMOLECULES, V27, P5471, DOI 10.1021/ma00097a029	41	66	74	5	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					645	650		10.1074/jbc.M209364200	http://dx.doi.org/10.1074/jbc.M209364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399455	hybrid			2022-12-25	WOS:000180255700082
J	Hiriart, E; Farjot, G; Gruffat, H; Nguyen, MVC; Sergean, A; Manet, E				Hiriart, E; Farjot, G; Gruffat, H; Nguyen, MVC; Sergean, A; Manet, E			A novel nuclear export signal and a REF interaction domain both promote mRNA export by the Epstein-Barr virus EB2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; EXON-EXON JUNCTIONS; SM PROTEIN; HUMAN HOMOLOG; TYPE-1; ICP27; TRANSCRIPTION; TRANSPORT; PATHWAY; MOTIF	A striking characteristic of mRNA export factors is that they shuttle continuously between the cytoplasm and the nucleus. This shuttling is mediated by specific factors interacting with peptide motifs called nuclear export signals (NES) and nuclear localization signals. We have identified a novel CRM-1-independent transferable NES and two nuclear localization signals in the Epstein-Barr virus mRNA export factor EB2 (also called BMLF1, Mta, or SM) localized at the N terminus of the protein between amino acids 61 and 146. We have also found that a previously described double NES (amino acids 213-236) does not mediate the nuclear shuttling of EB2, but is an interaction domain with the cellular export factor REF in vitro. This newly characterized REF interaction domain is essential for EB2-mediated mRNA export. Accordingly, in vivo, EB2 is found in complexes containing REF as well as the cellular factor TAP. However, these interactions are RNase-sensitive, suggesting that the RNA is an essential component of these complexes.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Manet, E (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.		Gruffat, Henri/I-2407-2016; MANET, Evelyne/G-5644-2019	Gruffat, Henri/0000-0002-4735-6894; MANET, Evelyne/0000-0001-7619-9982				Boyle SM, 1999, J VIROL, V73, P6872, DOI 10.1128/JVI.73.8.6872-6881.1999; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; Buisson M, 1999, J VIROL, V73, P4090, DOI 10.1128/JVI.73.5.4090-4100.1999; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; Chen L, 2001, VIROLOGY, V288, P119, DOI 10.1006/viro.2001.1057; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COOK ID, 1994, VIROLOGY, V205, P217, DOI 10.1006/viro.1994.1637; CORBO L, 1994, ONCOGENE, V9, P3299; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruffat H, 2002, J VIROL, V76, P9635, DOI 10.1128/JVI.76.19.9635-9644.2002; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Key SCS, 1998, J VIROL, V72, P8485, DOI 10.1128/JVI.72.11.8485-8492.1998; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Lischka P, 2001, EMBO J, V20, P7271, DOI 10.1093/emboj/20.24.7271; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Semmes OJ, 1998, J VIROL, V72, P9526, DOI 10.1128/JVI.72.12.9526-9534.1998; Soliman TM, 2000, J VIROL, V74, P7600, DOI 10.1128/JVI.74.16.7600-7609.2000; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang J, 2001, MOL CELL, V8, P397, DOI 10.1016/S1097-2765(01)00303-3; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	39	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					335	342		10.1074/jbc.M208656200	http://dx.doi.org/10.1074/jbc.M208656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403791	Green Published, hybrid			2022-12-25	WOS:000180255700045
J	Lova, P; Paganini, S; Hirsch, E; Barberis, L; Wymann, M; Sinigaglia, F; Balduini, C; Torti, M				Lova, P; Paganini, S; Hirsch, E; Barberis, L; Wymann, M; Sinigaglia, F; Balduini, C; Torti, M			A selective role for phosphatidylinositol 3,4,5-trisphosphate in the G(i)-dependent activation of platelet Rap1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; THROMBIN-RECEPTOR; LIPID PRODUCTS; AGGREGATION; PROTEIN; INTEGRIN; GAMMA; BETA; CYTOSKELETON; SUBUNITS	The small GTP-binding protein Rap1B is activated in human platelets upon stimulation of a G(i)-dependent signaling pathway. In this work, we found that inhibition of platelet adenylyl cyclase by dideoxyadenosine or SQ22536 did not cause activation of Rap1B and did not restore Rap1B activation in platelets stimulated by cross-linking of Fcgamma receptor IIA (FcgammaRIIA) in the presence of ADP scavengers. Moreover, elevation of the intracellular cAMP concentration did not impair the G(i)-dependent activation of Rap1B. Two unrelated inhibitors of phosphatidylinositol 3-kinase (PI3K), wortmannin and LY294002, totally prevented Rap1B activation in platelets stimulated by cross-linking of FcgammaRIIA by stimulation of the P2Y(12) receptor for ADP, or by epinephrine. However, in platelets from PI3Kgamma-deficient mice, both ADP and epinephrine were still able to normally stimulate Rap1B activation through a PI3K-dependent mechanism, suggesting the involvement of a different isoform of the enzyme. Moreover, the lack of PI3Kgamma did not prevent the ability of epinephrine to potentiate platelet aggregation through a G(i)-dependent pathway. The inhibitory effect of wortmannin on Rap1B activation was overcome by addition of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), but not PtdIns(3,4)P-2, although both lipids were found to support phosphorylation of Akt. Moreover, PtdIns (3,4,5)P3 was able to relieve the inhibitory effect of apyrase on Fc-gammaRIIA-mediated platelet aggregation. We conclude that stimulation of a Gi-dependent signaling pathway causes activation of the small GTPase Rap1B through the action of the PI3K product PtdIns(3,4,5)P-3, but not PtdIns(3,4)P-2, and that this process may contribute to potentiation of platelet aggregation.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; Univ Fribourg, Inst Biochem, Dept Med, CH-1700 Fribourg, Switzerland	University of Pavia; University of Eastern Piedmont Amedeo Avogadro; University of Turin; University of Fribourg	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 21, I-27100 Pavia, Italy.		Wymann, Matthias P/C-3227-2008; Hirsch, Emilio/F-4848-2013	Wymann, Matthias P/0000-0003-3349-4281; Hirsch, Emilio/0000-0002-9073-6024				Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gratacap MP, 2000, BLOOD, V96, P3439, DOI 10.1182/blood.V96.10.3439.h8003439_3439_3446; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P9776, DOI 10.1021/bi980163o; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; WINEGAR DA, 1991, J BIOL CHEM, V266, P4375; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	33	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					131	138		10.1074/jbc.M204821200	http://dx.doi.org/10.1074/jbc.M204821200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407113	hybrid			2022-12-25	WOS:000180255700018
J	Blander, G; Zalle, N; Daniely, Y; Taplick, J; Gray, MD; Oren, M				Blander, G; Zalle, N; Daniely, Y; Taplick, J; Gray, MD; Oren, M			DNA damage-induced translocation of the Werner helicase is regulated by acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; SYNDROME PROTEIN; FUNCTIONAL INTERACTION; REPLICATION CHECKPOINT; COVALENT MODIFICATION; PREMATURE SENESCENCE; POLYMERASE-DELTA; BINDING-PROTEIN; NUCLEAR-BODIES; SYNDROME CELLS	Werner syndrome is a rare autosomal recessive disorder involving the premature appearance of features reminiscent of human aging. Werner syndrome occurs by mutation of the WRN gene, encoding a DNA helicase. WRN contributes to the induction of the p53 tumor suppressor protein by various DNA damaging agents. Here we show that UV exposure leads to extensive translocation of WRN from the nucleolus to nucleoplasmic foci in a dose-dependent manner. Ionizing radiation also induces WRN translocation, albeit milder, partially through activation of the ATM kinase. The nucleoplasmic foci to which WRN is recruited display partial colocalization with PML nuclear bodies. The translocation of WRN into nucleoplasmic foci is significantly enhanced by the protein deacetylase inhibitor, Trichostatin A. Moreover, Trichostatin A delays the re-entry of WRN into the nucleolus at late times after irradiation. WRN is acetylated in vivo, and this is markedly stimulated by the acetyltransferase p300. Importantly, p300 augments the translocation of WRN into nucleoplasmic foci. These findings support the notion that WRN plays a role in the cellular response to DNA damage and suggest that the activity of WRN is modulated by DNA damage-induced post-translational modifications of WRN and possibly WRN-interacting proteins.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Weizmann Institute of Science; University of Washington; University of Washington Seattle	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blander G, 2000, FASEB J, V14, P2138; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Cooper MP, 2000, GENE DEV, V14, P907; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Frei C, 2000, J CELL SCI, V113, P2641; Frei C, 2000, GENE DEV, V14, P81; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hisama FM, 2000, CANCER RES, V60, P2372; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Shiloh Y., 2002, V36, P51; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Suzuki H, 2001, BIOCHEM BIOPH RES CO, V286, P322, DOI 10.1006/bbrc.2001.5387; Suzuki T, 2001, ONCOGENE, V20, P2551, DOI 10.1038/sj.onc.1204344; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	54	105	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50934	50940		10.1074/jbc.M210479200	http://dx.doi.org/10.1074/jbc.M210479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12384494	hybrid			2022-12-25	WOS:000180177700096
J	Esposito, G; Ligresti, A; Izzo, AA; Bisogno, T; Ruvo, M; Di Rosa, M; Di Marzo, V; Iuvone, T				Esposito, G; Ligresti, A; Izzo, AA; Bisogno, T; Ruvo, M; Di Rosa, M; Di Marzo, V; Iuvone, T			The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity - Mechanism and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; CANNABINOID RECEPTOR; AIDS DEMENTIA; GLIAL-CELLS; IN-VIVO; EXPRESSION; CB1; INHIBITION	Cannabinoids modulate nitric oxide (NO) levels in cells of the central nervous system. Here we studied the effect of cannabinoid CB1 and CB2 receptor agonists on the release of NO and cell toxicity induced by the human immuno-deficiency virus-1 Tat protein (HIV-1 Tat) in rat glioma C6 cells. The CB1 and CB2 agonist WIN 55,212-2 inhibited the expression of inducible NO synthase (iNOS) and NO release caused by treatment of C6 cells with HIV-1 Tat and interferon-gamma (IFN-gamma). The effect of WIN 55,212-2 was uniquely due to CB, receptors, as shown by experiments carried out with selective CB, and CB2 receptor agonists and antagonists. CB1 receptor stimulation also inhibited HIV-1 Tat + IFN-gamma-induced and NO-mediated cell toxicity. Moreover, cell treatment with HIV-1 Tat + IFN-gamma induced a significant inhibition of CB1, but not CB2, receptor expression. This effect was mimicked by the NO donor GSNO, suggesting that the inhibition of CB, expression was due to HIV-1 Tat + IFN-gamma-induced NO overexpression. HIV-1 Tat + IFN-gamma treatment also induced a significant inhibition of the uptake of the endocannabinoid anandamide by C6 cells with no effect on anandamide hydrolysis. These findings show that the endocannabinoid system, through the modulation of the L-arginine/NO pathway, reduces HIV-1 Tat-induced cytotoxicity, and is itself regulated by HIV-1 Tat.	Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy; CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80078 Naples, Italy; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR)	Di Marzo, V (corresponding author), Via D Montesano 49, I-80131 Naples, Italy.	vdimarzo@icmib.na.cnr.it; iuvone@unina.it	Bisogno, Tiziana/B-7891-2015; Di Marzo, Vincenzo/AAD-7742-2019; Esposito, Giuseppe/AAA-7949-2019; Ligresti, Alessia/B-7564-2015	Di Marzo, Vincenzo/0000-0002-1490-3070; Esposito, Giuseppe/0000-0001-8080-8218; Ligresti, Alessia/0000-0003-1787-3900; Izzo, Angelo/0000-0002-8557-2133				Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 2001, EUR J BIOCHEM, V268, P1982, DOI 10.1046/j.1432-1327.2001.02072.x; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Coffey RG, 1996, BIOCHEM PHARMACOL, V52, P743, DOI 10.1016/0006-2952(96)00356-5; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Epstein Leon G., 1997, P59; Esposito G, 2002, ANTICANCER RES, V22, P2827; Esposito G, 2001, J NEUROCHEM, V78, P835, DOI 10.1046/j.1471-4159.2001.00465.x; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Gavriil ES, 2000, BIOCHEM BIOPH RES CO, V267, P252, DOI 10.1006/bbrc.1999.1894; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P; Jin WZ, 1999, J NEUROSCI, V19, P3773; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; Kim H, 2001, NEUROSCI LETT, V309, P67, DOI 10.1016/S0304-3940(01)02028-6; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Mechoulam R, 1986, CANNABINOIDS THERAPE, P1; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Orsini MJ, 1996, J NEUROSCI, V16, P2546; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V287, P1038; ROTHWELL N, 1999, INFLAMMATORY CELLS M, P471; RUVO M, 1996, PEPTIDES, P771; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Suk K, 2002, J NEUROCHEM, V80, P230, DOI 10.1046/j.0022-3042.2001.00705.x; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Watson K, 1999, BIOCHEM PHARMACOL, V58, P1521, DOI 10.1016/S0006-2952(99)00209-9	54	45	46	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50348	50354		10.1074/jbc.M207170200	http://dx.doi.org/10.1074/jbc.M207170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12388547	hybrid			2022-12-25	WOS:000180177700019
J	Huang, WD; Lu, N; Eberspaecher, H; de Crombrugghe, B				Huang, WD; Lu, N; Eberspaecher, H; de Crombrugghe, B			A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CHONDROCYTE-SPECIFIC ENHANCER; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTORS; SKELETAL DEVELOPMENT; CARTILAGE FORMATION; DIFFERENTIATION; CHONDROGENESIS; PROTEIN	A new long form of the c-Maf transcription factor (Lc-Maf) was identified and shown to interact specifically with SOX9 in a yeast two-hybrid cDNA library screening. Lc-Maf encodes an extra 10 amino acids at the carboxyl terminus of c-Maf and contains a different 3'-untranslated region compared with c-Maf. The interaction between SOX9 and Lc-Maf was further confirmed by co-immunoprecipitation and glutathione S-transferase pull-down assays, which mapped the interacting domain of SOX9 to the high mobility group box DNA binding domain and that of Lc-Maf to the basic leucine zipper motif. In situ hybridizations showed that Lc-Maf RNA was coexpressed with Sox9 and Col2a1 RNA in areas of precartilaginous mesenchymal condensations during mouse embryo development. A DNA binding site of Lc-Maf was identified at the 5'-end of a 48-hp Col2a1 enhancer element near the high mobility group binding site of SOX9. Lc-Maf and SOX9 synergistically activated a luciferase reporter plasmid containing a Col2a1 enhancer and increased the transcription of the endogenous Col2a1 gene. In summary, Lc-Maf is the first transcription factor shown to interact with Sox9, to be coexpressed with Sox9 during an early step of chondrogenesis and to cooperate with Sox9 in activating a downstream target gene of Sox9.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd,Box 11, Houston, TX 77030 USA.	bdecromb@mdanderson.org			NCI NIH HHS [CA 16672] Funding Source: Medline; NIAMS NIH HHS [R01 AR42909, P01 AR42919-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR042909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Huang WD, 2001, P NATL ACAD SCI USA, V98, P160, DOI 10.1073/pnas.011393998; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; TACCHETTI C, 1992, EXP CELL RES, V200, P26, DOI 10.1016/S0014-4827(05)80067-9; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	31	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50668	50675		10.1074/jbc.M206544200	http://dx.doi.org/10.1074/jbc.M206544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381733	hybrid			2022-12-25	WOS:000180177700063
J	Schnick, C; Kortgen, N; Groth, G				Schnick, C; Kortgen, N; Groth, G			Complete inhibition of the tentoxin-resistant F-1-ATPase from Escherichia coli by the phytopathogenic inhibitor tentoxin after substitution of critical residues in the alpha- and beta-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST F-1-ATPASE; ATP SYNTHASES; STIMULATION; RESOLUTION; BINDING; F0F1; SITE	Substitution of critical residues in the alpha- and beta-subunit can turn the typically resistant ATP synthase from the bacterium Escherichia coli into an enzyme showing high sensitivity to the phytopathogenic inhibitor tentoxin, which usually affects only certain sensitive plant species. In contrast to recent results obtained with the thermophilic F-1 (Groth, G., Hisabori, T., Lill, H., and Bald, D. (2002) J. Biol. Chem. 277, 20117-20119), substitution of a critical serine in the beta-subunit (betaSer(59)), which is supposed to provide an important intermolecular hydrogen bond in the binding site, was not sufficient on its own for conferring tentoxin sensitivity to the E. coli F-1 complex. Superimposition of the chloroplast F-1-tentoxin inhibitor complex on a homology model of the E. coli F-1 complex provided detailed information on the critical residues in the alpha-subunit of the binding cleft and allowed us to model the binding site according to the steric requirements of the inhibitor. Substitution of the highly conserved residue alphaLeu(64) seems to be most important for allowing access of the inhibitor to the binding site. Combining this substitution with either additional replacements in the alpha-subunit Q49A, L95A, E96Q, I273M) or the replacement of Ser(59) in the beta-subunit enhanced the sensitivity to the inhibitor and resulted in a complete inhibition of the E. coli F-1-ATPase by the plant-specific inhibitor tentoxin.	Univ Dusseldorf, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Groth, G (corresponding author), Univ Dusseldorf, Univ Str 1, D-40225 Dusseldorf, Germany.	georg.groth@uni-duesseldorf.de						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHEN ZG, 1995, J BIOL CHEM, V270, P17124, DOI 10.1074/jbc.270.29.17124; DAHSE I, 1994, J PLANT PHYSIOL, V143, P615, DOI 10.1016/S0176-1617(11)81147-8; DeLano W.L., 2002, CCP4 NEWSL PROTEIN C, V40, P82; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Groth G, 2002, P NATL ACAD SCI USA, V99, P3464, DOI 10.1073/pnas.052546099; Groth G, 2002, J BIOL CHEM, V277, P20117, DOI 10.1074/jbc.C200168200; Groth G, 1998, J MOL BIOL, V281, P49, DOI 10.1006/jmbi.1998.1936; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Hu DL, 1997, J BIOL CHEM, V272, P5457, DOI 10.1074/jbc.272.9.5457; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Mochimaru M, 1997, FEBS LETT, V419, P23, DOI 10.1016/S0014-5793(97)01421-X; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Santolini J, 1999, J BIOL CHEM, V274, P849, DOI 10.1074/jbc.274.2.849; SELMAN BR, 1978, BIOCHIM BIOPHYS ACTA, V502, P29, DOI 10.1016/0005-2728(78)90128-7; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V504, P136, DOI 10.1016/0005-2728(78)90012-9; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tucker WC, 2000, J BIOL CHEM, V275, P906, DOI 10.1074/jbc.275.2.906; Tucker WC, 2001, BIOCHEMISTRY-US, V40, P7542, DOI 10.1021/bi0105227; Tucker WC, 2001, EUR J BIOCHEM, V268, P2179, DOI 10.1046/j.1432-1327.2001.02110.x	26	2	2	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51003	51007		10.1074/jbc.M206095200	http://dx.doi.org/10.1074/jbc.M206095200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399471	hybrid			2022-12-25	WOS:000180177700106
J	Suaud, L; Carattino, M; Kleyman, TR; Rubenstein, RC				Suaud, L; Carattino, M; Kleyman, TR; Rubenstein, RC			Genistein improves regulatory interactions between G551D-cystic fibrosis transmembrane conductance regulator and the epithelial sodium channel in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; CHLORIDE CHANNELS; DELTA-F508 CFTR; NA+ CHANNEL; CELL LINE; INHIBITION; ENAC; ACTIVATION; MECHANISM; TRANSPORT	The cystic fibrosis transmembrane conductance regulator (CFTR) in addition to its well defined Cl- channel properties regulates other ion channels. CFTR inhibits epithelial Na+ channel (ENaC) currents in many epithelial and non-epithelial cells, whereas the presence of ENaC increases CFTR functional expression. This interregulation is reproduced in Xenopus oocytes where both the open probability and surface expression of wild type CFTR Cl- channels are increased when CFTR is coexpressed with alphabetagamma-mouse ENaC (mENaC) and conversely when the activity of mENaC is inhibited after wild type CFTR activation. Using the Xenopus oocyte expression system, different functional regulatory interactions were observed between G551D-CFTR and alphabetagamma-mENaC. The co-expression of G551D-CFTR and alphabetagamma-mENaC resulted in a 5-fold increase in G551D-CFTR Cl- current compared with oocytes expressing G551D-CFTR alone. Oocytes co-injected with both G551D-CFTR and ENaC expressed an amiloride-sensitive whole cell current that was similar to that observed before and after G551D-CFTR activation with forskolin/isobutylmethyl-xanthine. Treatment with genistein both enhanced the functional expression of G551D-CFTR and improved regulatory interactions between G551D-CFTR and ENaC. These data suggest that genistein may be useful in patients with cystic fibrosis and the G551D-CFTR mutation.	Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rubenstein, RC (corresponding author), Childrens Hosp Philadelphia, Div Pulm Med, Abramson 410C,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Rubenstein, Ronald/0000-0002-3138-4006	NIDDK NIH HHS [DK56305, DK58046] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058046, R01DK056305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Andersson C, 2000, EUR RESPIR J, V15, P937, DOI 10.1034/j.1399-3003.2000.15e21.x; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Hopf A, 1999, J BIOL CHEM, V274, P13894, DOI 10.1074/jbc.274.20.13894; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; Illek B, 1999, AM J PHYSIOL-CELL PH, V277, pC833, DOI 10.1152/ajpcell.1999.277.4.C833; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Ling BN, 1997, J BIOL CHEM, V272, P594; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Suaud L, 2002, J BIOL CHEM, V277, P8928, DOI 10.1074/jbc.M111482200; Weinreich F, 1997, PFLUG ARCH EUR J PHY, V434, P484, DOI 10.1007/s004240050424; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	27	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50341	50347		10.1074/jbc.M209641200	http://dx.doi.org/10.1074/jbc.M209641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386156	hybrid			2022-12-25	WOS:000180177700018
J	Yuzenkova, J; Delgado, M; Nechaev, S; Savalia, D; Epshtein, V; Artsimovitch, I; Mooney, RA; Landick, R; Farias, RN; Salomon, R; Severinov, K				Yuzenkova, J; Delgado, M; Nechaev, S; Savalia, D; Epshtein, V; Artsimovitch, I; Mooney, RA; Landick, R; Farias, RN; Salomon, R; Severinov, K			Mutations of bacterial RNA polymerase leading to resistance to microcin J25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIFAMPICIN INHIBITION; BETA' SUBUNIT; STREPTOLYDIGIN RESISTANCE; RPOB GENE; TRANSCRIPTION; LOCALIZATION; ELONGATION; MECHANISM; TAGETITOXIN	A mutation in the conserved segment of the rpoC gene, which codes for the largest RNA polymerase (RNAP) subunit, beta', was found to make Escherichia coli cells resistant to microcin J25 (MccJ25), a bactericidal 21-amino acid peptide active against Gram-negative bacteria (Delgado, M. A., Rintoul, M. R., Farias, R. N., and Salomon, R. A. (2001) J. Bacteriol. 183, 4543-4550). Here, we report that mutant RNAP prepared from MccJ25-resistant cells, but not the wild-type RNAP, is resistant to MccJ25 in vitro, thus establishing that RNAP is a true cellular target of MccJ25. We also report the isolation of additional rpoC mutations that lead to MccJ25 resistance in vivo and in vitro. The new mutations affect beta' amino acids in evolutionarily conserved segments G, G', and F and are exposed into the RNAP secondary channel, a narrow opening that connects the enzyme surface with the catalytic center. We also report that previously known rpoB (RNAP beta subunit) mutations that lead to streptolydigin resistance cause resistance to MccJ25. We hypothesize that MccJ25 inhibits transcription by binding in RNAP secondary channel and blocking substrate access to the catalytic center.	Waksman Inst, Dept Genet, Piscataway, NJ 08854 USA; Univ Nacl Tucuman, Consejo Nacl Invest & Tech, Inst Super Invest Biol, RA-4000 San Miguel De Tucuman, Tucuman, Argentina; Publ Hlth Res Inst, New York, NY 10016 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional de Tucuman; University System of Ohio; Ohio State University; University of Wisconsin System; University of Wisconsin Madison	Severinov, K (corresponding author), Waksman Inst, Dept Genet, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016	Delgado, Monica/0000-0002-4283-6979; yuzenkova, yulia/0000-0003-4036-9235	NIGMS NIH HHS [GM64307, GM38660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R37GM038660, R29GM038660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; Blond A, 2001, EUR J BIOCHEM, V268, P2124, DOI 10.1046/j.1432-1327.2001.02090.x; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; Chiuchiolo MJ, 2001, J BACTERIOL, V183, P1755, DOI 10.1128/JB.183.5.1755-1764.2001; Delgado MA, 2001, J BACTERIOL, V183, P4543, DOI 10.1128/JB.183.15.4543-4550.2001; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LEGRICE SFJ, 1986, MOL GEN GENET, V204, P229, DOI 10.1007/BF00425503; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Nechaev S, 2002, J MOL BIOL, V320, P11, DOI 10.1016/S0022-2836(02)00420-5; Nedea EC, 1999, J BACTERIOL, V181, P2663, DOI 10.1128/JB.181.8.2663-2665.1999; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; SALOMON RA, 1992, J BACTERIOL, V174, P7428, DOI 10.1128/jb.174.22.7428-7435.1992; SALOMON RA, 1995, J BACTERIOL, V177, P3323, DOI 10.1128/jb.177.11.3323-3325.1995; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; Severinov K, 2000, CURR OPIN MICROBIOL, V3, P118, DOI 10.1016/S1369-5274(00)00062-X; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SEVERINOV K, 1993, J BIOL CHEM, V268, P14280; Solbiati JO, 1996, J BACTERIOL, V178, P3661, DOI 10.1128/jb.178.12.3661-3663.1996; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; VANDERHELM K, 1972, NATURE-NEW BIOL, V235, P82; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	35	119	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50867	50875		10.1074/jbc.M209425200	http://dx.doi.org/10.1074/jbc.M209425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401787	hybrid			2022-12-25	WOS:000180177700088
J	Zheng, ZL; Wang, ZM; Delbono, O				Zheng, ZL; Wang, ZM; Delbono, O			Insulin-like growth factor-1 increases skeletal muscle dihydropyridine receptor alpha(1s) transcriptional activity by acting on the cAMP-response element-binding protein element of the promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CHARGE MOVEMENT; CALCIUM-CHANNEL; CA2+ CHANNEL; GENE-EXPRESSION; RAT; FIBERS; CELLS; ALPHA-1; DIFFERENTIATION	Previous work from our laboratory has shown that insulin-like growth factor 1 (IGF-1) increases the expression of the skeletal muscle dihydropyridine receptor (DHPR) a, subunit by regulating DHPR alpha(1S) nuclear transcription. In this study, we investigated the mechanism by which IGF-1 enhances expression of the DHPR alpha(1S) gene. To this end, the promoter region of the mouse DHPR alpha(1S) gene was recently cloned and sequenced and various promoter deletion-luciferase reporter constructs were used. These constructs were transfected into C2C12 cells and IGF-1 effects were measured by recording luciferase activity. IGF-1 significantly enhanced DHPR a,, transcription in those constructs carrying cAMP-response element-binding protein (CREB) binding site but not in CREB core binding site mutants. Gel mobility shift assay using a double stranded oligonucleotide for the CREB site in the promoter region, and competition experiments with excess unlabeled or mutated promoter oligonucleotide, and unlabeled consensus CREB oligonucleotide demonstrated that IGF-1 induces CREB binding to the DHPR alpha(1S) promoter. IGF-1-mediated enhancement in charge movement was prevented by incubating the cells with antisense but not with sense oligonucleotides against CREB. These results support the conclusion that IGF-1 regulates DHPR alpha(1S) transcription in muscle cells by acting on the CREB element of the promoter.	Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Program Neurosci, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University	Delbono, O (corresponding author), Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	odelbono@wfubmc.edu			NIA NIH HHS [AG18775, AG13934, AG15820] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015820, R29AG013934, R01AG013934] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; Cheng ZQ, 2000, J ENDOCRINOL, V167, P175, DOI 10.1677/joe.0.1670175; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; Delbono O, 1997, J NEUROSCI, V17, P6918; DELBONO O, 1992, J PHYSIOL-LONDON, V451, P187, DOI 10.1113/jphysiol.1992.sp019160; DELBONO O, 1993, J PHYSIOL-LONDON, V460, P173, DOI 10.1113/jphysiol.1993.sp019465; DULHUNTY AF, 1983, J PHYSIOL-LONDON, V341, P213, DOI 10.1113/jphysiol.1983.sp014802; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; FLEIG A, 1995, J PHYSIOL-LONDON, V489, P41, DOI 10.1113/jphysiol.1995.sp021028; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLINGWORTH S, 1981, J PHYSIOL-LONDON, V321, P583, DOI 10.1113/jphysiol.1981.sp014004; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; Kim JG, 2001, ARCH ORAL BIOL, V46, P495, DOI 10.1016/S0003-9969(01)00013-9; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; Pereon Y, 1997, BIOCHEM BIOPH RES CO, V240, P612, DOI 10.1006/bbrc.1997.7712; Renganathan M, 1997, J MEMBRANE BIOL, V157, P247, DOI 10.1007/s002329900233; Renganathan M, 1998, J BIOL CHEM, V273, P28845, DOI 10.1074/jbc.273.44.28845; Renganathan M, 1997, FEBS LETT, V417, P13, DOI 10.1016/S0014-5793(97)01225-8; Renganathan M, 1999, PFLUG ARCH EUR J PHY, V438, P649, DOI 10.1007/s004240051089; Renganathan M, 1997, BIOCHEM BIOPH RES CO, V235, P784, DOI 10.1006/bbrc.1997.6881; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; SABORIDO A, 1995, PFLUG ARCH EUR J PHY, V429, P364, DOI 10.1007/BF00374151; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SIMON BJ, 1985, J GEN PHYSIOL, V85, P1, DOI 10.1085/jgp.85.1.1; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; Wang ZM, 1999, BIOPHYS J, V77, P2709, DOI 10.1016/S0006-3495(99)77104-3; Wang ZM, 2002, BIOPHYS J, V82, P1338, DOI 10.1016/S0006-3495(02)75489-1; ZHENG Z, 2001, 31 ANN M SAN DIEG CA, P266; Zheng ZL, 2002, J PHYSIOL-LONDON, V540, P397, DOI 10.1113/jphysiol.2001.013464; Zheng ZL, 2001, MECH AGEING DEV, V122, P373, DOI 10.1016/S0047-6374(00)00236-0	43	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50535	50542		10.1074/jbc.M210526200	http://dx.doi.org/10.1074/jbc.M210526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12407098	hybrid			2022-12-25	WOS:000180177700046
J	Chan, RS; Sakash, JB; Macol, CP; West, JA; Tsuruta, H; Kantrowitz, ER				Chan, RS; Sakash, JB; Macol, CP; West, JA; Tsuruta, H; Kantrowitz, ER			The role of intersubunit interactions for the stabilization of the T state of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; CATALYTIC CHAIN; DOMAIN CLOSURE; HETEROTROPIC INTERACTIONS; REGULATORY CHAIN; HOMOTROPIC COOPERATIVITY; RESIDUES 230-245; R-STATE; BINDING; CARBAMOYLTRANSFERASE	Homotropic cooperativity in Escherichia coli aspartate transcarbamoylase results from the substrate-induced transition from the T to the R state. These two alternate states are stabilized by a series of interdomain and intersubunit interactions. The salt link between Lys-143 of the regulatory chain and Asp-236 of the catalytic chain is only observed in the T state. When Asp-236 is replaced by alanine the resulting enzyme exhibits full activity, enhanced affinity for aspartate, no cooperativity, and no heterotropic interactions. These characteristics are consistent with an enzyme locked in the functional R state. Using small angle x-ray scattering, the structural consequences of the D236A mutant were characterized. The unliganded D236A holoenzyme appears to be in a new structural state that is neither T, R, nor a mixture of T and R states. The structure of the native D236A holoenzyme is similar to that previously reported for another mutant holoenzyme (E239Q) that also lacks intersubunit interactions. A hybrid version of aspartate transcarbamoylase in which one catalytic subunit was wild-type and the other had the D236A mutation was also investigated. The hybrid holoenzyme, with three of the six possible interactions involving Asp-236, exhibited homotropic cooperativity, and heterotropic interactions consistent with an enzyme with both T and R functional states. Small angle x-ray scattering analysis of the unligated hybrid indicated that the enzyme was in a new structural state more similar to the T than to the R state of the wild-type enzyme. These data suggest that three of the six intersubunit interactions involving D236A are sufficient to stabilize a T-like state of the enzyme and allow for an allosteric transition.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41 RR 01209] Funding Source: Medline; NIGMS NIH HHS [GM 26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1990, BIOCHEMISTRY-US, V29, P3716, DOI 10.1021/bi00467a018; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; HONZATKO RB, 1982, P NATL ACAD SCI-BIOL, V79, P7171, DOI 10.1073/pnas.79.23.7171; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macol CP, 2001, NAT STRUCT BIOL, V8, P423, DOI 10.1038/87582; Maniatis T., 1982, MOL CLONING LAB MANU; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; Sakash JB, 2000, J BIOL CHEM, V275, P28701, DOI 10.1074/jbc.M005079200; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, J BIOL CHEM, V264, P14860; Svergun DI, 1997, PROTEINS, V27, P110; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	39	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49755	49760		10.1074/jbc.M208919200	http://dx.doi.org/10.1074/jbc.M208919200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12399459	hybrid			2022-12-25	WOS:000180028900087
J	Olakanmi, O; Schlesinger, LS; Ahmed, A; Britigan, BE				Olakanmi, O; Schlesinger, LS; Ahmed, A; Britigan, BE			Intraphagosomal Mycobacterium tuberculosis acquires iron from both extracellular transferrin and intracellular iron pools - Impact of interferon-gamma and hemochromatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN-ACTIVITY; HEREDITARY HEMOCHROMATOSIS; HUMAN-MONOCYTES; NITRIC-OXIDE; LEGIONELLA-PNEUMOPHILA; NATURAL-RESISTANCE; HUMAN MACROPHAGES; GENETIC HEMOCHROMATOSIS; INFECTED MACROPHAGES; COMPLEMENT RECEPTORS	Mycobacterium tuberculosis multiplies within the macrophage phagosome and requires iron for growth. We examined the route(s) by which intracellular M. tuberculosis acquires iron. During intracellular growth of the virulent Erdman M. tuberculosis strain in human monocyte-derived macrophages (MDM), M. tuberculosis acquisition of Fe-59 from transferrin (TF) provided extracellularly (exogenous source) was compared with acquisition when MDM were loaded with Fe-59 from TF prior to M. tuberculosis infection (endogenous sources). M. tuberculosis Fe-59 acquisition required viable bacteria and was similar from exogenous and endogenous sources at 24 h and greater from exogenous iron at 48 h. Interferon-gamma treatment of MDM reduced Fe-59 uptake from TF 51% and TF receptor expression by 34%. Despite this, intraphagosomal M. tuberculosis iron acquisition in IFN-gamma-treated cells was decreased by only 30%. Macrophages from hereditary hemochromatosis patients have altered iron metabolism. Intracellular M. tuberculosis acquired markedly less iron in MDM from these individuals than in MDM from healthy donors, regardless of the iron source (exogenous and endogenous): 36 +/- 3.8% and 17 +/- 9.6% of control, respectively. Thus, intraphagosomal M. tuberculosis can acquire iron from both extracellular TF and endogenous macrophage sources. Acquisition of iron from macrophage cytoplasmic iron pools may be critical for the intracellular growth of M. tuberculosis. This acquisition is altered by IFN-gamma treatment to a small extent, but is markedly reduced in macrophages from hemochromatosis patients.	Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Res Serv, Iowa City, IA 52246 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Interdisciplinary Program Immunol, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Britigan, BE (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, Div Infect Dis, GH, SW54, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI043870, R29AI033004, R01AI033004] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43870, AI 33004, AI 24954] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; BARNEWALL RE, 1994, INFECT IMMUN, V62, P4804, DOI 10.1128/IAI.62.11.4804-4810.1994; BAYNES RD, 1989, AM J HEMATOL, V31, P21, DOI 10.1002/ajh.2830310104; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; Buu N, 2000, CLIN INFECT DIS, V31, pS81, DOI 10.1086/314067; BYRD TF, 1991, J CLIN INVEST, V88, P1103, DOI 10.1172/JCI115409; BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038; BYRD TF, 1993, J CLIN INVEST, V91, P969, DOI 10.1172/JCI116318; Cairo G, 1997, BLOOD, V89, P2546, DOI 10.1182/blood.V89.7.2546; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; DEJONG G, 1990, CLIN CHIM ACTA, V190, P1, DOI 10.1016/0009-8981(90)90278-Z; DOUVAS GS, 1985, INFECT IMMUN, V50, P1; EDEKER BL, 1995, J LEUKOCYTE BIOL, V58, P59, DOI 10.1002/jlb.58.1.59; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; ESCOBAR A, 1992, J BIOENERG BIOMEMBR, V24, P227, DOI 10.1007/BF00762681; Feder JN, 1999, IMMUNOL RES, V20, P175, DOI 10.1007/BF02786472; Finkelstein RA, 1983, REV INFECT DIS, V5, P5759; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; GEBRAN SJ, 1994, INFECT IMMUN, V62, P3197, DOI 10.1128/IAI.62.8.3197-3205.1994; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; Gomes MS, 1998, IMMUNOLOGY, V95, P165; Gomez F, 2000, CLIN BIOCHEM, V33, P191, DOI 10.1016/S0009-9120(00)00064-3; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237; JACOBS A, 1981, BRIT J HAEMATOL, V49, P649, DOI 10.1111/j.1365-2141.1981.tb07276.x; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kuhn DE, 2001, J LEUKOCYTE BIOL, V69, P43; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Moura E, 1998, BLOOD, V92, P2511, DOI 10.1182/blood.V92.7.2511.2511_2511_2519; Mulero V, 1999, BLOOD, V94, P2383, DOI 10.1182/blood.V94.7.2383.419k20_2383_2389; NIELANDS JB, 1981, ANNU REV BIOCHEM, V50, P715; North RJ, 1999, INFECT IMMUN, V67, P5811, DOI 10.1128/IAI.67.11.5811-5814.1999; Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Ragno S, 2001, IMMUNOLOGY, V104, P99, DOI 10.1046/j.1365-2567.2001.01274.x; Recalcati S, 1998, BLOOD, V91, P2565, DOI 10.1182/blood.V91.7.2565.2565_2565_2572; RICHARDSON DR, 1992, J BIOL CHEM, V267, P21384; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Schlesinger L. S., 1997, LUNG MACROPHAGES DEN, P437; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SIZEMORE DJ, 1984, AM J HEMATOL, V16, P347, DOI 10.1002/ajh.2830160405; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; TAETLE R, 1988, BLOOD, V71, P1590; Teitelbaum R, 1999, P NATL ACAD SCI USA, V96, P15190, DOI 10.1073/pnas.96.26.15190; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Waheed A, 2002, P NATL ACAD SCI USA, V99, P3117, DOI 10.1073/pnas.042701499; Wardrop SL, 2000, EUR J BIOCHEM, V267, P6586, DOI 10.1046/j.1432-1327.2000.01752.x; Wheeler Paul R., 1994, P353; XU SM, 1994, J IMMUNOL, V153, P2568; Zhong WJ, 2001, INFECT IMMUN, V69, P6618, DOI 10.1128/IAI.69.11.6618-6624.2001; Zwilling BS, 1999, INFECT IMMUN, V67, P1386, DOI 10.1128/IAI.67.3.1386-1392.1999	62	101	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49727	49734		10.1074/jbc.M209768200	http://dx.doi.org/10.1074/jbc.M209768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12399453	hybrid			2022-12-25	WOS:000180028900083
J	Pasternack, A; Coleman, SK; Jouppila, A; Mottershead, DG; Lindfors, M; Pasternack, M; Keinanen, K				Pasternack, A; Coleman, SK; Jouppila, A; Mottershead, DG; Lindfors, M; Pasternack, M; Keinanen, K			alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor channels lacking the N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; MOLECULAR DETERMINANTS; STRUCTURAL SIMILARITY; CRYSTAL-STRUCTURES; ION CHANNELS; SUBUNIT; DESENSITIZATION; PROTEINS	Ionotropic glutamate receptor (iGluR) subunits contain a similar to400-residue extracellular N-terminal domain ("X domain"), which is sequence-related to bacterial amino acid-binding proteins and to class C G-protein-coupled receptors. The X domain has been implicated in the assembly, transport to the cell surface, allosteric ligand binding, and desensitization in various members of the iGluR family, but its actual role in these events is poorly characterized. We have studied the properties of homomeric alpha-amino-3-hydroxy-5-methylisoxazolepropionate (AMPA)-selective GluR-D glutamate receptors carrying N-terminal deletions. Our analysis indicates that, surprisingly, transport to the cell surface, ligand binding properties, agonist-triggered channel activation, rapid desensitization, and allosteric potentiation by cyclothiazide can occur normally in the complete absence of the X domain (residues 22-402). The relatively intact ligand-gated channel function of a homomeric AMPA receptor in the absence of the X domain indirectly suggests more subtle roles for this domain in AMPA receptors, e.g. in the assembly of heteromeric receptors and in synaptic protein interactions.	Univ Helsinki, Dept Biosci, Div Biochem, Viikki Bioctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Div Biochem, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Keinanen, K (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikki Bioctr, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.		Keinanen, Kari/E-9122-2010; Mottershead, David G/B-7749-2013	Mottershead, David G/0000-0003-2593-0725; Pasternack, Arja/0000-0002-6088-4245; Coleman, Sarah/0000-0002-1066-8296				Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Banke TG, 2001, J NEUROSCI, V21, P3052, DOI 10.1523/JNEUROSCI.21-09-03052.2001; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fayyazuddin A, 2000, NEURON, V25, P683, DOI 10.1016/S0896-6273(00)81070-3; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Jespersen LK, 2000, EUR J BIOCHEM, V267, P1382, DOI 10.1046/j.1432-1327.2000.01137.x; Kessler M, 2000, NEUROSCI LETT, V287, P161, DOI 10.1016/S0304-3940(00)01180-0; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Masuko T, 1999, MOL PHARMACOL, V55, P957, DOI 10.1124/mol.55.6.957; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Sinnarajah S, 1999, SYNAPSE, V31, P203; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Villarroel A, 1998, NEURON, V20, P329, DOI 10.1016/S0896-6273(00)80460-2; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894	38	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49662	49667		10.1074/jbc.M208349200	http://dx.doi.org/10.1074/jbc.M208349200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393905	Green Published, hybrid			2022-12-25	WOS:000180028900075
J	Watanabe, R; Funato, K; Venkataramam, K; Futerman, AH; Riezman, H				Watanabe, R; Funato, K; Venkataramam, K; Futerman, AH; Riezman, H			Sphingolipids are required for the stable membrane association of glycosylphosphatidylinositol-anchored proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; FATTY-ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; GOLGI-APPARATUS; CERAMIDE SYNTHESIS; CELL-SURFACE; LIPID RAFTS; TRANSPORT	Ongoing sphingolipid synthesis is specifically required in vivo for the endoplasmic reticulum (ER) to Golgi transport of glycosylphosphatidylinositol (GPI)-anchored proteins. However, the sphingolipid intermediates that are required for transport nor their role(s) have been identified. Using stereoisomers of dihydrosphingosine, together with specific inhibitors and a mutant defective for sphingolipid synthesis, we now show that ceramides and/or inositol sphingolipids are indispensable for GPI-anchored protein transport. Furthermore, in the absence of sphingolipid synthesis, a significant fraction of GPI-anchored proteins is no longer associated tightly with the ER membrane. The loose membrane association is neither because of the lack of a GPI-anchor nor because of prolonged ER retention of GPI-anchored proteins. These results indicate that ceramides and/or inositol sphingolipids are required to stabilize the association of GPI-anchored proteins with membranes. They could act either by direct involvement as membrane components or as substrates for the remodeling of GPI lipid moieties.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	University of Basel; Weizmann Institute of Science	Riezman, H (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva, Switzerland.			Futerman, Anthony/0000-0003-0013-0115; Riezman, Howard/0000-0003-4680-9422; Watanabe, Reika/0000-0002-7427-7702				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; LESTER RL, 1993, ADV LIPID RES, V26, P253; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sipos G, 1997, EMBO J, V16, P3494, DOI 10.1093/emboj/16.12.3494; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Sutterlin C, 1997, J CELL SCI, V110, P2703; Venkataraman K, 2001, BBA-MOL CELL BIOL L, V1530, P219, DOI 10.1016/S1388-1981(01)00085-3; WANG E, 1991, J BIOL CHEM, V266, P14486; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhong WY, 1999, FEBS LETT, V463, P241, DOI 10.1016/S0014-5793(99)01633-6	38	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49538	49544		10.1074/jbc.M206209200	http://dx.doi.org/10.1074/jbc.M206209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393888	hybrid			2022-12-25	WOS:000180028900058
J	Xu, G; Arregui, C; Lilien, J; Balsamo, J				Xu, G; Arregui, C; Lilien, J; Balsamo, J			PTP1B modulates the association of beta-catenin with N-cadherin through binding to an adjacent and partially overlapping target site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; CELL-CELL-ADHESION; MEDIATED ADHESION; FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CARCINOMA-CELLS; KINASE FER; IN-VIVO	The nonreceptor tyrosine phosphatase PTP1B associates with the cytoplasmic domain of N-cadherin and may regulate cadherin function through dephosphorylation of beta-catenin. We have now identified the domain on N-cadherin to which PTP1B binds and characterized the effect of perturbing this domain on cadherin function. Deletion constructs lacking amino acids 872-891 fail to bind PTP1B. This domain partially overlaps with the beta-catenin binding domain. To further define the relationship of these two sites, we used peptides to compete in vitro binding. A peptide representing the most NH2-terminal 8 amino acids of the PTP1B binding site, the region of overlap with the beta-catenin target, effectively competes for binding of G-catenin but is much less effective in competing PTP1B, whereas two peptides representing the remaining 12 amino acids have no effect on beta-catenin binding but effectively compete for PTP1B binding. Introduction into embryonic chick retina cells of a cell-permeable peptide mimicking the 8 most COOH-terminal amino acids in the PTP1B target domain, the region most distant from the beta-catenin target site, prevents binding of PTP1B, increases the pool of free, tyrosine-phosphorylated beta-catenin, and results in loss of N-cadherin function. N-cadherin lacking this same region of the PTP1B target site does not associate with PTP1B or beta-catenin and is not efficiently expressed at the cell surface of transfected L cells. Thus, interaction of PTP1B with N-cadherin is essential for its association with P-catenin, stable expression at the cell surface, and consequently, cadherin function.	Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA	University of Iowa	Lilien, J (corresponding author), Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA.			Arregui, Carlos/0000-0003-0704-3321	NEI NIH HHS [EY 12132] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012132] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; BALSAMO J, 1995, J CELL BIOL, V129, P1391, DOI 10.1083/jcb.129.5.1391; BALSAMO J, 1991, J CELL BIOL, V113, P429, DOI 10.1083/jcb.113.2.429; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bonvini P, 2001, CANCER RES, V61, P1671; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KINCH MS, 1995, BIOCHEM SOC T, V23, P446, DOI 10.1042/bst0230446; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lambert M, 2000, J CELL SCI, V113, P2207; Li HD, 2000, J CELL BIOL, V149, P1275, DOI 10.1083/jcb.149.6.1275; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Lilien J, 1999, J NEUROSCI RES, V58, P727, DOI 10.1002/(SICI)1097-4547(19991215)58:6<727::AID-JNR1>3.0.CO;2-7; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Pathre P, 2001, J NEUROSCI RES, V63, P143, DOI 10.1002/1097-4547(20010115)63:2<143::AID-JNR1006>3.0.CO;2-1; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rhee J, 2001, J BIOL CHEM, V276, P6640, DOI 10.1074/jbc.M007656200; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	54	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49989	49997		10.1074/jbc.M206454200	http://dx.doi.org/10.1074/jbc.M206454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377785	hybrid			2022-12-25	WOS:000180028900116
J	Duez, H; Chao, YS; Hernandez, M; Torpier, G; Poulain, P; Mundt, S; Mallat, Z; Teissier, E; Burton, CA; Tedgui, A; Fruchart, JC; Fievet, C; Wright, SD; Staels, B				Duez, H; Chao, YS; Hernandez, M; Torpier, G; Poulain, P; Mundt, S; Mallat, Z; Teissier, E; Burton, CA; Tedgui, A; Fruchart, JC; Fievet, C; Wright, SD; Staels, B			Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; PPAR-GAMMA ACTIVATORS; E-DEFICIENT MICE; SECONDARY PREVENTION; TRANSGENIC MICE; GENE-EXPRESSION; CELLS; PROGRESSION	Several clinical and angiographic intervention trials have shown that fibrate treatment leads to a reduction of the coronary events associated to atherosclerosis. Fibrates are ligands for peroxisome proliferator-activated receptor a (PPARalpha) that modulate risk factors related to atherosclerosis by acting at both systemic and vascular levels. Here, we investigated the effect of treatment with the PPARalpha agonist fenofibrate (FF) on the development of atherosclerotic lesions in apolipoprotein (apo) E-deficient mice and human apoA-I transgenic apoE-deficient (hapoA-I Tg x apoE-deficient) mice fed a Western diet. In apoE-deficient mice, plasma lipid levels were increased by FF treatment with no alteration in the cholesterol distribution profile. FF treatment did not reduce atherosclerotic lesion surface area in the aortic sinus of 5-month-old apoE-deficient mice. By contrast, FF treatment decreased total cholesterol and esterified cholesterol contents in descending aortas of these mice, an effect that was more pronounced in older mice exhibiting more advanced lesions. Furthermore, FF treatment reduced MCP-1 mRNA levels in the descending aortas of apoE-deficient mice, whereas ABCA-1 expression levels were maintained despite a significant reduction of aortic cholesterol content. In apoE-deficient mice expressing a human apoA-I transgene, FF increased human apoA-I plasma and hepatic mRNA levels without affecting plasma lipid levels. This increase in human apoA-I expression was accompanied by a significant reduction in the lesion surface area in the aortic sinus. These data indicate that the PPARalpha agonist fenofibrate reduces atherosclerosis in these animal models of atherosclerosis.	Inst Pasteur, INSERM, F-59019 Lille, France; Merck Res Labs, Rahway, NJ 07065 USA; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Hop Lariboisiere, INSERM, U541, F-75475 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Merck & Company; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Staels, B (corresponding author), Inst Pasteur, INSERM, UR 545,1 Rue Calmette,BP 245, F-59019 Lille, France.		Chao, Yu-Sheng/D-2074-2010; Duez, Helene/AAC-3217-2019; Mallat, Ziad/D-4041-2012; Staels, Bart/N-9497-2016; Duez, Helene/M-7609-2017	Duez, Helene/0000-0002-4130-7987; Mallat, Ziad/0000-0003-0443-7878; Staels, Bart/0000-0002-3784-1503; 				Aiello RJ, 1999, ARTERIOSCL THROM VAS, V19, P1518, DOI 10.1161/01.ATV.19.6.1518; Assmann G, 1999, ARTERIOSCL THROM VAS, V19, P1819, DOI 10.1161/01.ATV.19.8.1819; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Gervois P, 2000, CLIN CHEM LAB MED, V38, P3, DOI 10.1515/CCLM.2000.002; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hyka N, 2001, BLOOD, V97, P2381, DOI 10.1182/blood.V97.8.2381; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 2002, CIRC RES, V90, P703, DOI 10.1161/01.RES.0000014225.20727.8F; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Neve BP, 2001, CIRCULATION, V103, P207; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; Sparrow CP, 2001, ARTERIOSCL THROM VAS, V21, P115, DOI 10.1161/01.ATV.21.1.115; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Steiner G, 2001, LANCET, V357, P905; Syvanne M, 1998, CIRCULATION, V98, P1993, DOI 10.1161/01.CIR.98.19.1993; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	46	162	168	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48051	48057		10.1074/jbc.M206966200	http://dx.doi.org/10.1074/jbc.M206966200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377786	hybrid			2022-12-25	WOS:000179789600012
J	Maeda, T; Chapman, DL; Stewart, AFR				Maeda, T; Chapman, DL; Stewart, AFR			Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; SERUM RESPONSE FACTOR; CAT BINDING-FACTOR; HELIX-LOOP-HELIX; GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; WING FORMATION; HISTONE ACETYLTRANSFERASES; CARDIAC MYOCYTES; FACTOR RTEF-1	Expression of many skeletal muscle-specific genes depends on TEF-1 (transcription enhancer factor-1) and MEF2 transcription factors. In Drosophila, the TEF-1 homolog Scalloped interacts with the cofactor Vestigial to drive differentiation of the wing and indirect flight muscles. Here, we identify three mammalian vestigial-like genes, Vgl-1, Vgl-2, and Vgl-3, that share homology in a TEF-1 interaction domain. Vgl-1 and Vgl-3 transcripts are enriched in the placenta, whereas Vgl-2 is expressed in the differentiating somites and branchial arches during embryogenesis and is skeletal muscle-specific in the adult. During muscle differentiation, Vgl-2 mRNA levels increase and Vgl-2 protein translocates from the cytoplasm to the nucleus. In situ hybridization revealed co-expression of Vgl-2 with myogenin in the differentiating muscle of embryonic myotomes but not in newly formed somites prior to muscle differentiation. Like Vgl-1, Vgl-2 interacts with TEF-1. In addition, we show that Vgl-2 interacts with MEF2 in a mammalian two-hybrid assay and that Vgl-2 selectively binds to MEF2 in vitro. Co-expression of Vgl-2 with MEF2 markedly co-activates an MEF2-dependent promoter through its MEF2 element. Overexpression of Vgl-2 in MyoD-transfected 10T 1/2 cells markedly increased myosin heavy chain expression, a marker of terminal muscle differentiation. These results identify Vgl-2 as an important new component of the myogenic program.	Univ Pittsburgh, Sch Med, Cardiovasc Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AFR (corresponding author), Univ Pittsburgh, Sch Med, Cardiovasc Inst, BST 1704-3,200 Lothrop St, Pittsburgh, PA 15213 USA.		Stewart, Alexandre F.R./A-5677-2011	Chapman, Deborah/0000-0002-8695-6243; Stewart, Alexandre/0000-0003-2673-9164	NHLBI NIH HHS [HL57211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; Borghi S, 2001, J CELL SCI, V114, P4477; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; Chen SL, 2000, GENE DEV, V14, P1209; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Deshpande N, 1997, J BIOL CHEM, V272, P10664; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; Halder G, 2001, DEVELOPMENT, V128, P3295; Hsu DKW, 1996, J BIOL CHEM, V271, P13786, DOI 10.1074/jbc.271.23.13786; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JIANG SW, 1994, J BIOL CHEM, V269, P10384; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Klein T, 1999, DEVELOPMENT, V126, P913; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Maeda T, 2002, BIOCHEM BIOPH RES CO, V294, P791, DOI 10.1016/S0006-291X(02)00556-9; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Nagel AC, 2001, MECH DEVELOP, V109, P241, DOI 10.1016/S0925-4773(01)00539-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; Paumard-Rigal S, 1998, DEV GENES EVOL, V208, P440, DOI 10.1007/s004270050201; Rogerson PJ, 2002, FEBS LETT, V524, P134, DOI 10.1016/S0014-5793(02)03024-7; Simmonds AJ, 1998, GENE DEV, V12, P3815, DOI 10.1101/gad.12.24.3815; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727; Yu YT, 1996, J BIOL CHEM, V271, P24675; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; Zider A, 1998, J NEUROGENET, V12, P87, DOI 10.3109/01677069809167258	52	116	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48889	48898		10.1074/jbc.M206858200	http://dx.doi.org/10.1074/jbc.M206858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376544	hybrid			2022-12-25	WOS:000179789600119
J	Spoerl, Z; Stumpf, M; Noegel, AA; Hasse, A				Spoerl, Z; Stumpf, M; Noegel, AA; Hasse, A			Oligomerization, F-actin interaction, and membrane association of the ubiquitous mammalian coronin 3 are mediated by its carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-VII SYNEXIN; PROTEIN-KINASE-C; BINDING PROTEIN; WD REPEAT; FAMILY; LOCALIZATION; CLONING; RAC; ARCHITECTURE; CYTOKINESIS	Coronin 3 is a ubiquitously expressed member of the coronin protein family in mammals. In fibroblasts and HEK 293 cells, it is localized both in the cytosol and in the submembranous cytoskeleton, especially at lamellipodia and membrane ruffles. The carboxyl terminus of all coronins contains a coiled coil suggested to mediate dimerization. We show here that in contrast to other coronin homologues, the recombinant human coronin 3 carboxyl terminus forms oligomers rather than dimers, and that this part is sufficient to bind to and cross-link F-actin in vitro. The carboxyl terminus alone also conferred membrane association in vivo, and removal of the coiled coil abolished membrane localization but not in vitro F-actin binding. Coronin 3 is exclusively extracted as an oligomer from both the cytosol and the membrane fraction. Because oligomerization was not reported for other coronins, it might be a key feature governing coronin 3-specific functions. Cytosolic coronin 3 showed a high degree of phosphorylation, which is likely to regulate the subcellular localization of the protein.	Univ Cologne, Fac Med, Inst Biochem 1, D-50931 Cologne, Germany	University of Cologne	Noegel, AA (corresponding author), Univ Cologne, Fac Med, Inst Biochem 1, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Asano S, 2001, GENES CELLS, V6, P225, DOI 10.1046/j.1365-2443.2001.00416.x; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Clemen CS, 1999, J MUSCLE RES CELL M, V20, P669, DOI 10.1023/A:1005524623337; David V, 1998, J CELL SCI, V111, P2877; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Fukui Y, 1999, CELL MOTIL CYTOSKEL, V42, P204, DOI 10.1002/(SICI)1097-0169(1999)42:3<204::AID-CM4>3.0.CO;2-L; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Grogan A, 1997, J CELL SCI, V110, P3071; Iizaka M, 2000, CYTOGENET CELL GENET, V88, P221, DOI 10.1159/000015555; Itoh S, 2002, BIOL PHARM BULL, V25, P837, DOI 10.1248/bpb.25.837; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Mishima M, 1999, J CELL SCI, V112, P2833; Nakamura T, 1999, J BIOL CHEM, V274, P13322, DOI 10.1074/jbc.274.19.13322; NOBES CD, 1995, J CELL SCI, V108, P225; Okumura M, 1998, DNA CELL BIOL, V17, P779, DOI 10.1089/dna.1998.17.779; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Parente JA, 1999, J BIOL CHEM, V274, P3017, DOI 10.1074/jbc.274.5.3017; Rappleye CA, 1999, GENE DEV, V13, P2838, DOI 10.1101/gad.13.21.2838; Reeves EP, 1999, BIOCHEM J, V344, P859, DOI 10.1042/0264-6021:3440859; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SELBERT S, 1995, J CELL SCI, V108, P85; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; WEINER OH, 1993, J CELL BIOL, V123, P23, DOI 10.1083/jcb.123.1.23; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	34	68	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48858	48867		10.1074/jbc.M205136200	http://dx.doi.org/10.1074/jbc.M205136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377779	hybrid			2022-12-25	WOS:000179789600115
J	Chang, BY; Harte, RA; Cartwright, CA				Chang, BY; Harte, RA; Cartwright, CA			RACK1: a novel substrate for the Src protein-tyrosine kinase	ONCOGENE			English	Article						Src; RACK1; PKC; signal transduction	MIDDLE TUMOR-ANTIGEN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; SH2 DOMAIN; C-SRC; PHOSPHORYLATION; PP60C-SRC; ACTIVATION; FAMILY; CELLS	RACK1 is one of a group of PKC-interacting proteins collectively called RACKs (Receptors for Activated C-Kinases). Previously, we showed that RACK1 also interacts with the Src tyrosine kinase, and is an inhibitor of Src activity and cell growth. PKC activation induces the intracellular movement and co-localization of RACK1 and Src, and the tyrosine phosphorylation of RACK1. To determine whether RACK1 is a Src substrate, we assessed phosphorylation of RACK1 by various tyrosine kinases in vitro, and by kinase-active and inactive mutants of Src in vivo. We found that RACK1 is a Src substrate. Moreover, Src activity is necessary for both the tyrosine phosphorylation of RACK1 and the binding of RACK1 to Src's SH2 domain that occur following PKC activation. To identify the tyrosine(s) on RACK1 that is phosphorylated by Src, we generated and tested a series of RACK1 mutants. We found that Src phosphorylates RACK1 on Tyr 228 and/or Tyr 246, highly-conserved tyrosines located in the sixth WD repeat that interact with Src's SH2 domain. We think that RACK1 is an important Src substrate that signals downstream of growth factor receptor tyrosine kinases and is involved in the regulation of Src function and cell growth.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Room 3115-C,269 Campus Dr, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [F32CA069810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER; NCI NIH HHS [CA69810] Funding Source: Medline; NIDDK NIH HHS [R01 DK43743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lou Q, 1996, BIOORGAN MED CHEM, V4, P677, DOI 10.1016/0968-0896(96)00063-6; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PARK J, 1995, MOL CELL BIOL, V15, P2374; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zhou Songyang, 1995, Nature (London), V373, P536	30	95	105	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7619	7629		10.1038/sj.onc.1206002	http://dx.doi.org/10.1038/sj.onc.1206002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400005				2022-12-25	WOS:000178756200002
J	De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A				De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A			Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines	ONCOGENE			English	Article						signal transduction; cytokine receptors; kinases; phosphatases growth factors; AIDS; HIV	PERIPHERAL-BLOOD LYMPHOCYTES; PROMONOCYTIC CELL-LINES; TAT-ASSOCIATED KINASE; FACTOR P-TEFB; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; HIV-1 TAT; IN-VITRO; INTERLEUKIN-6; TRANSCRIPTION	Cdk9 is a member of the Cdc2-like family of kinases. It binds to members of the family of cyclin T (T1, T2a and T2b) and to cyclin K. The Cdk9/cyclin T complex appears to be involved in regulating several physiological processes. In fact Cdk9 is the kinase of the P-TEFb complex, involved in basal transcription. Cdk9 has also been described as the kinase of the TAK complex, homologous to P-TEFb and involved in HIV replication. Here we show that Cdk9 interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines,,which includes Leukemia Inhibitory Factor (LIF), Oncostatin NI (OSM), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1). IL-6 is a key regulator of hematopoiesis, immunological responses and inflammation. In addition, IL-6 plays a major role in the endocrine and nervous systems. Signal transduction by gp130 is mediated by physical interaction of the cytoplasmic region of gp130 with cellular kinases and results in the transcriptional activation of cellular and viral genes. We found that Cdk9 interacts in vitro with the cytoplasmic region of gp130 and we succeded in reproducing this interaction in vivo. Cdk9 expression was found both in the nucleus and in the cytoplasm. The binding occurring between Cdk9 and gp130 increased upon IL-6 stimulation. We also observed that Cdk9 synergized with IL-6 in inducing the activation of an IL-6-responsive reporter plasmid. In summary, these results point to a previously undisclosed role for Cdk9 in signal transduction.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Ist Anat & Istol Patol, I-53100 Siena, Italy; Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, I-44100 Ferrara, Italy; CNR, Ist Citomorfol Normale & Patol, IOR, I-40137 Bologna, Italy; Univ Naples Federico II, Dipartimento Biol Evolut & Comparata, Naples, Italy; Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples 2, Ist Anat Topog, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Neri, Luca Maria/J-2462-2017; BELLAN, CRISTIANA/L-3903-2013; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; De Luca, Antonio/AAD-9562-2020; leoncini, lorenzo/P-8361-2018; Neri, Luca Maria/AAU-1772-2021	BELLAN, CRISTIANA/0000-0001-6119-9007; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; De Luca, Antonio/0000-0002-3905-6154; leoncini, lorenzo/0000-0002-7457-300X; Neri, Luca Maria/0000-0002-7924-1477				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BELLAN C, 2002, J CLIN PATHOL S1, V55, pA29; BOULTON TG, 1994, J BIOL CHEM, V269, P648; BULLRICH F, 1995, CANCER RES, V55, P1199; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DEFALCO G, 2002, CANC BIOL THER, V1, P66; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001; Giordano V, 1997, J IMMUNOL, V158, P4097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; OFFIT K, 1993, GENE CHROMOSOME CANC, V7, P1, DOI 10.1002/gcc.2870070102; ORLOW I, 1994, CANCER RES, V54, P2848; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; ULRICH A, 1990, CELL, V61, P203; von Laue S, 2000, J ENDOCRINOL, V165, P301, DOI 10.1677/joe.0.1650301; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	38	25	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7464	7470		10.1038/sj.onc.1205967	http://dx.doi.org/10.1038/sj.onc.1205967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386808				2022-12-25	WOS:000178618200001
J	Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS				Wang, K; Liu, N; Radulovich, N; Wigle, DA; Johnston, MR; Shepherd, FA; Minden, MD; Tsao, MS			Novel candidate tumor marker genes for lung adenocarcinoma	ONCOGENE			English	Article						lung cancer; biomarker; subtractive hybridization; microarray; differential expression	REPRESENTATIONAL DIFFERENCE ANALYSIS; MESSENGER-RNA EXPRESSION; BINDING PROTEIN PHBP; CHROMOSOMAL LOCALIZATION; CANCER; IDENTIFICATION; COLLAGEN; INTEGRIN; CLONING; DIAGNOSIS	Using the representational difference analysis (RDA) technique on pooled mRNA of five primary lung adenocarcinomas and their corresponding non-neoplastic lung tissues, we identified six genes that were putatively overexpressed in this type of lung cancer. Five corresponded to previously isolated genes, while one (Lc19) matched with the sequence of an unannotated EST. Real-time RT-PCR analyses of expression levels in a panel of 34 paired primary non-small cell lung cancer (NSCLC) and corresponding grossly normal appearing lung tissues confirmed the common overexpression of these genes in non-small cell lung cancer. Among these genes, overexpression of Lc19, hyaluronan binding protein 2 (HABP2) and crystalline-mu appeared more specific to adenocarcinoma, whereas ceruloplasmin, integrin alpha-11 and collagen type XI alpha 1 were overexpressed at high frequency among both adenocarcinoma and squamous cell carcinoma. These genes represent novel candidate tumor biomarker genes for NSCLC and its histological subtypes.	Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Ming.Tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHEN HM, 1992, GENOMICS, V14, P1115, DOI 10.1016/S0888-7543(05)80143-0; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith AJ, 1998, AM J HUM GENET, V62, P816, DOI 10.1086/301789; Hibi K, 1998, CANCER RES, V58, P5690; HIROTA M, 1985, CANCER RES, V45, P6453; Hsu NY, 2001, CANCER RES, V61, P2727; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Lehnert K, 1999, GENOMICS, V60, P179, DOI 10.1006/geno.1999.5909; Liloglou T, 2001, CANCER RES, V61, P1624; LINDER MC, 1981, JNCI-J NATL CANCER I, V67, P263; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; Manda R, 1999, GENOMICS, V61, P5, DOI 10.1006/geno.1999.5939; MAO L, 1994, CANCER RES, V54, P1634; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAH HD, 1992, J BIOL CHEM, V267, P22581; Palmisano WA, 2000, CANCER RES, V60, P5954; Pastorian K, 2000, ANAL BIOCHEM, V283, P89, DOI 10.1006/abio.2000.4622; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SCHRAML P, 1994, CANCER RES, V54, P5236; Sozzi G, 1999, CLIN CANCER RES, V5, P2689; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Wigle DA, 2002, CANCER RES, V62, P3005; WYNDER EL, 1994, CANCER RES, V54, P5284	38	75	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7598	7604		10.1038/sj.onc.1205953	http://dx.doi.org/10.1038/sj.onc.1205953			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386823				2022-12-25	WOS:000178618200016
J	Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE				Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE			gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth	ONCOGENE			English	Article						lung cancer; NSCLC; gamma-catenin; tumor suppressor; cell transformation	BETA-CATENIN; MALIGNANT-MELANOMA; COLORECTAL-CANCER; CARCINOMA-CELLS; FACTOR RECEPTOR; ALPHA-CATENIN; N-CADHERIN; CYCLIN D1; PLAKOGLOBIN; MUTATIONS	Lung cancer is a heterogeneous disease categorized into multiple subtypes of cancers which likely arise from distinct patterns of genetic alterations and disruptions. Precedent exists for a role of beta-catenin, a downstream component of the Writ signaling pathway that serves as a transcriptional co-activator with TCF/LEF, in several human cancers including colon carcinomas. In this study, we observed that beta-catenin was highly and uniformly expressed in a panel of NSCLC cell lines and primary lung tumors. By contrast gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in similar to30% of the specimens. Treatment of NSCLC cells expressing reduced gamma-catenin protein with 5-aza-2'-deoxycytidine (5aza2dc), a DNA methylation inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, increased gamma-catenin protein content in NSCLC cells with low gamma-catenin expression. Significantly, the activity of a beta-catenin/TCF-dependent luciferase reporter was markedly elevated in the NSCLC cell lines that underexpressed gamma-catenin relative to those lines that highly expressed gamma-catenin. Moreover, transfection of these cells with gamma-catenin expression plasmid reduced the elevated TCF activity by 85% and strongly inhibited cell growth on tissue culture plastic as well as anchorage-independent growth in soft agar. This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCFdependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, C272,4200 E 9th Ave, Denver, CO 80262 USA.			Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58187] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Beekman A, 1998, CANCER RES, V58, P910; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fukuchi T, 1998, CANCER RES, V58, P3526; Graziano SL, 1999, J CLIN ONCOL, V17, P668, DOI 10.1200/JCO.1999.17.2.668; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; IMRAVET S, 2002, J BIOL CHEM, V277, P1884; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 2000, GENE DEV, V14, P1319; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NICHOLSON RI, 2001, EUR J CANC S4, V3, P9; Ohsaki Y, 2000, ONCOL REP, V7, P603; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391; Polakis P, 2000, GENE DEV, V14, P1837; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyoyama H, 1999, ONCOL REP, V6, P81; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Westra WH, 1996, CANCER RES, V56, P2224; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	41	95	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7497	7506		10.1038/sj.onc.1205963	http://dx.doi.org/10.1038/sj.onc.1205963			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386812				2022-12-25	WOS:000178618200005
J	Oshima, A; Doi, T; Mitsuoka, K; Maeda, S; Fujiyoshi, Y				Oshima, A; Doi, T; Mitsuoka, K; Maeda, S; Fujiyoshi, Y			Roles of Met-34, Cys-64, and Arg-75 in the assembly of human connexin 26 - Implication for key amino acid residues for channel formation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION HEMICHANNELS; X-RAY-DIFFRACTION; HEARING-LOSS; 3-DIMENSIONAL STRUCTURE; TRAFFICKING PATHWAYS; MEMBRANE CHANNEL; LIVING CELLS; MUTATIONS; PROTEIN; LIVER	Connexins form a family of membrane proteins that assemble into communication channels and directly connect the cytoplasms of adjoining cells. Malfunctioning of connexin channels often cause disease, such as the mutations M34T and R75W in human connexin 26, which are associated with hereditary deafness. Another residue known to be essential for normal channel activity in the connexin is Cys-64. To obtain structural and functional insights of connexin 26, we studied the roles of these three residues by expressing mutant connexins in insect Sf9 and HeLa cells. The M34T and M34A mutants both formed gap junction plaques, but dye transfer assays showed that the M34A mutant had a significantly reduced permeability, suggesting that for proper channel function a side chain of adequate size is required at this position. We propose that Met-34 is located in the innermost helix of the channel, where it ensures a fully open channel structure via interactions with other transmembrane helices. Gap junction channels formed by the R75W and R75D mutants dissociated upon solubilization in dodecyl maltoside, whereas the R75A mutant remained hexameric. All gap junctions formed by Arg-75 mutants also showed only negligible activity in dye transfer experiments. These results suggest that residue Arg-75 plays a role in subunit interactions needed to retain a functional and stable connexin hexamer. The C64S mutant was suggested to be defective in oligomerization and/or protein folding even in the presence of wild type connexin.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Res Ctr Low Temp & Mat Sci, Sakyo Ku, Kyoto 6068502, Japan; Japan Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan; RIKEN, Harima Inst, Sayo, Hyogo 6795148, Japan	Kyoto University; Kyoto University; RIKEN	Fujiyoshi, Y (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Fujiyoshi, Yoshinori/E-5989-2012; Oshima, Atsunori/F-8346-2010	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Oshima, Atsunori/0000-0003-1174-1368; Maeda, Shoji/0000-0002-7762-9793				BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone R, 2001, CELL COMMUN ADHES, V8, P425, DOI 10.3109/15419060109080765; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CASPAR DLD, 1977, J CELL BIOL, V74, P605, DOI 10.1083/jcb.74.2.605; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DAHL G, 1991, EUR J BIOCHEM, V197, P141, DOI 10.1111/j.1432-1033.1991.tb15892.x; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Diez JA, 1999, EUR J BIOCHEM, V262, P142, DOI 10.1046/j.1432-1327.1999.00343.x; Essner JJ, 1996, DEV BIOL, V177, P449, DOI 10.1006/dbio.1996.0177; Falk MM, 2000, J CELL SCI, V113, P4109; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; George CH, 1998, J BIOL CHEM, V273, P29822, DOI 10.1074/jbc.273.45.29822; Griffith AJ, 2000, AM J HUM GENET, V67, P745, DOI 10.1086/303045; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Houseman MJ, 2001, J MED GENET, V38, P20, DOI 10.1136/jmg.38.1.20; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kikuchi T, 2000, BRAIN RES REV, V32, P163, DOI 10.1016/S0165-0173(99)00076-4; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; Martin PEM, 1999, HUM MOL GENET, V8, P2369, DOI 10.1093/hmg/8.13.2369; Martin PEM, 2001, J CELL SCI, V114, P3845; MESNIL M, 1995, CANCER RES, V55, P629; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; Perkins GA, 1998, J MOL BIOL, V277, P171, DOI 10.1006/jmbi.1997.1580; Pfahnl A, 1998, BIOPHYS J, V75, P2323, DOI 10.1016/S0006-3495(98)77676-3; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; RAHMAN S, 1991, J CELL SCI, V100, P567; Richard G, 1998, HUM GENET, V103, P393, DOI 10.1007/s004390050839; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202; Wilcox SA, 2000, HUM GENET, V106, P399, DOI 10.1007/s004390000273; Yeager M, 1998, J STRUCT BIOL, V121, P231, DOI 10.1006/jsbi.1998.3972; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	58	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1807	1816		10.1074/jbc.M207713200	http://dx.doi.org/10.1074/jbc.M207713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12384501	hybrid			2022-12-25	WOS:000180462200059
J	Reinbothe, S; Pollmann, S; Reinbothe, C				Reinbothe, S; Pollmann, S; Reinbothe, C			In situ conversion of protochlorophyllide b to protochlorophyllide a in barley - Evidence for a novel role of 7-formyl reductase in the prolamellar body of etioplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE-L; CHLOROPHYLL-B; SUBSTRATE-SPECIFICITY; CUCUMBER ETIOPLASTS; ENERGY-TRANSFER; OXIDOREDUCTASE; NADPH; PROTEIN; LIGHT; BIOSYNTHESIS	We recently put forth a model of a protochlorophyllide (Pchlide) light-harvesting complex operative during angiosperm seedling de-etiolation (Reinbothe, C., Lebedev, N., and Reinbothe, S. (1999) Nature 397, 80-84). This model, which was based on in vitro reconstitution experiments with zinc analogs of Pchlide a and Pchlide b and the two NADPH:protochlorophyllide oxidoreductases (PORs), PORA and PORB, of barley, predicted a 5-fold excess of Pchlide b, relative to Pchlide a, in the prolamellar body of etioplasts. Recent work (Scheumann, V., Klement, H., Helfrich, M., Oster, U., Schoch, S., and Rudiger, W. (1999) FEBS Lett. 445, 445-448), however, contradicted this model and reported that Pchlide b would not he present in etiolated plants. Here we demonstrate that Pchlide b is an abundant pigment in barley etioplasts but is rather metabolically unstable. It is rapidly converted to Pchlide a by virtue of 7-formyl reductase activity, an enzyme that had previously been implicated in the chlorophyll (Chl) b to Chl a reaction cycle. Our findings suggest that etiolated plants make use of 7-formyl reductase to fine tune the levels of Pchlide b and Pchlide a and thereby may regulate the steady-state level of light-harvesting POR-Pchlide complex.	Univ Bayreuth, Lehrstuhl Pflanzenphysiol, D-95447 Bayreuth, Germany; Univ Grenoble 1, F-38041 Grenoble 9, France; CNRS, UMR 5575, CERMO, F-38041 Grenoble 9, France; Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44801 Bochum, Germany	University of Bayreuth; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Ruhr University Bochum	Reinbothe, S (corresponding author), Univ Bayreuth, Lehrstuhl Pflanzenphysiol, Univ Str 30, D-95447 Bayreuth, Germany.		Pollmann, Stephan/C-2776-2009; Pollmann, Stephan/ABC-8203-2020; Reinbothe, Steffen/AAW-9893-2021	Pollmann, Stephan/0000-0002-5111-4425; Pollmann, Stephan/0000-0002-5111-4425; 				APEL K, 1980, EUR J BIOCHEM, V111, P251, DOI 10.1111/j.1432-1033.1980.tb06100.x; BOARDMAN NK, 1962, BIOCHIM BIOPHYS ACTA, V62, P63, DOI 10.1016/0006-3002(62)90492-4; BOGORAD L, 1976, CHEMISTRY BIOCHEMIST, V1, P64; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; FRADKIN LI, 1993, PHOTOSYNTHETICA, V29, P227; Fraser PD, 2000, PLANT J, V24, P551, DOI 10.1111/j.1365-313X.2000.00896.x; GRIFFITHS WT, 1978, BIOCHEM J, V174, P681, DOI 10.1042/bj1740681; GRIFFITHS WT, 1974, FEBS LETT, V49, P196, DOI 10.1016/0014-5793(74)80510-7; HOLTORF H, 1995, P NATL ACAD SCI USA, V92, P3254, DOI 10.1073/pnas.92.8.3254; HOUSSIER C, 1969, BIOCHIM BIOPHYS ACTA, V172, P492, DOI 10.1016/0005-2728(69)90145-5; IGNATOV NV, 1981, BIOFIZIKA+, V26, P664; ITO H, 1994, J BIOL CHEM, V269, P22034; ITO H, 1993, ARCH BIOCHEM BIOPHYS, V306, P148, DOI 10.1006/abbi.1993.1492; Ito H, 1996, J BIOL CHEM, V271, P1475, DOI 10.1074/jbc.271.3.1475; KAHN A, 1970, J MOL BIOL, V48, P85, DOI 10.1016/0022-2836(70)90220-2; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Klement H, 1999, EUR J BIOCHEM, V265, P862, DOI 10.1046/j.1432-1327.1999.00627.x; Lebedev N, 1995, PLANT CELL, V7, P2081, DOI 10.1105/tpc.7.12.2081; Lebedev N, 1998, PHOTOSYNTH RES, V58, P5, DOI 10.1023/A:1006082119102; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MATHIS P, 1972, BIOCHIM BIOPHYS ACTA, V267, P498, DOI 10.1016/0005-2728(72)90178-8; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; Neff MM, 2000, GENE DEV, V14, P257; OHNISHI T, 1994, FEBS LETT, V353, P103, DOI 10.1016/0014-5793(94)01021-8; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; Reinbothe C, 2003, J BIOL CHEM, V278, P807, DOI 10.1074/jbc.M209738200; Reinbothe C, 1999, NATURE, V397, P80, DOI 10.1038/16283; REINBOTHE S, 1995, PLANT CELL, V7, P161, DOI 10.1105/tpc.7.2.161; REINBOTHE S, 1995, J CELL BIOL, V129, P299, DOI 10.1083/jcb.129.2.299; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; Reinbothe S, 1996, EUR J BIOCHEM, V237, P323, DOI 10.1111/j.1432-1033.1996.00323.x; RYBERG M, 1983, PHYSIOL PLANTARUM, V57, P555, DOI 10.1111/j.1399-3054.1983.tb02785.x; Scheumann V, 1998, J BIOL CHEM, V273, P35102, DOI 10.1074/jbc.273.52.35102; Scheumann V, 1996, EUR J BIOCHEM, V242, P163, DOI 10.1111/j.1432-1033.1996.0163r.x; Scheumann V, 1999, FEBS LETT, V445, P445, DOI 10.1016/S0014-5793(99)00169-6; SCHOCH S, 1995, EUR J BIOCHEM, V229, P291, DOI 10.1111/j.1432-1033.1995.tb20468.x; SCHULZ R, 1989, MOL GEN GENET, V217, P355, DOI 10.1007/BF02464904; SHEDBALKAR VP, 1991, J BIOL CHEM, V266, P17151; SMITH JHC, 1954, PLANT PHYSIOL, V29, P135, DOI 10.1104/pp.29.2.135; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; Tomitani A, 1999, NATURE, V400, P159, DOI 10.1038/22101; VAUGHAN GD, 1974, BIOCHIM BIOPHYS ACTA, V347, P383, DOI 10.1016/0005-2728(74)90077-2; VON WETTSTEIN D, 1995, PLANT CELL, V7, P1039, DOI 10.1105/tpc.7.7.1039; Willows R, 1999, NATURE, V397, P27, DOI 10.1038/16161; Xu H, 2002, J BIOL CHEM, V277, P42726, DOI 10.1074/jbc.M205237200	45	32	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					800	806		10.1074/jbc.M209737200	http://dx.doi.org/10.1074/jbc.M209737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401789	hybrid			2022-12-25	WOS:000180321900016
J	Cherepanov, P; Maertens, G; Proost, P; Devreese, B; Van Beeumen, J; Engelborghs, Y; De Clercq, E; Debyser, Z				Cherepanov, P; Maertens, G; Proost, P; Devreese, B; Van Beeumen, J; Engelborghs, Y; De Clercq, E; Debyser, Z			HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; GROWTH-FACTOR LEDGF/P75; PREINTEGRATION COMPLEXES; SELF-ASSOCIATION; IN-VITRO; DNA; P52; ORGANIZATION; EXPRESSION; DOMAINS	We studied human immunodeficiency virus, type 1 (HIV-1) integrase (IN) complexes derived from nuclei of human cells stably expressing the viral protein from a synthetic gene. We show that in the nuclear extracts IN exists as part of a large distinct complex with an apparent Stokes radius of 61 Angstrom, which dissociates upon dilution yielding a core molecule of 41 Angstrom. We isolated the IN complexes from cells expressing FLAG-tagged IN and demonstrated that the 41 Angstrom core is a tetramer of IN, whereas 61 Angstrom molecules are composed of IN tetramers associated with a cellular protein with an apparent molecular mass of 76 kDa. This novel integrase interacting protein was found to be identical to lens epithelium-derived growth factor (LEDGF/p75), a protein implicated in regulation of gene expression and cellular stress response. HIV-1 IN and LEDGF co-localized in the nuclei of human cells stably expressing IN. Furthermore, recombinant LEDGF robustly enhanced strand transfer activity of HIV-1 IN in vitro. Our findings indicate that the minimal IN molecule in human cells is a homotetramer, suggesting that at least an octamer of IN is required to accomplish coordinated integration of both retroviral long terminal repeats and that LEDGF is a cellular factor involved in this process.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; State Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	KU Leuven; KU Leuven; Ghent University	Debyser, Z (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Maertens, Goedele/D-8628-2015; Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019; Proost, Paul/V-3052-2017; Cherepanov, Peter P/F-6859-2010	Maertens, Goedele/0000-0002-1963-8026; Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; Proost, Paul/0000-0002-0133-5545; Cherepanov, Peter P/0000-0002-0634-538X; De Clercq, Erik/0000-0002-2985-8890				Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Brown P. O., 1997, P161; Chen HM, 2001, MOL CELL BIOL, V21, P6758, DOI 10.1128/MCB.21.20.6758-6767.2001; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Coleman J, 1999, J BIOL CHEM, V274, P32842, DOI 10.1074/jbc.274.46.32842; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Debyser Zeger, 2002, Antiviral Chemistry & Chemotherapy, V13, P1; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Dietz F, 2002, BIOCHEM J, V366, P491, DOI 10.1042/BJ20011811; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Friedman DI, 1992, CURR OPIN GENET DEV, V2, P727, DOI 10.1016/S0959-437X(05)80133-9; Fujita M, 1997, J BIOL CHEM, V272, P10928; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Israel N, 1997, CELL MOL LIFE SCI, V53, P864, DOI 10.1007/s000180050106; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JI TH, 1983, METHOD ENZYMOL, V91, P580; JONES KS, 1992, J BIOL CHEM, V267, P16037; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Miller MD, 2001, CURR OPIN MICROBIOL, V4, P535, DOI 10.1016/S1369-5274(00)00247-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Ochs RL, 2000, J ALLERGY CLIN IMMUN, V105, P1211, DOI 10.1067/mai.2000.107039; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SCHULTE D, 1995, J CELL SCI, V108, P1381; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wilkins MR, 1996, CURR BIOL, V6, P1543, DOI 10.1016/S0960-9822(02)70764-1; Williams TL, 1999, GENE DEV, V13, P2725, DOI 10.1101/gad.13.20.2725; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959	56	533	560	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					372	381		10.1074/jbc.M209278200	http://dx.doi.org/10.1074/jbc.M209278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407101	hybrid			2022-12-25	WOS:000180255700050
J	Garcia-Ocana, A; Takane, KK; Reddy, VT; Lopez-Talavera, JC; Vasavada, RC; Stewart, AF				Garcia-Ocana, A; Takane, KK; Reddy, VT; Lopez-Talavera, JC; Vasavada, RC; Stewart, AF			Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic islet transplant performance and reduces beta cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; FACTOR SCATTER FACTOR; FACTOR/SCATTER FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; ACTIVATION; INSULIN; OVEREXPRESSION; PROLIFERATION; MASS; HYPERPLASIA	Hepatocyte growth factor (HGF) increases beta cell proliferation and function in rat insulin promoter (RIP)targeted transgenic mice. RIP-HGF mouse islets also function superiorly to normal islets in a transplant setting. Here, we aimed to determine whether viral gene transfer of the HGF gene into mouse islets ex vivo could enhance the performance of normal islets in a streptozotocin-diabetic severe combined immunodeficient mouse marginal islet mass model in which 300 uninfected or adenovirus (Adv) LacZ-transduced islet equivalents were insufficient to correct hyperglycemia. In dramatic contrast, 300 AdvHGF-transduced islet equivalents promptly (day 1) and significantly (p < 0.01) decreased random non-fasting blood glucose levels, from 351 +/- 20 mg/dl to an average of 191 +/- 7 mg/dl over 8 weeks. At day 1 post-transplant, beta cell death was significantly (p < 0.05) decreased, and the total insulin content was significantly (p < 0.05) increased in Adv-HGF-transduced islets containing grafts. This anti-beta cell death action of HGF was independently confirmed in RIP-HGF mice and in INS-1 cells, both treated with streptozotocin. Activation of the phosphatidylinositol 3-kinase/Akt intracellular-signaling pathway appeared to be involved in this beta cell protective effect of HGF in vitro. In summary, adenoviral delivery of HGF to murine islets ex vivo improves islet transplant survival and blood glucose control in a subcapsular renal graft model in immuno-incompetent diabetic mice.	Univ Pittsburgh, Sch Med, Div Endocrinol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Garcia-Ocana, A (corresponding author), Univ Pittsburgh, Sch Med, Div Endocrinol, 3550 Terrace St, Pittsburgh, PA 15213 USA.	ocana@msx.dept-med.pitt.edu			NIDDK NIH HHS [DK 55023, DK 47168] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047168, R01DK055023] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Biarnes M, 2002, DIABETES, V51, P66, DOI 10.2337/diabetes.51.1.66; Cebrian A, 2002, DIABETES, V51, P3003, DOI 10.2337/diabetes.51.10.3003; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Devedjian JC, 2000, J CLIN INVEST, V105, P731, DOI 10.1172/JCI5656; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Gahr S, 2002, J MOL ENDOCRINOL, V28, P99, DOI 10.1677/jme.0.0280099; Garcia-Ocana A, 2001, DIABETES, V50, P2752, DOI 10.2337/diabetes.50.12.2752; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; George M, 2002, J CLIN INVEST, V109, P1153, DOI 10.1172/JCI200212969; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HAYEK A, 1995, DIABETES, V44, P1458, DOI 10.2337/diabetes.44.12.1458; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; KRISTENSEN P, 1987, ENDOCRINOLOGY, V121, P2238, DOI 10.1210/endo-121-6-2238; Leibowitz G, 1999, DIABETES, V48, P745, DOI 10.2337/diabetes.48.4.745; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; MARS WM, 1993, AM J PATHOL, V143, P949; Mildner M, 2002, J BIOL CHEM, V277, P14146, DOI 10.1074/jbc.M110687200; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; Muruve DA, 1997, TRANSPLANTATION, V64, P542, DOI 10.1097/00007890-199708150-00031; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Newgard CB, 1997, DIABETOLOGIA, V40, pS42, DOI 10.1007/s001250051398; Otonkoski T, 1996, ENDOCRINOLOGY, V137, P3131, DOI 10.1210/en.137.7.3131; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; Porter SE, 1998, ENDOCRINOLOGY, V139, P3743, DOI 10.1210/en.139.9.3743; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Ramiya VK, 2000, NAT MED, V6, P278; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Vasavada RC, 1996, J BIOL CHEM, V271, P1200, DOI 10.1074/jbc.271.2.1200; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Weber M, 1997, J SURG RES, V69, P23, DOI 10.1006/jsre.1997.4995; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270	42	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					343	351		10.1074/jbc.M207848200	http://dx.doi.org/10.1074/jbc.M207848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403787	hybrid			2022-12-25	WOS:000180255700046
J	Vertegaal, ACO; Kuiperij, HB; Houweling, A; Verlaan, M; van der Eb, AJ; Zantema, A				Vertegaal, ACO; Kuiperij, HB; Houweling, A; Verlaan, M; van der Eb, AJ; Zantema, A			Differential expression of tapasin and immunoproteasome subunits in adenovirus type 5-versus type 12-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA-B; HIGHLY ONCOGENIC ADENOVIRUS-12; TRANSFORMED RAT-CELLS; BETA-INTERFERON GENE; ANTIGEN PRESENTATION; PROTEASOME SUBUNITS; DOWN-REGULATION; TARGETED DISRUPTION	Adenovirus type 12 (Ad12)-transformed baby rat kidney (BRK) cells are oncogenic in syngeneic immunocompetent rats in contrast to adenovirus type 5 (Ad5)-transformed BRK cells, which are not oncogenic in these animals. A significant factor contributing to the difference in oncogenicity may be the low levels of major histocompatibility complex (MHC) class I membrane expression in Ad12-transformed BRK cells as compared with those in Ad5-transformed BRK cells, which presumably results in escape from killing by cytotoxic T lymphocytes. Here we show that, in addition to the decreased levels of expression of the MHC class I heavy chain and the peptide transporter Tap-2, the expression levels of the chaperone Tapasin and the immunoproteasome components MECL-1, PA28-alpha, and PA28-beta also are much lower in Ad12- than in Ad5-transformed BRK cells. The low expression levels of these proteins may contribute to the escape from killing by cytotoxic T lymphocytes, because the generation of optimal peptides and loading of these peptides on MHC class I require these components. Increased levels of phosphorylated signal transducer and activator of transcription-1 protein and expression of IFN regulatory factor-7 were found in Ad5-versus Ad12-transformed BRK cells. Therefore, the critical alteration leading to the plethora of differences may be an interferon (-related) effect.	Leiden Univ, Med Ctr, Ctr Med Genet, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zantema, A (corresponding author), Leiden Univ, Med Ctr, Ctr Med Genet, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.		Vertegaal, Alfred CO/Y-3875-2018; Vertegaal, Alfred/ABG-8141-2021; Kuiperij, Bea/A-4737-2013	Vertegaal, Alfred CO/0000-0002-7989-0493; Vertegaal, Alfred/0000-0002-7989-0493; Kuiperij, Bea/0000-0002-0635-7428				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; ACKRILL AM, 1988, ONCOGENE, V3, P483; ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DIJKEMA R, 1984, NUCLEIC ACIDS RES, V12, P1227, DOI 10.1093/nar/12.2.1227; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Foss GS, 1998, BBA-MOL CELL RES, V1402, P17, DOI 10.1016/S0167-4889(97)00152-3; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; Grandea AG, 1998, IMMUNOGENETICS, V48, P260, DOI 10.1007/s002510050430; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; Groettrup M, 1996, EUR J IMMUNOL, V26, P863, DOI 10.1002/eji.1830260421; Herberg JA, 1998, EUR J IMMUNOL, V28, P459, DOI 10.1002/(SICI)1521-4141(199802)28:02<459::AID-IMMU459>3.3.CO;2-Q; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; Kohda K, 1998, J IMMUNOL, V160, P4923; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Li YH, 1999, IMMUNOGENETICS, V49, P149, DOI 10.1007/s002510050476; Liu XH, 1996, MOL CELL BIOL, V16, P398; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; MAUXION F, 1989, IMMUNOGENETICS, V29, P397, DOI 10.1007/BF00375868; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MEIJER I, 1991, ONCOGENE, V6, P911; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, J IMMUNOL, V156, P3174; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Nandi D, 1996, J IMMUNOL, V156, P2361; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; Pereira DS, 1996, ONCOGENE, V13, P445; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Ruuls SR, 1996, J IMMUNOL, V157, P5721; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHRIER PI, 1979, VIROLOGY, V99, P372, DOI 10.1016/0042-6822(79)90016-3; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STET RJM, 1987, TRANSPLANT P, V19, P3004; Stohwasser R, 1997, EUR J IMMUNOL, V27, P1182, DOI 10.1002/eji.1830270520; Stoltze L, 2000, IMMUNOL TODAY, V21, P317, DOI 10.1016/S0167-5699(00)01665-0; Suh WK, 1999, J IMMUNOL, V162, P1530; Tanaka K, 1998, IMMUNOL REV, V163, P161; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; van der Eb A J, 1980, Methods Enzymol, V65, P826; van Hall T, 2000, J EXP MED, V192, P483, DOI 10.1084/jem.192.4.483; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; York IA, 1999, IMMUNOL REV, V172, P49, DOI 10.1111/j.1600-065X.1999.tb01355.x	76	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					139	146		10.1074/jbc.M206267200	http://dx.doi.org/10.1074/jbc.M206267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407112	hybrid			2022-12-25	WOS:000180255700019
J	Chou, YT; Swain, JF; Gierasch, LM				Chou, YT; Swain, JF; Gierasch, LM			Functionally significant mobile regions of Escherichia coli SecA ATPase identified by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN EXPORT; PREPROTEIN TRANSLOCATION; PRESECRETORY PROTEINS; SECONDARY STRUCTURE; MEMBRANE INSERTION; SIGNAL SEQUENCES; TERMINAL REGION; BINDING DOMAIN; CHAPERONE SECB	SecA, a 204-kDa homodimeric protein, is a major component of the cellular machinery that mediates the translocation of proteins across the Escherichia coli plasma membrane. SecA promotes translocation by nucleotide-modulated insertion and deinsertion into the cytoplasmic membrane once bound to both the signal sequence and portions of the mature domain of the preprotein. SecA is proposed to undergo major conformational changes during translocation. These conformational changes are accompanied by major rearrangements of SecA structural domains. To understand the interdomain rearrangements, we have examined SecA by NMR and identified regions that display narrow resonances indicating high mobility. The mobile regions of SecA have been assigned to a sequence from the second of two domains with nucleotide-binding folds (NBF-II; residues 564-579) and to the extreme C-terminal segment of SecA (residues 864-901), both of which are essential for preprotein translocation activity. Interactions with ligands suggest that the mobile regions are involved in functionally critical regulatory steps in SecA.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; BENACH J, 2002, J BIOL CHEM     1027; BREUKINK E, 1993, FEBS LETT, V331, P19, DOI 10.1016/0014-5793(93)80289-7; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chen XC, 1998, J BACTERIOL, V180, P527, DOI 10.1128/JB.180.3.527-537.1998; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; DWEK RA, 1973, NMR BIOCH; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GRISHAM CM, 1988, METHOD ENZYMOL, V156, P353; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Kim J, 2001, BIOCHEMISTRY-US, V40, P3674, DOI 10.1021/bi002617z; KIMURA E, 1991, J BIOL CHEM, V266, P6600; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; Mildvan A S, 1972, Methods Enzymol, V26, P654; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nakatogawa H, 2000, J BIOL CHEM, V275, P33209, DOI 10.1074/jbc.C000550200; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; Volkert TL, 1999, BIOCHEM BIOPH RES CO, V264, P949, DOI 10.1006/bbrc.1999.1590; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; Woodbury RL, 2000, J BIOL CHEM, V275, P24191, DOI 10.1074/jbc.M002885200; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Wuthrich K, 1986, NMR PROTEINS NUCL AC	62	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50985	50990		10.1074/jbc.M209237200	http://dx.doi.org/10.1074/jbc.M209237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397065	hybrid			2022-12-25	WOS:000180177700103
J	Hanyaloglu, AC; Seeber, RM; Kohout, TA; Lefkowitz, RJ; Eidne, KA				Hanyaloglu, AC; Seeber, RM; Kohout, TA; Lefkowitz, RJ; Eidne, KA			Homo- and hetero-oligomerization of thyrotropin-releasing hormone (TRH) receptor subtypes - Differential regulation of beta-arrestins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; CENTRAL-NERVOUS-SYSTEM; C-TERMINAL TAIL; DEPENDENT INTERNALIZATION; RAPID DESENSITIZATION; FLUORESCENT PROTEIN; SIGNAL-TRANSDUCTION; OPIOID RECEPTORS; ENDOCYTOSIS; DYNAMIN	G-protein-coupled receptors (GPCRs) are regulated by a complex network of mechanisms such as oligomerization and internalization. Using the GPCR subtypes for thyrotropin-releasing hormone (TRHR1 and TRHR2), the aim of this study was to determine if subtype-specific differences exist in the trafficking process. If so, we wished to determine the impact of homo- and hetero-oligomerization on TRHR subtype trafficking as a potential mechanism for the differential cellular responses induced by TRH. Expression of either beta-arrestin 1 or 2 promoted TRHR1 internalization. In contrast, only beta-arrestin 2 could enhance TRHR2 internalization. The preference for beta-arrestin 2 by TRHR2 was supported by the impairment of TRHR2 trafficking in mouse embryonic fibroblasts (MEFs) from either a beta-arrestin 2 knockout or a beta-arrestin 1/2 knockout, while TRHR1 trafficking was only abolished in MEFs lacking both beta-arrestins. The differential beta-arrestin-dependence of TRHR2 was directly measured in live cells using bioluminescence resonance energy transfer (BRET). Both BRET and confocal microscopy were also used to demonstrate that TRHR subtypes form hetero-oligomers. In addition, these hetero-oligomers have altered internalization kinetics compared with the homo-oligomer. The formation of TRHR1/2 heteromeric complexes increased the interaction between TRHR2 and beta-arrestin 1. This may be due to conformational differences between TRHR1/2 hetero-oligomers versus TRHR2 homo-oligomers as a mutant TRHR1 (TRHR1 C335Stop) that does not interact with beta-arrestins, could also enhance TRHR2H/beta-arrestin 1 interaction. This study demonstrates that TRHR subtypes are differentially regulated by the beta-arrestins and also provides the first evidence that the interactions of TRHRs with beta-arrestin may be altered by hetero-oligomer formation.	Sir Charles Gairdner Hosp, Western Australian Inst Med Res, Keogh Inst Med Res, Nedlands, WA 6009, Australia; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27708 USA; Univ Western Australia, Med Res Ctr, 7TM Receptor Lab, Nedlands, WA 6009, Australia	University of Western Australia; Duke University; Howard Hughes Medical Institute; University of Western Australia	Eidne, KA (corresponding author), Sir Charles Gairdner Hosp, Western Australian Inst Med Res, Keogh Inst Med Res, Hosp Ave, Nedlands, WA 6009, Australia.	keidne@cyllene.uwa.edu.au	Seeber, Ruth/AAS-9411-2021; Lefkowitz, Robert/AAW-2649-2021	Seeber, Ruth/0000-0003-3265-7931; /0000-0003-4206-737X				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; ANDERSON L, 1993, J ENDOCRINOL, V136, P51, DOI 10.1677/joe.0.1360051; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Bilek R, 2000, PHYSIOL RES, V49, pS19; Cao J, 1998, J BIOL CHEM, V273, P32281, DOI 10.1074/jbc.273.48.32281; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; EIDNE KA, 1992, MOL CELL ENDOCRINOL, V90, pR5, DOI 10.1016/0303-7207(92)90116-N; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hanyaloglu AC, 2001, J BIOL CHEM, V276, P18066, DOI 10.1074/jbc.M009275200; Harder S, 2001, ENDOCRINOLOGY, V142, P1188, DOI 10.1210/en.142.3.1188; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Heuer H, 1999, ACTA MED AUST, V26, P119; Heuer H, 2000, J COMP NEUROL, V428, P319; Horita A, 1998, LIFE SCI, V62, P1443, DOI 10.1016/S0024-3205(98)00087-3; ISSAFRAS H, 2002, J BIOL CHEM; Itadani H, 1998, BIOCHEM BIOPH RES CO, V250, P68, DOI 10.1006/bbrc.1998.9268; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; LAVOIE C, 2002, J BIOL CHEM; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; Luttrell LM, 2002, J CELL SCI, V115, P455; Marshall FH, 1999, BIOCHEM SOC T, V27, P530, DOI 10.1042/bst0270530; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; O'Dowd BF, 2000, MOL ENDOCRINOL, V14, P183, DOI 10.1210/me.14.1.183; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Petrou C, 1997, J BIOL CHEM, V272, P2326; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; Smith J, 2001, MOL ENDOCRINOL, V15, P1539, DOI 10.1210/me.15.9.1539; Sun YH, 2002, ENDOCRINOLOGY, V143, P2886, DOI 10.1210/en.143.8.2886; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	59	62	64	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50422	50430		10.1074/jbc.M209340200	http://dx.doi.org/10.1074/jbc.M209340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393857	hybrid			2022-12-25	WOS:000180177700029
J	Kusner, DJ; Barton, JA; Wen, KK; Wang, XM; Rubenstein, PA; Iyer, SS				Kusner, DJ; Barton, JA; Wen, KK; Wang, XM; Rubenstein, PA; Iyer, SS			Regulation of phospholipase D activity by actin - Actin exerts bidirectional modulation of mammalian phospolipase D activity in a polymerization-dependent, isoform-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; U937 PROMONOCYTIC LEUKOCYTES; CELL-FREE SYSTEM; ADP-RIBOSYLATION FACTOR; RICH MEMBRANE DOMAINS; HUMAN NEUTROPHILS; BINDING-PROTEIN; D ACTIVATION; OPSONIZED PARTICLES; PHOSPHATIDIC-ACID	Many critical cellular processes, including proliferation, vesicle trafficking, and secretion, are regulated by both phospholipase D (PLD) and the actin microfilament system. Stimulation of human PLD1 results in its association with the detergent-insoluble actin cytoskeleton, but the molecular mechanisms and functional consequences of PLD-actin interactions remain incompletely defined. Biochemical and pharmacologic modulation of actin polymerization resulted in complex bidirectional effects on PLD activity, both in vitro and in vivo. Highly purified G-actin inhibited basal and stimulated PLD activity, whereas F-actin produced the opposite effects. Actin-induced modulation of PLD activity was independent of the activating stimulus. The efficacy and potency of the effects of actin were isoform-specific but broadly conserved among actin family members. Human betagamma-actin was only 45% as potent and 40% as efficacious as rabbit skeletal muscle alpha-actin, whereas its inhibitory profile was similar to the single actin species from the yeast, Saccharomyces cerevisiae. Use of actin polymerization-specific reagents indicated that PLD1 binds both monomeric alpha-actin, as well as actin filaments. These data are consistent with a model in which the physical state of the actin cytoskeleton is a critical determinant of its regulation of PLD activity.	Univ Iowa, Dept Internal Med, Div Infect Dis, Iowa City, IA 52242 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Immunol, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Kansas State University	Kusner, DJ (corresponding author), Univ Iowa, Dept Internal Med, Div Infect Dis, 200 Hawkins Dr SW 54-I,GH, Iowa City, IA 52242 USA.	david-kusner@uiowa.edu	Wang, Xuemin/M-2853-2013	wang, xuemin/0000-0002-6251-6745; Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062302] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM62302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPE C, 1999, GUIDEBOOK CYTOSKELET, P11; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; CAO LG, 1993, J CELL BIOL, V123, P173, DOI 10.1083/jcb.123.1.173; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Colton T., 1974, STAT MED, P189; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DE M, 2000, J CELL SCI, V113, P2331; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FALLMAN M, 1993, J IMMUNOL, V151, P330; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; Hodgkin MN, 1999, BIOCHEM J, V339, P87, DOI 10.1042/0264-6021:3390087; Holzinger A, 2001, METH MOL B, V161, P109; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; KANAHO Y, 1991, J IMMUNOL, V146, P3536; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; KLOTZ KN, 1994, J IMMUNOL, V152, P801; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Kusner DJ, 1999, J IMMUNOL, V162, P2266; Kusner DJ, 1996, J EXP MED, V184, P585, DOI 10.1084/jem.184.2.585; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Musib R, 2002, J BIOL CHEM, V277, P22699, DOI 10.1074/jbc.M203096200; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; RUBENSTEIN PA, 1981, ARCH BIOCHEM BIOPHYS, V210, P598, DOI 10.1016/0003-9861(81)90226-5; Shinjiro M, 2001, BBA-PROTEIN STRUCT M, V1547, P275, DOI 10.1016/S0167-4838(01)00196-0; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; Shuster CB, 1996, CELL MOTIL CYTOSKEL, V35, P175; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; STRZELECKAGOLAS.H, 2001, MOL INTERACTIONS ACT, P23; SUCHARD SJ, 1994, J BIOL CHEM, V269, P8063; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Wang XM, 2000, PROG LIPID RES, V39, P109, DOI 10.1016/S0163-7827(00)00002-3; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; Yao XY, 2002, J BIOL CHEM, V277, P22875, DOI 10.1074/jbc.M201685200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	71	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50683	50692		10.1074/jbc.M209221200	http://dx.doi.org/10.1074/jbc.M209221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12388543	hybrid			2022-12-25	WOS:000180177700065
J	Martin, AG; Fearnhead, HO				Martin, AG; Fearnhead, HO			Apocytochrome c blocks caspase-9 activation and Bax-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENE-DEPENDENT APOPTOSIS; WD-40 REPEAT REGION; CYTOCHROME-C; NEGATIVE REGULATION; APAF-1 APOPTOSOME; CELL-DEATH; FACTOR-I; RELEASE; PROCASPASE-9; MITOCHONDRIA	Complex networks of signaling pathways control the apoptotic response and, therefore, cell survival. However, these networks converge on a common machinery, of which the caspase cysteine proteases are key components. Diverse apoptotic stimuli release holocytochrome c from mitochondria, allowing holocytochrome c to bind apoptotic protease activating factor-1 (Apaf-1), which in turn binds caspase-9 both activating this caspase and forming an Apaf-1/caspase-9 holoenzyme. Cytochrome c lacking heme (the apo form) cannot support caspase activation, although the reason for this has not been studied. Here we show that apocytochrome c still binds Apaf-1 and that it can block holo-dependent caspase activation in a cell-free system. In addition we show that overexpression of apocytochrome c blocks Bax-induced apoptosis in cells. Thus it is possible to modulate cell survival by interfering with the Apaf-1/cytochrome c interaction. Given the key role played by Apaf-1/cytochrome c in the apoptotic process, and the role of apoptosis in degenerative disease, this interaction may serve as a novel therapeutic target.	NCI, Apoptosis Sect, Regulat Cell Growth Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fearnhead, HO (corresponding author), NCI, Apoptosis Sect, Regulat Cell Growth Lab, NIH, Frederick, MD 21702 USA.		Fearnhead, Howard O/D-4826-2012	Garcia Martin, Angel/0000-0002-3831-2769; Fearnhead, Howard/0000-0002-8054-9794				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 2001, DRUG DEVELOP RES, V52, P579, DOI 10.1002/ddr.1161; Diekert K, 2001, EMBO J, V20, P5626, DOI 10.1093/emboj/20.20.5626; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Hampton MB, 1998, BIOCHEM J, V329, P95; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mochizuki H, 2001, P NATL ACAD SCI USA, V98, P10918, DOI 10.1073/pnas.191107398; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nuttall ME, 2001, DRUG DISCOV TODAY, V6, P85, DOI 10.1016/S1359-6446(00)01601-9; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; Yue TL, 1999, CURR OPIN CHEM BIOL, V3, P474, DOI 10.1016/S1367-5931(99)80069-6; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50834	50841		10.1074/jbc.M209369200	http://dx.doi.org/10.1074/jbc.M209369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393884	hybrid			2022-12-25	WOS:000180177700084
J	Nagashima, H				Nagashima, H			Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban - II. Effects on fibrinolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR XA INHIBITOR; PLASMA PROCARBOXYPEPTIDASE-B; FACTOR-XI; THROMBIN INHIBITOR; TAFI; ACTIVATION; THROMBOMODULIN; COAGULATION; CLOT	The accompanying paper (Nagashima, H. (2002) J. Biol. Chem. 277, 50439-50444) has demonstrated that argatroban can yield a stronger inhibitory effect on thrombin generation than DX-9065a during extrinsic pathway-stimulated human plasma coagulation, while these anticoagulant compounds have comparable abilities to prolong clot time. Since thrombin generation is known to be an important determinant for fibrinolytic resistance of clots formed during coagulation, the two compounds are compared by tissue plasminogen activator-induced clot lysis assays. The results demonstrated that, in the presence of thrombomodulin, argatroban dose dependently accelerated fibrinolysis of the clots, whereas DX-9065a did not. The activation of thrombin activatable fibrinolysis inhibitor (TAFI) determined in separate assays reflected the differential influence on thrombin generation by these compounds. Moreover, TAFI activation correlated closely with the fibrinolytic resistance observed during tissue plasminogen activator-induced clot lysis. This study demonstrates the differential effects of DX-9065a and argatroban on thrombin generation, which in turn results in a differential acceleration of fibrinolysis as well as TAFI activation in the clots formed under the influence of these compounds. The data implicate a possible difference in the antifibrinolytic properties of clots formed during treatment with these compounds.	Daiichi Pharmaceut Co Ltd, Drug Safety Adm Dept, New Prod Res Labs 2, Chuo Ku, Tokyo 1048369, Japan	Daiichi Sankyo Company Limited	Nagashima, H (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Adm Dept, New Prod Res Labs 2, Chuo Ku, 16-1 Kyobashi 2 Chome, Tokyo 1048369, Japan.							Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Boeve TJ, 1998, J THROMB THROMBOLYS, V6, P103, DOI 10.1023/A:1008889202725; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Bouma BN, 1998, THROMB HAEMOSTASIS, V80, P24; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Bouma BN, 1999, THROMB HAEMOSTASIS, V82, P1703; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; Morishima Y, 1997, THROMB HAEMOSTASIS, V78, P1366; Mosnier LO, 2001, THROMB HAEMOSTASIS, V85, P5; Nagashima H, 2002, J BIOL CHEM, V277, P50439, DOI 10.1074/jbc.M208222200; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Sato K, 1997, EUR J PHARMACOL, V339, P141, DOI 10.1016/S0014-2999(97)01389-7; Sinha U, 2000, EUR J PHARMACOL, V395, P51, DOI 10.1016/S0014-2999(00)00219-3; TAMAO Y, 1986, THROMB HAEMOSTASIS, V56, P28; Tanabe K, 1999, THROMB HAEMOSTASIS, V81, P828, DOI 10.1055/s-0037-1614577; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412	19	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50445	50449		10.1074/jbc.M208223200	http://dx.doi.org/10.1074/jbc.M208223200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397070	hybrid			2022-12-25	WOS:000180177700032
J	Chamberlain, LH; Gould, GW				Chamberlain, LH; Gould, GW			The vesicle- and target-SNARE proteins that mediate Glut4 vesicle fusion are localized in detergent-insoluble lipid rafts present on distinct intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; ADIPOSE-CELLS; INSULIN; TRANSLOCATION; EXOCYTOSIS; INTERNALIZATION; REQUIRES; CAVEOLAE	Insulin stimulates the fusion of intracellular vesicles containing the glucose transporter Glut4 with the plasma membrane in adipocytes and muscle cells. Glut4 vesicle fusion is thought to be catalyzed by the interaction of the vesicle soluble N-ethyl-maleimide-sensitive fusion protein attachment protein receptor VAMP2 with the target soluble N-ethyl-maleimide-sensitive fusion protein attachment protein receptors SNAP-23 and syntaxin 4. Here, we use combined membrane fractionation, detergent solubility, and sucrose gradient flotation to demonstrate that the large majority (>70%) of SNAP-23 and a significant proportion of syntaxin 4 (similar to35%) are associated with plasma membrane lipid rafts in 3T3-L1 adipocytes. Furthermore, VAMP2 is shown to be concentrated in lipid rafts isolated from intracellular membranes. Insulin stimulation had no effect on the plasma membrane raft association of SNAP-23 or syntaxin 4 but promoted VAMP2 insertion into plasma membrane rafts. Immunofluorescence analysis revealed that SNAP-23 was clustered at the plasma membrane and almost completely segregated from the transferrin receptor. SNAP-23 distribution seemed to be distinct from caveolin-1, and clusters of SNAP-23 were dispersed after cholesterol extraction with methyl-beta-cyclodextrin, suggesting that the majority of SNAP-23 is associated with non-caveolar, cholesterol-rich lipid rafts. The results described implicate lipid rafts as important platforms for Glut4 vesicle fusion and suggest the hypothesis that such rafts may represent a spatial integration point of insulin signaling and membrane traffic.	Univ Glasgow, Henry Wellcome Lab Cell Biol, Div Biochem & Mol Biol, Fac Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Chamberlain, LH (corresponding author), Univ Glasgow, Henry Wellcome Lab Cell Biol, Div Biochem & Mol Biol, Fac Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.			Gould, Gwyn/0000-0001-6571-2875				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chamberlain LH, 2001, J CELL SCI, V114, P445; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Foster LJ, 1999, AM J PHYSIOL-CELL PH, V276, pC1108, DOI 10.1152/ajpcell.1999.276.5.C1108; FROST SC, 1985, J BIOL CHEM, V260, P2646; Grote E, 2000, J CELL BIOL, V151, P453, DOI 10.1083/jcb.151.2.453; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Hickson GRX, 2000, BIOCHEM BIOPH RES CO, V270, P841, DOI 10.1006/bbrc.2000.2525; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Kalus I, 2002, BIOCHEM J, V362, P433, DOI 10.1042/0264-6021:3620433; Kumar M, 2001, MOL BIOL CELL, V12, p74A; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Rowe J, 2001, J CELL SCI, V114, P3323; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Viard M, 2001, MOL BIOL CELL, V12, p332A; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	31	103	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49750	49754		10.1074/jbc.M206936200	http://dx.doi.org/10.1074/jbc.M206936200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376543	hybrid			2022-12-25	WOS:000180028900086
J	Xu, Z; Kandror, KV				Xu, Z; Kandror, KV			Translocation of small preformed vesicles is responsible for the insulin activation of glucose transport in adipose cells - Evidence from the in vitro reconstitution assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4-CONTAINING VESICLES; STIMULATED TRANSLOCATION; RAT ADIPOCYTES; GLUT4; MEMBRANE; PROTEINS; COMPARTMENTS; TISSUES; 3T3-L1	Insulin stimulates translocation of the glucose transporter isoform 4 (Glut4) from an intracellular storage compartment to the plasma membrane in fat and skeletal muscle cells. At present, the nature of the Glut4 storage compartment is unclear. According to one model, this compartment represents a population of preformed small vesicles that fuse with the plasma membrane in response to insulin stimulation. Alternatively, Glut4 may be retained in large donor membranes, and insulin stimulates the formation of transport vesicles that deliver Glut4 to the cell surface. Finally, insulin can induce plasma membrane fusion of the preformed vesicles and, also, stimulate the formation of new vesicles. In extracts of fat and skeletal muscle cells, Glut4 is predominantly found in small insulin-sensitive 60-70 S membrane vesicles that may or may not artificially derive from large donor membranes during cell homogenization. Here, we use a cell-free reconstitution assay to demonstrate that small Glut4-containing vesicles are formed from large rapidly sedimenting donor membranes in a cytosol-, ATP-, time-, and temperature-dependent fashion and, therefore, do not represent an artifact of homogenization. Thus, small insulin-responsive vesicles represent the major form of Glut4 storage in the living adipose cell. Fusion of these vesicles with the plasma membrane may be largely responsible for the primary effect of insulin on glucose transport in fat tissue. In addition, our results suggest that insulin may also stimulate the formation of Glut4 vesicles and accelerate Glut4 recycling to the plasma membrane.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K124D,715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NIDDK NIH HHS [DK56736, DK52057] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052057, R01DK052057, R01DK056736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; HEDO JA, 1984, J BIOL CHEM, V259, P1083; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JARETT L, 1974, J BIOL CHEM, V249, P7024; Jones AT, 1998, J BIOL CHEM, V273, P25301, DOI 10.1074/jbc.273.39.25301; Kandror KV, 1999, J BIOL CHEM, V274, P25210, DOI 10.1074/jbc.274.36.25210; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kristiansen S, 2002, AM J PHYSIOL-ENDOC M, V283, pE374, DOI 10.1152/ajpendo.00441.2001; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim SN, 2001, MOL BIOL CELL, V12, P981, DOI 10.1091/mbc.12.4.981; Malide D, 2000, J CELL SCI, V113, P4203; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Roh C, 2001, J BIOL CHEM, V276, P35990, DOI 10.1074/jbc.M102791200; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574	25	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					47972	47975		10.1074/jbc.C200486200	http://dx.doi.org/10.1074/jbc.C200486200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12393900	hybrid			2022-12-25	WOS:000179789600002
J	Zhou, H; Kartsogiannis, V; Quinn, JMW; Ly, C; Gange, C; Elliott, J; Ng, KW; Gillespie, MT				Zhou, H; Kartsogiannis, V; Quinn, JMW; Ly, C; Gange, C; Elliott, J; Ng, KW; Gillespie, MT			Osteoclast inhibitory lectin, a family of new osteoclast inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; KAPPA-B LIGAND; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR; BAC CONTIG; GENE; DIFFERENTIATION; SEQUENCE; LOCALIZATION; PROMOTER	We have identified two novel type H membrane-bound C-lectins, designated mOCILrP1 and mOCILrP2, of 218 and 217 amino acids, respectively, that share substantial identity with the murine osteoclast inhibitory lectin (OCIL). The extracellular domains of mOCILrP1 and mOCILrP2 share 83 and 75% identity, respectively, with the extracellular domain of mOCIL. When the extracellular domains were expressed as recombinant proteins, each inhibited osteoclast formation in murine bone marrow cultures treated with M-CSF and RANKL with Similar potencies to mOCIL, (IC50 of 0.2 ng/ml). Distinct but highly related genes encoded the three OCIL family members, with mOCIL and mOCILrP2 controlled by an inverted TATA promoter, and mOCILrP1 by a TTAAAA promoter. However only mOCIL was robustly regulated by calciotropic agents, while mOCILrP1 was not expressed, and mOCILrP2 was constitutively expressed in osteoblasts. Immunohistochemistry using antipeptide antibodies to the intracellular domain of mOCILrP1/mOCILrP2 and to mOCIL demonstrated that mOCIL and mOCILrP1/mOCILrP2 were concordantly expressed in osteoblasts, chondrocytes, and in extraskeletal tissues. Further, their cellular distribution was identical to that of RANKL. The identification of three distinct genes that were functionally related implies redundancy for OCIL, and their concordant expression with that of RANKL suggests that the RANKL:OPG axis may be further influenced by OCIL family members.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne	Gillespie, MT (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.			Zhou, Hong/0000-0001-5899-9660; Gillespie, Matthew/0000-0001-6543-8909				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; DANKS JA, 1990, J PATHOL, V161, P27, DOI 10.1002/path.1711610106; DAS AT, 1993, EUR J BIOCHEM, V211, P795, DOI 10.1111/j.1432-1033.1993.tb17611.x; Depatie C, 2000, GENOMICS, V66, P161, DOI 10.1006/geno.2000.6186; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; HOFSTETTER W, 2001, COLONY STIMULATING F, P943; HOROWITZ MC, 2001, PRINCIPLES BONE BIOL, P961; Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333; Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Kartsogiannis V, 1998, BONE, V22, P189, DOI 10.1016/S8756-3282(97)00278-0; Kiang DT, 1997, GENE, V199, P165, DOI 10.1016/S0378-1119(97)00365-X; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440-1711.1999.00815.x; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; Peng BL, 1999, ACTA BIOCH BIOPH SIN, V31, P313; Plougastel B, 2001, IMMUNOGENETICS, V53, P592, DOI 10.1007/s002510100367; Plougastel B, 2001, IMMUNOGENETICS, V53, P209, DOI 10.1007/s002510100319; Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhou H, 2001, J BIOL CHEM, V276, P14916, DOI 10.1074/jbc.M011554200	30	45	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48808	48815		10.1074/jbc.M209059200	http://dx.doi.org/10.1074/jbc.M209059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374791	hybrid			2022-12-25	WOS:000179789600109
J	Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y				Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y			Esophageal cancer in Chinese population: no polymorphism in codon 149 of P21(Waf1/Cip1) cyclin dependent kinase gene	ONCOGENE			English	Article						P21(Waf1/Cip1); esophageal cancer; single nucleotide polymorphism	DNA-REPLICATION; INHIBITOR GENE; CELL-CYCLE; EXPRESSION; P21; WAF1; P53; ASSOCIATION; WAF1/CIP1; SEQUENCE	It has recently been suggested that people of the Indian population who carried the codon 149 polymorphism (G (A) under barT-->G (G) under barT) of P21(Waf1/Cip1) gene were more susceptible to esophageal cancer and oral cancer than the individuals without that polymorphism. Since esophageal cancer is a high incident neoplasm in China, we analysed the same codon of P21(Waf1/Cip1) in the Chinese population. Blood samples from 80 esophageal cancer patients and 80 normal blood donors were collected for DNA extraction. Methods of Polymerase Chain Reaction (PCR) and direct sequencing were used for detection of the polymorphism in codon 149 of P21(Waf/Cip1). Bioinformatics analysis was also thoroughly performed for this gene. No polymorphism was found in all samples tested. Bioinformatics analysis revealed that the so-called polymorphism of codon 149 reported previously was a wrong one. In conclusion, no polymorphism exists in codon 149 of P21(Waf1/Cip1). It is not appropriate to use it as a susceptible site of the gene in cancer study.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, Beijing 100034, Peoples R China; Peking Union Med Coll, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100176, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Ke, Y (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, 1 Da Hong Luo Chang St,Western Dist, Beijing 100034, Peoples R China.			Xi, Yaguang/0000-0003-3681-9352; Ding, Keyue/0000-0002-3496-6415				Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN J, 1995, NATURE, V375, P386; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG HP, 1994, ONCOGENE, V9, P3397; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Zeng YX, 1996, ONCOGENE, V12, P1557	18	4	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7745	7748		10.1038/sj.onc.1205873	http://dx.doi.org/10.1038/sj.onc.1205873			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400017				2022-12-25	WOS:000178756200014
J	Wong, LF; Polson, JW; Murphy, D; Paton, JFR; Kasparov, S				Wong, LF; Polson, JW; Murphy, D; Paton, JFR; Kasparov, S			Genetic and pharmacological dissection of pathways involved in the angiotensin II-mediated depression of baroreflex function	FASEB JOURNAL			English	Article						hypertension; nucleus of the solitary tract; adenoviral gene transfer; calcium signaling	NITRIC-OXIDE SYNTHASE; NUCLEUS-TRACTUS-SOLITARII; PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; BRAIN-STEM; RAT; ACTIVATION; HYPERTENSION	Heart failure and hypertension are associated with increases in angiotensin II (ANG II) activity. One brain area where ANG II effects may be particularly important in these situations is the nucleus of the solitary tract (NTS). Located in the dorsomedial medulla, the NTS is the termination site of baroreceptor afferents and is essential for mediating the baroreflex. In hypertensive animals the baroreflex is impaired; this may be reversed by antagonizing ANG II AT(1) receptors in the NTS. Recently, we showed that the baroreflex depressant action of ANG II in the NTS is mediated by activation of endothelial nitric oxide synthase (eNOS) and enhanced release of GABA. Using conventional pharmacological tools and a range of adenoviral-mediated expression of dominant negative proteins, we have determined the intracellular pathway(s) in the NTS by which ANG II activates eNOS. Our data indicate that ANG II acting in the NTS depresses the baroreflex via a G(q) protein-mediated activation of phospholipase C, which through 1,4,5-inositol triphosphate causes release of calcium from the IP3-sensitive intracellular stores and calcium-calmodulin formation. In contrast, multiple site disruption of a pathway leading to eNOS activation via the serine/threonine kinase Akt was ineffective.	Univ Bristol, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Bristol Royal Infirm, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England	University of Bristol; Bristol Royal Infirmary; University of Bristol	Kasparov, S (corresponding author), Univ Bristol, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.	sergey.kasparov@bristol.ac.uk	Murphy, David/C-3967-2012; Kasparov, Sergey/C-4932-2014; Kasparov, Sergey/AAH-5286-2019; Paton, Julian/AAM-2121-2020	Murphy, David/0000-0003-2946-0353; Kasparov, Sergey/0000-0002-1824-1764; Kasparov, Sergey/0000-0002-1824-1764; 				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; CAJARAVILLE MP, 1993, HISTOL HISTOPATHOL, V8, P537; CAMPBELL DJ, 1995, HYPERTENSION, V25, P1014, DOI 10.1161/01.HYP.25.5.1014; CASTO R, 1986, AM J PHYSIOL, V250, pR193, DOI 10.1152/ajpregu.1986.250.2.R193; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; Cummins MM, 2000, IMMUNOL CELL BIOL, V78, P375, DOI 10.1046/j.1440-1711.2000.00932.x; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fang X, 2000, J NEUROCHEM, V75, P614, DOI 10.1046/j.1471-4159.2000.0750614.x; Ferguson AV, 2000, EXP PHYSIOL, V85, p153S, DOI 10.1111/j.1469-445X.2000.tb00019.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HEAGERTY AM, 1993, J HUM HYPERTENS, V7, P383; HEALY DP, 1989, BRAIN RES, V489, P1; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Kasparov S, 1999, J PHYSIOL-LONDON, V521, P227, DOI 10.1111/j.1469-7793.1999.00227.x; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Luoh HF, 1998, BRAIN RES, V782, P73, DOI 10.1016/S0006-8993(97)01198-0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MICHELINI LC, 1990, HYPERTENSION S1, V15, P145; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mollnau H, 2002, CIRC RES, V90, pE58, DOI 10.1161/01.RES.0000012569.55432.02; Pan SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC17, DOI 10.1152/ajpcell.2001.281.1.C17; Paton JFR, 2001, J PHYSIOL-LONDON, V531, P445, DOI 10.1111/j.1469-7793.2001.0445i.x; Paton JFR, 1999, J PHYSIOL-LONDON, V521, P213, DOI 10.1111/j.1469-7793.1999.00213.x; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Paton JFR, 2000, J AUTONOM NERV SYST, V80, P117, DOI 10.1016/S0165-1838(00)00077-1; PHILLIPS MI, 1977, NATURE, V270, P445, DOI 10.1038/270445a0; SENANAYAKE PD, 1994, PEPTIDES, V15, P919; Seyedabadi M, 2001, HYPERTENSION, V38, P1087, DOI 10.1161/hy1101.096054; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stanarius A, 1997, ACTA HISTOCHEM, V99, P411, DOI 10.1016/S0065-1281(97)80034-7; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TERUYA H, 1995, J HYPERTENS, V13, P883, DOI 10.1097/00004872-199508000-00009; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; WONG LF, 2001, SOC NEUR ABSTR, V27, P8374; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	42	48	48	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1595	1601		10.1096/fj.02-0099com	http://dx.doi.org/10.1096/fj.02-0099com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374782				2022-12-25	WOS:000179167600041
J	Waetzig, V; Herdegen, T				Waetzig, V; Herdegen, T			A single c-Jun N-terminal kinase isoform (JNK3-p54) is an effector in both neuronal differentiation and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; RAT PC12 CELLS; GROWTH-FACTOR; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; IN-VIVO; DEPENDENT REGULATION; SYMPATHETIC NEURONS; NEURITE OUTGROWTH	The c-Jun N-terminal kinases (JNKs) mediate degeneration and apoptosis in the brain. Particularly, JNK3 is considered to be a degenerative enzyme with c-Jun as a relevant substrate. The contribution of individual JNK isoforms, however, to pathological as well as to physiological processes remains to be defined. To analyze the effects of a single JNK isoform on neuronal cell death and differentiation, we transfected PC12 cells, which normally express only JNK1 and JNK2, with JNK3-p54. Transfected JNK3 significantly enhanced cell death after UV irradiation (0.5-6 J/cm(2)) and paclitaxel/taxol treatment (1-10 mum). In contrast, in the context of nerve growth factor-induced (10 or 50 ng/ml) differentiation of PC12 cells, JNK3 expression significantly increased the number and length of neurites. This functional dichotomy of JNK3 was mirrored by differential activation and induction of nuclear JNK substrates; although activating transcription factor-2 phosphorylation was enhanced by death signaling in response to UV and taxol, c-Jun protein expression and N-terminal phosphorylation were increased during nerve growth factor-induced differentiation. The absence of significant JNK activation or target phosphorylation in response to H2O2 (60 mum) further supports the hypothesis that JNK isoforms are not merely injury- or stress-specific kinases but also have context-specific physiological functions.	Univ Kiel, Med Ctr, Inst Pharmacol, D-24105 Kiel, Germany	University of Kiel	Herdegen, T (corresponding author), Univ Kiel, Med Ctr, Inst Pharmacol, Hosp Str 4, D-24105 Kiel, Germany.	t.herdegen@pharmakologie.uni-kiel.de	herdegen, thomas/E-5135-2010					Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Butterfield L, 1999, BIOCHEM J, V338, P681, DOI 10.1042/0264-6021:3380681; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Giasson BI, 1999, J NEUROCHEM, V72, P1081, DOI 10.1046/j.1471-4159.1999.0721081.x; Goodman MN, 1998, J NEUROBIOL, V36, P537, DOI 10.1002/(SICI)1097-4695(19980915)36:4<537::AID-NEU7>3.0.CO;2-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Herdegen T, 1997, NEUROSCIENCE, V81, P199, DOI 10.1016/S0306-4522(97)00170-X; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holmberg C, 2002, J BIOL CHEM, V277, P31918, DOI 10.1074/jbc.M200719200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Mc Gee MM, 2002, J BIOL CHEM, V277, P18383, DOI 10.1074/jbc.M112058200; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Savage MJ, 2002, J NEUROSCI, V22, P3376; Shackelford DA, 2001, MOL BRAIN RES, V94, P178, DOI 10.1016/S0169-328X(01)00245-5; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605	65	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					567	572		10.1074/jbc.M207391200	http://dx.doi.org/10.1074/jbc.M207391200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401814	hybrid			2022-12-25	WOS:000180255700074
J	Chan, PC; Liang, CC; Yu, KC; Chang, MC; Ho, WL; Chen, BH; Chen, HC				Chan, PC; Liang, CC; Yu, KC; Chang, MC; Ho, WL; Chen, BH; Chen, HC			Synergistic effect of focal adhesion kinase overexpression and hepatocyte growth factor stimulation on cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; PAXILLIN TYROSINE PHOSPHORYLATION; JUN NH2-TERMINAL KINASE; FACTOR-INDUCED SCATTER; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; STABLE ASSOCIATION; MET PROTOONCOGENE; MET/HGF RECEPTOR; INVASIVE GROWTH	Although an elevated level of focal adhesion kinase (FAK) has been observed in a variety of invasive human tumors, forced expression of FAK alone in cultured cells does not cause them to exhibit transformed phenotypes. Therefore, the role of FAK in oncogenic transformation remains unclear. In this study, we have demonstrated that FAK overexpression in Madin-Darby canine kidney epithelial cells rendered them susceptible to transformation by hepatocyte growth factor (HGF). Using various FAK mutants, we found that the simultaneous bindings of Src and p130(cas) were required for FAK to potentiate cell transformation. Expression of FAK-related nonkinase, kinase-deficient Src, or the Src homology 3 domain of p130(cas), which respectively serve as dominant negative versions of FAK, Src, and p130(cas), apparently reversed the transformed phenotypes of FAK-overexpressed cells upon HGF stimulation. Moreover, FAK overexpression was able to enhance HGF-elicited signals, leading to sustained activation of ERE, JNK, and AKT, which could be prevented by the expression of the Src homology 3 domain of p130(cas). Taken together, our results indicate that the synergistic effect of FAK overexpression and HGF stimulation leads to cell transformation and implicate a critical role of p130(cas) in this process.	Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Taichung Vet Gen Hosp, Dept Pathol, Taichung 40705, Taiwan	National Chung Hsing University; National Chung Hsing University; Taichung Veterans General Hospital	Chen, HC (corresponding author), Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan.		Liang, Richard Chun-Chi/C-6989-2013; Liang, Chun-Chi/D-7986-2016	Liang, Chun-Chi/0000-0002-8345-8564				Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakamura T, 1997, CANCER RES, V57, P3305; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; OWENS LV, 1995, CANCER RES, V55, P2752; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RANKIN S, 1994, J BIOL CHEM, V269, P704; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	57	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50373	50379		10.1074/jbc.M204691200	http://dx.doi.org/10.1074/jbc.M204691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393896	hybrid			2022-12-25	WOS:000180177700022
J	Hobert, ME; Sands, KA; Mrsny, RJ; Madara, JL				Hobert, ME; Sands, KA; Mrsny, RJ; Madara, JL			Cdc42 and Rac1 regulate late events in Salmonella typhimurium-induced interleukin-8 secretion from polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSE; KAPPA-B-ALPHA; TIGHT JUNCTIONS; INTESTINAL EPITHELIA; BACTERIAL FLAGELLIN; NUCLEAR RESPONSES; PLASMA-MEMBRANE; RHO GTPASES; PROTEINS; INVASION	Salmonella typhimurium colonization of the intestinal epithelium initiates biochemical cross-talk between pathogen and host that results in the secretion of chemokines, such as interleukin (IL)-8, that direct neutrophil migration to the site of infection. In nonpolarized cells, Rac1 and Cdc42 have been shown to regulate both bacterial invasion and signaling events leading to nuclear responses and IL-8 secretion. However, because the underlying actin cytoskeleton and the associated signaling machinery are distributed much differently in polarized epithelial cells, we used polarized Madin-Darby canine kidney monolayers to investigate the role of Rac1 and Cdc42 in S. typhimurium-induced pro-inflammatory responses in the more physiologically relevant polarized state. In Madin-Darby canine kidney monolayers expressing dominant-negative Rac1 or Cdc42, both Salmonella- and tumor necrosis factor a-induced activation of NFkappaB and mitogen-activated protein kinase signaling cascades proceeded normally, but IL-8 secretion was inhibited. We found that Rac1 and Cdc42 were not involved in early pro-inflammatory signaling events, as in nonpolarized cells, but rather regulated the basolateral exocytosis and secretion of IL-8. In contrast, dominant-negative Rac1 inhibited apical actin pedestal formation, indicating that pedestal formation and nuclear signaling for pro-inflammatory activation are not linked. These findings indicate that there are significant differences in the requirements of pathogen-induced host cell signaling pathways in polarized and nonpolarized cells.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Genentech Inc, San Francisco, CA 94080 USA	Emory University; Roche Holding; Genentech	Hobert, ME (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mhobert@bsd.uchicago.edu			NIDDK NIH HHS [DK-10085, DK-47622, DK-35932] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010085, R37DK035932, R01DK035932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; Criss AK, 2001, J CELL SCI, V114, P1331; Der CJ, 2000, NATURE, V405, P749, DOI 10.1038/35015654; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Elewaut D, 1999, J IMMUNOL, V163, P1457; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; FINLAY BB, 1989, SCIENCE, V243, P940, DOI 10.1126/science.2919285; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, J CELL BIOL, V107, P221, DOI 10.1083/jcb.107.1.221; FINLAY BB, 1989, J CELL SCI, P99; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; Lesser CF, 2000, TRENDS MICROBIOL, V8, P151, DOI 10.1016/S0966-842X(00)01727-3; MADARA JL, 1992, J CLIN INVEST, V89, P1938, DOI 10.1172/JCI115800; MADARA JL, 1988, AM J PHYSIOL, V254, pG416, DOI 10.1152/ajpgi.1988.254.3.G416; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; MCCORMICK BA, 1995, INFECT IMMUN, V63, P2302, DOI 10.1128/IAI.63.6.2302-2309.1995; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nelson W J, 1990, Semin Cell Biol, V1, P359; Reed KA, 2002, J BIOL CHEM, V277, P13346, DOI 10.1074/jbc.M200149200; Reed KA, 1996, FEMS MICROBIOL LETT, V145, P233, DOI 10.1016/S0378-1097(96)00415-6; REVEL M, 1966, BIOCHEM BIOPH RES CO, V25, P124, DOI 10.1016/0006-291X(66)90649-8; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; ZIERLER MK, 1995, INFECT IMMUN, V63, P4024, DOI 10.1128/IAI.63.10.4024-4028.1995	56	29	30	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51025	51032		10.1074/jbc.M210466200	http://dx.doi.org/10.1074/jbc.M210466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381718	hybrid			2022-12-25	WOS:000180177700109
J	Miyazaki, T; Yoshimi, T; Furutsu, Y; Hongo, K; Mizobata, T; Kanemori, M; Kawata, Y				Miyazaki, T; Yoshimi, T; Furutsu, Y; Hongo, K; Mizobata, T; Kanemori, M; Kawata, Y			GroEL-substrate-GroES ternary complexes are an important transient intermediate of the chaperonin cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; KINETIC-ANALYSIS; STEADY-STATE; IN-VIVO; PROTEINS; BINDING; POLYPEPTIDE; MECHANISM	GroEL C138W is a mutant form of Escherichia coli GroEL, which forms an arrested ternary complex composed of GroEL, the co-chaperonin GroES and the refolding protein molecule rhodanese at 25 degreesC. This state of arrest could be reversed with a simple increase in temperature. In this study, we found that GroEL C138W formed both stable trans- and cis-ternary complexes with a number of refolding proteins in addition to bovine rhodanese. These complexes could be reactivated by a temperature shift to obtain active refolded protein. The simultaneous binding of GroES and substrate to the cis ring suggested that an efficient transfer of substrate protein into the GroEL central cavity was assured by the binding of GroES prior to complete substrate release from the apical domain. Stopped-flow fluorescence spectroscopy of the mutant chaperonin revealed a temperature-dependent conformational change in GroEL C138W that acts as a trigger for complete protein release. The behavior of GroEL C138W was reflected closely in its in vivo characteristics, demonstrating the importance of this conformational change to the overall activity of GroEL.	Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan; Kanazawa Univ, Fac Sci, Dept Biol, Kanazawa, Ishikawa 9201192, Japan	Tottori University; Kanazawa University	Kawata, Y (corresponding author), Tottori Univ, Fac Engn, Dept Biotechnol, Koyama Minami, Tottori 6808552, Japan.		Kawata, Yasushi/ABA-9608-2021; Mizobata, Tomohiro/V-6672-2019	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Fridmann Y, 2000, J BIOL CHEM, V275, P37951, DOI 10.1074/jbc.M007594200; Fridmann Y, 2002, BIOCHEMISTRY-US, V41, P5938, DOI 10.1021/bi020117v; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Horovitz A, 2000, B MATH BIOL, V62, P241, DOI 10.1006/bulm.1999.0150; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANEMORI M, 1994, J BACTERIOL, V176, P4235, DOI 10.1128/jb.176.14.4235-4242.1994; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Kawata Y, 1998, PROTEIN ENG, V11, P1293, DOI 10.1093/protein/11.12.1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin J, 2002, BIOCHEMISTRY-US, V41, P5050, DOI 10.1021/bi015925l; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Mizobata T, 2000, J BIOL CHEM, V275, P25600, DOI 10.1074/jbc.M000795200; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	32	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50621	50628		10.1074/jbc.M209183200	http://dx.doi.org/10.1074/jbc.M209183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12377767	hybrid			2022-12-25	WOS:000180177700057
J	Remboutsika, E; Yamamoto, K; Harbers, M; Schmutz, M				Remboutsika, E; Yamamoto, K; Harbers, M; Schmutz, M			The bromodomain mediates transcriptional intermediary factor 1 alpha-nucleosome interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; CHROMATIN STRUCTURE; BINDING-PROTEIN; BIOCHEMICAL-ANALYSIS; REPRESSOR DOMAIN; LINKER HISTONES; HP1 PROTEINS; DNA-BINDING; IN-VITRO; FAMILY	Nuclear histone acetyltransferases, DNA-dependent ATPases, and transcriptional intermediary factors (TIFs) all harbor a distinct structural module known as the bromodomain (BrD). Although the BrD can interact with histones H3 and H4 and their acetylated N-terminal tails in vitro, its function in a chromosomal environment remains elusive. We used the nuclear receptor coregulator TIF1alpha, a protein kinase that associates tightly with euchromatin, to analyze the properties of the BrD in a nucleosomal environment in vitro. Here, we report that TIF1alpha-chromatin association is direct and involves DNA and nucleosome interactions mediated by the BrD. Mutation of the BrD signature peptide, PMDL, abolishes DNA binding and disrupts BrD-nucleosome interactions. Based on our results, we propose that the BrD plays a critical role in vivo by directing transregulators to their cognate location on nucleosomal DNA.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Remboutsika, E (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Ridgeway,Mill Hill, London NW7 1AA, England.	erembou@nimr.mrc.ac.uk	Schmutz, Marc/A-4953-2012	Schmutz, Marc/0000-0003-4059-7609; Harbers, Matthias/0000-0002-5613-7220				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Cammas F, 2002, J CELL SCI, V115, P3439; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Denis GV, 2001, FRONT BIOSCI, V6, pD1065; Denis GV, 2001, FRONT BIOSCI, V6, pD849, DOI 10.2741/Denis; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Dyson MH, 2001, FRONT BIOSCI, V6, pD853, DOI 10.2741/Dyson; Filetici P, 2001, FRONT BIOSCI-LANDMRK, V6, pD866, DOI 10.2741/Filetici; Florence B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1008, DOI 10.2741/Florence; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horn PJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD1019, DOI 10.2741/Horn; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; KAMAKAKA RT, 1993, COLD SPRING HARB SYM, V58, P205, DOI 10.1101/SQB.1993.058.01.025; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liedman D, 2001, CURR OPIN HEMATOL, V8, P218, DOI 10.1097/00062752-200107000-00007; Manning ET, 2001, MOL CELL BIOL, V21, P3876, DOI 10.1128/MCB.21.12.3876-3887.2001; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Niederreither K, 1999, MECH DEVELOP, V88, P111, DOI 10.1016/S0925-4773(99)00175-6; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Remboutsika E, 1999, J CELL SCI, V112, P1671; Remboutsika E, 2001, J BIOL CHEM, V276, P12781, DOI 10.1074/jbc.M100481200; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Thenot S, 1999, MOL ENDOCRINOL, V13, P2137, DOI 10.1210/me.13.12.2137; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Velloso ERP, 1996, LEUKEMIA LYMPHOMA, V21, P137, DOI 10.3109/10428199609067591; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhao T, 2000, J BIOL CHEM, V275, P28332; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; Zlatanova J, 1998, BIOESSAYS, V20, P584, DOI 10.1002/(SICI)1521-1878(199807)20:7<584::AID-BIES10>3.0.CO;2-W; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	67	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50318	50325		10.1074/jbc.M203759200	http://dx.doi.org/10.1074/jbc.M203759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12384511	hybrid			2022-12-25	WOS:000180177700015
J	Tam, JP; Lu, YA; Yang, JL				Tam, JP; Lu, YA; Yang, JL			Correlations of cationic charges with salt sensitivity and microbial specificity of cystine-stabilized beta-strand antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; MEMBRANOLYTIC SELECTIVITY; MACROCYCLIC PEPTIDES; CYCLIC-PEPTIDES; HEMOCYTES; ANALOGS; KNOT; MECHANISMS; MEMBRANES; MELITTIN	The electrostatic interaction of the charge cluster of an amphipathic peptide antibiotic with microbial membranes is a salt-sensitive step that often determines organism specificity. We have examined the correlation between charge clusters and salt insensitivity and microbial specificity in linear, cyclic, and retro-isomeric cystine-stabilized beta-strand (CSbeta) tachyplesin (TP) in a panel of 10 test organisms. Cyclic tachyplesins consisting of 14 and 18 amino acids are constrained by an end-to-end peptide backbone and two or three disulfide bonds to cross-brace the anti-parallel beta-strand that approximates a "beta-tile" structure. Circular dichroism measurements of beta-tile TPs showed that they displayed ordered structures. Control peptides containing the same number of basic amino acids as TP but lacking disulfide constraints were highly salt sensitive. Cyclic TP analogues with six cationic charges were more broadly active and salt-insensitive than those with fewer cationic charges. Reducing their proximity or number of cationic charges, particularly those with three or fewer basic amino acids, led to a significant decrease in potency and salt insensitivity, but an increased selectivity to certain Gram-positive bacteria. An end-group effect of the dibasic N-terminal Lys of TP in the open-chain TP and its retroisomer was observed in certain Gram-negative bacteria under high-salt conditions, an effect that was not found in the cyclic analogs. These results suggest that a stable folded structure together with three or more basic amino acids closely packed in a charged region in CSbeta peptides is important for salt insensitivity and organism specificity.	Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Tam, JP (corresponding author), Vanderbilt Univ, Dept Microbiol & Immunol, A-5119 MCN, Nashville, TN 37232 USA.	james.tam@vanderbilt.edu	Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046164] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46164] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; HOJO H, 1991, B CHEM SOC JPN, V64, P111, DOI 10.1246/bcsj.64.111; Juvvadi P, 1996, J AM CHEM SOC, V118, P8989, DOI 10.1021/ja9542911; Karig G, 2000, HELV CHIM ACTA, V83, P1049, DOI 10.1002/1522-2675(20000607)83:6<1049::AID-HLCA1049>3.0.CO;2-1; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P9799, DOI 10.1021/bi970588v; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NARASIMHAN L, 1994, NAT STRUCT BIOL, V1, P850, DOI 10.1038/nsb1294-850; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Rao AG, 1999, ARCH BIOCHEM BIOPHYS, V361, P127, DOI 10.1006/abbi.1998.0962; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Tam JP, 1998, PROTEIN SCI, V7, P1583, DOI 10.1002/pro.5560070712; Tam JP, 2000, EUR J BIOCHEM, V267, P3289, DOI 10.1046/j.1432-1327.2000.01359.x; Tam JP, 2000, BIOCHEMISTRY-US, V39, P7159, DOI 10.1021/bi0003487; Tam JP, 1999, J AM CHEM SOC, V121, P4316, DOI 10.1021/ja984480u; Tam JP, 2000, BIOCHEM BIOPH RES CO, V267, P783, DOI 10.1006/bbrc.1999.2035; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; YANG Y, 1994, PROTEIN SCI, V3, P1267, DOI 10.1002/pro.5560030813; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LS, 1999, J AM CHEM SOC, V121, P3311, DOI 10.1021/ja983859d; Zhang LS, 1997, J AM CHEM SOC, V119, P2363, DOI 10.1021/ja9621105	41	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50450	50456		10.1074/jbc.M208429200	http://dx.doi.org/10.1074/jbc.M208429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399464	hybrid			2022-12-25	WOS:000180177700033
J	Wang, Q; Limbird, LE				Wang, Q; Limbird, LE			Remilated interactions of the alpha(2A) adrenergic receptor with spinophilin, 14-3-3 zeta, and arrestin 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; PROTEIN-COUPLED RECEPTORS; GTP-BINDING PROTEINS; CANINE KIDNEY-CELLS; ALPHA(2A)-ADRENERGIC RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTORS; BASOLATERAL MEMBRANE; WILD-TYPE; SUBTYPES; SITES	The present studies demonstrate that no single stretch of sequence in the third intracellular (3i) loop of the alpha(2A) adrenergic receptor (alpha(2A)-AR) can fully account for its previously described interactions with spinophilin (Richman, J.G., Brady, A. E., Wang, Q., Hensel, J.L., Colbran, R.J., and Limbird, L. E. (2001) J. Biol. Chem. 276, 15003-15008), 14-3-3zeta (Prezeau, L., Richman, J. G., Edwards, S. W., and Limbird, L. E. (1999) J. Biol. Chem. 274,13462-13469), and arrestin 3 (Wu, G., Krupnick, J. G., Benovic, J. L., and Lanier, S. M. (1997) J. Biol. Chem. 272, 17836-17842), suggesting that a three-dimensional surface, rather than a linear sequence, provides the basis for these interactions as proposed for 3i loop tethering of the alpha(2A)-AR to the basolateral. surface of Madin-Darby canine kidney cells (Edwards, S. W., and Limbird, L. E. (1999) J. Biol. Chem. 274,16331-16336). Sequences at the extreme N-terminal and C-terminal ends of the 3i loop are critical for interaction with spinophilin but not for interaction with 14-3-3zeta or arrestin 3, for which the C-terminal half of the loop is more important. Competition binding for S-35-labeled alpha(2A)-AR 3i loop binding to glutathione S-transferase (GST)-spinophilin amino acids 151-444 revealed a relative affinity of spinophilincongruent toarrestin >14-3-3zeta for the unphosphorylated alpha(2A)-AR 3i loop. Agonist occupancy of the alpha(2A)-AR increases receptor association with spinophilin, and arrestin 3 appears to compete for this enrichment. However, when the G protein-coupled receptor kinase 2 substrate sequence was deleted from the 3i loop, arrestin 3 could not compete for the agonist-enriched binding of spinophilin to the mutant alpha(2A)-AR. These data are consistent with a model where sequential or competitive interactions among spinophilin, arrestin, and/or 14-3-3zeta play a role in alpha(2A)-AR functions.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 464 Robinson Res Bldg, Nashville, TN 37232 USA.			Wang, Qin/0000-0002-1079-5914	NIDDK NIH HHS [DK43879] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Audubert F, 1999, BBA-MOL CELL BIOL L, V1437, P265, DOI 10.1016/S1388-1981(99)00018-9; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Edwards SW, 1999, J BIOL CHEM, V274, P16331, DOI 10.1074/jbc.274.23.16331; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; Mishima K, 2001, JPN J PHARMACOL, V85, P214, DOI 10.1254/jjp.85.214; Pages C, 1999, BIOCHEM BIOPH RES CO, V265, P572, DOI 10.1006/bbrc.1999.1726; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Richman JG, 1998, AM J PHYSIOL-CELL PH, V274, pC654, DOI 10.1152/ajpcell.1998.274.3.C654; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	29	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50589	50596		10.1074/jbc.M208503200	http://dx.doi.org/10.1074/jbc.M208503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12376539	hybrid			2022-12-25	WOS:000180177700053
J	Groysman, M; Hornstein, I; Alcover, A; Katzav, S				Groysman, M; Hornstein, I; Alcover, A; Katzav, S			Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAMOLECULAR ACTIVATION CLUSTERS; NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; DISSOCIATION INHIBITOR; IMMUNOLOGICAL SYNAPSE; ACTIN CYTOSKELETON; MAST-CELLS; PROTOONCOGENE PRODUCT; STRUCTURAL BASIS	The Rho family GTPases are pivotal for T cell signaling; however, the regulation of these proteins is not fully known. One well studied regulator of Rho GTPases is Vav1; a hematopoietic cell-specific guanine nucleotide exchange factor critical for signaling in T cells, including stimulation of the nuclear factor of activated T cells (NFAT). Surprisingly, Vav1 associates with Ly-GDI, a hematopoietic cell-specific guanine nucleotide dissociation inhibitor of Rac. Here, we studied the functional significance of the interaction between Vav1 and LyGDI in T cells. Upon organization of the immunological synapse, both Ly-GDI and Vav1 relocalize to T cell extensions in contact with the antigen-presenting cell. LyGDI is phosphorylated on tyrosine residues following T cell receptor stimulation, and it associates with the Src homology 2 region of an adapter protein, Shc. In addition, the interaction between Ly-GDI and Vav1 requires tyrosine phosphorylation. Overexpression of Ly-GDI alone is inhibitory to NFAT stimulation and calcium mobilization. However, when co-expressed with Vav1, Ly-GDI enhances Vav1 induction of NFAT activation, phospholipase Cy phosphorylation, and calcium mobilization. Moreover, Ly-GDI does not alter the regulation of these phenomena when coexpressed with oncogenic Vav1. Since oncogenic Vav1 does not bind Ly-GDI, this suggests that the functional coperativity of Ly-GDI and Vav1 is dependent upon their association. Thus, our data suggest that the interaction of Vav1 and Ly-GDI creates a fine tuning mechanism for the regulation of intracellular signaling pathways leading to NFAT stimulation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91010 Jerusalem, Israel; Inst Pasteur, CNRS URA 1960, Unite Biol Interact Cellulaires, F-7524 Paris, France	Hebrew University of Jerusalem; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91010 Jerusalem, Israel.			Sherman, Maya/0000-0002-7421-9844; Alcover, Andres/0000-0002-9507-3450				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ADRA CN, 1993, GENE CHROMOSOME CANC, V8, P253, DOI 10.1002/gcc.2870080408; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Coppolino MG, 2001, J CELL SCI, V114, P4307; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Delaguillaumie A, 2002, J CELL SCI, V115, P433; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Gimona M, 1998, CURR BIOL, V8, pR674; Golovanov AP, 2001, J MOL BIOL, V305, P121, DOI 10.1006/jmbi.2000.4262; Gorvel JP, 1998, FEBS LETT, V422, P269, DOI 10.1016/S0014-5793(98)00020-9; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hong-Geller E, 2001, P NATL ACAD SCI USA, V98, P1154, DOI 10.1073/pnas.98.3.1154; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kasper B, 2000, BLOOD, V95, P2947, DOI 10.1182/blood.V95.9.2947.009k10_2947_2953; Katzav S, 1995, CRIT REV ONCOGENESIS, V6, P87; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Kuklina EM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P467, DOI 10.1023/A:1010238931555; Kupfer A, 2000, NAT MED, V6, P1097, DOI 10.1038/80421; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Niedergang F, 1997, J IMMUNOL, V159, P1703; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Potter TA, 2001, P NATL ACAD SCI USA, V98, P12624, DOI 10.1073/pnas.221458898; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Settleman J, 1999, Prog Mol Subcell Biol, V22, P201; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; VANOERS NS, 1996, J EXP MED, V13, P1053; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	73	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50121	50130		10.1074/jbc.M204299200	http://dx.doi.org/10.1074/jbc.M204299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386169	hybrid			2022-12-25	WOS:000180028900131
J	Peter, K; Varga, K; Bebok, Z; McNicholas-Bevensee, CM; Schwiebert, L; Sorscher, EJ; Schwiebert, EM; Collawn, JF				Peter, K; Varga, K; Bebok, Z; McNicholas-Bevensee, CM; Schwiebert, L; Sorscher, EJ; Schwiebert, EM; Collawn, JF			Ablation of internalization signals in the carboxyl-terminal tail of the cystic fibrosis transmembrane conductance regulator enhances cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; ENDOCYTIC PATHWAY; WATER CHANNELS; PROTEIN; MEMBRANE; TRAFFICKING; SEQUENCE; INSULIN; DOMAIN; SYNTAXIN	The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel that undergoes endocytosis through clathrin-coated pits. Previously, we demonstrated that Y1424A is important for CFTR endocytosis (Prince, L. S., Peter, K., Hatton, S. R., Zaliauskiene, L., Cotlin, L. F., Clancy, J. P., Marchase, R. B., and Collawn, J. F. (1999) J. Biol. Chem. 274,36023609). Here we show that a second substitution in the carboxyl-terminal tail of CFTR, I1427A, on Y1424A background more than doubles CFTR surface expression as monitored by surface biotinylation. Internalization assays indicate that enhanced surface expression of Y1424A,I1427A CFTR is caused by a 76% inhibition of endocytosis. Patch clamp recording of chloride channel activity revealed that there was a corresponding increase in chloride channel activity of Y1424A,I1427A CFTR, consistent with the elevated surface expression, and no change in CFTR channel properties. Y14124A showed an intermediate phenotype compared with the double mutation, both in terms of surface expression and chloride channel activity. Metabolic pulse-chase experiments demonstrated that the two mutations did not affect maturation efficiency or protein half-life. Taken together, our data show that there is an internalization signal in the COOH terminus of CFTR that consists of Tyr(1424)-X-X-Ile(1427) where both the tyrosine and the isoleucine are essential residues. This signal regulates CFTR surface expression but not CFTR biogenesis, degradation, or chloride channel function.	Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol, Birmingham, AL 35294 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Biophys, Birmingham, AL 35294 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Cell Biol, MCLM 350,1918 Univ Blvd, Birmingham, AL 35294 USA.			McNicholas-Bevensee, Carmel/0000-0002-7013-8764; Sorscher, Eric J./0000-0001-9341-3354; Collawn, James/0000-0002-2528-2759	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054367, R01DK060065] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54367, DK 60065] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lukacs GL, 1997, BIOCHEM J, V328, P353; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEBSTER P, 1994, AM J PHYSIOL, V267, P340; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200	25	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49952	49957		10.1074/jbc.M209275200	http://dx.doi.org/10.1074/jbc.M209275200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376531	hybrid			2022-12-25	WOS:000180028900111
J	Sidyelyeva, G; Fricker, LD				Sidyelyeva, G; Fricker, LD			Characterization of Drosophila carboxypeptidase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOCARBOXYPEPTIDASE GENE FAMILY; ANGIOTENSIN-CONVERTING ENZYME; B-VIRUS-PARTICLES; CYTOPLASMIC DOMAIN; EXPRESSION; CLONING; MEMBER; IDENTIFICATION; LOCALIZATION; PROTEIN	Metallocarboxypeptidase D (CPD), is a 180-kDa protein that contains three carboxypeptidase-like domains, a transmembrane domain, and a cytosolic tail and which functions in the processing of proteins that transit the secretory pathway. An initial report on the Drosophila melanogaster silver gene indicated a CPD-like protein with only two and a half carboxypeptidase-like domains with no transmembrane region (Settle, S. H., Jr., Green, M. M., and Burtis, K. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9470-9474). A variety of bioinformatics and experimental approaches were used to determine that the Drosophila silver gene corresponds to a CPD-like protein with three carboxypeptidase-like domains, a transmembrane domain, and a cytosolic tail. In addition, two alternative exons were found, which result in proteins with different carboxypeptidase-like domains, termed domains 1A and 1B. Northern blot, reverse transcriptase PCR, and sequence analysis were used to confirm the presence of the various mRNA forms. Individual domains of Drosophila CPD were expressed in insect Sf9 cells using the baculovirus expression system. Media from domain 1B- and domain 2-expressing cells showed substantial enzymatic activity, whereas medium from domain 1A-expressing cells was no different from cells infected with wild-type virus. Domains 1B and 2 were purified, and the enzymatic properties were examined. Both enzymes cleaved substrates with C-terminal Arg or Lys, but not Leu, and were inhibited by conventional metallopeptidase inhibitors and some divalent cations. Drosophila domain 1B is more active at neutral pH and greatly prefers C-terminal Arg over Lys, whereas domain 2 is more active at pH 5-6 and slightly prefers C-terminal Lys over Arg. The differences in pH optima and substrate specificity between Drosophila domains 1B and 2 are similar to the differences between duck CPD domains 1 and 2, suggesting that these properties are essential to CPD function.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu			NCI NIH HHS [CA 13330] Funding Source: Medline; NIDA NIH HHS [K02 DA 00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK 51271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Coates D, 2000, BIOCHEMISTRY-US, V39, P8963, DOI 10.1021/bi000593q; COLEMAN JE, 1962, J BIOL CHEM, V237, P3430; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; DAVIS LG, 1986, BASIC METHODS MOL BI, P152; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fricker L. D., 2002, ENZYMES, V23, P421; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1349; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Ishikawa T, 1998, GENE, V215, P361, DOI 10.1016/S0378-1119(98)00270-4; Kalinina E, 2002, J CELL BIOCHEM, V85, P101, DOI 10.1002/jcb.10112; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; Song LX, 1997, J BIOL CHEM, V272, P10543; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Taylor CAM, 1996, GENE, V181, P191, DOI 10.1016/S0378-1119(96)00503-3; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897	32	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49613	49620		10.1074/jbc.M209652200	http://dx.doi.org/10.1074/jbc.M209652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393882	hybrid			2022-12-25	WOS:000180028900068
J	Swamynathan, SK; Piatigorsky, J				Swamynathan, SK; Piatigorsky, J			Orientation-dependent influence of an intergenic enhancer on the promoter activity of the divergently transcribed mouse Shsp/alpha B-crystallin and Mkbp/HspB2 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NON-LENTICULAR TISSUES; ALPHA-A-CRYSTALLIN; BETA-GLOBIN; TRANSGENIC MICE; CORE PROMOTERS; SHARED ENHANCER; SKELETAL-MUSCLE; 3RD INTRON; LENS	The mouse Shsp/alphaB-crystallin and Mkbp/HspB2 genes are closely linked and divergently transcribed. In this study, we have analyzed the contribution of the intergenic enhancer to Sitsp/alphaB-crystallin and Mkbp/HspB2 promoter activity using dual-reporter vectors in transient transfection and transgenic mouse experiments. Deletion of the enhancer reduced Shsp/alphaB-crystallin promoter activity by 30- and 93-fold and Mkbp/HspB2 promoter activity by 6- and 10-fold in transiently transfected mouse lens alpha-TN4 and myoblast C2C12 cells, respectively. Surprisingly, inversion of the enhancer reduced Shsp/alphaB-crystallin promoter activity by 17-fold, but did not affect Mkbp/HspB2 promoter activity in the transfected cells. In contrast, enhancer activity was orientation-independent in combination with a heterologous promoter in transfected cells. Transgenic mouse experiments established the orientation dependence and Shsp/alphaB-crystallin promoter preference of the intergenic enhancer in its native context. The orientation dependence and preferential effect of the Shsp/alphaB-crystallin enhancer on the Shsp/alphaB-crystallin promoter provide an example of adaptive changes in gene regulation accompanying the functional diversification of duplicated genes during evolution.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 201,6 Ctr Dr, Bethesda, MD 20892 USA.			Swamynathan, Shivalingappa/0000-0002-9158-1511				Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Angulo A, 2000, J VIROL, V74, P2826, DOI 10.1128/JVI.74.6.2826-2839.2000; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; DUNCAN MK, 1995, GENE, V162, P189, DOI 10.1016/0378-1119(95)00363-B; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; Gopal-Srivastava R, 1998, J BIOL CHEM, V273, P17954, DOI 10.1074/jbc.273.28.17954; Gopal-Srivastava R, 2000, MECH DEVELOP, V92, P125, DOI 10.1016/S0925-4773(99)00341-X; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Herault Y, 1997, DEVELOPMENT, V124, P3493; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hough RB, 2002, P NATL ACAD SCI USA, V99, P8145, DOI 10.1073/pnas.122231099; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JONSSON JJ, 1994, GENE, V140, P187, DOI 10.1016/0378-1119(94)90543-6; Kappe G, 2001, BBA-GENE STRUCT EXPR, V1520, P1, DOI 10.1016/S0167-4781(01)00237-8; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Nolan EM, 1996, MOL CELL ENDOCRINOL, V124, P51, DOI 10.1016/S0303-7207(96)03927-5; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; Scohy S, 2000, NUCLEIC ACIDS RES, V28, P3743, DOI 10.1093/nar/28.19.3743; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Surinya KH, 1998, J BIOL CHEM, V273, P16798, DOI 10.1074/jbc.273.27.16798; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; Wei W, 2000, P NATL ACAD SCI USA, V97, P14518, DOI 10.1073/pnas.011529598; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272	63	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49700	49706		10.1074/jbc.M209700200	http://dx.doi.org/10.1074/jbc.M209700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12403771	hybrid			2022-12-25	WOS:000180028900080
J	Guo, Y; Waldron, GJ; Murrell-Lagnado, R				Guo, Y; Waldron, GJ; Murrell-Lagnado, R			A role for the middle C terminus of G-protein-activated inward rectifier potassium channels in regulating gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DEPENDENT ACTIVATION; RECTIFYING K+ CHANNELS; BETA-GAMMA-SUBUNITS; MECHANISM; DOMAINS; BINDING; PORE; RECTIFICATION; DETERMINANTS; SITES	We have used sulfhydryl-modifying reagents to investigate the regulation of G-protein-activated inward rectifier potassium (GIRK) channels via their cytoplasmic domains. Modification of either the conserved N-terminal cysteines (GIRK1C53 and GIRK2C65) or the middle C-terminal cysteines (GIRK1C310 and GIRK2C321) independently inhibited GIRK1/GIRK2 heteromeric channels. With the exception of GIRK2C65, these cysteines were relatively inaccessible to large modifying reagents. The accessibility was further reduced by a mutation at the end of the second transmembrane domain that stabilized the open state of the channel. Thus it is unlikely that these cysteines line the permeation pathway of the open pore. Cysteines introduced 3 and 6 amino acids upstream of GIRK2C321 (G318C and E315C) were considerably more accessible. The effect of modification was dependent on the charge of the reagent. Modification of E315C in GIRK2 and E304C in GIRK1 by sodium (2-sulfonatoethyl) methanethiosulfonate (MTSES(-)) increased the current by similar to17-fold, whereas modification by 2-aminoethyl methanethiosulfonate hydrochloride (MTSEA(+)), abolished the current. There was no effect on single-channel conductance. Thus a switch in charge at this middle C-terminal position was sufficient to gate the channel open and closed. This glutamate is conserved in all members of the Kir family. The E303K mutation in Kir2.1 inhibits channel function and causes Andersen's syndrome in humans (Plaster, N. M., Tawil, R., Tristani-Firouzi, M., Canun, S., Bendahhou, S., Tsunoda, A., Donaldson, M. R., Iannaccone, S. T., Brunt, E., Barohn, R., Clark, J., Deymeer, F., George, A. L., Jr., Fish, F. A., Hahn, A., Nitu, A., Ozdemir, C., Serdaroglu, P., Subramony, S. H., Wolfe, G., Fu, Y. H., and Ptacek, L. J. (2001) Cell 105, 511-519 and Preisig-Muller, R., Schlichthorl, G., Goerge, T., Heinen, S., Bruggemann, A., Rajan, S., Derst, C., Veh, R. W., and Daut, J. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7774-7779). Our results suggest that this residue regulates channel gating through an electrostatic mechanism.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Murrell-Lagnado, R (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	rdm1003@cam.ac.uk	Guo, Yuan/B-1319-2018	Guo, Yuan/0000-0003-4607-7356; Murrell-Lagnado, Ruth/0000-0003-2743-7977				Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Chen L, 2002, P NATL ACAD SCI USA, V99, P8430, DOI 10.1073/pnas.122682899; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Loussouarn G, 2001, P NATL ACAD SCI USA, V98, P4227, DOI 10.1073/pnas.061452698; Lu T, 1999, P NATL ACAD SCI USA, V96, P9926, DOI 10.1073/pnas.96.17.9926; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; Murrell-Lagnado RD, 2002, BIOPHYS J, V82, p593A; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Preisig-Muller R, 2002, P NATL ACAD SCI USA, V99, P7774, DOI 10.1073/pnas.102609499; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rogalski SL, 2001, J BIOL CHEM, V276, P14855, DOI 10.1074/jbc.M010097200; Ruppersberg JP, 2000, PFLUG ARCH EUR J PHY, V441, P1, DOI 10.1007/s004240000380; Sadja R, 2001, NEURON, V29, P669, DOI 10.1016/S0896-6273(01)00242-2; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Stevens EB, 1997, J PHYSIOL-LONDON, V503, P547, DOI 10.1111/j.1469-7793.1997.547bg.x; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Zeidner G, 2001, J BIOL CHEM, V276, P35564, DOI 10.1074/jbc.M105189200	38	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48289	48294		10.1074/jbc.M207987200	http://dx.doi.org/10.1074/jbc.M207987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376541	hybrid			2022-12-25	WOS:000179789600043
J	Ookawa, K; Kudo, T; Aizawa, S; Saito, H; Tsuchida, S				Ookawa, K; Kudo, T; Aizawa, S; Saito, H; Tsuchida, S			Transcriptional activation of the MUC2 gene by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; HUMAN COLORECTAL CARCINOMAS; HUMAN INTESTINAL MUCIN; CELL-LINES; GASTRIC CARCINOMAS; EXPRESSION; PROTEIN; CANCER; DIFFERENTIATION; IDENTIFICATION	MUC2 is one of the major components of mucins that provide a protective barrier between epithelial surfaces and the gut lumen. We investigated possible alterations of MUC2 gene expression by p53 and p21(Sdi1/Waf1/Cip1) in a human colon cancer cell line, DLD-1, establishing subclones in which a tetracycline-regulatable promoter controls exogenous p53 and p21. expression. MUC2 mRNA more significantly increased in response to p53 than to p21. Unexpectedly, MUC2 expression was also induced in human osteosarcoma cells, U-2OS and Saos-2, by exogenous p53. We next performed a reporter assay to test the direct regulation of MUC2 gene expression by p53. Deletion and mutagenesis of the MUC2 promoter region showed that it contains two sites for transactivation by p53. Furthermore, an electrophoretic mobility shift assay indicated that p53 binds to those elements. We analyzed MUC2 expression in other cell types possessing a functional p53 after exposure to various forms of stress. In MCF7 breast cancer and A427 lung cancer cells, MUC2 expression was increased along with the endogenous p53 level by actinomycin D, UVC, and x-ray, but not in RERF-LC-MS lung cancer cells carrying a mutated p53. These results suggest that p53 directly activates the MUC2 gene in many cell types.	Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Internal Med, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Ctr Educ & Res Lifelong Learning, Hirosaki, Aomori 0368560, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Ookawa, K (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem 2, Zaifucho 5, Hirosaki, Aomori 0368562, Japan.		Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; Aslam F, 2001, CANCER RES, V61, P570; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; BLANK M, 1994, INT J CANCER, V59, P301, DOI 10.1002/ijc.2910590302; CAMPO E, 1991, CANCER RES, V51, P4436; CASEY G, 1991, ONCOGENE, V6, P1791; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; Hanski C, 1997, LAB INVEST, V77, P685; HARPER JW, 1993, CELL, V75, P805; Higashi M, 1999, HEPATOLOGY, V30, P1347, DOI 10.1002/hep.510300609; HO SB, 1993, CANCER RES, V53, P641; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; LEHMAN TA, 1991, CANCER RES, V51, P4090; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Manne U, 2000, CLIN CANCER RES, V6, P4017; Mikami T, 1999, INT CONGR SER, V1172, P153; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Ookawa K, 2001, FEBS LETT, V500, P25, DOI 10.1016/S0014-5793(01)02583-2; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; RADINSKY R, 1994, ONCOGENE, V9, P1877; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Takahashi R, 1996, EUR J CANCER, V32A, P533, DOI 10.1016/0959-8049(95)00611-7; TYTGAT KMAJ, 1994, GASTROENTEROLOGY, V107, P1352, DOI 10.1016/0016-5085(94)90537-1; Utsunomiya T, 1998, CLIN CANCER RES, V4, P2605; Van Klinken BJW, 1998, ANAL BIOCHEM, V265, P103; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Winterford CM, 1999, J HISTOCHEM CYTOCHEM, V47, P1063, DOI 10.1177/002215549904700811; Yonezawa S, 1997, HUM PATHOL, V28, P344, DOI 10.1016/S0046-8177(97)90134-9; Zhao RB, 2000, GENE DEV, V14, P981	45	43	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48270	48275		10.1074/jbc.M207986200	http://dx.doi.org/10.1074/jbc.M207986200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374798	hybrid			2022-12-25	WOS:000179789600040
J	Qi, NN; Kazdova, L; Zidek, V; Landa, V; Kren, V; Pershadsingh, HA; St Lezin, E; Abumrad, NA; Pravenec, M; Kurtz, TW				Qi, NN; Kazdova, L; Zidek, V; Landa, V; Kren, V; Pershadsingh, HA; St Lezin, E; Abumrad, NA; Pravenec, M; Kurtz, TW			Pharmacogenetic evidence that Cd36 is a key determinant of the metabolic effects of pioglitazone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE FATTY-ACID; INSULIN-RESISTANCE; GENE-EXPRESSION; ADIPOSE-TISSUE; GLUCOSE-METABOLISM; PROTEIN; THIAZOLIDINEDIONE; DIFFERENTIATION; ACTIVATION; TRANSPORT	Pioglitazone, like other thiazolidinediones, is an insulin-sensitizing agent that activates the peroxisome proliferator-activated receptor gamma and influences the expression of multiple genes involved in carbohydrate and lipid metabolism. However, it is unknown which of these many target genes play primary roles in determining the antidiabetic and hypolipidemic effects of thiazolidinediones. To specifically investigate the role of the Cd36 fatty acid transporter gene in the insulin-sensitizing actions of thiazolidinediones, we studied the metabolic effects of pioglitazone in spontaneously hypertensive rats (SHR) that harbor a deletion mutation in Cd36 in comparison to congenic and transgenic strains of SHR that express wild-type Cd36. In congenic and transgenic SHR with wild-type Cd36, administration of pioglitazone was associated with significantly lower circulating levels of fatty acids, triglycerides, and insulin as well as lower hepatic triglyceride levels and epididymal fat pad weights than in SHR harboring mutant Cd36. Additionally, insulin-stimulated glucose oxidation in isolated soleus muscle was significantly augmented in pioglitazone-fed rats with wild-type Cd36 versus those with mutant Cd36. The Cd36 genotype had no effect on pioglitazone-induced changes in blood pressure. These findings provide direct pharmacogenetic evidence that in the SHR model, Cd36 is a key determinant of the insulin-sensitizing actions of a thiazolidinedione ligand of peroxisome proliferator-activated receptor gamma.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Inst Clin & Expt Med, Prague 14220, Czech Republic; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Ctr Integrated Genom, Prague 14220, Czech Republic; Acad Sci Czech Republ, Inst Mol Physiol & Genet, Prague 14220, Czech Republic; Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague, Czech Republic; Univ Calif Irvine, Dept Family Med, Bakersfield, CA 93305 USA; Kern Med Ctr, Bakersfield, CA 93305 USA; Dept Vet Affairs Med Ctr, San Francisco, CA 94143 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	University of California System; University of California San Francisco; Institute for Clinical & Experimental Medicine (IKEM); Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Charles University Prague; University of California System; University of California Irvine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kurtz, TW (corresponding author), Univ Calif San Francisco, Med Ctr, Long Hosp, Rm 518,505 Parnassus Ave,Box 0134, San Francisco, CA 94143 USA.	KurtzT@Labmed2.ucsf.edu	Zidek, Vaclav/C-6685-2012; Landa, Vladimir/B-8908-2012; Pravenec, Michal/B-1666-2012	Pravenec, Michal/0000-0001-9197-5871	FIC NIH HHS [R03 TW01236] Funding Source: Medline; NHLBI NIH HHS [R01 HL56028, P01 HL35018, R01 HL63709] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063709, R01HL056028, P01HL035018] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Boden G, 1999, P ASSOC AM PHYSICIAN, V111, P241, DOI 10.1046/j.1525-1381.1999.99220.x; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Hajri T, 2001, J BIOL CHEM, V276, P23661, DOI 10.1074/jbc.M100942200; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Hevener AL, 2001, DIABETES, V50, P2316, DOI 10.2337/diabetes.50.10.2316; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Martin G, 1998, ATHEROSCLEROSIS, V137, pS75, DOI 10.1016/S0021-9150(97)00315-8; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Oakes ND, 2001, DIABETES, V50, P1158, DOI 10.2337/diabetes.50.5.1158; Petersen HC, 2001, Z GESCHICHTSWISS, V49, P827; Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VRANA A, 1978, METABOLISM, V27, P885, DOI 10.1016/0026-0495(78)90131-2; VRANA A, 1988, NUTR REP INT, V38, P687; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Ye JM, 2001, DIABETES, V50, P411, DOI 10.2337/diabetes.50.2.411	29	46	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48501	48507		10.1074/jbc.M206655200	http://dx.doi.org/10.1074/jbc.M206655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12384507	hybrid			2022-12-25	WOS:000179789600071
J	Wu, MH; Yung, BYM				Wu, MH; Yung, BYM			UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR IRF-1; ACTIVATED PROTEIN-KINASE; LEUKEMIA HL-60 CELLS; SERUM GROWTH-FACTORS; INDUCED APOPTOSIS; DOWN-REGULATION; NPM GENE; C-FOS; REPAIR	Nucleophosmin/B23 (NPM/B23), a nucleolar protein, was rapidly up-regulated after UV irradiation (at 254 nm; 30 J/m(2)) in NIH 3T3 cells and HeLa/S3 cells. Levels of NPM/B23 mRNA peaked 45-60 min after UV treatment and returned to baseline by 12 h. Transcription inhibitor actinomycin D (5 mug/ml) prevented the UV-induced increase of NPM/B23 mRNA, suggesting that UV induction of NPM/B23 was mediated at the transcriptional level. Moreover, UV-induced NPM/B23 expression was super-induced by cycloheximide (20 mug/ml), which was characteristic of immediate-early gene response. The transcriptional activation of NPM/B23 by UV was also confirmed by NPM/B23 promoter activity assay. Thymine dinucleotide, mimicking the effects of UV-induced DNA damage, was able to trigger NPM/B23 expression in the absence of genomic DNA damage. UV-induced activation of NPM/B23 promoter could not be blocked by UV-inducible pathway inhibitors, such as those of growth factor tyrosine kinase, mitogen-activated protein kinase, AP-1, NF-kappaB, and DNA-dependent kinase. Our results indicate that UV stimulation of NPAVB23 expression may be mediated through a novel UV-inducible pathway and is an immediate-early gene response induced by damaged DNA. Induction of immediate-early gene is an initial step in the regulation of cellular and genomic responses to external stimuli. Our results thus provide important evidence for an involvement of NPM/B23 in the acute response of mammalian cells to environmental stress.	Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan; Natl Yang Ming Univ, Grad Inst Pharmacol, Taipei 112, Taiwan	Chang Gung University; National Yang Ming Chiao Tung University	Yung, BYM (corresponding author), Chang Gung Univ, Coll Med, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chou CC, 2001, MOL PHARMACOL, V59, P38, DOI 10.1124/mol.59.1.38; DEAN M, 1986, J BIOL CHEM, V261, P9161; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hirano J, 2000, CANCER LETT, V153, P183, DOI 10.1016/S0304-3835(00)00370-0; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; KELLY K, 1988, J BIOL CHEM, V263, P4828; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; Ljungman M, 1996, ONCOGENE, V13, P823; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; RAMSAMOOJ P, 1995, RADIAT RES, V143, P158, DOI 10.2307/3579152; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Wang SC, 2001, CANCER RES, V61, P2838; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wu MH, 2002, INT J CANCER, V97, P297, DOI 10.1002/ijc.1606; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; YUNG BYM, 1985, BIOCHEM PHARMACOL, V34, P4059, DOI 10.1016/0006-2952(85)90387-9; Zhao HC, 2000, CANCER RES, V60, P6276	51	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48234	48240		10.1074/jbc.M206550200	http://dx.doi.org/10.1074/jbc.M206550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374805	hybrid			2022-12-25	WOS:000179789600036
J	Yakubenko, VP; Lishko, VK; Lam, SCT; Ugarova, TP				Yakubenko, VP; Lishko, VK; Lam, SCT; Ugarova, TP			A molecular basis for integrin alpha(M)beta(2) ligand binding promiscuity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; FUNCTION-ASSOCIATED ANTIGEN-1; NEUTROPHIL INHIBITORY FACTOR; I-DOMAIN; MAC-1 CD11B/CD18; LEUKOCYTE INTEGRINS; CRYSTAL-STRUCTURE; BETA-2 INTEGRIN; A-DOMAIN; COMPLEMENT RECEPTOR	The leukocyte integrin alpha(M)beta(2) is a highly promiscuous leukocyte receptor capable of binding a multitude of unrelated ligands. To understand the molecular basis for the broad ligand recognition of alpha(M)beta(2) the inter-integrin chimera was created. In the chimeric integrin, the betaD-alpha5 loop-alpha5 helix segment comprised of residues Lys(245)-Arg(261). from the alpha(M)I domain of alpha(M)beta(2) was inserted into the framework of alpha(L)beta(2). The construct was expressed in HEK 293 cells, and the ability of generated cells to adhere to fibrinogen and its derivatives was characterized first. Grafting the alpha(M)(Lys(245)-Arg(261)) sequence converted alpha(L)beta(2) into a fibrinogen-binding protein capable of mediating efficient and specific adhesion similar to that of wild-type alpha(M)beta(2). Verifying a switch in the binding specificity of alpha(L)beta(2), the chimeric receptor became competent to support cell migration to fibrinogen. Mutations at positions Phe(246), Asp(254), and Pro(257) within Lys(245)-Arg(261) of alpha(M)beta(2) produced significant decreases in cell adhesion, illustrating, the critical role of these residues in ligand binding. The insertion of alpha(M)(Lys(245)-Arg(261)) imparted to the chimeric integrin the ability to recognize many typical alpha(M)beta(2) protein ligands. Furthermore, cells expressing the chimeric receptor, but not alpha(L)beta(2), were able to stick to uncoated plastic, which represents the hallmark of wild-type alpha(M)beta(2). These results suggest that am(Lys(245)-Arg(261)) serves as a consensus binding site for interaction with a variety of distinct molecules and, thus, may define the degenerate recognition properties inherent to alpha(M)beta(2).	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ugarova, TP (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Lerner Res Inst, Mail Code NB 50, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL 63199, HL 41793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793, R01HL063199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DiScipio RG, 1998, J IMMUNOL, V160, P4057; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Forsyth CB, 1996, CELL IMMUNOL, V170, P91, DOI 10.1006/cimm.1996.0138; Forsyth CB, 2001, J EXP MED, V193, P1123, DOI 10.1084/jem.193.10.1123; Frieser M, 1996, EUR J IMMUNOL, V26, P3127, DOI 10.1002/eji.1830261245; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Johansson MW, 1997, J CELL SCI, V110, P1133; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; KISHIMOTO TK, 1999, INFLAMMATION BASIC P; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, MOL BIOL CELL, V11, P677, DOI 10.1091/mbc.11.2.677; Lishko VK, 2001, BLOOD, V98, P2448, DOI 10.1182/blood.V98.8.2448; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MILLER JL, 1982, BLOOD, V60, P790; MONBOISSE JC, 1991, J LEUKOCYTE BIOL, V50, P373, DOI 10.1002/jlb.50.4.373; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; THOMPSON HL, 1992, CLIN EXP IMMUNOL, V90, P280; Thornton BP, 1996, J IMMUNOL, V156, P1235; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Ustinov VA, 2002, J BIOL CHEM, V277, P18769, DOI 10.1074/jbc.M110242200; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; XIE JL, 1995, J IMMUNOL, V155, P3619; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yalamanchili P, 2000, J BIOL CHEM, V275, P21877, DOI 10.1074/jbc.M908868199; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	64	96	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48635	48642		10.1074/jbc.M208877200	http://dx.doi.org/10.1074/jbc.M208877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377763	hybrid			2022-12-25	WOS:000179789600087
J	Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH				Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH			Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth	ONCOGENE			English	Article						AP-1; breast cancer; estrogen; peptide growth factor	DOMINANT-NEGATIVE MUTANT; C-JUN; ESTROGEN-RECEPTOR; RESISTANT PHENOTYPE; RETINOIC ACID; DNA-BINDING; CELL-GROWTH; FOS; ACTIVATION; TRANSFORMATION	AP-1 transcription factors play a critical role in signal transduction pathways in many cells. We have investigated the role of AP-1 in controlling proliferative signals in breast cells, and have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells. In this study, we investigated the role of AP-1 in transducing proliferative signals induced by peptide and steroid growth factors. We used MCF-7 clones that express a specific inhibitor of AP-1, a dominant-negative cJun mutant (TAM67), under the control of an inducible promoter to investigate the role of AP-1 in regulating breast cancer growth. In the presence of doxycycline (Dox), the AP-1 inhibitor was not expressed, and the MCF-7 clones proliferated normally in response to serum stimulation. However, when Dox was withdrawn, TAM67 was expressed, AP-1 activity was inhibited, and serum-induced proliferation was blocked. We next investigated whether the mitogenic response to specific growth factors also requires AP-1. MCF-7 Tet-Off-TAM67 cells were grown in the presence of increasing concentrations of IGF-1, EGF, heregulin-beta, bFGF, or estrogen under un-induced and induced conditions. These studies showed that the AP-1 inhibitor completely blocked proliferation in response to the peptide growth factors (IGF-1, EGF, heregulin-beta, and bFGF), and partially blocked the response to estrogen. To investigate the effect of AP-1 blockade on in vivo tumor growth, we injected the MCF-7 Tet-Off TAM67 cells into nude mice receiving doxycycline to suppress the expression of the AP-1 inhibitor. After the mice developed tumors, they were randomized to either continue to receive Dox or not. In mice not receiving Dox, the expression of TAM67 was induced, and tumor growth was inhibited, while the tumors in mice receiving Dox continued to grow. Analysis of the tumors from these mice showed that the expression of TAM67 caused reduced proliferation of the breast cancer cells without inducing apoptosis. These results demonstrate that AP-1 blockade supresses mitogenic signals from multiple different peptide growth factors as well as estrogen, and inhibits the growth of MCF-7 breast cancer cells both in vitro and in vivo. These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer.	Baylor Coll Med, Dept Med, Breast Ctr, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Dept Med, Breast Ctr, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NATIONAL CANCER INSTITUTE [P50CA058183] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DREBIN JA, 1988, ONCOGENE, V2, P387; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Liebermann DA, 1998, INT J ONCOL, V12, P685; Lin F, 2000, CANCER RES, V60, P3271; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; RAPP UR, 1994, ONCOGENE, V9, P3493; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yang LM, 1997, CANCER RES, V57, P4652	34	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7680	7689		10.1038/sj.onc.1205883	http://dx.doi.org/10.1038/sj.onc.1205883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400010				2022-12-25	WOS:000178756200007
J	Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM				Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM			ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth	ONCOGENE			English	Article						ATF3; p53; DNA damage; gene regulation	TRANSCRIPTION FACTOR; MOLECULAR-BIOLOGY; C-FOS; P53; GADD45; GENE; CYCLE; ACTIVATION; INHIBITOR; STRESS	Mammalian cells have a remarkable diverse repertoire of response to genotoxic stress that damage DNA. Cellular responses to DNA damaging agents will initially exhibit gene induction, which is regulated by complex mechanism(s) and probably involves multiple signaling pathways. In this paper, we demonstrate that induction of ATF3 protein, a member of the ATF/CREB family of transcription factors, by ionizing radiation (IR) requires normal cellular p53 function. In contrast, induction of ATF3 after UV radiation (UV) or Methyl methanesulphonate (MMS) is independent of p53 status. Induction of ATF3 by DNA damage is rapid, transient, and through a transcriptional mechanism. The ATF3 promoter is induced by UV and MMS, but not by IR. In addition, ATF3 promoter can be activated by MEKK1, an upstream activator of the ERK and JNK kinase pathway, but not induced following p53 expression. Those results indicate that regulation of ATF3 induction after DNA damage utilizes both the p53-dependent and independent pathways, and may also involve MAP kinase signaling pathways. Using the tetracycline-inducible system (tet-off), we have found that overexpression of ATF3 protein moderately suppresses cell growth. Interestingly, over-expression of ATF3 protein is able to slow down progression of cells from G1 to S phase, indicating that ATF3 protein might play a negative role in the control of cell cycle progression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; NCI, Lab Basic Sci, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.	qzhan+@pitt.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; mazzacurati, lucia/0000-0002-8336-8032				Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Holbrook N J, 1996, EXS, V77, P273; HOLLANDER MC, 1989, CANCER RES, V49, P1687; Ishiguro T, 2000, ONCOL RES, V12, P343, DOI 10.3727/096504001108747792; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kumari SR, 2000, CANCER INVEST, V18, P715, DOI 10.3109/07357900009012203; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; MIYASHITA T, 1995, CELL, V80, P293; Rajanbabu R, 1999, CRIT REV ONCOGENESIS, V10, P275; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Schmutte C, 1999, ANTICANCER RES, V19, P4665; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	50	151	159	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7488	7496		10.1038/sj.onc.1205896	http://dx.doi.org/10.1038/sj.onc.1205896			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386811				2022-12-25	WOS:000178618200004
J	Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N				Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N			P130 and its truncated form mediate p53-induced cell cycle arrest in Rb-/- Saos2 cells	ONCOGENE			English	Article						p53; cell cycle arrest; p130; p53 binding sequence; E2F	RETINOBLASTOMA GENE-PRODUCT; GROWTH SUPPRESSION; KINASE INHIBITOR; CARCINOMA CELLS; E2F PROTEINS; TUMOR-CELLS; G(1) ARREST; DNA-DAMAGE; P53 GENES; IN-VIVO	In the present study, we investigate the mechanism of how p53 induces growth arrest in Rb-defective Saos2 cells that express temperature-sensitive mutant p53 (ts p53). The activation of p53 at a permissive temperature (32.5degreesC) induces the cell cycle arrest at both the G1 and G2 stages. The induction of several p53-responsive genes as well as a small form of p130 (S-p130) was detected upon p53 activation. S-p130 retained the functions as a pocket protein and was dominant over p130 at the protein level after 36 h at 32.5degreesC. A canonical p53 binding site was identified in intron 4 of p130. Furthermore, a novel p53-inducible transcript containing a partial intron 4 sequence downstream of the p53 binding site and exon 5 of p 130 was detected by RT - PCR, suggesting S-p 130 is induced by p53 at transcriptional level. The results from gel shift assay and immunoprecipitation showed that S-p130 as well as p130 formed complexes with both E2F1 and E2F4 at a permissive temperature. Moreover, the transient expression of E1A (12S) and E2F1 effectively abrogated p53-induced cell cycle arrest. These results strongly suggested that p130 and its truncated form might substitute Rb in mediating p53-induced cell cycle arrest in Rb-/- Saos2 cells.	Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Craniofacial Embryol, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Tsuchida, N (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chan TA, 2000, GENE DEV, V14, P1584; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 1996, CANCER RES, V56, P2003; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1997, MOL CELL BIOL, V17, P38677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HERMEKING H, 1909, MOL CELL, V1, P3; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KATO J, 1993, GENE DEV, V7, P333; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Robles SJ, 1998, DNA CELL BIOL, V17, P9, DOI 10.1089/dna.1998.17.9; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stiegler P, 1998, CANCER RES, V58, P5049; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG NP, 1993, ONCOGENE, V8, P279; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yageta M, 1999, ONCOGENE, V18, P4767, DOI 10.1038/sj.onc.1203063; YAMATO K, 1995, ONCOGENE, V11, P1; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z	70	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7569	7579		10.1038/sj.onc.1205933	http://dx.doi.org/10.1038/sj.onc.1205933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386819				2022-12-25	WOS:000178618200012
J	Guo, Y; Stacey, DW; Hitomi, M				Guo, Y; Stacey, DW; Hitomi, M			Post-transcriptional regulation of cyclin D1 expression during G2 phase	ONCOGENE			English	Article						cell cycle; Ras; cyclin D1; in situ hybridization; single cell-based analysis; post-transcriptional regulation	INITIATION-FACTOR 4E; HISTONE MESSENGER-RNA; IN-SITU HYBRIDIZATION; CELL-CYCLE; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; NIH3T3 CELLS; RAS; PROGRESSION	During continuous proliferation, cyclin D1 protein is induced to high levels in a Ras-dependent manner as cells progress from S phase to G2 phase. To understand the mechanism of the Ras-dependent cyclin D1 induction, cyclin D1 mRNA levels were determined by quantitative image analysis following fluorescent in situ hybridization. Although a slight increase in mRNA expression levels was detected during the S/G2 transition, this increase could not explain the more robust induction of cyclin D1 protein levels. This suggested the involvement of post-transcriptional regulation as a mechanism of cyclin D1 protein induction. To directly test this hypothesis, the cyclin D1 transcription rate was determined by run-on assays. The transcription rate of cyclin D1 stayed steady during the synchronous transition from S the G2 phase. We further demonstrated that cyclin D1 protein levels could increase during G2 phase in the absence of new mRNA synthesis. alpha-Amanitin, a transcription inhibitor, did not suppress cyclin D1 protein elevation as the cells progressed from S to G2 phase, even though the inhibitor was able to completely block cyclin D1 protein induction during reentry into the cell cycle from quiescence. The half life of cyclin D1 protein was shortest during S phase indicating that a change in protein stability might play a role in post-translational induction of cyclin D1 in G2 phase. These data indicate a fundamental difference in the regulation of cyclin D1 production during continuous cell cycle progression and re-initiation of the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM 52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH S, 1993, J CELL SCI, V105, P113; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dirks RW, 1996, HISTOCHEM CELL BIOL, V106, P151; DIRKS RW, 1995, HISTOCHEM CELL BIOL, V104, P391, DOI 10.1007/BF01458133; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kotelnikov V, 1997, CLIN CANCER RES, V3, P669; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palakurthi SS, 2000, CANCER RES, V60, P2919; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Raap A K, 1997, Methods Mol Biol, V75, P367; Ramljak D, 2000, CARCINOGENESIS, V21, P1537, DOI 10.1093/carcin/21.8.1537; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Shu JY, 1996, ONCOGENE, V13, P2421; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Srivastava R A, 1994, Methods Mol Biol, V31, P281; Stacey DW, 2000, MOL CELL BIOL, V20, P9127, DOI 10.1128/MCB.20.24.9127-9137.2000; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	57	51	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7545	7556		10.1038/sj.onc.1205907	http://dx.doi.org/10.1038/sj.onc.1205907			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386817				2022-12-25	WOS:000178618200010
J	Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ				Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ			Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells	ONCOGENE			English	Article						autocrine TGF beta; carcinoma cell; growth; apoptosis	RECEPTOR SUPPRESSES TUMORIGENICITY; COLON-CARCINOMA-CELLS; II GENE MUTATION; TUMOR-SUPPRESSOR; MICROSATELLITE INSTABILITY; C-MYC; EXPRESSION CLONING; EPITHELIAL-CELLS; MCF-7 CELLS; APOPTOSIS	Using a cell model system established by ectopic expression of a soluble TGFbeta type III receptor (sRIII) containing the whole extracellular domain of the type III receptor in human breast cancer MDA-MB-231 cells, we observed that the expression of sRIII antagonized TGFbeta activity and inhibited both anchorage-dependent and anchorage-independent cell growth. Further studies revealed that sRIII expression induced apoptosis both in vitro and in vivo. Treatment with TGFbeta neutralizing antibodies or a recombinant human sRIII also induced apoptosis in the MDA-MB-231 parental cells, suggesting that the increased apoptosis after sRIII expression was specifically due to antagonization of autocrine TGFbeta signaling. Western blotting showed that sRIII clones had a higher PTEN expression level than the control cells did. Treatment with TGFbeta(1) decreased PTEN and inhibited apoptosis in sRIII cells to a level similar to that in the control cells. sRIII clones also showed a lower level of phosphorylated-Akt than the control cells, consistent with the inhibitory activity of PTEN on Akt activation. Treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, also induced apoptosis in a dose dependent manner in the control cells. Our results suggest that autocrine TGFbeta signaling is necessary for the growth and survival of MDA-MB-231 cells.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.		, LuZhe/AAW-4095-2021		NCI NIH HHS [CA75253, CA79683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075253, R01CA079683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GORSCH SM, 1992, CANCER RES, V52, P6949; Grady WM, 1998, CANCER RES, V58, P3101; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1998, CANCER RES, V58, P5667; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki K, 2000, CANCER RES, V60, P1394; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1991, TRANSFORMING GROWTH, P419; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schutte M, 1996, CANCER RES, V56, P2527; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tomita S, 1999, BREAST CANCER RES TR, V53, P33, DOI 10.1023/A:1006167210269; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WALKER RA, 1995, J PATHOL, V177, P123, DOI 10.1002/path.1711770204; Wang D, 2000, CANCER RES, V60, P4507; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wilentz RE, 2000, CANCER RES, V60, P2002; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; ZAR JH, 1984, BIOSTAT ANAL, P122; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	66	63	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7514	7523		10.1038/sj.onc.1205966	http://dx.doi.org/10.1038/sj.onc.1205966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386814				2022-12-25	WOS:000178618200007
J	Kumanovics, A; Levin, G; Blount, P				Kumanovics, A; Levin, G; Blount, P			Family ties of gated pores: evolution of the sensor module	FASEB JOURNAL			English	Article						MscL; TPTE; transient receptor potential; tyrosine phosphatases; voltage-gated channel	COMPLETE GENOME SEQUENCE; VOLTAGE SENSOR; GENE; CHANNEL; PROTEIN; IDENTIFICATION; DATABASE; MSCL; ACTIVATION; HOMOLOGY	The six-transmembrane channels are thought to be composed of two modules: pore and sensor. Whereas the modular design of the pore has been established, the modularity of the sensor remains hypothetical. As a first step toward establishing the modularity of this region, we searched for genes where the sensor is found independent of the pore and have identified new members of the sensor superfamily. Analysis of these sensors reveals a motif shared among not only these newly discovered members and voltage-gated, transient receptor potential, and polycystin channel sensors, but also MscL, a bacterial mechanosensitive channel. Mutational analyses presented here and in previous studies demonstrate that highly conserved residues within this motif are required for normal channel activity; mutations of residues within this motif in different subfamilies lead to consistent channel phenotypes. Previous studies have demonstrated that peptides containing this motif and the adjacent conserved transmembrane domain elicit channel activities when reconstituted into lipid membranes. These data provide evidence for the modularity of the sensor, imply a model for its evolution, suggest a common origin for mechano- and voltage-sensing, and may offer a glimpse of the properties of the first sensor/channel.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Harry Hines Blvd, Dallas, TX 75390 USA.	Paul.Blount@UTSouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60818] Funding Source: Medline; NIGMS NIH HHS [R01 GM061028, GM61028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], [No title captured]; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chen HM, 1999, HUM GENET, V105, P399, DOI 10.1007/s004390051122; Enklaar T, 2000, GENOMICS, V67, P179, DOI 10.1006/geno.2000.6234; Gil Z, 1999, P NATL ACAD SCI USA, V96, P14594, DOI 10.1073/pnas.96.25.14594; GROSS GJ, 1993, BIOPHYS J, V64, pA313; GROVE A, 1993, PROTEIN SCI, V2, P1918, DOI 10.1002/pro.5560021113; Gu CX, 2001, BIOPHYS J, V80, P2678, DOI 10.1016/S0006-3495(01)76237-6; Guipponi H, 2000, HUM GENET, V107, P127, DOI 10.1007/s004390000343; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Jones SE, 2000, BIOCHEM BIOPH RES CO, V279, P208, DOI 10.1006/bbrc.2000.3921; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; MCKEMY DD, 2002, NATURE, V416, P53; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; Moe PC, 2000, J BIOL CHEM, V275, P31121, DOI 10.1074/jbc.M002971200; Oghalai JS, 2000, SCIENCE, V287, P658, DOI 10.1126/science.287.5453.658; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; PETROV AG, 1994, EUR BIOPHYS J BIOPHY, V23, P1, DOI 10.1007/BF00192201; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; SALKOFF L, 1995, NEURON, V15, P489, DOI 10.1016/0896-6273(95)90137-X; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Snel B, 2000, TRENDS GENET, V16, P9, DOI 10.1016/S0168-9525(99)01924-1; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277	45	56	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1623	1629		10.1096/fj.02-0238hyp	http://dx.doi.org/10.1096/fj.02-0238hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374785				2022-12-25	WOS:000179167600044
J	Obreja, O; Rathee, PK; Lips, KS; Distler, C; Kress, M				Obreja, O; Rathee, PK; Lips, KS; Distler, C; Kress, M			IL-10 potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C	FASEB JOURNAL			English	Article						hyperalgesia; inflammation; cytokines; nociceptor	TUMOR-NECROSIS-FACTOR; GENE-RELATED PEPTIDE; INTERLEUKIN-1 RECEPTOR; RELEASE; SENSITIZATION; EXPRESSION; IRAK; HYPERALGESIA; BRADYKININ; INDUCTION	Interleukin 1beta (IL-1beta) is a proinflammatory cytokine that maintains thermal hyperalgesia and facilitates the release of calcitonin gene-related peptide from rat cutaneous nociceptors in vivo and in vitro. Brief applications of IL-1beta to nociceptive neurons yielded a potentiation of heat-activated inward currents (meat) and a shift of activation threshold toward lower temperature without altering intracellular calcium levels. The IL-1 beta-induced heat sensitization was not dependent on G-protein-coupled receptors but was mediated by activation of protein kinases. The nonspecific protein kinase inhibitor staurosporine, the specific protein kinase C inhibitor bisindolyhnaleimide BIM1, and the protein tyrosine kinase inhibitor genistein reduced the sensitizing effect of IL-1beta whereas negative controls were ineffective. RT-PCR and in situ hybridization revealed IL-1RI but not RII expression in neurons rather than surrounding satellite cells in rat dorsal root ganglia. IL-1beta acts on sensory neurons to increase their susceptibility for noxious heat via an IL-1RI/PTK/ PKC-dependent mechanism.	Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, D-91054 Erlangen, Germany; Univ Giessen, Inst Anat & Zellbiol, Giessen, Germany	University of Erlangen Nuremberg; Justus Liebig University Giessen	Kress, M (corresponding author), Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, Univ Str 17, D-91054 Erlangen, Germany.	kress@physiologiel.uni-erlangen.de		Kress, Michaela/0000-0002-8921-7470; Obreja, Otilia/0000-0002-0230-7538				Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barber LA, 1996, J NEUROCHEM, V67, P72; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Copray JCVM, 2001, J NEUROIMMUNOL, V118, P203, DOI 10.1016/S0165-5728(01)00324-1; Cunha JM, 2000, BRIT J PHARMACOL, V130, P1418, DOI 10.1038/sj.bjp.0703434; CUNNINGHAM ET, 1993, IMMUNOL TODAY, V14, P171; Dittert I, 1998, J NEUROSCI METH, V82, P195, DOI 10.1016/S0165-0270(98)00051-X; EASTGATE JA, 1988, LANCET, V2, P706; EIZIRIK DL, 1995, MOL CELL ENDOCRINOL, V111, P159, DOI 10.1016/0303-7207(95)03561-K; FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; Fu LW, 1999, J PHYSIOL-LONDON, V521, P249, DOI 10.1111/j.1469-7793.1999.00249.x; FUKUOKA H, 1994, BRAIN RES, V657, P133, DOI 10.1016/0006-8993(94)90960-1; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Inoue A, 1999, J NEUROCHEM, V73, P2206; KHASAR SG, 1993, NEUROSCI LETT, V153, P215, DOI 10.1016/0304-3940(93)90325-F; KOLTZENBURG M, 1992, NEUROSCIENCE, V46, P465, DOI 10.1016/0306-4522(92)90066-B; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; KUMAZAWA T, 1987, PAIN, V28, P255, DOI 10.1016/0304-3959(87)90120-5; KUMAZAWA T, 1991, J NEUROPHYSIOL, V66, P1819, DOI 10.1152/jn.1991.66.6.1819; NAKAMURA H, 1988, EUR J PHARMACOL, V149, P49, DOI 10.1016/0014-2999(88)90040-4; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; PERKINS MN, 1994, NEUROPHARMACOLOGY, V33, P657, DOI 10.1016/0028-3908(94)90171-6; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; RZYMKIEWICZ DM, 1995, KIDNEY INT, V47, P1354, DOI 10.1038/ki.1995.191; Saade NE, 1998, J NEUROIMMUNOL, V91, P171, DOI 10.1016/S0165-5728(98)00176-3; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sauer SK, 2001, EUR J NEUROSCI, V14, P1203, DOI 10.1046/j.0953-816x.2001.01741.x; Sauer SK, 1999, NEUROSCIENCE, V92, P319, DOI 10.1016/S0306-4522(98)00731-3; Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4; Souter AJ, 2000, PAIN, V86, P63, DOI 10.1016/S0304-3959(99)00315-2; Sweitzer SM, 1999, BRAIN RES, V829, P209, DOI 10.1016/S0006-8993(99)01326-8; Takii T, 1999, EUR CYTOKINE NETW, V10, P237; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Watkins LR, 1999, CYTOKINES PAIN; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Zeilhofer HU, 1996, J NEUROPHYSIOL, V76, P2834, DOI 10.1152/jn.1996.76.5.2834	45	183	191	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1497	1503		10.1096/fj.02-0101com	http://dx.doi.org/10.1096/fj.02-0101com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374772				2022-12-25	WOS:000179167600031
J	Di, YP; Harper, R; Zhao, YH; Pahlavan, N; Finkbeiner, W; Wu, R				Di, YP; Harper, R; Zhao, YH; Pahlavan, N; Finkbeiner, W; Wu, R			Molecular cloning and characterization of spurt, a human novel gene that is retinoic acid-inducible and encodes a secretory protein specific in upper respiratory tracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEOBRONCHIAL EPITHELIAL-CELLS; CASEIN KINASE-II; MESSENGER-RNA; VITAMIN-A; MUCIN GENES; PLUNC GENE; IN-VITRO; EXPRESSION; IDENTIFICATION; BPI	Retinoids, such as all-trans-retinoic acid, play an essential role in the regulation of airway epithelial cell growth, differentiation, and gene expression. Using cDNA microarray, we identified a clone, DD4, that contains the cDNA of a novel gene, spurt (secretory protein in upper respiratory tracts) that was significantly induced by all-trans-retinoic acid in primary cultured human tracheobroncheal epithelia. Two alternatively spliced spurt transcripts of 1090 and 1035 base pairs exist that contain the same open reading frame expressing a 256-amino acid peptide. The full-length spurt cDNA sequence spans a genomic DNA fragment of 7,313 bp, and the gene is located on chromosome 20q11.21. spurt mRNA is notably expressed at high levels in human nasal, tracheal, and lung tissues. In situ hybridization demonstrated that spurt message is often present in secretory cell types. The human spurt gene product is a secretory protein that contains a distinct signal peptide sequence in its first 19 amino acids. Mono-specific antibodies were generated to characterize spurt expression. Our data demonstrate that spurt is secreted onto the apical side of primary human airway epithelial cultures and is present in clinical sputum samples. spurt gene expression is higher in sputum and tissue samples obtained from patients with chronic obstructive lung disease. Our results provide the cloning and characterization of this tissue-specific novel gene and its possible relationship with airway diseases.	Univ Calif Davis, Med Ctr, Ctr Comparat Resp Biol & Med, Div Pulm & Crit Care Med,Sch Med, Davis, CA 95616 USA; Univ Calif Davis, Med Ctr, Dept Pathol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Di, YP (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.		Di, Yuanpu Peter/H-4191-2016; Harper, Richart W/F-9359-2013	Di, Yuanpu Peter/0000-0003-2028-2087; Harper, Richart W/0000-0001-8097-6465	NHLBI NIH HHS [5F32HL09573, HL35635, HL04404, F32 HL009573] Funding Source: Medline; NIEHS NIH HHS [ES06230, ES09701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009573, R37HL035635, R01HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009701, R01ES006230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aust MR, 1997, AM J RHINOL, V11, P293, DOI 10.2500/105065897781446685; BASBAUM CB, 1984, CIBA F SYMP, V109, P4, DOI 10.1002/9780470720905.ch2; BASBAUM CB, 1990, ANNU REV PHYSIOL, V52, P97; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Calafat J, 1998, BLOOD, V91, P4770, DOI 10.1182/blood.V91.12.4770.412k33_4770_4775; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chytil F, 1996, FASEB J, V10, P986, DOI 10.1096/fasebj.10.9.8801181; Cui HM, 1996, TRENDS GENET, V12, P506, DOI 10.1016/S0168-9525(96)90048-7; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; ELSBACH P, 1995, INFECT AGENT DIS, V4, P102; EMURA M, 1988, IN VITRO CELL DEV B, V24, P639; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Finkbeiner WE, 1999, RESP PHYSIOL, V118, P77, DOI 10.1016/S0034-5687(99)00080-8; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; HUANG TH, 1989, DIFFERENTIATION, V41, P78, DOI 10.1111/j.1432-0436.1989.tb00735.x; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Jeffery PK, 1997, EUR RESPIR J, V10, P1655, DOI 10.1183/09031936.97.10071655; Kim KC, 1997, EUR RESPIR J, V10, P2644, DOI 10.1183/09031936.97.10112644; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; KOMMINOTH P, 1995, LAB INVEST, V72, P424; Komminoth P, 1992, Diagn Mol Pathol, V1, P142, DOI 10.1097/00019606-199206000-00008; Koo JS, 1999, AM J RESP CELL MOL, V20, P43, DOI 10.1165/ajrcmb.20.1.3310; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClair EE, 2001, BIOCHEM BIOPH RES CO, V284, P792, DOI 10.1006/bbrc.2001.5024; MADSEN HO, 1985, NUCLEIC ACIDS RES, V13, P1, DOI 10.1093/nar/13.1.1; MIRELS L, 1992, J BIOL CHEM, V267, P2679; MORO I, 1984, J ORAL PATHOL MED, V13, P97, DOI 10.1111/j.1600-0714.1984.tb01405.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; REES DD, 1995, AM J PHYSIOL-LUNG C, V269, pL195, DOI 10.1152/ajplung.1995.269.2.L195; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592, DOI 10.1165/ajrcmb.17.5.2798; Rogers D F, 2000, Monaldi Arch Chest Dis, V55, P324; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seregni E, 1997, TUMORI J, V83, P625, DOI 10.1177/030089169708300301; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; SMITH TF, 1983, NUCLEIC ACIDS RES, V11, P2205, DOI 10.1093/nar/11.7.2205; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10301, DOI 10.1021/bi970176m; Wu R, 1999, AM J RESP CRIT CARE, V159, pA507; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; Yoon Joo-Heon, 1998, Rhinology (Utrecht), V36, P146	58	76	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1165	1173		10.1074/jbc.M210523200	http://dx.doi.org/10.1074/jbc.M210523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409287	hybrid			2022-12-25	WOS:000180321900062
J	Endo, M; Shirouzu, M; Yokoyama, S				Endo, M; Shirouzu, M; Yokoyama, S			The Cdc42 binding and scaffolding activities of the fission yeast adaptor protein Scd2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; SH3 DOMAIN; EFFECTOR PROTEINS; PC MOTIF; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SCHIZOSACCHAROMYCES-POMBE; PAK ACTIVATION; POTENTIAL ROLE; CELL-ADHESION; NADPH OXIDASE	The small GTP-binding protein Cdc42, the guanine nucleotide exchange factor Scd1, the p21-activated kinase Shk1, and the adaptor protein Scd2 are involved in the Cdc42-dependent signaling cascade in fission yeast. In the present study, we analyzed the Cdc42 binding and scaffolding activities of Scd2 by co-precipitation assays. We found that two SH3-containing regions, amino acid residues 1-87 (CB1 (Cdc42-binding region 1)) and 110266 (CB2), of Scd2 can bind to the GTP-bound form of Cdc42. CB2 is cryptic because of the intramolecular binding between the SH3 domain in CB2 (SH3(C)) and the PX domain and binds to Cdc42 only when the Scd2 PB1 domain binds to the PC motif-containing region (residues 760-872) of Scdl. This CB2.Cdc42 association, which would stabilize the open configuration of Scd2, enables the SH3(C) domain to bind to the polyproline motif of Shk1. We also found that the GTP-bound form of Cdc42 binds to the CRIB motif of Shk1 more strongly than to Scd2. Thus, Scd2 functions as a scaffold to form a protein complex, and the GTP-bound Cdc42 might be transferred effectively from the upstream activator Scdl to the downstream effector Shk1 via Scd2.	RIKEN, Genomic Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; RIKEN, Harima Inst Spring 8, Cellular Signaling Lab, Hyogo 6795143, Japan	RIKEN; University of Tokyo; RIKEN	Yokoyama, S (corresponding author), RIKEN, Genomic Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Endo, Makoto/0000-0002-2055-5471				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chang E, 1999, MOL CELL BIOL, V19, P8066; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gladfelter AS, 2001, MOL BIOL CELL, V12, P1239, DOI 10.1091/mbc.12.5.1239; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Isshiki T, 1994, Tanpakushitsu Kakusan Koso, V39, P429; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V262, P1, DOI 10.1006/bbrc.1999.1122; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Shirouzu M, 1998, J BIOL CHEM, V273, P7737, DOI 10.1074/jbc.273.13.7737; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tu H, 1999, MOL CELL BIOL, V19, P602; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	52	50	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					843	852		10.1074/jbc.M209714200	http://dx.doi.org/10.1074/jbc.M209714200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409291	hybrid			2022-12-25	WOS:000180321900022
J	Bernimoulin, MP; Zeng, XL; Abbal, C; Giraud, S; Martinez, M; Michielin, O; Schapira, M; Spertini, O				Bernimoulin, MP; Zeng, XL; Abbal, C; Giraud, S; Martinez, M; Michielin, O; Schapira, M; Spertini, O			Molecular basis of leukocyte rolling on PSGL-1 - Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; P-SELECTIN; IN-VIVO; ENDOTHELIAL-CELLS; AMINO-TERMINUS; SIDE-CHAINS; FUCT-VII; ADHESION; BINDING; PROTEINS	Interactions between the leukocyte adhesion receptor L-selectin and P-selectin glycoprotein ligand-1 play an important role in regulating the inflammatory response by mediating leukocyte tethering and rolling on adherent leukocytes. In this study, we have examined the effect of post-translational modifications of PSGL-1 including Tyr sulfation and presentation of sialylated and fucosylated O-glycans for L-selectin binding. The functional importance of these modifications was determined by analyzing soluble L-selectin binding and leukocyte rolling on CHO cells expressing various glycoforms of PSGL-1 or mutant PSGL-1 targeted at N-terminal Thr or Tyr residues. Simultaneous expression of core-2 beta1,6-N-acetylglucosaminyltransferase and fucosyltransferase VII was required for optimal L-selectin binding to PSGL-1. Substitution of Thr-57 by Ala but not of Thr-44, strongly decreased L-selectin binding and leukocyte rolling on PSGL-1. Substitution of Tyr by Phe revealed that PSGL-1 Tyr-51 plays a predominant role in mediating L-selectin binding and leukocyte rolling whereas Tyr-48 has a minor role, an observation that contrasts with the pattern seen for the interactions between PSGL-1 and P-selectin where Tyr-48 plays a key role. Molecular modeling analysis of L-selectin and P-selectin interactions with PSGL-1 further supported these observations. Additional experiments showed that core-2 O-glycans attached to Thr-57 were also of critical importance in regulating the velocity and stability of leukocyte rolling. These observations pinpoint the structural characteristics of PSGL-1 that are required for optimal interactions with L-selectin and may be responsible for the specific kinetic and mechanical bond properties of the L-selectin-PSGL-1 adhesion receptor-counterreceptor pair.	CHU Vaudois, Div Hematol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Cent Hematol Lab, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Inst Bioinformat, Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Ludwig Institute for Cancer Research; Swiss Institute of Bioinformatics	Spertini, O (corresponding author), Univ Lausanne, CHU Vaudois, Div Hematol, BH 18-544, CH-1011 Lausanne, Switzerland.	Olivier.Spertini@chuv.hospvd.ch	Michielin, Olivier/ABE-7924-2020	Giraud, Sylvain/0000-0002-3437-0849				Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jung U, 1996, AM J PHYSIOL-HEART C, V271, pH2740, DOI 10.1152/ajpheart.1996.271.6.H2740; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kunkel EJ, 1998, CIRC RES, V82, P30; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1993, BLOOD, V82, P1632; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Ma YQ, 2002, J IMMUNOL, V168, P1690, DOI 10.4049/jimmunol.168.4.1690; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Martin ACR, 1997, PROTEINS, P14; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCDONALD IK, 1995, PROTEIN ENG, V8, P217, DOI 10.1093/protein/8.3.217; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOULT J, 2001, PROTEIN-STRUCT FUNCT, V45, P2; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Norman KE, 2000, BLOOD, V96, P3585; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; Snapp KR, 2001, BLOOD, V97, P3806, DOI 10.1182/blood.V97.12.3806; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; SPERTINI O, 1991, J IMMUNOL, V147, P942; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TINGBEALL HP, 1993, BLOOD, V81, P2774; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xie X, 2000, J BIOL CHEM, V275, P34818, DOI 10.1074/jbc.M001257200; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	69	49	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					37	47		10.1074/jbc.M204360200	http://dx.doi.org/10.1074/jbc.M204360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403782	hybrid			2022-12-25	WOS:000180255700005
J	Elder, RH; Dianov, GL				Elder, RH; Dianov, GL			Repair of dihydrouracil supported by base excision repair in mNTH1 knock-out cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; TRANSCRIPTION-COUPLED REPAIR; COCKAYNE-SYNDROME; OXIDATIVE DAMAGE; MAMMALIAN-CELLS; THYMINE GLYCOL; DNA; HOMOLOG; 8-OXOGUANINE; LESIONS	In mammalian cells, thymine glycols and other oxidized pyrimidines such as 5,6-dihydrouracil are removed from DNA by the NTH1 protein, a bifunctional DNA-N-glycosylase. However, mNTH1 knock-out mice in common with other DNA glycosylase-deficient mice do not show any severe abnormalities associated with accumulation of DNA damage and mutations. In the present study we used an in vitro repair system to investigate the mechanism for the removal of 5,6-dihydrouracil from DNA by mNTH1-deficient cell-free extracts derived from testes of mNTH1 knock-out mice. We found that these extracts are able to support the removal of 5,6-dihydrouracil from DNA at about 20% of the efficiency of normal extracts. Furthermore, we also found that Single-nucleotide patch base excision repair is the major pathway for removal of 5,6-dihydrouracil in mNTH1-deficient cell extracts, suggesting the involvement of other DNA glycosylase(s) in the removal of oxidized pyrimidines.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Carcinogenesis Grp, Canc Res UK, Manchester M20 4BX, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Dianov, GL (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England.			Elder, Rhoderick/0000-0003-4614-175X				Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; ELDER RH, 2002, P AM ASS CANC RES, V43; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; FURLONG EA, 1986, BIOCHEMISTRY-US, V25, P4344, DOI 10.1021/bi00363a025; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465	25	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50487	50490		10.1074/jbc.M208153200	http://dx.doi.org/10.1074/jbc.M208153200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401779	hybrid			2022-12-25	WOS:000180177700039
J	Wojciechowski, CL; Kantrowitz, ER				Wojciechowski, CL; Kantrowitz, ER			Altering of the metal specificity of Escherichia coli alkaline phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; MAGNESIUM BINDING; BACILLUS-SUBTILIS; GENOME SEQUENCE; MECHANISM; CATALYSIS; GENE; MUTAGENESIS; MUTATIONS; CALCIUM	Analysis of sequence alignments of alkaline phosphatases revealed a correlation between metal specificity and certain amino acid side chains in the active site that are metal-binding ligands. The Zn2+-requiring Escherichia coli alkaline phosphatase has an Asp at position 153 and a Lys at position 328. Co2+-requiring alkaline phosphatases from Thermotoga maritima and Bacillus subtilis have a His and a Trp at these positions, respectively. The mutations D153H, K328W, and D153H/K328W were induced in E. coli alkaline phosphatase to determine whether these residues dictate the metal dependence of the enzyme. The wild-type and D153H enzymes showed very little activity in the presence of Co2+, but the K328W and especially the D153H/K328W enzymes effectively use Co2+ for catalysis. Isothermal titration calorimetry experiments showed that in all cases except for the D153H/K328W enzyme, a possible conformation change occurs upon binding Co2+. These data together indicate that the active site of the D153H/K328W enzyme has been altered significantly enough to allow the enzyme to utilize Co2+ for catalysis. These studies suggest that the active site residues His and Trp at the E. coli enzyme positions 153 and 328, respectively, at least partially dictate the metal specificity of alkaline phosphatase.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NIGMS NIH HHS [GM42833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asgeirsson B, 2001, BBA-PROTEIN STRUCT M, V1549, P99, DOI 10.1016/S0167-4838(01)00247-3; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; Dealwis CG, 1995, PROTEIN ENG, V8, P865, DOI 10.1093/protein/8.9.865; Dirnbach E, 2001, BIOCHEMISTRY-US, V40, P11219, DOI 10.1021/bi011399m; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; Holtz KM, 1999, FEBS LETT, V462, P7, DOI 10.1016/S0014-5793(99)01448-9; HULETT FM, 1991, J BIOL CHEM, V266, P1077; JANEWAY CML, 1993, BIOCHEMISTRY-US, V32, P1601, DOI 10.1021/bi00057a026; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Kim JW, 1998, FEMS MICROBIOL LETT, V159, P47, DOI 10.1111/j.1574-6968.1998.tb12840.x; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lee MH, 1999, J BACTERIOL, V181, P5790, DOI 10.1128/JB.181.18.5790-5799.1999; MA L, 1994, J BIOL CHEM, V269, P31614; MATLIN AR, 1992, BIOCHEMISTRY-US, V31, P8196, DOI 10.1021/bi00150a011; MURPHY JE, 1995, J MOL BIOL, V253, P604, DOI 10.1006/jmbi.1995.0576; MURPHY JE, 1993, J BIOL CHEM, V268, P21479; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; Rina M, 2000, EUR J BIOCHEM, V267, P1230, DOI 10.1046/j.1432-1327.2000.01127.x; SIMPSON RT, 1968, ANN NY ACAD SCI, V166, P670; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TRENTHAM DR, 1968, BIOCHEM J, V106, P455, DOI 10.1042/bj1060455; Wojciechowski CL, 2002, PROTEIN SCI, V11, P903, DOI 10.1110/ps.4260102; WULFSBERG G, 1987, PRINCIPLES DESCRIPTI, P25; XU X, 1991, BIOCHEMISTRY-US, V30, P7789, DOI 10.1021/bi00245a018; Zappa S, 2001, APPL ENVIRON MICROB, V67, P4504, DOI 10.1128/AEM.67.10.4504-4511.2001; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200	30	30	34	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50476	50481		10.1074/jbc.M209326200	http://dx.doi.org/10.1074/jbc.M209326200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399456	hybrid			2022-12-25	WOS:000180177700037
J	Woodworth, A; Fiete, D; Baenziger, JU				Woodworth, A; Fiete, D; Baenziger, JU			Spatial and temporal regulation of tenascin-R glycosylation in the cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATORY HALF-LIFE; CARBOHYDRATE EPITOPE; MANNOSE/N-ACETYLGALACTOSAMINE-4-SO4 RECEPTOR; SULFOGLUCURONYL GLYCOLIPIDS; HNK-1-REACTIVE ANTIGENS; N-ACETYLGALACTOSAMINE; POLYSIALIC ACID; CEREBRAL-CORTEX; RAT CEREBELLUM; MICE DEFICIENT	The cellular adhesion molecule tenascin-R is a multifunctional extracellular matrix component expressed exclusively in the central nervous system. The expression of tenascin-R by oligodendrocytes and small interneurons in the hippocampus and cerebellum is highly regulated during development of these regions. This complex glycoprotein displays both adhesive and anti-adhesive properties that contribute to the formation and maintenance of synapses. We have determined that tenascin-R associated with Purkinje cell bodies and their dendrites in the molecular layer of the cerebellum bears N-linked oligosaccharides terminating with beta1, 4-linked GalNAc-4-SO4, whereas tenascin-R in other regions of the cerebellum does not bear this modification. Expression of this unique sulfated carbohydrate structure is also temporally regulated, increasing throughout cerebellar development. The most dramatic increase in GalNAc-4-SO4 occurs between postnatal days 14 and 21, corresponding to a period of Purkinje cell dendrite extension and synaptogenesis. The spatially and temporally regulated addition of this unique sulfated carbohydrate to tenascin-R may serve to modulate its adhesive/anti-adhesive or other biological properties in vivo.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	Baenziger@pathology.wustl.edu	Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [R37-CA21923] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Angelov DN, 1998, J NEUROSCI, V18, P6218; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Nair SM, 1998, NEUROSCIENCE, V85, P759, DOI 10.1016/S0306-4522(97)00666-0; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8; Roseman DS, 2001, J BIOL CHEM, V276, P17052, DOI 10.1074/jbc.M101027200; Roth J, 1993, POLYSIALIC ACID MICR; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Sasaki T, 1999, GLIA, V28, P236, DOI 10.1002/(SICI)1098-1136(199912)28:3<236::AID-GLIA7>3.3.CO;2-R; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; Woodworth A, 2001, Results Probl Cell Differ, V33, P123; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200	30	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50941	50947		10.1074/jbc.M209876200	http://dx.doi.org/10.1074/jbc.M209876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393878	hybrid			2022-12-25	WOS:000180177700097
J	De Blas, G; Michaut, M; Trevino, CL; Tomes, CN; Yunes, R; Darszon, A; Mayorga, LS				De Blas, G; Michaut, M; Trevino, CL; Tomes, CN; Yunes, R; Darszon, A; Mayorga, LS			The intraacrosomal calcium pool plays a direct role in acrosomal exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MOUSE SPERM; INOSITOL TRISPHOSPHATE; HUMAN SPERMATOZOA; MEMBRANE-FUSION; ZONA-PELLUCIDA; RAB3A; CA2+; ACTIVATION; IDENTIFICATION	The acrosome reaction is a unique type of regulated exocytosis. The single secretory granule of the sperm fuses at multiple points with the overlying plasma membrane. In the past few years we have characterized several aspects of this process using streptolysin O-permeabilized human spermatozoa. Here we show that Rab3A triggers acrosomal exocytosis in the virtual absence of calcium in the cytosolic compartment. Interestingly, exocytosis is blocked when calcium is depleted from intracellular stores. By using a membrane-permeant fluorescent calcium probe, we observed that the acrosome actually behaves as a calcium store. Depleting calcium from this compartment by using a light-sensitive chelator prevents secretion promoted by Rab3A. LTV inactivation of the chelator restores exocytosis. Rab3A-triggered exocytosis is blocked by calcium pump and inositol 1,4,5-trisphosphate (IP3)-sensitive calcium channel inhibitors. Calcium measurements inside and outside the acrosome showed that Rab3A promotes a calcium efflux from the granule. Interestingly, release of calcium through IP3-sensitive calcium channels was necessary even when exocytosis was initiated by increasing free calcium in the extraacrosomal compartment in both permeabilized and intact spermatozoa. Our results show that a calcium efflux from the acrosome through IP3-sensitive channels is necessary downstream Rab3A activation during the membrane fusion process leading to acrosomal exocytosis.	Univ Nacl Cuyo, Lab Biol Celular & Mol, Inst Histol & Embriol,IHEM, CONICET,Fac Ciencias Med, RA-5500 Mendoza, Argentina; Univ Nacl Autonoma Mexico, Dept Genet & Fisiol Mol, Inst Biotechnol, Cuernavaca 62250, Morelos, Mexico	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Universidad Nacional Autonoma de Mexico	Mayorga, LS (corresponding author), Casilla Correo 56, RA-5500 Mendoza, Argentina.	lmayorga@fcm.uncu.edu.ar	Michaut, Marcela Alejandra/D-3725-2015	Michaut, Marcela Alejandra/0000-0002-0528-6605; Trevino, Claudia L/0000-0002-7281-0534; Darszon, Alberto/0000-0002-2502-0505; Mayorga, Luis S/0000-0002-5995-0671				Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Darszon A, 2001, DEV BIOL, V240, P1, DOI 10.1006/dbio.2001.0387; Dragileva E, 1999, BIOL REPROD, V61, P1226, DOI 10.1095/biolreprod61.5.1226; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Gonzalez-Martinez MT, 2001, DEV BIOL, V236, P220, DOI 10.1006/dbio.2001.0323; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Iida H, 1999, DEV BIOL, V211, P144, DOI 10.1006/dbio.1999.9302; Jagannathan S, 2002, J BIOL CHEM, V277, P8449, DOI 10.1074/jbc.M105345200; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; Llanos MN, 1998, MOL REPROD DEV, V51, P84, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;84::AID-MRD10&gt;3.0.CO;2-U; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; MEIZEL S, 1993, J EXP ZOOL, V267, P350, DOI 10.1002/jez.1402670312; MENDOZA C, 1992, J REPROD FERTIL, V95, P755; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Mills IG, 2001, J CELL SCI, V114, P1959; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PIIPER A, 1994, BIOCHEM BIOPH RES CO, V203, P756, DOI 10.1006/bbrc.1994.2247; Rossato M, 2001, MOL HUM REPROD, V7, P119, DOI 10.1093/molehr/7.2.119; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SULLIVAN KMC, 1995, P NATL ACAD SCI USA, V92, P8611, DOI 10.1073/pnas.92.19.8611; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Thirion S, 1999, P NATL ACAD SCI USA, V96, P3206, DOI 10.1073/pnas.96.6.3206; Tomes CN, 1996, MOL REPROD DEV, V43, P196, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;196::AID-MRD9&gt;3.0.CO;2-M; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Trevino CL, 1998, ZYGOTE, V6, P159, DOI 10.1017/S0967199498000094; Vaidyanathan VV, 1999, J NEUROCHEM, V72, P327, DOI 10.1046/j.1471-4159.1999.0720327.x; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Ward CR, 1999, MOL REPROD DEV, V53, P413, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;413::AID-MRD7&gt;3.0.CO;2-W; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	35	105	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49326	49331		10.1074/jbc.M208587200	http://dx.doi.org/10.1074/jbc.M208587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379648	hybrid			2022-12-25	WOS:000180028900029
J	Lee, KY; Kim, HG; Hwang, MR; Il Chae, J; Yang, JM; Lee, YC; Choo, YK; Lee, YI; Lee, SS; Do, SI				Lee, KY; Kim, HG; Hwang, MR; Il Chae, J; Yang, JM; Lee, YC; Choo, YK; Lee, YI; Lee, SS; Do, SI			The hexapeptide inhibitor of Gal beta 1,3GalNAc-specific alpha 2,3-sialyltransferase as a generic inhibitor of sialyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MOLECULAR-CLONING; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; SERUM SIALYLTRANSFERASE; LINKED OLIGOSACCHARIDES; CRYPTOCOCCUS-NEOFORMANS; SURFACE SIALYLATION; PEPTIDE STRUCTURE; O-GLYCANS; EXPRESSION	The mammalian Galbeta1,3Ga1NAc-specific alpha2,3-sialyl-transferase (ST3Gal I) was expressed as a secreted glycoprotein in High Five(TM) (Trichoplusia ni) cells. Using this recombinant ST3Gal I, we screened the synthetic hexapeptide combinatorial library to explore a sialyltransferase inhibitor. We found that the hexapeptide, NH2-GNWWWW, exhibited the most strong inhibition of ST3Gal I among five different hexapeptides that were finally selected. The kinetic analysis of ST3Gal I inhibition demonstrated that this hexapeptide could act as a competitive inhibitor (K-i = 1.1 mum) on CMP-NeuAc binding to the enzyme. Moreover, the hexapeptide was shown to strongly inhibit both N-glycan-specific alpha2,3-and alpha2,6-sialyltranferase in vitro, suggesting that this peptide may inhibit the broad range of sialyltrans-ferases regardless of their linkage specificity. The inhibitory activity in vivo was investigated by RCA-I lectin blot analyses and by metabolic D-[6-H-3]GlcNH(2) radio-labeling analyses of N- and O-linked oligosaccharides in Chillies hamster ovary cells. Our results demonstrate that the hexapeptide can act as a generic inhibitor of the N- and O-glycan-specific sialyltransferases in mammalian cells, which results in the significantly reduced NeuAc expression on cellular glycoproteins in vivo.	Korea Res Inst Biosci & Biotechnol, Cell Biol Div, Anim Cell & Med Glycobiol Lab, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Liver Cell Signal Transduct Lab, Taejon 305333, South Korea; Sogang Univ, Dept Life Sci, Seoul 100601, South Korea; Dong A Univ, Div Nat Resources & Life Sci, Pusan 604022, South Korea; WonKwang Univ, Div Biol Sci, Iksan 570749, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Sogang University; Dong A University; Wonkwang University; Pai Chai University	Do, SI (corresponding author), Korea Res Inst Biosci & Biotechnol, Cell Biol Div, Anim Cell & Med Glycobiol Lab, POB 115, Taejon 305333, South Korea.	sido@kribb.re.kr						Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BERNACKI RJ, 1977, SCIENCE, V195, P577, DOI 10.1126/science.835014; BERNACKI RJ, 1982, GLYCOCONJUGATES, V4, P245; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; BURTON PS, 1992, J CONTROL RELEASE, V19, P87, DOI 10.1016/0168-3659(92)90067-2; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CONRADI RA, 1992, PHARMACEUT RES, V9, P435, DOI 10.1023/A:1015867608405; DENNIS J, 1982, NATURE, V300, P274, DOI 10.1038/300274a0; DO SI, 1990, J BIOL CHEM, V265, P114; FOGEL M, 1983, J EXP MED, V157, P371, DOI 10.1084/jem.157.1.371; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Harder PG, 1997, GLYCOBIOLOGY, V7, P791, DOI 10.1093/glycob/7.6.791; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IRIMURA T, 1981, BIOCHEMISTRY-US, V20, P560, DOI 10.1021/bi00506a018; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KATASUTOSHI S, 1996, TRENDS GLYCOSCI GLYC, V8, P195; KHAN SH, 1993, J BIOL CHEM, V268, P2468; Kieber-Emmons T, 1999, NAT BIOTECHNOL, V17, P660, DOI 10.1038/10870; KIJIMA I, 1982, CHEM PHARM BULL, V30, P3278; KIJIMASUDA I, 1986, CANCER RES, V46, P858; KIJIMASUDA I, 1985, CHEM PHARM BULL, V33, P730; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KLOHS WD, 1979, CANCER RES, V39, P1231; Kobata A., 1993, GLYCOBIOLOGY PRACTIC, P103; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kulakosky PC, 1998, GLYCOBIOLOGY, V8, P741, DOI 10.1093/glycob/8.7.741; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUROSAWA N, 1995, BBA-GEN SUBJECTS, V1244, P216, DOI 10.1016/0304-4165(95)00012-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEMARER N, 1995, GLYCOBIOLOGY, V5, P219, DOI 10.1093/glycob/5.2.219; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; ORITA T, 1994, J BIOCHEM-TOKYO, V115, P345, DOI 10.1093/oxfordjournals.jbchem.a124340; PAHLSSON P, 1994, GLYCOCONJUGATE J, V11, P43, DOI 10.1007/BF00732431; PALCIC MM, 1989, J BIOL CHEM, V264, P17174; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Saarinen MA, 1999, BIOTECHNOL BIOENG, V63, P612, DOI 10.1002/(SICI)1097-0290(19990605)63:5&lt;612::AID-BIT11&gt;3.0.CO;2-C; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; Shimizu M, 1997, PEPTIDES, V18, P681, DOI 10.1016/S0196-9781(97)00002-8; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VAGHEFI MM, 1987, J MED CHEM, V30, P1391, DOI 10.1021/jm00391a021; Valadon P, 1998, J IMMUNOL, V161, P1829; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; VARKI A, 1983, J BIOL CHEM, V258, P2808; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227; WEN DX, 1992, J BIOL CHEM, V267, P21011; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WICKHAM TJ, 1993, BIOTECHNOL PROGR, V9, P25, DOI 10.1021/bp00019a004; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237; Zhang HL, 1997, INFECT IMMUN, V65, P1158, DOI 10.1128/IAI.65.4.1158-1164.1997; Zhou DP, 2000, ARCH BIOCHEM BIOPHYS, V374, P3, DOI 10.1006/abbi.1999.1622	61	20	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49341	49351		10.1074/jbc.M209618200	http://dx.doi.org/10.1074/jbc.M209618200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379642	hybrid			2022-12-25	WOS:000180028900031
J	Mishra, R; Gorlov, IP; Chao, LY; Singh, S; Saunders, GF				Mishra, R; Gorlov, IP; Chao, LY; Singh, S; Saunders, GF			PAX6, paired domain influences sequence recognition by the homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DNA-BINDING SUBDOMAINS; MISSENSE MUTATIONS; CRYSTAL-STRUCTURE; EYE DEVELOPMENT; ANIRIDIA; TRANSACTIVATION; REGION; EXPRESSION; DROSOPHILA	PAX6 functions as a transcription factor and has two DNA-binding domains, a paired domain (PD) and a homeodomain (111)), joined by a glycine-rich linker and followed by a proline-serine-threonine-rich (PST) trans-activation region at the C terminus. The mechanism of PAX6 function is not clearly understood, and few target genes in vertebrates have been identified. In this report we described the functional analyses of patient missense mutations from the paired domain region of PAX6 and a paireddomain-less isoform (PD-less) of Pax6 that lacks the paired domain and part of the glycine-rich linker. The PD-less was expressed in the brain, eyes, and pancreas of mouse. The level of expression of this isoform was relatively higher in brain. The mutation sites PAX6-L46R and -C52R were located in the PD of PAX6 on either end of the 5a-polypeptide insert of the alternatively spliced form of PAX6, PAX6-5a. Another PAX6 mutant V53L described in this report was adjacent to C5211. We created corresponding mutations in PAX6 and PAX65a, and evaluated their transcriptional activation and DNA binding properties. The PD mutants of PAX6 (L46R, C52R, and V53L) exhibited lower transactivation activities and variable DNA binding ability than wildtype PAX6 with PD DNA-binding consensus sequences. The mutated amino acids containing PAX6-5a isoforms showed unexpected transactivation properties with a reporter containing HD DNA-binding sequences. PAX65a-C52R, and -V53L showed lower transactivation activities, but PAX6-5a-L46R had greater transactivation ability than PAX6-5a. The PD-less isoform of Pax6 lost its transactivational ability but could bind to the HD DNA-binding sequences. Functional analysis of the PD-less isoform of Pax6 as well as findings related to missense mutations in the PD suggest that the PD of PAX6 is required for HD function.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Box 117, Houston, TX 77030 USA.	gsaunders@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY010608, R01EY009675] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline; NEI NIH HHS [EY 09675, EY 10608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000; Azuma N, 1999, AM J HUM GENET, V65, P656, DOI 10.1086/302529; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Azuma N, 1998, INVEST OPHTH VIS SCI, V39, P828; Bertuccioli C, 1996, DEVELOPMENT, V122, P2673; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; Chao LY, 2000, HUM MUTAT, V15, P332, DOI 10.1002/(SICI)1098-1004(200004)15:4<332::AID-HUMU5>3.0.CO;2-1; Chauhan BK, 2002, J BIOL CHEM, V277, P11539, DOI 10.1074/jbc.M110531200; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fortin AS, 1998, NUCLEIC ACIDS RES, V26, P4574, DOI 10.1093/nar/26.20.4574; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Gronskov K, 1999, EUR J HUM GENET, V7, P274, DOI 10.1038/sj.ejhg.5200308; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hanson I, 1999, HUM MOL GENET, V8, P165, DOI 10.1093/hmg/8.2.165; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Kondo-Saitoh A, 2000, EUR J OPHTHALMOL, V10, P167, DOI 10.1177/112067210001000213; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Love J, 1998, HUM MUTAT, V12, P128, DOI 10.1002/(SICI)1098-1004(1998)12:2<128::AID-HUMU8>3.0.CO;2-N; Malandrini A, 2001, CLIN GENET, V60, P151, DOI 10.1034/j.1399-0004.2001.600210.x; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; MIRZAYANS F, 1995, AM J HUM GENET, V57, P539; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; Punzo C, 2001, GENE DEV, V15, P1716, DOI 10.1101/gad.196401; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; Singh S, 2002, P NATL ACAD SCI USA, V99, P6812, DOI 10.1073/pnas.102691299; Singh S, 1998, ANAL BIOCHEM, V265, P185, DOI 10.1006/abio.1998.2882; Sonoda S, 2000, GRAEF ARCH CLIN EXP, V238, P552, DOI 10.1007/s004170000124; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; Tomarev SI, 1997, INT J DEV BIOL, V41, P835; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; van Heyningen V, 2002, HUM MOL GENET, V11, P1161, DOI 10.1093/hmg/11.10.1161; van Raamsdonk CD, 2000, DEVELOPMENT, V127, P5439; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wolf MTF, 1998, HUM MUTAT, V12, P304; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yamaguchi Y, 1997, GENES CELLS, V2, P255, DOI 10.1046/j.1365-2443.1997.1170315.x; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	59	64	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49488	49494		10.1074/jbc.M206478200	http://dx.doi.org/10.1074/jbc.M206478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388550	hybrid			2022-12-25	WOS:000180028900051
J	Pak, JH; Manevich, Y; Kim, HS; Feinstein, SI; Fisher, AB				Pak, JH; Manevich, Y; Kim, HS; Feinstein, SI; Fisher, AB			An antisense oligonucleotide to 1-cys peroxiredoxin causes lipid peroxidation and apoptosis in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; RAT LUNG; MAMMALIAN PEROXIREDOXIN; SECRETORY PROTEIN; CRYSTAL-STRUCTURE; BOVINE EYE; EXPRESSION; PHOSPHOLIPASE-A2; OVEREXPRESSION; IDENTIFICATION	1-cys peroxiredoxin (1-cysPrx), a member of the peroxiredoxin superfamily, reduces phospholipid hydroperoxides as well as organic peroxides and H2O2. To determine the physiological function(s) of 1-cysPrx, we have used an antisense strategy to suppress endogenous 1-cysPrx in L2 cells, a rat lung epithelial cell line. A 25-base antisense morpholino oligonucleotide was designed to bind a complementary sequence overlapping the translational start site (-18 to +7) in the rat 1-cysPrx mRNA, blocking protein synthesis. Treatment with an antisense oligonucleotide for 48 h resulted in approximately 60% suppression of the 1-cysPrx protein content as measured by immunoblot analysis and an approximately 44% decrease of glutathione peroxidase activity as compared with random oligonucleotide treated and control (vehicle only) cells. Accumulation of phosphatidylcholine hydroperoxide in plasma membranes was demonstrated by high pressure liquid chromatography assay for conjugated dienes (260 pMol/10(6) cells for antisense versus 70 pmol/10(6) cells for random oligonucleotide and control cells) and by fluorescence of diphenyl-1-pyrenylphosphine, a probe for lipid peroxidation. The percentage of cells showing positive staining for annexin V and propidium. iodide after antisense treatment was 40% at 28 h and 80% at 48 h. TdT-mediated dUTP nick end labeling assay at 48 h indicated DNA fragmentation in antisense-treated cells that was blocked by prior infection with adenovirus encoding 1-cysPrx or by pretreatment with a vitamin E analogue. The results indicate that 1-cysPrx can function in the intact cell as an antioxidant enzyme to reduce the accumulation of phospholipid hydroperoxides and prevent apoptotic cell death.	Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	abf@mail.med.upenn.edu	Kim, Han-Suk/D-5788-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; DOUGLAS WHJ, 1974, IN VITRO CELL DEV B, V10, P230; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Fujii T, 2001, EUR J BIOCHEM, V268, P218, DOI 10.1046/j.1432-1033.2001.01843.x; Hensley K, 2002, ARCH BIOCHEM BIOPHYS, V397, P377, DOI 10.1006/abbi.2001.2630; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim HS, 2002, AM J RESP CELL MOL, V27, P227, DOI 10.1165/ajrcmb.27.2.20010009oc; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Manevich Y, 1997, RADIAT RES, V148, P580, DOI 10.2307/3579734; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Parasassi T, 2001, FREE RADICAL BIO MED, V31, P82, DOI 10.1016/S0891-5849(01)00555-X; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; Peshenko IV, 1996, FEBS LETT, V381, P12, DOI 10.1016/0014-5793(96)00071-3; Peshenko IV, 2001, FREE RADICAL BIO MED, V31, P292, DOI 10.1016/S0891-5849(01)00579-2; Peshenko IV, 2001, J OCUL PHARMACOL TH, V17, P93, DOI 10.1089/108076801750125775; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Takahashi M, 2001, FREE RADICAL BIO MED, V31, P164, DOI 10.1016/S0891-5849(01)00575-5; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; Wang HP, 2001, FREE RADICAL BIO MED, V30, P825, DOI 10.1016/S0891-5849(01)00469-5; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200	37	103	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49927	49934		10.1074/jbc.M204222200	http://dx.doi.org/10.1074/jbc.M204222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12372839	hybrid			2022-12-25	WOS:000180028900108
J	Zeng, QH; McCauley, LK; Wang, CY				Zeng, QH; McCauley, LK; Wang, CY			Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2 - Implication in head and neck squamous cell carcinoma progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR; FACTOR-RECEPTOR; MAP KINASES; C-MET; EXPRESSION; APOPTOSIS; PATHWAY; CANCER; DEATH; ERK	Anoikis, also called suspension-induced apoptosis, plays an important role in tumor development, progression, and metastasis. Recently we found that hepatocyte growth factor (HGF) inhibited anoikis of human head and neck squamous cell carcinoma (HNSCC) cells by activating the extracellular signal-regulated kinase (ERK)-signaling pathway. However, the anti-apoptotic effectors that were regulated by the ERK-signaling pathway were unknown. Here we report that HGF-mediated inhibition of anoikis was dependent on activator protein-1 activity through the activation of the ERK-signaling pathway. Using a combination of microarray analysis and Northern blot analysis, we found that an anti-apoptotic gene cyclooxygenase-2 (cox-2) was induced by HGF in an activator protein-1-dependent fashion. Inhibition of Cox-2 activity partially abolished HGF-mediated cell survival, and overexpression of Cox-2 in HNSCC cells provided resistance against anoikis. Moreover, HNSCC cells stably expressing Cox-2 had aggressive tumor growth in a nude mouse model compared with control cells. Taken together, our results demonstrate that Cox-2 plays an important role in HGF-mediated anoikis resistance. HGF may stimulate the progression and growth of HNSCC in vivo by induction of Cox-2.	Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med & Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med & Dent, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wang, CY (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu			NIDCR NIH HHS [R01 DE 13848, R01 DE 13788] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013788, R01DE013848] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bol DK, 2002, CANCER RES, V62, P2516; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Dong G, 2001, CANCER RES, V61, P5911; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gallo O, 2001, NEOPLASIA, V3, P53, DOI 10.1038/sj.neo.7900127; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kang MK, 2001, CRIT REV ORAL BIOL M, V12, P38, DOI 10.1177/10454411010120010301; KEMIRALP B, 2002, ENDOCRINOLOGY, V143, P4038; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Mestre JR, 1999, ANN NY ACAD SCI, V889, P62, DOI 10.1111/j.1749-6632.1999.tb08724.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Myers JN, 2002, CLIN CANCER RES, V8, P293; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Patel V, 2001, CRIT REV ORAL BIOL M, V12, P55, DOI 10.1177/10454411010120010401; Qian CN, 2002, CANCER RES, V62, P589; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shillitoe EJ, 2000, ORAL ONCOL, V36, P1; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Uchida D, 2001, INT J CANCER, V93, P489, DOI 10.1002/ijc.1368; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	46	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50137	50142		10.1074/jbc.M208952200	http://dx.doi.org/10.1074/jbc.M208952200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393863	hybrid			2022-12-25	WOS:000180028900133
J	Gass, JN; Gifford, NM; Brewer, JW				Gass, JN; Gifford, NM; Brewer, JW			Activation of an unfolded protein response during differentiation of antibody-secreting B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; MAMMALIAN-CELLS; TRANSCRIPTION FACTORS; ANTIGEN-SPECIFICITY; GENE; IMMUNOGLOBULIN; EXPRESSION; IDENTIFICATION; INDUCTION	The unfolded protein response pathway (UPR) is believed to detect and compensate for excessive protein accumulation in the endoplasmic reticulum. (ER). The UPR can be induced by pharmacological agents that perturb ER functions, but may also occur during cellular developmental processes such as the transition of B-lymphocytes into antibody-secreting plasma cells. Here we show that major UPR components are activated in B cells stimulated to secrete antibody. Increased expression of UPR targets including the ER chaperones BiP and GRP94 and the transcription factor XBP-1 initiates early in the differentiation program prior to upregulated synthesis of Ig chains. Furthermore, these same kinetics are observed during differentiation for cleavage of the ER-localized ATF6alpha protein and splicing of XBP-1 mRNA to generate p50ATF6alpha and p54XBP-1, the two known UPR transcriptional activators. All of these UPR events reach maximal levels once Ig synthesis and secretion are markedly induced. Interestingly, these events are not accompanied by expression of CHOP, a transcription factor induced by ER stress agents commonly used to investigate the UPR. These results suggest that a physiological UPR elicited during differentiation of B-lymphocytes into high-rate secretory cells may be distinct from the UPR defined by agents that disrupt protein maturation in the ER.	Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA	Loyola University Chicago	Brewer, JW (corresponding author), Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, 2160 S 1st Ave, Maywood, IL 60153 USA.				NIGMS NIH HHS [GM61970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON J, 1972, EUR J IMMUNOL, V2, P349, DOI 10.1002/eji.1830020410; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LENNY N, 1991, J BIOL CHEM, V266, P20532; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; LOCASCIO NJ, 1984, J MOL CELL IMMUNOL, V1, P177; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; RANDALL TD, 1993, MOL CELL BIOL, V13, P3929, DOI 10.1128/MCB.13.7.3929; Reimold AM, 1996, J EXP MED, V183, P393, DOI 10.1084/jem.183.2.393; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; STOCKDALE AM, 1987, J IMMUNOL, V139, P3527; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; VASSALLI P, 1979, P NATL ACAD SCI USA, V76, P5515, DOI 10.1073/pnas.76.11.5515; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang Y, 2000, J BIOL CHEM, V275, P27013; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	45	229	241	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49047	49054		10.1074/jbc.M205011200	http://dx.doi.org/10.1074/jbc.M205011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374812	hybrid			2022-12-25	WOS:000179789600138
J	Reddy, VS; Reddy, ASN				Reddy, VS; Reddy, ASN			The calmodulin-binding domain from a plant kinesin functions as a modular domain in conferring Ca2+-calmodulin regulation to animal plus- and minus-end kinesins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR MOTOR; PROTEIN; ARABIDOPSIS; DIRECTION; MICROTUBULES; ISOFORMS; MUTATION; SITES	Plant kinesin-like calmodulin-binding protein (KCBP) is a novel member of the kinesin superfamily that interacts with calmodulin (CaM) via its CaM-binding domain (CBD). Activated CaM (Ca2+-CaM) has been shown to inhibit KCBP interaction with microtubules (MTs) thereby abolishing its motor- and MT-dependent ATPase activities. To test whether the fusion of CBD to non-CaM-binding kinesins confers Ca2+-CaM regulation, we fused the CBD of KCBP to the N or C terminus of a minus-end (non-claret disjunction) or C terminus of a plus-end (Drosophila kinesin) motor. Purified chimeric kinesins bound CaM in a Ca2+-dependent manner whereas non-claret disjunction, Drosophila kinesin, and KCBP that lack a CBD did not. As in the case of KCBP with CBD, the interaction of chimeric motors with MTs, as well as their MT-stimulated ATPase activity, was inhibited by Ca2+-CaM. The presence of a spacer between the motor and CBD did not alter Ca2+-CaM regulation. However, KCBP interaction with MTs and its MT-stimulated ATPase activity were not inhibited when the motor domain and CBD were added separately, suggesting that Ca2+-CaM regulation of CaM-binding motors occurs only when the CBD is attached to the motor domain. These results show that the fusion of the CBD to animal motors confers Ca2+-CaM regulation and suggest that the CBD functions as a modular domain in disrupting motor-MT interaction. Our data also support the hypothesis that CaM-binding kinesins may have evolved by addition of a CBD to a kinesin motor domain.	Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Program Mol & Cell Biol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@lamar.colostate.edu						Abdel-Ghany SE, 2000, DNA CELL BIOL, V19, P567, DOI 10.1089/104454900439791; Alonso MC, 1998, EMBO J, V17, P945, DOI 10.1093/emboj/17.4.945; Bowser J, 1997, PLANT J, V12, P1429, DOI 10.1046/j.1365-313x.1997.12061429.x; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Day IS, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-10-research0056; Deavours BE, 1998, CELL MOTIL CYTOSKEL, V40, P408, DOI 10.1002/(SICI)1097-0169(1998)40:4<408::AID-CM8>3.0.CO;2-6; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; Folkers U, 2002, EMBO J, V21, P1280, DOI 10.1093/emboj/21.6.1280; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Hackney DD, 2001, METH MOL B, V164, P65; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kirchner J, 1999, EMBO J, V18, P4404, DOI 10.1093/emboj/18.16.4404; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; Nishihama R, 2002, CELL, V109, P87, DOI 10.1016/S0092-8674(02)00691-8; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Phelps KK, 1999, BIOCHEMISTRY-US, V38, P10750, DOI 10.1021/bi990706+; Reddy A S, 2001, BMC Genomics, V2, P2, DOI 10.1186/1471-2164-2-2; Reddy ASN, 1996, PLANT J, V10, P9, DOI 10.1046/j.1365-313X.1996.10010009.x; Reddy ASN, 1996, J BIOL CHEM, V271, P7052, DOI 10.1074/jbc.271.12.7052; Reddy ASN, 2000, TRENDS PLANT SCI, V5, P503, DOI 10.1016/S1360-1385(00)01792-1; REDDY ASN, 2002, IN PRESS MOL MOTORS; REDDY ASN, 2001, INTL REV CYTOL CELL, V204, P98; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; Reddy VS, 1999, BIOINFORMATICS, V15, P1055; REILEIN AR, 2001, INT REV CYTOL CELL B, V204, P180; Rogers GC, 1999, J MOL BIOL, V294, P1, DOI 10.1006/jmbi.1999.3249; Sablin EP, 2000, CURR OPIN CELL BIOL, V12, P35, DOI 10.1016/S0955-0674(99)00054-X; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Safadi F, 2000, J BIOL CHEM, V275, P35457, DOI 10.1074/jbc.M002720200; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Schliwa M, 2001, NATURE, V411, P424, DOI 10.1038/35078167; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Takahashi M, 2001, J BIOL CHEM, V276, P1034, DOI 10.1074/jbc.M005370200; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vos JW, 2000, PLANT CELL, V12, P979, DOI 10.1105/tpc.12.6.979; Wang W, 1996, PLANT MOL BIOL, V31, P87, DOI 10.1007/BF00020609; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	55	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48058	48065		10.1074/jbc.M205459200	http://dx.doi.org/10.1074/jbc.M205459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379658	hybrid			2022-12-25	WOS:000179789600013
J	Wang, L; Ma, R; Flavell, RA; Choi, ME				Wang, L; Ma, R; Flavell, RA; Choi, ME			Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38 alpha and p38 delta MAPK Isoforms by TGF-beta 1 in murine mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SIGNAL-TRANSDUCTION PATHWAY; CELLULAR STRESSES; INDUCED APOPTOSIS; EPITHELIAL-CELLS; MAJOR ACTIVATOR; GENE-EXPRESSION; P38; CYTOKINES; ALPHA	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of extracellular matrix (ECM) synthesis that leads to renal fibrosis. Intracellular signaling mechanisms involved in this process remain incompletely understood. Mitogen-activated protein kinase (MAPK) is a major stress signal-transducing pathway, and we have previously reported activation of p38 MAPK by TGF-beta1 in rat mesangial cells and its role in the stimulation of pro-alpha1 (I) collagen. In this study, we further investigated the mechanism of p38 MAPK activation by TGF-beta1 and the role of MEK3, an upstream MAPK kinase of p38 MAPK, by examining the effect of targeted disruption of the Mkk3 gene. We first isolated glomerular mesangial cells from MKK3-null (Mkk3-/-) and wild-type (Mkk3+/+) control mice. Treatment with TGF-beta1 induced rapid phosphorylation of MKK3 as well as p38 MAPK within 15 min in cultured wild-type (Mkk3+/+) mouse mesangial cells. In contrast, TGF-beta1 failed to induce phosphorylation of either MKK3 or p38 MAPK in MKK3-deficient (Mkk3-/-) mouse mesangial cells, indicating that MKK3 is required for TGF-beta1-induced p38 MAPK activation. TGF-beta1 selectively activated the p38 MAPK isoforms p38alpha and p38delta in wild-type (Mkk3+/+) mesangial cells, but not in MKK3-deficient (Mkk3-/-) mesangial cells. Thus, activation of p38a and p38delta is dependent on the activation of upstream MKK3 by TGF-beta1. Furthermore, MKK3 deficiency resulted in a selective disruption of TGF-beta1-stimulated up-regulation of pro-alpha1(I) collagen expression but not TGF-beta1 induction of fibronectin and PAI-1. These data demonstrate that the MKK is a critical component of the TGF-beta1 signaling pathway, and its activation is required for subsequent p38a and p388 MAPK activation and collagen stimulation by TGF-beta1.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Howard Hughes Medical Institute	Choi, ME (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, E1158,Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.		Ma, Rui/B-2086-2010		NIDDK NIH HHS [R01 DK57661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bokemeyer D, 1998, KIDNEY INT, V54, pS189, DOI 10.1046/j.1523-1755.1998.06743.x; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Choi ME, 2000, KIDNEY INT, V58, pS53, DOI 10.1046/j.1523-1755.2000.07709.x; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dunlop ME, 2000, KIDNEY INT, V57, P464, DOI 10.1046/j.1523-1755.2000.t01-1-00866.x; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Guo YL, 2001, J CELL BIOCHEM, V82, P556, DOI 10.1002/jcb.1180; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Ju HS, 2002, J PHARMACOL EXP THER, V301, P15, DOI 10.1124/jpet.301.1.15; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	41	79	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47257	47262		10.1074/jbc.M208573200	http://dx.doi.org/10.1074/jbc.M208573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12374793	hybrid			2022-12-25	WOS:000179663700054
J	Dahm, K; Hubscher, U				Dahm, K; Hubscher, U			Colocalization of human Rad17 and PCNA in late S phase of the cell cycle upon replication block	ONCOGENE			English	Article						DNA replication checkpoint; hRad17; PCNA; hRad9; confocal microscopy	DNA-DAMAGE CHECKPOINT; FACTOR-C COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; NUCLEAR ANTIGEN; PROTEIN-KINASE; BUDDING YEAST; FISSION YEAST; SMALL-SUBUNIT	In response to replication block or DNA damage in S phase the DNA replication and DNA damage checkpoints are activated. The current model in human predicts, that a Rad17/Replication factor C (RF-C) complex might serve as a recruitment complex for the Rad9/Hus1/Rad1 complex to sites of replication block or DNA damage. In this study we have investigated the fate of the Rad17/RF-C complex after treatment of synchronized Hela cells with the replication inhibitor hydroxyurea. In hydroxyurea treated cells the RF-C p37 subunit became more resistant to extraction. Moreover, co-immunoprecipitation studies with extracts of hydroxyurea treated cells showed an interaction of RF-C p37 with Rad17 and of PCNA with Rad9 and RF-C p37. An enhanced colocalization of Rad17 and PCNA in late S phase after hydroxyurea treatment was observed. Our data suggested, that upon replication block a Rad17/RFC complex is recruited to sites of DNA lesions in late S phase, binds the Rad9/Hus1/Rad1 complex and enables it to interact with PCNA. An interaction of Rad17/RF-C with PCNA appears to be mediated by the small RF-C p37 subunit, suggesting that PCNA might provide communication between replication checkpoint control and DNA replication and repair.	Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Dahm, Kirsten/0000-0001-7194-6600				Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chang MS, 1999, J BIOL CHEM, V274, P36544, DOI 10.1074/jbc.274.51.36544; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Chen MS, 2001, GENE, V277, P145, DOI 10.1016/S0378-1119(01)00692-8; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; FOX MH, 1991, J CELL SCI, V99, P247; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Kai M, 2001, MOL CELL BIOL, V21, P3289, DOI 10.1128/MCB.21.10.3289-3301.2001; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mitchell A, 2001, NAT REV MOL CELL BIO, V2, P563, DOI 10.1038/35085000; Miura M, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.1; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	42	25	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7710	7719		10.1038/sj.onc.1205872	http://dx.doi.org/10.1038/sj.onc.1205872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400013	Green Accepted			2022-12-25	WOS:000178756200010
J	Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P				Perren, A; Barghorn, A; Schmid, S; Saremaslani, P; Roth, J; Heitz, PU; Komminoth, P			Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients	ONCOGENE			English	Article						SDHD; endocrine tumors; mutation; allelic loss	COMPARATIVE GENOMIC HYBRIDIZATION; PANCREATIC ENDOCRINE TUMORS; COMPLEX-II GENE; SUPPRESSOR GENE; HEREDITARY PARAGANGLIOMA; CARCINOID-TUMORS; HETEROZYGOSITY; CHROMOSOME-11; PHEOCHROMOCYTOMA; OXIDOREDUCTASE	Allelic loss of the long arm of chromosome 11 is frequent in neuroendocrine tumors (NET) of different organs. However, the MEN1 gene on 11q13 is mutated only in a subset of NET and allelic losses on 11q frequently extend to the telomere. In this genetic region lies the tumor suppressor gene SDHD which is associated with hereditary paragangliomas (PGL1). We sought to determine whether SDHD plays a role in the development of sporadic NET. By mutation and deletion analysis of SDHD we were unable to detect any SDHD mutation in 45 NET of the lung, gastrointestinal tract, pancreas or parathyroid. However, we found allelic deletions in 20 to 50% of all tumors but parathyroid adenomas. Furthermore, we found heterozygous germline variants in 2/8 paragangliomas. A first case of variant c.149 A > G (H50R) was found in a patient with an extra-adrenal pheochromocytoma, the other variant c.34 G > A (G12S) in a patient with a paratracheal paraganglioma, C-cell hyperplasia of the thyroid and hyperplasia of ACTH-producing cells of the pituitary gland. Both variants were absent in 93 controls. Our results demonstrate that somatic SDHD mutations are rare in sporadic NET. However, LOH alone could lead to a complete loss of function since SDHD is an imprinted gene. Furthermore, we describe two germline variants possibly causing hereditary paragangliomas.	Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Inst Pathol, CH-5404 Baden, Switzerland	University of Zurich; University Zurich Hospital	Perren, A (corresponding author), Univ Zurich Hosp, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Perren, Aurel/A-9383-2018; Perren, Aurel/N-5979-2019	Perren, Aurel/0000-0002-6819-6092; Perren, Aurel/0000-0002-6819-6092				Badenhop RF, 2001, GENE CHROMOSOME CANC, V31, P255, DOI 10.1002/gcc.1142; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y; D'Adda T, 1999, LAB INVEST, V79, P671; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; EUBANKS PJ, 1994, AM J SURG, V167, P180, DOI 10.1016/0002-9610(94)90071-X; Farnebo F, 1997, HUM GENET, V99, P342, DOI 10.1007/s004390050369; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FRIEDMAN E, 1992, CANCER RES, V52, P6804; Gimm O, 2000, CANCER RES, V60, P6822; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hirawake H, 1999, BBA-BIOENERGETICS, V1412, P295, DOI 10.1016/S0005-2728(99)00071-7; Iwasaki H, 1996, INT SURG, V81, P71; Jakobovitz G, 1996, J CLIN ENDOCR METAB, V81, P3164; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; KOMMINOTH P, 1994, AM J PATHOL, V145, P922; Malik K, 2000, CANCER RES, V60, P2356; Perren A, 1998, J PATHOL, V186, P363; Petzmann S, 2001, HUM PATHOL, V32, P333, DOI 10.1053/hupa.2001.22762; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Rigaud G, 2001, CANCER RES, V61, P285; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Speel EJM, 1999, AM J PATHOL, V155, P1787, DOI 10.1016/S0002-9440(10)65495-8; VANDERMEY AGL, 1989, LANCET, V2, P1291; Walch AK, 1998, AM J PATHOL, V153, P1089, DOI 10.1016/S0002-9440(10)65653-2; Zhao JM, 2000, AM J PATHOL, V157, P1431, DOI 10.1016/S0002-9440(10)64780-3	28	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7605	7608		10.1038/sj.onc.1205812	http://dx.doi.org/10.1038/sj.onc.1205812			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386824				2022-12-25	WOS:000178618200017
J	Zucchi, R; Ghelardoni, S; Carnicelli, V; Frascarelli, S; Ronca, F; Ronca-Testoni, S				Zucchi, R; Ghelardoni, S; Carnicelli, V; Frascarelli, S; Ronca, F; Ronca-Testoni, S			Ca2+ channel remodeling in perfused heart: effects of mechanical work and interventions affecting Ca2+ cycling on sarcolemmal and sarcoplasmic reticulum Ca2+ channels	FASEB JOURNAL			English	Article						intracellular signaling; plasticity; protein kinases; L-type channel; ryanodine receptor	CARDIAC RYANODINE RECEPTORS; PROTEIN-KINASE-II; SKELETAL-MUSCLE; RAT-HEART; CALCIUM-CHANNELS; RELEASE CHANNELS; CA-2+ CHANNEL; PHOSPHORYLATION; MODULATION; ACTIVATION	We investigated whether changes in cardiac work or in Ca2+ fluxes may affect the expression of sarcolemmal or sarcoplasmic reticulum Ca2+ channels (DHPRs and RyRs, respectively). Isolated rat hearts were perfused at low Ca2+ concentration (0.8 mM instead of 1.5 mM), at low preload (5 cm instead of 20 cm), in the presence of 100 nM nifedipine or with a cardioplegic solution. After 60 min, hypocalcemic perfusion produced significant reduction in [H-3]-PN 200-110 and [H-3]-ryanodine binding, due to approximate to30% reduction in Bmax (P<0.01), with unchanged Kd. Such modifications were reversible. Similar results were obtained in the nifedipine and cardioplegia groups. Low preload perfusion produced similar contractile effects as hypocalcemic perfusion, but it had no effect on radioligand binding. After hypocalcemic perfusion, DHPR and RyR gene expression, evaluated by RT-PCR, were not modified. Chelerythrine (protein kinase C inhibitor) and lavendustin C (Ca2+/calmodulin-dependent protein kinase II inhibitor), but not H-89 (protein kinase A inhibitor), abolished the effects of hypocalcemic perfusion on [H-3]-PN 200-110 and [H-3]-ryanodine binding. We conclude that reduced Ca2+ entry and/or intracellular Ca2+ cycling determines DHPR and RyR remodeling through posttranslational protein modifications. Both protein kinase C and Ca2+/calmodulin-dependent protein kinase II appear to play a role in this phenomenon.	Univ Pisa, Dipartimento Sci Uomo Ambiente, Sez Biochim, I-56100 Pisa, Italy	University of Pisa	Zucchi, R (corresponding author), Univ Pisa, Dipartimento Sci Uomo Ambiente, Sez Biochim, Via Roma 55, I-56100 Pisa, Italy.	r.zucchi@med.unipi.it	Zucchi, Riccardo/AAC-8963-2022	ZUCCHI, RICCARDO/0000-0002-6450-3788				Anger M, 1998, CIRCULATION, V98, P2477, DOI 10.1161/01.CIR.98.22.2477; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; GULATI J, 1990, J PHYSL, V327, P79; Houser SR, 2000, J MOL CELL CARDIOL, V32, P1595, DOI 10.1006/jmcc.2000.1206; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Lakatta EG, 1986, HEART CARDIOVASCULAR, P819; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MURPHY BJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P333, DOI 10.1016/0167-4889(90)90230-B; Nattel S, 1999, CARDIOVASC RES, V42, P298, DOI 10.1016/S0008-6363(99)00022-X; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; SainteBeuve C, 1997, J MOL CELL CARDIOL, V29, P1237; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; TAKAHASHI T, 1992, J CLIN INVEST, V90, P927, DOI 10.1172/JCI115969; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; Tavi P, 1998, CIRC RES, V83, P1165, DOI 10.1161/01.RES.83.11.1165; Temsah RM, 2001, FASEB J, V15, P2515, DOI 10.1096/fj.00-0870fje; Temsah RM, 1999, AM J PHYSIOL-HEART C, V277, pH584, DOI 10.1152/ajpheart.1999.277.2.H584; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vondriska TM, 2001, AM J PHYSIOL-HEART C, V280, pH1434, DOI 10.1152/ajpheart.2001.280.4.H1434; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zucchi R, 1998, CIRC RES, V83, P908; Zucchi R, 1997, PHARMACOL REV, V49, P1; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271; Zucchi R, 2002, J MOL CELL CARDIOL, V34, pA71, DOI 10.1016/S0022-2828(02)91010-2; Zucchi R, 1995, CARDIOVASC RES, V30, P769; Zucchi R, 2001, CARDIOVASC RES, V50, P56, DOI 10.1016/S0008-6363(00)00318-7; ZUCCHI R, 1995, CIRC RES, V76, P1049, DOI 10.1161/01.RES.76.6.1049	38	10	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1976	+		10.1096/fj.02-0402fje	http://dx.doi.org/10.1096/fj.02-0402fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397086				2022-12-25	WOS:000179167600004
J	Chang, CS; Magracheva, E; Kozlov, S; Fong, S; Tobin, G; Kotenko, S; Wlodawer, A; Zdanov, A				Chang, CS; Magracheva, E; Kozlov, S; Fong, S; Tobin, G; Kotenko, S; Wlodawer, A; Zdanov, A			Crystal structure of interleukin-19 defines a new subfamily of helical cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; RECEPTOR COMPLEXES; HOMOLOG; REVEALS; IDENTIFICATION; IL-19; CHAIN	Interleukin-19 (IL-19) is a novel cytokine that was initially identified during a sequence data base search aimed at finding potential IL-10 homologs. IL-19 shares a receptor complex with IL-20, indicating that the biological activities of these two cytokines overlap and that both may play an important role in regulating development and proper functioning of the skin. We determined the crystal structure of human recombinant IL-19 and refined it at 1.95-Angstrom resolution to an R-factor of 0.157. Unlike IL-10, which forms an intercalated dimer, the molecule of IL-19 is a monomer made of seven amphipathic helices, A-G, creating a unique helical bundle. On the basis of the observed structure, we propose that IL-19, IL-20, and other putative members of the proposed IL-10 family together form a distinct subfamily of helical cytokines.	NCI, Ctr Canc Res, Macromol Crystallog Lab, Prot Struct Sect,NIH, Frederick, MD 21702 USA; SAIC Frederick Inc, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Canc & Dev Biol Lab, NIH, Frederick, MD 21702 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center	Zdanov, A (corresponding author), NCI, Ctr Canc Res, Macromol Crystallog Lab, Prot Struct Sect,NIH, POB B, Frederick, MD 21702 USA.		Chang, Changsoo/X-3271-2018	Chang, Changsoo/0000-0003-1860-2969	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2002, EUR CYTOKINE NETW, V13, P5; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Jones BC, 2002, P NATL ACAD SCI USA, V99, P9404, DOI 10.1073/pnas.152147499; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Josephson K, 2002, STRUCTURE, V10, P981, DOI 10.1016/S0969-2126(02)00791-8; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Nagem RAP, 2002, STRUCTURE, V10, P1051, DOI 10.1016/S0969-2126(02)00797-9; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P80; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WALTER MR, 1995, BIOCHEMISTRY-US, V34, P12118, DOI 10.1021/bi00038a004; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zdanov A, 1996, PROTEIN SCI, V5, P1955, DOI 10.1002/pro.5560051001; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; [No title captured]	30	67	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3308	3313		10.1074/jbc.M208602200	http://dx.doi.org/10.1074/jbc.M208602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12403790	hybrid			2022-12-25	WOS:000180915000069
J	Molin, M; Norbeck, J; Blomberg, A				Molin, M; Norbeck, J; Blomberg, A			Dihydroxyacetone kinases in Saccharomyces cerevisiae are involved in detoxification of dihydroxyacetone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-RESPONSE; METHYLOTROPHIC YEAST; GLYOXALASE I; GENE; GLYCEROL; DEHYDROGENASE; PURIFICATION; EXPRESSION; INDUCTION; PROTEIN	The genes YML070W/DAK1 and YFL053W/DAK2 in the yeast Saccharomyces cerevisiae were characterized by a combined genetic and biochemical approach that firmly functionally classified their encoded proteins as dihydroxyacetone kinases (DAKs), an enzyme present in most organisms. The kinetic properties of the two isoforms were similar, exhibiting K-m(DHA) of 22 and 5 mum and K-m(ATP) of 0.5 and 0.1 mm for Dak1p and Dak2p, respectively. We furthermore show that their substrate, dihydroxyacetone (DRA), is toxic to yeast cells and that the detoxification is dependent on functional DAK. The importance of DAK was clearly apparent for cells where both isogenes were deleted (dak1Deltadak2Delta), since this strain was highly sensitive to DRA. In the opposite case, overexpression of either DAK1 or DAK2 made the dak1Deltadak2Delta highly resistant to DHA. In fact, overexpression of either DAK provided cells with the capacity to grow efficiently on DRA as the only carbon and energy source, with a generation time of about 5 h. The DRA toxicity was shown to be strongly dependent on the carbon and energy source utilized, since glucose efficiently suppresses the lethality, whereas galactose or ethanol did so to a much lesser extent. However, this suppression was found not to be explained by differences in DHA uptake, since uptake kinetics revealed a simple diffusion mechanism with similar capacity independent of carbon source. Salt addition strongly aggravated the DRA toxicity, independent of carbon source. Furthermore, the DHA toxicity was not linked to the presence of oxygen or to the known harmful agents methylglyoxal and formaldehyde. It is proposed that detoxification of DRA may be a vital part of the physiological response during diverse stress conditions in many species.	Univ Gothenburg, Lundberg Lab, Dept Cell & Mol Biol Microbiol, S-41390 Gothenburg, Sweden; Univ Gothenburg, Swegene Proteom Core Facil, S-41390 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Blomberg, A (corresponding author), Univ Gothenburg, Lundberg Lab, Dept Cell & Mol Biol Microbiol, Medicinaregatan 9C, S-41390 Gothenburg, Sweden.	anders.blomberg@gmm.gu.se		Molin, Mikael/0000-0002-3903-8503; Norbeck, Joakim/0000-0001-6017-2689				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Blomberg A, 2000, FEMS MICROBIOL LETT, V182, P1; BLOMBERG A, 1992, ADV MICROB PHYSIOL, V33, P145, DOI 10.1016/S0065-2911(08)60217-9; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Brachmann CB, 1998, YEAST, V14, P115; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; DANIEL R, 1995, J BACTERIOL, V177, P4392, DOI 10.1128/jb.177.15.4392-4401.1995; FERNANDEZ MR, 1995, FEBS LETT, V370, P23; FRAENKEL DG, 1982, MOL BIOL YEAST SACCH, P1; GANCEDO C, 1986, EUR J BIOCHEM, V159, P171, DOI 10.1111/j.1432-1033.1986.tb09848.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gonzalez E, 2000, J BIOL CHEM, V275, P35876, DOI 10.1074/jbc.M003035200; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KATO N, 1988, ARCH MICROBIOL, V150, P155, DOI 10.1007/BF00425155; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; Luers GH, 1998, YEAST, V14, P759; MARSHALL JH, 1986, J GEN MICROBIOL, V132, P2611; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Piper P, 2001, MICROBIOL-SGM, V147, P2635, DOI 10.1099/00221287-147-10-2635; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Sakai Y, 1998, J BACTERIOL, V180, P5885, DOI 10.1128/JB.180.22.5885-5890.1998; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; Valadi H, 2001, J MICROBIOL METH, V47, P51, DOI 10.1016/S0167-7012(01)00288-3; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; VIIKARI L, 1986, APPL MICROBIOL BIOT, V24, P471; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang ZX, 2002, YEAST, V19, P1447, DOI 10.1002/yea.928; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; Yoshihara K, 1996, APPL ENVIRON MICROB, V62, P4663, DOI 10.1128/AEM.62.12.4663-4665.1996	42	74	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1415	1423		10.1074/jbc.M203030200	http://dx.doi.org/10.1074/jbc.M203030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12401799	hybrid			2022-12-25	WOS:000180462200008
J	Canela, N; Rodriguez-Vilarrupla, A; Estanyol, JM; Diaz, C; Pujol, MJ; Agell, N; Bachs, O				Canela, N; Rodriguez-Vilarrupla, A; Estanyol, JM; Diaz, C; Pujol, MJ; Agell, N; Bachs, O			The SET protein regulates G(2)/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE UNDIFFERENTIATED LEUKEMIA; DNA-REPLICATION; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; RAN/TC4 GTPASE; IDENTIFICATION; GENE; TRANSCRIPTION; GADD45; PCNA	The SET protein and the cell cycle inhibitor p21(Cip1) interact in vivo and in vitro. We identified here the domain (LIF159)-L-157 of p21(Cip1) as essential for the binding of SET. We also found that SET contains at least two domains of interaction with p21(Cip1), one located in the fragment amino acids 81-180 and the other one in the fragment including amino acids 181-277. SET and p21(Cip1) co-localize in the cell nucleus in a temporal manner. Overexpression of SET blocks the cell cycle at the G(2)/M transition in COS and HCT116 cells. Moreover, SET inhibits cyclin B-CDK1 activity both in vivo and in vitro in both cell types. This effect is specific for these complexes since SET did not inhibit either cyclin A-CDK2 or cyclin E-CDK2 complexes. SET and p21(Cip1) cooperate in the inhibition of cyclin B-CDK1 activity. The inhibitory effect of SET resides in its acidic C terminus, as demonstrated by the ability of this domain to inhibit cyclin B-CDK1 activity and by the lack of blocking G(2)/M transition when a mutated form of SET lacking this C terminus domain was overexpressed in COS cells. These results indicate that SET might regulate G(2)/M transition by modulating cyclin B-CDK1 activity.	Univ Barcelona, Inst Invest Biomed August Pi Sunyer, Dept Biol Cellular & Anat Patol, Fac Med, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, Casanova 143, Barcelona 08036, Spain.	bachs@medicina.ub.es	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Canela, Núria/I-5401-2015	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Canela, Núria/0000-0003-0261-2396				ADACHI Y, 1994, FEBS LETT, V340, P231, DOI 10.1016/0014-5793(94)80144-4; ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; CHEN IT, 1995, ONCOGENE, V11, P1931; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vairapandi M, 1996, ONCOGENE, V12, P2579; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	31	121	130	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1158	1164		10.1074/jbc.M207497200	http://dx.doi.org/10.1074/jbc.M207497200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12407107	hybrid			2022-12-25	WOS:000180321900061
J	Cao, ZH; Warfel, P; Newton, SMC; Klebba, PE				Cao, ZH; Warfel, P; Newton, SMC; Klebba, PE			Spectroscopic observations of ferric enterobactin transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; BACTERIAL OUTER-MEMBRANE; MEDIATED IRON TRANSPORT; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; BINDING-SITES; CELL-ENVELOPE; FHUA PROTEIN; TONB PROTEIN; LIGAND	We characterized the uptake of ferric enterobactin (FeEnt), the native Escherichia coli ferric siderophore, through its cognate outer membrane receptor protein, FepA, using a site-directed fluorescence methodology. The experiments first defined locations in FepA that were accessible to covalent modification with fluorescein maleimide (FM) in vivo; among 10 sites that we tested by substituting single Cys residues, FM labeled W101C, S271C, F329C, and S397C, and all these exist within surface-exposed loops of the outer membrane protein. FeEnt normally adsorbed to the fluoresceinated S271C and S397C mutant FepA proteins in vivo, which we observed as quenching of fluorescence intensity, but the ferric siderophore did not bind to the FM-modified derivatives of W101C or F329C. These in vivo fluorescence determinations showed, for the first time, consistency with radioisotopic measurements of the affinity of the FeEnt-FepA interaction; K-d was 0.2 nm by both methods. Analysis of the FepA mutants with AlexaFluor(680), a fluorescein derivative with red-shifted absorption and emission spectra that do not overlap the absorbance spectrum of FeEnt, refuted the possibility that the fluorescence quenching resulted from resonance energy transfer. These and other data instead indicated that the quenching originated from changes in the environment of the fluor as a result of loop conformational changes during ligand binding and transport. We used the fluorescence system to monitor FeEnt uptake by live bacteria and determined its dependence on ligand concentration, temperature, pH, and carbon sources and its susceptibility to inhibition by the metabolic poisons. Unlike cyanocobalamin transport through the outer membrane, FeEnt uptake was sensitive to inhibitors of electron transport and phosphorylation, in addition to its sensitivity to proton motive force depletion.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Klebba, PE (corresponding author), Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.	peklebba@ou.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053836, R01 GM053836-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; Bos C, 1998, J BACTERIOL, V180, P605; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CAO Z, 1999, THESIS U OKLAHOMA; Cao ZH, 2000, MOL MICROBIOL, V37, P1306, DOI 10.1046/j.1365-2958.2000.02093.x; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; ECKER DJ, 1986, J BACTERIOL, V167, P666, DOI 10.1128/jb.167.2.666-673.1986; Einstein A, 1906, ANN PHYS-BERLIN, V19, P371; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FISS EH, 1982, BIOCHEMISTRY-US, V21, P4517, DOI 10.1021/bi00261a050; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KLEBBA PE, 1982, J BACTERIOL, V149, P880, DOI 10.1128/JB.149.3.880-888.1982; Klebba PE, 1998, CURR OPIN MICROBIOL, V1, P238, DOI 10.1016/S1369-5274(98)80017-9; KLUG CS, 1995, BIOCHEMISTRY-US, V34, P14230, DOI 10.1021/bi00043a030; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Langevin P, 1908, CR HEBD ACAD SCI, V146, P530; LEONG J, 1976, J BACTERIOL, V126, P823, DOI 10.1128/JB.126.2.823-830.1976; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; Locher KP, 1997, EUR J BIOCHEM, V247, P770, DOI 10.1111/j.1432-1033.1997.t01-1-00770.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Newton SMC, 1999, MOL MICROBIOL, V32, P1153, DOI 10.1046/j.1365-2958.1999.01424.x; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Payne MA, 1997, J BIOL CHEM, V272, P21950, DOI 10.1074/jbc.272.35.21950; POLLACK JR, 1970, BIOCHEM BIOPH RES CO, V38, P989, DOI 10.1016/0006-291X(70)90819-3; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PUGSLEY AP, 1976, J BACTERIOL, V127, P218, DOI 10.1128/JB.127.1.218-228.1976; PUGSLEY AP, 1977, J BACTERIOL, V130, P26, DOI 10.1128/JB.130.1.26-36.1977; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; Schalk IJ, 1999, BIOCHEMISTRY-US, V38, P9357, DOI 10.1021/bi990421x; Schalk IJ, 2002, BIOCHEMISTRY-US, V41, P1663, DOI 10.1021/bi0157767; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; Scott DC, 2002, J BACTERIOL, V184, P4906, DOI 10.1128/JB.184.17.4906-4911.2002; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Sprencel C, 2000, J BACTERIOL, V182, P5359, DOI 10.1128/JB.182.19.5359-5364.2000; Thulasiraman P, 1998, J BACTERIOL, V180, P6689, DOI 10.1128/JB.180.24.6689-6696.1998; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; WANG CC, 1971, J BIOL CHEM, V246, P2147; WANG CC, 1969, J BACTERIOL, V98, P1142, DOI 10.1128/JB.98.3.1142-1150.1969; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976	56	27	27	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1022	1028		10.1074/jbc.M210360200	http://dx.doi.org/10.1074/jbc.M210360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409288	hybrid			2022-12-25	WOS:000180321900044
J	Huang, YZ; Zang, MW; Xiong, WC; Luo, ZJ; Mei, L				Huang, YZ; Zang, MW; Xiong, WC; Luo, ZJ; Mei, L			Erbin suppresses the MAP kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; ACTIVATED PROTEIN-KINASE; BASOLATERAL PDZ PROTEIN; PHEOCHROMOCYTOMA CELLS; ERBB2/HER2 RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; RAF-BINDING; INTERACTS; DOMAIN	We present evidence here that Erbin is a negative regulator of the Ras-Raf-Erk signaling pathway. Expression of Erbin decreases transcription of the AChR E-subunit gene, an event that is mediated by Erk activation. Although it interacts with the ErbB2 C terminus through the PDZ domain, Erbin has no effect on ErbB2 tyrosine phosphorylation or binding to the adaptor proteins She and Grb2. In contrast, expression of Erbin greatly impairs activation of Erk, but not Akt, by ligands that activate receptor tyrosine kinases. Moreover, Erbin inhibits the Erk activation by active Ras, while it fails to do so in the presence of active Raf-1. Erbin associates with active Ras, but not inactive Ras nor Raf. Consistently, Erbin interferes with the interaction between Ras and Raf both in vivo and in vitro. Finally, overexpression of Erbin leads to inhibition of NGF-induced neuronal differentiation of PC12 cells, whereas down-regulation of endogenous Erbin by specific siRNA exhibits an opposite effect. Collectively, our study has identified Erbin as a novel suppressor of the Ras signaling by disrupting the Ras-Raf interaction.	Univ Alabama, Civitan Int Res Ctr, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Civitan Int Res Ctr, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Civitan Int Res Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Boston University	Mei, L (corresponding author), Univ Alabama, Civitan Int Res Ctr, Dept Neurobiol, Birmingham, AL 35294 USA.		Luo, Zhijun/AAE-9302-2019; Mei, Lin/G-8755-2012	Luo, Zhijun/0000-0001-8105-5289; Zang, Mengwei/0000-0002-2502-2586	NINDS NIH HHS [NS40480] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040480] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Apperson ML, 1996, J NEUROSCI, V16, P6839; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Li WQ, 2000, GENE DEV, V14, P895; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200	46	96	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1108	1114		10.1074/jbc.M205413200	http://dx.doi.org/10.1074/jbc.M205413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12379659	hybrid			2022-12-25	WOS:000180321900055
J	Reinbothe, C; Lepinat, A; Deckers, M; Beck, E; Reinbothe, S				Reinbothe, C; Lepinat, A; Deckers, M; Beck, E; Reinbothe, S			The extra loop distinguishing POR from the structurally related short-chain alcohol dehydrogenases is dispensable for pigment binding but needed for the assembly of light-harvesting POR-protochlorophyllide complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER; PROTEIN COMPLEX; CHLOROPHYLL-A; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; OXIDOREDUCTASE; NADPH; BARLEY; MEMBRANE; PRECURSOR	We have recently discovered a protochlorophyllide (Pehlide)-based light-harvesting complex involved in chlorophyll a biosynthesis. This complex consists of the two previously identified NADPH:protochlorophyllide oxidoreductases (PORs), PORA and PORB, their natural substrates (Pchlide b and Pehlide a, respectively), plus NADPH. These are all held together in a stoichiometry of five PORA-Pchlide b-NADPH complexes and one PORB-Pchlide a-NADPH complex in the prolamellar body of etioplasts. The assembly of this novel light-harvesting POR-Pchlide complex (LHPP) requires both the proper interaction of the PORA and PORB with their cognate substrates as well as the oligomerization of the resulting POR-pigment-NADPH ternary complexes into the native, lipid-containing structure of the etioplast. In this study, we demonstrate that the conserved extra sequence that distinguishes PORA and PORB from the structurally related short-chain alcohol dehydrogenases, is dispensable for pigment binding but needed for the assembly of LHPP. As shown by in vitro mutagenesis, deleting this extra sequence gave rise to assembly-incompetent but pigment-containing PORA and PORB polypeptides.	Univ Bayreuth, Lehrstuhl Pflanzenbiol, D-95447 Bayreuth, Germany; Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44801 Bochum, Germany; Univ Grenoble 1, UMR 5575, CERMO, F-38041 Grenoble, France; CNRS, UMR 5575, CERMO, F-38041 Grenoble, France	University of Bayreuth; Ruhr University Bochum; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Reinbothe, S (corresponding author), Univ Bayreuth, Lehrstuhl Pflanzenbiol, Univ Str 30, D-95447 Bayreuth, Germany.	christiane.reinbothe@uni-bayreuth.de	Reinbothe, Steffen/AAW-9893-2021					ARMSTRONG GA, 1995, PLANT PHYSIOL, V108, P1505, DOI 10.1104/pp.108.4.1505; BAKER ME, 1994, BIOCHEM J, V300, P605; Birve SJ, 1996, BIOCHEM J, V317, P549, DOI 10.1042/bj3170549; BOARDMAN NK, 1962, BIOCHIM BIOPHYS ACTA, V62, P63, DOI 10.1016/0006-3002(62)90492-4; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; Dahlin C, 1999, PLANT MOL BIOL, V39, P309, DOI 10.1023/A:1006135100760; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P829, DOI 10.1104/pp.106.3.829; EADS DD, 1989, J PHYS CHEM-US, V93, P8271, DOI 10.1021/j100363a001; FRADKIN LI, 1993, PHOTOSYNTHETICA, V29, P227; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GRANICK S, 1949, HARVEY LECT, V44, P220; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; HOLTORF H, 1995, P NATL ACAD SCI USA, V92, P3254, DOI 10.1073/pnas.92.8.3254; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; IGNATOV NV, 1981, BIOFIZIKA+, V26, P664; Innis MA, 1990, PCR PROTOCOLS GUIDE; KAHN A, 1970, J MOL BIOL, V48, P85, DOI 10.1016/0022-2836(70)90220-2; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; Martin GEM, 1997, BIOCHEM J, V325, P139, DOI 10.1042/bj3250139; MATHIS P, 1972, BIOCHIM BIOPHYS ACTA, V267, P498, DOI 10.1016/0005-2728(72)90178-8; Neff MM, 2000, GENE DEV, V14, P257; ORT DR, 1996, OXYGENIC PHOTOSYNTHE; PALSSON LO, 1994, FEBS LETT, V339, P134, DOI 10.1016/0014-5793(94)80400-1; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REINBOTHE C, 1995, MOL CELL BIOL, V15, P6206; Reinbothe C, 2003, J BIOL CHEM, V278, P807, DOI 10.1074/jbc.M209738200; Reinbothe C, 1997, P NATL ACAD SCI USA, V94, P8890, DOI 10.1073/pnas.94.16.8890; Reinbothe C, 1999, NATURE, V397, P80, DOI 10.1038/16283; REINBOTHE S, 1995, PLANT CELL, V7, P161, DOI 10.1105/tpc.7.2.161; REINBOTHE S, 1995, PLANT CELL, V7, P1933, DOI 10.1105/tpc.7.11.1933; REINBOTHE S, 1995, J CELL BIOL, V129, P299, DOI 10.1083/jcb.129.2.299; Reinbothe S, 1996, EUR J BIOCHEM, V237, P323, DOI 10.1111/j.1432-1033.1996.00323.x; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scheumann V, 1999, FEBS LETT, V445, P445, DOI 10.1016/S0014-5793(99)00169-6; SCHOCH S, 1995, EUR J BIOCHEM, V229, P291, DOI 10.1111/j.1432-1033.1995.tb20468.x; SCHULZ R, 1989, MOL GEN GENET, V217, P355, DOI 10.1007/BF02464904; SMITH JHC, 1954, PLANT PHYSIOL, V29, P135, DOI 10.1104/pp.29.2.135; SUZUKI JY, 1995, P NATL ACAD SCI USA, V92, P3749, DOI 10.1073/pnas.92.9.3749; Townley HE, 2001, PROTEINS, V44, P329, DOI 10.1002/prot.1098; TSIGELNY I, 1995, J STEROID BIOCHEM, V55, P445; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; VAUGHAN GD, 1974, BIOCHIM BIOPHYS ACTA, V347, P383, DOI 10.1016/0005-2728(74)90077-2; VIRGIN HI, 1963, PHOTOCHEM PHOTOBIOL, V2, P83, DOI 10.1111/j.1751-1097.1963.tb08205.x; VON WETTSTEIN D, 1995, PLANT CELL, V7, P1039, DOI 10.1105/tpc.7.7.1039; WIKTORSSON B, 1993, PHOTOSYNTHETICA, V29, P205; WILKS HM, 1995, P NATL ACAD SCI USA, V92, P724, DOI 10.1073/pnas.92.3.724; WOOLF TB, 1994, P NATL ACAD SCI USA, V91, P11631, DOI 10.1073/pnas.91.24.11631	53	12	12	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					816	822		10.1074/jbc.M209739200	http://dx.doi.org/10.1074/jbc.M209739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401791	hybrid			2022-12-25	WOS:000180321900018
J	Chen, SY; Kao, CF; Chen, CM; Shih, CM; Hsu, MJ; Chao, CH; Wang, SH; You, LR; Lee, YHW				Chen, SY; Kao, CF; Chen, CM; Shih, CM; Hsu, MJ; Chao, CH; Wang, SH; You, LR; Lee, YHW			Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LYMPHOTOXIN-BETA RECEPTOR; NUCLEAR-LOCALIZATION SIGNAL; GENOMIC RNA ENCAPSIDATION; AMINO-TERMINAL DOMAIN; TATA-BINDING PROTEIN; X-PROTEIN; REVERSE TRANSCRIPTION; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; DNA-SYNTHESIS	We have demonstrated previously that the core protein of hepatitis C virus (HCV) exhibits suppression activity on gene expression and replication of hepatitis B virus (HBV). Here we further elucidated the suppression mechanism of HCV core protein. We demonstrated that HCV core protein retained the inhibitory effect on HBV gene expression and replication when expressed as part of the full length of HCV polyprotein. Based on the substitution mutational analysis, our results suggested that mutation introduced into the bipartite nuclear localization signal of the HCV core protein resulted in the cytoplasmic localization of core protein but did not affect its suppression ability on HBV gene expression. Mutational studies also indicated that almost all dibasic residue mutations within the N-terminal 101-amino acid segment of the HCV core protein (except Arg(39)-Arg(40)) impaired the suppression activity on HBV replication but not HBV gene expression. The integrity of Arg residues at positions 101, 113, 114, and 115 was found to be essential for both suppressive effects, whereas the Arg residue at position 104 was important only in the suppression of HBV gene expression. Moreover, our results indicated that the suppression on HBV gene expression was mediated through the direct interaction of HCV core protein with the trans-activator HBx protein, whereas the suppression of HBV replication involved the complex formation between HBV polymerase (pol) and the HCV core protein, resulting in the structural incompetence for the HBV pol to bind the package signal and consequently abolished the formation of the HBV virion. Altogether, this study suggests that these two suppression effects on HBV elicited by the HCV core protein likely depend on different structural context but not on nuclear localization of the core protein, and the two effects can be decoupled as revealed by its differential targets (HBx or HBV pol) on these two processes of the HBV life cycle.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.		wang, shaohung/E-4017-2015	wang, shaohung/0000-0002-6824-0372; Chen, Chun-Ming/0000-0001-8873-7602; You, Li-Ru/0000-0003-1775-0097; Chao, Chi-Hong/0000-0001-9890-4902; Lee Wu, Yan-Hwa/0000-0001-7299-7354				Andrisani OM, 1999, INT J ONCOL, V15, P373; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; Beck J, 1998, MOL CELL BIOL, V18, P6265, DOI 10.1128/MCB.18.11.6265; Beck J, 1997, J VIROL, V71, P4971, DOI 10.1128/JVI.71.7.4971-4980.1997; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; BRADLEY DW, 1983, J MED VIROL, V11, P207, DOI 10.1002/jmv.1890110304; CHAN CY, 1991, SCAND J INFECT DIS, V23, P421, DOI 10.3109/00365549109075089; CHANG J, 1995, J VIROL, V69, P801, DOI 10.1128/JVI.69.2.801-808.1995; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen KL, 2001, J BIOMED SCI, V8, P492, DOI 10.1007/BF02256612; CHEN Y, 1994, J VIROL, V68, P5232, DOI 10.1128/JVI.68.8.5232-5238.1994; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Fattovich G, 1998, HEPATO-GASTROENTEROL, V45, P1206; FATTOVICH G, 1991, J INFECT DIS, V163, P400, DOI 10.1093/infdis/163.2.400; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ganem D, 2001, SCIENCE, V294, P2299, DOI 10.1126/science.1067850; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; Jardi R, 2001, HEPATOLOGY, V34, P404, DOI 10.1053/jhep.2001.26511; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MMC, 2000, HEPATOLOGY, V32, P427, DOI 10.1053/jhep.2000.9856; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIAW YF, 1994, GASTROENTEROLOGY, V106, P1048, DOI 10.1016/0016-5085(94)90766-8; LIAW YF, 1995, HEPATOLOGY, V22, P1101, DOI 10.1016/0270-9139(95)90615-0; LIAW YF, 1991, INFECTION, V250, P54; LIN CG, 1992, VIROLOGY, V188, P342, DOI 10.1016/0042-6822(92)90763-F; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lu FM, 1999, BIOCHEM BIOPH RES CO, V264, P69, DOI 10.1006/bbrc.1999.1424; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NAKATAKE H, 1993, VIROLOGY, V195, P305, DOI 10.1006/viro.1993.1381; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; NATOLI G, 1994, ONCOGENE, V9, P2837; OHKAWA K, 1995, J MED VIROL, V46, P258, DOI 10.1002/jmv.1890460316; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; ROYCHOUDHURY S, 1991, J VIROL, V65, P3617, DOI 10.1128/JVI.65.7.3617-3624.1991; Sagnelli E, 2000, HEPATOLOGY, V32, P1106, DOI 10.1053/jhep.2000.19288; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMOLKE S, 1995, J VIROL, V69, P1071, DOI 10.1128/JVI.69.2.1071-1078.1995; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; TAKEUCHI K, 1990, NUCLEIC ACIDS RES, V18, P4626, DOI 10.1093/nar/18.15.4626; Tavis JE, 1996, J VIROL, V70, P5741, DOI 10.1128/JVI.70.9.5741-5750.1996; TAVIS JE, 1994, J VIROL, V68, P3536, DOI 10.1128/JVI.68.6.3536-3543.1994; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; YU MW, 1991, CANCER RES, V51, P5621; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	119	118	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					591	607		10.1074/jbc.M204241200	http://dx.doi.org/10.1074/jbc.M204241200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401801	hybrid			2022-12-25	WOS:000180255700077
J	Gao, BC; Tsan, MF				Gao, BC; Tsan, MF			Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor a release by murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TOLL-LIKE RECEPTOR-4; MOLECULAR CHAPERONES; COATED VESICLES; CUTTING EDGE; INNATE; SIGNAL; LIPOPOLYSACCHARIDE; CLATHRIN; PATHWAY	Using commercially available recombinant human heat shock protein 70 (rhHsp70), recent studies have shown that rhHsp70 could induce the production of tumor necrosis factor alpha (TNFalpha) by macrophages and monocytes in a manner similar to lipopolysaccharide (LPS) e.g. via CD14 and Toll-like receptor 4-mediated signal transduction pathway. In the current study, we demonstrated that a highly purified rhHsp70 preparation (designated as rhHsp70-1) with a LPS content of 1.4 pg/mug was unable to induce TNFalpha release by RAW264.7 murine macrophages at concentrations up to 5 mug/ml. In contrast, a less purified rhHsp70 preparation (designated as rhHsp70-2) at 1 mug/ml with a LPS content of 0.2 ng/mug was able to induce TNFalpha release to the same extent as that induced by 0.2 ng/ml LPS. Failure of rhHsp70-1 to induce TNFalpha release was not because of defective physical properties since rhHsp70-1 and rhHsp70-2 contained identical hsp70 content as determined by SDS gels stained with Coomassie Blue and Western blots probed with an anti-rhHsp70 antibody. Both rhHsp70 preparations also had similar enzymatic activities as judged by their ability to remove clathrin from clathrin-coated vesicles. Removal of LPS from rhHsp70-2 by polymyxin B-agarose column or direct addition of polymyxin B to the incubation medium essentially eliminated the TNFalpha-inducing activity of rhHsp70-2. The addition of LPS at the concentration found in rhHsp70-2 to rhHsp70-1 resulted in the same TNFalpha-inducing activity as observed with rhHsp70-2. The TNFalpha-inducing activities of rhHsp-2, LPS alone, and LPS plus rhHsp70-1 were all equally sensitive to heat inactivation. These results suggest that rhHsp-70 does not induce TNFa release from murine macrophages and that the observed TNFa-inducing activity in the rhHsp70-2 preparation is entirely due to the contaminating LPS.	Vet Affairs Med Ctr, Washington, DC 20422 USA; Inst Clin Res, Washington, DC 20422 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gao, BC (corresponding author), Vet Affairs Med Ctr, 10R,50 Irving St NW, Washington, DC 20422 USA.	baochong.gao@med.va.gov						Antal-Szalmas P, 2000, EUR J CLIN INVEST, V30, P167; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617; Fisher R.A., 1963, STAT TABLES BIOL AGR, V6th; GAO BC, 1991, J BIOL CHEM, V266, P19565; Gao BC, 2002, AM J PHYSIOL-CELL PH, V283, pC1196, DOI 10.1152/ajpcell.00064.2002; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; JONES BW, 2001, ANN RHEUM DIS     S3, V60, P6; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Rea IM, 2001, EXP GERONTOL, V36, P341, DOI 10.1016/S0531-5565(00)00215-1; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Stelter F, 2000, CHEM IMMUNOL, V74, P25; Tapping RI, 2000, CHEM IMMUNOL, V74, P108; TSAN MF, 2001, AM J PHYSIOL-CELL PH, V280, P1422; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vikstrom EV, 2002, IMMUNOL LETT, V80, P15, DOI 10.1016/S0165-2478(01)00298-X; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8	33	317	332	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					174	179		10.1074/jbc.M208742200	http://dx.doi.org/10.1074/jbc.M208742200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403778	hybrid			2022-12-25	WOS:000180255700023
J	Golab, J; Nowis, D; Skrzycki, M; Czeczot, H; Baranczyk-Kuzma, A; Wilczynski, GM; Makowski, M; Mroz, P; Kozar, K; Kaminski, R; Jalili, A; Kopec, M; Grzela, T; Jakobisiak, M				Golab, J; Nowis, D; Skrzycki, M; Czeczot, H; Baranczyk-Kuzma, A; Wilczynski, GM; Makowski, M; Mroz, P; Kozar, K; Kaminski, R; Jalili, A; Kopec, M; Grzela, T; Jakobisiak, M			Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol - A superoxide dismutase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN METABOLITE; AMINOLEVULINIC ACID; HYDROGEN-PEROXIDE; BREAST-CANCER; FREE-RADICALS; GAMMA-RAYS; IN-VITRO; CARCINOMA; RADIATION; APOPTOSIS	Photodynamic therapy (PDT), a promising therapeutic modality for the management of solid tumors, is a two-phase treatment consisting of a photosensitizer and visible light. Increasing evidence indicates that tumor cells in regions exposed to sublethal doses of PDT can respond by rescue responses that lead to insufficient cell death. We decided to examine the role of superoxide dismutases (SODs) in the effectiveness of PDT and to investigate whether 2-methoxyestradiol (2-McOE(2)), an inhibitor of SODs, is capable of potentiating the antitumor effects of this treatment regimen. In the initial experiment we observed that PDT induced the expression of MnSOD but not Cu,Zn-SOD in cancer cells. Pretreatment of cancer cells with a cell-permeable SOD mimetic, Mn(II)-tetrakis(4-benzoic acid)porphyrin chloride, and transient transfection with the MnSOD gene resulted in a decreased effectiveness of PDT. Inhibition of SOD activity in tumor cells by preincubation with 2-MeOE2 produced synergistic antitumor effects when combined with PDT in 3 murine and 5 human tumor cell lines. The combination treatment was also effective in vivo producing retardation of the tumor growth and prolongation of the survival of tumor-bearing mice. We conclude that inhibition of MnSOD activity by 2-MeOE2 is an effective treatment modality capable of potentiating the antitumor effectiveness of PDT.	Med Univ Warsaw, Dept Immunol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Biochem, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Pathol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Histol & Embryol, Ctr Biostruct Res, PL-02004 Warsaw, Poland; Med Univ Warsaw, Dept Gen & Vasc Surg & Transplantat, PL-02004 Warsaw, Poland	Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw	Golab, J (corresponding author), Med Univ Warsaw, Dept Immunol, Ctr Biostruct Res, Chalubinskiego 5, PL-02004 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Mroz, Pawel/P-1258-2019; Golab, Jakub/K-6974-2013; Skrzycki, Michał/X-3743-2018; Nowis, Dominika/P-6866-2019; Nowis, Dominika/P-1213-2017; CZECZOT, HANNA/ABB-6415-2020	Golab, Jakub/0000-0002-2830-5100; Skrzycki, Michał/0000-0001-7087-1037; Nowis, Dominika/0000-0003-2748-9523; Nowis, Dominika/0000-0003-2748-9523; Kaminski, Rafal/0000-0003-4552-3596; Mroz, Pawel/0000-0003-3838-4743; CZECZOT, HANNA/0000-0001-8541-6619; Wilczynski, Grzegorz/0000-0001-6667-0291; Kozar-Kaminska, Katarzyna/0000-0002-2397-2975				ALLARDICE JT, 1994, SURG ONCOL, V3, P1, DOI 10.1016/0960-7404(94)90018-3; Allison R, 2001, CANCER, V91, P1, DOI 10.1002/1097-0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-P; Amorino GP, 2000, RADIAT RES, V153, P384, DOI 10.1667/0033-7587(2000)153[0384:EOREIV]2.0.CO;2; ATHAR M, 1988, BIOCHEM BIOPH RES CO, V151, P1054, DOI 10.1016/S0006-291X(88)80472-8; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Berr F, 2000, HEPATOLOGY, V31, P291, DOI 10.1002/hep.510310205; Bown SG, 2002, GUT, V50, P549, DOI 10.1136/gut.50.4.549; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Das Hiranmoy, 2000, International Journal of Clinical Oncology, V5, P97, DOI 10.1007/s101470050098; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gilaberte Y, 1997, PHOTODERMATOL PHOTO, V13, P43, DOI 10.1111/j.1600-0781.1997.tb00107.x; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2002, CLIN CANCER RES, V8, P1265; Golab J, 2001, LEUKEMIA, V15, P613; Goodell T T, 2001, J Neurosci Nurs, V33, P296; Hadjur C, 1997, J PHOTOCH PHOTOBIO B, V38, P196, DOI 10.1016/S1011-1344(96)07440-4; HENDERSON BW, 1987, CANCER RES, V47, P3110; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kachadourian R, 2001, ARCH BIOCHEM BIOPHYS, V392, P349, DOI 10.1006/abbi.2001.2455; Kashtan H, 1999, GASTROINTEST ENDOSC, V49, P760, DOI 10.1016/S0016-5107(99)70297-X; Kinuya S, 2001, EUR J NUCL MED, V28, P1306, DOI 10.1007/s002590100585; Klauber N, 1997, CANCER RES, V57, P81; Korbelik M, 2000, BRIT J CANCER, V82, P1835, DOI 10.1054/bjoc.2000.1157; Kuninaka S, 2000, BRIT J CANCER, V83, P928, DOI 10.1054/bjoc.2000.1367; Kuroda M, 2000, ANTICANCER RES, V20, P7; MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328; MARTINEZCAYUELA M, 1995, BIOCHIMIE, V77, P147, DOI 10.1016/0300-9084(96)88119-3; Mimura S, 1996, LASER SURG MED, V19, P168; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Morgan J, 2000, PHOTOCHEM PHOTOBIOL, V71, P747, DOI 10.1562/0031-8655(2000)071<0747:COPTIA>2.0.CO;2; Nakano T, 1996, CANCER RES, V56, P2771; RIGO A, 1975, BIOCHEM BIOPH RES CO, V63, P1013, DOI 10.1016/0006-291X(75)90670-1; Salet C, 1997, FREE RADICAL RES, V26, P201, DOI 10.3109/10715769709097800; Schumacher G, 1999, CLIN CANCER RES, V5, P493; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; Ueta E, 1999, JPN J CANCER RES, V90, P555, DOI 10.1111/j.1349-7006.1999.tb00783.x; Ueta E, 2001, INT J CANCER, V94, P545, DOI 10.1002/ijc.1513; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WHITE L, 1988, BRIT J CANCER, V57, P455, DOI 10.1038/bjc.1988.106; Wilson BC, 1997, PHOTOCHEM PHOTOBIOL, V65, P166, DOI 10.1111/j.1751-1097.1997.tb01894.x; Wood L, 2001, ANTI-CANCER DRUG DES, V16, P209; Wyss P, 2001, INT J CANCER, V93, P720, DOI 10.1002/ijc.1400; Zhang Y, 2002, CANCER RES, V62, P1205	46	103	110	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					407	414		10.1074/jbc.M209125200	http://dx.doi.org/10.1074/jbc.M209125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409296	hybrid			2022-12-25	WOS:000180255700054
J	Hinkle, A; Tobacman, LS				Hinkle, A; Tobacman, LS			Folding and function of the troponin tail domain - Effects of cardiomyopathic troponin T mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; RABBIT SKELETAL-MUSCLE; MYOSIN SUBFRAGMENT 1; PROTEIN-C GENE; THIN FILAMENT; ALPHA-TROPOMYOSIN; CRYSTAL-STRUCTURE; CA2+ SENSITIVITY; TERMINAL REGION; ATPASE ACTIVITY	Troponin contains a globular Ca2+-binding domain and an elongated tail domain composed of the N terminus of subunit troponin T (TnT). The tail domain anchors troponin to tropomyosin and actin, modulates myosin function, and is a site of cardiomyopathy-inducing mutations. Critical interactions between tropomyosin and troponin are proposed to depend on tail domain residues 112-136, which are highly conserved across phyla. Most cardiomyopathy mutations in TnT flank this region. Three such mutations were examined and had contrasting effects on peptide TnT-(1-156), promoting folding and thermal stability assessed by circular dichroism (F110I) or weakening folding and stability (T104V and to a small extent R92Q). Folding of both TnT-(1-156) and whole troponin was promoted by replacing bovine TnT Thr-104 with human TnT Ala-104, further indicating the importance of this cardiomyopathy site residue for protein folding. Mutation F110I markedly stabilized the troponin tail but weakened binding of holo-troponin to actin-tropomyosin 8-fold, suggesting that loss of flexibility impairs troponin tail function. The effect of the F110I mutation on troponin-tropomyosin binding to actin was much less, indicating this flexibility is particularly important for the interactions of troponin with tropomyosin. We suggest that most cardiomyopathic mutations in the troponin tail alter muscle function indirectly, by perturbing interactions between troponin and tropomyosin requisite for the complex effects of these proteins on myosin.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Dr,SE-610-GH, Iowa City, IA 52242 USA.	tobacman@uiowa.edu						BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Bottinelli R, 1998, CIRC RES, V82, P106; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; BYERS DM, 1979, FEBS LETT, V104, P106, DOI 10.1016/0014-5793(79)81093-5; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1981, BIOPHYS CHEM, V14, P31, DOI 10.1016/0301-4622(81)87004-4; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; Karibe A, 2001, CIRCULATION, V103, P65; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Maytum R, 2002, J BIOL CHEM, V277, P29774, DOI 10.1074/jbc.M201761200; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; Michele DE, 1999, NAT MED, V5, P1413; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PHILLIPS GN, 1979, NATURE, V278, P413, DOI 10.1038/278413a0; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; Smith DA, 2001, J PHYS A-MATH GEN, V34, P4507, DOI 10.1088/0305-4470/34/21/307; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2002, BIOPHYS J, V82, p170A; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; Torrealba JR, 2002, J MOL CELL CARDIOL, V34, P797, DOI 10.1006/jmcc.2002.2016; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806	64	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					506	513		10.1074/jbc.M209194200	http://dx.doi.org/10.1074/jbc.M209194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409295	hybrid			2022-12-25	WOS:000180255700067
J	Kim, HJ; Kim, JH; Bae, SC; Choi, JY; Kim, HJ; Ryoo, HM				Kim, HJ; Kim, JH; Bae, SC; Choi, JY; Kim, HJ; Ryoo, HM			The protein kinase c pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOBLAST DIFFERENTIATION; CROUZON-SYNDROME; CLEIDOCRANIAL DYSPLASIA; SIGNALING PATHWAYS; FACTOR RECEPTOR-2; OSTEOCALCIN GENE; DOWN-REGULATION; NEURONAL CELLS; FACTOR BETA-1	Fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling induces the expression of Runx2, a key transcription factor in osteoblast differentiation, but little is known about the molecular signaling mechanisms that mediate this. Here we examined the role of the protein kinase C (PKC) pathway in regulating Runx2 gene expression and its transactivation function. Treatment with FGF2 or FGF4, or transfection with a vector expressing a mutant FGFR2 that is constitutively activated in the absence of ligand, strongly stimulates Runx2 expression. Electrophoretic mobility shift assays also showed that FGF2 treatment increases the specific binding of Runx2 to the cognate response element in the osteocalcin gene promoter. Blocking PKC completely inhibited FGF2-induced Runx2 expression, whereas mitogen-activate protein kinase inhibitors had no effect. The FGF/FGFR-stimulated 6xOSE2 promoter activity was also blocked by inhibiting PKC, as was the FGF2 stimulation of the DNA-binding activity of Runx2. Experiments with PKC isoform-specific inhibitors and dominant negative isoforms of PKC indicate that PKCS is one of key isoforms involved in the FGF2-stimulated Runx2 expression. In addition, experiments with Runx2-knockout cells showed that, although the PKC pathway largely regulates FGF2-stimulated Runx2 activity by upregulating Runx2 expression, it also modifies Runx2 protein post-translationally and thereby increases its transcriptional activity. Thus, we show for the first time that FGF/FGFR signaling stimulates the DNA-binding and transcriptional activities of Runx2 as well as its expression, and these are largely regulated by the PKC pathway.	Kyungpook Natl Univ, Sch Dent, Dept Biochem, Jung Gu, Taegu 700422, South Korea; Kyungpook Natl Univ, Biomol Engn Ctr, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea; Kyungpook Natl Univ, Dept Pediat Dent, Taegu 700422, South Korea; Chungbuk Natl Univ, Sch Med, Dept Biochem, Chungju 361373, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University; Chungbuk National University	Ryoo, HM (corresponding author), Kyungpook Natl Univ, Sch Dent, Dept Biochem, Jung Gu, 101 Dong In Dong, Taegu 700422, South Korea.		Ryoo, Hyun-Mo/D-5839-2012	Ryoo, Hyun-Mo/0000-0001-6769-8341				Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; CANNALIS E, 1988, J CLIN INVEST, V81, P1572; Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Iseki S, 1999, DEVELOPMENT, V126, P5611; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; Jackson TA, 2001, MOL ENDOCRINOL, V15, P1517, DOI 10.1210/me.15.9.1517; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280; KLINT P, 1999, FRONT BIOSCI, V4, P165; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Li BJ, 2002, J BIOL CHEM, V277, P12418, DOI 10.1074/jbc.M111443200; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; Moerlooze L. D., 1997, CURR OPIN GENE DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; PITARU S, 1993, J BONE MINER RES, V8, P919; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RODAN SB, 1989, CONNECT TISSUE RES, V20, P283, DOI 10.3109/03008208909023898; Ryoo HM, 1997, J CELL BIOCHEM, V64, P106, DOI 10.1002/(SICI)1097-4644(199701)64:1<106::AID-JCB13>3.0.CO;2-J; Sanders JL, 1996, J BONE MINER RES, V11, P1862; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Suzuki A, 2000, J BONE MINER RES, V15, P95, DOI 10.1359/jbmr.2000.15.1.95; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tsuji K, 2001, J BONE MINER METAB, V19, P213, DOI 10.1007/s007740170023; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	56	197	205	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					319	326		10.1074/jbc.M203750200	http://dx.doi.org/10.1074/jbc.M203750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403780	hybrid			2022-12-25	WOS:000180255700043
J	Stein, T; Heinzmann, S; Solovieva, I; Entian, KD				Stein, T; Heinzmann, S; Solovieva, I; Entian, KD			Function of Lactococcus lactis nisin immunity genes nisI and nisFEG after coordinated expression in the surrogate host Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; PRECURSOR LIPID II; LANTIBIOTIC NISIN; ANTIMICROBIAL PEPTIDES; MEMBRANE LOCALIZATION; SELF-PROTECTION; PORE FORMATION; BIOSYNTHESIS; PROTEIN; CLUSTER	Nisin-producing Lactococcus lactis strains show a high degree of resistance to the action of nisin, which is based upon expression of the self-protection (immunity) genes nisI, nisF, nisE, and nisG. Different combinations of nisin immunity genes were integrated into the chromosome of a nisin-sensitive Bacillus subtilis host strain under the control of an inducible promoter. For the recipient strain, the highest level of acquired nisin tolerance was achieved after coordinated expression of all four nisin immunity genes. But either the lipoprotein NisI or the ABC transporter-homologous system NisFEG, respectively, were also able to protect the Bacillus host cells. The acquired immunity was specific to nisin and provided no tolerance to subtilin, a closely related lantibiotic. Quantitative in vivo peptide release assays demonstrated that NisFEG diminished the quantity of cell-associated nisin, providing evidence that one role of NisFEG is to transport nisin from the membrane into the extracellular space. NisI solubilized from B. subtilis membrane vesicles and recombinant hexahistidine-tagged NisI from Escherichia coli interacted specifically with nisin and not with subtilin. This suggests a function of NisI as a nisin-intercepting protein.	Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Entian, KD (corresponding author), Univ Frankfurt, Inst Mikrobiol, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Entian, Karl-Dieter/D-3080-2011					Altena K, 2000, APPL ENVIRON MICROB, V66, P2565, DOI 10.1128/AEM.66.6.2565-2571.2000; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1999, BBA-BIOMEMBRANES, V1462, P223, DOI 10.1016/S0005-2736(99)00208-4; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; DelvesBroughton J, 1996, ANTON LEEUW INT J G, V69, P193, DOI 10.1007/BF00399424; deRuyter PGGA, 1996, J BACTERIOL, V178, P3434, DOI 10.1128/jb.178.12.3434-3439.1996; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; DRIESSEN AJM, 1995, BIOCHEMISTRY-US, V34, P1606, DOI 10.1021/bi00005a017; Duan K, 1996, J APPL BACTERIOL, V81, P493; ENGELKE G, 1994, APPL ENVIRON MICROB, V60, P814, DOI 10.1128/AEM.60.3.814-825.1994; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; Entian KD, 1996, ANTON LEEUW INT J G, V69, P109, DOI 10.1007/BF00399416; GONZYTREBOUL G, 1992, J MOL BIOL, V224, P967, DOI 10.1016/0022-2836(92)90463-T; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; GUTOWSKIECKEL Z, 1994, APPL ENVIRON MICROB, V60, P1; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HARLOW E, 1999, USING ANTIBODIES LAB, P267; Heidrich C, 1998, APPL ENVIRON MICROB, V64, P3140; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Jack RW, 2000, CURR OPIN CHEM BIOL, V4, P310, DOI 10.1016/S1367-5931(00)00094-6; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; KLEIN C, 1994, APPL ENVIRON MICROB, V60, P2793, DOI 10.1128/AEM.60.8.2793-2801.1994; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; McAuliffe O, 2001, FEMS MICROBIOL REV, V25, P285, DOI 10.1016/S0168-6445(00)00065-6; Otto M, 1998, FEMS MICROBIOL LETT, V166, P203, DOI 10.1016/S0378-1097(98)00333-4; Pag U, 1999, APPL ENVIRON MICROB, V65, P591; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; QIAO MQ, 1995, FEMS MICROBIOL LETT, V131, P75, DOI 10.1111/j.1574-6968.1995.tb07757.x; Ra R, 1999, MICROBIOL-SGM, V145, P1227, DOI 10.1099/13500872-145-5-1227; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; Sambrook J., 2002, MOL CLONING LAB MANU; Saris PEJ, 1996, ANTON LEEUW INT J G, V69, P151, DOI 10.1007/BF00399420; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; Siegers K, 1996, J BIOL CHEM, V271, P12294, DOI 10.1074/jbc.271.21.12294; SIEGERS K, 1996, THESIS J WOLFGANG GO; Skaugen M, 1997, MOL GEN GENET, V253, P674, DOI 10.1007/s004380050371; Stein T, 2002, J BACTERIOL, V184, P1703, DOI 10.1128/JB.184.6.1703-1711.2002; Stein T, 2002, MOL MICROBIOL, V44, P403, DOI 10.1046/j.1365-2958.2002.02869.x; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; VANDERMEER JR, 1993, J BACTERIOL, V175, P2578, DOI 10.1128/JB.175.9.2578-2588.1993; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	141	150	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					89	94		10.1074/jbc.M207237200	http://dx.doi.org/10.1074/jbc.M207237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12379654	hybrid			2022-12-25	WOS:000180255700012
J	Waldron, RT; Rozengurt, E				Waldron, RT; Rozengurt, E			Protein kinase C phosphorylates protein kinase D activation loop Ser(744) and Ser(748) and releases autoinhibition by the pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SIGNAL-TRANSDUCTION PATHWAY; D PKD ACTIVATION; PHORBOL ESTERS; RAPID ACTIVATION; INTACT-CELLS; MOLECULAR-CLONING; CATALYTIC DOMAIN; PHOSPHOLIPASE-C; ALPHA-SUBUNIT	Persistent activation of protein kinase D (PKD) via protein kinase C (PKC)-mediated signal transduction is accompanied by phosphorylation at Ser(774) and Ser(748) located in the catalytic domain activation loop, but whether PKC isoforms directly phosphorylate these residues, induce PKD autophosphorylation, or recruit intermediate upstream kinase(s) is unclear. Here, we explore the mechanism whereby PKC activates PKD in response to cellular stimuli. We first assessed in vitro PKC-PKD transphosphorylation and PKD activation. A PKD738-753 activation loop peptide was well phosphorylated by immunoprecipitated PKC isoforms, consistent with similarities between the loop and their known substrate specificities. A similar peptide with glutamic acid replacing Ser(748) was preferentially phosphorylated by PKCepsilon, suggesting that PKD containing phosphate at Ser(748). is rapidly targeted by this isoform at Ser(744). When incubated in the presence of phosphatidylserine, phorbol 12,13-dibutyrate and ATP, intact PKD slowly auto-phosphorylated in the activation loop but only at Ser(748). In contrast, addition of purified PKCepsilon to the incubation mixture induced rapid Ser(744) and Ser(748) phosphorylation, concomitant with persistent 2-3-fold increases in PKD activity, measured using reimmunoprecipitated PKD to phosphorylate an exogenous peptide, syntide-2. We also further examined pleckstrin homology domain-mediated PKD regulation to determine its relationship with activation loop phosphorylation. The high constitutive activity of the pleckstrin homology (PH) domain deletion mutant PKD-DeltaPH was not abrogated by mutation of Ser(744) and Ser(748) to alanines, suggesting that one function of activation loop phosphorylation in the PKD activation mechanism is to relieve autoinhibition by the PH domain. These studies provide evidence of a direct PKCepsilon-PKD phosphorylation cascade and provide additional insight into the activation mechanism.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal, Div Digest Dis,CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal, Div Digest Dis,CURE,Digest Dis Res Ctr, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.		Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002834, R01DK056930] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [K01 DK 02834, DK 56930, DK 55003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2273, DOI 10.1006/jmcc.1997.0466; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Klein IK, 2000, CANCER RES, V60, P2077; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; REY O, 2001, J BIOL CHEM, V15, P15; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	64	153	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					154	163		10.1074/jbc.M208075200	http://dx.doi.org/10.1074/jbc.M208075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407104	hybrid			2022-12-25	WOS:000180255700021
J	Dobrzanska, M; Szurmak, B; Wyslouch-Cieszynska, A; Kraszewska, E				Dobrzanska, M; Szurmak, B; Wyslouch-Cieszynska, A; Kraszewska, E			Cloning and characterization of the first member of the Nudix family from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE; MANNOSE MANNOSYL HYDROLASE; ESCHERICHIA-COLI; ADP-RIBOSE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; NUCLEOTIDE PYROPHOSPHATASE; CATALYTIC DOMAIN; MUTT FAMILY; COENZYME-A	The sequence motif commonly called a Nudix box, rep. resented by (GX(5)EX(7)REVXEEKGU) is the marker of a widely distributed family of enzymes that catalyze the hydrolysis of a variety of nucleoside diphosphate derivatives. Here we describe the cloning and characterization of an Arabidopsis thaliana cDNA encoding a Nudix hydrolase that degrades NADH. The deduced amino acid sequence of AtNUDT1 contains 147 amino acids. The recombinant AtNUDT1 was expressed in Escherichia coli and purified. In the presence of Mn2+ and the optimal pH of 7.0, the recombinant AtNUDT1 catalyzed the hydrolysis of NADH with a K-m value of 0.36 mm. A V-max of 12. 7 units mg(-1) for NADH was determined. The recombinant AtNUDT1 migrated as a dimer on a gel filtration column. Biochemical analysis of recombinant AtNUDT1 indicated that the first characterized member of the Nudix family from A. thaliana is a NADH pyrophosphatase.	Polish Acad Sci, Dept Plant Biochem, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Polish Acad Sci, Mass Spectrometry Lab, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Dobrzanska, M (corresponding author), Polish Acad Sci, Dept Plant Biochem, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	martad@ibb.waw.pl	Hu, Ruogu/B-2203-2008	Kraszewska, Elzbieta/0000-0003-0353-6508; Wyslouch Cieszynska, Aleksandra/0000-0002-7006-2456				Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; AbdelRaheim SR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-5; AbdelRaheim SR, 2001, ARCH BIOCHEM BIOPHYS, V388, P18, DOI 10.1006/abbi.2000.2268; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Gasmi L, 2001, BIOCHEM J, V357, P33, DOI 10.1042/0264-6021:3570033; Hua LV, 2001, NEUROPSYCHOPHARMACOL, V24, P640, DOI 10.1016/S0893-133X(00)00233-5; JACOBSON KB, 1957, J BIOL CHEM, V226, P427; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; Legler PM, 2002, BIOCHEMISTRY-US, V41, P4655, DOI 10.1021/bi012118d; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; Medda R, 2000, J PROTEIN CHEM, V19, P209, DOI 10.1023/A:1007007803996; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MILLER JH, 1992, SHORT COURSE BACTERI, P193; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Ribeiro JM, 2001, BBA-GEN SUBJECTS, V1526, P86, DOI 10.1016/S0304-4165(01)00113-1; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; Xu WL, 2000, BIOCHEM BIOPH RES CO, V273, P753, DOI 10.1006/bbrc.2000.2999; Xu WL, 2002, J BIOL CHEM, V277, P23181, DOI 10.1074/jbc.M203325200; Yang HJ, 2000, J BIOL CHEM, V275, P8844, DOI 10.1074/jbc.275.12.8844; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434	44	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50482	50486		10.1074/jbc.M205207200	http://dx.doi.org/10.1074/jbc.M205207200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399474	hybrid, Green Published			2022-12-25	WOS:000180177700038
J	Li, F; Dluzewski, A; Coley, AM; Thomas, A; Tilley, L; Anders, RF; Foley, M				Li, F; Dluzewski, A; Coley, AM; Thomas, A; Tilley, L; Anders, RF; Foley, M			Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM MEROZOITES; MONOCLONAL-ANTIBODIES; CELL INVASION; BALB/C MICE; PARASITES; KNOWLESI; EPITOPES; RHOPTRY; LIBRARIES; RECEPTOR	Apical membrane antigen-1 (AMA1) is a transmembrane protein present on the surface of merozoites that is thought to be involved in the process of parasite invasion of host erythrocytes. Although it is the target of a natural immune response that can inhibit invasion, little is known about the molecular mechanisms by which AMA1 facilitates the invasion process. In an attempt to identify peptides that specifically interact with and block the function of AMA1, a random peptide library displayed on the surface of filamentous phage was panned on recombinant AMA1 from Plasmodium falciparum. Three peptides with affinity for AMA1 were isolated, and characterization of their fine binding specificities indicated that they bind to a similar region on the surface of AMA1. One of these peptides was found to be a potent inhibitor of the invasion of P. falciparum merozoites into human erythrocytes. We propose that this peptide blocks interaction between AMA1 and a ligand on the erythrocyte surface that is involved in a critical step in malarial invasion. The identification and characterization of these peptide inhibitors now permit an evaluation of the essential requirements that are necessary for efficient neutralization of merozoite invasion by blocking AMA1 function.	La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia; Kings Coll London, Cooperat Res Ctr Diagnost, London SE1 9RT, England; Kings Coll London, Cooperat Res Ctr Vaccine Technol, London SE1 9RT, England; Kings Coll London, Dept Immunobiol, London SE1 9RT, England; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands	La Trobe University; University of London; King's College London; University of London; King's College London; University of London; King's College London	Foley, M (corresponding author), La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia.	m.foley@latrobe.edu.au	Tilley, Leann/AAU-5281-2020	Tilley, Leann/0000-0001-9910-0199; Foley, Michael/0000-0003-1349-4698; Anders, Robin/0000-0002-0693-4547				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4; Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; BIANCO AE, 1988, AM J TROP MED HYG, V38, P258, DOI 10.4269/ajtmh.1988.38.258; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; CREWTHER PE, 1990, EXP PARASITOL, V70, P193, DOI 10.1016/0014-4894(90)90100-Q; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DLUZEWSKI AR, 1984, T ROY SOC TROP MED H, V78, P622, DOI 10.1016/0035-9203(84)90221-9; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; ETZION Z, 1991, MOL BIOCHEM PARASIT, V47, P51, DOI 10.1016/0166-6851(91)90147-X; HADLEY TJ, 1986, ANNU REV MICROBIOL, V40, P451, DOI 10.1146/annurev.mi.40.100186.002315; Harlow E., 1988, ANTIBODIES LAB MANUA; HARNYUTTANAKORN P, 1992, MOL BIOCHEM PARASIT, V55, P177, DOI 10.1016/0166-6851(92)90138-A; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Howard RF, 1998, INFECT IMMUN, V66, P380, DOI 10.1128/IAI.66.1.380-386.1998; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Isalan M, 2001, BIOCHEMISTRY-US, V40, P830, DOI 10.1021/bi001728v; Jost PJ, 2001, FEBS LETT, V489, P263, DOI 10.1016/S0014-5793(00)02236-5; Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; Lesinski GB, 2001, VACCINE, V19, P1717, DOI 10.1016/S0264-410X(00)00397-2; MCCONNELL SJ, 1994, GENE, V151, P115, DOI 10.1016/0378-1119(94)90640-8; MITCHELL GH, 1988, CRIT REV ONCOL HEMAT, V8, P255, DOI 10.1016/S1040-8428(88)80011-8; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; Qureshi SA, 1999, P NATL ACAD SCI USA, V96, P12156, DOI 10.1073/pnas.96.21.12156; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; THOMAS AW, 1990, PARASITE IMMUNOL, V12, P105, DOI 10.1111/j.1365-3024.1990.tb00940.x; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; WATERS AP, 1990, J BIOL CHEM, V265, P17974; Weiss GA, 2000, J MOL BIOL, V300, P213, DOI 10.1006/jmbi.2000.3845; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	50	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50303	50310		10.1074/jbc.M207985200	http://dx.doi.org/10.1074/jbc.M207985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381731	hybrid			2022-12-25	WOS:000180177700013
J	Lin, SE; Oyama, T; Nagase, T; Harigaya, K; Kitagawa, M				Lin, SE; Oyama, T; Nagase, T; Harigaya, K; Kitagawa, M			Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA MASTERMIND; HUMAN HOMOLOG; GENE; MUTATIONS; FRINGE; GLYCOSYLTRANSFERASE; ACTIVATOR; LOCUS; MICE	Mastermind (Mam) is one of the evolutionarily conserved elements of Notch signaling. Genetic analyses in Drosophila implicated it as an important positive regulator of the pathway. We show here identification of two new members of human Mam family (human Mastermind-2 (hMam-2) and human Mastermind-3 (hMam-3)), which retain characteristics similar to human Mastermind-1 (hMam-1) and Drosophila Mastermind. Both hMam-2 and hMam-3 stabilize and participate in the DNA-binding complex RBP-J/CBF-1 protein and the Notch intracellular domains that serve as intermediates of the signaling. Both hMam-2 and hMam-3 enhanced the activation of transcription from a target promoter by Notch signaling. However, we also show evidence that the activation of the target promoter by Notch3 and Notch4 is more efficiently potentiated by hMam-2 than by hMam-1 or -3. The multiplicity of Mam proteins in the mammalian system may help provide divergence to the strength of the Notch signals in different cell types.	Chiba Univ, Grad Sch Med, Dept Mol & Tumor Pathol, Chuo Ku, Chiba 2608670, Japan; Kazusa DNA Res Inst, Chiba 2920812, Japan	Chiba University; Kazusa DNA Research Institute	Kitagawa, M (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol & Tumor Pathol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	kitagawa@med.m.chiba-u.ac.jp	Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Lin, Sey-En/0000-0002-8994-9452				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Eldadah ZA, 2001, HUM MOL GENET, V10, P163, DOI 10.1093/hmg/10.2.163; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Helms W, 1999, DEV BIOL, V215, P358, DOI 10.1006/dbio.1999.9477; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; Krebs LT, 2000, GENE DEV, V14, P1343; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morrison SJ, 2001, CURR OPIN CELL BIOL, V13, P666, DOI 10.1016/S0955-0674(00)00269-6; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; SAKAI T, 1995, J BIOCHEM-TOKYO, V118, P621, DOI 10.1093/oxfordjournals.jbchem.a124955; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Shutter JR, 2000, GENE DEV, V14, P1313; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; Spinner NB, 2001, HUM MUTAT, V17, P18, DOI 10.1002/1098-1004(2001)17:1<18::AID-HUMU3>3.0.CO;2-T; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	45	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50612	50620		10.1074/jbc.M209529200	http://dx.doi.org/10.1074/jbc.M209529200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386158	hybrid			2022-12-25	WOS:000180177700056
J	Nath, N; McCartney, RR; Schmidt, MC				Nath, N; McCartney, RR; Schmidt, MC			Purification and characterization of Snf1 kinase complexes containing a defined beta subunit composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; YEAST SNF1; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; FUNCTIONAL DOMAINS; PHOSPHORYLATION; EXPRESSION; GENE; CELL	The Snf1 kinase complex of Saccharomyces cerevisiae contains one of three possible beta subunits encoded by either SIP1, SIP2, or GAL83. Snf1 kinase complexes were purified from cells expressing only one of the three beta subunits using a tandem affinity purification tag on the C terminus of the Snf1 protein. The purified kinase complexes were enzymatically active as judged by their ability to phosphorylate a recombinant protein containing the Snf1-responsive domain of the Mig1 protein. The Snf1 kinase complexes containing Gal83 or Sip2 as the beta subunit showed comparable and high levels of activity, whereas the Sip1-containing enzyme was significantly less active. Examination of the protein composition of the purified Snf1 enzyme complexes indicated that the Sip1 protein was present in substoichiometric levels. Increased gene dosage of SIP1 rescued the ethanol growth defect observed in cells expressing Sip1 as their only beta subunit and increased the in vitro activity of Snf1 kinase purified from these cells. Our studies indicate that the reduced activity of Snf1-Snf4-Sip1 kinase is due to low level of Sip1 accumulation rather than a limited ability of the Sip1 form of the enzyme to direct phosphorylation of specific substrates.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schmidt, MC (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046443, R01GM046443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; ESTRUCH F, 1992, GENETICS, V132, P639; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARDY TA, 1994, J BIOL CHEM, V269, P27907; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Honigberg SM, 1998, MOL CELL BIOL, V18, P4548, DOI 10.1128/MCB.18.8.4548; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Ostling J, 1996, MOL CELL BIOL, V16, P753; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Smith FC, 1999, FEBS LETT, V453, P219, DOI 10.1016/S0014-5793(99)00725-5; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; [No title captured]	32	24	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50403	50408		10.1074/jbc.M207058200	http://dx.doi.org/10.1074/jbc.M207058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393914	hybrid			2022-12-25	WOS:000180177700026
J	Piechotta, K; Lu, JM; Delpire, E				Piechotta, K; Lu, JM; Delpire, E			Cation chloride cotransporters interact with the stress-related kinases Ste20-kelated proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; NA-K-2CL COTRANSPORTER; MOLECULAR-CLONING; EXPRESSION; GENE; KCC3; MODULATION; P38	Cells respond to stress stimuli by mounting specific responses. During osmotic and oxidative stress, cation chloride cotransporters, e.g. Na-K-2Cl and K-Cl cotransporters, are activated to maintain fluid/ion homeostasis. Here we report the interaction of the stress-related serine-threonine kinases (S) under bar te20-related (p) under bar roline-(a) under bar lanine-rich (k) under bar inase (SPAK) and (o) under bar xidative (s) under bar tress (r) under bar esponse 1 (OSR1) with the cotransporters KCC3, NKCC1, and NKCC2 but not KCC1 and KCC4. The interaction was identified using yeast two-hybrid assays and confirmed via glutathione S-transferase pull-down experiments. Evidence for in vivo interaction was established by coimmunoprecipitation of SPAK from mouse brain with anti-N-KCC1 antibody. The interacting region of both kinases comprises the last 100 amino acids of the protein. The SPAK/OSR1 binding motif on the cotransporters consists of nine residues, starting with an (R/K)FX(V/I) sequence followed by five additional residues that are essential for binding but for which no consensus was found. Immunohistochemical analysis of choroid plexus epithelium revealed co-expression of NKCC1 and SPAK on the apical membrane. In contrast, in choroid plexus epithelium from NKCC1 null mice, SPAK immunostaining was found in the cytoplasm. We conclude that several cation chloride co-transporters interact with SPAK and/or OSR1, and we hypothesize that this interaction might play a role during the initiation of the cellular stress response.	Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Delpire, E (corresponding author), T-4202 Med Ctr N, Nashville, TN 37232 USA.	eric.delpire@vanderbilt.edu						Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Howard HC, 2002, NAT GENET, V32, P384, DOI 10.1038/ng1002; James P, 1996, GENETICS, V144, P1425; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kaplan MR, 1996, J CLIN INVEST, V98, P723, DOI 10.1172/JCI118844; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Leiserson WM, 2000, NEURON, V28, P793, DOI 10.1016/S0896-6273(00)00154-9; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; Mercado A, 2000, J BIOL CHEM, V275, P30326, DOI 10.1074/jbc.M003112200; Mercado Adriana, 1999, Journal of the American Society of Nephrology, V10, p38A; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Pearson MM, 2001, NEUROSCIENCE, V103, P481, DOI 10.1016/S0306-4522(00)00567-4; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Sambrook J, 2001, MOL CLONING LAB MANU; Shen MR, 2001, P NATL ACAD SCI USA, V98, P14714, DOI 10.1073/pnas.251388798; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736	28	295	299	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50812	50819		10.1074/jbc.M208108200	http://dx.doi.org/10.1074/jbc.M208108200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386165	hybrid			2022-12-25	WOS:000180177700081
J	Rezende, LF; Hollis, T; Ellenberger, T; Richardson, CC				Rezende, LF; Hollis, T; Ellenberger, T; Richardson, CC			Essential amino acid residues in the single-stranded DNA-binding protein of bacteriophage T7 - Identification of the dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; CARBOXYL-TERMINAL DOMAIN; GENE 2.5 PROTEIN; HELIX-DESTABILIZING PROTEIN; CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; REPLICATION FORK; SEQUENCE; MUTAGENESIS; POLYMERASE	Gene 2.5 of bacteriophage T7 is an essential gene that encodes a single-stranded DNA-binding protein. T7 phage with gene 2.5 deleted can grow only on Escherichia coli cells that express gene 2.5 from a plasmid. This complementation assay was used to screen for lethal mutations in gene 2.5. By screening a library of randomly mutated plasmids encoding gene 2.5, we identified 20 different single amino acid alterations in gene 2.5 protein that are lethal in vivo. The location of these essential residues within the three-dimensional structure of gene 2.5 protein assists in the identification of motifs in the protein. In this study we show that a subset of these alterations defines the dimer interface of gene 2.5 protein predicted by the crystal structure. Recombinantly expressed and purified gene 2.5 protein-P22L, gene 2.5 protein-F31S, and gene 2.5 protein-G36S do not form dimers at salt concentrations where the wild-type gene 2.5 protein exists as a dimer. The basis of the lethality of these mutations in vivo is not known because altered proteins retain the ability to bind single-stranded DNA, anneal complementary strands of DNA, and interact with T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54397-39] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BAYER I, 1989, EUR J BIOCHEM, V179, P399, DOI 10.1111/j.1432-1033.1989.tb14567.x; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chen JW, 1998, PROTEIN SCI, V7, P1781, DOI 10.1002/pro.5560070813; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Ferrari ME, 1997, BIOPHYS CHEM, V64, P235, DOI 10.1016/S0301-4622(96)02223-5; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Kumar JK, 2001, J BIOL CHEM, V276, P46151, DOI 10.1074/jbc.M106319200; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lohman TM, 1996, BIOCHEMISTRY-US, V35, P5272, DOI 10.1021/bi9527606; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; Pajunen MI, 2001, J BACTERIOL, V183, P1928, DOI 10.1128/JB.183.6.1928-1937.2001; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Reddy MS, 2001, J BIOL CHEM, V276, P45959, DOI 10.1074/jbc.M103523200; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; SAITO H, 1981, J VIROL, V37, P343, DOI 10.1128/JVI.37.1.343-351.1981; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SCHMITT MP, 1987, J MOL BIOL, V193, P479, DOI 10.1016/0022-2836(87)90261-0; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; TABOR S, 1989, J BIOL CHEM, V264, P6447; Taylor J D, 1994, Methods Mol Biol, V30, P263; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1980, P NATL ACAD SCI-BIOL, V77, P4614, DOI 10.1073/pnas.77.8.4614; Yu M, 2001, J BACTERIOL, V183, P1862, DOI 10.1128/JB.183.6.1862-1869.2001	48	23	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50643	50653		10.1074/jbc.M207359200	http://dx.doi.org/10.1074/jbc.M207359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12379653	hybrid, Green Published			2022-12-25	WOS:000180177700060
J	Roeb, E; Schleinkofer, K; Kernebeck, T; Potsch, S; Jansen, B; Behrmann, I; Matern, S; Grotzinger, J				Roeb, E; Schleinkofer, K; Kernebeck, T; Potsch, S; Jansen, B; Behrmann, I; Matern, S; Grotzinger, J			The matrix metalloproteinase 9 (MMP-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-2; COLLAGENOLYTIC ACTIVITY; EXTRACELLULAR-MATRIX; CIRCULAR-DICHROISM; FIBRONECTIN; EXPRESSION; MIGRATION; TYROSINE; CLONING; MUTANT	Matrix metalloproteinases (MMPs) are involved in the remodeling processes of the extracellular matrix and the basement membrane. Most MMPs are composed of a regulatory, a catalytic, and a hemopexin subunit. In many tumors the expression of MMP-9 correlates with local tumor growth, invasion, and metastasis. To analyze the role of the hemopexin domain in these processes, the MMP-9 hemopexin domain (MMP-9-PEX) was expressed as a glutathione S-transferase fusion protein in Escherichia coli. After proteolytic cleavage, the isolated PEX domain was purified by size exclusion chromatography. In a zymography assay, MMP-9-PEX was able to inhibit MMP-9 activity. The association and dissociation rates for the interaction of MMP-9-PEX with gelatin were determined by plasmon resonance. From the measured rate constants, the dissociation constant was calculated to be K-d = 2,4 x 10(-8) M, demonstrating a high affinity between MMP-9-PEX and gelatin. In Boyden chamber experiments the recombinant MMP-9-PEX was able to inhibit the invasion of melanoma cells secreting high amounts of MMP-9 in a dose-dependent manner. These data demonstrate for the first time that the hemopexin domain of MMP-9 has a high affinity binding site for gelatin, and the particular recombinant domain is able to block MMP-9 activity and tumor cell invasion. Because MMP-9 plays an important role in metastasis, this antagonistic effect may be utilized to design MMP inhibition-based cancer therapy.	Rhein Westfal TH Aachen, Med Klin 3, D-52057 Aachen, Germany; Rhein Westfal TH Aachen, Inst Biochem, D-52057 Aachen, Germany; Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; Amersham Biosci Europe, D-79111 Freiburg, Germany	RWTH Aachen University; RWTH Aachen University; University of Kiel	Roeb, E (corresponding author), Rhein Westfal TH Aachen, Med Klin 3, Pauwelsstr 30, D-52057 Aachen, Germany.	eroeb@ukaachen.de		Behrmann, Iris/0000-0003-3688-3645				ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Dekker C, 1999, J STRUCT BIOL, V128, P237, DOI 10.1006/jsbi.1999.4179; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hua J, 1996, CANCER RES, V56, P5279; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; O'Farrell TJ, 2000, J BIOL CHEM, V275, P27964; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Roeb E, 2000, FASEB J, V14, P1671; Roeb E, 2001, CANCER-AM CANCER SOC, V92, P2680, DOI 10.1002/1097-0142(20011115)92:10<2680::AID-CNCR1622>3.0.CO;2-7; Roeb E, 1999, J CELL BIOCHEM, V75, P346, DOI 10.1002/(SICI)1097-4644(19991101)75:2<346::AID-JCB16>3.3.CO;2-X; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Smith VF, 1996, PROTEIN SCI, V5, P488; Sopata I, 1974, Przegl Lek, V31, P435; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Sreerama N, 1999, BIOCHEMISTRY-US, V38, P10814, DOI 10.1021/bi990516z; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WAXMAN E, 1993, ANAL BIOCHEM, V210, P425, DOI 10.1006/abio.1993.1220; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	38	71	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50326	50332		10.1074/jbc.M207446200	http://dx.doi.org/10.1074/jbc.M207446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12384502	hybrid			2022-12-25	WOS:000180177700016
J	Xiao, S; Jodo, S; Sung, SSJ; Marshak-Rothstein, A; Ju, ST				Xiao, S; Jodo, S; Sung, SSJ; Marshak-Rothstein, A; Ju, ST			Novel signaling mechanism for soluble CD95 ligand synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappa B nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL ACTIVATION; HUMAN FAS LIGAND; IN-VIVO; MEDIATED CYTOTOXICITY; DOWN-REGULATION; GLD MICE; ANTI-FAS; EXPRESSION; RECEPTOR	Soluble CD95 (Fas) ligand (sFasL) is known to be deficient in transducing signals upon engagement with membrane Fas. Here we report that sFasL tranduces, in synergy with non-cytotoxic anti-Fas monoclonal antibody (mAb), signals for apoptosis and nuclear translocation of the NF-kappaB (p65/p50) heterodimer. Activation of the specific signaling pathways correlates with target Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitory protein expression. Synergy with anti-Fas mAb was demonstrated with a trimeric unit of sFasL bearing a single binding site for Fas trimer. In contrast, membrane-bound FasL as expressed on cell-derived vesicles was fully competent in transducing Fas-mediated signals for apoptosis and NF-kappaB nuclear translocation. We propose a model in which the trimeric sFasL signaling requires target expression of a high focal density of Fas, which is induced by the signaling-incompetent anti-Fas mAb. Membrane-bound FasL induces powerful Fas-mediated signals because it possesses both Fas-focusing and signal-transducing functions.	Univ Virginia, Dept Med, Div Rheumatol & Immunol, Charlottesville, VA 22908 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	University of Virginia; Boston University; Boston University; Boston University	Ju, ST (corresponding author), Univ Virginia, Dept Med, Div Rheumatol & Immunol, MED 5777 HSC, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA90691] Funding Source: Medline; NIAID NIH HHS [AI-36938] Funding Source: Medline; NIEHS NIH HHS [ES-10244] Funding Source: Medline; NIGMS NIH HHS [GM-58724] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES010244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058724] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; Aoki K, 2001, NAT IMMUNOL, V2, P333, DOI 10.1038/86336; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ETTINGER R, 1995, J IMMUNOL, V154, P4302; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; French LE, 1997, J IMMUNOL, V159, P2196; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hohlbaum AM, 2001, J IMMUNOL, V167, P6217, DOI 10.4049/jimmunol.167.11.6217; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Jodo S, 2000, J IMMUNOL, V165, P5487, DOI 10.4049/jimmunol.165.10.5487; Jodo S, 2001, J BIOL CHEM, V276, P39938, DOI 10.1074/jbc.M107005200; Jodo S, 2000, J IMMUNOL, V164, P5062, DOI 10.4049/jimmunol.164.10.5062; JONES B, 1986, J IMMUNOL, V136, P348; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; Jupp OJ, 2001, BIOCHEM J, V359, P525, DOI 10.1042/0264-6021:3590525; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Xiao S, 2001, EUR J IMMUNOL, V31, P3339, DOI 10.1002/1521-4141(200111)31:11<3339::AID-IMMU3339>3.0.CO;2-U; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	47	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50907	50913		10.1074/jbc.M206093200	http://dx.doi.org/10.1074/jbc.M206093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393889	hybrid			2022-12-25	WOS:000180177700093
J	Beffert, U; Morfini, G; Bock, HH; Reyna, H; Brady, ST; Herz, J				Beffert, U; Morfini, G; Bock, HH; Reyna, H; Brady, ST; Herz, J			Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONES; TYROSINE PHOSPHORYLATION; CYTOSOLIC ADAPTER; VLDL RECEPTOR; MICE LACKING; DISABLED 1; MOUSE; BINDING; BRAIN; MIGRATION	Reelin is a large secreted protein that controls cortical layering by signaling through the very low density lipoprotein receptor and apolipoprotein E receptor 2, thereby inducing tyrosine phosphorylation of the adaptor protein Disabled-1 (Dab1) and suppressing tau phosphorylation in vivo. Here we show that binding of Reelin to these receptors stimulates phosphatidylinositol 3-kinase, resulting in activation of protein kinase B and inhibition of glycogen synthase kinase 3beta. We present genetic evidence that this cascade is dependent on apolipoprotein E receptor 2, very low density lipoprotein receptor, and Dab1. Reelin-signaling components are enriched in axonal growth cones, where tyrosine phosphorylation of Dab1 is increased in response to Reelin. These findings suggest that Reelin-mediated phosphatidylinositol 3-kinase signaling in neuronal growth cones contributes to final neuron positioning in the mammalian brain by local modulation of protein kinase B an glycogen synthase kinase 3,6 kinase activities.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Bock, Hans/AAF-2635-2021	Beffert, Uwe/0000-0001-5877-922X	NHLBI NIH HHS [R37 HL063762, HL 63762, HL 20948] Funding Source: Medline; NINDS NIH HHS [NS 43408, NS 41170, NS 23320, NS 23868] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023868, R01NS043408, R01NS023868, R01NS041170, R01NS023320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANKER G, 1988, NATURE, V336, P185, DOI 10.1038/336185a0; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Ko J, 2001, J NEUROSCI, V21, P6758; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Nadarajah B, 2001, NAT NEUROSCI, V4, P143, DOI 10.1038/83967; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; Polleux F, 2002, DEVELOPMENT, V129, P3147; Ratner N, 1998, J NEUROSCI, V18, P7717; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8	36	230	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49958	49964		10.1074/jbc.M209205200	http://dx.doi.org/10.1074/jbc.M209205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376533	hybrid			2022-12-25	WOS:000180028900112
J	Chen, YM; Riley, DJ; Zheng, L; Chen, PL; Lee, WH				Chen, YM; Riley, DJ; Zheng, L; Chen, PL; Lee, WH			Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATORS; COILED-COIL PROTEIN; ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; MURINE NEK3; NIMA FAMILY; GENE; EXPRESSION; SUBSTRATE; SPINDLE	Heel (highly expressed in cancer) plays essential roles in chromosome segregation by interacting through its coiled-coil domains with several proteins that modulate the G(2)/M phase. Heel localizes to kinetochores, and its inactivation either by genetic deletion or antibody neutralization leads to severe and lethal chromosomal segregation errors, indicating that Hec1 plays a critical role in chromosome segregation. The mechanisms by which Heel is regulated, however, are not known. Here we show that human Heel is a serine phosphoprotein and that it binds specifically to the mitotic regulatory kinase Nek2 during G(2)/M. Nek2 phosphorylates Heel on serine residue 165, both in vitro and in vivo. Yeast cells are viable without scNek2/Kin3, a close structural homolog of Nek2 that binds to both human and yeast Heel. When the same yeasts carry an scNek2/Kin3 (D55G) or Nek2 (E38G) mutation to mimic a similar temperature-sensitive nima mutation in Aspergillus, their growth is arrested at the nonpermissive temperature, because the scNek2/Kin3 (D55G) mutant binds to Heel but fails to phosphorylate it. Whereas wild-type human Heel rescues lethality resulting from deletion of Heel in Saccharomyces cerevesiae, a human Heel mutant or yeast Heel mutant changing Ser(165) to Ala or yeast Heel mutant changing Ser(201) to Ala does not. Mutations changing the same Ser residues to Glu, to mimic the negative charge created by phosphorylation, partially rescue lethality but result in a high incidence of errors in chromosomal segregation. These results suggest that cell cycle-regulated serine phosphorylation of Heel by Nek2 is essential for faithful chromosome segregation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	leew@uthscsa.edu		Chen, Phang-Lang/0000-0002-0357-9017	NCI NIH HHS [CA 81020, R01 CA107568, CA 58318] Funding Source: Medline; NEI NIH HHS [EY 05758-18] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058318, R01CA107568, P01CA081020] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 1996, CANCER RES, V56, P3168; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kim YH, 2001, J ARTHROPLASTY, V16, P730, DOI 10.1054/arth.2001.23723; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Li MZ, 1999, CYTOGENET CELL GENET, V87, P271, DOI 10.1159/000015445; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Zheng L, 1999, MOL CELL BIOL, V19, P5417; Zheng L, 2000, MOL CELL BIOL, V20, P3529, DOI 10.1128/MCB.20.10.3529-3537.2000	37	111	118	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49408	49416		10.1074/jbc.M207069200	http://dx.doi.org/10.1074/jbc.M207069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386167	hybrid			2022-12-25	WOS:000180028900040
J	Cieslik, K; Zhu, Y; Wu, KK				Cieslik, K; Zhu, Y; Wu, KK			Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2 GENE-TRANSCRIPTION; INTERFERON-GAMMA; C/EBP-BETA; BACTERIAL LIPOPOLYSACCHARIDE; SODIUM-SALICYLATE; RESPONSE ELEMENT; RAW-264.7 CELLS; NUCLEAR-FACTOR; FACTOR NF-IL6; INDUCTION	We determined whether salicylate at pharmacological concentrations inhibits nitric-oxide synthase-2 (NOS-2) and cyclo-oxygenase-2 (COX-2) expressions in RAW 264.7 stimulated with lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma). Cells were treated with sodium salicylate (10(-7)-10(-4) M) or vehicle for 30 min followed by LPS+IFN-gamma for up to 24 h. Salicylate suppressed NOS-2 and COX-2 protein levels and promoter activities stimulated by LPS+IFN-gamma for 4 h in a concentration-dependent manner but had no effect on NOS-2 expression stimulated by the combined agonists for 24 h. Results from promoter analysis indicate that the binding of CCAAT/enhancer-binding protein beta (C/EBPbeta) to its cognate site at -150/-142 on the NOS-2 promoter region was essential for NOS-2 expression at 4 h but not at 24 h. Salicylate reduced C/EBP)3 binding at 4 h and did not alter its binding at 24 h. NOS-2 and COX-2 protein levels and C/EBPbeta binding stimulated by LPS+IFN-gamma for 4 h were inhibited by a similar battery of signaling inhibitors, suggesting a common pathway for NOS-2 and COX-2 expression. Kinetic analysis indicates that NOS-2, similar to COX-2 expression, at 4 h was largely due to the action of LPS, which induced C/EBPbeta binding, whereas its expression at a longer time point was contributed by IFN-gamma. Our findings implicate two distinct pathways for NOS-2 expression induced by LPS+IFN-gamma. Salicylate at pharmacological concentrations is capable of suppressing the early phase of NOS-2 and COX-2 expression by blocking C/EBPbeta binding.	Univ Texas, Hlth Sci Ctr, Inst Mol Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Wu, KK (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med, Vasc Biol Res Ctr, 6431 Fannin, Houston, TX 77030 USA.		Cieslik, Katarzyna/AAO-1982-2021; Wu, Kenneth Kun-Yu/B-1070-2010	Cieslik, Katarzyna/0000-0002-2167-7921; 	NHLBI NIH HHS [R01 HL 50675] Funding Source: Medline; NINDS NIH HHS [P50 NS 23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Chen CC, 1998, J IMMUNOL, V161, P6206; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; Dlaska M, 1999, J IMMUNOL, V162, P6171; Farivar RS, 1996, J BIOL CHEM, V271, P31585, DOI 10.1074/jbc.271.49.31585; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Salh B, 1998, J IMMUNOL, V161, P6947; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; TAUTWIN C, 1993, NATURE, V364, P544; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEISZ A, 1994, J BIOL CHEM, V269, P8324; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	28	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49304	49310		10.1074/jbc.M205030200	http://dx.doi.org/10.1074/jbc.M205030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379662	hybrid			2022-12-25	WOS:000180028900026
J	Couchman, JR; Vogt, S; Lim, ST; Lim, Y; Oh, ES; Prestwich, GD; Theibert, A; Lee, W; Woods, A				Couchman, JR; Vogt, S; Lim, ST; Lim, Y; Oh, ES; Prestwich, GD; Theibert, A; Lee, W; Woods, A			Regulation of inositol phospholipid binding and signaling through syndecan-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN; VINCULIN; ACTIN; ALPHA; PHOSPHORYLATION; INTEGRINS; MANNER; LIPIDS	Syndecan-4 is a transmembrane heparan sulfate proteoglyean that can regulate cell-matrix interactions and is enriched in focal adhesions. Its cytoplasmic domain contains a central region unlike that of any other vertebrate or invertebrate syndecan core protein with a cationic motif that binds inositol phospholipids. In turn, lipid binding stabilizes the syndecan in oligomeric form, with subsequent binding and activation of protein kinase C. The specificity of phospholipid binding and its potential regulation are investigated here. Highest affinity of the syndecan-4 cytoplasmic domain was seen with phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5P)(2)) and phosphatidylinositol 4-phosphate, and both promoted syndecan-4 oligomerization. Affinity was much reduced for 3-phosphorylated inositides while no binding of diacylglycerol was detected. Syndecan-2 cytoplasmic domain had negligible affinity for any lipid examined. Inositol hexakisphosphate, but not inositol tetrakisphosphate, also had high affinity for the syndecan-4 cytoplasmic domain and could compete effectively with PtdIns(4,5)P-2. Since inositol hexaphosphate binding to syndecan-4 does not promote oligomer formation, it is a potential down-regulator of syndecan-4 signaling. Similarly, phosphorylation of serine 183 in syndecan-4 cytoplasmic domain reduced PtdIns(4,5)P-2 binding affinity by over 100-fold, although interaction could still be detected by nuclear magnetic resonance spectroscopy. Only protein kinase Calpha was up-regulated in activity by the combination of syndecan-4 and PtdIns(4,5)P-2, with all other isoforms tested showing minimal response. This is consistent with the codistribution of syndecan-4 with the a isoform of protein kinase C in focal adhesions.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London SW7 2AZ, England; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA; Univ Utah, Ctr Cell Signaling, Salt Lake City, UT 84108 USA; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120740, South Korea; Yonsei Univ, Coll Sci, Prot Network Res Ctr, Seoul 120740, South Korea	Imperial College London; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Ewha Womans University; Ewha Womans University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Yonsei University; Yonsei University	Couchman, JR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	j.couchman@ic.ac.uk	LEE, WEON TAE/AAQ-9088-2021	Lim, Steve/0000-0003-0323-8607; Lee, Weontae/0000-0003-2347-1262	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050194] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50194] Funding Source: Medline; NINDS NIH HHS [NS 28632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Couchman JR, 1999, J CELL SCI, V112, P3415; Couchman JR, 2001, INT REV CYTOL, V207, P113; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hilton JM, 2001, J BIOL CHEM, V276, P16341, DOI 10.1074/jbc.M011122200; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Longley RL, 1999, J CELL SCI, V112, P3421; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; NEWTON AC, 1997, PROTEIN KINASE C, P25; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Shin J, 2001, BIOCHEMISTRY-US, V40, P8471, DOI 10.1021/bi002750r; Sims B, 1999, J BIOL CHEM, V274, P25701, DOI 10.1074/jbc.274.36.25701; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Theibert AB, 1997, PRACT APPROACH SER, V176, P117; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; WOODS A, 1992, J CELL SCI, V101, P277; Yamaguchi Y, 1996, J BIOL CHEM, V271, P27838, DOI 10.1074/jbc.271.44.27838; Zimmermann P, 1999, FASEB J, V13, pS91	44	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49296	49303		10.1074/jbc.M209679200	http://dx.doi.org/10.1074/jbc.M209679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377772	hybrid			2022-12-25	WOS:000180028900025
J	Davis, JP; Rall, JA; Reiser, PJ; Smillie, LB; Tikunova, SB				Davis, JP; Rall, JA; Reiser, PJ; Smillie, LB; Tikunova, SB			Engineering competitive magnesium binding into the first EF-hand of skeletal troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SPECIFIC REGULATORY SITES; FLUORESCENCE STOPPED-FLOW; MG2+ DISSOCIATION RATES; FROG-MUSCLE FIBERS; CALCIUM-BINDING; CA2+ BINDING; THIN FILAMENT; BIOLOGICAL-ACTIVITY; HIGH-AFFINITY; TRYPTOPHAN MUTANTS	The goal of this study was to examine the mechanism of magnesium binding to the regulatory domain of skeletal troponin C (TnC). The fluorescence of Trp(29), immediately preceding the first calcium-binding loop in TnC(F29W), was unchanged by addition of magnesium, but increased upon calcium binding with an affinity of 3.3 muM. However, the calcium-dependent increase in TnC(F29W) fluorescence could be reversed by addition of magnesium, with a calculated competitive magnesium affinity of 2.2 mm. When a Z acid pair was introduced into the first EF-hand of TnC(F29W), the fluorescence of G34DTnC(F29W) increased upon addition of magnesium or calcium with affinities of 295 and 1.9 mum, respectively. Addition of 3 mm magnesium decreased the calcium sensitivity of TnC(F29W) and G34DTnC(F29W) similar to2- and 6-fold, respectively. Exchange of G34DTnC(F29W) into skinned psoas muscle fibers decreased fiber calcium sensitivity similar to1.7-fold compared with TnC(F29W) at 1 mm [magnesium](free) and similar to3.2-fold at 3 mm [magnesium](free). Thus, incorporation of a Z acid pair into the first EF-hand allows it to bind magnesium with high affinity. Furthermore, the data suggests that the second EF-hand, but not the first, of TnC is responsible for the competitive magnesium binding to the regulatory domain.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Oral Biol, Columbus, OH 43210 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Alberta	Davis, JP (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 20792] Funding Source: Medline; NIDDK NIH HHS [DK 33727] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN TS, 1992, BIOPHYS J, V61, P399, DOI 10.1016/S0006-3495(92)81846-5; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Black DJ, 2000, BIOCHEMISTRY-US, V39, P13831, DOI 10.1021/bi001106+; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; DONALDSON SKB, 1975, J GEN PHYSIOL, V66, P427, DOI 10.1085/jgp.66.4.427; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Fitzsimons DP, 2001, J GEN PHYSIOL, V117, P133, DOI 10.1085/jgp.117.2.133; FRANCOIS JM, 1993, J MUSCLE RES CELL M, V14, P585, DOI 10.1007/BF00141555; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Gillis TE, 2000, AM J PHYSIOL-REG I, V279, pR1707, DOI 10.1152/ajpregu.2000.279.5.R1707; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; Henzl MT, 1996, BIOCHEMISTRY-US, V35, P5856, DOI 10.1021/bi952184d; HOU TT, 1991, J PHYSIOL-LONDON, V441, P285, DOI 10.1113/jphysiol.1991.sp018752; HOU TT, 1992, J PHYSIOL-LONDON, V449, P399, DOI 10.1113/jphysiol.1992.sp019092; IIO T, 1981, J BIOCHEM-TOKYO, V90, P163, DOI 10.1093/oxfordjournals.jbchem.a133446; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; KERRICK WGL, 1972, BIOCHIM BIOPHYS ACTA, V275, P117; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KOHAMA K, 1980, J BIOCHEM, V88, P591, DOI 10.1093/oxfordjournals.jbchem.a133007; Konishi M, 1998, JPN J PHYSIOL, V48, P421, DOI 10.2170/jjphysiol.48.421; Leblanc L, 2000, ARCH BIOCHEM BIOPHYS, V384, P296, DOI 10.1006/abbi.2000.2103; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; MAK AS, 1983, J BIOL CHEM, V258, P4330; Malmendal A, 1998, J BIOL CHEM, V273, P28994, DOI 10.1074/jbc.273.44.28994; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; METZGER JM, 1991, J GEN PHYSIOL, V98, P233, DOI 10.1085/jgp.98.2.233; Moncrieffe MC, 1999, BIOCHEMISTRY-US, V38, P11973, DOI 10.1021/bi982048j; Morimoto S, 1996, J BIOCHEM-TOKYO, V119, P737; MORIMOTO S, 1991, BIOCHIM BIOPHYS ACTA, V1073, P336, DOI 10.1016/0304-4165(91)90140-C; Morris CA, 2001, J BIOL CHEM, V276, P20245, DOI 10.1074/jbc.M007371200; MOSS RL, 1979, J PHYSIOL-LONDON, V292, P177, DOI 10.1113/jphysiol.1979.sp012845; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; PEARLSTONE JR, 1995, BIOCHEMISTRY-US, V34, P6932, DOI 10.1021/bi00021a004; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1981, FED PROC, V40, P2653; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; PROCYSHYN RM, 1994, J BIOL CHEM, V269, P1641; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; REID RE, 1995, ARCH BIOCHEM BIOPHYS, V323, P115, DOI 10.1006/abbi.1995.0016; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; She MD, 1998, EUR J BIOCHEM, V252, P600, DOI 10.1046/j.1432-1327.1998.2520600.x; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; Tikunova SB, 2001, BIOCHEMISTRY-US, V40, P3348, DOI 10.1021/bi0021333; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang ST, 1998, BIOCHEMISTRY-US, V37, P14539, DOI 10.1021/bi9814641; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; ZOT AS, 1987, J BIOL CHEM, V262, P1966; ZOT HG, 1987, J MUSCLE RES CELL M, V8, P428, DOI 10.1007/BF01578432	74	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49716	49726		10.1074/jbc.M208488200	http://dx.doi.org/10.1074/jbc.M208488200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397067	hybrid			2022-12-25	WOS:000180028900082
J	Dong, K; Tang, LQ; MacGregor, GG; Hebert, SC				Dong, K; Tang, LQ; MacGregor, GG; Hebert, SC			Localization of the ATP/phosphatidylinositol 4,5 diphosphate-binding site to a 39-amino acid region of the carboxyl terminus of the ATP-regulated K+ channel Kir1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; C-TERMINUS; INHIBITION; BINDING; DETERMINANTS; SENSITIVITY; PIP2; 5-TRIPHOSPHATE; NUCLEOTIDES; EXPRESSION	Intracellular ATP and membrane-associated phosphatidylinositol phospholipids, like PIP2 (PI(4,5)P-2), regulate the activity of ATP-sensitive K+ (K-ATP) and Kir1.1 channels by direct interaction with the pore-forming subunits of these channels. We previously demonstrated direct binding of TNP-ATP (2',3'-O-(2,4,6-trinitrophenylcyclohexadienylidene)-ATP) to the COOH-terminal cytosolic domains of the pore-forming subunits of Kir1.1 and Kir6.x channels. In addition, PIP2 competed for TNP-ATP binding on the COOH termini of Kir1.1 and Kir6.x channels, providing a mechanism that can account for PIP2 antagonism of ATP inhibition of these channels. To localize the ATP-binding site within the COOH terminus of Kir1.1, we produced and purified maltose-binding protein (MBP) fusion proteins containing truncated and/or mutated Kir1.1 COOH termini and examined the binding of TNP-ATP and competition by PIP2. A truncated COOH-terminal fusion protein construct, MBP_1.1CDeltaC170, containing the first 39 amino acid residues distal to the second transmembrane domain was sufficient to bind TNP-ATP with high affinity. A construct containing the remaining COOH-terminal segment distal to the first 39 amino acid residues did not bind TNP-ATP. Deletion of 5 or more amino acid residues from the NH2-terminal side of the C0011 terminus abolished nucleotide binding to the entire COOH terminus or to the first 49 amino acid residues of the COOH terminus. PIP2 competed TNP-ATP binding to MBP_ 1.1CDeltaC170 with an EC50 of 10.9 mum. Mutation of any one of three arginine residues (R188A/E, R203A, and R217A), which are conserved in Kir1.1 and K-ATP channels and are involved in ATP and/or PIP2 effects on channel activity, dramatically reduced TNP-ATP binding to MBP_1.1Delta C170. In contrast, mutation of a fourth conserved residue (R212A) exhibited slightly enhanced TNP-ATP binding and increased affinity for PIP2 competition of TNP-ATP (EC50 = 5.7 mum). These studies suggest that the first 39 COOH-terminal amino acid residues form an ATP-PIP2 binding domain in Kir1.1 and possibly the Kir6.x ATP-sensitive K+ channels.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,SHM B147,POB 208026, New Haven, CT 06520 USA.	steven.hebert@yale.edu			NIDDK NIH HHS [DK 54999] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Baukrowitz T, 2000, EUR J BIOCHEM, V267, P5842, DOI 10.1046/j.1432-1327.2000.01672.x; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; Fan Z, 1999, J GEN PHYSIOL, V114, P251, DOI 10.1085/jgp.114.2.251; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Karolyi L, 1997, HUM MOL GENET, V6, P17; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Vanoye CG, 2002, J BIOL CHEM, V277, P23260, DOI 10.1074/jbc.M112004200; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25	29	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49366	49373		10.1074/jbc.M208679200	http://dx.doi.org/10.1074/jbc.M208679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12381730	hybrid			2022-12-25	WOS:000180028900034
J	Liu, XH; Kirschenbaum, A; Lu, M; Yao, S; Dosoretz, A; Holland, JF; Levine, AC				Liu, XH; Kirschenbaum, A; Lu, M; Yao, S; Dosoretz, A; Holland, JF; Levine, AC			Prostaglandin E-2 induces hypoxia-inducible factor-1 alpha stabilization and nuclear localization in a human prostate cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; CYCLOOXYGENASE-2 INHIBITOR; FACTOR 1-ALPHA; COLON-CANCER; BCL-2 EXPRESSION; CARCINOMA CELLS; UP-REGULATION; HIF-ALPHA; ANGIOGENESIS	Hypoxia-induced up-regulation of vascular endothelial growth factor (VEGF) expression is a critical event leading to tumor neovascularization. Hypoxia stimulates hypoxia-inducible factor-1alpha (HIF-1alpha), a transcriptional activator of VEGF. Cyclooxygenase (COX)-2, an inducible enzyme that catalyzes the formation of prostaglandins (PGs) from arachidonic acid, is also induced by hypoxia. We reported previously that COX-2 inhibition prevents hypoxic up-regulation of VEGF in human prostate cancer cells and that prostaglandin E-2 (PGE(2)) restores hypoxic effects on VEGF. We hypothesized that PGE2 mediates hypoxic effects on VEGF by modulating HIF-1a expression. Addition of PGE(2) to PC-3ML human prostate cancer cells had no effect on HIF-1alpha mRNA levels. However, PGE2 significantly increased HIF-1alpha protein levels, particularly in the nucleus. This effect of PGE2 largely results from the promotion of HIF-1alpha translocation from the cytosol to the nucleus. PGE2 addition to PC-3 ML cells transfected with a GFP-HIF-1alpha vector induced a time-dependent nuclear accumulation of the HIF-1alpha protein. Two selective COX-2 inhibitors, meloxicam and NS398, decreased HIF-1alpha levels and nuclear localization, under both normoxic and hypoxic conditions. Of several prostaglandins tested, only PGE2 reversed the effects of a COX-2 inhibitor in hypoxic cells. Finally, PGE2 effects on HIF-1alpha were specifically inhibited by PD98059 (a MAPK inhibitor). These data demonstrate that PGE2 production via COX-2-catalyzed pathway plays a critical role in HIF-1alpha regulation by hypoxia and imply that COX-2 inhibitors can prevent hypoxic induction of HIF-mediated gene transcription in cancer cells.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Liu, XH (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1055,Annenberg Bldg,Rm 23-78,1 Gustave L Levy, New York, NY 10029 USA.			Levine, Alice/0000-0002-0634-4133	NCRR NIH HHS [1S10 RR 09145-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; BERRA E, 2001, EMBO REP, V21, P1; BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fang JM, 2001, CANCER RES, V61, P5731; FOLKMAN J, 1992, J NATL CANCER I, V82, P4; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jones MK, 1999, NAT MED, V5, P1418; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lissbrant IF, 1997, PROSTATE, V33, P38; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XH, 1998, CANCER RES, V58, P4245; Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549; Masferrer JL, 2000, CANCER RES, V60, P1306; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; PACCANIS R, 2002, J BIOL CHEM, V277, P1509; Reddy BS, 2000, CANCER RES, V60, P293; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Sawaoka H, 1999, LAB INVEST, V79, P1469; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; WEIDNER N, 1993, AM J PATHOL, V143, P401; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yu F, 2001, CANCER RES, V61, P4136; Zhong H, 2000, CANCER RES, V60, P1541	51	172	185	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50081	50086		10.1074/jbc.M201095200	http://dx.doi.org/10.1074/jbc.M201095200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12401798	hybrid			2022-12-25	WOS:000180028900127
J	Muh, SJ; Hovhannisyan, RH; Carstens, RP				Muh, SJ; Hovhannisyan, RH; Carstens, RP			A non-sequence-specific double-stranded RNA structural element regulates splicing of two mutually exclusive exons of fibroblast growth factor receptor 2 (FGFR2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRACT-BINDING-PROTEIN; SECONDARY STRUCTURE; ALTERNATIVE EXON; IN-VIVO; INTRON SEQUENCES; MOLECULAR-BASIS; SITE SELECTION; LOOP STRUCTURE; HNRNP H	Alternative splicing of fibroblast growth factor receptor 2 (FGFR2) mutually exclusive exons IIIb and IIIc represents a tightly regulated and functionally relevant example of post-transcriptional gene regulation. Rat prostate cancer DT3 and AT3 cell lines demonstrate exclusive selection of either exon IIIb or exon IIIc, respectively, and have been used to characterize regulatory FGFR2 RNA cis-elements that are required for splicing regulation. Two sequences termed ISE-2 and ISAR are located in the intron between exons IIIb and IIIc and are required for cell-type specific exon IIIb. Previous studies suggest that the function of these elements involves formation of an RNA stem structure, even though they are separated by more than 700 nucleotides. Using transfected minigenes, we performed a systematic analysis of the sequence and structural components of ISE-2 and ISAR that are required for their ability to regulate FGFR2 splicing. We found that the primary sequence of these elements can be replaced by completely unrelated sequences, provided that they are also predicted to form an RNA stem structure. Thus, a nonsequence-specific double stranded RNA stem constitutes a functional element required for FGFR2 splicing, suggesting that a double-stranded RNA binding protein is a component of the splicing regulatory machinery.	Univ Penn, Sch Med, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania	Carstens, RP (corresponding author), Univ Penn, Sch Med, Dept Med, Renal Electrolyte & Hypertens Div, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	russcars@mail.med.upenn.edu			NCI NIH HHS [K08 CA 72560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ASHIYA M, 1995, NUCL ACIDS S SER, V33, P215; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Beer HD, 2000, J BIOL CHEM, V275, P16091, DOI 10.1074/jbc.275.21.16091; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blanchette M, 1997, RNA, V3, P405; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Chou MY, 1999, MOL CELL BIOL, V19, P69; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DESHLER JO, 1991, GENE DEV, V5, P1252, DOI 10.1101/gad.5.7.1252; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; Hertel KJ, 1996, RNA, V2, P969; Hoffman BE, 2000, MOL CELL BIOL, V20, P181, DOI 10.1128/MCB.20.1.181-186.2000; Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jin W, 2000, CANCER RES, V60, P1221; Jones RB, 2001, NUCLEIC ACIDS RES, V29, P3557, DOI 10.1093/nar/29.17.3557; Jones RB, 2001, J BIOL CHEM, V276, P4158, DOI 10.1074/jbc.M006151200; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Le Guiner C, 2001, J BIOL CHEM, V276, P43677, DOI 10.1074/jbc.M107381200; LIBRI D, 1995, RNA, V1, P425; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIU HX, 1995, EMBO J, V14, P377, DOI 10.1002/j.1460-2075.1995.tb07012.x; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Perez I, 1997, RNA, V3, P764; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIRANDPUGNET P, 1995, J MOL BIOL, V251, P591, DOI 10.1006/jmbi.1995.0458; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530; Zhang WQ, 2002, RNA, V8, P671, DOI 10.1017/S1355838202027036; Zhang YZ, 1999, GENE, V230, P69, DOI 10.1016/S0378-1119(99)00047-5	81	41	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50143	50154		10.1074/jbc.M207409200	http://dx.doi.org/10.1074/jbc.M207409200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393912	hybrid			2022-12-25	WOS:000180028900134
J	Pang, QS; Christianson, TA; Keeble, W; Koretsky, T; Bagby, GC				Pang, QS; Christianson, TA; Keeble, W; Koretsky, T; Bagby, GC			The anti-apoptotic function of Hsp70 in the interferon-inducible double-stranded RNA-dependent protein kinase-mediated death signaling pathway requires the Fanconi anemia protein, FANCC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; HEMATOPOIETIC-CELLS; C-GENE; AUTOPHOSPHORYLATION SITES; INITIATION FACTOR-2-ALPHA; TRANSLATIONAL CONTROL; GAMMA-INTERFERON; NUCLEAR-COMPLEX; ACTIVATION LOOP	Proteins encoded by five of the six known Fanconi anemia (FA) genes form a heteromeric complex that facilitates repair of DNA damage induced by cross-linking agents. A certain number of these proteins, notably FANCC, also function independently to modulate apoptotic signaling, at least in part, by suppressing ground state activation of the pro-apoptotic interferon-inducible double-stranded RNA-dependent protein kinase (PKR). Because certain FANCC mutations interdict its anti-apoptotic function without interfering with the capacity of FANCC to participate functionally in the FA multimeric complex, we suspected that FANCC enhances cell survival independent of its participation in the complex. By investigating this function in both mammalian cells and in yeast, an organism with no FA orthologs, we show that FANCC inhibited the kinase activity of PKR both in vivo and in vitro, and this effect depended upon a physical interaction between FANCC and Hsp70 but not on interactions of FANCC with other Fanconi proteins. Hsp70, FANCC, and PKR form a ternary complex in lymphoblasts and in yeast expressing PKR. We conclude that Hsp70 requires the cooperation of FANCC to suppress PKR activity and support survival of hematopoietic cells and that FANCC does not require the multimeric FA complex to exert this function.	Oregon Hlth Sci Univ, Inst Canc, Dept med & Mol & Med Genet, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bagby, GC (corresponding author), Oregon Hlth Sci Univ, Inst Canc, Dept med & Mol & Med Genet, CR145, Portland, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048546] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48546] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; Buchwald M, 1998, MUTAT RES-DNA REPAIR, V408, P75, DOI 10.1016/S0921-8777(98)00024-X; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; Haneline LS, 1998, BLOOD, V91, P4092; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Naf D, 1998, MOL CELL BIOL, V18, P5952; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Otsuki T, 1999, J CELL PHYSIOL, V179, P79, DOI 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Rathbun RK, 2000, BLOOD, V96, P4204; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Taylor DR, 2001, J VIROL, V75, P1265, DOI 10.1128/JVI.75.3.1265-1273.2001; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Thulasiraman V, 1998, EUR J BIOCHEM, V255, P552, DOI 10.1046/j.1432-1327.1998.2550552.x; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Uma S, 1999, MOL CELL BIOL, V19, P5861; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Wang JX, 1998, CANCER RES, V58, P3538; Whitney MA, 1996, BLOOD, V88, P49; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	50	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49638	49643		10.1074/jbc.M209386200	http://dx.doi.org/10.1074/jbc.M209386200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397061	hybrid			2022-12-25	WOS:000180028900071
J	Pittman, MS; Corker, H; Wu, GH; Binet, MB; Moir, AJG; Poole, RK				Pittman, MS; Corker, H; Wu, GH; Binet, MB; Moir, AJG; Poole, RK			Cysteine is exported from the Escherichia coli cytoplasm by CydDC, an ATP-binding cassette-type transporter required for cytochrome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND FORMATION; GRAM-NEGATIVE BACTERIA; OXIDASE COMPLEX; SALMONELLA-TYPHIMURIUM; ALKALINE-PHOSPHATASE; RESPIRATORY CHAINS; TERMINAL OXIDASE; FORMATION INVIVO; GENE-PRODUCT; PROTEIN	Assembly of Escherichia coli cytochrome bd and periplasmic cytochromes requires the ATP-binding cassette transporter CydDC, whose substrate is unknown. Two-dimensional SDS-PAGE comparison of periplasm from wild-type and cydD mutant strains revealed that the latter was deficient in several periplasmic transport binding proteins, but no single major protein was missing in the cydD periplasm. Instead, CydDC exports from cytoplasm to periplasm the amino acid cysteine, demonstrated using everted membrane vesicles that transported radiolabeled cysteine inward in an ATP-dependent, uncoupler-independent manner. New pleiotropic cydD phenotypes are reported, including sensitivity to benzylpenicillin and dithiothreitol, and loss of motility, consistent with periplasmic defects in disulfide bond formation. Exogenous cysteine reversed these phenotypes and affected levels of periplasmic c-type cytochromes in cydD and wild-type strains but did not restore cytochrome d. Consistent with CydDC being a cysteine exporter, cydD mutant growth was hypersensitive to high cysteine concentrations and accumulated higher cytoplasmic cysteine levels, as did a mutant defective in orf299, encoding a transporter of the major facilitator superfamily. A cydD orf299 double mutant was extremely cysteine-sensitive and had higher cytoplasmic cysteine levels, whereas CydDC overexpression conferred resistance to high extracellular cysteine concentrations. We propose that CydDC exports cysteine, crucial for redox homeostasis in the periplasm.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Poole, RK (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Wu, Guanghui/A-3757-2016	Wu, Guanghui/0000-0002-9374-3190				ADLER LW, 1977, J SUPRAMOL STR CELL, V7, P15, DOI 10.1002/jss.400070103; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANDREWS JC, 1986, J BACTERIOL, V165, P428, DOI 10.1128/jb.165.2.428-433.1986; Bader M, 1999, NAT CELL BIOL, V1, pE57, DOI 10.1038/11025; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEBBINGTON KJ, 1993, FEMS MICROBIOL LETT, V112, P19; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONTHRON DT, 1990, GENE, V91, P101, DOI 10.1016/0378-1119(90)90168-Q; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Cook GM, 1998, MICROBIOL-UK, V144, P3297, DOI 10.1099/00221287-144-12-3297; Cook GM, 2002, ARCH MICROBIOL, V178, P358, DOI 10.1007/s00203-002-0467-6; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dartigalongue C, 2000, EMBO J, V19, P5980, DOI 10.1093/emboj/19.22.5980; Dassler T, 2000, MOL MICROBIOL, V36, P1101, DOI 10.1046/j.1365-2958.2000.01924.x; DATTA P, 1967, P NATL ACAD SCI USA, V58, P635, DOI 10.1073/pnas.58.2.635; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DELANEY JM, 1992, J BACTERIOL, V174, P1240, DOI 10.1128/jb.174.4.1240-1247.1992; Endley S, 2001, J BACTERIOL, V183, P2454, DOI 10.1128/JB.183.8.2454-2462.2001; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; GEORGIOU CD, 1987, J BACTERIOL, V169, P2107, DOI 10.1128/jb.169.5.2107-2112.1987; Goldman BS, 1996, J BACTERIOL, V178, P6348, DOI 10.1128/jb.178.21.6348-6351.1996; Goldman BS, 1996, J BACTERIOL, V178, P6338, DOI 10.1128/jb.178.21.6338-6347.1996; GOOLEY AA, 1997, PROTEOME RES NEW FRO, P63; GUTNICK D, 1969, J BACTERIOL, V100, P215, DOI 10.1128/JB.100.1.215-219.1969; HARSHEY RM, 1994, MOL MICROBIOL, V13, P389, DOI 10.1111/j.1365-2958.1994.tb00433.x; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; KITA K, 1984, J BIOL CHEM, V259, P3368; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; Lemberg R., 1973, CYTOCHROMES; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MOTTL H, 1992, J BACTERIOL, V174, P3261, DOI 10.1128/jb.174.10.3261-3269.1992; MULLER JH, 1972, EXPT MOL GENETICS; Nicholls D., 2002, BIOENERGETICS, V3; O'Brian MR, 2002, ADV MICROB PHYSIOL, V46, P257, DOI 10.1016/S0065-2911(02)46006-7; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; POOLE RK, 1994, FEMS MICROBIOL LETT, V117, P217, DOI 10.1111/j.1574-6968.1994.tb06768.x; Poole RK, 2000, ADV MICROB PHYSIOL, V43, P165, DOI 10.1016/S0065-2911(00)43005-5; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; QI SY, 1996, J BACTERIOL, V178, P12032; Reid E, 1998, FEMS MICROBIOL LETT, V166, P369, DOI 10.1016/S0378-1097(98)00357-7; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAMBONGI Y, 1994, FEBS LETT, V353, P235, DOI 10.1016/0014-5793(94)01053-6; Sambongi Y, 1996, FEBS LETT, V398, P265, DOI 10.1016/S0014-5793(96)01256-2; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Siegele DA, 1996, J BACTERIOL, V178, P6091, DOI 10.1128/jb.178.21.6091-6096.1996; SIEGELE DA, 1993, GENE DEV, V7, P2629, DOI 10.1101/gad.7.12b.2629; Silhavy T.J., 1984, EXPT GENE FUSIONS; SORENSEN MA, 1991, J BACTERIOL, V173, P5244, DOI 10.1128/jb.173.16.5244-5246.1991; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; STEWART V, 1988, J BACTERIOL, V170, P1589, DOI 10.1128/jb.170.4.1589-1597.1988; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; TYLER B, 1978, ANNU REV BIOCHEM, V47, P1127, DOI 10.1146/annurev.bi.47.070178.005403; Way SS, 1999, J BACTERIOL, V181, P1229, DOI 10.1128/JB.181.4.1229-1237.1999; WILLIS RC, 1974, ARCH BIOCHEM BIOPHYS, V161, P64, DOI 10.1016/0003-9861(74)90235-5; YIM HH, 1992, J BACTERIOL, V174, P3637, DOI 10.1128/JB.174.11.3637-3644.1992	74	85	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49841	49849		10.1074/jbc.M205615200	http://dx.doi.org/10.1074/jbc.M205615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393891	hybrid			2022-12-25	WOS:000180028900098
J	Roux, PP; Dorval, G; Boudreau, M; Angers-Loustau, A; Morris, SJ; Makkerh, J; Barker, PA				Roux, PP; Dorval, G; Boudreau, M; Angers-Loustau, A; Morris, SJ; Makkerh, J; Barker, PA			K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CHOLINE-ACETYLTRANSFERASE ACTIVITY; CHICK EMBRYONIC NEURONS; PROGRAMMED CELL-DEATH; FOCAL ADHESION KINASE; NF-KAPPA-B; PROTEIN-KINASE; SIGNALING PATHWAY; NEURITE OUTGROWTH; TYROSINE PHOSPHORYLATION	K252a is best known as a Trk inhibitor, but is also a neuroprotective compound. CEP1347, a K252a derivative, retains neuroprotective properties, but does not inhibit TrkA. CEP1347 has recently been shown to directly inhibit NLAPKKKs, including MLK3, but the effect of K252a on MAPKY.Ks remains unknown. K252a and CEP1347 not only prevent death, but also facilitate neurite outgrowth and maintenance, somal hypertrophy, and neurotransmitter synthesis. The biochemical basis for these trophic effects remains unknown. We have compared the effects of CEP1347 and K252a on MLK and JNK signaling and on neurotrophic pathways that support survival and growth. Our data show that K252a is a potent inhibitor of MLK3 activity in vivo and in vitro (IC50 similar to 5 nm). However, we also found that K252a and CEP1347 activate Akt and ERK and show that blockade of phosphatidylinositol 3-kinase or MEK activity ablates the effect of K252a and CEP1347 on cell survival. Activation of Akt and ERK occurs through an MLK-independent pathway that may involve c-Src. Together, these data show that the neuroprotective and neurotrophic effects of K252a and CEP1347 involve activation of several neurotrophic signaling pathways.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Aegera Therapeut Inc, Montreal, PQ H3E 1A8, Canada	McGill University	Barker, PA (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	phil.barker@mcgill.ca	Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250; Angers-Loustau, Alexandre/0000-0003-1425-4143				Anderson CNG, 1999, J NEUROSCI, V19, P664; Angeles TS, 1998, ARCH BIOCHEM BIOPHYS, V349, P267, DOI 10.1006/abbi.1997.0490; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BERG MM, 1992, J BIOL CHEM, V267, P13; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; BORASIO GD, 1990, NEUROSCI LETT, V108, P207, DOI 10.1016/0304-3940(90)90732-O; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GLICKSMAN MA, 1993, J NEUROCHEM, V61, P210, DOI 10.1111/j.1471-4159.1993.tb03557.x; GLICKSMAN MA, 1995, J NEUROCHEM, V64, P1502; Glicksman MA, 1998, J NEUROBIOL, V35, P361, DOI 10.1002/(SICI)1097-4695(19980615)35:4<361::AID-NEU3>3.3.CO;2-G; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; HARRIS C, 2000, SOC NEUR 30 ANN M NE; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; HASHIMOTO S, 1989, EXP CELL RES, V184, P351, DOI 10.1016/0014-4827(89)90334-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Lentz SI, 1999, J NEUROSCI, V19, P1038; MA Y, 1992, J CELL BIOL, V117, P135, DOI 10.1083/jcb.117.1.135; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; MARONEY AC, 1995, J NEUROCHEM, V64, P540; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; O'Ferrall EK, 2000, J NEUROCHEM, V75, P2358, DOI 10.1046/j.1471-4159.2000.0752358.x; OPPENHEIM RW, 1981, J NEUROSCI, V1, P141; Ozes ON, 1999, NATURE, V401, P82; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rubin LL, 1998, PROG BRAIN RES, V117, P3; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; TAPLEY P, 1992, ONCOGENE, V7, P371; TISCHLER AS, 1991, J BIOL CHEM, V266, P1141; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Wagner ACC, 2000, AM J PHYSIOL-GASTR L, V278, pG165, DOI 10.1152/ajpgi.2000.278.1.G165; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200	61	87	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49473	49480		10.1074/jbc.M203428200	http://dx.doi.org/10.1074/jbc.M203428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388555	hybrid			2022-12-25	WOS:000180028900049
J	Takasugi, N; Takahashi, Y; Morohashi, Y; Tomita, T; Iwatsubo, T				Takasugi, N; Takahashi, Y; Morohashi, Y; Tomita, T; Iwatsubo, T			The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in Drosophila melanogaster and mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE PRODUCTION; ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; MUTANT PRESENILIN-2; C-TERMINUS; WILD-TYPE; NOTCH; ENDOPROTEOLYSIS; STABILIZATION	Mutations in presenilin 1 (PS1) and PS2 genes contribute to the pathogenesis of early onset familial Alzheimer's disease by increasing secretion of the pathologically relevant Abeta42 polypeptides. PS genes are also implicated in Notch signaling through proteolytic processing of the Notch receptor in Caenorhabditis elegans, Drosophila melanogaster, and mammals. Here we show that Drosophila PS (Psn) protein undergoes endoproteolytic cleavage and forms a stable high molecular weight (HMW) complex in Drosophila S2 or mouse neuro2a (N2a) cells in a similar manner to mammalian PS. The loss-of-function recessive point mutations located in the C-terminal region of Psn, that cause an early pupal-lethal phenotype resembling Notch mutant in vivo, disrupted the HMW complex formation, and abolished gamma-secretase activities in cultured cells. The overexpression of Psn in mouse embryonic fibroblasts lacking PS1 and PS2 genes rescued the Notch processing. Moreover, disruption of the expression of Psn by double-stranded RNA-mediated interference completely abolished the gamma-secretase activity in S2 cells. Surprisingly, gamma-secretase activity dependent on wild-type Psn was associated with a drastic overproduction of Abeta1-42 from human betaAPP in N2a cells, but not in S2 cells. Our data suggest that the mechanism of gamma-secretase activities through formation of HMW PS complex, as well as its abolition by loss-of-function mutations located in the C terminus, are highly conserved features in Drosophila and mammals.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082				Arduengo PM, 1998, J CELL SCI, V111, P3645; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Boulianne GL, 1997, NEUROREPORT, V8, P1025, DOI 10.1097/00001756-199703030-00041; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Guo YQ, 1999, J NEUROSCI, V19, P8435; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIRASAKA S, 1998, J CELL SCI, V111, P667; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lukinova NI, 1999, GENETICS, V153, P1789; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Okochi M, 2000, J BIOL CHEM, V275, P40925, DOI 10.1074/jbc.M005254200; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	43	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50198	50205		10.1074/jbc.M205352200	http://dx.doi.org/10.1074/jbc.M205352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388554	hybrid			2022-12-25	WOS:000180028900141
J	Westling, C; Lindahl, U				Westling, C; Lindahl, U			Location of N-unsubstituted glucosamine residues in heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; AMINO-GROUPS; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; DIVERSITY; SULFOTRANSFERASE; DEPOLYMERIZATION; BIOSYNTHESIS; SPECIFICITY; GLYPICAN-1	Functional properties of heparan sulfate (HS) are generally ascribed to the sulfation pattern of the polysaccharide. However, recently reported functional implications of rare N-unsubstituted glucosamine (GlcNH(2)) residues in native HS prompted our structural characterization of sequences around such residues. HS preparations were cleaved with nitrous acid at either N-sulfated or N-unsubstituted glucosamine units followed by reduction with (NaBH4)-H-3,. The labeled products were characterized following complementary deamination steps. The proportion of GlcNH(2) units varied from 0.7-4% of total glucosamine in different HS preparations. The GlcNH(2) units occurred largely clustered at the polysaccharide-protein linkage region in intestinal HS, also more peripherally in aortic HS. They were preferentially located within N-acetylated domains, or in transition sequences between N-acetylated and N-sulfated domains, only 20-30% of the adjacent upstream and downstream disaccharide units being N-sulfated. The nearest downstream (toward the polysaccharide-protein linkage) hexuronic acid was invariably GlcUA, whereas the upstream neighbor could be either GlcUA or ldoUA. The highly sulfated but N-unsubstituted disaccharide unit, -IdoUA2S-GlcNH(2)6S-, was detected in human renal and porcine intestinal HS, but not in HS from human aorta. These results are interpreted in terms of a biosynthetic mechanism, whereby GlcNH(2) residues are formed through regulated, incomplete action of an N-deacetylase/N-sulfotransferase enzyme.	Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, SE-75123 Uppsala, Sweden	Uppsala University	Lindahl, U (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, POB 582, SE-75123 Uppsala, Sweden.							Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; BAME KJ, 1991, J BIOL CHEM, V266, P12461; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; CONRAD HE, 1998, HEPARIN BINDING PROT, P10; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAWES J, 1992, THROMB HAEMOSTASIS, V67, P468; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; NAVIA JL, 1983, ANAL BIOCHEM, V135, P134, DOI 10.1016/0003-2697(83)90741-8; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303	42	58	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49247	49255		10.1074/jbc.M209139200	http://dx.doi.org/10.1074/jbc.M209139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12374790	hybrid			2022-12-25	WOS:000180028900019
J	Galvan, DL; Mignery, GA				Galvan, DL; Mignery, GA			Carboxyl-terminal sequences critical for inositol 1,4,5-trisphosphate receptor subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL FUNCTION; LIGAND-BINDING SITE; RYANODINE RECEPTOR; INSP(3) RECEPTORS; EXPRESSION; DOMAIN; TYPE-1; CA2+; OLIGOMERIZATION; INVOLVEMENT	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is a tetrameric assembly of conserved subunits that each contains six transmembrane regions (TMRs) localized near the carboxyl terminus. Receptor subunit assembly into a tetramer appears to be a multideterminant process involving an additive contribution of membrane spanning helices and the short cytosolic carboxyl terminus (residues 2590-2749). Previous studies have shown that of the six membrane-spanning regions in each subunit, the 5th and 6th transmembrane regions, and the carboxyl terminus are strong determinants for assembly. The fifth and sixth TMRs contain numerous P-branched amino acids that may participate in coiled/coil formation via putative leucine zipper motifs. InsP(3)R truncation mutants were expressed in COS-1 cells and analyzed by sucrose density gradient sedimentation and gel filtration for their ability to assemble. Chemical cross-linking with the homobifunctional reagents sDST or DMS of mammalian and bacterially expressed carboxyl-terminal containing receptor fragments reveals that sequences within the carboxyl terminus confer the formation of subunit dimers. A series of InsP(3) receptor carboxyl-terminal fragments and glutathione S-transferase (GST)/InsP(3)R chimeras were expressed in Escherichia coli and used in an in vitro assay to elucidate the minimal sequence responsible for association of the carboxyl termini into dimers. The results presented here indicate that this minimal sequence is similar to30 residues in length and is localized between residues 2629 and 2654. These residues are highly conserved between the three InsP(3)R isoforms (similar to80% identity) as well as the ryanodine receptor (similar to40% identity) and suggest that a conserved assembly motif may exist between the two intracellular receptor families. We propose that assembly of the InsP(3) receptor to a tetramer involves intersubunit interactions mediated through both the membrane-spanning regions and residues 2629-2654 of the carboxyl terminus possibly through the formation of a dimer of dimers.	Loyola Univ Chicago, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Mignery, GA (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.		Galvan, Daniel L./L-2768-2019	Galvan, Daniel L./0000-0001-7541-6252	NIMH NIH HHS [MH533367] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Magnino F, 2001, EUR J BIOCHEM, V268, P5981, DOI 10.1046/j.0014-2956.2001.02559.x; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	28	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48248	48260		10.1074/jbc.M209990200	http://dx.doi.org/10.1074/jbc.M209990200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377774	hybrid			2022-12-25	WOS:000179789600038
J	Ozvegy, C; Varadi, A; Sarkadi, B				Ozvegy, C; Varadi, A; Sarkadi, B			Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter - Modulation of substrate specificity by a point mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; HALF-TRANSPORTER; P-GLYCOPROTEIN; BINDING SITES; BLAST CELLS; EXPRESSION; GENE; MXR; OVEREXPRESSION; MDR1	The overexpression of the human ATP-binding cassette half-transporter, AECG2 (placenta-specific ABC transporter, mitoxantrone resistance-associated protein, breast cancer resistance protein), causes multidrug resistance in tumor cells. An altered drug resistance profile and substrate recognition were suggested for wild-type ABCG2 and its mutant variants (R482G and R482T); the mutations were found in drug-selected tumor cells. In order to characterize the different human ABCG2 transporters without possible endogenous dimerization. partners, we expressed these proteins and a catalytic center mutant (K86M) in Sf9 insect cells. Transport activity was followed in intact cells, whereas the ATP binding and hydrolytic properties of ABCG2 were studied in isolated cell membranes. We found that the K86M mutant had no transport or ATP hydrolytic activity, although its ATP binding was retained. The wild-type AECG2 and its variants, R482G and R482T, showed characteristically different drug and dye transport activities; mitoxantrone and Hoechst 33342 were transported by all transporters, whereas rhodamine 123 was only pumped by the R482G and R482T mutants. In each case, ABCG2-dependent transport was blocked by the specific inhibitor, fumitremorgin C. A relatively high basal ABCG2-ATPase, inhibited by fumitremorgin C, was observed in all active proteins, but specific drug stimulation could only be observed in the case of R482G and R482T mutants. We found that ABCG2 is capable of a vanadate-dependent adenine nucleotide trapping. Nucleotide trapping was stimulated by the transported compounds in the R482G and R482T variants but not in the wild-type ABCG2. These experiments document the applicability of the Sf9 expression system for parallel, quantitative examination of the specific transport and ATP hydrolytic properties of different ABCG2 proteins and demonstrate significant differences in their substrate interactions.	Hungarian Acad Sci, Membrane Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Sarkadi, B (corresponding author), Hungarian Acad Sci, Membrane Res Grp, Inst Haematol & Immunol, Natl Med Ctr, Dioszegi 64, H-1113 Budapest, Hungary.	sarkadi@biomembrane.hu	Varadi, Andras/A-2055-2012; Sarkadi, Balazs/I-5024-2013					Allen JD, 2002, CANCER RES, V62, P2294; Allikmets R, 1998, CANCER RES, V58, P5337; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; CHEN AY, 1993, CANCER RES, V53, P1332; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAUGHLAND RP, 1996, HDB FLUORESCENT PROB, P151; Honjo Y, 2001, CANCER RES, V61, P6635; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kim M, 2002, CLIN CANCER RES, V8, P22; Knutsen T, 2000, GENE CHROMOSOME CANC, V27, P110, DOI 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.0.CO;2-4; Komatani H, 2001, CANCER RES, V61, P2827; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Muller M, 1996, J BIOL CHEM, V271, P1877; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Rabindran SK, 2000, CANCER RES, V60, P47; Robey RW, 2001, CLIN CANCER RES, V7, P145; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Sargent JM, 2001, BRIT J HAEMATOL, V115, P257, DOI 10.1046/j.1365-2141.2001.03122.x; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van Loevezijn A, 2001, BIOORG MED CHEM LETT, V11, P29, DOI 10.1016/S0960-894X(00)00588-6; Yang CH, 2000, BIOCHEM PHARMACOL, V60, P831, DOI 10.1016/S0006-2952(00)00396-8; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	42	183	189	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					47980	47990		10.1074/jbc.M207857200	http://dx.doi.org/10.1074/jbc.M207857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374800	hybrid			2022-12-25	WOS:000179789600004
J	Russo, A; Antignani, A; Giancola, C; D'Alessio, G				Russo, A; Antignani, A; Giancola, C; D'Alessio, G			Engineering the refolding pathway and the quaternary structure of seminal ribonuclease by newly introduced disuffide bridges	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BONDS; ANTITUMOR ACTION; CONFORMATIONAL STABILITY; DIMERIC STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; INHIBITOR; RNASE; CYTOTOXICITY; ISOFORMS	Seminal RNase (BS-RNase), a ribonuclease from bovine seminal vesicles, is a homodimeric enzyme with a strong cytotoxic activity selective for tumor cells. It displays the unusual structural feature of existing in solution as an equilibrium mixture of two quaternary isoforms. The major one is characterized by the swap between subunits of their N-terminal ends, whereas the minor isoform shows no swap. The tendency of the two isolated isoforms to interconvert into each other has so far made it difficult to attribute the functional properties of BS-RNase to either isoform. Herein, molecular modeling and site-directed mutagenesis were used to engineer the refolding pathway of BS-RNase and obtain a stable variant of its non-swapping isoform. The protein was engineered with two extra disulfide bridges linking the N-terminal helix of each subunit to the main body of the same subunit. Purified as an active enzyme, the BS-RNase variant was found to be very resistant to thermal denaturation. Its functional characterization revealed that the lack of swapping has a negative effect on the cytotoxic activity of BS-RNase.	Univ Naples Federico II, Dept Biol Chem, I-80134 Naples, Italy; Univ Naples Federico II, Dept Chem, I-80126 Naples, Italy; Univ Naples 2, Dept Life Sci, I-81100 Caserta, Italy	University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli	D'Alessio, G (corresponding author), Univ Naples Federico II, Dept Biol Chem, Via Mezzocannone 16, I-80134 Naples, Italy.		Giancola, Concetta/AAR-4536-2020	Russo, Aniello/0000-0001-5421-3552; Giancola, Concetta/0000-0002-0360-6062				Antignani A, 2001, BIOCHEMISTRY-US, V40, P3492, DOI 10.1021/bi002781m; Beintema J.J., 1997, RIBONUCLEASES STRUCT, P245; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; Bracale A, 2002, BIOCHEM J, V362, P553, DOI 10.1042/0264-6021:3620553; Burton RE, 2000, PROTEIN SCI, V9, P776; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cubellis MV, 2000, J MOL BIOL, V301, P775, DOI 10.1006/jmbi.2000.3985; D'Alessio G, 2001, METHOD ENZYMOL, V341, P248, DOI 10.1016/S0076-6879(01)41156-6; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; Giancola C, 2000, BIOCHEMISTRY-US, V39, P7964, DOI 10.1021/bi992953j; GILLILAND GL, 1997, RIBONUCLEASES STRUCT, P306; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUEX N, 1996, EXPERIENTIA, V52, P26; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; Klink TA, 2000, J BIOL CHEM, V275, P17463, DOI 10.1074/jbc.M001132200; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LACCETTI P, 1994, CANCER RES, V54, P4253; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MASTRONICOLA MR, 1995, EUR J BIOCHEM, V230, P242, DOI 10.1111/j.1432-1033.1995.tb20557.x; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Murthy BS, 1996, BIOCHEMISTRY-US, V35, P3880, DOI 10.1021/bi952429m; PACE CN, 1988, J BIOL CHEM, V263, P11820; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; PARENTE A, 1985, EUR J BIOCHEM, V149, P381, DOI 10.1111/j.1432-1033.1985.tb08936.x; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; Piccoli R, 2000, J BIOL CHEM, V275, P8000, DOI 10.1074/jbc.275.11.8000; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; Prescott J M, 1976, Methods Enzymol, V45, P530; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Russo N, 2000, BIOCHEMISTRY-US, V39, P3585, DOI 10.1021/bi992367q; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; VESCIA S, 1980, CANCER RES, V40, P3740; Vitagliano L, 1998, PROTEIN SCI, V7, P1691, DOI 10.1002/pro.5560070804; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; WETZEL R, 1987, TRENDS BIOCHEM SCI, V12, P478, DOI 10.1016/0968-0004(87)90234-9; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	51	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48643	48649		10.1074/jbc.M207141200	http://dx.doi.org/10.1074/jbc.M207141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377788	hybrid			2022-12-25	WOS:000179789600088
J	Siniossoglou, S; Pelham, HRB				Siniossoglou, S; Pelham, HRB			Vps51p links the VFT complex to the SNARE Tlg1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-SNARE; 3-DIMENSIONAL STRUCTURE; MEMBRANE-FUSION; EXOCYST; EFFECTOR; INTERACTS; VESICLES; GENES; COIL; FORM	Intracellular membrane fusion requires the complex coordination of SNARE, rab/ypt, and rab effector function. In the yeast Saccharomyces cerevisiae, fusion of endosome-derived vesicles with the late Golgi depends on a cascade of protein-protein interactions that results in the recruitment to Golgi membranes of a conserved docking complex, VFT. This complex binds to Ypt6-GTP, which is necessary for its localization to the Golgi, and also to the SNARE Tlg1p. We show here that the VFT complex contains a fourth, previously uncharacterized, subunit, Vps51p (Ykr020w). Yeast cells lacking VPS51 have defects in vacuole morphology and recycling of the SNARE Snc1p to the plasma membrane, but still assemble a core VFT complex consisting of Vps52p, Vps53p, and Vps54p that localizes properly to the Golgi. Binding to Ypt6-GTP is a property of Vps52p. In contrast, binding to Tlg1p is mediated by a short sequence at the N terminus of Vps51p. Recent evidence suggests that components of a number of rab/ypt effector complexes share a common, distantly related helical coiled-coil motif. We show that each VFT subunit requires this coiled-coil motif for assembly into the complex.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Pelham, HRB (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	hp@mrc-lmb.cam.ac.uk						Bidlingmaier Scott, 2002, Functional and Integrative Genomics, V1, P345, DOI 10.1007/s10142-001-0043-1; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Souciet JL, 2000, FEBS LETT, V487, P3, DOI 10.1016/S0014-5793(00)02272-9; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Tsui MMK, 2001, MOL BIOL CELL, V12, P521, DOI 10.1091/mbc.12.3.521; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	26	103	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48318	48324		10.1074/jbc.M209428200	http://dx.doi.org/10.1074/jbc.M209428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377769	hybrid			2022-12-25	WOS:000179789600047
J	Suardita, K; Fujimoto, K; Oda, R; Shimazu, A; Miyazaki, K; Kawamoto, T; Kato, Y				Suardita, K; Fujimoto, K; Oda, R; Shimazu, A; Miyazaki, K; Kawamoto, T; Kato, Y			Effects of overexpression of membrane-bound transferrin-like protein (MTf) on chondrogenic differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; CARTILAGE MATRIX PROTEIN; HUMAN-MALIGNANT MELANOMA; CELL-SURFACE; STRUCTURAL-CHARACTERIZATION; ANTIGEN P97; IRON UPTAKE; EXPRESSION; LINE; MELANOTRANSFERRIN	Membrane-bound transferrin-like protein (MTf) is expressed in parallel with the expression of cartilage-characteristic genes during differentiation of chondrocytes, and the MTf level is much higher in cartilage than in other tissues. To investigate the role of MTf in cartilage, we examined the effects of growth factors on MTf expression in mouse prechondrogenic ATDC5 cells and the effect of MTf overexpression on differentiation of ATDC5 and mouse pluripotent mesenchymal C3H10T1/2 cells. In ATDC5 cultures, bone morphogenetic protein-2 and transforming growth factor-P as well as insulin induced MTf mRNA expression when these peptides induced chondrogenic differentiation. Forced expression of rabbit MTf in ATDC5 cells induced aggrecan, type II collagen, matrilin-1, type X collagen mRNAs, and cell-shape changes from fibroblastic cells to spherical chondrocytes. Accordingly, the synthesis and accumulation of proteoglycans were higher in MTf-expressing cultures than in control cultures. These effects of MTf overexpression correlated with the MTf protein level on the cell surface and decreased in the presence of anti-MTf antibody. However, the aggrecan mRNA level in the ATDC5 cells overexpressing MTf was lower than that in wild type ATDC5 cells exposed to 10 mug/ml insulin. MTf overexpression in C3H10T1/2 cells also induced aggrecan and/or type II collagen mRNA but not the spherical phenotype. These findings suggest that the expression of MTf on the cell surface facilitates the differentiation of prechondrogenic cells, although MTf overexpression alone seems to be insufficient to commit pluripotent mesenchymal cells to the chondrocyte lineage.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Operat Dent, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Prevent Dent, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Kato, Y (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	ykato@hiroshima-u.ac.jp	Suardita, Ketut/Q-8651-2019; , 河本健/D-7938-2015	Suardita, Ketut/0000-0003-0492-5417; , 河本健/0000-0003-3337-1775				ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; BROWN JP, 1981, J IMMUNOL, V127, P539; CASELLAS P, 1982, INT J CANCER, V30, P437, DOI 10.1002/ijc.2910300410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Horejsi V, 1998, IMMUNOL LETT, V63, P63, DOI 10.1016/S0165-2478(98)00054-6; Jefferies WA, 1996, BRAIN RES, V712, P122, DOI 10.1016/0006-8993(95)01407-1; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KATO Y, 1980, EXP CELL RES, V130, P73, DOI 10.1016/0014-4827(80)90043-9; Kawamoto T, 1998, EUR J BIOCHEM, V256, P503, DOI 10.1046/j.1432-1327.1998.2560503.x; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; Richardson DR, 2000, EUR J BIOCHEM, V267, P1290, DOI 10.1046/j.1432-1327.2000.01079.x; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; Sekyere E, 2000, FEBS LETT, V483, P11, DOI 10.1016/S0014-5793(00)02079-2; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; WOODBURY RG, 1981, INT J CANCER, V27, P145, DOI 10.1002/ijc.2910270204; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183	37	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48579	48586		10.1074/jbc.M209243200	http://dx.doi.org/10.1074/jbc.M209243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374788	hybrid			2022-12-25	WOS:000179789600080
J	Blanchetot, C; Tertoolen, LG; Overvoorde, J; den Hertog, J				Blanchetot, C; Tertoolen, LG; Overvoorde, J; den Hertog, J			Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 POINT MUTATIONS; CATALYTIC DOMAINS; INTRAMOLECULAR INTERACTIONS; SIGNALING NETWORK; RPTP-MU; ALPHA; DIMERIZATION; CD45; ASSOCIATION; INHIBITION	The presence of two protein-tyrosine phosphatase (PTP) domains is a striking feature in most transmembrane receptor PTPs (RPTPs). The generally inactive membrane-distal PTP domains (RPTP-D2s) bind and are proposed to regulate the membrane-proximal PTP domains (RPTP-D1s). We set out to characterize the interactions between RPTP-D1s and RPTP-D2s in vivo by co-immunoprecipitation of hemagglutinin-tagged fusion proteins encoding the transmembrane domain and RPTP-D1 and myc-tagged RPTP-D2. Seven RPTPs from four different subfamilies were used: RPTPalpha, RPTPepsilon, LAR, RPTPsigma, RPTPdelta, CD45, and RPTPmu. We found that RPTP-D2s bound to RPTPs with different affinities. The presence of intrinsic RPTP-D2 altered the binding specificity toward other RPTP-D2s positively or negatively, depending on the identity of the RPTPs. Furthermore, the C terminus of RPTP-D2s and the "wedge" in RPTP-D1s played a central role in binding specificity. Finally, full-length RPTPa and LAR heterodimerized in an oxidative stress-dependent manner. Like RPTPalpha-D2, the LAR-D2 conformation was affected by oxidative stress, suggesting a common regulatory mechanism for RPTP complex formation. Taken together, interactions between RPTP-D1s and RPTP-D2s are a common but specific mechanism that is likely to be regulated. The RPTP-D2s and the wedge structures are crucial determinants of binding specificity, thus regulating crosstalk between RPTPs.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl		Blanchetot, christophe/0000-0001-9152-9978				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Aricescu AR, 2001, BIOCHEM BIOPH RES CO, V280, P319, DOI 10.1006/bbrc.2000.4094; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; den Hertog J, 1999, MECH DEVELOP, V85, P3, DOI 10.1016/S0925-4773(99)00089-1; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Desai CJ, 1997, DEVELOPMENT, V124, P1941; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Hayami-Noumi K, 2000, FEBS LETT, V468, P68, DOI 10.1016/S0014-5793(00)01200-X; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lim KL, 1999, BBA-PROTEIN STRUCT M, V1434, P275, DOI 10.1016/S0167-4838(99)00189-2; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; Sun Q, 2001, MOL CELL NEUROSCI, V17, P274, DOI 10.1006/mcne.2000.0939; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5	30	58	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47263	47269		10.1074/jbc.M205810200	http://dx.doi.org/10.1074/jbc.M205810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12376545	hybrid			2022-12-25	WOS:000179663700055
J	Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J				Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J			Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide	ONCOGENE			English	Article						Ewing's sarcoma; IFN-alpha; IFN-beta; ifosfamide; xenograft	SIGNAL-TRANSDUCTION; P53 MUTATIONS; THERAPY; SARCOMA; CANCER; GENE; ANGIOGENESIS; SUPPRESSION; CISPLATIN; ETOPOSIDE	Ewing sarcoma is the second most common bone tumor in childhood. Despite aggressive chemotherapy and radiotherapy strategies, the prognosis of patients with metastatic disease remains poor. We have recently reported that Ewing tumor cell proliferation was strongly inhibited by IFN-beta and to a lesser degree by IFN-alpha. Moreover, under IFN-beta treatment, some cell lines undergo apoptosis. Since the possibility of using IFNs for Ewing tumor treatments may be of interest, we have evaluated the efficacy of Hu-IFNs in a nude mice model of Ewing tumor xenografts. The results reported here show that human type I IFNs, Hu-IFN-alpha and Hu-IFN-beta impaired tumor xenograft take and displayed an anti-growth effect toward established xenografts. Furthermore, we have also shown that combined therapy with Hu-IFNs and ifosfamide (IFO), an alkylating agent widely used in high-dose chemotherapy of Ewing tumors, results in a strong antitumor effect. Pathological analysis showed that Hu-IFN-alpha/IFO and Hu-IFN-beta/IFO were characterized by a dramatic decrease in the mitotic index and marked necrosis, as well as extensive fibrosis associated with numerous calcifications. To our knowledge, this is the first demonstration of a potential antitumor effect of human type I IFNs and IFO on Ewing tumors, providing a rational foundation for a promising therapeutic approach to Ewing sarcoma.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; Inst Curie, Sect Rech, CNRS, UMR 147, F-75248 Paris 05, France; Inst Curie, Sect Rech, INSERM, U509, F-75248 Paris 05, France; Inst Curie, Med Sect, Dept Pathol, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	Jeanne.Wietzerbin@curie.fr		Sastre-Garau, Xavier/0000-0001-5992-2083; delattre, olivier/0000-0002-8730-2276				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brockmeyer NH, 1998, CHEMOTHERAPY, V44, P174, DOI 10.1159/000007112; BROSJO O, 1985, CANCER RES, V45, P5598; Chapman BA, 2001, NEW ZEAL MED J, V114, P103; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Daponte A, 2000, CANCER, V89, P2630, DOI 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dong ZY, 1999, CANCER RES, V59, P872; Eck SL, 2001, HUM GENE THER, V12, P97; Faderl S, 1999, ONCOLOGY-NY, V13, P169; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Garmendia G, 2001, J INTERF CYTOK RES, V21, P31, DOI 10.1089/107999001459132; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Grander D, 1997, EUR J HAEMATOL, V59, P129; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hall GL, 1997, TRENDS NEUROSCI, V20, P63, DOI 10.1016/S0166-2236(96)10071-0; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Horowitz Marc E., 1997, P831; Horton HM, 1999, CANCER RES, V59, P4064; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KURZROCK R, 1991, BRIT J HAEMATOL, V79, P17, DOI 10.1111/j.1365-2141.1991.tb08112.x; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mizuno M, 1998, CANCER IMMUNOL IMMUN, V47, P227, DOI 10.1007/s002620050525; Monshouwer M, 1996, TOXICOL APPL PHARM, V137, P237, DOI 10.1006/taap.1996.0077; Nemati F, 2000, CLIN CANCER RES, V6, P2075; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Ozawa S, 2001, NEOPLASIA, V3, P154, DOI 10.1038/sj.neo.7900128; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Rosito P, 1999, CANCER-AM CANCER SOC, V86, P421, DOI 10.1002/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O; Rosolen A, 1997, MODERN PATHOL, V10, P55; Ross C, 2000, ANN NEUROL, V48, P706, DOI 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.3.CO;2-M; Rumi MG, 1997, BLOOD, V89, P3529; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sandler AB, 1998, SEMIN ONCOL, V25, P38; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Surin B, 2002, INT J MOL MED, V10, P25; Tada H, 2001, J CLIN INVEST, V108, P83, DOI 10.1172/JCI9841; Talpaz M, 2001, SEMIN HEMATOL, V38, P22, DOI 10.1053/shem.2001.27080; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Todesco A, 2000, CANCER-AM CANCER SOC, V89, P2661, DOI 10.1002/1097-0142(20001215)89:12<2661::AID-CNCR20>3.0.CO;2-9; Wadler, 1997, Oncologist, V2, P254; WADLER S, 1990, CANCER RES, V50, P3473; Wexler LH, 1996, CANCER, V78, P901; Wollina U, 2001, J AM ACAD DERMATOL, V44, P253, DOI 10.1067/mjd.2001.110645; Worle H, 1999, EUR J PEDIATR, V158, P344, DOI 10.1007/s004310051089	60	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7700	7709		10.1038/sj.onc.1205881	http://dx.doi.org/10.1038/sj.onc.1205881			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400012				2022-12-25	WOS:000178756200009
J	Szuba, A; Skobe, M; Karkkainen, MJ; Shin, WS; Beynet, DP; Rockson, NB; Dakhil, N; Spilman, S; Goris, ML; Strauss, HW; Quertermous, T; Alitalo, K; Rockson, SG				Szuba, A; Skobe, M; Karkkainen, MJ; Shin, WS; Beynet, DP; Rockson, NB; Dakhil, N; Spilman, S; Goris, ML; Strauss, HW; Quertermous, T; Alitalo, K; Rockson, SG			Therapeutic lymphangiogenesis with human recombinant VEGF-C	FASEB JOURNAL			English	Article						lymphedema; lymphatics; microcirculation; growth factors; angiogenesis	LYMPHATIC ENDOTHELIUM; TRANSGENIC MICE; GROWTH-FACTORS; BREAST-CANCER; BLOOD-VESSELS; UPPER-LIMB; LYMPHEDEMA; ANGIOGENESIS; RECEPTOR; MODEL	Chronic regional impairments of the lymphatic circulation often lead to striking architectural abnormalities in the lymphedematous tissues. Lymphedema is a common, disabling disease that currently lacks a cure. Vascular endothelial growth factors C and D mediate lymphangiogenesis through the VEGFR-3 receptor on lymphatic endothelia. The purpose of this study was to investigate the therapeutic potential for lymphangiogenesis with VEGF-C. We developed a rabbit ear model to simulate human chronic postsurgical lymphatic insufficiency. Successful, sustained surgical ablation of the ear lymphatics was confirmed by water displacement volumetry. After complete healing, the experimental animals (n=8) received a single, s.c. 100 mug dose of VEGF-C in the operated ear; controls (n=8) received normal saline. Radionuclide lymphoscintigraphy was performed to quantitate lymphatic function. Immunohistochemistry (IHC) was performed 7-8 days following treatment. After VEGF-C, there was a quantifiable amelioration of lymphatic function. IHC confirmed a significant increase in lymphatic vascularity, along with reversal of the intense tissue hypercellularity of untreated lymphedema. This study confirms the capacity of a single dose of VEGF-C to induce therapeutic lymphangiogenesis in acquired lymphedema. In addition to improving lymphatic function and vascularity, VEGF-C can apparently reverse the abnormalities in tissue architecture that accompany chronic lymphatic insufficiency.	Stanford Univ, Sch Med, Div Cardiovasc Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA; Derald H Ruttenberg Canc Ctr, Mt Sinai Sch Med, New York, NY USA; Univ Helsinki, Haartman Inst, Helsinki, Finland	Stanford University; Icahn School of Medicine at Mount Sinai; University of Helsinki	Rockson, NB (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA.	srockson@cvmed.stanford.edu	Szuba, Andrzej/AAY-1162-2020; Alitalo, Kari K/J-5013-2014; Szuba, Andrzej/C-1655-2013	Alitalo, Kari K/0000-0002-7331-0902; rockson, stanley/0000-0003-1253-474X; Szuba, Andrzej/0000-0002-7555-6201; Quertermous, Thomas/0000-0002-7645-9067				Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bourgeois P, 1998, CANCER-AM CANCER SOC, V83, P2805; CHEN HC, 1989, PLAST RECONSTR SURG, V83, P1022, DOI 10.1097/00006534-198906000-00016; Daroczy J, 1995, CLIN DERMATOL, V13, P433, DOI 10.1016/0738-081X(95)00086-U; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Erhard H, 1996, J INVEST DERMATOL, V106, P135, DOI 10.1111/1523-1747.ep12329708; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerber LH, 1998, CANCER, V83, P2803, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2803::AID-CNCR29>3.3.CO;2-N; HUANG G-K, 1983, Microsurgery, V4, P236; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P1751; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KANTER MA, 1990, PLAST RECONSTR SURG, V85, P573, DOI 10.1097/00006534-199004000-00012; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lee-Donaldson L, 1999, LYMPHOLOGY, V32, P111; Mortimer PS, 1998, CANCER, V83, P2798, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2798::AID-CNCR28>3.3.CO;2-5; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olszewski W, 1970, Pol Med J, V9, P1441; OLSZEWSKI W, 1968, J CARDIOVASC SURG, V9, P178; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PECKING A, 1991, B CANCER, V78, P373; Petrek JA, 1998, CANCER-AM CANCER SOC, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; PILLER NB, 1980, LYMPHOLOGY, V13, P109; PILLER NB, 1990, ARCH HISTOL CYTOL, V53, P209, DOI 10.1679/aohc.53.Suppl_209; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; ROCKSON S, 2000, CURRENT THERAPY VASC; Rockson SG, 1998, CANCER, V83, P2882, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0; Rockson SG, 2001, AM J MED, V110, P288, DOI 10.1016/S0002-9343(00)00727-0; Ruiter D J, 1993, Behring Inst Mitt, P258; Ryan TJ, 1995, CLIN DERMATOL, V13, P451, DOI 10.1016/0738-081X(95)00091-S; SAARISTO A, IN PRESS FASEB J; SCHIRGER A, 1962, JAMA-J AM MED ASSOC, V182, P124; SCHLINGEMANN RO, 1985, LAB INVEST, V52, P71; SEGERSTROM K, 1992, SCAND J PLAST RECONS, V26, P223, DOI 10.3109/02844319209016016; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; SUKUL DMKSK, 1993, J BIOMED ENG, V15, P477, DOI 10.1016/0141-5425(93)90062-4; Szuba A, 1998, Vasc Med, V3, P145, DOI 10.1177/1358836X9800300209; SZUBA A, IN PRESS NUCL MED CO; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223	46	178	194	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1985	+		10.1096/fj.02-0401fje	http://dx.doi.org/10.1096/fj.02-0401fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397087				2022-12-25	WOS:000179167600007
J	Thum, T; Borlak, J				Thum, T; Borlak, J			Testosterone, cytochrome P450, and cardiac hypertrophy	FASEB JOURNAL			English	Article						CYP; cytochrome P450 mono-oxygenases; testosterone metabolism; cardiac hypertrophy	SPONTANEOUSLY HYPERTENSIVE RATS; NUCLEAR TRANSCRIPTION FACTORS; ANDROGEN RECEPTORS; GENE-EXPRESSION; HEART-FAILURE; RESPONSE ELEMENT; MESSENGER-RNA; ENZYMES; ACID; CARDIOMYOCYTES	Cytochrome P450 mono-oxygenases (CYP) play an essential role in steroid metabolism, and there is speculation that sex hormones might influence cardiac mass and physiology. As CYP mono-oxygenases activity is frequently altered during disease, we tested our hypothesis that CYP mono-oxygenase expression and testosterone metabolism are altered in cardiac hypertrophy. We investigate major CYP mono-oxygenase isoforms and other steroid-metabolizing enzymes and the androgen receptor in normal, hypertrophic, and assist device-supported human hearts and in spontaneously hypertensive rats (SHR). We show increased and idiosyncratic metabolism of testosterone in hypertrophic heart and link these changes to altered CYP mono-oxygenase expression. We show significant induction of 5-alpha steroid reductase and P450 aromatase gene expression and enhanced production of dihydrotestosterone, which can be inhibited by the 5-alpha reductase inhibitor finasteride. We show increased gene expression of the androgen receptor and increased levels of lipid peroxidation in diseased hearts, the latter being markedly inhibited by CYP mono-oxygenase inactivation. We show alpha-MHC to be significantly repressed in cardiac hypertrophy and restored to normal on testosterone supplementation. We conclude that heart-specific steroid metabolism is of critical importance in cardiac hypertrophy.	Fraunhofer Inst Toxicol & Aerosol Res, Ctr Drug Res & Med Biotechnol, D-30659 Hannover, Germany	Fraunhofer Gesellschaft	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Aerosol Res, Ctr Drug Res & Med Biotechnol, Nicolai Fuchs Str 1, D-30659 Hannover, Germany.	Borlak@ita.fhg.de		Thum, Thomas/0000-0003-4360-1511				Ahmad SR, 2001, LANCET, V357, P1766, DOI 10.1016/S0140-6736(00)04891-1; ARLOTTO MP, 1991, METHOD ENZYMOL, V206, P454; BASU AK, 1994, HYPERTENSION, V24, P480, DOI 10.1161/01.HYP.24.4.480; Baumer AT, 2000, J MOL CELL CARDIOL, V32, P121, DOI 10.1006/jmcc.1999.1061; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; BONDY SC, 1994, BIOCHEM PHARMACOL, V48, P155, DOI 10.1016/0006-2952(94)90235-6; Borlak J, 2001, BIOCHEM PHARMACOL, V61, P145, DOI 10.1016/S0006-2952(00)00537-2; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Coley KC, 1997, PHARMACOTHERAPY, V17, P379; Csonka C, 2000, FREE RADICAL BIO MED, V29, P612, DOI 10.1016/S0891-5849(00)00365-8; Davydov DR, 2001, TRENDS BIOCHEM SCI, V26, P155, DOI 10.1016/S0968-0004(00)01749-7; de Leeuw PW, 1998, J CARDIOVASC PHARM, V32, pS9, DOI 10.1097/00005344-199800003-00003; Dickerman RD, 1998, CARDIOLOGY, V90, P145, DOI 10.1159/000006834; Dodic M, 2001, CIRC RES, V89, P623, DOI 10.1161/hh1901.097086; FULTON D, 1995, BRIT J PHARMACOL, V114, P99, DOI 10.1111/j.1476-5381.1995.tb14911.x; GEORGE J, 1995, BIOCHEM PHARMACOL, V49, P873, DOI 10.1016/0006-2952(94)00515-N; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; GILLARDON F, 1991, NEUROSCI LETT, V125, P77, DOI 10.1016/0304-3940(91)90135-G; Guengerich F. P., 1995, CYTOCHROME P, P473; Hayward CS, 2001, LANCET, V357, P1354, DOI 10.1016/S0140-6736(00)04523-2; Hingtgen SD, 2001, ANTIOXID REDOX SIGN, V3, P433, DOI 10.1089/15230860152409077; Izumi Y, 2000, HYPERTENSION, V36, P511, DOI 10.1161/01.HYP.36.4.511; Jurkovicova D, 2001, PHYSIOL RES, V50, P35; KARARA A, 1989, J BIOL CHEM, V264, P19822; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kivisto KT, 1996, BRIT J CLIN PHARMACO, V42, P387, DOI 10.1046/j.1365-2125.1996.42615.x; Kivisto KT, 1996, N-S ARCH PHARMACOL, V353, P207; LIN AL, 1985, ARTERIOSCLEROSIS, V5, P659, DOI 10.1161/01.ATV.5.6.659; LIN AL, 1981, CIRC RES, V49, P1010, DOI 10.1161/01.RES.49.4.1010; LIN MC, 1993, J STEROID BIOCHEM, V45, P333; Marsh JD, 1998, CIRCULATION, V98, P256, DOI 10.1161/01.CIR.98.3.256; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MORANO I, 1990, CIRC RES, V66, P1585, DOI 10.1161/01.RES.66.6.1585; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; Omdahl JL, 2001, STEROIDS, V66, P381, DOI 10.1016/S0039-128X(00)00157-4; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; PORTO CS, 1995, J STEROID BIOCHEM, V53, P561, DOI 10.1016/0960-0760(95)00111-C; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Shorofsky SR, 1999, CIRC RES, V84, P424, DOI 10.1161/01.RES.84.4.424; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Skelton R, 1998, ARCH DIS CHILD-FETAL, V78, pF133, DOI 10.1136/fn.78.2.F133; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; STERN JO, 1974, J BIOL CHEM, V249, P7495; Thum T, 2000, BRIT J PHARMACOL, V130, P1745, DOI 10.1038/sj.bjp.0703465; Thum T, 2000, LANCET, V355, P979, DOI 10.1016/S0140-6736(00)99016-0; Thum T, 2000, XENOBIOTICA, V30, P1063, DOI 10.1080/00498250010005196; Thum T, 2000, FASEB J, V14, P740, DOI 10.1096/fasebj.14.5.740; Tilakaratne A, 2002, ARCH ORAL BIOL, V47, P59, DOI 10.1016/S0003-9969(01)00087-5; Walles M, 2001, DRUG METAB DISPOS, V29, P761; WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003-9861(81)90095-3; Wu S, 1996, J BIOL CHEM, V271, P3460; Xiao YF, 1998, J PHYSIOL-LONDON, V508, P777, DOI 10.1111/j.1469-7793.1998.777bp.x; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	60	111	115	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1537	1549		10.1096/fj.02-0138com	http://dx.doi.org/10.1096/fj.02-0138com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374776				2022-12-25	WOS:000179167600035
J	Brezillon, S; Lannoy, V; Franssen, JD; Le Poul, E; Dupriez, V; Lucchetti, J; Detheux, M; Parmentier, M				Brezillon, S; Lannoy, V; Franssen, JD; Le Poul, E; Dupriez, V; Lucchetti, J; Detheux, M; Parmentier, M			Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; BETA-ADRENERGIC-RECEPTOR; ENDOGENOUS LIGAND; PEPTIDE LIGAND; GENE; NEUROPEPTIDE; ENCODES; CLONING; FAMILY	GPR7 and GPR8 are two structurally related orphan G protein-coupled receptors, presenting high similarities with opioid and somatostatin receptors. Two peptides, L8 and L8C, derived from a larger precursor, were recently described as natural ligands for GPR8 (Mori, M., Shimomura, Y., Harada, M., Kurihara, M., Kitada, C., Asami, T., Matsumoto, Y., Adachi, Y., Watanabe, T., Sugo, T., and Abe, M. (December, 27,2001) World Patent Cooperation Treaty, Patent Application WO 01/98494Al). L8 is a 23-amino acid peptide, whereas L8C is the same peptide with a C terminus extension of 7 amino acids, running through a dibasic motif of proteolytic processing. Using as a query the amino acid sequence of the LS peptide, we have identified in DNA databases a human gene predicted to encode related peptides and its mouse ortholog. By analogy with LS and L8C, two peptides, named L7 and L7C could result from the processing of a 125-amino acid human precursor through the alternative usage of a dibasic amino acid motif. The activity of these four peptides was investigated on GPR7 and GPR8. In binding assays, L7, L7C, L8, and L8C were found to bind with low nanomolar affinities to the GPR7 and GPR8 receptors expressed in Chinese hamster ovary (CHO)-K1 cells. They inhibited forskolin-stimulated cAMP accumulation through a pertussis toxin-sensitive mechanism. The tissue distribution of prepro-L7 (ppL7) and prepro-L8 (ppL8) was investigated by reverse transcription-PCR. Abundant ppL7 transcripts were found throughout the brain as well as in spinal cord, spleen, testis, and placenta; ppL8 transcripts displayed a more restricted distribution in brain, with high levels in substantia nigra, but were more abundant in peripheral tissues. The ppL7 and ppL8 genes therefore encode the precursors of a class of peptide ligands, active on two receptor subtypes, GPR7 and GPR8. The distinct tissue distribution of the receptor and peptide precursors suggest that each ligand and receptor has partially overlapping but also specific roles in this signaling system.	Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Euroscreen, B-1070 Brussels, Belgium; Eurogentec, B-4102 Seraing, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Campus Erasme,Bldg C,5th Floor,808 Route Lennik, B-1070 Brussels, Belgium.	mparment@ulb.ac.be		BREZILLON, stephane/0000-0001-7954-8340; Parmentier, Marc/0000-0001-8081-4685				Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Costagliola S, 1998, J IMMUNOL, V160, P1458; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; Fujii R, 2002, J BIOL CHEM, V277, P34010, DOI 10.1074/jbc.M205883200; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; JOLY C, 1995, J NEUROSCI, V15, P3970; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee DK, 1999, MOL BRAIN RES, V71, P96, DOI 10.1016/S0169-328X(99)00171-0; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MORI M, 2001, Patent No. 0198494; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimomura Y, 2002, J BIOL CHEM, V277, P35826, DOI 10.1074/jbc.M205337200; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ZARATIN PF, 2002, 13 NOORDW CAM S NOOR	32	97	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					776	783		10.1074/jbc.M206396200	http://dx.doi.org/10.1074/jbc.M206396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401809	hybrid			2022-12-25	WOS:000180321900013
J	Duan, S; Hajek, P; Lin, C; Shin, SK; Attardi, G; Chomyn, A				Duan, S; Hajek, P; Lin, C; Shin, SK; Attardi, G; Chomyn, A			Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; THYMIDINE KINASE; CYCLOSPORINE-A; IN-VIVO; PROTEIN; CELLS; GALACTOKINASE; RESPIRATION; INHIBITION; TRANSITION	We have shown here that the apoptosis inducer staurosporine causes an early decrease in the endogenous respiration rate in intact 143B.TK- cells. On the other hand, the activity of cytochrome c oxidase is unchanged for the first 8 h after staurosporine treatment, as determined by oxygen consumption measurements in intact cells. The decrease in the endogenous respiration rate precedes the release of cytochrome c from mitochondria. Moreover, we have ruled out caspases, permeability transition, and protein kinase C inhibition as being responsible for the decrease in respiration rate. Furthermore, overexpression of the gene for Bcl-2 does not prevent the decrease in respiration rate. The last finding suggests that Bcl-2 acts downstream of the perturbation in respiration. The evidence of normal enzymatic activities of complex I and complex III in staurosporine-treated 143B.TK- osteosarcoma cells indicates that the cause of the respiration decrease is probably an alteration in the permeability of the outer mitochondrial membrane. Presumably, the voltage-dependent anion channel closes, thereby preventing ADP and oxidizable substrates from being taken up into mitochondria. This interpretation was confirmed by another surprising finding, namely that, in staurosporine-treated 143B.TK- cells permeabilized with digitonin at a concentration not affecting the mitochondrial membranes in naive cells, the outer mitochondrial membrane loses its integrity; this leads to a reversal of its impermeability to exogenous substrates. The loss of outer membrane integrity leads also to a massive premature release of cytochrome c from mitochondria. Most significantly, Bcl-2 overexpression prevents the staurosporine-induced hypersensitivity of the outer membrane to digitonin. Our experiments have thus revealed early changes in the outer mitochondrial membrane, which take place long before cytochrome c is released from mitochondria in intact cells.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Chomyn, A (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	chomyn@caltech.edu			NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COLOMBINI M, 1987, J BIOENERG BIOMEMBR, V19, P309, DOI 10.1007/BF00768534; CROMPTON M, 1988, BIOCHEM J, V255, P357; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Harkin ST, 1998, MOL PHARMACOL, V54, P663; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luetjens CM, 2001, MOL PHARMACOL, V60, P1008, DOI 10.1124/mol.60.5.1008; MCBREEN P, 1977, CYTOGENET CELL GENET, V19, P7, DOI 10.1159/000130789; ORKWISZEWSKI KG, 1976, SOMAT CELL GENET, V2, P21, DOI 10.1007/BF01539239; ORKWISZEWSKI KG, 1976, CYTOGENET CELL GENET, V16, P427, DOI 10.1159/000130650; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZIZI M, 1994, J BIOL CHEM, V269, P1614	46	50	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1346	1353		10.1074/jbc.M209269200	http://dx.doi.org/10.1074/jbc.M209269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12403774	Green Accepted, hybrid			2022-12-25	WOS:000180321900084
J	Kawakatsu, T; Shimizu, K; Honda, T; Fukuhara, T; Hoshino, T; Takai, Y				Kawakatsu, T; Shimizu, K; Honda, T; Fukuhara, T; Hoshino, T; Takai, Y			trans-interactions of nectins induce formation of filopodia and lamellipodia through the respective activation of Cdc42 and Rac small G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; BINDING PROTEIN; MDCK CELLS; V-DOMAIN; CADHERIN; AFADIN; RHO; JUNCTIONS	Nectins and afadin constitute a novel cell-cell adhesion system that plays a cooperative role with cadherins in the organization of adherens junctions (AJs). Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules, and afadin is a nectin- and actin filament-binding protein that connects nectins to the actin cytoskeleton. Rac and Cdc42 small G proteins have been implicated in the organization of AJs, but their modes of action remain unknown. The trans-interaction of E-cadherin has recently been shown to induce the activation of Rac, but not that of Cdc42. We show here that the trans-interactions of nectins induce the formation of filopodia and lamellipodia through the respective activation of Cdc42 and Rac. The Cdc42 activation is necessary, but not sufficient, for the Rac-induced formation of lamellipodia, whereas the Rac activation is not necessary for the Cdc42-induced formation of filopodia. These effects of nectins require their cytoplasmic tail but not their association with afadin. We propose here the functional relationship between nectins and the small G proteins in the organization of AJs.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takenawa T, 2001, J CELL SCI, V114, P1801; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Weber K, 1972, Methods Enzymol, V26, P3; Yagi T, 2000, GENE DEV, V14, P1169	46	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50749	50755		10.1074/jbc.M209846200	http://dx.doi.org/10.1074/jbc.M209846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12379640	hybrid			2022-12-25	WOS:000180177700072
J	Wang, XD; He, K; Gerhart, M; Huang, Y; Jiang, J; Paxton, RJ; Yang, SS; Lu, CS; Menon, RK; Black, RA; Baumann, G; Frank, SJ				Wang, XD; He, K; Gerhart, M; Huang, Y; Jiang, J; Paxton, RJ; Yang, SS; Lu, CS; Menon, RK; Black, RA; Baumann, G; Frank, SJ			Metalloprotease-mediated GH receptor proteolysis and GHBP shedding - Determination of extracellular domain stem region cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; NECROSIS-FACTOR-ALPHA; CONVERTING-ENZYME TACE; BINDING-PROTEIN; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; IDENTIFICATION; JAK2; SERUM; INTERNALIZATION	Growth hormone-binding protein (GHBP) is complexed to a substantial fraction of circulating GH. In humans, rabbits, and other species, GHBP derives from proteolytic shedding of the GH receptor (GHR) extracellular domain. In cell culture studies, stimuli such as phorbol ester, platelet-derived growth factor, or serum induce GHR proteolysis, which concomitantly yields shed GHBP in cell supernatants and a cell-associated cytoplasmic domain-containing GHR remnant. This process is sensitive to metalloprotease inhibition, and genetic reconstitution studies identify tumor necrosis factor-a converting enzyme (TACE/ADAM-17), a transmembrane metalloprotease, as a GHR sheddase. Stimuli that induce GHR proteolysis render cells less responsive to GH, but the mechanism(s) of this desensitization is not yet understood. In this study, we mapped the rabbit (rb) GHR cleavage site. We adenovirally expressed a C-terminal epitope-tagged rbGHR lacking most of its cytoplasmic domain, purified the remnant protein induced by the phorbol ester, PMA, and derived the cleavage site by N-terminal sequencing of the purified remnant. The N-terminal sequence, (FTCEEDFR246)-F-239, matched perfectly the rbGHR and suggests that cleavage occurs eight residues from the membrane in the proximal extracellular domain stem region. Deletion and alanine substitution mutagenesis indicated that, similar to other TACE substrates, the spacing of residues in this region, more than their identity, influences GHR cleavage susceptibility. Further, we determined that PMA pretreatment desensitized a cleavage-sensitive GHR mutant, but not a cleavage-insensitive mutant, to GH-induced JAK2 activation. These results suggest that inducible GHR proteolysis can regulate GH signaling.	Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Immunex Corp, Seattle, WA 98101 USA; Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Northwestern Univ, Sch Med, Ctr Endocrinol Metab & Mol Med, Dept Med, Chicago, IL 60611 USA; Vet Adm Chicago Hlth Syst, Lakeside Div, Chicago, IL 60611 USA; Vet Adm Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Immunex Corporation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu	He, Kai/AHB-3118-2022	He, Kai/0000-0002-4378-9297	NIDDK NIH HHS [DK46395, DK58259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R01DK046395, R56DK058259, R56DK046395, R01DK058259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Amit T, 2001, J ENDOCRINOL, V169, P397, DOI 10.1677/joe.0.1690397; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Baumann G, 2001, J PEDIATR ENDOCR MET, V14, P355; BAUMANN G, 1989, METABOLISM, V38, P683, DOI 10.1016/0026-0495(89)90108-X; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Conte F, 2002, BIOCHEM BIOPH RES CO, V290, P851, DOI 10.1006/bbrc.2001.6261; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; Frank SJ, 2002, CYTOKINE REFERENCE O, P1; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kovanen PE, 2000, BLOOD, V95, P1626, DOI 10.1182/blood.V95.5.1626.005k21_1626_1632; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lu CX, 2001, J BIOL CHEM, V276, P22892, DOI 10.1074/jbc.M011647200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; Schlondorff J, 1999, J CELL SCI, V112, P3603; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhang Y, 2001, J BIOL CHEM, V276, P24565, DOI 10.1074/jbc.M101281200; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342	44	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50510	50519		10.1074/jbc.M208738200	http://dx.doi.org/10.1074/jbc.M208738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12403792	hybrid			2022-12-25	WOS:000180177700043
J	Nandan, D; Yi, TL; Lopez, M; Lai, C; Reiner, NE				Nandan, D; Yi, TL; Lopez, M; Lai, C; Reiner, NE			Leishmania EF-1 alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR 1-ALPHA; INFECTED MACROPHAGES; MURINE LEISHMANIASIS; PHOSPHOTYROSINE PHOSPHATASES; MONONUCLEAR PHAGOCYTES; MEXICANA AMASTIGOTES; PROTEIN-KINASE; INHIBITION; PROTEOPHOSPHOGLYCAN; PHOSPHORYLATION	The human leishmaniasis are persistent infections of macrophages caused by protozoa of the genus Leishmania. The chronic nature of these infections is in part related to induction of macrophage deactivation, linked to activation of the Src homology 2 domain containing tyrosine phosphatase-1 (SHP-1) in infected cells. To investigate the mechanism of SHP-1 activation, lysates of Leishmania donovani promastigotes were subjected to SHP-1 affinity chromatography and proteins bound to the matrix were sequenced by mass spectrometry. This resulted in the identification of Leishmania elongation factor-1alpha (EF-1alpha) as a SHP-1-binding protein. Purified Leishmania EF-1alpha, but not host cell EF-1alpha, bound directly to SHP-1 in vitro leading to its activation. Three independent lines of evidence indicated that Leishmania EF-1alpha may be exported from the phagosome thereby enabling targeting of host SHP-1. First, cytosolic fractions prepared from macrophages infected with [S-35]methionine-labeled organisms contained Leishmania EF-1alpha. Second, confocal, fluorescence microscopy using Leishmania-specific antisera detected Leishmania EF-1alpha in the cytosol of infected cells. Third, co-immunoprecipitation showed that Leishmania EF-1alpha was associated with SHP-1 in vivo in infected cells. Finally, introduction of purified Leishmania EF-1alpha, but not the corresponding host protein into macrophages activated SHP-1 and blocked the induction of inducible nitric-oxide synthase expression in response to interferon-gamma. Thus, Leishmania EF-1alpha is identified as a novel SHP-1-binding and activating protein that recapitulates the deactivated phenotype of infected macrophages.	Univ British Columbia, Fac Med, Div Infect Dis, Dept Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Div Infect Dis, Dept Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Vancouver Hosp & Hlth Sci Ctr, Res Inst, Vancouver, BC V5Z 3J5, Canada; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Cleveland Clinic Foundation	Reiner, NE (corresponding author), Univ British Columbia, Fac Med, Div Infect Dis, Dept Med, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.							Aebischer T, 1999, INFECT IMMUN, V67, P5379, DOI 10.1128/IAI.67.10.5379-5385.1999; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; BillautMulot O, 1996, GENE, V174, P19, DOI 10.1016/0378-1119(96)00254-5; Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11&lt;3737::AID-IMMU3737&gt;3.0.CO;2-S; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DEMMA M, 1990, J BIOL CHEM, V265, P2286; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt;3185::AID-IMMU3185&gt;3.0.CO;2-J; FORGET G, 1999, J LEUKOCYTE BIOL   S, V31, P33; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gopfert U, 1999, BIOCHEM J, V344, P787, DOI 10.1042/0264-6021:3440787; GUTIERREZ Y, 1984, AM J PATHOL, V114, P222; Horta MF, 1997, TRENDS MICROBIOL, V5, P363, DOI 10.1016/S0966-842X(97)01109-8; ILG T, 1994, PARASITOLOGY, V108, P63; Izawa T, 2000, BIOCHEM BIOPH RES CO, V278, P72, DOI 10.1006/bbrc.2000.3772; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; LANG T, 1994, J CELL SCI, V107, P2137; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; Nandan D, 1999, INFECT IMMUN, V67, P4055, DOI 10.1128/IAI.67.8.4055-4063.1999; Nandan D, 2000, J LEUKOCYTE BIOL, V67, P464, DOI 10.1002/jlb.67.4.464; Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944; Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Piani A, 1999, MICROBES INFECT, V1, P589, DOI 10.1016/S1286-4579(99)80058-6; PRINA E, 1990, INFECT IMMUN, V58, P1730, DOI 10.1128/IAI.58.6.1730-1737.1990; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; Schaible UE, 1999, J CELL SCI, V112, P681; Stierhof YD, 1999, EUR J CELL BIOL, V78, P675, DOI 10.1016/S0171-9335(99)80036-3; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wang LL, 1999, J IMMUNOL, V162, P1318; YANG W, 1994, J BIOL CHEM, V269, P3852; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	43	128	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50190	50197		10.1074/jbc.M209210200	http://dx.doi.org/10.1074/jbc.M209210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384497	hybrid			2022-12-25	WOS:000180028900140
J	Rostagno, A; Revesz, T; Lashley, T; Tomidokoro, Y; Magnotti, L; Braendgaard, H; Plant, G; Bojsen-Moller, M; Holton, J; Frangione, B; Ghiso, J				Rostagno, A; Revesz, T; Lashley, T; Tomidokoro, Y; Magnotti, L; Braendgaard, H; Plant, G; Bojsen-Moller, M; Holton, J; Frangione, B; Ghiso, J			Complement activation in chromosome 13 dementias - Similarities with Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL BRITISH DEMENTIA; MEMBRANE ATTACK COMPLEX; AMYLOID-BETA-PEPTIDE; C1Q A-CHAIN; NEUROFIBRILLARY TANGLES; SPASTIC PARAPARESIS; SENILE PLAQUES; RESIDUES 14-26; IMMUNE-SYSTEM; PROTEINS	Chromosome 13 dementias, familial British dementia (FBD) and familial Danish dementia (FDD), are associated with neurodegeneration and cerebrovascular amyloidosis, with striking neuropathological similarities to Alzheimer's disease (AD). Despite the structural differences among the amyloid subunits (ABri in FBD, ADan in FDD, and Abeta in AD), these disorders are all characterized by the presence of neurofibrillary tangles and parenchymal and vascular amyloid deposits co-localizing with markers of glial activation, suggestive of local inflammation. Proteins of the complement system an their pro-inflammatory activation products are among the inflammation markers associated with AD lesions. Immunohistochemistry of FBD and FDD brain sections demonstrated the presence of complement activation components of the classical and alternative pathways as well as the neo-epitope of the membrane attack complex. Hemolytic experiments and enzyme-linked immunosorbent assays specific for the activation products iC3b, C4d, Bb, and C5b-9 indicated that A.Bri and ADan are able to fully activate the complement cascade at levels comparable to those generated by Abeta1-42. ABri and ADan specifically bound C1q with high affinity and formed stable complexes in physiological conditions. Activation proceeds similar to70-75% through the classical pathway while only similar to25-30% seems to occur through the alternative pathway. The data suggest that the chronic inflammatory response generated by the amyloid peptides in vivo might be a contributing factor for the pathogenesis of FBD and FDD and, in more general terms, to other neurodegenerative conditions.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; UCL, Queen Sq Brain Bank, London WC1N 3BG, England; UCL, Dept Mol Pathogenesis, Div Neuropathol, Inst Neurol, London WC1N 3BG, England; Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Neuropathol, DK-8000 Aarhus, Denmark; Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	New York University; New York University; University of London; University College London; University of London; University College London; Aarhus University; Aarhus University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Rostagno, A (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,TH-435, New York, NY 10016 USA.	rostaa02@popmail.med.nyu.edu	Lashley, Tammaryn/D-2583-2009; Rostagno, Agueda/A-5801-2008; Holton, Janice L/F-6831-2011; Revesz, Tamas/A-8732-2010	Holton, Janice L/0000-0002-3882-5249; Revesz, Tamas/0000-0003-2501-0259; Rostagno, Agueda/0000-0002-6817-2074; Lashley, Tammaryn/0000-0001-7389-0348				Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; BERKENBOSCH F, 1992, RES IMMUNOL, V143, P657, DOI 10.1016/0923-2494(92)80052-M; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; EIKELENBOOM P, 1991, VIRCHOWS ARCH B, V60, P329, DOI 10.1007/BF02899564; Emmerling MR, 1997, IMMUNOPHARMACOLOGY, V38, P101, DOI 10.1016/S0162-3109(97)00067-2; Emmerling MR, 2000, BBA-MOL BASIS DIS, V1502, P158, DOI 10.1016/S0925-4439(00)00042-9; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ghiso J, 2001, AMYLOID, V8, P277, DOI 10.3109/13506120108993826; Hafer-Macko CE, 2000, J PERIPHER NERV SYST, V5, P131, DOI 10.1046/j.1529-8027.2000.00018.x; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Holton JL, 2002, J NEUROPATH EXP NEUR, V61, P254, DOI 10.1093/jnen/61.3.254; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; Houlden H, 2000, ANN NEUROL, V48, P806, DOI 10.1002/1531-8249(200011)48:5<806::AID-ANA18>3.0.CO;2-F; Iseki E, 2000, NEUROSCI LETT, V286, P69, DOI 10.1016/S0304-3940(00)01090-9; ISHIHARA C, 1985, VACCINE, V3, P370, DOI 10.1016/0264-410X(85)90125-2; ISHII T, 1984, ACTA NEUROPATHOL, V63, P296, DOI 10.1007/BF00687336; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG HX, 1992, J BIOL CHEM, V267, P25597; JIANG HX, 1994, J IMMUNOL, V152, P5050; KAWAMATA T, 1992, AM J PATHOL, V140, P691; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; Mead S, 2000, BRAIN, V123, P975, DOI 10.1093/brain/123.5.975; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Morgan B.P., 2000, COMPLEMENT METHODS P; MORI H, 1992, J BIOL CHEM, V267, P17082; NAGASAWA S, 1980, J IMMUNOL, V125, P578; Narkio-Makela M, 2001, CLIN IMMUNOL, V100, P118, DOI 10.1006/clim.2001.5043; PARKER CJ, 1999, CURRENT PROTOCOLS IM, V3; RABSON AR, 1997, MANUAL CLIN LAB IMMU, P187; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROSS GD, 1985, ADV IMMUNOL, V37, P217, DOI 10.1016/S0065-2776(08)60341-7; ROZEMULLER JM, 1992, NEUROSCI LETT, V140, P137, DOI 10.1016/0304-3940(92)90087-N; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; SALVARREY M, 1989, CLIN EXP IMMUNOL, V76, P92; SCHULTZ J, 1994, NEUROSCI LETT, V175, P99, DOI 10.1016/0304-3940(94)91088-X; Schwab C, 1997, ACTA NEUROPATHOL, V94, P486, DOI 10.1007/s004010050737; SHEN Y, 1995, BRAIN RES, V671, P282, DOI 10.1016/0006-8993(94)01264-I; Shen Y, 2001, NEUROSCI LETT, V305, P165, DOI 10.1016/S0304-3940(01)01842-0; Steiner H, 2001, J BIOL CHEM, V276, P7233, DOI 10.1074/jbc.M007183200; Stoltzner SE, 2000, AM J PATHOL, V156, P489, DOI 10.1016/S0002-9440(10)64753-0; Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2; Tekirian TL, 1998, J NEUROPATH EXP NEUR, V57, P76, DOI 10.1097/00005072-199801000-00009; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Verbeek MM, 1998, ACTA NEUROPATHOL, V96, P628, DOI 10.1007/s004010050944; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Watson MD, 1997, AMYLOID, V4, P147, DOI 10.3109/13506129709014379; Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0; Webster S, 1997, J NEUROCHEM, V69, P388; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WENER MH, 1997, MANUAL CLIN LAB IMMU, P208; YASUHARA O, 1994, BRAIN RES, V652, P346, DOI 10.1016/0006-8993(94)90246-1; YING SC, 1993, J IMMUNOL, V150, P169	64	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49782	49790		10.1074/jbc.M206448200	http://dx.doi.org/10.1074/jbc.M206448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388551	hybrid			2022-12-25	WOS:000180028900091
J	Sanna, B; Kramer, D; Genazzani, AA				Sanna, B; Kramer, D; Genazzani, AA			The expression of the PDZ protein MALS-1/Velis is regulated by calcium and calcineurin in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; GENE-EXPRESSION; NMDA RECEPTOR; TRANSCRIPTION FACTORS; CREB PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; MESSENGER-RNA; BRAIN; CHANNELS; DIFFERENTIATION	Activity-dependent gene expression is thought to be important in shaping neuronal development and in modifying the protein content of neurons. Ca2+ entry into neurons appears to be one of the key effectors of activity-dependent gene expression. Among the possible downstream targets of calcium, the protein phosphatase calcineurin represents a prime candidate. We hereby report that in cultured cerebellar granule cells the activation of the Ca2+/calcineurin pathway via either voltage- or ligand- operated Ca2+ channels regulates MALS-1 and MALS-2 expression at the transcriptional level. These proteins are integral parts of the post-synaptic density and are also involved in receptor trafficking. MALS regulation is not at the level of mRNA stability and does not require de novo protein synthesis, thereby suggesting a direct pathway. These data suggest that Ca2+ entry by means of calcineurin is capable of controlling the structure of the post-synaptic density by controlling the expression of key components at the transcriptional level.	Dept Pharmacol, Cambridge CB2 1PD, England; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	University of Sassari	Genazzani, AA (corresponding author), Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.		Genazzani, Armando/AAI-8280-2020	Genazzani, Armando/0000-0003-1923-7430				Bading H, 1999, EPILEPSY RES, V36, P225, DOI 10.1016/S0920-1211(99)00053-4; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Carafoli E, 1999, BIOCHEM BIOPH RES CO, V266, P624, DOI 10.1006/bbrc.1999.1879; Chang KT, 2001, NEURON, V32, P855, DOI 10.1016/S0896-6273(01)00516-5; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; COPANI A, 1992, J NEUROCHEM, V58, P1199, DOI 10.1111/j.1471-4159.1992.tb11329.x; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GALLO V, 1987, J NEUROSCI, V7, P2203; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Guerini D, 2000, J BIOL CHEM, V275, P3706, DOI 10.1074/jbc.275.5.3706; Guerini D, 1999, J BIOL CHEM, V274, P1667, DOI 10.1074/jbc.274.3.1667; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mellstrom B, 2001, CURR OPIN NEUROBIOL, V11, P312, DOI 10.1016/S0959-4388(00)00213-0; Misawa H, 2001, J BIOL CHEM, V276, P9264, DOI 10.1074/jbc.M009334200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MURPHY SN, 1988, P NATL ACAD SCI USA, V85, P8737, DOI 10.1073/pnas.85.22.8737; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sato M, 2001, J NEUROSCI, V21, P3797, DOI 10.1523/JNEUROSCI.21-11-03797.2001; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Tascedda F, 1996, MOL BRAIN RES, V40, P171; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	34	1	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49585	49590		10.1074/jbc.M207826200	http://dx.doi.org/10.1074/jbc.M207826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393911	hybrid			2022-12-25	WOS:000180028900064
J	Brunner, S; Everard-Gigot, V; Stuart, RA				Brunner, S; Everard-Gigot, V; Stuart, RA			Su e of the yeast F1Fo-ATP synthase forms homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; BOVINE F-1-ATPASE; INHIBITOR PROTEIN; SUBUNIT-E; MEMBRANE; DIMERIZATION; MITOCHONDRIA; COMPLEXES; BINDING; DIMER	The yeast F1Fo-ATP synthase forms a dimeric complex in the mitochondrial inner membrane. Dimerization of two F1Fo monomeric complexes involves the physical association of two membrane-embedded F-o sectors and in a manner, which is dependent on the F-o subunit, Su e. Sequence analysis of Su e protein family members indicated the presence of a conserved coiled-coil motif. As this motif is often the basis for protein homodimerization events, it was hypothesized that Su e forms homodimers in the inner membrane and that formation of Su e dimers between two neighboring F-o complexes would facilitate dimerization of the F1Fo-ATP synthase complex (Arnold, I., Pfeiffer, K., Neupert, W., Stuart, R. A., and Schagger, H. (1998) EMBO J. 17, 7170-7178). Using a histidine-tagged derivative of yeast Su e, Su e-His(12), combined with cross-linking and affinity purification approaches, we have directly demonstrated the ability of the yeast Su e protein to form homodimers. Functionality of the Su e-His(12) derivative was confirmed by its ability to assemble into the F1Fo-ATP synthase complex and to support its dimerization in the Deltasu e null mutant yeast cells. The close association of two neighboring Su e proteins was also demonstrated using cross-linking with Cu2+, which binds and cross-links a unique Cys residue in neighboring Su e proteins. Finally, we propose a model for the molecular basis of the homodimerization of the Su e proteins.	Marquette Univ, Dept Biol Sci, Milwaukee, WI 53233 USA; Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany	Marquette University; University of Munich	Stuart, RA (corresponding author), Marquette Univ, Dept Biol Sci, 530 N 15th St, Milwaukee, WI 53233 USA.				NIGMS NIH HHS [GM61573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Belogrudov GI, 1996, J BIOL CHEM, V271, P20340, DOI 10.1074/jbc.271.34.20340; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547	23	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48484	48489		10.1074/jbc.M209382200	http://dx.doi.org/10.1074/jbc.M209382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377768	hybrid			2022-12-25	WOS:000179789600069
J	Dutton, JL; Bansal, PS; Hogg, RC; Adams, DJ; Alewood, PF; Craik, DJ				Dutton, JL; Bansal, PS; Hogg, RC; Adams, DJ; Alewood, PF; Craik, DJ			A new level of conotoxin diversity, a non-native disulfide bond connectivity in alpha-conotoxin AuIB reduces structural definition but increases biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; INTERPROTON DISTANCE RESTRAINTS; 2-DIMENSIONAL NMR-SPECTROSCOPY; 1.1 ANGSTROM RESOLUTION; CONUS VENOM PEPTIDES; SOLUTION CONFORMATION; CRYSTAL-STRUCTURE; PAIRWISE INTERACTIONS	alpha-Conotoxin AuIB and a disulfide bond variant of AuIB have been synthesized to determine the role of disulfide bond connectivity on structure and activity. Both of these peptides contain the 15 amino acid sequence GCCSYPPCFATNPDC, with the globular (native) isomer having the disulfide connectivity Cys(2-8 and 3-15) and the ribbon isomer having the disulfide connectivity Cys(2-15 and 3-8). The solution structures of the peptides were determined by NAIR spectroscopy, and their ability to block the nicotinic acetylcholine receptors on dissociated neurons of the rat parasympathetic ganglia was examined. The ribbon disulfide isomer, although having a less well defined structure, is surprisingly found to have approximately 10 times greater potency than the native peptide. To our knowledge this is the first demonstration of a non-native disulfide bond isomer of a conotoxin exhibiting greater biological activity than the native isomer.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Craik, David/B-1695-2010; Adams, David John/K-3578-2019; Adams, David/J-9125-2014	Craik, David/0000-0003-0007-6796; Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Dutton, Julie/0000-0002-9798-1284; Alewood, Paul/0000-0001-7454-6522				Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; ALMQUIST RG, 1989, INT J PEPT PROT RES, V34, P455; Andersen NH, 1997, J AM CHEM SOC, V119, P8547, DOI 10.1021/ja963250h; Balaji RA, 2000, J BIOL CHEM, V275, P39516, DOI 10.1074/jbc.M006354200; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Cho JH, 2000, J BIOL CHEM, V275, P8680, DOI 10.1074/jbc.275.12.8680; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P133; Dutton JL, 2001, CURR MED CHEM, V8, P327, DOI 10.2174/0929867013373453; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; Franco A, 1999, LETT PEPT SCI, V6, P199, DOI 10.1023/A:1008826505893; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gehrmann J, 1999, J MED CHEM, V42, P2364, DOI 10.1021/jm990114p; Gouda H, 1999, BBA-PROTEIN STRUCT M, V1431, P384, DOI 10.1016/S0167-4838(99)00065-5; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HASHIMOTO K, 1985, EUR J PHARMACOL, V118, P351, DOI 10.1016/0014-2999(85)90147-5; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kaerner A, 1999, BIOCHEMISTRY-US, V38, P5459, DOI 10.1021/bi9826658; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; Luo SQ, 1998, J NEUROSCI, V18, P8571; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; McIntosh JM, 2000, EUR J PHARMACOL, V393, P205, DOI 10.1016/S0014-2999(99)00887-0; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; McIntosh JM, 2000, J BIOL CHEM, V275, P32391, DOI 10.1074/jbc.M003619200; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Mok KH, 1999, BIOCHEMISTRY-US, V38, P11895, DOI 10.1021/bi990558n; Olivera BM, 1999, J COMP PHYSIOL A, V185, P353, DOI 10.1007/s003590050394; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Poth K, 1997, J NEUROSCI, V17, P586; Quiram PA, 1999, J BIOL CHEM, V274, P19517, DOI 10.1074/jbc.274.28.19517; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P176; ZHANG RM, 1989, J BIOL CHEM, V264, P18472; ZHANG RM, 1991, BIOCHEMISTRY-US, V30, P11343, DOI 10.1021/bi00111a021; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9	59	109	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48849	48857		10.1074/jbc.M208842200	http://dx.doi.org/10.1074/jbc.M208842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376538	hybrid, Green Published			2022-12-25	WOS:000179789600114
J	Freedman, NJ; Kim, LK; Murray, JP; Exum, ST; Brian, L; Wu, JH; Peppel, K				Freedman, NJ; Kim, LK; Murray, JP; Exum, ST; Brian, L; Wu, JH; Peppel, K			Phosphorylation of the platelet-derived growth factor receptor-beta and epidermal growth factor receptor by G protein-coupled receptor kinase-2 - Mechanisms for selectivity of desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SRC TYROSINE KINASE; PDGF RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SERINE PHOSPHORYLATION; ACTIVATION; EXPRESSION; INHIBITION; SUBUNITS; INSULIN	Accumulating evidence suggests that receptor protein-tyrosine kinases, like the platelet-derived growth factor receptor-beta (PDGFRbeta) and epidermal growth factor receptor (EGFR), may be desensitized by serine/threonine kinases. One such kinase, G protein-coupled receptor kinase-2 (GRK2), is known to mediate agonist-dependent phosphorylation and desensitization of multiple heptahelical receptors. In testing whether GRK2 could phosphorylate and desensitize the PDGFRbeta, we first found by phosphoamino acid analysis that cells expressing GRK2 could serine-phosphorylate the PDGFRbeta in an agonist-dependent manner. Augmentation or inhibition of GRK2 activity in cells, respectively, reduced or enhanced tyrosine phosphorylation of the PDGFRbeta but not the EGFR. Either overexpressed in cells or as a purified protein, GRK2 demonstrated agonist-promoted serine phosphorylation of the PDGFRbeta and, unexpectedly, the EGFR as well. Because GRK2 did not phosphorylate a kinase-dead (K634R) PDGFRbeta mutant, GRK2-mediated PDGFRbeta phosphorylation required receptor tyrosine kinase activity, as does PDGFRbeta ubiquitination. Agonist-induced ubiquitination of the PDGFRbeta, but not the EGFR, was enhanced in cells overexpressing GRK2. Nevertheless, GRK2 overexpression did not augment PDGFRbeta down-regulation. Like the vast majority of GRK2 substrates, the PDGFRbeta, but not the EGFR, activated heterotrimeric G proteins allosterically in membranes from cells expressing physiologic protein levels. We conclude that GRK2 can phosphorylate and desensitize the PDGFRbeta, perhaps through mechanisms related to receptor ubiquitination. Specificity of GRK2 for receptor protein-tyrosine kinases, expressed at physiologic levels, may be determined by the ability of these receptors to activate heterotrimeric G proteins, among other factors.	Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA	Duke University	Freedman, NJ (corresponding author), Duke Univ, Med Ctr, Dept Med Cardiol, Box 3187, Durham, NC 27710 USA.	neil.freedman@duke.edu			NHLBI NIH HHS [HL63288] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063288] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bernard A, 1999, EXP CELL RES, V253, P704, DOI 10.1006/excr.1999.4715; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P35920, DOI 10.1074/jbc.M002490200; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MORI S, 1992, J BIOL CHEM, V267, P6429; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Peppel K, 2002, J MOL CELL CARDIOL, V34, P1399, DOI 10.1006/jmcc.2002.2092; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Pukac LA, 1997, J CELL PHYSIOL, V172, P69, DOI 10.1002/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; Tang T, 2002, J BIOL CHEM, V277, P18365, DOI 10.1074/jbc.M109812200; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YANG LJ, 1993, J BIOL CHEM, V268, P3739	51	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48261	48269		10.1074/jbc.M204431200	http://dx.doi.org/10.1074/jbc.M204431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12381737	hybrid			2022-12-25	WOS:000179789600039
J	Nagai, R; Hayashi, CM; Xia, L; Takeya, M; Horiuchi, S				Nagai, R; Hayashi, CM; Xia, L; Takeya, M; Horiuchi, S			Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ADVANCED MAILLARD REACTION; LIPID-PEROXIDATION; OXIDATIVE STRESS; METHYLGLYOXAL; N-EPSILON-(CARBOXYMETHYL)LYSINE; GLYOXAL; GLUCOSE; 3-DEOXYGLUCOSONE; MECHANISM	Glycolaldehyde (GA) is formed from serine by action of myeloperoxidase and reacts with proteins to form several products. Prominent among them is N-epsilon-(carboxymethyl)lysine (CML), which is also known as one of the advanced glycation end products. Because CML is formed from a wide range of precursors, we have attempted to identify unique structures characteristic of the reaction of GA with protein. To this end, monoclonal (GA5 and 1A12) and polyclonal (non-CML-GA) antibodies specific for GA-modified proteins were prepared. These antibodies specifically reacted with GA-modified and with hypochlorous acid-modified BSA, but not with BSA modified by other aldehydes, indicating that the epitope of these antibodies could be a specific marker for myeloperoxidase-induced protein modification. By HPLC purification from GA-modified N-alpha-(carbobenzyloxy)-L-lysine, GA5-reactive compound was isolated, and its chemical structure was characterized as 3-hydroxy-4-hydroxymethyl-l-(5-amino-5-carboxypentyl) pyridinium cation. This compound named as GA-pyridine was recognized both by 1A12 and non-CML-GA, indicating that GA-pyridine is an important antigenic structure in GA-modified proteins. Immunohistochemical studies with GA5 demonstrated the accumulation of GA-pyridine in the cytoplasm of foam cells and extracellularly in the central region of atheroma in human atherosclerotic lesions. These results suggest that myeloperoxidase-mediated protein modification via GA may contribute to atherogenesis.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Pathol 2, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, Honjo 2-2-1, Kumamoto 8600811, Japan.	horiuchi@gpo.kumamoto-u.ac.jp						ACHARYA AS, 1983, P NATL ACAD SCI-BIOL, V80, P3590, DOI 10.1073/pnas.80.12.3590; Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Glomb MA, 2001, J AGR FOOD CHEM, V49, P366, DOI 10.1021/jf000493r; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HAYASHI T, 1977, J AGR FOOD CHEM, V25, P1282, DOI 10.1021/jf60214a047; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; Iiljima K, 2000, BIOCHEM J, V347, P23, DOI 10.1042/0264-6021:3470023; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953; KUME S, 1995, AM J PATHOL, V147, P654; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; Nagai R, 1997, BIOCHEM BIOPH RES CO, V234, P167, DOI 10.1006/bbrc.1997.6608; NAKAMURA K, 1992, J CHEM SOC CHEM COMM, P992, DOI 10.1039/c39920000992; Nakamura K, 1997, BIOCHEM BIOPH RES CO, V232, P227, DOI 10.1006/bbrc.1997.6262; NEWMAN I, 1992, J IMMUNOL METHODS, V147, P43, DOI 10.1016/S0022-1759(12)80027-5; Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285; NIWA T, 1993, BIOCHEM BIOPH RES CO, V196, P837, DOI 10.1006/bbrc.1993.2325; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; Oya T, 1998, BIOCHEM BIOPH RES CO, V246, P267, DOI 10.1006/bbrc.1998.8595; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; Robison TW, 1996, ENVIRON HEALTH PERSP, V104, P852, DOI 10.2307/3432939; Sakata N, 1998, ATHEROSCLEROSIS, V141, P61, DOI 10.1016/S0021-9150(98)00149-X; SELL DR, 1989, J BIOL CHEM, V264, P21597; SZWERGOLD BS, 1990, SCIENCE, V247, P451, DOI 10.1126/science.2300805; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027	38	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48905	48912		10.1074/jbc.M205688200	http://dx.doi.org/10.1074/jbc.M205688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377783	hybrid			2022-12-25	WOS:000179789600121
J	Yoshida, K; Miki, Y; Kufe, D				Yoshida, K; Miki, Y; Kufe, D			Activation of SAPK/JNK signaling by protein kinase C delta in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; LYN TYROSINE KINASE; TRANSDUCTION PATHWAY; IONIZING-RADIATION; PROTEOLYTIC ACTIVATION; INDUCED APOPTOSIS; GENE-EXPRESSION; FUNCTIONAL INTERACTION; CELLULAR-RESPONSE; JUN PROTOONCOGENE	The cellular response to genotoxic stress includes activation of protein kinase Cdelta (PKCdelta). The functional role of PKCdelta in the DNA damage response is unknown. The present studies demonstrate that PKCdelta is required in part for induction of the stress-activated protein kinase (SAPK/JNK) in cells treated with 1-beta-D-arabinofuranosylcytosine (araC) and other genotoxic agents. DNA damage-induced SAPK activation was attenuated by W treatment with rottlerin, (ii) expression of a kinase-inactive PKCdelta(K-R) mutant, and (iii) down-regulation of PKCdelta by small interfering RNA (siRNA). Coexpression studies demonstrate that PKCdelta activates SAPK by an MKK7-dependent, SEK1-independent mechanism. Previous work has shown that the nuclear Lyn tyrosine kinase activates the MEKK1 --> MKK7 --> SAPK pathway but not through a direct interaction with MEKK1. The present results extend those observations by demonstrating that Lyn activates PKCdelta, and in turn, MEKK1 is activated by a PKCdelta-dependent mechanism. These findings indicate that PKCdelta functions in the activation of SAPK through a Lyn --> PKCdelta -> MEKK1 --> MKK7 --> SAPK signaling cascade in response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Tokyo 1138510, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tokyo Medical & Dental University (TMDU)	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA55241, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DATTA R, 1990, MOL PHARMACOL, V38, P435; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KONISHI H, 1997, P NATL ACAD SCI USA, V94, P11223; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RUBIN E, 1991, MOL PHARMACOL, V39, P697; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	46	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48372	48378		10.1074/jbc.M205485200	http://dx.doi.org/10.1074/jbc.M205485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377781	hybrid			2022-12-25	WOS:000179789600054
J	Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P				Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P			Expression profiling of primary non-small cell lung cancer for target identification	ONCOGENE			English	Article						lung; cancer; microarray; expression; target identification	TUMOR-SUPPRESSOR; GENE-EXPRESSION; OVARIAN-CANCER; MESSENGER-RNA; S100A2; CLASSIFICATION; ADENOCARCINOMA; DISTINCT; MUTATION; PROTEINS	Using a panel of cDNA microarrays comprising 47 650 transcript elements, we have carried out a dual-channel analysis of gene expression in 39 resected primary human non-small cell lung tumours versus normal lung tissue. Whilst similar to11000 elements were scored as differentially expressed at least twofold in at least one sample, 96 transcripts were scored as over-represented fourfold or more in at least seven out of 39 tumours and 30 sequences 16-fold in at least two out of 39 tumours, including 24 transcripts in common. Transcripts (178) were found under-represented fourfold in at least seven out of 39 tumours, 31 of which are under-represented 16-fold in at least two out of 39 lesions. The relative expression levels of representative genes from these lists were analysed by comparative multiplex RT-PCR and found to be broadly consistent with the microarray data. Two dramatically over-represented genes, previously designated as potential tumour suppressors in breast (maspin) and lung and breast (S100A2) cancers, were analysed more extensively and demonstrate the effectiveness of this approach in identifying potential lung cancer diagnostic or therapeutic targets. Whilst it has been reported that S100A2 is downregulated in NSCLC at an early stage, our microarray, cmRT-PCR, Western and immunohistochemistry data indicate that it is strongly expressed in the majority of tumours.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Incyte Genom Inc, Palo Alto, CA 94304 USA	University of Liverpool; University of Bern; Incyte	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool, Merseyside, England.		Betticher, Daniel C/G-5849-2013; Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Agrawal D, 2002, J NATL CANCER I, V94, P513; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonomi P, 2002, SEMIN ONCOL, V29, P78, DOI 10.1053/sonc.2002.31528; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Feng G, 2001, CANCER RES, V61, P7999; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; FRAIRE AE, 1987, CANCER, V60, P370, DOI 10.1002/1097-0142(19870801)60:3<370::AID-CNCR2820600314>3.0.CO;2-W; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Hayashi K, 2001, CANCER RES, V61, P2361; HEIGHWAY J, 2003, METHODS MOL MED; Hough CD, 2001, CANCER RES, V61, P3869; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kolligs FT, 2000, GENE DEV, V14, P1319; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Liu D, 2000, BRIT J CANCER, V83, P1473, DOI 10.1054/bjoc.2000.1488; Maass N, 2001, CLIN CANCER RES, V7, P812; Matsumoto Y, 2001, JPN J CANCER RES, V92, P1133, DOI 10.1111/j.1349-7006.2001.tb01069.x; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Pabon C, 2001, BIOTECHNIQUES, V31, P874, DOI 10.2144/01314mt05; Seftor REB, 1998, CANCER RES, V58, P5681; Sunday ME, 1999, ONCOGENE, V18, P4336, DOI 10.1038/sj.onc.1202810; THURLBECK WM, 1995, PATHOLOGY LUNG, P445; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhu Y, 2001, CANCER RES, V61, P7825	33	133	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7749	7763		10.1038/sj.onc.1205979	http://dx.doi.org/10.1038/sj.onc.1205979			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400018				2022-12-25	WOS:000178756200015
J	Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S				Modugno, M; Tagliabue, E; Ardini, E; Berno, V; Galmozzi, E; De Bortoli, M; Castronovo, V; Menard, S			p53-dependent downregulation of metastasis-associated laminin receptor	ONCOGENE			English	Article						p53; laminin receptor; transcriptional regulation; AP-2; promoter	WILD-TYPE P53; GENE-EXPRESSION; OVARIAN-CARCINOMA; BREAST-CARCINOMA; CELL-GROWTH; PROTEIN; PRECURSOR; PROMOTER; ESTROGEN; CANCER	Based on observations suggesting a role for the tumor suppressor protein p53 in regulating expression of the 67-kDa laminin receptor precursor, 37LRP, we analysed the 37LRP promoter activity in a wild-type p53 (wt p53) ovarian carcinoma cell line and in a cisplatin-resistant subline with mutated p53. We observed an increased promoter activity in wt p53 cells as compared to the mutated-p53 line when the first intron of the 37LRP gene was present in the reporter construct. Cotransfection experiments showed that the promoter is downregulated by both wt and mutated p53. Deletion analysis of the first intron localized an enhancer activity in the first 5' 214 bp that upregulates both 37LRP and SV40 promoter activity and is repressed by both wt and mutant p53. Cotransfection, mutagenesis and gel-shift experiments identified a functional AP-2 cis-acting element in this intron region that is repressed by increased levels of both wt and mutated p53. Coimmunoprecipitation studies revealed AP-2 in physical association in vivo with both wt and mutated p53, indicating for the first time that interaction of p53 with AP-2 is involved in the repression mechanism and in the regulation of genes involved in cancer growth and progression.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Inst Canc Res & Treatment, Candiolo, Italy; Metastasis Res Lab, B-4000 Liege, Belgium	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione del Piemonte per l'Oncologia	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.		Berno, Valeria/AAN-3997-2020; De Bortoli, Michele/B-5418-2013; Tagliabue, Elda/B-9377-2017; menard, sylvie mm/C-7940-2011	Berno, Valeria/0000-0001-5848-494X; De Bortoli, Michele/0000-0002-6666-9052; Tagliabue, Elda/0000-0001-9877-2903; Galmozzi, Enrico/0000-0001-8831-2401				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; Buto S, 1997, INT J BIOL MARKER, V12, P1; CASTRONOVO V, 1990, BIOCHEM BIOPH RES CO, V68, P1110; Clausse N, 1998, BIOCHEM BIOPH RES CO, V251, P564, DOI 10.1006/bbrc.1998.9431; DiLeo A, 1995, EUR J CANCER, V31A, P2248, DOI 10.1016/0959-8049(95)00481-5; Foley J, 1996, CANCER RES, V56, P4056; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jackers P, 1996, ONCOGENE, V13, P495; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDOWSKI TH, 1995, BIOCHEMISTRY-US, V34, P11276, DOI 10.1021/bi00035a037; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Nadji M, 1999, CANCER-AM CANCER SOC, V85, P432, DOI 10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J; Pal S, 2001, CANCER RES, V61, P6952; Perego P, 1996, CANCER RES, V56, P556; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; PERREM K, 1995, ONCOGENE, V11, P1299; RAGHUNATH PN, 1993, J BIOL REG HOMEOS AG, V7, P22; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; Righetti SC, 1996, CANCER RES, V56, P689; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAO KS, 1995, CANCER RES, V55, P4367; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	37	28	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7478	7487		10.1038/sj.onc.1205957	http://dx.doi.org/10.1038/sj.onc.1205957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386810				2022-12-25	WOS:000178618200003
J	Zhang, JY; Herscovitz, H				Zhang, JY; Herscovitz, H			Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; TRIGLYCERIDE TRANSFER PROTEIN; MCA-RH7777 CELLS; SECRETORY PATHWAY; HEPG2 CELLS; APO-B; QUALITY-CONTROL; MEMBRANE-PROTEIN; RAT HEPATOCYTES; CYCLOSPORINE-A	We have previously demonstrated that endoplasmic reticulum (ER)-resident molecular chaperones interact with apolipoprotein B-100 (apoB) during its maturation. The initial stages of apoB folding occur while it is bound to the ER membrane, where it becomes partially lipi-dated to form a primordial intermediate. We determined whether this intermediate is dependent on the assistance of molecular chaperones for its subsequent folding steps. To that end, microsomes were prepared from HepG2 cells and luminal contents were subjected to KBr density gradient centrifugation. Immunoprecipitation of apoB followed by Western blotting showed that the luminal pool floated at a density of 1.12 g/ml and, like the membrane-bound pool, was associated with GRP94, ERp72, BiP, calreticulin, and cyclophilin B. Except for calreticulin, chaperone/apoB ratio in the lumen was severalfold higher than that in the membrane, suggesting a role for these chaperones both in facilitating the release of the primordial intermediate into the ER lumen and in providing stability. Subcellular fractionation on sucrose gradients showed that apoB in the Golgi was associated with the same array of chaperones as the pool of apoB recovered from heavy microsomes containing the ER, except that chaperone/apoB ratio was lower. KBr density gradient fractionation showed that the major pool of luminal apoB in the Golgi was recovered from 1.02 < d < 1.08 g/ml, whereas apoB in ER was recovered primarily from 1.08 < d < 1.2 g/ml. Both fractions were associated with the same spectrum of chaperones. Together With the finding that GRP94 was found associated with sialylated apoB, we conclude that correct folding of apoB is dependent on the assistance of molecular chaperone, which play multiple roles in its maturation throughout the secretory pathway including distal compartments such as the trans-Golgi network.	Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University	Herscovitz, H (corresponding author), Boston Univ, Sch Med, Ctr Adv Biomed Res, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.			Herscovitz, Haya/0000-0001-8067-6091	NHLBI NIH HHS [HL-58833, HL-26335] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058833, R29HL058833, P01HL026335] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P897, DOI 10.1042/bj3100897; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DAVID V, 1993, J BIOL CHEM, V268, P9585; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1984, J BIOL CHEM, V259, P3383; DIXON JL, 1993, J LIPID RES, V34, P167; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hamilton RL, 1998, J LIPID RES, V39, P1543; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KAPTEIN A, 1994, ARTERIOSCLER THROMB, V14, P780, DOI 10.1161/01.ATV.14.5.780; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; PATEL SB, 1995, J LIPID RES, V36, P2090; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Sakata N, 2001, J LIPID RES, V42, P1947; SARASTE J, 1991, J CELL SCI, V100, P415; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SMALL DM, 1997, CIRCULATION, V96, P1; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; SPARKS JD, 1988, J BIOL CHEM, V263, P5001; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Swift LL, 1996, J BIOL CHEM, V271, P31491; SWIFT LL, 1995, J LIPID RES, V36, P395; Swift LL, 2001, J LIPID RES, V42, P218; TAILLEUX A, 1993, J LIPID RES, V34, P719; Tatu U, 1999, BIOSCIENCE REP, V19, P189, DOI 10.1023/A:1020225803282; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yao ZM, 1997, J LIPID RES, V38, P1937; Zapun A, 1999, STRUCT FOLD DES, V7, pR173, DOI 10.1016/S0969-2126(99)80112-9; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	74	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7459	7468		10.1074/jbc.M207976200	http://dx.doi.org/10.1074/jbc.M207976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12397072	hybrid			2022-12-25	WOS:000181195100107
J	Minko, IG; Washington, MT; Kanuri, M; Prakash, L; Prakash, S; Lloyd, RS				Minko, IG; Washington, MT; Kanuri, M; Prakash, L; Prakash, S; Lloyd, RS			Translesion synthesis past acrolein-derived DNA adduct, gamma-hydroxypropanodeoxyguanosine, by yeast and human DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; THYMINE-THYMINE DIMER; XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; DEOXYGUANOSINE ADDUCT; LESION BYPASS; POL-ETA; PROPANODEOXYGUANOSINE; REPLICATION; MUTAGENESIS	gamma-Hydroxy-1,N-2-propano-2' deoxyguanosine (gamma-HOPdG) is a major deoxyguanosine adduct derived from acrolein, a known mutagen. In vitro, this adduct has previously been shown to pose a severe block to translesion synthesis by a number of polymerases (pol). Here we show that both yeast and human pol eta can incorporate a C opposite gamma-HOPdG at similar to190- and similar to100-fold lower efficiency relative to the control deoxyguanosine and extend from a C paired with the adduct at similar to8- and similar to19-fold lower efficiency. Although DNA synthesis past gamma-HOPdG by yeast pol eta was relatively accurate, the human enzyme misincorporated nucleotides opposite the lesion with frequencies of similar to 10(-1) to 10(-2). Because gamma-HOPdG can adopt both ring closed and ring opened conformations, comparative replicative bypass studies were also performed with two model adducts, propanodeoxyguanosine and reduced gamma-HOPdG. For both yeast and human pol eta, the ring open reduced gamma-HOPdG adduct was less blocking than gamma-HOPdG, whereas the ring closed propanodeoxyguanosine adduct was a very strong block. Replication of DNAs containing gamma-HOPdG in wild type and xeroderma pigmentosum variant cells revealed a somewhat decreased mutation frequency in xeroderma pigmentosum variant cells. Collectively, the data suggest that pol eta might potentially contribute to both error-free and mutagenic bypass of gamma-HOPdG.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Lloyd, R. Stephen/0000-0001-7273-372X; Washington, Todd/0000-0001-8680-2992; Prakash, Louise/0000-0001-9143-6261	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267, ES06676] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1984, CANCER RES, V44, P990; COHEN SM, 1992, CANCER RES, V52, P3577; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kanuri M, 2002, J BIOL CHEM, V277, P18257, DOI 10.1074/jbc.M112419200; Kawanishi M, 1998, MUTAT RES-GEN TOX EN, V417, P65, DOI 10.1016/S1383-5718(98)00093-X; Kuraoka I, 2001, J BIOL CHEM, V276, P49283, DOI 10.1074/jbc.M107779200; Kurtz AJ, 2002, BIOCHEMISTRY-US, V41, P7054, DOI 10.1021/bi020026y; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; MARNETT LJ, 1985, MUTAT RES, V148, P25; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MCDIARMID MA, 1991, MUTAT RES, V248, P93, DOI 10.1016/0027-5107(91)90091-2; McDonald JP, 1997, GENETICS, V147, P1557; Minko IG, 2001, J BIOL CHEM, V276, P2517, DOI 10.1074/jbc.M007867200; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pan J, 2002, CHEM RES TOXICOL, V15, P367, DOI 10.1021/tx010136q; Penn A, 2001, ENVIRON HEALTH PERSP, V109, P219, DOI 10.2307/3434688; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER B, 1999, IARC SCI PUBL, V150, P1; SINGH US, 1993, CHEM RES TOXICOL, V6, P825, DOI 10.1021/tx00036a012; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Weisenseel JP, 2002, CHEM RES TOXICOL, V15, P127, DOI 10.1021/tx0101090; Yang IY, 2002, CHEM RES TOXICOL, V15, P160, DOI 10.1021/tx010123c; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717	46	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					784	790		10.1074/jbc.M207774200	http://dx.doi.org/10.1074/jbc.M207774200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401796	hybrid			2022-12-25	WOS:000180321900014
J	Taylor, RD; McHale, BJ; Nargang, FE				Taylor, RD; McHale, BJ; Nargang, FE			Characterization of Neurospora crassa Tom40-deficient mutants and effect of specific mutations on Tom40 assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROTEIN IMPORT; OUTER-MEMBRANE PROTEIN; BLUE NATIVE ELECTROPHORESIS; RECEPTOR COMPLEX; TRANSLOCATION CHANNEL; PRECURSOR PROTEINS; CORE COMPONENT; PORE; IDENTIFICATION; BIOGENESIS	The TOM complex (Translocase of the Outer mitochondrial Membrane) is responsible for the recognition of mitochondrial preproteins synthesized in the cytosol and for their translocation across or into the outer mitochondrial membrane. Tom40 is the major component of the TOM complex and forms the translocation pore. We have created a tom40 mutant of Neurospora crassa and have demonstrated that the gene is essential for the viability of the organism. Mitochondria with reduced levels of Tom40 were deficient for import of mitochondrial preproteins and contained reduced levels of the TOM complex components Tom22 and Tom6, suggesting that the import and/or stability of these proteins is dependent on the presence of Tom40. Mutant Tom40 preproteins were analyzed for their ability to be assembled into the TOM complex. In vitro import assays revealed that conserved regions near the N terminus (residues 51-60) and the C terminus (residues 321-323) of the 349-amino acid protein were required for assembly beyond a 250-kDa intermediate form. Mutant strains expressing Tom40 with residues 51-60 deleted were viable but exhibited growth defects. Slow growing mutants expressing Tom40, where residues 321-323 were changed to Ala residues, were isolated but showed TOM complex defects, whereas strains in which residues 321-323 were deleted could not be isolated. Analysis of the assembly of mutant Tom40 precursors in vitro supported a previous model in which Tom40 precursors progress from the 250-kDa intermediate to a 100-kDa form and then assemble into the 400-kDa TOM complex. Surprisingly, when wild type mitochondria containing Tom40 precursors arrested at the 250-kDa intermediate were treated with sodium carbonate, further assembly of intermediates into the TOM complex occurred, suggesting that disruption of protein-protein interactions may facilitate assembly. Import of wild type Tom40 precursor into mitochondria containing a mutant Tom40 lacking residues 40-48 revealed an alternate assembly pathway and demonstrated that the N-terminal region of pre-existing Tom40 molecules in the TOM complex plays a role in the assembly of incoming Tom40 molecules.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Nargang, FE (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	frank.nargang@ualberta.ca	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; [Anonymous], [No title captured]; AUSTIN B, 1990, GENE, V93, P157, DOI 10.1016/0378-1119(90)90152-H; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; COURT DA, 1995, CAN J BOT, V73, pS193; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; GOOD AG, 1989, PLANT PHYSIOL, V90, P1305, DOI 10.1104/pp.90.4.1305; Gordon DM, 2001, BIOCHEM J, V356, P207, DOI 10.1042/0264-6021:3560207; Grad LI, 1999, CURR GENET, V36, P137, DOI 10.1007/s002940050483; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HARKNESS TAA, 1994, GENETICS, V136, P107; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kunkele KP, 1998, J BIOL CHEM, V273, P31032, DOI 10.1074/jbc.273.47.31032; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MARGOLIN BS, 2000, FUNGAL GENET NEWSL, V47, P112; Margolin BS, 1997, FUNGAL GENET NEWSLET, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PASCHEN S, 2001, LIFE, V52, P101; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rapaport D, 2002, TRENDS BIOCHEM SCI, V27, P191, DOI 10.1016/S0968-0004(02)02065-0; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schwartz MP, 1999, P NATL ACAD SCI USA, V96, P13086, DOI 10.1073/pnas.96.23.13086; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Wendland J., 1996, FUNGAL GENETICS REPO, V43, P54; White B., 1995, FUNGAL GENET NEWSL, V42, P79	57	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					765	775		10.1074/jbc.M208083200	http://dx.doi.org/10.1074/jbc.M208083200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12399467	hybrid			2022-12-25	WOS:000180321900012
J	Zhang, XC; Shan, PY; Otterbein, LE; Alam, J; Flavell, RA; Davis, RJ; Choi, AMK; Lee, PJ				Zhang, XC; Shan, PY; Otterbein, LE; Alam, J; Flavell, RA; Davis, RJ; Choi, AMK; Lee, PJ			Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HYPEROXIA-INDUCED APOPTOSIS; NITRIC-OXIDE; HEME OXYGENASE; ISCHEMIA/REPERFUSION INJURY; TERMINAL KINASE; ERK ACTIVATION; CELL APOPTOSIS; HELA-CELLS; SURVIVAL	Carbon monoxide (CO), a reaction product of the cytoprotective gene heme oxygenase, has been shown to be protective against organ injury in a variety of models. One potential mechanism whereby CO affords cytoprotection is through its anti-apoptotic properties. Our studies show that low level, exogenous CO attenuates anoxiareoxygenation (A-R)-induced lung endothelial cell apoptosis. Exposure of primary rat pulmonary artery endothelial cells to minimal levels of CO inhibits apoptosis and enhances phospho-p38 mitogen-activated protein kinase (MAPK) activation in A-R. Transfection of p38alpha dominant negative mutant or inhibition of p38 MAPK activity with SB203580 ablates the anti-apoptotic effects of CO in A-R. CO, through p38 MAPK indirectly modulates caspase 3. Furthermore, we correlate our in vitro apoptosis model with an in vivo model of A-R by showing that CO can attenuate I-R injury of the lung. Taken together, our data are the first to demonstrate in models of A-R that the anti-apoptotic effects of CO are via modulation of p38 MAPK and caspase 3.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Pittsburgh, Div Pulm Allergy & Crit Care, Pittsburgh, PA 15213 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ochsner Health System; Yale University; University of Massachusetts System; University of Massachusetts Worcester	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St,LCI 105, New Haven, CT 06520 USA.	patty.lee@yale.edu	Alam, Jawed/F-2596-2010; zhang, xu/GYE-3558-2022	Alam, Jawed/0000-0001-6520-482X; Zhang, Xuchen/0000-0002-1484-4672	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055330, R01HL060234, R01HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-55330, HL-60234] Funding Source: Medline; NIAID NIH HHS [AI-42365] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggeli IKS, 2001, MOL CELL BIOCHEM, V221, P63, DOI 10.1023/A:1010933013533; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Ceran C, 2001, J PEDIATR SURG, V36, P1764, DOI 10.1053/jpsu.2001.28816; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Cursio R, 2000, Transpl Int, V13 Suppl 1, pS568, DOI 10.1111/j.1432-2277.2000.tb02108.x; Czarnowska E, 2001, FOLIA HISTOCHEM CYTO, V39, P179; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Foresti R, 2001, AM J PHYSIOL-HEART C, V281, pH1976, DOI 10.1152/ajpheart.2001.281.5.H1976; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gilca M, 1997, BIOCHEM MOL MED, V61, P136, DOI 10.1006/bmme.1997.2610; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Hall JL, 2001, CIRC RES, V88, P1247, DOI 10.1161/hh1201.091796; Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; HarrisonShostak DC, 1997, BIOCHEM BIOPH RES CO, V231, P844, DOI 10.1006/bbrc.1997.6129; Hegazy KA, 2000, NEUROREPORT, V11, P1185, DOI 10.1097/00001756-200004270-00008; Holleyman C, 2001, J Extra Corpor Technol, V33, P175; Howlett CE, 1999, AM J PHYSIOL-LUNG C, V277, pL596, DOI 10.1152/ajplung.1999.277.3.L596; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Khandoudi N, 2002, DIABETES, V51, P1507, DOI 10.2337/diabetes.51.5.1507; Kitazono M, 1998, BIOCHEM BIOPH RES CO, V253, P797, DOI 10.1006/bbrc.1998.9852; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 1998, AM J PHYSIOL-LUNG C, V275, pL14, DOI 10.1152/ajplung.1998.275.1.L14; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Sanford G. L., 1999, J GRAVIT PHYSL, V6, P27; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Shimizu H, 2000, CRIT CARE MED, V28, P809, DOI 10.1097/00003246-200003000-00033; Stammberger U, 2000, ANN THORAC SURG, V69, P1532, DOI 10.1016/S0003-4975(00)01228-5; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; STUPFEL M, 1970, ANN NY ACAD SCI, V174, P342, DOI 10.1111/j.1749-6632.1970.tb49799.x; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Teoh N, 2002, HEPATOLOGY, V36, P94, DOI 10.1053/jhep.2002.33134; Tetreau C, 1999, BIOCHEMISTRY-US, V38, P7210, DOI 10.1021/bi9901026; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thrane EV, 2001, TOXICOL SCI, V61, P83, DOI 10.1093/toxsci/61.1.83; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; ZHANG X, 2002, AM J PHYSIOL-LUNG C, V283, P624; Zhao TC, 2001, CIRC RES, V89, P915, DOI 10.1161/hh2201.099452	69	240	264	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1248	1258		10.1074/jbc.M208419200	http://dx.doi.org/10.1074/jbc.M208419200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12399465	hybrid			2022-12-25	WOS:000180321900072
J	Green, HP; Portela, MDM; St Jean, EN; Lugli, EB; Raper, J				Green, HP; Portela, MDM; St Jean, EN; Lugli, EB; Raper, J			Evidence for a Trypanosoma brucei lipoprotein scavenger receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; TRANSFERRIN-BINDING PROTEIN; B TYPE-I; HIGH-AFFINITY RECEPTOR; FATTY-ACID SYNTHESIS; BLOOD-STREAM FORMS; SR-BI; MEDIATED ENDOCYTOSIS; AFRICAN TRYPANOSOMES; SERUM-LIPOPROTEINS	African trypanosomes are lipid auxotrophs that live in the bloodstream of their human and animal hosts. Trypanosomes require lipoproteins in addition to other serum components in order to multiply under axenic culture conditions. Delipidation of the lipoproteins abrogates their capacity to support trypanosome growth. Both major classes of serum lipoproteins, LDL and HDL, are primary sources of lipids, delivering cholesterol esters, cholesterol, and phospholipids to trypanosomes. We show evidence for the existence of a trypanosome lipoprotein scavenger receptor, which facilitates the endocytosis of both native and modified lipoproteins, including HDL and LDL. This lipoprotein scavenger receptor also exhibits selective lipid uptake, whereby the uptake of the lipid components of the lipoprotein exceeds that of the protein components. Trypanosome lytic factor (TLF1), an unusual HDL found in human serum that protects from infection by lysing Trypanosoma brucei brucei, is also bound and endocytosed by this lipoprotein scavenger receptor. HDL and LDL compete for the binding and uptake of TLF1 and thereby attenuate the trypanosome lysis mediated by TLF1. We also show that a mammalian scavenger receptor facilitates lipid uptake from TLF1 in a manner similar to the trypanosome scavenger receptor. Based on these results we propose that HDL, LDL, and TLF1 are all bound and taken up by a lipoprotein scavenger receptor, which may constitute the parasite's major pathway mediating the uptake of essential lipids.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	New York University	Raper, J (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA.	jr57@nyu.edu		Lugli, Elena/0000-0003-0687-7412; Raper, Jayne/0000-0002-8723-9748	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041233, K02AI001660, R29AI041233] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41233, AI01660] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; BLACK S, 1989, MOL BIOCHEM PARASIT, V37, P65, DOI 10.1016/0166-6851(89)90103-5; Calvo D, 1998, J LIPID RES, V39, P777; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; COPPENS I, 1995, J BIOL CHEM, V270, P5736, DOI 10.1074/jbc.270.11.5736; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; COPPENS I, 1993, MOL BIOCHEM PARASIT, V58, P223, DOI 10.1016/0166-6851(93)90044-X; Crombie R, 1998, J BIOL CHEM, V273, P4855, DOI 10.1074/jbc.273.9.4855; Delrieu I, 2002, MOL BIOCHEM PARASIT, V121, P11, DOI 10.1016/S0166-6851(02)00016-6; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1993, J BIOL CHEM, V268, P9215; Drain J, 2001, J BIOL CHEM, V276, P30254, DOI 10.1074/jbc.M010198200; GILLETT MPT, 1992, BIOCHIM BIOPHYS ACTA, V1123, P239, DOI 10.1016/0005-2760(92)90002-D; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; Hammad SM, 2000, J BIOL CHEM, V275, P12003, DOI 10.1074/jbc.275.16.12003; HUMLE EC, 1993, RECEPTOR LIGAND INTE, V3; Jeffries TR, 2001, J CELL SCI, V114, P2617; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kubata BK, 2000, J EXP MED, V192, P1327, DOI 10.1084/jem.192.9.1327; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; Lorenz P, 1995, MOL BIOCHEM PARASIT, V74, P113, DOI 10.1016/0166-6851(95)02479-4; LOW P, 1991, J BIOL CHEM, V266, P19250; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; Morgan GW, 2001, J CELL SCI, V114, P2605; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Paul KS, 2001, TRENDS PARASITOL, V17, P381, DOI 10.1016/S1471-4922(01)01984-5; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; POUMAY Y, 1985, J LIPID RES, V26, P1476; Raper J, 1999, INFECT IMMUN, V67, P1910; RIFKIN MR, 1991, J LIPID RES, V32, P639; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; Shimamura M, 2001, MOL BIOCHEM PARASIT, V115, P227, DOI 10.1016/S0166-6851(01)00292-4; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; TOMLINSON S, 1995, MOL BIOCHEM PARASIT, V70, P131, DOI 10.1016/0166-6851(95)00019-W; VANDEWEERD V, 1989, MOL BIOCHEM PARASIT, V37, P201, DOI 10.1016/0166-6851(89)90152-7; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1	54	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					422	427		10.1074/jbc.M207215200	http://dx.doi.org/10.1074/jbc.M207215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401813	hybrid			2022-12-25	WOS:000180255700056
J	Moorthy, AK; Ghosh, G				Moorthy, AK; Ghosh, G			P105 center dot I kappa B gamma and prototypical I kappa Bs use a similar mechanism to bind but a different mechanism to regulate the subcellular localization of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN REPEAT DOMAIN; NUCLEAR EXPORT SIGNAL; GLYCINE-RICH REGION; PRECURSOR P105; DNA-BINDING; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; P50/P65 HETERODIMER; PROTEIN FAMILY; REL PROTEINS	p105, also known as NF-kappaB1, is an atypical IkappaB molecule with a multi-domain organization distinct from other prototypical IkappaBs, like IkappaBalpha and IkappaBbeta. To understand the mechanism by which p105 binds and inhibits NF-kappaB, we have used both p105 and its C-terminal inhibitory segment known as IkappaBgamma for our study. We show here that one IkappaBgamma molecule binds to NF-kappaB dimers wherein at least one NF-kappaB subunit is p50. We suggest that the obligatory p50 subunit in IkappaBgamma(.)NF-kappaB complexes is equivalent to the N-terminal p50 segment in all p105-NF-kappaB complexes. The nuclear localization signal (NLS) of the obligatory p50 subunit is masked by IkappaBgamma, whereas the NLS of the nonobligatory NF-kappaB subunit is exposed. Thus, the global binding mode of all kappaKB-NF-kappaB complexes seems to be similar where one obligatory (or specific) NF-kappaB subunit makes intimate contact with IkappaB and the nonobligatory (or nonspecific) subunit is bound primarily through its ability to dimerize. In the case of IkappaBalpha and IkappaBbeta, the specific NF-kappaB subunit in the complex is p65. In contrast to IkappaBalpha(.)NF-kappaB complexes, where the exposed NLS of the nonspecific subunit imports the complex to the nucleus, p105-NF-kappaB and IkappaBgamma(.)NF-kappaB complexes are cytoplasmic. We show that the death domain of p105 (also of IkappaBgamma) is essential for the cytoplasmic sequestration of NF-kappaB by p105 and IkappaBgamma. However, the death domain does not mask the exposed NLS of the complex. We also demonstrate that the death domain alone is not sufficient for cytoplasmic retention and instead functions only in conjunction with other parts in the three-dimensional scaffold formed by the association of the ankyrin repeat domain (ARD) and NF-kappaB dimer. We speculate that additional cytoplasmic protein(s) may sequester the entire p105-NF-kappaB complex by binding through the death domain and other segments, including the exposed NLS.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200	52	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					556	566		10.1074/jbc.M207515200	http://dx.doi.org/10.1074/jbc.M207515200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399470	hybrid			2022-12-25	WOS:000180255700073
J	Shringarpure, R; Grune, T; Mehlhase, J; Davies, KJA				Shringarpure, R; Grune, T; Mehlhase, J; Davies, KJA			Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; OXIDATIVE STRESS; ACTIVATING ENZYME; MAMMALIAN-CELLS; SELECTIVE DEGRADATION; 26S PROTEASOME; GLUTAMINE-SYNTHETASE; MODIFIED HEMOGLOBIN; CELLULAR PROTEINS; EPITHELIAL-CELLS	Oxidatively modified proteins that accumulate in aging and many diseases can form large aggregates because of covalent cross-linking or increased surface hydrophobicity. Unless repaired or removed from cells, these oxidized proteins are often toxic, and threaten cell viability. Most oxidatively damaged proteins appear to undergo selective proteolysis, primarily by the proteasome. Previous work from our laboratory has shown that purified 20 S proteasome degrades oxidized proteins without ATP or ubiquitin in vitro, but there have been no studies to test this mechanism in vivo. The aim of this study was to determine whether ubiquitin conjugation is necessary for the degradation of oxidized proteins in intact cells. We now show that cells with compromised ubiquitin-conjugating activity still preferentially degrade oxidized intracellular proteins, at near normal rates, and this degradation is still inhibited by proteasome inhibitors. We also show that progressive oxidation of proteins such as lysozyme and ferritin does not increase their ubiquitinylation, yet the oxidized forms of both proteins are preferentially degraded by proteasome. Furthermore, rates of oxidized protein degradation by cell lysates are not significantly altered by addition of ATP, excluding the possibility of an energy requirement for this pathway. Contrary to earlier popular belief that most proteasomal degradation is conducted by the 26 S proteasome with ubiquitinylated substrates, our work suggests that oxidized proteins are degraded without ubiquitin conjugation (or ATP hydrolysis) possibly by the 20 S proteasome, or the immunoproteasome, or both.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Ctr Res Neurosci, D-10098 Berlin, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, GER 306C,3715 McClintock Ave, Los Angeles, CA 90089 USA.			Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NIEHS NIH HHS [ES03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R23ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; COUX O, 1996, ANNU REV BIOCHEM, V29, P10289; COX JH, 1995, J IMMUNOL, V154, P511; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V329, P137, DOI 10.1006/abbi.1996.0202; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GILLIN FD, 1972, GENETICS, V72, P239; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GROPPER R, 1991, J BIOL CHEM, V266, P3602; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRSCHBERG J, 1982, J CELL PHYSIOL, V113, P159, DOI 10.1002/jcp.1041130125; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; RICE RH, 1971, J BIOL CHEM, V246, P831; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALO DC, 1990, J BIOL CHEM, V265, P11919; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	60	338	344	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					311	318		10.1074/jbc.M206279200	http://dx.doi.org/10.1074/jbc.M206279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401807	hybrid			2022-12-25	WOS:000180255700042
J	Lin, GQ; Tiedemann, K; Vollbrandt, T; Peters, H; Batge, B; Brinckmann, J; Reinhardt, DP				Lin, GQ; Tiedemann, K; Vollbrandt, T; Peters, H; Batge, B; Brinckmann, J; Reinhardt, DP			Homo- and heterotypic fibrillin-1 and -2 interactions constitute the basis for the assembly of microfibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX MICROFIBRILS; MARFAN-SYNDROME; DEVELOPMENTAL EXPRESSION; GENETIC-DISORDERS; MOLECULAR-CLONING; FIBER SYSTEM; PROTEIN; IDENTIFICATION; ORGANIZATION; MUTATIONS	Fibrillin-1 and fibrillin-2 constitute the backbone of extracellular filaments, called microfibrils. Fibrillin assembly involves complex multistep mechanisms to result in a periodical head-to-tail alignment in microfibrils. Impaired assembly potentially plays a role in the molecular pathogenesis of genetic disorders caused by mutations in fibrillin-1 (Marfan syndrome) and fibrillin-2 (congenital contractural arachnodactyly). Presently, the basic molecular interactions involved in fibrillin assembly are obscure. Here, we have generated recombinant full-length human fibrillin-1, and two overlapping recombinant polypeptides spanning the entire human fibrillin-2 in a mammalian expression system. Characterization by gel electrophoresis, electron microscopy after rotary shadowing, and reactivity with antibodies demonstrated correct folding of these recombinant polypeptides. Analyses of homotypic and heterotypic interaction repertoires showed N- to C-terminal binding of fibrillin-1, and of fibrillin-1 with fibrillin-2. The interactions were of high affinity with dissociation constants in the low nanomolar range. However, the Nand C-terminal fibrillin-2 polypeptides did not interact with each other. These results demonstrate that fibrillins can directly interact in an N- to C-terminal fashion to form homotypic fibrillin-1 or heterotypic fibrillin-1/ fibrillin-2 microfibrils. This conclusion was further strengthened by double immunofluorescence labeling of microfibrils. In addition, the binding epitopes as well as the entire fibrillin molecules displayed very stable properties.	Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Univ Lubeck, Dept Chem, D-23538 Lubeck, Germany; Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	University of Lubeck; University of Lubeck; University of Lubeck	Reinhardt, DP (corresponding author), Univ Lubeck, Dept Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Tiedemann, one/A-9739-2016; Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872				AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ashworth JL, 1999, J CELL SCI, V112, P3549; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; CHARBONNEAU NL, 2002, J BIOL CHEM; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GODFREY M, 1995, AM J PATHOL, V146, P1414; Hanssen E, 1998, BIOL CELL, V90, P223, DOI 10.1016/S0248-4900(98)80018-X; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; ISOGAI Z, 2002, J BIOL CHEM; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Park ES, 1998, AM J MED GENET, V78, P350, DOI 10.1002/(SICI)1096-8628(19980724)78:4<350::AID-AJMG9>3.3.CO;2-#; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; QUONDAMATTEO F, 2002, IN PRESS MATRIX BIOL; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	46	101	105	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50795	50804		10.1074/jbc.M210611200	http://dx.doi.org/10.1074/jbc.M210611200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399449	hybrid			2022-12-25	WOS:000180177700079
J	Mo, JY; Fang, SJJ; Chen, W; Blobe, GC				Mo, JY; Fang, SJJ; Chen, W; Blobe, GC			Regulation of ALK-1 signaling by the nuclear receptor LXR beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; STEROID-HORMONE RECEPTORS; TGF-BETA; ENDOTHELIAL-CELLS; MICE LACKING; I RECEPTORS; CHOLESTEROL-METABOLISM; ESTROGEN-RECEPTOR; RESPONSE PATHWAY	The transforming growth factor beta (TGF-beta) receptor, ALK-1, is expressed specifically on endothelial cells and is essential for angiogenesis, as demonstrated by its targeted deletion in mice and its mutation in the human disease hereditary hemorrhagic telangiectasia. Although ALK-1 and another endothelial-specific TGF-beta receptor, endoglin, both bind TGF-beta with identical isoform specificity and form a complex together, neither has been shown to signal in response to TGF-beta, and the mechanism by which these receptors signal in endothelial cells remains unknown. Here we report the identification of the nuclear receptor liver X receptor beta (LXRbeta) as a modulator/mediator of ALK-1 signaling. The cytoplasmic domain of ALK-1 specifically binds to LXRbeta in vitro and in vivo. Expression of activated ALK-1 results in translocation of LXRbeta from the nuclear compartment to the cytoplasmic compartment. The interaction of activated ALK-1 with LXRbeta in the cytoplasmic compartment results in the specific phosphorylation of LXRbeta by ALK-1, primarily on serine residues. LXRbeta subsequently modulates signaling by ALK-1 and the closely related TGF-beta receptor, ALK-2, as demonstrated by specific and potent inhibition of ALK-1- and ALK-2-mediated transcriptional responses, establishing LXRbeta as a potential modulator/mediator of ALK-1/A.LK-2 signaling.	Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med & Pharmacol, Box 2631, Durham, NC 27710 USA.		Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Chen, Wei/0000-0002-9934-4000	NATIONAL CANCER INSTITUTE [T32CA009307, K22CA091816] Funding Source: NIH RePORTER; NCI NIH HHS [CA-91816, 5-T32-CA09307-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Armes NA, 1997, DEVELOPMENT, V124, P3797; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; James P, 1996, GENETICS, V144, P1425; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lizard G, 1996, AM J PATHOL, V148, P1625; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; NEYSES L, 1985, BIOCHEM J, V227, P105, DOI 10.1042/bj2270105; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Panchenko MP, 1996, AM J PHYSIOL-LUNG C, V270, pL547, DOI 10.1152/ajplung.1996.270.4.L547; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Zwaagstra JC, 2000, EXP CELL RES, V258, P121, DOI 10.1006/excr.2000.4905; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	54	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50788	50794		10.1074/jbc.M210376200	http://dx.doi.org/10.1074/jbc.M210376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393874	hybrid			2022-12-25	WOS:000180177700078
J	Ohara-Imaizumi, M; Nakamichi, Y; Nishiwaki, C; Nagamatsu, S				Ohara-Imaizumi, M; Nakamichi, Y; Nishiwaki, C; Nagamatsu, S			Transduction of MIN6 beta cells with TAT-syntaxin SNARE motif inhibits insulin exocytosis in biphasic insulin release in a distinct mechanism analyzed by evanescent wave microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; HUMAN IMMUNODEFICIENCY VIRUS; N-TERMINAL DOMAIN; PROTEIN INTERACTIONS; PANCREATIC-ISLETS; COMPLEX-FORMATION; MEMBRANE-FUSION; VESICLE DOCKING; H3 DOMAIN; IN-VITRO	To investigate the in vivo interaction of syntaxin-mediated soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) assembly and insulin exocytosis in biphasic release, we examined the dynamics of insulin granule motion such as docking and fusion with the plasma membrane when the syntaxin SNARE motif (113 domain) was transduced into living MIN6 beta cells. TAT-H3, produced by fusion of the protein transduction domain of human immunodeficiency virus-1 TAT to the syntaxin-H3 domain, was rapidly transduced into the subplasmalemmal region in living MIN6 cells. Immunoblotting analysis followed by immunoprecipitation on TAT-H3-treated MIN6 cells showed that TAT-H3 binds SNAP-25 and VAMP-2 in vivo. Transduction of MIN6 cells with TAT-H3 caused a decrease in both the first and second phase of insulin release. We therefore quantitatively analyzed approaching, docking, and fusing of green fluorescent protein-labeled single insulin granules in TAT-H3-transduced MIN6 cells by evanescent wave microscopy. Under high glucose stimulation, TAT-H3 treatment not only reduced the fusion events from previously docked granules for the first 120 s (first phase of release) but also strongly inhibited the docking and fusion from newly recruited insulin granules after this point (second phase of release). During the second phase of release we observed a marked reduction in the accumulation of newly docked insulin granules; subsequently, fusion events were significantly decreased. TAT-H3 treatment by itself, however, did not alter the number of previously docked granules without stimulation. We conclude that introduction of the H3 domain into MIN6 cells inhibits biphasic insulin release by two mechanisms. 1) In the first phase of insulin release, the H3 domain interferes with previously docked granules to be fused, and 2) in the second phase of insulin release reduced fusion events result from a marked decline of newly docked granules. Thus, syntaxin-mediated SNARE assembly modulates insulin exocytosis in biphasic insulin release in a distinct way.	Kyorin Univ, Sch Med, Dept Biochem, Tokyo 1818611, Japan	Kyorin University	Nagamatsu, S (corresponding author), Kyorin Univ, Sch Med, Dept Biochem, Shinkawa 6-20-2, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp						AXELROD D, 1989, METHOD CELL BIOL, V30, P245; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fujiwara T, 2001, BBA-MOL CELL RES, V1539, P225, DOI 10.1016/S0167-4889(01)00109-4; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kawano Y, 2000, P SOC PHOTO-OPT INS, V4098, P142, DOI 10.1117/12.401623; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Martin F, 1996, BIOCHEM J, V320, P201, DOI 10.1042/bj3200201; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nagamatsu S, 1999, J BIOL CHEM, V274, P8053, DOI 10.1074/jbc.274.12.8053; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLLHEIM CB, 1984, J BIOL CHEM, V259, P2262; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408	40	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50805	50811		10.1074/jbc.M207988200	http://dx.doi.org/10.1074/jbc.M207988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393909	hybrid			2022-12-25	WOS:000180177700080
J	Park, M; Ko, SBH; Choi, JY; Muallem, G; Thomas, PJ; Pushkin, A; Lee, MS; Kim, JY; Lee, MG; Muallem, S; Kurtz, I				Park, M; Ko, SBH; Choi, JY; Muallem, G; Thomas, PJ; Pushkin, A; Lee, MS; Kim, JY; Lee, MG; Muallem, S; Kurtz, I			The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO3- salvage transporter human Na+-HCO3- cotransport isoform 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; TISSUE DISTRIBUTION; CL-/HCO3-EXCHANGE; CFTR; EXPRESSION; MEMBRANE; NBC3; DUCT; H+; COLOCALIZATION	Cystic fibrosis transmembrane conductance regulator (CFTR) regulates both HCO3- secretion and HCO3- salvage in secretory epithelia. At least two luminal transporters mediate HCO3- salvage, the Na+/H+ exchanger (NHE3) and the Na+-HCO3- cotransport (NBC3). In a previous work, we show that CFTR interacts with NHE3 to regulate its activity (Ahn, W., Kim, K.W., Lee, J.A., Kim, J.Y., Choi, J.Y., Moe, O.M., Milgram, S.L., Muallem, S., and Lee, M. G. (2001) J. Biol. Chem. 276,17236-17243). In this work, we report that transient or stable expression of human NBC3 (hNBC3) in HEK cells resulted in a Na+-dependent, DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid)- and 5-ethylisopropylamiloride-insensitive HCO3- transport. Stimulation of CFTR with forskolin markedly inhibited NBC3 activity. This inhibition was prevented by the inhibition of protein kinase A. NBC3 and CFTR could be reciprocally coimmunoprecipitated from transfected HEK cells and from the native pancreas and submandibular and parotid glands. Precipitation of NBC3 or CFTR from transfected HEK293 cells and from the pancreas and submandibular gland also coimmunoprecipitated EBP50. Glutathione S-transferase-EBP50 pulled down CFTR and hNBC3 from cell lysates when expressed individually and as a complex when expressed together. Notably, the deletion of the C-terminal PDZ binding motifs of CFTR or hNBC3 prevented coimmunoprecipitation of the proteins and inhibition of hNBC3 activity by CFTR. We conclude that CFTR and NBC3 reside in the same HCO3--transporting complex with the aid of PDZ domain-containing scaffolds, and this interaction is essential for regulation of NBC3 activity by CFTR. Furthermore, these findings add additional evidence for the suggestion that CFTR regulates the overall trans-cellular HCO3- transport by regulating the activity of all luminal HCO3- secretion and salvage mechanisms of secretory epithelial cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Calif Los Angeles, Dept Med, Div Nephrol, Los Angeles, CA 90095 USA; Sookmyung Womens Univ, Dept Sci Biol, Seoul 140742, South Korea; Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; Sookmyung Women's University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu	Lee, Min Goo/AAS-4636-2020; Thomas, Philip J/F-7115-2012; Ko, Shigeru/H-3450-2012; Lee, Min Goo/D-5635-2012; Kim, Joo Young/X-7562-2019	Lee, Min Goo/0000-0001-7436-012X; Ko, Shigeru/0000-0003-1913-6357; Lee, Min Goo/0000-0001-7436-012X; Kim, Joo Young/0000-0003-2623-1491	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058563] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK58563] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; ARGENT BE, 1994, PHYSL GASTROINTESTIN, P1478; Blackstone C, 2002, FRONT BIOSCI, V7, pD872, DOI 10.2741/blacksto; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; Kwon TH, 2002, AM J PHYSIOL-RENAL, V282, pF341, DOI 10.1152/ajprenal.00104.2001; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 2000, J CLIN INVEST, V105, P1651, DOI 10.1172/JCI9207; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Luo X, 2001, J BIOL CHEM, V276, P9808, DOI 10.1074/jbc.M008548200; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Praetorius J, 2001, AM J PHYSIOL-GASTR L, V280, pG332, DOI 10.1152/ajpgi.2001.280.3.G332; Pushkin A, 2000, J ANDROL, V21, P708; Pushkin A, 1999, AM J PHYSIOL-RENAL, V277, pF974, DOI 10.1152/ajprenal.1999.277.6.F974; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; TIZZANO EF, 1995, ANN INTERN MED, V123, P305, DOI 10.7326/0003-4819-123-4-199508150-00009; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57	29	77	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50503	50509		10.1074/jbc.M201862200	http://dx.doi.org/10.1074/jbc.M201862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12403779	hybrid			2022-12-25	WOS:000180177700042
J	Rohn, JL; Zhang, YH; Aalbers, RIJM; Otto, N; den Hertog, J; Henriquez, NV; van de Velde, CJH; Kuppen, PJK; Mumberg, D; Donner, P; Noteborn, MHM				Rohn, JL; Zhang, YH; Aalbers, RIJM; Otto, N; den Hertog, J; Henriquez, NV; van de Velde, CJH; Kuppen, PJK; Mumberg, D; Donner, P; Noteborn, MHM			A tumor-specific kinase activity regulates the viral death protein apoptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ANEMIA VIRUS; CAUSES APOPTOSIS; CELLS; INFECTION; CANCER; INDIVIDUALS; AGENT; CYCLE	Apoptin, a chicken anemia virus-encoded protein, is thought to be activated by a general tumor-specific pathway, because it induces apoptosis in a large number of human tumor or transformed cells but not in their normal, healthy counterparts. Here, we show that Apoptin is phosphorylated robustly both in vitro and in vivo in tumor cells but negligibly in normal cells, and we map the site to threonine 108. A gain-of-function point mutation (T108E) conferred upon Apoptin the ability to accumulate in the nucleus and kill normal cells, implying that phosphorylation is a key regulator of the tumor-specific properties of Apoptin. An activity that could phosphorylate Apoptin on threonine 108 was found specifically in tumor and transformed cells from a variety of tissue origins, suggesting that activation of this kinase is generally associated with the cancerous or precancerous state. Moreover, analyses of human tissue samples confirm that Apoptin kinase activity is detectable in primary malignancies but not in tissue derived from healthy individuals. Taken together, our results support a model whereby the dysregulation of the cellular pathway leading to the phosphorylation of Apoptin contributes to human tumorigenesis.	Leadd BV, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; Schering AG, Res Labs, D-13342 Berlin, Germany; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Schering AG; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Noteborn, MHM (corresponding author), Leadd BV, NL-2300 RA Leiden, Netherlands.	noteborn@leadd.nl	Kuppen, Peter/J-2342-2016; Henriquez, Nico/C-3758-2008	Kuppen, Peter/0000-0002-0294-3251; Rohn, Jennifer/0000-0001-8766-6056				Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; GELDERBLOM H, 1989, ARCH VIROL, V109, P115, DOI 10.1007/BF01310522; GUOREN D, 1996, SCIENCE, V274, P2057; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JEURISSEN SHM, 1992, J VIROL, V66, P7383, DOI 10.1128/JVI.66.12.7383-7388.1992; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; NOTEBORN MHM, 1995, AVIAN PATHOL, V24, P11, DOI 10.1080/03079459508419046; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; NOTEBORN MHM, 2002, TARGETS CANC CHEMOTH; Peters MA, 2002, J BIOL CHEM, V277, P39566, DOI 10.1074/jbc.M201752200; Pietersen AM, 1999, GENE THER, V6, P882, DOI 10.1038/sj.gt.3300876; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Sobin L.H., 2017, TNM CLASSIFICATION M, V8th ed.; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; van der Eb MM, 2002, CANCER GENE THER, V9, P53, DOI 10.1038/sj.cgt.7700397; VANOORSCHOT AAA, 1999, LEUKEMIA S1, V13, pS75; VANOORSCHOT AAA, 2001, THESIS WAGENINGEN NE; VANOORSCHOT AAA, 1997, P NATL ACAD SCI USA, V11, P5843; YUASA N, 1980, AVIAN DIS, V24, P202, DOI 10.2307/1589780; Zhang YH, 1999, CANCER RES, V59, P3010; ZHUANG SM, 1995, LEUKEMIA, V9, pS118; ZHUANG SM, 1995, CANCER RES, V55, P486	31	96	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50820	50827		10.1074/jbc.M208557200	http://dx.doi.org/10.1074/jbc.M208557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393903	hybrid			2022-12-25	WOS:000180177700082
J	Tanowitz, M; von Zastrow, M				Tanowitz, M; von Zastrow, M			Ubiquitination-independent trafficking of G protein-coupled receptors to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-OPIOID RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR MECHANISMS; DOWN-REGULATION; ENDOCYTOSIS; PROTEASOME; RESENSITIZATION; INTERNALIZATION; MU; DESENSITIZATION	Ubiquitination of cytoplasmic lysine residues can target G protein-coupled receptors (GPCRs) to proteasomes and has recently been shown to also be required for sorting of certain GPCRs to lysosomes following ligand-induced endocytosis. We addressed the generality of this mechanism by examining regulated proteolysis of the murine 5 opioid receptor (DOR) expressed in human embryonic kidney 293 cells, a well characterized model system in which receptors are sorted to lysosomes. Incubation of cells in the presence of the highly specific proteasome inhibitor lactacystin did not detectably affect ligand-induced proteolysis of DOR but significantly delayed ligand-induced proteolysis of epidermal growth factor receptors. Mutation of all cytoplasmic lysine residues in DOR, creating a mutant opioid receptor that is unable to be ubiquitinated, did not detectably inhibit either ligand-induced endocytosis or proteolytic degradation of endocytosed receptors. Furthermore, the lysine-mutated DOR, like its wild type counterpart, colocalized extensively with lysosomes after ligand-induced endocytosis. These results demonstrate that ubiquitination of DOR is not required either for its ligand-induced endocytosis or for postendocytic trafficking to lysosomes.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tanowitz, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, Box 0984 IRE,Room LP-A104 LPPI,401 Parnassus Ave, San Francisco, CA 94143 USA.							Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308	36	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50219	50222		10.1074/jbc.C200536200	http://dx.doi.org/10.1074/jbc.C200536200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401797	hybrid			2022-12-25	WOS:000180177700002
J	Hu, CM; Jang, SY; Fanzo, JC; Pernis, AB				Hu, CM; Jang, SY; Fanzo, JC; Pernis, AB			Modulation of T cell cytokine production by interferon regulatory factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IL-4 PROMOTER; ATP-DEFICIENT MICE; TRANSCRIPTION FACTOR; NF-ATC; GENE-EXPRESSION; FACTOR FAMILY; IN-VIVO; ACTIVATION; DIFFERENTIATION; LYMPHOCYTE	Production of cytokines is one of the major mechanisms employed by CD4(+) T cells to coordinate immune responses. Although the molecular mechanisms controlling T cell cytokine production have been extensively studied, the factors that endow T cells with their ability to produce unique sets of cytokines have not been fully characterized. Interferon regulatory factor (IRF)-4 is a lymphoid-restricted member of the interferon regulatory factor family of transcriptional regulators, whose deficiency leads to a profound impairment in the ability of mature CD4(+) T cells to produce cytokines. In these studies, we have investigated the mechanisms employed by IRF-4 to control cytokine synthesis. We demonstrate that stable expression of IRF-4 in Jurkat T cells not only leads to a strong enhancement in the synthesis of interleukin (IL)-2, but also enables these cells to start producing considerable amounts of IL-4, IL-10, and IL-13. Transient transfection assays indicate that IRF-4 can transactivate luciferase reporter constructs driven by either the human IL-2 or the human IL-4 promoter. A detailed analysis of the effects of IRF-4 on the IL-4 promoter reveals that IRF-4 binds to a site adjacent to a functionally important NFAT binding element and that IRF-4 cooperates with NFATcl. These studies thus support the notion that IRF-4 represents one of the lymphoid-specific components that control the ability of T lymphocytes to produce a distinctive array of cytokines.	Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University	Pernis, AB (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	abp1@columbia.edu	Fanzo, Jessica/HCH-3533-2022	Fanzo, Jessica/0000-0002-6760-1359				Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Bunn PA, 1996, J CELL BIOCHEM, P12; Copeland KFT, 1996, MICROBIOL REV, V60, P722, DOI 10.1128/MMBR.60.4.722-742.1996; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Glimcher LH, 2000, GENE DEV, V14, P1693; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Grossman A, 1996, GENOMICS, V37, P229, DOI 10.1006/geno.1996.0547; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; Gupta S, 1998, J IMMUNOL, V161, P5997; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Huang H, 1998, J EXP MED, V187, P1305, DOI 10.1084/jem.187.8.1305; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Li-Weber M, 1998, J IMMUNOL, V161, P1380; Li-Weber M, 1997, IMMUNOBIOLOGY, V198, P170, DOI 10.1016/S0171-2985(97)80038-1; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; LIDA S, 1997, NAT GENET, V17, P226; LiWeber M, 1997, J IMMUNOL, V158, P1194; Lohoff M, 2002, P NATL ACAD SCI USA, V99, P11808, DOI 10.1073/pnas.182425099; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Noble A, 2000, IMMUNOLOGY, V101, P289, DOI 10.1046/j.1365-2567.2000.00133.x; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Pernis AB, 2002, J INTERF CYTOK RES, V22, P111, DOI 10.1089/107999002753452728; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Schuh K, 1998, EUR J IMMUNOL, V28, P2456, DOI 10.1002/(SICI)1521-4141(199808)28:08<2456::AID-IMMU2456>3.0.CO;2-9; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; Solymar DC, 2002, IMMUNITY, V17, P41, DOI 10.1016/S1074-7613(02)00334-5; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Thanos D, 1996, HYPERTENSION, V27, P1025, DOI 10.1161/01.HYP.27.4.1025; Wenner CA, 1997, J IMMUNOL, V158, P765; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	59	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49238	49246		10.1074/jbc.M205895200	http://dx.doi.org/10.1074/jbc.M205895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12374808	hybrid			2022-12-25	WOS:000180028900018
J	Bettahi, H; Marker, CL; Roman, MI; Wickman, K				Bettahi, H; Marker, CL; Roman, MI; Wickman, K			Contribution of the Kir3.1 subunit to the muscarinic-gated atrial potassium channel I-KACh	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; BETA-GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION; MOLECULAR-PROPERTIES; TRANSGENIC MICE; HEART-RATE; KNOCKOUT; PROTEINS; DESENSITIZATION; STOICHIOMETRY	The muscarinic-gated atrial potassium (I-KACh) channel contributes to the heart rate decrease triggered by the parasympathetic nervous system. I-KACh is a heteromultimeric complex formed by Kir3.1 and Kir3.4 subunits, although Kir3.4 homomultimers have also been proposed to contribute to this conductance. While Kir3.4 homomultimers evince many properties of I-KACh, the contribution of Kir3.1 to I-KACh is less well understood. Here, we explored the significance of Kir3.1 using knock-out mice. Kir3.1 knock-out mice were viable and appeared normal. The loss of Kir3.1 did not affect the level of atrial Kir3.4 protein but was correlated with a loss of carbachol-induced current in atrial myocytes. Low level channel activity resembling recombinant Kir3.4 homomultimers was observed in 40% of the cell-attached patches from Kir3.1 knock-out myocytes. Channel activity typically ran down quickly, however, and was not recovered in the inside-out configuration despite the addition of GTP and ATP to the bath. Both Kir3.1 knock-out and Kir3.4 knock-out mice exhibited mild resting tachycardias and blunted responses to pharmacological manipulation intended to activate I-KACh. We conclude that Kir3.1 confers properties to I-KACh that enhance channel activity and that Kir3.4 homomultimers do not contribute significantly to the muscarinic-gated potassium current.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wickman, K (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Wickman, Kevin/0000-0002-5179-9540; Marker, Cheryl/0000-0003-4676-5853	NIMH NIH HHS [R01 MH61933, R01 MH061933] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061933] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bender K, 2001, J BIOL CHEM, V276, P28873, DOI 10.1074/jbc.M102328200; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; GUPTA RC, 1994, AM J PHYSIOL, V266, pH1138, DOI 10.1152/ajpheart.1994.266.3.H1138; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jelacic TM, 2000, J BIOL CHEM, V275, P36211, DOI 10.1074/jbc.M007087200; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Johansson C, 1997, ACTA PHYSIOL SCAND, V160, P133, DOI 10.1046/j.1365-201X.1997.00134.x; Kim D, 1997, AM J PHYSIOL-HEART C, V272, pH195, DOI 10.1152/ajpheart.1997.272.1.H195; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Kovoor P, 2001, J AM COLL CARDIOL, V37, P2136, DOI 10.1016/S0735-1097(01)01304-3; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; Neumann J, 1995, EUR J PHARMACOL, V294, P451, DOI 10.1016/0014-2999(95)00569-2; Neumann J, 1998, EUR J PHARMACOL, V350, P189, DOI 10.1016/S0014-2999(98)00235-0; Picciotto MR, 1998, PHYSIOL REV, V78, P1131, DOI 10.1152/physrev.1998.78.4.1131; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; ROHRER D, 1996, P NATL ACAD SCI USA, V93, P7357; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Torrecilla M, 2002, J NEUROSCI, V22, P4328, DOI 10.1523/JNEUROSCI.22-11-04328.2002; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Wickman K, 2002, GENE, V284, P241, DOI 10.1016/S0378-1119(01)00884-8; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	36	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48282	48288		10.1074/jbc.M209599200	http://dx.doi.org/10.1074/jbc.M209599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374786	hybrid			2022-12-25	WOS:000179789600042
J	Schlomann, U; Wildeboer, D; Webster, A; Antropova, O; Zeuschner, D; Knight, CG; Docherty, AJP; Lambert, M; Skelton, L; Jockusch, H; Bartsch, JW				Schlomann, U; Wildeboer, D; Webster, A; Antropova, O; Zeuschner, D; Knight, CG; Docherty, AJP; Lambert, M; Skelton, L; Jockusch, H; Bartsch, JW			The metalloprotease disintegrin ADAM8 - Processing by autocatalysis is required for proteolytic activity and cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; INTRACELLULAR MATURATION; SECRETASE CLEAVAGE; GENE FAMILY; PROTEIN; DOMAIN; SURFACE; CLONING; TACE	ADAMs (a disintegrin and metalloprotease domains) are metalloprotease and disintegrin domain-containing transmembrane glycoproteins with proteolytic, cell adhesion, cell fusion, and cell signaling properties. ADAM8 was originally cloned from monocytic cells, and its distinct expression pattern indicates possible roles in both immunology and neuropathology. Here we describe our analysis of its biochemical properties. In transfected COS-7 cells, ADAM8 is localized to the plasma membrane and processed into two forms derived either by prodomain removal or as remnant protein comprising the extracellular region with the disintegrin domain at the N terminus. Proteolytic removal of the ADAM8 propeptide was completely blocked in mutant ADAM8 with a Glu(330) to Gln exchange (EQ-A8) in the Zn2+ binding motif (HE(330)LGHNLGMSHD), arguing for autocatalytic prodomain removal. In co-transfection experiments, the ectodomain but not the entire MP domain of ADAM8 was able to remove the prodomain from EQ-ADAM8. With cells expressing ADAM8, cell adhesion to a substrate-bound recombinant ADAM8 disintegrin/Cys-rich domain was observed in the absence of serum, blocked by an antibody directed against the ADAM8 disintegrin domain. Soluble ADAM8 protease, consisting of either the metalloprotease domain or the complete ectodomain, cleaved myelin basic protein and a fluorogenic peptide substrate, and was inhibited by batimastat (BB-94, IC50 similar to50 nM) but not by recombinant tissue inhibitor of matrix metalloproteinases 1, 2, 3, and 4. Our findings demonstrate that ADAM8 processing by autocatalysis leads to a potential sheddase and to a form of ADAM8 with a function in cell adhesion.	Univ Bielefeld, D-33501 Bielefeld, Germany; Celltech R&D, Slough SL1 4EN, Berks, England; Univ Munster, Inst Med Biochem, Ctr Mol Biol Inflammat, ZMBE, D-4400 Munster, Germany; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Bielefeld; Celltech Group Ltd; University of Munster; University of Cambridge	Bartsch, JW (corresponding author), Univ Bielefeld, D-33501 Bielefeld, Germany.		Schlomann, Uwe/F-6419-2012; Bartsch, Joerg Walter/AAB-2951-2020	Bartsch, Prof. Joerg Walter/0000-0002-2773-3357				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHANTRY A, 1989, J BIOL CHEM, V264, P21603; Choi SJ, 2001, J BONE MINER RES, V16, P814, DOI 10.1359/jbmr.2001.16.5.814; Clarke HRG, 1998, PROTEIN EXPRES PURIF, V13, P104, DOI 10.1006/prep.1998.0861; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Sagane K, 1999, GENE, V236, P79, DOI 10.1016/S0378-1119(99)00253-X; Schlomann U, 2000, J NEUROSCI, V20, P7964; Schluesener HJ, 1998, J NEUROIMMUNOL, V87, P197, DOI 10.1016/S0165-5728(98)00080-0; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	39	126	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48210	48219		10.1074/jbc.M203355200	http://dx.doi.org/10.1074/jbc.M203355200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372841	hybrid			2022-12-25	WOS:000179789600033
J	Xu, XM; Shi, YC; Gao, W; Mao, GZ; Zhao, GJ; Agrawal, S; Chisolm, GM; Sui, DX; Cui, MZ				Xu, XM; Shi, YC; Gao, W; Mao, GZ; Zhao, GJ; Agrawal, S; Chisolm, GM; Sui, DX; Cui, MZ			The novel presenilin-1-associated protein is a proapoptotic mitochondrial protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; EXPRESSING MUTANT PRESENILIN-1; PERTURBED CALCIUM HOMEOSTASIS; IN-VIVO; INDUCED APOPTOSIS; CELL-DEATH; NEURONAL DIFFERENTIATION; PRECURSOR PROTEIN; TRANSGENIC MICE	Recent studies have suggested a possible role for presenilin proteins in apoptotic cell death observed in Alzheimer's disease. The mechanism by which presenilin proteins regulate apoptotic cell death is not well understood. Using the yeast two-hybrid system, we previously isolated a novel protein, presenilin-associated protein (PSAP) that specifically interacts with the C terminus of presenilin 1 (PSI), but not presenilin 2 (PS2). Here we report that PSAP is a mitochondrial resident protein sharing homology with mitochondrial carrier protein. PSAP was detected in a mitochondria-enriched fraction, and PSAP immunofluorescence was present in a punctate pattern that colocalized with a mitochondrial marker. More interestingly, overexpression of PSAP caused apoptotic death. PSAP-induced apoptosis was documented using multiple independent approaches, including membrane blebbing, chromosome condensation and fragmentation, DNA laddering, cleavage of the death substrate poly(ADP-ribose) polymerase, and flow cytometry. PSAP-induced cell death was accompanied by cytochrome c release from mitochondria and caspase-3 activation. Moreover, the general caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, which blocked cell death, did not block the release of cytochrome c from mitochondria caused by overexpression of PSAP, indicating that PSAP-induced cytochrome c release was independent of caspase activity. The mitochondrial localization and proapoptotic activity of PSAP suggest that it is an important regulator of apoptosis.	Univ Tennessee, Coll Vet Med, Dept Pathol, Knoxville, TN 37996 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Cleveland Clinic Foundation; Michigan State University	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathol, 2407 River Dr, Knoxville, TN 37996 USA.			Cui, Mei-Zhen/0000-0003-4745-6999; xu, xuemin/0000-0002-7426-272X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582] Funding Source: Medline; NINDS NIH HHS [NS37869, NS42314] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Alberici A, 1999, J BIOL CHEM, V274, P30764, DOI 10.1074/jbc.274.43.30764; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ankarcrona M, 2002, BIOCHEM BIOPH RES CO, V295, P766, DOI 10.1016/S0006-291X(02)00735-0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bursztajn S, 1998, J NEUROSCI, V18, P9790; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hong CS, 1999, J NEUROSCI, V19, P637; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Keller JN, 1998, J NEUROSCI, V18, P4439; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mattson MP, 2000, J NEUROSCI, V20, P1358; McCarthy NJ, 1998, CURR TOP DEV BIOL, V36, P259; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Sramkoski RM, 1999, CYTOMETRY, V35, P274, DOI 10.1002/(SICI)1097-0320(19990301)35:3<274::AID-CYTO11>3.0.CO;2-O; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vezina J, 1999, NEUROSCI LETT, V263, P65, DOI 10.1016/S0304-3940(99)00097-X; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Wang XD, 2001, GENE DEV, V15, P2922; Weihl CC, 1999, J NEUROSCI, V19, P5360; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1998, NEUROBIOL AGING, V19, pS23, DOI 10.1016/S0197-4580(98)00041-4; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhou Y, 2002, NEUROBIOL DIS, V9, P126, DOI 10.1006/nbdi.2001.0472	62	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48913	48922		10.1074/jbc.M209613200	http://dx.doi.org/10.1074/jbc.M209613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377771	hybrid			2022-12-25	WOS:000179789600122
J	Zhao, YL; Piao, CQ; Hei, TK				Zhao, YL; Piao, CQ; Hei, TK			Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells	ONCOGENE			English	Article						asbestos; Betaig-h3; tumor suppression; human bronchial epithelial cells	GROWTH-FACTOR-BETA; SMOOTH-MUSCLE; MALIGNANT MESOTHELIOMA; EXTRACELLULAR-MATRIX; MAMMALIAN-CELLS; IN-VITRO; BETA-IG-H3; LOCALIZATION; EXPRESSION; PROTEIN	Although Betaig-h3 gene has been suggested to modulate cell adhesion and tumor formation, its physiological functions are not well understood. Using human papillomavirus immortalized human bronchial epithelial (BEP2D) cells, we found that Betaig-h3 expression was markedly decreased in asbestos-induced tumorigenic cells. Fusion of tumorigenic and control BEP2D cells resulted in the recovery of Betaig-h3 gene expression to control level and the loss of tumorigenic phenotype. Furthermore, ectopic expression of Betaig-h3 gene in asbestos-induced tumorigenic cells inhibited cell growth in vitro, anchorage independent phenotype, as well as tumorigenicity in nude mice. Betaig-h3 gene is ubiquitously expressed in various normal human tissues, with the exception of the brain, where there is little or no expression. In contrast, there was a decrease or absence in expression of the Betaig-h3 gene in 14 human tumor cell lines of diverse histological types examined, when compared with normal human cells or tissues. The result strongly suggests that loss of Betaig-h3 expression is a frequent event in human cancer and causally related to acquisition of tumorigenic phenotype in asbestos-treated BEP2D cells.	Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Joseph Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Zhao, YL (corresponding author), Columbia Univ, Coll Phys & Surg, Joseph Mailman Sch Publ Hlth, Ctr Radiol Res, VC 11-128,630 W 168th St, New York, NY 10032 USA.	yz93@columbia.edu			NCI NIH HHS [CA49062] Funding Source: Medline; NIEHS NIH HHS [P30 ES 09089, ES07890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES007890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; Brezinova J, 2000, CANCER GENET CYTOGEN, V117, P45, DOI 10.1016/S0165-4608(99)00142-9; Brody AR, 1997, ENVIRON HEALTH PERSP, V105, P1165, DOI 10.2307/3433527; Bron AJ, 2000, CORNEA, V19, P699, DOI 10.1097/00003226-200009000-00015; FEARON ER, 1995, CANCER SURV, V24, P3; FITZPATRICK DR, 1995, AM J RESP CELL MOL, V12, P455, DOI 10.1165/ajrcmb.12.5.7742009; Genini M, 1996, INT J CANCER, V66, P571; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; HEI TK, 1992, CANCER RES, V52, P6305; Hei TK, 2000, INHAL TOXICOL, V12, P141, DOI 10.1080/08958378.2000.11463207; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; HEINTZ NH, 1993, P NATL ACAD SCI USA, V90, P3299, DOI 10.1073/pnas.90.8.3299; Jagirdar J, 1997, ENVIRON HEALTH PERSP, V105, P1197, DOI 10.2307/3433532; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; Kamp DW, 1999, THORAX, V54, P638, DOI 10.1136/thx.54.7.638; Kane AB, 1996, IARC SCI PUBL, P11; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Ni ZY, 2000, MUTAT RES-GEN TOX EN, V468, P87, DOI 10.1016/S1383-5718(00)00043-7; Pass HI, 1996, J CELL BIOCHEM, P142; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; PERDUE TD, 1994, J HISTOCHEM CYTOCHEM, V42, P1061, DOI 10.1177/42.8.8027525; Piao CQ, 2001, ONCOGENE, V20, P7301, DOI 10.1038/sj.onc.1204908; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Salih HR, 2001, EUR J MED RES, V6, P323; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Suzuki M, 2001, INT J MOL MED, V8, P43; WILLEY JC, 1991, CANCER RES, V51, P5370; Wu XF, 1998, INT J CANCER, V79, P490, DOI 10.1002/(SICI)1097-0215(19981023)79:5<490::AID-IJC8>3.3.CO;2-D; Xu A, 1999, CANCER RES, V59, P5922; Zanella CL, 1996, CANCER RES, V56, P5334; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	37	54	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7471	7477		10.1038/sj.onc.1205891	http://dx.doi.org/10.1038/sj.onc.1205891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386809				2022-12-25	WOS:000178618200002
J	del Prete, MJ; Robles, MS; Guio, A; Martinez, C; Izquierdo, M; Garcia-Sanz, JA				del Prete, MJ; Robles, MS; Guio, A; Martinez, C; Izquierdo, M; Garcia-Sanz, JA			Degradation of cellular mRNA is a general early apoptosis-induced event	FASEB JOURNAL			English	Article						RNA metabolism; caspase inhibitors; signaling pathways; in vivo apoptosis	ACTIVATION-INDUCED APOPTOSIS; 28S RIBOSOMAL-RNA; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; T-CELLS; DEATH; LYMPHOCYTE; RECEPTOR; CASPASE; FAS	The fate of cellular mRNAs was analyzed in several cell lines of lymphoid origin, after induction of apoptosis by different mechanisms. Cytoplasmic mRNAs are specifically degraded as part of the early apoptotic response. This degradation is not species restricted and is independent of the cell line, the apoptotic stimulus, the intrinsic half-life of the mRNAs, and the transcriptional status of the gene (constitutive or inducible). mRNA degradation precedes DNA fragmentation and correlates with the appearance of phosphatidylserine in the outer cell membrane. In addition, apoptosis-induced mRNA degradation is an active process that can be dissected from other apoptotic hallmarks (degradation of annexin V, DNA, and poly(ADP-ribose) polymerase [PARP]), which suggests that apoptosis-induced mRNA degradation is controlled by a distinct signaling pathway. Furthermore, mRNA degradation also occurs in vivo, specifically during thymocyte apoptosis. Taken together, these data support the notion that degradation of mRNA is a general early apoptotic event that may become a new apoptotic hallmark.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Valladolid, Fac Med, CSIC, Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Garcia-Sanz, JA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco UAM, E-28049 Madrid, Spain.	jasanz@cnb.uam.es	Robles, Maria S/D-6307-2015; Garcia-Sanz, Jose A./AAA-2956-2019; Robles, Maria/ABH-1497-2020; Izquierdo, Manuel/D-2971-2017; Izquierdo, Manuel/I-4812-2013; Garcia-Sanz, Jose A/E-7684-2011; Izquierdo, Manuel/I-4812-2013	Robles, Maria S/0000-0001-9149-8761; Garcia-Sanz, Jose A./0000-0002-1153-6025; Robles, Maria/0000-0001-9149-8761; Izquierdo, Manuel/0000-0002-7701-1002; Izquierdo, Manuel/0000-0002-7701-1002; Garcia-Sanz, Jose A/0000-0002-1153-6025; Izquierdo, Manuel/0000-0002-7261-404X; Guio-Carrion, Ana/0000-0002-8963-4389				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P1295, DOI 10.1016/S0891-5849(96)00544-8; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; GARCIASANZ JA, 1993, EUR J IMMUNOL, V23, P1877, DOI 10.1002/eji.1830230822; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; Gonalons E, 1998, J IMMUNOL, V161, P1837; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hieronymus T, 2000, CELL DEATH DIFFER, V7, P538, DOI 10.1038/sj.cdd.4400684; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Izquierdo M, 1996, J IMMUNOL, V157, P21; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LANIER LL, 1981, J IMMUNOL, V127, P1691; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; MAMALAKI C, 1993, INT IMMUNOL, V5, P1285, DOI 10.1093/intimm/5.10.1285; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PING L, 1992, J IMMUNOL, V148, P3354; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Rutjes SK, 1999, J BIOL CHEM, V274, P24799, DOI 10.1074/jbc.274.35.24799; Samali A, 1997, CELL DEATH DIFFER, V4, P289, DOI 10.1038/sj.cdd.4400246; SANTIS AG, 1995, EUR J IMMUNOL, V25, P2142, DOI 10.1002/eji.1830250804; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shortman K, 1990, Semin Immunol, V2, P3; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SULVERMAN RH, 1997, RIBONUCLEASES STRUCT, P515; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	65	49	54	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2003	+		10.1096/fj.02-0392fje	http://dx.doi.org/10.1096/fj.02-0392fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397088	Green Submitted			2022-12-25	WOS:000179167600015
J	Usuda, J; Chiu, SM; Murphy, ES; Lam, M; Nieminen, AL; Oleinick, NL				Usuda, J; Chiu, SM; Murphy, ES; Lam, M; Nieminen, AL; Oleinick, NL			Domain-dependent photodamage to Bcl-2 - A membrane anchorage region is needed to form the target of phthalocyanine photosensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAK; PROGRAMMED CELL-DEATH; PHOTODYNAMIC THERAPY; MITOCHONDRIAL-MEMBRANE; MEDIATED APOPTOSIS; DNA-REPAIR; IN-VIVO; OVEREXPRESSION; LOCALIZATION; ACTIVATION	Photodynamic therapy using the photosensitizer Pc 4 and red light photochemically destroys the antiapoptotic protein Bcl-2 and induces apoptosis. To characterize the requirements for photodamage, we transiently transfected epitope-tagged Bcl-2 deletion mutants into DU-145 cells. Using confocal microscopy and Western blots, wild-type Bcl-2 and mutants with deletions near the N terminus were found in mitochondria, endoplasmic reticulum., and nuclear membranes and were photodamaged. A mutant missing the C terminus, including the transmembrane domain, spread diffusely in cells and was not photodamaged. Bcl-2 missing a-helices 5/6 was also not photodamaged. Bcl-2 missing only one of those a-helices, with or without substitutions of the singlet oxygen-targeted amino acids, behaved like wild-type Bcl-2 with respect to localization and photodamage. Using green fluorescent protein (GFP)-tagged Bcl-2 or mutants in live cells, no change in either the localization or the intensity of GFP fluorescence was observed in response to Pc 4 photodynamic therapy. Western blot analysis of either GFP- or Xpress-tagged Bcl-2 revealed that the photodynamic therapy-induced disappearance of the Bcl-2 band was accompanied by the appearance of bands indicative of heavily cross-linked Bcl-2 protein. Therefore, the alpha(5)/alpha(6) region of Bcl-2 is required for photodamage and cross-linking, and domain-dependent photodamage to Bcl-2 offers a unique mechanism for activation of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave,BRB 324, Cleveland, OH 44106 USA.				NCI NIH HHS [R01 CA83971, P30 CA43730, P01 CA48735] Funding Source: Medline; NINDS NIH HHS [NS39469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGARWAL ML, 1991, CANCER RES, V51, P5993; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi WS, 2000, J NEUROCHEM, V74, P1621, DOI 10.1046/j.1471-4159.2000.0741621.x; Conus S, 2000, EMBO J, V19, P1534, DOI 10.1093/emboj/19.7.1534; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; DOUGHERTY TJ, 1978, CANCER RES, V38, P2628; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HALLIWELL B, 1989, FREE RADICAL BIO MED, P66; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim HRC, 1999, CANCER RES, V59, P3429; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KVAM E, 1994, PHOTOCHEM PHOTOBIOL, V59, P437, DOI 10.1111/j.1751-1097.1994.tb05061.x; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Morliere P, 1998, CANCER RES, V58, P3571; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rousset N, 2000, J PHOTOCH PHOTOBIO B, V56, P118, DOI 10.1016/S1011-1344(00)00053-1; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Usuda J, 2002, PHOTOCHEM PHOTOBIOL, V76, P217, DOI 10.1562/0031-8655(2002)076<0217:POPTIA>2.0.CO;2; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441	50	100	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					2021	2029		10.1074/jbc.M205219200	http://dx.doi.org/10.1074/jbc.M205219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12379660	hybrid			2022-12-25	WOS:000180462200087
J	Brzeski, J; Jerzmanowski, A				Brzeski, J; Jerzmanowski, A			Deficient in DNA methylation 1 (DDM1) defines a novel family of chromatin-remodeling factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; N-TERMINAL DOMAINS; HISTONE MODIFICATIONS; SNF2 FAMILY; IN-VITRO; ARABIDOPSIS; ISWI; TRANSCRIPTION; COMPLEXES; THALIANA	Deficient in DNA Methylation 1 (DDM1) protein is required to maintain the DNA methylation status of Arabidopsis thaliana. DDMI is a member of the broad SW12/SNF2 protein family. Because of its phylogenetic position, DDMI has been speculated to act as a chromatin-remodeling factor. Here we used a purified recombinant DDM1 protein to investigate whether it can remodel chromatin in vitro. We show that DDMI is an ATPase stimulated by both naked and nucleosomal DNA. DDM1 binds to the nucleosome and promotes chromatin remodeling in an ATP-dependent manner. Specifically, it induces nucleosome repositioning on a short DNA fragment. The enzymatic activity of DDM1 is not affected by DNA methylation. The relevance of these findings to the in vivo role of DDM1 is discussed.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Warsaw Univ, Lab Plant Mol Biol, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Warsaw	Brzeski, J (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	jbrzeski@ibb.waw.pl						Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Darst RP, 2001, EMBO J, V20, P2028, DOI 10.1093/emboj/20.8.2028; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hirochika H, 2000, PLANT CELL, V12, P357, DOI 10.1105/tpc.12.3.357; Imhof A, 2001, MOL BIOTECHNOL, V17, P1, DOI 10.1385/MB:17:1:01; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kishimoto N, 2001, PLANT MOL BIOL, V46, P171, DOI 10.1023/A:1010636222327; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Mizuguchi G, 2001, J BIOL CHEM, V276, P14773, DOI 10.1074/jbc.M100125200; Moggs JG, 1999, BIOCHIMIE, V81, P45, DOI 10.1016/S0300-9084(99)80037-6; Morel JB, 2000, CURR BIOL, V10, P1591, DOI 10.1016/S0960-9822(00)00862-9; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Schlissel MS, 2000, SCIENCE, V287, P438, DOI 10.1126/science.287.5452.438; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Verbsky ML, 2001, CURR OPIN PLANT BIOL, V4, P494, DOI 10.1016/S1369-5266(00)00206-5; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wade PA, 1996, MOL CELL BIOL, V16, P1641; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Yoo EJ, 2000, NUCLEIC ACIDS RES, V28, P2004, DOI 10.1093/nar/28.9.2004; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	52	138	151	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					823	828		10.1074/jbc.M209260200	http://dx.doi.org/10.1074/jbc.M209260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12403775	hybrid			2022-12-25	WOS:000180321900019
J	Somerville, L; Krynetski, EY; Krynetskaia, NF; Beger, RD; Zhang, WX; Marhefka, CA; Evans, WE; Kriwacki, RW				Somerville, L; Krynetski, EY; Krynetskaia, NF; Beger, RD; Zhang, WX; Marhefka, CA; Evans, WE; Kriwacki, RW			Structure and dynamics of thioguanine-modified duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMINO PROTON-EXCHANGE; BASE-PAIR; MOLECULAR-DYNAMICS; MISMATCH REPAIR; 6-THIOGUANINE; MECHANISM; BINDING; ALTERS; NMR; SUBSTITUTION	Mercaptopurine and thioguanine, two of the most widely used antileukemic agents, exert their cytotoxic, therapeutic effects by being incorporated into DNA as deoxy-6-thioguanosine. However, the molecular mechanism(s) by which incorporation of these thiopurines into DNA translates into cytotoxicity is unknown. The solution structure of thioguanine-modified duplex DNA presented here shows that the effects of the modification on DNA structure were subtle and localized to the modified base pair. Specifically, thioguanine existed in the keto form, formed weakened Watson-Crick hydrogen bonds with cytosine and caused a modest similar to10degrees opening of the modified base pair toward the major groove. In contrast, thioguanine significantly altered base pair dynamics, causing an similar to80-fold decrease in the base pair lifetime with cytosine compared with normal guanine. This perturbation was consistent with the similar to6 degreesC decrease in DNA melting temperature of the modified oligonucleotide, the 1.13 ppm upfield shift of the thioguanine imino proton resonance, and the large increase in the exchange rate of the thioguanine imino proton with water. Our studies provide new mechanistic insight into the effects of thioguanine incorporation into DNA at the level of DNA structure and dynamics, provide explanations for the effects of thioguanine incorporation on the activity of DNA-processing enzymes, and provide a molecular basis for the specific recognition of thioguanine-substituted sites by proteins. These combined effects likely cooperate to produce the cellular responses that underlie the therapeutic effects of thiopurines.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Natl Ctr Toxicol Res, Div Chem, Jefferson, AR 72079 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Food & Drug Administration (FDA)	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	William.Evans@stjude.org; Richard.Kriwacki@stjude.org	Evans, William E./C-2069-2012; Kriwacki, Richard/N-8154-2018	Evans, William E./0000-0002-9333-5322; Kriwacki, Richard/0000-0002-9798-6018	NATIONAL CANCER INSTITUTE [R37CA036401] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA36401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham MH, 2001, J ORG CHEM, V66, P3484, DOI 10.1021/jo001765s; Arudchandran A, 2000, GENES CELLS, V5, P789, DOI 10.1046/j.1365-2443.2000.00373.x; Beger RD, 1998, J BIOL CHEM, V273, P15565, DOI 10.1074/jbc.273.25.15565; Berkhout B, 1999, J VIROL, V73, P2365, DOI 10.1128/JVI.73.3.2365-2375.1999; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cheatham TE, 1999, J BIOMOL STRUCT DYN, V16, P845, DOI 10.1080/07391102.1999.10508297; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; Dhavan GM, 1999, J MOL BIOL, V288, P659, DOI 10.1006/jmbi.1999.2690; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Eriksson MAL, 1999, J MED CHEM, V42, P868, DOI 10.1021/jm980277y; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Krishnamurthy VV, 1996, J MAGN RESON SER B, V113, P46, DOI 10.1006/jmrb.1996.0153; Krynetskaia NF, 1999, MOL PHARMACOL, V56, P841; Krynetskaia NF, 2001, FASEB J, V15, P1902, DOI 10.1096/fj.01-0124com; Krynetskaia NF, 2000, FASEB J, V14, P2339, DOI 10.1096/fj.00-0089com; Krynetski EY, 2001, MOL PHARMACOL, V59, P367, DOI 10.1124/mol.59.2.367; LEE SH, 1981, CANCER BIOCHEM BIOPH, V5, P189; LEIJON M, 1992, NUCLEIC ACIDS RES, V20, P5339, DOI 10.1093/nar/20.20.5339; LEPAGE GA, 1963, CANCER RES, V23, P1202; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LING YH, 1991, MOL PHARMACOL, V40, P508; LING YH, 1992, MOL PHARMACOL, V42, P802; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; Marathias VM, 1999, NUCLEIC ACIDS RES, V27, P2860, DOI 10.1093/nar/27.14.2860; MAYBAUM J, 1983, CANCER RES, V43, P3852; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; Nitiss JL, 1998, CONT CANC RES, P517; PAULING L, 1988, GEN CHEM, P197; RADHAKRISHNAN I, 1992, BIOCHEMISTRY-US, V31, P2514, DOI 10.1021/bi00124a011; Relling MV, 2001, NAT REV CANCER, V1, P99, DOI 10.1038/35101056; ROONGTA VA, 1990, BIOCHEMISTRY-US, V29, P5245, DOI 10.1021/bi00474a005; SAENGE RW, 1984, SPRINGER ADV TEXTS C, P185; Schmitz U, 1995, METHOD ENZYMOL, V261, P3; SHEFTER E, 1968, J PHARM SCI, V57, P1157, DOI 10.1002/jps.2600570714; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Sponer J, 1997, J PHYS CHEM A, V101, P9489, DOI 10.1021/jp9720404; Stefl R, 2001, BIOPHYS J, V80, P455, DOI 10.1016/S0006-3495(01)76028-6; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; WARREN DJ, 1995, CANCER RES, V55, P1670; WOTRING LL, 1980, CANCER RES, V40, P1458; Wuthrich K, 1986, NMR PROTEINS NUCL AC; XU YZ, 1992, TETRAHEDRON, V48, P1729, DOI 10.1016/S0040-4020(01)88731-7	49	86	89	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1005	1011		10.1074/jbc.M204243200	http://dx.doi.org/10.1074/jbc.M204243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401802	hybrid			2022-12-25	WOS:000180321900042
J	Sachchidanand; Lequin, O; Staunton, D; Mulloy, B; Forster, MJ; Yoshida, K; Campbell, ID				Sachchidanand; Lequin, O; Staunton, D; Mulloy, B; Forster, MJ; Yoshida, K; Campbell, ID			Mapping the heparin-binding site on the (13-14)F3 fragment of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; CELL-ADHESION; CRYSTAL-STRUCTURE; TYPE-2 MODULE; FORCE-FIELD; SULFATE; DOMAIN; RESIDUES; REGION; NMR	Fibronectin, a multifunctional glycoprotein of the extracellular matrix, plays a major role in cell adhesion. Various studies have revealed that the human 13th and 14th fibronectin type III domains (labeled (13)F3 and (14)F3 here) contain a heparin-binding site. Mapping of the heparin-binding sites of (13-14)F3, (13)F3, and (14)F3 by NMR chemical shift perturbation, isothermal titration calorimetry, and molecular modeling show that (13)F3 provides the dominant heparin-binding site and that the residues involved are within the first 29 amino acids of (13)F3. Predictions from earlier biochemical and modeling studies as well as the x-ray structure of (12-14)F3 were tested. It was shown that the positively charged residues that project into the solvent from the ABE face of the triple-stranded beta sheet on (13)F3 are involved in binding, but (14)F3 does not appear to contribute significantly to heparin binding.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Mizutani Fdn Glycosci, Chuo Ku, Tokyo 1030023, Japan	University of Oxford; University of Oxford; National Institute for Biological Standards & Control	Campbell, ID (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	idc@bioch.ox.ac.uk		LEQUIN, Olivier/0000-0001-5307-3068				AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; BANGHAM D R, 1959, Bull World Health Organ, V20, P1201; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BENTLEY KL, 1985, J BIOL CHEM, V260, P7250; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Conrad H. E., 1998, HEPARIN BINDING PROT; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; COUCHMAN JR, 1990, J INVEST DERMATOL, V94, pS7, DOI 10.1111/1523-1747.ep12874973; DALTON BA, 1995, J CELL SCI, V108, P2083; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HYNES RO, 1984, CIBA F SYMP, V108, P75; Hynes RO, 1990, FIBRONECTINS; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MA YH, 1994, J LIPID RES, V35, P2049; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Mosher DF, 1989, FIBRONECTIN; Mostafavi-Pour Z, 2001, MATRIX BIOL, V20, P63, DOI 10.1016/S0945-053X(00)00131-1; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; POTTS JR, 1995, NAT STRUCT BIOL, V2, P946, DOI 10.1038/nsb1195-946; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P4359; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Sticht H, 1998, J MOL BIOL, V276, P177, DOI 10.1006/jmbi.1997.1528; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	66	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50629	50635		10.1074/jbc.M208956200	http://dx.doi.org/10.1074/jbc.M208956200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12377765	hybrid			2022-12-25	WOS:000180177700058
J	Takeuchi, H; Kobayashi, Y; Ishigaki, S; Doyu, M; Sobue, G				Takeuchi, H; Kobayashi, Y; Ishigaki, S; Doyu, M; Sobue, G			Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; ENDOPLASMIC-RETICULUM STRESS; CU,ZN-SUPEROXIDE DISMUTASE; ALZHEIMERS-DISEASE; HYALINE INCLUSIONS; HYDROGEN-PEROXIDE; MOTOR-NEURONS; LON PROTEASE; WILD-TYPE; APOPTOSIS	The mutations in superoxide dismutase 1 (SOD1) cause similar to20% of familial amyotrophic lateral sclerosis cases. A toxic gain of function has been considered to be the cause of the disease, but its molecular mechanism remains uncertain. To determine whether the subcellular localization of mutant SOD1 is crucial to mutant SOD1-mediated cell death, we produced neuronal cell models with accumulation of SOD1 in each subcellular fraction/organelle, such as the cytosol, nucleus, endoplasmic reticulum, and mitochondria. We showed that the localization of mutant SOD1 in the mitochondria triggered the release of mitochondrial cytochrome c followed by the activation of caspase cascade and induced neuronal cell death without cytoplasmic mutant SOD1 aggregate formation. Nuclear and endoplasmic reticulum localization of mutant SOD1 did not induce cell death. These results suggest that the localization of mutant SOD1 in the mitochondria is critical in the pathogenesis of mutant SOD1-associated familial amyotrophic lateral sclerosis.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		ISHIGAKI, Shinsuke/I-7305-2014	Takeuchi, Hideyuki/0000-0001-5912-7581; Ishigaki, Shinsuke/0000-0002-9555-0659				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beal MF, 2000, BRAIN, V123, P1291, DOI 10.1093/brain/123.7.1291; Bendotti C, 2001, J NEUROL SCI, V191, P25, DOI 10.1016/S0022-510X(01)00627-X; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Hirano A, 1996, NEUROLOGY, V47, pS63, DOI 10.1212/WNL.47.4_Suppl_2.63S; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ishigaki S, 2002, J NEUROCHEM, V82, P576, DOI 10.1046/j.1471-4159.2002.00998.x; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kong JM, 1998, J NEUROSCI, V18, P3241; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Mattson MP, 1998, J NEUROCHEM, V70, P1; Menzies FM, 2002, NEUROCHEM INT, V40, P543, DOI 10.1016/S0197-0186(01)00125-5; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shibata N, 1998, ACTA NEUROPATHOL, V95, P136, DOI 10.1007/s004010050777; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Takeuchi H, 2002, BRAIN RES, V949, P11, DOI 10.1016/S0006-8993(02)02568-4; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	52	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50966	50972		10.1074/jbc.M209356200	http://dx.doi.org/10.1074/jbc.M209356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393885	hybrid			2022-12-25	WOS:000180177700100
J	Yang, LK; Manithody, C; Rezaie, AR				Yang, LK; Manithody, C; Rezaie, AR			Localization of the heparin binding exosite of factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR IXA; PROTEIN-C ACTIVATION; FACTOR XA REACTION; BLOOD-COAGULATION; ANTITHROMBIN; THROMBIN; RESIDUES; INHIBITION; CALCIUM; DOMAIN	Factor IXa (FIXa) is known to have a binding site for heparin that has not been mapped by a mutagenesis study. By homology modeling based on structural data, we identified eight basic residues in the catalytic domain of FIXa that can potentially bind to heparin. These residues, Lys(98), Lys(126), Arg(165), Arg(170), Lys(173), Lys(230), Arg(233), and Lys(239) (chymotrypsin numbering) were substituted with Ala in separate constructs in Gla-domain-less forms. Following activation, it was found that all FIXa derivatives cleaved the chromogenic substrate CBS 31.39 with near normal catalytic efficiencies. Similarly, antithrombin inactivated FIXa derivatives with a similar second-order association rate constant (k(2)) in both the absence and presence of pentasaccharide. In the presence of a full-length heparin, however, k(2) values were dramatically impaired with certain mutants. Direct binding studies revealed that the same mutants lost their affinities for binding to heparin-Sepharose. Both kinetic and direct binding data indicated that five basic residues of FIXa in the following order of importance, Arg(233) > Arg(165) > Lys(230) > Lys(126) > Arg(170) are critical for binding to heparin. Consistent with these results, examination of the crystal structure of the catalytic domain of FIXa indicated that all five basic residues are spatially aligned in a manner optimal for interaction with heparin.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NHLBI NIH HHS [HL 68571, HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JAM, 2001, J BIOL CHEM, V276, P9755, DOI 10.1074/jbc.M010048200; BARROW RT, 1994, J BIOL CHEM, V269, P26796; BEDSTED T, 2002, 3 INT S SERP BIOL ST; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAN ZR, 1994, J BIOL CHEM, V269, P1301; He XH, 1997, BIOCHEMISTRY-US, V36, P8969, DOI 10.1021/bi9704717; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; Larson PJ, 1996, J BIOL CHEM, V271, P3869; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STENFLO J, 1991, BLOOD, V78, P1637; WIEBE E, 2001, THROMB HAEMOST S, pP2101; Wilkinson FH, 2002, J BIOL CHEM, V277, P5734, DOI 10.1074/jbc.M107753200; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; YE J, 1994, J BIOL CHEM, V269, P17965; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	33	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50756	50760		10.1074/jbc.M208485200	http://dx.doi.org/10.1074/jbc.M208485200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397068	hybrid			2022-12-25	WOS:000180177700073
J	Steen, M; Villoutreix, BO; Norstrom, EA; Yamazaki, T; Dahlback, B				Steen, M; Villoutreix, BO; Norstrom, EA; Yamazaki, T; Dahlback, B			Defining the factor Xa-binding site on factor Va by site-directed glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; ACTIVATED PROTEIN-C; THROMBIN-CATALYZED ACTIVATION; AMINO-ACID-SEQUENCE; FACTOR-VIII; FACTOR-IXA; COFACTOR FUNCTION; HEMOPHILIA-A; LIGHT-CHAIN; CLEAVAGE	Activated Factor V (FVa) functions as a membrane-bound cofactor to the enzyme Factor Xa (FXa) in the conversion of prothrombin to thrombin, increasing the catalytic efficiency of FXa by several orders of magnitude. To map regions on FVa that are important for binding of FXa, site-directed mutagenesis resulting in novel potential glycosylation sites on FV was used as strategy. The consensus sequence for N-linked glycosylation was introduced at sites, which according to a computer model of the A domains of FVa, were located at the surface of FV. In total, thirteen different regions on the FVa surface were probed, including sites that are homologous to FIXa-binding sites on FVIIIa. The interaction between the FVa variants and FXa and prothrombin were studied in a functional prothrombin activation assay, as well as in a direct binding assay between FVa and FXa. In both assays, the four mutants carrying a carbohydrate side chain at positions 467, 511, 652, or 1683 displayed attenuated FXa binding, whereas the prothrombin affinity was unaffected. The affinity toward FXa could be restored when the mutants were expressed in the presence of tunicamycin to inhibit glycosylation, indicating the lost FXa affinity to be caused by the added carbohydrates. The results suggested regions surrounding residues 467, 511, 652, and 1683 in FVa to be important for FXa binding. This indicates that the enzyme:cofactor assembly of the prothrombinase and the tenase complexes are homologous and provide a useful platform for further investigation of specific structural elements involved in the FVa-FXa complex assembly.	Lund Univ, Dept Clin Chem, Div Lab Med, Wallenberg Lab,Malmo Gen Hosp, SE-20502 Malmo, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France	Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Lund Univ, Dept Clin Chem, Div Lab Med, Wallenberg Lab,Malmo Gen Hosp, SE-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015	Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				Amano K, 1998, BLOOD, V91, P538, DOI 10.1182/blood.V91.2.538.538_538_548; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Celie PHN, 1999, BRIT J HAEMATOL, V106, P792, DOI 10.1046/j.1365-2141.1999.01590.x; Cook BC, 2000, J BIOL CHEM, V275, P38774, DOI 10.1074/jbc.M004573200; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ESMON CT, 1979, J BIOL CHEM, V254, P964; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Furie B.C., 1976, Methods Enzymol, V45, P191; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JENNY RJ, 1994, HAEMOSTASIS THROMBOS, P456; JORQUERA JI, 1992, CIRCULATION, V86, P685; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Katsumi A, 1996, BLOOD, V87, P4164, DOI 10.1182/blood.V87.10.4164.bloodjournal87104164; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nicolaes GAF, 1999, BIOCHEMISTRY-US, V38, P13584, DOI 10.1021/bi991165r; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; Steinberg M, 1987, HEMOSTASIS THROMBOSI, P112; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; TRACY PB, 1982, BLOOD, V60, P59; Ueda T, 1996, J BIOCHEM-TOKYO, V119, P157; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607	49	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50022	50029		10.1074/jbc.M205609200	http://dx.doi.org/10.1074/jbc.M205609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384508	hybrid			2022-12-25	WOS:000180028900120
J	Elmore, CL; Porter, TD				Elmore, CL; Porter, TD			Modification of the nucleotide cofactor-binding site of cytochrome P-450 reductase to enhance turnover with NADH in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NADH-CYTOCHROME-B5 REDUCTASE; NITRATE REDUCTASE; OXIDOREDUCTASE; DEHYDROGENASE; EXPRESSION; PROTOTYPE; SEQUENCE; BACTERIA; CLONING	NADPH-cytochrome P-450 reductase is the electron transfer partner for the cytochromes P-450, heme oxygenase, and squalene monooxygenase and is a component of the nitric-oxide synthases and methionine-synthase reductase. P-450 reductase shows very high selectivity for NADPH and uses NADH only poorly. Substitution of tryptophan 677 with alanine has been shown to yield a 3-fold increase in turnover with NADH, but profound inhibition by NADP(+) makes the enzyme unsuitable for in vivo applications. In the present study site-directed mutagenesis of amino acids in the 2'-phosphate-binding site of the NADPH domain, coupled with the W677A substitution, was used to generate a reductase that was able to use NADH efficiently without inhibition by NADP(+). Of 11 single, double, and triple mutant proteins, two (R597M/W677A and R597M/K602W/W677A) showed up to a 500-fold increase in catalytic efficiency (k(cat)/K-m) with NADH. Inhibition by NADP(+) was reduced by up to 4 orders of magnitude relative to the W677A protein and was equal to or less than that of the wildtype reductase. Both proteins were 2-3-fold more active than wild-type reductase with NADH in reconstitution assays with cytochrome P-450 1A2 and with squalene monooxygenase. In a recombinant cytochrome P-450 2E1 Ames bacterial mutagenicity assay, the R597M/W677A protein increased the sensitivity to dimethylnitrosamine by similar to2-fold, suggesting that the ability to use NADH afforded a significant advantage in this in vivo assay.	Univ Kentucky, Coll Pharm, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Porter, TD (corresponding author), Univ Kentucky, Coll Pharm, Grad Ctr Toxicol, Lexington, KY 40536 USA.				NIEHS NIH HHS [ES-07266] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; Cooper MT, 2000, MUTAT RES-FUND MOL M, V454, P45, DOI 10.1016/S0027-5107(00)00099-3; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Guengerich FP, 1995, ENVIRON HEALTH PERSP, V103, P25, DOI 10.2307/3432473; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; MITTL PRE, 1993, J MOL BIOL, V231, P191, DOI 10.1006/jmbi.1993.1274; OKAMOTO PM, 1991, MOL GEN GENET, V227, P213, DOI 10.1007/BF00259673; Porter TD, 1999, DRUG METAB REV, V31, P159, DOI 10.1081/DMR-100101912; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Shet MS, 1997, ARCH BIOCHEM BIOPHYS, V339, P218, DOI 10.1006/abbi.1996.9868; SLACK F, 1998, CURRENT PROTOCOLS MO, V42; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609	26	41	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48960	48964		10.1074/jbc.M210173200	http://dx.doi.org/10.1074/jbc.M210173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12381719	hybrid, Green Submitted			2022-12-25	WOS:000179789600128
J	Usacheva, A; Sandoval, R; Domanski, P; Kotenko, SV; Nelms, K; Goldsmith, MA; Colamonici, OR				Usacheva, A; Sandoval, R; Domanski, P; Kotenko, SV; Nelms, K; Goldsmith, MA; Colamonici, OR			Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA RECEPTOR; GROWTH-HORMONE RECEPTOR; SIGNAL TRANSDUCER GP130; ERYTHROPOIETIN RECEPTOR; BETA-CHAIN; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; TYROSINE KINASE; GAMMA RECEPTOR; PROTEIN	Kinases of the Jak family (Jak1/2/3 and Tyk2) interact with the membrane proximal domain of different cytokine receptors and play a critical role in the activation of cytokine and growth factor signaling pathways. In this report we demonstrate that both the Box 1 and Box 2 motif collaborate in the association and activation of Jak1 by type I interferons. Mutational analysis of the beta chain of type I interferon receptor (IFNalphaRbetaL/IFNAR2) revealed that Box 1 plays a more significant role in activation than in the association with Jak1. On the contrary, the Box 2 motif contributes more to the association with Jak1 than to kinase activation. Additionally, the study of the Jak1 binding sites on the IL2 receptor beta (IL2Rbeta), IFNgammaRalpha/IFNGR1, and IL10Ralpha/IL10R1 chains suggests that cytokine receptors have two different kinds of interaction with Jak1. One form of interaction involves the Box 1 and the previously described Box 2 motif, which we now designate as Box 2A, characterized by the VEVI and LEVL sequences present in IFNalphaRbetaL/IFNAR2 and IL2Rbeta subunits, respectively. The second form of interaction requires a motif termed Box 2B, which is present in the IFNgammaRalpha/IFNGR1 (SILLPKS) and IL10Ralpha/IL10R1 (SVLLFKK) chains. Interestingly, Box 2B localizes close to the membrane region (8-10 amino acids from the membrane) similar to Box 1, whereas Box 2A is more distal (38-58 amino acids from the membrane).	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Inhibitex Inc, Alpharretta, GA 30004 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; John Curtin Sch Med Res, Immunogenom Lab, Canberra, ACT 2601, Australia; Univ Calif San Francisco, Sch Med, San Francisco, CA 94106 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94106 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Australian National University; John Curtin School of Medical Research; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, M-C868,835 S Wolcott Ave,E403, Chicago, IL 60612 USA.		Usacheva, Anna/J-7543-2018	Usacheva, Anna/0000-0001-7508-6513	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709, R01GM054351] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54709, GM54351] Funding Source: Medline; PHS HHS [55079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLOSI P, 1993, J BIOL CHEM, V268, P12617; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; Hackett RH, 1997, J BIOL CHEM, V272, P11128; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; KOTENKO SV, 1997, EMBO J, V19, P5894; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Usacheva A, 2002, J IMMUNOL, V169, P1302, DOI 10.4049/jimmunol.169.3.1302; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1998, J BIOL CHEM, V273, P4046, DOI 10.1074/jbc.273.7.4046; Yan H, 1996, MOL CELL BIOL, V16, P2074; YIN TG, 1994, J BIOL CHEM, V269, P26614; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	37	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48220	48226		10.1074/jbc.M205757200	http://dx.doi.org/10.1074/jbc.M205757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374810	hybrid			2022-12-25	WOS:000179789600034
J	Wennerberg, K; Ellerbroek, SM; Liu, RY; Karnoub, AE; Burridge, K; Der, CJ				Wennerberg, K; Ellerbroek, SM; Liu, RY; Karnoub, AE; Burridge, K; Der, CJ			RhoG signals in parallel with Rac1 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NUCLEOTIDE EXCHANGE FACTORS; ACTIN STRESS FIBERS; DBL FAMILY; EXPRESSION CLONING; NEURITE OUTGROWTH; FOCAL ADHESIONS; ACTIVATES RAC1; C-JUN; RAS	RhoG is a member of the Rho family of small GTPases and shares high sequence identity with Rac1 and Cdc42. Previous studies suggested that RhoG mediates its effects through activation of Rac1 and Cdc42. To further understand the mechanism of RhoG signaling, we studied its potential activation pathways, downstream signaling properties, and functional relationship to Rac1 and Cdc42 in vivo. First, we determined that RhoG was regulated by guanine nucleotide exchange factors that also activate Rac and/or Cdc42. Vav2 (which activates RhoA, Rac1, and Cdc42) and to a lesser degree Dbs (which activates RhoA and Cdc42) activated RhoG in vitro. Thus, RhoG may be activated concurrently with Rac1 and Cdc42. Second, some effectors of Rac/Cdc42 (IQGAP2, MLK-3, PLD1), but not others (e.g. PAKs, POSH, WASP, Par-6, IRSp53), interacted with RhoG in a GTP-dependent manner. Third, consistent with this differential interaction with effectors, activated RhoG stimulated some (JNK and AM) but not other (SRF and NF-kappaB) downstream signaling targets of activated Rac1 and Cdc42. Finally, transient transduction of a tat-tagged Rac1(17N) dominant-negative fusion protein inhibited the induction of lamellipodia by the Rac-specific activator, Tiam1, but not by activated RhoG. Together, these data argue that RhoG function is mediated by signals independent of Rac1 and Cdc42 activation and instead by direct utilization of a subset of common effectors.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wennerberg, K (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	krister@med.unc.edu	Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA63071] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Blangy A, 2000, J CELL SCI, V113, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lambert JM, 2002, J BIOL CHEM, V277, P4770, DOI 10.1074/jbc.M109379200; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Vocero-Akbani A, 2001, METHOD ENZYMOL, V332, P36; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	56	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47810	47817		10.1074/jbc.M203816200	http://dx.doi.org/10.1074/jbc.M203816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12376551	Green Published, hybrid			2022-12-25	WOS:000179663700126
J	Shin, SY; Ko, JS; Chang, JS; Min, DS; Choi, C; Bae, SS; Kim, MJ; Hyun, DS; Kim, JH; Han, MY; Kim, YH; Kim, YS; Na, DS; Suh, PG; Lee, YH				Shin, SY; Ko, JS; Chang, JS; Min, DS; Choi, C; Bae, SS; Kim, MJ; Hyun, DS; Kim, JH; Han, MY; Kim, YH; Kim, YS; Na, DS; Suh, PG; Lee, YH			Negative regulatory role of overexpression of PLC gamma 1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts	FASEB JOURNAL			English	Article						Egr-1; tumor suppressor; PLG gamma 1 overexpression	TRANSCRIPTION FACTOR EGR-1; TERNARY COMPLEX FACTORS; PROTEIN-SYNTHESIS INHIBITORS; FIBROSARCOMA HT1080 CELLS; COLONY-STIMULATING FACTOR; PHOSPHOLIPASE C-GAMMA-1; C-FOS; TRANSFORMING GROWTH-FACTOR-BETA-1; DIFFERENTIAL REGULATION; ELEVATED CONTENT	The early growth response 1 (Egr-1) gene product is a transcription factor that functions as an oikis factor. Loss of Egr-1 expression is closely associated with tumor formation. Phospholipase Cgammal (PLCgamma1) is overexpressed in some tumors, and its overexpression causes anchorage-independent growth. Here we report that overexpression of PLCgammal and SH2-SH3 domain of PLCgamma1 decreased induction of Egr-1 and the Egr-1-regulated genes TSP-1 and PAI-1. Results from the nuclear run-on assay and transfection experiment with the proximal 455 base pair region of the Egr-1 promoter (-454 to +1) showed that Egr-1 transcriptional activity was suppressed in PLCgamma1-3Y1 cells whereas decay of Egr-1 mRNA was similar in both cell lines. Serum response element- and ternary complex factor Elk-l-mediated transcriptional activation of the reporter gene in response to EGF were also inhibited in PLCgamma1-3Y1 cells. Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgammal-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells. Our results demonstrated that overexpression of PLCgamma1 functions as a negative modulator of the tumor suppressor Egr-1 gene expression, possibly through inhibition of Elk-l-dependent transcriptional activity.	Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Nam Gu 705717, Daegu, South Korea; Kyungpook Natl Univ, Dept Microbiol, Taegu 702701, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Daejin Univ, Dept Biol, Pochon Gun 487800, Kyeonggido, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Chonnam Natl Univ, Res Inst Med Sci, Kwangju 501746, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Green Cross Inst Med Genet, Seoul 135260, South Korea; Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Clin Res Inst,Dept Psychiat, Seoul 151742, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea	Yeungnam University; Kyungpook National University; University of Ulsan; Daejin University; Catholic University of Korea; Chonnam National University; Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University Hospital; University of Ulsan	Lee, YH (corresponding author), Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, 317-1 Daemyung Dong, Nam Gu 705717, Daegu, South Korea.	younglee@med.yu.ac.kr	Suh, Pann-Ghill/F-3610-2010					ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; CAO XM, 1992, J BIOL CHEM, V267, P1345; Chang JS, 1997, CANCER RES, V57, P5465; Chen CY, 1996, MOL CELL BIOL, V16, P6582; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HUANG KJ, 1995, CHINESE J CHEM ENG, V3, P1; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Liao HJ, 2001, J BIOL CHEM, V276, P8627, DOI 10.1074/jbc.C100030200; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORELLO D, 1990, ONCOGENE, V5, P1511; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NANNEY LB, 1992, CELL GROWTH DIFFER, V3, P233; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PARK JG, 1994, CANCER RES, V54, P2240; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIM M, 1992, ONCOGENE, V7, P2065; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Shin SY, 2001, J BIOL CHEM, V276, P7797, DOI 10.1074/jbc.M009465200; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YEATMAN TJ, 1994, BIOCHEM BIOPH RES CO, V201, P1043, DOI 10.1006/bbrc.1994.1807; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	47	13	13	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1504	1514		10.1096/fj.02-0022com	http://dx.doi.org/10.1096/fj.02-0022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374773				2022-12-25	WOS:000179167600032
J	Burgi, S; Baltensperger, K; Honegger, UE				Burgi, S; Baltensperger, K; Honegger, UE			Antidepressant-induced switch of beta(1)-adrenoceptor trafficking as a mechanism for drug action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CLATHRIN-MEDIATED ENDOCYTOSIS; EXCHANGER REGULATORY FACTOR; BETA-ADRENERGIC RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; BETA-2-ADRENERGIC RECEPTORS; DOWN-REGULATION; DESIPRAMINE; DESENSITIZATION	Reduction in surface beta(1)-adrenoceptor (beta1AR) density is thought to play a critical role in mediating the therapeutic long term effects of antidepressants. Since antidepressants are neither agonists nor antagonists for G protein-coupled receptors, receptor density must be regulated through processes independent of direct receptor activation. Endocytosis and recycling of the beta1AR fused to green fluorescent protein at its carboxyl-terminus (beta1AR-GFP) were analyzed by confocal fluorescence microscopy of live cells and complementary ligand binding studies. In stably transfected C6 glioblastoma cells, beta1AR-GFP displayed identical ligand-binding isotherms and adenylyl cyclase activation as native beta1AR. Upon exposure to isoproterenol, a fraction of beta1AR-GFP (10-15%) internalized rapidly and colocalized with endocytosed transferrin receptors in an early endosomal compartment in the perinuclear region. Chronic treatment with the tricyclic antidepressant desipramine (DMI) did not affect internalization characteristics of beta1AR-GFP when challenged with isoproterenol. However, internalized receptors were not able to recycle back to the cell surface in DMI-treated cells, whereas recycling of transferrin receptors was not affected. Endocytosed receptors were absent from structures that stained with fluorescently labeled dextran, and inhibition of lysosomal protease activity did not restore receptor recycling, indicating that beta1AR-GFP did not immediately enter the lysosomal compartment. The data suggest a new mode of drug action causing a "switch" of receptor fate from a fast recycling pathway to a slowly exchanging perinuclear compartment. Antidepressant-induced reduction of receptor surface expression may thus be caused by modulation of receptor trafficking routes.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Honegger, UE (corresponding author), Univ Bern, Dept Pharmacol, Friedbuehlstr 49, CH-3010 Bern, Switzerland.	ulrich.honegger@pki.unibe.ch						ARGENTI D, 1994, NEUROPHARMACOLOGY, V33, P1117, DOI 10.1016/0028-3908(94)90151-1; BALDESSARINI RJ, 1989, J CLIN PSYCHIAT, V50, P117; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BANERJEE SP, 1977, NATURE, V268, P455, DOI 10.1038/268455a0; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Bevan N, 1999, FEBS LETT, V462, P61, DOI 10.1016/S0014-5793(99)01467-2; Bohm SK, 1997, BIOCHEM J, V322, P1; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Ferguson SSG, 1997, NEWS PHYSIOL SCI, V12, P145; FISHMAN PH, 1987, J NEUROCHEM, V49, P282, DOI 10.1111/j.1471-4159.1987.tb03427.x; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; FRIELLE T, 1988, TRENDS NEUROSCI, V11, P321, DOI 10.1016/0166-2236(88)90095-1; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GONZALEZNORIEGA A, 1993, ARCH BIOCHEM BIOPHYS, V306, P331, DOI 10.1006/abbi.1993.1519; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONEGGER UE, 1986, BIOCHEM PHARMACOL, V35, P1899, DOI 10.1016/0006-2952(86)90309-6; HONEGGER UE, 1983, J PHARMACOL EXP THER, V225, P436; HUANG LY, 1993, J BIOL CHEM, V268, P25769; Innamorati G, 1999, J RECEPT SIGNAL TR R, V19, P315, DOI 10.3109/10799899909036654; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kientsch U, 2001, PHARMACOPSYCHIATRY, V34, pS56, DOI 10.1055/s-2001-15452; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; MOOR M, 1988, BIOCHEM PHARMACOL, V37, P2035, DOI 10.1016/0006-2952(88)90553-9; Moore RH, 1999, J CELL SCI, V112, P329; MOORE RH, 1995, J CELL SCI, V108, P2983; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ORDWAY GA, 1988, J PHARMACOL EXP THER, V247, P379; PAUL IA, 1988, J PHARMACOL EXP THER, V246, P956; PEROUTKA SJ, 1980, SCIENCE, V210, P88, DOI 10.1126/science.6251550; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RIVA MA, 1989, MOL PHARMACOL, V36, P211; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; TOPLAK H, 1990, BIOCHEM PHARMACOL, V39, P1437, DOI 10.1016/0006-2952(90)90425-K; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; VETULANI J, 1975, NATURE, V257, P495, DOI 10.1038/257495a0; VON ZM, 1992, J BIOL CHEM, V267, P3530; WOLFE BB, 1978, J PHARMACOL EXP THER, V207, P446; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	61	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1044	1052		10.1074/jbc.M209972200	http://dx.doi.org/10.1074/jbc.M209972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12393876	hybrid			2022-12-25	WOS:000180321900047
J	Patel, NA; Eichler, DC; Chappell, DS; Illingworth, PA; Chalfant, CE; Yamamoto, M; Dean, NM; Wyatt, JR; Mebert, K; Watson, JE; Cooper, DR				Patel, NA; Eichler, DC; Chappell, DS; Illingworth, PA; Chalfant, CE; Yamamoto, M; Dean, NM; Wyatt, JR; Mebert, K; Watson, JE; Cooper, DR			The protein kinase C beta II exon confers mRNA instability in the presence of high glucose concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MESSENGER-RNA STABILITY; GROWTH-FACTOR; 3'-UNTRANSLATED REGION; BINDING-PROTEIN; INSULIN-LIKE; PROLIFERATION; IDENTIFICATION; EXPRESSION; ELEMENT	Previous studies showed that short term exposure of cells to high glucose destabilized protein kinase C (PKC) betaII mRNA, whereas PKCbetaI mRNA levels remained unaltered. Because PKCbeta mRNAs share common sequences other than the PKCbetaII exon encoding a different carboxyl terminus, we examined PKCbetaII mRNA for a cis-acting region that could confer glucose-induced destabilization. A beta-globin/growth hormone reporter con struct containing the PKCbetaII exon was transfected into human aorta and rat vascular smooth muscle cells (A10) to follow glucose-induced destabilization. Glucose (25 mm) exposure destabilized PKCbetaII chimeric mRNA but not control mRNA. Deletion analysis and electrophoretic mobility shift assays followed by UV cross-linking experiments demonstrated that a region introduced by inclusion of the betaII exon was required to confer destabilization. Although a cis-acting element mapped to 38 nucleotides within the betaII exon was necessary to bestow destabilization, it was not sufficient by itself to confer complete mRNA destabilization. Yet, in intact cells antisense oligonucleotides complementary to this region blocked glucose-induced destabilization. These results suggest that this region must function in context with other sequence elements created by exon inclusion involved in affecting mRNA stability. In summary, inclusion of an exon that encodes PKCbetaII mRNA introduces a cis-acting region that confers destabilization to the mRNA in response to glucose.	James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA; Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biol Mol, Tampa, FL 33612 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Isis Pharmaceuticals Inc; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cooper, DR (corresponding author), James A Haley Vet Hosp, Res Serv, VAR 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Eichler, Duane/A-1906-2012; Cooper, Denise R./A-4740-2012; Patel, Niketa/A-1392-2012	Patel, Niketa A./0000-0003-4811-8596	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054393] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amara FM, 1996, BIOCHEM BIOPH RES CO, V228, P347, DOI 10.1006/bbrc.1996.1664; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BONINI J, 1992, BIOTECHNIQUES, V11, P708; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1988, MOL CELL BIOL, V8, P1687; Canete-Soler R, 1998, J BIOL CHEM, V273, P12650, DOI 10.1074/jbc.273.20.12650; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COOPER DR, 1993, ARCH BIOCHEM BIOPHYS, V302, P490, DOI 10.1006/abbi.1993.1244; COOPER DR, 1993, ENDOCRINOLOGY, V133, P2241, DOI 10.1210/en.133.5.2241; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; HALLER H, 1995, KIDNEY INT, V47, P1057, DOI 10.1038/ki.1995.152; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KOSTURA M, 1986, BIOCHEMISTRY-US, V25, P6384, DOI 10.1021/bi00369a007; Kulkarni RD, 1997, MOL MICROBIOL, V24, P1131, DOI 10.1046/j.1365-2958.1997.4201768.x; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALMER LA, 2001, MOL CELL BIOL, V21, P2070; Patel NA, 1999, FASEB J, V13, P103, DOI 10.1096/fasebj.13.1.103; Patel NA, 2002, ARCH BIOCHEM BIOPHYS, V403, P111, DOI 10.1016/S0003-9861(02)00208-4; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS R, 1978, J CELL PHYSIOL, V97, P497, DOI 10.1002/jcp.1040970325; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHEPER W, 1995, MOL CELL BIOL, V15, P235, DOI 10.1128/MCB.15.1.235; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; STEINBERG RA, 1975, CELL, V5, P29, DOI 10.1016/0092-8674(75)90088-4; Yamamoto M, 1998, EXP CELL RES, V240, P349, DOI 10.1006/excr.1998.3999; Yamamoto M, 1999, INT J CANCER, V83, P98, DOI 10.1002/(SICI)1097-0215(19990924)83:1<98::AID-IJC18>3.0.CO;2-V; Yamamoto M, 2000, AM J PHYSIOL-CELL PH, V279, pC587, DOI 10.1152/ajpcell.2000.279.3.C587; YAMAMOTO M, 1998, J ANTI-AGING MED, V1, P207	34	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1149	1157		10.1074/jbc.M206797200	http://dx.doi.org/10.1074/jbc.M206797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12407109	hybrid			2022-12-25	WOS:000180321900060
J	Reinbothe, C; Buhr, F; Pollmann, S; Reinbothe, S				Reinbothe, C; Buhr, F; Pollmann, S; Reinbothe, S			In vitro reconstitution of light-harvesting POR-protochlorophyllide complex with protochlorophyllides a and b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE-L; CHLOROPHYLL-B; PROTEIN COMPLEX; ENERGY-TRANSFER; SPINACH-CHLOROPLASTS; ENVELOPE MEMBRANES; NADPH; OXIDOREDUCTASE; PURIFICATION; ARABIDOPSIS	NADPH:protochlorophyllide oxidoreductase (POR; EC 1.1.33.1) is a key enzyme for the light-induced greening of angiosperms. In barley, two POR proteins exist, termed PORA and PORB. These have previously been proposed to form higher molecular weight light-harvesting complexes in the prolamellar body of etioplasts (Reinbothe, C., Lebedev, N., and Reinbothe, S. (1999) Nature 397,80-84). Here we report the in vitro reconstitution of such complexes from chemically synthesized protochlorophyllides (Pchlides) a and b and galacto- and sulfolipids. Low temperature (77 K) fluorescence measurements revealed that the reconstituted, lipid-containing complex displayed the same characteristics of photoactive Pchlide 650/657 as the presumed native complex in the prolamellar body. Moreover, Pchlide F650/657 was converted to chlorophyllide (Chlide) 684/690 upon illumination of the reconstituted complex with a 1-ms flash of white light. Identification and quantification of acetone-extractable pigments revealed that only the PORB-bound Pchlide a had been photoactive and was converted to Chlide a, whereas Pchlide b bound to the PORA remained photoinactive. Nondenaturing PAGE of the reconstituted Pchlide a/b-containing complex further demonstrated a size similar to that of the presumed native complex in vivo, suggesting that both complexes may be identical.	Univ Bayreuth, Lehrstuhl Pflanzenphysiol, D-95447 Bayreuth, Germany; Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44801 Bochum, Germany; Univ Grenoble 1, UMR 5575, CERMO, F-38041 Grenoble 9, France; CNRS, UMR 5575, CERMO, F-38041 Grenoble 9, France	University of Bayreuth; Ruhr University Bochum; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Reinbothe, S (corresponding author), Univ Bayreuth, Lehrstuhl Pflanzenphysiol, Univ Str 30, D-95447 Bayreuth, Germany.	christiane.reinbothe@uni-bayreuth.de	Pollmann, Stephan/ABC-8203-2020; Reinbothe, Steffen/AAW-9893-2021; Pollmann, Stephan/C-2776-2009	Pollmann, Stephan/0000-0002-5111-4425; Pollmann, Stephan/0000-0002-5111-4425				APEL K, 1980, EUR J BIOCHEM, V111, P251, DOI 10.1111/j.1432-1033.1980.tb06100.x; Armstrong GA, 2000, TRENDS PLANT SCI, V5, P40, DOI 10.1016/S1360-1385(99)01513-7; BOARDMAN NK, 1962, BIOCHIM BIOPHYS ACTA, V62, P63, DOI 10.1016/0006-3002(62)90492-4; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; FRADKIN LI, 1993, PHOTOSYNTHETICA, V29, P227; Fraser PD, 2000, PLANT J, V24, P551, DOI 10.1111/j.1365-313X.2000.00896.x; GERHARDT R, 1984, PLANT PHYSIOL, V75, P542, DOI 10.1104/pp.75.3.542; GRIFFITHS WT, 1975, BIOCHEM J, V152, P623, DOI 10.1042/bj1520623; GRIFFITHS WT, 1978, BIOCHEM J, V174, P681, DOI 10.1042/bj1740681; HOLTORF H, 1995, P NATL ACAD SCI USA, V92, P3254, DOI 10.1073/pnas.92.8.3254; IGNATOV NV, 1981, BIOFIZIKA+, V26, P664; INNIS MA, 1990, PCR PROTOCOLS; JOYARD J, 1990, J BIOL CHEM, V265, P21820; KAHN A, 1970, J MOL BIOL, V48, P85, DOI 10.1016/0022-2836(70)90220-2; Klement H, 1999, EUR J BIOCHEM, V265, P862, DOI 10.1046/j.1432-1327.1999.00627.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lebedev N, 1999, P NATL ACAD SCI USA, V96, P9954, DOI 10.1073/pnas.96.17.9954; Lebedev N, 1995, PLANT CELL, V7, P2081, DOI 10.1105/tpc.7.12.2081; Maniatis T., 1982, MOL CLONING LAB MANU; MATHIS P, 1972, BIOCHIM BIOPHYS ACTA, V267, P498, DOI 10.1016/0005-2728(72)90178-8; MCFEETERS RF, 1971, PLANT PHYSIOL, V47, P609, DOI 10.1104/pp.47.5.609; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; PINEAU B, 1986, J BIOL CHEM, V261, P9210; Reinbothe C, 1997, P NATL ACAD SCI USA, V94, P8890, DOI 10.1073/pnas.94.16.8890; Reinbothe C, 1999, NATURE, V397, P80, DOI 10.1038/16283; REINBOTHE S, 1995, PLANT CELL, V7, P161, DOI 10.1105/tpc.7.2.161; Reinbothe S, 2003, J BIOL CHEM, V278, P800, DOI 10.1074/jbc.M209737200; REINBOTHE S, 1991, EUR J BIOCHEM, V198, P365, DOI 10.1111/j.1432-1033.1991.tb16024.x; REINBOTHE S, 1995, J CELL BIOL, V129, P299, DOI 10.1083/jcb.129.2.299; RYBERG M, 1982, PHYSIOL PLANTARUM, V56, P125, DOI 10.1111/j.1399-3054.1982.tb00313.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; Scheumann V, 1999, FEBS LETT, V445, P445, DOI 10.1016/S0014-5793(99)00169-6; SCHOCH S, 1995, EUR J BIOCHEM, V229, P291, DOI 10.1111/j.1432-1033.1995.tb20468.x; SCHULZ R, 1989, MOL GEN GENET, V217, P355, DOI 10.1007/BF02464904; SMITH JHC, 1954, PLANT PHYSIOL, V29, P135, DOI 10.1104/pp.29.2.135; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; Tomitani A, 1999, NATURE, V400, P159, DOI 10.1038/22101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN GD, 1974, BIOCHIM BIOPHYS ACTA, V347, P383, DOI 10.1016/0005-2728(74)90077-2; Xu H, 2002, J BIOL CHEM, V277, P42726, DOI 10.1074/jbc.M205237200; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298	43	37	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					807	815		10.1074/jbc.M209738200	http://dx.doi.org/10.1074/jbc.M209738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401790	hybrid			2022-12-25	WOS:000180321900017
J	Garcia, A; Sekowski, A; Subramanian, V; Brasaemle, DL				Garcia, A; Sekowski, A; Subramanian, V; Brasaemle, DL			The central domain is required to target and anchor perilipin A to lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEINS; STORAGE; TIP47; EXPRESSION; LIPOLYSIS; CAVEOLIN; BODIES; GOLGI; ADRP	The perilipins are the most abundant proteins coating the surfaces of lipid droplets in adipocytes and are found at lower levels surrounding lipid droplets in steroidogenic cells. Perilipins drive triacylglycerol storage in adipocytes by regulating the rate of basal lipolysis and are also required to maximize hormonally stimulated lipolysis. To map the domains that target and anchor perilipin A to lipid droplets, we stably expressed fragments of perilipin A in 3T3-L1 fibroblasts. Immunofluorescence microscopy and immunoblotting of proteins from isolated lipid droplets revealed that neither the amino nor the carboxyl terminus is required to target perilipin A to lipid droplets; however, there are multiple, partially redundant targeting signals within a central domain including 25% of the primary amino acid sequence. A peptide composed of the central domain of perilipin A directed a fused green fluorescent protein to the surfaces of lipid droplets. Full-length perilipin A associates with lipid droplets via hydrophobic interactions, as shown by the persistence of perilipins on lipid droplets after centrifugation through an alkaline carbonate solution. Results of the mutagenesis studies indicate that the sequences responsible for anchoring perilipin A to lipid droplets are most likely domains of moderately hydrophobic amino acids located within the central 25% of the protein. Thus, we conclude that the central 25% of the perilipin A sequence contains all of the amino acids necessary to target and anchor the protein to lipid droplets.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	brasaemle@aesop.rutgers.edu		Brasaemle, Dawn/0000-0002-8553-8285	NIDDK NIH HHS [DK54797] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 2001, J BIOL CHEM, V276, P24348, DOI 10.1074/jbc.M102468200; Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hanna J, 2002, P NATL ACAD SCI USA, V99, P7450, DOI 10.1073/pnas.112198799; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; PELHAM HRB, 1992, P ROY SOC B-BIOL SCI, V250, P1, DOI 10.1098/rspb.1992.0123; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200	34	86	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					625	635		10.1074/jbc.M206602200	http://dx.doi.org/10.1074/jbc.M206602200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407111	hybrid			2022-12-25	WOS:000180255700080
J	Manganello, JM; Huang, JS; Kozasa, T; Voyno-Yasenetskaya, TA; Le Breton, GC				Manganello, JM; Huang, JS; Kozasa, T; Voyno-Yasenetskaya, TA; Le Breton, GC			Protein kinase A-mediated phosphorylation of the G alpha(13) switch I region alters the G alpha beta gamma(13)-G protein-coupled receptor complex and inhibits Rho activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; DEPENDENT PHOSPHORYLATION; CRYSTAL-STRUCTURES; ALPHA-SUBUNIT; BINDING; DESENSITIZATION; IDENTIFICATION; PURIFICATION; RESOLUTION; MECHANISM	The present studies mapped the protein kinase A (PKA) phosphorylation site of Galpha(13) and studied the consequences of its phosphorylation. Initial experiments using purified human Galpha(13) and the PKA catalytic subunit established that PKA directly phosphorylates Galpha(13). The location of this phosphorylation site was next investigated with a new synthetic peptide (G(13)SRI(pep)) containing the PKA consensus sequence (Arg-Arg-Pro-Thr(203)) within the switch I region of Galpha(13). G(13)SRI(pep) produced a dose-dependent inhibition of PKA-mediated Ga13 phosphorylation. On the other hand, the Thr-phosphorylated derivative of G(13)SRI(pep) possessed no inhibitory activity, suggesting that Galpha(13) Thr(203) may represent the phosphorylation site. Confirmation of this notion was obtained by showing that the Galpha(13)-T203A mutant (in COS-7 cells) could not be phosphorylated by PKA. Additional studies using co-elution affinity chromatography and co-immunoprecipitation demonstrated that Ga13 phosphorylation stabilized coupling of Galpha(13) with platelet thromboxane A(2) receptors but destabilized coupling of Galpha(13) to its betagamma subunits. In order to determine the functional consequences of this phosphorylation on Ga13 signaling, activation of the Rho pathway was investigated. Specifically, Chinese hamster ovary cells over-expressing human Ga13 wild type (Galpha(13)-WT) or Galpha(13)- T203A mutant were generated and assayed for Rho activation. It was found that 8-bromo-cyclic AMP caused a significant decrease (50%; p < 0.002) of Rho activation in Galpha(13) wild type cells but produced no change of basal Rho activation levels in the mutant (p > 0.4). These results therefore suggest that PKA blocks Rho activation by phosphorylation of Galpha(13) Thr(203).	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave MC 868, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-24530] Funding Source: Medline; NIGMS NIH HHS [GM 54159, GM59427, GM65160] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065160] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen YB, 2001, J BIOL CHEM, V276, P45751, DOI 10.1074/jbc.M107191200; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; IMAIZUMI T, 1991, EUR J PHARM-MOLEC PH, V207, P189, DOI 10.1016/0922-4106(91)90030-L; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; SAGIEISENBERG R, 1989, TRENDS BIOCHEM SCI, V14, P355, DOI 10.1016/0968-0004(89)90001-7; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200	33	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					124	130		10.1074/jbc.M209219200	http://dx.doi.org/10.1074/jbc.M209219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399457	hybrid			2022-12-25	WOS:000180255700017
J	Ren, Y; Schulz, H				Ren, Y; Schulz, H			Metabolic functions of the two pathways of oleate beta-oxidation double bond metabolism during the beta-oxidation of oleic acid in rat heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; COENZYME-A; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; LIVER MITOCHONDRIA; ESCHERICHIA-COLI; REVISED PATHWAY; ENZYME; DEHYDROGENASE; PURIFICATION; PEROXISOMES	Unsaturated fatty acids with odd-numbered double bonds, e.g. oleic acid, can be degraded by P-oxidation via the isomerase-dependent pathway or the reductase-dependent pathway that differ with respect to the metabolism of the double bond. In an attempt to elucidate the metabolic functions of the two pathways and to determine their contributions to the beta-oxidation of unsaturated fatty acids, the degradation of 2-trans,5-cis-tetradecadienoyl-CoA, a metabolite of oleic acid, was studied with rat heart mitochondria. Kinetic measurements of metabolite and cofactor formation demonstrated that more than 80% of oleate beta-oxidation occurs via the classical isomerase-dependent pathway whereas the more recently discovered reductase-dependent pathway is the minor pathway. However, the reductase-dependent pathway is indispensable for the degradation of 3,5-cis-tetradecadienoyl-CoA, which is formed from 2-trans,5cis-tetradecadienoyl-CoA by Delta(3),Delta(2)-enoyl-CoA isomerase the auxiliary enzyme that is essential for the operation of the major pathway of oleate beta-oxidation. The degradation of 3,5-cis-tetradecadienoyl-CoA is limited by the capacity of 2,4-dienoyl-CoA reductase to reduce 2-trans,4-trans-tetradecadienoyl-CoA, which is rapidly formed from its 3,5 isomer by Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase. It is concluded that both pathways are essential for the degradation of unsaturated fatty acids with odd-numbered double bonds inasmuch as the isomerase-dependent pathway facilitates the major flux through)beta-oxidation and the reductase-dependent pathway prevents the accumulation of an otherwise undegradable metabolite.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Sch, New York, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.				NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CHU CH, 1994, BIOCHEM J, V302, P23, DOI 10.1042/bj3020023; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; FONG JC, 1978, J BIOL CHEM, V253, P6917; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; HANSFORD RG, 1975, J BIOL CHEM, V250, P8361; HE XY, 1989, ANAL BIOCHEM, V180, P105, DOI 10.1016/0003-2697(89)90095-X; He XY, 1998, BBA-LIPID LIPID MET, V1392, P119, DOI 10.1016/S0005-2760(98)00031-9; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Liang XQ, 1999, J BIOL CHEM, V274, P13830, DOI 10.1074/jbc.274.20.13830; LINESTEAD RP, 1931, J CHEM SOC, P740; LUO MJ, 1994, J BIOL CHEM, V269, P2384; LUO MJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P266, DOI 10.1006/abbi.1993.1348; NADA MA, 1995, BBA-LIPID LIPID MET, V1255, P244, DOI 10.1016/0005-2760(94)00223-L; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; YANG SY, 1986, J BIOL CHEM, V261, P5390; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	29	19	20	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					111	116		10.1074/jbc.M209261200	http://dx.doi.org/10.1074/jbc.M209261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12397064	hybrid			2022-12-25	WOS:000180255700015
J	Vierke, G; Engelmann, A; Hebbeln, C; Thomm, M				Vierke, G; Engelmann, A; Hebbeln, C; Thomm, M			A novel archaeal transcriptional regulator of heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; THERMOSOME; MECHANISM; KANDLERI; PROMOTER; SEQUENCE; HOMOLOG; COMPLEX; SYSTEM	Archaea have a eukaryotic type of transcriptional machinery containing homologues of the transcription factors TATA-binding protein (TBP) and TFIIB (TFB) and a pol II type of RNA polymerase, whereas transcriptional regulators identified in archaeal genomes have bacterial counterparts. We describe here a novel regulator of heat shock response, Phr, from the hyperthermophilic archaeon Pyrococcus furiosus that is conserved among Euryarchaeota. The protein specifically inhibited cell-free transcription of its own gene and from promoters of a small heat shock protein, Hsp20, and of an AAA(+) ATPase. Inhibition of transcription was brought about by abrogating RNA polymerase recruitment to the TBP/ TFB promoter complex. Phr bound to a 29-bp DNA sequence overlapping the transcription start site. Three sequences conserved in the binding sites of Phr, TTTA at -10, TGGTAA at the transcription start site, and AAAA at position +10, were required for Phr binding and are proposed as consensus regulatory sequences of Pyrococcus heat shock promoters. Shifting the growth temperature from 95 to 103 degreesC caused a dramatic increase of mRNA levels for the aaa(+) atpase and phr genes, but expression of the Phr protein was only weakly stimulated. Our findings suggest that heat shock response in Archaea is negatively regulated by a mechanism involving binding of Phr to conserved sequences.	Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany		Thomm, M (corresponding author), Univ Regensburg, Univ Str 31, D-93040 Regensburg, Germany.	Michael.Thomm@Biologie.Uni-Regensburg.de						Andra S, 1998, EUR J BIOCHEM, V255, P93, DOI 10.1046/j.1432-1327.1998.2550093.x; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P4658, DOI 10.1093/nar/27.23.4658; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bell SD, 2001, BIOCHEM SOC T, V29, P392, DOI 10.1042/BST0290392; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dahlke I, 2002, NUCLEIC ACIDS RES, V30, P701, DOI 10.1093/nar/30.3.701; Diruggiero Jocelyne, 1995, P97; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Fernandes M., 1994, BIOL HEAT SHOCK PROT, P375; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; HAUSNER W, 1995, J BIOL CHEM, V270, P17649, DOI 10.1074/jbc.270.30.17649; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hausner W, 2001, J BACTERIOL, V183, P3025, DOI 10.1128/JB.183.10.3025-3031.2001; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Laksanalamai P, 2001, J BACTERIOL, V183, P5198, DOI 10.1128/JB.183.17.5198-5202.2001; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Maupin-Furlow JA, 2000, FRONT BIOSCI-LANDMRK, V5, pD837, DOI 10.2741/furlow; Minuth T, 1999, BIOL CHEM, V380, P55, DOI 10.1515/BC.1999.007; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Narberhaus F, 1999, MOL MICROBIOL, V31, P1, DOI 10.1046/j.1365-2958.1999.01166.x; Plosser P, 2002, MOL MICROBIOL, V45, P511, DOI 10.1046/j.1365-2958.2002.03031.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; Thompson DK, 1998, MOL MICROBIOL, V27, P541, DOI 10.1046/j.1365-2958.1998.00698.x; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	34	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					18	26		10.1074/jbc.M209250200	http://dx.doi.org/10.1074/jbc.M209250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12381724	hybrid			2022-12-25	WOS:000180255700003
J	Walcott, JL; Merry, DE				Walcott, JL; Merry, DE			Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPANDED ANDROGEN RECEPTOR; POLYGLUTAMINE DISEASE; HUNTINGTONS-DISEASE; AGGREGATE FORMATION; NUCLEAR INCLUSIONS; TRANSGENIC MICE; IN-VITRO; LOCALIZATION; BRAIN; PROTEIN	Spinal and bulbar muscular atrophy (SBMA, Kennedy's disease) is one of a group of progressive neurodegenerative diseases resulting from a polyglutamine repeat expansion. In SBMA the polymorphic trinucleotide CAG repeat in exon 1 of the androgen receptor (AR) gene is increased, resulting in expansion of a polyglutamine tract. Patient autopsy material reveals neuronal intranuclear inclusions (NII) in affected regions that contain only amino-terminal epitopes of the AR. Cell models have previously been unable to produce intranuclear inclusions containing only a portion of the AR. We report here the creation of an inducible cell model of SBMA that reproduces this important characteristic of disease pathology. PC12 cells expressing highly expanded AR form ubiquitinated intranuclear inclusions containing amino-terminal epitopes of the AR as well as heat shock proteins. Inclusions appear as distinct granular electron-dense structures in the nucleus by immunoelectron microscopy. Dihydrotestosterone treatment of mutant AR-expressing cells results in increased inclusion load. This model mimics the formation of ubiquitinated intranuclear inclusions containing the amino-terminal portion of AR observed in patient tissue and reveals a role for ligand in the pathogenesis of SBMA.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Grad Grp Pharmacol Sci, Philadelphia, PA 19104 USA	Jefferson University; University of Pennsylvania	Merry, DE (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 208 Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.	diane.merry@mail.tju.edu						Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Abel A, 2001, HUM MOL GENET, V10, P107, DOI 10.1093/hmg/10.2.107; ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Butler R, 1998, HUM MOL GENET, V7, P121, DOI 10.1093/hmg/7.1.121; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Hayashi Y, 1998, ACTA NEUROPATHOL, V96, P547, DOI 10.1007/s004010050933; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KUJAWA KA, 1991, J NEUROSCI, V11, P3898; KURZ EM, 1986, SCIENCE, V232, P395, DOI 10.1126/science.3961488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; PAUL L, 1997, AM BOOK REV, V19, P1; Perez J, 1996, J NEUROSCI, V16, P6625; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; TeclemariamMesbah R, 1997, J HISTOCHEM CYTOCHEM, V45, P619, DOI 10.1177/002215549704500414; Welch WJ, 2001, HUM MOL GENET, V10, P3063, DOI 10.1093/hmg/10.26.3063; YU WHA, 1989, J NEUROSCI, V9, P3908; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	38	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50855	50859		10.1074/jbc.M209466200	http://dx.doi.org/10.1074/jbc.M209466200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12388541	hybrid			2022-12-25	WOS:000180177700086
J	Buck, E; Schatz, P; Scarlata, S; Iyengar, R				Buck, E; Schatz, P; Scarlata, S; Iyengar, R			Role of dynamic interactions in effective signal transfer for G beta stimulation of phospholipase C-beta 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ALPHA-SUBUNIT; G-PROTEINS; ACTIVATION; BINDING; REGION; DOMAIN	Heterotrimeric G protein subunits regulate their effectors by protein-protein interactions. The regions involved in these direct interactions have either signal transfer or general binding functions (Buck, E., Li, J., Chen, Y., Weng, G., Scarlata, S., and lyengar, R. (1999) Science 283, 1332-1335). Although key determinants of signal transfer regions for G protein subunits have been identified, the mechanisms of signal transfer are not fully understood. We have used a combinatorial peptide approach to analyze one Gbeta region, Gbeta86-105, involved in signal transfer to the effector phospholipase C (PLC)-beta2 to gain a more mechanistic understanding of Gbeta/PLC-beta2 signaling. Binding and functional studies with the combinatorial peptides on interaction with and stimulation/inhibition of phospholipase Cbeta2 indicate that binding affinity can be resolved from EC50 for functional effects, such that peptides that have wild type binding affinities have 15- to 20-fold lower EC50 values. Although more potent, these peptides display a much lower extent of maximal stimulation. These peptides synergize with Gbetagamma or peptides encoding the second Gbeta42-54 signal transfer region in maximally stimulating phospholipase C-beta2. Other combinatorial peptides from the Gbeta86-105 region that bind to PLC-beta2 by themselves submaximally stimulate and extensively inhibit Gbetagamma stimulation of PLC-beta2. The intrinsic stimulation function can be attributed to Arg-96 and Ser-97, the synergy function to Trp-99, and the binding affinity to Thr-87, Val-90, Pro-94, Arg-96, Ser-97, and Val-100. These results indicate that, even within signal transfer regions, residues involved in binding can be resolved from those involved in signal transfer and that signal transfer is likely to be achieved through dynamic rather than steady-state interactions.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Affymax Corp, Palo Alto, CA 94304 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol, Stony Brook, NY 11729 USA	Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Iyengar, R (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, T32DK007135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07135, DK 38761] Funding Source: Medline; NIGMS NIH HHS [GM 53132] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Buck E, 2001, J BIOL CHEM, V276, P36014, DOI 10.1074/jbc.M103228200; Chen YB, 2001, J BIOL CHEM, V276, P45751, DOI 10.1074/jbc.M107191200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gilchrist A, 2000, METHOD ENZYMOL, V315, P388; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; Walker SJ, 2000, J BIOL CHEM, V275, P15665, DOI 10.1074/jbc.M000076200; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466	17	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49707	49715		10.1074/jbc.M205553200	http://dx.doi.org/10.1074/jbc.M205553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388553	hybrid			2022-12-25	WOS:000180028900081
J	Gerken, TA; Zhang, JX; Levine, J; Elhammer, A				Gerken, TA; Zhang, JX; Levine, J; Elhammer, A			Mucin core O-glycosylation is modulated by neighboring residue glycosylation status - Kinetic modeling of the site-specific glycosylation of the APO-porcine submaxillary mucin tandem repeat by UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferases T1 AND T2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; IN-VIVO; LINKED GLYCOSYLATION; CHARGE-DISTRIBUTION; CDNA CLONING; 3 MEMBERS; EXPRESSION; SEQUENCE; PEPTIDE; FAMILY	The influence of peptide sequence and environment on the initiation and elongation of mucin O-glycosylation is not well understood. The in vivo glycosylation pattern of the porcine submaxillary gland mucin (PSM) tandem repeat containing 31 O-glycosylation sites (Gerken, T. A., Gilmore, M., and Zhang, J. (2002) J. Biol. Chem. 277, 7736-7751) reveals a weak inverse correlation with hydroxyamino acid density (and by inference the density of glycosylation) with the extent of GalNAc glycosylation and core-1 substitution. We now report the time course of the in vitro glycosylation of the apoPSM tandem repeat by recombinant UDP-GalNAc:polypeptide alpha-GalNAc transferases (ppGalNAc transferase) T1 and T2 that confirm these findings. A wide range of glycosylation rates are found, with several residues showing apparent plateaus in glycosylation. An adjustable kinetic model that reduces the first-order rate constants proportional to neighboring glycosylation status, plus or minus three residues of the site of glycosylation, was found to reasonably reproduce the experimental rate data for both transferases, including apparent plateaus in glycosylation. The unique, transferase-specific, positional weighting constants reveal information on the peptide/glycopeptide recognition site for each transferase. Both transferases displayed high sensitivities to neighboring Ser/Thr glycosylation, whereas ppGalNAc T2 displayed additional high sensitivities to the presence of nonglycosylated Ser/Thr residues. This is the first demonstration of the ability to model mucin O-glycosylation kinetics, confirming that under the appropriate conditions neighboring glycosylation status can be a significant factor modulating the first step of mucin O-glycan biosynthesis.	Case Western Reserve Univ, Sch Med, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res,BRB, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, WA Bernbaum Ctr Cyst Fibrosis Res,BRB, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Univ Hosp Res Inst, Cleveland, OH 44106 USA; Pharmacia Corp, Kalamazoo, MI 49001 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Pfizer	Gerken, TA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res,BRB, 2109 Adelbert Rd, Cleveland, OH 44106 USA.				NCI NIH HHS [R01 CA 78834, R01 CA078834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; CHOU KC, 1995, PROTEIN SCI, V4, P1365, DOI 10.1002/pro.5560040712; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Fukuda M, 1999, BBA-MOL BASIS DIS, V1455, P205, DOI 10.1016/S0925-4439(99)00067-8; Gerken TA, 1998, J BIOL CHEM, V273, P26580, DOI 10.1074/jbc.273.41.26580; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GERKEN TA, 1984, BIOCHEMISTRY-US, V23, P1485, DOI 10.1021/bi00302a023; Gerken TA, 2002, J BIOL CHEM, V277, P7736, DOI 10.1074/jbc.M111690200; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Guo JM, 2002, FEBS LETT, V524, P211, DOI 10.1016/S0014-5793(02)03007-7; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; Hanisch FG, 2001, GLYCOBIOLOGY, V11, P731, DOI 10.1093/glycob/11.9.731; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hennebicq S, 1998, GLYCOCONJUGATE J, V15, P275, DOI 10.1023/A:1006949129456; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HOMA FL, 1995, PROTEIN EXPRES PURIF, V6, P141, DOI 10.1006/prep.1995.1017; Iida S, 1999, FEBS LETT, V449, P230, DOI 10.1016/S0014-5793(99)00445-7; Kato K, 2001, BIOCHEM BIOPH RES CO, V287, P110, DOI 10.1006/bbrc.2001.5562; Kirnarsky L, 1998, BIOCHEMISTRY-US, V37, P12811, DOI 10.1021/bi981034a; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; Nehrke K, 1997, GLYCOBIOLOGY, V7, P1053, DOI 10.1093/glycob/7.8.1053-c; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Sugahara T, 1996, J BIOL CHEM, V271, P20797, DOI 10.1074/jbc.271.34.20797; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; YOSHIDA A, 1995, GLYCOCONJUGATE J, V12, P824, DOI 10.1007/BF00731244	54	35	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49850	49862		10.1074/jbc.M205851200	http://dx.doi.org/10.1074/jbc.M205851200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397077	hybrid			2022-12-25	WOS:000180028900099
J	Keller, DM; Lu, H				Keller, DM; Lu, H			P53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2 center dot hSPT16 center dot SSRP1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; PROTEIN-KINASE CK2; WILD-TYPE P53; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; CATALYTIC SUBUNIT; GAMMA-RADIATION; DAMAGE; MDM2; ACCUMULATION	Previously, we purified a UV-responsive p53 serine 392 kinase from F9 and HeLa cells and found that its activity is attributed to a high molecular weight protein complex containing the protein kinase CK2, along with the chromatin-associated factors hSPT16 and SSRP1. Here we determine that these proteins interact in vitro and in cells via non-overlapping domains and provide evidence consistent with the idea that hSPT16 and SSRP1 change the conformation of CK2 upon binding such that it specifically targets p53 over other substrates. Also, UV irradiation apparently induces the association of the complex, thereby increasing the specificity of CK2 for p53 at the expense of other cellular CK2 substrates and leading to an overall increase in p53 serine 392 phosphorylation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	luh@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA093614, R01CA095441] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93614, CA 095441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; John S, 2000, GENE DEV, V14, P1196; Kang SW, 2000, GENES CELLS, V5, P251, DOI 10.1046/j.1365-2443.2000.00323.x; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1991, CANCER RES, V51, P6304; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TISHLER RB, 1993, CANCER RES, V53, P2212; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540	48	98	107	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50206	50213		10.1074/jbc.M209820200	http://dx.doi.org/10.1074/jbc.M209820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393879	hybrid			2022-12-25	WOS:000180028900142
J	Lechner, E; Xie, DX; Grava, S; Pigaglio, E; Planchais, S; Murray, JAH; Parmentier, Y; Mutterer, J; Dubreucq, B; Shen, WH; Genschik, P				Lechner, E; Xie, DX; Grava, S; Pigaglio, E; Planchais, S; Murray, JAH; Parmentier, Y; Mutterer, J; Dubreucq, B; Shen, WH; Genschik, P			The AtRbx1 protein is part of plant SCF complexes, and its down-regulation causes severe growth and developmental defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; CELL-CYCLE; ARABIDOPSIS-THALIANA; DEPENDENT PROTEOLYSIS; RING-H2 FINGER; SALICYLIC-ACID; AUXIN RESPONSE; GENE; DEGRADATION; SUBUNIT	Recently in yeast and animal cells, one particular class of ubiquitin ligase (E3), called the SCF, was demonstrated to regulate diverse processes including cell cycle and development. In plants SCF-dependent proteolysis is also involved in different developmental and hormonal regulations. To further investigate the function of SCF, we characterized at the molecular level the Arabidopsis RING-H2 finger protein AtRbx1. We demonstrated that the plant gene is able to functionally complement a yeast knockout mutant strain and showed that AtRbx1 protein interacts physically with at least two members of the Arabidopsis cullin family (AtCul1 and AtCul4). AtRbx1 also associates with AtCul1 and the Arabidopsis SKP1-related proteins in planta, indicating that it is part of plant SCIP complexes. AtRbx1 mRNAs accumulate in various tissues of the plant, but at higher levels in tissues containing actively dividing cells. Finally to study the function of the gene in planta, we either overexpressed AtRbx1 or reduced its expression by a dsRNA strategy. Down-regulation of AtRbx1 impaired seedling growth and development, indicating that the gene is essential in plants. Furthermore, the AtRbx1-silenced plants showed a reduced level of AtCul1 protein, but accumulated higher level of cyclin D3.	CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Natl Univ Singapore, Inst Mol Agrobiol, Lab Plant Signal Transduct, Singapore 117604, Singapore; Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; INRA, INAPG, Lab Biol Semences, F-78026 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National University of Singapore; University of Cambridge; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Genschik, P (corresponding author), CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	pascal.genschik@bmp-ulp.u-strasbg.fr	DUBREUCQ, Bertrand/AAY-9948-2020; Shen, Wen Hui/E-7941-2017; Murray, James AH/D-3399-2009; PLANCHAIS, Séverine/J-8502-2019; xie, daoxin d/C-8646-2017	DUBREUCQ, Bertrand/0000-0003-2661-5479; Murray, James AH/0000-0002-2282-3839; PLANCHAIS, Séverine/0000-0002-4033-9813; GENSCHIK, Pascal/0000-0002-4107-5071; Shen, Wen-Hui/0000-0001-7988-6382				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bachmair A, 2001, TRENDS PLANT SCI, V6, P463, DOI 10.1016/S1360-1385(01)02080-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHABOUTE ME, 1987, PLANT MOL BIOL, V8, P179, DOI 10.1007/BF00025329; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Criqui MC, 2000, PLANT J, V24, P763, DOI 10.1111/j.1365-313X.2000.t01-1-.x; del Pozo JC, 2000, PLANT MOL BIOL, V44, P123, DOI 10.1023/A:1006413007456; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; del Pozo JC, 1999, TRENDS PLANT SCI, V4, P107, DOI 10.1016/S1360-1385(99)01382-5; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dharmasiri S, 2002, PLANT MOL BIOL, V49, P401, DOI 10.1023/A:1015203013208; Dieterle M, 2001, GENE DEV, V15, P939, DOI 10.1101/gad.197201; Gagne JM, 2002, P NATL ACAD SCI USA, V99, P11519, DOI 10.1073/pnas.162339999; GENSCHIK P, 1994, PLANT J, V6, P537, DOI 10.1046/j.1365-313X.1994.6040537.x; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P795; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Healy JMS, 2001, J BIOL CHEM, V276, P7041, DOI 10.1074/jbc.M009074200; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kang HG, 1999, PLANT J, V20, P127, DOI 10.1046/j.1365-313X.1999.00575.x; Kim HS, 2002, PLANT CELL, V14, P1469, DOI 10.1105/tpc.001867; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lechner E, 2002, GENE, V290, P63, DOI 10.1016/S0378-1119(02)00556-5; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; Leyser O, 2001, CURR OPIN PLANT BIOL, V4, P382, DOI 10.1016/S1369-5266(00)00189-8; Maeda I, 2001, FEBS LETT, V494, P181, DOI 10.1016/S0014-5793(01)02343-2; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; McCarty DR, 2000, CELL, V103, P201, DOI 10.1016/S0092-8674(00)00113-6; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nelson DC, 2000, CELL, V101, P331, DOI 10.1016/S0092-8674(00)80842-9; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Samach A, 1999, PLANT J, V20, P433, DOI 10.1046/j.1365-313x.1999.00617.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultz TF, 2001, PLANT CELL, V13, P2659, DOI 10.1105/tpc.13.12.2659; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shen WH, 2002, MOL BIOL CELL, V13, P1916, DOI 10.1091/mbc.E02-02-0077; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Vaucheret H, 2001, J CELL SCI, V114, P3083; Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8; Woo HR, 2001, PLANT CELL, V13, P1779, DOI 10.1105/tpc.13.8.1779; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Xu LH, 2002, PLANT CELL, V14, P1919, DOI 10.1105/tpc.003368; Yang M, 1999, P NATL ACAD SCI USA, V96, P11416, DOI 10.1073/pnas.96.20.11416; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhao DH, 1999, DEV GENET, V25, P209, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;209::AID-DVG4&gt;3.0.CO;2-O; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	71	52	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50069	50080		10.1074/jbc.M204254200	http://dx.doi.org/10.1074/jbc.M204254200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12381738	Green Published, hybrid			2022-12-25	WOS:000180028900126
J	Stade, K; Vogel, F; Schwienhorst, I; Meusser, B; Volkwein, C; Nentwig, B; Dohmen, RJ; Sommer, T				Stade, K; Vogel, F; Schwienhorst, I; Meusser, B; Volkwein, C; Nentwig, B; Dohmen, RJ; Sommer, T			A lack of SUMO conjugation affects cNLS-dependent nuclear protein import in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PORE COMPLEX PROTEINS; RNA-BINDING-PROTEINS; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SIGNALS; TRANSPORT KINETICS; UBIQUITIN; NUCLEOPORIN; NUP2P; EXPORT	Yeast SUMO (Smt3) and its mammalian ortholog SUMO-1 are ubiquitin-like proteins that can reversibly be conjugated to other proteins. Among the substrates for SUMO modification in vertebrates are RanGAP1 and RanBP2/Nup358, two proteins previously implicated in nucleocytoplasmic transport. Sumoylated RanGAP1 binds to the nuclear pore complex via RanBP2/Nup358, a giant nucleoporin, which was recently reported to act as a SUMO E3 ligase on some nuclear substrates. However, no direct evidence for a role of the SUMO system in nuclear transport has been obtained so far. By the use of conditional yeast mutants, we examined nuclear protein import in vivo. We show here that cNLS-dependent protein import is impaired in mutants with defective Ulp1 and Uba2, two enzymes involved in the SUMO conjugation reaction. In contrast, other transport pathways such as rgNLS-mediated protein import and mRNA export are not affected. Furthermore, we find that the yeast importin-a subunit Srp1 accumulates in the nucleus of ulp1 and uba2 strains but not the importin-beta subunit Kap95, indicating that a lack of Srp1 export might impair cNLS import. In summary, our results provide evidence that SUMO modification in yeast, as has been suspected for vertebrates, plays an important role in nucleocytoplasmic trafficking.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Cologne, Inst Genet, D-50674 Cologne, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Cologne	Stade, K (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780				Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; [Anonymous], 1991, Methods Enzymol, V194, P1; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Brown AJP, 1998, METHOD MICROBIOL, V26, P471; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Fahrenkrog B, 2000, J STRUCT BIOL, V129, P295, DOI 10.1006/jsbi.2000.4223; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kops AD, 2001, EMBO J, V20, P4183, DOI 10.1093/emboj/20.15.4183; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493	67	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49554	49561		10.1074/jbc.M207991200	http://dx.doi.org/10.1074/jbc.M207991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393908	hybrid			2022-12-25	WOS:000180028900060
J	Cai, XJ; Zhang, K; Lytton, J				Cai, XJ; Zhang, K; Lytton, J			A novel topology and redox regulation of the rat brain K+-dependent Na+/Ca2+ exchanger, NCKX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; NA+-CA2+ EXCHANGER; RECEPTOR; PROTEIN; STOICHIOMETRY; PALMITOYLATION; TRANSPORTER; MODULATION	In this study we have examined the roles of endogenous cysteine residues in the rat brain K+-dependent Na+/Ca+ exchanger protein, NCKX2, by site-directed mutagenesis. We found that mutation of Cys-614 or Cys-666 to Ala inhibited expression of the exchanger protein in HEK-293 cells, but not in an in vitro translation system. We speculated that Cys-614 and Cys-666 might form an extracellular disulfide bond that stabilized protein structure. Such an arrangement would place the C terminus of the exchanger outside the cell, contrary to the original topological model. This hypothesis was tested by adding a hemagglutinin A epitope to the C terminus of the protein. The hemagglutinin A epitope could be recognized with a specific antibody without permeabilization of the cell membrane, supporting an extracellular location for the C terminus. Additionally, the exchanger molecule could be labeled with biotin maleimide only following extracellular application of beta-mercaptoethanol. Surprisingly, mutation of Cys-395, located in the large intracellular loop, to Ala, prevented reduction-dependent labeling of the protein. The activity of wild-type exchanger, but not the Cys-395 --> Ala mutant, was stimulated after application of beta-mercaptoethanol. Co-immunoprecipitation experiments demonstrated self-association between wild-type and FLAG-tagged exchanger proteins that could not be inhibited by Cys-395 --> Ala mutation. These results suggest that NCKX2 associates as a dimer, an interaction that does not require, but may be stabilized by, a disulfide linkage through Cys-395. This linkage, perhaps by limiting protein mobility along the dimer interface, reduces the transport activity of NCKX2.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca	Cai, Xinjiang/F-4843-2010; Cai, Xinjiang/A-9617-2008	Cai, Xinjiang/0000-0001-8933-7133; Lytton, Jonathan/0000-0003-4770-2512				AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Bauer PJ, 2002, BBA-BIOMEMBRANES, V1559, P121, DOI 10.1016/S0005-2736(01)00444-8; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai XJ, 2002, BIOPHYS J, V82, p566A; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; DAHAN D, 1991, J BIOL CHEM, V266, P2067; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fujinaga J, 1999, J BIOL CHEM, V274, P6626, DOI 10.1074/jbc.274.10.6626; Fujioka Y, 2000, J PHYSIOL-LONDON, V529, P611, DOI 10.1111/j.1469-7793.2000.00611.x; Haarmann CS, 1999, BIOPHYS J, V77, P3010, DOI 10.1016/S0006-3495(99)77132-8; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KIMURA M, 1993, J BIOL CHEM, V268, P6874; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Lytton J, 1999, BIOPHYS J, V76, pA251; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Narahashi T, 2001, ALCOHOL CLIN EXP RES, V25, p182S, DOI 10.1111/j.1530-0277.2001.tb02394.x; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REEVES JP, 1986, J BIOL CHEM, V261, P4948; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; Saaf A, 2001, J BIOL CHEM, V276, P18905, DOI 10.1074/jbc.M101716200; Sambrook J, 2001, MOL CLONING LAB MANU; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; SCHNETKAMP PPM, 1995, J BIOL CHEM, V270, P13231, DOI 10.1074/jbc.270.22.13231; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; Seal RP, 1998, METHOD ENZYMOL, V296, P318; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Szerencsei RT, 2001, BIOCHEMISTRY-US, V40, P6009, DOI 10.1021/bi0102353; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Zeidner G, 2001, J BIOL CHEM, V276, P35564, DOI 10.1074/jbc.M105189200; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	57	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48923	48930		10.1074/jbc.M208818200	http://dx.doi.org/10.1074/jbc.M208818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377762	hybrid			2022-12-25	WOS:000179789600123
J	Hasegawa, M; Fujiwara, H; Nonaka, T; Wakabayashi, K; Takahashi, H; Lee, VMY; Trojanowski, JQ; Mann, D; Iwatsubo, T				Hasegawa, M; Fujiwara, H; Nonaka, T; Wakabayashi, K; Takahashi, H; Lee, VMY; Trojanowski, JQ; Mann, D; Iwatsubo, T			Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; GLIAL CYTOPLASMIC INCLUSIONS; PAIRED HELICAL FILAMENTS; CORTICAL LEWY BODIES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BODY DISEASE; DEMENTIA; IMMUNOREACTIVITY; COMPONENT	alpha-Synuclein is one of the major components of intracellular fibrillary aggregates in the brains of a subset of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and Hallervorden-Spatz disease, which are referred to as alpha-synucleinopathies. We have shown previously (Fujiwara, H., Hasegawa, IVL, Dohmae, N., Kawashima, A., Masliah, E., Goldberg, IVL S., Shen, J., Takio, K., and lwatsubo, T. (2002) Nat. Cell Biol. 4, 160-164) that alpha-synuclein deposited in synucleinopathy brains is extensively phosphorylated at Ser-129 and migrates at 15 kDa. Here we examined the biochemical characteristics of the additional, higher molecular mass species of phosphorylated alpha-synuclein-positive polypeptides that also are recovered in the Sarkosyl-insoluble fraction of synucleinopathy and migrate at about 22 and 29 kDa. These 22 and 29 kDa bands were positive for three different anti-ubiquitin antibodies and comigrated perfectly with in vitro ubiquitinated alpha-synuclein that may correspond to mono- and diubiquitinated alpha-synuclein, respectively. Furthermore, cyanogen bromide cleavage of the 22 and 29 kDa polypeptides shifted the mobility to 19 and 26 kDa, respectively, and they retained immunoreactivity for both ubiquitin and alpha-synuclein. Finally, protein sequence analysis showed that the 19 kDa band contained two amino-terminal sequences of alpha-synuclein and ubiquitin. These results strongly suggest that phosphorylated alpha-synuclein is targeted to mono- and diubiquitination in synucleinopathy brains, which may have implications for mechanisms of these diseases.	Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Hirosaki Univ, Sch Med, Dept Neuropathol, Hirosaki, Aomori 0368562, Japan; Niigata Univ, Brain Res Inst, Dept Pathol, Niigata 9518585, Japan; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Hope Hosp, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England	Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Hirosaki University; Niigata University; University of Pennsylvania	Hasegawa, M (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 1568585, Japan.		Nonaka, Takashi/L-8572-2017	Nonaka, Takashi/0000-0002-0830-9403				Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GALLOWAY PG, 1988, J NEUROPATH EXP NEUR, V47, P654, DOI 10.1097/00005072-198811000-00008; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; GOLDMANN JE, 1986, SCIENCE, V221, P1081; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Piao YS, 2001, ACTA NEUROPATHOL, V101, P285; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SHAW G, 1988, P NATL ACAD SCI USA, V85, P2854, DOI 10.1073/pnas.85.8.2854; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P331, DOI 10.1007/s004010050049; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8	35	321	334	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49071	49076		10.1074/jbc.M208046200	http://dx.doi.org/10.1074/jbc.M208046200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377775	hybrid			2022-12-25	WOS:000179789600141
J	Lee, D; Lim, C; Seo, T; Kwon, H; Min, H; Choe, J				Lee, D; Lim, C; Seo, T; Kwon, H; Min, H; Choe, J			The viral oncogene human papillomavirus E7 deregulates transcriptional silencing by Brm-related gene 1 via molecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; MAMMALIAN SWI/SNF COMPLEXES; CELL-CYCLE ARREST; C-FOS GENE; TYPE-16 E7; HISTONE ACETYLATION; SACCHAROMYCES-CEREVISIAE; TRANSFORMING ACTIVITY; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES	BRG-1, a component of the human SWI/SNF complex, either activates or represses cellular promoters by modulating chromatin structure via the formation of a multiple polypeptide complex. Human papillomavirus E7 binds and destabilizes pRb, resulting in the blockage of G(1) arrest in the cell cycle. We show here that the high-risk human papillomavirus E7 protein group binds BRG-1 and modulates repression of the c-fos promoter mediated by this protein. In addition, both wild-type and Rb binding-defective E7 proteins abolish flat cell formation by BRG-1 in SW13 cells, whereas E7 COOH-terminal mutants do not affect this process. BRG-1-triggered repression of the c-fos promoter is sensitive to trichostatin A. We further establish that BRG-1 contains an activation domain and a trichostatin A-sensitive repression domain. These results collectively suggest that the viral oncogene E7 targets both pRb and BRG-1 via protein-protein interactions, resulting in the deregulation of host cell cycle control.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Hankuk Univ Foreign Studies, Dept Biosci & Biotechnol, Yongin 449791, Kyongki Do, South Korea; Hannam Univ, Dept Food & Nutr, Taejon 306791, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Hankuk University Foreign Studies; Hannam University	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	jchoe@mail.kaist.ac.kr	Lim, Chunghun/AAB-1253-2020; Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011	Lim, Chunghun/0000-0001-8473-9272; Lee, Daeyoup/0000-0003-2006-1823; 				BANKS L, 1990, ONCOGENE, V5, P1383; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	45	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48842	48848		10.1074/jbc.M203583200	http://dx.doi.org/10.1074/jbc.M203583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372840	hybrid			2022-12-25	WOS:000179789600113
J	Millan, C; Lujan, R; Shigemoto, R; Sanchez-Prieto, J				Millan, C; Lujan, R; Shigemoto, R; Sanchez-Prieto, J			Subtype-specific expression of group III metabotropic glutamate receptors and Ca2+ channels in single nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNAPTIC TRANSMISSION; PRESYNAPTIC LOCALIZATION; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION; CALCIUM CURRENTS; RAT HIPPOCAMPUS; MODULATION	The release properties of glutamatergic nerve terminals are influenced by a number of factors, including the subtype of voltage-dependent calcium channel and the presence of presynaptic autoreceptors. Group III metabotropic glutamate receptors (mGluRs) mediate feedback inhibition of glutamate release by inhibiting Ca2+ channel activity. By imaging Ca2+ in preparations of cerebrocortical nerve terminals, we show that voltage-dependent Ca2+ channels are distributed in a heterogeneous manner in individual nerve terminals. Presynaptic terminals contained only N-type (47.5%; conotoxin GVIA-sensitive), P/Q-type (3.9%; agatoxin IVA-sensitive), or both N- and P/Q-type (42.6%) Ca2+ channels, although the remainder of the terminals (6.1%) were insensitive to these two toxins. In this preparation, two mGluRs with high and low affinity for L(+)-2-amino-4-phosphonobutyrate were identified by immunocytochemistry as mGluR4 and mGluR7, respectively. These receptors were responsible for 22.2 and 24.1% reduction of glutamate release, and they reduced the Ca2+ response in 24.4 and 30.3% of the nerve terminals, respectively. Interestingly, mGluR4 was largely (73.7%) located in nerve terminals expressing both N- and P/Q-type Ca2+ channels, whereas mGluR7 was predominantly (69.9%) located in N-type Ca2+ channel-expressing terminals. This specific coexpression of different group III mGluRs and Ca2+ channels may endow synaptic terminals with distinct release properties and reveals the existence of a high degree of presynaptic heterogeneity.	Univ Complutense, Fac Vet, Dept Bioquim, Madrid 28040, Spain; Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Albacete 02071, Spain; Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	Complutense University of Madrid; Universidad de Castilla-La Mancha; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Sanchez-Prieto, J (corresponding author), Univ Complutense, Fac Vet, Dept Bioquim, Madrid 28040, Spain.		Lujan, Rafael/G-2555-2015; Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444; Lujan Miras, Rafael/0000-0003-2001-9545; Sanchez-Prieto, Jose/0000-0002-8513-3501				Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bradley SR, 1996, J NEUROSCI, V16, P2044; Bradley SR, 1998, J NEUROCHEM, V71, P636; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 2002, NEUROSCIENCE, V110, P403, DOI 10.1016/S0306-4522(01)00591-7; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; GEREAU RW, 1995, J NEUROSCI, V15, P6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herrero I, 1996, EUR J NEUROSCI, V8, P700, DOI 10.1111/j.1460-9568.1996.tb01255.x; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; Kinoshita A, 1998, J COMP NEUROL, V393, P332; Kinoshita A, 1996, NEUROSCI LETT, V207, P61, DOI 10.1016/0304-3940(96)12489-7; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; LUJAN R, 1998, EUR J NEUROSCI S128, V10; Millan C, 2002, J BIOL CHEM, V277, P14092, DOI 10.1074/jbc.M109044200; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Pekhletski R, 1996, J NEUROSCI, V16, P6364; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Qian J, 2001, J NEUROSCI, V21, P3721, DOI 10.1523/JNEUROSCI.21-11-03721.2001; Reid CA, 1997, J NEUROSCI, V17, P2738; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; SCHOLZ KP, 1995, J NEUROSCI, V15, P4612; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Takamori S, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-22-j0002.2001; TANABE Y, 1993, J NEUROSCI, V13, P1372; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; Vazquez E, 1997, EUR J NEUROSCI, V9, P2009, DOI 10.1111/j.1460-9568.1997.tb01369.x; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Wu LG, 1999, J NEUROSCI, V19, P726	48	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47796	47803		10.1074/jbc.M207531200	http://dx.doi.org/10.1074/jbc.M207531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12376542	hybrid			2022-12-25	WOS:000179663700124
J	Copani, A; Sortino, MA; Caricasole, A; Chiechio, S; Chisari, M; Battaglia, G; Giuffrida-Stella, AM; Vancheri, C; Nicoletti, F				Copani, A; Sortino, MA; Caricasole, A; Chiechio, S; Chisari, M; Battaglia, G; Giuffrida-Stella, AM; Vancheri, C; Nicoletti, F			Erratic expression of DNA polymerases by beta-amyloid causes neuronal death	FASEB JOURNAL			English	Article						Alzheimer's; cell cycle; DNA replication; apoptosis	CYCLIN-DEPENDENT KINASES; BASE EXCISION-REPAIR; REPLICATION; INVOLVEMENT; OVEREXPRESSION; REQUIREMENT; INSTABILITY; ACTIVATION; APOPTOSIS; PROTEINS	An ectopic reentrance into the cell cycle with ensuing DNA replication is required for neuronal apoptosis induced by beta-amyloid. Here, we investigate the repertoire of DNA polymerases expressed in beta-amyloid-treated neurons, and their specific role in DNA synthesis and apoptosis. We show that exposure of cultured cortical neurons to beta-amyloid induces the expression of DNA polymerase-beta, proliferating cell nuclear antigen, and the p49 and p58 subunits of DNA primase. Induction requires the activity of cyclin-dependent kinases. The knockdown of the p49 primase subunit prevents beta-amyloid-induced neuronal DNA synthesis and apoptosis. Similar effects are observed by knocking down DNA polymerase-beta or by using dideoxycytidine, a preferential inhibitor of this enzyme. Thus, the reparative enzyme DNA polymerase-beta unexpectedly mediates a large component of de novo DNA synthesis and apoptotic death in neurons exposed to beta-amyloid. These data indicate that DNA polymerases become death signals when erratically expressed by differentiated neurons.	Univ Catania, Dept Pharmaceut Sci, I-95125 Catania, Italy; Univ Catania, Dept Expt & Clin Pharmacol, I-95125 Catania, Italy; Univ Catania, Dept Chem Sci, I-95125 Catania, Italy; Univ Catania, Inst Resp Dis, I-95125 Catania, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; INM Neuromed, I-86077 Pozzilli, Italy	University of Catania; University of Catania; University of Catania; University of Catania; Sapienza University Rome; IRCCS Neuromed	Copani, A (corresponding author), Univ Catania, Dept Pharmaceut Sci, Viale A Doria 6, I-95125 Catania, Italy.	acopani@katamail.com	Chiechio, Santina/E-2212-2018; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016; Battaglia, Giuseppe/A-7709-2010; VANCHERI, Carlo/K-9417-2016; Nicoletti, Ferdinando/A-2446-2010	Chiechio, Santina/0000-0003-4648-391X; Battaglia, Giuseppe/0000-0001-7571-3417; NICOLETTI, Ferdinando/0000-0003-3366-7269; Sortino, Maria Angela/0000-0002-2734-1521; VANCHERI, Carlo/0000-0002-5120-9926; Nicoletti, Ferdinando/0000-0003-0917-443X				Blasko I, 2000, FEBS LETT, V470, P221, DOI 10.1016/S0014-5793(00)01323-5; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Frechet M, 2002, ONCOGENE, V21, P2320, DOI 10.1038/sj.onc.1205295; Frechet M, 2001, FEBS LETT, V505, P229, DOI 10.1016/S0014-5793(01)02834-4; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Rao KS, 2001, ANN NY ACAD SCI, V928, P113; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; SIEGEL RL, 1982, J BIOL CHEM, V257, P1785; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	34	51	52	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2006	+		10.1096/fj.02-0422fje	http://dx.doi.org/10.1096/fj.02-0422fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397084				2022-12-25	WOS:000179167600002
J	Garrido, JL; Godoy, J; Alvarez, A; Bronfman, M; Inestrosa, NC				Garrido, JL; Godoy, J; Alvarez, A; Bronfman, M; Inestrosa, NC			Protein kinase C inhibits amyloid beta-peptide neurotoxicity by acting on members of the Wnt pathway	FASEB JOURNAL			English	Article						A beta neurotoxicity; PKC; Wnt signaling	GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAY; PRECURSOR PROTEIN; CATENIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; CELLS	Current evidence supports the notion that the amyloid beta-peptide (Abeta) plays a major role in the neurotoxicity observed in the brain in Alzheimer's disease. However, the signal transduction mechanisms involved still remain unknown. In the present work, we analyzed the effect of protein kinase C (PKC) on some members of the Writ signaling pathway and its implications for Abeta neurotoxicity. Activation of PKC by phorbol 12-myristate 13-acetate protected rat hippocampal neurons from A(3 toxicity. This effect was accomplished by inhibition of glycogen synthase kinase-3beta (GSK-3beta) activity, which led to the accumulation of cytoplasmic beta-catenin and transcriptional activation via beta-catenin/T-cell factor/lymphoid enhancer factor-1 (TCF/LEF-1) of Writ target genes, which in the present study were engrailed-1 (en-1) and cyclin D1 (cycD1). In contrast, inhibition of Ca2+-dependent PKC isoforms activated GSK-3beta and offered no protection from Abeta neurotoxicity. Wnt-3a and lithium salts, classical activators of the Writ pathway, mimicked PKC activation. Our results suggest that regulation of members of the Writ signaling pathway by Ca2+-dependent PKC isoforms may be important in controlling the neurotoxic process induced by Abeta.	Pontificia Univ Catolica Chile, Mol Neurobiol Unit, Ctr Regulac Celular & Patol, MIFAB,Fac Ciencias Biol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, Mol Neurobiol Unit, Ctr Regulac Celular & Patol, MIFAB,Fac Ciencias Biol, Alameda 340, Santiago, Chile.	ninestr@genes.bio.puc.cl	Godoy, Juan A/F-5398-2018	Godoy, Juan A/0000-0001-9920-6698; Alvarez Rojas, Alejandra/0000-0002-8129-9280				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alvarez A, 1998, J NEUROSCI, V18, P3213; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BRUEL A, 1991, NEUROSCI LETT, V133, P89, DOI 10.1016/0304-3940(91)90064-Z; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calderon FH, 1998, MOL PSYCHIATR, V3, P247, DOI 10.1038/sj.mp.4000383; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; DEFERRARI GV, 2002, IN PRESS MOL PSYCHIA; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Favit A, 1998, P NATL ACAD SCI USA, V95, P5562, DOI 10.1073/pnas.95.10.5562; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Galceran J, 2000, DEVELOPMENT, V127, P469; Garcia-Huidobro T, 1999, EUR J BIOCHEM, V266, P855, DOI 10.1046/j.1432-1327.1999.00923.x; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GOODE N, 1992, J BIOL CHEM, V267, P16878; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kang DE, 1999, J NEUROSCI, V19, P4229; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Ma WY, 2001, EUR J NEUROSCI, V13, P1125, DOI 10.1046/j.1460-9568.2001.01475.x; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibamoto S, 1998, GENES CELLS, V3, P659; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Xie J, 2000, MOL BRAIN RES, V82, P107, DOI 10.1016/S0169-328X(00)00187-X; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	43	137	145	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1982	+		10.1096/fj.02-0327fje	http://dx.doi.org/10.1096/fj.02-0327fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397090				2022-12-25	WOS:000179167600001
J	Mascolo, N; Izzo, AA; Ligresti, A; Costagliola, A; Pinto, L; Cascio, MG; Maffia, P; Cecio, A; Capasso, F; Di Marzo, V				Mascolo, N; Izzo, AA; Ligresti, A; Costagliola, A; Pinto, L; Cascio, MG; Maffia, P; Cecio, A; Capasso, F; Di Marzo, V			The endocannabinoid system and the molecular basis of paralytic ileus in mice	FASEB JOURNAL			English	Article						anandamide transport; cannabinoid receptors; intestine; myenteric plexus	GUINEA-PIG ILEUM; IRRITATION-INDUCED ILEUS; GASTROINTESTINAL TRANSIT; PERITONEAL-IRRITATION; POSTOPERATIVE ILEUS; CANNABINOID RECEPTORS; LONGITUDINAL MUSCLE; CHOLINERGIC NEURONS; CIRCULAR MUSCLE; SMALL-INTESTINE	The endocannabinoid system (i.e., the cannabinoid receptors and their endogenous ligands) plays an important role in the physiological control of intestinal motility. However, its participation in intestinal pathological states is still poorly understood. In the present study, we investigated the possible role of the endocannabinoid system in the pathogenesis of paralytic ileus, a pathological state consisting of decreased intestinal motility following peritonitis, surgery, or other noxious situations. Ileus was induced by i.p. administration of acetic acid, and gastrointestinal propulsion was assessed by the charcoal method. Endocannabinoid levels were measured by isotope-dilution gas chromatography-mass spectrometry, whereas cannabinoid CB1 receptors were identified by immunohistochemistry. Acetic acid administration inhibited gastrointestinal transit (ileus), and this effect was accompanied by increased levels of the endocannabinoid anandamide compared with control mice and by overexpression of CB1 receptors in myenteric nerves. Furthermore, acetic acid-induced ileus was alleviated by the CB1 receptor antagonist SR141716A and worsened by VDM11, a selective inhibitor of anandamide cellular uptake (and hence inactivation). From these findings, it can be concluded that the intestinal hypomotility typical of paralytic ileus is due, at least in part, to the enhancement of anandamide levels and CB1 expression during this condition, and that selective, nonpsychotropic CB1 receptor antagonists could represent new drugs to treat this disorder.	Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy; CNR, Inst Biomol Chem, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Dept Biol Struct Funct & Technol, I-80137 Naples, Italy; Dept Pharmaceut Sci, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Izzo, AA (corresponding author), Univ Naples Federico II, Dept Expt Pharmacol, Via D Montesano 49, I-80131 Naples, Italy.	aaizzo@unina.it; vdimarzo@icmib.na.cnr.it	Ligresti, Alessia/B-7564-2015; Di Marzo, Vincenzo/AAD-7742-2019	Ligresti, Alessia/0000-0003-1787-3900; Di Marzo, Vincenzo/0000-0002-1490-3070; Izzo, Angelo/0000-0002-8557-2133				Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Brown DR, 2001, ADV EXP MED BIOL, V493, P197; Bueno L, 1978, DIGEST DIS SCI, V23, P690; Calignano A, 1997, EUR J PHARMACOL, V340, pR7; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; COUSINS HM, 1995, NEUROSCIENCE, V65, P193, DOI 10.1016/0306-4522(94)00466-I; Coutts AA, 2002, J COMP NEUROL, V448, P410, DOI 10.1002/cne.10270; Coutts AA, 1997, BRIT J PHARMACOL, V121, P1557, DOI 10.1038/sj.bjp.0701301; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DeWinter BY, 1997, BRIT J PHARMACOL, V120, P464, DOI 10.1038/sj.bjp.0700913; Di Marzo V, 2000, CURR PHARM DESIGN, V6, P1361; FONTAINE J, 1984, BRIT J PHARMACOL, V81, P231, DOI 10.1111/j.1476-5381.1984.tb10070.x; FRIDE E, 1995, BRAIN RES, V697, P83, DOI 10.1016/0006-8993(95)00790-W; Friese N, 1997, LIFE SCI, V60, P625, DOI 10.1016/S0024-3205(96)00647-9; FURNESS JB, 1974, MED BIOL, V52, P82; GALLIGAN JJ, 1986, J PHARMACOL EXP THER, V238, P594; GRISPOON L, 1997, MARIHUANA FORBIDDEN; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Heinemann A, 1999, NEUROPHARMACOLOGY, V38, P1289, DOI 10.1016/S0028-3908(99)00056-8; HOLZER P, 1986, GASTROENTEROLOGY, V91, P360, DOI 10.1016/0016-5085(86)90569-X; HOLZER P, 1984, BRIT J PHARMACOL, V82, P259, DOI 10.1111/j.1476-5381.1984.tb16466.x; Izzo AA, 2001, BRIT J PHARMACOL, V132, P1411, DOI 10.1038/sj.bjp.0703975; Izzo AA, 2000, BRIT J PHARMACOL, V129, P1627, DOI 10.1038/sj.bjp.0703265; Izzo AA, 1998, BRIT J PHARMACOL, V124, P1363, DOI 10.1038/sj.bjp.0701964; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Izzo Angelo A., 2001, Current Opinion in Pharmacology, V1, P597, DOI 10.1016/S1471-4892(01)00102-3; Kalff JC, 1999, GASTROENTEROLOGY, V117, P378, DOI 10.1053/gast.1999.0029900378; Kalff JC, 2000, GASTROENTEROLOGY, V118, P316, DOI 10.1016/S0016-5085(00)70214-9; Kulkarni-Narla A, 2000, CELL TISSUE RES, V302, P73, DOI 10.1007/s004410000261; LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233; MAGGI CA, 1994, N-S ARCH PHARMACOL, V350, P529; Mang CF, 2001, BRIT J PHARMACOL, V134, P161, DOI 10.1038/sj.bjp.0704220; MILLER MS, 1981, J PHARMACOL METHOD, V6, P211, DOI 10.1016/0160-5402(81)90110-8; OKASORA T, 1986, GASTROENTEROLOGY, V90, P1964, DOI 10.1016/0016-5085(86)90268-4; PAIRET M, 1989, J PHARM PHARMACOL, V41, P757, DOI 10.1111/j.2042-7158.1989.tb06360.x; Pertwee RG, 1996, BRIT J PHARMACOL, V118, P2199, DOI 10.1111/j.1476-5381.1996.tb15663.x; Pertwee RG, 2001, GUT, V48, P859, DOI 10.1136/gut.48.6.859; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; RIVIERE PJM, 1993, GASTROENTEROLOGY, V104, P724, DOI 10.1016/0016-5085(93)91007-5; RIVIERE PJM, 1994, J PHARMACOL EXP THER, V270, P846; Sang Q, 1998, ANAT REC, V251, P185; Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605; SIMS SM, 1986, TRENDS PHARMACOL SCI, V11, P1; Tache Y., 1991, J GASTROINTEST MOTIL, V3, P19; Tallarida RJ, 1986, MANUAL PHARM CALCULA; UNEKWE PC, 1991, PHARMACOL RES, V23, P389, DOI 10.1016/1043-6618(91)90053-Z; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Van Sickle MD, 2001, GASTROENTEROLOGY, V121, P767, DOI 10.1053/gast.2001.28466; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343	53	76	79	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1973	+		10.1096/fj.02-0338fje	http://dx.doi.org/10.1096/fj.02-0338fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397089				2022-12-25	WOS:000179167600008
J	MacFarlane, AJ; Burghardt, KM; Kelly, J; Simell, T; Simell, O; Altosaar, I; Scott, FW				MacFarlane, AJ; Burghardt, KM; Kelly, J; Simell, T; Simell, O; Altosaar, I; Scott, FW			A type 1 diabetes-related protein from wheat (Triticum aestivum) - cDNA clone of a wheat storage globulin, Glb1, linked to islet damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROVIRUS INFECTION; CELIAC-DISEASE; IGE-BINDING; INSULIN; CHILDREN; GLUTEN; ONSET; DIET; IDENTIFICATION; PERMEABILITY	The development of autoimmune type 1 diabetes involves complex interactions among several genes and environmental agents. Human patients with type 1 diabetes show an unusually high frequency of wheat gluten-sensitive enteropathy; T-cell response to wheat proteins is increased in some patients, and high concentrations of wheat antibodies in blood have been reported. In both major models of spontaneous type 1 diabetes, the BioBreeding (BB) rat and non-obese diabetic mouse, at least half of the cases are diet-related. In studies of BB rats fed defined semipurified diets, wheat gluten was the most potent diabetes-inducing protein source. A major limitation in understanding how wheat or other dietary antigens affect type 1 diabetes has been the difficulty in identifying specific diabetes-related dietary proteins. To address this issue, we probed a wheat cDNA expression library with polyclonal IgG antibodies from diabetic BB rats. Three clones were identified, and the intensity of antibody binding to one of them, WP5212, was strongly associated with pancreatic islet inflammation and damage. The WP5212 putative protein has high amino acid sequence homology with a wheat storage globulin, G1b1. Serum IgG antibodies from diabetic rats and humans recognized low molecular mass (33-46 kDa) wheat proteins. Furthermore, antibodies to G1b1 protein were found in serum from diabetic patients but not in age-, sex-, and HILA-DQ-matched controls. This study raises the possibility that in some individuals, type 1 diabetes may be induced by wheat proteins. Also, it provides a first candidate wheat protein that is not only antigenic in diabetic rats and human patients but is also closely linked with the autoimmune attack in the pancreas.	Ottawa Hlth Res Inst, Autoimmune Dis Grp Diabet, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Hlth Canada, Nutr Res Div, Ottawa, ON K1A 0L2, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; National Research Council Canada; University of Turku; Health Canada	Scott, FW (corresponding author), Ottawa Hlth Res Inst, Autoimmune Dis Grp Diabet, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	fscott@ohri.ca	ALTOSAAR, ILLIMAR/A-4668-2008	ALTOSAAR, ILLIMAR/0000-0001-5018-036X; Burghardt, Karolina/0000-0002-5942-5308				Akerblom HK, 1998, DIABETES METAB REV, V14, P31, DOI 10.1002/(SICI)1099-0895(199803)14:1&lt;31::AID-; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; BAEKKESKOV S, 1984, SCIENCE, V224, P1348, DOI 10.1126/science.6374896; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Bao F, 1999, J AUTOIMMUN, V13, P143, DOI 10.1006/jaut.1999.0303; Beales PE, 2002, DIABETOLOGIA, V45, P1240, DOI 10.1007/s00125-002-0898-2; BUESAGOMEZ J, 1994, J MED VIROL, V42, P193, DOI 10.1002/jmv.1890420217; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Carratu R, 1999, J PEDIATR GASTR NUTR, V28, P264, DOI 10.1097/00005176-199903000-00010; COLEMAN DL, 1990, DIABETES, V39, P432, DOI 10.2337/diabetes.39.4.432; FABIJANSKI S, 1985, FEBS LETT, V182, P465, DOI 10.1016/0014-5793(85)80355-0; Field LL, 2002, DIABETOLOGIA, V45, P21, DOI 10.1007/s125-002-8241-7; Foulis AK, 1997, DIABETOLOGIA, V40, P53, DOI 10.1007/s001250050642; Funda DP, 1999, DIABETES-METAB RES, V15, P323; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gianibelli MC, 2001, CEREAL CHEM, V78, P635, DOI 10.1094/CCHEM.2001.78.6.635; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; GRAVELAND A, 1979, J SCI FOOD AGR, V30, P71, DOI 10.1002/jsfa.2740300112; HOORFAR J, 1993, BRIT J NUTR, V69, P597, DOI 10.1079/BJN19930059; HOORFAR J, 1991, J NUTR, V121, P908, DOI 10.1093/jn/121.6.908; Imagawa A, 2001, DIABETES, V50, P1269, DOI 10.2337/diabetes.50.6.1269; Juhela S, 2000, DIABETES, V49, P1308, DOI 10.2337/diabetes.49.8.1308; Karges W, 1997, DIABETES, V46, P557, DOI 10.2337/diabetes.46.4.557; Klemetti P, 1998, SCAND J IMMUNOL, V47, P48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampasona V, 1999, DIABETOLOGIA, V42, P1195, DOI 10.1007/s001250051291; MacMurray AJ, 2002, GENOME RES, V12, P1029, DOI 10.1101/gr.412702; Marcone MF, 1998, FOOD CHEM, V62, P27, DOI 10.1016/S0308-8146(97)00158-1; MARCONE MF, 1995, J FOOD BIOCHEM, V18, P123, DOI 10.1111/j.1745-4514.1994.tb00493.x; Meddings JB, 1999, AM J PHYSIOL-GASTR L, V276, pG951, DOI 10.1152/ajpgi.1999.276.4.G951; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Patterson CC, 2000, DIABETOLOGIA, V43, P684; Rao GN, 1996, FUND APPL TOXICOL, V32, P102, DOI 10.1006/faat.1996.0112; ROBERT LS, 1985, PLANT PHYSIOL, V78, P812, DOI 10.1104/pp.78.4.812; ROSSINI AA, 1979, DIABETES, V28, P1031, DOI 10.2337/diabetes.28.11.1031; Scott F W, 1988, Adv Exp Med Biol, V246, P277; Scott FW, 1996, DIABETES METAB REV, V12, P341, DOI 10.1002/(SICI)1099-0895(199612)12:4&lt;341::AID-DMR173&gt;3.0.CO;2-O; SHEWRY PR, 1995, BIOL REV, V70, P375, DOI 10.1111/j.1469-185X.1995.tb01195.x; Singh J, 2001, J CEREAL SCI, V34, P85, DOI 10.1006/jcrs.2001.0380; Vaarala O, 2002, DIABETOLOGIA, V45, P531, DOI 10.1007/s00125-002-0787-8; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; Viskari HR, 2002, DIABETES, V51, P2568, DOI 10.2337/diabetes.51.8.2568	47	64	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					54	63		10.1074/jbc.M210636200	http://dx.doi.org/10.1074/jbc.M210636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409286	hybrid			2022-12-25	WOS:000180255700007
J	Hagihara, Y; Shiraki, K; Nakamura, T; Uegaki, K; Takagi, M; Imanaka, T; Yumoto, N				Hagihara, Y; Shiraki, K; Nakamura, T; Uegaki, K; Takagi, M; Imanaka, T; Yumoto, N			Screening for stable mutants with amino acid pairs substituted for the disulfide bond between residues 14 and 38 of bovine pancreatic trypsin inhibitor (BPTI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FOLDING KINETICS; STABILITY; BINDING; SECRETION; YEAST; THERMODYNAMICS; EFFICIENCY; VARIANTS; FRAGMENT	We have developed a screening method to identify stable protein mutants from a large number of sequences using a cellular quality control system. This method was used to screen amino acid pairs substituted for the disulfide (S-S) bond between residues 14 and 38 of bovine pancreatic trypsin inhibitor. The mutants selected could be divided into two groups: one with mutation C14G and the other with mutation C38V. Although each mutation did not fully compensate for the destabilizing effect of removal of the S-S bond, these mutants have midpoint temperatures of thermal unfolding that are 12-17 degreesC higher than that of the C14A/C38A mutant. This fact indicates that these mutations are better substitutions for the S-S bond than C14A/C38A. The C14G mutants inhibited trypsin more strongly at 37 degreesC than did the C14A/C38A mutant, although bulky amino acids at position 14 largely diminished the inhibitory activity of the C38V mutants. Thermodynamic analysis indicated that the enthalpy of unfolding of the C14G and C38V mutant groups differed considerably, which suggests different stabilizing mechanisms in these two groups. Because renaturation of S-S bonds is often difficult in the large scale production of proteins, this method should provide a useful tool with which to increase the production of recombinant proteins by eliminating S-S bonds with minimum concomitant stability loss.	Natl Inst Adv Ind Sci & Technol, Special Div Human Life Technol, Osaka 5638577, Japan; Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Advanced Institute of Science & Technology (JAIST); Kyoto University	Hagihara, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Special Div Human Life Technol, 1-8-31 Midorigaoka, Osaka 5638577, Japan.	hagihara-kappael@aist.go.jp; n-yumoto@aist.go.jp	Nakamura, Tsutomu/M-3412-2018; HAGIHARA, Yoshihisa/K-4996-2016	Nakamura, Tsutomu/0000-0002-5511-8087; HAGIHARA, Yoshihisa/0000-0002-5980-1764				BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Castro MJM, 1996, BIOCHEMISTRY-US, V35, P11435, DOI 10.1021/bi960515w; CLEMENTS JM, 1991, GENE, V106, P267, DOI 10.1016/0378-1119(91)90209-T; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; Hagihara Y, 2002, P NATL ACAD SCI USA, V99, P6619, DOI 10.1073/pnas.102172099; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; HURLE MR, 1990, BIOCHEMISTRY-US, V29, P4410, DOI 10.1021/bi00470a021; Kassell B., 1970, METHODS ENZYMOLOGY, VVolume 19, P844, DOI [10.1016/0076-6879(70)19074-4, DOI 10.1016/0076-6879(70)19074-4]; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; Kjeldsen T, 2002, J BIOL CHEM, V277, P18245, DOI 10.1074/jbc.C200137200; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; Kuroda Y, 2000, J MOL BIOL, V298, P493, DOI 10.1006/jmbi.2000.3622; KUROKI R, 1992, BIOCHEMISTRY-US, V31, P8323, DOI 10.1021/bi00150a028; Liu Y, 1997, BIOCHEMISTRY-US, V36, P5323, DOI 10.1021/bi962423c; MAKHATADZE GI, 1993, PROTEIN SCI, V2, P2028, DOI 10.1002/pro.5560021204; MAYR LM, 1994, PROTEIN SCI, V3, P227; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; PACE CN, 1988, J BIOL CHEM, V263, P11820; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Ramm K, 1999, J MOL BIOL, V290, P535, DOI 10.1006/jmbi.1999.2854; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; Sambrook J, 2001, MOL CLONING LAB MANU; SCHWARZ H, 1987, BIOCHEMISTRY-US, V26, P3544, DOI 10.1021/bi00386a044; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; TACHIBANA H, 1994, BIOCHEMISTRY-US, V33, P15008, DOI 10.1021/bi00254a009; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; WEISSMAN JS, 1995, NAT STRUCT BIOL, V2, P1123, DOI 10.1038/nsb1295-1123; YU MH, 1995, J MOL BIOL, V249, P388, DOI 10.1006/jmbi.1995.0304; Zavodszky M, 2001, PROTEIN SCI, V10, P149, DOI 10.1110/ps.26801	38	22	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51043	51048		10.1074/jbc.M208893200	http://dx.doi.org/10.1074/jbc.M208893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393867	hybrid			2022-12-25	WOS:000180177700111
J	Sakamoto, H; Tosaki, T; Nakagawa, Y				Sakamoto, H; Tosaki, T; Nakagawa, Y			Overexpression of phospholipid hydroperoxide glutathione peroxidase modulates acetyl-CoA, 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; HUMAN-ENDOTHELIAL-CELLS; DEPENDENT PROTEIN-KINASE; LYSO-PAF-ACETYLTRANSFERASE; P38 SIGNALING PATHWAYS; NECROSIS-FACTOR-ALPHA; HUMAN-NEUTROPHILS; MAP KINASE; HYDROGEN-PEROXIDE; PROSTAGLANDIN D-2	The synthesis of platelet-activating factor (PAF) by A23187-stimulated RBL-2H3 cells was significantly suppressed by overexpression. of phospholipid hydroperoxide glutathione peroxidase (PHGPx). When the cells overexpressing PHGPx (L9 cells) were pretreated with diethyl maleate, which reduces PHGPx activity, PAF synthesis upon A23187 stimulation rose to levels seen in mock-transfected cells (S1 cells). Hydroperoxide levels, which are reduced in L9 cells, are involved in regulating PAF synthesis, because the addition of hydroperoxyeicosatetraenoic acid increased PAF production in A23187-stimulated L9 cells to control cell levels. The activity of acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase, which is involved in the last step of PAF synthesis, is also reduced in L9 cells. p38 kinase inhibitors block acetyltransferase activity in normal A23187-stimulated cells, suggesting that p38 kinase is involved in regulating acetyltransferase activity. Recombinant active p38 kinase activates acetyltransferase, whereas alkaline phosphatase reverses this, suggesting p38 kinase directly phosphorylates acetyltransferase. p38 kinase phosphorylation is blocked in L9 cells, indicating that high hydroperoxide levels are needed for the activation of p38 kinase. Thus, intracellular hydroperoxide levels participate in regulating p38 kinase phosphorylation, which in turn controls the activation of acetyltransferase and thus the synthesis of PAF. These observations suggest that PHGPx is an important component of the mechanisms regulating inflammation.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Kitasato University	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.							Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BAKER SS, 1983, J IMMUNOL, V130, P2856; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; BRYANT RW, 1983, BIOCHEM BIOPH RES CO, V117, P183, DOI 10.1016/0006-291X(83)91558-9; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; Chiu C, 2001, INT J MOL MED, V8, P251; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GOMEZCAMBRONERO J, 1987, BIOCHEM J, V245, P893, DOI 10.1042/bj2450893; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P516, DOI 10.1016/0167-4889(85)90219-8; Guiney DG, 1997, J CLIN INVEST, V99, P565, DOI 10.1172/JCI119196; HAMPEL G, 1989, BIOCHIM BIOPHYS ACTA, V1006, P151, DOI 10.1016/0005-2760(89)90189-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hashimoto S, 1999, EUR RESPIR J, V13, P1357, DOI 10.1034/j.1399-3003.1999.13f21.x; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Krull M, 1996, J IMMUNOL, V157, P4133; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin TJ, 1996, BIOCHEM PHARMACOL, V51, P1237, DOI 10.1016/0006-2952(96)00067-6; MOLLINEDO F, 1988, BIOCHEM BIOPH RES CO, V154, P1232, DOI 10.1016/0006-291X(88)90271-9; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; NAKAGAWA Y, 1992, BIOCHIM BIOPHYS ACTA, V1126, P277, DOI 10.1016/0005-2760(92)90241-M; NIETO ML, 1988, J BIOL CHEM, V263, P4607; NINIO E, 1987, J IMMUNOL, V139, P154; Nixon AB, 1999, J BIOL CHEM, V274, P5469, DOI 10.1074/jbc.274.9.5469; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrakhovitch EA, 2001, BIOCHEM PHARMACOL, V62, P743, DOI 10.1016/S0006-2952(01)00707-9; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Sakamoto H, 1999, J BIOCHEM-TOKYO, V125, P90, DOI 10.1093/oxfordjournals.jbchem.a022274; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schnurr K, 1999, FASEB J, V13, P143, DOI 10.1096/fasebj.13.1.143; Schnurr K, 1996, J BIOL CHEM, V271, P4653; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; THOMAS JP, 1990, J BIOL CHEM, V265, P454; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WAGNER G, 1994, BIOCHEM PHARMACOL, V48, P1137, DOI 10.1016/0006-2952(94)90150-3; WYKLE RL, 1980, J BIOL CHEM, V255, P256; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	67	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50431	50438		10.1074/jbc.M204190200	http://dx.doi.org/10.1074/jbc.M204190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397078	hybrid			2022-12-25	WOS:000180177700030
J	Fierobe, HP; Bayer, EA; Tardif, C; Czjzek, M; Mechaly, A; Belaich, A; Lamed, R; Shoham, Y; Belaich, JP				Fierobe, HP; Bayer, EA; Tardif, C; Czjzek, M; Mechaly, A; Belaich, A; Lamed, R; Shoham, Y; Belaich, JP			Degradation of cellulose substrates by cellulosome chimeras - Substrate targeting versus proximity of enzyme components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAFFOLDING PROTEIN CIPC; CLOSTRIDIUM-THERMOCELLUM CELLULOSOME; COHESIN-DOCKERIN INTERACTION; BINDING DOMAINS; CELLULOLYTICUM; PURIFICATION; CELLULASES; REVEALS; COMPLEX; HYDROLYSIS	A library of 75 different chimeric cellulosomes was constructed as an extension of our previously described approach for the production of model functional complexes (Fierobe, H.-P., Mechaly, A., Tardif, C., Belaich, A., Lamed, R., Shoham, Y., Belaich, J.-P., and Bayer, E. A (2001) J. BioL Chem. 276,21257-21261), based on the high affinity species-specific cohesin-dockerin interaction. Each complex contained three protein components: (i) a chimeric scaffoldin possessing an optional cellulose-binding module and two cohesins of divergent specificity, and (ii) two cellulases, each bearing a dockerin complementary to one of the divergent cohesins. The activities of the resultant ternary complexes were assayed using different types of cellulose substrates. Organization of cellulolytic enzymes into cellulosome chimeras resulted in characteristically high activities on recalcitrant substrates, whereas the cellulosome chimeras showed little or no advantage over free enzyme systems on tractable substrates. On recalcitrant cellulose, the presence of a cellulose-binding domain on the scaffoldin and enzyme proximity on the resultant complex contributed almost equally to their elevated action on the substrate. For certain enzyme pairs, however, one effect appeared to predominate over the other. The results also indicate that substrate recalcitrance is not necessarily a function of its crystallinity but reflects the overall accessibility of reactive sites.	CNRS, IBSM, IFR1, Bioenerget & Ingn Prot, F-13402 Marseille, France; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Aix Marseille 1, F-13331 Marseille, France; CNRS, IBSM, Architecture Fonctionnelle Macromol, F-13402 Marseille, France; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Weizmann Institute of Science; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Tel Aviv University; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Fierobe, HP (corresponding author), CNRS, IBSM, IFR1, Bioenerget & Ingn Prot, F-13402 Marseille, France.	hpfierob@ibsm.cnrs-mrs.fr	FIEROBE, Henri-Pierre/P-4372-2019; Shoham, Yuval/M-4409-2013					ATALLA RH, 1999, COMPREHENSIVE NATURA, V3, P529; BAYER EA, 1994, TRENDS BIOTECHNOL, V12, P379, DOI 10.1016/0167-7799(94)90039-6; Bayer EA, 1998, J STRUCT BIOL, V124, P221, DOI 10.1006/jsbi.1998.4065; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; BAYER EA, 2000, PROKARYOTES EVOLVING; Beguin P, 1996, CRIT REV BIOCHEM MOL, V31, P201, DOI 10.3109/10409239609106584; Belaich JP, 1997, J BIOTECHNOL, V57, P3, DOI 10.1016/S0168-1656(97)00085-0; Blum DL, 2000, J BACTERIOL, V182, P1346, DOI 10.1128/JB.182.5.1346-1351.2000; Boisset C, 2000, APPL ENVIRON MICROB, V66, P1444, DOI 10.1128/AEM.66.4.1444-1452.2000; Boisset C, 1999, BIOCHEM J, V340, P829, DOI 10.1042/0264-6021:3400829; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; COUTINHO PM, 1999, GENETICS BIOCH ECOLO, P15; DOI RH, 1994, CRIT REV MICROBIOL, V20, P87, DOI 10.3109/10408419409113548; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FELIX CR, 1993, ANNU REV MICROBIOL, V47, P791, DOI 10.1146/annurev.micro.47.1.791; FIEROBE HP, 1993, EUR J BIOCHEM, V217, P557, DOI 10.1111/j.1432-1033.1993.tb18277.x; FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; Fierobe HP, 2001, J BIOL CHEM, V276, P21257, DOI 10.1074/jbc.M102082200; Gal L, 1997, APPL ENVIRON MICROB, V63, P903, DOI 10.1128/AEM.63.3.903-909.1997; Gal L, 1997, J BACTERIOL, V179, P6595, DOI 10.1128/jb.179.21.6595-6601.1997; Gaudin C, 2000, J BACTERIOL, V182, P1910, DOI 10.1128/JB.182.7.1910-1915.2000; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGGETT ASG, 1957, LANCET, V2, P368; Irwin D, 1998, J BACTERIOL, V180, P1709, DOI 10.1128/JB.180.7.1709-1714.1998; Kataeva IA, 2002, APPL ENVIRON MICROB, V68, P4292, DOI 10.1128/AEM.68.9.4292-4300.2002; LAMED R, 1983, J BACTERIOL, V156, P828, DOI 10.1128/JB.156.2.828-836.1983; Levy I, 2002, BIOMOL ENG, V19, P17, DOI 10.1016/S1389-0344(02)00007-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mechaly A, 2001, J BIOL CHEM, V276, P9883, DOI 10.1074/jbc.M009237200; OSullivan AC, 1997, CELLULOSE, V4, P173, DOI 10.1023/A:1018431705579; Pages S, 1997, J BACTERIOL, V179, P2810, DOI 10.1128/jb.179.9.2810-2816.1997; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Pages S, 1996, J BACTERIOL, V178, P2279, DOI 10.1128/jb.178.8.2279-2286.1996; PARK JT, 1949, J BIOL CHEM, V181, P149; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; ReverbelLeroy C, 1996, MICROBIOL-SGM, V142, P1013, DOI 10.1099/00221287-142-4-1013; ReverbelLeroy C, 1997, J BACTERIOL, V179, P46, DOI 10.1128/jb.179.1.46-52.1997; Samejima M, 1997, CARBOHYD RES, V305, P281, DOI 10.1016/S0008-6215(97)10034-9; Schaeffer F, 2002, BIOCHEMISTRY-US, V41, P2106, DOI 10.1021/bi011853m; Schwarz WH, 2001, APPL MICROBIOL BIOT, V56, P634, DOI 10.1007/s002530100710; Tamaru Y, 2001, P NATL ACAD SCI USA, V98, P4125, DOI 10.1073/pnas.071045598; Valjamae P, 1999, EUR J BIOCHEM, V266, P327, DOI 10.1046/j.1432-1327.1999.00853.x; WALSETH CS, 1952, TAPPI, V35, P228; Watson DL, 2002, APPL BIOCHEM BIOTECH, V101, P97, DOI 10.1385/ABAB:101:2:097; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J; Yaron S, 1996, J BIOTECHNOL, V51, P243, DOI 10.1016/S0168-1656(96)01602-1	51	236	252	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49621	49630		10.1074/jbc.M207672200	http://dx.doi.org/10.1074/jbc.M207672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397074	hybrid			2022-12-25	WOS:000180028900069
J	Hetman, M; Hsuan, SL; Habas, A; Higgins, MJ; Xia, ZG				Hetman, M; Hsuan, SL; Habas, A; Higgins, MJ; Xia, ZG			ERK1/2 antagonizes glycogen synthase kinase-3 beta-induced apoptosis in cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CEREBELLAR GRANULE NEURONS; SIGNAL-REGULATED KINASE; ELEMENT-BINDING PROTEIN; CELL-SURVIVAL; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL REGULATION; GROWTH-FACTOR; BAD PHOSPHORYLATION	Inhibition of glycogen synthase kinase-3beta (GSK3beta) is one of the mechanisms by which phosphatidylinositol 3-kinase (PI3K) activation protects neurons from apoptosis. Here, we report that inhibition of ERK1/2 increased the basal activity of GSK3beta in cortical neurons and that both ERK1/2 and PI3K were required for brain-derived neurotrophic factor (BDNF) suppression of GSK3beta activity. Moreover, cortical neuron apoptosis induced by expression of recombinant GSK3beta was inhibited by coexpression of constitutively active MKK1 or PI3K. Activation of both endogenous ERK1/2 and PI3K signaling pathways was required for BDNF to block apoptosis induced by expression of recombinant GSK3beta. Furthermore, cortical neuron apoptosis induced by LY294002-mediated activation of endogenous GSK3beta was blocked by expression of constitutively active MKK1 or by BDNF via stimulation of the endogenous ERK1/2 pathway. Although both PI3K and ERK1/2 inhibited GSK3beta activity, neither had an effect on GSK3beta phosphorylation at Tyr-216. Interestingly, PI3K (but not ERK1/2) induced the inhibitory phosphorylation of GSK3beta at Ser-9. Significantly, coexpression of constitutively active MKK1 (but not PI3K) still suppressed neuronal apoptosis induced by expression of the GSK3beta(S9A) mutant. These data suggest that activation of the ERK1/2 signaling pathway protects neurons from GSK3beta-induced apoptosis and that inhibition of GSK3beta may be a common target by which ERK1/2 and PI3K protect neurons from apoptosis. Furthermore, ERK1/2 inhibits GSK3beta activity via a novel mechanism that is independent of Ser-9 phosphorylation and likely does not involve Tyr-216 phosphorylation.	Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; M Nencki Inst Expt Biol, PL-02109 Warsaw, Poland; Int Inst Mol & Cellular Biol, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Xia, ZG (corresponding author), Univ Washington, Dept Environm Hlth, Box 357234, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019193] Funding Source: NIH RePORTER; NIA NIH HHS [AG 19193] Funding Source: Medline; NINDS NIH HHS [NS 37359] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; DEL PL, 1997, SCIENCE, V278, P687; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GOODE N, 1992, J BIOL CHEM, V267, P16878; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parrizas M, 1997, J BIOL CHEM, V272, P154; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Skaper SD, 1998, J NEUROCHEM, V70, P1859, DOI 10.1046/j.1471-4159.1998.70051859.x; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Thiels E, 2002, J NEUROSCI, V22, P2054, DOI 10.1523/JNEUROSCI.22-06-02054.2002; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Valjent E, 2000, J NEUROSCI, V20, P8701; Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; Wang H, 2001, BIOCHEM BIOPH RES CO, V286, P869, DOI 10.1006/bbrc.2001.5482; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yan CYI, 1998, J NEUROSCI, V18, P4042; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	59	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49577	49584		10.1074/jbc.M111227200	http://dx.doi.org/10.1074/jbc.M111227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393899	hybrid			2022-12-25	WOS:000180028900063
J	Li, J; Chen, PL; Sinogeeva, N; Gorospe, M; Wersto, RP; Chrest, FJ; Barnes, J; Liu, YS				Li, J; Chen, PL; Sinogeeva, N; Gorospe, M; Wersto, RP; Chrest, FJ; Barnes, J; Liu, YS			Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-RETINOIC ACID; INDUCED APOPTOSIS; DOWN-REGULATION; PMLRAR-ALPHA; IN-VITRO; PHOSPHORYLATION; TRANSCRIPTION; DEACETYLASE; REMISSION; APL	Arsenic trioxide (As2O3) is highly effective for the treatment of acute promyelocytic leukemia, even in patients who are unresponsive to all-trans-retinoic acid therapy. As2O3 is believed to function primarily by promoting apoptosis, but the underlying molecular mechanisms remain largely unknown. In this report, using cDNA arrays, we have examined the changes in gene expression profiles triggered by clinically achievable doses of As2O3 in acute promyelocytic leukemia NB4 cells. CASPASE-10 expression was found to be potently induced by As2O3. Accordingly, caspase-10 activity also substantially increased in response to AS(2)O(3) treatment. A selective inhibitor of caspase-10, Z-AEVD-FMK, effectively blocked caspase-3 activation and significantly attenuated AS(2)O(3)-triggered apoptosis. Interestingly, the treatment of NB4 cells with AS(2)O(3) markedly increased histone H3 phosphorylation at serine 10, an event that is associated with acetylation of the lysine 14 residue. Chromatin immunoprecipitation assays revealed that AS(2)O(3) potently enhances histone H3 phosphoacetylation at the CASPASE-10 locus. These results suggest that the effect of As2O3 on histone H3 phosphoacetylation at the CASPASE-10 gene may play an important role in the induction of apoptosis and thus contribute to its therapeutic effects on acute promyelocytic leukemia.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Liu, YS (corresponding author), NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Chen GQ, 1996, BLOOD, V88, P1052; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Heusterspreute M, 1996, HUM GENET, V98, P77, DOI 10.1007/s004390050163; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Powell BL, 2001, CURR OPIN ONCOL, V13, P8, DOI 10.1097/00001622-200101000-00003; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Soignet SL, 2001, ONCOLOGIST, V6, P11; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Warrell R P Jr, 1999, Haematologica, V84 Suppl EHA-4, P75; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	38	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49504	49510		10.1074/jbc.M207836200	http://dx.doi.org/10.1074/jbc.M207836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388546	hybrid			2022-12-25	WOS:000180028900053
J	Paschos, A; Bauer, A; Zimmermann, A; Zehelein, E; Bock, A				Paschos, A; Bauer, A; Zimmermann, A; Zehelein, E; Bock, A			HypF, a carbamoyl phosphate-converting enzyme involved in [NiFe] hydrogenase maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HYDROGENASE-3; CRYSTAL-STRUCTURE; HOST STRAINS; HYDA LOCUS; NICKEL; PROTEINS; IDENTIFICATION; SEQUENCES; MUTANTS; FORMATE	HypF has been characterized as an auxiliary protein whose function is required for the synthesis of active [NiFe] hydrogenases in Escherichia coli and other bacteria. To approach the functional analysis, in particular the involvement in CO/CN ligand synthesis, HypF was purified from an overproducing strain to apparent homogeneity. The purified protein behaves as a monomer on size exclusion chromatography, and it is devoid of nickel or other cofactors. As indicated by the existence of a sequence motif also present in several O-carbamoyltransferases, HypF interacts with carbamoyl phosphate as a substrate and releases inorganic phosphate. In addition, HypF also possesses ATP cleavage activity that gives rise to AMP and pyrophosphate as products and that is dependent on the presence of carbamoyl phosphate. This and the fact that HypF catalyzes a carbamoyl phosphate-dependent pyrophosphate ATP exchange reaction suggest that the protein catalyzes activation of carbamoyl phosphate. Extensive mutagenesis of the putative functional motifs deduced from the derived amino acid sequence showed a full correlation of the resulting variants between their activity in hydrogenase maturation and the in vitro reactivity with carbamoyl phosphate. The results are discussed in terms of the involvement of HypF in the conversion of carbamoyl phosphate to the CN ligand.	Univ Munich, Dept Biol 1, Fac Biol, D-80638 Munich, Germany; Ascen GmbH, D-85764 Oberschleissheim, Germany	University of Munich	Bock, A (corresponding author), Univ Munich, Dept Biol 1, Fac Biol, Maria Ward Str 1A, D-80638 Munich, Germany.							Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BEGG YA, 1977, FEMS MICROBIOL LETT, V2, P47, DOI 10.1111/j.1574-6968.1977.tb00905.x; Bock A., 1996, ESCHERICHIA COLI SAL, V2, P262; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Drapal N, 1998, BIOCHEMISTRY-US, V37, P2941, DOI 10.1021/bi9720078; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; Fritsche E, 1999, J MOL BIOL, V288, P989, DOI 10.1006/jmbi.1999.2719; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CL, 1999, STRUCTURE, V7, P1155, DOI 10.1016/S0969-2126(99)80182-8; Magalon A, 2000, J BIOL CHEM, V275, P21114, DOI 10.1074/jbc.M000987200; Magalon A, 2001, FEBS LETT, V499, P73, DOI 10.1016/S0014-5793(01)02525-X; Maier T, 1996, ARCH MICROBIOL, V165, P333, DOI 10.1007/s002030050335; Maier T, 1996, BIOCHEMISTRY-US, V35, P10089, DOI 10.1021/bi960567l; MAIER T, 1996, MECH METALLOCENTER A, P173; MILLER JH, 1992, SHORT COURSE BACTERI, P439; MIZUNO Y, 1989, ANAL BIOCHEM, V183, P46, DOI 10.1016/0003-2697(89)90169-3; OCHMAN H, 1988, GENETICS, V120, P621; Olson JW, 1997, MOL MICROBIOL, V24, P119, DOI 10.1046/j.1365-2958.1997.3251690.x; Paschos A, 2001, FEBS LETT, V488, P9, DOI 10.1016/S0014-5793(00)02408-X; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; ROBSON R, 2001, HYDROGEN FUEL LEARNI, P57; ROSSMANN R, 1995, EUR J BIOCHEM, V227, P545, DOI 10.1111/j.1432-1033.1995.tb20422.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMLOT MM, 1973, FEBS LETT, V35, P201, DOI 10.1016/0014-5793(73)80284-4; Theodoratou E, 2000, EUR J BIOCHEM, V267, P1995, DOI 10.1046/j.1432-1327.2000.01202.x; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; Wolf I, 1998, ARCH MICROBIOL, V170, P451, DOI 10.1007/s002030050666; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; YAMAMOTO T, 1990, FEMS MICROBIOL LETT, V66, P187; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	101	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49945	49951		10.1074/jbc.M204601200	http://dx.doi.org/10.1074/jbc.M204601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377778	hybrid			2022-12-25	WOS:000180028900110
J	Saxena, A; Morozov, P; Frank, D; Musalo, R; Lemmon, MA; Skolnik, EY; Tycko, B				Saxena, A; Morozov, P; Frank, D; Musalo, R; Lemmon, MA; Skolnik, EY; Tycko, B			Phosphoinositide binding by the pleckstrin homology domains of Ipl and Tih1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PH-DOMAIN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; MEMBRANE ASSOCIATION; IN-VIVO; ACTIVATION; IDENTIFICATION; TRANSLOCATION; SPECIFICITY; RECEPTOR	The Ipl protein consists of a single pleckstrin homology (PH) domain with short N- and C-terminal extensions. This protein is highly conserved among vertebrates, and it acts to limit placental growth in mice. However, its biochemical function is unknown. The closest paralogue of Ipl is Tih1, another small PH domain protein. By sequence comparisons, Ipl and Tih1 define an outlying branch of the PH domain superfamily. Here we describe phosphatidylinositol phosphate (PIP) binding by these proteins. Ipl and Tih1 bind to immobilized PIPs with moderate affinity, but this binding is weaker and more promiscuous than that of prototypical PH domains from the general receptor for phosphoinositides (GRP1), phospholipase C 51, and dual adaptor for phosphoinositides and phosphotyrosine 1. In COS7 cells exposed to epidermal growth factor, green fluorescent protein (GFP)-Ipl and GFP-Tih1 accumulate at membrane ruffles without clearing from the cytoplasm, whereas control GFP-GRP1 translocates rapidly to the plasma membrane and clears from the cytoplasm. Ras*-Ipl and Ras*-Tih1 fusion proteins both rescue cdc25ts Saccharomyces cerevisiae, but Ras*-Ipl rescues more efficiently in the presence of phosphatidylinositol 3-kinase (PI3K), whereas PI3K-independent rescue is more efficient with Ras*-Tih1. Site-directed mutagenesis defines amino acids in the beta1-loopl-beta2 regions of Ipl and Tih1 as essential for growth rescue in this assay. Thus, Ipl and Tih1 are bona fide PH domain proteins, with broad specificity and moderate affinity for PIPs.	Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Genome Ctr, New York, NY 10032 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; NYU, Med Ctr, Dept Pharmacol, Skirball Inst Biomol Med, New York, NY 10016 USA	Columbia University; Columbia University; Columbia University; University of Pennsylvania; New York University	Tycko, B (corresponding author), Columbia Univ, Inst Canc Genet, Berrie Res Pavillion,1150 St Nicholas Ave, New York, NY 10032 USA.	bt12@columbia.edu	Saxena, Anjana/AAZ-5244-2020	Saxena, Anjana/0000-0001-8884-5179; Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [K08CA076454, R01CA060765] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA 76454, R01 CA 60765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bobe R, 2001, BLOOD, V97, P678, DOI 10.1182/blood.V97.3.678; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Frank D, 2002, P NATL ACAD SCI USA, V99, P7490, DOI 10.1073/pnas.122039999; Frank D, 1999, MAMM GENOME, V10, P1150, DOI 10.1007/s003359901182; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Thomas CC, 2001, BIOCHEM J, V358, P287, DOI 10.1042/0264-6021:3580287; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Xu SB, 1999, J BIOL CHEM, V274, P35676, DOI 10.1074/jbc.274.50.35676; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	40	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49935	49944		10.1074/jbc.M206497200	http://dx.doi.org/10.1074/jbc.M206497200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12374806	hybrid			2022-12-25	WOS:000180028900109
J	Kai, HST; Butler, GS; Morrison, CJ; King, AE; Pelman, GR; Overall, CM				Kai, HST; Butler, GS; Morrison, CJ; King, AE; Pelman, GR; Overall, CM			Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis - The importance of acidic residues in binding the MMP-2 hemopexin C domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GELATINASE-A; HUMAN 72-KDA GELATINASE; HIGH-AFFINITY BINDING; MATRIX-METALLOPROTEINASE; IV COLLAGENASE; CELL-SURFACE; POSTTRANSCRIPTIONAL REGULATION; EXTRACELLULAR-MATRIX; HUMAN FIBROBLASTS; COMPLEX-FORMATION	Tissue inhibitor of metalloproteinase (TIMP)-4 binds pro-matrix metalloproteinase (MMP)-2 and efficiently inhibits MT1-MMP, but unlike TIMP-2 neither forms a trimolecular complex nor supports pro-AMP-2 activation. To investigate the structural and functional differences between these two TIMPs, the C-terminal domains (C-TIMP-4 and C-TIMP-2) were expressed independently from their N domains and mutations were introduced into the C-terminal tails. Myoglobin was used as a novel recombinant fusion protein partner because spectroscopic measurement of the heme Soret absorbance at 408 nm readily enabled calculation of the molar equivalent of the red-colored recombinant protein, even in complex protein mixtures. Both C-TIMP-4 and C-TIMP-2 bound pro-MMP-2 and blocked concanavalin A-induced cellular activation of the enzyme. Measurement of k(on) rates revealed that the inhibition of MMP-2 by TIMP-4 is preceded by a C domain docking interaction, but in contrast to TIMP-2, this is not enhanced by a C-terminal tail interaction and so occurs at a slower rate. Indeed, the binding stability of C-TIMP-4 was unaltered by deletion of the C-terminal tail, but replacement with the tail of TIMP-2 increased its affinity for pro-AMP-2 by similar to2-fold, as did substitution with the TIMP-2 C-terminal tail acidic residues in the tail of C-TIMP-4 (V193E/Q1941). Conversely, substitution of the C-terminal tail of C-TIMP-2 with that of TIMP-4 reduced pro-MMP-2 binding by similar to75%, as did reduction of its acidic character by mutation to the corresponding TIMP-4 amino acid residues (E192V/D193Q). Together, this shows the importance of Glu(192) and Asp(193) in TIMP-2 binding to pro-MMP-2; the lack of these acidic residues in the TIMP-4 C-terminal tail, which reduces the stability of complex formation with the MMP-2 hemopexin C domain, probably precludes TIMP-4 from supporting the activation of pro-AMP-2.	Univ British Columbia, Canadian Inst Hlth, Res Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Fac Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Canadian Inst Hlth, Res Grp Matrix Dynam, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Maurus R, 1997, BBA-PROTEIN STRUCT M, V1341, P1, DOI 10.1016/S0167-4838(97)00064-2; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schonbeck U, 1998, J IMMUNOL, V161, P3340; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WILLENBROCK F, 1994, AM J RESP CRIT CARE, V150, pS165, DOI 10.1164/ajrccm/150.6_Pt_2.S165; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yu Q, 2000, GENE DEV, V14, P163; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	54	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48696	48707		10.1074/jbc.M209177200	http://dx.doi.org/10.1074/jbc.M209177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374789	hybrid			2022-12-25	WOS:000179789600095
J	Xu, BE; Min, XS; Stippec, S; Lee, BH; Goldsmith, EJ; Cobb, MH				Xu, BE; Min, XS; Stippec, S; Lee, BH; Goldsmith, EJ; Cobb, MH			Regulation of WNK1 by an autoinhibitory domain and autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; MAP KINASE; DOCKING; RECOGNITION; REVEALS; CELLS; MEK1; ERK2	WNK family protein kinases are large enzymes that contain the catalytic lysine in a unique position compared with all other protein kinases. These enzymes have been linked to a genetically defined form of hypertension. In this study we introduced mutations to test hypotheses about the position of the catalytic lysine, and we examined mechanisms involved in the regulation of WNK1 activity. Through the analysis of enzyme fragments and sequence alignments, we have identified an autoinhibitory domain of WNK1. This isolated domain, conserved in all four WNKs, suppressed the activity of the WNK1 kinase domain. Mutation of two key residues in this autoinhibitory domain attenuated its ability to inhibit WNK kinase activity. Consistent with these results, the same mutations in a WNK1 fragment that contain the autoinhibitory domain increased its kinase activity. We also found that WNK1 expressed in bacteria is autophosphorylated; autophosphorylation on serine 382 in the activation loop is required for its activity.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473; Lee, Byung-Hoon/0000-0002-7101-0471	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; COBB MH, 1989, J BIOL CHEM, V264, P18701; FROST JA, 1998, J BIOL CHEM, V273, P28253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Ito M, 2001, CANCER RES, V61, P2038; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Murakami-Kojima M, 2002, PLANT CELL PHYSIOL, V43, P675, DOI 10.1093/pcp/pcf084; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUIZPEREZ VL, 1995, CURR GENET, V28, P309, DOI 10.1007/BF00326428; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	26	119	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48456	48462		10.1074/jbc.M207917200	http://dx.doi.org/10.1074/jbc.M207917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374799	hybrid			2022-12-25	WOS:000179789600065
J	Venturini, G; Colasanti, M; Persichini, T; Fioravanti, E; Ascenzi, P; Palomba, L; Cantoni, O; Musci, G				Venturini, G; Colasanti, M; Persichini, T; Fioravanti, E; Ascenzi, P; Palomba, L; Cantoni, O; Musci, G			beta-Amyloid inhibits NOS activity by subtracting NADPH availability	FASEB JOURNAL			English	Article						Alzheimer's disease; nitric oxide; constitutive NOS inhibition	NITRIC-OXIDE SYNTHASE; ENZYME COMPLEX RECEPTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IN-VITRO; PEPTIDE; ACCUMULATION; MODULATION; GENERATION; ASTROCYTES	The amyloid peptides Abeta1-42 and Abeta25-35 strongly inhibited the activity of constitutive neuronal and endothelial nitric oxide synthases (i.e., NOS-I and NOS-III, respectively) in cell-free assays. The molecular mechanism of NOS inhibition by Abeta fragments was studied in detail with Abeta25-35. The inhibitory ability was mostly NADPH-dependent and specific for the soluble form of Abeta25-35. Optical, fluorescence, and NMR spectroscopy showed that the soluble, but not aggregated, Abeta25-35 interacted with NADPH, thus suggesting that a direct recruitment of NADPH may result in diminished availability of the redox cofactor for NOS functioning. To assess the physiological relevance of our findings, rat neuronal-like PC12 and glioma C6 cell lines were used as cellular models. After Abeta25-35 internalization into cells was verified, the activity of constitutive NOS was measured using the DAF-2DA detection system and found to be severely impaired upon Abeta25-35 uptake. Consistent with previous results on the molecular cross-talk between NOS isoforms, repression of constitutive NOS by Abeta25-35 resulted in enhanced expression of inducible NOS (NOS-II) mRNA in C6 cells. Our results represent the first evidence that amyloid fragments impair constitutive NOS activity in cell-free and cellular systems, providing a possible molecular mechanism for the onset and/or maintenance of Alzheimer's disease.	Univ Messina, Dept Microbiol Genet & Mol Sci, I-98166 Messina, Italy; Univ Urbino, Inst Pharmacol & Pharmacognosy, I-61029 Urbino, Italy; Univ Roma Tre, Dept Biol, Rome, Italy	University of Messina; University of Urbino; Roma Tre University	Musci, G (corresponding author), Univ Messina, Dept Microbiol Genet & Mol Sci, Salita Sperone 31, I-98166 Messina, Italy.	musci@unime.it	Musci, Giovanni/H-2862-2012; COLASANTI, MARCO/A-5616-2010	Musci, Giovanni/0000-0002-5196-709X; COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V246, P453, DOI 10.1006/bbrc.1998.8642; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; Colasanti M, 2000, BIOCHEM BIOPH RES CO, V275, P776, DOI 10.1006/bbrc.2000.3396; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; Huang AN, 2001, AM J PHYSIOL-CELL PH, V281, pC719, DOI 10.1152/ajpcell.2001.281.2.C719; Hudetz AG, 1998, AM J PHYSIOL-HEART C, V274, pH982, DOI 10.1152/ajpheart.1998.274.3.H982; Hudetz AG, 1999, J APPL PHYSIOL, V87, P505, DOI 10.1152/jappl.1999.87.2.505; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; LEONI S, 1986, CELL MOL BIOL, V32, P247; Lopez-Figueroa MO, 2000, BRAIN RES, V852, P239, DOI 10.1016/S0006-8993(99)02241-6; McCarty MF, 1999, MED HYPOTHESES, V53, P369, DOI 10.1054/mehy.1998.0783; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; PIACENTINI M, 1983, BIOCHIM BIOPHYS ACTA, V731, P151, DOI 10.1016/0005-2736(83)90004-4; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Price JM, 2001, NEUROL RES, V23, P506, DOI 10.1179/016164101101198758; Qu XW, 2001, FASEB J, V15, P439, DOI 10.1096/fj.99-0343com; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; Sanz MJ, 2001, BRIT J PHARMACOL, V134, P305, DOI 10.1038/sj.bjp.0704234; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Stefano GB, 2000, PROG NEUROBIOL, V60, P513, DOI 10.1016/S0301-0082(99)00038-6; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Venturini G, 2000, BIOCHEM PHARMACOL, V60, P539, DOI 10.1016/S0006-2952(00)00352-X; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan SD, 1997, NATURE, V389, P689; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	53	35	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1970	+		10.1096/fj.02-0186fje	http://dx.doi.org/10.1096/fj.02-0186fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397094				2022-12-25	WOS:000179167600006
J	Romier, C; Cocchiarella, F; Mantovani, R; Moras, D				Romier, C; Cocchiarella, F; Mantovani, R; Moras, D			The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR CBF; SUBUNIT INTERACTION; CRYSTAL-STRUCTURE; ACTIVATION DOMAINS; FUNCTIONAL DOMAINS; B-SUBUNIT; COMPLEX; YEAST; ASSOCIATION; CLONING	The heterotrimeric transcription factor NF-Y recognizes with high specificity and affinity the CCAAT regulatory element that is widely represented in promoters and enhancer regions. The CCAAT box acts in concert with neighboring elements, and its bending by NF-Y is thought to be a major mechanism required for transcription activation. We have solved the structure of the NF-YC/NF-YB subcomplex of NF-Y, which shows that the core domains of both proteins interact through histone fold motifs. This histone-like pair is closely related to the H2A/H2B and NC2alpha/NC2beta families, with features that are both common to this class of proteins and unique to NF-Y. The structure together with the modeling of the nonspecific interaction of NF-YC/NF-YB with DNA and the full NF-Y/CCAAT box complex highlight important structural features that account for different and possibly similar biological functions of the transcriptional regulators NF-Y and NC2. In particular, it emphasizes the role of the newly described alphaC helix of NF-YC, which is both important for NF-Y trimerization and a target for regulatory proteins, such as MYC and p53.	Univ Strasbourg 1, INSERM, CNRS,Dept Biol & Genomique Struct, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universita di Modena e Reggio Emilia	Moras, D (corresponding author), Univ Strasbourg 1, INSERM, CNRS,Dept Biol & Genomique Struct, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr		Romier, Christophe/0000-0002-3680-935X				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Gusmaroli G, 2001, GENE, V264, P173, DOI 10.1016/S0378-1119(01)00323-7; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Izumi H, 2001, J CELL SCI, V114, P1533; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; KIM CG, 1990, J BIOL CHEM, V265, P13362; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAITY SN, 1992, J BIOL CHEM, V267, P8286; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; Otwinowski Z, 1993, P CCP4 STUD WEEK DAT, P55; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; ROUSSEL A, 1992, SILICON GRAPHICS GEO, P86; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; XING YY, 1994, P NATL ACAD SCI USA, V91, P3009, DOI 10.1073/pnas.91.8.3009; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496	48	209	219	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1336	1345		10.1074/jbc.M209635200	http://dx.doi.org/10.1074/jbc.M209635200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401788	hybrid			2022-12-25	WOS:000180321900083
J	Hokuto, I; Perl, AKT; Whitsett, JA				Hokuto, I; Perl, AKT; Whitsett, JA			Prenatal, but not postnatal, inhibition of fibroblast growth factor receptor signaling causes emphysema	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; MOUSE LUNG; BRANCHING MORPHOGENESIS; EXPRESSION; GENE; FGF-10; LIMB; ORGANOGENESIS; LOCALIZATION; TISSUES	Although fibroblast growth factor (FGF) signaling is required for the formation of the lung in the embryonic period, it is unclear whether FGF receptor activity influences lung morphogenesis later in development. We generated transgenic mice expressing a soluble FGF receptor (FGFR-HFc) under conditional control of the lung-specific surfactant protein C promoter (SP-C-rtTA), to inhibit FGF activity at various times in late gestation and postnatally. Although expression of FGFR-HFc early in development caused severe fetal lung hypoplasia, activation of the transgene in the postnatal period did not alter alveolarization, lung size, or histology. In contrast, expression of the transgene at post-conception day E14.5 decreased lung tubule formation before birth and caused severe emphysema at maturity. FGFR-HFc caused mild focal emphysema when expressed from E16.5 but did not alter alveolarization when expressed after birth. Although FGF signaling was required for branching morphogenesis early in lung development, postnatal alveolarization was not influenced by FGFR-HFc.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Neonatol, 333 Burnet Ave, Cincinnati, OH 45229 USA.		Perl, Anne-Karina T/M-7174-2013; Hokuto, Isamu/AAP-5051-2021	Perl, Anne-Karina T/0000-0002-8445-4565; 	NHLBI NIH HHS [HL56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056387, P01HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bellusci S, 1997, DEVELOPMENT, V124, P4867; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Colvin JS, 1999, DEV DYNAM, V216, P72; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; HAN RNN, 1992, PEDIATR RES, V31, P435, DOI 10.1203/00006450-199205000-00004; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; KORHONEN J, 1992, INT J DEV BIOL, V36, P323; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; Powell PP, 1998, AM J RESP CELL MOL, V19, P563, DOI 10.1165/ajrcmb.19.4.2994; SANNES PL, 1992, AM J RESP CELL MOL, V7, P230, DOI 10.1165/ajrcmb/7.2.230; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Zhou L, 1996, AM J PHYSIOL-LUNG C, V271, pL987, DOI 10.1152/ajplung.1996.271.6.L987; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	35	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					415	421		10.1074/jbc.M208328200	http://dx.doi.org/10.1074/jbc.M208328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399466	Green Submitted, hybrid			2022-12-25	WOS:000180255700055
J	Whelan, MC; Senger, DR				Whelan, MC; Senger, DR			Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBE FORMATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; CALCEIN-AM; INTEGRIN; ANGIOGENESIS; EXPRESSION; MODULATION; LAMININ; INVITRO	Collagen I provokes endothelial cells to assume a spindle-shaped morphology and to align into solid cord-like assemblies. These cords closely imitate the solid precapillary cords of embryonic angiogenesis, raising interesting questions about underlying mechanisms. Studies described here identify a critical mechanism beginning with collagen I ligation of integrins alpha(1)beta(1) and alpha(2)beta(1) followed by suppression of cyclic AMP and cyclic AMP (cAMP)-dependent protein kinase X and marked induction of actin polymerization to form prominent stress fibers. In contrast to collagen 1, laminin-1 neither suppressed cAMP nor protein kinase A activity nor induced actin polymerization or changes in cell shape. Moreover, fibroblasts did not respond to collagen I with changes in cAMP, actin polymerization, or cell shape, thus indicating that collagen signaling, as observed in endothelial cells, does not extend to all cell types. Pharmacological elevation of cAMP blocked collagen-induced actin polymerization and formation of cords by endothelial cells; conversely, pharmacological suppression of either cAMP or protein kinase A induced actin polymerization. Collectively, these studies identify a previously unrecognized and critical mechanism, involving suppression of cAMP-dependent protein kinase A and induction of actin polymerization, through which collagen I drives endothelial cell organization into multicellular precapillary cords.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Senger, DR (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Res N,99 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA077357] Funding Source: NIH RePORTER; NCI NIH HHS [CA77357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALOISI M, 1971, VIRCHOWS ARCH B, V8, P328; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Decherchi P, 1997, J NEUROSCI METH, V71, P205, DOI 10.1016/S0165-0270(96)00146-X; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DELVOS U, 1982, LAB INVEST, V46, P61; Drake CJ, 1999, J HISTOCHEM CYTOCHEM, V47, P1351, DOI 10.1177/002215549904701101; Drake CJ, 1998, ANN NY ACAD SCI, V857, P155, DOI 10.1111/j.1749-6632.1998.tb10115.x; Drake CJ, 1997, DEV BIOL, V192, P17, DOI 10.1006/dbio.1997.8751; Drake CJ, 2000, BLOOD, V95, P1671, DOI 10.1182/blood.V95.5.1671.005k39_1671_1679; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FOUSER L, 1991, J BIOL CHEM, V266, P18345; Gatti R, 1998, J HISTOCHEM CYTOCHEM, V46, P895, DOI 10.1177/002215549804600804; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilan N, 1998, J CELL SCI, V111, P3621; INGBER D, 1988, LAB INVEST, V59, P44; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JACKSON CJ, 1994, CELL BIOL INT, V18, P859, DOI 10.1006/cbir.1994.1122; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; PAKU S, 1991, LAB INVEST, V65, P334; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; St Croix B, 2000, SCIENCE, V289, P1197; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; VERNON RB, 1995, AM J PATHOL, V147, P873; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389	40	121	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					327	334		10.1074/jbc.M207554200	http://dx.doi.org/10.1074/jbc.M207554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399469	hybrid			2022-12-25	WOS:000180255700044
J	Arroyo, A; Modriansky, M; Serinkan, FB; Bello, RI; Matsura, T; Jiang, JF; Tyurin, VA; Tyurina, YY; Fadeel, B; Kagan, VE				Arroyo, A; Modriansky, M; Serinkan, FB; Bello, RI; Matsura, T; Jiang, JF; Tyurin, VA; Tyurina, YY; Fadeel, B; Kagan, VE			NADPH oxidase-dependent oxidation and externalization of phosphatidylserine during apoptosis in Me2SO-differentiated HL-60 cells - Role in phagocytic clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PHOSPHATIDYLSERINE; NEUTROPHIL APOPTOSIS; SURFACE EXPOSURE; RECOGNITION; MECHANISM; RELEASE; DIMETHYLSULFOXIDE; MACROPHAGES; EXPRESSION; CASPASES	Resolution of inflammation requires clearance of activated neutrophils by phagocytes in a manner that protects adjacent tissues from injury. Mechanisms governing apoptosis and clearance of activated neutrophils from inflamed areas are still poorly understood. We used dimethylsulfoxide-differentiated HL-60 cells showing inducible oxidase activity to study NADPH oxidase-induced apoptosis pathways typical of neutrophils. Activation of the NADPH oxidase by phorbol myristate acetate caused oxidative stress as shown by production of superoxide and hydrogen peroxide, depletion of intracellular glutathione, and peroxidation of all three major classes of membrane phospholipids, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. In addition, phorbol myristate acetate stimulation of the NADPH oxidase caused apoptosis, as evidenced by apoptosis-specific phosphatidylserine externalization, increased caspase-3 activity, chromatin condensation, and nuclear fragmentation. Furthermore, phorbol myristate acetate- stimulation of the NADPH oxidase caused recognition and ingestion of dimethylsulfoxide-differentiated HL-60 cells by J774AA macrophages. To reveal the apoptosis-related component of oxidative stress in the phorbol myristate acetate-induced response, we pretreated cells with a pancaspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethyI ketone (z-VAD-fmk), and found that it caused partial inhibition of hydrogen peroxide formation as well as selective protection of only phosphatidylserine, whereas more abundant phospholipids, phosphatidylcholine and phosphatidylethanolamine, were oxidized to the same extent in the absence or presence of z-VAD-fmk. In contrast, inhibitors of NADPH oxidase activity, diphenylene iodonium and staurosporine, as well as antioxidant enzymes, superoxide dismutase/catalase, completely protected all phospholipids against peroxidation, inhibited expression of apoptotic biomarkers and externalization of phosphatidylserine, and reduced phagocytosis of differentiated HL-60 cells by J774A.1 macrophages. Similarly, zymosan-induced activation of the NADPH oxidase resulted in the production of superoxide and oxidation of different classes of phospholipids of which only phosphatidylserine was protected by z-VAD-fmk. Accordingly, zymosan caused apoptosis in differentiated HL-60 cells, as evidenced by caspase-3 activation and phosphatidylserine externalization. Finally, zymosan triggered caspase-3 activation and extensive SOD/catalase-inhibitable phosphatidylserine exposure in human neutrophils. Overall, our results indicate that NADPH oxidase-induced oxidative stress in neutrophil-like cells triggers apoptosis and subsequent recognition and removal of these cells through pathways dependent on oxidation and externalization of phosphatidylserine.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15260 USA; Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Russian Acad Sci, IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia; Palacky Univ, Dept Med Chem & Biochem, Olomouc 77126, Czech Republic; Univ Cordoba, Dept Cell Biol Physiol & Immunol, E-14071 Cordoba, Spain; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry; Palacky University Olomouc; Universidad de Cordoba; Karolinska Institutet	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.	kagan@pitt.edu	Modriansky, Martin/A-6338-2008	Modriansky, Martin/0000-0001-7692-0338; Tyurin, Vladimir/0000-0002-3474-1697; Tyurina, Yulia/0000-0003-0287-2091	NHLBI NIH HHS [1R01 HL 64145-01A1, 1R01 HL 70755-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070755, R01HL064145] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahlemeyer B, 2002, BRAIN RES, V934, P107, DOI 10.1016/S0006-8993(02)02365-X; AHMED N, 1991, BIOCHEM INT, V23, P591; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Balasubramanian K, 2001, BIOCHEMISTRY-US, V40, P8672, DOI 10.1021/bi010841y; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown SB, 1999, J IMMUNOL, V162, P480; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Clark P, 1998, SEMIN REPROD ENDOCR, V16, P57; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Etzioni A, 2000, IMMUNOL REV, V178, P138, DOI 10.1034/j.1600-065X.2000.17805.x; Fabisiak JP, 1998, BIOCHEMISTRY-US, V37, P13781, DOI 10.1021/bi9808262; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hua J, 2000, J LEUKOCYTE BIOL, V68, P216; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 1999, MOL PHARMACOL, V56, P494, DOI 10.1124/mol.56.3.494; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Lundqvist-Gustafsson H, 1999, J LEUKOCYTE BIOL, V65, P196, DOI 10.1002/jlb.65.2.196; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsura T, 2002, FEBS LETT, V524, P25, DOI 10.1016/S0014-5793(02)02990-3; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Narayanan PK, 1997, J LEUKOCYTE BIOL, V61, P481, DOI 10.1002/jlb.61.4.481; O'Neill AJ, 2000, SHOCK, V14, P605, DOI 10.1097/00024382-200014060-00006; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; Takei H, 1996, J LEUKOCYTE BIOL, V59, P229, DOI 10.1002/jlb.59.2.229; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; TSUKIMORI K, 1993, OBSTET GYNECOL, V81, P536; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; vanPelt LJ, 1996, J IMMUNOL METHODS, V191, P187, DOI 10.1016/0022-1759(96)00024-5; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Vladimirov YA, 2000, ARCH BIOCHEM BIOPHYS, V384, P154, DOI 10.1006/abbi.2000.2109; von Dadelszen P, 1999, AM J OBSTET GYNECOL, V181, P408, DOI 10.1016/S0002-9378(99)70570-3; Webb PR, 2000, APOPTOSIS, V5, P451, DOI 10.1023/A:1009601220552; WIJERMANS PW, 1987, LEUKEMIA RES, V11, P641, DOI 10.1016/0145-2126(87)90037-3	45	121	123	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49965	49975		10.1074/jbc.M204513200	http://dx.doi.org/10.1074/jbc.M204513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376550	hybrid			2022-12-25	WOS:000180028900113
J	Steiglitz, BM; Keene, DR; Greenspan, DS				Steiglitz, BM; Keene, DR; Greenspan, DS			PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; HEPARAN-SULFATE; IDENTIFICATION; MODULE; ORGANIZATION; GLYCOPROTEIN; FIBROBLASTS; GENE	The procollagen COOH-terminal proteinase enhancer (PCPE) is a glycoprotein that binds the COOH-terminal propeptide of type I procollagen and potentiates its cleavage by procollagen C-proteinases, such as bone morphogenetic protein-1 (BMP-1). Recently, sequencing of a human expressed sequence tag, which maps near the primary open angle glaucoma region on chromosome 3q21, showed it to encode a novel protein with only 43% identity with PCPE but with a similar domain structure. Here we show this novel protein to be a functional procollagen COOH-terminal proteinase enhancer wit activity comparable with that of PCPE and thus propose the designations PCPE2 and PCPE1, respectively. PCPE2 is shown to have a much more limited distribution of expression than does PCPE1, with strong expression primarily in nonossified cartilage in developing tissues and at high levels in the adult heart. PCPE2 is shown to be a glycoprotein that differs markedly in the nature of its glycosylation from that of PCPE1. PCPE2 is also shown to have markedly stronger affinity for heparin than PCPE1, which may account for higher affinities for cell layers. Unexpectedly, both PCPE1 and PCPE2 were found to be collagen-binding proteins, capable of binding at multiple sites on the triple helical portions of fibrillar collagens and also capable of competing for such binding with procollagen C-proteinases. The latter observations may provide insights into the ways PCPEs affect the kinetics of the C-proteinase reaction and into the physical interactions that occur between procollagen C-proteinases and their substrates.	Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Shriners Hosp Children, Portland, OR 97201 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.			Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, R01GM063471] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47746] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07215, GM 63471] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAR R, 1986, COLLAGEN REL RES, V6, P267; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Friedl A, 1997, AM J PATHOL, V150, P1443; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Masuda M, 1998, CELL GROWTH DIFFER, V9, P381; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, GENOMICS, V55, P229, DOI 10.1006/geno.1998.5663; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Xu H, 2000, GENOMICS, V66, P264, DOI 10.1006/geno.2000.6229	23	93	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49820	49830		10.1074/jbc.M209891200	http://dx.doi.org/10.1074/jbc.M209891200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393877	hybrid			2022-12-25	WOS:000180028900096
J	Liu, GL; Robillard, L; Banihashemi, B; Albert, PR				Liu, GL; Robillard, L; Banihashemi, B; Albert, PR			Growth hormone-induced diacylglycerol and ceramide formation via G alpha(i)3 and G beta y in GH4 pituitary cells - Potentiation by dopamine-D2 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANTERIOR-PITUITARY; MESSENGER-RIBONUCLEIC-ACID; NB2 LYMPHOMA-CELLS; C-FOS GENE; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; KIDNEY-CELLS; SPHINGOMYELIN SYNTHASE; ADENYLYL-CYCLASE; TRANSGENIC MICE	Growth hormone (GH) secretion is regulated by indirect negative feedback mechanisms. To address whether GH has direct actions on pituitary cells, lipid signaling in GH(4)ZR(7) somatomammotroph cells was examined. GH (EC50 = 5 nM) stimulated diacylglycerol (DAG) and ceramide formation in parallel by over 10-fold within 15 min and persisting for >3 h. GH-induced DAG/ceramide formation was blocked by pertussis toxin (PTX) implicating G(i)/G(o) proteins and was potentiated 1.5-fold by activation of G(i)/G(o)-coupled dopamine-D2S receptors, which had no effect alone. Following PTX pretreatment, only PTX-resistant Galpha(i)3, not Galpha(o) or Galpha(i)2, rescued GH-induced DAG/ceramide signaling. GH-induced DAG/ceramide formation was also blocked in cells expressing Gbetagamma blocker GRK-ct. In GH(4)ZR(7) cells, GH induced phosphorylation of JAK2 and STAT5, which was blocked by PTX and mimicked by ceramide analogue C2-ceramide or sphingomyelinase treatment to increase endogenous ceramide. We conclude that in GH(4) pituitary cells, GH induces formation of DAG/ceramide via a novel Galpha(i)3/Gbetagamma-dependent pathway. This novel pathway suggests a mechanism for autocrine feedback regulation by GH of pituitary function.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute	Albert, PR (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Neurosci 451 Smyth Rd,Room 2464, Ottawa, ON K1H 8M5, Canada.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554				ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; Asa SL, 2000, AM J PATHOL, V156, P1009, DOI 10.1016/S0002-9440(10)64968-1; Banihashemi B, 2002, MOL ENDOCRINOL, V16, P2393, DOI 10.1210/me.2001-0220; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CATALIOTO RM, 1990, BIOCHEM BIOPH RES CO, V173, P840, DOI 10.1016/S0006-291X(05)80863-0; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Colao A, 1998, LANCET, V352, P1455, DOI 10.1016/S0140-6736(98)03356-X; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; Doris RA, 1998, J ENDOCRINOL, V158, P295, DOI 10.1677/joe.0.1580295; Finidori J, 2000, Vitam Horm, V59, P71, DOI 10.1016/S0083-6729(00)59004-9; FRASER RA, 1991, J ENDOCRINOL, V128, pR9, DOI 10.1677/joe.0.128R009; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HARVEY S, 1993, ENDOCRINOLOGY, V133, P1125, DOI 10.1210/en.133.3.1125; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kamegai J, 1998, ENDOCRINOLOGY, V139, P3554, DOI 10.1210/en.139.8.3554; KELLY PA, 1994, HORM RES, V42, P133, DOI 10.1159/000184185; KLEMPT M, 1993, ENDOCRINOLOGY, V132, P1071, DOI 10.1210/en.132.3.1071; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LARSEN JL, 1988, ENDOCRINOLOGY, V123, P438, DOI 10.1210/endo-123-1-438; LARSEN JL, 1992, J BIOL CHEM, V267, P10583; Lembo PMC, 1999, MOL ENDOCRINOL, V13, P138, DOI 10.1210/me.13.1.138; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Maziere C, 2001, FEBS LETT, V507, P163, DOI 10.1016/S0014-5793(01)02977-5; Melmed S, 1996, RECENT PROG HORM RES, V51, P189; MERTANI HC, 1995, J CLIN ENDOCR METAB, V80, P3361, DOI 10.1210/jc.80.11.3361; MERTANI HC, 1994, NEUROENDOCRINOLOGY, V59, P483, DOI 10.1159/000126695; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; NAKAMOTO JM, 1986, J CLIN ENDOCR METAB, V62, P822, DOI 10.1210/jcem-62-5-822; Negishi T, 1999, ENDOCRINOLOGY, V140, P5691, DOI 10.1210/en.140.12.5691; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Peng XD, 2001, ENDOCRINOLOGY, V142, P1117, DOI 10.1210/en.142.3.1117; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; ROSS RJM, 1987, CLIN ENDOCRINOL, V26, P117, DOI 10.1111/j.1365-2265.1987.tb03645.x; ROUPAS P, 1991, P NATL ACAD SCI USA, V88, P1691, DOI 10.1073/pnas.88.5.1691; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Sjoholm A, 2000, J BIOL CHEM, V275, P21033, DOI 10.1074/jbc.M001212200; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1990, BIOCHEM BIOPH RES CO, V173, P48, DOI 10.1016/S0006-291X(05)81019-8; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; Waters MJ, 1999, CLIN EXP PHARMACOL P, V26, P760, DOI 10.1046/j.1440-1681.1999.03129.x; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Yip RGC, 1999, ENDOCRINOLOGY, V140, P1219, DOI 10.1210/en.140.3.1219; Zheng H, 1997, MOL ENDOCRINOL, V11, P1709, DOI 10.1210/me.11.11.1709; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	67	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48427	48433		10.1074/jbc.M202130200	http://dx.doi.org/10.1074/jbc.M202130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376552	hybrid			2022-12-25	WOS:000179789600061
J	Yao, XJ; Lemay, J; Rougeau, N; Clement, M; Kurtz, S; Belhumeur, P; Cohen, EA				Yao, XJ; Lemay, J; Rougeau, N; Clement, M; Kurtz, S; Belhumeur, P; Cohen, EA			Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-PROTEIN-R; YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE ARREST; HIV-1 VPR; NUCLEAR-LOCALIZATION; G(2) ARREST; TYROSINE PHOSPHORYLATION; HELICAL STRUCTURE; GROWTH ARREST; G2 ARREST	Human immunodeficiency virus 1 (HIV-1) encodes a gene product, Vpr, that facilitates the nuclear uptake of the viral pre-integration complex in non-dividing cells and causes infected cells to arrest in the G(2) phase of the cell cycle. Vpr was also shown to cause mitochondrial dysfunction in human cells and budding yeasts, an effect that was proposed to lead to growth arrest and cell killing in budding yeasts and apoptosis in human cells. In this study, we used a genetic selection in Saccharomyces cerevisiae to identify hexameric peptides that suppress the growth arrest phenotype mediated by Vpr. Fifteen selected glutathione S-transferase (GST)-fused peptides were found to overcome to different extents Vpr-mediated growth arrest. Amino acid analysis of the inhibitory peptide sequences revealed the conservation of a di-tryptophan (diW) motif. DiW-containing GST-peptides interacted with Vpr in GST pull-down assays, and their level of interaction correlated with their ability to overcome Vpr-mediated growth arrest. Importantly, Vpr-binding GST-peptides were also found to alleviate Vpr-mediated apoptosis and G, arrest in HIV-1-producing CD4(+) T cell lines. Furthermore, they colocalized with Vpr and interfered with its nuclear translocation. Overall, this study defines a class of diW-containing peptides that inhibit HIV-1 Vpr biological activities most likely by interacting with Vpr and interfering with critical protein interactions.	Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada; NW Neurol Inc, Portland, OR 97210 USA	Universite de Montreal	Cohen, EA (corresponding author), Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada.	eric.cohen@umontreal.ca		Yao, Xiaojian/0000-0002-5022-1309; Lemay, Julie/0000-0002-4029-9911				Adams A, 1997, METHODS YEAST GENETI; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Berglez JM, 1999, BIOCHEM BIOPH RES CO, V264, P287, DOI 10.1006/bbrc.1999.1511; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Chen MZ, 1999, J VIROL, V73, P3236, DOI 10.1128/JVI.73.4.3236-3245.1999; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Elder RT, 2000, VIRUS RES, V68, P161, DOI 10.1016/S0168-1702(00)00167-2; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Fukumori T, 2000, MICROBES INFECT, V2, P1011, DOI 10.1016/S1286-4579(00)01255-7; Gaynor EM, 2001, EXP CELL RES, V267, P243, DOI 10.1006/excr.2001.5247; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; Gu JR, 1997, MOL CELL BIOL, V17, P4033, DOI 10.1128/MCB.17.7.4033; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kulkosky J, 1999, VIROLOGY, V255, P77, DOI 10.1006/viro.1998.9544; KURTZ S, 2002, IN PRESS BIOTECHNOL; LAVALLEE C, 1994, J VIROL, V68, P1926; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; Macreadie IG, 1997, FEBS LETT, V410, P145, DOI 10.1016/S0014-5793(97)00542-5; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nishino Y, 1997, BIOCHEM BIOPH RES CO, V232, P550, DOI 10.1006/bbrc.1997.6186; Nishizawa M, 2000, VIROLOGY, V276, P16, DOI 10.1006/viro.2000.0534; Nishizawa M, 2000, J VIROL, V74, P6058, DOI 10.1128/JVI.74.13.6058-6067.2000; Okui N, 2000, HUM GENE THER, V11, P537, DOI 10.1089/10430340050015725; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TANG WM, 1995, MOL BIOL CELL, V6, P1231, DOI 10.1091/mbc.6.9.1231; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhao YQ, 2000, FRONT BIOSCI-LANDMRK, V5, pD905, DOI 10.2741/zhao; Zhou Y, 2000, J VIROL, V74, P6520, DOI 10.1128/JVI.74.14.6520-6527.2000; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028	64	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48816	48826		10.1074/jbc.M207982200	http://dx.doi.org/10.1074/jbc.M207982200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379652	hybrid			2022-12-25	WOS:000179789600110
J	Yabana, N; Shibuya, M				Yabana, N; Shibuya, M			Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity	ONCOGENE			English	Article						Vav; guanine nucleotide; exchange factor; calponin; homology domain	SH2 DOMAINS; PROTOONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; C-CBL; FAMILY; ACTIVATION; RHO; DBL; MEMBER	The N-terminal calponin homology (CH) domain of Vav guanine nucleotide exchange factor is thought to serve a regulatory role in the autoinhibition, however, its precise function is not entirely clear. We found that the adaptor molecule APS could bind the CH domain of Vav3, a member of the vav proto-oncogene family. The binding of Vav3 and APS was apparently stabilized by the tyrosine phosphorylation of Vav3 by Lck, and the association of APS with Vav3 in turn enhanced the Lck-mediated phosphorylation of Vav3. Focus formation assays demonstrated that APS could increase the transforming activity of proto-Vav3. Further analyses revealed that the Vav3 CH domain could bind the pleckstrin homology (PH) domain of APS and that this binding was indispensable to enhance the transforming activity of Vav3. We present here a novel stimulatory mechanism of Vav3 in which APS directly relieves the autoinhibitory CH domain and furthermore enhances its tyrosine phosphorylation by Lck.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Shirokanedai 4-6-1, Tokyo, Japan.	shibuya@ims.u-tokyo.ac.jp						Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; ADAMS JM, 1992, ONCOGENE, V7, P611; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Gimona M, 1998, CURR BIOL, V8, pR674; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Iseki M, 2000, BIOCHEM BIOPH RES CO, V272, P45, DOI 10.1006/bbrc.2000.2736; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; RON D, 1989, ONCOGENE, V4, P1067; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Takaki S, 2000, IMMUNITY, V13, P599, DOI 10.1016/S1074-7613(00)00060-1; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; VAN AL, 1997, GENE DEV, V11, P2295; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	48	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7720	7729		10.1038/sj.onc.1205927	http://dx.doi.org/10.1038/sj.onc.1205927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400014				2022-12-25	WOS:000178756200011
J	Arispe, N; Doh, M				Arispe, N; Doh, M			Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease A beta P (1-40) and (1-42) peptides	FASEB JOURNAL			English	Article						amyloid-beta-peptide; A beta P ion channels; calcium; phosphatidylserine; membrane interaction	AMYLOID PRECURSOR PROTEIN; RAPID CELLULAR DEGENERATION; CULTURED CORTICAL-NEURONS; BILAYER-MEMBRANES; ZN2+-SENSITIVE CHANNEL; CALCIUM CHANNELS; ION CHANNELS; PC12 CELLS; CONGO RED; BRAIN	Cell degeneration in Alzheimer's disease is mediated by a toxic mechanism that involves interaction of the AbetaP peptide with the plasma membrane of the target cell. We report here that PC12 cells become resistant to the cytotoxic action of AbetaP when incubated in a medium that enriches cholesterol levels of the surface membrane. On the other hand, making cholesterol-deficient membranes by either cholesterol extraction with cyclodextrin or by inhibiting de novo synthesis of cholesterol makes PC12 cells more vulnerable to the action of AbetaP. Increasing cholesterol content of PS liposomes also suppresses AbetaP-dependent liposome aggregation. We suggest that by modifying the fluidity of the neuronal membranes, cholesterol modulates the incorporation and pore formation of AbetaP into cell membranes. This idea is supported by our finding that the enhanced cytotoxicity generated by lowering the membrane cholesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.	USUHS, Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; USUHS, Uniformed Serv Univ Sch Med, Inst Mol Med, Bethesda, MD 20814 USA		Arispe, N (corresponding author), USUHS, Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	narispe@usuhs.mil						ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; Arispe NJ, 2002, BIOPHYS J, V82, p17A; Arispe NJ, 2001, BIOPHYS J, V80, p135A; ARISPE NJ, 2001, SOC NEUR ABSTR, V27; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; BI X, 2001, SOC NEUR ABSTR, V27; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Chochina SV, 2001, J LIPID RES, V42, P1292; DEA D, 2001, SOC NEUR ABSTR, V27; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; Eckert GP, 2001, NEUROREPORT, V12, P883, DOI 10.1097/00001756-200104170-00003; ENDO A, 1992, J LIPID RES, V33, P1569; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; FURUKAWA K, 1994, NEUROREPORT, V5, P2016, DOI 10.1097/00001756-199410270-00006; GALDZICKI Z, 1994, BRAIN RES, V646, P332, DOI 10.1016/0006-8993(94)90101-5; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hirakura Y, 2000, AMYLOID, V7, P194, DOI 10.3109/13506120009146834; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kawahara M, 2001, CELL MOL NEUROBIOL, V21, P1, DOI 10.1023/A:1007168910582; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P173, DOI 10.1023/A:1010932603406; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; LEE G, 2002, IN PRESS PEPTIDES; Lee KYC, 2001, BIOPHYS J, V80, p23A; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; LIN MC, 2002, IN PRESS PEPTIDES; Lundbaek JA, 1996, BIOCHEMISTRY-US, V35, P3825, DOI 10.1021/bi952250b; Lutjohann D, 2000, J LIPID RES, V41, P195; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; Mason RP, 1996, BIOCHEM BIOPH RES CO, V222, P78, DOI 10.1006/bbrc.1996.0699; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; Muller WE, 1998, AMYLOID, V5, P10, DOI 10.3109/13506129809007284; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SELKOE JD, 2000, JAMA-J AM MED ASSOC, V238, P1615; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Vargas J, 2000, BIOPHYS J, V79, P934, DOI 10.1016/S0006-3495(00)76348-X; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhou Y, 1996, NEUROREPORT, V7, P2487; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	63	169	174	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1526	1536		10.1096/fj.02-0829com	http://dx.doi.org/10.1096/fj.02-0829com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374775				2022-12-25	WOS:000179167600034
J	Buresi, MC; Buret, AG; Hollenberg, MD; MacNaughton, WK				Buresi, MC; Buret, AG; Hollenberg, MD; MacNaughton, WK			Activation of proteinase-activated receptor 1 stimulates epithelial chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway	FASEB JOURNAL			English	Article						epidermal growth factor; PAR-1; inflammatory bowel disease; PCR	EPIDERMAL GROWTH-FACTOR; INFLAMMATORY BOWEL-DISEASE; CYTOSOLIC PHOSPHOLIPASE A(2); SMOOTH-MUSCLE CELLS; EGF RECEPTOR; COUPLED RECEPTORS; IN-VITRO; ION-TRANSPORT; T-84 CELLS; THROMBIN	Proteinase-activated receptor 1 (PAR-1) is activated by thrombin and induces chloride secretion by intestinal epithelial cells. To elucidate further the mechanisms whereby PAR -1 stimulates secretion, monolayers of SCBN intestinal epithelial cells were studied in modified Ussing chambers. Short circuit current responses were determined after basolateral application of thrombin and the PAR-1 -activating peptide, Ala-parafluoro-Phe-Arg-cyclohexyl-Ala-Citrulline-Tyr (Cit-NH2) in the presence or absence of a variety of signal transduction and cyclo-oxygenase (COX) pathway inhibitors. Increased kinase activity was monitored by immunoprecipitation and Western blot analysis of target phosphoproteins. The PAR 1-induced chloride secretory response was significantly attenuated by inhibitors of the EGF receptor tyrosine kinase, Src-kinase, MEK1/2, as well as by inhibitors of cytosolic phospholipase (cPL) A(2), COX-1 and COX-2. PAR-1-induced activation of cPLA(2), as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation. Our data show that PAR 1-induced chloride secretion in SCBN cells involves Src, EGF receptor trans-activation, activation of a MAPK pathway, phosphorylation of cPLA2, COX activity, but not PGF(2alpha) or PGE(2). These findings may be of clinical importance in inflammatory diseases of the intestine where secretory dysfunction is evident and thrombin levels are elevated.	Univ Calgary, Mucosal Inflammat Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	MacNaughton, WK (corresponding author), Univ Calgary, Mucosal Inflammat Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wmacnaug@ucalgary.ca	Hollenberg, Morley/AFV-6966-2022					AUTHI KS, 1985, FEBS LETT, V180, P95, DOI 10.1016/0014-5793(85)80239-8; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Beubler E, 2001, J PHARMACOL EXP THER, V297, P940; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bos M, 1997, CLIN CANCER RES, V3, P2099; Buresi MC, 2001, AM J PHYSIOL-GASTR L, V281, pG323, DOI 10.1152/ajpgi.2001.281.2.G323; Chamouard P, 1995, EUR J GASTROEN HEPAT, V7, P1183; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEJONG E, 1989, GUT, V30, P188, DOI 10.1136/gut.30.2.188; Derian CK, 1997, EXP CELL RES, V232, P1, DOI 10.1006/excr.1997.3483; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GHOSH S, 1983, ACTA HAEMATOL-BASEL, V70, P50, DOI 10.1159/000206688; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Haas M, 2000, J BIOL CHEM, V275, P27832; Halushka P V, 1988, Eicosanoids, V1, P41; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; HINTERLEITNER TA, 1991, P SOC EXP BIOL MED, V197, P249; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KOCHINTORN U, 1993, AM J PHYSIOL, V264, pC671; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lepple-Wienhues A, 2001, FASEB J, V15, P927, DOI 10.1096/fj.00-0264com; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MacNaughton WK, 2000, J PHARMACOL EXP THER, V293, P539; OKAZAKI T, 1981, J BIOL CHEM, V256, P7316; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pang G, 1996, GASTROENTEROLOGY, V111, P8, DOI 10.1053/gast.1996.v111.pm8698229; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rao RK, 1996, J PHARMACOL EXP THER, V278, P193; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; Samokhin GP, 1999, EUR J PHARMACOL, V386, P297, DOI 10.1016/S0014-2999(99)00737-2; Seymour ML, 2001, FASEB J, V15, pA830; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Stadnicki A, 1997, DIGEST DIS SCI, V42, P2356, DOI 10.1023/A:1018891323205; Teoh DA, 2000, J PARASITOL, V86, P800; Tognetto M, 2000, BRIT J PHARMACOL, V131, P689, DOI 10.1038/sj.bjp.0703618; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Waltenberger J, 1999, CIRC RES, V85, P12; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wong PYD, 1999, J PHYSIOL-LONDON, V514, P809, DOI 10.1111/j.1469-7793.1999.809ad.x; WOOD JD, 1993, PHARMACOLOGY, V47, P7; WU W, 2002, IN PRESS J BIOL CHEM; Zheng XL, 1998, J PHARMACOL EXP THER, V285, P325	60	45	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1515	1525		10.1096/fj.02-0039com	http://dx.doi.org/10.1096/fj.02-0039com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374774				2022-12-25	WOS:000179167600033
J	Zhang, L; Wang, CY				Zhang, L; Wang, CY			PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27(Kip1), a potential role for elevated Skp2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27; FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE PROGRESSION; ALVEOLAR RHABDOMYOSARCOMA; FUSION PROTEIN; CHROMOSOMAL TRANSLOCATION; PAX3 HOMEODOMAIN; DOWN-REGULATION; GENE; PHOSPHORYLATION	PAX3-FKHR is an oncogenic form of the developmental regulator Pax3 transcription factor. PAX3-FKHR results from a t(2,13) chromosomal translocation, a unique genetic marker of alveolar rhabdomyosarcoma. In this study, we showed that ectopic expression of PAX3-FKHR, but not Pax3, in fibroblasts altered cell cycle control and accelerated G(0)/G(1) to S cell cycle transition. PAX3-FKHR-expressing cells had reduced expression of p27(Kip1) protein, a key cell cycle regulator. The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of P27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments. The reduced p27(Kip1) protein level in PAX3-FKHR-expressing cells was restored to the level of control cells by treatment with chemical inhibitors that specifically blocked 26 S proteasome activity. Along with the reduction in p27(Kip1) protein, PAX3-FKHR-expressing cells exhibited elevated expression of F-box Skp2 protein, a substrate-specific component of SCF (Skp1-Cullin-F box protein) ligase involved in the cell cycle-dependent control of p27(Kip1) ubiquitination and 26 S proteasome dependent degradation. Finally, we showed that ectopic expression of P27(Kip1) in PAX3-FKHR-expressing cells significantly reduced the proliferation and colony-forming potential of these cells, implicating that down-regulation of p27(Kip1) protein played an active role in the PAX3-FKHR-directed cell transformation.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, CY (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St, Chicago, IL 60612 USA.	chiayeng@tigger.ac.uic.edu			NCI NIH HHS [CA-74907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074907, R01CA074907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Ayalon D., 2001, Growth Hormone and IGF Research, V11, P289, DOI 10.1054/ghir.2001.0244; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BRESLOW NE, 1983, INT J CANCER, V32, P703, DOI 10.1002/ijc.2910320609; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; Chao Y, 1999, CANCER LETT, V139, P1, DOI 10.1016/S0304-3835(98)00352-8; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2869; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ENZINGER FM, 1983, SOFT TISSUE TUMORS, P363; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kempf BE, 1999, CELL GROWTH DIFFER, V10, P813; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LATTES R, 1982, RHABDOMYOSARCOMA TUM, P1699; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; NEWTON WA, 1988, J CLIN ONCOL, V6, P67, DOI 10.1200/JCO.1988.6.1.67; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Raney Jr RB, 1993, PRINCIPLES PRACTICE, P769; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang QM, 1996, CANCER RES, V56, P264; Wang-Wuu S, 1988, Cancer Res, V48, P983; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZHU X, 1996, J CELL BIOL	68	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					27	36		10.1074/jbc.M205424200	http://dx.doi.org/10.1074/jbc.M205424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401804	hybrid			2022-12-25	WOS:000180255700004
J	Alpy, F; Wendling, C; Rio, MC; Tomasetto, C				Alpy, F; Wendling, C; Rio, MC; Tomasetto, C			MENTHO, a MLN64 homologue devoid of the START domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK-C-DISEASE; BREAST-CANCER; CHOLESTEROL; IDENTIFICATION; PROTEIN; HYBRIDIZATION; TRANSLATION; TRANSPORT; SEQUENCES; GENE	MLN64 is a late endosomal membrane protein containing a carboxyl-terminal cholesterol binding START domain and is presumably involved in intracellular cholesterol transport. In the present study, we have cloned a human cDNA encoding a novel protein that we called MENTHO as an acronym for MLN64 N-terminal domain homologue because this protein is closely related to the amino-terminal half of MLN64. MLN64 and MENTHO share 70% identity and 83% similarity in an original protein domain encompassing 171 amino acids that we designated as the MENTAL (MLN64 N-terminal) domain. By translation initiation scanning MENTHO is synthesized as two isoforms of 234 (alpha) and 227 (beta) amino acids that can be phosphorylated. As MLN64, MENTHO is ubiquitously expressed and is located in the membrane of late endosomes, its amino and carboxyl-terminal extremities projecting toward the cytoplasm. We show that MENTHO overexpression does not rescue the Niemann-Pick type C lipid storage phenotype. However, MENTHO overexpression alters severely the endocytic compartment by leading at steady state to the accumulation of enlarged endosomes. These results indicate that in addition to its previously established function in addressing and anchoring proteins to the membrane of late endosomes, the MENTAL domain possesses an intrinsic biological function in endocytic transport.	Univ Strasbourg 1, IGBMC, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tomasetto, C (corresponding author), Univ Strasbourg 1, IGBMC, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, France.		Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020; Alpy, Fabien/H-8941-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720				Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Bieche I, 1996, CANCER RES, V56, P3886; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Ioannou YA, 2001, NAT REV MOL CELL BIO, V2, P657, DOI 10.1038/35089558; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Vanier MT, 1996, AM J HUM GENET, V58, P118; Vanier MT, 1998, BRAIN PATHOL, V8, P163; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	34	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50780	50787		10.1074/jbc.M208290200	http://dx.doi.org/10.1074/jbc.M208290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393907	hybrid			2022-12-25	WOS:000180177700077
J	Berghagen, H; Ragnhildstveit, E; Krogsrud, K; Thuestad, G; Apriletti, J; Saatcioglu, F				Berghagen, H; Ragnhildstveit, E; Krogsrud, K; Thuestad, G; Apriletti, J; Saatcioglu, F			Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3R alpha from a negative hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL SEQUENCE; GENE; TRANSCRIPTION; REPRESSOR; ACTIVATION; MECHANISMS; BINDING; PROTEIN; DOMAIN; ERBA	Nuclear receptors are ligand-modulated transcription factors that transduce the presence of lipophilic ligands into changes in gene expression. Nuclear receptor activity is regulated by ligand-induced interactions with coactivator or corepressor molecules. From a positive hormone response element (pHRE) and in the absence of hormone, corepressors SMRT and N-CoR are bound to some nuclear receptors such as the thyroid hormone (T3Rs) and retinoic acid receptors and mediate inhibition of basal levels of transcription. Ligand binding results in dissociation of corepressors and association of coactivators, resulting in the reversal of inhibition and a net activation of transcription. However, the role of cofactors on the activity of nuclear receptors from negative HREs (nHREs) is poorly understood. Here we show that corepressor SMRT can act as a potent coactivator for T3Ralpha from a nHRE; N-CoR has a similar but significantly attenuated activity. Mutagenesis of residues in the hinge region of T3Ralpha that block binding of SAMT and N-CoR inhibits ligand-independent transcriptional activation by T3Ralpha from a nHRE. These mutations also abrogate SMRT-mediated increase in transcriptional activity by T3Ralpha at a nHRE without significantly affecting ligand-dependent activation at a pHRE. Partial protease digestion coupled to the mobility shift assay indicate differences in the conformation of T3Ralpha-SMRT complexes bound to a pHRE versus a nHRE. These results suggest that allosteric changes resulting from binding of T3Ralpha to different response elements, ie. pHREs versus nHREs, dictate whether a cofactor will function as a coactivator or a corepressor. This, in turn, greatly expands the repertoire of mechanisms used in modulating transcription without the need for expression of new regulatory molecules.	Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway; Univ Oslo, Dept Biol, N-0316 Oslo, Norway; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of Oslo; University of Oslo; University of California System; University of California San Francisco	Saatcioglu, F (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Postboks 1050 Blindern, N-0316 Oslo, Norway.							APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Ogbourne S, 1998, BIOCHEM J, V331, P1; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Satoh T, 1999, MOL CELL ENDOCRINOL, V154, P137, DOI 10.1016/S0303-7207(99)00032-5; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	24	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49517	49522		10.1074/jbc.M209546200	http://dx.doi.org/10.1074/jbc.M209546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388540	hybrid			2022-12-25	WOS:000180028900055
J	Kunjathoor, VV; Febbraio, M; Podrez, EA; Moore, KJ; Andersson, L; Koehn, S; Rhee, JS; Silverstein, R; Hoff, HF; Freeman, MW				Kunjathoor, VV; Febbraio, M; Podrez, EA; Moore, KJ; Andersson, L; Koehn, S; Rhee, JS; Silverstein, R; Hoff, HF; Freeman, MW			Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; OXIDIZED LDL; IN-VITRO; SR-PSOX; EXPRESSION; CELLS; CHOLESTEROL; PHOSPHATIDYLSERINE; OXIDATION; MEMBRANE	Modification of low density lipoprotein (LDL) can result in the avid uptake of these lipoproteins via a family of macrophage transmembrane proteins referred to as scavenger receptors (SRs). The genetic inactivation of either of two SR family members, SR-A or CD36, has been shown previously to reduce oxidized LDL uptake in vitro and atherosclerotic lesions in mice. Several other SRs are reported to bind modified LDL, but their contribution to macrophage lipid accumulation is uncertain. We generated mice lacking both SR-A and CD36 to determine their combined impact on macrophage lipid uptake and to assess the contribution of other SRs to this process. We show that SR-A and CD36 account for 75-90% of degradation of LDL modified by acetylation or oxidation. Cholesteryl ester derived from modified lipoproteins fails to accumulate in macrophages taken from the double null mice, as assessed by histochemistry and gas chromatography-mass spectrometry. These results demonstrate that SR-A and CD36 are responsible for the preponderance of modified LDL uptake in macrophages and that other scavenger receptors do not compensate for their absence.	Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Ctr Vasc Biol, New York, NY 10021 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Harvard University; Massachusetts General Hospital; Cornell University; Cornell University; Cleveland Clinic Foundation	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Dept Med, Lipid Metab Unit, Boston, MA 02114 USA.		Moore, Kathryn/ABE-6416-2020	Moore, Kathryn/0000-0003-2505-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315, F32HL010366, U01HL066678, R01HL045098] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL 10366, HL 45098, HL 66678, HL 53315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Jacobs NL, 1997, J LIPID RES, V38, P1973; Kataoka H, 2000, ANN NY ACAD SCI, V902, P328; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kruth HS, 2002, J BIOL CHEM, V277, P34573, DOI 10.1074/jbc.M205059200; Kruth HS, 2001, FRONT BIOSCI-LANDMRK, V6, pD429, DOI 10.2741/Kruth; Lougheed M, 1999, ARTERIOSCL THROM VAS, V19, P1881, DOI 10.1161/01.ATV.19.8.1881; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Minami M, 2001, ARTERIOSCL THROM VAS, V21, P1796, DOI 10.1161/hq1001.096652; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Moore KJ, 1998, ARTERIOSCL THROM VAS, V18, P1647, DOI 10.1161/01.ATV.18.10.1647; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; PODREZ EA, 2002, J BIOL CHEM, V8, P8; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0	30	742	789	2	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49982	49988		10.1074/jbc.M209649200	http://dx.doi.org/10.1074/jbc.M209649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376530	hybrid			2022-12-25	WOS:000180028900115
J	Yang, Y; Dieter, MZ; Chen, Y; Shertzer, HG; Nebert, DW; Dalton, TP				Yang, Y; Dieter, MZ; Chen, Y; Shertzer, HG; Nebert, DW; Dalton, TP			Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse - Novel model system for a severely compromised oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HUMAN OVARIAN-CANCER; AMINO-ACID-SEQUENCE; RAT-KIDNEY; GLUTATHIONE SYNTHESIS; GENE-EXPRESSION; INTRACELLULAR GLUTATHIONE; LIGHT SUBUNITS; CELLS; DEFICIENCY	Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the GSH biosynthesis pathway. In higher eukaryotes, this enzyme is a heterodimer comprising a catalytic subunit (GCLC) and a modifier subunit (GCLM), which change the catalytic characteristics of the holoenzyme. To define the cellular function of GCLM, we disrupted the mouse Gclm gene to create a null allele. Gclm(-/-) mice are viable and fertile and have no overt phenotype. In liver, lung, pancreas, erythrocytes, and plasma, however, GSH levels in Gclm(-/-) mice were 9-16% of that in Gclm(+/+) littermates. Cysteine levels in Gclm(-/-) mice were 9,35, and 40% of that in Gclm(+/+) mice in kidney, pancreas, and plasma, respectively, but remained unchanged in the liver and erythrocytes. Comparing the hepatic GCL holoenzyme with GCLC in the genetic absence of GCLM, we found the latter had an similar to2-fold increase in K-m for glutamate and a dramatically enhanced sensitivity to GSH inhibition. The major decrease in GSH, combined with diminished GCL activity, rendered Gclm(-/-) fetal fibroblasts strikingly more sensitive to chemical oxidants such as H2O2. We conclude that the Gclm(-/-) mouse represents a model of chronic GSH depletion that will be very useful in evaluating the role of the GCLM subunit and GSH in numerous pathophysiological conditions as well as in environmental toxicity associated with oxidant insult.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Dalton, TP (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	tim.dalton@uc.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010416, P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009235] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG 09235] Funding Source: Medline; NIEHS NIH HHS [P30 ES 06096, R01 ES 10416] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON ME, 1994, METHOD ENZYMOL, V234, P492; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693; COOKE JE, 1993, METHOD ENZYMOL, V225, P37; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; Droge W, 1997, Adv Pharmacol, V38, P581; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hammond CL, 2001, J HEPATOL, V34, P946, DOI 10.1016/S0168-8278(01)00037-X; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Khamaisi M, 2000, BIOCHEM J, V349, P579, DOI 10.1042/bj3490579; Kijima H, 1998, BIOCHEM BIOPH RES CO, V247, P697, DOI 10.1006/bbrc.1998.8878; LEE FYF, 1989, BRIT J CANCER, V60, P291, DOI 10.1038/bjc.1989.273; Lieberman MW, 1996, P NATL ACAD SCI USA, V93, P7923, DOI 10.1073/pnas.93.15.7923; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Maier A, 2000, MOL CARCINOGEN, V28, P225, DOI 10.1002/1098-2744(200008)28:4<225::AID-MC5>3.0.CO;2-O; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MULCAHY RT, 1995, CANCER RES, V55, P4771; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Ookhtens M, 1998, SEMIN LIVER DIS, V18, P313, DOI 10.1055/s-2007-1007167; Plummer J L, 1981, Methods Enzymol, V77, P50; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Solis WA, 2002, BIOCHEM PHARMACOL, V63, P1739, DOI 10.1016/S0006-2952(02)00897-3; Soltaninassab SR, 2000, J CELL PHYSIOL, V182, P163, DOI 10.1002/(SICI)1097-4652(200002)182:2<163::AID-JCP4>3.0.CO;2-1; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; YAN N, 1990, J BIOL CHEM, V265, P1588; YAO KS, 1995, CANCER RES, V55, P4367	41	197	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49446	49452		10.1074/jbc.M209372200	http://dx.doi.org/10.1074/jbc.M209372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384496	hybrid			2022-12-25	WOS:000180028900045
J	Goel, M; Sinkins, WG; Schilling, WP				Goel, M; Sinkins, WG; Schilling, WP			Selective association of TRPC channel subunits in rat brain synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; DOMAIN-CONTAINING PROTEIN; STORE-OPERATED CHANNEL; FUNCTIONAL EXPRESSION; TRANSIENT RECEPTOR; CA2+ ENTRY; INAD; COEXPRESSION; ACTIVATION; HOMOLOG	TRPC genes encode a ubiquitous family of ion channel proteins responsible for Ca2+ influx following stimulation of G-protein-coupled membrane receptors linked to phospholipase C. These channels may be localized to large multimeric signaling complexes via association with PDZ-containing scaffolding proteins. Based on sequence homology, the TRPC channel family can be divided into two major subgroups: TRPC1, -C4, and -C5 and TRPC3, -C6, and -C7. Although TRPC channels are thought to be tetramers, the actual subunit composition remains unknown. To determine subunit arrangement, individual TRPC channel pairs were heterologously expressed in Sf9 insect cells and immunoprecipitated using affinity-purified rabbit polyclonal antibodies specific for each channel subtype. Reciprocal co-immunoprecipitations showed that TRPC1, -C4, and -C5 co-associate and that TRPC3, -C6, and -C7 co-associate but that cross-association between the two major subgroups does not occur. Additionally, the interaction between each TRPC channel and the PDZ-containing protein, INAD (protein responsible for the inactivation-no-after-potential Drosophila mutant), was examined. TRPC1, -C4, and -C5 co-immunoprecipitated with INAD, whereas TRPC3, -C6, and -C7 did not. To define channel subunit interactions in vivo, immunoprecipitations were performed from isolated rat brain synaptosomal preparations. The results revealed that TRPC1, -C4, and -C5 co-associate and that TRPC3, -C6, and -C7 co-associate in both cortex and cerebellum but that cross-association between the two major subgroups does not occur. These results demonstrate that TRPC channels are present in nerve terminals and provide the first direct evidence for selective assembly of channel subunits in vivo.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Schilling, WP (corresponding author), Metrohlth Med Ctr, Rammelkamp Ctr, Rm R322,2500 MetroHlth Dr, Cleveland, OH 44109 USA.	wschilling@metrohealth.org			NIGMS NIH HHS [GM52019] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cotman C W, 1974, Methods Enzymol, V31, P445; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; LOO TW, 1994, J BIOL CHEM, V269, P7750; MONTELL C, 2001, 90RE1 STKE; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Rao US, 2002, J BIOL CHEM, V277, P4900, DOI 10.1074/jbc.M108258200; Schwarz D, 2001, XENOBIOTICA, V31, P345, DOI 10.1080/00498250110055947; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	40	245	260	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48303	48310		10.1074/jbc.M207882200	http://dx.doi.org/10.1074/jbc.M207882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377790	hybrid			2022-12-25	WOS:000179789600045
J	Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL				Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL			Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells	ONCOGENE			English	Article						Stat3; Bcl-2; chemoresistance	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; FACTOR-I RECEPTOR; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; CARCINOMA CELLS; APOPTOSIS; EXPRESSION; STAT3	Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3-Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.	Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Santander 39008, Spain; Hosp Univ Marques de Valdecilla, Med Oncol Serv, Santander 39008, Spain; Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Ctr Invest Energet Medioambientales & Tecnol, Madrid 28040, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Av Valdecilla S-N, Santander 39008, Spain.	inmflj@humv.es	Segovia, Jose Carlos/L-2922-2014; Real, Pedro J./K-2994-2014; Real, Pedro J./ABH-3493-2021	Segovia, Jose Carlos/0000-0003-4101-6124; Real, Pedro J./0000-0001-7968-5353; Sierra, Angels/0000-0003-1023-3492				Alas S, 2001, CANCER RES, V61, P5137; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Bartucci M, 2001, CANCER RES, V61, P6747; BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruns CJ, 2000, CANCER RES, V60, P2926; Bundred NJ, 2001, ENDOCR-RELAT CANCER, V8, P183, DOI 10.1677/erc.0.0080183; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Ellis PA, 1998, BREAST CANCER RES TR, V48, P107, DOI 10.1023/A:1005933815809; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PRICE JE, 1990, CANCER RES, V50, P717; Sanz C, 2001, EXP HEMATOL, V29, P728, DOI 10.1016/S0301-472X(01)00635-X; Schorr K, 1999, CANCER RES, V59, P2541; Sierra A, 2000, INT J CANCER, V89, P142, DOI 10.1002/(SICI)1097-0215(20000320)89:2<142::AID-IJC7>3.3.CO;2-2; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Sierra A, 1997, LAB INVEST, V77, P357; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu JX, 1996, ANTICANCER RES, V16, P2233; Yarden RI, 2001, J CELL BIOCHEM, P232; Yu DH, 1996, ONCOGENE, V13, P1359; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	44	251	271	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7611	7618		10.1038/sj.onc.1206004	http://dx.doi.org/10.1038/sj.onc.1206004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400004				2022-12-25	WOS:000178756200001
J	Wyatt, AW; Steinert, JR; Wheeler-Jones, CPD; Morgan, AJ; Sugden, D; Pearson, JD; Sobrevia, L; Mann, GE				Wyatt, AW; Steinert, JR; Wheeler-Jones, CPD; Morgan, AJ; Sugden, D; Pearson, JD; Sobrevia, L; Mann, GE			Early activation of the p42/p44(MAPK) pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism	FASEB JOURNAL			English	Article						mitogen-activated protein kinases; NO; L-arginine; A(2a) purinoceptors	L-ARGININE TRANSPORT; PROTEIN-KINASE; CYCLIC-AMP; A(2B) RECEPTORS; CULTURED HUMAN; SYSTEM Y(+); SYNTHASE; RELAXATION; CHANNELS; RELEASE	Adenosine is released from the myocardium, endothelial cells, and skeletal muscle in ischemia and is an important regulator of coronary blood flow. We have already shown that acute (2 min) activation of A(2a) purinoceptors stimulates NO production in human fetal umbilical vein endothelial cells (1) and now report a key role for p42/p44 mitogen-activated protein kinases (p42/p44(MAPK)) in the regulation of the L-arginine-nitric oxide (NO) signaling pathway. Expression of mRNA for the A(2a)-, A(2b)-, and A(3) -adenosine receptor subtypes was abundant whereas A(1)-adenosine receptor mRNA levels were negligible. Activation of A(2a) purinoceptors by adenosine (10 muM) or the A(2a) receptor agonist CGS21680 (100 nM) resulted in an increase in L-arginine transport and NO release that was not mediated by changes in intracellular Ca2+, pH, or cAMP. Stimulation of endothelial cells with adenosine was associated with a membrane hyperpolarization and phosphorylation of p42/p44(MAPK). L-NAME abolished the adenosine-induced hyperpolarization and stimulation of L-arginine transport whereas sodium nitroprusside activated an outward potassium current. Genistein (10 muM) and PD98059 (10 muM), an inhibitor of MAPK kinase 1/2 (MEK1/2), inhibited adenosine-stimulated L-arginine transport, NO production, and phosphorylation of p42/p44(MAPK). We found no evidence for activation of eNOS via the serine/threonine kinase Akt/ PKB (protein kinase B) in adenosine-stimulated cells. Our results provide the first evidence that adenosine stimulates the endothelial cell L-arginine-NO pathway in a Ca2+-insensitive manner involving p42/p44(MAPK), with release of NO leading to a membrane hyperpolarization and activation of L-arginine transport.	Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England; Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0UT, England; Kings Coll London, GKT Sch Biomed Sci, Endocrinol & Reprod Res Grp, London SE1 1UL, England; Univ Concepcion, Fac Biol Sci, Cellular & Mol Physiol Lab, Concepcion, Chile	University of London; King's College London; University of London; University of London Royal Veterinary College; University of London; King's College London; Universidad de Concepcion	Mann, GE (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Sobrevia, Luis/H-9608-2016; Steinert, Joern/A-6678-2008; Steinert, Joern R/AAI-2742-2020; Stroka, Deborah M/F-1806-2013; Wenger, Roland H./B-7953-2009; Steinert, Joern/ABB-4561-2020	Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Wenger, Roland H./0000-0001-7592-4839; Mann, Giovanni/0000-0001-7311-2044; Sobrevia, Luis/0000-0001-5802-2243				ABEBE W, 1995, AM J PHYSIOL-HEART C, V269, pH1672, DOI 10.1152/ajpheart.1995.269.5.H1672; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duszyk R, 2000, FREE RADICAL RES, V33, P449, DOI 10.1080/10715760000300991; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Ferro A, 1999, BRIT J PHARMACOL, V126, P1872, DOI 10.1038/sj.bjp.0702512; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GRAIER WF, 1993, BIOCHEM J, V291, P263, DOI 10.1042/bj2910263; GRAIER WF, 1992, BIOCHEM J, V288, P345, DOI 10.1042/bj2880345; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hein T, 1998, FASEB J, V12, pA13; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; JACOB R, 1991, CELL CALCIUM, V12, P127, DOI 10.1016/0143-4160(91)90014-6; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; Li JM, 1998, J SURG RES, V80, P357, DOI 10.1006/jsre.1998.5439; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; MARTIN PL, 1994, J PHARMACOL EXP THER, V270, P893; MAY MJ, 1998, AM J PHYSIOL, V43, pC789; Ogonowski AA, 2000, AM J PHYSIOL-CELL PH, V278, pC136; Olanrewaju HA, 2000, GEN PHARMACOL-VASC S, V35, P171, DOI 10.1016/S0306-3623(01)00107-0; Olanrewaju HA, 2000, AM J PHYSIOL-HEART C, V279, pH650, DOI 10.1152/ajpheart.2000.279.2.H650; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARRATT JR, 1994, CARDIOVASC RES, V28, P783, DOI 10.1093/cvr/28.6.783; Prentice DJ, 2000, N-S ARCH PHARMACOL, V362, P427, DOI 10.1007/s002100000292; Richard LF, 1998, AM J PHYSIOL-HEART C, V274, pH35, DOI 10.1152/ajpheart.1998.274.1.H35; Rolleston S, 2000, J PHYSIOL-LONDON, V523, p151P; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; Skinner MR, 1996, J PHYSIOL-LONDON, V495, P553, DOI 10.1113/jphysiol.1996.sp021615; SMITS P, 1995, CIRCULATION, V92, P2135, DOI 10.1161/01.CIR.92.8.2135; SOBREVIA L, 1994, AM J PHYSIOL, V267, pC39, DOI 10.1152/ajpcell.1994.267.1.C39; Sobrevia L, 1997, J PHYSIOL-LONDON, V499, P135, DOI 10.1113/jphysiol.1997.sp021916; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; STEINHORN RH, 1994, J PHYSIOL-LONDON, V266, P2001; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VIALS A, 1993, BRIT J PHARMACOL, V109, P424, DOI 10.1111/j.1476-5381.1993.tb13586.x; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9; Wyatt AW, 1998, J PHYSIOL-LONDON, V506P, p32P	58	108	110	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1584	1594		10.1096/fasebj.16.12.1584	http://dx.doi.org/10.1096/fasebj.16.12.1584			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374781	Green Published			2022-12-25	WOS:000179167600040
J	Davies, PA; Wang, W; Hales, TG; Kirkness, EF				Davies, PA; Wang, W; Hales, TG; Kirkness, EF			A novel class of ligand-gated ion channel is activated by Zn2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT3 RECEPTOR; SUBUNIT; GABA; GENE; ZINC	In mammals, the superfamily of "Cys loop," ligand-gated ion channels (LGICs), is assembled from a pool of more than 40 homologous subunits. These subunits have been classified into four families representing channels that are gated by acetylcholine, serotonin, gamma-aminobutyric acid, or glycine. By searching anonymous genomic sequence data for exons that encode characteristic motifs of the channel subunits, we have identified a novel LGIC that defines a fifth family member. Putative exons were used to isolate a full-length cDNA that encodes a protein of 411 amino acid residues. This protein (ZAC) contains all of the motifs that are characteristic of Cys loop channel subunits but cannot be assigned to any of the four established families on the basis of sequence similarity. Genes for ZAC are present in human and dog but appear to have been lost from mouse and rat genomes. Transcripts of ZAC subunits were detected in human placenta, trachea, spinal cord, stomach, and fetal brain. Transfection of human embryonic kidney cells with ZAC subunit cDNA caused expression of spontaneous current. By screening with a broad range of potential agonists and antagonists, we determined that tubocurarine inhibits the spontaneous current whereas Zn2+ activates the expressed receptors. The absence of Zn2+ activated channels in rats and mice may explain why this fifth member of the LGIC superfamily has evaded detection until now.	Inst Genom Res, Rockville, MD 20850 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA	J. Craig Venter Institute; George Washington University; George Washington University	Kirkness, EF (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	ekirknes@tigr.org	Davies, Paul A/P-4595-2017	Davies, Paul A/0000-0002-3973-3143				ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BLOOMENTHAL AB, 1994, MOL PHARMACOL, V46, P1156; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Davies PA, 2001, J PHYSIOL-LONDON, V537, P101, DOI 10.1111/j.1469-7793.2001.0101k.x; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Lustig LR, 2001, GENOMICS, V73, P272, DOI 10.1006/geno.2000.6503; Mohler H, 2001, Curr Opin Pharmacol, V1, P22, DOI 10.1016/S1471-4892(01)00008-X; Morinaga T, 2002, BIOCHEM BIOPH RES CO, V294, P630, DOI 10.1016/S0006-291X(02)00536-3; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Palma E, 1998, P NATL ACAD SCI USA, V95, P10246, DOI 10.1073/pnas.95.17.10246; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79	25	116	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					712	717		10.1074/jbc.M208814200	http://dx.doi.org/10.1074/jbc.M208814200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12381728	hybrid			2022-12-25	WOS:000180321900004
J	Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL				Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL			Failure to insert the iron-sulfur cluster into the Rieske iron-sulfur protein impairs both center N and center P of the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; SACCHAROMYCES-CEREVISIAE; C REDUCTASE; UBIQUINOL-OXIDATION; MUTATIONAL ANALYSIS; ELECTRON-TRANSFER; SINGLE-STEP; BC1 COMPLEX; MITOCHONDRIA; PRESEQUENCE	Mutation of a serine that forms a hydrogen bond to the iron-sulfur cluster of the Rieske iron-sulfur protein to a cysteine results in a respiratory-deficient yeast strain due to formation of iron-sulfur protein lacking the iron-sulfur cluster. The Rieske apoprotein lacking the iron-sulfur cluster is inserted into both monomers of the dimeric cytochrome bc(1) complex and processed to mature size, but the protein lacking iron-sulfur cluster is more susceptible to proteolysis. In addition, the protein environment of center P in one half of the dimer is affected by failure to insert the iron-sulfur cluster as indicated by the fact that only one molecule of myxothiazol can be bound to the cytochrome be, dimer. Although the be, complex lacking the Rieske iron-sulfur cluster cannot oxidize ubiquinol through center P, rates of reduction of cytochrome b by menaquinol through center N are normal. However, less cytochrome b is reduced through center N, and only one molecule of antimycin can be bound at center N in the bc(1) dimer lacking iron-sulfur cluster. These results indicate that failure to insert the [2Fe-2S] cluster impairs assembly of the Rieske protein into the bc(1) complex and that this interferes with proper assembly of both center P and center N in one half of the dimeric enzyme.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Gutierrez Cirlos, Emma Berta/D-4463-2011; Gutiérrez, Emma/AAG-5191-2021	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V256, P199, DOI 10.1016/0005-2728(72)90053-9; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRANDT U, 1991, J BIOL CHEM, V266, P19958; Brasseur G, 1997, BIOCHEMISTRY-US, V36, P11685, DOI 10.1021/bi970777d; CAVAZZONI M, 1993, ARCH BIOCHEM BIOPHYS, V303, P246, DOI 10.1006/abbi.1993.1279; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; Nett JH, 1997, J BIOL CHEM, V272, P2212; Nett JH, 1999, J BIOL CHEM, V274, P9253, DOI 10.1074/jbc.274.14.9253; Nett JH, 1998, J BIOL CHEM, V273, P8652, DOI 10.1074/jbc.273.15.8652; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; VONJAGOW G, 1981, FEBS LETT, V136, P19, DOI 10.1016/0014-5793(81)81206-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2001, J BIOL CHEM, V276, P46125, DOI 10.1074/jbc.M107436200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50703	50709		10.1074/jbc.M208556200	http://dx.doi.org/10.1074/jbc.M208556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12377760	hybrid			2022-12-25	WOS:000180177700067
J	Pardo, PS; Leung, JK; Lucchesi, JC; Pereira-Smith, OM				Pardo, PS; Leung, JK; Lucchesi, JC; Pereira-Smith, OM			MRG15, a novel chromodomain protein, is present in two distinct multiprotein complexes involved in transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE-COMPENSATION; B-MYB; GENE; PROLIFERATION; BINDING; DOMAIN; EVOLUTION; FAMILY; YEAST; TIP60	MRG15 is a novel chromodomain protein that is a member of a family of genes related to MORF4. MORF4 (mortality factor on chromosome 4) induces senescence in a subset of human tumor cell lines. Our previous results indicated that MRG15 (MORF-related gene on chromosome 15) could derepress the B-myb promoter by association with Rb. In this study, sucrose gradient analysis demonstrated that MRG15 was present in two distinct nuclear protein complexes, MAF1 (MRG15-associated factor 1) and MAF2.. Rb was associated with MRG15 and PAM14 (a novel coil-coil protein) in MAF1, and a histone acetyl transferase, hMOF, was an MRG15 partner in MAF2. Analysis of deletion mutants of MRG15 indicated that the leucine zipper at the C-terminal region of MRG15 was important for the protein associations in MAF1 and that the N-terminal chromodomain was required for the assembly of the MAF2 protein complex. Consistent with these data was the fact that a histone acetyltransferase activity associated with MRG15 was lost when the chromodomain was deleted and that both mutant MRG15 proteins failed to activate the B-myb promoter. The various mechanisms by which MRG15 could activate gene transcription are discussed.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Baylor College of Medicine; Emory University	Pereira-Smith, OM (corresponding author), Univ Texas, Hlth Sci Ctr San Antonio, S Texas Ctr Biol Med,Dept Cellular & Struct Biol, Sam & Ann Barshop Ctr Longev & Aging Studies, 15355 Lambda Dr,Rm 2-200, San Antonio, TX 78245 USA.	smitho@uthscsa.edu			NIA NIH HHS [P01AG13663, R37AG05333, T32AG00183] Funding Source: Medline; NIGMS NIH HHS [GM15691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000183, R37AG005333, P01AG013663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Cowell IG, 1997, BBA-PROTEIN STRUCT M, V1337, P198, DOI 10.1016/S0167-4838(96)00165-3; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Leung JK, 2001, J BIOL CHEM, V276, P39171, DOI 10.1074/jbc.M103435200; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Marin I, 2000, MOL BIOL EVOL, V17, P1240, DOI 10.1093/oxfordjournals.molbev.a026407; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Pannuti A, 2000, CURR OPIN GENET DEV, V10, P644, DOI 10.1016/S0959-437X(00)00136-2; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1999, J CELL PHYSIOL, V179, P245; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804	23	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50860	50866		10.1074/jbc.M203839200	http://dx.doi.org/10.1074/jbc.M203839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397079	hybrid			2022-12-25	WOS:000180177700087
J	Yan, F; Polk, DB				Yan, F; Polk, DB			Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MOUSE LYMPHOCYTE-PROLIFERATION; LACTOBACILLUS-RHAMNOSUS GG; ACTIVATED PROTEIN-KINASE; ULCERATIVE-COLITIS; CROHNS-DISEASE; INTERLEUKIN-10; MICE; SUPPRESSOR; CHILDREN	Probiotic bacteria are microorganisms that benefit the host by preventing or ameliorating disease. However, little information is known regarding the scientific rationale for using probiotics as alternative medicine. The purpose of this paper is to investigate the mechanisms of probiotic beneficial effects on intestinal cell homeostasis. We now report that one such probiotic, Lactobacillus rhamnosus GG (LGG), prevents cytokine-induced apoptosis in two different intestinal epithelial cell models. Culture of LGG with either mouse or human colon cells activates the anti-apoptotic Akt/protein kinase B. This model probiotic also inhibits activation of the pro-apoptotic p38/mitogen-activated protein kinase by tumor necrosis factor, interieukin-1alpha, or gamma-interferon. Furthermore, products recovered from LGG culture broth supernatant show concentration-dependent activation of Akt and inhibition of cytokine-induced apoptosis. These observations suggest a novel mechanism of communication between probiotic microorganisms and epithelia that increases survival of intestinal cells normally found in an environment of pro-apoptotic cytokines.	Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Polk, DB (corresponding author), S4322 MCN,21st & Garland Ave, Nashville, TN 37232 USA.				Intramural NIH HHS [Z01 DK056008] Funding Source: Medline; NCI NIH HHS [P30 CA068485, CA68485] Funding Source: Medline; NIDDK NIH HHS [R01 DK081134, DK58404, P30 DK058404, K01 DK065744, R01 DK056008, F32 DK010105, DK10105] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056008, R01DK056008, R01DK081134, P30DK058404, K01DK065744, F32DK010105] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; BERNET MF, 1994, GUT, V35, P483, DOI 10.1136/gut.35.4.483; BernetCamard MF, 1997, APPL ENVIRON MICROB, V63, P2747, DOI 10.1128/AEM.63.7.2747-2753.1997; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FABIA R, 1993, DIGESTION, V54, P248, DOI 10.1159/000201045; Favier C, 1997, DIGEST DIS SCI, V42, P817, DOI 10.1023/A:1018876400528; Gill HS, 2000, BRIT J NUTR, V83, P167, DOI 10.1017/S0007114500000210; GORBACH SL, 1987, LANCET, V2, P1519; Gotteland M, 2001, ALIMENT PHARM THER, V15, P11, DOI 10.1046/j.1365-2036.2001.00898.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Iwamoto M, 1996, J PATHOL, V180, P152; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kirjavainen PV, 1999, CLIN DIAGN LAB IMMUN, V6, P799, DOI 10.1128/CDLI.6.6.799-802.1999; Kirjavainen PV, 1999, FEMS IMMUNOL MED MIC, V26, P131, DOI 10.1111/j.1574-695X.1999.tb01380.x; LILLY DM, 1965, SCIENCE, V147, P747, DOI 10.1126/science.147.3659.747; Maassen CBM, 2000, VACCINE, V18, P2613, DOI 10.1016/S0264-410X(99)00378-3; Madsen KL, 1999, GASTROENTEROLOGY, V116, P1107, DOI 10.1016/S0016-5085(99)70013-2; Malin M, 1996, ANN NUTR METAB, V40, P137, DOI 10.1159/000177907; Marteau PR, 2001, AM J CLIN NUTR, V73, p430S, DOI 10.1093/ajcn/73.2.430s; Miettinen M, 1996, INFECT IMMUN, V64, P5403, DOI 10.1128/IAI.64.12.5403-5405.1996; Miettinen M, 1998, INFECT IMMUN, V66, P6058, DOI 10.1128/IAI.66.12.6058-6062.1998; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PERDIGON G, 1986, INFECT IMMUN, V53, P404, DOI 10.1128/IAI.53.2.404-410.1986; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Rodrigues ACP, 2000, J APPL MICROBIOL, V89, P404, DOI 10.1046/j.1365-2672.2000.01128.x; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; Schultz M, 2002, INFLAMM BOWEL DIS, V8, P71, DOI 10.1097/00054725-200203000-00001; Shanahan F, 2000, SCIENCE, V289, P1311, DOI 10.1126/science.289.5483.1311; Szajewska H, 2001, J PEDIATR-US, V138, P361, DOI 10.1067/mpd.2001.111321; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099; VAN AD, 1996, SCIENCE, V274, P787; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan F, 2001, CANCER RES, V61, P8668; Yan F, 2001, CANCER RES, V61, P963; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	41	379	440	1	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50959	50965		10.1074/jbc.M207050200	http://dx.doi.org/10.1074/jbc.M207050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393915	Green Accepted, hybrid			2022-12-25	WOS:000180177700099
J	Sumichika, H; Sakata, K; Sato, N; Takeshita, S; Ishibuchi, S; Nakamura, M; Kamahori, T; Ehara, S; Itoh, K; Ohtsuka, T; Ohbora, T; Mishina, T; Komatsu, H; Naka, Y				Sumichika, H; Sakata, K; Sato, N; Takeshita, S; Ishibuchi, S; Nakamura, M; Kamahori, T; Ehara, S; Itoh, K; Ohtsuka, T; Ohbora, T; Mishina, T; Komatsu, H; Naka, Y			Identification of a potent and orally active non-peptide C5a receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ISCHEMIA-REPERFUSION INJURY; PROTEIN-COUPLED RECEPTORS; ALZHEIMERS-DISEASE; PHARMACOLOGICAL CHARACTERIZATION; ANAPHYLATOXIN RECEPTOR; COMPLEMENT ACTIVATION; RHEUMATOID-ARTHRITIS; MOLECULAR-CLONING; ARTHUS REACTION	The anaphylatoxin C5a is a potent chemotactic factor for neutrophils and other leukocytes, and functions as an important inflammatory mediator. Through a high capacity screening followed by chemical optimization, we identified a novel non-peptide C5a receptor antagonist, N-[(4-dimethylaminophenyl)methyl]-N-(4-isopropylphenyl)-7-methoxy-1,2,3,4-tetrahydronaphthalen-1-carboxamide hydrochloride (W-54011). W-54011 inhibited the binding of I-125-labeled C5a to human neutrophils with a K-i value of 2.2 nm. W-54011 also inhibited C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of reactive super oxide species in human neutrophils with IC50 values of 3.1, 2.7, and 1.6 nm, respectively. In C5a-induced intracellular Ca2+ mobilization assay with human neutrophils, W-54011 did not show agonistic activity at up to 10 muM and shifted rightward the concentration-response curves to C5a without depressing the maximal responses. Examination on the species specificity of W-54011 revealed that it was able to inhibit C5a-induced intracellular Ca2+ mobilization in neutrophils of cynomolgus monkeys and gerbils but not mice, rats, guinea pigs, rabbits, and dogs. In gerbils, oral administration of W-54011 (3-30 mg/kg) inhibited C5a-induced neutropenia in a dose-dependent manner. The present report is the first description of an orally active non-peptide C5a receptor antagonist that could contribute to the treatment of inflammatory diseases mediated by C5a.	Mitsubishi Pharma Co, Pharmaceut Res Div, Aoba Ku, Yokohama, Kanagawa 2270033, Japan	Mitsubishi Tanabe Pharma Corporation	Sumichika, H (corresponding author), Mitsubishi Pharma Co, Pharmaceut Res Div, Aoba Ku, 100 Kamoshida Cho, Yokohama, Kanagawa 2270033, Japan.	sumichika.hiroshi@mg.m-pharma.co.jp						Alvarez V, 1996, IMMUNOGENETICS, V44, P446, DOI 10.1007/BF02602806; Arumugam TV, 2002, J SURG RES, V103, P260, DOI 10.1006/jsre.2002.6369; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Astles PC, 1997, BIOORG MED CHEM LETT, V7, P907, DOI 10.1016/S0960-894X(97)00124-8; Bachvarov DR, 1999, BRIT J PHARMACOL, V128, P321, DOI 10.1038/sj.bjp.0702812; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BENGTSON A, 1988, ARCH SURG-CHICAGO, V123, P645; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Cooper NR, 2000, IMMUNOL RES, V21, P159, DOI 10.1385/IR:21:2-3:159; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; deLaszlo SE, 1997, BIOORG MED CHEM LETT, V7, P213, DOI 10.1016/S0960-894X(96)00606-3; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Fukuoka Y, 1998, INT IMMUNOL, V10, P275, DOI 10.1093/intimm/10.3.275; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GIVEN WP, 1984, ARTHRITIS RHEUM, V27, P631, DOI 10.1002/art.1780270605; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heller T, 1999, J IMMUNOL, V163, P985; HOGASEN K, 1995, J RHEUMATOL, V22, P24; Huber-Lang MS, 2001, FASEB J, V15, P568; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; JOSE PJ, 1990, ANN RHEUM DIS, V49, P747, DOI 10.1136/ard.49.10.747; Kassahn D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411b; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; Kondo C, 2001, CLIN EXP IMMUNOL, V124, P323, DOI 10.1046/j.1365-2249.2001.01513.x; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; Matsuki Y, 1998, J CLIN APHERESIS, V13, P108, DOI 10.1002/(SICI)1098-1101(1998)13:3<108::AID-JCA3>3.0.CO;2-Z; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; O'Barr S, 2000, J NEUROIMMUNOL, V109, P87, DOI 10.1016/S0165-5728(00)00291-5; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; Pellas TC, 1998, J IMMUNOL, V160, P5616; PELLAS TC, 1993, J PHARMACOL TOX MET, V30, P137, DOI 10.1016/1056-8719(93)90036-E; Pellas TC, 1999, CURR PHARM DESIGN, V5, P737; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; Rothermel E, 1997, MOL IMMUNOL, V34, P877, DOI 10.1016/S0161-5890(97)00104-1; Schaller M, 2001, NAT IMMUNOL, V2, P746, DOI 10.1038/90696; Schubert D, 2002, NAT IMMUNOL, V3, P411, DOI 10.1038/ni0502-411a; Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; SPRONK PE, 1995, LUPUS, V4, P86, DOI 10.1177/096120339500400202; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; Wong A K, 1999, IDrugs, V2, P686; Zhang XL, 1997, PROTEIN SCI, V6, P65	53	81	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49403	49407		10.1074/jbc.M209672200	http://dx.doi.org/10.1074/jbc.M209672200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384495	hybrid			2022-12-25	WOS:000180028900039
J	Kitao, H; Yuan, ZA				Kitao, H; Yuan, ZA			Regulation of ionizing radiation-induced Rad52 nuclear foci formation by c-Abl-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATIONAL REPAIR; DOUBLE-STRAND BREAKS; DNA-DAMAGE; VERTEBRATE CELLS; TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; MAMMALIAN RAD51; SOMATIC-CELLS; PROTEIN	The RAD52 epistasis group of proteins, including Rad51, Rad52, and Rad54, plays an important role in the homologous recombination repair of double strand breaks. A well characterized feature associated with the ability of these proteins to repair double strand breaks is inducible nuclear foci formation at the sites of damage. How the process is functionally regulated in response to DNA damage, however, remains elusive. We show here that c-Abl tyrosine kinase associates with and phosphorylates Rad52 on tyrosine 104. Importantly, the very same site of Rad52 is phosphorylated on exposure of cells to ionizing radiation (IR). The functional significance of c-Abl-dependent phosphorylation of Rad52 is underscored by our findings that cells that express the phosphorylation-resistant Rad52 mutant, in which tyrosine 104 is replaced by phenylalanine, exhibit compromised nuclear foci formation in response to IR. Furthermore, IR-induced Rad52 nuclear foci formation is markedly suppressed by the expression of dominant-negative c-Abl. Together our data support a mode of post-translational regulation of Rad52 mediated by the c-Abl tyrosine kinase.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R29CA076275] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76275-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Fujimori A, 2001, EMBO J, V20, P5513, DOI 10.1093/emboj/20.19.5513; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Morrison C, 2000, INT J BIOCHEM CELL B, V32, P817, DOI 10.1016/S1357-2725(00)00033-9; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	37	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48944	48948		10.1074/jbc.M208151200	http://dx.doi.org/10.1074/jbc.M208151200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379650	hybrid			2022-12-25	WOS:000179789600126
J	Page, EL; Robitaille, GA; Pouyssegur, J; Richard, DE				Page, EL; Robitaille, GA; Pouyssegur, J; Richard, DE			Induction of hypoxia-inducible factor-1 alpha by transcriptional and translational mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SENSITIVE SIGNALING PATHWAYS; FACTOR 1-ALPHA HIF-1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; ANGIOTENSIN-II; KINASE-C; STIMULATES PHOSPHORYLATION; PROLYL HYDROXYLATION; HIF-ALPHA	Hypoxia-inducible factor-1 (HIF-1) regulates the transcription of many genes induced by low oxygen conditions. Recent studies have demonstrated that non-hypoxic stimuli can also activate HIF-1 in a cell-specific manner. Here, we define two key mechanisms that are implicated in increasing the active subunit of the HIF-1 complex, HIF-1alpha, following the stimulation of vascular smooth muscle cells (VSMC) with angiotensin II(Ang II). We show that, in contrast to hypoxia, the induction of HIF-1alpha by Ang II in VSMC is dependent on active transcription and ongoing translation. We demonstrate that stimulation of VSMC by Ang II strongly increases HIF-1alpha gene expression. The activation of diacylglycerol-sensitive protein kinase C (PKC) plays a major role in the increase of HIF-1alpha gene transcription. We also demonstrate that Ang II relies on ongoing translation to maintain elevated HIF-1alpha protein levels. Ang H increases HIF-1alpha translation by a reactive oxygen species (ROS)-dependent activation of the phosphatidylinositol 3-kinase pathway, which acts on the 5'-untranslated region of HIF-1alpha mRNA. These results establish that the non-hypoxic induction of the HIF-1 transcription factor via vasoactive hormones (Ang II and thrombin) is triggered by a dual mechanism, i.e. a PKC-mediated transcriptional action and a ROS-dependent increase in HIF-1alpha protein expression. Elucidation of these signaling pathways that up-regulate the vascular endothelial growth factor (VEGF) could have a strong impact on different aspects of vascular biology.	Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada; CNRS, UMR6543, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Antoine Lacassagne	Richard, DE (corresponding author), Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada.		Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				Brasier AR, 2000, MOL CELL BIOCHEM, V212, P155, DOI 10.1023/A:1007133710837; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; RAO GN, 1994, J BIOL CHEM, V269, P7180; Rao GN, 2000, J BIOL CHEM, V275, P16993, DOI 10.1074/jbc.275.22.16993; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Touyz RM, 2000, PHARMACOL REV, V52, P639; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	40	317	325	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48403	48409		10.1074/jbc.M209114200	http://dx.doi.org/10.1074/jbc.M209114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379645	hybrid			2022-12-25	WOS:000179789600058
J	van der Schaft, DWJ; Dings, RPM; de Lussanet, QG; van Eijk, LI; Nap, AW; Beets-Tan, RGH; Steege, JCABT; Wagstaff, J; Mayo, KH; Griffioen, AW				van der Schaft, DWJ; Dings, RPM; de Lussanet, QG; van Eijk, LI; Nap, AW; Beets-Tan, RGH; Steege, JCABT; Wagstaff, J; Mayo, KH; Griffioen, AW			The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models	FASEB JOURNAL			English	Article						apoptosis; melanoma; migration; ovarian carcinoma	ANGIOGENESIS INHIBITOR; MICROVESSEL DENSITY; PLATELET FACTOR-4; APOPTOSIS; ANGIOSTATIN; ENDOSTATIN; CARCINOMA; SURFACE; CANCER; PROLIFERATION	The de novo designed angiogenesis inhibitor anginex was tested in vitro and in vivo for its mechanism of action and antitumor activity. The data presented here demonstrate that anginex is a powerful antiangiogenic agent with significant antitumor activity. The mechanism of action of anginex was found to be the induction of anoikis leading to apoptosis in angiogenically activated endothelial cells, resulting in an up to 90% inhibition of migration in the wound assay. Anginex inhibited angiogenesis as demonstrated in the in vitro mouse aortic ring assay. In addition, tumor-induced angiogenesis in the chick chorioallantoic membrane was markedly inhibited. Anginex showed profound antitumor activity in the syngeneic mouse B16F10 melanoma model and in a xenograft human tumor model. Microvessel density determination as well as magnetic resonance imaging showed that the antitumor activity in these tumor models resulted from the antiangiogenic activity of anginex. A complete absence of toxicity was observed in these models. The data presented here demonstrate that anginex is a promising agent for further clinical development.	Univ Maastricht, Angiogenesis Lab, Dept Internal Med, GROW, Maastricht, Netherlands; Univ Maastricht, Dept Radiol, Maastricht, Netherlands; Univ Maastricht, Dept Obstet & Gynecol, Maastricht, Netherlands; Univ Maastricht, Dept Pathol, Maastricht, Netherlands; Univ Minnesota, Ctr Hlth Sci, Dept Biochem, Minneapolis, MN USA	Maastricht University; Maastricht University; Maastricht University; Maastricht University; University of Minnesota System; University of Minnesota Twin Cities	Griffioen, AW (corresponding author), Univ Hosp Maastricht, Angiogenesis Lab, Dept Pathol, P Debyelaan 25, NL-6202 AZ Maastricht, Netherlands.	a.griffioen@intmed.unimaas.nl	Beets-Tan, Regina/AAZ-9119-2020; Dings, Ruud/C-6188-2008	Wagstaff, John/0000-0002-1140-5981; Dings, Ruud/0000-0001-7686-1331				BOUMATERSTEEGE JCA, 2002, CRIT REV EUKAR GENE, V11, P41; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; GRIFFIOEN AW, 2001, BIOCHEM J, P233; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; Hillen HFP, 1997, INT J CANCER, V74, P81; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; Molema G, 1998, IMMUNOL TODAY, V19, P392, DOI 10.1016/S0167-5699(98)01314-0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181; van der Schaft DWJ, 2002, ANN MED, V34, P19; vanDijke CF, 1996, RADIOLOGY, V198, P813, DOI 10.1148/radiology.198.3.8628876; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; YAMAOKA M, 1993, CANCER RES, V53, P4262; YAMAOKA M, 1993, CANCER RES, V53, P5233; Yokoyama Y, 2000, CANCER RES, V60, P2190	34	91	99	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1991	+		10.1096/fj.02-0509fje	http://dx.doi.org/10.1096/fj.02-0509fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397082				2022-12-25	WOS:000179167600013
J	Benach, J; Chou, YT; Fak, JJ; Itkin, A; Nicolae, DD; Smith, PC; Wittrock, G; Floyd, DL; Golsaz, CM; Gierasch, LM; Hunt, JF				Benach, J; Chou, YT; Fak, JJ; Itkin, A; Nicolae, DD; Smith, PC; Wittrock, G; Floyd, DL; Golsaz, CM; Gierasch, LM; Hunt, JF			Phospholipid-induced monomerization and signal-peptide-induced oligomerization of SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; ATPASE ACTIVITY; MICELLE FORMATION; MODEL MEMBRANES; CRYSTAL-STRUCTURES; CATALYTIC CYCLE; MOLAL VOLUMES; HELICASE	The SecA ATPase drives the processive translocation of the N terminus of secreted proteins through the cytoplasmic membrane in eubacteria via cycles of binding and release from the SecYEG translocon coupled to ATP turnover. SecA forms a physiological dimer with a dissociation constant that has previously been shown to vary with temperature and ionic strength. We now present data showing that the oligomeric state of SecA in solution is altered by ligands that it interacts with during protein translocation. Analytical ultracentrifugation, chemical cross-linking, and fluorescence anisotropy measurements show that the physiological dimer of SecA is monomerized by long-chain phospholipid analogues. Addition of wild-type but not mutant signal sequence peptide to these SecA monomers redimerizes the protein. Physiological dimers of SecA do not change their oligomeric state when they bind signal sequence peptide in the compact, low temperature conformational state but polymerize when they bind the peptide in the domain-dissociated, high-temperature conformational state that interacts with SecYEG. This last result shows that, at least under some conditions, signal peptide interactions drive formation of new intermolecular contacts distinct from those stabilizing the physiological dimer. The observations that signal peptides promote conformationally specific oligomerization of SecA while phospholipids promote subunit dissociation suggest that the oligomeric state of SecA could change dynamically during the protein translocation reaction. Cycles of SecA subunit recruitment and dissociation could potentially be employed to achieve processivity in polypeptide transport.	Columbia Univ, Dept Sci Biol, New York, NY 10027 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Columbia University; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Hunt, JF (corresponding author), Columbia Univ, Dept Sci Biol, New York, NY 10027 USA.	hunt@sid.bio.columbia.edu	Gierasch, Lila M/D-1494-2009	Smith, Paul/0000-0003-4098-4588	NCRR NIH HHS [S10RR12848] Funding Source: Medline; NIGMS NIH HHS [GM58549, GM34962] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058549, R01GM034962] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; Ahn T, 2001, ARCH BIOCHEM BIOPHYS, V395, P14, DOI 10.1006/abbi.2001.2565; AKITA M, 1990, J BIOL CHEM, V265, P8164; ALUE TM, 1992, ANAL ULTRACENTRIFUGA, P90; BAUD C, 2002, J BIOL CHEM; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BROWN GM, 1970, CAN J CHEMISTRY, V48, P2525, DOI 10.1139/v70-427; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; Doyle SM, 2000, BIOCHEMISTRY-US, V39, P11667, DOI 10.1021/bi000299y; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Eastoe J, 1998, LANGMUIR, V14, P5719, DOI 10.1021/la980053i; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; Heerklotz H, 2001, BIOPHYS J, V80, P271, DOI 10.1016/S0006-3495(01)76012-2; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kresheck GC, 1998, J AM CHEM SOC, V120, P10964, DOI 10.1021/ja982156t; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 1999, J BIOL CHEM, V274, P23868, DOI 10.1074/jbc.274.34.23868; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; OLOFSSON G, 1985, J PHYS CHEM-US, V89, P1473, DOI 10.1021/j100254a034; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; PAULA S, 1995, J PHYS CHEM-US, V99, P11742, DOI 10.1021/j100030a019; Ramamurthy V, 1998, J BACTERIOL, V180, P6419; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shilton B, 1998, FEBS LETT, V436, P277, DOI 10.1016/S0014-5793(98)01141-7; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; VIKINGSTAD E, 1980, J COLLOID INTERF SCI, V74, P16, DOI 10.1016/0021-9797(80)90166-6; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; WENNERSTROM H, 1979, PHYS REP, V52, P1, DOI 10.1016/0370-1573(79)90087-5; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393	70	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3628	3638		10.1074/jbc.M205992200	http://dx.doi.org/10.1074/jbc.M205992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12403785	hybrid			2022-12-25	WOS:000180869700016
J	Ferber, M; Sporning, A; Jeserich, G; DeLaCruz, R; Watkins, M; Olivera, BM; Terlau, H				Ferber, M; Sporning, A; Jeserich, G; DeLaCruz, R; Watkins, M; Olivera, BM; Terlau, H			A novel Conus peptide ligand for K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-CONOTOXIN PVIIA; VENOM PEPTIDES; ACETYLCHOLINE-RECEPTOR; DIVERSITY; TARGETS; SNAILS	Voltage-gated ion channels determine the membrane excitability of cells. Although many Conus peptides that interact with voltage-gated Na+ and Ca2+ channels have been characterized, relatively few have been identified that interact with K+ channels. We describe a novel Conus peptide that interacts with the Shaker K+ channel, M-kappa-conotoxin RIIIK from Conus radiatus. The peptide was chemically synthesized. Although M-kappa-conotoxin RIIIK is structurally similar to the mu-conotoxins that are sodium channel blockers, it does not affect any of the sodium channels tested, but blocks Shaker K+ channels. Studies using Shaker K+ channel mutants with single residue substitutions reveal that the peptide interacts with the pore region of the channel. Introduction of a negative charge at residue 427 (K427D) greatly increases the affinity of the toxin, whereas the substitutions at two other residues, Phe(425) and Thr (449), drastically reduced toxin affinity. Based on the Shaker results, a teleost homolog of the Shaker K+ channel, TSha1 was identified as a M-kappa-conotoxin RIIIK target. Binding of M-kappa-conotoxin RIIIK is state-dependent, with an IC50 of 20 nM for the closed state and 60 nm at 0 mV for the open state of TSha1 channels.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Osnabruck, Dept Anim Physiol, D-40069 Osnabruck, Germany; Max Planck Inst Expt Med, AG Mol & Zellulare Neuropharmakol, D-37075 Gottingen, Germany	Utah System of Higher Education; University of Utah; University Osnabruck; Max Planck Society	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.	olivera@biology.utah.edu			NIGMS NIH HHS [GM 48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bulaj G, 2001, BIOCHEMISTRY-US, V40, P13201, DOI 10.1021/bi010683a; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; COLLEDGE CJ, 1992, TOXICON, V30, P1111, DOI 10.1016/0041-0101(92)90056-B; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; Duda TF, 2001, BIOL J LINN SOC, V73, P391, DOI 10.1006/bijl.2001.0544; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Jacobsen R, 1998, J PEPT RES, V51, P173; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; Nguyen TD, 2000, J NEUROSCI RES, V60, P174, DOI 10.1002/(SICI)1097-4547(20000415)60:2<174::AID-JNR6>3.0.CO;2-I; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolsys.33.010802.150424; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Sambrook J, 2001, MOL CLONING LAB MANU; SATO S, 1983, FEBS LETT, V155, P277, DOI 10.1016/0014-5793(82)80620-0; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P9581, DOI 10.1021/bi970235w; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; Shon KJ, 1998, J NEUROSCI, V18, P4473; SPENCE I, 1977, LIFE SCI, V21, P1759, DOI 10.1016/0024-3205(77)90156-4; STONE BL, 1982, ARCH BIOCHEM BIOPHYS, V216, P765, DOI 10.1016/0003-9861(82)90268-5; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Terlau H, 1999, J GEN PHYSIOL, V114, P125, DOI 10.1085/jgp.114.1.125; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x	28	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2177	2183		10.1074/jbc.M205953200	http://dx.doi.org/10.1074/jbc.M205953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12399472	hybrid			2022-12-25	WOS:000180562000015
J	Demasi, M; Silva, GM; Netto, LES				Demasi, M; Silva, GM; Netto, LES			20 S proteasome from Saccharomyces cerevisiae is responsive to redox modifications and is S-glutathionylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; CYSTEINE-SULFENIC ACID; HYDROGEN-PEROXIDE; SUBCELLULAR-LOCALIZATION; OXIDATIVE STRESS; IDENTIFICATION; MITOCHONDRIAL; DEGRADATION; CATALYSIS; SULFHYDRYLS	The 20 S proteasome core purified from Saccharomyces cerevisiae is inhibited by reduced glutathione (GSH), cysteine (Cys), or the GSH precursor gamma-glutamylcysteine. Chymotrypsin-like activity was more affected by GSH than trypsin-like activity, whereas the peptidylglutamyl-hydrolyzing activity (caspase-like) was not inhibited by GSH. Cys-sulfenic acid formation in the 20 S core was demonstrated by spectral characterization of the Cys-S(O)-4-nitrobenzo-2-oxa-1,3-diazole adduct, indicating that 20 S proteasome Cys residues might react with reduced sulfhydryls (GSH, Cys, and gamma-glutamylcysteine) through the oxidized Cys-sulfenic acid form. S-Glutahionylation of the 20 S core was demonstrated in vitro by GSH-biotin incorporation and by decreased alkylation with monobromobimane. Compounds such as N-ethyl-maleimide (-S-sulfhydril H alkylating), dimedone (-SO sulfenic acid H reactant), or 7-chloro-4-nitrobenzo-2oxa-1,3-diazole (either -SH or -SOH reactant) highly inhibited proteasomal chymotrypsin-like activity. In vivo experiments revealed that 20 S proteasome extracted from H2O2-treated cells showed decreased chymotrypsin-like activity accompanied by S-glutathionylation as demonstrated by GSH release from the 20 S core after reduction with NaBH,. Moreover, cells pretreated with H2O2 showed decreased reductive capacity assessed by determination of the GSH/oxidized glutathione ratio and increased protein carbonyl levels. The present results indicate that at the physiological level the yeast 20 S proteasome is regulated by its sulfhydryl content, thereby coupling intracellular redox signaling to proteasome-mediated proteolysis.	Univ Sao Paulo, Dept Biol, Inst Biociencias, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo	Demasi, M (corresponding author), Univ Sao Paulo, Dept Biol, Inst Biociencias, Rua Matao 277 Sao Paulo, BR-05508900 Sao Paulo, Brazil.	mari_mais@hotmail.com	Netto, Luis/A-3783-2008; Demasi, Marilene/E-5873-2012	Netto, Luis/0000-0002-4250-9177; Demasi, Marilene/0000-0002-3749-1160				Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bellomo G, 1997, MICROSC RES TECHNIQ, V36, P243, DOI 10.1002/(SICI)1097-0029(19970215)36:4<243::AID-JEMT3>3.0.CO;2-N; BENITEZ LV, 1973, ARCH BIOCHEM BIOPHYS, V159, P89, DOI 10.1016/0003-9861(73)90432-3; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Demasi M, 2001, ARCH BIOCHEM BIOPHYS, V389, P254, DOI 10.1006/abbi.2001.2332; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Netto LES, 1996, ARCH BIOCHEM BIOPHYS, V333, P233, DOI 10.1006/abbi.1996.0386; Nulton-Persson AC, 2002, FREE RADICAL BIO MED, V33, pS90; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; RADI R, 1991, J BIOL CHEM, V266, P4244; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	38	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					679	685		10.1074/jbc.M209282200	http://dx.doi.org/10.1074/jbc.M209282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409293	hybrid			2022-12-25	WOS:000180255700086
J	Johnson, JE; Xie, MT; Singh, LMR; Edge, R; Cornell, RB				Johnson, JE; Xie, MT; Singh, LMR; Edge, R; Cornell, RB			Both acidic and basic amino acids in an amphitropic enzyme, CTP : phosphocholine cytidylyltransferase, dictate its selectivity for anionic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; PROTEIN FUNCTION; BINDING DOMAIN; FUSION PEPTIDE; HELA-CELLS; PH; INSERTION; PHOSPHOLIPIDS; ALPHA; PHOSPHORYLATION	Amphitropic proteins are regulated by reversible membrane interaction. Anionic phospholipids generally promote membrane binding of such proteins via electrostatics between the negatively charged lipid head-groups and clusters of basic groups on the proteins. In this study of one amphitropic protein, a cytidylyltransferase (CT) that regulates phosphatidylcholine synthesis, we found that substitution of lysines to glutamine along both interfacial strips of the membrane-binding amphipathic helix eliminated electrostatic binding. Unexpectedly, three glutamates also participate in the selectivity for anionic membrane surfaces. These glutamates become protonated in the low pH milieu at the surface of anionic, but not zwitterionic membranes, increasing protein positive charge and hydrophobicity. The binding and insertion into lipid vesicles of a synthetic peptide containing the three glutamates was pH-dependent with an apparent pK(a) that varied with anionic lipid content. Glutamate to glutamine substitution eliminated the pH dependence of the membrane interaction, and reduced anionic membrane selectivity of both the peptide and the whole CT enzyme examined in cells. Thus anionic lipids, working via surface-localized pH effects, can promote membrane binding by modifying protein charge and hydrophobicity, and this novel mechanism contributes to the membrane selectivity of CT in vivo.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Cornell, RB (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	cornell@sfu.ca		Xie, Mingtang/0000-0002-2797-0598				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLAND AG, 1999, BIOCHIM BIOPHYS ACTA, V1483, P199; BUSER CA, 1995, MOL MEMBR BIOL, V12, P69, DOI 10.3109/09687689509038498; CALDERON V, 1992, BIOCHIM BIOPHYS ACTA, V1106, P251, DOI 10.1016/0005-2736(92)90003-5; CASTELL JV, 1979, ANAL BIOCHEM, V99, P379, DOI 10.1016/S0003-2697(79)80022-6; CERBON J, 1991, INT J BIOCHEM, V23, P161, DOI 10.1016/0020-711X(91)90184-O; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; Dubovskii PV, 2000, PROTEIN SCI, V9, P786; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; EVANS RW, 1987, BIOCHEM J, V245, P455, DOI 10.1042/bj2450455; Friesen JA, 2001, BBA-MOL CELL BIOL L, V1533, P86, DOI 10.1016/S1388-1981(01)00145-7; Hanakam F, 1996, BIOCHEMISTRY-US, V35, P11036, DOI 10.1021/bi960789j; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; LEENHOUTS JM, 1995, FEBS LETT, V370, P189, DOI 10.1016/0014-5793(95)00823-R; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MALLAMPALLI RK, 1995, J CELL PHYSIOL, V162, P410, DOI 10.1002/jcp.1041620313; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murray D, 2001, J BIOL CHEM, V276, P45153, DOI 10.1074/jbc.M101784200; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Pinheiro TJT, 1997, BIOCHEMISTRY-US, V36, P13122, DOI 10.1021/bi971235z; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; TOCANNE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P111, DOI 10.1016/0304-4157(90)90005-W; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5512; Weers PMM, 2001, BIOCHEMISTRY-US, V40, P7754, DOI 10.1021/bi010410f; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Xia XF, 2000, BIOCHEM J, V349, P835, DOI 10.1042/bj3490835; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433; Zhelev DV, 2001, BIOPHYS J, V81, P285, DOI 10.1016/S0006-3495(01)75699-8	59	80	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					514	522		10.1074/jbc.M206072200	http://dx.doi.org/10.1074/jbc.M206072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401806	hybrid			2022-12-25	WOS:000180255700068
J	Singh, US; Pan, J; Kao, YL; Joshi, S; Young, KL; Baker, KM				Singh, US; Pan, J; Kao, YL; Joshi, S; Young, KL; Baker, KM			Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; BINDING PROTEIN-RHO; NERVE GROWTH-FACTOR; GTP-BINDING; NEURITE OUTGROWTH; GENE-EXPRESSION; PC12 CELLS; CARCINOMA-CELLS; CONE GUIDANCE; AXON GUIDANCE	All-trans-retinoic acid (RA) plays a crucial role in survival and differentiation of neurons. For elucidating signaling mechanisms involved in RA-induced neuronal differentiation, we have selected SH-SY5Y cells, which are an established in vitro cell model for studying RA signaling. Here we report that RA-induced neuronal differentiation of SH-SY5Y cells is coupled with increased expression/activation of TGase and in vivo transamidation and activation of RhoA. In addition, RA promotes formation of stress fibers and focal adhesion complexes, and activation of ERK1/2, JNK1, and p38alpha/beta/gamma MAP kinases. Using C-3 exoenzyme (RhoA inhibitor) or monodansylcadaverine (TGase inhibitor), we show that transamidated RhoA regulates cytoskeletal rearrangement and activation of ERK1/2 and p38gamma MAP kinases. Further, by using stable SH-SY5Y cell lines (overexpressing wild-type, C277S mutant, and antisense TGase), we demonstrate that transglutaminase activity is required for activation of RhoA, ERK1/2, JNK1, and p38gamma MAP kinases. Activated MAP kinases differentially regulate RA-induced neurite outgrowth and neuronal marker expression. The results of our studies suggest a novel mechanism of RA signaling, which involves activation of TGase and transamidation of RhoA. RA-induced activation of TGase is proposed to induce multiple signaling pathways that regulate neuronal differentiation.	Texas A&M Univ, Inst Cardiovasc Res, Div Mol Cardiol, Coll Med,Syst Hlth Sci Ctr, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Singh, US (corresponding author), Texas A&M Univ, Inst Cardiovasc Res, Div Mol Cardiol, Coll Med,Syst Hlth Sci Ctr, Bldg 162,1901 S 1st St, Temple, TX 76504 USA.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058439, R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58439, HL-44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Arendt T, 2000, NEUROBIOL AGING, V21, P783, DOI 10.1016/S0197-4580(00)00216-5; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hebert SS, 2000, J BIOL CHEM, V275, P32482, DOI 10.1074/jbc.M006528200; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; HUNTER K, 1991, P NATL ACAD SCI USA, V88, P3666, DOI 10.1073/pnas.88.9.3666; JALAVA A, 1993, J CELL PHYSIOL, V155, P301, DOI 10.1002/jcp.1041550211; JALAVA A, 1992, FEBS LETT, V300, P114, DOI 10.1016/0014-5793(92)80176-H; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Klinz FJ, 1996, J NEUROSCI RES, V46, P720, DOI 10.1002/(SICI)1097-4547(19961215)46:6<720::AID-JNR8>3.0.CO;2-H; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Maden W, 1999, METH MOL B, V97, P491; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; Matarrese P, 1998, INT J CANCER, V76, P531, DOI 10.1002/(SICI)1097-0215(19980518)76:4<531::AID-IJC15>3.0.CO;2-A; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Olsson AK, 2001, EXP CELL RES, V265, P21, DOI 10.1006/excr.2001.5163; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Singh US, 1998, J BIOL CHEM, V273, P1946, DOI 10.1074/jbc.273.4.1946; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Smith SM, 1998, J NUTR, V128, p467S, DOI 10.1093/jn/128.2.467S; STENBERG P, 1975, BIOCHEM J, V147, P153; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wang H, 2001, FEBS LETT, V503, P91, DOI 10.1016/S0014-5793(01)02699-0; White JC, 2000, DEV BIOL, V220, P263, DOI 10.1006/dbio.2000.9635; Zetterstrom RH, 1999, EUR J NEUROSCI, V11, P407, DOI 10.1046/j.1460-9568.1999.00444.x; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	59	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					391	399		10.1074/jbc.M206361200	http://dx.doi.org/10.1074/jbc.M206361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401808	hybrid			2022-12-25	WOS:000180255700052
J	Erdreich-Epstein, A; Tran, LB; Bowman, NN; Wang, HT; Cabot, MC; Durden, DL; Vlckova, J; Reynolds, CP; Stins, MF; Groshen, S; Millard, M				Erdreich-Epstein, A; Tran, LB; Bowman, NN; Wang, HT; Cabot, MC; Durden, DL; Vlckova, J; Reynolds, CP; Stins, MF; Groshen, S; Millard, M			Ceramide signaling in fenretinide-induced endothelial cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CANCER-CELLS; SERINE PALMITOYLTRANSFERASE; IONIZING-RADIATION; NEUROBLASTOMA; INDUCTION; STRESS; GROWTH; LINES; BRAIN	Stress stimuli can mediate apoptosis by generation of the lipid second messenger, ceramide. Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)). 4-HPR, a synthetic derivative of retinoic acid that induces ceramide in tumor cell lines, has been shown to have antiangiogenic effects, but the molecular mechanism of these is largely unknown. We report that 4-HPR was cytotoxic to endothelial cells (50% cytotoxicity at 2.4 mum, 90% at 5.36 mum) and induced a caspase-dependent endothelial apoptosis. 4-HPR (5 mum) increased ceramide levels in endothelial cells 5.3-fold, and the increase in ceramide was required to achieve the apoptotic effect of 4-HPR. The 4-HPR-induced increase in ceramide was suppressed by inhibitors of ceramide synthesis, fumonisin B, myriocin, and L-cycloserine, and 4-HPR transiently activated serine palmitoyltransferase, demonstrating that 4-HPR induced de novo ceramide synthesis. Sphingomyelin levels were not altered by 4-HPR, and desipramine had no effect on ceramide level, suggesting that sphingomyelinase did not contribute to the 4-HPR-induced ceramide increase. Finally, the pancaspase inhibitor, t-butyloxy-carbonyl-aspartyl[O-methyl]-fluoromethyl ketone, suppressed 4-HPR-mediated apoptosis but not ceramide accumulation, suggesting that ceramide is upstream of caspases. Our results provide the first evidence that increased ceramide biosynthesis is required for 4-HPR-induced endothelial apoptosis and present a molecular mechanism for its antiangiogenic effects.	Childrens Hosp Los Angeles, Div Hematol Oncol, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch med, Dept Prevent Med, Los Angeles, CA 90027 USA; John Wayne Canc Inst, St Johns Hlth Ctr, Santa Monica, CA 90404 USA; Indiana Univ, Sch Med, Hematol Oncol Sect, Dept Pediat,Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Johns Hopkins Sch Med, Dept Pediat, Div Infect Dis, Baltimore, MD 21205 USA	Children's Hospital Los Angeles; University of Southern California; John Wayne Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; Johns Hopkins Medicine	Erdreich-Epstein, A (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, Dept Pediat, 4650 Sunset Blvd,Mailstop 57, Los Angeles, CA 90027 USA.		Erdreich-Epstein, Anat/B-5750-2009; Stins, Monique/W-2621-2018	Erdreich-Epstein, Anat/0000-0003-4269-4373; Reynolds, C. Patrick/0000-0002-2827-8536	NATIONAL CANCER INSTITUTE [P01CA081403] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ciacci-Zanella JR, 1999, FOOD CHEM TOXICOL, V37, P703, DOI 10.1016/S0278-6915(99)00034-4; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; DiPietrantonio AM, 2000, CANCER RES, V60, P4331; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Garzotto M, 1999, CANCER RES, V59, P5194; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; Hsieh TC, 1997, PROSTATE, V33, P97; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Le Doze O, 2000, DRUG METAB DISPOS, V28, P205; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Donnell PH, 2002, LEUKEMIA, V16, P902, DOI 10.1038/sj.leu.2402485; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; PIENTA KJ, 1993, CANCER RES, V53, P224; Puduvalli VK, 1999, CLIN CANCER RES, V5, P2230; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Ribatti D, 2001, INT J CANCER, V94, P314, DOI 10.1002/ijc.1441; Stins MF, 2001, J NEUROVIROL, V7, P125; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Stins MF, 1997, IN VITRO CELL DEV-AN, V33, P243; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang HT, 2002, MOL CANCER THER, V1, P719; Wang HT, 2001, CANCER RES, V61, P5102; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001	43	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49531	49537		10.1074/jbc.M209962200	http://dx.doi.org/10.1074/jbc.M209962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388538	hybrid			2022-12-25	WOS:000180028900057
J	Hirosaki, T; Tsubota, Y; Kariya, Y; Moriyama, K; Mizushima, H; Miyazaki, K				Hirosaki, T; Tsubota, Y; Kariya, Y; Moriyama, K; Mizushima, H; Miyazaki, K			Laminin-6 is activated by proteolytic processing and regulates cellular adhesion and migration differently from laminin-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; HOMOZYGOUS NONSENSE MUTATION; GASTRIC-CARCINOMA CELLS; GAMMA-2 CHAIN; ALPHA-3 CHAIN; G-DOMAIN; STRUCTURAL REQUIREMENT; BASEMENT-MEMBRANES; SCATTER FACTOR; INTEGRIN	Laminin-6 (LN6) and laminin-5 (LN5), which share the common integrin-binding domain in the laminin alpha3 chain, are thought to cooperatively regulate cellular functions, but the former has poorly been characterized. Human fibrosarcoma HT1080 cells expressing an exogenous alpha3 chain were found to secrete LN6 with the fulllength alpha3 chain and a smaller amount of its processed form lacking the carboxyl-terminal G4-5 domain, besides mature LN5 without G4-5 (mat-LN5). We prepared the unprocessed LN6 and mat-LN5, as well as LN6 mutants without G4-5 (LN6AG4-5) or G5 (LN6AG5). These laminins supported attachment of HT1080 cells and human keratinocytes (HaCaT) through integrins alpha(3)beta(1) and/or alpha(6)beta(1). LN6DeltaG4-5, LN6DeltaG5, and mat-LN5 promoted rapid cell spreading, whereas LN6 did hardly. A purified G4-5 fragment of the laminin alpha3 chain supported cell attachment through interaction with heparan sulfate proteoglycans and promoted cell spreading in combination with mat-LN5 or LN6AG4-5. These results imply that the G4-5 domain within the LN6 molecule suppresses cell adhesion, while the released G4-5 promotes it. The presence of G5 rather than the heparin-binding domain G4 was responsible for the impaired cell spreading activity of LN6. However, the unprocessed LN6 promoted cell spreading in the presence of mat-LN5. Unlike mat-LN5, both LN6AG4-5 and LN6 did weakly or did not stimulate cell motility. These findings demonstrate that LN6 and LN5 have distinct biological activities, but they may cooperatively support cell adhesion. The proteolytic processing of the alpha3 chain seems to regulate the physiological functions of LN6.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 642-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.							Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Gagnoux-Palacios L, 2001, J CELL BIOL, V153, P835, DOI 10.1083/jcb.153.4.835; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; KIVIRIKKO S, 1995, HUM MOL GENET, V4, P959, DOI 10.1093/hmg/4.5.959; Koshikawa N, 1999, CANCER RES, V59, P5596; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lotz MM, 1997, AM J PATHOL, V150, P747; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; ROUSSELLE P, 1995, J BIOL CHEM, V270, P13766, DOI 10.1074/jbc.270.23.13766; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Sung U, 1997, MOL CELLS, V7, P272; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; VERRANDO P, 1988, BIOCHIM BIOPHYS ACTA, V942, P45, DOI 10.1016/0005-2736(88)90273-8	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49287	49295		10.1074/jbc.M111096200	http://dx.doi.org/10.1074/jbc.M111096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379663	hybrid			2022-12-25	WOS:000180028900024
J	Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK				Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK			Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-I-infected T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; HTLV-I; TAX TRANSACTIVATION; TYPE-1 PROMOTER; CREB BINDING; PROTEIN CREB; REGULATORY SEQUENCES; 21-BASE-PAIR REPEATS; MOLECULAR MECHANISM; COACTIVATOR CBP	The human T-cell leukemia virus (HTLV-I)-encoded Tax protein is a potent transcriptional activator that stimulates expression of the integrated provirus. Biochemical studies indicate that Tax, together with cellular transcription factors, interacts with viral cAMP-response element enhancer elements to recruit the pleiotropic coactivators CREB-binding protein and p300. Histone acetylation by these coactivators has been shown to play a major role in activating HTLV-I transcription from chromatin templates in vitro. However, the extent of histone modification and the precise identity of the cellular regulatory proteins bound at the HTLV-I promoter in vivo is not known. Chromatin immunoprecipitation analysis was used to investigate factor binding and histone modification at the integrated HTLV-I provirus in infected T-cells (SLB-1). These studies reveal the presence of Tax, a variety of ATF/CREB and AP-1 family members (CREB, CREB-2, ATF-1, ATF-2, c-Fos, and c-Jun), and both p300 and CREB-binding protein at the HTLV-I promoter. Consistent with the binding of these coactivators, we observed histone H3 and H4 acetylation at three regions within the proviral genome. Histone deacetylases were also present at the viral promoter and, following their inhibition, we observe an increase in histone H4 acetylation on the HTLV-I promoter and a concomitant increase in viral RNA. Together, these results suggest that a variety of transcriptional activators, coactivators, and histone deacetylases participate in the regulation of HTLV-I transcription in infected T-cells.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.		Lemasson, Isabelle/N-1355-2013	polakowski, Nicholas/0000-0003-4949-5799	NCI NIH HHS [R01 CA055035-09, R01 CA055035, CA 55035, CA 87540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055035, R01CA087540, R55CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Datta S, 2001, VIROLOGY, V283, P207, DOI 10.1006/viro.2000.0895; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; Dehee A, 2002, J VIROL METHODS, V102, P37, DOI 10.1016/S0166-0934(01)00445-1; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Fujii M, 1995, INTERVIROLOGY, V38, P221, DOI 10.1159/000150436; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Goodman RH, 2000, GENE DEV, V14, P1553; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KRUH J, 1992, CR SOC BIOL, V186, P12; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Leclercq I, 2000, J VIROL, V74, P2305, DOI 10.1128/JVI.74.5.2305-2312.2000; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; MIWA M, 1984, GANN, V75, P752; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; NUMATA N, 1991, NEW BIOL, V3, P896; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Schubeler D, 2000, GENE DEV, V14, P940; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Tsavachidou D, 2001, J VIROL, V75, P9909, DOI 10.1128/JVI.75.20.9909-9917.2001; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wattel E, 1996, J ACQUIR IMMUNE D S1, V13, P92; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P21; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yeh JH, 2002, NUCLEIC ACIDS RES, V30, P1944, DOI 10.1093/nar/30.9.1944; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	67	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49459	49465		10.1074/jbc.M209566200	http://dx.doi.org/10.1074/jbc.M209566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386157	hybrid			2022-12-25	WOS:000180028900047
J	Miedlich, S; Gama, L; Breitwieser, GE				Miedlich, S; Gama, L; Breitwieser, GE			Calcium sensing receptor activation by a calcimimetic suggests a link between cooperativity and intracellular calcium oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; EXTRACELLULAR CA2+-SENSING RECEPTOR; CHRONIC-RENAL-FAILURE; SECONDARY HYPERPARATHYROIDISM; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; CA2+ OSCILLATIONS; GENE-EXPRESSION; GB2 SUBUNITS; PROLIFERATION	Activation of the calcium sensing receptor (CaR) by small increments in extracellular calcium (Ca-e(2+)) induces intracellular calcium (Ca-i(2+)) oscillations that are dependent on thapsigargin-sensitive intracellular calcium stores. Phenylalkylamines such as NPS R-568 are allosteric modulators (calcimimetics) that activate CaR by increasing the apparent affinity of the receptor for calcium. We determined, by fluorescence imaging with fura-2, whether the calcimimetic NPS R-568 could activate Ca-i(2+) oscillations in HEK-293 cells expressing human CaR. NPS R-568 was more potent than Ca2+. at eliciting Ca-i(2+) oscillations, particularly at low [Ca2+](e) (as low as 0.1 mm). The oscillation frequencies elicited by NPS R-568 varied over a 2-fold range from peak to peak intervals of 60-70 to 30-45 s, depending upon the concentrations of both Ca2+. and NPS R-568. Finally, NPS R-568 induced sustained (>15 min after drug removal) Ca-i(2+) oscillations, suggesting slow release of the drug from its binding site. We exploited the potency of NPS R-568 for eliciting Ca-i(2+) oscillations for structural studies. Truncation of the CaR carboxyl terminus from 1077 to 886 amino acids had no effect on the ability of Ca2+ or NPS R-568 to induce Ca-i(2+) oscillations, but further truncation (to 868 amino acids) eliminated both highly cooperative Ca2+-dependent activation and regular Ca-i(2+) oscillations. Alanine scanning within the amino acid sequence from Arg(873) to His(879) reveals a linkage between the cooperativity for Ca2+-dependent activation and establishment and maintenance of intracellular Ca2+ oscillations. The amino acid residues critical to both functions of CaR may contribute to interactions with either G proteins or between CaR monomers within the functional dimer.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Syracuse University	Breitwieser, GE (corresponding author), 122 Lyman Hall,108 Coll Pl, Syracuse, NY 13244 USA.		Centeno, Patricia Pacios/O-8368-2016	Gama, Lucio/0000-0001-9511-012X; Breitwieser, Gerda/0000-0001-9081-0362	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58578] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIANCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P691, DOI 10.1006/bbrc.1994.2515; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Chang WH, 2001, J BIOL CHEM, V276, P44129, DOI 10.1074/jbc.M104834200; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Goodman WG, 2001, CURR OPIN NEPHROL HY, V10, P575, DOI 10.1097/00041552-200109000-00005; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P775; HAWKINS D, 1989, ENDOCRINOLOGY, V124, P838, DOI 10.1210/endo-124-2-838; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; LEBOFF MS, 1983, ENDOCRINOLOGY, V113, P277, DOI 10.1210/endo-113-1-277; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; MIKI H, 1995, ENDOCRINOLOGY, V136, P2954, DOI 10.1210/en.136.7.2954; NAVEHMANY T, 1989, ENDOCRINOLOGY, V125, P275, DOI 10.1210/endo-125-1-275; NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224; Nemeth EF, 1999, TRENDS ENDOCRIN MET, V10, P66, DOI 10.1016/S1043-2760(98)00119-2; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; NICHOLLS JA, 1995, PFLUG ARCH EUR J PHY, V429, P477, DOI 10.1007/BF00704152; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RIDEFELT P, 1995, BIOCHEM BIOPH RES CO, V215, P903, DOI 10.1006/bbrc.1995.2549; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Roussanne MC, 2001, EUR J CLIN INVEST, V31, P610, DOI 10.1046/j.1365-2362.2001.00809.x; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; TSUKAMOTO Y, 1995, AM J KIDNEY DIS, V25, P879, DOI 10.1016/0272-6386(95)90570-7; Wada M, 2000, KIDNEY INT, V57, P50, DOI 10.1046/j.1523-1755.2000.00837.x; Wada M, 1997, J CLIN INVEST, V100, P2977, DOI 10.1172/JCI119851; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001	37	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49691	49699		10.1074/jbc.M205578200	http://dx.doi.org/10.1074/jbc.M205578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12399473	hybrid			2022-12-25	WOS:000180028900079
J	Raspe, E; Mautino, G; Duval, C; Fontaine, C; Duez, H; Barbier, O; Monte, D; Fruchart, J; Fruchart, JC; Staels, B				Raspe, E; Mautino, G; Duval, C; Fontaine, C; Duez, H; Barbier, O; Monte, D; Fruchart, J; Fruchart, JC; Staels, B			Transcriptional regulation of human Rev-erb alpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ROR-ALPHA; STAGGERER MOUSE; DNA-BINDING; MEDIATED TRANSCRIPTION; FUNCTIONAL INTERACTION; OPPOSITE STRAND; PROMOTER; IDENTIFICATION; RVR	The Rev-erb and retinoic acid-related orphan receptors (ROR) are two related families of orphan nuclear receptors that recognize similar response elements but have opposite effects on transcription. Recently, the Rev-erbalpha gene promoter has been characterized and shown to harbor a functional Rev-erbalpha-binding site known as Rev-DR2, responsible for negative feedback down-regulation of promoter activity by Rev-erbalpha itself. The present study aimed to investigate whether Reverbalpha gene expression is regulated by RORalpha. Gel shift analysis demonstrated that in vitro translated hRORalpha1 protein binds to the Rev-DR2 site, both as monomer and dimer. Chromatin immunoprecipitation assays demonstrated that binding of RORa to this site also occurred in vivo in human hepatoma HepG2 cells. The Rev-DR2 site was further shown to be functional as it conferred hRORalpha1 responsiveness to a heterologous promoter and to the natural human Rev-erbalpha gene promoter in these cells. Mutation of this site in the context of the natural Rev-erbalpha gene promoter abolished its activation by RORalpha, indicating that this site plays a key role in hRORalpha1 action. Finally, adenoviral overexpression of hRORalpha1 in HepG2 cells led to enhanced hRev-erbalpha mRNA accumulation, further confirming the physiological importance of RORalpha1 in the regulation of Rev-erbalpha expression.	Inst Pasteur, INSERM, UR 545, F-59019 Lille, France; Ctr Rech & Dev, Grp Merck, F-69003 Lyon, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Inst Pasteur, Inst Biol, UMR 8117, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Merck & Company; Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Staels, B (corresponding author), Inst Pasteur, INSERM, UR 545, 1 Rue Pr Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Fontaine, Coralie/N-3814-2017; Staels, Bart/N-9497-2016; Duez, Helene/AAC-3217-2019; Duez, Helene/M-7609-2017	Staels, Bart/0000-0002-3784-1503; Duez, Helene/0000-0002-4130-7987; Fontaine, Coralie/0000-0002-7253-922X; Barbier, Olivier/0000-0002-3067-1134; monte, didier/0000-0002-0613-6203				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755; Besnard S, 2002, CIRC RES, V90, P820, DOI 10.1161/01.RES.0000014489.24705.71; Bois-Joyeux B, 2000, DNA CELL BIOL, V19, P589, DOI 10.1089/104454900750019344; Bordji K, 2000, J BIOL CHEM, V275, P12243, DOI 10.1074/jbc.275.16.12243; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; Chomez P, 2000, DEVELOPMENT, V127, P1489; Chu K, 1999, J MOL ENDOCRINOL, V23, P337, DOI 10.1677/jme.0.0230337; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GIGUERE V, 1995, GENOMICS, V28, P596, DOI 10.1006/geno.1995.1197; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Jin P, 1998, J BIOL CHEM, V273, P13208, DOI 10.1074/jbc.273.21.13208; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; Koibuchi N, 1998, ENDOCRINOLOGY, V139, P2335, DOI 10.1210/en.139.5.2335; KOPMELS B, 1992, J NEUROCHEM, V58, P192, DOI 10.1111/j.1471-4159.1992.tb09295.x; Kopmels B, 1991, Eur Cytokine Netw, V2, P345; Kuno-Murata M, 2000, ENDOCRINOLOGY, V141, P2275, DOI 10.1210/en.141.6.2275; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; Matsui T, 1996, BIOCHEM BIOPH RES CO, V220, P405, DOI 10.1006/bbrc.1996.0418; Matsui T, 1997, GENES CELLS, V2, P263, DOI 10.1111/j.1365-2443.1997.119gc0317.x; Meyer T, 2000, P NATL ACAD SCI USA, V97, P9197, DOI 10.1073/pnas.150246097; Missbach M, 1996, J BIOL CHEM, V271, P13515, DOI 10.1074/jbc.271.23.13515; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Moraitis AN, 1999, MOL ENDOCRINOL, V13, P431, DOI 10.1210/me.13.3.431; Nomoto S, 1999, GENE, V236, P259, DOI 10.1016/S0378-1119(99)00280-2; Raspe E, 2001, CIRCULATION, V104, P15; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; VUDAC N, 1994, J BIOL CHEM, V269, P31012; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2	65	58	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49275	49281		10.1074/jbc.M206215200	http://dx.doi.org/10.1074/jbc.M206215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377782	hybrid			2022-12-25	WOS:000180028900022
J	Sohn, J; Ryu, KS; Sievert, G; Jeoung, MK; Ji, I; Ji, TH				Sohn, J; Ryu, KS; Sievert, G; Jeoung, MK; Ji, I; Ji, TH			Follicle-stimulating hormone interacts with exoloop 3 of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HIGH-AFFINITY; FUNCTIONAL EXPRESSION; HINGE REGION; BINDING; ACTIVATION; SEQUENCE; CDNA; RAT	The human follicle-stimulating hormone (FSH) receptor consists of two distinct domains of similar to330 amino acids, the N-terminal extracellular exodomain and membrane-associated endodomain including three exoloops and seven transmembrane helices. The exodomain binds the hormone with high affinity, and the resulting hormone/exodomain complex modulates the endodomain where receptor activation occurs. It has been an enigma whether the hormone interacts with the endodomain. In a step to address the question, exoloop 3 of (580)KVPLITVSKAK(590) was examined by Ala scan, multiple substitution, assays for hormone binding, cAMP and inositol phosphate (IP) induction, and photoaffinity labeling. We present the evidence for the interaction of FSH and exoloop 3. A peptide mimic of exoloop 3 specifically and saturably photoaffinity-labels FSH alpha but not FSH beta. This is in contrast to photoaffinity labeling of FSH beta by the peptide mimic of the N-terminal region of the receptor. Leu(583) and Ile(584) are crucial for the interaction of FSH and exoloop 3. Substitutions of these two residues enhanced the hormone binding affinity. This is due to the loss of the original side chains but not the introduction of new side chains. The Leu(583) and Ile(584) side chains appear to project in opposite directions. Ile(584) appears to be so specific and to require flexibility and stereo specificity so that no other amino acids can fit into its place. Leu(583) is less specific. The improvement in hormone binding by substitutions was offset by the severe impairment of signal generation of cAMP and/or inositol phosphate. For example, the Phe or Tyr substitution of Leu(583) improved the hormone binding and cAMP induction but impaired IP induction. On the other hand, the substitutions for Ile(584) and Lys(590) abolished the cAMP and IP induction. Our results open a logical question whether Leu(583), Ile(584), and Lys(590) interact with the exodomain and/or the hormone. The answers will provide new insights into the mechanisms of hormone binding and signal generation.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Catholic Univ, Coll Med, Dept Obstet & Gynecol, Seoul 150713, South Korea	University of Kentucky; Catholic University of Korea	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18702] Funding Source: Medline; NIDDK NIH HHS [DK 51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELOVA K, 2002, J BIOL CHEM, V17, P17; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Creighton T. E., 1993, PROTEINS STRUCTURES, P141; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	28	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50165	50175		10.1074/jbc.M207646200	http://dx.doi.org/10.1074/jbc.M207646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12374801	hybrid			2022-12-25	WOS:000180028900137
J	Lin, YS; Khokhlatchev, A; Figeys, D; Avruch, J				Lin, YS; Khokhlatchev, A; Figeys, D; Avruch, J			Death-associated protein 4 binds MST1 and augments MST1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							58,000-DALTON CELLULAR INHIBITOR; GENE DUPLICATION; CASPASE CLEAVAGE; KINASE PKR; ACTIVATION; P58(IPK); P53; IDENTIFICATION; CLONING; PHOSPHORYLATION	The protein kinase MST1 is proapoptotic when overexpressed in an active form, however, its physiologic regulation and cellular targets are unknown. An overexpressed inactive MST1 mutant associates in COS-7 cells with an endogenous 761-amino acid polypeptide known as "death-associated protein 4" (DAP4). The DAPs are a functionally heterogeneous array of polypeptides previously isolated by Kimchi and colleagues (Kimchi, A. (1998) Biochim Biophys. Acta 1377, F13-F33 in a screen for elements involved in the interferon gamma-induced apoptosis of HeLa cells. DAP4, which is encoded by a member of a vertebrate-only gene family, contains no identifiable domains, but is identical over its amino-terminal 488 amino acids to p52(rIPK), a putative modulator of protein kinase R. DAP4 is a widely expressed, constitutively nuclear polypeptide that homodimerizes through its amino terminus and binds MST1 through its carboxyl-terminal segment. MST1 is predominantly cytoplasmic, but cycles continuously through the nucleus, as evidenced by its rapid accumulation in the nucleus after addition of the Crm1 inhibitor, leptomycin B. Overexpression of DAP4 does not cause apoptosis, however, coexpression of DAP4 with a submaximal amount of MST1 enhances MST1-induced apoptosis in a dose-dependent fashion. DAP4 is not significantly phosphorylated by MST1 nor does it alter MST1 kinase activity in vivo or in vitro. MST1-induced apoptosis is suppressed by a dominant interfering mutant of p53. MST1 is unable to directly phosphorylate p53, however, DAP4 binds endogenous and recombinant p53. DAP4 may promote MST1-induced apoptosis by enabling colocalization of MST with p53.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; MDS Proteom, Toronto, ON M9W 7H4, Canada	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.			Figeys, Daniel/0000-0002-5373-7546	NIDDK NIH HHS [T32 DK07028] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Figeys D, 2001, METHODS, V24, P230, DOI 10.1006/meth.2001.1184; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Friedman R, 2001, GENOME RES, V11, P1842, DOI 10.1101/gr.200601; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holland PWH, 1999, SEMIN CELL DEV BIOL, V10, P541, DOI 10.1006/scdb.1999.0335; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kondrashov AS, 1999, CURR OPIN GENET DEV, V9, P624, DOI 10.1016/S0959-437X(99)00027-1; Korth MJ, 1996, GENE, V170, P181, DOI 10.1016/0378-1119(95)00883-7; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; Ohno S, 1999, SEMIN CELL DEV BIOL, V10, P517, DOI 10.1006/scdb.1999.0332; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Rubin GM, 2001, NATURE, V409, P820, DOI 10.1038/35057277; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766	47	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					47991	48001		10.1074/jbc.M202630200	http://dx.doi.org/10.1074/jbc.M202630200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12384512	hybrid, Green Published			2022-12-25	WOS:000179789600005
J	Ren, GH; Doshi, M; Hack, BK; Alexander, JJ; Quigg, RJ				Ren, GH; Doshi, M; Hack, BK; Alexander, JJ; Quigg, RJ			Isolation and characterization of a novel rat factor H-related protein that is up-regulated in glomeruli under complement attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL MEMBRANOUS NEPHROPATHY; SYSTEMIC LUPUS-ERYTHEMATOSUS; PASSIVE HEYMANN NEPHRITIS; EPITHELIAL-CELLS; BINDING-PROTEIN; IMMUNE DEPOSITS; C3B; IDENTIFICATION; RECEPTOR; DISTINCT	The factor H family in humans is composed of seven distinct proteins, including factor H-related proteins (FHR) 1-5. All members contain tandemly arranged short consensus repeats (SCR) typical of the regulators of complement activation gene family. FHR-5 is unusual for this group of proteins, as it was initially identified as a component of immune deposits in glomerular diseases. During our cloning of the cDNA for rat factor H from glomerular epithelial cells (GEC), we identified an alternative 2729-bp cDNA transcript. The translated sequence encoded a protein containing 11 SCRs, most similar to SCRs 7-15 and 19-20 in native rat factor H, which is the same basic structure of human FHR-5. As such, this rat protein was termed FHR. Recombinant rat FHR produced in a eukaryotic expression system had a molecular mass of 78 kDa. In functional studies, recombinant FHR bound C3b and inhibited the complement alternative pathway in a dose-dependent fashion. Given the prominent expression of FHR-5 in human membranous nephropathy, a disease in which complement activation occurs in the vicinity of GEC, the expression of FHR in a rat model of this disease was evaluated. In both in vitro and in vivo models of complement activation on the GEC, FHR mRNA was up-regulated by a factor of 3-6-fold compared with controls in which complement could not be activated. Thus, we have identified a novel factor H family member in rats. This FHR protein is analogous to human FHR-5, both in structure and in potential involvement in glomerular immune complex diseases.	Univ Chicago, Nephrol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Quigg, RJ (corresponding author), Univ Chicago, Nephrol Sect, Dept Med, 5841 S Maryland Ave,MC5100, Chicago, IL 60637 USA.	rquigg@medicine.uchicago.edu	Ren, Guohui/E-5388-2018; Alexander, Jessy/ABA-7664-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007510] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK48173, T32DK07510] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander JJ, 2001, J BIOL CHEM, V276, P32129, DOI 10.1074/jbc.M101299200; BAELDE JJ, 1994, NEPHROL DIAL TRANSPL, V9, P304; BIESECKER G, 1981, J EXP MED, V154, P1779, DOI 10.1084/jem.154.6.1779; BRENCHLEY PE, 1992, KIDNEY INT, V41, P933, DOI 10.1038/ki.1992.143; CAMPBELL RD, 1988, ANNU REV IMMUNOL, V6, P161, DOI 10.1146/annurev.iy.06.040188.001113; COUSER WG, 1990, J AM SOC NEPHROL, V1, P13; Cunningham PN, 2001, KIDNEY INT, V60, P900, DOI 10.1046/j.1523-1755.2001.060003900.x; CYBULSKY AV, 1986, J CLIN INVEST, V77, P1096, DOI 10.1172/JCI112408; DiScipio RG, 1998, J IMMUNOL, V160, P4057; ESTALLER C, 1991, J IMMUNOL, V146, P3190; Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; KAZATCHKINE MD, 1982, J CLIN INVEST, V69, P900, DOI 10.1172/JCI110529; Kerjaschki D, 1996, J AM SOC NEPHROL, V7, P2518; KRISTENSEN T, 1986, J IMMUNOL, V136, P3407; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200; Morgan H.C, 1999, COMPLEMENT REGULATOR, P41; Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873; MURPHY BF, 1988, PATHOLOGY, V20, P130, DOI 10.3109/00313028809066623; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; QUIGG RJ, 1989, J IMMUNOL, V142, P877; QUIGG RJ, 1988, KIDNEY INT, V34, P43, DOI 10.1038/ki.1988.143; Quigg RJ, 2000, IMMUNOLOGY, V99, P46, DOI 10.1046/j.1365-2567.2000.00945.x; QUIGG RJ, 1993, KIDNEY INT, V43, P730, DOI 10.1038/ki.1993.104; QUIGG RJ, 1995, KIDNEY INT, V48, P412, DOI 10.1038/ki.1995.309; QUIGG RJ, 1995, J IMMUNOL, V154, P3437; Ren GH, 2002, CLIN IMMUNOL, V103, P43, DOI 10.1006/clim.2002.5168; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; SALANT DJ, 1988, METHOD ENZYMOL, V162, P421; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; SALANT DJ, 1980, J CLIN INVEST, V66, P1339, DOI 10.1172/JCI109987; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; SCHULZE M, 1991, KIDNEY INT, V40, P533, DOI 10.1038/ki.1991.242; SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SKERKA C, 1991, J BIOL CHEM, V266, P12015; SKERKA C, 1992, J IMMUNOL, V148, P3313; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6; Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248	47	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48351	48358		10.1074/jbc.M205135200	http://dx.doi.org/10.1074/jbc.M205135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374811	hybrid			2022-12-25	WOS:000179789600051
J	Harper, ME; Antoniou, A; Villalobos-Menuey, E; Russo, A; Trauger, R; Vendemelio, M; George, A; Bartholomew, R; Carlo, D; Shaikh, A; Kupperman, J; Newell, EW; Bespalov, IA; Wallace, SS; Liu, Y; Rogers, JR; Gibbs, GL; Leahy, JL; Camley, RE; Melamede, R; Newell, MK				Harper, ME; Antoniou, A; Villalobos-Menuey, E; Russo, A; Trauger, R; Vendemelio, M; George, A; Bartholomew, R; Carlo, D; Shaikh, A; Kupperman, J; Newell, EW; Bespalov, IA; Wallace, SS; Liu, Y; Rogers, JR; Gibbs, GL; Leahy, JL; Camley, RE; Melamede, R; Newell, MK			Characterization of a novel metabolic strategy used by drug-resistant tumor cells	FASEB JOURNAL			English	Article						cancer; mitochondria; uncoupling proteins; membrane potential; oxygen consumption	UNCOUPLING PROTEIN-2; PROTON LEAK; MITOCHONDRIA; PHOSPHORYLATION; GENE; SENSITIVITY; GLUTATHIONE; APOPTOSIS	Acquired or inherent drug resistance is the major problem in achieving successful cancer treatment. However, the mechanism(s) of pleiotropic drug resistance remains obscure. We have identified and characterized a cellular metabolic strategy that differentiates drug-resistant cells from drug-sensitive cells. This strategy may serve to protect drug-resistant cells from damage caused by chemotherapeutic agents and radiation. We show that drug-resistant cells have low mitochondrial membrane potential, use nonglucose carbon sources (fatty acids) for mitochondrial oxygen consumption when glucose becomes limited, and are protected from exogenous stress such as radiation. In addition, drug-resistant cells express high levels of mitochondrial uncoupling protein 2 (UCP2). The discovery of this metabolic strategy potentially facilitates the design of novel therapeutic approaches to drug resistance.	Univ Colorado, Dept Biol, Colorado Springs, CO 80918 USA; Univ Colorado, Dept Phys, Colorado Springs, CO 80918 USA; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Vermont, Coll Med, Dept Med, Div Endocrinol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Div Immunobiol, Burlington, VT 05405 USA; Immune Response Corp, San Diego, CA USA; Univ Toronto, Toronto Western Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT USA; Colorado Associates Med Phys, Colorado Springs, CO USA	University of Colorado System; University of Colorado at Colorado Springs; University of Colorado System; University of Colorado at Colorado Springs; University of Ottawa; University of Vermont; University of Vermont; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Vermont	Newell, MK (corresponding author), Univ Colorado, Dept Biol, 134 Sci Bldg,1420 Austin Bluffs Pkwy, Colorado Springs, CO 80918 USA.	mnewell@mail.uccs.edu	Newell, Evan W/F-9711-2012	Newell, Evan W/0000-0002-2889-243X; Wallace, Susan S./0000-0002-3906-0321; Harper, Mary-Ellen/0000-0003-3864-5886; Shaikh, Allison/0000-0002-2548-4166	NHLBI NIH HHS [R01 HL61346] Funding Source: Medline; NIDDK NIH HHS [DK 56818] Funding Source: Medline; NIGMS NIH HHS [R01 GM62562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056818, R56DK056818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arceci R J, 1995, Curr Opin Hematol, V2, P268; Bhushan A, 1998, IMMUNOL CELL BIOL, V76, P350, DOI 10.1046/j.1440-1711.1998.00758.x; Bhushan A, 1996, BIOCHEM PHARMACOL, V51, P477, DOI 10.1016/0006-2952(96)84208-0; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; BRAND MD, 1993, BIOCHEM J, V291, P739, DOI 10.1042/bj2910739; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; HALICKA HD, 1995, CANCER RES, V55, P444; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HIMMSHAGEN J, 1990, BROWN ADIPOSE TISSUE; Landowski TH, 1997, BLOOD, V89, P1854, DOI 10.1182/blood.V89.6.1854; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOBES CD, 1990, J BIOL CHEM, V265, P12903; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; WALLACE S, 1997, OXIDATIVE STRESS MOL; Yu DS, 1997, J UROLOGY, V157, P727, DOI 10.1016/S0022-5347(01)65259-5	25	145	153	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1550	1557		10.1096/fj.02-0541com	http://dx.doi.org/10.1096/fj.02-0541com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374777				2022-12-25	WOS:000179167600036
J	Traweger, A; Fuchs, R; Krizbai, IA; Weiger, TM; Bauer, HC; Bauer, H				Traweger, A; Fuchs, R; Krizbai, IA; Weiger, TM; Bauer, HC; Bauer, H			The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONULA OCCLUDENS-1; BINDING PARTNERS; SAF-B; DOMAINS; ACTIN; IDENTIFICATION; COMPONENT; TRANSCRIPTION; POLYPEPTIDE; EXPRESSION	Zonula occludens proteins (ZOPs), currently comprising ZO-1, ZO-2, and ZO-3, belong to the family of membrane-associated guanylate kinase homologue (MAGUK) proteins that are involved in the organization of epithelial and endothelial intercellular junctions. ZOPs bind to the cytoplasmic C termini of junctional transmembrane proteins linking them to the actin cytoskeleton. They are characterized by several conserved modules, including three PDZ domains, one SH3 domain, and a guanylate kinase-like domain, elements indicating that ZOPs may serve multiple purposes. Interestingly, ZOPs contain some unique motifs not shared by other MAGUK family members, including nuclear localization and nuclear export signals and a leucine zipper-like sequence. Their potential involvement in cell growth and proliferation has been suggested earlier based on the observation that the N-terminal half of ZOPs displays significant similarity to the product of the Drosophila tumor suppressor gene lethal(l)discs-large (dlg). The nuclear targeting of ZOPs in subconfluent epithelial cell cultures is well documented, although the action of the junctional MAGUKs in the nucleus has remained elusive. Here we show for the first time that nuclear ZO-2 directly interacts with the DNA-binding protein scaffold attachment factor-B (SAF-B). Our results from two-hybrid assays and in vivo co-immunoprecipitation studies provide evidence to suggest that ZO-2 associates with the C-terminal portion of SAF-B via its PDZ-1 domain. We further demonstrate that enhanced green fluorescent protein (EGFP)- and DsRed-tagged ZO-2 and SAF-B fusion proteins partially co-localize in nuclei of transfected epithelial cells. As shown by laser confocal microscopy and epifluorescent analysis, nuclear ZO-2 is present in epithelial and endothelial cells, particularly in response to environmental stress conditions. Interestingly, no association of SAF-B with ZO-1 was found, which supports the notion that junctional MAGUKs serve nonredundant functions.	Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; Inst Biophys, Biol Res Ctr, H-6723 Szeged, Hungary; Salzburg Univ, Inst Zool, A-5020 Salzburg, Austria	Austrian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Salzburg University	Bauer, HC (corresponding author), Austrian Acad Sci, Inst Mol Biol, Billrothstr 11, A-5020 Salzburg, Austria.	hcbauer@imb.oeaw.ac.at	Weiger, Thomas M/D-8133-2017; Traweger, Andreas/M-1460-2015	Weiger, Thomas M/0000-0002-5231-930X; Traweger, Andreas/0000-0002-0220-4766; Krizbai, Istvan/0000-0002-0764-1527				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BAUER H, 2001, ENDOTHELIUM, V8, P294; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Chlenski A, 2000, BBA-GENE STRUCT EXPR, V1493, P319, DOI 10.1016/S0167-4781(00)00185-8; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gonzalez-Mariscal L, 1999, MOL BIOL CELL, V10, p407A; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HOWARTH AG, 1995, CELL MOTIL CYTOSKEL, V31, P323, DOI 10.1002/cm.970310408; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; OBERLEITHNER H, 1994, P NATL ACAD SCI USA, V91, P9784, DOI 10.1073/pnas.91.21.9784; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Weighardt F, 1999, J CELL SCI, V112, P1465; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	44	124	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2692	2700		10.1074/jbc.M206821200	http://dx.doi.org/10.1074/jbc.M206821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12403786	hybrid			2022-12-25	WOS:000180562000082
J	Sprules, T; Green, N; Featherstone, M; Gehring, K				Sprules, T; Green, N; Featherstone, M; Gehring, K			Lock and key binding of the HOX YPWM peptide to the PBX homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; NUCLEIC-ACIDS; PROTEINS; COMPLEX; DOMAIN; HEXAPEPTIDE; EXPRESSION; MOTIF; EXTRADENTICLE; RECOGNITION	HOX homeodomain proteins bind short core DNA sequences to control very specific developmental processes. DNA binding affinity and sequence selectivity are increased by the formation of cooperative complexes with the PBX homeodomain protein. A conserved YPWM motif in the HOX protein is necessary for cooperative binding with PBX. We have determined the structure of a PBX homeodomain bound to a 14-mer DNA duplex. A relaxation-optimized procedure was developed to measure DNA residual dipolar couplings at natural abundance in the 20-kDa binary complex. When the PBX homeodomain binds to DNA, a fourth a-helix is formed in the homeodomain. This helix rigidifies the DNA recognition helix of PBX and forms a hydrophobic binding site for the HOX YPWM peptide. The HOX peptide itself shows some structure in solution and suggests that the interaction between PBX and HOX is an example of "lock and key" binding. The NAIR structure explains the requirement of DNA for the PBX-HOX interaction and the increased affinity of DNA binding.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Chem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.		Featherstone, Mark/E-8057-2010; Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Featherstone, Mark/0000-0003-1576-046X; Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				*AM BIOSC, 1998, GLUT SEPH 4B; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Billeter M, 1995, J BIOMOL NMR, V5, P1; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Fiala R, 2000, J BIOMOL NMR, V16, P291, DOI 10.1023/A:1008388400601; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Jabet C, 1999, J MOL BIOL, V291, P521, DOI 10.1006/jmbi.1999.2983; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Marino JP, 1997, J AM CHEM SOC, V119, P7361, DOI 10.1021/ja964379u; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pervushin K, 1998, J AM CHEM SOC, V120, P6394, DOI 10.1021/ja980742g; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Riek R, 2001, J AM CHEM SOC, V123, P658, DOI 10.1021/ja9938276; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Slupsky CM, 2001, PROTEIN SCI, V10, P1244, DOI 10.1110/ps.50901; Sprules T, 2000, BIOCHEMISTRY-US, V39, P9943, DOI 10.1021/bi0001067	46	24	26	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1053	1058		10.1074/jbc.M207504200	http://dx.doi.org/10.1074/jbc.M207504200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409300	hybrid			2022-12-25	WOS:000180321900048
J	Hiroi, M; Ohmori, Y				Hiroi, M; Ohmori, Y			The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-gamma gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COACTIVATORS; MOUSE PERITONEAL-MACROPHAGES; TUMOR-NECROSIS-FACTOR; IFN-GAMMA; HISTONE ACETYLTRANSFERASE; TNF-ALPHA; P300/CBP-ASSOCIATED FACTOR; SIGNALING PATHWAYS; MEDIATE INDUCTION; CBP	Signal transducers and activators of transcription 1 (STAT1) and NF-kappaB cooperatively regulate the expression of many inflammatory genes. In the present study, we demonstrate that the transcriptional coactivator CREB-binding protein (CBP) mediated the STAT1/ NF-kappaB synergy for transcription of the gene for CXC ligand 9 (CXCL9), an interferon-gamma (IFN-gamma)-inducible chemokine. Reporter gene analysis showed that expression of CBP potentiated IFN-gamma and tumor necrosis factor (TNFalpha)-induced promoter activity and that the CBP-mediated synergy depended upon STAT1- and NF-kappaB-binding sites in the promoter. Experiments with CBP mutants indicated that the N-terminal and C-terminal regions were necessary for the transcriptional synergy, although the histone acetyltransferase activity of CBP was dispensable. A co-immunoprecipitation assay demonstrated that STAT1 and NF-kappaB RelA (p65) simultaneously associated with CBP in vivo. Furthermore, chromatin immunoprecipitation revealed that, although costimulation with IFN-gamma and TNFa did not cooperatively enhance the levels of acetylated histones, it did result in increased recruitment of STAT1, CBP, and RNA polymerase II at the promoter region of the CXCL 9 gene. Together, these results demonstrate that the STAT1/NF-kappaB-dependent transcriptional synergy could result from the enhanced recruitment of RNA polymerase II complex to the promoter via simultaneous interaction of CBP with STAT1 and NF-kappaB.	Meikai Univ, Sch Dent, Ctr Biol Mol, Dept Basic Dent Sci, Sakado, Saitama 3500283, Japan	Meikai University	Ohmori, Y (corresponding author), Meikai Univ, Sch Dent, Ctr Biol Mol, Dept Basic Dent Sci, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan.			Ohmori, Yoshihiro/0000-0002-6069-357X				Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1994, J IMMUNOL, V153, P2204; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Westin S, 2000, ADV PHARMACOL, V47, P89; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	54	79	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					651	660		10.1074/jbc.M204544200	http://dx.doi.org/10.1074/jbc.M204544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403783	hybrid			2022-12-25	WOS:000180255700083
J	Hoffmann, L; Maury, S; Martz, F; Geoffroy, P; Legrand, M				Hoffmann, L; Maury, S; Martz, F; Geoffroy, P; Legrand, M			Purification, cloning, and properties of an acyltransferase controlling shikimate and quinate ester intermediates in phenylpropanoid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN BIOSYNTHESIS; 4-COUMARATE-COENZYME-A LIGASE; HYDROXYCINNAMOYL TRANSFERASE; O-METHYLTRANSFERASES; MOLECULAR-BIOLOGY; HIGHER-PLANTS; CDNA CLONING; TOBACCO; EXPRESSION; COENZYME	A protein hydrolyzing hydroxycinnamoyl-CoA esters has been purified from tobacco stem extracts by a series of high pressure liquid chromatography steps. The determination of its N-terminal amino acid sequence allowed design of primers permitting the corresponding cDNA to be cloned by PCR. Sequence analysis revealed that the tobacco gene belongs to a plant acyltransferase gene family, the members of which have various functions. The tobacco cDNA was expressed in bacterial cells as a recombinant protein fused to glutathione S-transferase. The fusion protein was affinity-purified and cleaved to yield the recombinant enzyme for use in the study of catalytic properties. The enzyme catalyzed the synthesis of shikimate and quinate esters shown recently to be substrates of the cytochrome P450 3-hydroxylase involved in phenylpropanoid biosynthesis. The enzyme has been named hydroxycinnamoyl-CoA: shikimate/quinate hydroxycinnamoyltransferase. We show that p-coumaroyl-CoA and caffeoyl-CoA are the best acyl group donors and that the acyl group is transferred more efficiently to shikimate than to quinate. The enzyme also catalyzed the reverse reaction, i.e. the formation of caffeoyl-CoA from chlorogenate (5-O-caffeoyl quinate ester). Thus, hydroxycinnamoyl-CoA:shikimate/ quinate hydroxycinnamoyltransferase appears to control the biosynthesis and turnover of major plant phenolic compounds such as lignin and chlorogenic acid.	Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, F-67000 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Legrand, M (corresponding author), Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67000 Strasbourg, France.		Martz, Francoise/C-6354-2017	Martz, Francoise/0000-0002-5693-4529; Maury, Stephane/0000-0003-0481-0847				Allina SM, 1998, PLANT PHYSIOL, V116, P743, DOI 10.1104/pp.116.2.743; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; BOUDET AM, 1995, NEW PHYTOL, V129, P203, DOI 10.1111/j.1469-8137.1995.tb04292.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen F, 1999, PLANTA, V207, P597, DOI 10.1007/s004250050523; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Douglas CJ, 1996, TRENDS PLANT SCI, V1, P171, DOI 10.1016/1360-1385(96)10019-4; Franke R, 2002, PLANT J, V30, P33, DOI 10.1046/j.1365-313X.2002.01266.x; Franke R, 2002, PLANT J, V30, P47, DOI 10.1046/j.1365-313X.2002.01267.x; FRITIG B, 1972, VIROLOGY, V47, P845, DOI 10.1016/0042-6822(72)90578-8; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HERRMANN KM, 1995, PLANT CELL, V7, P907; Humphreys JM, 2002, CURR OPIN PLANT BIOL, V5, P224, DOI 10.1016/S1369-5266(02)00257-1; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; LEGRAND M, 1978, PLANTA, V144, P101, DOI 10.1007/BF00385014; LEGRAND M, 1971, CR ACAD SCI D NAT, V273, P525; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LUDERITZ T, 1982, EUR J BIOCHEM, V123, P583; Martz F, 1998, PLANT MOL BIOL, V36, P427, DOI 10.1023/A:1005969825070; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P31, DOI 10.1016/0031-9422(84)83072-1; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PETERSEN M, 1999, ANN PLANT REV, V2, P151; Pincon G, 2001, PHYTOCHEMISTRY, V57, P1167, DOI 10.1016/S0031-9422(01)00098-X; RHODES MJC, 1976, PHYTOCHEMISTRY, V15, P947, DOI 10.1016/S0031-9422(00)84376-9; RHODES MJC, 1979, PHYTOCHEMISTRY, V18, P1125, DOI 10.1016/0031-9422(79)80119-3; Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STOCKIGT J, 1974, FEBS LETT, V42, P131, DOI 10.1016/0014-5793(74)80769-6; STRACK D, 1990, PLANT PHYSIOL, V92, P41, DOI 10.1104/pp.92.1.41; ULBRICH B, 1980, PHYTOCHEMISTRY, V19, P1625, DOI 10.1016/S0031-9422(00)83782-6; ULBRICH B, 1979, PHYTOCHEMISTRY, V18, P929, DOI 10.1016/S0031-9422(00)91451-1; Walker K, 2002, P NATL ACAD SCI USA, V99, P9166, DOI 10.1073/pnas.082115799; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; ZENK MH, 1979, RECENT ADV PHYTOCHEM, V12, P139	39	295	331	6	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					95	103		10.1074/jbc.M209362200	http://dx.doi.org/10.1074/jbc.M209362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12381722	hybrid			2022-12-25	WOS:000180255700013
J	Kaiser, JT; Bruno, S; Clausen, T; Huber, R; Schiaretti, F; Mozzarelli, A; Kessler, D				Kaiser, JT; Bruno, S; Clausen, T; Huber, R; Schiaretti, F; Mozzarelli, A; Kessler, D			Snapshots of the cystine lyase C-DES during catalysis - Studies in solution and in the crystalline state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; O-ACETYLSERINE SULFHYDRYLASE; NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; S-LYASE; SELENOCYSTEINE LYASE; TRYPTOPHAN SYNTHASE; GENE; IDENTIFICATION	The cystine lyase (C-DES) of Synechocystis is a pyridoxal-5'-phosphate-dependent enzyme distantly related to the family of NifS-like proteins. The crystal structure of an N-terminal modified variant has recently been determined. Herein, the reactivity of this enzyme variant was investigated spectroscopically in solution and in the crystalline state to follow the course of the reaction and to determine the catalytic mechanism on a molecular level. Using the stopped-flow technique, the reaction with the preferred substrate cystine was found to follow biphasic kinetics leading to the formation of absorbing species at 338 and 470 nm, attributed to the external aldimine and the a-aminoacrylate; the reaction with cysteine also exhibited biphasic behavior but only the external aldimine accumulated. The same reaction intermediates were formed in crystals as seen by polarized absorption microspectrophotometry, thus indicating that C-DES is catalytically competent in the crystalline state. The three-dimensional structure of the catalytically inactive mutant C-DESK223A in the presence of cystine showed the formation of an external aldimine species, in which two alternate conformations of the substrate were observed. The combined results allow a catalytic mechanism to be proposed involving interactions between cystine and the active site residues Arg-360, Arg-369, and Trp-251*; these residues reorient during the beta-elimination reaction, leading to the formation of a hydrophobic pocket that stabilizes the enolimine tautomer of the aminoacrylate and the cysteine persulfide product.	Heidelberg Univ, Biochemiezentrum, D-69120 Heidelberg, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Italian Natl Inst Phys Matter, I-43100 Parma, Italy	Ruprecht Karls University Heidelberg; Max Planck Society; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Kaiser, JT (corresponding author), Heidelberg Univ, Biochemiezentrum, Neuenheimer Feld 501, D-69120 Heidelberg, Germany.	kaiser@biochem.mpg.de	Bruno, Stefano/A-4582-2011; Mozzarelli, Andrea/C-3615-2014	Bruno, Stefano/0000-0002-7890-2472; Mozzarelli, Andrea/0000-0003-3762-0062; Clausen, Tim/0000-0003-1582-6924				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruno S, 2001, J BIOL CHEM, V276, P16, DOI 10.1074/jbc.C000588200; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; KALLEN RG, 1985, TRANSAMINASES, P37; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacourciere GM, 2000, J BIOL CHEM, V275, P23769, DOI 10.1074/jbc.M000926200; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leibrecht I, 1997, J BIOL CHEM, V272, P10442; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; MOZZARELLI A, 1979, EUR J BIOCHEM, V98, P173, DOI 10.1111/j.1432-1033.1979.tb13174.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; TURK D, 1996, P 1996 M INT UN CRYS; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	33	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					357	365		10.1074/jbc.M209862200	http://dx.doi.org/10.1074/jbc.M209862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12386155	hybrid			2022-12-25	WOS:000180255700048
J	Lopez-Casillas, F; Riquelme, C; Perez-Kato, Y; Ponce-Castaneda, MV; Osses, N; Esparza-Lopez, J; Gonzalez-Nunez, G; Cabello-Verrugio, C; Mendoza, V; Troncoso, V; Brandan, E				Lopez-Casillas, F; Riquelme, C; Perez-Kato, Y; Ponce-Castaneda, MV; Osses, N; Esparza-Lopez, J; Gonzalez-Nunez, G; Cabello-Verrugio, C; Mendoza, V; Troncoso, V; Brandan, E			Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation - Cloning of murine betaglycan gene promoter and its modulation by myoD, retinoic acid, and transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-DEPENDENT MECHANISM; FIBROBLAST GROWTH; MYOBLAST DIFFERENTIATION; III RECEPTOR; MYOGENIC DIFFERENTIATION; PROTEOGLYCAN BETAGLYCAN; SATELLITE CELLS; LIGAND-BINDING; TERMINAL DIFFERENTIATION; MEMBRANE PROTEOGLYCAN	Betaglycan is a membrane-anchored proteoglycan co-receptor that binds transforming growth factor beta (TGF-beta) via its core protein and basic fibroblast growth factor through its glycosaminoglycan chains. In this study we evaluated the expression of betaglycan during the C2C12 skeletal muscle differentiation. Betaglycan expression, as determined by Northern and Western blot, was up-regulated during the conversion of myoblasts to myotubes. The mouse betaglycan gene promoter was cloned, and its sequence showed putative binding sites for SP1, Smad3, Smad4, muscle regulatory factor elements such as MyoD and MEF2, and retinoic acid receptor. Transcriptional activity of the mouse betaglycan promoter reporter was also up-regulated in differentiating C2C12 cells. We found that MyoD, but not myogenin, stimulated this transcriptional activity even in the presence of high serum. Betaglycan promoter activity was increased by RA and inhibited by the three isoforms of TGF-beta. On the other hand, basic fibroblast growth factor, BMP-2, and hepatocyte growth factor/scatter factor, which are inhibitors of myogenesis, had little effect. In myotubes, up-regulated betaglycan was also detectable by TGF-beta affinity labeling and immunofluorescence microscopy studies. The latter indicated that betaglycan was localized both on the cell surface and in the ECM Forced expression of betaglycan in C2C12 myoblasts increases their responsiveness to TGF-beta2, suggesting that it performs a TGF-beta presentation function in this cell lineage. These results indicate that betaglycan expression is up-regulated during myogenesis and that MyoD and RA modulate its expression by a mechanism that is independent of myogenin.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Regulac Celular & Patol,Millenium Inst Fundam, Santiago, Chile; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Pontificia Universidad Catolica de Chile; Universidad Nacional Autonoma de Mexico	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Regulac Celular & Patol,Millenium Inst Fundam, Casilla 114-D, Santiago, Chile.	ebrandan@genes.bio.puc.cl	ESPARZA-LOPEZ, JOSE/AAQ-7199-2021; Osses, Nelson/V-9065-2019; Cabello-Verrugio, Claudio/AAD-1454-2020; Brandan, Enrique/A-7063-2017	ESPARZA-LOPEZ, JOSE/0000-0003-3701-6607; Osses, Nelson/0000-0003-0974-1051; Cabello-Verrugio, Claudio/0000-0001-7273-2102; Brandan, Enrique/0000-0002-6820-5059				ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; Bernard DJ, 2002, MOL ENDOCRINOL, V16, P207, DOI 10.1210/me.16.2.207; BERNFIELD M, 1993, DEVELOPMENT, P205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; Brandan E, 1996, EUR J CELL BIOL, V71, P170; Carey DJ, 1997, BIOCHEM J, V327, P1; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; Fuentealba L, 1999, J BIOL CHEM, V274, P37876, DOI 10.1074/jbc.274.53.37876; Gray PC, 2002, MOL CELL ENDOCRINOL, V188, P253, DOI 10.1016/S0303-7207(02)00037-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Itoh N, 1996, DEVELOPMENT, V122, P291; JENNISCHE E, 1993, AM J PHYSIOL, V265, pC122, DOI 10.1152/ajpcell.1993.265.1.C122; Ji CH, 1999, J BIOL CHEM, V274, P30487, DOI 10.1074/jbc.274.43.30487; Kastner S, 2000, J HISTOCHEM CYTOCHEM, V48, P1079, DOI 10.1177/002215540004800805; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Larrain J, 1997, J BIOL CHEM, V272, P18418, DOI 10.1074/jbc.272.29.18418; Larrain J, 1998, J BIOL CHEM, V273, P32288, DOI 10.1074/jbc.273.48.32288; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Li SG, 1999, DEV BIOL, V211, P335, DOI 10.1006/dbio.1999.9317; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Mollard R, 2000, MECH DEVELOP, V94, P223, DOI 10.1016/S0925-4773(00)00303-8; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKAYAMA H, 1994, EXP CELL RES, V211, P301, DOI 10.1006/excr.1994.1091; Olson E N, 1992, Semin Cell Biol, V3, P127; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; Ponce-Castaneda MV, 1998, BBA-PROTEIN STRUCT M, V1384, P189, DOI 10.1016/S0167-4838(98)00033-8; RALPHS JR, 1990, DEVELOPMENT, V109, P51; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Riquelme C, 2001, J BIOL CHEM, V276, P3589, DOI 10.1074/jbc.M004602200; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sakuma K, 2000, ACTA NEUROPATHOL, V99, P177, DOI 10.1007/PL00007422; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Scata KA, 1999, EXP CELL RES, V250, P10, DOI 10.1006/excr.1999.4506; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	63	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					382	390		10.1074/jbc.M208520200	http://dx.doi.org/10.1074/jbc.M208520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399463	hybrid			2022-12-25	WOS:000180255700051
J	Sheu, TJ; Schwarz, EM; Martinez, DA; O'Keefe, RJ; Rosier, RN; Zuscik, MJ; Puzas, JE				Sheu, TJ; Schwarz, EM; Martinez, DA; O'Keefe, RJ; Rosier, RN; Zuscik, MJ; Puzas, JE			A phage display technique identifies a novel regulator of cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RECEPTOR-INTERACTING PROTEIN; BONE MORPHOGENETIC PROTEIN-2; TITANIUM SURFACE-ROUGHNESS; ACID-PHOSPHATASE ACP-5; TGF-BETA; ALKALINE-PHOSPHATASE; TRANSFORMING GROWTH-FACTOR-BETA-1; MANNOSE-6-PHOSPHATE RECEPTORS; OSTEOBLAST RESPONSE	The formation of new bone during the process of bone remodeling occurs almost exclusively at sites of prior bone resorption. In an attempt to discover what regulatory pathways are utilized by osteoblasts to effect this site-specific formation event we probed components of an active bone resorption surface with an osteoblast phage expression library. In these experiments primary cultures of rat osteoblasts were used to construct a phage display library in T7 phage. Tartrate-resistant acid phosphatase (type V) (TRAP) was used as the bait in a biopanning procedure. 40 phage clones with very high affinity for TRAP were sequenced, and of the clones with multiple consensus sequences we identified a regulatory protein that modulates osteoblast differentiation. This protein is the TGFbeta receptor-interacting protein (TRIP-1). Our data demonstrate that TRAP activation of TRIP-1 evokes a TGFbeta-like differentiation process. Specifically, TRIP-1 activation increases the activity and expression of osteoblast alkaline phosphatase, osteoprotegerin, collagen, and Runx2. Moreover, we show that TRAP interacts with TRIP intracellularly, that activation of the TGFbeta type II receptor by TRIP-1 occurs in the presence of TRAP and that the differentiation process is mediated through the Smad2/3 pathway. A final experiment demonstrates that osteoblasts, when cultured in osteoclast lacunae containing TRAP, rapidly and specifically differentiate into a mature bone-forming phenotype. We hypothesize that binding to TRAP may be one mechanism by which the full osteoblast phenotype is expressed during the process of bone remodeling.	Univ Rochester, Sch Med & Dent, Dept Orthopaed, Mcclure Musculoskeletal Res Ctr, Rochester, NY 14642 USA; Univ Houston, Dept Biol & Biochem, Connect Tissue Physiol Lab, Houston, TX 77204 USA	University of Rochester; University of Houston System; University of Houston	Puzas, JE (corresponding author), Univ Rochester, Sch Med & Dent, Dept Orthopaed, Mcclure Musculoskeletal Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.		Martinez, Daniel/A-5825-2008	Zuscik, Michael/0000-0003-0461-8708	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008121] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 12011] Funding Source: Medline; NIEHS NIH HHS [R01 ES 08121] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; Bikle DD, 1999, J BONE MINER METAB, V17, P233, DOI 10.1007/s007740050090; BONEWALD LF, 1992, BONE MINER, V17, P139, DOI 10.1016/0169-6009(92)90725-S; Boyan BD, 2001, J BIOMED MATER RES, V55, P350, DOI 10.1002/1097-4636(20010605)55:3<350::AID-JBM1023>3.0.CO;2-M; Cheifetz S, 1996, CONNECT TISSUE RES, V35, P71, DOI 10.3109/03008209609029176; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Chung CY, 1999, BIOCHEM BIOPH RES CO, V265, P246, DOI 10.1006/bbrc.1999.1639; Deligianni DD, 2001, BIOMATERIALS, V22, P87, DOI 10.1016/S0142-9612(00)00174-5; FROST HM, 1966, J BONE JOINT SURG AM, VA 48, P1192, DOI 10.2106/00004623-196648060-00018; Gray C, 1996, BONE, V18, P115, DOI 10.1016/8756-3282(95)00456-4; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HARRIS WH, 1969, NEW ENGL J MED, V280, P303, DOI 10.1056/NEJM196902062800605; HARRIS WH, 1969, NEW ENGL J MED, V280, P253, DOI 10.1056/NEJM196901302800507; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hayman AR, 2000, J ANAT, V196, P433, DOI 10.1046/j.1469-7580.2000.19630433.x; Hirano T, 2000, BONE, V27, P13, DOI 10.1016/S8756-3282(00)00284-2; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Jiang JR, 2001, PLANT J, V26, P35, DOI 10.1046/j.1365-313x.2001.01007.x; JONES SJ, 1994, ANAT EMBRYOL, V190, P339; Kassem M, 2000, EUR J CLIN INVEST, V30, P429; LING P, 1993, J BIOL CHEM, V268, P6896; MARTINEZ DA, 1995, J CELL BIOCHEM, V59, P246, DOI 10.1002/jcb.240590213; Parfitt AM., 1983, BONE HISTOMORPHOMETR, V1983, P143; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Romano PR, 1997, J PERIODONTAL RES, V32, P143, DOI 10.1111/j.1600-0765.1997.tb01396.x; Schwartz Z, 1999, Adv Dent Res, V13, P38; Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097-4636(20010905)56:3<417::AID-JBM1111>3.0.CO;2-K; Seeman E, 2001, TRENDS ENDOCRIN MET, V12, P281, DOI 10.1016/S1043-2760(01)00460-X; Sheu TJ, 2002, J BONE MINER RES, V17, P915, DOI 10.1359/jbmr.2002.17.5.915; Tiffee JC, 1997, J ORAL MAXIL SURG, V55, P1108, DOI 10.1016/S0278-2391(97)90291-3; WERGEDAL JE, 1969, J HISTOCHEM CYTOCHEM, V17, P799, DOI 10.1177/17.12.799; Yamada T, 1999, HISTOCHEM J, V31, P687, DOI 10.1023/A:1003855922395; YAMAMOTO T, 1992, J BONE MINER RES, V7, P1267	34	63	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					438	443		10.1074/jbc.M208292200	http://dx.doi.org/10.1074/jbc.M208292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403789	hybrid			2022-12-25	WOS:000180255700058
J	Yu, ST; Matsusue, K; Kashireddy, P; Cao, WQ; Yeldandi, V; Yeldandi, AV; Rao, MS; Gonzalez, FJ; Reddy, JK				Yu, ST; Matsusue, K; Kashireddy, P; Cao, WQ; Yeldandi, V; Yeldandi, AV; Rao, MS; Gonzalez, FJ; Reddy, JK			Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma 1 (PPAR gamma 1) overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-ALPHA; BETA-OXIDATION; TRANSCRIPTIONAL REGULATION; ADIPOSE DIFFERENTIATION; C/EBP-ALPHA; TARGET GENE; PROTEIN; ACID; TISSUE; INDUCTION	Peroxisome proliferator activated-receptor (PPAR) isoforms, alpha and gamma, function as important coregulators of energy (lipid) homeostasis. PPARalpha regulates fatty acid oxidation primarily in liver and to a lesser extent in adipose tissue, whereas PPARgamma serves as a key regulator of adipocyte differentiation and lipid storage. Of the two PPARgamma isoforms, PPARgamma1 and PPARgamma2 generated by alternative splicing, PPARgamma1 isoform is expressed in liver and other tissues, whereas PPARgamma2 isoform is expressed exclusively in adipose tissue where it regulates adipogenesis and lipogenesis. Since the function of PPARgamma1 in liver is not clear, we have, in this study, investigated the biological impact of overexpression of PPARgamma1 in mouse liver. Adenovirus-PPARgamma1 injected into the tail vein induced hepatic steatosis in PPARalpha(-/-) mice. Northern blotting and gene expression profiling results showed that adipocyte-specific genes and lipogenesis-related genes are highly induced in PPARalpha(-/-) livers with PPARgamma1 overexpression. These include adipsin, adiponectin, aP2, caveolin-1, fasting-induced adipose factor, fat-specific gene 27 (FSP27), CD36, Delta(9) desaturase, and malic enzyme among others, implying adipogenic transformation of hepatocytes. Of interest is that hepatic steatosis per se, induced either by feeding a diet deficient in choline or developing in fasted PPARalpha(-/-) mice, failed to induce the expression of these PPARgamma-regulated adipogenesis-related genes in steatotic liver. These results suggest that a high level of PPARgamma1 in mouse liver is sufficient for the induction of adipogenic transformation of hepatocytes with adipose tissue-specific gene expression and lipid accumulation. We conclude that excess PPARgamma activity can lead to the development of a novel type of adipogenic hepatic steatosis.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.				NCI NIH HHS [CA84472] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal VR, 2000, CANCER RES, V60, P6033; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Bernlohr DA, 1999, SEMIN CELL DEV BIOL, V10, P43, DOI 10.1006/scdb.1998.0271; Bleck B, 1998, GENE, V215, P123, DOI 10.1016/S0378-1119(98)00262-5; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cherkaoui-Malki M, 2001, GENE EXPRESSION, V9, P291, DOI 10.3727/000000001783992533; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; FAN JY, 1983, J CELL SCI, V61, P219; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lazar MA, 2002, GENE DEV, V16, P1, DOI 10.1101/gad.964002; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lee Y, 2002, P NATL ACAD SCI USA, V99, P11848, DOI 10.1073/pnas.182420899; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 2002, MOL ENDOCRINOL, V16, P1040, DOI 10.1210/me.16.5.1040; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; MUELLER E, 2002, IN PRESS J BIOL CHEM; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rao MS, 2002, IN VIVO, V16, P145; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333, DOI 10.1152/ajpgi.2001.281.6.G1333; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Walczak R, 2002, J LIPID RES, V43, P177; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Yu ST, 2001, J BIOL CHEM, V276, P42485, DOI 10.1074/jbc.M106480200; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	61	490	511	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					498	505		10.1074/jbc.M210062200	http://dx.doi.org/10.1074/jbc.M210062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401792	hybrid			2022-12-25	WOS:000180255700066
J	Chen, M; Orozco, A; Spencer, DM; Wang, J				Chen, M; Orozco, A; Spencer, DM; Wang, J			Activation of initiator caspases through a stable dimeric intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL DEATH SWITCHES; INDUCED-PROXIMITY MODEL; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; SIGNALING COMPLEX; CRYSTAL-STRUCTURE; RECEPTOR; APOPTOSIS; DOMAIN	Structural and biochemical studies have revealed that procaspases form dimers prior to proteolytic activation. How the two procaspases interact in the dimer is unclear. To study the mechanisms of dimer-dependent caspase activation we used a heterodimeric system so that two caspase molecules can be specifically brought together. Surprisingly, only one caspase partner in the dimer needs to be enzymatically active for caspase processing and activation to occur. Caspase activation is inefficient in the dimer in the absence of intramolecular processing, suggesting that caspase activation is initiated via intramolecular processing. Homodimerization of caspase-8 or caspase-9 leads to the formation of a stable dimeric complex. However, heterodimerization between caspase-8 and caspases-3, -9, or -10 failed to induce stable dimer formation or caspase activation. Our data suggest that the formation of a stable dimeric intermediate initiates caspase activation.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Wang, J (corresponding author), Baylor Coll Med, Dept Immunol, 1 Baylor Plaza,M929, Houston, TX 77030 USA.			Chen, Min/0000-0002-0093-9056; Wang, Jin/0000-0002-3116-0838				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shi YG, 2002, STRUCTURE, V10, P285, DOI 10.1016/S0969-2126(02)00732-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang J, 2000, J CELL SCI, V113, P753; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	39	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50761	50767		10.1074/jbc.M210356200	http://dx.doi.org/10.1074/jbc.M210356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399450	hybrid			2022-12-25	WOS:000180177700074
J	D'Orso, I; Frasch, ACC				D'Orso, I; Frasch, ACC			TcUBP-1, an mRNA destabilizing factor from trypanosomes, homodimerizes and interacts with novel AU-rich element- and poly(A)-binding proteins forming a ribonucleoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; PRE-MESSENGER-RNA; U1A PROTEIN; 3'-UNTRANSLATED REGION; RECOGNITION MOTIFS; GENE-EXPRESSION; SEX-LETHAL; CRUZI; DOMAIN; BRUCEI	Trypanosomes, protozoan parasites causing worldwide infections in human and animals, mostly regulate protein expression through post-transcriptional mechanisms and not at the transcription initiation level. We have previously identified a Trypanosoma cruzi RNA-binding protein named TcUBP-1. This protein is involved in mRNA destabilization in vivo through binding to AU-rich elements in the W-untranslated region of SMUG mucin mRNAs (D'Orso, I., and Frasch, A. C. (2001) J. Biol. Chem. 276, 34801-34809). In this work we show that TcUBP-1 is part of an similar to450-kDa ribonucleoprotein complex with a poly(A)-binding protein and a novel 18-kDa RNA-binding protein, named TcUBP-2. Recombinant TcUBP-1 and TcUBP-2 proteins recognize U-rich RNAs with similar specificity and affinity through the similar to92-amino acid RNA recognition motif. TcUBPs can homo- and heterodimerize in vitro through the glycine-rich C-terminal region. This interaction was also detected in vivo by co-immunoprecipitation of the ribonucleoprotein complex and using yeast two-hybrid assay. The poly(A)-binding protein identified was shown to disrupt the formation of TcUBP-1, but not TcUBP-2, homodimers in vitro. The possible role of TcUBP-1 ligands in the pathways that govern mRNA-stability and stage-specific expression in trypanosomes is discussed.	UNSAM, IIB, INTI, CONICET, RA-1650 San Martin, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Instituto Nacional de Tecnologia Industrial (INTI)	Frasch, ACC (corresponding author), UNSAM, IIB, INTI, CONICET, Av Gral Paz S-N,Edificio 24,Casilla Correo 30, RA-1650 San Martin, Buenos Aires, Argentina.			Frasch, Alberto Carlos/0000-0001-7532-653X				Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BATISTA JAN, 1994, MOL BIOCHEM PARASIT, V67, P301, DOI 10.1016/0166-6851(94)00133-2; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; D'Orso I, 2001, J BIOL CHEM, V276, P15783, DOI 10.1074/jbc.M010959200; D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200; DeMaria CT, 1997, NUCL ACIDS S SER, V36, P12; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; DiNitto JP, 2001, BIOCHEMISTRY-US, V40, P12645, DOI 10.1021/bi011439m; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gilinger G, 2001, NUCLEIC ACIDS RES, V29, P1556, DOI 10.1093/nar/29.7.1556; Gunnewiek JMTK, 2000, MOL CELL BIOL, V20, P2209, DOI 10.1128/MCB.20.6.2209-2217.2000; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; Irmer H, 2001, NUCLEIC ACIDS RES, V29, P4707, DOI 10.1093/nar/29.22.4707; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Wan LL, 2001, J BIOL CHEM, V276, P7681, DOI 10.1074/jbc.M010207200; Weston D, 1999, MOL BIOCHEM PARASIT, V102, P53, DOI 10.1016/S0166-6851(99)00079-1; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zingales B, 1997, MEM I OSWALDO CRUZ, V92, P811, DOI 10.1590/S0074-02761997000600016	37	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50520	50528		10.1074/jbc.M209092200	http://dx.doi.org/10.1074/jbc.M209092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12403777	hybrid			2022-12-25	WOS:000180177700044
J	Rodrigues, CO; Ruiz, FA; Vieira, M; Hill, JE; Docampo, R				Rodrigues, CO; Ruiz, FA; Vieira, M; Hill, JE; Docampo, R			An acidocalcisomal exopolyphosphatase from Leishmania major with high affinity for short chain polyphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; INORGANIC POLYPHOSPHATE; SACCHAROMYCES-CEREVISIAE; TRYPANOSOMA-BRUCEI; ESCHERICHIA-COLI; PURIFICATION; YEAST; GENE; MITOCHONDRIA; PHOSPHATE	We report the cloning, overexpression, purification, and characterization of the Leishmania major exopolyphosphatase (LmPPX). The product of this gene (LmPPX), the first related to polyphosphate (polyP) metabolism isolated from an eukaryotic organism different from yeast, has 388 amino acids and a molecular mass of 48 kDa. LmPPX differs from other exopolyphosphatases previously investigated. Heterologous expression of LmPPX in Escherichia coli produced a functional enzyme that was similar to the yeast exopolyphosphatase with respect to its Mg2+ requirement, optimum pH, and sensitivity to cations, amino acids, and heparin but that, in contrast to the yeast enzyme and other exopolyphosphatases investigated before, acts on polyP of short chain lengths with higher rates and affinity. LmPPX is a processive enzyme, and it does not hydrolyze pyrophosphate, ATP, or p-nitrophenylphosphate. Confocal immunofluorescence microscopy using affinity-purified antibodies against the recombinant enzyme indicated an acidocalcisomal and cytosolic localization. High levels of short chain (21.4+/-3.0 mM) and long chain polyP (55.9+/-5.6 mM) were detected in L. major promastigotes. The unique characteristics of LmPPX and L major polyP metabolism may facilitate the development of novel antileishmanial agents.	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Med, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Hill, Janet E./B-5001-2011; Ruiz, Felix A./B-1032-2008	Hill, Janet E./0000-0002-2187-6277; Ruiz, Felix A./0000-0003-0748-5015				AKIYAMA M, 1993, J BIOL CHEM, V268, P633; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; Andreeva NA, 2001, BIOCHEMISTRY-MOSCOW+, V66, P147, DOI 10.1023/A:1002883229300; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; BLUM JJ, 1989, J PROTOZOOL, V36, P254, DOI 10.1111/j.1550-7408.1989.tb05358.x; Bolesch DG, 2000, J BIOL CHEM, V275, P33814, DOI 10.1074/jbc.M002039200; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Kornberg A, 1999, ANNU REV BIOCHEM, V68, P89, DOI 10.1146/annurev.biochem.68.1.89; Kulaev I, 2000, ANNU REV MICROBIOL, V54, P709, DOI 10.1146/annurev.micro.54.1.709; Kulaev IS, 1997, MICROBIOL RES, V152, P221; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; Kumble KD, 1996, J BIOL CHEM, V271, P27146, DOI 10.1074/jbc.271.43.27146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichko LP, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1146; Lichko LP, 2000, BIOCHEMISTRY-MOSCOW+, V65, P355; LORENZ B, 1994, J BIOL CHEM, V269, P22198; Lorenz B, 2001, BBA-PROTEIN STRUCT M, V1547, P254, DOI 10.1016/S0167-4838(01)00193-5; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; SAMBROOK J, 1989, MOL CLONING, V2, P9; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Sethuraman A, 2001, P NATL ACAD SCI USA, V98, P8542, DOI 10.1073/pnas.151269398; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Vieira LL, 1996, BIOCHEM J, V319, P691, DOI 10.1042/bj3190691; WURST H, 1994, J BIOL CHEM, V269, P10996; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	33	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50899	50906		10.1074/jbc.M208940200	http://dx.doi.org/10.1074/jbc.M208940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393865	hybrid			2022-12-25	WOS:000180177700092
J	Rossman, KL; Worthylake, DK; Snyder, JT; Cheng, L; Whitehead, IP; Sondek, J				Rossman, KL; Worthylake, DK; Snyder, JT; Cheng, L; Whitehead, IP; Sondek, J			Functional analysis of Cdc42 residues required for guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; DBL HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; RHO-FAMILY; RAS; ACTIVATION; TRANSFORMATION; MUTAGENESIS; EXPRESSION; REGULATOR	Guanine nucleotide exchange factors (GEFs) directly engage small GTPases to facilitate the exchange of bound GDP for GTP, leading to GTPase activation. Several recent crystal structures of GEFs in complex with Rho family GTPases highlight the conserved interactions and conformational alterations necessary for catalyzing exchange. In the present study, functional roles were defined for specific residues within Cdc42 implicated by the crystal structures as important for physiological exchange of guanine nucleotides within Rho GTPases. In particular, this study highlights the paramount importance of the phosphate-binding loop and interactions with the magnesium co-factor as critical for proper regulation of RhoGEF-catalyzed exchange. Other conformational alterations of the GTPases affecting interactions with the sugar and base of guanine nucleotides are also important but are secondary. Of particular note, substitution of alanine for cysteine at position 18 of Cdc42 leads to a fast cycling phenotype for Cdc42 with heightened affinity for RhoGEFs and produces a dominant negative form of Cdc42 capable of inhibiting RhoGEFs both in vitro and in vivo.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Rutgers State University New Brunswick; Rutgers State University Medical Center	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 EJ Bldg, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL CANCER INSTITUTE [R29CA077493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77493] Funding Source: Medline; NIGMS NIH HHS [R01-GM62299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Demunter A, 2001, CANCER RES, V61, P4916; Friebel A, 2001, J BIOL CHEM, V276, P34035, DOI 10.1074/jbc.M100609200; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, ONCOGENE, V10, P713; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	34	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50893	50898		10.1074/jbc.M208580200	http://dx.doi.org/10.1074/jbc.M208580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401782	Green Published, hybrid			2022-12-25	WOS:000180177700091
J	Caillaud, A; Prakash, A; Smith, E; Masumi, A; Hovanessian, AG; Levy, DE; Marie, I				Caillaud, A; Prakash, A; Smith, E; Masumi, A; Hovanessian, AG; Levy, DE; Marie, I			Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; VIRUS-INFECTION; POSITIVE FEEDBACK; ACTIVATION; GENES; IRF-7; PHOSPHORYLATION; INDUCTION; DISTINCT; DOMAIN	Interferon regulatory factor 7 (IRF7) is an interferon-inducible transcription factor required for induction of delayed early interferon a genes and the onset of a potent antiviral state. After induction of IRF7 by autocrine interferon, latent IRF7 is activated by virus-induced phosphorylation on serine residues within the C-terminal regulatory domain. Although it is likely that IRF7 is subjected to a cascade of events responsible for regulating its biological activity, to date no mechanism other than phosphorylation has been reported to modulate IRF7 activity. Here, we report that IRF7 is acetylated in vivo by the histone acetyltransferases p300/CBP-associ ated factor (PCAF) and GCN5. The single lysine residue target for acetylation, lysine 92, is located in the DNA-binding domain and is conserved throughout the entire IRF family. Mutation of lysine 92 resulted in complete abolition of DNA binding ability. However, a mutant that cannot be acetylated by PCAF due to a change in the surrounding amino acid context of lysine 92 showed increased DNA binding and activity compared with wild type IRF7. Conversely, we showed that acetylated IRF7 displayed impaired DNA binding capability and that over-expression of PCAF led to decreased IRF7 activity. Together, our results strongly suggest that acetylation of lysine 92 negatively modulates IRF7 DNA binding.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan comprehens Canc Ctr, New York, NY 10016 USA; Inst Pasteur, Unite Virol & Immunol Cellulaire, F-75724 Paris, France; Natl Inst Infect Dis, Tokyo 2080011, Japan	New York University; New York University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institute of Infectious Diseases (NIID)	Marie, I (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave,MSB 556, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; Marie, Isabelle/0000-0002-3091-7624	NIAID NIH HHS [R01 AI 46503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046503] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; TAKEMURA R, 1992, J CELL SCI, V103, P953; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	30	62	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49417	49421		10.1074/jbc.M207484200	http://dx.doi.org/10.1074/jbc.M207484200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12374802	hybrid			2022-12-25	WOS:000180028900041
J	Sheng, SH; Perry, CJ; Kleyman, TR				Sheng, SH; Perry, CJ; Kleyman, TR			External nickel inhibits epithelial sodium channel by binding to histidine residues within the extracellular domains of alpha and gamma subunits and reducing channel open probability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN SECONDARY STRUCTURE; XENOPUS-LAEVIS OOCYTES; SENSITIVE NA+ CHANNEL; CONFORMATIONAL-CHANGE; CALCIUM-CHANNELS; DIVALENT-CATIONS; ION CHANNELS; STRUCTURE PREDICTION; SELECTIVITY FILTER; CRYSTAL-STRUCTURES	Epithelial sodium channels (ENaC) are regulated by various intracellular and extracellular factors including divalent cations. We studied the inhibitory effect and mechanism of external Ni2+ on cloned mouse alpha-beta-gamma ENaC expressed in Xenopus oocytes. Ni2+ reduced amiloride-sensitive Na+ currents of the wild type mouse ENaC in a dose-dependent manner. The Ni2+ block was fast and partially reversible at low concentrations and irreversible at high concentrations. ENaC inhibition by Ni2+ was accompanied by moderate inward rectification at concentrations higher than 0.1 mm. ENaC currents were also blocked by the histidine-reactive reagent diethyl pyrocarbonate. Pretreatment of the oocytes with the reagent reduced Ni2+ inhibition of the remaining current. Mutations at alphaHis(282) and gammaHis(239) located within the extracellular loops significantly decreased Ni2+ inhibition of ENaC currents. The mutation alphaH282D or double mutations alphaH282R/gammaH239R eliminated Ni2+ block. All mutations at gammaHis(239) eliminated Ni2+-induced inward current rectification. Ni2+ block was significantly enhanced by introduction of a histidine at alphaArg(280). Lowering extracellular pH to 5.5 and 4.4 decreased or eliminated Ni2+ block. Although alphaH282C-beta-gamma channels were partially inhibited by the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl] methanethiosulfonate bromide (MTSET), alpha-beta-gamma H239C channels were insensitive to MTSET. From patch clamp studies, Ni2+ did not affect unitary current but decreased open probability when perfused into the recording pipette. Our results suggest that external Ni2+ reduces ENaC open probability by binding to a site consisting of alphaHis(282) and gammaHis(239) and that these histidine residues may participate in ENaC gating.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, 929 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK 51391, DK 54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, R37DK051391, R01DK051391] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Appleberry OK, 2002, FASEB J, V16, pA477; Appleberry OK, 2001, FASEB J, V15, pA431; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Bal W, 2000, CHEM RES TOXICOL, V13, P823, DOI 10.1021/tx000060i; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 2000, BIOPHYS J, V78, P1881, DOI 10.1016/S0006-3495(00)76737-3; BYERLY L, 1989, J PHYSIOL-LONDON, V413, P75, DOI 10.1113/jphysiol.1989.sp017642; Chalfant ML, 1996, AM J PHYSIOL-RENAL, V271, pF861, DOI 10.1152/ajprenal.1996.271.4.F861; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; Cottrell GA, 2001, FEBS LETT, V489, P71, DOI 10.1016/S0014-5793(01)02081-6; Cummins PM, 1999, J BIOL CHEM, V274, P16003, DOI 10.1074/jbc.274.23.16003; Dardel F, 1998, J MOL BIOL, V280, P501, DOI 10.1006/jmbi.1998.1882; DASILVA JJR, 2001, BIOL CHEM ELEMENTS I, P39; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; EDER C, 1995, PFLUG ARCH EUR J PHY, V430, P526, DOI 10.1007/BF00373889; Ermler U, 1998, CURR OPIN STRUC BIOL, V8, P749, DOI 10.1016/S0959-440X(98)80095-X; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fisher JL, 1998, J NEUROSCI, V18, P2944; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Fuller CM, 1996, J BIOL CHEM, V271, P26602, DOI 10.1074/jbc.271.43.26602; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Hannan JP, 2000, J INORG BIOCHEM, V79, P365, DOI 10.1016/S0162-0134(99)00235-4; HAUSINGER RP, 1987, MICROBIOL REV, V51, P22, DOI 10.1128/MMBR.51.1.22-42.1987; HAUSINGER RP, 1986, J BIOL CHEM, V261, P7866; HAUSINGER RP, 1993, BIOCH NICKEL, V12, P14; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Ho WK, 1999, BIOPHYS J, V76, P1959, DOI 10.1016/S0006-3495(99)77355-8; Hong K, 2000, J NEUROSCI, V20, P2575; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleyman TR, 1999, SEMIN NEPHROL, V19, P524; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lacinova L, 2000, GEN PHYSIOL BIOPHYS, V19, P121; Magistretti J, 2001, J MEMBRANE BIOL, V179, P243, DOI 10.1007/s002320010050; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Marunaka Y, 1996, PFLUG ARCH EUR J PHY, V431, P748, DOI 10.1007/BF02253839; Marunaka Y, 2002, BIOCHEM PHARMACOL, V63, P1547, DOI 10.1016/S0006-2952(02)00880-8; Marunaka Y, 1999, J PHYSIOL-LONDON, V515, P669, DOI 10.1111/j.1469-7793.1999.669ab.x; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; MCCLELLAND JL, 1988, EXPLORATIONS PARALLE, V3, P318; McFarlane MB, 1998, J NEUROPHYSIOL, V80, P1678, DOI 10.1152/jn.1998.80.4.1678; MLINAR B, 1993, J PHYSIOL-LONDON, V469, P639, DOI 10.1113/jphysiol.1993.sp019835; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PALMER LG, 1985, J MEMBRANE BIOL, V87, P191, DOI 10.1007/BF01871218; PARK CS, 1983, AM J PHYSIOL, V245, pF716, DOI 10.1152/ajprenal.1983.245.6.F716; Pauling L., 1960, NATURE CHEM BOND, P644; Perchenet L, 2001, J MEMBRANE BIOL, V183, P51, DOI 10.1007/s00232-001-0052-y; Perez-Reyes E, 1999, ANN NY ACAD SCI, V868, P131, DOI 10.1111/j.1749-6632.1999.tb11283.x; Pommer AJ, 1999, J BIOL CHEM, V274, P27153, DOI 10.1074/jbc.274.38.27153; Quinteiro-Blondin S, 2001, GEN PHYSIOL BIOPHYS, V20, P331; Ragsdale SW, 1998, CURR OPIN CHEM BIOL, V2, P208, DOI 10.1016/S1367-5931(98)80062-8; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schmidt KF, 1999, NEUROSCI LETT, V262, P109, DOI 10.1016/S0304-3940(99)00072-5; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; SHEETS MF, 1992, J PHYSIOL-LONDON, V454, P299, DOI 10.1113/jphysiol.1992.sp019265; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, FASEB J, V16, pA478; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Sheng SH, 2002, BIOPHYS J, V82, p211A; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Song DK, 1999, PFLUG ARCH EUR J PHY, V438, P147, DOI 10.1007/s004240050892; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; TAKAHASHI M, 1993, EUR J BIOCHEM, V217, P665, DOI 10.1111/j.1432-1033.1993.tb18291.x; Telgkamp P, 1996, GLIA, V16, P140, DOI 10.1002/(SICI)1098-1136(199602)16:2<140::AID-GLIA6>3.0.CO;2-7; Tozawa K, 2001, J BIOCHEM, V130, P527, DOI 10.1093/oxfordjournals.jbchem.a003015; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; Ueno T, 2001, J NEUROCHEM, V78, P1009, DOI 10.1046/j.1471-4159.2001.00473.x; van der Westhuizen FH, 2000, J BIOCHEM MOL TOXIC, V14, P102, DOI 10.1002/(SICI)1099-0461(2000)14:2<102::AID-JBT6>3.0.CO;2-H; Varrot A, 2000, J MOL BIOL, V297, P819, DOI 10.1006/jmbi.2000.3567; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Voilley N, 1997, COMP BIOCHEM PHYS A, V118, P193, DOI 10.1016/S0300-9629(97)00066-2; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3; Zoroddu MA, 2000, BBA-GEN SUBJECTS, V1475, P163, DOI 10.1016/S0304-4165(00)00066-0	121	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50098	50111		10.1074/jbc.M209975200	http://dx.doi.org/10.1074/jbc.M209975200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397059	hybrid			2022-12-25	WOS:000180028900129
J	Han, QW; Leng, J; Bian, DF; Mahanivong, C; Carpenter, KA; Pan, ZXK; Han, JH; Huang, S				Han, QW; Leng, J; Bian, DF; Mahanivong, C; Carpenter, KA; Pan, ZXK; Han, JH; Huang, S			Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; P38 MAP KINASE; PROTEIN-KINASE; BINDING PROTEIN; RECEPTOR EXPRESSION; SIGNALING PATHWAY; CYCLE PROGRESSION; INTEGRIN; GROWTH	We reported previously that down-regulating or functionally blocking alphav integrins inhibits endogenous p38 mitogen-activated protein kinase (MAPK) activity and urokinase plasminogen activator (uPA) expression in invasive MDA-MB-231 breast cancer cells whereas engaging av integrins with vitronectin activates p38 MAPK and up-regulates uPA expression (Chen, J., Baskerville, C., Han, Q., Pan, Z., and Huang, S. (2001) J. Biol. Chem. 276, 47901-47905). Currently, it is not clear what upstream and downstream signaling molecules of p38 MAPK mediate alphav integrin-mediated uPA up-regulation. In the present study, we found that av integrin ligation activated small GTPase Rac1 preferentially, and dominant negative Rac1 inhibited av integrin-mediated p38 MAPK activation. Using constitutively active MAPK kinases, we found that both constitutively active MKK3 and MKK6 mutants were able to activate p38 MAPK and up-regulate uPA expression, but only dominant negative MKK3 blocked alphav integrin-mediated p38 MAPK activation and uPA up-regulation. These results suggest that MKK3, rather than MKK6, mediates av integrin-induced p38 MAPK activation. Among the potential downstream effectors of p38 MAPK, we found that only MAPK-activated protein kinase 2 affects alphav integrin-mediated uPA up-regulation significantly. Finally, using beta-globin reporter gene constructs containing uPA mRNA 3'-untranslated region (UTR) and adenosineturidine-rich elements-deleted 3'-UTR, we demonstrated that p38 MAPK/MAPK-activated protein kinase 2 signaling pathway regulated uPA mRNA stability through a mechanism involving the adenosine/uridine-rich elements sequence in 3'-UTR of uPA mRNA.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Chemicon Int Inc, Temecula, CA 92590 USA	Scripps Research Institute; Scripps Research Institute	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu	Han, J/G-4671-2010		NCI NIH HHS [R01 CA93926] Funding Source: Medline; NHLBI NIH HHS [T32 HL07195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Bouchet C, 1998, BRIT J CANCER, V77, P1495, DOI 10.1038/bjc.1998.246; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Bugge TH, 1997, BLOOD, V90, P4522; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chan SY, 2001, CELL, V106, P117, DOI 10.1016/S0092-8674(01)00418-4; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Dubuisson L, 2000, J PATHOL, V190, P190, DOI 10.1002/(SICI)1096-9896(200002)190:2<190::AID-PATH511>3.0.CO;2-H; DUGGAN C, 1995, INT J CANCER, V61, P597, DOI 10.1002/ijc.2910610502; Farina AR, 1998, INT J CANCER, V75, P721; Foekens JA, 2000, CANCER RES, V60, P636; Frandsen TL, 2001, CANCER RES, V61, P532; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hildenbrand R, 2000, HISTOPATHOLOGY, V36, P499, DOI 10.1046/j.1365-2559.2000.00899.x; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Koshelnick Y, 1999, THROMB HAEMOSTASIS, V82, P305, DOI 10.1055/s-0037-1615847; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mayo LD, 2001, J BIOL CHEM, V276, P25184, DOI 10.1074/jbc.M102932200; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Montero L, 1999, CANCER RES, V59, P5286; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Philip A, 2000, J BIOL CHEM, V275, P5911, DOI 10.1074/jbc.275.8.5911; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	73	75	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48379	48385		10.1074/jbc.M209542200	http://dx.doi.org/10.1074/jbc.M209542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377770	hybrid			2022-12-25	WOS:000179789600055
J	van Dam, EM; ten Broeke, T; Jansen, K; Spijkers, P; Stoorvogel, W				van Dam, EM; ten Broeke, T; Jansen, K; Spijkers, P; Stoorvogel, W			Endocytosed transferrin receptors recycle via distinct dynamin and phosphatidylinositol 3-kinase-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; POLARIZED MDCK CELLS; EARLY ENDOSOMES; MEMBRANE-TRANSPORT; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; IRON UPTAKE; 3-KINASE; WORTMANNIN	Recycling of endocytosed membrane proteins involves passage through early endosomes and recycling endosomes. Previously, we demonstrated a role for clathrin-coated vesicles in transferrin receptor recycling. These clathrin-coated vesicles are formed from recycling endosomes in a process that was inhibited in dynamin-1(G273D)-overexpressing cells. Here we show a second transferrin recycling pathway, which requires phosphatidylinositol 3-kinase activity. Two unrelated phosphatidylinositol 3-kinase inhibitors, LY294002 and wortmannin, retained endocytosed transferrin in early endosomes but did not affect transfer through recycling endosomes. The inhibitory effects of LY294002 and dynamin-1(G273D) on transferrin recycling were additive. In combination with brefeldin A, a drug that prevents the formation of clathrin-coated buds at recycling endosomes, LY294002 inhibited transferrin recycling synergistically. Collectively, these data indicate two distinct recycling pathways. One pathway involves transfer from early endosomes to recycling endosomes, from where clathrin/dynamin-coated vesicles provide for further transport, whereas the other route bypasses recycling endosomes and requires phosphatidylinositol 3-kinase activity.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	Stoorvogel, W (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, AZU G02-525,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Bright NA, 2001, TRAFFIC, V2, P631, DOI 10.1034/j.1600-0854.2001.20906.x; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; Ko KWS, 2001, BIOCHEMISTRY-US, V40, P752, DOI 10.1021/bi001797+; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Trischler M, 1999, J CELL SCI, V112, P4773; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; WIMONSEN A, 2001, NAT CELL BIOL, V3, pE179; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	60	119	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48876	48883		10.1074/jbc.M206271200	http://dx.doi.org/10.1074/jbc.M206271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372835	hybrid			2022-12-25	WOS:000179789600117
J	Wang, YR; Ho, GY; Zhang, JJ; Nieuwenhuijsen, B; Edris, W; Chanda, PK; Young, KH				Wang, YR; Ho, GY; Zhang, JJ; Nieuwenhuijsen, B; Edris, W; Chanda, PK; Young, KH			Regulator of G protein signaling Z1 (RGSZ1) interacts with G alpha(i) Subunits and regulates G alpha(i)-mediated cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ALPHA-SUBUNITS; FUNCTIONAL INTERACTION; TRANSITION-STATE; NERVOUS-SYSTEM; P115 RHOGEF; C-ELEGANS; GAIP; INHIBITION; KINASE	Regulator of G protein signaling (RGS) proteins constitute a family of over 20 proteins that negatively regulate heterotrimeric G protein-coupled receptor signaling pathways by enhancing endogenous GTPase activities of G protein alpha subunits. RGSZ1, one of the RGS proteins specifically localized to the brain, has been cloned previously and described as a selective GTPase accelerating protein for Galpha(z) subunit. Here, we employed several methods to provide new evidence that RGSZ1 interacts not only with Galpha(z), but also with Galpha(i), as supported by in vitro binding assays and functional studies. Using glutathione S-transferase fusion protein pull-down assays, glutathione S-transferase-RGSZ1 protein was shown to bind S-35-labeled Galpha(i1) protein in an AlF(4)(-)dependent manner. The interaction between RGSZ1 and Galpha(i) was confirmed further by co-immunoprecipitation studies and yeast two-hybrid experiments using a quantitative luciferase reporter gene. Extending these observations to functional studies, RGSZ1 accelerated endogenous GTPase activity of Gai, in single-turnover GTPase assays. Human RGSZ1 functionally regulated GPA1 (a yeast Galpha(i)-like protein)-mediated yeast pheromone response when expressed in a SST2 (yeast RGS protein) knockout strain. In PC12 cells, transfected RGSZ1 blocked mitogen-activated protein kinase activity induced by UIK14304, an alpha(2)-adrenergic receptor agonist. Furthermore, RGSZ1 attenuated D2 dopamine receptor agonist-induced serum response element reporter gene activity in Chinese hamster ovary cells. In summary, these data suggest that RGSZ1 serves as a GTPase accelerating protein for Galpha(i) and regulates Galpha(i)-mediated signaling, thus expanding the potential role of RGSZ1 in G protein-mediated cellular activities.	Wyeth Ayerst Res, Neurosci Discovery Res, Princeton, NJ 08543 USA	Pfizer	Wang, YR (corresponding author), Wyeth Ayerst Res, Neurosci Discovery Res, CN-8000, Princeton, NJ 08543 USA.	wangy4@wyeth.com	Edris, Wade/AAL-9216-2021					ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1529, DOI 10.1006/bbrc.1994.1624; Barker SA, 2001, GENOMICS, V78, P223, DOI 10.1006/geno.2001.6659; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Dong MQ, 2000, GENE DEV, V14, P2003; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; NEER EJ, 1994, PROTEIN SCI, V3, P3; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Nixon AB, 2002, J BIOL CHEM, V277, P18127, DOI 10.1074/jbc.M201065200; Okuhara DY, 1996, SYNAPSE, V23, P246, DOI 10.1002/(SICI)1098-2396(199608)23:4<246::AID-SYN2>3.0.CO;2-7; OZENBERGER BA, 1995, MOL ENDOCRINOL, V9, P1321, DOI 10.1210/me.9.10.1321; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	65	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48325	48332		10.1074/jbc.M206116200	http://dx.doi.org/10.1074/jbc.M206116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379657	hybrid			2022-12-25	WOS:000179789600048
J	Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C				Bierkamp, C; Kowalski-Chauvel, A; Dehez, S; Fourmy, D; Pradayrol, L; Seva, C			Gastrin mediated cholecystokinin-2 receptor activation induces loss of cell adhesion and scattering in epithelial MDCK cells	ONCOGENE			English	Article						epithelial cells; cell adhesion; Gastrin; CCK-2R; catenin; migration; cancer	CADHERIN-CATENIN COMPLEX; HEPATOCYTE GROWTH-FACTOR; HUMAN COLORECTAL-CANCER; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; B/GASTRIN RECEPTOR; P120 CATENIN; BETA-CATENIN; PROTEIN INTERACTIONS	The presence of gastrin and CCK-2/gastrin receptors in human preneoplastic and neoplastic lesions of pancreas and colon suggests a role in cancer development. Gastrin's growth-promoting action has been established, but a role in cellular morphogenetic processes promoting tumor invasion has been elusive. Our aim was (i) to investigate whether activation of the CCK-2R affects cellular morphology, intercellular adhesion and motility, as crucial parameters of epithelial differentiation, and (ii) to identify the signaling pathways and mechanisms implicated. Madin-Darby Canine Kidney (MDCK) cells were chosen to generate an epithelial non-tumorigenic model system expressing human CCK-2R. Epithelial differentiation and motility were analysed upon CCK-2R activation using immunocytochemistry and invasion assays. The functionality of adhesion complexes and activity of signaling proteins was determined with biochemical techniques. CCK-2R activation induced cell dissociation and enhanced invasion, preceded by decreased membrane localization of adherens junction molecules and nuclear accumulation of beta-catenin. Concomitantly, and requiring the activation of several signaling pathways, catenins were shifted from the cytoskeletal to the cytoplasmic fraction, suggesting the detachment of the cytoskeleton from the adherens complex. These data represent the first evidence for the CCK-2R, regulating cell-cell and cell-substrate adhesion and support a role for CCK-2R in the progression of carcinoma.	CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bierkamp, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, Dept Biol & Pathol Digest, INSERM,U531, 1 Av Jean Poulhes, F-31403 Toulouse, France.		SEVA, Catherine/O-9166-2014; Kowalski-Chauvel, Aline/O-9212-2014; Fourmy, Daniel/AAE-3703-2019	SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; Ding WQ, 2002, CANCER RES, V62, P947; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirata M, 1996, FEBS LETT, V383, P241, DOI 10.1016/0014-5793(96)00245-1; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Saillan-Barreau C, 1998, GASTROENTEROLOGY, V115, P988, DOI 10.1016/S0016-5085(98)70271-9; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; SEVA C, 1990, DIGESTION, V46, P166, DOI 10.1159/000200381; Skoudy A, 1996, INT J CANCER, V68, P14, DOI 10.1002/(SICI)1097-0215(19960927)68:1<14::AID-IJC3>3.0.CO;2-#; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Taniguchi T, 1996, ONCOGENE, V12, P1357; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Todisco A, 2001, AM J PHYSIOL-GASTR L, V280, pG298, DOI 10.1152/ajpgi.2001.280.2.G298; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 2001, CANCER RES, V61, P625; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	53	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7656	7670		10.1038/sj.onc.1205999	http://dx.doi.org/10.1038/sj.onc.1205999			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400008				2022-12-25	WOS:000178756200005
J	Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y				Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y			Involvement of nectin in the localization of junctional adhesion molecule at tight junctions	ONCOGENE			English	Article						nectin; JAM; cadherin; adherens junctions; tight junctions	CELL-CELL-ADHESION; KIDNEY EPITHELIAL-CELLS; SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC DOMAIN; ADHERENS JUNCTIONS; ALPHA-CATENIN; DESMOPLAKIN ORGANIZATION; SPATIAL REGULATION	Junctional adhesion molecule (JAM) is a Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at tight junctions (TJs). Claudin is a key cell-cell adhesion molecule that forms TJ strands at TJs. JAM is associated with claudin through their cytoplasmic tail-binding protein, ZO-1. JAM is furthermore associated with Par-3, a cell polarity protein which forms a ternary complex with Par-6 and atypical protein kinase C. Nectin is another Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at adherens junctions (AJs). Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. We show here that nectin is furthermore involved in the localization of JAM at TJs. During the formation of the junctional complex consisting of AJs and Us in Madin-Darby canine kidney (MDCK) cells, JAM was recruited to the nectin-based cell-cell adhesion sites. This recruitment of JAM was inhibited by nectin inhibitors, which inhibited the trans-interaction of nectin. Microbeads coated with the extracellular fragment of nectin, that interacted with cellular nectin, also recruited JAM to the bead-MDCK cell contact sites. Furthermore, when cadherin-deficient L fibroblasts stably expressing both exogenous JAM and nectin (nectin-JAM-L cells) were co-cultured with L fibroblasts expressing only nectin (nectin-L cells), JAM was concentrated at the cell-cell adhesion sites between nectin-JAM-L and nectin-L cells without the trans-interaction of JAM. Analyses of the localization and immunoprecipitation of JAM revealed that it was associated with nectin through afadin and ZO-1. These results suggest that nectin has a role in the localization of JAM at Us in the process of the formation of the junctional complex in epithelial cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Kyoto Univ, Fac Med, Dept Geriatr Med, Kyoto 6068501, Japan	Osaka University; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018; Ikeda, Wataru/V-8531-2019	Fukuhara, Atsunori/0000-0002-6289-3778; Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; AOKI J, 1994, J BIOL CHEM, V269, P8431; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 2000, J CELL SCI, V113, P2363; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127	78	102	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7642	7655		10.1038/sj.onc.1205875	http://dx.doi.org/10.1038/sj.onc.1205875			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400007				2022-12-25	WOS:000178756200004
J	Forlow, SB; Foley, PL; Ley, K				Forlow, SB; Foley, PL; Ley, K			Severely reduced neutrophil adhesion and impaired host defense against fecal and commensal bacteria in CD18-/- P-selectin-/- double null mice	FASEB JOURNAL			English	Article						integrins; knockout; intravital microscopy; inflammation; adhesion molecules	DOUBLE-MUTANT MICE; LUNG INJURY; GLYCOPROTEIN LIGAND; MONOCLONAL-ANTIBODY; CD18-INDEPENDENT MECHANISMS; INFLAMMATORY REACTIONS; LEUKOCYTE RECRUITMENT; ENDOTHELIAL-CELLS; INDUCED PNEUMONIA; GENE-EXPRESSION	Leukocyte recruitment to sites of inflammation requires the functions of selectors and integrins. P-selector null (CD62P- /-) mice show a mild and CD18 null (CD18 /-) mice a more severe neutrophil recruitment defect in some inflammatory models. To investigate the possible cooperative interactions between CD18 integrins and P-selector in mediating neutrophil recruitment, we generated CD18 - /- CD62P - /- double null mice. CD18 /- CD62P /- mice were apparently normal at weaning and fertile but later failed to gain weight, showed increased susceptibility to infection by fecal and commensal bacteria, and survived only 5-6 months. Some CD18-/-CD62P-/- mice showed severe spontaneous skin lesions; most showed neutrophil infiltration in the lungs and liver, and positive bacterial cultures from internal organs. The number and velocity of rolling leukocytes in tumor necrosis factor a treated venules of CD18-/-CD62P-/- mice was similar to those in wild-type mice, but neutrophil adhesion was severely reduced. Only 25% of adhered leukocytes were neutrophils in CD18-/-CD62P-/mice vs. >90% in wild-type, CD62P-/-, and CD18-/- single mutants. Our data show that removing both P-selectin and CD18 integrins from mice leads to severe neutrophil recruitment defects and spontaneous pathology.	Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Comparat Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ley, K (corresponding author), Univ Virginia, Dept Biomed Engn, Hlth Sci Ctr Box 800759, Charlottesville, VA 22908 USA.	klausley@virginia.edu		Foley, Patricia/0000-0001-5735-9485	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136, F32HL010447] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL10447, HL54136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; Bunting M, 2002, CURR OPIN HEMATOL, V9, P30, DOI 10.1097/00062752-200201000-00006; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Essani NA, 1998, J LEUKOCYTE BIOL, V63, P288, DOI 10.1002/jlb.63.3.288; Forlow SB, 2000, J CLIN INVEST, V106, P1457, DOI 10.1172/JCI10555; Gopalan PK, 1997, J IMMUNOL, V158, P367; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HELLMAN P, 1994, AIDS RES HUM RETROV, V10, P391, DOI 10.1089/aid.1994.10.391; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; ISSEKUTZ AC, 1993, CLIN IMMUNOL IMMUNOP, V67, P257, DOI 10.1006/clin.1993.1073; ISSEKUTZ AC, 1992, IMMUNOLOGY, V76, P655; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Jung U, 1999, J IMMUNOL, V162, P6755; Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KEENEY SE, 1994, AM J RESP CRIT CARE, V149, P311, DOI 10.1164/ajrccm.149.2.7905767; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; Lawson JA, 2000, TOXICOL SCI, V54, P509, DOI 10.1093/toxsci/54.2.509; Ley K, 2001, IMMUNOL RES, V24, P87, DOI 10.1385/IR:24:1:87; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Motosugi H, 1998, AM J RESP CRIT CARE, V157, P192, DOI 10.1164/ajrccm.157.1.9602095; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; Norman KE, 2001, MICROCIRCULATION, V8, P243, DOI 10.1080/713774036; NORTON CR, 1993, BIOCHEM BIOPH RES CO, V195, P250, DOI 10.1006/bbrc.1993.2037; NOURSHARGH S, 1989, J IMMUNOL, V142, P3193; Pan JL, 1998, J BIOL CHEM, V273, P10068, DOI 10.1074/jbc.273.16.10068; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; PRICE TH, 1987, J IMMUNOL, V139, P4174; PRIES AR, 1988, INT J MICROCIRC, V7, P327; Qin L, 1996, J IMMUNOL, V157, P5016; Ramamoorthy C, 1997, J LEUKOCYTE BIOL, V61, P167, DOI 10.1002/jlb.61.2.167; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Sharar SR, 1996, J IMMUNOL, V157, P2555; SHERMAN MP, 1992, J INFECT DIS, V166, P818, DOI 10.1093/infdis/166.4.818; Shi JL, 1998, BLOOD, V92, P520, DOI 10.1182/blood.V92.2.520.414k17_520_528; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Steeber DA, 1997, J IMMUNOL, V159, P952; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; Wickel DJ, 1998, SHOCK, V10, P265, DOI 10.1097/00024382-199810000-00006; WINN RK, 1993, J CLIN INVEST, V92, P1168, DOI 10.1172/JCI116686; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	50	14	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1488	1496		10.1096/fj.02-0230com	http://dx.doi.org/10.1096/fj.02-0230com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374771				2022-12-25	WOS:000179167600030
J	Roberts, MS; Woods, AJ; Shaw, PE; Norman, JC				Roberts, MS; Woods, AJ; Shaw, PE; Norman, JC			ERK1 associates with alpha(v)beta(3) integrin and regulates cell spreading on vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BETA-CYTOPLASMIC DOMAINS; MAP KINASE; FOCAL ADHESIONS; TYROSINE PHOSPHORYLATION; LINKED KINASE; LIPID RAFTS; RECRUITMENT; COMPLEXES; MEMBRANE	Kinases that associate with integrins are likely to mediate the assembly/disassembly of cell:matrix junctions during cell migration. Here we show that ERK1 associates with alpha(v)beta(3) integrin following the addition of platelet-derived growth factor to serum-starved Swiss or NIH 3T3 fibroblasts in an interaction that is mediated by the central region of the beta(3) integrin cytodomain. alpha(v)beta(3)-ERK1 association occurred prior to focal complex formation and was seen to initiate in small punctate complexes primarily in the peripheral regions of the plasma membrane. Expression of a dominant negative mutant of ERK1 (but not ERK2) significantly reduced the spreading of cells on vitronectin, whereas cell spreading on fibronectin was unaffected by inhibition of ERK1. In contrast, inhibition of ERK activation by PD98059 had no effect on the platelet-derived growth factor-regulated Rab4-dependent flux of alpha(v)beta(3) integrin from early endosomes to the plasma membrane, an event that is also necessary for cells to spread efficiently on vitronectin. We propose that alpha(v)beta(3) integrin must recycle to the plasma membrane via the Rab4 pathway and recruit active ERK1 in order to function efficiently.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Leicester; University of Nottingham	Norman, JC (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	jcn2@le.ac.uk		NORMAN, Jim/0000-0002-0098-3014; SHAW, Peter/0000-0002-2598-4283				Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bodeau AL, 2001, J CELL SCI, V114, P2795; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; CHEN YP, 1994, BLOOD, V84, P1857; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KORTENJANN M, 1995, ONCOGENE, V11, P2105; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Skubitz KM, 1996, J IMMUNOL, V157, P3617; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; YLANNE J, 1995, J BIOL CHEM, V270, P9550; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	45	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1975	1985		10.1074/jbc.M208607200	http://dx.doi.org/10.1074/jbc.M208607200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12393886	hybrid			2022-12-25	WOS:000180462200081
J	Baldwin, TA; Ostergaard, HL				Baldwin, TA; Ostergaard, HL			The protein-tyrosine phosphatase CD45 reaches the cell surface via Golgi-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; T-CELLS; CLASS-I; INTRACELLULAR-TRANSPORT; MEMBRANE-GLYCOPROTEINS; IMMATURE THYMOCYTES; NEGATIVE REGULATION; LIVING CELLS; BREFELDIN-A	CD45 is a receptor protein-tyrosine phosphatase essential for T cell development and lymphocyte activation. It is highly glycosylated, with multiple isoforms and glycoforms expressed on the cell surface depending on the cell type and stage of differentiation. Interestingly, we found two pools of newly synthesized CD45 expressed on plasma membrane, one of which arrived by 5 min after synthesis. The remaining pool of CD45 was fully glycosylated and began to arrive at the cell surface at similar to15 min. The rapidly expressed population of CD45 possessed exclusively endoglycosidase H-sensitive N-linked carbohydrate. Additionally, this rapidly expressed pool of CD45 appeared on the cell surface in a brefeldin A (BFA)-insensitive manner, suggesting that it reached the cell surface independent of the Golgi complex. The remaining CD45 trafficked through the Golgi complex, and transport proceeded via a BFA-sensitive mechanism. These data suggest that CD45 is able to reach the cell surface via two distinct routes. The first is a conventional Golgi-dependent pathway that allows fully processed CD45 to be expressed. The second utilizes an ill defined mechanism that is independent of the Golgi, is BFA-resistant, and allows for the expression of CD45 with immature carbohydrate on the cell surface.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ostergaard, HL (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 6-70 HMRC, Edmonton, AB T6G 2S2, Canada.							ARENDT CW, 1995, J BIOL CHEM, V270, P2313; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Baldwin TA, 2001, J IMMUNOL, V167, P3829, DOI 10.4049/jimmunol.167.7.3829; Baldwin TA, 2000, J BIOL CHEM, V275, P32071, DOI 10.1074/jbc.M003088200; Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Berg NN, 1997, J IMMUNOL, V159, P1753; Briken V, 2002, EMBO J, V21, P825, DOI 10.1093/emboj/21.4.825; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOBMAN TC, 1993, J CELL BIOL, V121, P269, DOI 10.1083/jcb.121.2.269; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; Jourdan N, 1997, J VIROL, V71, P8268, DOI 10.1128/JVI.71.11.8268-8278.1997; Klumperman J, 2000, NAT CELL BIOL, V2, pE217, DOI 10.1038/35046635; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Maksymowych WP, 1998, INFECT IMMUN, V66, P4624, DOI 10.1128/IAI.66.10.4624-4632.1998; Martin PEM, 2001, J CELL SCI, V114, P3845; Mezghrani A, 2000, J BIOL CHEM, V275, P1920, DOI 10.1074/jbc.275.3.1920; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; NORI M, 1988, MOL CELL BIOL, V8, P833, DOI 10.1128/MCB.8.2.833; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Pace KE, 1999, J IMMUNOL, V163, P3801; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Pieters J, 1997, BIOL CHEM, V378, P751; PULIDO R, 1992, EUR J IMMUNOL, V22, P463, DOI 10.1002/eji.1830220226; Roche PA, 1999, IMMUNITY, V11, P391, DOI 10.1016/S1074-7613(00)80114-4; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Uemura K, 1996, J BIOL CHEM, V271, P4581; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	51	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50333	50340		10.1074/jbc.M209075200	http://dx.doi.org/10.1074/jbc.M209075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386161	hybrid			2022-12-25	WOS:000180177700017
J	Qi, HY; Hyndman, JB; Bernstein, HD				Qi, HY; Hyndman, JB; Bernstein, HD			DnaK promotes the selective export of outer membrane protein precursors in SecA-deficient Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; MALTOSE-BINDING PROTEIN; HEAT-SHOCK PROTEINS; TRIGGER FACTOR; SUBSTRATE-SPECIFICITY; TARGETING PATHWAY; IN-VIVO; TRANSLOCATION; INSERTION; SECRETION	Consistent with many other results indicating that SecA plays an essential role in the translocation of presecretory proteins across the Escherichia coli inner membrane, we previously found that a similar to95% depletion of SecA completely blocks the export of periplasmic proteins in vivo. Surprisingly, we found that about 25% of the outer membrane protein (OMP) OmpA synthesized after SecA depletion was gradually translocated across the inner membrane. In this study we analyzed the export of several other OMPs after SecA depletion. We found that 25-50% of each OMP as well as an OmpA-alkaline phosphatase fusion protein was exported from SecA-deficient cells. This partial export was completely abolished by the SecA inhibitor sodium azide and therefore still required the participation of SecA. Examination of a variety of OmpA derivatives, however, ruled out the possibility that OMPs are selectively translocated in SecA-deficient cells because SecA binds to their N termini with unusually high affinity. Export after SecA depletion was observed in cells that lack SecB, the primary targeting factor for OMPs, but was abolished by partial inactivation of DnaK. Furthermore, OmpA could be isolated in a stable complex with DnaK. The data strongly suggest that OMPs require only a relatively low level of translocase activity to cross the inner membrane because they can be preserved in a prolonged export-competent state by DnaK.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 5,Rm 201, Bethesda, MD 20892 USA.	harris_bernstein@nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052022, ZIADK052022] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACALLAO R, 1986, J BIOL CHEM, V261, P2907; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; KADOKURA H, 1995, J BACTERIOL, V177, P3596, DOI 10.1128/jb.177.12.3596-3600.1995; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KLOSE M, 1988, J BIOL CHEM, V263, P13297; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE C, 1986, ANNU REV CELL BIOL, V2, P315, DOI 10.1146/annurev.cellbio.2.1.315; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MILLER JH, 1992, SHORT COURS BACT GEN; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; NILSSON B, 1991, J BIOL CHEM, V266, P2970; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Randall LL, 1998, PROTEIN SCI, V7, P2384, DOI 10.1002/pro.5560071115; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; TOPPING TB, 1994, PROTEIN SCI, V3, P730; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Yang YB, 1997, J BIOL CHEM, V272, P13660, DOI 10.1074/jbc.272.21.13660; Yang YB, 1997, J BACTERIOL, V179, P7386, DOI 10.1128/jb.179.23.7386-7393.1997; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51077	51083		10.1074/jbc.M209238200	http://dx.doi.org/10.1074/jbc.M209238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12403776	hybrid			2022-12-25	WOS:000180177700115
J	Schumacher, MM; Choi, JY; Voelker, DR				Schumacher, MM; Choi, JY; Voelker, DR			Phosphatidylserine transport to the mitochondria is regulated by ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INTRACELLULAR TRAFFICKING; INTERORGANELLE TRANSPORT; PROTEIN TRANSLOCATION; TRANSCRIPTION FACTOR; FUSOGENIC PROTEIN; PHOSPHATIDYLETHANOLAMINE; MEMBRANE; IMPORT; YEAST	Mitochondrial membrane biogenesis requires the interorganelle transport of phospholipids. Phosphatidylserine (PtdSer) synthesized in the endoplasmic reticulum and related membranes (mitochondria-associated membrane (MAM)) is transported to the mitochondria by unknown gene products and decarboxylated to form phosphatidylethanolamine at the inner membrane by PtdSer decarboxylase 1 (Psd1p). We have designed a screen for strains defective in PtdSer transport (pstA mutants) between the endoplasmic reticulum and Psd1p that relies on isolating ethanolamine auxotrophs in suitable (psd2Delta) genetic backgrounds. Following chemical mutagenesis, we isolated an ethanolamine auxotroph that we designate pstA1-1. Using in vivo and in vitro phospholipid synthesis/transport measurements, we demonstrate that the pstA1-1 mutant is defective in PtdSer transport between the MAM and mitochondria. The gene that complements the growth defect and PtdSer transport defect of the pstA1-1 mutant is MET30, which encodes a substrate recognition subunit of the SCF (suppressor of kinetochore protein 1, cullin, F-box) ubiquitin ligase complex. Reconstitution of different permutations of MAM and mitochondria from wild type and pstAl-1 strains demonstrates that the MET30 gene product affects both organelles. These data provide compelling evidence that interorganelle PtdSer traffic is regulated by ubiquitination.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [GM 32453, R01 GM032453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032453, R37GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; CAMICI O, 1995, J MEMBRANE BIOL, V148, P169; Camici O, 1997, MOL CELL BIOCHEM, V175, P71, DOI 10.1023/A:1006889328983; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; MENON AK, 1992, J BIOL CHEM, V267, P15277; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; RAKOWSKA M, 1994, J MEMBRANE BIOL, V142, P35; Rospert S, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P277; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Shiao YJ, 1998, BIOCHEM J, V331, P217, DOI 10.1042/bj3310217; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Vance JE, 1996, ANTICANCER RES, V16, P1333; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; Voelker DR, 2000, BBA-MOL CELL BIOL L, V1486, P97, DOI 10.1016/S1388-1981(00)00051-2; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WOJTCZAK L, 1972, ACTA BIOCHIM POL, V19, P227	50	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51033	51042		10.1074/jbc.M205301200	http://dx.doi.org/10.1074/jbc.M205301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393893	hybrid			2022-12-25	WOS:000180177700110
J	Belogurov, GA; Lahti, R				Belogurov, GA; Lahti, R			A lysine substitute for K+ - A460K mutation eliminates K+ dependence in H+-pyrophosphatase of Carboxydothermus hydrogenoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC PYROPHOSPHATASE; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; VACUOLAR; MEMBRANE; PROTEINS; BINDING; BACTERIUM; SYNTHASE; RESIDUES	The H+ proton-translocating inorganic pyrophosphatase (H+-PPase) family is composed of two phylogenetically distinct types of enzymes: K+-dependent and K+-independent. However, to date, the sequence criteria governing this dichotomy have remained unknown. In this study, we describe the heterologous expression and functional characterization of H+-PPase from the thermophilic bacterium Carboxydothermus hydrogenoformans. Both PPi-hydrolyzing and PPi-energized H+ translocation activities of the recombinant enzyme in Escherichia coli inner membrane vesicles are strictly K+-dependent. Here we deduce the K+ requirement of all available H+-PPase sequences based on the K+ dependence of C hydrogenoformans H+-PPase in conjunction with phylogenetic analyses. Our data reveal that K+-independent H+-PPases possess conserved Lys and Thr that are absent in K+-dependent H+-PPases. We further demonstrate that a A460K substitution in C. hydrog-enoformans H+-PPase is sufficient to confer K+ independence to both PPi hydrolysis and PPi-energized H+ translocation. In contrast, a A463T mutation does not affect the K+ dependence of H+-PPase.	Turku Univ, Dept Biochem & Food Chem, FIN-20014 Turku, Finland; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Turku; Lomonosov Moscow State University	Belogurov, GA (corresponding author), Turku Univ, Dept Biochem & Food Chem, FIN-20014 Turku, Finland.			Belogurov, Georgiy/0000-0002-3070-6843				BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; Baltscheffsky M, 1999, FEBS LETT, V452, P121, DOI 10.1016/S0014-5793(99)00617-1; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Belogurov GA, 2002, J BIOL CHEM, V277, P22209, DOI 10.1074/jbc.M202951200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Drozdowicz YM, 2000, PLANT PHYSIOL, V123, P353, DOI 10.1104/pp.123.1.353; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; Perez-Castineira JR, 2001, FEBS LETT, V496, P6, DOI 10.1016/S0014-5793(01)02390-0; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SATO MH, 1994, J BIOL CHEM, V269, P6725; SATO MH, 1991, FEBS LETT, V290, P177, DOI 10.1016/0014-5793(91)81254-6; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; SVETLICHNY VA, 1991, SYST APPL MICROBIOL, V14, P254, DOI 10.1016/S0723-2020(11)80377-2; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER RR, 1981, PLANTA, V153, P150, DOI 10.1007/BF00384096; WU JJ, 1991, FEBS LETT, V283, P57, DOI 10.1016/0014-5793(91)80552-E; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	30	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49651	49654		10.1074/jbc.M210341200	http://dx.doi.org/10.1074/jbc.M210341200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12401795	hybrid			2022-12-25	WOS:000180028900073
J	Karvar, S; Yao, XB; Crothers, JM; Liu, YC; Forte, JG				Karvar, S; Yao, XB; Crothers, JM; Liu, YC; Forte, JG			Localization and function of soluble N-ethylmaleimide-sensitive factor attachment protein-25 and vesicle-associated membrane protein-2 in functioning gastric parietal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CHROMAFFIN CELLS; H+-K+-ATPASE; REGULATED EXOCYTOSIS; ALPHA-SUBUNITS; BETA-SUBUNITS; C-TERMINUS; SNAP-25; FUSION; TUBULOVESICLES; RECRUITMENT	The soluble N-ethylmaleimide-sensitive factor attachment protein of 25 kDa (SNAP-25) plays an important role in vesicle trafficking. Together with vesicle-associated membrane protein-2 (VAMP-2) and syntaxin, SNAP-25 forms a ternary complex implicated in docking and fusion of secretory vesicles with the plasma membrane during exocytosis. These so-called SNARE proteins are believed to regulate tubulovesicle trafficking and fusion during the secretory cycle of the gastric parietal cell. Here we examined the cellular localization and functional importance of SNA-P-25 in parietal cell cultures. Adenoviral constructs were used to express SNAP-25 tagged with cyan fluorescent protein, VAMP-2 tagged with yellow fluorescent protein, and SNAP-25 in which the C-terminal 25 amino acids were deleted (SNAP-25 181-206). Membrane fractionation experiments and fluorescent imaging showed that SNAP-25 is localized to the apical plasma membrane. The expression of the mutant SNAP-25 Delta181-226 inhibited the acid secretory response of parietal cells. Also, SNAP Delta181-226 bound poorly in vitro with recombinant syntaxin-1 compared with wild type SNAP-25, indicating that pairing between syntaxin-1 and SNAP-25 is required for parietal cell activation. Dual expression of SNAP-25 tagged with cyan fluorescent protein and VAMP-2 tagged with yellow fluorescent protein revealed a dynamic change in distribution associated with acid secretion. In resting cells, SNAP-25 is at the apical plasma membrane and VAMP-2 is associated with cytoplasmic H,K-ATPase-rich tubulovesicles. After stimulation, the two proteins colocalize on the apical plasma membrane. These data demonstrate the functional significance of SNAP-25 as a SNARE protein in the parietal cell and show the dynamic stimulation-associated redistribution of VAMP-2 from H,K-ATPase-rich tubulovesicles to co-localize with SNAP-25 on the apical plasma membrane.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA	University of California System; University of California Berkeley; University of Oklahoma System; University of Oklahoma Health Sciences Center	Forte, JG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 145 Life Sci Addit,3200, Berkeley, CA 94720 USA.		Yao, Xuebiao/P-5771-2014		NIDDK NIH HHS [DK 56292, DK 10141, DK 38972] Funding Source: Medline; NINDS NIH HHS [NS 35167] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK010141, R01DK038972, R01DK056292, R01DK010141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035167] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agnew BJ, 1999, J CELL SCI, V112, P2639; Ammar DA, 2002, AM J PHYSIOL-GASTR L, V282, pG23, DOI 10.1152/ajpgi.00277.2002; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Calhoun BC, 1997, BIOCHEM J, V325, P559, DOI 10.1042/bj3250559; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, J BIOL CHEM, V276, P28503, DOI 10.1074/jbc.M103009200; CHEW CS, 1994, ANNU REV PHYSIOL, V56, P445; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; Gil A, 2002, J BIOL CHEM, V277, P9904, DOI 10.1074/jbc.M110182200; Graham ME, 2001, J CELL SCI, V114, P4397; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; Huang XH, 2001, PANCREAS, V23, P125, DOI 10.1097/00006676-200108000-00002; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jons T, 1999, EUR J CELL BIOL, V78, P779; Karvar S, 2002, GASTROENTEROLOGY, V123, P281, DOI 10.1053/gast.2002.34217; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Okamoto CT, 2002, J CONTROL RELEASE, V78, P35, DOI 10.1016/S0168-3659(01)00479-5; Okamoto CT, 2001, J PHYSIOL-LONDON, V532, P287, DOI 10.1111/j.1469-7793.2001.0287f.x; Okamoto CT, 2000, AM J PHYSIOL-CELL PH, V278, pC727, DOI 10.1152/ajpcell.2000.278.4.C727; Peng XR, 1997, MOL BIOL CELL, V8, P399, DOI 10.1091/mbc.8.3.399; REENSTRA WW, 1990, METHOD ENZYMOL, V192, P151; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; WARD CL, 1994, J BIOL CHEM, V269, P25710; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Xia ZP, 2001, J BIOL CHEM, V276, P1766, DOI 10.1074/jbc.M008741200; Yang YZ, 2000, J BIOL CHEM, V275, P29482, DOI 10.1074/jbc.M003237200	35	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50030	50035		10.1074/jbc.M207694200	http://dx.doi.org/10.1074/jbc.M207694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386166	hybrid			2022-12-25	WOS:000180028900121
J	Miyauchi, Y; Yogosawa, S; Honda, R; Nishida, T; Yasuda, H				Miyauchi, Y; Yogosawa, S; Honda, R; Nishida, T; Yasuda, H			Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; SUMO-1 MODIFICATION; P53-DEPENDENT APOPTOSIS; CONJUGATING ENZYME; E3 LIGASE; P53; PHOSPHORYLATION; P19(ARF); PML; COMPLEX	Mdm2, a ubiquitin ligase that acts on p53, is regulated by sumoylation. In the current study, we identify the enzymes responsible for the sumoylation of Mdm2. When mammalian cells are co-transfected with cDNAs encoding Mdm2 and PIAS1 or PIASxbeta (protein inhibitor of activated STAT) as sumoylation enzymes, Mdm2 is highly sumoylated. Mdm2 is also sumoylated in an in vitro system containing PIASxbeta, PIAS1, and RanBP2. When several lysine residues of Mdm2 were sequentially mutated to arginine, the K182R mutant was not sumoylated in intact cells; however, in the in vitro system this mutant was sumoylated by PIAS1, PIASxbeta, and RanBP2 as efficiently as the wild-type Mdm2 protein. Lysine residues 182 and 185 map within the nuclear localization signal of Mdm2. A K185R mutant of Mdm2 is sumoylated in intact cells, whereas a K182R protein is not. Only a Mdm2 protein bearing the K182R mutation is localized exclusively in the cytoplasm. Because RanBP2 is a nuclear pore protein and PIAS proteins are localized within the nucleus, our data suggest that Mdm2 is sumoylated during nuclear translocation by RanBP2 and then further sumoylated once in the nucleus by PIASxbeta and PIAS1.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Yasuda, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	h-yasuda@yk9.so-net.ne.jp						Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Buschmann T, 2001, CELL, V107, P549; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hochstrasser M, 2002, MOL CELL, V9, P453, DOI 10.1016/S1097-2765(02)00486-0; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	77	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50131	50136		10.1074/jbc.M208319200	http://dx.doi.org/10.1074/jbc.M208319200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393906	hybrid			2022-12-25	WOS:000180028900132
J	Muro, I; Hay, BA; Clem, RJ				Muro, I; Hay, BA; Clem, RJ			The Drosophila DIAP1 protein is required to prevent accumulation of a continuously generated, processed form of the apical caspase DRONC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; IAP PROTEINS; APOPTOSIS; REAPER; HID; DEGRADATION; ACTIVATION; GRIM; PATHWAY	Although loss of the inhibitor of apoptosis (LAP) protein DIAP1 has been shown to result in caspase activation and spontaneous cell death in Drosophila cells and embryos, the point at which DIAP1 normally functions to inhibit caspase activation is unknown. Depletion of the DIAP1 protein in Drosophila S2 cells or the Sf-IAP protein in Spodoptera frugiperda Sf21 cells by RNA interference (RNAi) or cycloheximide treatment resulted in rapid and widespread caspase-dependent apoptosis. Co-silencing of dronc or dark largely suppressed this apoptosis, indicating that DIAP1 is normally required to inhibit an activity dependent on these proteins. Silencing of dronc also inhibited DRICE processing following stimulation of apoptosis, demonstrating that DRONC functions as an apical caspase in S2 cells. Silencing of diap1 or treatment with UV light induced DRONC processing, which occurred in two steps. The first step appeared to occur continuously even in the absence of an apoptotic signal and to be dependent on DARK because full-length DRONC accumulated when dark was silenced in non-apoptotic cells. In addition, treatment with the proteasome inhibitor MG132 resulted in accumulation of this initially processed form of DRONC, but not full-length DRONC, in non-apoptotic cells. The second step in DRONC processing was observed only in apoptotic cells. These results indicate that the initial step in DRONC processing occurs continuously via a DARK-dependent mechanism in Drosophila cells and that DIAP1 is required to prevent excess accumulation of this first form of processed DRONC, presumably through its ability to act as a ubiquitin-protein ligase.	Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Kansas State University; California Institute of Technology	Clem, RJ (corresponding author), Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, 232 Ackert Hall, Manhattan, KS 66506 USA.	rclem@ksu.edu		Clem, Rollie/0000-0002-2368-720X	NATIONAL CANCER INSTITUTE [T32CA009418, R29CA078602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78602, CA 09418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang QH, 2000, P NATL ACAD SCI USA, V97, P1427, DOI 10.1073/pnas.97.4.1427; Igaki T, 2002, J BIOL CHEM, V277, P23103, DOI 10.1074/jbc.C200222200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lisi S, 2000, GENETICS, V154, P669; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wang XD, 2001, GENE DEV, V15, P2922; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	42	134	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49644	49650		10.1074/jbc.M203464200	http://dx.doi.org/10.1074/jbc.M203464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397080	hybrid, Green Accepted			2022-12-25	WOS:000180028900072
J	Wolkow, CA; Munoz, MJ; Riddle, DL; Ruvkun, G				Wolkow, CA; Munoz, MJ; Riddle, DL; Ruvkun, G			Insulin receptor substrate and p55 orthologous adaptor proteins function in the Caenorhabditis elegans daf-2/insulin-like signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-1 PI3 KINASE; LIFE-SPAN; MICE LACKING; PHOSPHOINOSITIDE 3-KINASE; INTERACTING GENES; DAUER FORMATION; FAMILY-MEMBER; LONGEVITY; DAF-16; DIAPAUSE	An insulin-like signaling pathway regulates development and lifespan in Caenorhabditis elegdns. Genetic screens that identified many components of the C. elegans insulin pathway did not identify homologs of insulin receptor substrates or the phosphoinositide 3-kinase (PI3K) adaptor/regulatory subunit, which are both required for signaling by mammalian insulin/insulin-like growth factor I pathways. The C. elegans genome contains one homolog of each protein. The C. elegans versions of insulin receptor substrate (IST-1) and PI3K p50/p55 (AAP-1) share moderate sequence similarity with their vertebrate and Drosophila counterparts. Genetic experiments show that ist-1 and aap-1 potentiate C. elegans insulin-like signaling, although they are not required for signaling in the pathway under most conditions. Worms lacking AAP-1 activity because of the mutation aap-1(m889) constitutively arrest development at the dauer larval stage when raised at high temperatures. aap-1 mutants also live longer than wild-type animals, a phenotype observed in other C. elegans mutants with defects in DAF-2 signaling. Interestingly, IST-1 appears to be required for signaling through a pathway that may act in parallel to AGE-1/PI3K.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; NIA, Neurosci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wolkow, CA (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA.	wolkowca@grc.nia.nih.gov	Muñoz, Manuel J/F-7841-2016	Muñoz, Manuel J/0000-0002-0111-1541	Intramural NIH HHS [NIH0011061953, Z01 AG000320-06] Funding Source: Medline; NIA NIH HHS [AG 14161, AG 12689, R01 AG014161] Funding Source: Medline; NIGMS NIH HHS [GM 60151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014161, R01AG012689, R37AG014161, Z01AG000320] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BRENNER S, 1974, GENETICS, V77, P71; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; DORMAN JB, 1995, GENETICS, V141, P1399; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gems D, 1998, GENETICS, V150, P129; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOTTLIEB S, 1994, GENETICS, V137, P107; Gutch MJ, 1998, GENE DEV, V12, P571, DOI 10.1101/gad.12.4.571; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LARSEN PL, 1995, GENETICS, V139, P1567; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MUNOZ MI, 2003, IN PRESS GENETICS; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tissenbaum HA, 1998, GENETICS, V148, P703; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; VOWELS JJ, 1992, GENETICS, V130, P105; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	79	90	3	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49591	49597		10.1074/jbc.M207866200	http://dx.doi.org/10.1074/jbc.M207866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393910	hybrid			2022-12-25	WOS:000180028900065
J	Moore, MJ; Kanter, JR; Jones, KC; Taylor, SS				Moore, MJ; Kanter, JR; Jones, KC; Taylor, SS			Phosphorylation of the catalytic subunit of protein kinase A - Autophosphorylation versus phosphorylation by phosphoinositide-dependent kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACTIVATION; PDK1; FAMILY; INHIBITOR; FRAMEWORK; SEQUENCE; DOMAIN; SITES	The identification of phosphoinositide-dependent kinase-1 (PDK-1) as an activating kinase for members of the AGC family of kinases has. led to its implication as the activating kinase for cAMP-dependent protein kinase. It has been established in vitro that PDK-1 can phosphorylate the catalytic (C) subunit (19), but the Escherichia coli-expressed C-subunit undergoes autophosphorylation. To assess which of these mechanisms occurs in mammalian cells, a set of mutations was engineered flanking the site of PDK-1 phosphorylation, Thr-197, on the activation segment of the C-subunit. Two distinct requirements appeared for autophosphorylation and phosphorylation by PDK-1. Autophosphorylation was disrupted by mutations that compromised activity (Thr-201 and Gly-200) or altered substrate recognition (Arg-194). Conversely, only residues peripheral to Thr-197 altered PDK-1 phosphorylation, including a potential hydrophobic PDK-1 binding site at the C terminus. To address the in vivo requirements for phosphorylation, select mutant proteins were transfected into COS-7 cells, and their phosphorylation state was assessed with phospho-specific antibodies. The phosphorylation pattern of these mutant proteins indicates that autophosphorylation is not the maturation mechanism in the eukaryotic cell; instead, a heterologous kinase with properties resembling the in vitro characteristics of PDK-1 is responsible for in vivo phosphorylation of PKA.	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIDDK NIH HHS [DK07233] Funding Source: Medline; NIGMS NIH HHS [GM19301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019301, R37GM019301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Batkin M, 2000, BIOCHEMISTRY-US, V39, P5366, DOI 10.1021/bi000153z; BEEBE SJ, 1986, ENZYMES CONTROL PHOS; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Cauthron RD, 1998, MOL CELL BIOL, V18, P1416, DOI 10.1128/MCB.18.3.1416; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEMP BE, 1979, J BIOL CHEM, V254, P2638; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	36	100	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47878	47884		10.1074/jbc.M204970200	http://dx.doi.org/10.1074/jbc.M204970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372837	hybrid			2022-12-25	WOS:000179663700134
J	Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP				Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP			Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation	ONCOGENE			English	Article						cell cycle; CDC25B; pEg3; kinase; human cells	MITOTIC INDUCER; HELA-CELLS; MITOSIS; LOCALIZATION; TYROSINE; HOMOLOG; 14-3-3-PROTEINS; THREONINE-14; ACTIVATION; TRANSITION	The pEg3 protein is a member of the evolutionarily conserved KIN1/PAR-1/MARK kinase family which is involved in cell polarity and microtubule dynamics. In Xenopus, pEg3 has been shown to be a cell cycle dependent kinase whose activity increases to a maximum level during mitosis of the first embryonic cell division. CDC25B is one of the three CDC25 phosphatase genes identified in human. It is thought to regulate the G2/M progression by dephosphorylating and activating the CDK/cyclin complexes. In the present study we show that the human pEg3 kinase is able to specifically phosphorylate CDC25B in vitro. One phosphorylation site was identified and corresponded to serine 323. This residue is equivalent to serine 216 in human CDC25C which plays an important role in the regulation of phosphatase during the cell cycle and at the G2 checkpoint. pEg3 is also able to specifically associate with CDC25B in vitro and in vivo. We show that the ectopic expression of active pEg3 in human U2OS cells induces an accumulation of cells in G2. This effect is counteracted by overexpression of CDC25B. Taken together these results suggest that pEg3 is a potential regulator of the G2/M progression and may act antagonistically to the CDC25B phosphatase.	Univ Rennes 1, IFR 97, CNRS, UMR 6061, F-35043 Rennes, France; Univ Toulouse 3, CNRS, UMR 5088, LBCMCP, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tassan, JP (corresponding author), Univ Rennes 1, IFR 97, CNRS, UMR 6061, 2 Ave Professeur Leon Bernard,CS34317, F-35043 Rennes, France.		DUCOMMUN, Bernard/B-3208-2008; BALDIN, Véronique/Y-8397-2019	BALDIN, Véronique/0000-0001-8523-0494; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blot J, 2002, DEV BIOL, V241, P327, DOI 10.1006/dbio.2001.0525; Cans C, 1999, ANTICANCER RES, V19, P1241; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NAGATA A, 1991, NEW BIOL, V3, P959; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	38	84	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7630	7641		10.1038/sj.onc.1205870	http://dx.doi.org/10.1038/sj.onc.1205870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400006				2022-12-25	WOS:000178756200003
J	Rosenkranz, S; Knirel, D; Dietrich, H; Flesch, M; Erdmann, E; Bohm, M				Rosenkranz, S; Knirel, D; Dietrich, H; Flesch, M; Erdmann, E; Bohm, M			Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox"	FASEB JOURNAL			English	Article						catechin; atherosclerosis; vascular smooth muscle cells	CORONARY HEART-DISEASE; E-DEFICIENT MICE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; BETA-RECEPTOR; NEOINTIMAL FORMATION; IN-VIVO; HUMAN PLASMA; ALCOHOL; ATHEROSCLEROSIS	The mortality rate from coronary artery disease (CAD) in France is similar to50% compared to other European countries and the United States ("French paradox"). Epidemiological studies indicate an inverse relationship between moderate wine consumption and CAD mortality. Here, we demonstrate that preincubation of vascular smooth muscle cells (VSMCs) with red wine, but not white wine, inhibits ligand binding and the subsequent tyrosine phosphorylation of the platelet-derived growth factor beta receptor (betaPDGFR), which plays a critical role in the pathogenesis of atherosclerosis. As a consequence, red wine abrogates the ligand-induced recruitment of betaPDGFR-associated signaling molecules (RasGAP, SHP-2, PI3K, PLCgamma), PDGF-dependent downstream events such as Erk activation and induction of immediate early genes, and VSMC proliferation and migration. Wine analysis revealed flavonoids of the catechin family as major constituents of red wine, and these were identified as potent inhibitors of betaPDGFR signaling. Importantly, the concentrations of red wine/catechins shown to inhibit the PDGFR in vitro correlate with the serum levels after red wine consumption in humans. We conclude that nonalcoholic constituents of red wine, which accumulate during the "mash fermentation," inhibit betaPDGFR activation and PDGF-dependent cellular responses in VSMCs. Therefore, catechin-mediated inhibition of betaPDGFR signaling offers a molecular explanation for the "French paradox."	Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany; Univ Saarlandes Kliniken, Homburg, Germany	University of Cologne; Universitatsklinikum des Saarlandes	Rosenkranz, S (corresponding author), Univ Cologne, Innere Med Klin 3, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	Stephan.Rosenkranz@medizin.uni-koeln.de	Böhm, Michael/C-3638-2011					Abe J, 1998, HEART, V79, P400, DOI 10.1136/hrt.79.4.400; Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; American Heart Association, 2000, 2001 HEART STROK STA; Arts ICW, 2001, AM J CLIN NUTR, V74, P227; Banai S, 1998, CIRCULATION, V97, P1960, DOI 10.1161/01.CIR.97.19.1960; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bell JRC, 2000, AM J CLIN NUTR, V71, P103; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bilder G, 1999, CIRCULATION, V99, P3292, DOI 10.1161/01.CIR.99.25.3292; CHAMLEY JH, 1979, PHYSIOL REV, V39, P1; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; Davies MG, 2000, CIRC RES, V86, P779, DOI 10.1161/01.RES.86.7.779; Donovan JL, 1999, J NUTR, V129, P1662, DOI 10.1093/jn/129.9.1662; Feng AN, 1999, CIRCULATION, V100, P2254, DOI 10.1161/01.CIR.100.22.2254; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Fishbein I, 2000, ARTERIOSCL THROM VAS, V20, P667, DOI 10.1161/01.ATV.20.3.667; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183, DOI 10.1152/ajpheart.1998.275.4.H1183; Flesch M, 2001, BASIC RES CARDIOL, V96, P128, DOI 10.1007/s003950170062; Goldberg IJ, 2001, CIRCULATION, V103, P472; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; Hayek T, 1997, ARTERIOSCL THROM VAS, V17, P2744, DOI 10.1161/01.ATV.17.11.2744; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; LINDNER V, 1995, AM J PATHOL, V146, P1488; Miura Y, 2001, J NUTR, V131, P27, DOI 10.1093/jn/131.1.27; Rechner A, 1998, DEUT LEBENSM-RUNDSCH, V94, P363; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruidavets JB, 2000, ATHEROSCLEROSIS, V153, P107, DOI 10.1016/S0021-9150(00)00377-4; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Schwartz SM, 1997, J CLIN INVEST, V99, P2814, DOI 10.1172/JCI119472; Tanizawa S, 1996, HEART, V75, P549, DOI 10.1136/hrt.75.6.549; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635	45	95	103	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1958	+		10.1096/fj.02-0207fje	http://dx.doi.org/10.1096/fj.02-0207fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397093				2022-12-25	WOS:000179167600011
J	Mo, Y; Campos, B; Mealy, TR; Commodore, L; Head, JF; Dedman, JR; Seaton, BA				Mo, Y; Campos, B; Mealy, TR; Commodore, L; Head, JF; Dedman, JR; Seaton, BA			Interfacial basic cluster in annexin V couples phospholipid binding and trimer formation on membrane surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; CRYSTAL-STRUCTURE; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBOTIC SHIELD; ACIDIC PHOSPHOLIPIDS; ELECTRON-MICROSCOPY; MECHANISM; RESOLUTION; PROTEINS; RESIDUES	Annexin V is an abundant eukaryotic protein that binds phospholipid membranes in a Ca2+-dependent manner. In the present studies, site-directed mutagenesis was combined with x-ray crystallography and solution liposome binding assays to probe the functional role of a cluster of interfacial basic residues in annexin V. Four mutants were investigated: R23E, K27E, R61E, and R149E. All four mutants exhibited a significant reduction in adsorption to phospholipid membranes relative to the wild-type protein, and the R23E mutation was the most deleterious. Crystal structures of wild-type and mutant proteins were similar except for local changes in salt bridges involving basic cluster residues. The combined data indicate that Arg(23) is a major determinant for interfacial phospholipid binding and participates in an intermolecular salt bridge that is key for trimer formation on the membrane surface. Together, crystallographic and solution data provide evidence that the interfacial basic cluster is a locus where trimerization is synergistically coupled to membrane phospholipid binding.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45220 USA	Boston University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Seaton, BA (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.			Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709	NICHD NIH HHS [HD40363] Funding Source: Medline; NIDDK NIH HHS [DK-46433] Funding Source: Medline; NIGMS NIH HHS [GM-55445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM055445] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Avila-Sakar AJ, 2000, J STRUCT BIOL, V130, P54, DOI 10.1006/jsbi.2000.4246; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; BEWLEY MC, 1993, BIOCHEMISTRY-US, V32, P3923, DOI 10.1021/bi00066a011; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burden LM, 1999, BIOCHEMISTRY-US, V38, P15141, DOI 10.1021/bi991571a; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; DRIESSEN HPC, 1992, FEBS LETT, V306, P75, DOI 10.1016/0014-5793(92)80841-4; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; Jones T. A., 1992, MANUAL; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lee BI, 1999, BIOCHEMISTRY-US, V38, P7811, DOI 10.1021/bi9906017; Martin BA, 2001, J BIOCHEM-TOKYO, V129, P843, DOI 10.1093/oxfordjournals.jbchem.a002928; Megli FM, 1998, BIOCHEMISTRY-US, V37, P10540, DOI 10.1021/bi9801255; Mollenhauer J, 1997, CELL MOL LIFE SCI, V53, P506, DOI 10.1007/s000180050063; Oling F, 2001, J STRUCT BIOL, V133, P55, DOI 10.1006/jsbi.2000.4337; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; OLOFSSON A, 1994, J STRUCT BIOL, V113, P199, DOI 10.1006/jsbi.1994.1054; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rand JH, 1999, THROMB HAEMOSTASIS, V82, P649; Rand JH, 2000, J AUTOIMMUN, V15, P107, DOI 10.1006/jaut.2000.0410; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; SOPKOVA J, 1993, J MOL BIOL, V234, P816, DOI 10.1006/jmbi.1993.1627; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, BIOCHEMISTRY-US, V33, P10944, DOI 10.1021/bi00202a013; Venien-Bryan C, 1998, BIOPHYS J, V74, P2649, DOI 10.1016/S0006-3495(98)77970-6; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; Wu FJ, 1998, BIOPHYS J, V74, P3273, DOI 10.1016/S0006-3495(98)78034-8; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	43	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2437	2443		10.1074/jbc.M210286200	http://dx.doi.org/10.1074/jbc.M210286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12401794	hybrid			2022-12-25	WOS:000180562000051
J	Smith, CV; Huang, CC; Miczak, A; Russell, DG; Sacchettini, JC; Bentrup, KHZ				Smith, CV; Huang, CC; Miczak, A; Russell, DG; Sacchettini, JC; Bentrup, KHZ			Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CITRATE SYNTHASE; ISOCITRATE LYASE; ANOMALOUS DIFFRACTION; ANGSTROM RESOLUTION; CATALYTIC RESIDUES; GENOME SEQUENCE; GLYOXYLATE; PERSISTENCE	Establishment or maintenance of a persistent infection by Mycobacterium tuberculosis requires the glyoxylate pathway. This is a bypass of the tricarboxylic acid cycle in which isocitrate lyase and malate synthase (GlcB) catalyze the net incorporation of carbon during growth of microorganisms on acetate or fatty acids as the primary carbon source. The glcB gene from M. tuberculosis, which encodes malate synthase, was cloned, and GlcB was expressed in Escherichia coli. The influence of media conditions on expression in M. tuberculosis indicated that this enzyme is regulated differentially to isocitrate lyase. Purified GlcB had K-m values of 57 and 30 muM for its substrates glyoxylate and acetyl coenzyme A, respectively, and was inhibited by bromopyruvate, oxalate, and phosphoenolpyruvate. The GlcB structure was solved to 2.1-Angstrom resolution in the presence of glyoxylate and magnesium. We also report the structure of Glcbeta in complex with the products of the reaction, coenzyme A and malate, solved to 2.7-Angstrom resolution. Coenzyme A binds in a bent conformation, and the details of its interactions are described, together with implications on the enzyme mechanism.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Cornell Univ, Coll Vet Med, Dept Immunol & Microbiol, Ithaca, NY 14853 USA; Univ Szeged, Dept Med Microbiol, H-6701 Szeged, Hungary	Texas A&M University System; Texas A&M University College Station; Cornell University; Szeged University	Russell, DG (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	dgr8@cornell.edu; sacchett@tamu.edu	Russell, David G/N-5280-2019; Russell, David G/D-4533-2009	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046392] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46392] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTER GM, 1990, BIOCHEMISTRY-US, V29, P7557, DOI 10.1021/bi00485a003; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEECKMANS S, 1994, BIOCHEM J, V303, P413, DOI 10.1042/bj3030413; Bentrup KHZ, 1999, J BACTERIOL, V181, P7161; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER J, 1999, SPOCL STRUCTURAL PRO; CIONI M, 1981, COMP BIOCHEM PHYS B, V70, P1, DOI 10.1016/0305-0491(81)90118-8; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOK JR, 1970, J PROTOZOOL, V17, P232, DOI 10.1111/j.1550-7408.1970.tb02362.x; Copley RR, 2000, J MOL BIOL, V303, P627, DOI 10.1006/jmbi.2000.4152; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cozzone AJ, 1998, ANNU REV MICROBIOL, V52, P127, DOI 10.1146/annurev.micro.52.1.127; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Evans CT, 1996, BIOCHEMISTRY-US, V35, P10661, DOI 10.1021/bi960336e; Gerlt JA, 2000, NAT STRUCT BIOL, V7, P171, DOI 10.1038/73249; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; Gupta U D, 1997, Indian J Lepr, V69, P385; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hong PC, 2000, INFECT IMMUN, V68, P4102, DOI 10.1128/IAI.68.7.4102-4107.2000; Howard BR, 2000, BIOCHEMISTRY-US, V39, P3156, DOI 10.1021/bi992519h; Huttner S, 1997, GENE, V188, P239, DOI 10.1016/S0378-1119(96)00817-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannan K B, 1985, Indian J Lepr, V57, P542; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; Kelly BG, 2002, MICROBIOL-SGM, V148, P793, DOI 10.1099/00221287-148-3-793; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; Kuhnel K, 2001, J MOL BIOL, V313, P583, DOI 10.1006/jmbi.2001.5065; Kurz LC, 1998, BIOCHEMISTRY-US, V37, P9724, DOI 10.1021/bi980325g; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MOLINA I, 1994, EUR J BIOCHEM, V224, P541, DOI 10.1111/j.1432-1033.1994.00541.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 2001, INT TABLES CRYSTALLO, VF; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; REINSCHEID DJ, 1994, MICROBIOL-SGM, V140, P3099, DOI 10.1099/13500872-140-11-3099; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; REMINGTON SJ, 1992, CURR TOP CELL REGUL, V33, P209; RUSSOMARIE F, 1993, P NATL ACAD SCI USA, V90, P8194, DOI 10.1073/pnas.90.17.8194; Segel I.H., 1975, ENZYME KINETICS; Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SUNDARAM TK, 1980, ARCH BIOCHEM BIOPHYS, V199, P515, DOI 10.1016/0003-9861(80)90309-4; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANDERWI.E, 1968, EUR J BIOCHEM, V5, P81, DOI 10.1111/j.1432-1033.1968.tb00340.x; Vereecke D, 2002, J BACTERIOL, V184, P1112, DOI 10.1128/jb.184.4.1112-1120.2002; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; WAYNE LG, 1982, INFECT IMMUN, V37, P1042, DOI 10.1128/IAI.37.3.1042-1049.1982; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P4325, DOI 10.1021/bi00013a022; WIEGAND G, 1984, J MOL BIOL, V174, P205, DOI 10.1016/0022-2836(84)90373-5; Wierenga RK, 2001, FEBS LETT, V492, P193, DOI 10.1016/S0014-5793(01)02236-0; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; ZOLLNER H, 1989, HDB ENZYME INHIBITOR	66	121	128	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1735	1743		10.1074/jbc.M209248200	http://dx.doi.org/10.1074/jbc.M209248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12393860	hybrid			2022-12-25	WOS:000180462200050
J	Xu, GM; Gonzalez-Perrett, S; Essafi, M; Timpanaro, GA; Montalbetti, N; Arnaout, MA; Cantiello, HF				Xu, GM; Gonzalez-Perrett, S; Essafi, M; Timpanaro, GA; Montalbetti, N; Arnaout, MA; Cantiello, HF			Polycystin-1 activates and stabilizes the polycystin-2 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-DISEASE; CATION CHANNEL; PROTEIN; PKD2; GENE; INTERACTS	Autosomal dominant polycystic kidney disease (AD-PKD) is a prevalent genetic disorder largely caused by mutations in the PKD1 and PKD2 genes that encode the transmembrane proteins polycystin-1 and -2, respectively. Both proteins appear to be involved in the regulation of cell growth and maturation, but the precise mechanisms are not yet well defined. Polycystin-2 has recently been shown to function as a Ca2+-permeable, non-selective cation channel. Polycystin-2 interacts through its cytoplasmic carboxyl-terminal region with a coiled-coil motif in the cytoplasmic tail of polycystin-1 (P1CC). The functional consequences of this interaction on its channel activity, however, are unknown. In this report, we show that P1CC enhanced the channel activity of polycystin-2. R742X, a disease-causing polycystin-2 mutant lacking the polycystin-1 interacting region, fails to respond to P1CC. Also, P1CC containing a disease-causing mutation in its coiled-coil motif loses its stimulatory effect on wild-type polycystin-2 channel activity. The modulation of polycystin-2 channel activity by polycystin-1 may be important for the various biological processes mediated by this molecular complex.	Massachusetts Gen Hosp, Renal Unit, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Fac Farm & Bioquim, Fac Fisioquim & Quim Anal, RA-1113 Buenos Aires, DF, Argentina; Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina	Harvard University; Massachusetts General Hospital; Harvard University; University of Buenos Aires	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Dept Med, 149 13th St, Charlestown, MA 02129 USA.		Montalbetti, Nicolas/T-4212-2019; Essafi, Makram/V-8411-2019	Montalbetti, Nicolas/0000-0003-2897-9540; 	NIDDK NIH HHS [DK54711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Badenas C, 1999, KIDNEY INT, V55, P1225, DOI 10.1046/j.1523-1755.1999.00368.x; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; SNEDECOR MM, 1973, STAT METHODS, P104; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200	19	83	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1457	1462		10.1074/jbc.M209996200	http://dx.doi.org/10.1074/jbc.M209996200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12407099	hybrid			2022-12-25	WOS:000180462200013
J	Daniel, T; Carling, D				Daniel, T; Carling, D			Functional analysis of mutations in the gamma(2) subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BETA-SUBUNIT; IDENTIFICATION; GLUCOSE; COMPLEX; SUBFAMILY; ISOFORM; STRESS; CELLS; LIVER	Mutations in the gene encoding the gamma(2) subunit of the AMP-activated protein kinase (AMPK) have recently been shown to cause cardiac hypertrophy and ventricular pre-excitation (Wolff-Parkinson-White syndrome). We have examined the effect of four of these mutations on AMPK activity. The mutant gamma(2) polypeptides are all able to form functional complexes following co-expression with either alpha(1)beta(1) or alpha(2)beta(1) in mammalian cells. None of the mutations caused any detectable change in the phosphorylation of threonine 172 within the alpha subunit of AMPK. Consequently, in the absence of an appropriate stimulus the mutant complexes, like the wild-type complex, exist in an inactive form demonstrating that the mutations do not lead to constitutive activation of the kinase. Three of the mutations we studied occur within the cystathionine beta-synthase (CBS) domains of gamma(2). Two of these mutations lead to a marked decrease in AMP dependence, whereas the third reduces AMP sensitivity. These findings suggest that the CBS domains play an important role in AMP-binding within the complex. In contrast, a fourth mutation, which lies between adjacent CBS domains, has no significant effect on AMPK activity in vitro. These results indicate that mutations in gamma(2) have different effects on AMPK function, suggesting that they may lead to abnormal development of the heart through distinct mechanisms.	Hammersmith Hosp, Cellular Stress Grp, MRC, Ctr Clin Sci, London W12 0NN, England	Imperial College London	Carling, D (corresponding author), Hammersmith Hosp, Cellular Stress Grp, MRC, Ctr Clin Sci, DuCane Rd, London W12 0NN, England.		Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830				Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bak MI, 1998, AM J PHYSIOL-CELL PH, V274, pC992, DOI 10.1152/ajpcell.1998.274.4.C992; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Daniel T, 2002, BIOCHEM J, V365, P629, DOI 10.1042/BJ20020124; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Kluijtmans LAJ, 1996, J CLIN INVEST, V98, P285, DOI 10.1172/JCI118791; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Miller J.H., 1972, EXPT MOL GENETICS; PACKARD JM, 1954, CIRCULATION, V10, P384, DOI 10.1161/01.CIR.10.3.384; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; ZHENG D, 2001, J APPL PHYSIOL, V91, P1167	37	101	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51017	51024		10.1074/jbc.M207093200	http://dx.doi.org/10.1074/jbc.M207093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397075	hybrid			2022-12-25	WOS:000180177700108
J	Badciong, JC; Haas, AL				Badciong, JC; Haas, AL			MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; POLYUBIQUITIN CHAINS; EMBRYONIC LETHALITY; ACTIVATING ENZYME; MULTIUBIQUITIN CHAIN; MDM2-DEFICIENT MICE; PROTEIN LIGASE; DNA-DAMAGE; C-CBL; DOMAIN	It has been well documented that Mdm2 and its homologue MdmX not only are critical negative regulators of the tumor suppressor p53 but that both Mdm2 and MdmX interact to affect the function of the other. The mechanisms through which these effects are manifested, however, remain unclear. Although Mdm2 has been established as a RING finger ubiquitin ligase, MdmX has not been shown to possess this activity despite the extensive sequence homology between their respective RING finger domains. Here we demonstrate that MdmX acts as a ubiquitin ligase in vitro, being capable of autoubiquitination, as well as mediating the ubiquitination of p53. The addition of Mdm2 to in vitro ubiquitination assays containing MdmX results in a synergistic increase of ubiquitin conjugation. Analysis of the resulting ubiquitin conjugates reveals that this observed synergy reflects an increase in Mdm2 ubiquitination. This study also suggests that ubiquitination of Mdm2 and MdmX may not serve as a signal for degradation, as we show that each are capable of synthesizing non-lysine 48 polyubiquitin chains and, in fact, utilize multiple lysine linkages. Taken together, these findings suggest a more active role for MdmX in the Mdm2-MdmX-p53 regulatory network than has been proposed previously.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baboshina OV, 2001, J BIOL CHEM, V276, P39428, DOI 10.1074/jbc.M106967200; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUNA RMD, 1995, NATURE, V378, P203; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PICKART CM, 1992, J BIOL CHEM, V267, P14418; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shumaker DK, 1998, CELL CALCIUM, V23, P151, DOI 10.1016/S0143-4160(98)90114-2; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strous GJ, 1999, J CELL SCI, V112, P1417; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	54	92	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49668	49675		10.1074/jbc.M208593200	http://dx.doi.org/10.1074/jbc.M208593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393902	hybrid			2022-12-25	WOS:000180028900076
J	Basanez, G; Sharpe, JC; Galanis, J; Brandt, TB; Hardwick, JM; Zimmerberg, J				Basanez, G; Sharpe, JC; Galanis, J; Brandt, TB; Hardwick, JM; Zimmerberg, J			Bax-type apoptotic proteins porate pure lipid bilayers through a mechanism sensitive to intrinsic monolayer curvature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONBILAYER LIPIDS; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHOLIPID-MEMBRANES; LYSOPHOSPHATIDIC ACID; CATALYTIC DOMAIN; LEADER PEPTIDASE; PORE FORMATION; BCL-X(L); PHOSPHATIDYLETHANOLAMINE; MITOCHONDRION	During apoptosis, Bax-type proteins permeabilize the outer mitochondrial membrane to release intermembrane apoptogenic factors into the cytosol via a poorly understood mechanism. We have proposed that Bax and DeltaN76Bcl-X-L (the Bax-like cleavage fragment of Bcl-X-L) function by forming pores that are at least partially composed of lipids (lipidic pore formation). Since the membrane monolayer must bend during lipidic pore formation, we here explore the effect of intrinsic membrane monolayer curvature on pore formation. Nonlamellar lipids with positive intrinsic curvature such as lysophospholipids promoted membrane permeabilization, whereas nonlamellar lipids with negative intrinsic curvature such as diacylglycerol and phosphatidylethanolamine inhibited membrane permeabilization. The differential effects of nonlamellar lipids on membrane permeabilization were not correlated with lipid-induced changes in membrane binding or insertion of Bax or DeltaN76Bcl-X-L. Altogether, these results are consistent with a model whereby Bax-type proteins change the bending propensity of the membrane to form pores comprised at least in part of lipids in a structure of net positive monolayer curvature.	NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA; NIH, Gen Inst Med Sci, Bethesda, MD 20892 USA; Johns Hopkins Sch Publ Hlth & Med, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Publ Hlth & Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Publ Hlth & Med, Dept Neurol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Zimmerberg, J (corresponding author), NICHD, Lab Cellular & Mol Biophys, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	joshz@helix.nih.gov	Basanez, Gorka/L-9509-2014	Basanez, Gorka/0000-0002-7475-7861	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001409] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001409] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alonso A, 2000, BIOCHEMISTRY-US, V39, P14019, DOI 10.1021/bi001739o; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Basanez G, 2002, CELL MOL LIFE SCI, V59, P1478, DOI 10.1007/s00018-002-8523-6; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 2001, J EXP MED, V193, pF11, DOI 10.1084/jem.193.4.F11; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bezrukov SM, 1998, FARADAY DISCUSS, V111, P173; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; CHERNOMORDIK LV, 1985, BIOCHIM BIOPHYS ACTA, V812, P643, DOI 10.1016/0005-2736(85)90257-3; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; Fuller N, 2001, BIOPHYS J, V81, P243, DOI 10.1016/S0006-3495(01)75695-0; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; KELLER SL, 1993, BIOPHYS J, V65, P23, DOI 10.1016/S0006-3495(93)81040-3; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Leikin S, 1996, BIOPHYS J, V71, P2623, DOI 10.1016/S0006-3495(96)79454-7; Lewis JR, 1999, BIOCHEMISTRY-US, V38, P5932, DOI 10.1021/bi9828167; Malev VV, 2002, BIOPHYS J, V82, P1985, DOI 10.1016/S0006-3495(02)75547-1; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Melikov KC, 2001, BIOPHYS J, V80, P1829, DOI 10.1016/S0006-3495(01)76153-X; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Szule JA, 2002, BIOPHYS J, V83, P977, DOI 10.1016/S0006-3495(02)75223-5; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; Wang XD, 2001, GENE DEV, V15, P2922; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; Zimmerberg J, 2000, TRAFFIC, V1, P366, DOI 10.1034/j.1600-0854.2000.010409.x; Zimmerberg J, 1999, SCIENCE, V284, P1475, DOI 10.1126/science.284.5419.1475	40	200	209	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49360	49365		10.1074/jbc.M206069200	http://dx.doi.org/10.1074/jbc.M206069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12381734	hybrid			2022-12-25	WOS:000180028900033
J	Brand, GD; Leite, JRSA; Silva, LP; Albuquerque, S; Prates, MV; Azevedo, RB; Carregaro, V; Silva, JS; Sa, VCL; Brandao, RA; Bloch, C				Brand, GD; Leite, JRSA; Silva, LP; Albuquerque, S; Prates, MV; Azevedo, RB; Carregaro, V; Silva, JS; Sa, VCL; Brandao, RA; Bloch, C			Dermaseptins from Phyllomedusa oreades and Phyllomedusa distincta - Anti-Trypanosoma cruzi activity without cytotoxicity to mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE; FROG-SKIN; BACTERIOCINS; BRUCEI; ACID; TRYPOMASTIGOTES; MICROORGANISMS; ANTIBIOTICS; SELECTIVITY; MAGAININ-2	Amphibian skin secretions are known as a rich source of biologically active molecules, most of which are alkaloids, biogenic amines, and peptides. Dermaseptins are a class of antimicrobial peptides present in tree frogs of the Phyllomedusa genus. They are cationic molecules of 28-34 residues that permeabilize the membrane of Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi, showing little or no hemolytic activity. This work reports the isolation, molecular mass analysis, primary structure determination, biological activities, and potential therapeutic applications of an antimicrobial peptide found in the skin secretion of Phyllomedusa oreades, which is a newly described amphibian species endemic of the Brazilian savanna. DS 01 is a 29-residue-long peptide with a molecular mass of 2793.39 Da showing antibacterial properties against Gram-positive and Gram-negative bacteria in the range of 3-25 mum. Anti-protozoan activity was investigated using T. cruzi in its trypomatigote and epimastigote forms cultivated in both cell culture and blood media. Within 2 h after incubation with DS 01 at a final concentration of similar to6 muM, no protozoan cells were detected. Two synthetic dermaseptins, described previously by our group and named dermadistinctins K and L (DD K and DD L), also had their anti-Trypanosoma cruzi activity investigated and demonstrated similar properties. Toxicity of DS 01 to mouse erythrocytes and white blood cells was evaluated by means of atomic force microscopy and flow cytometry. No morphological alterations were observed at a lytic concentration of DS 01, suggesting its therapeutic value especially as an anti-T. cruzi agent to prevent infections during blood transfusion.	EMBRAPA, Lab Espectrometria Massa, Recursos Geneticos & Biotecnol, BR-70770900 Brasilia, DF, Brazil; Univ Brasilia, Dept Biol Celular, Inst Biol, BR-70910900 Brasilia, DF, Brazil; Univ Brasilia, Dept Genet & Morfol, Inst Biol, BR-70910900 Brasilia, DF, Brazil; Univ Sao Paulo, Dept Ciencias Farmaceuticas, Fac Ciencias Farmaceuticas Ribeirao Preto, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Bioquim & Imunol, Escola Med Ribeirao Preto, Sao Paulo, Brazil; Lab SABIN Anal Clin, Brasilia, DF, Brazil; Univ Brasilia, Inst Biol, BR-70910900 Brasilia, DF, Brazil	Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade de Brasilia; Universidade de Brasilia; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Brasilia	Bloch, C (corresponding author), EMBRAPA, Lab Espectrometria Massa, Recursos Geneticos & Biotecnol, Estacao Parque Biol,Final W5,Asa Norte, BR-70770900 Brasilia, DF, Brazil.	cbloch@cenargen.embrapa.br	Silva, Luciano Paulino/G-4915-2012; de Albuquerque, Sergio/B-9885-2012; Brandão, Reuber A/A-3427-2013; , Reuber/N-5217-2019; Brand, Guilherme/B-5603-2015; Carregaro, Vanessa/D-2913-2012; Silva, Joao/A-4484-2008; Prates, Maura/S-8399-2019; Azevedo, Ricardo/D-6273-2012; Leite, José Roberto/H-9065-2013; Bloch, Carlos/S-8375-2019	Silva, Luciano Paulino/0000-0001-9075-7725; de Albuquerque, Sergio/0000-0003-2530-9226; Brandão, Reuber A/0000-0003-3940-2544; , Reuber/0000-0003-3940-2544; Brand, Guilherme/0000-0002-1615-0009; Silva, Joao/0000-0002-3410-3927; Prates, Maura/0000-0002-0206-5890; Leite, José Roberto/0000-0002-1096-3236; Carregaro, Vanessa/0000-0002-8435-0766; Bloch Jr, Carlos/0000-0003-2799-6883; Azevedo, Ricardo/0000-0002-2137-9588				ABOUDY Y, 1994, INT J PEPT PROT RES, V43, P573; Agusti R, 2000, MEM I OSWALDO CRUZ, V95, P97, DOI 10.1590/S0074-02762000000100016; Amiche M, 1999, FEBS LETT, V456, P352, DOI 10.1016/S0014-5793(99)00964-3; Ammar B, 1998, BIOCHEM BIOPH RES CO, V247, P870, DOI 10.1006/bbrc.1998.8879; [Anonymous], LAB HEMATOL; Batista CVF, 1999, PEPTIDES, V20, P679, DOI 10.1016/S0196-9781(99)00050-9; BIGNAMI GS, 1993, TOXICON, V31, P817, DOI 10.1016/0041-0101(93)90389-Z; BRANDAO RAA, 2002, IN PRESS J HERPETOL; BULET P, 1991, J BIOL CHEM, V266, P24520; COPPENS I, 1995, MOL BIOCHEM PARASIT, V73, P179, DOI 10.1016/0166-6851(95)00114-G; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; Dathe M, 2002, BBA-BIOMEMBRANES, V1558, P171, DOI 10.1016/S0005-2736(01)00429-1; Dathe M, 2001, FEBS LETT, V501, P146, DOI 10.1016/S0014-5793(01)02648-5; Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200; GILLETT MPT, 1991, T ROY SOC TROP MED H, V85, P612, DOI 10.1016/0035-9203(91)90365-6; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; Hove LV, 2000, LAB HEMATOL, V6, P93; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Krugliak M, 2000, ANTIMICROB AGENTS CH, V44, P2442, DOI 10.1128/AAC.44.9.2442-2451.2000; La Rocca P, 1999, BBA-BIOMEMBRANES, V1462, P185, DOI 10.1016/S0005-2736(99)00206-0; LADHOKIN AS, 2001, BIOCHIM BIOPHYS ACTA, V1514, P253; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOCAIO A, 1997, WORLD HLTH STAT Q, V50, P195; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; Naka H, 1998, BUNSEKI KAGAKU, V47, P203; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Park CB, 1996, BIOCHEM BIOPH RES CO, V218, P408, DOI 10.1006/bbrc.1996.0071; Pierre TN, 2000, EUR J BIOCHEM, V267, P370, DOI 10.1046/j.1432-1327.2000.01012.x; Prenner EJ, 2001, BBA-BIOMEMBRANES, V1510, P83, DOI 10.1016/S0005-2736(00)00337-0; Rodrigues CO, 2001, J EUKARYOT MICROBIOL, V48, P588, DOI 10.1111/j.1550-7408.2001.tb00195.x; Salzet M, 2001, TRENDS IMMUNOL, V22, P285, DOI 10.1016/S1471-4906(01)01895-6; Shai Y, 2001, PEPTIDES, V22, P1629, DOI 10.1016/S0196-9781(01)00498-3; SILVA JS, 1992, MEM I OSWALDO CRUZ, V87, P345, DOI 10.1590/S0074-02761992000300003; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; STORINO R, 1997, MED B AIRES, V57, P512; VENEMA K, 1995, TRENDS MICROBIOL, V3, P299, DOI 10.1016/S0966-842X(00)88958-1; VOORHEIS HP, 1979, BIOCHEM J, V180, P11, DOI 10.1042/bj1800011; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5	47	95	105	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49332	49340		10.1074/jbc.M209289200	http://dx.doi.org/10.1074/jbc.M209289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379643	hybrid			2022-12-25	WOS:000180028900030
J	Chen, X; Resh, MD				Chen, X; Resh, MD			Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; METHYL-BETA-CYCLODEXTRIN; EGF-RECEPTOR; LIPID RAFTS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CELL-MEMBRANES; PC12 CELLS; KINASE; TRANSACTIVATION	We recently demonstrated that depletion of plasma membrane cholesterol with methyl-beta-cyclodextrin (MbetaCD) caused activation of MAPK (Chen, X., and Resh, M. D. (2001) J. Biol. Chem. 276, 34617-34623). MAPK activation was phosphatidylinositol 3-kinase (PI3K)-dependent and involved increased tyrosine phosphorylation of the p85 subunit of PI3K. We next determined whether MbetaCD treatment induced tyrosine phosphorylation of other cellular proteins. Here we report that cholesterol depletion of serum-starved COS-1 cells with MbetaCD or filipin caused an increase in Tyr(P) levels of a 180-kDa protein that was identified as the epidermal growth factor receptor (EGFR). Cross-linking experiments showed that MbetaCD induced dimerization of EGFR, indicative of receptor activation. Reagents that block release of membrane-bound EGFR ligands did not affect MbetaCD-induced tyrosine phosphorylation of EGFR, indicating that MbetaCD activation of EGFR is ligand-independent. Moreover, MbetaCD treatment resulted in increased tyrosine phosphorylation. of EGFR downstream targets and Ras activation. Incubation of cells with the specific EGFR inhibitor AG4178 blocked MbetaCD-induced phosphorylation of EGFR, SHC, phospholipase C-gamma, and Gab-1 as well as MAPK activation. We conclude that cholesterol depletion from the plasma membrane by MbetaCD causes ligand-independent activation of EGFR, resulting in MAPK activation by PI3K and Ras-dependent mechanisms. Moreover, these studies reveal a novel mode of action of MbetaCD, in addition to its ability to disrupt membrane rafts.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.			chen, xu/0000-0003-2524-4979; Resh, Marilyn/0000-0001-6118-9466	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; ALLAND L, 1994, J BIOL CHEM, V269, P16701; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; Boerner JL, 2000, J CELL SCI, V113, P935; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Lijnen P, 1996, METHOD FIND EXP CLIN, V18, P123; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; MCGOOKEY DJ, 1983, J CELL BIOL, V96, P1273, DOI 10.1083/jcb.96.5.1273; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ringerike T, 2002, J CELL SCI, V115, P1331; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Wei ZH, 2001, AM J PHYSIOL-HEART C, V281, pH2226, DOI 10.1152/ajpheart.2001.281.5.H2226; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	58	143	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49631	49637		10.1074/jbc.M208327200	http://dx.doi.org/10.1074/jbc.M208327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397069	hybrid			2022-12-25	WOS:000180028900070
J	Koike, K; Oleschuk, CJ; Haimeur, A; Olsen, SL; Deeley, RG; Cole, SPC				Koike, K; Oleschuk, CJ; Haimeur, A; Olsen, SL; Deeley, RG; Cole, SPC			Multiple membrane-associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION-TRANSPORTER; ATP-DEPENDENT TRANSPORT; AMINO-ACID RESIDUE; LEUKOTRIENE C-4; PSEUDOXANTHOMA ELASTICUM; ABC TRANSPORTER; TERMINAL HALF; GLUTATHIONE; GENE; MUTATIONS	The multidrug resistance protein, MRP1, is a clinically important ATP-binding cassette transporter in which the three membrane-spanning domains (MSDs), which contain up to 17 transmembrane (TM) helices, and two nucleotide binding domains (NEDs) are configured MSD1-MSD2-NIBD1-MSD3-NBD2. In tumor cells, MRP1 confers resistance to a broad spectrum of drugs, but in normal cells, it functions as a primary active transporter of organic anions such as leukotriene C-4 and 17beta-estradiol 17beta-(D-glucuronide). We have previously shown that mutation of TM17-Trp(1246) eliminates 17beta-estradiol 17p-(D-glucuronide) transport and drug resistance conferred by MRP1 while leaving leukotriene C4 transport intact. By mutating the 11 remaining Trp residues that are in predicted TM segments of MRP1, we have now determined that five of them are also major determinants of MRP1 function. Ala substitution of three of these residues, Trp(445) (TMS), Trp(553) (TM10), and Trp(1198) (TM16), eliminated or substantially reduced transport levels of five organic anion substrates of MRP1. In contrast, Ala substitutions of Trp(361) (TM7) and Trp(459) (TM9) caused a more moderate and substrate-selective reduction in MRP1 function. More conservative substitutions (Tyr and Phe) of the TrP445, Trp 553, and Trp(1198) mutants resulted in substrate selective retention of transport in some cases (Trp(445) and Trp(1198)) but not others (Trp553). Our findings suggest that the bulky polar aromatic indole side chain of each of these five Trp residues contributes significantly to the transport activity and substrate specificity of MRP1.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, 3rd Floor,Botterell Hall, Kingston, ON K7L 3N6, Canada.	coles@post.queensu.ca	Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 2002, ENCY CANC, P255; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; DEELEY RG, 2002, ABC PROTEINS BACTERI, P393; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kwan T, 2000, MOL PHARMACOL, V58, P37, DOI 10.1124/mol.58.1.37; Le Saux O, 2001, AM J HUM GENET, V69, P749, DOI 10.1086/323704; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1993, J BIOL CHEM, V268, P19965; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; OLESCHUK CJ, 2003, IN PRESS AM J PHYSL, V284; Orozco L, 2000, HUM GENET, V106, P360, DOI 10.1007/s004390051051; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1999, BIOCHEM PHARMACOL, V58, P557; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Sirangelo I, 2000, EUR J BIOCHEM, V267, P3937, DOI 10.1046/j.1432-1327.2000.01401.x; Strandberg E, 2002, BIOCHEMISTRY-US, V41, P7190, DOI 10.1021/bi012047i; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Tsujii H, 1999, GASTROENTEROLOGY, V117, P653, DOI 10.1016/S0016-5085(99)70459-2; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Wallace BA, 1999, ADV EXP MED BIOL, V467, P789; Wallace LA, 2000, BBA-PROTEIN STRUCT M, V1478, P325, DOI 10.1016/S0167-4838(00)00023-6; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; ZIELENSKI J, 1995, HUM MUTAT, V5, P43, DOI 10.1002/humu.1380050106	68	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49495	49503		10.1074/jbc.M206896200	http://dx.doi.org/10.1074/jbc.M206896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388549	hybrid			2022-12-25	WOS:000180028900052
J	Borges, CR; Geddes, T; Watson, JT; Kuhn, DM				Borges, CR; Geddes, T; Watson, JT; Kuhn, DM			Dopamine biosynthesis is regulated by S-glutathionylation - Potential mechanism of tyrosine hydroxylase inhibition during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; NEURODEGENERATIVE-DISEASES; RAT-BRAIN; GLUTATHIOLATION; INACTIVATION; THIOLATION; PEROXYNITRITE; NITRATION; THIOLTRANSFERASE	Tyrosine hydroxylase (TH), the initial and rate-limiting enzyme in the biosynthesis of the neurotransmitter dopamine, is inhibited by the sulfhydryl oxidant diamide in a concentration-dependent manner. The inhibitory effect of diamide on TH catalytic activity is enhanced significantly by GSH. Treatment of TH with diamide in the presence of [S-35]GSH results in the incorporation of S-35 into the enzyme. The effect of diamide-GSH on TH activity is prevented by dithiothreitol (DTT), as is the binding of [S-35]GSH, indicating the formation of a disulfide linkage between GSH and TH protein cysteinyls. Loss of TH catalytic activity caused by diamide-GSH is partially recovered by DTT and glutaredoxin, whereas the disulfide linkage of GSH with TH is completely reversed by both. Treatment of intact PC12 cells with diamide results in a concentration-dependent inhibition of TH activity. Incubation of cells with [S-35]cysteine, to label cellular GSH prior to diamide treatment followed by immunoprecipitation of TH shows that the loss of TH catalytic activity is associated with a DTT-reversible incorporation of [S-35]GSH into the enzyme. A combination of matrix-assisted laser desorption/ionization/mass spectrometry and liquid chromatography/tandem mass spectrometry was used to identify the sites of S-glutathionylation in TH. Six cysteines (177, 249, 263, 329, 330, and 380) of the seven cysteine residues in TH were confirmed as substrates for modification. Only Cys-311 was not S-glutathionylated. These results establish that TH activity is influenced in a reversible manner by S-glutathionylation and suggest that cellular GSH may regulate dopamine biosynthesis under conditions of oxidative stress or drug-induced toxicity.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Wayne State University; Wayne State University; Michigan State University	Kuhn, DM (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 2125 Scott Hall,540 E Cranfield, Detroit, MI 48201 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010756] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10756] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Balijepalli S, 1999, J NEUROCHEM, V72, P1170, DOI 10.1046/j.1471-4159.1999.0721170.x; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Ehrhart J, 2001, J NEUROCHEM, V77, P1496, DOI 10.1046/j.1471-4159.2001.00355.x; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FERRARO TN, 1986, NEUROPHARMACOLOGY, V25, P1071, DOI 10.1016/0028-3908(86)90205-4; Gibb J W, 1997, NIDA Res Monogr, V173, P128; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUTTERIDGE JMC, 1994, ANN NY ACAD SCI, V738, P201; Harold C, 2000, EUR J PHARMACOL, V400, P99, DOI 10.1016/S0014-2999(00)00392-7; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Kuhn DM, 1999, J NEUROSCI, V19, P10289; KUHN DM, 1987, NEUROCHEM INT, V11, P463, DOI 10.1016/0197-0186(87)90036-2; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; KUHN DM, 2002, J BIOL CHEM; LERNER P, 1978, NEUROCHEM RES, V3, P641, DOI 10.1007/BF00963765; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Moszczynska A, 1998, NEUROSCI LETT, V255, P49, DOI 10.1016/S0304-3940(98)00711-3; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Owen AD, 1996, ANN NY ACAD SCI, V786, P217, DOI 10.1111/j.1749-6632.1996.tb39064.x; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; PERUMAL AS, 1989, BRAIN RES, V504, P139, DOI 10.1016/0006-8993(89)91611-9; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Slama P, 2001, FEBS LETT, V491, P55, DOI 10.1016/S0014-5793(01)02147-0; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	51	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48295	48302		10.1074/jbc.M209042200	http://dx.doi.org/10.1074/jbc.M209042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376535	hybrid			2022-12-25	WOS:000179789600044
J	Mandrich, L; Caputo, E; Martin, BM; Rossi, M; Manco, G				Mandrich, L; Caputo, E; Martin, BM; Rossi, M; Manco, G			The Aes protein and the monomeric alpha-galactosidase from Escherichia coli form a non-covalent complex - Implications for the regulation of carbohydrate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ARCHAEON ARCHAEOGLOBUS-FULGIDUS; SEQUENCE SIMILARITY; TRANSCRIPTIONAL ACTIVATOR; THERMOPHILIC ESTERASE; THERMOSTABLE ESTERASE; HIGH-TEMPERATURE; MALTOSE SYSTEM; SUBFAMILY; EXPRESSION	Aes, a 36-kDa acetylesterase from Escherichia coli, belongs to the hormone-sensitive lipase family, and it is involved in the regulation of MaIT, the transcriptional activator of the maltose regulon. The activity of MaIT is depressed through a direct protein-protein interaction with Aes. Although the effect is clear-cut, the meaning of this interaction and the conditions that trigger it still remain elusive. To perform a comparative thermodynamic study between the mesophilic Aes protein and two homologous thermostable enzymes, Aes was overexpressed in E. coli and purified. At the last step of the purification procedure the enzyme was eluted from a Mono Q HR 5/5 column as a major form migrating, anomalously, at 56 kDa on a calibrated Superdex 75 column. A minor peak that contains the Aes protein and a polypeptide of 50 kDa was also detected. By a combined analysis of size-exclusion chromatography and surface-enhanced laser desorption ionization-time of flight mass spectrometry, it was possible to demonstrate the presence in this peak of a stable 87-kDa complex containing the Aes protein itself and the 50-kDa polypeptide in a 1:1 ratio. The homodimeric molecular species of Aes and of the 50-kDa polypeptide were also detected. The esterase activity associated with the 87-kDa complex, when assayed with p-nitrophenyl butanoate as substrate, proved 6-fold higher than the activity of the major Aes form of 56 kDa. Amino-terminal sequencing highlighted that the 50-kDa partner of Aes in the complex was the alpha-galactosidase from E. coli. The E. coli cells harboring plasmid pT7-SCII-aes and, therefore, expressing Aes were hampered in their growth on a minimal medium containing raffinose as a sole carbon source. Because alpha-galactosidase is involved in the metabolism of raffinose, the above findings suggest a potential role of Aes in the regulation of carbohydrate metabolism in E. coli.	CNR, Ist Biochim Prot, I-80131 Naples, Italy; NIMH, Unit Mol Struct, Bethesda, MD 20892 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Manco, G (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	manco@dafne.ibpe.na.cnr.it	Mandrich, Luigi/AAH-9328-2020; MANDRICH, Luigi/L-7198-2019; Caputo, Emilia/AAW-1300-2020; Manco, Giuseppe/AAL-3777-2020	Mandrich, Luigi/0000-0002-0025-9544; MANDRICH, Luigi/0000-0002-0025-9544; Manco, Giuseppe/0000-0001-6191-3952; CAPUTO, EMILIA/0000-0002-6485-8802				Belyaeva TA, 2000, MOL MICROBIOL, V36, P211, DOI 10.1046/j.1365-2958.2000.01849.x; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BROWN WC, 1993, GENE, V127, P99, DOI 10.1016/0378-1119(93)90622-A; Clausen T, 2000, EMBO J, V19, P831, DOI 10.1093/emboj/19.5.831; D'Auria S, 2000, PROTEINS, V38, P351, DOI 10.1002/(SICI)1097-0134(20000301)38:4<351::AID-PROT1>3.0.CO;2-6; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; De Schrijver A, 1999, MICROBIOL-UK, V145, P1287, DOI 10.1099/13500872-145-6-1287; De Simone G, 2000, J MOL BIOL, V303, P761, DOI 10.1006/jmbi.2000.4195; De Simone G, 2001, J MOL BIOL, V314, P507, DOI 10.1006/jmbi.2001.5152; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; Del Vecchio P, 2002, BIOCHEMISTRY-US, V41, P1364, DOI 10.1021/bi011146t; Joly N, 2002, J BIOL CHEM, V277, P16606, DOI 10.1074/jbc.M200991200; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Manco G, 2000, ARCH BIOCHEM BIOPHYS, V373, P182, DOI 10.1006/abbi.1999.1497; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Manco G, 2001, J BIOL CHEM, V276, P37482, DOI 10.1074/jbc.M103017200; NAGAO Y, 1988, BIOCHEM BIOPH RES CO, V151, P236, DOI 10.1016/0006-291X(88)90584-0; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; Schlegel A, 2002, J BACTERIOL, V184, P3069, DOI 10.1128/JB.184.11.3069-3077.2002; SCHMID K, 1976, EUR J BIOCHEM, V67, P95, DOI 10.1111/j.1432-1033.1976.tb10637.x; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; Valdez F, 1999, MICROBIOL-UK, V145, P2365, DOI 10.1099/00221287-145-9-2365; Weinberger S R, 2000, Pharmacogenomics, V1, P395, DOI 10.1517/14622416.1.4.395; ZDICH E, 1995, J BACTERIOL, V177, P5035	32	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48241	48247		10.1074/jbc.M207398200	http://dx.doi.org/10.1074/jbc.M207398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374803	hybrid			2022-12-25	WOS:000179789600037
J	Valbuzzi, A; Yanofsky, C				Valbuzzi, A; Yanofsky, C			Zinc is required for assembly and function of the anti-trp RNA-binding attenuation protein, AT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; MOLECULAR CHAPERONE; UNKNOWN FUNCTION; TRAP; DNAJ; DOMAIN	The anti-TRAP protein (AT) of Bacillus subtilis regulates expression of the trp operon and other genes concerned with tryptophan metabolism. AT acts by inhibiting the tryptophan-activated trp RNA-binding attenuation protein (TRAP). AT is an oligomer of identical 53-residue polypeptides; it is produced in response to the accumulation of uncharged tRNA(Trp). Each AT polypeptide has two cysteine-rich clusters that correspond to the signature motif of the cysteine-rich zinc-binding domain of the chaperone protein DnaJ. Here we characterize the putative zinc-binding domain of AT and establish the importance of zinc for AT assembly and activity. AT is shown to contain Zn(II) at a ratio of one ion per monomer. Bound zinc is necessary for maintenance of the quaternary structure of AT; the removal of zinc converts the AT complex into inactive monomers. All four cysteine residues in the AT polypeptide are involved in Zn(II) coordination. Chemical cross-linking analyses indicate that the AT functional oligomer is a hexamer composed of two trimers. Substituting alanine for any cysteine residue of AT results in rapid degradation of the mutant protein in vivo. We propose a model for the AT trimer in which three AT chains are held together by three zinc atoms, each coordinated by the N-terminal segment and the C-terminal. segment of separate AT polypeptides.	Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA.							Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Azem A, 1998, METHOD ENZYMOL, V290, P253, DOI 10.1016/S0076-6879(98)90024-6; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Gollnick P., 2002, BACILLUS SUBTILIS IT, P233; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; STEINBERG W, 1974, J BACTERIOL, V117, P1023, DOI 10.1128/JB.117.3.1023-1034.1974; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Valbuzzi A, 2002, J BIOL CHEM, V277, P10608, DOI 10.1074/jbc.M111813200; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	25	14	14	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48574	48578		10.1074/jbc.M208980200	http://dx.doi.org/10.1074/jbc.M208980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12386162	hybrid			2022-12-25	WOS:000179789600079
J	Badran, BM; Wolinsky, SM; Burny, A; Willard-Gallo, KE				Badran, BM; Wolinsky, SM; Burny, A; Willard-Gallo, KE			Identification of three NFAT binding motifs in the 5 '-upstream region of the human CD3 gamma gene that differentially bind NFATc1, NFATc2, and NF-kappa B p50	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; IMMUNE-DEFICIENCY SYNDROME; NECROSIS-FACTOR-ALPHA; ANTIGEN RECEPTOR; DOWN-REGULATION; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; CYCLOSPORINE-A; LEUKEMIA-CELLS	Human immunodeficiency virus, type 1 (HIV-1) infection of CD4(+) T cells progressively abrogates T cell receptor (TCR)-CD3 function and surface expression by specifically interfering with CD3gamma gene transcription. Our data show that the loss of CD3gamma transcripts begins very early after infection and accumulates to a >90% deficiency before a significant effect on surface receptor density is apparent. Blocking TCR-CD3-directed NFAT activation with cyclosporin A provokes a partial re-expression of CD3gamma gene transcripts and surface complexes in a time- and dose-dependent manner. We have identified three NFAT consensus sequences (5'-GGAAA-3') in the 5'-upstream region of the human CD3gamma gene at: -124 to -120 (NFAT(gamma1)), -384 to -380 (NFAT(gamma2)), and +450 to +454 (NFAT(gamma3)) from the first transcription initiation site. Using electrophoretic mobility shift and supershift assays, we show that NFATc2 alone binds to the NFAT(gamma2) motif, however, complexes containing either NFATc2 or NFATc1 plus NF-kappaB p50 bind to the NFAT(gamma1) and NFAT(gamma3) sites. We further demonstrate that NFATc1 and NF-kappaB p50 bind in the same protein-DNA complex and that a fourth Ala added to the core sequence (5'-GGAAA (A) under bar -3') in NFAT(gamma1), and NFAT(gamma3) is critical for their binding. Finally, we have shown that an increase in the binding of nuclear NFATc2, NFATc1, and NF-kappaB p50 to these three motifs is correlated with a progressive loss of CD3gamma transcripts after HIV-1 infection.	Univ Brussels, Fac Med, Lab Expt Hematol, B-1000 Brussels, Belgium; Northwestern Univ, Sch Med, Dept Med, Div Infect Dis, Chicago, IL 60611 USA	Northwestern University	Willard-Gallo, KE (corresponding author), Univ Brussels, Fac Med, Lab Expt Hematol, 121 Blvd Waterloo, B-1000 Brussels, Belgium.		Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Willard-Gallo, Karen/0000-0002-1150-1295	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD37356] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BORIES JC, 1990, J EXP MED, V171, P75, DOI 10.1084/jem.171.1.75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; CLEVERS H, 1989, EMBO J, V8, P2527, DOI 10.1002/j.1460-2075.1989.tb08390.x; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; DAUTRYVARSAT A, 1988, BLOOD, V72, P588; DEWAAL M, 1990, J IMMUNOL, V145, P2297; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN BF, 1990, IMMUNOGENETICS, V31, P13, DOI 10.1007/BF00702484; FURUKAWA M, 1994, J IMMUNOL, V152, P5768; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Geertsma MF, 1999, J INFECT DIS, V180, P649, DOI 10.1086/314941; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; Howe AYM, 1998, J VIROL, V72, P9827, DOI 10.1128/JVI.72.12.9827-9834.1998; Itoh Y, 1999, J IMMUNOL, V162, P2073; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P2204, DOI 10.1073/pnas.88.6.2204; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lauritsen JPH, 1998, J IMMUNOL, V161, P260; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Long HY, 1996, EXP HEMATOL, V24, P1402; LURIA S, 1987, EMBO J, V6, P3307, DOI 10.1002/j.1460-2075.1987.tb02650.x; LUSSO P, 1991, J IMMUNOL, V147, P685; LUTON F, 1994, J IMMUNOL, V153, P63; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; MATSUOKA M, 1986, BLOOD, V67, P1070; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; MCDOUGALL S, 1988, SCIENCE, V241, P205, DOI 10.1126/science.2968651; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; Rubin B, 2002, SCAND J IMMUNOL, V55, P111, DOI 10.1046/j.1365-3083.2002.01044.x; Schaefer TM, 2000, J VIROL, V74, P3273, DOI 10.1128/JVI.74.7.3273-3283.2000; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Segura I, 1999, J VIROL, V73, P5207, DOI 10.1128/JVI.73.6.5207-5213.1999; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Stefanova I, 1996, J CLIN INVEST, V98, P1290, DOI 10.1172/JCI118915; SUZUSHIMA H, 1991, CANCER RES, V51, P6084; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; TSUDA H, 1984, BRIT J CANCER, V50, P843, DOI 10.1038/bjc.1984.266; TUNNACLIFFE A, 1990, NUCLEIC ACIDS RES, V18, P459, DOI 10.1093/nar/18.3.459; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x; TUNNACLIFFE A, 1988, EUR J IMMUNOL, V18, P1639, DOI 10.1002/eji.1830181027; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; von Essen M, 2002, J IMMUNOL, V168, P4519, DOI 10.4049/jimmunol.168.9.4519; WANG L, 1995, INT IMMUNOL, V7, P1627, DOI 10.1093/intimm/7.10.1627; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585; Willard-Gallo KE, 2001, EUR J IMMUNOL, V31, P969, DOI 10.1002/1521-4141(200104)31:4<969::AID-IMMU969>3.0.CO;2-2; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713; WillardGallo KE, 1996, AIDS RES HUM RETROV, V12, P715, DOI 10.1089/aid.1996.12.715; WILLARDGALLO KE, 1986, RECENT PROGR 2 DIMEN, P205; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Yang T, 2001, J BIOL CHEM, V276, P39569, DOI 10.1074/jbc.M102961200; YSSEL H, 1989, J IMMUNOL, V142, P2279; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zauli G, 1996, J IMMUNOL, V157, P2216; Zier K, 1996, IMMUNOL TODAY, V17, P39, DOI 10.1016/0167-5699(96)80567-6	96	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47136	47148		10.1074/jbc.M206330200	http://dx.doi.org/10.1074/jbc.M206330200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12374807	hybrid			2022-12-25	WOS:000179663700040
J	Jacques, KM; Nie, ZZ; Stauffer, S; Hirsch, DS; Chen, LX; Stanley, KT; Randazzo, PA				Jacques, KM; Nie, ZZ; Stauffer, S; Hirsch, DS; Chen, LX; Stanley, KT; Randazzo, PA			Arf1 dissociates from the clathrin adaptor GGA prior to being inactivated by arf GTPase-activating proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; BINDING PROTEINS; AMINO-TERMINUS; IMPORTIN-BETA; CHOLERA-TOXIN; NONCATALYTIC DOMAIN; KDEL RECEPTOR; GOLGI-COMPLEX; RAN-GTP; TRANSPORT	The effectors of monomeric GTP-binding proteins can influence interactions with GTPase-activating proteins (GAPs) in two ways. In one case, effector and GAP binding to the GTP-binding protein is mutually exclusive. In another case, the GTP-binding protein bound to an effector is the substrate for the GTPase-activating protein. Here predictions for these two mechanisms were tested for the Arf1 effector GGA and ASAP family Arf GAPs. GGA inhibited Arf GAP activity of ASAP1, AGAP1, ARAP1, and Arf GAP1 and inhibited binding of Arf1.GTPgammaS to AGAP1 with K-i values correlating with the K-d for the GGA.Arf1 complex. ASAP1 blocked Arf1.GTPgammaS binding to GGA with a K-i similar to the (K)d for the ASAP-Arf1-GTPgammaS complex. No interaction of GGA with ASAP1 was detected. Consistent with GGA sequestering Arf from GAPs, overexpression of GGA slowed the rate of Arf dissociation from the Golgi apparatus following treatment with brefeldin A. Mutational analysis revealed the amino-terminal a-helix and switch I of Arf1 contributed to interaction with both GGA and GAPs. These data exclude the mechanism previously documented for Arf GAP1/coatomer in which Arf1 is inactivated in a tripartite complex. Instead, termination of Arf1 signals mediated through GGA require that Arf1-GTP dissociates from GGA prior to interaction with GAP and consequent hydrolysis of GTP.	NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Randazzo, PA (corresponding author), NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 6032, Bethesda, MD 20892 USA.							Andreev J, 1999, MOL CELL BIOL, V19, P2338; Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Geyer M, 1999, BIOCHEMISTRY-US, V38, P11250, DOI 10.1021/bi9904306; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HONG JX, 1994, J BIOL CHEM, V269, P9743; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Kuai J, 2000, J BIOL CHEM, V275, P4022, DOI 10.1074/jbc.275.6.4022; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; RANDAZZO P, 2000, SCI STKE; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 2001, METHOD ENZYMOL, V329, P343; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	49	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47235	47241		10.1074/jbc.M208875200	http://dx.doi.org/10.1074/jbc.M208875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12376537	hybrid			2022-12-25	WOS:000179663700051
J	Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK				Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK			Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells	ONCOGENE			English	Article						VEGF; BRCA1; estrogen; estrogen receptors; breast cancer cells; transcriptional regulation	MAMMARY-CARCINOMA CELLS; EXON 7-ENCODED DOMAIN; TYROSINE KINASE; FACTOR GENE; MITOGENIC STIMULATION; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; OVARIAN-CANCER; TUMOR-CELLS; ANGIOGENESIS	Mutational inactivation of BRCA1 confers increased risk for breast cancer. However, the underlying basis for the breast tissue-restricted, tumor-suppressive properties of BRCA1 remains poorly defined. Here, we show that BRCA1 and the estrogen receptor alpha (ER-alpha) modulated vascular endothelial growth factor (VEGF) gene transcription and secretion in breast cancer cells. ER-alpha interacted in vitro and in vivo with BRCA1, and this interaction was mediated by the AF-2 domain of ER-alpha and two domains of BRCA1, the amino-acid residues 1-306 and 428-683. Endogenous interaction of ER-alpha with BRCA1 was observed in normal MCF-10A breast epithelial cells and in breast cancer cells (MCF-7 and T47D), and this interaction was significantly reduced in the presence of estrogen. Furthermore, ER-alpha induced activation of VEGF gene transcription, using human VEGF promoter-luciferase reporter constructs. The AF-2 domain of ER-alpha was also shown to induce VEGF gene transcription activation similar to that obtained with the full-length ER-alpha. However, in the presence of BRCA1, VEGF gene transcription activation and VEGF protein secretion were significantly inhibited in a dose-dependent manner. The BRCA1 domain of 1-683 amino acid residues was required for this inhibition of VEGF gene transcription activation. Three mutated forms of BRCA1 (A1708E, M1775R and Y1853X), that have been identified in familial breast cancers, failed to associate with ER-alpha and to suppress VEGF promoter activity and VEGF protein secretion. Overexpression of wild-type BRCA1 in HCC-1937 breast cancer cells that lack endogenous functional BRCA1 significantly reduced VEGF secretion in these cells. These results demonstrate a novel pathogenic mechanism whereby mutations in BRCA1, via their interaction with ER-alpha, could promote tumorigenesis through the hormonal regulation of mammary epithelial cell proliferation and impaired VEGF function, which may lead to cancer growth and angiogenesis.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Avraham, HK (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA076226, R21CA087290] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87290, CA76226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2000, CANCER RES, V60, P7094; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Altucci L, 1996, ONCOGENE, V12, P2315; Bachelder RE, 2001, CANCER RES, V61, P5736; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gasparini G, 1997, ENDOCR-RELAT CANCER, V4, P423, DOI 10.1677/erc.0.0040423; Grunstein J, 1999, CANCER RES, V59, P1592; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hyder SM, 2000, CANCER RES, V60, P3183; Jordan VC, 2001, CANCER RES, V61, P5683; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; Kranz A, 1999, INT J CANCER, V84, P293, DOI 10.1002/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levine AC, 1998, ENDOCRINOLOGY, V139, P4672, DOI 10.1210/en.139.11.4672; LIPPMAN M, 1976, CANCER RES, V36, P4595; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OSBORNE CK, 1983, CANCER RES, V43, P3583; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Santin AD, 1999, EUR J GYNAECOL ONCOL, V20, P177; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tomlinson GE, 1998, CANCER RES, V58, P3237; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weidner Noel, 1996, P167; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; Yoshiji H, 1997, CANCER RES, V57, P3924; Yoshiji H, 1996, CANCER RES, V56, P2013; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	61	97	108	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7730	7739		10.1038/sj.onc.1205971	http://dx.doi.org/10.1038/sj.onc.1205971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400015	Bronze			2022-12-25	WOS:000178756200012
J	Raju, GP; Dimova, N; Klein, PS; Huang, HC				Raju, GP; Dimova, N; Klein, PS; Huang, HC			SANE, a novel LEM domain protein, regulates bone morphogenetic protein signaling through interaction with Smad1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; NEURAL INDUCTION; XENOPUS-EMBRYOS; I RECEPTORS; VENTRALIZING FACTOR; SPEMANNS ORGANIZER; MESODERM INDUCTION; PATTERN-FORMATION; TUMOR-SUPPRESSOR; GROWTH-FACTORS	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-beta) superfamily that play important roles in bone formation, embryonic patterning, and epidermal-neural cell fate decisions. BMPs signal through pathway specific mediators such as Smads1 and 5, but the upstream regulation of BMP-specific Smads has not been fully characterized. Here we report the identification of SANE (Smad1 Antagonistic Effector), a novel protein with significant sequence similarity to nuclear envelop proteins such as MAN1. SANE binds to Smad1/5 and to BMP type I receptors and regulates BMP signaling. SANE specifically blocks BMP-dependent signaling in Xenopus embryos and in a mammalian model of bone formation but does not inhibit the TGF-beta/Smad2 pathway. Inhibition of BMP signaling by SANE requires interaction between SANE and Smad1, because a SANE mutant that does not bind Smad1 does not inhibit BMP signaling. Furthermore, inhibition appears to be mediated by inhibition of BMP-induced Smad1 phosphorylation, blocking ligand-dependent nuclear translocation. of Smad1. These studies define a new mode of regulation for intracellular BW/Smad1 signaling.	Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Huang, HC (corresponding author), Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA.				NIAMS NIH HHS [AR45587] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045587] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Aoki H, 2001, J CELL SCI, V114, P1483; Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497; Candia AF, 1997, DEVELOPMENT, V124, P4467; Casellas R, 1998, DEV BIOL, V198, P1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1992, DEVELOPMENT, V115, P573; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GELBART WM, 1989, DEVELOPMENT, V107, P65; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Harland R, 2000, CURR OPIN GENET DEV, V10, P357, DOI 10.1016/S0959-437X(00)00096-4; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONES CM, 1992, DEVELOPMENT, V115, P639; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; Lee KK, 2000, MOL BIOL CELL, V11, P3089, DOI 10.1091/mbc.11.9.3089; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Mullins MC, 1996, DEVELOPMENT, V123, P81; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Ray RP, 2001, CELL, V104, P801, DOI 10.1016/S0092-8674(01)00275-6; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Schier AF, 2001, CURR OPIN GENET DEV, V11, P393, DOI 10.1016/S0959-437X(00)00209-4; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; SIVE HL, 2000, EARLY DEV XENOPUS LA; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; Weinstein DC, 1999, ANNU REV CELL DEV BI, V15, P411, DOI 10.1146/annurev.cellbio.15.1.411; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Wilson PA, 1997, NEURON, V18, P699, DOI 10.1016/S0896-6273(00)80311-6; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu W, 2002, J CELL SCI, V115, P1361; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	67	73	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					428	437		10.1074/jbc.M210505200	http://dx.doi.org/10.1074/jbc.M210505200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12393873	hybrid			2022-12-25	WOS:000180255700057
J	Zhang, Y; Iwasaki, H; Wang, H; Kudo, T; Kalka, TB; Hennet, T; Kubota, T; Cheng, LM; Inaba, N; Gotoh, M; Togayachi, A; Guo, JM; Hisatomi, H; Nakajima, K; Nishihara, S; Nakamura, M; Marth, JD; Narimatsu, H				Zhang, Y; Iwasaki, H; Wang, H; Kudo, T; Kalka, TB; Hennet, T; Kubota, T; Cheng, LM; Inaba, N; Gotoh, M; Togayachi, A; Guo, JM; Hisatomi, H; Nakajima, K; Nishihara, S; Nakamura, M; Marth, JD; Narimatsu, H			Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COLON-CANCER; MOLECULAR-CLONING; CDNA CLONING; O-GLYCOSYLATION; ANTIBODY MLS-128; TANDEM REPEAT; TN ANTIGEN; 3 MEMBERS; IN-VIVO; MUCIN	To date, 10 members of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (pp-GaINAc-T) family have been cloned and analyzed in human. In this study, we cloned and analyzed a novel human pp-GaINAc-T from an NT2 cell cDNA library, and we named it pp-GaINAc-T13. In amino acid sequences, pp-GaINAc-T13 was highly homologous, showing 84.3% identity, to pp-GaINAc-T1. Real time PCR analysis revealed pp-GalNAc-T13 to be highly and restrictively expressed in the brain and present at very low or undetectable levels in other tissues, in contrast to the ubiquitous expression of pp-GalNAc-T1. pp-GakNAc-T13 was abundantly expressed in all neuroblastoma cells examined and primary cultured neurons but not in glioblastoma cells and primary cultured astrocytes. pp-GalNAc-T13 exhibited much stronger activity to transfer GalNAc to mucin peptides, such as Muc5Ac and MUC7, than did pp-GaINAc-T1. In addition, pp-GaINAc-T13 differed in substrate specificity to pp-GaINAc-T1. pp-Gal-NAc-T13 was able to form a triplet Tn epitope, three consecutive GalNAc-Ser/Thr structures, on peptides en- coded in syndecan-3, a proteoglycan expressed in neurons. pp-GalNAc-T13-deficient mice have been established in a previous work. Immunohistochemical study showed a remarkable decrease in Tn antigen expression in the cerebellum of the pp-GalNAc-T13knockout mouse. pp-GalNAc-T13 would be a major enzyme responsible for the synthesis of O-glycan and specifically the Tn antigen epitope in neurons.	Natl Inst Adv Ind Sci & Technol, Glycogene Funct Team, Res Ctr Glycosci, Open Space Lab, Tsukuba, Ibaraki 3058568, Japan; Natl Inst Adv Ind Sci & Technol, Cell Regulat Anal Team, Res Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shiku, Tokyo 1690073, Japan; JGS Japan Genome Solut Inc, Hachioji, Tokyo 1920031, Japan; SRL Inc, Ctr Mol Biol & Cytogenet, Hino, Tokyo 1910002, Japan; Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, San Diego, CA 92103 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Soka Univ, Inst Life Sci, Hachioji, Tokyo 1928577, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); SRL Inc.; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Zurich; Soka University	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Glycogene Funct Team, Res Ctr Glycosci, Open Space Lab, Cent-2,1-1-1 Umezomo, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Narimatsu, Hisashi/M-4757-2018; Togayachi, Akira/M-4144-2018; Kubota, Tomomi/J-1492-2018; Yang, Fang/AAF-3024-2019	Narimatsu, Hisashi/0000-0002-8402-133X; Togayachi, Akira/0000-0003-3600-9149; Kubota, Tomomi/0000-0002-0723-135X; Nishihara, Shoko/0000-0002-1668-2603				Akita K, 2001, CELL STRUCT FUNCT, V26, P271, DOI 10.1247/csf.26.271; Akita K, 2001, J NEUROSCI RES, V65, P595, DOI 10.1002/jnr.1190; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Berndt C, 2001, J CELL BIOCHEM, V82, P246, DOI 10.1002/jcb.1119; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; DAVID L, 1992, APMIS, V100, P162; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GUM JR, 1989, J BIOL CHEM, V264, P6480; Guo JM, 2002, FEBS LETT, V524, P211, DOI 10.1016/S0014-5793(02)03007-7; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HIROHASHI S, 1985, P NATL ACAD SCI USA, V82, P7039, DOI 10.1073/pnas.82.20.7039; HOMA FL, 1993, J BIOL CHEM, V268, P12609; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Kato K, 2001, GLYCOBIOLOGY, V11, P821, DOI 10.1093/glycob/11.10.821; Kato K, 2001, BIOCHEM BIOPH RES CO, V287, P110, DOI 10.1006/bbrc.2001.5562; Kingsley PD, 2000, GLYCOBIOLOGY, V10, P1317, DOI 10.1093/glycob/10.12.1317; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; MANDEL U, 1991, J INVEST DERMATOL, V97, P713, DOI 10.1111/1523-1747.ep12484064; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NAGATA K, 1993, J NEUROSCI RES, V34, P357, DOI 10.1002/jnr.490340313; NAKADA H, 1991, J BIOL CHEM, V266, P12402; NAKADA H, 1993, P NATL ACAD SCI USA, V90, P2495, DOI 10.1073/pnas.90.6.2495; Nakanishi T, 1997, OBSTET GYNECOL, V90, P285, DOI 10.1016/S0029-7844(97)00237-8; Nehrke K, 1998, GLYCOBIOLOGY, V8, P367, DOI 10.1093/glycob/8.4.367; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Tetaert D, 2001, CARBOHYD RES, V333, P165, DOI 10.1016/S0008-6215(01)00135-5; Tetaert D, 2001, BIOCHEM J, V357, P313, DOI 10.1042/0264-6021:3570313; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	54	106	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					573	584		10.1074/jbc.M203094200	http://dx.doi.org/10.1074/jbc.M203094200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407114	hybrid			2022-12-25	WOS:000180255700075
J	Calbo, J; Parreno, M; Sotillo, E; Yong, T; Mazo, A; Garriga, J; Grana, X				Calbo, J; Parreno, M; Sotillo, E; Yong, T; Mazo, A; Garriga, J; Grana, X			G(1) cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA-PROTEIN; ECTOPIC EXPRESSION; GROWTH SUPPRESSION; IN-VIVO; S-PHASE; P107; P130; PRB; G1	Mitogenic stimulation leads to activation of G(1) cyclin-dependent kinases (CDKs), which phosphorylate pocket proteins and trigger progression through the G(0)/G(1) and G(1)/S transitions of the cell cycle. However, the individual role of G(1) cyclin-CDK complexes in the coordinated regulation of pocket proteins and their interaction with E2F family members is not fully understood. Here we report that individually or in concert cyclin D1-CDK and cyclin E-CDK complexes induce distinct and coordinated phosphorylation of endogenous pocket proteins, which also has distinct consequences in the regulation of pocket protein interactions with E2F4 and the expression of p107 and E2F1, both E2F-regulated genes. The up-regulation of these two proteins and the release of p130 and pRB from E2F4 complexes allows formation of E2F1 complexes not only with pRB but also with p130 and p107 as well as the formation of p107-E2F4 complexes. The formation of these complexes occurs in the presence of active cyclin D1-CDK and cyclin E-CDK complexes, indicating that whereas phosphorylation plays a role in the abrogation of certain pocket protein/E2F interactions, these same activities induce the formation of other complexes in the context of a cell expressing endogenous levels of pocket and E2F proteins. Of note, phosphorylated p130 "form 3," which does not interact with E2F4, readily interacts with E2F1. Our data also demonstrate that ectopic overexpression of either cyclin is sufficient to induce mitogen-independent growth in human T98G and Rat-1 cells, although the effects of cyclin D1 require downstream activation of cycilin E-CDK2 activity. Interestingly, in T98G cells, cyclin D1 induces cell cycle progression more potently than cyclin E. This suggests that cyclin D1 activates pathways independently of cyclin E that ensure timely progression through the cell cycle.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Barcelona	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, AHP Bldg,Rm 308,3307 N Broad St, Philadelphia, PA 19140 USA.	xavier@unix.temple.edu		Grana, Xavier/0000-0001-7134-0473; Sotillo, Elena/0000-0002-3993-1932	NCI NIH HHS [R24 CA88261-01] Funding Source: Medline; NIAID NIH HHS [AI45450, K02AI01823] Funding Source: Medline; NIGMS NIH HHS [GM54894] Funding Source: Medline; PHS HHS [NIH R01, NIH-R29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001823, R01AI045450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reed MF, 1998, ONCOGENE, V17, P2961, DOI 10.1038/sj.onc.1202450; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takahashi Y, 2000, GENE DEV, V14, P804; Winston JT, 1996, ONCOGENE, V12, P127; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	49	72	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50263	50274		10.1074/jbc.M209181200	http://dx.doi.org/10.1074/jbc.M209181200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401786	hybrid			2022-12-25	WOS:000180177700009
J	Lim, S; Zou, YL; Friedman, E				Lim, S; Zou, YL; Friedman, E			The transcriptional activator Mirk/Dyrk1B is sequestered by p38 alpha/beta MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; PROTEIN-KINASE; SPECIFICITY; CELLS; MINIBRAIN; SUBSTRATE; FAMILY; DYRK; DIFFERENTIATION; EXPRESSION	Mirk/Dyrk1B protein kinase was shown in an earlier study to function as a transcriptional activator of HNF1alpha, which Mirk phosphorylates at Ser(249) within its CREB (cAMP-response element-binding protein)-binding protein (CBP) binding domain (1). The MAPK kinase MKK3 was also shown to activate Mirk as a protein kinase, implicating Mirk in the biological response to certain stress agents. Another MKK3 substrate, p38MAPK, is now shown to inhibit the function of Mirk as a transcriptional activator in a kinase-independent manner. Co-immunoprecipitation experiments demonstrated that kinase-inactive p38AF, as well as wild-type p38, sequestered Mirk and prevented its association with MKK3. Only the p38alpha and p38beta isoforms, but not the gamma or 5 isoforms, complexed with Mirk. p38alphaMAPK blocked Mirk activation of HNF1alpha in a dose-dependent manner, with high levels of kinase-inactive p38aAF completely suppressing the activity of Mirk. Size fractionation by fast protein liquid chromatography on Super-dex 200 demonstrated that Mirk is not found as a monomer in vivo, but is found within 150-700 kDa subnuclear complexes, which co-migrate with the nuclear body scaffolding protein PML. Endogenous Mirk, p38, and AWK3 co-migrate within 500-700-kDa protein complexes, which accumulate when nuclear export is blocked by leptomycin B. Stable overexpression of Mirk increases the fraction of Mirk protein and p38 protein within these 500-700 kDa complexes, suggesting that the complexes act as nuclear depots for Mirk and p38. Sequestration of Mirk by p38 may occur within these subnuclear complexes. Synchronization experiments demonstrated that Mirk levels fluctuate about 10-fold within the cell cycle, while p38 levels do not, leading to the speculation that endogenous p38 could only block Mirk function when Mirk levels were low in S phase and not when Mirk levels were elevated in G(0)/G(1). These data suggest a novel cell cycle-dependent function for p38, suppression of the function of Mirk as a transcriptional activator only when cells are proliferating, and thus limiting Mirk function to growth-arrested cells.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Lim, Seunghwan/0000-0001-8920-0890	NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fuchsova B, 2002, J CELL BIOL, V158, P463, DOI 10.1083/jcb.200202035; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kemp DM, 2001, ENDOCRINOLOGY, V142, P1179, DOI 10.1210/en.142.3.1179; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; SMITH DJ, 1997, NAT GENET, V16, P8; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; YAN ZF, 1992, ONCOGENE, V7, P801; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	29	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49438	49445		10.1074/jbc.M206840200	http://dx.doi.org/10.1074/jbc.M206840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384504	hybrid			2022-12-25	WOS:000180028900044
J	Leonard, AS; Bayer, KU; Merrill, MA; Lim, IA; Shea, MA; Schulman, H; Hell, JW				Leonard, AS; Bayer, KU; Merrill, MA; Lim, IA; Shea, MA; Schulman, H; Hell, JW			Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; LONG-TERM POTENTIATION; NMDA RECEPTOR; NR2B SUBUNIT; CALCIUM-CHANNELS; SPLICE VARIANTS; AMPA RECEPTORS; CALMODULIN; CAMKII; PHOSPHORYLATION	Ca2+ influx through the N-methyl-D-aspartate (NMDA)-type glutamate receptor leads to activation and postsynaptic accumulation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and ultimately to long term potentiation, which is thought to be the physiological correlate of learning and memory. The NMDA receptor also serves as a CaMKII docking site in dendritic spines with high affinity binding sites located on its NR1 and NR2B subunits. We demonstrate that high affinity binding of CaMKII to NR1 requires autophosphorylation of Thr(286). This autophosphorylation reduces the off rate to a level (t(1/2) = similar to23 min) that is similar to that observed for dissociation of the T286D mutant CaMKII (t(1/2) = similar to30 min) from spines after its glutamate-induced accumulation (Shen, K., Teruel, M. N., Connor, J. H., Shenolikar, S., and Meyer, T. (2000) Nat. Neurosci. 3, 881-886). CaMKII as well as the previously identified NR1 binding partners calmodulin and a-actinin bind to the short C-terminal portion of the C0 region of NR1. Like Ca2+/calmodulin, autophosphorylated CaMKII competes with alpha-actinin-2 for binding to NR1. We conclude that the NR1 C0 region is a key site for recruiting CaMKII to the postsynaptic site, where it may act in concert with calmodulin to modulate the stimulatory role of a-actinin interaction with the NMDA receptor.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; Stanford University; University of Iowa	Hell, JW (corresponding author), Univ Iowa, Dept Pharmacol, 2-512 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	johannes-hell@uiowa.edu	Hell, Johannes W./P-5085-2019; Shea, Madeline A/F-5798-2010	Shea, Madeline/0000-0003-0814-7069	NIA NIH HHS [AG00213] Funding Source: Medline; NIGMS NIH HHS [GM30179] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM030179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; ROTHMAN SM, 1987, TRENDS NEUROSCI, V22, P227; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	43	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48441	48448		10.1074/jbc.M205164200	http://dx.doi.org/10.1074/jbc.M205164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379661	hybrid			2022-12-25	WOS:000179789600063
J	Magalon, A; Frixon, C; Pommier, J; Giordano, G; Blasco, F				Magalon, A; Frixon, C; Pommier, J; Giordano, G; Blasco, F			In vivo interactions between gene products involved in the final stages of molybdenum cofactor biosynthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; DIMETHYL-SULFOXIDE REDUCTASE; CRYSTAL-STRUCTURE; NITRATE REDUCTASE; PROTEIN GEPHYRIN; CHLAMYDOMONAS-REINHARDTII; UBIQUITIN ACTIVATION; UREASE APOPROTEIN; CARRIER PROTEIN; MOLYBDATE	The final stages of bacterial molybdenum cofactor (Moco) biosynthesis correspond to molybdenum chelation and nucleotide attachment onto an unique and ubiquitous structure, the molybdopterin. Using a bacterial two-hybrid approach, here we report on the in vivo interactions between MogA, MoeA, MobA, and MobB implicated in several distinct although linked steps in Escherichia coli. Numerous interactions among these proteins have been identified. Somewhat surprisingly, MobB, a GTPase with a yet unclear function, interacts with MogA, MoeA, and MobA. Probing the effects of various mo. mutations on the interaction map allowed us (i) to distinguish Moco-sensitive interactants from insensitive ones involving MobB and (ii) to demonstrate that molybdopterin is a key molecule triggering or facilitating MogA-MoeA and MoeA-MobA interactions. These results suggest that, in vivo, molybdenum cofactor biosynthesis occurs on protein complexes rather than by the separate action of molybdenum cofactor biosynthetic proteins.	CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, F-13402 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS)	Magalon, A (corresponding author), CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille 09, France.			Magalon, Axel/0000-0002-3375-738X				AGUILAR M, 1992, FEBS LETT, V307, P162, DOI 10.1016/0014-5793(92)80758-9; AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; Buc J, 1999, MOL MICROBIOL, V32, P159, DOI 10.1046/j.1365-2958.1999.01340.x; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Jeon WB, 2001, J BIOL CHEM, V276, P38602, DOI 10.1074/jbc.M104945200; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; KAMDAR KP, 1994, GENETICS, V137, P791; Karimova G, 2000, METHOD ENZYMOL, V328, P59, DOI 10.1016/S0076-6879(00)28390-0; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; LESTER RL, 1971, J BACTERIOL, V105, P1006, DOI 10.1128/JB.105.3.1006-1014.1971; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Millar LJ, 2001, MOL GENET GENOMICS, V266, P445, DOI 10.1007/s004380100543; MILLER JH, 1992, MOL CLONING LAB MANU; MILLER JH, 1972, MOL CLONING LAB MANU; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Potter LC, 2000, FEMS MICROBIOL LETT, V185, P51, DOI 10.1016/S0378-1097(00)00070-7; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Stevenson CEM, 2000, STRUCTURE, V8, P1115, DOI 10.1016/S0969-2126(00)00518-9; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Witte CP, 1998, FEBS LETT, V431, P205, DOI 10.1016/S0014-5793(98)00756-X; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	51	29	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48199	48204		10.1074/jbc.M205806200	http://dx.doi.org/10.1074/jbc.M205806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372836	hybrid			2022-12-25	WOS:000179789600031
J	Nie, ZZ; Stanley, KT; Stauffer, S; Jacques, KM; Hirsch, DS; Takei, J; Randazzo, PA				Nie, ZZ; Stanley, KT; Stauffer, S; Jacques, KM; Hirsch, DS; Takei, J; Randazzo, PA			AGAP1, an endosome-associated, phosphoinositide-dependent ADP-ribosylation factor GTPase-activating protein that affects actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ARF; FAMILY; BINDING; DOMAIN; ASAP1; REQUIREMENT; HYDROLYSIS	We have identified three members of the AGAP subfamily of ASAP family ADP-ribosylation factor GTPase-activating proteins (Arf GAPs). In addition to the Arf GAP domain, these proteins contain GTP-binding protein-like, ankyrin repeat and pleckstrin homology domains. Here, we have characterized the ubiquitously expressed AGAP1/KIAA1099. AGAP1 had Arf GAP activity toward Arf1>Arf5>Arf6. Phosphatidylinositol 4,5-bisphosphate and phosphatidic acid synergistically stimulated GAP activity. As found for other ASAP family Arf GAPs, the pleckstrin homology domain was necessary for activity. Deletion of the GTP-binding protein-like domain affected lipid dependence of Arf GAP activity. In vivo effects of AGAP1 were distinct from other ASAP family Arf GAPs. Overexpressed AGAP1 induced the formation of and was associated with punctate structures containing the endocytic markers transferrin and Rab4. AP1 was redistributed from the trans-Golgi to the punctate structures. Like other ASAP family members, AGAP1 overexpression inhibited the formation of PDGF-induced ruffles. However, distinct from other ASAP family members, AGAP1 also induced the loss of actin stress fibers. Thus, AGAP1 is a phosphoinositide-dependent Arf GAP that impacts both the endocytic compartment and actin.	NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Randazzo, PA (corresponding author), NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 4118, Bethesda, MD 20892 USA.	randazzo@helix.nih.gov						Andreev J, 1999, MOL CELL BIOL, V19, P2338; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; JACQUES KM, 2003, IN PRESS J BIOL CHEM; KAHN RA, 1984, J BIOL CHEM, V259, P6228; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; RANDAZZO PA, 2000, SCI STKE, pRE1; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5	45	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48965	48975		10.1074/jbc.M202969200	http://dx.doi.org/10.1074/jbc.M202969200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12388557	hybrid			2022-12-25	WOS:000179789600129
J	Zhang, CY; Wu, YL; Boxer, LM				Zhang, CY; Wu, YL; Boxer, LM			Impaired proliferation and survival of activated B cells in transgenic mice that express a dominant-negative cAMP-response element-binding protein transcription factor in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CREB PROTEINS; BCL-2 PROTEIN; PHOSPHORYLATION; APOPTOSIS; INDUCTION; PROMOTER; MUTATION; HAIR	The cAMP-response element-binding protein (CREB) is activated by phosphorylation on serine 133 and mediates the proliferative response to a number of different signals. A mutant CREB with a serine to alanine substitution at position 133 (CREBM1) functions as a dominant-negative inhibitor. Transgenic mice that express the dominant-negative CREB protein in B lymphocytes were developed as a means to study the effects of the inhibition of CREB function on B-cell proliferation and survival. We have shown previously that CREB up-regulates Bcl-2 expression in B cells in response to activation signals. B cells from CREBM1 transgenic mice expressed lower levels of Bcl-2 with and without stimulation. Proliferation of B cells from the transgenic mice was impaired in part by lack of induction of activator protein 1 (AP1) transcription factors. B cells from the transgenic mice were more susceptible to induction of apoptosis with several different agents, consistent with the decreased expression of Bcl-2. These studies demonstrate that B-cell activation requires phosphorylation of CREB for the proliferative response and to protect against activation-induced apoptosis.	Stanford Univ, Sch Med, Ctr Mol Biol & Med, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Ctr Mol Biol & Med, Vet Affairs Palo Alto Hlth Care Syst, CCSR 1155, Stanford, CA 94305 USA.	lboxer@stanford.edu						Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; OFIR R, 1991, GENE EXPRESSION, V1, P55; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zhang F, 2000, J IMMUNOL, V165, P1762, DOI 10.4049/jimmunol.165.4.1762	26	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48359	48365		10.1074/jbc.M209329200	http://dx.doi.org/10.1074/jbc.M209329200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374787	hybrid			2022-12-25	WOS:000179789600052
J	Bass, R; Fernandez, AMM; Ellis, V				Bass, R; Fernandez, AMM; Ellis, V			Maspin inhibits cell migration in the absence of protease inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; EPITHELIUM-DERIVED FACTOR; RECEPTOR-BOUND UROKINASE; SMOOTH-MUSCLE-CELLS; BREAST-CANCER; SERPIN; MECHANISM; BINDING; SURFACE; PAI-1	Maspin is a member of the serpin family of protease inhibitors and is a tumor suppressor gene acting at the level of tumor invasion and metastasis. This in vivo activity correlates with the ability of maspin to inhibit cell migration in vitro. This behavior suggests that maspin inhibits matrix-degrading proteases, such as those of the plasminogen activation system, in a similar manner to the serpin PAI-1. However, there is controversy concerning the protease inhibitory activity of maspin. It is devoid of activity against a wide range of proteases, in common with other non-inhibitory serpins, but has recently been reported to inhibit plasminogen activators associated with cells and other biological surfaces (Sheng, S. J., Truong, B., Fredrickson, D., Wit, R. L., Pardee, A. B., and Sager, R. (1998) Proc. Natl. Acad. Sci. U. S. A 95, 499-504; McGowen, R., Biliran, H., Jr., Sager, R., and Sheng, S. (2000) Cancer Res. 60, 4771-4778). We have compared the effects of maspin with those of PAI-1 in a range of situations in which plasminogen activation is potentiated, reflecting the biological context of this proteolytic system: urokinase-type plasminogen activator bound to its receptor on the surface of tumor cells, tissue-type plasminogen activator specifically bound to vascular smooth muscle cells, fibrin, and the prion protein. Maspin was found to have no inhibitory effect in any of these situations, in contrast to the efficient inhibition observed with PAI-1, but nevertheless maspin inhibited the migration of both tumor and vascular smooth muscle cells. We conclude that maspin is a non-inhibitory serpin and that protease inhibition does not account for its activity as a tumor suppressor.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Ellis, V (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	v.ellis@uea.ac.uk	Bass, Rosemary A/A-5328-2009; Ellis, Vincent/D-1860-2009	Bass, Rosemary A/0000-0003-4997-5207; Ellis, Vincent/0000-0003-1956-073X				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Biliran H, 2001, CANCER RES, V61, P8676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Duffy MJ, 2002, CLIN CHEM, V48, P1194; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Ellis V, 1999, BIOCHEMISTRY-US, V38, P651, DOI 10.1021/bi981714d; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Ellis V, 2002, BIOCHEMISTRY-US, V41, P6891, DOI 10.1021/bi025676g; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; Hawley SB, 2000, THROMB HAEMOSTASIS, V84, P882; Hendrix MJC, 2000, NAT MED, V6, P374, DOI 10.1038/74624; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; McGowen R, 2000, CANCER RES, V60, P4771; OSWALD RE, 1989, NATURE, V337, P579, DOI 10.1038/337579a0; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Shi HY, 2001, CANCER RES, V61, P6945; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werner F, 1999, J BIOL CHEM, V274, P21555, DOI 10.1074/jbc.274.31.21555; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	44	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46845	46848		10.1074/jbc.C200532200	http://dx.doi.org/10.1074/jbc.C200532200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12384513	hybrid			2022-12-25	WOS:000179663700002
J	Hancock, MK; Yammani, RD; Dahms, NM				Hancock, MK; Yammani, RD; Dahms, NM			Localization of the carbohydrate recognition sites of the insulin-like growth factor II/mannose 6-phosphate receptor to domains 3 and 9 of the extracytoplasmic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; HIGH-MANNOSE OLIGOSACCHARIDES; DISCOIDEUM LYSOSOMAL-ENZYMES; N-LINKED OLIGOSACCHARIDES; DICTYOSTELIUM-DISCOIDEUM; LIGAND-BINDING; MANNOSE-6-PHOSPHATE RECEPTOR; STRUCTURAL-ANALYSIS; UROKINASE RECEPTOR; PICHIA-PASTORIS	The insulin-like growth factor II/mannose 6-phosphate receptor is a multifunctional receptor that binds to a diverse array of mannose 6-phosphate (Man-6-P) modified proteins as well as nonglycosylated ligands. Previous studies have mapped its two Man-6-P binding sites to a minimum of three domains, 1-3 and 7-9, within its 15-domain extracytoplasmic region. Since the primary amino acid determinants of carbohydrate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor are predicted by sequence alignment to the cation-dependent mannose 6-phosphate receptor to reside within domains 3 and 9, constructs encoding either domain 3 alone or domain 9 alone were expressed in a Pichia pastoris expression system and tested for their ability to bind several carbohydrate ligands, including Man-6-P, pentamannosyl phosphate, the lysosomal enzyme, beta-glucuronidase, and the carbohydrate modifications (mannose 6-sulfate and Man-6-P methyl ester) found on Dictyostelium discoideum lysosomal enzymes. Although both constructs were functional in ligand binding and dissociation, these studies demonstrate the ability of domain 9 alone to fold into a high affinity (K-d=0.3+/-0.1 nM) carbohydrate-recognition domain whereas the domain 3 alone construct is capable of only low affinity binding (K(d)similar to500 nM) toward beta-glucuronidase, suggesting that residues in adjacent domains (domains 1 and/or 2) are important, either directly or indirectly, for optimal binding by domain 3.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R01DK042667, R56DK042667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; BURKHARDT JK, 1989, P NATL ACAD SCI USA, V86, P7128, DOI 10.1073/pnas.86.18.7128; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Cacia J, 1998, BIOCHEMISTRY-US, V37, P15154, DOI 10.1021/bi981465t; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Devi GR, 1999, CANCER RES, V59, P4314; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FREEZE HH, 1985, ARCH BIOCHEM BIOPHYS, V243, P690, DOI 10.1016/0003-9861(85)90547-8; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FREEZE HH, 1985, J BIOL CHEM, V260, P8857; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; GABEL CA, 1989, J VIROL, V63, P4264, DOI 10.1128/JVI.63.10.4264-4276.1989; GABEL CA, 1984, J BIOL CHEM, V259, P3762; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Grimme S, 2000, J BIOL CHEM, V275, P33697, DOI 10.1074/jbc.M003789200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; Ikushima H, 2000, P NATL ACAD SCI USA, V97, P8439, DOI 10.1073/pnas.97.15.8439; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; Marron-Terada PG, 1998, BIOCHEMISTRY-US, V37, P17223, DOI 10.1021/bi981883y; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Reddy ST, 2002, PROTEIN EXPRES PURIF, V26, P290, DOI 10.1016/S1046-5928(02)00542-9; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; THIBAULT C, 1984, J BIOL CHEM, V259, P3361; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	69	44	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47205	47212		10.1074/jbc.M208534200	http://dx.doi.org/10.1074/jbc.M208534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12374794	hybrid			2022-12-25	WOS:000179663700048
J	Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM				Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM			Aplidin (TM) induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta	ONCOGENE			English	Article						Aplidin (TM); oxidative damage; JNK; p38; caspascs; PKC-delta	N-TERMINAL KINASE; SIGNAL-REGULATED KINASE; CELL-DEATH; GAMMA-RADIATION; GLUTATHIONE; CASPASES; DIDEMNIN; ALPHA; BCL-2; ERK	Aplidin(TM), a new antitumoural drug presently in phase II clinical trials, has shown both in vitro and in vivo activity against human cancer cells. Aplidin(TM) effectively inhibits cell viability by triggering a canonical apoptotic program resulting in alterations in cell morphology, caspase activation, and chromatin fragmentation. Pro-apoptotic concentrations of Aplidin(TM) induce early oxidative stress, which results in a rapid and persistent activation of both JNK and p38 MAPK and a biphasic activation of ERK. Inhibition of JNK and p38 MAPK blocks the apoptotic program induced by Aplidin(TM), demonstrating its central role in the integration of the cellular stress induced by the drug. JNK and p38 MAPK activation results in downstream cytochrome c release and activation of caspases -9 and -3 and PARP cleavage, demonstrating the mediation of the mitochondrial apoptotic pathway in this process. We also demonstrate that protein kinase C delta (PKC-delta) mediates the cytotoxic effect of Aplidin(TM), and that it is concomitantly processed and activated late in the apoptotic process by a caspase mediated mechanism. Remarkably, cells deficient in PKC-delta show enhanced survival upon drug treatment as compared to its wild type counterpart. PKC-delta thus appears as an important component necessary for full caspase cascade activation and execution of apoptosis, which most probably initiates a positive feedback loop further amplifying the apoptotic process.	PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Ctr Citrometria Flujo, E-28040 Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cell Biol, Fukuoka 8128582, Japan	PharmaMar; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Kyushu University; Kyushu University	Sanchez-Puelles, JM (corresponding author), PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain.	jmspuelles@pharmamar.com	Losada, Alejandro/AAW-8589-2021; Munoz, Alberto/O-6393-2014; Cuadrado, Ana/AAA-9277-2019; Alvarez-Barrientos, Alberto/L-9299-2014; Cuadrado, Ana/HGU-4777-2022; Sanchez-Puelles, Jose Maria/E-4159-2018	Munoz, Alberto/0000-0003-3890-4251; Cuadrado, Ana/0000-0002-9752-5932; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Sanchez-Puelles, Jose Maria/0000-0002-4283-4885				Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; ANTHONEY A, 2000, J CLIN ONCOL S, V19, pA734; ARMAND JP, 2001, P AM SOC CLIN ONCOL, V20; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOWMAN A, 2001, P AM SOC CLIN ONCOL, V20; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROGGINI M, 2000, P 11 NCI EORTC AACR; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CIRUELOS EM, 2002, P AM SOC CLIN ONCOL, V20; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Crews CM, 1996, P NATL ACAD SCI USA, V93, P4316, DOI 10.1073/pnas.93.9.4316; CREWS CM, 1994, J BIOL CHEM, V269, P15411; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Ding W, 2000, TOXICOL APPL PHARM, V162, P93, DOI 10.1006/taap.1999.8829; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERBA E, 1999, P AACR NCI EORTC INT; FAIRCLOTH G, 1999, P AM ASS CANC RES, V40; FAIRCLOTH G, 1998, P AM ASS CANC RES, V39; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Grubb DR, 2001, ONCOGENE, V20, P4085, DOI 10.1038/sj.onc.1204545; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Huang CS, 1999, CANCER RES, V59, P3053; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; KOJI U, 1999, J BIOL CHEM, V274, P2234; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Krupinski J, 2000, NEUROBIOL DIS, V7, P332, DOI 10.1006/nbdi.2000.0310; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUROUN JA, 2001, P AM SOC CLIN ONCOL, V20; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Miyanishi K, 2001, GASTROENTEROLOGY, V121, P865, DOI 10.1053/gast.2001.27982; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Persons DL, 1999, CLIN CANCER RES, V5, P1007; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rinehart KL, 2000, MED RES REV, V20, P1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; STEMPKA L, 1998, ASBMB S PROT KIN C C; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Whelan R D, 1989, Cancer Commun, V1, P359; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Yu WP, 2001, CANCER RES, V61, P6569; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	77	122	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7533	7544		10.1038/sj.onc.1205972	http://dx.doi.org/10.1038/sj.onc.1205972			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386816				2022-12-25	WOS:000178618200009
J	Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A				Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A			High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice	ONCOGENE			English	Article						patched-knockout mice; X-rays; medulloblastoma; LOH	CELL CARCINOMA SYNDROME; HUMAN HOMOLOG; GORLIN SYNDROME; UNITED-STATES; PATCHED GENE; MUTATIONS; CANCER; P53	Individuals affected with the Gorlin syndrome inherit a germ-line mutation of the patched (Ptc1) developmental gene and, analogously to Ptc1 heterozygous mice, show an increased susceptibility to spontaneous tumor development. Human and mouse Ptc1 heterozygotes (Ptc1(+/-)) are also hypersensitive to ionizing radiation (IR)-induced tumorigenesis in terms of basal cell carcinoma (BCC) induction. We have analysed the involvement of Ptc1 in the tumorigenic response to a single dose of 3 Gy X-rays in neonatal and adult Ptc1 heterozygous and wild type mice. We report that irradiation dramatically increased the incidence of medulloblastoma development (51%) over the spontaneous rate (7%) in neonatal but not adult Ptc1 heterozygotes, indicating that medulloblastoma induction by IR is subjected to temporal restriction. Analysis of Ptc1 allele status in the tumors revealed loss of the wild type allele in 17 of 18 medulloblastomas from irradiated mice and in two of three spontaneous medulloblastomas. To our knowledge, irradiated newborn Ptc1(+/-) heterozygous mice constitute the first mouse model of IR-induced medulloblastoma tumorigenesis, providing a useful tool to elucidate the molecular basis of medulloblastoma development.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; GSF Munich, Natl Res Ctr, Inst Pathol, Munich, Germany; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Goettingen, Inst Human Genet, Gottingen, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Gottingen	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Atkinson, Michael J/E-5537-2011; Atkinson, Michael/AAU-5127-2020	Atkinson, Michael J/0000-0003-3358-2089; Atkinson, Michael/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Chidambaram A, 1996, CANCER RES, V56, P4599; COREY R, 1997, CANCER RES, V57, P842; Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; LACOMBE D, 1990, Genetic Counseling, V1, P273; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Unden AB, 1996, CANCER RES, V56, P4562; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wicking C, 1997, AM J HUM GENET, V60, P21; Xie JW, 1997, CANCER RES, V57, P2369; ZURAWEL RH, 1997, CANCER RES, V577, P842; ZURAWEL RH, 2000, GENES CHROMOSOMES CA, V28	24	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7580	7584		10.1038/sj.onc.1205973	http://dx.doi.org/10.1038/sj.onc.1205973			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386820				2022-12-25	WOS:000178618200013
J	Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H				Turpin, E; Bieche, I; Bertheau, P; Plassa, LF; Lerebours, F; de Roquancourt, A; Olivi, M; Espie, M; Marty, M; Lidereau, R; Vidaud, M; de The, H			Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer	ONCOGENE			English	Article						oncogene; amplification; quantitative PCR; therapy	TRANSCRIPTION-PCR ASSAY; P53 GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; C-MYC; MULTIVARIATE-ANALYSIS; MONOCLONAL-ANTIBODY; CARCINOMAS; CHEMOTHERAPY; EXPRESSION	Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.	Hop St Louis, Serv Biochim B, F-75475 Paris 10, France; Hop St Louis, CNRS, UPR9051, F-75475 Paris 10, France; UPRES, Fac Sci Pharmaceut & Biol, Genet Mol Lab, JE 2195, F-75006 Paris, France; Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, F-92210 St Cloud, France; Hop St Louis, Serv Anat Pathol, F-75475 Paris 10, France; Hop St Louis, INSERM, ERM 0220, F-75475 Paris 10, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Hop St Louis, Serv Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr	Vidaud, Michel/O-7346-2017; Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				BERTHEAU P, 2002, IN PRESS LANCET; Bieche I, 1999, CANCER RES, V59, P2759; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Bieche I, 1999, CLIN CHEM, V45, P1148; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang S, 1998, CANCER, V82, P2366; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COLES C, 1992, CANCER RES, V52, P5291; Cuny M, 2000, CANCER RES, V60, P1077; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Degeorges A, 1998, BREAST CANCER RES TR, V47, P47, DOI 10.1023/A:1005824216444; Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P5, DOI 10.1089/cbr.1999.14.5; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P303; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; GARCIA I, 1989, CANCER RES, V49, P6675; Gradishar WJ, 1996, SEMIN SURG ONCOL, V12, P352; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUERIN M, 1988, ONCOGENE RES, V3, P21; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kerangueven F, 1997, CANCER RES, V57, P5469; Nakopoulou LL, 1996, J PATHOL, V179, P31, DOI 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sainsbury JRC, 2000, BRIT MED J, V321, P745, DOI 10.1136/bmj.321.7263.745; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Sjostrom J, 1998, BRIT J CANCER, V78, P812, DOI 10.1038/bjc.1998.584; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Turpin E, 1999, ONCOGENE, V18, P7834, DOI 10.1038/sj.onc.1203196; *UICC, 1909, TNM CLASS MAL TUM, P123; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincent-Salomon A, 2000, EUR J CANCER, V36, P586, DOI 10.1016/S0959-8049(99)00339-1; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	43	61	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7593	7597		10.1038/sj.onc.1205932	http://dx.doi.org/10.1038/sj.onc.1205932			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386822				2022-12-25	WOS:000178618200015
J	Yu, Y; Feig, LA				Yu, Y; Feig, LA			Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells	ONCOGENE			English	Article						breast cancer; Ral; R-Ras	GTP-BINDING PROTEINS; TAMOXIFEN RESISTANCE; C-SRC; RECEPTOR; ACTIVATION; GROWTH; SPECIFICITY; ALPHA; RAP1; EGF	A key step in the progression of breast cancer is the conversion of cells front an estrogen-dependent to an estrogen-independent state. Yet the molecular mechanisms underlying this transition in the control of cell proliferation of breast cancer cells remain poorly understood. A potential role for Ras-related GTPases in this process was suggested by the finding that BCAR3/AND-34, a protein isolated on the basis of its ability to convert MCF-7 and ZR-75 breast cancer cell lines to estrogen independence and tamoxifen resistance, is a guanine nucleotide exchange factor with the potential to activate the Ras-related Ral, R-Ras and Rap GTPases. In this study we investigated the potential contribution of these GTPases to the generation of estrogen-independence in MCF-7 cells. We found that elevated R-Ras but not Ral or Rap activity was sufficient to induce estrogen-independent proliferation of MCF-7 cells. The effect of R-Ras was dependent upon its ability to constitutively activate the AKT kinase. Interestingly, although AKT was also constitutively activated when estrogen-independent proliferation was induced by overexpression of EGF receptors, this mechanism of hormone independence did not require AKT activation. In contrast, EGF receptors did require Ral activation to induce estrogen-independent proliferation, while Ral activation was not required for estrogen-induced proliferation of MCF-7 cells. These findings suggest that Ral activity takes on a significant role in controlling cell proliferation of breast cancer cells when progression to estrogen-independence is associated with over-expression of EGF receptor family members. Moreover, because R-Ras promotes hormone-independent growth in a manner distinct from EGF receptors, it may participate in the conversion of breast cancer cells to estrogen independence when over-expression of EGF receptor family members is not involved.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA047391] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; OHTSUKA T, 1996, J BIOL CHEM, V271, P1253; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tian XJ, 2002, EMBO J, V21, P1327, DOI 10.1093/emboj/21.6.1327; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	39	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7557	7568		10.1038/sj.onc.1205961	http://dx.doi.org/10.1038/sj.onc.1205961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386818				2022-12-25	WOS:000178618200011
J	Rader, C; Popkov, M; Neves, JA; Barbas, CF				Rader, C; Popkov, M; Neves, JA; Barbas, CF			Integrin alpha v beta 3-targeted therapy for Kaposi's sarcoma with an in vitro-evolved antibody	FASEB JOURNAL			English	Article						cancer; HIV; antibody engineering	IMMUNODEFICIENCY-VIRUS TYPE-1; FIBROBLAST-GROWTH-FACTOR; PHAGE DISPLAY APPROACH; TAT PROTEIN; MONOCLONAL-ANTIBODY; AFFINITY MATURATION; TRANSGENIC MICE; FC-RECEPTORS; CELL; ALPHA(V)BETA(3)	Here, we define integrin alphavbeta3 as a molecular target for antibody therapy for Kaposi's sarcoma (KS). We previously reported, using a new phage display strategy based on designed combinatorial V gene libraries, the humanization of mouse monoclonal antibody LM609 directed to human integrin alphavbeta3. In the present study, we describe the in vitro affinity maturation of humanized LM609 by using a phage display strategy for the sequential and parallel optimization of three complementarity determining regions of the antibody molecule. The evolved Fab had an affinity of 150 pM and was converted into IgG1 by use of a new mammalian expression vector. The resulting whole antibody, designated JC-7U IgG1, was found to selectively target human KS in a nude mouse model and inhibit tumor growth at a therapeutically relevant dose. Because of its high affinity and its high degree of humanization, JC-7U IgG1 is an excellent drug candidate for therapeutic applications that involve integrin alphavbeta3 as the molecular target. Of particular interest is therapy for KS, breast cancer, melanoma, and other cancers in which integrin alphavbeta3 is expressed on both angiogenic endothelial cells and tumor cells, which would allow a dual antiangiogenic and antitumor strike with a single drug.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rader, C (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-526,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	crader@scripps.edu; carlos@scripps.edu		Rader, Christoph/0000-0001-9955-3454				Barbas C. F., 2001, PHAGE DISPLAY LAB MA; Barbas CF, 1996, TRENDS BIOTECHNOL, V14, P230, DOI 10.1016/0167-7799(96)10029-9; BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; Barillari G, 1999, BLOOD, V94, P663; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Barillari G, 1999, J IMMUNOL, V163, P1929; BATOR JM, 1989, J IMMUNOL METHODS, V125, P167, DOI 10.1016/0022-1759(89)90090-2; Beiboer SHW, 2000, J MOL BIOL, V296, P833, DOI 10.1006/jmbi.2000.3512; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dezube BJ, 2000, CURR OPIN ONCOL, V12, P445, DOI 10.1097/00001622-200009000-00010; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; JESPERS LS, 1994, BIO-TECHNOL, V12, P899, DOI 10.1038/nbt0994-899; Kaaya EE, 1996, HISTOPATHOLOGY, V29, P337, DOI 10.1111/j.1365-2559.1996.tb01417.x; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Marcinkiewicz C, 1996, BIOCHEM J, V317, P817, DOI 10.1042/bj3170817; Natali PG, 1997, CANCER RES, V57, P1554; Nor JE, 2001, CANCER RES, V61, P2183; Park JW, 2001, ADV PROTEIN CHEM, V56, P369; Prakash O, 2000, JNCI-J NATL CANCER I, V92, P721, DOI 10.1093/jnci/92.9.721; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SIEGAL B, 1990, CANCER, V65, P492, DOI 10.1002/1097-0142(19900201)65:3<492::AID-CNCR2820650320>3.0.CO;2-C; Steinberger P, 2000, J BIOL CHEM, V275, P36073, DOI 10.1074/jbc.M002765200; Tanaka F, 2000, J AM CHEM SOC, V122, P4835, DOI 10.1021/ja0005441; UCCINI S, 1994, J PATHOL, V173, P23, DOI 10.1002/path.1711730105; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	44	41	46	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2000	+		10.1096/fj.02-0281fje	http://dx.doi.org/10.1096/fj.02-0281fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397091				2022-12-25	WOS:000179167600012
J	Pollok-Kopp, B; Schwarze, K; Baradari, VK; Oppermann, M				Pollok-Kopp, B; Schwarze, K; Baradari, VK; Oppermann, M			Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; IN-VIVO; MOLECULAR MECHANISM; COUPLED RECEPTORS; HIV-1 CORECEPTOR; DESENSITIZATION; SITES; IDENTIFICATION	Human CC chemokine receptor 5 (CCR5), a member of the superfamily of G protein-coupled receptors, regulates the activation and directed migration of leukocytes and serves as the main coreceptor for the entry of R5 tropic strains of human immunodeficiency viruses. We have previously shown that RANTES/CCL5 binding to CCR5 induces GPCR kinase (GRK)- and protein kinase C (PKC)-mediated phosphorylation of four distinct C-terminal serine residues. To study these phosphorylation events in vivo, we have generated monoclonal antibodies, which specifically react only with either phosphorylated or nonphosphorylated CCR5. These phosphosite-specific antibodies reveal that following ligand stimulation of the receptor serine 337 is exclusively phosphorylated by a PKC-mediated mechanism, while GRKs phosphorylate serine 349. GRK-mediated receptor phosphorylation proceeds in a regular time-dependent manner (t(1/2),similar to2 min) with an apparent EC50 of 5 nm. In contrast, PKC phosphorylates serine 337 at 50-fold lower concentrations and in a very rapid, albeit transient manner. Protein phosphatases that are active at neutral pH and are inhibited by okadaic acid rapidly dephosphorylate phosphoserine 337, but less efficiently phosphoserine 349, in intact cells and in an in vitro assay. Immunofluorescence microscopy demonstrates that phosphorylated receptors accumulate in a perinuclear compartment, which resembles recycling endosomes. This study is the first to analyze in detail the spatial and temporal dynamics of GRK- versus PKC-mediated phosphorylation of a G protein-coupled receptor and its subsequent dephosphorylation on the level of individual phosphorylation sites.	Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany	University of Gottingen	Oppermann, M (corresponding author), Univ Gottingen, Dept Immunol, Kreuzbergring 57, D-37075 Gottingen, Germany.							ALI H, 1993, J BIOL CHEM, V268, P24247; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Bohm SK, 1997, BIOCHEM J, V322, P1; Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Krueger KM, 1997, J BIOL CHEM, V272, P5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Olbrich H, 1999, J LEUKOCYTE BIOL, V65, P281, DOI 10.1002/jlb.65.3.281; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281	43	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2190	2198		10.1074/jbc.M209844200	http://dx.doi.org/10.1074/jbc.M209844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12403770	hybrid			2022-12-25	WOS:000180562000017
J	Liu, CJ; Dib-Hajj, SD; Renganathan, M; Cummins, TR; Waxman, SG				Liu, CJ; Dib-Hajj, SD; Renganathan, M; Cummins, TR; Waxman, SG			Modulation of the cardiac sodium channel Na(v)1.5 by fibroblast growth factor homologous factor 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; PROTEIN-KINASE-C; NA+ CHANNEL; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; MOLECULAR MECHANISMS; LQT-3 MUTATION; BETA-SUBUNITS; FACTOR FGF; RAT	We have previously shown that fibroblast growth factor homologous factor 1B (FHF1B), a cytosolic member of the fibroblast growth factor family, associates with the sensory neuron-specific channel Na(v)1.9 but not with the other sodium channels present in adult rat dorsal root ganglia neurons. We show in this study that FHF1B binds to the C terminus of the cardiac voltage-gated sodium channel Na(v)1.5 and modulates the properties of the channel. The N-terminal 41 amino acid residues of FHF1B are essential for binding to Na(v)1.5, and the conserved acidic rich domain (amino acids 1773-1832) in the C terminus of Na(v)1.5 is sufficient for association with this factor. Binding of the growth factor to recombinant wild type human Na(v)1.5 in human embryonic kidney 293 cells produces a significant hyperpolarizing shift in the voltage dependence of channel inactivation. An aspartic acid to glycine substitution at position 1790 of the channel, which underlies one of the LQT-3 phenotypes of cardiac arrythmias, abolishes the interaction of the Na(v)1.5 channel with FHF1B. This is the first report showing that interaction with a growth factor can modulate properties of a voltage-gated sodium channel.	Yale Univ, Sch Med, Neurosci Res Ctr, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurosci Res Ctr, Paralyzed Vet Amer Eastern Paralyzed Vet Assoc, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Dib-Hajj, SD (corresponding author), Yale Univ, Sch Med, Paralyzed Vet Amer Eastern Paralyzed Vet Assoc Ne, 127A,Bldg 34,950 Campbell Ave, West Haven, CT 06516 USA.		Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; liu, chuanju/0000-0002-7181-8032				Abriel H, 2000, CIRCULATION, V102, P921; Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; Balser JR, 2001, TRENDS CARDIOVAS MED, V11, P229, DOI 10.1016/S1050-1738(01)00116-5; Benhorin J, 2000, CIRCULATION, V101, P1698; Cantrell AR, 1999, J NEUROSCI, V19, P5301; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; Dib-Hajj S, 2002, TRENDS NEUROSCI, V25, P253, DOI 10.1016/S0166-2236(02)02150-1; Fahmi AI, 2001, J PHYSIOL-LONDON, V537, P693; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gee SH, 1998, J NEUROSCI, V18, P128; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Hartmann HA, 1999, NAT NEUROSCI, V2, P593, DOI 10.1038/10147; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P46553, DOI 10.1074/jbc.M108699200; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; Malhotra JD, 2001, CIRCULATION, V103, P1303; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Murphy BJ, 1996, J BIOL CHEM, V271, P28837, DOI 10.1074/jbc.271.46.28837; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; Qu YS, 1996, J GEN PHYSIOL, V108, P375, DOI 10.1085/jgp.108.5.375; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Renganathan M, 2002, J NEUROPHYSIOL, V87, P761, DOI 10.1152/jn.00369.2001; Renganathan M, 2002, MOL BRAIN RES, V106, P70, DOI 10.1016/S0169-328X(02)00411-4; Rivolta I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/jbc.M104471200; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Waxman SG, 2001, NAT REV NEUROSCI, V2, P652, DOI 10.1038/35090026; Wehrens XHT, 2000, CIRCULATION, V102, P584; Wei J, 1999, CIRCULATION, V99, P3165, DOI 10.1161/01.CIR.99.24.3165	52	115	117	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1029	1036		10.1074/jbc.M207074200	http://dx.doi.org/10.1074/jbc.M207074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401812	hybrid			2022-12-25	WOS:000180321900045
J	Muller, L; Barret, A; Etienne, E; Meidan, R; Valdenaire, O; Corvol, P; Tougard, C				Muller, L; Barret, A; Etienne, E; Meidan, R; Valdenaire, O; Corvol, P; Tougard, C			Heterodimerization of endothelin-converting enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BIG ENDOTHELIN-1; INTRACELLULAR COMPARTMENT; PLASMA-MEMBRANE; MESSENGER-RNA; PROPROTEIN CONVERTASE; CELL-SURFACE; B RECEPTOR; 3 ISOFORMS; EXPRESSION	Endothelin-converting enzyme (ECE) is a membrane metalloprotease that generates endothelin from its direct precursor big endothelin. Four isoforms of ECE-1 are produced from a single gene through the use of alternate promoters. These isoforms share the same extracellular catalytic domain and contain unique cytosolic tails, which results in their specific subcellular targeting. We investigated the distribution of ECE-1 isoforms in transfected AtT-20 neuroendocrine cells. Whereas ECE-1a and le were present at the plasma membrane, ECE-1b and ECE-1d were retained inside the cells. We found that both intracellular isoforms were concentrated in the endosomal system: ECE-1d in recycling endosomes, and ECE-1b in late endosomestmultivesicular bodies. Leucine-based motifs were involved in the intracellular retention of these isoforms, and the targeting of ECE-1b to the degradation pathway required an additional signal in the N terminus. The concentration of ECE-1 isoforms in the endosomal system suggested new functions for these enzymes. Potential novel functions include redistribution of other isoforms through direct interaction. We have showed that ECE-1 isoforms could heterodimerize, and that in such heterodimers the ECE-1b targeting signal was dominant. Interaction of a plasma membrane isoform with ECE-1b resulted in its intracellular localization and decreased its extracellular activity. These data demonstrated that the targeting signals specific for ECE-1b constitute a regulatory domain per se that could modulate the localization and the activity of other isoforms.	Coll France, INSERM, U36, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Muller, L (corresponding author), Coll France, INSERM, U36, 11 Pl M Berthelot, F-75005 Paris, France.		muller, laurent/S-1990-2016	muller, laurent/0000-0001-9634-4323				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Barker S, 2001, MOL PHARMACOL, V59, P163, DOI 10.1124/mol.59.2.163; Barnes K, 1997, NEUROCHEM RES, V22, P1033, DOI 10.1023/A:1022435111928; Barnes K, 1996, J CELL SCI, V109, P919; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Blais V, 2002, FEBS LETT, V524, P43, DOI 10.1016/S0014-5793(02)02998-8; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Egidy G, 2001, HYPERTENSION, V38, P1137, DOI 10.1161/hy1001.092652; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; Haynes WG, 1998, J HYPERTENS, V16, P1081, DOI 10.1097/00004872-199816080-00001; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; IKDEDA S, 2002, BIOCHEM BIOPH RES CO, V293, P421; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Johnson GD, 2000, ANAL BIOCHEM, V286, P112, DOI 10.1006/abio.2000.4772; Kanyicska B, 1998, ENDOCRINOLOGY, V139, P5164, DOI 10.1210/en.139.12.5164; Kido T, 1997, EUR J BIOCHEM, V244, P520, DOI 10.1111/j.1432-1033.1997.00520.x; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; Korth P, 1997, FEBS LETT, V417, P365, DOI 10.1016/S0014-5793(97)01323-9; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Levy N, 2001, ENDOCRINOLOGY, V142, P5254, DOI 10.1210/en.142.12.5254; Lorenzo MN, 2001, BBA-GENE STRUCT EXPR, V1522, P46, DOI 10.1016/S0167-4781(01)00283-4; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Morawietz H, 2000, J PHYSIOL-LONDON, V525, P761, DOI 10.1111/j.1469-7793.2000.00761.x; Muller L, 2000, J CARDIOVASC PHARM, V36, pS15, DOI 10.1097/00005344-200036051-00007; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; Parnot C, 1997, HYPERTENSION, V30, P837, DOI 10.1161/01.HYP.30.4.837; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Russell FD, 1998, CIRC RES, V83, P314, DOI 10.1161/01.RES.83.3.314; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Savage P, 1998, J CARDIOVASC PHARM, V31, pS16, DOI 10.1097/00005344-199800001-00007; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schmidt-Ott KM, 1998, J CARDIOVASC PHARM, V31, pS364, DOI 10.1097/00005344-199800001-00102; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Schweizer A, 1999, BIOCHEM J, V340, P649, DOI 10.1042/0264-6021:3400649; Shao R, 1999, J BIOL CHEM, V274, P3228, DOI 10.1074/jbc.274.5.3228; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Suzuki H, 1997, GEN COMP ENDOCR, V107, P12, DOI 10.1006/gcen.1997.6899; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; Tripiciano A, 1999, J CELL BIOL, V145, P1027, DOI 10.1083/jcb.145.5.1027; Turner AJ, 1998, TRENDS PHARMACOL SCI, V19, P483, DOI 10.1016/S0165-6147(98)01251-6; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447	65	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					545	555		10.1074/jbc.M208949200	http://dx.doi.org/10.1074/jbc.M208949200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12393864	Green Published, hybrid			2022-12-25	WOS:000180255700072
J	van Leeuwen, FN; Olivo, C; Grivell, S; Giepmans, BNG; Collard, JG; Moolenaar, WH				van Leeuwen, FN; Olivo, C; Grivell, S; Giepmans, BNG; Collard, JG; Moolenaar, WH			Rac activation by lysophosphatidic acid LPA(1) receptors through the guanine nucleotide exchange factor Tiam1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE-BETA; CELLULAR-RESPONSES; NEURITE RETRACTION; EPITHELIAL-CELLS; RHO ACTIVITY; MAP KINASE; INVASION; MORPHOLOGY	Lysophosphatidic acid (LPA) is a serum-borne phospholipid that activates its own G protein-coupled receptors present in numerous cell types. In addition to stimulating cell proliferation, LPA also induces cytoskeletal. changes and promotes cell migration in a RhoA- and Rac-dependent manner. Whereas RhoA is activated via Galpha(12/13)-linked Rho-specific guanine nucleotide exchange factors, it is unknown how LPA receptors may signal to Rac. Here we report that the prototypic LPA, receptor (previously named Edg2), when expressed in B103 neuroblastoma cells, mediates transient activation of RhoA and robust, prolonged activation of Rac leading to cell spreading, lamellipodia formation, and stimulation of cell migration. LPA-induced Rac activation is inhibited by pertussis toxin and requires phosphoinositide 3-kinase activity. Strikingly, LPA fails to activate Rac in cell types that lack the Rac-specific exchange factor Tiam1; however, enforced expression of Tiam1 restores LPA-induced Rac activation in those cells. Tiam1-deficient cells show enhanced RhoA activation, stress fiber formation, and cell rounding in response to LPA, consistent with Tiam1/Rac counteracting RhoA. We conclude that LPA, receptors couple to a G(i)-phosphoinositide 3-kinase-Tiam1 pathway to activate Rac, with consequent suppression of RhoA activity, and thereby stimulate cell spreading and motility.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.moolenaar@nki.nl	van Leeuwen, Frank/AAQ-6799-2020; Giepmans, Ben N.G./R-4564-2016	van Leeuwen, Frank/0000-0003-1107-6513; Giepmans, Ben N.G./0000-0001-5105-5915				Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	43	144	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					400	406		10.1074/jbc.M210151200	http://dx.doi.org/10.1074/jbc.M210151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12393875	hybrid, Green Published			2022-12-25	WOS:000180255700053
J	Mbele, GO; Deloulme, JC; Gentil, BJ; Delphin, C; Ferro, M; Garin, J; Takahashi, M; Baudier, J				Mbele, GO; Deloulme, JC; Gentil, BJ; Delphin, C; Ferro, M; Garin, J; Takahashi, M; Baudier, J			The zinc- and calcium-binding S100B interacts and co-localizes with IQGAP1 during dynamic rearrangement of cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CDC42; CALMODULIN; DOMAIN; BRAIN; P53; TARGET; RAC1; S100-ALPHA-ALPHA; IMMUNOREACTIVITY	The Zn2+- and Ca2+-binding S100B protein is implicated in multiple intracellular and extracellular regulatory events. In glial cells, a relationship exists between cytoplasmic S100B accumulation and cell morphological changes. We have identified the IQGAP1 protein as the major cytoplasmic S100B target protein in different rat and human glial cell lines in the presence of Zn2+ and Ca2+. Zn2+ binding to S100B is sufficient to promote interaction with IQGAP1. IQ motifs on IQGAP1 represent the minimal interaction sites for S100B. We also provide evidence that, in human astrocytoma cell lines, S100B co-localizes with IQGAP1 at the polarized leading edge and areas of membrane ruffling and that both proteins relocate in a Ca2+-dependent manner within newly formed vesicle-like structures. Our data identify IQGAP1 as a potential target protein of S100B during processes of dynamic rearrangement of cell membrane morphology. They also reveal an additional cellular function for IQGAP1 associated with Zn2+/Ca2+-dependent relocation of S100B.	INSERM, EMI 0104, DRDC TS,CEA, Dept Response & Differenciat Cellulaires Commissa, F-38054 Grenoble, France; DRDC CP, CEA, Lab Chim Prot, F-38054 Grenoble, France; Syn X Pharma Inc, Mississauga, ON L4V 1HA, Canada	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Baudier, J (corresponding author), INSERM, EMI 0104, DRDC TS,CEA, Dept Response & Differenciat Cellulaires Commissa, F-38054 Grenoble, France.		Baudier, Jacques/O-2183-2016; GENTIL, Benoit/B-9459-2012; Deloulme, Jean Christophe/P-6858-2017; jacques, baudier/T-3300-2019; FERRO, Myriam/O-6588-2014; Christian, Delphin/P-9284-2017	Deloulme, Jean Christophe/0000-0002-2234-5865; FERRO, Myriam/0000-0002-4222-6847; Christian, Delphin/0000-0003-3240-8695; GENTIL, Benoit/0000-0003-2022-1890; jacques, baudier/0000-0001-8427-4444				Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1169, DOI 10.1515/CCLM.2000.180; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAGLID KG, 1975, NATURE, V258, P748, DOI 10.1038/258748a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McClintock KA, 2002, BIOCHEMISTRY-US, V41, P5421, DOI 10.1021/bi011732m; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Portela LVC, 2002, CLIN DIAGN LAB IMMUN, V9, P164, DOI 10.1128/CDLI.9.1.164-166.2002; RICKMANN M, 1995, HISTOCHEM CELL BIOL, V103, P135, DOI 10.1007/BF01454011; Rustandi RR, 1999, PROTEIN SCI, V8, P1743, DOI 10.1110/ps.8.9.1743; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1999, MOL CELL BIOL, V19, P7168; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Takahashi M, 1999, CLIN CHEM, V45, P1307; VANELDIK LJ, 1986, J HISTOCHEM CYTOCHEM, V34, P977, DOI 10.1177/34.8.3734419; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Zimmer DB, 1998, J BIOL CHEM, V273, P4705, DOI 10.1074/jbc.273.8.4705	42	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49998	50007		10.1074/jbc.M205363200	http://dx.doi.org/10.1074/jbc.M205363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377780	hybrid			2022-12-25	WOS:000180028900117
J	Sandusky, G; Berg, DT; Richardson, MA; Myers, L; Grinnell, BW				Sandusky, G; Berg, DT; Richardson, MA; Myers, L; Grinnell, BW			Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ANTAGONIST; DYSFUNCTION; INHIBITION; MECHANISMS; PROMOTER; RECEPTOR; CELLS; RISK	Protein C is a plasma protease that in its active form plays a central role in the regulation of vascular function by modulating thrombosis, inflammation, and apoptosis. A central player in this pathway is the cytokine-regulated receptor thrombomodulin (TM), which functions as a co-factor for the thrombin-dependent generation of activated protein C. We have found that tumor necrosis factor-beta (TGF-beta)-dependent suppression of TM on endothelial cells is differentially regulated by endothelial Smad6s and Smad7. Overexpression of Smad6s resulted in activation of a TGF-beta reporter alone and enhanced TGF-beta response. Moreover, Smad6s overexpression suppressed TM and subsequently reduced activated protein C generation. Antisense inhibition of Smad6s expression enhanced the TM-dependent activation of protein C, whereas blocking the inhibitory Smad7 by antisense resulted in reduced TM-dependent activation of protein C. The effect of Smad6s appeared to be due, at least in part, to up-regulation of TGF-beta itself. Immunohistochemisty studies in normal versus atherosclerotic vessels showed that TM levels were suppressed in the endothelium over plaque. Consistent with the in vitro data, we found differential expression of Smad6s and Smad7 in normal versus atherosclerotic vessels, with Smad6s expression low in normal vessels but elevated in atherosclerotic vessels. In contrast, the opposite expression pattern was observed for Smad7. Overall, our results suggest that the relative balance of these intracellular Smads modulate the balance of endothelial function with regard to protein C activation.	Lilly Corp Ctr, Lilly Res Labs, Div Res Technol, Indianapolis, IN 46285 USA	Eli Lilly	Grinnell, BW (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Div Res Technol, Indianapolis, IN 46285 USA.	grinnell@lilly.com						ANTONOV AS, 1992, THROMB RES, V67, P135, DOI 10.1016/0049-3848(92)90133-U; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Calnek DS, 1998, EXP CELL RES, V238, P294, DOI 10.1006/excr.1997.3812; Esmon C, 2000, CRIT CARE MED, V28, pS44, DOI 10.1097/00003246-200009001-00010; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gimbrone M A Jr, 1989, J Card Surg, V4, P180, DOI 10.1111/j.1540-8191.1989.tb00275.x; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Grinnell BW, 1998, CORONARY ARTERY DIS, V9, P89; Grinnell BW, 2001, CRIT CARE MED, V29, pS53, DOI 10.1097/00003246-200107001-00020; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Joyce DE, 2002, CRIT CARE MED, V30, pS288, DOI 10.1097/00003246-200205001-00019; Keaney John F. Jr., 2000, Molecular Aspects of Medicine, V21, P99, DOI 10.1016/S0098-2997(00)00005-4; Kiechl S, 1999, CIRCULATION, V99, P614, DOI 10.1161/01.CIR.99.5.614; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Landmesser U, 2000, SEMIN THROMB HEMOST, V26, P529, DOI 10.1055/s-2000-13209; Laszik ZG, 2001, AM J PATHOL, V159, P797, DOI 10.1016/S0002-9440(10)61753-1; Lentz SR, 1999, ARTERIOSCL THROM VAS, V19, P1744, DOI 10.1161/01.ATV.19.7.1744; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Miyazono K, 2000, J CELL SCI, V113, P1101; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; OHJI T, 1995, THROMB HAEMOSTASIS, V73, P812; Richardson MA, 2000, ENDOCRINOLOGY, V141, P3908, DOI 10.1210/en.141.10.3908; Richter KK, 1997, RADIOTHER ONCOL, V44, P65, DOI 10.1016/S0167-8140(97)00063-7; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Tran ND, 1999, STROKE, V30, P1671, DOI 10.1161/01.STR.30.8.1671; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Yamada M, 1999, DEV BIOL, V215, P48, DOI 10.1006/dbio.1999.9419; Yan S. Betty, 1994, Perspectives in Drug Discovery and Design, V1, P503, DOI 10.1007/BF02171862; YAN SB, 1994, ANNU REP MED CHEM, V29, P103	48	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49815	49819		10.1074/jbc.C200543200	http://dx.doi.org/10.1074/jbc.C200543200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12407115	hybrid			2022-12-25	WOS:000180028900095
J	Granneman, S; Pruijn, GJM; Horstman, W; van Venrooij, WJ; Luhrmann, R; Watkins, NJ				Granneman, S; Pruijn, GJM; Horstman, W; van Venrooij, WJ; Luhrmann, R; Watkins, NJ			The hU3-55K protein requires 15.5K binding to the box B/C motif as well as flanking RNA elements for its association with the U3 small nucleolar RNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; CONSERVED ELEMENTS; C/D MOTIF; U4 SNRNA; IN-VIVO; RIBONUCLEOPROTEIN; SNORNA; YEAST; COMMON	The 15.5K protein directly binds to the 5' stem-loop of the U4 small nuclear RNA, the small nucleolar (sno) RNA box C/D motif, and the U3 snoRNA-specific box B/C motif. The box B/C motif has also been shown to be essential for the association of the U3 small nucleolar ribonucleoprotein-specific protein hU3-55K. We therefore set out to determine how 15.5K and hU3-55K recognize the box B/C motif. By using an in vitro assembly assay, we show that hU3-55K effectively binds a sub-fragment of the U3 snoRNA surrounding the B/C motif that we have named the U3BC RNA. The association of hU3-55K with the U3BC RNA is dependent on the binding of 15.5K to the box B/C motif. The association of hU3-55K with the U3BC RNA was found to be also dependent on a conserved RNA structure that flanks the box B/C motif. Furthermore, we show that hU3-55K, a WD 40 repeat containing protein, directly cross-links to the U3BC RNA. Our data support a new structural model of the box B/C region of the U3 snoRNA in which the box B/C motif is base-paired to form a structure highly similar to that of both the U4 5' stem-loop and the box C/D motif.	Max Planck Inst Biophys Chem, Abt Zellulare Biochem, D-37077 Gottingen, Germany; Univ Nijmegen, Dept Biochem 161, NL-6500 HB Nijmegen, Netherlands	Max Planck Society; Radboud University Nijmegen	Watkins, NJ (corresponding author), Max Planck Inst Biophys Chem, Abt Zellulare Biochem, Fassberg 11, D-37077 Gottingen, Germany.		Granneman, Sander/A-3150-2015; Pruijn, Ger/D-6664-2012	Granneman, Sander/0000-0003-4387-1271; Watkins, Nicholas/0000-0003-1256-3874				BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; Caffarelli E, 1998, MOL CELL BIOL, V18, P1023, DOI 10.1128/MCB.18.2.1023; Colley A, 2000, MOL CELL BIOL, V20, P7238, DOI 10.1128/MCB.20.19.7238-7246.2000; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Hughes JMX, 1996, J MOL BIOL, V259, P645, DOI 10.1006/jmbi.1996.0346; JEPPESEN C, 1988, NUCLEIC ACIDS RES, V16, P2127, DOI 10.1093/nar/16.5.2127; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; Lukowiak AA, 2000, NUCLEIC ACIDS RES, V28, P3462, DOI 10.1093/nar/28.18.3462; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Mereau A, 1997, J MOL BIOL, V273, P552, DOI 10.1006/jmbi.1997.1320; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; Nottrott S, 2002, EMBO J, V21, P5527, DOI 10.1093/emboj/cdf544; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; Pluk H, 1998, MOL CELL BIOL, V18, P488, DOI 10.1128/MCB.18.1.488; Samarsky DA, 1998, MOL CELL BIOL, V18, P3431, DOI 10.1128/MCB.18.6.3431; SAVINO R, 1991, BIOCHIMIE, V73, P805, DOI 10.1016/0300-9084(91)90060-E; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P1; Sharma K, 1999, MOL CELL BIOL, V19, P6012; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Speckmann W, 1999, MOL CELL BIOL, V19, P8412; Speckmann WA, 2000, NUCLEIC ACIDS RES, V28, P4467, DOI 10.1093/nar/28.22.4467; Terns MP, 2002, GENE EXPRESSION, V10, P17; TYE K, 1989, EMBO J, V8, P3113; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Vidovic I, 2000, MOL CELL, V6, P1331, DOI 10.1016/S1097-2765(00)00131-3; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Watkins NJ, 2002, MOL CELL BIOL, V22, P8342, DOI 10.1128/MCB.22.23.8342-8352.2002; Watkins NJ, 1996, RNA, V2, P118; Watkins NJ, 1998, RNA, V4, P582, DOI 10.1017/S1355838298980128; Wormsley S, 2001, RNA, V7, P904, DOI 10.1017/S1355838201010238; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	45	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48490	48500		10.1074/jbc.M206631200	http://dx.doi.org/10.1074/jbc.M206631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12381732	Green Published, hybrid			2022-12-25	WOS:000179789600070
J	Oliveriusova, J; Kery, V; Maclean, KN; Kraus, JP				Oliveriusova, J; Kery, V; Maclean, KN; Kraus, JP			Deletion mutagenesis of human cystathionine beta-synthase - Impact on activity, oligomeric status, and S-adenosylmethionine regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME PROTEIN; ESCHERICHIA-COLI; PYRIDOXAL-5'-PHOSPHATE-DEPENDENT ENZYMES; PYRIDOXAL 5'-PHOSPHATE; DOMAIN; HOMOCYSTINURIA; YEAST; TRANSSULFURATION; MUTATIONS; DISEASE	Cystathionine beta-synthase is a tetrameric hemeprotein that catalyzes the pyridoxal 5'-phosphate-dependent condensation of serine and homocysteine to cystathionine. We have used deletion mutagenesis of both the N and C termini to investigate the functional organization of the catalytic and regulatory regions of this enzyme. Western blot analysis of these mutants expressed in Escherichia coli indicated that residues 497-543 are involved in tetramer formation. Deletion of the 70 N-terminal residues resulted in a heme-free protein retaining 20% of wild type activity. Additional deletion of 151 C-terminal residues from this mutant resulted in an inactive enzyme. Expression of this double-deletion mutant as a glutathione S-transferase fusion protein generated catalytically active protein (15% of wild type activity) that was unaffected by subsequent removal of the fusion partner. The function of the N-terminal region appears to be primarily steric in nature and involved in the correct folding of the enzyme. The C-terminal region of human cystathionine beta-synthase contains two hydrophobic motifs designated "CBS domains." Partial deletion of the most C-terminal of these domains decreased activity and caused enzyme aggregation and instability. Removal of both of these domains resulted in stable constitutively activated enzyme. Deletion of as few as 8 C-terminal residues increased enzyme activity and abolished any further activation by S-adenosylmethionine indicating that the autoinhibitory role of the C-terminal region is not exclusively a function of the CBS domains.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Sch Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraus, JP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Sch Med, C233,4200 E 9th Ave, Denver, CO 80262 USA.				NHLBI NIH HHS [HL65217] Funding Source: Medline; NICHD NIH HHS [P01HD0805] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065217] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BRAUNSTE.AE, 1971, BIOCHIM BIOPHYS ACTA, V242, P247, DOI 10.1016/0005-2744(71)90105-7; Bruno S, 2001, J BIOL CHEM, V276, P16, DOI 10.1074/jbc.C000588200; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Janosik M, 2001, ACTA CRYSTALLOGR D, V57, P289, DOI 10.1107/S0907444900017893; Janosik M, 2001, AM J HUM GENET, V68, P1506, DOI 10.1086/320597; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kabil O, 1999, J BIOL CHEM, V274, P31256, DOI 10.1074/jbc.274.44.31256; Kery V, 1999, BIOCHEMISTRY-US, V38, P2716, DOI 10.1021/bi981808n; KERY V, 1995, ARCH BIOCHEM BIOPHYS, V316, P24, DOI 10.1006/abbi.1995.1005; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; KERY V, 1994, J BIOL CHEM, V269, P25283; Kluijtmans LAJ, 1996, J CLIN INVEST, V98, P285, DOI 10.1172/JCI118791; Kozich Viktor, 1992, Human Mutation, V1, P113, DOI 10.1002/humu.1380010206; KRAUS JP, 1987, METHOD ENZYMOL, V143, P388; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maclean KN, 2000, J INORG BIOCHEM, V81, P161, DOI 10.1016/S0162-0134(00)00100-8; Maclean KN, 2002, HUM MUTAT, V19, P641, DOI 10.1002/humu.10089; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; Mudd S., 2001, METABOLIC MOL BASES, P2007; Nozaki T, 2001, J BIOL CHEM, V276, P6516, DOI 10.1074/jbc.M009774200; Ojha S, 2002, BIOCHEMISTRY-US, V41, P4649, DOI 10.1021/bi011827o; ROLLAND N, 1993, ARCH BIOCHEM BIOPHYS, V300, P213, DOI 10.1006/abbi.1993.1030; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; Salzmann D, 2000, BIOCHEM BIOPH RES CO, V270, P576, DOI 10.1006/bbrc.2000.2460; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Shan XY, 2001, HUM MOL GENET, V10, P635, DOI 10.1093/hmg/10.6.635; Taoka S, 2002, J BIOL CHEM, V277, P22421, DOI 10.1074/jbc.M202513200; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	43	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48386	48394		10.1074/jbc.M207087200	http://dx.doi.org/10.1074/jbc.M207087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379655	hybrid			2022-12-25	WOS:000179789600056
J	Higuchi, H; Yoon, JH; Grambihler, A; Werneburg, N; Bronk, SF; Gores, GJ				Higuchi, H; Yoon, JH; Grambihler, A; Werneburg, N; Bronk, SF; Gores, GJ			Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; HEPATOCYTE APOPTOSIS; CELL-DEATH; CASPASE HOMOLOG; RECEPTOR; ACTIVATION; EXPRESSION; FAS; INHIBITION; GENE	Bile acids induce hepatocyte injury by enhancing death receptor-mediated apoptosis. In this study, bile acid effects on TRAIL-mediated apoptosis were examined to gain insight into bile acid potentiation of death receptor signaling. TRAIL-induced apoptosis of HuH-7 cells, stably transfected with a bile acid transporter, was enhanced by bile acids. Caspase 8 and 10 activation, bid cleavage, cytosolic cytochrome c, and caspase 3 activation by TRAIL were all increased by the bile acid glycochenodeoxycholate (GCDCA). GCDCA (100 muM) did not alter expression of TRAIL-R1/DR4, TRAIL-R2/DR5, procaspase 8, cFLIP-L, cFLIP-s, Bax, Bcl-xL, or Bax. However, both caspase 8 and caspase 10 recruitment and processing within the TRAIL death-inducing signaling complex (DISC) were greater in GCDCA-treated cells whereas recruitment of cFLIP long and short was reduced. GCDCA stimulated phosphorylation of both cFLIP isoforms, which was associated with decreased binding to GST-FADD. The protein kinase C antagonist chelerythrine prevented bile acid-stimulated cFLIP-L and -s phosphorylation, restored cFLIP binding to GST-FADD, and attenuated bile acid potentiation of TRAIL-induced apoptosis. These results provide new insights into the mechanisms of bile acid cytotoxicity and the proapoptotic effects of cFLIP phosphorylation in TRAIL signaling.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu	Yoon, Jung Hwan/J-5563-2012	Yoon, Jung-Hwan/0000-0002-9128-3610	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041876, R37DK041876, R01DK041876] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41876] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burns TF, 2001, J BIOL CHEM, V276, P37879; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; HOFMANN AF, 1990, HEPATOLOGY, V12, P17; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Im EO, 2001, CANCER LETT, V163, P83, DOI 10.1016/S0304-3835(00)00671-6; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones BA, 1997, AM J PHYSIOL-GASTR L, V272, pG1109, DOI 10.1152/ajpgi.1997.272.5.G1109; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kullak-Ublick G A, 2000, Clin Liver Dis, V4, P357, DOI 10.1016/S1089-3261(05)70114-8; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; Ozoren N, 2000, INT J ONCOL, V16, P917; Popper H, 1970, Hum Pathol, V1, P1, DOI 10.1016/S0046-8177(70)80002-8; POPPER H, 1968, ANNU REV MED, V19, P39, DOI 10.1146/annurev.me.19.020168.000351; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ravi R, 2002, CANCER RES, V62, P1583; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Sheikh MS, 1998, CANCER RES, V58, P1593; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; SRINIVASULA SM, 1997, J BIOL CHEM, V272, P18452; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Takikawa Y, 2001, GASTROENTEROLOGY, V120, P1810, DOI 10.1053/gast.2001.24835; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3	53	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					454	461		10.1074/jbc.M209387200	http://dx.doi.org/10.1074/jbc.M209387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407100	hybrid			2022-12-25	WOS:000180255700060
J	Li, YZ; Hansotia, T; Yusta, B; Ris, F; Halban, PA; Drucker, DJ				Li, YZ; Hansotia, T; Yusta, B; Ris, F; Halban, PA; Drucker, DJ			Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT INSULINOTROPIC POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; IN-VITRO; ENDOCRINE PANCREAS; GLUCOSE-TOLERANCE; SECRETORY SYSTEM; GENE-EXPRESSION; DIABETIC RATS; GROWTH-FACTOR; ISLET CELLS	Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.	Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada; Univ Geneva, Med Ctr, Louis Jeantet Res Labs, CH-1211 Geneva 4, Switzerland	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Geneva	Drucker, DJ (corresponding author), Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, 200 Elizabeth St,MBRW4R-402, Toronto, ON M5G 2C4, Canada.		Ris, Frederic/H-7030-2019; Drucker, Daniel J/A-4092-2010; Tuluc, Petronel/C-2527-2011	Ris, Frederic/0000-0001-7421-6101; 				Baggio L, 2000, ENDOCRINOLOGY, V141, P3703, DOI 10.1210/en.141.10.3703; Barsig J, 1997, INFECT IMMUN, V65, P4075, DOI 10.1128/IAI.65.10.4075-4081.1997; Borboni P, 1999, ENDOCRINOLOGY, V140, P5530, DOI 10.1210/en.140.12.5530; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Boushey RP, 2001, CANCER RES, V61, P687; BREGENHOLT S, 2001, 61 ANN M AM DIAB ASS, V50, pOR125; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; de la Tour DD, 2001, MOL ENDOCRINOL, V15, P476; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 1996, BLOOD, V87, P5152, DOI 10.1182/blood.V87.12.5152.bloodjournal87125152; Drucker DJ, 1999, TRENDS ENDOCRIN MET, V10, P153, DOI 10.1016/S1043-2760(98)00136-2; Drucker DJ, 1997, AM J PHYSIOL-GASTR L, V273, pG1252, DOI 10.1152/ajpgi.1997.273.6.G1252; Drucker DJ, 2001, J CLIN ENDOCR METAB, V86, P1759, DOI 10.1210/jc.86.4.1759; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Edvell A, 1999, ENDOCRINOLOGY, V140, P778, DOI 10.1210/en.140.2.778; Edwards CMB, 1999, DIABETES, V48, P86, DOI 10.2337/diabetes.48.1.86; Finegood DT, 2001, DIABETES, V50, P1021, DOI 10.2337/diabetes.50.5.1021; Flamez D, 1999, DIABETES, V48, P1979, DOI 10.2337/diabetes.48.10.1979; Greig NH, 1999, DIABETOLOGIA, V42, P45, DOI 10.1007/s001250051111; Hansen L, 1999, ENDOCRINOLOGY, V140, P5356, DOI 10.1210/en.140.11.5356; Heller RS, 1997, DIABETES, V46, P785, DOI 10.2337/diabetes.46.5.785; Hui HX, 2001, DIABETES, V50, P785, DOI 10.2337/diabetes.50.4.785; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KOLLIGS F, 1995, DIABETES, V44, P16, DOI 10.2337/diabetes.44.1.16; KOMATSU R, 1989, DIABETES, V38, P902, DOI 10.2337/diabetes.38.7.902; Kowluru A, 2002, BIOCHEM PHARMACOL, V63, P1027, DOI 10.1016/S0006-2952(02)00849-3; KREYMANN B, 1987, LANCET, V2, P1300; Ling Z, 2001, VIRCHOWS ARCH, V438, P382, DOI 10.1007/s004280000374; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MORGAN NG, 1994, BIOSCIENCE REP, V14, P243, DOI 10.1007/BF01209729; Nie Y, 2000, J CLIN INVEST, V105, P955, DOI 10.1172/JCI7456; OBrien BA, 1996, J PATHOL, V178, P176; ORSKOV C, 1988, FEBS LETT, V229, P175, DOI 10.1016/0014-5793(88)80821-4; ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467, DOI 10.1210/endo-119-4-1467; Perfetti R, 2000, ENDOCRINOLOGY, V141, P4600, DOI 10.1210/en.141.12.4600; ROSSINI AA, 1977, DIABETES, V26, P916, DOI 10.2337/diabetes.26.10.916; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172/JCI1349; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Scrocchi LA, 2000, DIABETES, V49, P1552, DOI 10.2337/diabetes.49.9.1552; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Tourrel C, 2001, DIABETES, V50, P1562, DOI 10.2337/diabetes.50.7.1562; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; Wang XL, 1999, ENDOCRINOLOGY, V140, P4904, DOI 10.1210/en.140.10.4904; WANG YH, 1995, ENDOCRINOLOGY, V136, P4910, DOI 10.1210/en.136.11.4910; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172/JCI119482; WETTERGREN A, 1993, DIGEST DIS SCI, V38, P665, DOI 10.1007/BF01316798; Xiao QA, 1999, GASTROENTEROLOGY, V117, P99, DOI 10.1016/S0016-5085(99)70555-X; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	65	481	534	2	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					471	478		10.1074/jbc.M209423200	http://dx.doi.org/10.1074/jbc.M209423200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12409292	hybrid, Green Published			2022-12-25	WOS:000180255700062
J	Maier, O; Hoekstra, D				Maier, O; Hoekstra, D			Trans-golgi network and subapical compartment of HepG2 cells display different properties in sorting and exiting of sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; MULTIDRUG-RESISTANCE PROTEIN; PLASMA-MEMBRANE PROTEINS; GPI-ANCHORED PROTEINS; MDCK CELLS; ENDOCYTIC PATHWAY; MAMMALIAN-CELLS; HEPATOMA-CELLS; CACO-2 CELLS; HT29 CELLS	In HepG2 cells, the subapical compartment (SAC) is involved in the biogenesis of membrane polarity. By contrast, direct apical transport originating from the trans-Golgi network (TGN), which may contribute to polarity establishment, has been poorly defined in these cells. Thus, although newly synthesized sphingolipids can be directly transported from the TGN to the apical membrane, numerous apical resident proteins are traveling via the transcytotic route. Here, we developed an in vitro transport assay and compared the molecular sorting of 6-[N-(7-nitrobenz-2-oxa-1,3 diazol-4-yl)amino] hexanoyl-sphingomyelin (C6NBD-SM) and C6NBD-glucosylceramide (C6NBD-GlcCer) in TGN and SAC. SM is released from both TGN and SAC in the lumenal leaflet of transport vesicles. This holds also for GlcCer released from the SAC but not for a substantial fraction that departed from the Golgi. Distinct transport vesicles, enriched in either SM or GlcCer are released from SAC, consistent with their rigid sorting in this compartment. Different vesicle populations could not be recovered from TGN, although in situ experiments reveal that GlcCer is preferentially transported to the apical membrane, reflecting different transport mechanisms. The results indicate that in HepG2 cells sphingolipids are mainly sorted in the SAC membrane and that the release of SM from SAC and TGN is differentially regulated.	Univ Groningen, Dept Membrane Cell Biol, Fac Med Sci, NL-9713 AV Groningen, Netherlands	University of Groningen	Hoekstra, D (corresponding author), Univ Groningen, Dept Membrane Cell Biol, Fac Med Sci, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.							BABIA T, 1994, EUR J CELL BIOL, V63, P172; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; Bastaki M, 2002, MOL BIOL CELL, V13, P225, DOI 10.1091/mbc.01-07-0376; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Ihrke G, 1998, J CELL BIOL, V141, P115, DOI 10.1083/jcb.141.1.115; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; KISHIMOTO Y, 1975, CHEM PHYS LIPIDS, V15, P33, DOI 10.1016/0009-3084(75)90029-8; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KOK JW, 1991, J CELL BIOL, V114, P231, DOI 10.1083/jcb.114.2.231; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Maier O, 2002, CHEM PHYS LIPIDS, V116, P3, DOI 10.1016/S0009-3084(02)00017-8; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Raggers RJ, 1999, J CELL SCI, V112, P415; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Roelofsen H, 1997, GASTROENTEROLOGY, V112, P511, DOI 10.1053/gast.1997.v112.pm9024305; Rothman JE, 1996, PROTEIN SCI, V5, P185; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; SLIMANE TA, 2003, IN PRESS MOL BIOL CE; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; van Ijzendoorn SCD, 1999, TRENDS CELL BIOL, V9, P144, DOI 10.1016/S0962-8924(99)01512-3; van IJzendoorn SCD, 1998, J CELL BIOL, V142, P683, DOI 10.1083/jcb.142.3.683; van Ijzendoorn SCD, 1999, MOL BIOL CELL, V10, P3449, DOI 10.1091/mbc.10.10.3449; van Ijzendoorn SCD, 2000, MOL BIOL CELL, V11, P1093, DOI 10.1091/mbc.11.3.1093; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanIjzendoorn SCD, 1997, J CELL BIOL, V137, P347, DOI 10.1083/jcb.137.2.347; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; Zegers MMP, 1997, BIOCHEM J, V328, P489, DOI 10.1042/bj3280489; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307	50	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					164	173		10.1074/jbc.M208259200	http://dx.doi.org/10.1074/jbc.M208259200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407103	hybrid			2022-12-25	WOS:000180255700022
J	Fujimoto, K; Shibasaki, T; Yokoi, N; Kashima, Y; Matsumoto, M; Sasaki, T; Tajima, N; Iwanaga, T; Seino, S				Fujimoto, K; Shibasaki, T; Yokoi, N; Kashima, Y; Matsumoto, M; Sasaki, T; Tajima, N; Iwanaga, T; Seino, S			Piccolo, a Ca2+ sensor in pancreatic beta-cells - Involvement of cAMP-GEFII center dot Rim2 center dot Piccolo complex in cAMP-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC ACTIVE ZONES; INSULIN-SECRETION; ENDOCRINE-CELLS; RAB3 EFFECTOR; PROTEIN; SYNAPTOTAGMIN; RIM; C-2-DOMAIN; FAMILY; ARCHITECTURE	We have previously shown that cAMP-binding protein cAMP-guanidine nucleotide exchange factor II (GEFII) (or Epac2) interacting with Rim2 is involved in cAMP-dependent, protein kinase A-independent exocytosis in pancreatic beta-cells. The action of the cAMP-GEFII.Rim2 complex requires both intracellular cAMP and Ca2+. Although Rim2 has C-2 domains, its role as a Ca2+ sensor has remained unclear. In the present investigation, we have discovered that Piccolo, a CAZ ((c) under bar ytoskeletal matrix associated with the (a) under bar ctive (z) under bar one) protein in neurons that is structurally related to Rim2, also binds to cAMP-GEFII and that it forms both homodimer and heterodimer with Rim2 in a Ca2+-dependent manner, whereas Rim2 alone does not form the homodimer. The association of Piccolo.Rim2 heterodimerization is stronger than Piccolo.Piccolo homodimerization. Treatment of pancreatic islets with antisense oligodeoxynucleotides against Piccolo inhibits insulin secretion induced by cAMP analog 8-bromo-cyclic AMP plus high glucose stimulation. These results suggest that Piccolo serves as a Ca2+ sensor in exocytosis in pancreatic beta-cells and that the formation of a cAMP-GEFII.Rim2.Piccolo complex is important in cAMP-induced insulin secretion. In addition, this study suggests that CAZ proteins similar to those in neurons are also function in pancreatic beta-cells.	Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Jikei Univ, Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, Tokyo 1058461, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan	Chiba University; Jikei University; Hokkaido University	Seino, S (corresponding author), Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	seino@med.m.chiba-u.ac.jp		Sasaki, Takashi/0000-0002-1413-6983				Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; GOTOW T, 1991, NEUROSCIENCE, V40, P587, DOI 10.1016/0306-4522(91)90143-C; Gut A, 2001, J CELL SCI, V114, P1709; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kasai H, 2002, DIABETES, V51, pS19, DOI 10.2337/diabetes.51.2007.S19; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; LANDIS DMD, 1988, J ELECTRON MICR TECH, V10, P129, DOI 10.1002/jemt.1060100203; LARSSON LI, 1980, INVEST CELL PATHOL, V3, P73; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; MALAISSE WJ, 1967, J CLIN INVEST, V46, P1724, DOI 10.1172/JCI105663; Naraghi M, 1997, J NEUROSCI, V17, P6961; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; SIEGEL EG, 1980, J CLIN INVEST, V65, P233, DOI 10.1172/JCI109665; Tanaka J, 1996, ARCH HISTOL CYTOL, V59, P485, DOI 10.1679/aohc.59.485; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; YORIFUJI H, 1989, J ELECTRON MICR TECH, V12, P160, DOI 10.1002/jemt.1060120210; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	36	152	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50497	50502		10.1074/jbc.M210146200	http://dx.doi.org/10.1074/jbc.M210146200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401793	hybrid			2022-12-25	WOS:000180177700041
J	Inman, GJ; Hill, CS				Inman, GJ; Hill, CS			Stoichiometry of active Smad-transcription factor complexes on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CRYSTAL-STRUCTURE; PROTEINS; ACTIVATION; PROMOTER; BINDING; INDUCTION; XENOPUS; PHOSPHORYLATION; TRIMERIZATION	Transforming growth factor (TGF)-beta signals through a heteromeric complex of serine/threonine kinase receptors. The type I receptor phosphorylates and activates the receptor-regulated Smads (R-Smads), Smad2 and Smad3, which form hetero-oligomeric complexes with the co-Smad, Smad4, and translocate to the nucleus. Smad3 and Smad4 can bind directly to consensus DNA-binding elements in the promoters of target genes, whereas Smad2/Smad4 complexes are targeted to DNA by interacting with sequence-specific DNA-binding transcription factors that contain a well-defined Smad interaction motif (SIM). The exact stoichiometry of Smad homo- and hetero-oligomers both before and after ligand stimulation is controversial. Here we determine the stoichiometry of TGF-beta-induced Smad-transcription factor complexes on DNA. We show that complexes of Smad2/Smad4 with the transcription factors Fast-1 or Fast-3 contain one Fast, two Smad2s, and one Smad4. In contrast, Smad3/Smad4 complexes that bind the Smad-binding element from the c-jun promoter, are heterodimers. Furthermore, these Smad3/Smad4 complexes contain at least two additional components essential for complex formation, one of which contains a SIM. Our data suggest that the R-Smads can form heterodimers or heterotrimers with Smad4, and we propose that the exact stoichiometries of active Smad complexes on DNA may be determined by the transcription factors with which they associate.	Canc Res UK London Res Inst, Lab Dev Signalling, London WC2A 3PX, England	Cancer Research UK	Hill, CS (corresponding author), Canc Res UK London Res Inst, Lab Dev Signalling, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Inman, Gareth/0000-0002-6264-4253; Hill, Caroline/0000-0002-8632-0480				Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Germain S, 2000, GENE DEV, V14, P435; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Howell M, 2002, DEVELOPMENT, V129, P2823; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	45	64	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51008	51016		10.1074/jbc.M208532200	http://dx.doi.org/10.1074/jbc.M208532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12374795	hybrid			2022-12-25	WOS:000180177700107
J	Nakashima, K; Hagiwara, T; Yamada, M				Nakashima, K; Hagiwara, T; Yamada, M			Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; HAIR FOLLICLE; ANTIFILAGGRIN AUTOANTIBODIES; NUCLEOTIDE-SEQUENCE; CITRULLINE RESIDUES; HUMAN EOSINOPHILS; RETINOIC ACID; CDNA CLONES; RAT	Peptidylarginine deiminase (PAD) deiminates 2 arginine residues in proteins to citrulline residues Ca2+ dependently. There are four types of PADs, I, II, III, and V, in humans. We studied the subcellular distribution of PAD V in HL-60 granulocytes and peripheral blood granulocytes. Expression of green fluorescent protein-tagged PADs in HeLa cells revealed that PAD V is localized in the nucleus, whereas PAD I, II, and III are localized in the cytoplasm. PAD V deletion mutants indicated that the sequence residues 45-74 have a nuclear localization signal (NLS). A sequence feature of this NLS is a three-lysine residue cluster preceded by a proline residue and is not found in the three other PADs. Substitution of the lysine cluster by an alanine cluster abrogated the nuclear import activity. These results suggested that the NLS is a classical monopartite NLS. HL-60 granulocytes, neutrophils, and eosinophils stained with antibody specific for PAD V exhibited distinct positive signals in the nucleus. Subcellular fractionation of HL-60 granulocytes also showed the nuclear localization of the enzyme. When neutrophils were stimulated with calcium ionophore A23187, protein deimination occurred in the nucleus. The major deiminated proteins were identified as histones H2A, H3, and H4. The implication of PAD V in histone modifications is discussed.	Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan	Yokohama City University	Yamada, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan.	myamada@yokohama-cu.ac.jp						Abu Rus'd A, 1999, EUR J BIOCHEM, V259, P660; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Akiyama K, 1999, NEUROSCI LETT, V274, P53, DOI 10.1016/S0304-3940(99)00678-3; Asaga H, 2001, J LEUKOCYTE BIOL, V70, P46; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Boggs JM, 1999, J NEUROSCI RES, V57, P529, DOI 10.1002/(SICI)1097-4547(19990815)57:4<529::AID-JNR12>3.0.CO;2-0; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; HALLET MB, 1997, MOL IONIC SIGNALING; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; HUR SJ, 1989, J BIOL CHEM, V264, P8542; Ishida-Yamamoto A, 2002, J INVEST DERMATOL, V118, P282, DOI 10.1046/j.0022-202x.2001.01671.x; Ishigami A, 1998, FEBS LETT, V433, P113, DOI 10.1016/S0014-5793(98)00893-X; Kanno T, 2000, J INVEST DERMATOL, V115, P813, DOI 10.1046/j.1523-1747.2000.00131.x; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahmudi-Azer S, 1998, J IMMUNOL METHODS, V217, P113, DOI 10.1016/S0022-1759(98)00105-7; Masson-Bessiere C, 2001, J IMMUNOL, V166, P4177, DOI 10.4049/jimmunol.166.6.4177; Moscarello MA, 2002, J NEUROCHEM, V81, P335, DOI 10.1046/j.1471-4159.2002.00834.x; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nakashima K, 1999, J BIOL CHEM, V274, P27786, DOI 10.1074/jbc.274.39.27786; Nishijyo T, 1997, J BIOCHEM, V121, P868; Ohsawa T, 2001, BIOMED RES-TOKYO, V22, P91, DOI 10.2220/biomedres.22.91; Pritzker LB, 1999, NEUROSCI LETT, V266, P161, DOI 10.1016/S0304-3940(99)00276-1; Rogers G, 1997, J INVEST DERMATOL, V108, P700, DOI 10.1111/1523-1747.ep12292083; Sambrook J, 2001, MOL CLONING LAB MANU; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; SENSHU T, 1992, ANAL BIOCHEM, V203, P94, DOI 10.1016/0003-2697(92)90047-B; Senshu T, 1999, J DERMATOL SCI, V21, P113, DOI 10.1016/S0923-1811(99)00026-2; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; TSUCHIDA M, 1993, EUR J BIOCHEM, V215, P677, DOI 10.1111/j.1432-1033.1993.tb18079.x; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; WATANABE K, 1989, J BIOL CHEM, V264, P15255; Welch K, 1999, MOL CELL BIOL, V19, P8400; Yamakoshi A, 1998, BBA-PROTEIN STRUCT M, V1386, P227, DOI 10.1016/S0167-4838(98)00084-3	48	257	273	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49562	49568		10.1074/jbc.M208795200	http://dx.doi.org/10.1074/jbc.M208795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393868	hybrid			2022-12-25	WOS:000180028900061
J	Servant, L; Cazaux, C; Bieth, A; Iwai, S; Hanaoka, F; Hoffmann, JS				Servant, L; Cazaux, C; Bieth, A; Iwai, S; Hanaoka, F; Hoffmann, JS			A role for DNA polymerase beta in mutagenic UV lesion bypass	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; CUTANEOUS MALIGNANT-MELANOMA; XERODERMA-PIGMENTOSUM; TRANSLESION SYNTHESIS; SEQUENCE CONTEXT; SUN EXPOSURE; REPLICATION; MUTATIONS; TEMPLATE; GENE	We report here that DNA polymerase beta (pol beta), the base excision repair polymerase, is highly expressed in human melanoma tissues, known to be associated with LTV radiation exposure. To investigate the potential role of pol beta in UV-induced genetic instability, we analyzed the cellular and molecular effects of excess pol beta. We firstly demonstrated that mammalian cells overexpressing pol beta are resistant and hypermutagenic after LTV irradiation and that replicative extracts from these cells are able to catalyze complete translesion replication of a thymine-thymine cyclobutane pyrimidine dimer (CPD). By using in vitro primer extension reactions with purified pol beta, we showed that CPD as well as, to a lesser extent, the thymine-thymine pyrimidine-pyrimidone (6-4) photoproduct, were bypassed. pol 13 mostly incorporates the correct dATP opposite the 3'-terminus of both CPD and the (6-4) photoproduct but can also misinsert dCTP at a frequency of 32 and 26%, respectively. In the case of CPD, efficient and error-prone extension of the correct dATP was found. These data support a biological role of pol 6 in LTV lesion bypass and suggest that deregulated pol beta may enhance UV-induced genetic instability.	CNRS, UMR 5089, Grp Genet Instabil & Canc, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Osaka Univ & Core Res Engn Sci & Technol, Grad Sch Frontier Biosci, CREST, Japan Sci & Technol Corp, Suita, Osaka 5650871, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Japan Science & Technology Agency (JST)	Hanaoka, F (corresponding author), CNRS, UMR 5089, Grp Genet Instabil & Canc, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France.	fhanaoka@imcb.osaka-u.ac.jp; jseb@ipbs.fr	Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				Bergoglio V, 2002, CANCER RES, V62, P3511; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Daube SS, 2000, BIOCHEMISTRY-US, V39, P397, DOI 10.1021/bi991443m; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Efrati E, 1997, J BIOL CHEM, V272, P2559; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; HOFFMANN JS, 1993, CANCER RES, V53, P2895; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOLMAN CDJ, 1986, J NATL CANCER I, V76, P403; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LICHTENAUERKALIGIS EGR, 1995, MUTAT RES-FUND MOL M, V326, P131, DOI 10.1016/0027-5107(94)00160-7; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928	44	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50046	50053		10.1074/jbc.M207101200	http://dx.doi.org/10.1074/jbc.M207101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388548	hybrid			2022-12-25	WOS:000180028900123
J	Ward, SM; Desgrosellier, JS; Zhuang, XL; Barnett, JV; Galper, JB				Ward, SM; Desgrosellier, JS; Zhuang, XL; Barnett, JV; Galper, JB			Transforming growth factor beta (TGF beta) signaling via differential activation of activin receptor-like kinases 2 and 5 during cardiac development - Role in regulating parasympathetic responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; EMBRYONIC CHICK HEART; I RECEPTORS; ATRIAL CELLS; K+ CHANNEL; EXPRESSION; PROTEINS; GENE; MEVINOLIN; INDUCTION	Little is known regarding factors that induce parasympathetic responsiveness during cardiac development. We demonstrated previously that in atrial cells cultured from chicks 14 days in ovo, transforming growth factor beta (TGFbeta) decreased parasympathetic inhibition of beat rate by the muscarinic agonist, carbamylcholine, by 5-fold and decreased expression of Ga-i2. Here in atrial cells 5 days in ovo, TGFbeta increased carbamylcholine inhibition of beat rate 2.5-fold and increased expression of Galpha(i2). TGFbeta also stimulated Ga-i2 mRNA expression and promoter activity at day 5 while inhibiting them at day. 14 in ovo. Over the same time course expression of type I TGFbeta receptors, chick activin receptor-like kinase 2 and 5 increased with a 2.3-fold higher increase in activin receptor-like kinase 2. Constitutively active activin receptor-like kinase 2 inhibited Galpha(i2), promoter activity, whereas constitutively active activin receptor-like kinase 5 stimulated Ga-i2 promoter activity independent of embryonic age. In 5-day atrial cells, TGFbeta stimulated the p3TP-lux reporter, which is downstream of activin receptor-like kinase 5 and had no effect on the activity of the pVent reporter, which is downstream of activin receptor-like kinase 2. In 14-day cells, TGFbeta stimulated both pVent and p3TP-lux. Thus TGFbeta exerts opposing effects on parasympathetic response and Ga-i2 expression by activating different type I TGFbeta receptors at distinct stages during cardiac development.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Harvard University; Brigham & Women's Hospital; Vanderbilt University	Galper, JB (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Thorn Res Bldg,75 Francis St, Boston, MA 02115 USA.		Desgrosellier, Jay S/A-8756-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052922, R01HL054225] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL052922, R01 HL052922-10, HL 52922, HL 54225] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARNETT JV, 1993, BIOCHEM J, V292, P395, DOI 10.1042/bj2920395; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; DEHAAN RL, 1967, CIRCULATION, V35, P821, DOI 10.1161/01.CIR.35.5.821; Donahue JK, 2000, NAT MED, V6, P1395; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; GALPER JB, 1977, J BIOL CHEM, V252, P8692; GALPER JB, 1995, PHYSL PATHOPHYSIOLOG, P431; HAIGH LS, 1988, J BIOL CHEM, V263, P15608; HAMBERGER U, 1945, J MORPHOL, V88, P49; Hanatani A, 1998, JPN HEART J, V39, P375; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; KILBOURNE EJ, 1994, GENE, V150, P341, DOI 10.1016/0378-1119(94)90449-9; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lai YT, 2000, DEV BIOL, V222, P1, DOI 10.1006/dbio.2000.9698; LIANG BT, 1986, J BIOL CHEM, V261, P9011; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Schuler-Metz A, 2000, J BIOL CHEM, V275, P34365, DOI 10.1074/jbc.M003915200; SCHWARTZ PJ, 1992, CIRCULATION S1, V85, P177; Suzuki A, 1997, DEV BIOL, V189, P112, DOI 10.1006/dbio.1997.8652; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; Ward SM, 2002, J MOL CELL CARDIOL, V34, P1217, DOI 10.1006/jmcc.2002.7023; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	33	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50183	50189		10.1074/jbc.M209668200	http://dx.doi.org/10.1074/jbc.M209668200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393881	hybrid			2022-12-25	WOS:000180028900139
J	Zhu, XH; Tang, GL; Galili, G				Zhu, XH; Tang, GL; Galili, G			The activity of the Arabidopsis bifunctional lysine-ketoglutarate reductase/saccharopine dehydrogenase enzyme of lysine catabolism is regulated by functional interaction between its two enzyme domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-SACCHAROPINE DEHYDROGENASE; OXOGLUTARATE REDUCTASE; SEEDS; PURIFICATION; COMPOSITE; PATHWAY; PLANTS; MAIZE; LOCUS	Lysine-ketoglutarate reductase/saccharopine dehydrogenase (LKR/SDH) is a bifunctional enzyme catalyzing the first two steps of lysine catabolism in animals and plants. To elucidate the biochemical signification of the linkage between the two enzymes of LKR/SDH, namely lysine ketoglutarate and saccharopine dehydrogenase, we employed various truncated and mutated Arabidopsis LKR/SDH polypeptides expressed in yeast. Activity analyses of the different recombinant polypeptides under conditions of varying NaCl levels implied that LKR, but not SDH activity, is regulated by functional interaction between the LKR and SDH domains, which is mediated by the structural conformation of the linker region connecting them. Because LKR activity of plant LKR/SDH enzymes is also regulated by casein kinase 2 phosphorylation, we searched for such potential regulatory phosphorylation sites using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and site-directed mutagenesis. This analysis identified Ser-458 as a candidate for this function. We also tested a hypothesis suggesting that an EF-hand-like sequence at the C-terminal part of the LKR domain functions in a calcium-dependent assembly of LKR/SDH into a homodimer. We found that this region is essential for LKR activity but that it does not control a calcium-dependent assembly of LKR/SDH. The relevance of our results to the in vivo function of LKR/SDH in lysine catabolism in plants is discussed. In addition, because the linker region between LKR and SDH exists only in plants but not in animal LKR/SDH enzymes, our results suggest that the regulatory properties of LKR/SDH and, hence, the regulation of lysine catabolism are different between plants and animals.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Galili, G (corresponding author), Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel.		Tang, Guiliang/C-7989-2012; Tang, Guiliang/F-1450-2010					Arruda P, 2000, TRENDS PLANT SCI, V5, P324, DOI 10.1016/S1360-1385(00)01688-5; Galili G, 2002, ANNU REV PLANT BIOL, V53, P27, DOI 10.1146/annurev.arplant.53.091401.110929; Galili G, 2001, CURR OPIN PLANT BIOL, V4, P261, DOI 10.1016/S1369-5266(00)00170-9; Gaziola SA, 1997, EUR J BIOCHEM, V247, P364, DOI 10.1111/j.1432-1033.1997.00364.x; KARCHI H, 1995, PLANT CELL, V7, P1963, DOI 10.1105/tpc.7.11.1963; KARCHI H, 1994, P NATL ACAD SCI USA, V91, P2577, DOI 10.1073/pnas.91.7.2577; Kemper EL, 1999, PLANT CELL, V11, P1981, DOI 10.1105/tpc.11.10.1981; Kemper EL, 1998, EUR J BIOCHEM, V253, P720, DOI 10.1046/j.1432-1327.1998.2530720.x; MARKOVITZ PJ, 1984, J BIOL CHEM, V259, P1643; Miron D, 2000, PLANT PHYSIOL, V123, P655, DOI 10.1104/pp.123.2.655; Miron D, 1997, PLANT J, V12, P1453, DOI 10.1046/j.1365-313x.1997.12061453.x; Moulin M, 2000, PLANT PHYSIOL BIOCH, V38, P577, DOI 10.1016/S0981-9428(00)00777-4; Papes F, 2001, FEBS LETT, V488, P34, DOI 10.1016/S0014-5793(00)02401-7; Tang GL, 2000, PLANT J, V23, P195, DOI 10.1046/j.1365-313x.2000.00770.x; Tang GL, 2002, PLANT PHYSIOL, V130, P147, DOI 10.1104/pp.005660; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WOODY NC, 1964, AM J DIS CHILD, V108, P543, DOI 10.1001/archpedi.1964.02090010545015; Zhu XH, 2000, BIOCHEM J, V351, P215, DOI 10.1042/0264-6021:3510215; Zhu XH, 2000, PLANT PHYSIOL, V124, P1363, DOI 10.1104/pp.124.3.1363; Zhu XH, 2001, PLANT PHYSIOL, V126, P1539, DOI 10.1104/pp.126.4.1539	20	20	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49655	49661		10.1074/jbc.M205466200	http://dx.doi.org/10.1074/jbc.M205466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393892	hybrid			2022-12-25	WOS:000180028900074
J	Kang, TB; Park, HI; Suh, Y; Zhao, YG; Tschesche, H; Sang, QXA				Kang, TB; Park, HI; Suh, Y; Zhao, YG; Tschesche, H; Sang, QXA			Autolytic processing at Glu(586)-Ser(587) within the cysteine-rich domain of human adamalysin 19/disintegrin-metalloproteinase 19 is necessary for its proteolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AMYLOID PRECURSOR PROTEIN; TYPE-1 MATRIX-METALLOPROTEINASE; ALPHA-CONVERTING-ENZYME; L1 ADHESION MOLECULE; GROWTH-FACTOR; L-SELECTIN; TGF-ALPHA; IL-6 RECEPTOR; MELTRIN BETA	We investigated the regulation of the proteolytic activity of human adamalysin 19 (a disintegrin and metalloproteinase 19, hADAM19). It was processed at Glu(586) (P1)-Ser(587)(P1') site in the cysteine-rich domain as shown by protein N-terminal sequencing. This truncation was autolytic as illustrated by its R199A/R200A or E346A mutation that prevented the zymogen activation by furin or abolished the catalytic activity. Reagents that block furin-mediated activation of pro-hADAM19, decRVKR-CMK, A23187, and brefeldin A abrogated this processing. The sizes of the side chains of the P1 and P1' residues are critical for the processing of hADAM19. The amount of processing product in the E586Q or S587A mutant with a side chain almost the same size as that in the wild type was almost equal. Conversely, very little processing was observed when the size of the side chain was changed significantly, such as in the E586A, E586G, or S587F mutants. Two mutants with presumably subtle structural distinctions from wild type hADAM19, E586D and S587T, displayed rare or little processing and had very low capacities to cleave alpha2-macroglobulin and a peptide substrate. Therefore, this processing is necessary for hADAM19 to exert its proteolytic activities. Moreover, a new peptide substrate, Ac-RPLE-SNAV, which is identical to the processing site sequence, was cleaved at the E-S bond by soluble hADAM19 containing the catalytic and disintegrin domains. This enzyme cleaved the substrate with K-m, k(cat), and k(cat)/K-m of 2.0 mm, 2.4/min, and 1200 M-1 min(-1), respectively, using a fluorescamine assay. Preliminary studies showed that a protein kinase C activator, phorbol 12-myristate 13-acetate, promoted the cellular processing of hADAM19; however, three calmodulin antagonists, trifluoperazine, W7, and calmidazolium, impaired this cleavage, indicating complex signal pathways may be involved in the processing.	Florida State Univ, Dept Chem & Biochem, 203 DLC,Chem Res Bldg,Rm 203, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Univ Bielefeld, Fac Chem, Dept Biochem, D-33615 Bielefeld, Germany	State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of Bielefeld	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, 203 DLC,Chem Res Bldg,Rm 203, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu			NATIONAL CANCER INSTITUTE [R29CA078646] Funding Source: NIH RePORTER; NCI NIH HHS [CA78646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfalah M, 2001, J BIOL CHEM, V276, P21105, DOI 10.1074/jbc.M100339200; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fors BP, 2001, J IMMUNOL, V167, P3642, DOI 10.4049/jimmunol.167.7.3642; Fritsche J, 2000, BLOOD, V96, P732; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kurohara K, 2000, BIOCHEM BIOPH RES CO, V270, P522, DOI 10.1006/bbrc.2000.2429; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MULLBERG J, 1994, J IMMUNOL, V152, P4958; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Nath D, 2001, J CELL SCI, V114, P1213; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Wei P, 2001, BIOCHEM BIOPH RES CO, V280, P744, DOI 10.1006/bbrc.2000.4200; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zhao YG, 2001, BIOCHEM BIOPH RES CO, V289, P288, DOI 10.1006/bbrc.2001.5958	67	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48514	48522		10.1074/jbc.M208961200	http://dx.doi.org/10.1074/jbc.M208961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12393862				2022-12-25	WOS:000179789600073
J	Salehi, AH; Xanthoudakis, S; Barker, PA				Salehi, AH; Xanthoudakis, S; Barker, PA			NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; N-TERMINAL KINASE; ZINC-FINGER PROTEIN; C-JUN; NEURONAL APOPTOSIS; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; CEP-1347 KT7515; PC12 CELLS; INHIBITOR	The p75 neurotrophin receptor (p75NTR) mediates signaling events leading to activation of the JNK pathway and cell death in a variety of cell types. We recently identified NRAGE, a protein that directly interacts with the p75NTR cytosolic region and facilitates p75NTR-mediated cell death. For the present study, we developed an inducible recombinant NRAGE adenovirus to dissect the mechanism of NRAGE-mediated apoptosis. Induced NRAGE expression resulted in robust activation of the JNK pathway that was not inhibited by the pharmacological mixed lineage kinase (MLK) inhibitor CEP1347. NRAGE induced cytosolic accumulation of cytochrome c, activation of Caspases-3, -9 and -7, and caspase-dependent cell death. Blocking JNK and c-Jun action by overexpression of the JNK-binding domain of JIP1 or dominant-negative c-Jun ablated NRAGE-mediated caspase activation and NRAGE-induced cell death. These findings identify NRAGE as a p75NTR interactor capable of inducing caspase activation and cell death through a JNK-dependent mitochondrial apoptotic pathway.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada	McGill University; Merck & Company	Barker, PA (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							Agerman K, 2000, MOL CELL NEUROSCI, V16, P258, DOI 10.1006/mcne.2000.0875; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chen YR, 2000, INT J ONCOL, V16, P651; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1996, NATURE, V383, P166; Frago LM, 1998, J CELL SCI, V111, P549; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460; Gu CH, 1999, J NEUROSCI, V19, P3043; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Majdan M, 1997, J NEUROSCI, V17, P6988; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; *QUANT BIOT INC, 2000, AD EAS VECT SYST APP; Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200; ROUX PP, 2002, IN PRESS J BIOL CHEM; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273	58	110	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48043	48050		10.1074/jbc.M205324200	http://dx.doi.org/10.1074/jbc.M205324200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376548	hybrid			2022-12-25	WOS:000179789600011
J	Morishita, T; Tsutsui, M; Shimokawa, H; Horiuchi, M; Tanimoto, A; Suda, O; Tasaki, H; Huang, PL; Sasaguri, Y; Yanagihara, N; Nakashima, Y				Morishita, T; Tsutsui, M; Shimokawa, H; Horiuchi, M; Tanimoto, A; Suda, O; Tasaki, H; Huang, PL; Sasaguri, Y; Yanagihara, N; Nakashima, Y			Vasculoprotective roles of neuronal nitric oxide synthase	FASEB JOURNAL			English	Article						arteriosclerosis; neointimal formation; vascular remodeling	SMOOTH-MUSCLE-CELLS; SELECTIVE-INHIBITION; GENETIC DEFICIENCY; LESION FORMATION; VASCULAR LESION; ANGIOTENSIN-II; NO; INJURY; EXPRESSION; INCREASES	Nitric oxide (NO) has multiple important actions that contribute to the maintenance of vascular homeostasis. NO is synthesized by three different isoforms of NO synthase (NOS), all of which have been reported to be expressed in human atherosclerotic vascular lesions. Although the regulatory roles of endothelial NOS (eNOS) and inducible NOS (iNOS) on the development of atherosclerosis have been described, little is known about the role of neuronal NOS (nNOS). Here, we show that nNOS also exerts important vasculoprotective effects in vivo. In a carotid artery ligation model, nNOS gene-deficient (nNOS-KO) mice exhibited accelerated neointimal formation and constrictive vascular remodeling caused by blood flow disruption. In a rat balloon injury model, the selective inhibition of nNOS activity potently enhanced vasoconstrictor responses to a variety of calcium-mobilizing stimuli, suppressed tissue cGMP concentrations, a marker of vascular NO production, and exacerbated neointimal formation. In both models, nNOS was absent before injury and was up-regulated only after the injury, and was predominantly expressed in the neointima and medial smooth muscle cells. These results provide the first direct evidence that nNOS plays important roles in suppressing arteriosclerotic vascular lesion formation in vivo.	Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pathol & Cell Biol, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kyushu University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tsutsui, M (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	mt2498@med.uoeh-u.ac.jp		Huang, Paul/0000-0002-5436-8658				Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; Chyu KY, 1999, CIRC RES, V85, P1192; DeSanctis GT, 1997, AM J PHYSIOL-LUNG C, V273, pL883, DOI 10.1152/ajplung.1997.273.4.L883; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GUTHRIE GP, 1995, CLIN CARDIOL S3, V18, P29; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; Kawashima S, 2001, ARTERIOSCL THROM VAS, V21, P201, DOI 10.1161/01.ATV.21.2.201; Koglin J, 1998, CIRCULATION, V97, P2059, DOI 10.1161/01.CIR.97.20.2059; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kumar A, 1997, CIRCULATION, V96, P4333; LUSCHER TF, 1990, ENDOTHELIUM MODULATO; MAJOR TC, 1995, AM J PHYSIOL-HEART C, V269, pH988, DOI 10.1152/ajpheart.1995.269.3.H988; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MITSUHASHI T, 1989, J CLIN INVEST, V84, P635, DOI 10.1172/JCI114209; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI200214940; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841; THOMAS G, 1991, BIOCHEM BIOPH RES CO, V179, P1677, DOI 10.1016/0006-291X(91)91768-8; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Yogo K, 2000, ARTERIOSCL THROM VAS, V20, pE96, DOI 10.1161/01.ATV.20.11.e96	36	78	82	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12								10.1096/fj.02-0155fje	http://dx.doi.org/10.1096/fj.02-0155fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397095				2022-12-25	WOS:000179167600014
J	Lochard, N; Silversides, DW; van Kats, JP; Mercure, C; Reudelhuber, TL				Lochard, N; Silversides, DW; van Kats, JP; Mercure, C; Reudelhuber, TL			Brain-specific restoration of angiotensin II corrects renal defects seen in angiotensinogen-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL PEPTIDE PUMP; 1A RECEPTOR GENE; TRANSGENIC MICE; BLOOD-PRESSURE; MESSENGER-RNA; GROWTH-FACTOR; HUMAN RENIN; EXPRESSION; INHIBITORS; MORPHOLOGY	Mice deficient for angiotensinogen (AGT), or other components of the renin-angiotensin system, show a high rate of neonatal mortality correlated with severe renal abnormalities including hydronephrosis, hypertrophy of renal arteries, and an impaired ability to concentrate urine. Although transgenic replacement of systemic or adipose, but not renal, AGT in AGT-deficient mice has previously been reported to correct some of these renal abnormalities, the tissue target for this complementation has not been defined. In the current study, we have used a novel transgenic strategy to restore the peptide product of the renin-angiotensin system, angiotensin II, exclusively in the brain of AGT-deficient mice and demonstrate that brain-specific angiotensin 11 can correct the hydronephrosis and partially correct renal dysfunction seen in AGT-deficient mice. Taken together, these results suggest that the renin-angiotensin system affects renal development and function through systemically accessible targets in the brain.	Clin Res Inst Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Reudelhuber, TL (corresponding author), Clin Res Inst Montreal, Lab Mol Biochem Hypertens, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.		van Kats, Jorge/A-8284-2008					Bader J, 2001, J MOL MED, V79, P76, DOI 10.1007/s001090100210; BARR M, 1991, TERATOLOGY, V44, P485, DOI 10.1002/tera.1420440503; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Chen XM, 1997, AM J PHYSIOL-RENAL, V272, pF299, DOI 10.1152/ajprenal.1997.272.3.F299; Clark AF, 1997, J BIOL CHEM, V272, P18185, DOI 10.1074/jbc.272.29.18185; Davisson RL, 1997, J CLIN INVEST, V99, P1258, DOI 10.1172/JCI119283; DiBona GF, 2002, CURR OPIN NEPHROL HY, V11, P197, DOI 10.1097/00041552-200203000-00011; Ding YM, 2001, J BIOL CHEM, V276, P7431, DOI 10.1074/jbc.M003892200; Ganong WF, 2000, CLIN EXP PHARMACOL P, V27, P422, DOI 10.1046/j.1440-1681.2000.03259.x; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Inokuchi S, 1998, VIRCHOWS ARCH, V433, P349, DOI 10.1007/s004280050259; Ishida J, 1998, BIOCHEM BIOPH RES CO, V252, P610, DOI 10.1006/bbrc.1998.9707; IWAI N, 1992, BIOCHEM BIOPH RES CO, V188, P298, DOI 10.1016/0006-291X(92)92384-A; JOHNSON AK, 1975, PHARMACOL BIOCHEM BE, V3, P1077; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V185, P688, DOI 10.1016/0006-291X(92)91680-O; Kessler SP, 2002, J BIOL CHEM, V277, P4271, DOI 10.1074/jbc.M109474200; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Marcinkiewicz M, 1997, NEUROSCIENCE, V76, P425, DOI 10.1016/S0306-4522(96)00318-1; Massiera F, 2001, FASEB J, V15, P2727, DOI 10.1096/fj.01-0457fje; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; Matsusaka T, 2002, ANNU REV PHYSIOL, V64, P551, DOI 10.1146/annurev.physiol.64.081501.155721; Methot D, 1999, CIRC RES, V84, P1067, DOI 10.1161/01.RES.84.9.1067; METHOT D, 1995, NUCLEIC ACIDS RES, V23, P4551, DOI 10.1093/nar/23.22.4551; Methot D, 2001, AM J HYPERTENS, V14, p38S, DOI 10.1016/S0895-7061(01)02068-4; Murakami K, 1999, IMMUNOPHARMACOLOGY, V44, P1, DOI 10.1016/S0162-3109(99)00142-3; Niimura F, 1995, J CLIN INVEST, V96, P2947, DOI 10.1172/JCI118366; Phillips VR, 2001, J AGR ENG RES, V78, P1, DOI 10.1006/jaer.2000.0618; PIPER JM, 1992, OBSTET GYNECOL, V80, P429; Prescott G, 2000, PHYSIOL GENOMICS, V4, P67, DOI 10.1152/physiolgenomics.2000.4.1.67; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; Sharp MGF, 1996, HYPERTENSION, V28, P1126, DOI 10.1161/01.HYP.28.6.1126; SHOTAN A, 1994, AM J MED, V96, P451, DOI 10.1016/0002-9343(94)90172-4; van Kats JP, 2001, J BIOL CHEM, V276, P44012, DOI 10.1074/jbc.M106132200; VANHOUTEN M, 1980, BRAIN RES, V186, P480, DOI 10.1016/0006-8993(80)90995-6; VOLICER L, 1971, NEUROPHARMACOLOGY, V10, P631, DOI 10.1016/0028-3908(71)90029-3; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968; Zou LX, 1998, AM J HYPERTENS, V11, P570, DOI 10.1016/S0895-7061(97)00410-X	41	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2184	2189		10.1074/jbc.M209933200	http://dx.doi.org/10.1074/jbc.M209933200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12399452	hybrid			2022-12-25	WOS:000180562000016
J	Newton, DC; Bevan, SC; Choi, S; Robb, GB; Millar, A; Wang, Y; Marsden, PA				Newton, DC; Bevan, SC; Choi, S; Robb, GB; Millar, A; Wang, Y; Marsden, PA			Translational regulation of human neuronal nitric-oxide synthase by an alternatively spliced 5 '-untranslated region leader exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; 5' UNTRANSLATED REGION; BINDING-PROTEIN; SECONDARY STRUCTURE; OXIDATIVE STRESS; NO SYNTHASE; GENE; EXPRESSION; IDENTIFICATION	Expression of the neuronal nitric-oxide synthase (nNOS) mRNA is subject to complex cell-specific transcriptional regulation, which is mediated by alternative promoters. Unexpectedly, we identified a 89-nucleotide alternatively spliced exon located in the 5'-untranslated region between exon 1 variants and a common exon 2 that contains the translational initiation codon. Alternative splicing events that do not affect the open reading frame are distinctly uncommon in mammals; therefore, we assessed its functional relevance. Transient transfection of reporter RNAs performed in a variety of cell types revealed that this alternatively spliced exon acts as a potent translational repressor. Stably transfected cell lines confirmed that the alternatively spliced exon inhibited translation of the native nNOS open reading frame. Reverse transcription-PCR and RNase protection assays indicated that nNOS mRNAs containing this exon are common and expressed in both a promoter-specific and tissue-restricted fashion. Mutational analysis identified the functional cis-element within this novel exon, and a secondary structure prediction revealed that it forms a putative stem-loop. RNA electrophoretic mobility shift assay techniques revealed that a specific cytoplasmic RNA-binding complex interacts with this motif. Hence, a unique splicing event within a 5'-untranslated region is demonstrated to introduce a translational control element. This represents a newer model for the translational control of a mammalian mRNA.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Choi, Stephen/AAS-5123-2021; Marsden, Philip A/B-1441-2012	Choi, Stephen/0000-0003-3662-9073; Robb, Gregory Brett/0000-0002-2382-2256				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Boissel JP, 1998, NITRIC OXIDE-BIOL CH, V2, P337, DOI 10.1006/niox.1998.0189; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Catania MV, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-11-j0002.2001; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Duga S, 1999, EUR J BIOCHEM, V259, P188, DOI 10.1046/j.1432-1327.1999.00029.x; Ehresmann C, 1995, BIOCHEM CELL BIOL, V73, P1131, DOI 10.1139/o95-122; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Gu W, 1996, MOL CELL BIOL, V16, P4535; HALL AV, 1994, J BIOL CHEM, V269, P33082; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Huo L, 1999, GENE, V233, P213, DOI 10.1016/S0378-1119(99)00135-3; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Kim KW, 2001, GENE, V273, P163, DOI 10.1016/S0378-1119(01)00595-9; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; RAO SM, 1993, J BIOL CHEM, V268, P22164; Roczniak A, 1998, AM J PHYSIOL-RENAL, V275, pF46, DOI 10.1152/ajprenal.1998.275.1.F46; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Sun XL, 1996, J BIOL CHEM, V271, P25539; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; THEIL EC, 1990, ENZYME, V44, P68, DOI 10.1159/000468748; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 2002, AM J PATHOL, V160, P369, DOI 10.1016/S0002-9440(10)64380-5; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhu WY, 2001, J CELL BIOCHEM, V81, P205, DOI 10.1002/1097-4644(20010501)81:2<205::AID-JCB1036>3.0.CO;2-S	67	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					636	644		10.1074/jbc.M209988200	http://dx.doi.org/10.1074/jbc.M209988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403769	hybrid			2022-12-25	WOS:000180255700081
J	Zhang, P; Jimenez, SA; Stokes, DG				Zhang, P; Jimenez, SA; Stokes, DG			Regulation of human COL9A1 gene expression - Activation of the proximal promoter region by SOX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; II COLLAGEN; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTOR; CARTILAGE; ELEMENTS; IX; CHONDROGENESIS; IDENTIFICATION	The COL9A1 gene contains two promoter regions, one driving expression of a long alpha1(IX) chain in cartilage (upstream) and one driving expression of a shorter chain in the cornea and vitreous (downstream). To determine how the chondrocyte-specific expression of the COL9A1 gene is regulated, we have begun to characterize the upstream chondrocyte-specific promoter region of the human COL9A1 gene. Transient-transfection analyses performed in rat chondrosarcoma (RCS) cells, human chondrosarcoma (HTB) cells, and NIH/3T3 cells showed that the COL9A1 promoter was active in RCS cells but not HTB or NIH/3T3 cells. Inclusion of the first intron had no effect on promoter activity. In transient-transfection analyses with promoter deletion constructs, it was found that full promoter activity in RCS cells depended on the region from -560 bp to +130 bp relative to the transcriptional start site (+1). Sequence analysis of the region from -890 bp to the transcriptional start predicted five putative SOX/Sry-binding sites. Mutation analysis revealed that two of three putative SOX/Sry binding sites within the -560 to +130 bp region are responsible for most of the COL9A1 promoter activity in RCS cells. Co-transfection experiments with a SOX9 expression plasmid revealed that a construct containing the five putative SOX/Sry-binding sites was transactivated 20- to 30-fold in both HTB and NIH/3T3 cells. Further co-transfection experiments showed that two of the SOX/Sry-binding sites located within the -560 to + 130 bp region were required for full transactivation. However, mutation and deletion analyses indicated that a region from -560 to -357 bp, which does not contain any other conspicuous SOX9 sites, is also important for full promoter activity. DNA-protein binding assays and super-shift analysis revealed that SOX9 can form a specific complex with one of the SOX/Sry-binding sites with in the -560 to +130 region.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA	Jefferson University	Stokes, DG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, 233 S 10th St,Rm 511 BLSB, Philadelphia, PA 19107 USA.	david.g.stokes@mail.tju.edu		Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR-39740, AR07583-08] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, T32AR007583] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; KIMURA T, 1989, EUR J BIOCHEM, V179, P71, DOI 10.1111/j.1432-1033.1989.tb14522.x; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Stokes DG, 2001, BIOCHEM J, V360, P461, DOI 10.1042/0264-6021:3600461; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1985, J BIOL CHEM, V260, P220; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8	30	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					117	123		10.1074/jbc.M208049200	http://dx.doi.org/10.1074/jbc.M208049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12399468	hybrid			2022-12-25	WOS:000180255700016
J	Baron, A; Deval, E; Salinas, M; Lingueglia, E; Voilley, N; Lazdunski, M				Baron, A; Deval, E; Salinas, M; Lingueglia, E; Voilley, N; Lazdunski, M			Protein kinase C stimulates the acid-sensing ion channel ASIC2a via the PDZ domain-containing protein PICK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; GATED NA+ CHANNEL; AMPA RECEPTOR; SENSORY NEURONS; SYNAPTIC TRANSMISSION; BINDING-PROTEIN; HIPPOCAMPAL SLICES; DOWN-REGULATION; RAT; INTERACTS	Acid-sensing ion channels (ASICs) are cationic channels activated by extracellular protons. They are expressed in central and sensory neurons where they are involved in neuromodulation and in pain perception. Recently, the PDZ domain-containing protein PICK1 (protein interacting with C-kinase) has been shown to interact with ASIC1a and ASIC2a, raising the possibility that protein kinase C (PKC) could regulate ASICs. We now show that the amplitude of the ASIC2a current, which was only modestly increased (similar to+30%) by the PKC activator 1-oleyl-2-acetyl-sn-glycerol (OAG, 50 muM) in the absence of PICK1, was strongly potentiated (similar to+300%) in the presence of PICK1. This PICK1-dependent regulatory effect was inhibited in the presence of a PKC inhibitory peptide and required the PDZ domain of PICK1 as well as the PDZ-binding domain of ASIC2a. We have also shown the direct PICK1-dependent phosphorylation of ASIC2a by [P-32]phosphate labeling and immunoprecipitation and identified a major phosphorylation site, (TIR)-T-39, on the N terminus part of ASIC2a. The OAG-induced increase in ASIC2a current amplitude did not involve any change in the unitary conductance of the ASIC2a channel, whether co-expressed with PICK1 or not. These data provide the first demonstration of a regulation of ASICs by protein kinase phosphorylation and its potentiation by the partner protein PICK1.	CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	SALINAS, Miguel/N-6380-2016; DEVAL, Emmanuel/N-6280-2016; BARON, Anne/N-5691-2016; LINGUEGLIA, Eric/F-5509-2013	SALINAS, Miguel/0000-0002-7445-123X; DEVAL, Emmanuel/0000-0002-0215-9379; BARON, Anne/0000-0002-8026-6380; LINGUEGLIA, Eric/0000-0003-3902-3405				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Bolshakov KV, 2002, NEUROSCIENCE, V110, P723, DOI 10.1016/S0306-4522(01)00582-6; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Boudin H, 2001, J BIOL CHEM, V276, P30270, DOI 10.1074/jbc.M102991200; Braithwaite SP, 2002, P NATL ACAD SCI USA, V99, P7096, DOI 10.1073/pnas.102156099; BROCKWAY LM, 2002, AM J PHYSIOL, V283, pC123; Carroll RC, 1998, J NEUROPHYSIOL, V80, P2797, DOI 10.1152/jn.1998.80.5.2797; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, J NEUROPHYSIOL, V81, P1104, DOI 10.1152/jn.1999.81.3.1104; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MCGUIRK SM, 1992, NEUROSCIENCE, V49, P117, DOI 10.1016/0306-4522(92)90079-H; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; OHNO M, 1989, Neurological Research, V11, P153; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Perroy J, 2002, EMBO J, V21, P2990, DOI 10.1093/emboj/cdf313; Petruska JC, 2000, J NEUROPHYSIOL, V84, P2365, DOI 10.1152/jn.2000.84.5.2365; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Steen KH, 1996, PAIN, V66, P163, DOI 10.1016/0304-3959(96)03034-5; Sutherland S P, 2000, Prog Brain Res, V129, P21; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3	72	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50463	50468		10.1074/jbc.M208848200	http://dx.doi.org/10.1074/jbc.M208848200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399460	hybrid			2022-12-25	WOS:000180177700035
J	Bennaars-Eiden, A; Higgins, L; Hertzel, AV; Kapphahn, RJ; Ferrington, DA; Bernlohr, DA				Bennaars-Eiden, A; Higgins, L; Hertzel, AV; Kapphahn, RJ; Ferrington, DA; Bernlohr, DA			Covalent modification of epithelial fatty acid-binding protein by 4-hydroxynonenal in vitro and in vivo - Evidence for a role in antioxidant biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; MESSENGER-RNA; SKIN-TYPE; EXPRESSION; IDENTIFICATION; PURIFICATION; NEURONS; RETINA; FAMILY; CELLS	4-Hydroxynonenal (4-HNE) is a cytotoxic alpha,beta-unsaturated acyl aldehyde that is naturally produced from lipid peroxidation and cleavage in response to oxidative stress and aging. Such reactive lipids covalently modify cellular target proteins, thereby affecting biological structure and function. Herein we report the identification of the epithelial fatty acid-binding protein (E-FABP) as a molecular target for 4-HNE modification both in vitro and in vivo. 4-HNE covalently modified (t(1/2) < 60 s) E-FABP in vitro, as revealed by a combination of matrix-assisted laser desorption ionization-time of flight mass spectrometry and immunochemical reactivity using antibodies directed to 4-HNE-protein conjugates. Identification of Cys-120 as the major site of modification was determined through tandem mass spectral sequencing of tryptic peptides, as well as analysis of E-FABP mutants C120A, C127A, and C120A/C127A. The in vitro modification of Cys-120 by 4-HNE was relatively insensitive to pH (6.4-8.4), and temperature (4-37 degrees C) but was markedly potentiated by noncovalently bound fatty acids. 4-HNE-modified E-FABP was more stable than unmodified E-FABP to chemical denaturation by guanidine hydrochloride, as assessed by changes in intrinsic tryptophan fluorescence. Analysis of soluble protein extracts from rat retina with antibodies directed to 4-HNE-protein conjugates revealed immunoreactivity with a 15-kDa protein that was identified by electrospray ionization and matrix-assisted laser desorption ionization-time of flight mass spectrometry as E-FABP. Evaluation of retinal pigment epithelial cell extracts derived from E-FABP null mice by two-dimensional gel electrophoresis using anti-4-HNE antibodies revealed increased modification in the null cells relative to those from wild type cells. These results indicate that E-FABP is a molecular target for 4-HNE modification and the hypothesis that E-FABP functions as an antioxidant protein by scavenging reactive lipids through covalent modification of Cys-120.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.	bern1001@umn.edu		Ferrington, Deborah/0000-0003-2561-7464	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG019024] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07741] Funding Source: Medline; NIA NIH HHS [R03 AG19024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; DeLeon M, 1996, J NEUROSCI RES, V44, P283; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ESTERBAUER H, 1989, FREE RADICAL BIO MED, V7, P197, DOI 10.1016/0891-5849(89)90015-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gutierrez-Gonzalez LH, 2002, BIOCHEM J, V364, P725, DOI 10.1042/BJ20020039; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; HAUPTLORENZ S, 1985, BIOCHEM PHARMACOL, V34, P3803, DOI 10.1016/0006-2952(85)90428-9; Herbst U, 1999, J CELL PHYSIOL, V181, P295, DOI 10.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Hohoff C, 1999, BIOCHEMISTRY-US, V38, P12229, DOI 10.1021/bi990305u; ISACSSON U, 1974, ANAL CHIM ACTA, V68, P339, DOI 10.1016/S0003-2670(01)82590-3; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Kane CD, 1996, BIOCHEMISTRY-US, V35, P2894, DOI 10.1021/bi952476e; Kingma PB, 1998, BIOCHEMISTRY-US, V37, P3250, DOI 10.1021/bi972520l; KRIEG P, 1993, J BIOL CHEM, V268, P17362; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; Kruman I, 1997, J NEUROSCI, V17, P5089; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599; McArthur MJ, 1999, J LIPID RES, V40, P1371; Ostergaard M, 1997, CANCER RES, V57, P4111; Owada Y, 1996, MOL BRAIN RES, V42, P156, DOI 10.1016/S0169-328X(96)00182-9; Owada Y, 2002, J INVEST DERMATOL, V118, P430, DOI 10.1046/j.0022-202x.2001.01616.x; Owada Y, 1997, NEUROSCI LETT, V223, P25, DOI 10.1016/S0304-3940(97)13390-0; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Pizzimenti S, 1999, FREE RADICAL BIO MED, V26, P1578, DOI 10.1016/S0891-5849(99)00022-2; Poli G, 2000, IUBMB LIFE, V50, P315, DOI 10.1080/15216540051081092; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simpson MA, 1998, BIOCHEMISTRY-US, V37, P10980, DOI 10.1021/bi980507a; Singh SK, 2002, J BIOL CHEM, V277, P7567, DOI 10.1074/jbc.M107908200; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Terrasa A, 1998, MOL CELL BIOCHEM, V178, P181, DOI 10.1023/A:1006839413757; VANKUIJK FJGM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P116, DOI 10.1016/0005-2760(90)90118-H; Watanabe R, 1996, ARCH DERMATOL RES, V288, P481, DOI 10.1007/BF02505239; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITE JS, 1984, CHEM-BIOL INTERACT, V52, P233, DOI 10.1016/0009-2797(84)90076-0	47	108	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50693	50702		10.1074/jbc.M209493200	http://dx.doi.org/10.1074/jbc.M209493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386159	hybrid			2022-12-25	WOS:000180177700066
J	Dohadwala, M; Batra, RK; Luo, J; Lin, Y; Krysan, K; Pold, M; Sharma, S; Dubinett, SM				Dohadwala, M; Batra, RK; Luo, J; Lin, Y; Krysan, K; Pold, M; Sharma, S; Dubinett, SM			Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED EXPRESSION; HYALURONAN RECEPTOR; UP-REGULATION; INHIBITION; CARCINOMA; APOPTOSIS; COX-2; MATRIX-METALLOPROTEINASE-9; PROLIFERATION; GROWTH	Tumor cyclooxygenase-2 (COX-2) expression is known to be associated with enhanced tumor invasiveness. In the present study, we evaluated the importance of the COX-2 product prostaglandin E2 (PGE2) and its signaling through the EP4 receptor in mediating non-small cell lung cancer (NSCLC) invasiveness. Genetic inhibition of tumor COX-2 led to diminished matrix metalloproteinase (MMP)-2, CD44, and EP4 receptor expression and invasion. Treatment of NSCLC cells with exogenous 16,16-dimethylprostaglandin E2 significantly increased EP4 receptor, CD44, and MMP-2 expression and matrigel invasion. In contrast, anti-PGE2 decreased EP4 receptor, CD44, and MMP-2 expression in NSCLC cells. EP4 receptor signaling was found to be central to this process, because antisense oligonucleotide-mediated inhibition of tumor cell EP4 receptors significantly decreased CD44 expression. In addition, agents that increased intracellular cAMP, as is typical of EP4 receptor signaling, markedly increased CD44 expression. Moreover, MMP-2-AS treatment decreased PGE2-mediated CD44 expression, and CD44-AS treatment decreased MMP-2 expression. Thus, PGE2-mediated effects through EP4 required the parallel induction of both CD44 and MMP-2 expression because genetic inhibition of either MMP-2 or CD44 expression effectively blocked PGE2-mediated invasion in NSCLC. These findings indicate that PGE2 regulates COX-2-dependent, CD44- and MMP-2-mediated invasion in NSCLC in an autocrine/paracrine manner via EP receptor signaling. Thus, blocking PGE2 production or activity by genetic or pharmacological interventions may prove to be beneficial in chemoprevention or treatment of NSCLC.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Hlth Care Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu		Batra, Raj K./0000-0002-1126-543X	NCI NIH HHS [R01CA71818, P50 CA90388, P50 CA090388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, R01CA071818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attiga FA, 2000, CANCER RES, V60, P4629; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Bramhall SR, 1997, INT J PANCREATOL, V21, P1; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Chan G, 1999, CANCER RES, V59, P991; Chen Y, 2000, BRIT J CANCER, V82, P2000; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Ding XZ, 2000, ANTICANCER RES, V20, P2625; Dohadwala M, 2001, J BIOL CHEM, V276, P20809, DOI 10.1074/jbc.C100140200; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 1998, ANTICANCER RES, V18, P775; Hida T, 2000, CLIN CANCER RES, V6, P2006; Huang M, 1998, CANCER RES, V58, P1208; Huang M, 1996, J IMMUNOL, V157, P5512; Iizasa T, 1999, CLIN CANCER RES, V5, P149; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Jabbour HN, 2001, BRIT J CANCER, V85, P1023; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kakiuchi Y, 2002, CANCER RES, V62, P1567; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KOHN EC, 1995, CANCER RES, V55, P1856; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina MA, 1999, CANCER RES, V59, P4356; Mutoh M, 2002, CANCER RES, V62, P28; Niki T, 2002, AM J PATHOL, V160, P1129, DOI 10.1016/S0002-9440(10)64933-4; Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x; PANETTIERI RA, 1995, J IMMUNOL, V154, P2358; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; STETLERSTEVENSON WG, 1994, INVAS METAST, V14, P259; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun LK, 2001, KIDNEY INT, V59, P190, DOI 10.1046/j.1523-1755.2001.00479.x; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Tanji N, 2000, ANTICANCER RES, V20, P2313; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Watkins DN, 1999, EUR RESPIR J, V14, P412, DOI 10.1034/j.1399-3003.1999.14b28.x; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wolff H, 1998, CANCER RES, V58, P4997; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Zhang YY, 2002, CANCER RES, V62, P3962	60	222	240	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50828	50833		10.1074/jbc.M210707200	http://dx.doi.org/10.1074/jbc.M210707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393872	Green Accepted, hybrid			2022-12-25	WOS:000180177700083
J	Fried, MG; Stickle, DF; Smirnakis, KV; Adams, C; MacDonald, D; Lu, PZ				Fried, MG; Stickle, DF; Smirnakis, KV; Adams, C; MacDonald, D; Lu, PZ			Role of hydration in the binding of lac repressor to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP RECEPTOR; NUCLEIC-ACID INTERACTIONS; ESCHERICHIA-COLI; OSMOTIC-STRESS; THERMODYNAMIC ORIGINS; OPERATOR INTERACTION; MACROMOLECULAR HYDRATION; GEL-ELECTROPHORESIS; LACTOSE REPRESSOR; CRYSTAL-STRUCTURE	The osmotic stress technique was used to measure changes in macromolecular hydration that accompany binding of wild-type Escherichia coli lactose (lac) repressor to its regulatory site (operator O1) in the lac promoter and its transfer from site O1 to nonspecific DNA. Binding at O1 is accompanied by the net release of 260 +/- 32 water molecules. If all are released from macromolecular surfaces, this result is consistent with a net reduction of solvent-accessible surface area of 2370 550 Angstrom(2). This area is only slightly smaller than the macromolecular interface calculated for a crystalline repressor dimer-O1 complex but is significantly smaller than that for the corresponding complex with the symmetrical optimized O-sym operator. The transfer of repressor from site O1 to nonspecific DNA is accompanied by the net uptake of 93 +/- 10 water molecules. Together these results imply that formation of a nonspecific complex is accompanied by the net release of 165 +/- 43 water molecules. The enhanced stabilities of repressor-DNA complexes with increasing osmolality may contribute to the ability of Escherichia coli cells to tolerate dehydration and/or high external salt concentrations.	Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Massachusetts General Hospital; University of Pennsylvania	Fried, MG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, POB 850, Hershey, PA 17033 USA.		Stickle, Douglas F/A-9682-2009	Stickle, Douglas/0000-0002-2033-4943				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bourgeois S, 1976, Adv Protein Chem, V30, P1, DOI 10.1016/S0065-3233(08)60478-7; BRODERSEN R, 1987, EUR J BIOCHEM, V169, P487, DOI 10.1111/j.1432-1033.1987.tb13636.x; Brown MP, 1999, PROTEIN SCI, V8, P1276, DOI 10.1110/ps.8.6.1276; BUTLER AP, 1977, BIOCHEMISTRY-US, V16, P4757, DOI 10.1021/bi00641a001; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FRIED MG, 1984, BIOPOLYMERS, V23, P2141, DOI 10.1002/bip.360231104; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Fried MG, 2001, J BIOL CHEM, V276, P11226, DOI 10.1074/jbc.M009087200; FRIED MG, 1993, EUR J BIOCHEM, V218, P469, DOI 10.1111/j.1432-1033.1993.tb18398.x; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GERSTEIN M, 1995, J MOL BIOL, V249, P955, DOI 10.1006/jmbi.1995.0351; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HOILAND H, 1986, THERMODYNAMIC DATA B, P2; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; Kalodimos CG, 2002, NAT STRUCT BIOL, V9, P193, DOI 10.1038/nsb763; LARSEN PI, 1987, ARCH MICROBIOL, V147, P1, DOI 10.1007/BF00492896; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Lynch TW, 2000, J BIOL CHEM, V275, P30561, DOI 10.1074/jbc.M000266200; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; Mller-Hill B., 1996, LAC OPERON; Moraitis MI, 2001, BIOCHEMISTRY-US, V40, P8109, DOI 10.1021/bi0028643; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; OVERMAN LB, 1994, J MOL BIOL, V236, P165, DOI 10.1006/jmbi.1994.1126; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RECORD MT, 1987, RNA POLYM REGULATION, P61; RICHEY B, 1987, J BIOL CHEM, V262, P7157; Robinson CR, 1995, METHOD ENZYMOL, V259, P395; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Royer CA, 1995, METHOD ENZYMOL, V259, P357; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPRAGUE ED, 1980, ANAL BIOCHEM, V101, P175, DOI 10.1016/0003-2697(80)90057-3; STICKLE DF, 1994, J THEOR BIOL, V168, P1, DOI 10.1006/jtbi.1994.1082; STICKLE DF, 1994, EUR J BIOCHEM, V226, P869, DOI 10.1111/j.1432-1033.1994.00869.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; von Hippel P.H., 1975, PROTEIN LIGAND INTER, P270; Vossen KM, 1996, J MOL BIOL, V255, P44, DOI 10.1006/jmbi.1996.0005; Vossen KM, 1997, BIOCHEMISTRY-US, V36, P11640, DOI 10.1021/bi971193e; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	73	44	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50676	50682		10.1074/jbc.M208540200	http://dx.doi.org/10.1074/jbc.M208540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12379649	hybrid			2022-12-25	WOS:000180177700064
J	Hales, CM; Vaerman, JP; Goldenring, JR				Hales, CM; Vaerman, JP; Goldenring, JR			Rab11 family interacting protein 2 associates with myosin Vb and regulates plasma membrane recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; LINKS RAB27A; IDENTIFICATION; VA; TRANSFERRIN; KIDNEY; TRAFFICKING; MELANOSOMES; MUTATIONS; RECEPTOR	Plasma membrane recycling is an important process necessary for maintaining membrane composition. The motor protein myosin Vb regulates plasma membrane recycling through its association with Rab11a. Overexpression of the tail of myosin Vb disrupts trafficking out of plasma membrane recycling systems and leads to the accumulation of Rab11a in both polarized and non-polarized cells. We have investigated the association of Rab11 family interacting protein 2 (Rab11-FIP2) with myosin Vb as an adapter protein between Rab11a and myosin Vb. Immunofluorescence studies indicated a colocalization of endogenous Rab11-FIP2 with green fluorescent protein-myosin Vb tail overexpressed in Madin-Darby canine kidney (MDCK) cells. Yeast two hybrid assays showed that amino acids 129-356 of Rab11-FIP2 were important for binding to myosin Vb tail. In vitro association assays and co-transfection experiments in both MDCK and HeLa cells confirmed this result but further refined the binding site to amino acids 129-290 of Rab11-FIP2. Like myosin Vb, functional studies indicated that Rab11-FIP2 is also important for normal plasma membrane recycling. Green fluorescent protein-Rab11-FIP2 (129-512), which lacks its amino-terminal C2 domain, functioned as a dominant negative acting truncation that caused accumulation of Rab11a and disrupted IgA trafficking in MDCK cells and transferrin trafficking in HeLa cells. The ternary association of myosin Vb and Rab11-FIP2 with Rab11a suggests that a multimeric protein complex is involved in vesicle trafficking through plasma membrane recycling systems.	Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Nashville Vet Affairs Med Ctr, Nashville, TN 37232 USA; Catholic Univ Louvain, C Duve Inst Cell Pathol, B-1200 Brussels, Belgium; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	Vanderbilt University; Universite Catholique Louvain; University System of Georgia; Augusta University	Goldenring, JR (corresponding author), Vanderbilt Univ, Sch Med, Dept Surg, 4160 A MRB 3,465 21st St S, Nashville, TN 37232 USA.	jim.goldenring@vanderbilt.edu			NIDDK NIH HHS [DK48370, DK43405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043405, R01DK048370, R01DK043405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Green EG, 1997, BIOCHEM BIOPH RES CO, V239, P612, DOI 10.1006/bbrc.1997.7520; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rodriguez OC, 2002, J CELL SCI, V115, P991; Schuster F, 2001, BONE MARROW TRANSPL, V28, P409, DOI 10.1038/sj.bmt.1703114; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	31	200	208	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50415	50421		10.1074/jbc.M209270200	http://dx.doi.org/10.1074/jbc.M209270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393859	hybrid			2022-12-25	WOS:000180177700028
J	Carrodeguas, JA; Pinz, KG; Bogenhagen, DF				Carrodeguas, JA; Pinz, KG; Bogenhagen, DF			DNA binding properties of human pol gamma B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; ACCESSORY SUBUNIT; MITOCHONDRIAL-DNA; PROCESSIVITY FACTOR; POLYMERASE-GAMMA; STRANDED-DNA; PROGRAM	We have recently reported the crystal structure of the accessory subunit of mitochondrial DNA polymerase, pol gammaB, and identified a region of the protein involved in DNA binding. The DNA employed in previous studies was presumed to be single-stranded, because it was generated by single-sided PCR. Further characterization of this DNA indicated that, due to a strand transfer event during synthesis by single-sided PCR, the DNA adopts a double-stranded hairpin conformation under native conditions. We used a series of double- and singlestranded oligonucleotides of different lengths to confirm that human pol gammaB prefers to bind double-stranded DNA longer than 40 bp with little apparent sequence specificity. Site-specific deletion mutagenesis identified clusters of basic residues in two surface loops required for DNA binding located on opposite sides of the symmetrical pol gammaB dimer. A heterodimer of pol gammaB that contains one mutant and one wild-type DNA binding region was shown to be unable to bind double-stranded DNA, suggesting that a single DNA molecule must contact both DNA binding sites in the pol gammaB dimer. The ability to bind double-stranded DNA is not essential for pol gammaB stimulation of pol gammaA activity in vitro, but may play a role in DNA replication or repair.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bogenhagen, DF (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		Carrodeguas, Jose/L-7334-2014	Carrodeguas, Jose/0000-0003-0062-1029	NIGMS NIH HHS [R01 GM 296801] Funding Source: Medline; NCEH CDC HHS [NIEHS P01 04068] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCEH CDC HHS		Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Dou XW, 2001, J MOL BIOL, V305, P451, DOI 10.1006/jmbi.2000.4312; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lechler A, 1998, J MOL BIOL, V278, P897, DOI 10.1006/jmbi.1998.1744; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999	18	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50008	50014		10.1074/jbc.M207030200	http://dx.doi.org/10.1074/jbc.M207030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379656	hybrid			2022-12-25	WOS:000180028900118
J	Shen, M; Yoshida, E; Yan, WQ; Kawamoto, T; Suardita, K; Koyano, Y; Fujimoto, K; Noshiro, M; Kato, Y				Shen, M; Yoshida, E; Yan, WQ; Kawamoto, T; Suardita, K; Koyano, Y; Fujimoto, K; Noshiro, M; Kato, Y			Basic helix-loop-helix protein DEC1 promotes chondrocyte differentiation at the early and terminal stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE (PTH)/PTH-RELATED PEPTIDE; ADENOSINE-MONOPHOSPHATE PATHWAY; MESENCHYMAL STEM-CELLS; CHONDROGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; CBFA1-DEFICIENT MICE; TRANSCRIPTION FACTOR; RABBIT CHONDROCYTES; RETINOIC ACID	The mRNA level of basic helix-loop-helix transcription factor DEC1 (BHLHB2)/Stra13/Sharp2 was up-regulated during chondrocyte differentiation in cultures of ATDC5 cells and growth plate chondrocytes, and in growth plate cartilage in vivo. Forced expression of DEC1 in ATDC5 cells induced chondrogenic differentiation, and insulin increased this effect of DEC1 overexpression. Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) suppressed DEC1 expression and the differentiation of ATDC5 cells, but DEC1 overexpression antagonized this inhibitory action of PTH/PTHrP. Transforming growth factor-beta or bone morphogenetic protein-2, as well as insulin, induced DEC1 expression in ATDC5 cultures where it induced chondrogenic differentiation. In pellet cultures of bone marrow mesenchymal stem cells exposed to transforming growth factor-beta and insulin, DEC1 was induced at the earliest stage of chondrocyte differentiation and also at the hypertrophic stage. Overexpression of DEC1 in the mesenchymal cells induced the mRNA expressions of type II collagen, Indian hedgehog, and Runx2, as well as cartilage matrix accumulation; overexpression of DEC1 in growth plate chondrocytes at the prehypertrophic stage increased the mRNA levels of Indian hedgehog, Runx2, and type X collagen, and also increased alkaline phosphatase activity and mineralization. To our knowledge, DEC1 is the first transcription factor that can promote both chondrogenic differentiation and terminal differentiation.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Hiroshima 7348553, Japan; Jilin Univ, Inst Frontier Med Sci, Changchun 130021, Peoples R China; Jikei Univ, Sch Med, Dept Orthopaed Surg, Tokyo 105, Japan	Hiroshima University; Jilin University; Jikei University	Kato, Y (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Hiroshima 7348553, Japan.		Suardita, Ketut/Q-8651-2019; , 河本健/D-7938-2015	Suardita, Ketut/0000-0003-0492-5417; , 河本健/0000-0003-3337-1775				ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Azmi S, 2002, MECH DEVELOP, V114, P181, DOI 10.1016/S0925-4773(02)00049-7; BESSEY OA, 1946, J BIOL CHEM, V164, P321; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Ferguson CM, 2000, ENDOCRINOLOGY, V141, P4728, DOI 10.1210/en.141.12.4728; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; GITELMAN HJ, 1967, ANAL BIOCHEM, V18, P521, DOI 10.1016/0003-2697(67)90110-8; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Jikko A, 1996, ENDOCRINOLOGY, V137, P122, DOI 10.1210/en.137.1.122; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; KATO Y, 1981, J BIOCHEM-TOKYO, V90, P1377, DOI 10.1093/oxfordjournals.jbchem.a133603; Kawamoto T, 1998, EUR J BIOCHEM, V256, P503, DOI 10.1046/j.1432-1327.1998.2560503.x; Kawashima-Ohya Y, 1998, ENDOCRINOLOGY, V139, P2120, DOI 10.1210/en.139.4.2120; Kawashima-Ohya Y, 1999, ENDOCRINOLOGY, V140, P1075, DOI 10.1210/en.140.3.1075; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYAZAKI K, 2002, J BIOL CHEM; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Seimiya M, 2002, BIOCHEM BIOPH RES CO, V292, P121, DOI 10.1006/bbrc.2002.6605; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Yoshida E, 2001, EXP CELL RES, V265, P64, DOI 10.1006/excr.2001.5161; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	59	91	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50112	50120		10.1074/jbc.M206771200	http://dx.doi.org/10.1074/jbc.M206771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384505	hybrid			2022-12-25	WOS:000180028900130
J	Tafani, M; Cohn, JA; Karpinich, NO; Rothman, RJ; Russo, MA; Farber, JL				Tafani, M; Cohn, JA; Karpinich, NO; Rothman, RJ; Russo, MA; Farber, JL			Regulation of intracellular pH mediates Bax activation in HeLa cells treated with staurosporine or tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-X-L; DEPENDENT ACTIVATION; INDUCED APOPTOSIS; CHLORIDE CHANNEL; TRANSLOCATION; INDUCTION; MITOCHONDRIA; CYTOSOL; COTRANSPORT	Induction of apoptosis in HeLa cells with staurosporine produced a rise in the intracellular pH (pH(i)). Intracellular alkalinization was accompanied by translocation of Bax to the mitochondria, cytochrome c release, and cell death. The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax translocation, cytochrome c release, and cell death. Translocation of full-length Bid to the mitochondria was also prevented by furosemide. The cleavage product of Bid degradation (truncated Bid, tBid) was not detectable in the mitochondria. Its accumulation in the cytosol was prevented by furosemide. Apoptosis induced by tumor necrosis factor-alpha (TNF) lowered pH(i), an effect also accompanied by Bax translocation, cytochrome c release, and cell killing. Furosemide prevented all of these events. TNF induced a depletion of full-length Bid from the mitochondria and the cytosol but induced an accumulation of mitochondrial tBid. Furosemide only delayed full-length Bid depletion and tBid accumulation. The caspase 8 inhibitor IETD did not prevent the translocation of Bax. Although IETD did inhibit the cleavage of Bid and the accumulation of tBid, cell killing was reduced only slightly. It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pHi is linked to Bax translocation, cytochrome c release, and cell killing. With TNF Bax translocation occurs as Bid is depleted and can be dissociated from the accumulation of tBid. With staurosporine a role for full-length Bid in Bax translocation cannot be excluded but is not necessary as evidenced by the data with TNF.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	Jefferson University; Sapienza University Rome	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	john.farber@mail.tju.edu	Tafani, Marco/C-3275-2017; Tafani, Marco/U-7230-2019	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X; Cohn, Joshua/0000-0002-4953-3321	NIAAA NIH HHS [T32 AA 07463] Funding Source: Medline; NIDDK NIH HHS [DK 38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; BIZE I, 1994, AM J PHYSIOL, V266, pC759, DOI 10.1152/ajpcell.1994.266.3.C759; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Flatman PW, 1999, J PHYSIOL-LONDON, V517, P699, DOI 10.1111/j.1469-7793.1999.0699s.x; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JENTSCH TJ, 1999, EUR J PHYSL, V473, P783; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim JA, 2001, BIOCHEM BIOPH RES CO, V281, P511, DOI 10.1006/bbrc.2001.4371; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nietsch HH, 2000, J BIOL CHEM, V275, P20556, DOI 10.1074/jbc.M002535200; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; REBOLLO A, 1995, EXP CELL RES, V218, P581, DOI 10.1006/excr.1995.1195; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Tafani M, 2001, CANCER RES, V61, P2459; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wong SGW, 2000, TOXICOL LETT, V116, P171, DOI 10.1016/S0378-4274(00)00218-6; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	46	110	113	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49569	49576		10.1074/jbc.M208915200	http://dx.doi.org/10.1074/jbc.M208915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393866	hybrid			2022-12-25	WOS:000180028900062
J	Fukumoto, H; Deng, A; Irizarry, MC; Fitzgerald, ML; Rebeck, GW				Fukumoto, H; Deng, A; Irizarry, MC; Fitzgerald, ML; Rebeck, GW			Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted A beta levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; HIGH-DENSITY-LIPOPROTEIN; TANGIER-DISEASE PATIENTS; TRANSGENIC MOUSE MODEL; IN-SITU HYBRIDIZATION; E EPSILON-4 ALLELE; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; CELLULAR CHOLESTEROL; HEAD-INJURY	The expression, function, and regulation of the cholesterol efflux molecule, ABCA1, has been extensively examined in peripheral tissues but only poorly studied in the brain. Brain cholesterol metabolism is of interest because several lines of evidence suggest that elevated cholesterol increases the risk of Alzheimer's disease. We found a largely neuronal expression of ABCA1 in normal rat brain by in situ hybridization. ABCA1 message was dramatically up-regulated in neurons and glia in areas of damage by hippocampal AMPA lesion after 3-7 days. Immunoblot analysis demonstrated ABCA1 protein in cultured neuronal and glial cells, and expression was induced by ligands of the nuclear hormone receptors of the retinoid X receptor and liver X receptor family. ABCA1 was induced by treatment with retinoic acid and several oxysterols, including 22(R)-hydroxycholesterol and 24-hydroxycholesterol. Expression of an ABCA1-green fluorescent protein construct in neuroblastoma cells demonstrated fluorescence in perinuclear compartments and on the plasma membrane. Because the Abeta peptide is important in Alzheimer's disease pathogenesis, we examined whether ABCA1 induction altered Abeta levels. Treatment of neuroblastoma cells with retinoic acid and 22(R)-hydroxycholesterol caused significant increases in secreted Abeta40 (29%) and Abeta42 (65%). Treatment with a nonsteroidal liver X receptor ligand, TO-901317, similarly increased levels of secreted Abeta40 (25%) and Abeta42 (126%). The increase in secreted Abeta levels was reduced by RNAi blocking of ABCA1 expression. These data suggest that the cholesterol efflux molecule ABCA1 may also be involved in the secretion of the membrane-associated molecule, Abeta.	Massachusetts Gen Hosp, Alzheimer Res Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Rebeck, GW (corresponding author), Alzheimer Res Unit, 114 16th St, Charlestown, MA 02129 USA.		Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NHLBI NIH HHS [HL68988, HL10398] Funding Source: Medline; NIA NIH HHS [R01 AG14473, K08 AG00793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068988, F32HL010398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000793, R01AG014473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bjorkhem I, 2002, ARTERIOSCL THROM VAS, V22, P734, DOI 10.1161/01.ATV.0000013312.32196.49; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; Costet P, 2000, J BIOL CHEM, V275, P28240; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Fukumoto H, 1999, NEUROREPORT, V10, P2965, DOI 10.1097/00001756-199909290-00017; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 2001, AM J PATHOL, V158, P173, DOI 10.1016/S0002-9440(10)63955-7; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Koch S, 2001, J LIPID RES, V42, P1143; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Locatelli S, 2002, ARCH NEUROL-CHICAGO, V59, P213, DOI 10.1001/archneur.59.2.213; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Oram JF, 2001, J LIPID RES, V42, P1173; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Page K, 1996, P NATL ACAD SCI USA, V93, P14020, DOI 10.1073/pnas.93.24.14020; Page KJ, 1998, NEUROSCIENCE, V85, P1161, DOI 10.1016/S0306-4522(97)00661-1; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; REBECK GW, 1993, NEURON, V11, P575; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Schonknecht P, 2002, NEUROSCI LETT, V324, P83, DOI 10.1016/S0304-3940(02)00164-7; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439	60	137	142	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48508	48513		10.1074/jbc.M209085200	http://dx.doi.org/10.1074/jbc.M209085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12384498	hybrid			2022-12-25	WOS:000179789600072
J	Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY				Yuen, ST; Chan, TL; Ho, JWC; Chan, ASY; Chung, LP; Lam, PWY; Tse, CW; Wyllie, AH; Leung, SY			Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers	ONCOGENE			English	Article						microsatellite instability; promoter methylation; mismatch repair gene mutation; colorectal cancer; HNPCC	MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; YOUNG-PATIENTS; COLON-CANCER; CELL-LINES; MUTATIONS; METHYLATION; EXPRESSION; TUMORS; GENE	High-frequency microsatellite instability (MSI-H) results from deficiency in nucleotide mismatch repair. It contributes significantly to carcinogenesis in the human colorectal mucosa. Here we study 41 colorectal and three other HNPCC-related cancers with MSI-H to provide comprehensive information on the mechanisms of inactivation of the two major proteins involved, hMLH1 and hMSH2. Seventeen of the patients had family histories meeting the criteria for Bethesda grades 1, 2 or 3. Of these familial cases, 14 (83%) had early-onset disease, defined on the basis of diagnosis prior to the age of 50, but in three the disease was of late onset (>50 years). A second subset of 20 patients had early onset disease without family history. The remaining seven patients were selected to allow comparisons with sporadic, late-onset disease, the molecular basis of which has been extensively reported elsewhere. We stratified the tumours initially on the basis of hMLH1 or hMSH2 protein deficiency, detected by immunohistochemistry, and then by analysis of germline and somatic mutation, mRNA transcription, loss of heterozygosity (LOH) at the hMLH1 and hMSH2 loci, and methylation status in two regions of the hMLH1 promoter. The functional significance of several of these changes in the MSI-H tumours was confirmed by comparisons with 16 tumours with low-frequency microsatellite instability and 56 tumours with stable microsatellites. As anticipated, patients with family histories usually showed germline mutation of hMSH2 or hMLH1. In many cases the residual normal allele was silenced in their tumours by loss of heterozygosity (LOH). The small subset of late-onset, sporadic cases confirmed the preponderance in this group of biallelic hMLH1 promoter methylation. In the early-onset, apparently sporadic subset there were 11 tumours with hMLH1 deficiency, five with hMSH2 deficiency and four with no detectable abnormality in expression of either protein. These showed a complex mixture of lesions, including germline and somatic mutations, promoter methylation, LOH, suppression of wild-type RNA by as yet undiscovered mechanisms, or no detectable abnormality in any of these parameters. Evidence is presented to indicate that methylation in proximal region of the hMLH1 promoter is a more reliable correlate of transcriptional silencing in colorectal cancers than methylation in upstream region. These observations have significant implications for management of patients with MSI-H tumours.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Cambridge	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Chung, Lap Ping/C-4258-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.0.CO;2-1; Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376; Cunningham JM, 1998, CANCER RES, V58, P3455; Deng G, 2002, BRIT J CANCER, V86, P574, DOI 10.1038/sj.bjc.6600148; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shin KH, 2002, CANCER RES, V62, P38; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	22	60	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7585	7592		10.1038/sj.onc.1205968	http://dx.doi.org/10.1038/sj.onc.1205968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386821				2022-12-25	WOS:000178618200014
J	van Balkom, BWM; van Raak, M; Breton, S; Pastor-Soler, N; Bouley, R; van der Sluijs, P; Brown, D; Deen, PMT				van Balkom, BWM; van Raak, M; Breton, S; Pastor-Soler, N; Bouley, R; van der Sluijs, P; Brown, D; Deen, PMT			Hypertonicity is involved in redirecting the aquaporin-2 water channel into the basolateral, instead of the apical, plasma membrane of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; DARBY CANINE KIDNEY; RAT-KIDNEY; BRATTLEBORO RATS; COLLECTING DUCT; MDCK CELLS; EXPRESSION; VASOPRESSIN; TRAFFICKING; RECEPTOR	In renal collecting ducts, vasopressin increases the expression of and redistributes aquaporin-2 (AQP2) water channels from intracellular vesicles to the apical membrane, leading to urine concentration. However, basolateral membrane expression of AQP2, in addition to AQP3 and AQP4, is often detected in inner medullary principal cells in vivo. Here, potential mechanisms that regulate apical versus basolateral targeting of AQP2 were examined. The lack of,AQP2-4 association into heterotetramers and the complete apical expression of AQP2 when highly expressed in Madin-Darby canine kidney cells indicated that neither heterotetramerization of AQP2 with AQP3 and/or AQP4, nor high expression levels of AQP2 explained the basolateral AQP2 localization. However, long term hypertonicity, a feature of the inner medullary interstitium, resulted in an insertion of AQP2 into the basolateral membrane of Madin-Darby canine kidney cells after acute forskolin stimulation. Similarly, a marked insertion of AQP2 into the basolateral membrane of principal cells was observed in the distal inner medulla from normal rats and Brattleboro rats after acute vasopressin treatment of tissue slices that had been chronically treated with vasopressin to increase interstitial osmolality in the medulla, but not in tissues from vasopressin-deficient Brattleboro rats. These data reveal for the first time that chronic hypertonicity can program cells in vitro and in vivo to change the insertion of a protein into the basolateral membrane instead of the apical membrane.	UMC St Radbound Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Massachusetts Gen Hosp, Program Membrane Biol & Renal Unit, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Radboud University Nijmegen; Harvard University; Massachusetts General Hospital; Harvard University; Utrecht University	Deen, PMT (corresponding author), UMC St Radbound Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, POB 9101,160, NL-6500 HB Nijmegen, Netherlands.		Deen, Peter MT/B-9854-2013; Deen, P.M.T./H-8023-2014	Deen, Peter MT/0000-0002-7868-4655; Deen, P.M.T./0000-0002-7868-4655	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08684] Funding Source: Medline; NIDDK NIH HHS [DK38452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTANI B, 1991, J CLIN INVEST, V88, P126, DOI 10.1172/JCI115268; Beck FX, 1998, PFLUG ARCH EUR J PHY, V436, P814, DOI 10.1007/s004240050710; BONDY CA, 1989, MOL ENDOCRINOL, V3, P1409, DOI 10.1210/mend-3-9-1409; Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Breton S, 1998, J AM SOC NEPHROL, V9, P155; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; BROWN D, 2000, KIDNEY; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Deen PMT, 2002, AM J PHYSIOL-RENAL, V282, pF330, DOI 10.1152/ajprenal.0168.2001; Deen PMT, 1998, CURR OPIN CELL BIOL, V10, P435, DOI 10.1016/S0955-0674(98)80055-0; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Deen PMT, 1997, PFLUG ARCH EUR J PHY, V433, P780, DOI 10.1007/s004240050345; DEEN PMT, 2001, TRAFFICKING NATIVE M; Dove SK, 1999, BIOCHEM SOC T, V27, P674, DOI 10.1042/bst0270674; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FLAMION B, 1995, AM J PHYSIOL-RENAL, V268, pF53, DOI 10.1152/ajprenal.1995.268.1.F53; GELLAI M, 1984, AM J PHYSIOL, V246, pF819, DOI 10.1152/ajprenal.1984.246.6.F819; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Hasler L, 1998, J MOL BIOL, V279, P855, DOI 10.1006/jmbi.1998.1796; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; Ishibashi K, 1997, AM J PHYSIOL-RENAL, V272, pF235, DOI 10.1152/ajprenal.1997.272.2.F235; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lu MQ, 1996, P NATL ACAD SCI USA, V93, P10908, DOI 10.1073/pnas.93.20.10908; Marr N, 2002, HUM MOL GENET, V11, P779, DOI 10.1093/hmg/11.7.779; Matsumura Y, 1997, J AM SOC NEPHROL, V8, P861; Matsuzaki T, 2001, AM J PHYSIOL-CELL PH, V281, pC55, DOI 10.1152/ajpcell.2001.281.1.C55; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; Reid JM, 2000, BIOCHEM BIOPH RES CO, V271, P429, DOI 10.1006/bbrc.2000.2638; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sabolic I, 1997, KIDNEY INT, V51, P125, DOI 10.1038/ki.1997.16; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; Shayakul C, 2000, AM J PHYSIOL-RENAL, V278, pF620, DOI 10.1152/ajprenal.2000.278.4.F620; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	56	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1101	1107		10.1074/jbc.M207339200	http://dx.doi.org/10.1074/jbc.M207339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12374804	hybrid, Green Published			2022-12-25	WOS:000180321900054
J	Wendt, S; Schlattner, U; Wallimann, T				Wendt, S; Schlattner, U; Wallimann, T			Differential effects of peroxynitrite on human mitochondrial creatine kinase isoenzymes - Inactivation, octamer destabilization, and identification of involved residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE; CRYSTAL-STRUCTURE; BRAIN-TYPE; EXPRESSION; SUPEROXIDE; ALZHEIMERS; OXIDATION; ENZYME; BB	Creatine kinase isoenzymes are very susceptible to free radical damage and are inactivated by superoxide radicals and peroxynitrite. In this study, we have analyzed the effects of peroxynitrite on enzymatic activity and octamer stability of the two human mitochondrial isoenzymes (ubiquitous mitochondrial creatine kinase (uMtCK) and sarcomeric mitochondrial creatine kinase (sMtCK)), as well as of chicken sMtCK, and identified the involved residues. Inactivation by peroxynitrite was concentration-dependent and similar for both types of MtCK isoenzymes. Because peroxynitrite did not lower the residual activity of a sMtCK mutant missing the active site cysteine (C278G), oxidation of this residue is sufficient to explain MtCK inactivation. Mass spectrometric analysis confirmed oxidation of Cys-278 and further revealed oxidation of the C-terminal Cys-358, possibly involved in MtCK/membrane interaction. Peroxynitrite also led to concentration-dependent dissociation of MtCK octamers into dimers. In this study, ubiquitous uMtCK was much more stable than sarcomeric sMtCK. Mass spectrometric analysis revealed chemical modifications in peptide Gly-263-Arg-271 located at the dimer/dimer interface, including oxidation of Met-267 and nitration of Trp-268 and/or Trp-264, the latter being a very critical residue for octamer stability. These data demonstrate that peroxynitrite affects the octameric state of MtCK and confirms human sMtCK as the generally more susceptible isoenzyme. The results provide a molecular explanation of how oxidative damage can lead to inactivation and decreased octamer/dimer ratio of MtCE as seen in neurodegenerative diseases and heart pathology, respectively.	Swiss Fed Inst Technol, Inst Cell Biol, Honggerberg HPM, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schlattner, U (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, Honggerberg HPM, CH-8093 Zurich, Switzerland.	schlattn@cell.biol.ethz.ch	Wallimann, Theo/C-6047-2008; Schlattner, Uwe/D-1267-2009	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911				ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; Aksenov M, 2000, J NEUROCHEM, V74, P2520, DOI 10.1046/j.1471-4159.2000.0742520.x; Aksenov MY, 1997, EXP NEUROL, V146, P458, DOI 10.1006/exnr.1997.6550; Aksenova MV, 1999, J NEUROSCI RES, V58, P308, DOI 10.1002/(SICI)1097-4547(19991015)58:2<308::AID-JNR11>3.0.CO;2-#; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P979, DOI 10.1006/jmcc.1998.0662; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Beal MF, 2000, ANN NY ACAD SCI, V924, P164; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1990, BIOCHIM BIOPHYS ACTA, V1018, P234, DOI 10.1016/0005-2728(90)90256-4; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; Herce-Pagliai C, 1998, NITRIC OXIDE-BIOL CH, V2, P324, DOI 10.1006/niox.1998.0192; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Khuchua ZA, 1998, J BIOL CHEM, V273, P22990, DOI 10.1074/jbc.273.36.22990; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Koufen P, 1999, BIOCHEM J, V344, P413, DOI 10.1042/0264-6021:3440413; Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327, DOI 10.1152/ajpheart.1997.272.5.H2327; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Perrin D, 2000, ARCH BIOCHEM BIOPHYS, V377, P266, DOI 10.1006/abbi.2000.1787; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; RADI R, 1991, J BIOL CHEM, V266, P4244; Richter C, 1997, BIOCHEM SOC T, V25, P914, DOI 10.1042/bst0250914; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Schlattner U, 2000, J BIOL CHEM, V275, P17314, DOI 10.1074/jbc.M001919200; Schlattner U, 2001, J BIOL CHEM, V276, P48027, DOI 10.1074/jbc.M106524200; Schlattner U, 2000, BIOL CHEM, V381, P1063, DOI 10.1515/BC.2000.131; SCHNYDER T, 1991, J CELL BIOL, V112, P95, DOI 10.1083/jcb.112.1.95; Schulz R, 1997, AM J PHYSIOL-HEART C, V272, pH1212, DOI 10.1152/ajpheart.1997.272.3.H1212; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; THOMAS C, 1994, FREE RADICAL RES, V21, P387, DOI 10.3109/10715769409056591; Tokarska-Schlattner M, 2002, MOL PHARMACOL, V61, P516, DOI 10.1124/mol.61.3.516; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1999, GUANIDINO COMPOUNDS, V5, P117; WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x; Wendt S, 2002, FREE RADICAL BIO MED, V32, P920, DOI 10.1016/S0891-5849(02)00784-0; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; YUAN GX, 1992, BIOCHIM BIOPHYS ACTA, V1140, P78, DOI 10.1016/0005-2728(92)90022-T; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449	61	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1125	1130		10.1074/jbc.M208572200	http://dx.doi.org/10.1074/jbc.M208572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401781	hybrid			2022-12-25	WOS:000180321900057
J	Wu, DF; Cederbaum, AI				Wu, DF; Cederbaum, AI			Role of p38 MAPK in CYP2E1-dependent arachidonic acid toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; SIGNAL-REGULATED KINASE; SODIUM-SALICYLATE; RAT HEPATOCYTES; CYCLOSPORINE-A; CELL-LINE; FISH-OIL; INHIBITION; NECROSIS	Polyunsaturated fatty acids such as arachidonic acid (AA) play an important role in alcohol-induced liver injury. AA promotes toxicity in rat hepatocytes with high levels of cytochrome P4502E1 (CYP2E1) and in HepG2 E47 cells, which express CYP2E1. The possible role of mitogen-activated protein kinase (MAPK) members in this process was evaluated. SB203580, a p38 MAPK inhibitor, and PD98059, an ERK inhibitor, but not wortmannin a phosphatidylinositol 3-kinase (PI3K) inhibitor, prevented AA toxicity in pyrazole hepatocytes and E47 cells. SB203580 prevented the enhancement of AA toxicity by salicylate. SB203580 neither lowered the levels of CYP2E1 nor affected CYP2E1-dependent oxidative stress. The decrease in mitochondrial membrane potential produced by AA was prevented by SB203580. Treating CYP2E1-induced cells with AA activated p38 MAPK but not ERK or AKT. This activation was blocked by antioxidants. AA increased the translocation of NF-kappaB to the nucleus. Salicylate blocked this translocation, which may contribute to the enhancement of AA toxicity by salicylate. SB203580 restored AA-induced NF-kappaB translocation, which may contribute to protection against toxicity. In conclusion, AA toxicity was related to lipid peroxidation and oxidative stress, and to the activation of p38 MAPK, as a consequence of CYP2E1-dependent production of reactive oxygen species. Activation of p38 MAPK by AA coupled to AA-induced oxidative stress may synergize to cause cell toxicity by affecting mitochondrial membrane potential and by modulation of NF-kappaB activation.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 1Gustave L Levy Pl,Box 1603, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu			NIAAA NIH HHS [AA03312, AA 06610] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R37AA006610, R01AA003312, R56AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alexander LD, 2001, KIDNEY INT, V59, P2039, DOI 10.1046/j.1523-1755.2001.00718.x; Alpert D, 2000, J BIOL CHEM, V275, P10925, DOI 10.1074/jbc.275.15.10925; Arbabi S, 2002, CRIT CARE MED, V30, pS74, DOI 10.1097/00003246-200201001-00010; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BIBAN C, 1995, BIOCHEM PHARMACOL, V50, P497, DOI 10.1016/0006-2952(95)00165-V; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; Caro AA, 2002, J BIOL CHEM, V277, P104, DOI 10.1074/jbc.M107864200; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chang LC, 2000, J PHARM PHARMACOL, V52, P539, DOI 10.1211/0022357001774336; Chang LC, 2001, J LEUKOCYTE BIOL, V69, P659; Chen LC, 1999, BIOCHEM J, V342, P503, DOI 10.1042/0264-6021:3420503; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen RF, 2000, RARE METALS, V19, P231; CHOW SC, 1990, J BIOL CHEM, V265, P902; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rizzo MT, 2002, PROSTAG LEUKOTR ESS, V66, P31, DOI 10.1054/plef.2001.0330; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; TSUKAMOTO H, 1990, HEPATOLOGY, V12, P599, DOI 10.1002/hep.1840120325; Wu DF, 2002, HEPATOLOGY, V35, P1420, DOI 10.1053/jhep.2002.33639; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Wu DF, 2001, MOL PHARMACOL, V59, P795, DOI 10.1124/mol.59.4.795; WU DF, 1990, HEPATOLOGY, V12, P1379, DOI 10.1002/hep.1840120620; Wu DF, 2000, MOL CELL BIOCHEM, V204, P157, DOI 10.1023/A:1007064706101; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	51	52	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1115	1124		10.1074/jbc.M207856200	http://dx.doi.org/10.1074/jbc.M207856200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12403788	hybrid			2022-12-25	WOS:000180321900056
J	Altroff, H; Choulier, L; Mardon, HJ				Altroff, H; Choulier, L; Mardon, HJ			Synergistic activity of the ninth and tenth FIII domains of human fibronectin depends upon structural stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; III MODULES; 9TH; BINDING; SITE; RGD; SPECIFICITY; ACTIVATION	The ninth and tenth FIII domains (FIII9-10) of human fibronectin act in synergy to promote cell adhesion via the interaction with integrin receptors. Here we describe the functional and structural properties of a set of recombinant FIII9-10 mutants containing various alanine substitutions within the key synergistic site, DRVPHSRN in FIII9, either alone or in combination with another substitution (Leu(1408) to Pro), on the opposite face of FIII9, that increases stability and the functional capacity of FIII9-10. We show that the introduction of mutations into the synergistic sequence of FIII9-10 has a negative effect on the adhesion of baby hamster kidney fibroblasts and results in reduced ability of these ligands to recognize integrin alpha(5)beta(1). Conformational stability of the FIII9 domain in the synergy site mutants is likewise reduced in comparison with native FIII9. The Leu(1408) to Pro substitution in mutant FIII9-10 proteins carrying substitutions in the synergy site results in a substantial recovery of the adhesive activity of the mutants and affinity to alpha(5)beta(1). In keeping with the enhancement of functional activity, the Leu1408 to Pro substitution in the FIII9-10 synergy site mutants also causes a significant increase in conformational stability of FIII9. These observations imply a strong positive correlation between the biological activity and conformational stability of the assessed FIII9-10 mutants and suggest that a Leu(1408) to Pro substitution restores the biological activity of the mutants via their ability to restore their conformational stability. We conclude that domain stability may be a major determinant of the synergistic potential of FIII9. Our data underscore the value of using more than one approach in such structure-function studies and the requirement for validating the global structural integrity of protein ligands in which sequences that disrupt function have been perturbed.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Womens Ctr, Oxford OX3 9DU, England	University of Oxford	Mardon, HJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Womens Ctr, Headington, Oxford OX3 9DU, England.		Altroff, Harri/B-3544-2011	Choulier, Laurence/0000-0003-1493-9775	Wellcome Trust [073028] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Copie V, 1998, J MOL BIOL, V277, P663; Craig D, 2001, P NATL ACAD SCI USA, V98, P5590, DOI 10.1073/pnas.101582198; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hotchin NA, 1999, J CELL SCI, V112, P2937; Johansson S, 1997, FRONT BIOSCI, V2, P126; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; Plaxco KW, 1997, J MOL BIOL, V270, P763, DOI 10.1006/jmbi.1997.1148; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; VANDERWALLE CF, 2002, IN PRESS PROTEIN ENG, V15; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yin ZN, 1999, BLOOD, V93, P1221	24	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					491	497		10.1074/jbc.M209992200	http://dx.doi.org/10.1074/jbc.M209992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12376529	Green Accepted, hybrid			2022-12-25	WOS:000180255700065
J	Getting, SJ; Mahoney, DJ; Cao, T; Rugg, MS; Fries, E; Milner, CM; Perretti, M; Day, AJ				Getting, SJ; Mahoney, DJ; Cao, T; Rugg, MS; Fries, E; Milner, CM; Perretti, M; Day, AJ			The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha-inhibitor-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; BINDING PROTEIN TSG-6; EXTRACELLULAR-MATRIX; TRYPSIN INHIBITOR; EXPRESSION; CARTILAGE; RECEPTOR; LOCALIZATION; ARTHRITIS; CELLS	TSG-6 protein (the secreted product of the tumor necrosis factor-stimulated gene-6), a hyaluronan-binding protein comprised mainly of a Link and CUB module arranged in a contiguous fashion, has been shown previously to be a potent inhibitor of neutrophil migration in an in vivo model of acute inflammation (Wisniewski, H. G., Hua, J. C., Poppers, D. M., Naime, D., Vilcek, J., and Cronstein, B. N. (1996) J. Immunol. 156, 1609-1615). It was hypothesized that this activity of TSG-6 was likely to be mediated by its potentiation of inter-alpha-inhibitor anti-plasmin activity (causing a down-regulation of the protease network), which was reliant on these proteins forming a stable, probably covalent similar to120-kDa complex. Here we have shown that the recombinant Link module from human TSG-6 (Link_TSG6; expressed in Escherichia coli) has an inhibitory effect on neutrophil influx into zymosan A-stimulated murine air pouches, equivalent to that of full-length protein (which we produced in a Drosophila expression system). The active dose of 1 mug of Link_TSG6 per mouse (administered intravenously) also resulted in a significant reduction in the concentrations of various inflammatory mediators (i.e. tumor necrosis factor-alpha, KC, and prostaglandin E-2) in air pouch exudates. Link_TSG6, although unable to form a stable complex with inter-alpha-inhibitor (under conditions that promote maximum complex formation with the full-length protein), could potentiate its anti-plasmin activity. This demonstrates that formation of an similar to120-kDa TSG-6.inter-alpha-inhibitor complex is not required for TSG-6 to enhance the serine protease inhibitory activity of inter-alpha-inhibitor. Six single-site Link_TSG6 mutants (with wild-type folds) were compared for their abilities to inhibit neutrophil migration in vivo, bind hyaluronan, and potentiate inter-alpha-inhibitor. These experiments indicate that all of the inhibitory activity of TSG-6 resides within the Link module domain, and that this anti-inflammatory property is not related to either its hyaluronan binding function or its potentiation of the anti-plasmin activity of inter-alpha-inhibitor.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Oxford; University of London; Queen Mary University London; Uppsala University	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Milner, Caroline M/P-5526-2015; Day, Anthony/O-1658-2015	Milner, Caroline M/0000-0001-7355-9655; Day, Anthony/0000-0002-1415-3134				Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Belayet HM, 1999, MOL HUM REPROD, V5, P261, DOI 10.1093/molehr/5.3.261; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; Blundell C. D., 2002, HYALURONAN, P161; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; Getting SJ, 1999, J IMMUNOL, V162, P7446; Hii CST, 2001, IMMUNOLOGY, V102, P59, DOI 10.1046/j.1365-2567.2001.01156.x; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Mackarel AJ, 1999, AM J RESP CELL MOL, V20, P1209; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; Mizon C, 1996, J IMMUNOL METHODS, V190, P61, DOI 10.1016/0022-1759(95)00257-X; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; PERRETTI M, 1993, J IMMUNOL, V150, P992; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Ushigoe K, 2000, BIOL REPROD, V63, P121, DOI 10.1095/biolreprod63.1.121; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski Hans-Georg, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR225, DOI 10.1007/BF02346350; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289	43	99	104	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51068	51076		10.1074/jbc.M205121200	http://dx.doi.org/10.1074/jbc.M205121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401803	hybrid			2022-12-25	WOS:000180177700114
J	Nuthall, HN; Joachim, K; Palaparti, A; Stifani, S				Nuthall, HN; Joachim, K; Palaparti, A; Stifani, S			A role for cell cycle-regulated phosphorylation in Groucho-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-LIKE-ENHANCER; GROUCHO/TRANSDUCIN-LIKE ENHANCER; DROSOPHILA GROUCHO; DEPENDENT KINASES; OKADAIC ACID; MITOTIC PHOSPHORYLATION; COREPRESSOR GROUCHO; SPLIT PROTEINS; TUMOR PROMOTER; NUCLEAR MATRIX	Transcriptional corepressors of the Groucho/transducin-like Enhancer of split (Gro/TLE) family are involved in a variety of cell differentiation mechanisms in both invertebrates and vertebrates. They become recruited to specific promoter regions by forming complexes with a number of different DNA-binding proteins thereby contributing to the regulation of multiple genes. To understand how the functions of Gro/TLE proteins are regulated, it was asked whether their ability to mediate transcriptional repression might be controlled by cell cycle-dependent phosphorylation events. It is shown here that activation of p34(cdc2) kinase (cdc2) with okadaic acid is correlated with hyperphosphorylation of Gro/TLEs. Moreover, pharmacological inhibition of cdc2 activity results in Gro/TLE dephosphorylation. In agreement with these findings, a purified cdc2-cyclin B complex can directly phosphorylate Gro/TLEs in vitro. Two separate Gro/TLE domains, the CcN and SP regions, contain sequences that are phosphorylated by cdc2. Deletion of these sequences is correlated with loss of Gro/ TLE phosphorylation by cdc2 in vitro and okadaic acid-induced Gro/TLE hyperphosphorylation in vivo. In addition, Gro/TLEs are phosphorylated during the G(2)/M phase of the cell cycle, and this is correlated with a decreased nuclear interaction. Finally, the transcription repression ability of Gro/TLEs is enhanced by pharmacological inhibition of cdc2. Taken together, these results demonstrate that Gro/TLE proteins are phosphorylated as a function of the cell cycle and implicate phosphorylation events occurring during mitosis in the negative regulation of Gro/TLE activity.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	McGill University	Stifani, S (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	stefano.stifani@mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; DELIDAKIS C, 1991, GENETICS, V129, P803; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Flores-Saaib RD, 2000, NUCLEIC ACIDS RES, V28, P4189, DOI 10.1093/nar/28.21.4189; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gao XM, 2001, J CELL BIOL, V154, P1161, DOI 10.1083/jcb.200104058; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Javed A, 2000, J CELL SCI, V113, P2221; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Prymakowska-Bosak M, 2001, MOL CELL BIOL, V21, P5169, DOI 10.1128/MCB.21.15.5169-5178.2001; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sugiyama S, 2000, DEV BIOL, V221, P168, DOI 10.1006/dbio.2000.9643; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Umbhauer M, 2001, MECH DEVELOP, V109, P61, DOI 10.1016/S0925-4773(01)00517-2; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	57	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51049	51057		10.1074/jbc.M111660200	http://dx.doi.org/10.1074/jbc.M111660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397081	hybrid			2022-12-25	WOS:000180177700112
J	Senin, II; Fischer, T; Komolov, KE; Zinchenko, DV; Philippov, PP; Koch, KW				Senin, II; Fischer, T; Komolov, KE; Zinchenko, DV; Philippov, PP; Koch, KW			Ca2+-myristoyl switch in the neuronal calcium sensor recoverin requires different functions of Ca2+-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; RHODOPSIN KINASE; GUANYLATE-CYCLASE; S-MODULIN; CA2+-DEPENDENT INTERACTION; PHOTORECEPTOR CELLS; NUCLEOTIDE EXCHANGE; BINDING PROTEINS; PHOSPHORYLATION; ACTIVATION	Recoverin is an EF-hand Ca2+-binding protein that is suggested to control the activity of the G-protein-coupled receptor kinase GRK-1 or rhodopsin kinase in a Ca2+-dependent manner. It undergoes a Ca2+-myristoyl switch when Ca2+ binds to EF-hand 2 and 3. We investigated the mechanism of this switch by the use of point mutations in EF-hand 2 (E85Q) and 3 (E121Q) that impair their Ca2+ binding. EF-hand 2 and 3 display different properties and serve different functions. Binding of Ca2+ to recoverin is a sequential process, wherein EF-hand 3 is occupied first followed by the filling of EF-hand 2. After EF-hand 3 bound Ca2+, the subsequent filling of EF-hand 2 triggers the exposition of the myristoyl group and in turn binding of recoverin to membranes. In addition, EF-hand 2 controls the mean residence time of recoverin at membranes by decreasing the dissociation rate of recoverin from membranes by 10-fold. We discuss this mechanism as one critical step for inhibition of rhodopsin kinase by recoverin.	Branch Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 142292, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Koch, KW (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung 1, Postfach 1913, D-52425 Julich, Germany.	k.w.koch@fz-juelich.de	Zinchenko, Dmitry/C-8000-2014; Senin, Ivan I/D-9163-2012; Philippov, Pavel P/A-8939-2012; Koch, Karl-Wilhelm/C-9551-2015; Komolov, Konstantin/ABC-5194-2021	Zinchenko, Dmitry/0000-0001-7181-6283; Koch, Karl-Wilhelm/0000-0003-1501-0044; 				Alekseev AM, 1998, FEBS LETT, V440, P116, DOI 10.1016/S0014-5793(98)01426-4; Ames JB, 2000, METHOD ENZYMOL, V316, P121; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHUR A M, 1991, Biokhimiya, V56, P225; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GORODOVIKOVA EN, 1994, FEBS LETT, V349, P187, DOI 10.1016/0014-5793(94)00661-X; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; Lange C, 1997, BIOCHEMISTRY-US, V36, P12019, DOI 10.1021/bi970938d; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Neubert TA, 1997, PROTEIN SCI, V6, P843; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Permyakov SE, 2000, PROTEIN ENG, V13, P783, DOI 10.1093/protein/13.11.783; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Satpaev DK, 1998, BIOCHEMISTRY-US, V37, P10256, DOI 10.1021/bi9804986; SENIN II, 2002, IN PRESS PHOTORECEPT; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	47	59	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50365	50372		10.1074/jbc.M204338200	http://dx.doi.org/10.1074/jbc.M204338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393897	Green Published, hybrid			2022-12-25	WOS:000180177700021
J	Sukumaran, SK; Quon, MJ; Prasadarao, NV				Sukumaran, SK; Quon, MJ; Prasadarao, NV			Escherichia coli K1 internalization via caveolae requires caveolin-1 and protein kinase C alpha interaction in human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELLULAR CAVEOLAE; MEMBRANE DOMAINS; INVASION; INVOLVEMENT; RECEPTOR; PHOSPHORYLATION; ENDOCYTOSIS; ACTIVATION; REVEALS	The morbidity and mortality associated with Escherichia coli K1 meningitis during the neonatal period have remained significant over the last decade and are once again on the rise. Transcytosis of brain microvascular endothelial cells (BMEC) by E. coli within an endosome to avoid lysosomal fusion is crucial for dissemination into the central nervous system. Central to E. coli internalization of BMEC is the expression of OmpA (outer membrane protein A), which interacts with its receptor for the actin reorganization that leads to invasion. However, nothing is known about the nature of the signaling events for the formation of endosomes containing E. coli K1. We show here that E. coli K1 infection of human BMEC (HBMEC) results in activation of caveolin-1 for bacterial uptake via caveolae. The interaction of caveolin-1 with phosphorylated protein kinase Calpha (PKCalpha) at the E. coli attachment site is critical for the invasion of HBMEC. Optical sectioning of confocal images of infected HBMEC indicates continuing association of caveolin-1 with E. coli during transcytosis. Overexpression of a dominant-negative form of caveolin-1 containing mutations in the scaffolding domain blocked the interaction of phospho-PKCalpha with caveolin-1 and the E. coli invasion of HBMEC, but not actin cytoskeleton rearrangement or the phosphorylation of PKCalpha. The interaction of caveolin-1 with phospho-PKCalpha was completely abrogated in HBMEC overexpressing dominant-negative forms of either focal adhesion kinase or PKCalpha. Treatment of HBMEC with a cell-permeable peptide that represents the scaffolding domain, which was coupled to an antennapedia motif of a Drosophila transcription factor significantly blocked the interaction of caveolin-1 with phospho-PKCalpha and E. coli invasion. These results show that E. coli K1 internalizes HBAMC via caveolae and that the scaffolding domain of caveolin-1 plays a significant role in the formation of endosomes.	Childrens Hosp, Div Infect Dis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA; NIH, Diabet Unit, Clin Invest Lab, NCCAM, Bethesda, MD 20892 USA	Children's Hospital Los Angeles; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Prasadarao, NV (corresponding author), Childrens Hosp, Div Infect Dis, MS 51,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NIAID NIH HHS [AI40567] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z02AT000001, Z01AT000001, ZIAAT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040567, R29AI040567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bannantine JP, 1998, MOL MICROBIOL, V28, P1017, DOI 10.1046/j.1365-2958.1998.00867.x; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Chen YZ, 1999, EXP CELL RES, V246, P83, DOI 10.1006/excr.1998.4301; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Gines S, 2001, MOL PHARMACOL, V59, P1314, DOI 10.1124/mol.59.5.1314; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; Matveev S, 2001, ADV DRUG DELIVER REV, V49, P237, DOI 10.1016/S0169-409X(01)00138-7; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Norkin LC, 2001, EXP CELL RES, V266, P229, DOI 10.1006/excr.2001.5202; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; PRASADARAO NV, 1993, J BIOL CHEM, V268, P10356; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Prasadarao NV, 2002, INFECT IMMUN, V70, P4556, DOI 10.1128/IAI.70.8.4556-4563.2002; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Shin JS, 2001, IMMUNOLOGY, V102, P2, DOI 10.1046/j.1365-2567.2001.01173.x; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; Skretting G, 1999, J CELL SCI, V112, P3899; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Stan RV, 2002, MICROSC RES TECHNIQ, V57, P350, DOI 10.1002/jemt.10089; STINS MF, 1994, AM J PATHOL, V145, P1228; Sukumaran SK, 2002, J BIOL CHEM, V277, P12253, DOI 10.1074/jbc.M110740200; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6	38	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50716	50724		10.1074/jbc.M208830200	http://dx.doi.org/10.1074/jbc.M208830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12386163	hybrid			2022-12-25	WOS:000180177700069
J	Caterina, JJ; Skobe, Z; Shi, J; Ding, YL; Simmer, JP; Birkedal-Hansen, H; Bartlett, JD				Caterina, JJ; Skobe, Z; Shi, J; Ding, YL; Simmer, JP; Birkedal-Hansen, H; Bartlett, JD			Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEINS; MOUSE ENAMELYSIN; MESSENGER-RNAS; BOVINE ENAMEL; CLONING; TOOTH; GENE; EXPRESSION; LOCALIZATION; CELLS	Enamelysin is a tooth-specific matrix metalloproteinase that is expressed during the early through middle stages of enamel development. The enamel matrix proteins amelogenin, ameloblastin, and enamelin are also expressed during this same approximate developmental time period, suggesting that enamelysin may play a role in their hydrolysis. In support of this interpretation, recombinant enamelysin was previously demonstrated to cleave recombinant amelogenin at virtually all of the precise sites known to occur in vivo. Thus, enamelysin is likely an important amelogenin-processing enzyme. To characterize the in vivo biological role of enamelysin during tooth development, we generated an enamelysin-deficient mouse by gene targeting. Although mice heterozygous for the mutation have no apparent phenotype, the enamelysin null mouse has a severe and profound tooth phenotype. Specifically, the null mouse does not process amelogenin properly, possesses an altered enamel matrix and rod pattern, has hypoplastic enamel that delaminates from the dentin, and has a deteriorating enamel organ morphology as development progresses. Our findings demonstrate that enamelysin activity is essential for proper enamel development.	Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA; NIDCR, Matrix Metalloproteinase Unit, NIH, Bethesda, MD 20892 USA; Forsyth Inst, Biostruct Core Facil, Boston, MA 02115 USA; Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48108 USA; Harvard Univ, Sch Med, Dept Oral & Dev Biol, Boston, MA 02115 USA	Harvard University; Forsyth Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Harvard University; Forsyth Institute; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School	Bartlett, JD (corresponding author), Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA.	jbartlett@forsyth.org	Bartlett, John/L-9832-2017	Bartlett, John/0000-0003-2052-6299; Simmer, James/0000-0002-7192-6105	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, R01DE014084] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE014084, DE 14084] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aoba T, 1987, Adv Dent Res, V1, P252; AOBA T, 1987, CALCIFIED TISSUE INT, V41, P281, DOI 10.1007/BF02555230; Bartlett JD, 1996, GENE, V183, P123, DOI 10.1016/S0378-1119(96)00525-2; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; Bartlett JD, 1998, CONNECT TISSUE RES, V39, P101, DOI 10.3109/03008209809023916; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Caterina J, 1999, GENOMICS, V62, P308, DOI 10.1006/geno.1999.5990; Caterina J, 2000, J DENT RES, V79, P1697, DOI 10.1177/00220345000790091001; COLE AS, 1988, BIOCH ORAL BIOL, P460; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; CUISINIER FJG, 1992, CALCIFIED TISSUE INT, V51, P259, DOI 10.1007/BF00334485; DACULSI G, 1978, J ULTRA MOL STRUCT R, V65, P163, DOI 10.1016/S0022-5320(78)90053-9; DEAKINS M., 1941, JOUR DENTAL RES, V20, P117, DOI 10.1177/00220345410200020201; Den Besten PK, 1998, EUR J ORAL SCI, V106, P345, DOI 10.1111/j.1600-0722.1998.tb02196.x; EASTOE JE, 1979, J DENT RES, V58, P753, DOI 10.1177/00220345790580022701; Fukae M, 1996, Adv Dent Res, V10, P111; Fukae M, 1998, J DENT RES, V77, P1580, DOI 10.1177/00220345980770080501; Fukae M, 1977, Tsurumi Shigaku, V3, P15; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hu CC, 1997, J DENT RES, V76, P1720, DOI 10.1177/00220345970760110201; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Hu CC, 1997, J DENT RES, V76, P641, DOI 10.1177/00220345970760020401; Hu JCC, 2000, GENE, V251, P1, DOI 10.1016/S0378-1119(00)00203-1; Hu JCC, 2000, J DENT RES, V79, P70, DOI 10.1177/00220345000790011301; Kimura A, 2001, BIOL REPROD, V65, P1462, DOI 10.1095/biolreprod65.5.1462; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LEFEVRE ML, 1932, J AM DENT ASSOC, V24, P233; Li W, 2001, MATRIX BIOL, V19, P755, DOI 10.1016/S0945-053X(00)00121-9; Li W, 1999, EUR J ORAL SCI, V107, P352, DOI 10.1046/j.0909-8836.1999.eos107506.x; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Murakami C, 1997, HISTOCHEM CELL BIOL, V107, P485, DOI 10.1007/s004180050136; Rajpar MH, 2001, HUM MOL GENET, V10, P1673, DOI 10.1093/hmg/10.16.1673; ROBINSON C, 1988, CARIES RES, V22, P321, DOI 10.1159/000261131; ROBINSON C, 1983, ARCH ORAL BIOL, V28, P993, DOI 10.1016/0003-9969(83)90053-5; ROBINSON C, 1990, J BIOL BUCCALE, V18, P355; Ryu O H, 1996, Adv Dent Res, V10, P150; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; Ryu OH, 1998, CONNECT TISSUE RES, V38, P207, DOI 10.3109/03008209809017038; Scully JL, 1998, CONNECT TISSUE RES, V39, P111, DOI 10.3109/03008209809023917; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; Simmer JP, 1998, J DENT RES, V77, P377, DOI 10.1177/00220345980770020601; Smith C E, 1996, Adv Dent Res, V10, P159; SMITH CE, 1989, ANAT REC, V224, P292, DOI 10.1002/ar.1092240219; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Takata T, 2000, HISTOCHEM J, V32, P223, DOI 10.1023/A:1004051017425; Takata T, 2000, J DENT RES, V79, P1608, DOI 10.1177/00220345000790081401; Tan J, 1998, J DENT RES, V77, P1388, DOI 10.1177/00220345980770060301; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; Vaananen A, 2001, J DENT RES, V80, P1884, DOI 10.1177/00220345010800100501; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4	54	197	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49598	49604		10.1074/jbc.M209100200	http://dx.doi.org/10.1074/jbc.M209100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393861	hybrid			2022-12-25	WOS:000180028900066
J	Matsui, H; Hikichi, Y; Tsuji, I; Yamada, T; Shintani, Y				Matsui, H; Hikichi, Y; Tsuji, I; Yamada, T; Shintani, Y			LIGHT, a member of the tumor necrosis factor ligand superfamily, prevents tumor necrosis factor-alpha-mediated human primary hepatocyte apoptosis, but not Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; NF-KAPPA-B; HERPESVIRUS ENTRY MEDIATOR; T-CELL PROLIFERATION; TNF RECEPTOR; FACTOR FAMILY; OSTEOCLAST DIFFERENTIATION; LYMPHOCYTE-ACTIVATION; DNA-REPLICATION; DEFICIENT MICE	LIGHT is a member of tumor necrosis factor (TNF) superfamily, and its receptors have been identified as lymphotoxin-beta receptor (LTbetaR) and the herpesvirus entry mediator (HVEM)/ATAR/TR2, both of which lack the cytoplasmic sequence termed the "death domain." The present study has demonstrated that LIGHT inhibits TNFalpha-mediated apoptosis of human primary hepatocytes sensitized by actinomycin D (ActD), but not Fas- or TRAIL-mediated apoptosis. Furthermore, LIGHT does not prevent some cell lines such as HepG2 or HeLa from undergoing ActD/TNFalpha-induced apoptosis. This protective effect requires LIGHT pretreatment at least 3 h prior to ActD sensitization. LIGHT stimulates nuclear factor-kappaB (NF-kappaB)-dependent transcriptional activity in human hepatocytes like TNFalpha. The time course of NF-kappaB activation after LIGHT administration is similar to that of the pretreatment required for the anti-apoptotic effect of LIGHT. LIGHT inhibits caspase-3 processing on the apoptotic protease cascade in TNFa-mediated apoptosis but not Fas-mediated apoptosis. In addition, increased caspase-3 and caspase-8 activities in ActD/ TNFalpha-treated cells are effectively blocked by LIGHT pretreatment. However, LIGHT does not change the expression of TNFRp55, TNFRp75, and Fas. These results indicate that LIGHT may act as an anti-apoptotic agent against TNFa-mediated liver injury by blocking the activation of both caspase-3 and caspase-8.	Takeda Chem Ind Ltd, Pharmacol Res Labs 1, Div Pharmaceut Res, Yodogawa Ku, Osaka 5328686, Japan; Takeda Chem Ind Ltd, Pharmacol Res Labs 1, Pharmaceut Discovery Ctr, Yodogawa Ku, Osaka 5328686, Japan; Takeda Chem Ind Ltd, Pharmaceut Res Div, Discovery Labs 2, Tsukuba, Ibaraki 305, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Shintani, Y (corresponding author), Takeda Chem Ind Ltd, Pharmacol Res Labs 1, Div Pharmaceut Res, Yodogawa Ku, 17-85 Jusohonmachi 2-Chome, Osaka 5328686, Japan.							Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fu YX, 1997, J EXP MED, V185, P2111, DOI 10.1084/jem.185.12.2111; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GANTNER F, 1995, HEPATOLOGY, V21, P190, DOI 10.1002/hep.1840210131; GRUSS HJ, 1995, CYTOKINES MOL THER, V1, P75; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Harrop JA, 1998, J IMMUNOL, V161, P1786; Hikichi Y, 2001, BIOCHEM BIOPH RES CO, V289, P670, DOI 10.1006/bbrc.2001.6039; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Kunstle G, 1999, HEPATOLOGY, V30, P1241, DOI 10.1002/hep.510300517; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1994, J IMMUNOL, V153, P1778; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nagaki M, 2000, HEPATOLOGY, V32, P1272, DOI 10.1053/jhep.2000.20239; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shaikh RB, 2001, J IMMUNOL, V167, P6330, DOI 10.4049/jimmunol.167.11.6330; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; VAN AD, 1996, SCIENCE, V274, P787; van Eyndhoven WG, 1999, MOL IMMUNOL, V36, P647, DOI 10.1016/S0161-5890(99)00079-6; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; Watanabe Y, 1997, J IMMUNOL, V159, P4840; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181	57	30	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50054	50061		10.1074/jbc.M206562200	http://dx.doi.org/10.1074/jbc.M206562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393901	hybrid			2022-12-25	WOS:000180028900124
J	Stamatakis, K; Cernuda-Morollon, E; Hernandez-Perera, O; Perez-Sala, D				Stamatakis, K; Cernuda-Morollon, E; Hernandez-Perera, O; Perez-Sala, D			Isoprenylation of RhoB is necessary for its degradation - A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS; VASCULAR ENDOTHELIAL-CELLS; GTP-BINDING PROTEIN; COA REDUCTASE; CHOLESTEROL EFFLUX; TANGIER-DISEASE; FAMILY PROTEINS; RAS; SIMVASTATIN	Statins improve vascular functions by mechanisms independent from their cholesterol-lowering effect. Rho GTPases are emerging as key targets for the vascular effects of statins. RhoB is a short-lived, early-response inducible protein involved in receptor endocytosis, apoptosis, and gene expression. Here we show that statins regulate RhoB expression by acting at multiple levels. Simvastatin increased RhoB protein levels by 8- to 10-fold. This effect was related to a depletion of isoprenoid intermediates, as deduced from the observation that several metabolites of the cholesterol biosynthetic pathway, namely, mevalonate and geranylgeranyl-pyrophosphate, attenuated simvastatin-induced RhoB up-regulation. Moreover, prenyltransferase inhibitors mimicked simvastatin effect. Cholesterol supplementation did not prevent simvastatin-elicited up-regulation but increased RhoB levels per se. Simvastatin moderately augmented RhoB transcript levels, but markedly impaired the degradation of RhoB protein, which accumulated in the cytosol in its non-isoprenylated form. Inhibition of RhoB isoprenylation was apparently required for simvastatin-induced up-regulation, because levels of an isoprenylation-deficient RhoB mutant were not affected by simvastatin. Moreover, this mutant was found to be markedly more stable than the wild-type protein. These results show that RhoB isoprenylation is necessary for rapid turnover of this protein and identify a novel link between the cholesterol biosynthetic pathway and the regulation of G-protein expression.	CSIC, Dept Estructura & Funct Prot, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Perez-Sala, D (corresponding author), CSIC, Dept Estructura & Funct Prot, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Stamatakis, Konstantinos/A-6596-2017; Perez-Sala, Dolores/L-5969-2014	Stamatakis, Konstantinos/0000-0001-9934-3502; Perez-Sala, Dolores/0000-0003-0600-665X				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088-199631050-00003; DIMSTERDENK D, 1995, MOL BIOL CELL, V6, P59, DOI 10.1091/mbc.6.1.59; EICHSTADT HW, 1995, AM J CARDIOL, V76, pA122, DOI 10.1016/S0002-9149(05)80033-5; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Gadbut AP, 1997, EMBO J, V16, P7250, DOI 10.1093/emboj/16.24.7250; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; JAFFE EA, 1972, CIRCULATION, V46, P211; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Laezza C, 1998, BIOCHEM BIOPH RES CO, V248, P469, DOI 10.1006/bbrc.1998.9007; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; PEREZSALA D, 2001, EUR J BIOCH S1, V268, P143; Petras SF, 1999, J LIPID RES, V40, P24; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Romano M, 2000, J INVEST MED, V48, P183; Saura M, 1996, BIOCHEM J, V313, P641, DOI 10.1042/bj3130641; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; Shack S, 1999, ONCOGENE, V18, P6021, DOI 10.1038/sj.onc.1203002; Utech M, 2001, BIOCHEM BIOPH RES CO, V280, P229, DOI 10.1006/bbrc.2000.4061; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Wojcik C, 2000, INT J BIOCHEM CELL B, V32, P957, DOI 10.1016/S1357-2725(00)00044-3; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	46	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49389	49396		10.1074/jbc.M204049200	http://dx.doi.org/10.1074/jbc.M204049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384510	hybrid			2022-12-25	WOS:000180028900037
J	Zhou, Y; Larsen, PH; Hao, CH; Yong, VW				Zhou, Y; Larsen, PH; Hao, CH; Yong, VW			CXCRA is a major chemokine receptor on glioma cells and mediates their survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; HUMAN ASTROCYTES; SIGNAL-TRANSDUCTION; GENE AMPLIFICATION; HUMAN GLIOBLASTOMA; MALIGNANT GLIOMAS; NEURONAL CELLS; MESSENGER-RNAS; IN-VITRO	Chemokines were described originally in the context of providing migrational cues for leukocytes. They are now known to have broader activities, including those that favor tumor growth. We addressed whether and which chemokines may be important promoters of the growth of the incurable brain neoplasm, malignant gliomas. Analyses of 16 human glioma. lines for the expression of chemokine receptors belonging to the CXCR and CCR series revealed low to negligible levels of all receptors, with the exception of CXCR4 that was expressed by 13 of 16 lines. All six resected human glioma specimens showed similarly high CXCR4 expression. The CXCR4 on glioma lines is a signaling receptor in that its agonist, stromal cell-derived factor-1 (SDF-1; CXCL12), produced rapid phosphorylation of mitogen-activated protein kinases. Furthermore, SDF-1 induced the phosphorylation of Akt (protein kinase B), a kinase associated with survival, and prevented the apoptosis of glioma cells when serum was withdrawn from the culture medium. SDF-1 also mediated glioma chemotaxis, in accordance with this better known role of chemokines. We conclude that glioma cells express a predominant chemokine receptor, CXCR4, and that this functions to regulate survival in part through activating pathways such as Akt.	Univ Calgary, Dept Oncol & Clin Neurosci, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada	University of Calgary; University of Alberta	Yong, VW (corresponding author), Univ Calgary, Dept Oncol & Clin Neurosci, 3333 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca		Yong, V. Wee/0000-0002-2600-3563				Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han YL, 2001, BRAIN RES, V888, P1, DOI 10.1016/S0006-8993(00)02924-3; Hao CH, 2001, CANCER RES, V61, P1162; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; HORNEY B, 2002, NATURE REV IMMUNOL, V2, P175; Klein R, 2001, ACTA NEUROPATHOL, V101, P245; Leung SY, 1997, ACTA NEUROPATHOL, V93, P518, DOI 10.1007/s004010050647; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Moriyama T, 1996, INT J CANCER, V66, P678, DOI 10.1002/(SICI)1097-0215(19960529)66:5<678::AID-IJC16>3.0.CO;2-0; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; NITTA T, 1992, NEUROSURG REV, V15, P203, DOI 10.1007/BF00345934; Noe KH, 1999, J VIROL, V73, P3117, DOI 10.1128/JVI.73.4.3117-3124.1999; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Oh JW, 1999, J NEUROVIROL, V5, P82, DOI 10.3109/13550289909029749; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Opdenakker G, 1999, CONT CANC RES, P51; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Scott JN, 1999, ANN NEUROL, V46, P183, DOI 10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.3.CO;2-Z; Sehgal A, 1998, J SURG ONCOL, V69, P99, DOI 10.1002/(SICI)1096-9098(199810)69:2<99::AID-JSO10>3.0.CO;2-M; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Taichman RS, 2002, CANCER RES, V62, P1832; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; VAN MEIR E, 1992, CANCER RES, V52, P4297; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YONG VW, 1987, J NEUROSCI METH, V21, P9, DOI 10.1016/0165-0270(87)90098-7; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yoshimura T, 1999, CONT CANC RES, P227; Zheng JL, 1999, J NEUROIMMUNOL, V98, P185, DOI 10.1016/S0165-5728(99)00049-1	56	317	347	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49481	49487		10.1074/jbc.M206222200	http://dx.doi.org/10.1074/jbc.M206222200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388552	hybrid			2022-12-25	WOS:000180028900050
J	Cai, H; Li, ZM; Dikalov, S; Holland, SM; Hwang, JN; Jo, H; Dudley, SC; Harrison, DG				Cai, H; Li, ZM; Dikalov, S; Holland, SM; Hwang, JN; Jo, H; Dudley, SC; Harrison, DG			NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SUPEROXIDE PRODUCTION; RECEPTOR STIMULATION; NADPH OXIDASE; ACTIVATION; INCREASES; GENERATION; EXPRESSION	Recently, it has been shown that the exogenous addition of hydrogen peroxide (H2O2) increases endothelial nitric oxide (NO.) production. The current study is designed to determine whether endogenous levels of H2O2 are ever sufficient to stimulate NO. production in intact endothelial cells. NO. production was detected by a NO.- specific microelectrode or by an electron spin resonance spectroscopy using Fe2+-(DETC)(2) as a NO.-specific spin trap. The addition of H2O2 to bovine aortic endothelial cells caused a potent and dose-dependent increase in NO. release. Incubation with angiotensin II (10(-7) mol) elevated intracellular H2O2 levels, which were attenuated with PEG-catalase. Angiotensin II increased NO' production by 2-fold, and this was prevented by Losartan and by PEG-catalase, suggesting a critical role of AT1 receptor and H2O2 in this response. In contrast, NO. production evoked by either bradykinin or calcium ionophore A23187 was unaffected by PEG-catalase. As in bovine aortic endothelial cells, angiotensin II doubled NO. production in aortic endothelial cells from C57BL/6 mice but had no effect on NO. production in endothelial cells from p47(phox-/-) mice. In contrast, A23187 stimulated NO. production to a similar extent in endothelial cells from wild-type and p47(phox-/-) mice. In summary, the present study provides direct evidence that endogenous H2O2, derived from the NAD(P)H oxidase, mediates endothelial NO. production in response to angiotensin II. Under disease conditions associated with elevated levels of angiotensin II, this response may represent a compensatory mechanism. Because angiotensin II also stimulates O-2((center dot) over bar) production from the NAD(P)H oxidase, the H2O2 stimulation of NO. may facilitate peroxynitrite formation in response to this octapeptide.	Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA; Georgia Tech, Dept Biomed Engn, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	Emory University; University System of Georgia; Georgia Institute of Technology; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Cai, H (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, Suite 319,Woodruff Mem Res Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.	chua@emory.edu	Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021; li, zongming/S-5232-2019; Jo, Hanjoong/L-6216-2019	Dudley, Samuel/0000-0001-5843-5961; li, zongming/0000-0003-4804-8866; Jo, Hanjoong/0000-0003-1833-372X; Dikalov, Sergey/0000-0003-2976-6184	NHLBI NIH HHS [HL59248, HL39006, HL64828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064828, R01HL059248, R01HL039006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Friedemann MN, 1996, ANAL CHEM, V68, P2621, DOI 10.1021/ac960093w; Gohlke P, 1998, HYPERTENSION, V31, P349, DOI 10.1161/01.HYP.31.1.349; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; Hill-Kapturczak N, 1999, J AM SOC NEPHROL, V10, P481; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Kleschyov AL, 2000, BIOCHEM BIOPH RES CO, V275, P672, DOI 10.1006/bbrc.2000.3361; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kramar EA, 1998, REGUL PEPTIDES, V74, P185, DOI 10.1016/S0167-0115(98)00039-1; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Lang D, 2000, CIRC RES, V86, P463, DOI 10.1161/01.RES.86.4.463; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MOHAZZAB HKM, 1999, AM J PHYSIOL, V276, pH235; Moore AF, 2001, HYPERTENSION, V37, P1285, DOI 10.1161/01.HYP.37.5.1285; Nickenig G, 2002, CIRCULATION, V105, P393, DOI 10.1161/hc0302.102618; Patel JM, 1998, AM J PHYSIOL-LUNG C, V275, pL1061, DOI 10.1152/ajplung.1998.275.6.L1061; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Saito S, 1996, Hypertens Res, V19, P201, DOI 10.1291/hypres.19.201; SEYEDI N, 1995, HYPERTENSION, V26, P164, DOI 10.1161/01.HYP.26.1.164; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Siragy HM, 1999, P NATL ACAD SCI USA, V96, P6506, DOI 10.1073/pnas.96.11.6506; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Thorup C, 1999, J AM SOC NEPHROL, V10, pS220; Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Warnholtz A, 1999, CIRCULATION, V99, P2027, DOI 10.1161/01.CIR.99.15.2027; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2	44	144	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48311	48317		10.1074/jbc.M208884200	http://dx.doi.org/10.1074/jbc.M208884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12377764	hybrid			2022-12-25	WOS:000179789600046
J	Mulligan-Kehoe, MJ; Kleinman, HK; Drinane, M; Wagner, RJ; Wieland, C; Powell, RJ				Mulligan-Kehoe, MJ; Kleinman, HK; Drinane, M; Wagner, RJ; Wieland, C; Powell, RJ			A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; TISSUE-TYPE; STRUCTURAL REQUIREMENTS; TUMOR ANGIOGENESIS; FACTOR-RECEPTOR; CELL APOPTOSIS; UROKINASE-TYPE; SITE LOOP; VITRONECTIN; ANGIOSTATIN	We have made deletions of the porcine plasminogen activator inhibitor-1 (PAI-1) gene to obtain recombinant truncated PAI-1 proteins to examine functions of the PAI-1 isoforms. We previously reported that one recombinant truncated protein, rPAI-1(23), induces the formation of angiostatin by cleaving plasmin. The rPAI-1(23) protein is also able to bind urokinase plasminogen activator and plasminogen and then reduce the amount of plasmin that is formed. We have now prepared three different truncated rPAI-1 proteins and demonstrate that PAI-1 conformations control the release of heparin-binding vascular endothelial growth factor (VEGF) isoforms. The rPAI-1(23) isoform can regulate the functional activity of heparan sulfate-binding VEGF-A isoforms by blocking the activation of VEGF from heparan sulfate. The rPAI-1(23) conformation induced extensive apoptosis in cultured endothelial cells and thus reduced the number of proliferating cells. The rPAI-1(23) isoform inhibited migration of VEGF-stimulated sprouting from chick aortic rings by 65%, thus displaying a role in anti-angiogenic mechanisms. This insight into anti-angiogenic functions related to PAI-1 conformational changes could provide potential intervention points in angiogenesis associated with atherosclerotic plaques and cancer.	Dartmouth Coll, Dartmouth Med Sch, Vasc Surg Sect, Dept Surg, Hanover, NH 03756 USA; NIDCR, Craniofacial Dev Biol & Res Branch, NIH, Bethesda, MD 20892 USA	Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mulligan-Kehoe, MJ (corresponding author), Dartmouth Coll Sch Med, Borwell 530 E,1 Med Ctr Dr, Lebanon, NH 03756 USA.	mary.j.mulligan-kehoe@dartmouth.edu		Jarrahian, Courtney/0000-0003-3046-6891; Drinane, Mary/0000-0001-6081-5330	NHLBI NIH HHS [R01-HL59590] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059590] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aleshkov SB, 1996, J BIOL CHEM, V271, P21231, DOI 10.1074/jbc.271.35.21231; Allaire E, 1998, CIRCULATION, V98, P249, DOI 10.1161/01.CIR.98.3.249; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 1997, ANN NY ACAD SCI, V811, P191, DOI 10.1111/j.1749-6632.1997.tb52002.x; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Egelund R, 1997, EUR J BIOCHEM, V248, P775, DOI 10.1111/j.1432-1033.1997.t01-1-00775.x; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Freyberg MA, 2000, BIOCHEM BIOPH RES CO, V271, P584, DOI 10.1006/bbrc.2000.2678; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; KEIJER J, 1991, BLOOD, V78, P401; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lijnen HR, 2000, J BIOL CHEM, V275, P37645, DOI 10.1074/jbc.M006475200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOSKUTOFF DJ, 1990, ANN NY ACAD SCI, V598, P238, DOI 10.1111/j.1749-6632.1990.tb42296.x; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; Moses MA, 1995, INT REV CYTOL, V161, P1; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Mulligan-Kehoe MJ, 2001, J BIOL CHEM, V276, P8588, DOI 10.1074/jbc.M006434200; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Redmond EM, 2001, CIRCULATION, V103, P597, DOI 10.1161/01.CIR.103.4.597; REILLY CF, 1992, J BIOL CHEM, V267, P17128; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tucker HM, 1996, EUR J BIOCHEM, V237, P180, DOI 10.1111/j.1432-1033.1996.0180n.x; vanMeijer M, 1997, BLOOD, V90, P1874, DOI 10.1182/blood.V90.5.1874; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; YORK JD, 1991, J BIOL CHEM, V266, P8495	77	9	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49077	49089		10.1074/jbc.M208757200	http://dx.doi.org/10.1074/jbc.M208757200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12381729	hybrid			2022-12-25	WOS:000179789600142
J	Yaoi, K; Mitsuishi, Y				Yaoi, K; Mitsuishi, Y			Purification, characterization, cloning, and expression of a novel xyloglucan-specific glycosidase, oligoxyloglucan reducing end-specific cellobiohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUXIN-STIMULATED GROWTH; PEA STEM SEGMENTS; STRUCTURAL-ANALYSIS; MASS-SPECTROMETRY; GENOME SEQUENCE; CELL WALLS; OLIGOSACCHARIDES; INHIBITION; PLANTS; ENZYME	A novel oligoxyloglucan-specific glycosidase, oligoxyloglucan reducing end-specific cellobiohydrolase (OXG-RCBH), with a molecular mass of 97 kDa and a pI of 6.1, was isolated from the fungus Geotrichum sp. M128. Analysis of substrate specificity using various xyloglucan oligosaccharide structures revealed that OXG-RCBH had exoglucanase activity. It recognized the reducing end of oligoxyloglucan and released two glucosyl residue segments from the main chain. The full-length cDNA encoding OXG-RCBH was cloned and sequenced, and it had a 2436-bp open reading frame encoding an 812-amino acid protein. The deduced protein showed similar to35% identity to members of glycoside hydrolase family 74. The cDNA encoding OXG-RCBH was then expressed in Escherichia coli. Although the recombinant protein was expressed as an inclusion body, renaturation was successful, and enzymatically active recombinant OXG-RCBH was obtained.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Yaoi, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		Yaoi, Katsuro/K-1491-2018	Yaoi, Katsuro/0000-0002-4037-0087				AUGUR C, 1992, PLANT PHYSIOL, V99, P180, DOI 10.1104/pp.99.1.180; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; Gibbs MD, 2000, CURR MICROBIOL, V40, P333, DOI 10.1007/s002849910066; Hasper AA, 2002, APPL ENVIRON MICROB, V68, P1556, DOI 10.1128/AEM.68.4.1556-1560.2002; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; Kato Y., 1994, METH CARBOH, VX, P207; Konishi T, 1998, BIOSCI BIOTECH BIOCH, V62, P2421, DOI 10.1271/bbb.62.2421; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; MCDOUGALL GJ, 1990, PLANT PHYSIOL, V93, P1042, DOI 10.1104/pp.93.3.1042; MCDOUGALL GJ, 1988, PLANTA, V175, P412, DOI 10.1007/BF00396348; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nelson N, 1944, J BIOL CHEM, V153, P375; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Pauly M, 1999, GLYCOBIOLOGY, V9, P93, DOI 10.1093/glycob/9.1.93; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; SOMOGYI M, 1945, J BIOL CHEM, V160, P61; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Takeda T, 2002, P NATL ACAD SCI USA, V99, P9055, DOI 10.1073/pnas.132080299; Vincken JP, 1997, CARBOHYD RES, V298, P299, DOI 10.1016/S0008-6215(96)00325-4; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; Yamagaki T, 1998, BIOSCI BIOTECH BIOCH, V62, P2470, DOI 10.1271/bbb.62.2470; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295	29	60	62	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48276	48281		10.1074/jbc.M208443200	http://dx.doi.org/10.1074/jbc.M208443200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374797	hybrid			2022-12-25	WOS:000179789600041
J	You, J; Jacobs, CR; Steinberg, TH; Donahue, HJ				You, J; Jacobs, CR; Steinberg, TH; Donahue, HJ			P2Y purinoceptors are responsible for oscillatory fluid flow-induced intracellular calcium mobilization in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CULTURED BONE-CELLS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; SHEAR-STRESS; ATP; RECEPTORS; RELEASE; GENE; OSTEOPONTIN	We previously found that oscillatory fluid flow activated MC3T3-E1 osteoblastic cell Ca2+ (i) mobilization via the inositol 1,4,5-trisphosphate pathway in the presence of 2% fetal bovine serum (FBS). However, the molecular mechanism of fluid flow-induced Ca2+ (i) mobilization is unknown. In this study, we first demonstrated that oscillatory fluid flow in the absence of FBS failed to increase [Ca2+](i) in MC3T3-E1 cells. Apyrase (10 units/ml), which rapidly hydrolyzes 5' nucleotide triphosphates to monosphophates, prevented the fluid flow induced increases in [Ca2+](i) in the presence of FBS. Adding ATP or UTP to flow medium without FBS restored the ability of fluid flow to increase [Ca2+](i), suggesting that ATP or UTP may mediate the effect of fluid flow on [Ca2+](i). Furthermore, adenosine, ADP, UDP, or adenosine 5'-O-(3-thiotriphosphate) did not induce Ca2+ (i) mobilization under oscillatory fluid flow without FBS. Pyridoxal phosphate 6-azophenyl-2,4'-disulfonic acid, an antagonist of P2X purinoceptors, did not alter the effect of fluid flow on the Ca2+ (i) response, whereas pertussis toxin, a G(i/o)-protein inhibitor, inhibited fluid flow-induced increases in [Ca2+](i) in the presence of 2% FBS. Thus, by the process of elimination, our data suggest that P2Y purinoceptors (P2Y2 or P2Y4) are involved in the Ca2+ (i) response to fluid flow. Finally, a decreased percentage of MC3T3-E1 osteoblastic cells treated with P2Y2 antisense oligodeoxynucleotides responded to fluid flow with an increase in [Ca2+](i), and an increased percentage of ROS 17/2.8 cells, which do not normally express P2Y2 purinoceptors, transfected with P2Y2 purinoceptors responded to fluid flow in the presence of 2% FBS, confirming that P2Y2 purinoceptors are responsible for oscillatory fluid flow-induced Ca2+ (i) mobilization. Our findings shed new light of the molecular mechanisms responsible for oscillatory fluid flow-induced Ca2+ (i) mobilization in osteoblastic cells.	Penn State Univ, Coll Med, Musculoskeletal Res Lab, Dept Orthopaed & Rehabil, Hershey, PA 17033 USA; Stanford Univ, Biomed Engn Div, Dept Engn Mech, Stanford, CA 94305 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Stanford University; Washington University (WUSTL)	You, J (corresponding author), Penn State Univ, Coll Med, Musculoskeletal Res Lab, Dept Orthopaed & Rehabil, Hershey, PA 17033 USA.	jxy118@psu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR049129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013087] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49129] Funding Source: Medline; NIA NIH HHS [AG13087] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; Allen F. D., 1996, Cellular Engineering, V1, P117; Allen FD, 2000, J BIOMECH, V33, P1585, DOI 10.1016/S0021-9290(00)00144-5; Anderson CM, 1997, TRENDS PHARMACOL SCI, V18, P387, DOI 10.1016/S0165-6147(97)01106-1; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Carvalho RS, 1998, J CELL BIOCHEM, V70, P376, DOI 10.1002/(SICI)1097-4644(19980901)70:3<376::AID-JCB11>3.0.CO;2-J; Communi D, 1997, TRENDS PHARMACOL SCI, V18, P83, DOI 10.1016/S0165-6147(96)01035-8; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Donahue HJ, 2000, BONE, V26, P417, DOI 10.1016/S8756-3282(00)00245-3; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; Hillsley MV, 1997, CALCIFIED TISSUE INT, V60, P48, DOI 10.1007/s002239900185; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Hung CT, 1996, J BIOMECH, V29, P1403, DOI 10.1016/0021-9290(96)84535-0; Jacobs CHRISTOPHER R., 2000, Comput Methods Biomech Biomed Engin, V3, P31, DOI 10.1080/10255840008915252; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Kawashima K, 1998, CELL STRUCT FUNCT, V23, P221, DOI 10.1247/csf.23.221; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; Lambrecht G, 2000, N-S ARCH PHARMACOL, V362, P340, DOI 10.1007/s002100000312; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Meyer MP, 2001, DEV DYNAM, V222, P494, DOI 10.1002/dvdy.1196; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; SCHOFL C, 1992, J BONE MINER RES, V7, P485; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Stella N, 1997, J NEUROSCI, V17, P2939; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; van der Meulen MCH, 2002, J BIOMECH, V35, P401, DOI 10.1016/S0021-9290(01)00184-1; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Yamamoto K, 2000, CIRC RES, V87, P385; Yoshikawa T, 1997, BIO-MED MATER ENG, V7, P369; You J, 2000, J BIOMECH ENG-T ASME, V122, P387, DOI 10.1115/1.1287161; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200	44	69	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48724	48729		10.1074/jbc.M209245200	http://dx.doi.org/10.1074/jbc.M209245200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376532	hybrid			2022-12-25	WOS:000179789600098
J	Huber-Lang, MS; Riedeman, NC; Sarma, JV; Younkin, EM; McGuire, SR; Laudes, IJ; Lu, KT; Guo, RF; Neff, TA; Padgaonkar, VA; Lambris, JD; Spruce, L; Mastellos, D; Zetoune, FS; Ward, PA				Huber-Lang, MS; Riedeman, NC; Sarma, JV; Younkin, EM; McGuire, SR; Laudes, IJ; Lu, KT; Guo, RF; Neff, TA; Padgaonkar, VA; Lambris, JD; Spruce, L; Mastellos, D; Zetoune, FS; Ward, PA			Protection of innate immunity by C5aR antagonist in septic mice	FASEB JOURNAL			English	Article						sepsis; neutrophil; oxidative burst; blood clearance	RECEPTOR ANTAGONIST; COMPLEMENT ACTIVATION; NEUTROPHIL DYSFUNCTION; SEPSIS; MODELS; EXPRESSION; INJURY; SHOCK; AGONISTS; PEPTIDE	Innate immune functions are known to be compromised during sepsis, often with lethal consequences. There is also evidence in rats that sepsis is associated with excessive complement activation and generation of the potent anaphylatoxin C5a. In the presence of a cyclic peptide antagonist (C5aRa) to the C5a receptor (C5aR), the binding of murine I-125-C5a to murine neutrophils was reduced, the in vitro chemotactic responses of mouse neutrophils to mouse C5a were markedly diminished, the acquired defect in hydrogen peroxide (H2O2) production of C5a-exposed neutrophils was reversed, and the lung permeability index (extravascular leakage of albumin) in mice after intrapulmonary deposition of IgG immune complexes was markedly diminished. Mice that developed sepsis after cecal ligation/puncture (CLP) and were treated with C5aRa had greatly improved survival rates. These data suggest that C5aRa interferes with neutrophil responses to C5a, preventing C5a-induced compromise of innate immunity during sepsis, with greatly improved survival rates after CLP.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Pennsylvania	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020; Lambris, John/Q-5633-2018; Mohammed, Imran/J-8271-2012; Riedemann, Niels C/C-1633-2010	Lambris, John/0000-0002-9370-5776; Mohammed, Imran/0000-0002-8412-0768; Mastellos, Dimitrios/0000-0002-6634-3271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R01GM029507, R37GM029507] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61656, GM 29507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuebor MN, 1999, J IMMUNOL, V162, P1685; BARTON PA, 1993, INFECT IMMUN, V61, P1474, DOI 10.1128/IAI.61.4.1474-1481.1993; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DRAPEAU G, 1993, BIOCHEM PHARMACOL, V45, P1289, DOI 10.1016/0006-2952(93)90282-2; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Faist E, 1996, WORLD J SURG, V20, P454, DOI 10.1007/s002689900071; Fildes J, 1998, J TRAUMA, V45, P479, DOI 10.1097/00005373-199809000-00008; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; FUREDER W, 1995, J IMMUNOL, V155, P3152; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002; Gommerman JL, 2000, J IMMUNOL, V165, P6915, DOI 10.4049/jimmunol.165.12.6915; GOYA T, 1994, SURGERY, V115, P145; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Heller T, 1999, J IMMUNOL, V163, P985; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; KANERVA L, 1995, EUR J DERMATOL, V5, P149; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Koch T, 1997, SHOCK, V7, P42, DOI 10.1097/00024382-199701000-00005; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; Matsukawa A, 2001, J EXP MED, V193, P679, DOI 10.1084/jem.193.6.679; Miller CG, 1996, MOL IMMUNOL, V33, P1135, DOI 10.1016/S0161-5890(96)00077-6; MOLLISON KW, 1992, FASEB J, V6, pA2058; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; Nishiura H, 1998, LAB INVEST, V78, P1615; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Pellas TC, 1998, J IMMUNOL, V160, P5616; Pellas TC, 1999, CURR PHARM DESIGN, V5, P737; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Riley RD, 2000, J THORAC CARDIOV SUR, V120, P350, DOI 10.1067/mtc.2000.107281; SHARMA SD, 1991, J ORG CHEM, V56, P4981, DOI 10.1021/jo00016a035; Shi FD, 2001, TRENDS IMMUNOL, V22, P97, DOI 10.1016/S1471-4906(00)01821-4; Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338; Short AJ, 1999, BRIT J PHARMACOL, V128, P511, DOI 10.1038/sj.bjp.0702847; SOLOMKIN JS, 1981, SURGERY, V90, P319; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; TSUJI RF, 1992, BIOSCI BIOTECH BIOCH, V56, P2034, DOI 10.1271/bbb.56.2034; UTOH J, 1989, JPN J SURG, V19, P462, DOI 10.1007/BF02471629; Ward PA, 1996, AM J PATHOL, V149, P1079; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Williams MA, 1999, ARCH SURG-CHICAGO, V134, P1360, DOI 10.1001/archsurg.134.12.1360; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651; ZIMMERMAN JJ, 1985, CRIT CARE MED, V13, P143, DOI 10.1097/00003246-198503000-00001; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	54	126	146	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1567	1574		10.1096/fj.02-0209com	http://dx.doi.org/10.1096/fj.02-0209com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374779	Green Submitted			2022-12-25	WOS:000179167600038
J	Guillaume, P; Legler, DF; Boucheron, N; Doucey, MA; Cerottini, JC; Luescher, IF				Guillaume, P; Legler, DF; Boucheron, N; Doucey, MA; Cerottini, JC; Luescher, IF			Soluble major histocompatibility complex-peptide Octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; MHC CLASS-I; LIGAND INTERACTIONS; MEDIATED CYTOTOXICITY; EFFECTOR FUNCTIONS; LYMPHOCYTES-T; ACTIVATION; ANTIGEN; TCR; CTL	Fluorescence-labeled soluble major histocompatibility complex class I-peptide "tetramers" constitute a powerful tool to detect and isolate antigen-specific CD8(+) T cells by flow cytometry. Conventional "tetramers" are prepared by refolding of heavy and light chains with a specific peptide, enzymatic biotinylation at an added C-terminal biotinylation sequence, and "tetramerization" by reaction with phycoerythrin- or allophycocyanin-labeled avidin derivatives. We show here that such preparations are heterogeneous and describe a new procedure that allows the preparation of homogeneous tetra- or octameric major histocompatibility complex-peptide complexes. These compounds were tested on T1 cytotoxic T lymphocytes (CTLs), which recognize the Plasmodium berghei circumsporzoite peptide 252-260 (SYIPSAEKI) containing photoreactive 4-azidobenzoic acid on Lys(259) in the context of H-2K(d). We report that mutation of the CD8 binding site of K-d greatly impairs the binding of tetrameric but not octameric or multimeric K-d-PbCS(ABA) complexes to CTLs. This mutation abolishes the ability of the octamer to elicit significant phosphorylation of CD3, intracellular calcium mobilization, and CTL degranulation. Remarkably, however, this octamer efficiently activates CTLs for Fas (CD95)-dependent apoptosis.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne	Luescher, IF (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1015 Lausanne, Switzerland.			Boucheron, Nicole/0000-0002-4979-8311; Legler, Daniel F./0000-0001-8610-4764				Bodinier M, 2000, NAT MED, V6, P707, DOI 10.1038/76292; Burrows SR, 2000, J IMMUNOL, V165, P6229, DOI 10.4049/jimmunol.165.11.6229; CAO WX, 1995, NATURE, V378, P295, DOI 10.1038/378295a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Denkberg G, 2001, J IMMUNOL, V167, P270, DOI 10.4049/jimmunol.167.1.270; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Esser MT, 1996, J EXP MED, V183, P1697, DOI 10.1084/jem.183.4.1697; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fuller CL, 1999, J IMMUNOL, V162, P6337; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GRAY LS, 1988, J IMMUNOL, V141, P2424; HOCHMAN JH, 1991, J IMMUNOL, V146, P1862; Hudrisier D, 1998, J IMMUNOL, V161, P553; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kalergis AM, 2000, J IMMUNOL METHODS, V234, P61, DOI 10.1016/S0022-1759(99)00215-X; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kessler B, 1998, J IMMUNOL, V161, P6939; Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; OROURKE AM, 1991, J EXP MED, V173, P241, DOI 10.1084/jem.173.1.241; Pestano GA, 1999, SCIENCE, V284, P1187, DOI 10.1126/science.284.5417.1187; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Sousa CRE, 1996, J EXP MED, V184, P149, DOI 10.1084/jem.184.1.149; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Walter JB, 1998, J IMMUNOL METHODS, V214, P41, DOI 10.1016/S0022-1759(98)00035-0; Wang JH, 2002, MOL IMMUNOL, V38, P1039, DOI 10.1016/S0161-5890(02)00033-0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Ybarrondo B, 1997, IMMUNOLOGY, V91, P186, DOI 10.1046/j.1365-2567.1997.00237.x; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	39	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4500	4509		10.1074/jbc.M208863200	http://dx.doi.org/10.1074/jbc.M208863200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12407102	hybrid, Green Published			2022-12-25	WOS:000180968900020
J	Aslan, M; Ryan, TM; Townes, TM; Coward, L; Kirk, MC; Barnes, S; Alexander, CB; Rosenfeld, SS; Freeman, BA				Aslan, M; Ryan, TM; Townes, TM; Coward, L; Kirk, MC; Barnes, S; Alexander, CB; Rosenfeld, SS; Freeman, BA			Nitric oxide-dependent generation of reactive species in sickle cell disease - Actin tyrosine nitration induces defective cytoskeletal polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; MANGANESE SUPEROXIDE-DISMUTASE; FREE-RADICAL GENERATION; SYNTHASE KNOCKOUT MICE; ACUTE LUNG INJURY; IN-GEL DIGESTION; BINDING PROTEINS; ENDOTHELIAL-CELLS; OXIDATIVE DAMAGE; EPITHELIAL-CELLS	The intermittent vascular occlusion occurring in sickle cell disease (SCD) leads to ischemia-reperfusion injury and activation of inflammatory processes including enhanced production of reactive oxygen species and increased expression of inducible nitric-oxide synthase (NOS2). Appreciating that impaired nitric oxide-dependent vascular function and the concomitant formation of oxidizing and nitrating species occur in concert with increased rates of tissue reactive oxygen species production, liver and kidney NOS2 expression, tissue 3-nitrotyrosine (NO(2)Tyr) formation and apoptosis were evaluated in human SCD tissues and a murine model of SCD. Liver and kidney NOS2 expression and NO(2)Tyr immunoreactivity were significantly increased in SCD mice and humans, but not in nondiseased tissues. TdT-mediated nick end-label (TUNEL) staining showed apoptotic cells in regions expressing elevated levels of NOS2 and NO(2)Tyr in all SCD tissues. Gas chromatography mass spectrometry analysis revealed increased plasma protein NO(2)Tyr content and increased levels of hepatic and renal protein NO(2)Tyr derivatives in SCD (21.4 +/- 2.6 and 37.5 +/- 7.8 ng/mg) versus wild type mice (8.2 +/- 2.2 and 10 +/- 1.2 ng/mg), respectively. Western blot analysis and immunoprecipitation of SCD mouse liver and kidney proteins revealed one principal NO(2)Tyr-containing protein of 42 kDa, compared with controls. Enzymatic in-gel digestion and MALDI-TOF mass spectrometry identified this nitrated protein as actin. Electrospray ionization and fragment analysis by tandem mass spectrometry revealed that 3 of 15 actin tyrosine residues are nitrated (Tyr(91), Tyr(198), and Tyr(240)) at positions that significantly modify actin assembly. Confocal microscopy of SCD human and mouse tissues revealed that nitration led to morphologically distinct disorganization of filamentous actin. In aggregate, we have observed that the hemoglobin point mutation of sickle cell disease that mediates hemoglobin polymerization defects is translated, via inflammatory oxidant reactions, into defective cytoskeletal polymerization.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Comprehens Sickle Cell Dis Ctr, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Mass Spectrometry Shared Facil, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Freeman, BA (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, BIomed Res Bldg 2,901 19th St S, Birmingham, AL 35233 USA.	Bruce.Freeman@ccc.uab.edu	Freeman, Bruce A/H-9342-2012; Aslan, Mutay/C-7566-2016	Aslan, Mutay/0000-0002-0660-971X; Ryan, Thomas/0000-0002-8982-0253	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064937, R01HL058115, P60HL058418] Funding Source: NIH RePORTER; NHLBI NIH HHS [P6-HL58418, R01-HL58115, R01-HL64937] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Baldus S, 2001, J CLIN INVEST, V108, P1759; Banan A, 2001, AM J PHYSIOL-GASTR L, V280, pG1234, DOI 10.1152/ajpgi.2001.280.6.G1234; Bank N, 1996, KIDNEY INT, V50, P184, DOI 10.1038/ki.1996.301; BAUER TW, 1980, AM J MED, V69, P833, DOI 10.1016/S0002-9343(80)80008-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; Bian K, 1999, AM J PHYSIOL-RENAL, V277, pF33, DOI 10.1152/ajprenal.1999.277.1.F33; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; COOPER JA, 1992, CYTOSKELETON PRACTIC, P74; Crow JP, 1997, J NEUROCHEM, V69, P1936; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Eiserich JP, 1999, P NATL ACAD SCI USA, V96, P6365, DOI 10.1073/pnas.96.11.6365; ENGERSON TD, 1987, J CLIN INVEST, V79, P1564, DOI 10.1172/JCI112990; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Frost MT, 2000, BIOCHEM J, V345, P453, DOI 10.1042/0264-6021:3450453; Good PF, 1996, AM J PATHOL, V149, P21; Gow Andrew J., 1998, V100, P291; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENNESSEY ES, 1993, BIOCHEM J, V291, P657, DOI 10.1042/bj2910657; HENRY TD, 1990, CIRC RES, V67, P1453, DOI 10.1161/01.RES.67.6.1453; HINSHAW DB, 1991, ARCH BIOCHEM BIOPHYS, V288, P311, DOI 10.1016/0003-9861(91)90200-3; HINSHAW DB, 1988, AM J PATHOL, V132, P479; Isobe M, 1999, TRANSPLANTATION, V68, P803, DOI 10.1097/00007890-199909270-00013; Isobe M, 2000, TRANSPLANT P, V32, P1650, DOI 10.1016/S0041-1345(00)01435-4; JOHNSON CS, 1985, MEDICINE, V64, P349, DOI 10.1097/00005792-198509000-00007; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KNOWLES ME, 1974, NATURE, V247, P288, DOI 10.1038/247288a0; Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Lang JD, 2000, AM J PHYSIOL-LUNG C, V279, pL994, DOI 10.1152/ajplung.2000.279.5.L994; Lee VG, 2001, SHOCK, V16, P355, DOI 10.1097/00024382-200116050-00006; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Ling H, 1998, KIDNEY INT, V53, P1642, DOI 10.1046/j.1523-1755.1998.00913.x; LUCCHESI BR, 1990, AM J CARDIOL, V65, pI14; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Maitre B, 2000, CHEST, V117, P1386, DOI 10.1378/chest.117.5.1386; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; McGough A, 1998, CURR OPIN STRUC BIOL, V8, P166, DOI 10.1016/S0959-440X(98)80034-1; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; Nath KA, 2001, AM J PATHOL, V158, P893, DOI 10.1016/S0002-9440(10)64037-0; Osarogiagbon UR, 2000, BLOOD, V96, P314, DOI 10.1182/blood.V96.1.314.013k39_314_320; Osei SY, 1996, BLOOD, V88, P3583, DOI 10.1182/blood.V88.9.3583.bloodjournal8893583; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Ottesen LH, 2001, FREE RADICAL BIO MED, V31, P790, DOI 10.1016/S0891-5849(01)00647-5; Paller MS, 1998, RENAL FAILURE, V20, P459, DOI 10.3109/08860229809045135; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pham PTT, 2000, KIDNEY INT, V57, P1, DOI 10.1046/j.1523-1755.2000.00806.x; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Radi R, 1999, METHOD ENZYMOL, V301, P353; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; REES DC, 1995, BRIT J HAEMATOL, V91, P834, DOI 10.1111/j.1365-2141.1995.tb05397.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suarez-Huerta N, 2000, J CELL PHYSIOL, V184, P239, DOI 10.1002/1097-4652(200008)184:2<239::AID-JCP12>3.0.CO;2-R; Tilney NL, 2001, TRANSPL P, V33, P843, DOI 10.1016/S0041-1345(00)02341-1; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WAY M, 1990, NATURE, V344, P292, DOI 10.1038/344292a0; WEEDS AG, 1991, BIOCHEM SOC T, V19, P1016, DOI 10.1042/bst0191016; WERNS SW, 1988, FREE RADICAL BIO MED, V4, P31, DOI 10.1016/0891-5849(88)90008-1; Wildhirt SM, 1996, BIOCHEM BIOPH RES CO, V227, P328, DOI 10.1006/bbrc.1996.1509; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x; Zhou WH, 2001, HEPATOLOGY, V33, P902, DOI 10.1053/jhep.2001.23073; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	83	143	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					4194	4204		10.1074/jbc.M208916200	http://dx.doi.org/10.1074/jbc.M208916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12401783	hybrid			2022-12-25	WOS:000180869700087
J	Hanson, CL; Fucini, P; Ilag, LL; Nierhaus, KH; Robinson, CV				Hanson, CL; Fucini, P; Ilag, LL; Nierhaus, KH; Robinson, CV			Dissociation of intact Escherichia coli ribosomes in a mass spectrometer - Evidence for conformational change in a ribosome elongation factor g complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN L7/L12; CROSS-LINKING; 70S RIBOSOME; EF-G; RNA; BINDING; TRANSLOCATION; THIOSTREPTON; SUBUNIT; HYDROLYSIS	We used mass spectrometry to identify proteins that are released in the gas phase from Escherichia coli ribosomes in response to a range of different solution conditions and cofactor binding. From solution at neutral pH the spectra are dominated by just 4 of the 54 ribosomal proteins (L7/L12, L11, and L10). Lowering the pH of the solution leads to the gas phase dissociation of four additional proteins as well as the 5 S RNA. Replacement of Mg2+ by Li+ ions in solutions of ribosomes induced the dissociation of 17 ribosomal proteins. Correlation of these results with available structural information for ribosomes revealed that a relatively high interaction surface area of the protein with RNA was the major force in preventing dissociation. By using the proteins that dissociate to probe their interactions with RNA, we examined different complexes of the ribosome formed with the elongation factor G and inhibited by fusidic acid or thiostrepton. Mass spectra recorded for the fusidic acid-inhibited complex reveal subtle changes in peak intensity of the proteins that dissociate. By contrast gas phase dissociation from the thiostrepton-inhibited complex is markedly different and demonstrates the presence of L5 and LIS, two proteins that interact exclusively with the 5 S RNA. These results allow us to propose that the ribosome elongation factor-G complex inhibited by thiostrepton, but not fusidic acid, involves destabilization of 5 S RNA-protein interactions.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany	University of Cambridge; Max Planck Society	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Fucini, Paola/M-1118-2014	Fucini, Paola/0000-0003-1724-8507; Ilag, Leopold/0000-0003-3678-7100; robinson, carol/0000-0001-7829-5505				Agrawal RK, 1999, INT J BIOCHEM CELL B, V31, P243, DOI 10.1016/S1357-2725(98)00149-6; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; BODLEY JW, 1970, J BIOL CHEM, V245, P5662; BODLEY JW, 1970, J BIOL CHEM, V245, P5656; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Dey D, 1998, J BIOL CHEM, V273, P1670, DOI 10.1074/jbc.273.3.1670; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; GUDKOV AT, 1984, FEBS LETT, V176, P32, DOI 10.1016/0014-5793(84)80906-0; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; HUBBARD SJ, 1992, THESIS U LONDON LOND; Huppler A, 2002, NAT STRUCT BIOL, V9, P431, DOI 10.1038/nsb800; KALTSCHMIDT E, 1971, ANAL BIOCHEM, V43, P25, DOI 10.1016/0003-2697(71)90103-5; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; Montesano-Roditis L, 2001, J BIOL CHEM, V276, P14117, DOI 10.1074/jbc.M008430200; Moore PB, 2001, BIOCHEMISTRY-US, V40, P3243, DOI 10.1021/bi0029402; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Nierhaus K., 1990, RIBOSOMES PROTEIN SY, P161; Ramakrishnan V, 2001, CURR OPIN STRUC BIOL, V11, P144, DOI 10.1016/S0959-440X(00)00184-6; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; ROSTOM AA, 1999, THESIS U OXFORD OXFO; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; THOMPSON J, 1991, BIOCHIMIE, V73, P1131, DOI 10.1016/0300-9084(91)90156-U; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	41	48	48	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1259	1267		10.1074/jbc.M208966200	http://dx.doi.org/10.1074/jbc.M208966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409297	hybrid			2022-12-25	WOS:000180321900073
J	Hommers, LG; Lohse, MJ; Bunemann, M				Hommers, LG; Lohse, MJ; Bunemann, M			Regulation of the inward rectifying properties of G-protein-activated inwardly rectifying K+ (GIRK) channels by G beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; I-KACH; ATRIAL MYOCYTES; RECTIFICATION; BINDING; CELLS; BLOCK; IDENTIFICATION; MECHANISM; KIR2.1	Gbetagamma subunits are known to bind to and activate G-protein-activated inwardly rectifying K+ channels (GIRK) by regulating their open probability and bursting behavior. Studying G-protein regulation of either native GIRK (I-KACh) channels in feline atrial myocytes or heterologously expressed GIRK1/4 channels in Chinese hamster ovary cells and HEK 293 cells uncovered a novel Gbetagamma subunit mediated regulation of the inwardly rectifying properties of these channels. I-KACh activated by submaximal concentrations of acetylcholine exhibited a similar to2.5-fold stronger inward rectification than I-KACh activated by saturating concentrations of acetylcholine. Similarly, the inward rectification of currents through GIRK1/4 channels expressed in HEK cells was substantially weakened upon maximal stimulation with co-expressed Gbetagamma subunits. Analysis of the outward current block underlying inward rectification demonstrated that the fraction of instantaneously blocked channels was reduced when Gbetagamma was over-expressed. The Gbetagamma induced weakening of inward rectification was associated with reduced potencies for Ba2+ and Cs+ to block channels from the extracellular side. Based on these results we propose that saturation of the channel with Gbetagamma leads to a conformational change within the pore of the channel that reduced the potency of extracellular cations to block the pore and increased the fraction of channels inert to a pore block in outward direction.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Bunemann, M (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacherstr 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; CAMPBELL GD, 1989, J PHYSIOL-LONDON, V415, P57, DOI 10.1113/jphysiol.1989.sp017711; Corey S, 2001, J BIOL CHEM, V276, P11409, DOI 10.1074/jbc.M100058200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY RD, 1988, J GEN PHYSIOL, V91, P593, DOI 10.1085/jgp.91.4.593; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; IvanovaNikolova TT, 1997, J GEN PHYSIOL, V109, P245, DOI 10.1085/jgp.109.2.245; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Lee JK, 1999, J GEN PHYSIOL, V113, P555, DOI 10.1085/jgp.113.4.555; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Nemec J, 1999, BIOPHYS J, V76, P246, DOI 10.1016/S0006-3495(99)77193-6; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Sadja R, 2002, P NATL ACAD SCI USA, V99, P10783, DOI 10.1073/pnas.162346199; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Wickman K, 1999, ANN NY ACAD SCI, V868, P386, DOI 10.1111/j.1749-6632.1999.tb11300.x; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YAMADA M, 1995, J BIOL CHEM, V270, P9289, DOI 10.1074/jbc.270.16.9289; Yamada M, 1998, PHARMACOL REV, V50, P723; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0; Zhou H, 1996, AM J PHYSIOL-CELL PH, V271, pC1949, DOI 10.1152/ajpcell.1996.271.6.C1949	41	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1037	1043		10.1074/jbc.M205325200	http://dx.doi.org/10.1074/jbc.M205325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12403784	hybrid			2022-12-25	WOS:000180321900046
J	Tischkau, SA; Mitchell, JW; Tyan, SH; Buchanan, GF; Gillette, MU				Tischkau, SA; Mitchell, JW; Tyan, SH; Buchanan, GF; Gillette, MU			Ca2+/cAMP response element-binding protein (CREB)-dependent activation of Per1 is required for light-induced signaling in the Suprachiasmatic nucleus circadian clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PHASE ADVANCES; IMMEDIATE-EARLY GENES; CREB PHOSPHORYLATION; BIOLOGICAL CLOCK; PERIOD HOMOLOGS; KINASE-II; EXPRESSION; RHYTHMS; SHIFTS; MPER1	Light is a prominent stimulus that synchronizes endogenous circadian rhythmicity to environmental light/dark cycles. Nocturnal light elevates mRNA of the Period1 (Per1) gene and induces long term state changes, expressed as phase shifts of circadian rhythms. The cellular mechanism for Per1 elevation and light-induced phase advance in the suprachiasmatic nucleus (SCN), a process initiated primarily by glutamatergic neuro-transmission from the retinohypothalamic tract, was examined. Glutamate (GLU)-induced phase advances in the rat SCN were blocked by antisense oligodeoxynucleotide (ODN) against Perl and Ca2+/cAMP response element (CRE)-decoy ODN. CRE-decoy ODN also blocked light-induced phase advances in vivo. Furthermore, the CRE-decoy blocked GLU-induced accumulation of Perl mRNA. Thus, Ca2+/cAMP response element-binding protein (CREB) and Perl are integral components of the pathway transducing light-stimulated GLU neurotransmission into phase advance of the circadian clock.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Program Neurosci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, B107 CLSL,601 S Goodwin Ave, Urbana, IL 61801 USA.	mgillett@uiuc.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Buchanan, Gordon/0000-0003-2371-4455	NHLBI NIH HHS [HL67007, R01 HL067007] Funding Source: Medline; NIMH NIH HHS [MH12351] Funding Source: Medline; NINDS NIH HHS [R01 NS022155, NS22155, NS10170, NS11158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH012351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155, F32NS010170, F32NS011158] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Beaule C, 1999, BRAIN RES, V821, P95, DOI 10.1016/S0006-8993(99)01073-2; Best JD, 1999, J NEUROSCI, V19, P828; Cermakian N, 2001, EMBO J, V20, P3967, DOI 10.1093/emboj/20.15.3967; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Ding JM, 1997, J NEUROSCI, V17, P667; Ding JM, 1998, NATURE, V394, P381, DOI 10.1038/28639; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Edelstein K, 2000, BRAIN RES, V870, P54, DOI 10.1016/S0006-8993(00)02401-X; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Fukushima T, 1997, NEUROSCI LETT, V227, P45, DOI 10.1016/S0304-3940(97)00297-8; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; Gillette MU, 1999, RECENT PROG HORM RES, V54, P33; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOLOMBEK DA, 1994, NEUROREPORT, V5, P1638, DOI 10.1097/00001756-199408150-00024; Guido ME, 1999, J BIOL RHYTHM, V14, P275, DOI 10.1177/074873099129000687; Hurst WJ, 2002, BIOCHEM BIOPH RES CO, V298, P133, DOI 10.1016/S0006-291X(02)02346-X; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; Mathur A, 1996, AM J PHYSIOL-REG I, V270, pR1031, DOI 10.1152/ajpregu.1996.270.5.R1031; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mintz EM, 1999, J NEUROSCI, V19, P5124; Miyake S, 2000, NEUROSCI LETT, V294, P41, DOI 10.1016/S0304-3940(00)01545-7; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; PROSSER RA, 1989, J NEUROSCI, V9, P1073; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SHIBATA S, 1994, AM J PHYSIOL, V267, pR360, DOI 10.1152/ajpregu.1994.267.2.R360; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SHIRAKAWA T, 1994, NEUROSCI LETT, V178, P47, DOI 10.1016/0304-3940(94)90286-0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tischkau SA, 2000, J NEUROSCI, V20, P7830; TISCHKAU SA, 1999, J NEUROSCI, V15, P1; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; WEBER ET, 1995, NEUROSCI LETT, V197, P227, DOI 10.1016/0304-3940(95)11961-U; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; Yokota S, 2001, J NEUROCHEM, V77, P618, DOI 10.1046/j.1471-4159.2001.00270.x; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	55	209	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					718	723		10.1074/jbc.M209241200	http://dx.doi.org/10.1074/jbc.M209241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409294	hybrid			2022-12-25	WOS:000180321900005
J	Velkov, T; Lawen, A				Velkov, T; Lawen, A			Mapping and molecular modeling of S-adenosyl-L-methionine binding sites in N-methyltransferase domains of the multifunctional polypeptide cyclosporin synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; RAT GUANIDINOACETATE METHYLTRANSFERASE; CRYSTAL-STRUCTURE; SEQUENCE MOTIFS; ACETYLCHOLINE-BINDING; BIOMIMETIC CATALYSIS; PEPTIDE SYNTHETASES; PROTEIN TEMPLATES; SWISS-MODEL; ENZYME	We employed a highly specific photoaffinity labeling procedure, using C-14-labeled S-adenosyl-L-methionine (AdoMet) to define the chemical structure of the AdoMet binding centers on cyclosporin synthetase (CySyn). Tryptic digestion of CySyn photolabeled with either [methyl-C-14]AdoMet or [carboxyl-C-14]AdoMet yielded the sequence H2N-Asn-Asp-Gly-Leu-Glu-Ser-Tyr-Val-Gly-Ile-Glu-Pro-Ser-Arg-COOH (residues 10644-10657), situated within the N-methyltransferase domain of module 8 of CySyn. Radiosequencing detected Glu(10654). and Pro 10655 as the major sites of derivatization. [carboxyl-C-14]AdoMet in addition labeled Tyr(10650). Chymotryptic digestion generated the radiolabeled peptide H2N-Ile-Gly-Leu-Glu-Pro-Ser-Gln-Ser-Ala-Val-Gln-Phe-COOH, corresponding to amino acids 2125-2136 of the N-methyltransferase domain of module 2. The radiolabeled amino acids were identified as Glu(2128) and Pro(2129), which are equivalent in position and function to the modified residues identified with tryptic digestions in module 8. Homology modeling of the N-methyltransferase domains indicates that these regions conserve the consensus topology of the AdoMet binding fold and consensus cofactor interactions seen in structurally characterized AdoMet-dependent methyltransferases. The modified sequence regions correspond to the motif II consensus sequence element, which is involved in directly complexing the adenine and ribose components of AdoMet. We conclude that the AdoMet binding to nonribosomal peptide synthetase N-methyltransferase domains obeys the consensus cofactor interactions seen among most structurally characterized low molecular weight AdoMet-dependent methyltransferases.	Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Monash University	Lawen, A (corresponding author), Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Bldg 13D, Melbourne, Vic 3800, Australia.	Alfons.Lawen@med.monash.edu.au	Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945; velkov, tony/0000-0002-0017-7952				BELL A, 1994, BIOCHEM PHARMACOL, V48, P495, DOI 10.1016/0006-2952(94)90279-8; Borel JF, 1999, TRANSPL P, V31, P1464, DOI 10.1016/S0041-1345(99)00009-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAVAN AJ, 1993, J BIOL CHEM, V268, P16437; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Ciancio G, 2000, Expert Opin Pharmacother, V1, P1307, DOI 10.1517/14656566.1.7.1307; Cruz MC, 2000, ANTIMICROB AGENTS CH, V44, P143, DOI 10.1128/AAC.44.1.143-149.2000; deFerra F, 1997, J BIOL CHEM, V272, P25304, DOI 10.1074/jbc.272.40.25304; DITTMANN J, 1994, J BIOL CHEM, V269, P2841; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ELAD D, 1969, J CHEM SOC CHEM COMM, P305, DOI 10.1039/c29690000305; FAUNAM EB, 1999, S ADENOSYLMETHIONINE, P1; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; Gokhale RS, 2000, CURR OPIN CHEM BIOL, V4, P22, DOI 10.1016/S1367-5931(99)00046-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hacker C, 2000, J BIOL CHEM, V275, P30826, DOI 10.1074/jbc.M002614200; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; Hamahata A, 1996, BIOCHEM J, V317, P141, DOI 10.1042/bj3170141; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Keating TA, 2001, CHEMBIOCHEM, V2, P99, DOI 10.1002/1439-7633(20010202)2:2<99::AID-CBIC99>3.0.CO;2-3; Komoto J, 2002, J MOL BIOL, V320, P223, DOI 10.1016/S0022-2836(02)00448-5; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; Lawen A, 1996, Prog Med Chem, V33, P53, DOI 10.1016/S0079-6468(08)70303-5; LAWEN A, 1990, J BIOL CHEM, V265, P11355; LINSCHITZ H, 1968, J AM CHEM SOC, V90, P2979; LIPMANN F, 1971, ADV ENZYMOL RAMB, V35, P1; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Marahiel MA, 1997, CHEM BIOL, V4, P561, DOI 10.1016/S1074-5521(97)90242-8; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; Ngola SM, 1996, J ORG CHEM, V61, P4355, DOI 10.1021/jo960521y; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; ORTIZ AR, 1992, BIOCHEMISTRY-US, V31, P2887, DOI 10.1021/bi00126a007; PATAKI G, 1967, Chromatographic Reviews, V9, P23, DOI 10.1016/0009-5907(67)80007-3; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; PIEPER R, 1995, EUR J BIOCHEM, V230, P119, DOI 10.1111/j.1432-1033.1995.tb20541.x; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUEGGER A, 1976, HELV CHIM ACTA, V59, P1075, DOI 10.1002/hlca.19760590412; Schluckebier G, 1998, BIOL CHEM, V379, P389; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Schubert HL, 1998, NAT STRUCT BIOL, V5, P585, DOI 10.1038/846; Scrutton NS, 1996, BIOCHEM J, V319, P1; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; STEINMAUS H, 1969, J AM CHEM SOC, V91, P4921, DOI 10.1021/ja01045a057; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKATA Y, 1992, BIOCHEMISTRY-US, V31, P4369, DOI 10.1021/bi00132a030; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trauger JW, 2000, NATURE, V407, P215, DOI 10.1038/35025116; Tsuji SY, 2001, BIOCHEMISTRY-US, V40, P2317, DOI 10.1021/bi002462v; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walsh CT, 2001, CURR OPIN CHEM BIOL, V5, P525, DOI 10.1016/S1367-5931(00)00235-0; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; Weinreb PH, 1998, BIOCHEMISTRY-US, V37, P1575, DOI 10.1021/bi9719859; XU Q, 1992, J BIOL CHEM, V267, P11968	67	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1137	1148		10.1074/jbc.M209719200	http://dx.doi.org/10.1074/jbc.M209719200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12399454	hybrid, Green Published			2022-12-25	WOS:000180321900059
J	East, L; Rushton, S; Taylor, ME; Isacke, CM				East, L; Rushton, S; Taylor, ME; Isacke, CM			Characterization of sugar binding by the mannose receptor family member, Endo180	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; CYSTEINE-RICH DOMAIN; SECRETORY PHOSPHOLIPASES A(2); LIGAND-BINDING; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; PROTEIN; LECTIN; IDENTIFICATION; GLYCOPROTEIN	Members of the mannose receptor family, the mannose receptor, the phospholipase A(2) receptor, DEC-205, and Endo180, contain multiple C-type lectin-like domains (CTLDs) within a single polypeptide. In addition, at their N termini, all four family members contain a cysteine-rich domain similar to the R-type carbohydrate recognition domains of ricin. However, despite the common presence of multiple lectin-like domains, these four endocytic receptors have divergent ligand binding activities, and it is clear that the majority of these domains do not bind sugars. Here the functions of the lectin-like domains of the most recently discovered family member, Endo180, have been investigated. Endo180 is shown to bind in a Ca2+-dependent manner to mannose, fucose, and N-acetylglucosamine but not to galactose. This activity is mediated by one of the eight CTLDs, CTLD2. Competition assays indicate that the monosaccharide binding specificity of Endo180 CTLD2 is similar to that of mannose receptor CTLD4. However, additional experiments indicate that, unlike the cysteine-rich domain of the mannose receptor, the cysteine-rich domain of Endo180 does not bind sulfated sugars. Thus, although Endo180 and the mannose receptor are now both known to be mannose binding lectins, each receptor is likely to have a distinct set of glycoprotein ligands in vivo.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, Chester Beatty Labs, London SW3 6JB, England; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, Chester Beatty Labs, Mary Jean Mitchell Green Bldg,237 Fulham Rd, London SW3 6JB, England.			Isacke, Clare/0000-0002-9222-3345; Taylor, Maureen/0000-0001-8300-4987				Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Burrows L, 1997, BIOCHEM J, V324, P673, DOI 10.1042/bj3240673; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Engelholm LH, 2001, TRENDS CARDIOVAS MED, V11, P7, DOI 10.1016/S1050-1738(01)00076-7; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Howard MJ, 2002, J BIOL CHEM, V277, P32320, DOI 10.1074/jbc.M203631200; Irjala H, 2001, J EXP MED, V194, P1033, DOI 10.1084/jem.194.8.1033; ISACKE CM, 1990, MOL CELL BIOL, V10, P2606, DOI 10.1128/MCB.10.6.2606; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; LEW DB, 1994, J CLIN INVEST, V94, P1855, DOI 10.1172/JCI117535; Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Napper CE, 2001, J BIOL CHEM, V276, P14759, DOI 10.1074/jbc.M100425200; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Nielsen BS, 2002, INT J CANCER, V98, P656, DOI 10.1002/ijc.10227; PAPKOFF H, 1970, ARCH BIOCHEM BIOPHYS, V136, P522, DOI 10.1016/0003-9861(70)90224-9; Schweizer A, 2000, J BIOL CHEM, V275, P29694, DOI 10.1074/jbc.M000571200; Sheikh H, 2000, J CELL SCI, V113, P1021; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; Simpson DZ, 1999, BIOCHEM J, V343, P403, DOI 10.1042/0264-6021:3430403; St Croix B, 2000, SCIENCE, V289, P1197; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor ME, 1997, GLYCOBIOLOGY, V7, pR5; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WILEMAN TE, 1986, P NATL ACAD SCI USA, V83, P2501, DOI 10.1073/pnas.83.8.2501; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	47	66	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50469	50475		10.1074/jbc.M208985200	http://dx.doi.org/10.1074/jbc.M208985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399458	hybrid			2022-12-25	WOS:000180177700036
J	Finking, R; Solsbacher, J; Konz, D; Schobert, M; Schafer, A; Jahn, D; Marahiel, MA				Finking, R; Solsbacher, J; Konz, D; Schobert, M; Schafer, A; Jahn, D; Marahiel, MA			Characterization of a new type of phosphopantetheinyl transferase for fatty acid and siderophore synthesis in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULAR PEPTIDE SYNTHETASES; CARRIER PROTEIN) SYNTHASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; 2-HYBRID SYSTEM; IN-VITRO; YEAST; BINDING; SFP; RECONSTITUTION	Phosphopantetheinyl-dependent carrier proteins are part of fatty-acid synthases (primary metabolism), polyketide synthases, and non-ribosomal peptide synthetases (secondary metabolism). For these proteins to become functionally active, they need to be primed with the 4'-phosphopantetheine moiety of coenzyme A by a dedicated phosphopantetheine transferase (PPTase). Most organisms that employ more than one phosphopantetheinyl-dependent pathway also have more than one PPTase. Typically, one of these PPTases is optimized for the modification of carrier proteins of primary metabolism and rejects those of secondary metabolism (AcpS-type PPTases), whereas the other, Sfp-type PPTase, efficiently modifies carrier proteins involved in secondary metabolism. We present here a new type of PPTase, the carrier protein synthase of Pseudomonas aeruginosa, an organism that harbors merely one PPTase, namely PcpS. Gene deletion experiments clearly show that PcpS is essential for growth of P. aeruginosa, and biochemical data indicate its association with both fatty acid synthesis and siderophore metabolism. At first sight, PcpS is a PPTase of the monomeric Sfp-type and was consequently expected to have catalytic properties typical for this type of enzyme. However, in vitro characterization of PcpS with natural protein partners and non-cognate substrates revealed that its catalytic properties differ significantly from those of Sfp. Thus, the situation in P. aeruginosa is not simply the result of the loss of an AcpS-type PPTase. PcpS exhibits high catalytic efficiency with the carrier protein of fatty acid synthesis and shows a reduced although significant conversion rate of the carrier proteins of non-ribosomal peptide synthetases from their apo to holo form. This association with enzymes of primary and secondary metabolism indicates that PcpS belongs to a new sub-class of PPTases.	Univ Marburg, Fachbereich Chem Biochem, D-35043 Marburg, Germany; Phylos GmbH, D-65926 Frankfurt, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Mikrobiol, D-38106 Braunschweig, Germany	Philipps University Marburg; Braunschweig University of Technology	Marahiel, MA (corresponding author), Univ Marburg, Fachbereich Chem Biochem, Hans Meerwein Str, D-35032 Marburg, Germany.			Jahn, Dieter/0000-0002-4064-9205				BODEY GP, 1983, REV INFECT DIS, V5, P279; COX CD, 1985, INFECT IMMUN, V48, P130, DOI 10.1128/IAI.48.1.130-138.1985; COX CD, 1979, J BACTERIOL, V137, P357, DOI 10.1128/JB.137.1.357-364.1979; Fichtlscherer F, 2000, EUR J BIOCHEM, V267, P2666, DOI 10.1046/j.1432-1327.2000.01282.x; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kohler T, 2001, CLIN MICROBIOL INFEC, V7, P7, DOI 10.1046/j.1469-0691.2001.00066.x; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; May JJ, 2001, J BIOL CHEM, V276, P7209, DOI 10.1074/jbc.M009140200; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mofid MR, 2002, J BIOL CHEM, V277, P17023, DOI 10.1074/jbc.M200120200; Mofid MR, 1999, ACTA CRYSTALLOGR D, V55, P1098, DOI 10.1107/S0907444999003674; Mootz HD, 2002, FEMS MICROBIOL LETT, V213, P51, DOI 10.1016/S0378-1097(02)00760-7; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Patel HM, 2001, BIOCHEMISTRY-US, V40, P9023, DOI 10.1021/bi010519n; Pessi G, 2001, J BACTERIOL, V183, P6676, DOI 10.1128/JB.183.22.6676-6683.2001; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; Sambrook J., 2002, MOL CLONING LAB MANU; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B; Takase H, 2000, INFECT IMMUN, V68, P1834, DOI 10.1128/IAI.68.4.1834-1839.2000; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230	33	79	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50293	50302		10.1074/jbc.M205042200	http://dx.doi.org/10.1074/jbc.M205042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381736	hybrid			2022-12-25	WOS:000180177700012
J	Guo, L; Nakamura, K; Lynch, J; Opas, M; Olson, EN; Agellon, LB; Michalak, M				Guo, L; Nakamura, K; Lynch, J; Opas, M; Olson, EN; Agellon, LB; Michalak, M			Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HEART; FORM	Calreticulin is an endoplasmic reticulum. resident Ca2+-binding chaperone. The importance of the protein is illustrated by embryonic lethality because of impaired cardiac development in calreticulin-deficient mice. The molecular details underlying this phenotype are not understood. In this study, we show that overexpression of activated calcineurin reverses the defect in cardiac development observed in calreticulin-deficient mice and rescues them from embryonic lethality. The surviving mice show no defect in cardiac development but exhibited growth retardation, hypoglycemia, increased levels of serum triacylglycerols, and cholesterol. Reversal of embryonic lethality because of calreticulin deficiency by activated calcineurin underscores the impact of the calreticulin-calcineurin functions on the Ca2+- dependent signaling cascade during early cardiac development. These findings show that calreticulin and calcineurin play fundamental roles in Ca2+-dependent pathways essential for normal cardiac development and explain the molecular basis for the rescue of calreticulin-deficient phenotype.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Mol & Cell Biol Lipids Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Dept Pathol & Lab Med, Toronto, ON M5S 1A8, Canada; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA	Institute for Work & Health; University of Alberta; Institute for Work & Health; University of Alberta; University of Toronto; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.		Guo, Lei/E-9232-2011	guo, lei/0000-0002-0402-4152; , Kimitoshi/0000-0003-4903-2428				Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Conzen SD, 1995, ONCOGENE, V11, P2295; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JA, 2002, J CELL BIOL, V158, P103, DOI 10.1083/jcb.200204092; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0	17	82	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50776	50779		10.1074/jbc.M209900200	http://dx.doi.org/10.1074/jbc.M209900200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12377773	hybrid			2022-12-25	WOS:000180177700076
J	Hink-Schauer, C; Estebanez-Perpina, E; Wilharm, E; Fuentes-Prior, P; Klinkert, W; Bode, W; Jenne, DE				Hink-Schauer, C; Estebanez-Perpina, E; Wilharm, E; Fuentes-Prior, P; Klinkert, W; Bode, W; Jenne, DE			The 2.2-angstrom crystal structure of human pro-granzyme K reveals a rigid zymogen with unusual features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; DIPEPTIDYL PEPTIDASE-I; PANCREATIC TRYPSIN-INHIBITOR; COMPLEMENT FACTOR-D; CRYSTALLOGRAPHIC REFINEMENT; BOVINE TRYPSINOGEN; ACTIVE-SITE; HUMAN CHYMASE; CATHEPSIN-C; FACTOR IXA	Granzyme K (GzmK) belongs to a family of trypsin-like serine proteases localized in electron dense cytoplasmic granules of activated natural killer and cytotoxic T-cells. Like the related granzymes A and B, GzmK can trigger DNA fragmentation and is involved in apoptosis. We expressed the Ser(195)-->Ala variant of human pro-GzmK in Escherichia coli, crystallized it, and determined its 2.2-Angstrom x-ray crystal structure. Pro-GzmK possesses a surprisingly rigid structure, which is most similar to activated serine proteases, in particular complement factor D, and not their proforms. The N-terminal peptide Met(14)-Ile(17) projects freely into solution and can be readily approached by cathepsin C, the natural convertase of pro-granzymes. The pre-shaped S1 pocket is occupied by the ion paired residues Lys(181B)-Asp(194) and is hence not available for proper substrate binding. The Ser(214)-Cys(220) segment, which normally provides a template for substrate binding, bulges out of the active site and is distorted. With analogy to complement factor D, we suggest that this strand will maintain its nonproductive conformation in mature GzmK, mainly due to the unusual residues Gly(215), Glu(219), and Val(94). We hypothesize that GzmK is proteolytically active only toward specific, as yet unidentified substrates, which upon approach transiently induce a functional active-site conformation.	Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Planegg Martinsried, Germany; Max Planck Inst Biochem, Dept Struct Res, D-82152 Planegg Martinsried, Germany	Max Planck Society; Max Planck Society	Jenne, DE (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	djenne@neuro.mpg.de	Estebanez-Perpina, Eva/L-4021-2014; Jenne, Dieter Erich/AAP-1414-2020; Hu, Ruogu/B-2203-2008	Fuentes-Prior, Pablo/0000-0002-6618-3204; Estebanez-Perpina, Eva/0000-0003-2687-5801				Babe LM, 1998, BIOTECHNOL APPL BIOC, V27, P117; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole LB, 1997, ACTA CRYSTALLOGR D, V53, P143, DOI 10.1107/S0907444996012991; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Estebanez-Perpina E, 2000, BIOL CHEM, V381, P1203, DOI 10.1515/BC.2000.148; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FINK TM, 1993, GENOMICS, V18, P401, DOI 10.1006/geno.1993.1483; Grzesiak A, 2000, J MOL BIOL, V301, P205, DOI 10.1006/jmbi.2000.3935; HAMEED A, 1988, J IMMUNOL, V141, P3142; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; KIM S, 1995, J BIOL CHEM, V270, P24399, DOI 10.1074/jbc.270.41.24399; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; McEuen AR, 1998, EUR J BIOCHEM, V253, P300, DOI 10.1046/j.1432-1327.1998.2530300.x; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SINGH TP, 1980, ACTA CRYSTALLOGR B, V36, P621, DOI 10.1107/S0567740880003949; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; Suemoto T, 1999, MOL BRAIN RES, V70, P273, DOI 10.1016/S0169-328X(99)00166-7; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Trapani JA, 2001, GENOME BIOL, V2; Turk D, 2001, EMBO J, V20, P6570, DOI 10.1093/emboj/20.23.6570; TURK D, 1992, WEITERENTWICKLUNG PR; TURK D, 1991, NATO SCI 1, V325, P148; URATA H, 1993, J BIOL CHEM, V268, P24318; Wilharm E, 1999, J BIOL CHEM, V274, P27331, DOI 10.1074/jbc.274.38.27331; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582; Xu YY, 2001, IMMUNOL REV, V180, P123, DOI 10.1034/j.1600-065X.2001.1800111.x	62	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50923	50933		10.1074/jbc.M207962200	http://dx.doi.org/10.1074/jbc.M207962200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12384499	hybrid			2022-12-25	WOS:000180177700095
J	Kim, DY; Ingano, LAM; Kovacs, DM				Kim, DY; Ingano, LAM; Kovacs, DM			Nectin-1 alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ADHERENS JUNCTIONS; COMPLEX-FORMATION; NOTCH; CADHERIN; ASSOCIATION; RELEASE; DOMAIN; FAMILY; ENTRY	Nectin-1 is a member of the immunoglobulin superfamily and a Ca2+-independent adherens junction protein involved in synapse formation. Here we show that nectin-la undergoes intramembrane proteolytic processing analogous to that of the Alzheimer's disease amyloid precursor protein, mediated by a presenilin (PS)-dependent gamma-secretase-like activity. 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of Chinese hamster ovary cells activated a first proteolytic event, resulting in ectodomain shedding of nectin-la. Subsequent cleavage of the remaining 26-kDa membrane-anchored C-terminal fragment (CTF) was inhibited independently by three specific gamma-secretase inhibitors and by expression of the dominant negative form of PS1. The PS/gamma-secretase-like cleavage product was detected in vivo following proteasome inhibitor treatment of cells. An in vitro gamma-secretase assay confirmed the generation of a 24-kDa nectin-la intracellular domain, peripherally associated with the membrane fraction. We also found nectin-la to interact with the N-terminal fragment of PS1. Finally, gamma-secretase inhibition resulted in beta-catenin release from cell junctions, concomitantly with the accumulation of the 26-kDa nectin-la CTF, suggesting that high levels of nectin-la CTF interfere with TPA-induced remodeling of cell-cell junctions. Our results are consistent with a previously reported role for PS/gamma-secretase in adherens junction function involving cleavage of cadherins. Similar to nectin-1, other members of the immunoglobulin superfamily involved in synapse formation may also serve as substrates for PS/gamma-secretase-like intramembrane proteolytic activity.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Aging Genet & Neurodegenerat, Neurobiol Dis Lab,Genet & Aging Res Unit, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kovacs, DM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Aging Genet & Neurodegenerat, Neurobiol Dis Lab,Genet & Aging Res Unit, 114 16th St, Boston, MA 02129 USA.							Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gandy S, 2000, BBA-MOL BASIS DIS, V1502, P44, DOI 10.1016/S0925-4439(00)00031-4; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; LAMMICH S, 2002, J BIOL CHEM; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Noh JS, 1997, EXP NEUROL, V146, P604, DOI 10.1006/exnr.1997.6569; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yamamoto Y, 2002, ONCOGENE, V21, P2545, DOI 10.1038/sj.onc.1205335	31	153	158	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49976	49981		10.1074/jbc.M210179200	http://dx.doi.org/10.1074/jbc.M210179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376527	hybrid			2022-12-25	WOS:000180028900114
J	Li, JX; Moazed, D; Gygi, SP				Li, JX; Moazed, D; Gygi, SP			Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; PRE-MESSENGER-RNA; KINASE-I; SACCHAROMYCES-CEREVISIAE; PROLYL ISOMERASE; WW DOMAINS; YEAST; PROTEIN; PHOSPHORYLATION; METHYLATION	The Saccharomyces cerevisiae protein, Set2, has recently been shown to be a histone methyltransferase. To elucidate the function of Set2, its associated proteins were identified using tandem affinity purification and mass spectrometry. We found that Set2 associates with RNA polymerase II. The interaction between the Set2 protein and RNA polymerase 11 requires the WW domain in Set2 and phosphorylation of the carboxyl-terminal domain of the largest subunit of RNA polymerase II. Set2 directly binds to the carboxyl-terminal domain with phosphorylated Ser(2) in the heptapeptide repeats. set2 deletion mutant is sensitive to 6-azauracil, a property often associated with impaired transcription elongation. Together, our results suggest that Set2 through association with the elongating form of RNA polymerase II plays an important role in transcription elongation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gygi, SP (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061641] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG 00041] Funding Source: Medline; NIGMS NIH HHS [GM 61641] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Guthrie C, 1991, GUIDE YEAST GENETICS; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hirose Y, 2000, GENE DEV, V14, P1415; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kornberg RD, 2001, BIOL CHEM, V382, P1103, DOI 10.1515/BC.2001.140; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee JM, 1997, J BIOL CHEM, V272, P10990; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Logie C, 1999, METHOD ENZYMOL, V304, P726; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Svejstrup JQ, 2002, CURR OPIN GENET DEV, V12, P156, DOI 10.1016/S0959-437X(02)00281-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	50	206	216	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49383	49388		10.1074/jbc.M209294200	http://dx.doi.org/10.1074/jbc.M209294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12381723	hybrid			2022-12-25	WOS:000180028900036
J	Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS				Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS			Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; IN-VIVO; AXON GUIDANCE; ADULT-RATS; NEURONAL APOPTOSIS; MOLECULAR-BIOLOGY; TRANSGENIC MICE; III COLLAPSIN-1; HUMAN BRAIN; EXPRESSION	Damage to the optic nerve in mammals induces retrograde degeneration and apoptosis of the retinal ganglion cell (RGC) bodies. The mechanisms that mediate the response of the neuronal cells to the axonal injury are still unknown. We have previously shown that semaphorins, axon guidance molecules with repulsive cues, are capable of mediating apoptosis in cultured neuronal cells (Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I., Melamed, E., and Brazilai, A. (1999) J. Neurochem. 73, 961-971). In this study, we examined the involvement of semaphorins in an in vivo experimental animal model of complete axotomy of the rat optic nerve. We demonstrate that a marked induction of type III semaphorin proteins takes place in ipsilateral retinas at early stages following axotomy, well before any morphological signs of RGC apoptosis can be detected. Time course analysis revealed that a peak of expression occurred after 2-3 days and then declined. A small conserved peptide derived from semaphorin 3A that was previously shown to induce neuronal death in culture was capable of inducing RGC loss upon its intravitreous injection into the rat eye. Moreover, we demonstrate a marked inhibition of RGC loss when axotomized eyes were co-treated by intravitreous injection of function-blocking antibodies against the semaphorin 3A-derived peptide. Marked neuronal protection from degeneration was also observed when the antibodies were applied 24 h post-injury. We therefore suggest that semaphorins are key proteins that modulate the cell fate of axotomized RGC. Neutralization of the semaphorin repulsive function may serve as a promising new approach for treatment of traumatic injury in the adult mammalian central nervous system or of opthalmologic diseases such as glaucoma and ischemic optic neuropathy that induce apoptotic RGC death.	Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Sackler Sch Med, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, San Rothberg Glaucoma Ctr, Goldschleger Eye Res Inst, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University; Tel Aviv University	Shirvan, A (corresponding author), NST Ltd, 5 Odem St, IL-49170 Petah Tiqwa, Israel.		Solomon, Arieh/AAF-4361-2021					Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bonfanti L, 1996, J NEUROSCI, V16, P4186; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chierzi S, 1998, VISION RES, V38, P1537, DOI 10.1016/S0042-6989(97)00332-5; Cuevas P, 1998, NEUROSCI LETT, V255, P1, DOI 10.1016/S0304-3940(98)00672-7; Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252; Djamgoz MBA, 1996, J NEUROSCI METH, V64, P237, DOI 10.1016/0165-0270(95)00109-3; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Fujita H, 2001, BRAIN RES, V914, P1, DOI 10.1016/S0006-8993(01)02765-2; Gagliardini V, 1999, MOL CELL NEUROSCI, V14, P301, DOI 10.1006/mcne.1999.0787; GARCIAVALENZUEL.E, 1994, EXP EYE RES, V61, P33; Giger RJ, 1998, J NEUROSCI RES, V52, P27, DOI 10.1002/(SICI)1097-4547(19980401)52:1<27::AID-JNR4>3.0.CO;2-M; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HARLOW E, 1988, LAB MANUAL, P490; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hirsch E, 1999, BRAIN RES, V823, P67, DOI 10.1016/S0006-8993(99)01103-8; Isenmann S, 1999, CELL DEATH DIFFER, V6, P673, DOI 10.1038/sj.cdd.4400538; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EXP NEUROL, V147, P28, DOI 10.1006/exnr.1997.6585; Jin Z, 1997, J NEUROSCI, V17, P6256; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kermer P, 1998, J NEUROSCI, V18, P4656; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863; Lazarov-Spiegler O, 1999, VISION RES, V39, P169, DOI 10.1016/S0042-6989(98)00089-3; Levin LA, 1999, SURV OPHTHALMOL, V43, pS98, DOI 10.1016/S0039-6257(99)00027-2; Lieberman AR., 1974, ESSAYS NERVOUS SYSTE, P71; Lucius R, 1997, MOL BRAIN RES, V48, P181, DOI 10.1016/S0169-328X(97)00170-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Mark MD, 1997, CELL TISSUE RES, V290, P299, DOI 10.1007/s004410050934; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101; Nieto MA, 1996, NEURON, V17, P1039, DOI 10.1016/S0896-6273(00)80237-8; Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 1998, EXP NEUROL, V153, P313, DOI 10.1006/exnr.1998.6886; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Schwartz M, 1996, J GLAUCOMA, V5, P427; Seigel G M, 1997, Mol Vis, V3, P14; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shirvan A, 2000, MOL BRAIN RES, V83, P81, DOI 10.1016/S0169-328X(00)00198-4; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; So KF, 1998, VISION RES, V38, P1525, DOI 10.1016/S0042-6989(97)00226-5; Solomon AS, 1996, J NEUROSCI METH, V70, P21, DOI 10.1016/S0165-0270(96)00098-2; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1993, J NEUROSCI, V13, P455; Van Vactor D, 1999, CURR BIOL, V9, pR201; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Verma MJ, 1999, INVEST OPHTH VIS SCI, V40, P2465; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8	69	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49799	49807		10.1074/jbc.M204793200	http://dx.doi.org/10.1074/jbc.M204793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376549	hybrid			2022-12-25	WOS:000180028900093
J	Silverman, AP; Bu, WM; Cohen, SM; Lippard, SJ				Silverman, AP; Bu, WM; Cohen, SM; Lippard, SJ			2.4-A crystal structure of the asymmetric platinum complex {Pt(ammine)(cyclohexylamine)}(2+) bound to a dodecamer DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRASTRAND CROSS-LINK; CARRIER LIGAND; GEOMETRIC PARAMETERS; MAJOR ADDUCT; CISPLATIN; DUPLEX; CRYSTALLIZATION; RECOGNITION; LIPPARD; O6	Cis-trans-cis-Ammine(cyclohexylamine)diacetatodichloroplatinum(IV) is an oral analog of the platinum anticancer drug cisplatin that is currently in phase III clinical trials. Its active form, {Pt(ammine)(cyclohexylamine)}(2+), binds to DNA similarly to cisplatin, forming intra- and interstrand cross-links between adjacent purine bases. Since {Pt(ammine)(cyclohexylamine)}(2+) contains two different ligands, it can form two isomeric 1,2-d(GpG) intrastrand cross-links. Here we report the 2.4-Angstrom resolution x-ray crystal structure of the major adduct between {Pt(ammine)(cyclohexylamine)}(2+) and a DNA dodecamer, using the same sequence as previously reported for crystal structures of cisplatin-DNA (Takahara, P. M., Rosenzweig, A. C., Frederick C. A., and Lippard, S. J. (1995) Nature 377, 649-652) and oxaliplatin-DNA (Spingler, B., Whittington, D. A., and Lippard, S. J. (2001) Inorg. Chem 40, 5596-5602). Both duplexes in the asymmetric unit contain 1,2-intrastrand cross-links in which the cyclohexylamine ligand is directed toward the 3'-end of the platinated strand. The chair conformation of the cyclohexyl group is clearly resolved. Platination distorts the duplex, resulting in a global bend angle of about 38degrees and a dihedral angle between platinated guanine bases of similar to31degrees. Both end-to-end and end-to-groove packing interactions occur in the crystal lattice, the latter positioned in the minor groove across from the site of the platinum cross-link. A high degree of homology observed between this structure and the previously reported platinum-DNA structures suggests that these platinum complexes distort the DNA duplex in a very similar manner. These results suggest that differences in activity between these drugs are unlikely to result from gross conformational distortions in DNA structure following platinum intrastrand cross-link formation.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu						ABRAMS MJ, 1987, INORG CHIM ACTA, V131, P3, DOI 10.1016/S0020-1693(00)87896-2; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Barton SJ, 1998, INORG CHIM ACTA, V273, P8, DOI 10.1016/S0020-1693(97)05912-4; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Carlone M, 2000, INORG CHEM, V39, P634, DOI 10.1021/ic990517f; CHU G, 1994, J BIOL CHEM, V269, P787; Clowney L, 1996, J AM CHEM SOC, V118, P509, DOI 10.1021/ja952883d; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Drenth J, 1994, PRINCIPLES PROTEIN X; Ferrante K, 1999, CANCER CHEMOTH PHARM, V43, pS61, DOI 10.1007/s002800051100; FREDERICK CA, 1989, EUR J BIOCHEM, V181, P295, DOI 10.1111/j.1432-1033.1989.tb14724.x; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; Gelbin A, 1996, J AM CHEM SOC, V118, P519, DOI 10.1021/ja9528846; Hambley TW, 1997, COORDIN CHEM REV, V166, P181, DOI 10.1016/S0010-8545(97)00023-4; HARTWIG JF, 1992, J AM CHEM SOC, V114, P5646, DOI 10.1021/ja00040a026; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Lu XJ, 1999, J MOL BIOL, V285, P1563, DOI 10.1006/jmbi.1998.2390; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sandman KE, 1999, CHEM BIOL, V6, P541, DOI 10.1016/S1074-5521(99)80086-6; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; Sheldrick G.M., 1997, SHELX972 PROGRAM REF; Spingler B, 2001, INORG CHEM, V40, P5596, DOI 10.1021/ic010790t; Sullivan ST, 2002, J AM CHEM SOC, V124, P1558, DOI 10.1021/ja0121742; Sullivan ST, 2001, J AM CHEM SOC, V123, P9345, DOI 10.1021/ja010483m; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; WANG AHJ, 1988, J CRYST GROWTH, V90, P295, DOI 10.1016/0022-0248(88)90325-9; Wei M, 2001, J BIOL CHEM, V276, P38774, DOI 10.1074/jbc.M106374200; Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h; Ziegler CJ, 2000, J BIOL INORG CHEM, V5, P774, DOI 10.1007/s007750000170	37	57	65	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49743	49749		10.1074/jbc.M206979200	http://dx.doi.org/10.1074/jbc.M206979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377787	hybrid			2022-12-25	WOS:000180028900085
J	Kang, ZG; Pirskanen, A; Janne, OA; Palvimo, JJ				Kang, ZG; Pirskanen, A; Janne, OA; Palvimo, JJ			Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; STEROID-HORMONE RECEPTORS; DEPENDENT DEGRADATION; MEDIATED DEGRADATION; BINDING PROTEIN; KAPPA-B; PHOSPHORYLATION; RECRUITMENT; ACTIVATION; ACETYLATION	We have used the chromatin immunoprecipitation technique to analyze the formation of the androgen receptor (AR) transcription complex onto prostate-specific antigen (PSA) and kallikrein 2 promoters in LNCaP cells. Our results show that loading of holo-AR and recruitment of RNA polymerase II to the promoters occur transiently. The cyclic nature of AR transcription complex assembly is also illustrated by transient association of coactivators GRIP1 and CREB-binding protein and acetylated histone H3 with the PSA promoter. Treatment of cells with the pure antiandrogen bicalutamide also elicits occupancy of the promoter by AR. In contrast to the agonist-liganded AR, bicalutamide-bound receptor is not capable of recruiting polymerase II, GRIP1, or CREB-binding protein, indicating that the conformation of AR bound to anti-androgen is not competent to assemble transcription complexes. Proteasome is involved in the regulation of AR-dependent transcription, as a proteasome inhibitor, MG-132, prevents the release of the receptor from the PSA promoter, and it also blocks the androgen-induced PSA mRNA accumulation. Furthermore, occupancy of the PSA promoter by the 19 S proteasome subcomplex parallels that by AR. Collectively, formation of the AR transcription complex, encompassing AR, polymerase II, and coactivators, on a regulated promoter is a cyclic process involving proteasome function.	Univ Helsinki, Inst Biomed Physiol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Palvimo, JJ (corresponding author), Univ Helsinki, Inst Biomed, Biomedicum Helsinki, Rm C103B,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinski.fi		Palvimo, Jorma/0000-0003-2373-0578; Kang, zhigang/0000-0003-3444-4315				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; CULIG Z, 1994, CANCER RES, V54, P5474; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Farmer G, 2001, PROSTATE, V46, P76; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Karvonen U, 2002, FEBS LETT, V523, P43, DOI 10.1016/S0014-5793(02)02929-0; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kumar A, 2000, PROSTATE, V44, P248, DOI 10.1002/1097-0045(20000801)44:3<248::AID-PROS10>3.0.CO;2-D; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mitchell SH, 2000, MOL CELL ENDOCRINOL, V168, P89, DOI 10.1016/S0303-7207(00)00319-1; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sadar MD, 2000, CANCER RES, V60, P5825; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	62	160	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48366	48371		10.1074/jbc.M209074200	http://dx.doi.org/10.1074/jbc.M209074200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376534	hybrid			2022-12-25	WOS:000179789600053
J	Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL				Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinase B/Akt pathways	ONCOGENE			English	Article						Muc4; ErbB2; tyrosine phosphorylation; apoptosis; p27(kip); signaling	SURFACE SIALOMUCIN COMPLEX; RECEPTOR TYROSINE KINASE; GLYCOPROTEIN COMPLEX; SIGNALING NETWORK; MOLECULAR-CLONING; OCULAR SURFACE; RAT MUC4; GROWTH; LOCALIZATION; CELLS	Muc4/sialomucin complex (SMC) is a multifunctional glycoprotein complex which can repress apoptosis in transfected tumor cells. Its transmembrane subunit acts as an intramembrane ligand for the receptor tyrosine kinase ErbB2 to induce the phosphorylation of ErbB2 and, by acting synergistically with the ErbB3 ligand neuregulin, can potentiate the phosphorylation of ErbB2 and ErbB3. In the present study we show that Muc4/SMC alone robustly induces the phosphorylation of ErbB2 to enhance the tyrosine phosphate epitope (Tyr1248) recognized by anti-phospho-ErbB2. Although this tyrosine phosphorylation has been implicated in cell transformation, it does not activate any of the three mitogen-activated protein kinases (MAPKs) or protein kinase B/Akt of the phosphatidyl inositol 3-kinase pathway. Instead, Muc4/SMC expression induces up-regulation of the cell cycle inhibitor p27(kip), consistent with the expression of Muc4/SMC in differentiated, rather than proliferative, epithelial cells. Interestingly, a combination of Muc4/SMC and neuregulin down-regulate p27(kip) and activate protein kinase B/Akt. These observations suggest that Muc4/SMC acts as a regulator of differentiation by inducing a limited phosphorylation of ErbB2 and a modulator of proliferation when acting synergistically with neuregulin to induce a more extensive phosphorylation on both ErbB2 and ErbB3.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, R-124,POB 016960, Miami, FL 33101 USA.	Kcarrawa@med.miami.edu		Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Idris N, 2001, J CELL PHYSIOL, V189, P162, DOI 10.1002/jcp.10012; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Klapper LN, 2000, ADV CANCER RES, V77, P25; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li P, 2001, TISSUE CELL, V33, P111, DOI 10.1054/tice.2000.0162; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pflugfelder SC, 2000, INVEST OPHTH VIS SCI, V41, P1316; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; RICCI A, 1995, ONCOGENE, V11, P1519; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Weed DT, 2001, OTOLARYNG HEAD NECK, V124, P127, DOI 10.1067/mhn.2001.112575; WU K, 1994, J BIOL CHEM, V269, P11950; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	106	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7524	7532		10.1038/sj.onc.1205970	http://dx.doi.org/10.1038/sj.onc.1205970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386815				2022-12-25	WOS:000178618200008
J	Plug-Demaggio, AW; McDougall, JK				Plug-Demaggio, AW; McDougall, JK			The human papillomavirus type 16 E6 oncogene induces premature mitotic chromosome segregation	ONCOGENE			English	Article						genetic instability; chromosome segregation; HPV 16 E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN KERATINOCYTES; GENOMIC INSTABILITY; SPINDLE CHECKPOINT; MAMMALIAN-CELLS; ONCOPROTEINS; P53; DEGRADATION; PROGRESSION; DISRUPTION	Expression of the human papillomavirus type 16 E6 and E7 oncogenes initiates and maintains abnormal cell replication, by interacting with the p53 and retinoblastoma (Rb) gene products. Subsequent changes in host cell gene expression, as a consequence of genetic instability, can result in progression to invasive carcinoma. In addition to previously described effects of these viral oncogenes on centrosome synthesis, primarily associated with the expression of E7, the results described herein demonstrate that the E6 oncogene can induce premature chromosome segregation in human cells.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	McDougall, JK (corresponding author), Univ Washington, Dept Pathol, 1959 Pacific St NE, Seattle, WA 98195 USA.	jmcdouga@fhcrc.org			NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burger MPM, 1997, INT J GYNECOL PATHOL, V16, P10, DOI 10.1097/00004347-199701000-00002; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; MANTOVANI F, 2001, SEMIN CANCER BIOL, V9, P387; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MUNGER K, 1989, J VIROL, V63, P4417; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; THERMAN E, 1984, CANCER GENET CYTOGEN, V11, P185, DOI 10.1016/0165-4608(84)90113-4; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; VANLEEUWEN AM, 1995, VIRCHOWS ARCH, V427, P139, DOI 10.1007/BF00196518; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	28	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7507	7513		10.1038/sj.onc.1205903	http://dx.doi.org/10.1038/sj.onc.1205903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386813				2022-12-25	WOS:000178618200006
J	Horn, TFW; Wolf, G; Duffy, S; Weiss, S; Keilhoff, G; MacVicar, BA				Horn, TFW; Wolf, G; Duffy, S; Weiss, S; Keilhoff, G; MacVicar, BA			Nitric oxide promotes intracellular calcium release from mitochondria in striatal neurons	FASEB JOURNAL			English	Article						nitric oxide synthase; NOS isoform; NMDA; NO production	PERMEABILITY TRANSITION PORE; RAT HIPPOCAMPAL-NEURONS; CYTOCHROME-C RELEASE; CYCLIC ADP-RIBOSE; GLUTAMATE EXCITOTOXICITY; FOREBRAIN ISCHEMIA; NMDA RECEPTORS; DEPOLARIZATION; INHIBITION; SYNTHASE	Overproduction of nitric oxide by NMDA receptor stimulation is implicated in calcium deregulation and neurodegeneration of striatal neurons. We investigated the involvement of nitric oxide (NO) in inducing intracellular calcium release and in modifying calcium transients evoked by NMDA. NO application (4-10 muM) reversibly and repeatedly increased the intracellular calcium concentration [Ca2+](i) in Fura-2- or fluo-3-loaded cultured mouse striatal neurons. NO-induced [Ca2+](i) responses persisted in the absence of extracellular calcium, indicating that Ca2+ was released from intracellular stores. The source of calcium was distinct from [Ca2+](i)- activated (ruthenium red and ryanodine sensitive) or IP3-activated (thapsigargin-sensitive) Ca2+ stores and was not dependent on cGMP production because a cell permeant analog, 8-bromo-cGMP, did not increase basal [Ca2+](i). Glucose removal potentiated the NO-induced release of [Ca2+](i). In contrast, pretreatment with either the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone or cyclosporin A, a blocker of the mitochondrial permeability transition pore, prevented the [Ca2+](i) increase after NO. The rise in [Ca2+](i) during NO exposure was preceded by a decrease in mitochondrial membrane potential that was partly reversible during washout. Repeated applications of NMDA induced irreversible [Ca2+](i) responses in a subpopulation of striatal cells that were greatly reduced by the NOS inhibitor N-omega-nitro-L-arginine. Calcium transients were prolonged by conjoint application of NMDA and NO. We conclude that NMDA-evoked [Ca2+](i) transients are modulated by endogenous NO production, which leads to release of calcium from the mitochondrial pool. An NO-activated mitochondrial permeability transition pore may lead to cell death after overstimulation of NMDA receptors.	Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Univ Calgary, Neurosci Res Grp, Calgary, AB T2N 1N4, Canada	Otto von Guericke University; University of Alberta; University of Calgary	Horn, TFW (corresponding author), Univ Magdeburg, Inst Med Neurobiol, Leipziger Str 44, D-39120 Magdeburg, Germany.	thomas.horn@medizin.uni-magde-burg.de	MacVicar, Brian/P-1553-2015; MacVicar, Brian/AAI-7729-2020	MacVicar, Brian/0000-0003-4596-4623; MacVicar, Brian/0000-0003-4596-4623				AKIRA T, 1994, BRAIN RES, V652, P190, DOI 10.1016/0006-8993(94)90226-7; Bal-Price A, 2000, J NEUROCHEM, V75, P1455, DOI 10.1046/j.1471-4159.2000.0751455.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bolanos JP, 1998, BRAIN RES, V787, P117, DOI 10.1016/S0006-8993(97)01530-8; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BUTLER AR, 1995, TRENDS PHARMACOL SCI, V16, P18, DOI 10.1016/S0165-6147(00)88968-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHEN J, 1991, NEUROREPORT, V2, P121, DOI 10.1097/00001756-199103000-00002; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; DAWSON VL, 1993, J NEUROSCI, V13, P2651; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; KOLLEGGER H, 1993, BIOCHEM PHARMACOL, V45, P260, DOI 10.1016/0006-2952(93)90401-H; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Kristian T, 1996, LIFE SCI, V59, P357, DOI 10.1016/0024-3205(96)00314-1; Laffranchi R, 1995, BIOCHEM BIOPH RES CO, V217, P584, DOI 10.1006/bbrc.1995.2815; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MANZONI O, 1992, NEUROREPORT, V3, P77, DOI 10.1097/00001756-199201000-00020; MARIN P, 1993, NEUROPHARMACOLOGY, V32, P29, DOI 10.1016/0028-3908(93)90126-N; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; OKADA D, 1995, J NEUROCHEM, V64, P1298; ONEILL SK, 1993, J PHARMACOL TOXICOL, V29, P217, DOI 10.1016/1056-8719(93)90028-D; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Sarti P, 1999, FASEB J, V13, P191, DOI 10.1096/fasebj.13.1.191; Schinder AF, 1996, J NEUROSCI, V16, P6125; Stadler J, 1996, ADV EXP MED BIOL, V387, P187; STOUT AK, 1994, NEUROPHARMACOLOGY, V33, P1367, DOI 10.1016/0028-3908(94)90038-8; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; WARD SM, 1994, BRAIN RES, V648, P249, DOI 10.1016/0006-8993(94)91124-X; WEISS S, 1990, J PHARMACOL EXP THER, V252, P380; WEISS S, 1993, BRAIN RES, V627, P63, DOI 10.1016/0006-8993(93)90749-D; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; White RJ, 1996, J NEUROSCI, V16, P5688; Willmott N, 1996, J BIOL CHEM, V271, P3699; Zaidan E, 1999, J NEUROCHEM, V73, P2214	51	62	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1611	1622		10.1096/fj.02-0126com	http://dx.doi.org/10.1096/fj.02-0126com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374784				2022-12-25	WOS:000179167600043
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL			Determinants of nuclear and cytoplasmic ubiquitin-mediated degradation of MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL RESIDUE; KAPPA-B-ALPHA; TRANSCRIPTIONAL ACTIVATION; DEPENDENT DEGRADATION; PROTEASOME PATHWAY; EXPORT; LOCALIZATION; TRANSPORT; BINDING; PROTEIN	The ubiquitin-proteasome system is responsible for the regulation and turnover of many short-lived proteins both in the cytoplasm and in the nucleus. Degradation can occur via two distinct pathways, an Nterminus dependent pathway and a lysine-dependent pathway. The pathways are characterized by the site of initial ubiquitination of the protein, the N terminus or an internal lysine, respectively. MyoD, a basic helix-loop-helix transcription factor, is a substrate for the ubiquitin proteasome pathway and is degraded in the nucleus. It is preferentially tagged for degradation on the N terminus and thus is degraded by the N terminus-dependent pathway. Addition of a 6x Myc tag to the N terminus of MyoD can force degradation through the lysine-dependent pathway by preventing ubiquitination at the N-terminal site. Modifications of the nuclear localization signal and nuclear export signal of MyoD restrict ubiquitination and degradation to the cytoplasm or the nucleus. Using these mutants, we determined which degradation pathway is dominant in the cytoplasm and the nucleus. Our results suggest that the lysine-dependent pathway is the more active pathway within the cytoplasm, whereas in the nucleus the two pathways are both active in protein degradation.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Phar, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Biochem, Fac Med, IL-31096 Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Moroianu J, 1999, J CELL BIOCHEM, P76; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	40	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1817	1823		10.1074/jbc.M208815200	http://dx.doi.org/10.1074/jbc.M208815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12397066	hybrid			2022-12-25	WOS:000180462200060
J	Wolfe, MD; Lipscomb, JD				Wolfe, MD; Lipscomb, JD			Hydrogen peroxide-coupled cis-diol formation catalyzed by naphthalene 1,2-dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; DIOXYGENASE; DIHYDROXYLATION; INTERMEDIATE; ACTIVATION; COMPONENT; SITE	Naphthalene 1,2-dioxygenase (NDOS) catalyzes the NAD(P)H and O-2-dependent oxidation of naphthalene to (+)-cis-(1R,2S)-dihydroxy-1,2-dihydronaphthalene. NDOS consists of three protein components: a flavo-[2Fe-2S] reductase (NDR), a ferredoxin electron transfer protein (NDF), and an (alphabeta)(3) oxygenase (NDO) containing a mononuclear iron site and a Rieske-type [2Fe-2S] cluster in each a-subunit. The active site is built across a subunit-subunit boundary, and each subunit contributes one type of metal center. Our previous studies have shown that NDO with both metal centers reduced is capable of an O-2-coupled single turnover to yield the correct cis-diol product in the absence of the NDR and NDF components (Wolfe, M. D., Parales, J. V., Gibson, D. T., and Lipscomb, J. D. (2001) J. Biol. Chem. 276, 1945-1953). It is shown here that addition of H2O2 to NDO allows reaction with naphthalene to rapidly yield the correct product in a "peroxide shunt" reaction that does not require a reduced Rieske cluster. The mononuclear Fe2+ center is oxidized during turnover, while the Rieske cluster remains in the oxidized state. Peroxide shunt turnover in the presence of O-18-labeled H2O2, H2O, or O-2 shows that both oxygen atoms in the product derive primarily from H2O2. The peroxide shunt halts after one turnover despite the presence of excess H2O2 and naphthalene, but this is not the result of enzyme inactivation. Rather, it appears that the product cannot be released when the mononuclear iron is in the Fe3+ state, blocking a second turnover. This work supports the hypotheses that the cis-dihydroxylation activity of NDOS requires only the NDO component, that a peroxo intermediate is formed during normal catalysis, and that product release requires an additional reducing equivalent beyond those necessary for the first turnover.	Univ Minnesota, Dept Biochem Mol Biol & Cellular, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalysis, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lipscomb, JD (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Cellular, 6-155 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.	lipsc001@tc.umn.edu		Lipscomb, John/0000-0002-8158-5594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008277, R37GM024689, R01GM024689] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM024689, R01 GM024689, GM24689, GM08277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1991, NEW J CHEM, V15, P411; Bassan A, 2002, J AM CHEM SOC, V124, P11056, DOI 10.1021/ja026488g; Carredano E, 2000, J MOL BIOL, V296, P701, DOI 10.1006/jmbi.1999.3462; Chen K, 1999, ANGEW CHEM INT EDIT, V38, P2227, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2227::AID-ANIE2227>3.0.CO;2-B; Chen K, 1999, CHEM COMMUN, P1375, DOI 10.1039/a901678c; Chen K, 2002, J AM CHEM SOC, V124, P3026, DOI 10.1021/ja0120025; Costas M, 2001, J AM CHEM SOC, V123, P6722, DOI 10.1021/ja015601k; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; JEFFREY AM, 1975, BIOCHEMISTRY-US, V14, P575, DOI 10.1021/bi00674a018; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Lee K, 1999, J BACTERIOL, V181, P2719, DOI 10.1128/JB.181.9.2719-2725.1999; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; Parales RE, 2000, J BACTERIOL, V182, P1641, DOI 10.1128/JB.182.6.1641-1649.2000; Resnick SM, 1996, J IND MICROBIOL BIOT, V17, P438, DOI 10.1007/BF01574775; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Tierney DL, 1999, BIOCHEMISTRY-US, V38, P11051, DOI 10.1021/bi990431y; Twilfer H, 2000, EUR J BIOCHEM, V267, P5926, DOI 10.1046/j.1432-1327.2000.01662.x; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; WHITTAKER JW, 1990, METHOD ENZYMOL, V188, P82; Wolfe MD, 2002, BIOCHEMISTRY-US, V41, P9611, DOI 10.1021/bi025912n; Wolfe MD, 2001, J BIOL CHEM, V276, P1945, DOI 10.1074/jbc.M007795200	24	98	98	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					829	835		10.1074/jbc.M209604200	http://dx.doi.org/10.1074/jbc.M209604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12403773	hybrid			2022-12-25	WOS:000180321900020
J	Pullikuth, AK; Weidman, PJ				Pullikuth, AK; Weidman, PJ			In vitro transport on cis and trans sides of the Golgi involves two distinct types of coatomer and ADP-ribosylation factor-independent transport intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; GTP-BINDING PROTEIN; LIVING CELLS; SUCCESSIVE COMPARTMENTS; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; COATED VESICLES; INTRACELLULAR-TRANSPORT; VESICULAR TRANSPORT; ELECTRON-MICROSCOPY	The cisternal maturation model proposes that secretory proteins transit the Golgi in cisternae that mature by the continuous retrograde transport of Golgi enzymes in vesicles. We have tested the hypothesis that de novo generation of transport intermediates containing medial, trans, and trans Golgi network (TGN) enzymes is reconstituted in vitro. Our analysis shows that the majority of transport is mediated by a steady state of transport intermediate production and consumption by Golgi cisternae, with only a minor contribution of pre-existing transport intermediates. Transport in the medial and trans regions of the stack involved intermediates containing Golgi enzymes, apparently moving in a retrograde direction. In contrast, transport between the trans Golgi and TGN was exclusively mediated by intermediates containing secretory protein, as expected for anterograde transport. These intermediates may be physiologically relevant, because only these two specific types of intermediates can be detected in cell homogenates. By analogy to the coatomer (COPI)-independent transport of Golgi enzymes to the endoplasmic reticulum, the steady-state production of intra-Golgi transport intermediates was not impaired by inhibition of COPI vesicle formation. These data suggest a model for COPI-independent intra-Golgi transport by cisternal maturation with a shift in mechanism to anterograde transport at the trans Golgi and TGN boundary.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Weidman, PJ (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd,M173, St Louis, MO 63104 USA.	weidmanp@slu.edu	Pullikuth, Ashok K/M-3100-2018; Pullikuth, Ashok/AAT-2717-2020	Pullikuth, Ashok K/0000-0002-0041-3310; 	NIGMS NIH HHS [GM54428] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barr FA, 2002, TRENDS CELL BIOL, V12, P101, DOI 10.1016/S0962-8924(01)02240-1; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CLARY DO, 1990, J BIOL CHEM, V265, P10109; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dominguez M, 1999, J CELL BIOL, V145, P673, DOI 10.1083/jcb.145.4.673; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Echard A, 2000, MOL BIOL CELL, V11, P3819, DOI 10.1091/mbc.11.11.3819; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Griffiths G, 2000, TRAFFIC, V1, P738, DOI 10.1034/j.1600-0854.2000.010906.x; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; Happe S, 2000, TRAFFIC, V1, P342, DOI 10.1034/j.1600-0854.2000.010407.x; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin CC, 1999, J CELL BIOL, V147, P1457, DOI 10.1083/jcb.147.7.1457; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; LUCOCQ J, 1991, J CELL SCI, V100, P753; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Marsh BJ, 2001, BIOCHEM SOC T, V29, P461, DOI 10.1042/BST0290461; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Orci L, 2000, J CELL BIOL, V150, P1263, DOI 10.1083/jcb.150.6.1263; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Stephens DJ, 2001, J CELL SCI, V114, P1053; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; Valsdottir R, 2001, FEBS LETT, V508, P201, DOI 10.1016/S0014-5793(01)02993-3; Volchuk A, 2000, CELL, V102, P335, DOI 10.1016/S0092-8674(00)00039-8; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	66	2	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50355	50364		10.1074/jbc.M209341200	http://dx.doi.org/10.1074/jbc.M209341200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393871	hybrid			2022-12-25	WOS:000180177700020
J	Watty, A; Burden, SJ				Watty, A; Burden, SJ			MuSK glycosylation restrains MuSK activation and acetylcholine receptor clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC KINASE; NEUROMUSCULAR-JUNCTION FORMATION; SYNAPSE-SPECIFIC CARBOHYDRATE; SKELETAL-MUSCLE; POSTSYNAPTIC APPARATUS; INSULIN-RECEPTOR; IN-VIVO; AGRIN; GROWTH; PHOSPHORYLATION	MuSK, a muscle-specific receptor tyrosine kinase that is activated by agrin, has a critical role in neuromuscular synapse formation. In cultured myotubes, agrin stimulates the rapid phosphorylation of MuSK, leading to MuSK activation and tyrosine phosphorylation and clustering of acetylcholine receptors. Agrin, however, fails to stimulate tyrosine phosphorylation of MuSK that is force-expressed in myoblasts and fibroblasts, indicating that myotubes contain an additional activity that is required for agrin to stimulate MuSK. Certain glycosyltransferases are expressed selectively at synaptic sites in skeletal muscle, raising the possibility that carbohydrate modifications of MuSK, catalyzed by glycosyltransferases expressed selectively in myotubes, may be essential for agrin to bind and activate MuSK. We identifed two N-linked glycosylation sites in MuSK, and we expressed MuSK mutants lacking one or both N-linked sites into MuSK mutant myotubes to determine whether N-linked carbohydrate modifications of MuSK have a role in MuSK activation. We found that N-linked glycosylation restrains ligand-independent tyrosine phosphorylation of MuSK and downstream signaling but is not necessary for agrin to stimulate MuSK.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA	New York University	Burden, SJ (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, 540 1st Ave, New York, NY 10016 USA.			Burden, Steven/0000-0002-3550-6891	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036193, R37NS036193] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36193, R01 NS036193, R01 NS036193-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Arber S, 2002, CURR OPIN NEUROBIOL, V12, P100, DOI 10.1016/S0959-4388(02)00296-9; Borges LS, 2001, J CELL BIOL, V153, P1, DOI 10.1083/jcb.153.1.1; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; CROWLEY JF, 1984, ARCH BIOCHEM BIOPHYS, V231, P524, DOI 10.1016/0003-9861(84)90417-X; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Elleman TC, 2000, BIOCHEM J, V347, P771, DOI 10.1042/0264-6021:3470771; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; Fu AKY, 1999, EUR J NEUROSCI, V11, P373, DOI 10.1046/j.1460-9568.1999.00443.x; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Grow WA, 1999, J NEUROBIOL, V40, P356, DOI 10.1002/(SICI)1097-4695(19990905)40:3<356::AID-NEU7>3.3.CO;2-6; Grow WA, 1999, DEV NEUROSCI-BASEL, V21, P436, DOI 10.1159/000017411; Grow WA, 2000, CELL TISSUE RES, V299, P273, DOI 10.1007/s004410050025; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; Hopf C, 1998, J BIOL CHEM, V273, P6467, DOI 10.1074/jbc.273.11.6467; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; Martin PT, 2002, GLYCOBIOLOGY, V12, p1R, DOI 10.1093/glycob/12.1.1R; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Parkhomovskiy N, 2000, MOL CELL NEUROSCI, V15, P380, DOI 10.1006/mcne.2000.0835; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SCOTT LJC, 1990, J NEUROSCI, V10, P346; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; Wallace BG, 1996, BIOESSAYS, V18, P777, DOI 10.1002/bies.950181002; WANG WC, 1988, J BIOL CHEM, V263, P4576; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Watty A, 2000, P NATL ACAD SCI USA, V97, P4585, DOI 10.1073/pnas.080061997	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50457	50462		10.1074/jbc.M208664200	http://dx.doi.org/10.1074/jbc.M208664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399462	hybrid			2022-12-25	WOS:000180177700034
J	Greenleaf, WB; Silverman, DN				Greenleaf, WB; Silverman, DN			Activation of the proton transfer pathway in catalysis by iron superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-BINDING-PROPERTIES; CARBONIC-ANHYDRASE-II; ACTIVE-SITE; CONTAINING PROTEIN; MANGANESE; ENZYME; MECHANISM; INHIBITION; GLUTAMINE	Catalysis by Escherichia coli and Porphyromonas gingivalis iron superoxide dismutase was activated by addition of primary amines, as measured by pulse radiolysis and stopped-flow spectrophotometry. This activation was saturable for most amines investigated, and a free energy plot of the apparent second-order rate constant of activation was linear as a function of the pK(a) of the amine, indicating activation by proton transfer. Amines provide an alternate rather than the only pathway for proton transfer, and catalysis was appreciable in the absence of amines. Solvent hydrogen isotope effects were near unity for amine activation, which is consistent with rate-contributing proton transfer if the pK(a) of the proton acceptor on the enzyme is not in the region of the pK(a) values of the amines studied, from 7.8 to 10.6. The activation of catalysis by these amines was uncompetitive with respect to superoxide, interpreted as proton transfer in a ternary complex of amine with the enzyme-bound peroxide dianion.	Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Silverman, DN (corresponding author), Univ Florida, Dept Pharmacol & Therapeut, Box 100267, Gainesville, FL 32610 USA.	silvermn@college.med.ufl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An HQ, 2002, BIOCHEMISTRY-US, V41, P3235, DOI 10.1021/bi0120695; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BENOVIC J, 1983, ARCH BIOCHEM BIOPHYS, V221, P329, DOI 10.1016/0003-9861(83)90151-0; BERGMAN NA, 1978, J AM CHEM SOC, V100, P5954, DOI 10.1021/ja00486a064; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; Cabelli DE, 1999, BIOCHEMISTRY-US, V38, P11686, DOI 10.1021/bi9909142; Cabelli DE, 2000, BIOMIMETIC OXIDATIONS CATALYZED BY TRANSITION METAL COMPLEXES, P461, DOI 10.1142/9781848160699_0010; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; COX MM, 1978, J AM CHEM SOC, V100, P5956, DOI 10.1021/ja00486a065; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FEE JA, 1981, ISRAEL J CHEM, V21, P54, DOI 10.1002/ijch.198100014; FEE JA, 1986, SUPEROXIDE SUPEROXID, P205; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Hearn AS, 2001, BIOCHEMISTRY-US, V40, P12051, DOI 10.1021/bi011047f; Hiraoka BY, 2000, BIOCHEM J, V345, P345, DOI 10.1042/0264-6021:3450345; Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; JONSSON BH, 1976, FEBS LETT, V64, P310, DOI 10.1016/0014-5793(76)80317-1; Kresge AJ, 1999, METHODS ENZYMOL, V308, P276; KRESGE AJ, 1975, ACCOUNTS CHEM RES, V8, P354, DOI 10.1021/ar50094a006; KRESGE AJ, 1975, PROTON TRANSFER REAC, P179; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; MCCLUNE GJ, 1978, BIOPHYS J, V24, P65, DOI 10.1016/S0006-3495(78)85340-5; Miller A.-F., 1997, COMMENTS MOL CELL BI, V9, P1; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; POCKER Y, 1985, ZINC ENZYMES, P341; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; Schwartz AL, 2000, J INORG BIOCHEM, V80, P247, DOI 10.1016/S0162-0134(00)00086-6; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; Segel I. H., 1975, ENZYME KINETICS, P183; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; Silverman DN, 2002, METHOD ENZYMOL, V349, P61, DOI 10.1016/S0076-6879(02)49321-4; SLYKHOUSE TO, 1976, J BIOL CHEM, V251, P5472; Sorkin DL, 1997, BIOCHEMISTRY-US, V36, P4916, DOI 10.1021/bi963047z; STALLINGS WC, 1984, J BIOL CHEM, V259, P695; Sugio S, 2000, EUR J BIOCHEM, V267, P3487, DOI 10.1046/j.1432-1327.2000.01373.x; TAOKA S, 1994, J BIOL CHEM, V269, P17988; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; WESTHEIMER FH, 1961, CHEM REV, V61, P265, DOI 10.1021/cr60211a004; Xie J, 2002, J AM CHEM SOC, V124, P3769, DOI 10.1021/ja016254h	47	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49282	49286		10.1074/jbc.M208629200	http://dx.doi.org/10.1074/jbc.M208629200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377761	hybrid			2022-12-25	WOS:000180028900023
J	Sawyer, GW; Chiara, DC; Olsen, RW; Cohen, JB				Sawyer, GW; Chiara, DC; Olsen, RW; Cohen, JB			Identification of the bovine gamma-aminobutyric acid type A receptor alpha subunit residues photolabeled by the imidazobenzodiazepine [H-3]Ro15-4513	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE BINDING-SITE; NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA-A RECEPTORS; H-3 FLUNITRAZEPAM; ION CHANNELS; RAT-BRAIN; PROTEINS; LIGANDS; SUBTYPES; <H-3>FLUNITRAZEPAM	Ligands binding to the benzodiazepine-binding site in gamma-aminobutyric acid type A (GABA(A)) receptors may allosterically modulate function. Depending upon the ligand, the coupling can either be positive (flunitrazepam), negative (Ro15-4513), or neutral (flumazenil). Specific amino acid determinants of benzodiazepine binding affinity and/or allosteric coupling have been identified within GAEA(A) receptor alpha and gamma subunits that localize the binding site at the subunit interface. Previous photolabeling studies with [H-3]flunitrazepam identified a primary site of incorporation at alpha(1)His-102, whereas studies with [H-3]Ro15-4513 suggested incorporation into the a, subunit at unidentified amino acids C-terminal to alpha(1)His-102. To determine the site(s) of photoincorporation by Ro15-4513, we affinity-purified (similar to200-fold) GABAA receptor from detergent extracts of bovine cortex, photolabeled it with [H-3]Ro15-4513, and identified H-3-labeled amino acids by N-terminal sequence analysis of subunit fragments generated by sequential digestions with a panel of proteases. The patterns of 3 H release seen after each digestion of the labeled fragments determined the number of amino acids between the cleavage site and labeled residue, and the use of sequential proteolytic fragmentation identified patterns of cleavage sites unique to the different a subunits. Based upon this radiochemical sequence analysis, [H-3]Ro15-4513 was found to selectively label the homologous tyrosines alpha(1)Tyr-210, alpha(2)Tyr-209, and alpha(3)Tyr-234, in GABAA receptors containing those subunits. These results are discussed in terms of a homology model of the benzodiazepine-binding site based on the molluscan acetylcholine-binding protein structure.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmaocl, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Harvard Medical School	Olsen, RW (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmaocl, Los Angeles, CA 90095 USA.			Sawyer, Gregory/0000-0003-4612-3754	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS011015] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58448] Funding Source: Medline; NINDS NIH HHS [F32 NS 11015] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; Araujo F, 1996, J BIOL CHEM, V271, P27902, DOI 10.1074/jbc.271.44.27902; Barnard EA, 1998, PHARMACOL REV, V50, P291; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; Chang YC, 1996, J NEUROSCI, V16, P5415; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Davies M, 1996, NEUROPHARMACOLOGY, V35, P1199, DOI 10.1016/S0028-3908(96)00085-8; Davies M, 1998, BIOCHEM BIOPH RES CO, V246, P650, DOI 10.1006/bbrc.1998.8679; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Duncalfe LL, 1996, EUR J PHARMACOL, V298, P313, DOI 10.1016/0014-2999(95)00811-X; Dunn SMJ, 1999, MOL PHARMACOL, V56, P768; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FUCHS K, 1988, NEUROSCI LETT, V90, P314, DOI 10.1016/0304-3940(88)90208-X; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GIVENS RS, 1986, INT J PHARM, V29, P67, DOI 10.1016/0378-5173(86)90200-0; He XH, 2001, MED CHEM RES, V10, P269; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; Kucken AM, 2000, MOL PHARMACOL, V57, P932; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; McKernan RM, 1998, MOL PHARMACOL, V54, P33, DOI 10.1124/mol.54.1.33; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; Olsen RW, 2000, HANDB EXP PHARM, V147, P499; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pratt MB, 2000, BIOCHEMISTRY-US, V39, P11452, DOI 10.1021/bi0011680; RICE KC, 1979, NATURE, V278, P854, DOI 10.1038/278854a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; Sigel E, 1998, MOL PHARMACOL, V54, P1097, DOI 10.1124/mol.54.6.1097; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Smith GB, 2000, NEUROPHARMACOLOGY, V39, P55, DOI 10.1016/S0028-3908(99)00104-5; STAUBER GB, 1987, EUR J BIOCHEM, V167, P125, DOI 10.1111/j.1432-1033.1987.tb13313.x; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; Strakhova MI, 2000, MOL PHARMACOL, V58, P1434, DOI 10.1124/mol.58.6.1434; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Wang D, 2000, J BIOL CHEM, V275, P28666, DOI 10.1074/jbc.M005441200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wingrove PB, 2002, EUR J PHARMACOL, V437, P31, DOI 10.1016/S0014-2999(02)01279-7	51	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50036	50045		10.1074/jbc.M209281200	http://dx.doi.org/10.1074/jbc.M209281200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388542	hybrid			2022-12-25	WOS:000180028900122
J	Wrede, CE; Dickson, LM; Lingohr, MK; Briaud, I; Rhodes, CJ				Wrede, CE; Dickson, LM; Lingohr, MK; Briaud, I; Rhodes, CJ			Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; SKELETAL-MUSCLE CELLS; SIGNAL-TRANSDUCTION; ISLET CELLS; CERAMIDE; GLUCOSE; PATHWAY; GROWTH; ACTIVATION; PHOSPHORYLATION	Free fatty acids (FFA) have been reported to reduce pancreatic beta-cell mitogenesis and to increase apoptosis. Here we show that the FFA, oleic acid, increased apoptosis 16-fold in the pancreatic beta-cell line, INS-1, over a 18-h period as assessed by Hoechst 33342/propidium iodide staining and caspase-3 and -9 activation, with negligible necrosis. A parallel analysis of the phosphorylation activation of protein kinase B (PKB) showed this was reduced in the presence of FFA that correlated with the incidence of apoptosis. At stimulatory 15 mm glucose and/or in the added presence of insulin-like growth factor 1, FFA-induced beta-cell apoptosis was lessened compared with that at a basal 5 mm glucose. However, most strikingly, adenoviral mediated expression of a constitutively active PKB, but not a "kinase-dead" PKB variant, essentially prevented FFA-induced beta-cell apoptosis under all glucose/insulin-like growth factor 1 conditions. Further analysis of pro-apoptotic downstream targets of PKB, implicated a role for PKB-mediated phosphorylation inhibition of glycogen synthase kinase3alpha/beta and the forkhead transcription factor, FoxO1, in protection of FFA-induced beta-cell apoptosis. In addition, down-regulation of the pro-apoptotic tumor suppresser protein, p53, via PKB-mediated phosphorylation of MDM2 might also play a role in partially protecting beta-cells from FFA-induced apoptosis. Adenoviral mediated expression of wild type p53 potentiated FFA-induced beta-cell apoptosis, whereas expression of a dominant negative p53 partly inhibited beta-cell apoptosis by similar to50%. Hence, these data demonstrate that PKB activation plays an important role in promoting pancreatic beta-cell survival in part via inhibition of the pro-apoptotic proteins glycogen synthase kinase-3alpha/beta, FoxO1, and p53. This, in turn, provides novel insight into the mechanisms involved in FFA-induced beta-cell apoptosis.	Univ Washington, Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Univ Washington, Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.							Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bonner-Weir S, 2001, DIABETES, V50, pS20, DOI 10.2337/diabetes.50.2007.S20; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cnop M, 2002, BIOCHEM PHARMACOL, V63, P1281, DOI 10.1016/S0006-2952(02)00860-2; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Ikeda Y, 2001, DIABETES, V50, P584, DOI 10.2337/diabetes.50.3.584; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stratford S, 2001, BIOCHEM J, V354, P359, DOI 10.1042/0264-6021:3540359; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	46	211	231	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49676	49684		10.1074/jbc.M208756200	http://dx.doi.org/10.1074/jbc.M208756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393870	hybrid			2022-12-25	WOS:000180028900077
J	Zhao, LH; Lobo, S; Dong, XW; Ault, AD; Deschenes, RJ				Zhao, LH; Lobo, S; Dong, XW; Ault, AD; Deschenes, RJ			Erf4p and Erf2p form an endoplasmic reticulum-associated complex involved in the plasma membrane localization of yeast Ras proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; TERMINAL PROTEOLYSIS; RESTRICTION SITES; ESCHERICHIA-COLI; POLYBASIC DOMAIN; SHUTTLE VECTORS; FUSION PROTEINS; BUDDING YEAST	Ras oncogene proteins are plasma membrane-associated signal transducers that are found in all eukaryotes. Posttranslational addition of lipid to a carboxyl-terminal CaaX box (where "C" represents a cysteine, "a" is generally an aliphatic residue, and X can be any amino acid) is required to target Ras proteins to the cytosolic surface of the plasma membrane. The pathway by which Ras translocates from the endoplasmic reticulum to the plasma membrane is currently not clear. We have performed a genetic screen to identify components of the Ras plasma membrane localization pathway. Mutations in two genes, ERF2 and ERF4/SHR5, have been shown to affect the palmitoylation and subcellular localization o Ras proteins. In this report, we show that Erf4p is localized on the endoplasmic reticulum. as a peripheral membrane protein in a complex with Erf2p, an integral membrane protein that was identified from the same genetic screen. Erf2p, has been shown to be required for the plasma membrane localization of GFP-Ras2p via a pathway distinct from the classical secretory pathway M. Dong and R. J. Deschenes, manuscript in preparation). We show here that Erf4p, like Erf2p, is involved in the plasma membrane localization of Ras2p. Erf2p and Erf4p represent components of a previously uncharacterized subcellular transport pathway involved in the plasma membrane targeting of Ras proteins.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Genet Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Deschenes, RJ (corresponding author), Univ Iowa, Dept Biochem, 3135 MERF, Iowa City, IA 52242 USA.	robert-deschenes@uiowa.edu	Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257; Zhao, Lihong/0000-0002-9615-6047	NCI NIH HHS [R01 CA050211-15A2, R01 CA050211, CA 50211] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050211] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; HJELMELAND LM, 1990, METHOD ENZYMOL, V182, P253; James P, 1996, GENETICS, V144, P1425; JUNG V, 1995, MOL CELL BIOL, V15, P1333; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MITCHELL DA, 1994, J BIOL CHEM, V269, P21540; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Prior IA, 2001, J CELL SCI, V114, P1603; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P625, DOI 10.1042/bst0170625; SIKORSKI RS, 1989, GENETICS, V122, P19; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Thomson JM, 1998, BIOTECHNIQUES, V24, P922, DOI 10.2144/98246bm04; VANCURA A, 1994, J BIOL CHEM, V269, P19271; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	55	71	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49352	49359		10.1074/jbc.M209760200	http://dx.doi.org/10.1074/jbc.M209760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379641	hybrid			2022-12-25	WOS:000180028900032
J	Bateman, JM; Iacovino, M; Perlman, PS; Butow, RA				Bateman, JM; Iacovino, M; Perlman, PS; Butow, RA			Mitochondrial DNA instability mutants of the bifunctional protein Ilv5p have altered organization in mitochondria and are targeted for degradation by Hsp78 and the Pim1p protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; YEAST SACCHAROMYCES-CEREVISIAE; MOBILITY GROUP PROTEIN; ESCHERICHIA-COLI; PROTEOLYSIS; LON; EXPRESSION; GENE; MAINTENANCE; RESPIRATION	Ilv5p is a bifunctional mitochondrial protein in Saccharomyces cerevisiae required for branched-chain amino acid biosynthesis and for the stability of wildtype (rho(+)) mitochondrial DNA (mtDNA). Mutant forms of Ilv5p defective in mtDNA stability (a(+)D(-)) are present as 5-10 punctate structures in mitochondria, whereas mutants lacking enzymatic function (a(-)D(+)) show a reticular distribution, as does wild-type Ilv5p. a(+)D(-) ilv5 mutations are recessive, and the mutant protein is redistributed to a reticular form when co-expressed with wild-type Ilv5p. Ilv5p proteins that are punctate in vivo are also less soluble in detergent extracts of isolated mitochondria, suggesting that the punctate foci in a(+)D(-) Ilv5p mutants are aggregates of the protein. a(+)D(-) Ilv5p proteins are selectively degraded in cells lacking a functional mitochondrial genome, but only in cells grown under derepressing conditions. The targeted degradation of a(+)D(-) Ilv5p, which occurs even when co-expressed with wild-type Ilv5p, is mediated by the glucose-repressible chaperone, Hsp78, and by the ATP-dependent Pim1p protease, whose activity may be modulated by rho(+) mtDNA.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Butow, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	ronald.butow@UTSouthwestern.edu	Bateman, Joseph M/F-3625-2011	iacovino, michelina/0000-0002-1076-3146; Bateman, Joseph/0000-0003-0754-1785	NIGMS NIH HHS [GM33510] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman JM, 2002, GENETICS, V161, P1043; Biou V, 1997, EMBO J, V16, P3405, DOI 10.1093/emboj/16.12.3405; CHUNG CH, 1982, P NATL ACAD SCI-BIOL, V79, P795, DOI 10.1073/pnas.79.3.795; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAKAR SN, 1964, GENETICS, V49, P213; KANDROR O, 1994, J BIOL CHEM, V269, P23575; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; MacAlpine DM, 2000, EMBO J, V19, P767, DOI 10.1093/emboj/19.4.767; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Newman SM, 1996, NUCLEIC ACIDS RES, V24, P386, DOI 10.1093/nar/24.2.386; OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; ROTHERMEL BA, 1995, J BIOL CHEM, V270, P29476, DOI 10.1074/jbc.270.49.29476; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Zelenaya-Troitskaya O, 1998, GENETICS, V148, P1763; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x	36	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47946	47953		10.1074/jbc.M209071200	http://dx.doi.org/10.1074/jbc.M209071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12381727	hybrid			2022-12-25	WOS:000179663700142
J	He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK				He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK			Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice	ONCOGENE			English	Article						dyskerin; dyskeratosis congenita; Dkc1; deficient mice; telomerase	RIBOSOMAL-RNA; IN-VIVO; SHORT TELOMERES; MUTATIONS; INACTIVATION; COMPONENT; CBF5P	Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome associated with increased cancer susceptibility. The X-linked form is due to mutations in the DKC1 gene encoding dyskerin, a nucleolar protein predicted to be involved in rRNA processing and associated with the telomerase complex. Available evidence suggests the pathology of DC is due to telomerase defects. We have used the inducible Cre/loxP system to produce deletions in the murine Dkc1 gene in early embryogenesis. A large deletion lacking exons 12-15 and a small deletion lacking only the last exon, were produced. We found both deletions showed a parent-of-origin effect with 100% embryonic lethality when the mutation occurred on the maternal Dkc1. Embryonic analysis at day E7.5 and E9.5 showed no male embryos carrying either deletion whereas females with maternally derived deletions died around day E9.5, with degeneration of the extra embryonic tissue, in which the paternal X-chromosome is inactivated. Female mice carrying the deletion in the paternally derived Dkc1 show extreme skewing of X-inactivation with the wild type X-chromosome active in all cells. Since mice with no telomerase are viable in the first generations the lethality we observe is unlikely to be due to the effects of mutated dyskerin on telomerase activity.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Hematol, Div Invest Sci, London W12 0NN, England	Washington University (WUSTL); Imperial College London	Bessler, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S euclid Ave,Box 8125, St Louis, MO 63110 USA.			Dokal, Inderjeet/0000-0003-4462-4782	NCI NIH HHS [CA-89091, P30CA91842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089091, P30CA091842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P216; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; HARPER MI, 1982, J EMBRYOL EXP MORPH, V67, P127; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Keller P, 1999, P NATL ACAD SCI USA, V96, P7479, DOI 10.1073/pnas.96.13.7479; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Knight SW, 2001, HUM GENET, V108, P299, DOI 10.1007/s004390100494; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Spedaliere CJ, 2000, BIOCHEMISTRY-US, V39, P9459, DOI 10.1021/bi001079n; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6; Vulliamy TJ, 1999, BLOOD, V94, P1254, DOI 10.1182/blood.V94.4.1254.416k24_1254_1260; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	27	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7740	7744		10.1038/sj.onc.1205969	http://dx.doi.org/10.1038/sj.onc.1205969			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400016				2022-12-25	WOS:000178756200013
J	Arikkath, J; Chen, CC; Ahern, C; Allamand, V; Flanagan, JD; Coronado, R; Gregg, RG; Campbell, KP				Arikkath, J; Chen, CC; Ahern, C; Allamand, V; Flanagan, JD; Coronado, R; Gregg, RG; Campbell, KP			gamma(1) subunit interactions within the skeletal muscle L-type voltage-gated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOGLYCAN-DEFICIENT MICE; DIHYDROPYRIDINE RECEPTOR; BETA-SUBUNIT; CA2+ CHANNELS; 1,4-DIHYDROPYRIDINE RECEPTOR; ALPHA(2)DELTA SUBUNIT; MUSCULAR DYSGENESIS; EXPRESSION; ABSENCE; MOUSE	Voltage-gated calcium channels mediate excitation-contraction coupling in the skeletal muscle. Their molecular composition, similar to neuronal channels, includes the pore-forming alpha(1) and auxiliary alpha(2)delta beta, and gamma subunits. The gamma subunits are the least characterized, and their subunit interactions are unclear. The physiological importance of the neuronal gamma is emphasized by epileptic stargazer mice that lack gamma(2). In this study, we examined the molecular basis of interaction between skeletal gamma(1) and the calcium channel. Our data show that the alpha(1)1.1, beta(1a), and alpha(2)delta subunits are still associated in gamma(1), null mice. Reexpression of gamma(1) and gamma(2) showed that gamma(1), but not gamma(2), incorporates into gamma null channels. By using chimeric constructs, we demonstrate that the first half of the gamma(1) subunit, including the first two transmembrane domains, is important for subunit interaction. Interestingly, this chimera also restores calcium conductance in gamma(1) null myotubes, indicating that the domain mediates both subunit interaction and current modulation. To determine the subunit of the channel that interacts with gamma(1), we examined the channel in muscular dysgenesis mice. Cosedimentation experiments showed that gamma(1) and alpha(2)delta are not associated. Moreover, alpha(1)1.1 and gamma(1) subunits form a complex in transiently transfected cells, indicating direct interaction between the gamma(1) and alpha(1)1.1 subunits. Our data demonstrate that the first half of gamma(1) subunit is required for association with the channel through alpha(1)1.1. Because subunit interactions are conserved, these studies have broad implications for gamma heterogeneity, function and subunit association with voltage-gated calcium channels.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Neurol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Louisville, Sch Med, Dept Biochem, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of Louisville; University of Louisville; University of Louisville	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 EMRB, Iowa City, IA 52242 USA.		Allamand, Valerie/M-4333-2017; Chen, Chien-Chang/D-2023-2015; Tuluc, Petronel/C-2527-2011; Allamand, Valérie/AAH-6272-2021	Chen, Chien-Chang/0000-0001-8850-4278; Allamand, Valérie/0000-0001-8997-9742; Ahern, Christopher/0000-0002-7975-2744; Campbell, Kevin/0000-0003-2066-5889; Gregg, Ronald/0000-0001-5805-224X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046448] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 47053] Funding Source: Medline; NIAMS NIH HHS [R01 AR 46448] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; AHERN CA, 2001, BMC PHYSL; Allamand V, 2000, GENE THER, V7, P1385, DOI 10.1038/sj.gt.3301247; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHU P, 2002, BIOPH SOC 46 ANN M F; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; FLUCHER BE, 1991, J CELL BIOL, V115, P1345, DOI 10.1083/jcb.115.5.1345; Flucher BE, 2000, J CELL BIOL, V151, P467, DOI 10.1083/jcb.151.2.467; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Klugbauer N, 1999, J NEUROSCI, V19, P684; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Moss FJ, 2002, EMBO J, V21, P1514, DOI 10.1093/emboj/21.7.1514; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Rahkila P, 2001, EXP CELL RES, V267, P61, DOI 10.1006/excr.2001.5101; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Sipos I, 2000, PFLUG ARCH EUR J PHY, V439, P691, DOI 10.1007/s004240050994; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Ursu D, 2001, J PHYSIOL-LONDON, V533, P367, DOI 10.1111/j.1469-7793.2001.0367a.x	40	36	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1212	1219		10.1074/jbc.M208689200	http://dx.doi.org/10.1074/jbc.M208689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409298	hybrid, Green Submitted			2022-12-25	WOS:000180321900068
J	Tan, YSH; Morcos, PA; Cannon, JF				Tan, YSH; Morcos, PA; Cannon, JF			Pho85 phosphorylates the Glc7 protein phosphatase regulator Glc8 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE; BACTERIOPHAGE-T7 RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOPROTEIN PHOSPHATASE; CHROMOSOME SEGREGATION; CATALYTIC SUBUNIT; SYNTHETIC LETHAL; SHUTTLE VECTORS; BUDDING YEAST; INHIBITOR-2	The budding yeast Glc7 serine/threonine protein phosphatase-1 is regulated by Glc8, the yeast ortholog of mammalian phosphatase inhibitor-2. In this work, we demonstrated that similarly to inhibitor-2, Glc8 function is regulated by phosphorylation. The cyclin-dependent protein kinase, Pho85, in conjunction with the related cyclins Pcl6 and Pcl7 comprise the major Glc8 kinase in vivo and in vitro. Several glc7 mutations are dependent on the presence of Glc8 for viability. For example, glc7 alleles R121K, R142H, and R198D are lethal in combination with a glc8 deletion. We found that glc7-R121K is lethal in combination with a pho85 deletion. This finding indicates that Pho85 is the sole Glc8 kinase in vivo. Furthermore, glc7-R121K is also lethal when combined with deletions of pcl6, plc7, pcl8, and pcl10, indicating that these related cyclins redundantly activate Pho85 for Glc8 phosphorylation in vivo. In vitro kinase assays and genetic results indicate that Pho85 cyclins Pcl6 and Pcl7 comprise the predominant Glc8 kinase.	Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Cannon, JF (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, 1 Hosp Dr, Columbia, MO 65212 USA.	CannonJ@missouri.edu		Cannon, John/0000-0001-6698-176X				Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Akada R, 2000, BIOTECHNIQUES, V28, P668, DOI 10.2144/00284st02; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JF, 1994, GENETICS, V136, P485; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Haut DD, 1998, J VIROL, V72, P1834, DOI 10.1128/JVI.72.3.1834-1843.1998; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Hong G, 2000, ARCH BIOCHEM BIOPHYS, V376, P288, DOI 10.1006/abbi.2000.1715; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE EYC, 1999, FRONT BIOSCI, V4, P270; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Nigavekar SS, 2002, ARCH BIOCHEM BIOPHYS, V404, P71, DOI 10.1016/S0003-9861(02)00231-X; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; Phizicky EM, 2002, METHOD ENZYMOL, V350, P546; Ramaswamy NT, 1998, GENETICS, V149, P57; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Wang Z, 2001, FEBS LETT, V506, P277, DOI 10.1016/S0014-5793(01)02914-3; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zheng JH, 2000, J BIOL CHEM, V275, P18070, DOI 10.1074/jbc.M000918200; Zheng JH, 1998, METH MOL B, V93, P293	60	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					147	153		10.1074/jbc.M208058200	http://dx.doi.org/10.1074/jbc.M208058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12407105	hybrid			2022-12-25	WOS:000180255700020
J	Yano, JK; Blasco, F; Li, HY; Schmid, RD; Henne, A; Poulos, TL				Yano, JK; Blasco, F; Li, HY; Schmid, RD; Henne, A; Poulos, TL			Preliminary characterization and crystal structure of a thermostable cytochrome P450 from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON SULFOLOBUS-SOLFATARICUS; HYPERTHERMOPHILIC PROTEINS; MOLECULAR REPLACEMENT; ELECTRON-TRANSFER; SALT BRIDGES; STABILITY; SUBSTRATE; PROGRAM; CYP119; ACID	The second structure of a thermophile cytochrome P450, CYP175A1 from the thermophilic bacterium Thermus thermophilus HB27, has been solved to 1.8-Angstrom resolution. The overall P450 structure remains conserved despite the low sequence identity between the various P450s. The CYP175A1 structure lacks the large aromatic network found in the only other thermostable P450, CYP119, thought to contribute to thermal stability. The primary difference between CYP175A1 and its mesophile counterparts is the investment of charged residues into salt-link networks at the expense of single chargecharge interactions. Additional factors involved in the thermal stability increase are a decrease in the overall size, especially shortening of loops and connecting regions, and a decrease in the number of labile residues such as Asn, Gln, and Cys.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Stuttgart, Inst Tech Biochem, D-70569 Stuttgart, Germany; Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Stuttgart; University of Gottingen	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	poulos@uci.edu		Yano, Jason/0000-0002-9774-2611	NIGMS NIH HHS [GM32688] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Chang YT, 2000, BIOCHEMISTRY-US, V39, P2484, DOI 10.1021/bi991966u; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DELANO WL, 2002, PYMOL 0 78; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOTOH O, 1992, J BIOL CHEM, V267, P83; Graham SE, 1999, ARCH BIOCHEM BIOPHYS, V369, P24, DOI 10.1006/abbi.1999.1350; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Koo LS, 2002, J AM CHEM SOC, V124, P5684, DOI 10.1021/ja017174g; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Maves SA, 2001, PROTEIN SCI, V10, P161, DOI 10.1110/ps.17601; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; OMURA T, 1964, J BIOL CHEM, V239, P2370; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tijet N, 2001, GENE, V262, P189, DOI 10.1016/S0378-1119(00)00533-3; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Wright RL, 1996, FEBS LETT, V384, P235, DOI 10.1016/0014-5793(96)00322-5; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Zeikus JG, 1998, EXTREMOPHILES, V2, P179, DOI 10.1007/s007920050058	47	71	72	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					608	616		10.1074/jbc.M206568200	http://dx.doi.org/10.1074/jbc.M206568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401810	hybrid			2022-12-25	WOS:000180255700078
J	Zhang, YQ; Kast-Woelbern, HR; Edwards, PA				Zhang, YQ; Kast-Woelbern, HR; Edwards, PA			Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; BILE-ACID; FUNCTIONAL DOMAINS; ORPHAN RECEPTORS; HORMONE-RECEPTOR; BINDING DOMAINS; TARGET GENES; PROTEIN GENE; COACTIVATOR; IDENTIFICATION	The Farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily that has been shown to play an important role in bile acid and cholesterol homeostasis. Here we identify four murine FXR transcripts, derived from a single gene, that encode four isoforms, FXRalpha1, FXRalpha2, FXRbeta1, and FXRbeta2. FXRalpha and FXRbeta differ at their amino terminus, and FXRalpha1 and FXRbeta1 have a four-amino acid residue insertion in the hinge region immediately adjacent to the DNA binding domain. Real time PCR and 5'-rapid amplification of cDNA ends followed by Southern blotting reveal that these four transcripts are expressed differentially in liver, intestine, kidney, adrenals, stomach, fat, and heart. Electrophoretic mobility shift assays demonstrate that FXRa2 and FXRbeta2 bind to FXR response elements with a higher affinity as compared with FXRalpha1 and FXRbeta1, suggesting that the four-amino acid insert may affect FXR function. Consistent with this idea, the results of transient transfection experiments demonstrate that the four FXR isoforms differentially transactivated a number of promoter-reporter genes; activation of an ileal bile acid-binding protein promoter-reporter gene varied 20-fold depending on the FXR isoform; the rank order of activation was FXRbeta2 > FXRalpha2 much greater than FXRalpha1 = FXRbeta1. In contrast, SHP reporter or BSEP reporter genes were activated to similar degrees by each of the FXR isoforms. Finally, NIH3T3 cells were stably infected with individual murine FXR isoforms, and the cells were treated with FXR ligands. The endogenous ileal bile acid-binding protein gene was activated by the four FXR isoforms with the same rank order as seen in transfections. This effect was gene-specific, since induction of bile salt export pump mRNA was independent of the FXR isoform. These observations suggest that there are four distinct murine FXR isoforms that differentially regulate gene expression in numerous tissues in vivo.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068445, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL68445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Edwards PA, 2002, J LIPID RES, V43, P2; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; ONATE SA, 1995, SCIENCE, V270, P1354; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	38	212	232	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					104	110		10.1074/jbc.M209505200	http://dx.doi.org/10.1074/jbc.M209505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12393883	hybrid			2022-12-25	WOS:000180255700014
J	Biesiadecki, BJ; Elder, BD; Yu, ZB; Jin, JP				Biesiadecki, BJ; Elder, BD; Yu, ZB; Jin, JP			Cardiac troponin T variants produced by aberrant splicing of multiple exons in animals with high instances of dilated cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT ISOFORMS; HYPERTROPHIC CARDIOMYOPATHY; CONFORMATIONAL MODULATION; MOLECULAR-BASIS; HEART; EXPRESSION; BINDING; DISEASE; MODEL; GENE	Adult cardiac muscle normally expresses a single cardiac troponin T (cTnT). As a potential pathogenic mechanism for turkey dilated cardiomyopathy, the splice-out of a normally constitutive exon generates an additional low molecular weight cTnT with altered conformation and function. We further found that aberrant splicing of cTnT also occurs in several mammals correlating to dilated cardiomyopathy. Skipping of the same exon as that in the turkey was found in the canine cTnT. Splice-out of the adjacent exon 6 occurred in the guinea pig cTnT. Retention of the embryonic exon 5 was found in the cTnT of cat, dog, and guinea pig. These aberrant splicing variants significantly altered the structure of cTnT to sustain functional effects as that in the myopathic turkey cTnT. The genomic sequence of canine cTnT gene shows no specific alterations. However, the alternative splicing patterns of canine cTnT are different in developing cardiac and skeletal muscles, suggesting abnormality of trans-regulatory factors. Transgenic expression of the aberrant cTnT variants resulted in contractile changes in mouse cardiomyocytes. The findings support the hypothesis that thin filament heterogeneity due to the co-expression of alternatively spliced cTnT variants may desynchronize myocardial contraction and contribute to the pathogenesis and pathophysiology of cardiomyopathy and heart failure.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxj12@po.cwru.edu		Jin, JP/0000-0001-9932-1063	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007887] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07887] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; April M, 1998, AM COLL LAB, P245; Biesiadecki BJ, 2002, J BIOL CHEM, V277, P18459, DOI 10.1074/jbc.M200788200; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CZARNECKI CM, 1984, COMP BIOCHEM PHYS A, V77, P591, DOI 10.1016/0300-9629(84)90169-5; Dambach DM, 1999, J VET INTERN MED, V13, P65, DOI 10.1892/0891-6640(1999)013&lt;0065:FDCOYP&gt;2.3.CO;2; Everett RM, 1999, VET PATHOL, V36, P221, DOI 10.1354/vp.36-3-221; Farza H, 1998, J MOL CELL CARDIOL, V30, P1247, DOI 10.1006/jmcc.1998.0698; FOX PR, 1995, CIRCULATION, V92, P2645, DOI 10.1161/01.CIR.92.9.2645; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; HAJJAR RJ, 1993, CARDIOVASC RES, V27, P2212, DOI 10.1093/cvr/27.12.2212; Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; HUNSAKER WG, 1971, POULTRY SCI, V50, P1720, DOI 10.3382/ps.0501720; JANKUS EF, 1973, RES ANIMALS MED, P53; Jin JP, 2000, AM J PHYSIOL-CELL PH, V279, pC1067, DOI 10.1152/ajpcell.2000.279.4.C1067; Jin JP, 2000, BIOCHEMISTRY-US, V39, P11702, DOI 10.1021/bi9927437; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1989, J BIOL CHEM, V264, P14471; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; JIN JP, 2000, BASIC APPL MYOL, V20, P17; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LIU SK, 1979, AM J PATHOL, V94, P497; LIU SK, 1980, YALE J BIOL MED, V53, P191; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; Meurs KR, 1998, VET CLIN N AM-SMALL, V28, P1449, DOI 10.1016/S0195-5616(98)50131-3; Montgomery DE, 2001, AM J PHYSIOL-HEART C, V280, pH1011, DOI 10.1152/ajpheart.2001.280.3.H1011; PAN BS, 1991, J BIOL CHEM, V266, P12432; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; TILLEY LP, 1977, AM J PATHOL, V86, P493; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; Vanburen P, 2002, AM J PHYSIOL-HEART C, V282, pH1665, DOI 10.1152/ajpheart.00938.2001; VANVLEET JF, 1986, AM J PATHOL, V124, P95; Vollmar AC, 1999, J AM ANIM HOSP ASSOC, V35, P279, DOI 10.5326/15473317-35-4-279; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yu ZB, 2001, BIOPHYS J, V80, p83A	48	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50275	50285		10.1074/jbc.M206369200	http://dx.doi.org/10.1074/jbc.M206369200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12377784	hybrid			2022-12-25	WOS:000180177700010
J	Martinu, L; Santiago-Walker, A; Qi, HW; Chou, MM				Martinu, L; Santiago-Walker, A; Qi, HW; Chou, MM			Endocytosis of epidermal growth factor receptor regulated by Grb2-mediated recruitment of the Rab5 GTPase-activating protein RN-tre	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EGF-RECEPTOR; ADAPTER PROTEIN; TYROSINE KINASE; DOWN-REGULATION; SH3 DOMAIN; C-CBL; GRB2; RAS; DYNAMIN	The Grb2 adaptor protein is best known for its role in signaling to the small GTPase p21(ras), mediated through its interaction with the SOS guanine nucleotide exchange factor. Here, we demonstrate that Grb2 also signals to Rab5, a small GTPase that plays a key role in early endocytic trafficking. Grb2 functions through association with RN-tre, a GTPase-activating protein for Rab5. Grb2 and RN-tre associate both in vitro and in vivo, with interaction mediated by both SH3 domains of Grb2 and extended proline-rich sequences in RN-tre. Association between Grb2 and RN-tre is constitutive and occurs independently of Eps8, a previously identified binding partner of RN-tre. Epidermal growth factor (EGF) stimulates recruitment of RN-tre to the EGF receptor (EGFR) in a Grb2-dependent manner. Grb2 and the EGFR are internalized and co-localized in endocytic vesicles in response to EGF. Overexpression of RN-tre blocks the internalization of both proteins, consistent with its function as a negative regulator of Rab5 and endocytosis. Strikingly, RN-tre does not block EGF-induced internalization of a Grb2 mutant deficient in RN-tre binding. These results 1) suggest that the ability of RN-tre to inhibit internalization of the EGFR requires Grb2-mediated binding to the receptor and 2) identify Grb2 as a critical regulator of Rab5 and EGFR endocytosis.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 421 Curie Blvd,BRBII Rm 1011, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Matoskova B, 1996, ONCOGENE, V12, P2679; Matoskova B, 1996, ONCOGENE, V12, P2563; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; Vitale G, 1995, COLD SPRING HARB SYM, V60, P211, DOI 10.1101/SQB.1995.060.01.024; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zerial M., 1993, Cytotechnology, V11, pS47, DOI 10.1007/BF00746052	49	51	52	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50996	51002		10.1074/jbc.M204869200	http://dx.doi.org/10.1074/jbc.M204869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399475	hybrid			2022-12-25	WOS:000180177700105
J	Schafer, MKH; Varoqui, H; Defamie, N; Weihe, E; Erickson, JD				Schafer, MKH; Varoqui, H; Defamie, N; Weihe, E; Erickson, JD			Molecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC-PHOSPHATE COTRANSPORTER; BRAIN SYNAPTIC VESICLES; CENTRAL-NERVOUS-SYSTEM; NEUROTRANSMITTER TRANSPORTERS; RAT-BRAIN; GABAERGIC INTERNEURONS; MONOAMINE TRANSPORTER; REGIONAL EXPRESSION; CEREBRAL-ISCHEMIA; DOPAMINE NEURONS	We have cloned and functionally characterized a third isoform of a vesicular glutamate transporter (VGLUT3) expressed on synaptic vesicles that identifies a distinct glutamatergic system in the brain that is partly and selectively promiscuous with cholinergic and serotoninergic transmission. Transport activity was specific for glutamate, was H+-dependent, was stimulated by Cl- ion, and was inhibited by Rose Bengal and trypan blue. Northern analysis revealed higher mRNA levels in early postnatal development than in adult brain. Restricted patterns of mRNA expression were observed in presumed interneurons in cortex and hippocampus, and projection systems were observed in the lateral and ventrolateral hypothalamic nuclei, limbic system, and brainstem. Double in situ hybridization histochemistry for vesicular acetylcholine transporter identified VGLUT3 neurons in the striatum. as cholinergic interneurons, whereas VGLUT3 mRNA and protein were absent from all other cholinergic cell groups. In the brainstem VGLUT3 mRNA was concentrated in mesopontine raphe nuclei. VGLUT3 immunoreactivity was present throughout the brain in a diffuse system of thick and thin beaded varicose fibers much less abundant than, and strictly separated from, VGLUT1 or VGLUT2 synapses. Co-existence of VGLUT3 in VMAT2-positive and tyrosine hydroxylase -negative varicosities only in the cerebral cortex and hippocampus and in subsets of tryptophan hydroxylase-positive cell bodies and processes in differentiating primary raphe neurons in vitro indicates selective and target-specific expression of the glutamatergic/serotoninergic synaptic phenotype.	Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA; Univ Marburg, Inst Anat & Cell Biol, Dept Mol Neurosci, D-35033 Marburg, Germany	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Philipps University Marburg	Erickson, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, 2020 Gravier St,Ste D, New Orleans, LA 70112 USA.	jerick@lsuhsc.edu	defamie, norah/AAB-7702-2020	defamie, norah/0000-0002-7504-7538	NCRR NIH HHS [1P29RR16816] Funding Source: Medline; NINDS NIH HHS [NS36936] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aihara Y, 2000, J NEUROCHEM, V74, P2622, DOI 10.1046/j.1471-4159.2000.0742622.x; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BEAUDET A, 1981, J PHYSIOLOGY PARIS, V77, P193; BEAUDET A, 1981, BRAIN RES, V206, P305, DOI 10.1016/0006-8993(81)90534-5; Bellocchio EE, 1998, J NEUROSCI, V18, P8648; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brierley MJ, 1997, J NEUROPHYSIOL, V78, P3396, DOI 10.1152/jn.1997.78.6.3396; Buzsaki G, 2001, NEUROCHEM RES, V26, P899, DOI 10.1023/A:1012324231897; CALZA L, 1985, BRAIN RES, V347, P135, DOI 10.1016/0006-8993(85)90900-X; Centonze D, 1999, BRAIN RES REV, V31, P1, DOI 10.1016/S0165-0173(99)00018-1; CHANPALAY V, 1978, P NATL ACAD SCI USA, V75, P1582, DOI 10.1073/pnas.75.3.1582; CHERUBINI E, 1988, J PHYSIOL-LONDON, V400, P677, DOI 10.1113/jphysiol.1988.sp017143; COOPER JR, 1996, BIOCH BASIS NEUROPHA, P352; Dahlstrom A, 1999, BRAIN RES BULL, V50, P365, DOI 10.1016/S0361-9230(99)00107-0; DESCARRIES L, 1975, BRAIN RES, V100, P563, DOI 10.1016/0006-8993(75)90158-4; DISBROW JK, 1982, BIOCHEM BIOPH RES CO, V108, P1221, DOI 10.1016/0006-291X(82)92130-1; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; Fricker D, 2001, NEURON, V32, P771, DOI 10.1016/S0896-6273(01)00528-1; FUNG SJ, 1989, NEUROSCI LETT, V103, P185, DOI 10.1016/0304-3940(89)90573-9; Gasnier B, 2000, BIOCHIMIE, V82, P327, DOI 10.1016/S0300-9084(00)00221-2; Gras C, 2002, J NEUROSCI, V22, P5442; Greene R, 2001, HIPPOCAMPUS, V11, P569, DOI 10.1002/hipo.1072.abs; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Gu Q, 2002, NEUROSCIENCE, V111, P815, DOI 10.1016/S0306-4522(02)00026-X; Gundersen V, 1998, J NEUROSCI, V18, P6059; Haycock JW, 2002, J NEUROSCI METH, V114, P205, DOI 10.1016/S0165-0270(01)00530-1; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; Hisano S, 2000, MOL BRAIN RES, V83, P34, DOI 10.1016/S0169-328X(00)00194-7; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; JIANG ZG, 1991, J PHYSIOL-LONDON, V443, P533, DOI 10.1113/jphysiol.1991.sp018850; JOHNSON MD, 1994, NEURON, V12, P433, DOI 10.1016/0896-6273(94)90283-6; JOHNSON MD, 1995, NEUROSCIENCE, V67, P609, DOI 10.1016/0306-4522(95)00010-G; KANEKO T, 1992, NEUROSCIENCE, V49, P329, DOI 10.1016/0306-4522(92)90100-G; Kaneko T, 2002, J COMP NEUROL, V444, P39, DOI 10.1002/cne.10129; Lanza M, 2000, N-S ARCH PHARMACOL, V361, P33, DOI 10.1007/s002109900161; Lautenschlager M, 2000, NEUROSCIENCE, V99, P519, DOI 10.1016/S0306-4522(00)00222-0; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Li YQ, 2001, NEUROSCI LETT, V299, P33, DOI 10.1016/S0304-3940(00)01771-7; LUNDBERG JM, 1994, ADV SEC MESS PHOSPH, V29, P223; Manns ID, 2001, NEUROSCIENCE, V107, P249, DOI 10.1016/S0306-4522(01)00302-5; Masson J, 1999, PHARMACOL REV, V51, P439; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; MOLLIVER ME, 1990, ANN NY ACAD SCI, V600, P640, DOI 10.1111/j.1749-6632.1990.tb16916.x; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NI BH, 1995, J NEUROSCI, V15, P5789; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; NICHOLAS AP, 1992, NEUROSCIENCE, V48, P545, DOI 10.1016/0306-4522(92)90401-M; Nohr D, 1999, NEUROSCIENCE, V93, P759, DOI 10.1016/S0306-4522(99)00180-3; Ogita K, 2001, J NEUROCHEM, V77, P34, DOI 10.1046/j.1471-4159.2001.t01-1-00200.x; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; Ozkan ED, 1998, JPN J PHARMACOL, V77, P1, DOI 10.1254/jjp.77.1; PAN ZZ, 1989, J NEUROPHYSIOL, V62, P481, DOI 10.1152/jn.1989.62.2.481; PARK MR, 1982, BRAIN RES, V243, P49, DOI 10.1016/0006-8993(82)91119-2; PICKEL VM, 1984, J COMP NEUROL, V225, P291, DOI 10.1002/cne.902250212; POW DV, 1993, J NEUROSCI METH, V48, P51, DOI 10.1016/S0165-0270(05)80007-X; ROELING TAP, 1994, NEUROSCIENCE, V59, P1001, DOI 10.1016/0306-4522(94)90302-6; Roseth S, 1998, BIOCHEM PHARMACOL, V56, P1243, DOI 10.1016/S0006-2952(98)00200-7; SAJI M, 1991, NEUROSCI LETT, V123, P175, DOI 10.1016/0304-3940(91)90924-I; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Schafer M, 1993, IMAGING DRUG ACTION, P337; Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446; SCHAFER MKH, 1995, METH NEUROSCI, V23, P16; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Soghomonian J. J., 1988, NEURONAL SEROTONIN, P57; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Sulzer D, 1998, J NEUROSCI, V18, P4588, DOI 10.1523/jneurosci.18-12-04588.1998; Sulzer D, 2000, AMINO ACIDS, V19, P45, DOI 10.1007/s007260070032; Suzuki M, 2001, SYNAPSE, V41, P329, DOI 10.1002/syn.1089; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Takamori S, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-22-j0002.2001; Takamori S, 2002, EMBO REP, V3, P798, DOI 10.1093/embo-reports/kvf159; Traub R D, 1999, Adv Neurol, V79, P709; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; Varoqui H, 2002, J NEUROSCI, V22, P142, DOI 10.1523/JNEUROSCI.22-01-00142.2002; Weihe E, 2000, FASEB J, V14, P2435, DOI 10.1096/fj.00-0202rev; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730; Whitaker-Azmitia PM, 2001, BRAIN RES BULL, V56, P479, DOI 10.1016/S0361-9230(01)00615-3; Wong WT, 2001, NAT NEUROSCI, V4, P351, DOI 10.1038/85987	88	318	341	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50734	50748		10.1074/jbc.M206738200	http://dx.doi.org/10.1074/jbc.M206738200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12384506	hybrid			2022-12-25	WOS:000180177700071
J	Uchida, N; Hoshino, S; Imataka, H; Sonenberg, N; Katada, T				Uchida, N; Hoshino, S; Imataka, H; Sonenberg, N; Katada, T			A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in cap/poly(A)-dependent translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BINDING-PROTEIN; RELEASE FACTORS; CAP-POLY(A) SYNERGY; HUMAN HOMOLOG; POLY(A) TAIL; YEAST; INITIATION; TERMINATION; PAB1	The mammalian GSPT, which consists of amino-terminal (N) and carboxyl-terminal (C) domains, functions as the eukaryotic releasing factor 3 (eRF3) by interacting with eRF1 in translation termination. This function requires only the C-domain that is homologous to the elongation factor (EF) 1alpha, while the N-domain interacts with polyadenylate-binding protein (PABP), which binds the poly(A) tail of mRNA and associates with the eukaryotic initiation factor (eIF) 4G. Here we describe a novel role of GSPT in translation. We first determined an amino acid sequence required for the PABP interaction in the N-domain. Inhibition of this interaction significantly attenuated translation of capped/poly(A)-tailed mRNA not only in an in vitro translation system but also in living cells. There was a PABP-dependent linkage between the termination factor complex eRF1-GSPT and the initiation factor eIF4G associating with 5' cap through eIF4E. Although the inhibition of the GSPT-PABP interaction did not affect the de novo formation of an 80 S ribosomal initiation complex, it appears to suppress the subsequent recycle of ribosome. These results indicate that GSPT/eRF3 plays an important role in translation cycle through the interaction with PABP, in addition to mediating the termination with eRF1.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Tokyo; McGill University	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				Bi XP, 2000, J BIOL CHEM, V275, P17740, DOI 10.1074/jbc.M909464199; Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Ebihara K, 1999, RNA, V5, P739, DOI 10.1017/S135583829998216X; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hansen LL, 1999, CYTOGENET CELL GENET, V86, P250, DOI 10.1159/000015353; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Hoshino S, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1367; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Makeyev EV, 1996, FEBS LETT, V378, P166, DOI 10.1016/0014-5793(95)01438-1; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Morrissey JP, 1999, YEAST, V15, P687, DOI 10.1002/(SICI)1097-0061(19990615)15:8<687::AID-YEA412>3.0.CO;2-L; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; OZAWA K, 1992, SOMAT CELL MOLEC GEN, V18, P189, DOI 10.1007/BF01233164; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Proweller A, 1996, J BIOL CHEM, V271, P10859, DOI 10.1074/jbc.271.18.10859; Ross J, 1997, BIOESSAYS, V19, P527, DOI 10.1002/bies.950190612; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Svitkin YV, 2001, RNA, V7, P1743; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Wang WR, 2001, EMBO J, V20, P880, DOI 10.1093/emboj/20.4.880; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wyers F, 2000, MOL CELL BIOL, V20, P3538, DOI 10.1128/MCB.20.10.3538-3549.2000; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	39	174	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50286	50292		10.1074/jbc.M203029200	http://dx.doi.org/10.1074/jbc.M203029200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381739	hybrid			2022-12-25	WOS:000180177700011
J	Ben-Zvi, AP; Goloubinoff, P				Ben-Zvi, AP; Goloubinoff, P			Proteinaceous infectious behavior in non-pathogenic proteins is controlled by molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNAK; MECHANISM; HSP70; DISAGGREGATION; AGGREGATION; DISEASE; COMMON	External stresses or mutations may cause labile proteins to lose their distinct native conformations and seek alternatively stable aggregated forms. Molecular chaperones that specifically act on protein aggregates were used here as a tool to address the biochemical nature of stable homo- and hetero-aggregates from nonpathogenic proteins formed by heat-stress. Confirmed by sedimentation and activity measurements, chaperones demonstrated that a single polypeptide chain can form different species of aggregates, depending on the denaturing conditions. Indicative of a cascade reaction, sub-stoichiometric amounts of one fast-aggregating protein strongly accelerated the conversion of another soluble, slow-aggregating protein into insoluble, chaperone-resistant aggregates. Chaperones strongly inhibited seed-induced protein aggregation, suggesting that they can prevent and cure proteinaceous infectious behavior in homo- and hetero-aggregates from common and disease-associated proteins in the cell.	Univ Lausanne, IE, BPV, CH-1015 Lausanne, Switzerland; Hebrew Univ Jerusalem, Dept Plant Sci, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	University of Lausanne; Hebrew University of Jerusalem	Goloubinoff, P (corresponding author), Univ Lausanne, IE, BPV, Biol Bldg, CH-1015 Lausanne, Switzerland.	Pierre.Goloubinoff@ie-bpv.unil.ch	BEN-ZVI, ANAT/F-1674-2012	BEN-ZVI, ANAT/0000-0003-2477-6519; Goloubinoff, Pierre/0000-0002-4802-0807				Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Borchsenius AS, 2001, EMBO J, V20, P6683, DOI 10.1093/emboj/20.23.6683; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; JAENICKE R, 1995, PHILOS T ROY SOC B, V348, P97, DOI 10.1098/rstb.1995.0050; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAKAHIRA H, 2002, IN PRESS P NATL ACAD; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Soti C, 2000, BIOGERONTOLOGY, V1, P225, DOI 10.1023/A:1010082129022; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WOO KM, 1992, J BIOL CHEM, V267, P20429	40	33	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49422	49427		10.1074/jbc.M209163200	http://dx.doi.org/10.1074/jbc.M209163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377766	hybrid			2022-12-25	WOS:000180028900042
J	He, YZ; Szapary, D; Simons, SS				He, YZ; Szapary, D; Simons, SS			Modulation of induction properties of glucocorticoid receptor-agonist and -antagonist complexes by coactivators involves binding to receptors but is independent of ability of coactivators to augment transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; HORMONE-BINDING; INTERACTING PROTEIN-1; NUCLEAR RECEPTORS; ACTIVATION; DOMAINS; GRIP1; SRC-1; PATHWAYS	Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes. These properties of coactivators differ from their initially defined activities of binding to, and increasing the total levels of transactivation by, agonist-bound steroid receptors. We now report that constructs of TIF2 and SRC-1 lacking the two activation domains (AD1 and AD2) have significantly less ability to increase transactivation but retain most of the activity for modulating the dose-response curve and partial agonist activity. Mammalian two-hybrid experiments show that the minimum TIF2 segment with modulatory activity (TIF2.4) does not interact with p300, CREB-binding protein, or PCAF, which also modulates GR activities. DRIP150 and DRIP205 have been implicated in coactivator actions but are unable to modulate GR activities. The absence of synergism by PCAF or DRIP150 with SRC-1 or TIF2, respectively, further suggests that these other factors are not involved. The ability of a TIF2.4 fragment (i.e. TIF2.37), which is not known to interact with proteins, to block the actions of TIF2.4 suggests that an unidentified binder mediates the modulatory activity of TIF2. Pull-down experiments with GST/TIF2.4 demonstrate a direct interaction of TIF2 with GR in a hormone-dependent fashion that requires the receptor interaction domains of TIF2 and is equally robust with agonists and most antiglucocorticoids. These observations, which are confirmed in mammalian two-hybrid assays, suggest that the capacity of coactivators such as TIF2 to modulate the partial agonist activity of antisteroids is mediated by the binding of coactivators to GR-antagonist complexes. In conclusion, the modulatory activity of coactivators with GR-agonist and -antagonist complexes is mechanistically distinct from the ability of coactivators to augment the total levels of transactivation and appears to involve the binding to both GR-steroid complexes and an unidentified TIF2-associated factor(s).	NIDDK, LMCB, Steroid Hormones Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormones Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.	steroids@helix.nih.gov		He, Yuanzheng/0000-0001-9131-140X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK057800, Z01DK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen J, 2002, J BIOL CHEM, V277, P22053, DOI 10.1074/jbc.M202311200; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN S, 2002, IN PRESS MOL CELL EN; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Giannoukos G, 2001, MOL ENDOCRINOL, V15, P255, DOI 10.1210/me.15.2.255; Glass CK, 2000, GENE DEV, V14, P121; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Issa LL, 2001, ENDOCRINOLOGY, V142, P1606, DOI 10.1210/en.142.4.1606; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mak HY, 2001, MOL CELL BIOL, V21, P4379, DOI 10.1128/MCB.21.13.4379-4390.2001; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sarlis NJ, 1999, J STEROID BIOCHEM, V68, P89, DOI 10.1016/S0960-0760(99)00021-7; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1987, STEROID STEROL HORMO, P251; SIMONS SS, 1998, PROG GENE EXPRESS, P35; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zeng HW, 2000, MOL CELL ENDOCRINOL, V162, P221, DOI 10.1016/S0303-7207(99)00208-7; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	73	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49256	49266		10.1074/jbc.M205536200	http://dx.doi.org/10.1074/jbc.M205536200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12376547	hybrid			2022-12-25	WOS:000180028900020
J	Qin, CB; Wang, CX; Wang, XM				Qin, CB; Wang, CX; Wang, XM			Kinetic analysis of Arabidopsis phospholipase D delta - Substrate preference and mechanism of activation by Ca2+ and phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED MICELLES; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; PLASMA-MEMBRANE; TRITON X-100; RAT-BRAIN; PLD-ALPHA; D-BETA; BINDING; DETERGENTS	Phospholipase D (PLD) is a major plant phospholipase family involved in many cellular processes such as signal transduction, membrane remodeling, and lipid degradation. Five classes of PLDs have been identified in Arabidopsis thaliana, and Ca2+ and polyphosphoinositides have been suggested as key regulators for these enzymes. To investigate the catalysis and regulation mechanism of individual PLDs, surface-dilution kinetics studies were carried out on the newly identified PLDdelta from Arabidopsis. PLDdelta activity was dependent on both bulk concentration and surface concentration of substrate phospholipids in the Triton X-100/phospho-lipid mixed micelles. V-max K-8(A), and K-m(B) values for PLDdelta toward phosphatidylcholine or phosphatidylethanolamine were determined; phosphatidylethanolamine was the preferred substrate. PLDdelta activity was stimulated greatly by phosphatidylinositol 4,5-bisphosphate (PIP2). Maximal activation was observed at a PIP2 molar ratio around 0.01. Kinetic analysis indicates that PIP2 activates PLD by promoting substrate binding to the enzyme, without altering the bulk binding of the enzyme to the micelle surface. Ca2+ is required for PLDdelta activity, and it significantly decreased the interfacial Michaelis constant K,, B. This indicates that Ca2+ activates PLD by promoting the binding of phospholipid substrate to the catalytic site of the enzyme.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Wang, XM (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.		Wang, Xuemin/M-2853-2013	wang, xuemin/0000-0002-6251-6745				BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chalifa-Caspi V, 1998, NEUROCHEM RES, V23, P589, DOI 10.1023/A:1022422418388; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Escriba PV, 1997, P NATL ACAD SCI USA, V94, P11375, DOI 10.1073/pnas.94.21.11375; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; Katagiri T, 2001, PLANT J, V26, P595, DOI 10.1046/j.1365-313x.2001.01060.x; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1990, J BIOL CHEM, V265, P166; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MCDONALD ML, 1988, J BIOL CHEM, V263, P1584; Nakamura SI, 1996, P NATL ACAD SCI USA, V93, P4300, DOI 10.1073/pnas.93.9.4300; Pappan K, 1998, ARCH BIOCHEM BIOPHYS, V353, P131, DOI 10.1006/abbi.1998.0640; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; ROBSON RJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P513, DOI 10.1016/0005-2736(78)90096-2; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; WALSH JP, 1990, J BIOL CHEM, V265, P4374; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Wang XM, 2001, ANNU REV PLANT PHYS, V52, P211, DOI 10.1146/annurev.arplant.52.1.211; WARNER TG, 1975, J BIOL CHEM, V250, P8004; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200; Zheng L, 2002, BIOCHEMISTRY-US, V41, P4546, DOI 10.1021/bi0158775; Zien CA, 2001, BBA-MOL CELL BIOL L, V1530, P236, DOI 10.1016/S1388-1981(01)00091-9	34	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49685	49690		10.1074/jbc.M209598200	http://dx.doi.org/10.1074/jbc.M209598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397060	hybrid			2022-12-25	WOS:000180028900078
J	Rabin, SJ; Bachis, A; Mocchetti, I				Rabin, SJ; Bachis, A; Mocchetti, I			Gangliosides activate Trk receptors by inducing the release of neurotrophins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CEREBELLAR GRANULE CELLS; GM1 GANGLIOSIDE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; DOPAMINERGIC-NEURONS; REGULATED SECRETION; SIGNALING PATHWAYS; MOLECULAR-CLONING; PRIMARY CULTURES	We used NIH-3T3 fibroblasts expressing the different Trk receptors to examine whether GM1 ganglioside and its semisynthetic derivative LIGA20 activate various neurotrophin receptors. GM1 induced autophosphorylation of TrkC more potently than TrkA or TrkB receptors. In contrast, LIGA20 activated TrkB tyrosine phosphorylation only. Therefore, Scatchard analysis was performed to determine whether GM1 binds to TrkC. GM1 failed to displace neurotrophin-3 binding, suggesting that this ganglioside does not act as a ligand for Trk receptors. In addition, GM1 failed to induce autophosphorylation of a chimeric receptor consisting of the extracellular domain of the tumor necrosis factor receptor and the intracellular domain of TrkA, suggesting that GM1 does not affect the tyrosine kinase domain. We next determined whether GM1 induces the release of neurotrophins from fibroblast cells. GM1 induced a rapid and significant increase in the amount of neurotrophin-3, but not other neurotrophins. This effect was independent of the presence of Trk because K252a did not prevent GM1-mediated release of neurotrophin-3. Moreover, GM1-mediated TrkC autophosphorylation was blocked by TrkC-IgG (but not TrkB-IgG) receptor bodies, further suggesting that GM1 activates TrkC by inducing the release of neurotrophin-3. This hypothesis was also tested in cultured cerebellar granule cells. GM1 induced neurotrophin-3 (but not brain-derived neurotrophic factor or nerve growth factor) release. In contrast, LIGA20 increased the secretion of brain-derived neurotrophic factor. Our data show that gangliosides may activate different Trk receptors by differentially affecting the release of neurotrophins.	Georgetown Univ, Ctr Med, Dept Neurosci, Washington, DC 20057 USA	Georgetown University	Mocchetti, I (corresponding author), Georgetown Univ, Ctr Med, Dept Neurosci, Res Bldg,Rm EP04,POB 571464, Washington, DC 20057 USA.							ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bachis A, 2002, NEUROTOX RES, V4, P225, DOI 10.1080/10298420290015836; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Bothwell M., 2001, NEUROBIOLOGY NEUROTR, P29; Brandoli C, 1998, J NEUROSCI, V18, P7953; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Canossa M, 2001, EMBO J, V20, P1640, DOI 10.1093/emboj/20.7.1640; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAO MV, 1986, SCIENCE, V232, P418; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; COLANGELO AM, 1994, GLIA, V12, P117, DOI 10.1002/glia.440120205; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DERRY DM, 1967, SCIENCE, V158, P1450, DOI 10.1126/science.158.3807.1450; DIPATRE PL, 1989, BRAIN RES, V480, P219, DOI 10.1016/0006-8993(89)91585-0; Farinas I, 1998, NEURON, V21, P325, DOI 10.1016/S0896-6273(00)80542-5; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GOUY H, 1995, J IMMUNOL, V155, P5160; HADJICONSTANTINOU M, 1989, BRAIN RES, V484, P297, DOI 10.1016/0006-8993(89)90373-9; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAMBERGER A, 1971, J NEUROCHEM, V18, P1821, DOI 10.1111/j.1471-4159.1971.tb09587.x; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; HILBUSH BS, 1991, P NATL ACAD SCI USA, V88, P5616, DOI 10.1073/pnas.88.13.5616; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARPIAK SE, 1990, CRIT REV NEUROBIOL, V5, P221; KHARLAMOV A, 1994, P NATL ACAD SCI USA, V91, P6303, DOI 10.1073/pnas.91.14.6303; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Ledeen RW, 1998, ANN NY ACAD SCI, V845, P161, DOI 10.1111/j.1749-6632.1998.tb09669.x; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; MacPhee I, 1999, J NEUROCHEM, V72, P1423, DOI 10.1046/j.1471-4159.1999.721423.x; MANEV H, 1990, J PHARMACOL EXP THER, V252, P419; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MAYSINGER D, 1993, NEUROREPORT, V4, P971, DOI 10.1097/00001756-199307000-00034; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PURPURA DP, 1976, BRAIN RES, V116, P1, DOI 10.1016/0006-8993(76)90245-6; Rabin SJ, 1998, MOL BRAIN RES, V56, P273, DOI 10.1016/S0169-328X(98)00020-5; RABIN SJ, 1995, J NEUROCHEM, V65, P1; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Reichardt L.F., 2001, NEUROBIOLOGY NEUROTR, P3; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; SABAL B, 1984, SCIENCE, V225, P340; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; SEREN MS, 1990, STROKE, V21, P1607, DOI 10.1161/01.STR.21.11.1607; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; Xie X, 2002, J NEUROCHEM, V81, P1185, DOI 10.1046/j.1471-4159.2002.00917.x; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	70	74	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49466	49472		10.1074/jbc.M203240200	http://dx.doi.org/10.1074/jbc.M203240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388556	hybrid			2022-12-25	WOS:000180028900048
J	Ahn, J; Prives, C				Ahn, J; Prives, C			Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FHA DOMAIN; PROTEIN PHOSPHATASE; IONIZING-RADIATION; BINDING DOMAIN; CELL-CYCLE; P53; ACTIVATION; RAD53; CDS1; ATM	We have purified and characterized human Chk2 both from baculovirus-infected insect cells and from either untreated or DNA damage-stressed human HCT116 cells. Chk2 from unstressed human cells is largely monomeric and inactive in phosphorylating its substrate, Cdc25C. It is also unphosphorylated at Thr-68, a site that is the target of the ataxia telangiectasia-mutated protein kinase. After treatment of HCT116 cells with a radiomimetic compound neocarzinostatin, active Chk2 exists as stable Thr-68-phosphorylated dimers as well as interconvertable Thr-68-unphosphorylated monomers and dimers. Interestingly, Chk2 from insect cells behaves by all criteria tested like active Chk2 from neocarzinostatin-treated HCT116 cells. Based on Stokes radius and sedimentation coefficient values, Chk2 monomers and dimers have asymmetric rather than globular shapes. Both Thr-68-phosphorylated and Thr-68-unphosphorylated forms of active Chk2 are capable of phosphorylating Cdc25C. Thus, although phosphorylation of Thr-68 may be required for initial oligomerization and activation of Chk2, it is not needed for maintenance of dimerization or kinase activity.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NCI NIH HHS [CA87497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P608; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morris MC, 1999, J MOL BIOL, V286, P475, DOI 10.1006/jmbi.1998.2475; OGG S, 1994, J BIOL CHEM, V269, P30461; RENZING J, 1995, ONCOGENE, V10, P1865; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; Shieh SY, 2000, GENE DEV, V14, P289; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Vahteristo P, 2001, CANCER RES, V61, P5718; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002	42	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48418	48426		10.1074/jbc.M208321200	http://dx.doi.org/10.1074/jbc.M208321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12386164	hybrid			2022-12-25	WOS:000179789600060
J	Chai, WH; Ford, LP; Lenertz, L; Wright, WE; Shay, JW				Chai, WH; Ford, LP; Lenertz, L; Wright, WE; Shay, JW			Human Ku70/80 associates physically with telomerase through interaction with hTERT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNPS; MAMMALIAN TELOMERASE; LENGTH MAINTENANCE; HUMAN FIBROBLASTS; RNA COMPONENT; HUMAN-CELLS; IN-VITRO; PROTEIN; END; KU	Telomere length maintenance, an activity essential for chromosome stability and genome integrity, is regulated by telomerase- and telomere-associated factors. The DNA repair protein Ku (a heterodimer of Ku70 and Ku80 subunits) associates with mammalian telomeres and contributes to telomere maintenance. Here, we analyzed the physical association of Ku with human telomerase both in vivo and in vitro. Antibodies specific to human Ku proteins precipitated human telomerase in extracts from tumor cells, as well as from telomerase-immortalized normal cells, regardless of the presence of DNA-dependent protein kinase catalytic subunit. The same Ku antibodies also precipitated in vitro reconstituted telomerase, suggesting that this association does not require telomeric DNA. Moreover, Ku associated with the in vitro translated catalytic subunit of telomerase (hTERT) in the absence of telomerase RNA (hTR) or telomeric DNA. The results presented here are the first to report that Ku associates with hTERT, and this interaction may function to regulate the access of telomerase to telomeric DNA ends.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011; Chai, Weihang/AAG-5194-2021		NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	52	100	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47242	47247		10.1074/jbc.M208542200	http://dx.doi.org/10.1074/jbc.M208542200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12377759	hybrid			2022-12-25	WOS:000179663700052
J	Sonveaux, P; Dessy, C; Brouet, A; Jordan, BF; Gregoire, V; Gallez, B; Balligand, JL; Feron, O				Sonveaux, P; Dessy, C; Brouet, A; Jordan, BF; Gregoire, V; Gallez, B; Balligand, JL; Feron, O			Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery	FASEB JOURNAL			English	Article						nitric oxide; tumor endothelium; oxygenation; irradiation	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; PARTIAL-PRESSURE; MURINE TUMORS; EPR OXIMETRY; SOLID TUMORS; BLOOD-FLOW; OXYGEN; THERAPY; CANCER	The ultimate goal of radiotherapy is to induce irreversible damages in genetically unstable, fast-growing cancer cells while minimizing the cytotoxic effects on host tissues. The satus of the tumor vasculature is particular because it is located within the tumor but mostly arises from host cells. The aim of this study was to characterize the effects of low-dose irradiation on the function of endothelial cells lining tumor vessels. Using isolated arterioles mounted on a pressure myograph, we first documented that the nitric oxide(NO)-mediated vasorelaxation that was defective in tumor vessels was completely restored following local tumor irradiation. Immunoblot analyses revealed that this was attributable to an increase in the abundance of the endothelial NO synthase while the expression of its physiological inhibitor, caveolin-1, was reduced. We further showed that the potentiation of the NO-dependent pathway induced a marked increase in tumor blood flow and oxygenation that determined the higher sensitivity of the tumor to further irradiation. Finally, we documented that the NO-mediated effects of irradiation on the tumor vasculature increased the delivery and expression of a reporter gene into the tumor. Thus, low-dose irradiation of endothelial cells within a tumor is a key determinant of the effectiveness of radiotherapy and may offer a new strategy to increase gene and/or drug delivery to the tumor.	Univ Louvain, Sch Med, Pharmacol & Therapeut Unit, FATH 5349, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Biomed Magnet Resonance Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Med Chem & Radiopharm Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Radiobiol & Radioprotect Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Feron, O (corresponding author), Univ Catholique Louvain, Sch Med, Unit Pharmacol & Therapeut, FATH 5349, 53 Ave E Mounier, B-1200 Brussels, Belgium.	feron@mint.ucl.ac.be	FERON, Olivier/AAM-6395-2020; Balligand, Jean-Luc J/D-7543-2012	FERON, Olivier/0000-0001-5360-0286; BALLIGAND, Jean-Luc/0000-0002-0522-4156; Sonveaux, Pierre/0000-0001-6484-8834				Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Chaplin DJ, 1998, SEMIN RADIAT ONCOL, V8, P151, DOI 10.1016/S1053-4296(98)80041-6; Denekamp J, 1998, ADV ENZYME REGUL, V38, P281, DOI 10.1016/S0065-2571(97)00015-0; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; Folkman J, 2001, SCIENCE, V293, P227, DOI 10.1126/science.1062892; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gallez B, 1999, MAGN RESON MED, V42, P627, DOI 10.1002/(SICI)1522-2594(199910)42:4<627::AID-MRM2>3.0.CO;2-M; Goda F, 1996, CANCER RES, V56, P3344; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; JAMES PE, 1995, FREE RADICAL BIO MED, V18, P641, DOI 10.1016/0891-5849(94)00179-N; Jordan BF, 2002, CANCER RES, V62, P3555; Jordan BF, 2000, INT J RADIAT ONCOL, V48, P565, DOI 10.1016/S0360-3016(00)00694-5; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kong G, 2000, CANCER RES, V60, P4440; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Ljungkvist ASE, 2000, INT J RADIAT ONCOL, V48, P1529, DOI 10.1016/S0360-3016(00)00787-2; MILAS L, 1995, CANCER RES, V55, P3564; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Peters L, 2001, INT J RADIAT ONCOL, V49, P501, DOI 10.1016/S0360-3016(00)01469-3; TAPER HS, 1966, CANCER RES, V26, P143; TEICHER BA, 1992, CANCER RES, V52, P6702; Thews O, 2001, INT J ONCOL, V19, P1243; Thews O, 2000, BRIT J CANCER, V83, P225, DOI 10.1054/bjoc.2000.1229; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; TOZER GM, 1991, INT J RADIAT BIOL, V60, P327, DOI 10.1080/09553009114552081; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; VOLPE JP, 1985, CLIN EXP METASTAS, V3, P281, DOI 10.1007/BF01585082; Zhao DW, 2001, AM J CLIN ONCOL-CANC, V24, P462, DOI 10.1097/00000421-200110000-00010	38	83	88	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1979	+		10.1096/fj.02-0487fje	http://dx.doi.org/10.1096/fj.02-0487fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397083				2022-12-25	WOS:000179167600005
J	Maulen, NP; Henriquez, EA; Kempe, S; Carcamo, JG; Schmid-Kotsas, A; Bachem, M; Grunert, A; Bustamante, ME; Nualart, F; Vera, JC				Maulen, NP; Henriquez, EA; Kempe, S; Carcamo, JG; Schmid-Kotsas, A; Bachem, M; Grunert, A; Bustamante, ME; Nualart, F; Vera, JC			Up-regulation and polarized expression of the sodium-ascorbic acid transporter SVCT1 in post-confluent differentiated CaCo-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; VITAMIN-C; DEHYDROASCORBIC ACID; FUNCTIONAL-CHARACTERIZATION; SUGAR-TRANSPORT; PLASMA-MEMBRANE; SMALL-INTESTINE; LINE CACO-2; FAMILY; KIDNEY	Human cells acquire vitamin C using two different transporter systems, the sodium-ascorbic acid co-transporters with specificity for ascorbic acid, and the facilitative glucose transporters with specificity for dehydroascorbic acid. There is no information on the mechanism of vitamin C transport across the intestinal barrier, a step that determines the bioavailability of vitamin C in humans. We used the colon carcinoma cell line CaCo-2 as an in vitro model for vitamin C transport in enterocyte-like cells. The results of transport kinetics, sodium dependence, inhibition studies, and reverse transcriptase-PCR analysis indicated that CaCo-2 cells express the sodium-ascorbate co-transporters SVCT1 and SVCT2, the dehydroascorbic acid transporters GLUT1 and GLUT3, and a third dehydroascorbic acid transporter with properties expected for GLUT2. Analysis by real time quantitative PCR revealed that the post-confluent differentiation of CaCo-2 cells was accompanied by a marked increase (4-fold) in the steadystate level of SVCT1 mRNA, without changes in SVCT2 mRNA levels. Functional studies revealed that the differentiated cells expressed only one functional ascorbic acid transporter having properties expected for SVCT1, and transported ascorbic acid with a V(max) that was increased at least 2-fold compared with pre-confluent cells. Moreover, post-confluent Caco-2 cells growing as monolayers in permeable filter inserts showed selective sorting of SVCT1 to the apical membrane compartment, without functional evidence for the expression of SVCT2. The identification of SVCT1 as the transporter that allows vectorial uptake of ascorbic acid in differentiated CaCo-2 cells has a direct impact on our understanding of the mechanism for vitamin C transport across the intestinal barrier.	Univ Concepcion, Fac Ciencias Biol, Dept Fisiopatol, Concepcion, Chile; Univ Concepcion, Fac Ciencias Biol, Dept Histol & Embriol, Concepcion, Chile; Univ Catolica Santisima Concepcion, Fac Med, Dept Mol Biol, Concepcion, Chile; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile; Univ Ulm, Inst Clin Chem, Fac Med, D-8907 Ulm, Germany	Universidad de Concepcion; Universidad de Concepcion; Universidad Catolica de la Santisima Concepcion; Universidad Austral de Chile; Ulm University	Vera, JC (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Fisiopatol, Barrio Univ S-N, Concepcion, Chile.	juvera@udec.el	Nualart, Francisco/AAB-9342-2021	Carcamo, Juan Guillermo/0000-0002-2595-4375				Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG833, DOI 10.1152/ajpgi.1996.270.5.G833; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG153, DOI 10.1152/ajpgi.1996.270.1.G153; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BriskeAnderson MJ, 1997, P SOC EXP BIOL MED, V214, P248; BrotLaroche E, 1996, P NUTR SOC, V55, P201, DOI 10.1079/PNS19960021; BROTLAROCHE E, 1987, BIOCHIM BIOPHYS ACTA, V904, P71, DOI 10.1016/0005-2736(87)90088-5; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Faaland CA, 1998, BBA-GENE STRUCT EXPR, V1442, P353, DOI 10.1016/S0167-4781(98)00151-1; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HODGES RE, 1969, AM J CLIN NUTR, V22, P535; Ikeda S, 1998, J NUTR, V128, P832, DOI 10.1093/jn/128.5.832; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LEVITSKY LL, 1994, AM J PHYSIOL, V267, pE88, DOI 10.1152/ajpendo.1994.267.1.E88; LIENHARD GE, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0192-86; Maeda N, 2000, P NATL ACAD SCI USA, V97, P841, DOI 10.1073/pnas.97.2.841; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; MAHRAOUI L, 1994, BIOCHEM J, V298, P629, DOI 10.1042/bj2980629; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 1999, BIOCHEM PHARMACOL, V57, P1275, DOI 10.1016/S0006-2952(99)00040-4; MESONERO J, 1994, BIOCHEM SOC T, V22, P681, DOI 10.1042/bst0220681; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NAVAS P, 1994, BBA-REV BIOMEMBRANES, V1197, P1, DOI 10.1016/0304-4157(94)90016-7; RAJAN DP, 1999, BIOCHEM BIOPH RES CO, V250, P627; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; ROSE RC, 1986, AM J PHYSIOL, V250, pF627, DOI 10.1152/ajprenal.1986.250.4.F627; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Rumsey SC, 1999, J BIOL CHEM, V274, P23215, DOI 10.1074/jbc.274.33.23215; SAUBERLICH HE, 1994, ANNU REV NUTR, V14, P371, DOI 10.1146/annurev.nu.14.070194.002103; SPEARS G, 1971, BIOCHEM J, V125, P1149, DOI 10.1042/bj1251149; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929	40	93	97	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9035	9041		10.1074/jbc.M205119200	http://dx.doi.org/10.1074/jbc.M205119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12381735	hybrid			2022-12-25	WOS:000181524000023
J	Bertenshaw, GP; Norcum, MT; Bond, JS				Bertenshaw, GP; Norcum, MT; Bond, JS			Structure of homo- and hetero-oligomeric meprin metalloproteases - Dimers, tetramers, and high molecular mass multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA-SUBUNIT; MOUSE KIDNEY; ELECTRON-MICROSCOPY; MAM DOMAIN; IN-VITRO; EXPRESSION; MEMBRANE; PROTEINASE; ACTIVATION	Meprin A and B, metalloproteases consisting of evolutionarily related alpha and/or beta subunits, are membrane-bound and secreted enzymes expressed by kidney and intestinal epithelial cells, leukocytes, and cancer cells. Previous work established that the multidomain meprin subunits (each similar to80 kDa) form disulfide-bridged homo-and heterodimers, and differ in substrate and peptide bond specificities. The work herein clearly demonstrates that meprin dimers differ markedly in their ability to oligomerize. Electrophoresis, light scattering, size exclusion chromatography, and electron microscopy were used to characterize quaternary structures of recombinant rat meprins. Meprin B, consisting of meprin beta subunits only, was dimeric under a wide range of conditions. By contrast, meprin alpha homodimers formed heterogeneous multimers (ring-, circle-, spiral-, and tube-like structures) containing up to 100 subunits, with molecular masses at protein peaks ranging from similar to1.0 to 6.0 MDa. The size of the meprin alpha homo-oligomers was dependent on protein concentration, ionic strength, and activation state. Meprin alphabeta heterodimers tended to form tetramers but not higher oligomers. Thus, the presence of meprin beta, which has a transmembrane domain in vivo, restricts the oligomerization potential of meprin molecules and localizes meprins to the plasma membrane. By contrast, the propensity of secreted meprin alpha homodimers to self-associate concentrates proteolytic potential into high molecular mass multimers and thus allows for autocompartmentalization. The work indicates that different mechanisms exist to localize and concentrate the proteolytic activity of membrane-bound and secreted meprin metalloproteinases.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Mississippi; University of Mississippi Medical Center	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.			Bertenshaw, Greg/0000-0003-4903-3412	NIDDK NIH HHS [DK 19691, DK 54625] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK054625, R37DK019691, R01DK019691] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; Bank U, 1999, FEBS LETT, V461, P235, DOI 10.1016/S0014-5793(99)01466-0; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Bertenshaw GP, 2002, BIOL CHEM, V383, P1175, DOI 10.1515/BC.2002.129; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; Bertrand P, 2000, MACROMOL RAPID COMM, V21, P319, DOI 10.1002/(SICI)1521-3927(20000401)21:7<319::AID-MARC319>3.0.CO;2-7; Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Brandstetter H, 2001, NATURE, V414, P466, DOI 10.1038/35106609; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; CRAIG SS, 1987, AM J PHYSIOL, V253, P535; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; Johnson G.S., 1998, HDB PROTEOLYTIC ENZY, P1222; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; Kohler D, 2000, FEBS LETT, V465, P2, DOI 10.1016/S0014-5793(99)01712-3; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; Lottaz D, 1999, CANCER RES, V59, P1127; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; MOFFETT DF, 1993, HUMAN PHYSL FDN FRON; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Rosmann S, 2002, J BIOL CHEM, V277, P40650, DOI 10.1074/jbc.M206203200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Uren AG, 1996, TRENDS BIOCHEM SCI, V21, P244, DOI 10.1016/S0968-0004(96)30022-4; Walker PD, 1998, KIDNEY INT, V53, P1673, DOI 10.1046/j.1523-1755.1998.00949.x; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	43	79	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2522	2532		10.1074/jbc.M208808200	http://dx.doi.org/10.1074/jbc.M208808200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12399461	hybrid			2022-12-25	WOS:000180562000061
J	Paranavitane, V; Coadwell, WJ; Eguinoa, A; Hawkins, PT; Stephens, L				Paranavitane, V; Coadwell, WJ; Eguinoa, A; Hawkins, PT; Stephens, L			LL5 beta is a phosphatidylinositol (3,4,5)-trisphosphate sensor that can bind the cytoskeletal adaptor, gamma-filamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; PROTEIN-KINASE-B; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; TRANSLOCATION; ACTIVATION; 3-PHOSPHOINOSITIDES; PHOSPHORYLATION; IDENTIFICATION; SURVIVAL	We identified a potential phosphatidylinositol (3,4,5)trisphosphate (Ptdlns(3,4,5)P-3) binding pleckstrin homology domain in the data bases and have cloned and expressed its full coding sequence (LL5beta). The protein bound Ptdlns(3,4,5)P-3 selectively in vitro. Strikingly, a substantial proportion of LL5beta became associated with an unidentified intracellular vesicle population in the context of low Ptdlns(3,4,5)P-3 levels produced by the addition of wortmannin or LY294002. In addition, expression of platelet-derived growth factor-receptor mutants unable to activate type 1A phosphoinositide 3-kinase (PI3K) or serum starvation in porcine aortic endothelial cells lead to redistribution of LL5beta to this vesicle population. Importantly, pleckstrin homology domain mutants of LL5beta that could not bind PtdIns(3,4,5)p3 were constitutively localized to this vesicle population. At increased PtdIns(3,4,5)P3 levels, LL5beta was redirected to a predominantly cytoplasmic distribution, presumably through a PI3K-dependent block on its targeting to the vesicular compartment. Furthermore, at high, hormone-stimulated PtdIns(3,4,5)P3 levels, it became significantly plasma-membrane localized. The distribution of LL5beta is thus dramatically and uniquely sensitive to low levels of Ptdlns(3,4,5)p3 indicating it can act as a sensor of both low and hormone-stimulated levels of Ptdlns(3,4,5)P-3. In addition, LL5beta bound to the cytoskeletal adaptor, gamma-filamin, tightly and in a PI3K-independent fashion, both in vitro and in vivo. This interaction could co-localize heterologously expressed gamma-filamin with GFP-LL5beta in the unidentified vesicles.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Babraham Inst, Bioinformat Grp, Cambridge CB2 4AT, England; Natl Biotechnol Ctr, Dept Immunol & Oncol, Madrid 28045, Spain	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Stephens, L (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.			stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464				Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LEVI L, 1993, BIOCHIM BIOPHYS ACTA, V1216, P342, DOI 10.1016/0167-4781(93)90171-9; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Nagano T, 2002, NAT CELL BIOL, V4, P495, DOI 10.1038/ncb808; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; YANO H, 1993, J BIOL CHEM, V268, P25846	31	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1328	1335		10.1074/jbc.M208352200	http://dx.doi.org/10.1074/jbc.M208352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12376540	hybrid			2022-12-25	WOS:000180321900082
J	Hayes, GM; Chiu, R; Carpenito, C; Dougherty, ST; Dougherty, GJ				Hayes, GM; Chiu, R; Carpenito, C; Dougherty, ST; Dougherty, GJ			Identification of sequence motifs responsible for the adhesive interaction between exon v10-containing CD44 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; SULFATE PROTEOGLYCAN; HYALURONAN-BINDING; SPLICED EXONS; CELLS; RECOGNITION; DISTINCT; GLYCOSYLATION; INVOLVEMENT; STIMULATION	Previous studies have demonstrated that CD44 isoforms containing the alternatively spliced exon v10 promote cell-cell adhesion via a mechanism that involves the recognition of chondroitin sulfate side chains presented on the surface of interacting cells in association with other CD44 molecules. Sequence analysis revealed the presence within exon v10 of two motifs that may be relevant to this interaction, a B[X-7]B motif that may contribute to the recognition and binding of chondroitin sulfate and a serine-glycine motif that may serve as a site of chondroitin sulfate attachment. To determine whether either of these two motifs explain the unique adhesive activity of exon v10-containing CD44 isoforms, each was targeted by site-directed mutagenesis, and the adhesive activity of the resultant mutants was determined using a quantitative cell-cell binding assay. The data obtained demonstrate conclusively that it is the exon v10-encoded B[X-7]B motif that is solely responsible for the enhanced adhesive activity of exon v10-containing CD44 isoforms.	Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; Univ Maastricht, Dept Radiat Oncol, NL-6200 MD Maastricht, Netherlands	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of British Columbia; Maastricht University	Dougherty, GJ (corresponding author), Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Ctr Hlth Sci, Rm B3-109,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	graeme@radonc.ucla.edu			NCI NIH HHS [1-R01-CA-82296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Chiu RK, 1999, EXP CELL RES, V248, P314, DOI 10.1006/excr.1999.4391; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; FINN L, 1994, BIOCHEM BIOPH RES CO, V200, P1015, DOI 10.1006/bbrc.1994.1551; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; GALLUZZO E, 1995, EUR J IMMUNOL, V25, P2932, DOI 10.1002/eji.1830251033; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; MANN DM, 1990, J BIOL CHEM, V265, P5317; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; NAOT D, 1997, ADV CANCER RES, V71, P241; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Rudzki Z, 1997, J CLIN PATHOL-MOL PA, V50, P57, DOI 10.1136/mp.50.2.57; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Weg-Remers S, 1998, ANN NY ACAD SCI, V859, P304, DOI 10.1111/j.1749-6632.1998.tb11151.x; YANG BH, 1993, J BIOL CHEM, V268, P8617	28	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50529	50534		10.1074/jbc.M206719200	http://dx.doi.org/10.1074/jbc.M206719200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12407110	Green Published, hybrid			2022-12-25	WOS:000180177700045
J	Tanaka, Y; Ueda, K; Ozawa, T; Sakuragawa, N; Yokota, S; Sato, R; Okamura, S; Morita, M; Imanaka, T				Tanaka, Y; Ueda, K; Ozawa, T; Sakuragawa, N; Yokota, S; Sato, R; Okamura, S; Morita, M; Imanaka, T			Intracellular accumulation of antithrombin Morioka (C95R), a novel mutation causing type I antithrombin deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEIN; HEPARIN-BINDING SITE; ANTI-THROMBIN-III; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; SECRETORY PROTEINS; TRANSGENIC MICE; DEGRADATION; MUTANT; ALPHA-1-ANTITRYPSIN	Antithrombin (AT) is a major plasma protease inhibitor with three intramolecular disulfide bonds, and its deficiency is associated with increased venous thrombosis. Recently, we found a novel missense mutation named AT Morioka (C95R), which causes the loss of one of the three disulfide bonds. In this study, we prepared Chinese hamster ovary cells stably overexpressing wild type or mutant AT and examined the intracellular fate of the ATs. In pulse-chase experiments, newly synthesized wild type AT was secreted into the medium with a half-life of similar to1.5 h. In contrast, most of the mutant type AT was not secreted during the chase period of 9 h and, surprisingly, was not degraded in the cells. The kinetics of the secretion suggests that the mutant was secreted about 50 times more slowly into the medium. Most of the mutant AT in the cells had high mannose type oligosaccharides, suggesting that it was retained in the endoplasmic reticulum (ER). In addition, half of the mutant AT existed in a dimeric form with an intermolecular disulfide bond. On immunoelectron microscopy, the mutant AT was found to have accumulated in variously sized structures surrounded by a single membrane in the cytoplasm. Immunogold particles exhibiting calnexin immunoreactivity were detected on the membranes. Ribosomes were attached to some of the small structures that had accumulated the mutant AT. Further, we prepared Chinese hamster ovary cells stably overexpressing another mutant AT in which two cysteine residues at 21 and 95, responsible for disulfide bond formation, were substituted for arginines. In pulse-chase experiments, the mutant AT (C21C,C95R) was secreted faster than that of AT Morioka (C95R) into the medium. These results suggest that AT Morioka remained for a long time in ER without being degraded and accumulated in newly formed membrane structures derived from the ER. The dimerization of AT Morioka (C95R) through Cys-21 seems to be critical for its intracellular accumulation.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Clin Lab & Med, Toyama 9300194, Japan; Yamanashi Med Univ, Biol Lab, Tamaho, Yamanashi 4093898, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	University of Toyama; University of Toyama; University of Yamanashi; University of Tokyo	Imanaka, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, 2630 Sugitani, Toyama 9300194, Japan.			Imanaka, Tsuneo/0000-0003-4677-1356				Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BJORK I, 1986, PROTEINASE INHIBITOR, P489; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CHANDRA T, 1983, P NATL ACAD SCI-BIOL, V80, P1845, DOI 10.1073/pnas.80.7.1845; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; EMMERICH J, 1994, ARTERIOSCLER THROMB, V14, P1958, DOI 10.1161/01.ATV.14.12.1958; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KRUSIUS T, 1976, FEBS LETT, V71, P117, DOI 10.1016/0014-5793(76)80911-8; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P197; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MILLE B, 1994, J BIOL CHEM, V269, P29435; MIZUOCHI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P458, DOI 10.1016/0003-9861(80)90199-X; OGUMA Y, 1992, THROMB RES, V65, P519, DOI 10.1016/0049-3848(92)90203-M; OZAWA T, 1996, THROMB HAEMOSTASIS, V77, P403; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHWEITZER PA, 1991, J CELL BIOL, V114, P35, DOI 10.1083/jcb.114.1.35; SHEFFIELD WP, 1995, BLOOD, V86, P3461, DOI 10.1182/blood.V86.9.3461.bloodjournal8693461; Shirotani H, 1999, J BIOCHEM-TOKYO, V125, P253, DOI 10.1093/oxfordjournals.jbchem.a022281; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THALER E, 1981, CLIN HAEMATOL, V10, P369; Tokunaga F, 1997, FEBS LETT, V412, P65, DOI 10.1016/S0014-5793(97)00745-X; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Umebayashi K, 1997, YEAST, V13, P1009; Urade R, 2000, J BIOCHEM-TOKYO, V127, P211, DOI 10.1093/oxfordjournals.jbchem.a022597; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VANBOVEN HH, 1994, BLOOD, V84, P4209, DOI 10.1182/blood.V84.12.4209.bloodjournal84124209; WATTON J, 1993, BIOCHEMISTRY-US, V32, P7286, DOI 10.1021/bi00079a027; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wigley WC, 1999, J CELL BIOL, V145, P481; Yokota S, 2000, HISTOCHEM CELL BIOL, V114, P433	50	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					51058	51067		10.1074/jbc.M210231200	http://dx.doi.org/10.1074/jbc.M210231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12399451	hybrid			2022-12-25	WOS:000180177700113
J	Biswas, SC; Greene, LA				Biswas, SC; Greene, LA			Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL APOPTOSIS; C-JUN; FAMILY MEMBER; CYTOCHROME-C; PC12 CELLS; DEATH; SURVIVAL; ACTIVATION; PATHWAY; RESCUE	Bim is a proapoptotic, BH3-domain-only member of the Bcl-2 family that plays a role in death of trophic factor-deprived sympathetic neurons as well as in other paradigms of apoptotic death. We report here that nerve growth factor (NGF) leads to both a slow down-regulation of Bim expression in neuronal PC 12 cells and rapid Bim phosphorylation. Both effects appear to be mediated by the MEK/MAPK pathway. An assay for Bim-mediated death revealed that NGF-promoted phosphorylation suppresses the proapoptotic activity of Bim. The phosphorylation sites responsible for this effect in the extra long form of rBim were identified as Ser-109 and Thr-110. Thus, NGF protects neurons from the proapoptotic effects of Bim both by acute phosphorylation and the longer term repression of expression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Greene, LA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.		biswas, subhas/E-7876-2013					Bouillet P, 2002, J CELL SCI, V115, P1567; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Harris CA, 2001, J BIOL CHEM, V276, P37754; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wakabayashi T, 2002, NEUROSCI LETT, V318, P77, DOI 10.1016/S0304-3940(01)02487-9; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Yan CYI, 1998, J NEUROSCI, V18, P4042; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	29	153	160	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49511	49516		10.1074/jbc.M208086200	http://dx.doi.org/10.1074/jbc.M208086200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388545	hybrid			2022-12-25	WOS:000180028900054
J	Han, YH; Chung, CY; Wessels, D; Stephens, S; Titus, MA; Soll, DR; Firtel, RA				Han, YH; Chung, CY; Wessels, D; Stephens, S; Titus, MA; Soll, DR; Firtel, RA			Requirement of a vasodilator-stimulated phosphoprotein family member for cell adhesion, the formation of filopodia, and chemotaxis in dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION; LISTERIA-MONOCYTOGENES; PROTEIN; MOTILITY; BINDING; VASP; DOMAIN; CYTOSKELETON; DYNAMICS; PROFILIN	We have examined the function of a member of the vasodilator-stimulated phosphoprotein family of proteins (DdVASP) in Dictyostelium. Ddvasp null cells lack filopodia, whereas targeting DdVASP to the plasma membrane with a myristoyl tag results in a significant increase in filopodia. The proline-rich domain-Ena/ VASP homology 2 structure is required for both actin polymerization activity and filopodia formation. Ddvasp null cells exhibit a chemotaxis defect, which appears to be due to a defect in the ability of the cells to properly adhere to the substratum and to suppress lateral pseudopod extension. We demonstrate that during chemotaxis, the anterior similar to50% of the cell lifts from the substratum and remains elevated for up to 1 min. These defects lead to a significant decrease in chemotaxis efficiency. DdVASP localizes to the leading edge in migrating cells and to the tips of filopodia. In addition, Ddvasp null cells have a defect in particle adhesion but internalize particles normally. Our results provide new insights into the function of DdVASP in controlling the actin cytoskeleton during chemotaxis and filopodia formation.	Univ Calif San Diego, Ctr Mol Genet, Sect Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Iowa, WM Keck Dynam Image Anal Facil, Dept Biol Sci, Iowa City, IA 52242 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 56455 USA	University of California System; University of California San Diego; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities	Firtel, RA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Sect Cell & Dev Biol, Div Biol Sci, Room 225,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu	Chung, Chang Y/G-7522-2012					Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; ARGUINZONIS MIG, 2002, IN PRESS J BIOL CHEM; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Castellano F, 2001, EMBO J, V20, P5603, DOI 10.1093/emboj/20.20.5603; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; Harlow E., 1988, ANTIBODIES LAB MANUA; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, NATURE, V401, P542, DOI 10.1038/44044; Machesky LM, 1999, NAT CELL BIOL, V1, pE29, DOI 10.1038/10020; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Pang KM, 1998, CURR BIOL, V8, P405, DOI 10.1016/S0960-9822(98)70159-9; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Shutt DC, 1998, J CELL SCI, V111, P99; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Soll DR, 2000, SCANNING, V22, P249, DOI 10.1002/sca.4950220404; SOLL DR, 1987, METHOD CELL BIOL, V28, P413; Soll DR, 1998, TECH MOD B, P25; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; VOGEL G, 1980, J CELL BIOL, V86, P456; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; Wessels D, 1998, TECH MOD B, P101; WESSELS D, 1994, CELL MOTIL CYTOSKEL, V27, P1, DOI 10.1002/cm.970270102	42	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49877	49887		10.1074/jbc.M209107200	http://dx.doi.org/10.1074/jbc.M209107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388544	hybrid			2022-12-25	WOS:000180028900102
J	Raja, SM; Wang, BK; Dantuluri, M; Desai, UR; Demeler, B; Spiegel, K; Metkar, SS; Froelich, CJ				Raja, SM; Wang, BK; Dantuluri, M; Desai, UR; Demeler, B; Spiegel, K; Metkar, SS; Froelich, CJ			Cytotoxic cell granule-mediated apoptosis - Characterization of the macromolecular complex of granzyme B with serglycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ELECTROPHORESIS; HEMATOPOIETIC-CELLS; HEPARIN; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; BINDING; PURIFICATION; PROTEASE-1; CARTILAGE; PROTEIN	We have recently shown that the physiological mediator of granule-mediated apoptosis is a macromolecular complex of granzymes and perforin complexed with the chondroitin-sulfate proteoglycan, serglycin (Metkar, S. S., Wang, B., Aguilar-Santelises, M., Raja, S. M., Uhlin-Hansen, L., Podack, E., Trapani, J. A., and Froelich, C. J. (2002) Immunity 16,417-428). We now report our biophysical studies establishing the nature of granzyme B-serglycin (GrB-SG) complex. Dynamic laser light scattering studies establish that SG has a hydrodynamic radius of similar to 140 +/- 23 nm, comparable to some viral particles. Agarose mobility shift gels and surface plasmon resonance (SPR), show that SG binds tightly to GrB and has the capacity to hold 30-60 GrB molecules. SPR studies also indicate equivalent binding affinities (K-d similar to 0.8 pm), under acidic (granule pH) and neutral isotonic conditions (extra-cytoplasmic pH), for GrB-SG interaction. Finally, characterization of GrB-SG interactions within granules revealed complexes of two distinct molecular sizes, one held similar to4-8 molecules of GrB, whereas the other contained as many as 32 molecules of GrB or other granule proteins. These studies provide a firm biophysical basis for our earlier reported observations that the proapoptotic granzyme is exocytosed predominantly as a macromolecular complex with SG.	Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Virginia Commonwealth University; University of Texas System; University of Texas Health San Antonio; Northwestern University	Raja, SM (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, 2650 Ridge Av, Evanston, IL 60201 USA.		Desai, Umesh/D-3741-2013	Desai, Umesh/0000-0002-1976-6597; Demeler, Borries/0000-0002-2414-9518	NIAID NIH HHS [5R01 AI 04494-03] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALHAKIM A, 1991, ANAL BIOCHEM, V195, P68, DOI 10.1016/0003-2697(91)90296-6; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; DESAI UR, 1993, ANAL BIOCHEM, V213, P120, DOI 10.1006/abio.1993.1394; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawson CL, 1974, SOLVING LEAST SQUARE; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Lindstedt L, 2001, ATHEROSCLEROSIS, V155, P87, DOI 10.1016/S0021-9150(00)00544-X; LIU J, 1994, J BIOL CHEM, V269, P28366; Mao WJ, 2002, BIOMED CHROMATOGR, V16, P77, DOI 10.1002/bmc.153; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Oynebraten I, 2000, J LEUKOCYTE BIOL, V67, P183, DOI 10.1002/jlb.67.2.183; Park YM, 1999, BIOCHEM J, V344, P723, DOI 10.1042/0264-6021:3440723; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; PEJLER G, 1994, J BIOL CHEM, V269, P14451; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Seet BT, 2001, J BIOL CHEM, V276, P30504, DOI 10.1074/jbc.M011401200; THUY LP, 1992, CLIN CHIM ACTA, V212, P17, DOI 10.1016/0009-8981(92)90134-C; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	29	89	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49523	49530		10.1074/jbc.M209607200	http://dx.doi.org/10.1074/jbc.M209607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12388539	hybrid, Green Submitted			2022-12-25	WOS:000180028900056
J	Yu, CC; Shen, KF; Lin, MY; Chen, PC; Lin, CC; Chang, GD; Chen, HW				Yu, CC; Shen, KF; Lin, MY; Chen, PC; Lin, CC; Chang, GD; Chen, HW			GCMa regulates the syncytin-mediated trophoblastic fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PLACENTAL EXPRESSION; TRANSCRIPTION FACTOR; HERV-W; CELLS; GLYCOPROTEIN; DROSOPHILA; PROTEIN; GENE; HOMOLOG	The human placental trophohlast cell can be classified as either a cytotrophoblast or a syncytiotrophoblast. Cytotrophoblasts can function as stem cells for the development of the syncytiotrophoblast layer via cell fusion. An envelope gene of the human endogenous retrovirus family W (HERV-W) called syncytin is specifically expressed in the syncytiotrophoblast layer. Syncytin is a fusogenic membrane protein; therefore, it can mediate the fusion of cytotrophoblasts into the syncytiotrophoblast layer, which is essential for pregnancy maintenance. GCMa is a placenta-specific transcription factor and is required for placental development. To study the placenta-specific fusion mediated by syncytin, we tested whether GCMa is involved in this process by regulating syncytin gene expression. In this report, we demonstrate that GCMa was able to regulate syncytin gene expression via two GCMa-binding sites upstream of the 5'-long terminal repeat of the syncytin-harboring HERV-W family member in BeWo and JEG3 cells but not in HeLa cells. Furthermore, adenovirus-directed expression of GCMa enhanced syncytin gene expression and syncytin-mediated cell fusion in BeWo and JEG3 cells but not in HeLa cells. Therefore, the integration site of the syncytin-harboring HERV-W family member in the human genome is close to the functional GCMa-binding sites by which GCMa can specifically transactivate syncytin gene expression in trophoblast cells. Our results may help to explain the mechanism underlying the cell fusion event specific for syncytiotrophoblast formation.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw						Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BENIRSCHKE K, 2001, PATHOLOGY HUMAN PLAC, P49; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Blond JL, 1999, J VIROL, V73, P1175, DOI 10.1128/JVI.73.2.1175-1185.1999; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; CHEN HW, 1994, BIOCHEMISTRY-US, V33, P9615, DOI 10.1021/bi00198a030; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Knerr I, 2002, AM J OBSTET GYNECOL, V186, P210, DOI 10.1067/mob.2002.119636; Knofler M, 2001, PLACENTA, V22, pS83, DOI 10.1053/plac.2001.0648; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Miller AA, 1998, EMBO J, V17, P6316, DOI 10.1093/emboj/17.21.6316; Nait-Oumesmar B, 2000, J HISTOCHEM CYTOCHEM, V48, P915, DOI 10.1177/002215540004800704; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337	22	207	214	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50062	50068		10.1074/jbc.M209316200	http://dx.doi.org/10.1074/jbc.M209316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12397062	hybrid, Green Published			2022-12-25	WOS:000180028900125
J	Shinjo, SK; Tersariol, ILS; Oliveira, V; Nakaie, CR; Oshiro, MEM; Ferreira, AT; Santos, IA; Dietrich, CP; Nader, HB				Shinjo, SK; Tersariol, ILS; Oliveira, V; Nakaie, CR; Oshiro, MEM; Ferreira, AT; Santos, IA; Dietrich, CP; Nader, HB			Heparin and heparan sulfate disaccharides bind to the exchanger inhibitor peptide region of Na+/Ca2+exchanger and reduce the cytosolic calcium of smooth muscle cell lines - Requirement of C4-C5 unsaturation and 1 -> 4 glycosidic linkage for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; INTRACELLULAR CALCIUM; CA-2+ TRANSPORT; THAPSIGARGIN; CONTRACTION; PROTEIN; IDENTIFICATION; SPECTROSCOPY; MECHANISMS	Heparin and heparan sulfate fragments, obtained by bacterial heparinase and heparitinases, bearing an unsaturation at C4-C5 of the uronic acid moiety, are able to produce up to 80% reduction of the cytosolic calcium of smooth muscle cell lines. Unsaturated disaccharides from chondroitin sulfate, dermatan sulfate, and hyaluronic acid are inactive, indicating that, besides the unsaturation of the uronic acid, a vicinal 1 --> 4 glycosidic linkage is needed. An inverse correlation between the molecular weight and activity is observed. Thus, the ED50 of the N-acetylated disaccharide derived from heparan sulfate (430 Da) is 88 muMm compared with 250 muMm of the trisulfated disaccharide (650 Da) derived from heparin. Except for enoxaparin (which contains an unsaturation at the non-reducing end and 1 --> 4 glycosidic linkage), other low molecular weight heparins and native heparin are practically inactive in reducing the cytosolic calcium levels. Thapsigargin (sarcoplasmic reticulum. Ca2+-ATPase inhibitor), vanadate (cytoplasmic membrane Ca2+-ATPase inhibitor), and nifedipine and verapamil (Ca2+ channel antagonists) do not interfere with the effect of the trisulfated disaccharide upon the decrease of the intracellular calcium. A significant decrease of the activity of the trisulfated disaccharide is observed by reducing extracellular sodium, suggesting that the fragments might act upon the Na+/Ca2+ exchanger promoting the extrusion of Ca2+. This was further substantiated by binding experiments and circular dichroism analysis with the exchanger inhibitor peptide.	Univ Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-05508 Sao Paulo, Brazil; Univ Mogi Cruzes, Ctr Interdisciplinar Invest Bioquim, Mogi Cruzes, Brazil; Univ Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Mogi das Cruzes; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Nader, HB (corresponding author), Univ Sao Paulo, Escola Paulista Med, Dept Bioquim, Rua 3 Maio 100, BR-05508 Sao Paulo, Brazil.		Shinjo, Samuel/C-2878-2012; Shinjo, Samuel K/AAF-6221-2021; Oliveira, Vitor/L-3709-2013; Oliveira, Vitor/AAT-5981-2020; Nader, Helena Bonciani/D-9253-2012; Nakaie, Clovis R./B-3444-2014; Dos Santos Tersariol, Ivarne Luis/G-4042-2012	Shinjo, Samuel/0000-0002-3682-4517; Shinjo, Samuel K/0000-0002-3682-4517; Oliveira, Vitor/0000-0002-4662-1377; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; NADER, HELENA/0000-0002-7569-2166				ABOULAFIA J, 1989, PFLUG ARCH EUR J PHY, V415, P230, DOI 10.1007/BF00370597; Antman EM, 2002, EUR HEART J, V23, P308, DOI 10.1053/euhj.2001.2779; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GJ, 1992, J BIOL CHEM, V267, P18383; BLAUSTEIN MP, 1989, CURR TOP MEMBR TRANS, V1, P189; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BOND GH, 1980, BIOCHIM BIOPHYS ACTA, V600, P781, DOI 10.1016/0005-2736(80)90480-0; BUHLER FR, 1982, J CARDIOVASCULAR PHA, V4, P350; BUONASSISI V, 1976, P NATL ACAD SCI USA, V73, P1612, DOI 10.1073/pnas.73.5.1612; BUONASSISI V, 1980, ADV MICROCIRCULAT, V9, P76; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CILI EM, 1996, J ORG CHEM, V61, P8992; DIPOLO R, 1979, J GEN PHYSIOL, V73, P91, DOI 10.1085/jgp.73.1.91; DIPOLO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P549, DOI 10.1016/0304-4157(88)90007-X; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; EGGERMONT JA, 1988, CIRC RES, V62, P266, DOI 10.1161/01.RES.62.2.266; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTSHORNE DJ, 1980, CHEST, V78, P140, DOI 10.1378/chest.78.1_Supplement.140; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; Hodl R, 2002, AM J CARDIOL, V89, P589, DOI 10.1016/S0002-9149(01)02300-1; Hoffmann E, 2002, Z KARDIOL, V91, P24, DOI 10.1007/s392-002-8368-6; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JAQUES LB, 1981, PHARMACOL REV, V31, P166; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; NADER HB, 1990, J BIOL CHEM, V265, P16807; NADER HB, 1989, FASEB J, V3, P2420, DOI 10.1096/fasebj.3.12.2529161; OHYA Y, 1991, CIRC RES, V68, P763, DOI 10.1161/01.RES.68.3.763; RAGAZZI M, 1993, J CARBOHYD CHEM, V12, P523, DOI 10.1080/07328309308019405; ROSSI JPF, 1980, BIOCHIM BIOPHYS ACTA, V600, P796; Saba RI, 2001, BIOCHEMISTRY-US, V40, P3324, DOI 10.1021/bi0010672; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; SOMLYO AP, 1985, CIRC RES, V57, P497, DOI 10.1161/01.RES.57.4.497; SOMMERVILLE LE, 1986, CELL CALCIUM, V7, P353, DOI 10.1016/0143-4160(86)90038-2; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; YAMAMOTO H, 1983, BRIT J EXP PATHOL, V64, P156; ZHAOPING H, 2000, AM J PHYSIOL, V278, P661; Zwick N, 2001, CIRCULATION, V104, P774	44	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48227	48233		10.1074/jbc.M205867200	http://dx.doi.org/10.1074/jbc.M205867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12374809	hybrid			2022-12-25	WOS:000179789600035
J	Rajagopal, R; Sivakumar, S; Agrawal, N; Malhotra, P; Bhatnagar, RK				Rajagopal, R; Sivakumar, S; Agrawal, N; Malhotra, P; Bhatnagar, RK			Silencing of midgut aminopeptidase N of Spodoptera litura by double-stranded RNA establishes its role as bacillus thuringiensis toxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; MANDUCA-SEXTA; GENETIC INTERFERENCE; DELTA-ENDOTOXIN; VESICLES; ELEGANS; BINDING	Insecticidal crystal proteins of Bacillus thuringiensis bind to receptors in the midgut of susceptible insects leading to pore formation and death of the insect. The identity of the receptor is not clearly established. Recently a direct interaction between a cloned and heterologously expressed aminopeptidase (slapn) from Spodoptera litura and the Cry1C protein was demonstrated by immunofluorescence and in vitro ligand blot interaction. Here we show that administration of slapn double-stranded RNA to S. litura larvae reduces its expression. As a consequence of the reduced expression, a corresponding decrease in the sensitivity of these larvae to Cry1C toxin was observed. The gene silencing was retained during the insect's moulting and development and transmitted to the subsequent generation albeit with a reduced effect. These results directly implicate larval midgut aminopeptidase N as receptor for Bacillus thuringiensis insecticidal proteins.	ICGEB, Insect Resistance Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Rajagopal, R (corresponding author), ICGEB, Insect Resistance Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, India.			Swaminathan, Sivakumar/0000-0003-3931-275X				Agrawal N, 2002, APPL ENVIRON MICROB, V68, P4583, DOI 10.1128/AEM.68.9.4583-4592.2002; Carroll J, 1997, J CELL SCI, V110, P3099; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Gould F, 1998, ANNU REV ENTOMOL, V43, P701, DOI 10.1146/annurev.ento.43.1.701; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Jenkins J L, 2000, Genet Eng (N Y), V22, P33; Jenkins JL, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-12; KENDERDELL JR, 2000, NAT BIOTECHNOL, V18, P896; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; Lee MK, 1996, APPL ENVIRON MICROB, V62, P2845, DOI 10.1128/AEM.62.8.2845-2849.1996; LEE MK, 1992, J BIOL CHEM, V267, P3115; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	23	234	284	2	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46849	46851		10.1074/jbc.C200523200	http://dx.doi.org/10.1074/jbc.C200523200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12377776	hybrid			2022-12-25	WOS:000179663700003
J	Pratt, RL; Kinch, MS				Pratt, RL; Kinch, MS			Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade	ONCOGENE			English	Article						Eph kinase; Eck; signal transduction	TERNARY COMPLEX FACTORS; MAP KINASE; PROTEIN-KINASE; GROWTH; LIGANDS; TRANSFORMATION; EXPRESSION; RECEPTORS; FAMILY; DOMAIN	Intracellular signaling by receptor tyrosine kinases regulates many different aspects of cell behavior. Recent studies in our laboratory and others have demonstrated that the EphA2 receptor tyrosine kinase critically regulates tumor cell growth, migration and invasiveness. Although the cellular consequences of EphA2 signaling have been the focus of recent attention, the biochemical changes that are triggered by ligand-mediated activation of EphA2 remain largely unknown. Herein, we demonstrate that ligand stimulation of EphA2 promotes the nucleus translocation and phosphorylation of ERK kinases, followed by an increase in nuclear induction of the Elk-1 transcription factor. Ligand-mediated activation allows EphA2 to form a molecular complex with the SHC and GRB2 adaptor proteins. Specifically, we demonstrate that tyrosine phosphorylated EphA2 interacts with the PTB and SH2 domains of SHC. We also show that the interaction of EphA2 with GRB2 is indirect and mediated by SHC and that this complex is necessary for EphA2-mediated activation of ERK kinases. These studies provide a novel mechanism to demonstrate how EphA2 can convey information from the cell exterior to the nucleus.	Medimmune Inc, Gaithersburg, MD 20878 USA; Purdue Univ, Ctr Canc, Dept Basic Med Sci, W Lafayette, IN 47907 USA	AstraZeneca; Medimmune; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kinch, MS (corresponding author), Medimmune Inc, 35 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	kinchm@medimmune.com		Kinch, Michael/0000-0003-3939-3756				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Brennan C, 1997, DEVELOPMENT, V124, P655; Brunet Anne, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P43; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lu Q, 2002, BIOL REPROD, V66, P29, DOI 10.1095/biolreprod66.1.29; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCORMICK BA, 1992, PHARMACOL THERAPEUT, V53, P239, DOI 10.1016/0163-7258(92)90011-N; MCNEIL PL, 1989, METHOD CELL BIOL, V29, P153; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Schramek H, 1997, J BIOL CHEM, V272, P11426; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Verlhac MH, 2000, EMBO J, V19, P6065, DOI 10.1093/emboj/19.22.6065; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	56	112	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7690	7699		10.1038/sj.onc.1205758	http://dx.doi.org/10.1038/sj.onc.1205758			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400011				2022-12-25	WOS:000178756200008
J	Ellis, JG; Davila, M; Chakrabarti, R				Ellis, JG; Davila, M; Chakrabarti, R			Potential involvement of extracellular signal-regulated kinase 1 and 2 in encystation of a primitive eukaryote, Giardia lamblia - Stage-specific activation and intracellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL PROTEIN; MAP-KINASE; IN-VITRO; PHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; (SREBP)-1A; TYROSINE; BIOLOGY	Mitogen-activated protein kinase (MAPK) pathways are major signaling systems by which eukaryotic cells convert environmental cues to intracellular events such as proliferation and differentiation. We have identified Giardia lamblia homologues of two members of the MAPK family ERK1 and ERK2. Functional characterization of giardial ERK1 and ERK2 revealed that both kinases were expressed in trophozoites and encysting cells as 44- and 41-kDa polypeptides, respectively, and were catalytically active. Analysis of the kinetic parameters of the recombinant proteins showed that ERK2 is similar to5 times more efficient than ERK1 in phosphorylating myelin basic protein as a substrate, although the phosphorylating efficiency of the native ERK1 and ERK2 appeared to be the same. Immunofluorescence analysis of the subcellular localization of ERK1 and ERK2 in trophozoites showed ERK1 staining mostly in the median body and in the outer edges of the adhesive disc and ERK2 staining in the nuclei and in the caudal flagella. Our study also showed a noticeable change in the subcellular distribution of ERK2 during encystation, which became more punctate and mostly cytoplasmic, but no significant change in the ERK1 localization at any time during encystation. Interestingly, both ERK1 and ERK2 enzymes exhibited a significantly reduced kinase activity during encystation reaching a minimum at 24 h, except for an initial similar to2.5-fold increase in the ERK1 activity at 2 h, which resumed back to the normal levels at 48 h despite no apparent change in the expression level of either one of these kinases in encysting cells. A reduced concentration of the phosphorylated ERK1 and ERK2 was also evident in these cells at 24 h. Our study suggests a functional distinction between ERK1 and ERK2 and that these kinases may play a critical role in trophozoite differentiation into cysts.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	State University System of Florida; University of Central Florida	Chakrabarti, R (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.		Davila, Monica/I-4170-2018	Davila, Monica/0000-0002-4638-9766				Abel ES, 2001, J BIOL CHEM, V276, P10320, DOI 10.1074/jbc.M006589200; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Antonsson B, 1999, ANAL BIOCHEM, V267, P294, DOI 10.1006/abio.1998.2986; Bernander R, 2001, CELL MICROBIOL, V3, P55, DOI 10.1046/j.1462-5822.2001.00094.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Eriksson M, 2002, J BIOL CHEM, V277, P15992, DOI 10.1074/jbc.M107340200; Erlandsen S.L., 1984, P33; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hua SB, 1997, J BIOL CHEM, V272, P10797, DOI 10.1074/jbc.272.16.10797; Jarroll EL, 2001, J EUKARYOT MICROBIOL, V48, P22, DOI 10.1111/j.1550-7408.2001.tb00412.x; KANE AV, 1991, J PARASITOL, V77, P974, DOI 10.2307/3282752; Kaul D, 2001, MOL CELL BIOCHEM, V225, P167, DOI 10.1023/A:1012277001794; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Kim HJ, 2002, ANN NY ACAD SCI, V967, P34; Kotzka J, 2000, J LIPID RES, V41, P99; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1996, P NATL ACAD SCI USA, V93, P7628, DOI 10.1073/pnas.93.15.7628; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 1998, PARASITOL TODAY, V14, P446, DOI 10.1016/S0169-4758(98)01333-7; Luongo D, 2002, MOL CELL BIOCHEM, V231, P43, DOI 10.1023/A:1014476706382; Marshall MM, 1997, CLIN MICROBIOL REV, V10, P67, DOI 10.1128/CMR.10.1.67; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Recio JA, 2000, CANCER RES, V60, P1720; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; RUBEN L, 2002, MOL MED PARASITOLOGY, P241; Sambrook J., 2002, MOL CLONING LAB MANU; Smith MW, 1998, MOL BIOCHEM PARASIT, V95, P267, DOI 10.1016/S0166-6851(98)00113-3; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	45	55	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1936	1945		10.1074/jbc.M209274200	http://dx.doi.org/10.1074/jbc.M209274200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12397063	hybrid			2022-12-25	WOS:000180462200077
J	Schmidt, M; Giessl, A; Laufs, T; Hankeln, T; Wolfrum, U; Burmester, T				Schmidt, M; Giessl, A; Laufs, T; Hankeln, T; Wolfrum, U; Burmester, T			How does the eye breathe? Evidence for neuroglobin-mediated oxygen supply in the mammalian retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MYOGLOBIN; CONSUMPTION; HEMOGLOBIN; GLOBIN; CELLS; TRAFFICKING; NEURONS; LIGHT; CONES	Visual performance of the vertebrate eye requires large amounts of oxygen, and thus the retina is one of the highest oxygen-consuming tissues of the body. Here we show that neuroglobin, a neuron-specific respiratory protein distantly related to hemoglobin and myoglobin, is present at high amounts in the mouse retina (similar to100 muM). The estimated concentration of neuroglobin in the retina is thus about 100-fold higher than in the brain and is in the same range as that of myoglobin in the muscle. Neuroglobin is expressed in all neurons of the retina but not in the retinal pigment epithelium. Neuroglobin mRNA was detected in the perikarya of the nuclear and ganglion layers of the neuronal retina, whereas the protein was present mainly in the plexiform layers and in the ellipsoid region of photoreceptor inner segment. The distribution of neuroglobin correlates with the subcellular localization of mitochondria and with the relative oxygen demands, as the plexiform layers and the inner segment consume most of the retinal oxygen. These findings suggest that neuroglobin supplies oxygen to the retina, similar to myoglobin in the myocardium and the skeletal muscle.	Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Genet Mol, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Burmester, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany.	burmeste@mail.uni-mainz.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Giessl, Andreas/0000-0002-9768-2049				AMES A, 1992, CAN J PHYSIOL PHARM, V70, pS158, DOI 10.1139/y92-257; ANDERSON B, 1964, ARCH OPHTHALMOL-CHIC, V72, P792; Anderson B Jr, 1968, Trans Am Ophthalmol Soc, V66, P423; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922; Cringle SJ, 2002, COMP BIOCHEM PHYS A, V132, P61, DOI 10.1016/S1095-6433(01)00530-X; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Germer A, 1998, J NEUROCYTOL, V27, P347, DOI 10.1023/A:1006938825474; Karakucuk S, 2000, OPHTHALMIC RES, V32, P30, DOI 10.1159/000055584; McGinnis JF, 2002, J NEUROSCI RES, V67, P290, DOI 10.1002/jnr.10120; Merx Marc W., 2001, FASEB Journal, V15, P1077; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; NORK TM, 1993, INVEST OPHTH VIS SCI, V34, P2918; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Qiu Y, 1998, J BIOL CHEM, V273, P23426, DOI 10.1074/jbc.273.36.23426; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Richardson RS, 2001, J APPL PHYSIOL, V91, P2679, DOI 10.1152/jappl.2001.91.6.2679; SCHUDER S, 1979, ANAL BIOCHEM, V92, P473, DOI 10.1016/0003-2697(79)90687-0; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Tsacopoulos M, 1998, PROG RETIN EYE RES, V17, P429, DOI 10.1016/S1350-9462(98)00010-X; vonGersdorff H, 1996, NEURON, V16, P1221, DOI 10.1016/S0896-6273(00)80148-8; Wiedman M, 1999, OPHTHALMOLOGY, V106, P1924, DOI 10.1016/S0161-6420(99)90402-5; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1975, COMP BIOCHEM PHYS A, V51, P425, DOI 10.1016/0300-9629(75)90390-4; WOLFRUM U, 1991, CELL TISSUE RES, V263, P399, DOI 10.1007/BF00318782; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; [No title captured]	36	272	305	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1932	1935		10.1074/jbc.M209909200	http://dx.doi.org/10.1074/jbc.M209909200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12409290	hybrid			2022-12-25	WOS:000180462200076
J	Luo, ZL; Gallwitz, D				Luo, ZL; Gallwitz, D			Biochemical and genetic evidence for the involvement of yeast Ypt6-GTPase in protein retrieval to different Golgi compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; ALPHA-1,3 MANNOSYLTRANSFERASE; NUCLEOTIDE EXCHANGE; FUNCTIONAL-ANALYSIS; SECRETORY PATHWAY; RAB GTPASES; LOCALIZATION; ER	Yeast Ypt6p, the homologue of the mammalian Rab6 GTPase, is not essential for cell viability. Based on previous studies with ypt6 deletion mutants, a regulatory role of the GTPase either in protein retrieval to the trans-Golgi network or in forward transport between the endoplasmic reticulum (ER) and early Golgi compartments was proposed. To assess better the primary role(s) of Ypt6p, temperature-sensitive ypt6 mutants were generated and analyzed biochemically and genetically. Defects in N-glycosylation of proteins passing the Golgi and of Golgi-resident glycosyltransferases as well as protein sorting defects in the trans-Golgi were recorded shortly after functional loss of Ypt6p. ER-to-Golgi transport and protein secretion were delayed but not interrupted. Mis-sorting of the vesicular SNARE Sec22p to the late Golgi was also observed. Combination of the ypt6-2 mutant allele with a number of mutants in forward and retrograde transport between ER, Golgi, and endosomes led to synthetic negative growth defects. The results obtained indicate that Ypt6p acts in endosome-to-Golgi, in intra-Golgi retrograde transport, and possibly also in Golgi-to-ER trafficking.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Gallwitz, D (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.	Dieter.Gallwitz@mpi-bpc.mpg.de						Abeliovich H, 1998, J BIOL CHEM, V273, P11719, DOI 10.1074/jbc.273.19.11719; Andag U, 2001, J BIOL CHEM, V276, P39150, DOI 10.1074/jbc.M105833200; Ballensiefen W, 1998, J CELL SCI, V111, P1507; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bensen ES, 2001, MOL BIOL CELL, V12, P13, DOI 10.1091/mbc.12.1.13; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Li BJ, 1998, YEAST, V14, P915, DOI 10.1002/(SICI)1097-0061(199807)14:10<915::AID-YEA291>3.3.CO;2-P; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Nothwehr SF, 1999, MOL BIOL CELL, V10, P875, DOI 10.1091/mbc.10.4.875; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Peng RW, 2000, J BIOL CHEM, V275, P11521, DOI 10.1074/jbc.275.15.11521; Peyroche A, 2001, METHOD ENZYMOL, V329, P290; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; REID GA, 1983, METHOD ENZYMOL, V97, P324; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Seron K, 1998, MOL BIOL CELL, V9, P2873, DOI 10.1091/mbc.9.10.2873; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; Tsukada M, 1999, MOL BIOL CELL, V10, P63, DOI 10.1091/mbc.10.1.63; Tsukada M, 1996, J CELL SCI, V109, P2471; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	55	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					791	799		10.1074/jbc.M209120200	http://dx.doi.org/10.1074/jbc.M209120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12401784	Green Published, hybrid			2022-12-25	WOS:000180321900015
J	Claus, P; Doring, F; Gringel, S; Muller-Ostermeyer, F; Fuhlrott, J; Kraft, T; Grothe, C				Claus, P; Doring, F; Gringel, S; Muller-Ostermeyer, F; Fuhlrott, J; Kraft, T; Grothe, C			Differential intranuclear localization of fibroblast growth factor-2 isoforms and specific interaction with the survival of motoneuron protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DISEASE GENE-PRODUCT; MOLECULAR-WEIGHT; NUCLEAR-LOCALIZATION; FACTOR-II; CARDIAC MYOCYTES; IN-VITRO; ENDOTHELIAL-CELLS; OVER-EXPRESSION; FGF RECEPTOR-1	Fibroblast growth factor 2 (FGF-2) is an important modulator of cell growth and differentiation and a neurotrophic factor. FGF-2 occurs in isoforms, at a low molecular weight of 18,000 and at least two high molecular weight forms (21,000 and 23,000), representing alternative translation products from a single mRNA. In addition to its role as an extracellular ligand, FGF-2 localizes to the nuclei of cells. Here we show differential localization of the 18- and 23-kDa isoforms in the nuclei of rat Schwann cells. Whereas the 18-kDa isoform was found in the nucleoli, nucleoplasm, and Cajal bodies, the 23-kDa isoform localized in a punctuate pattern and associates with mitotic chromosomes suggesting different functional roles of the isoforms. Moreover, we show here that the 23-kDa FGF-2 isoform co-immunoprecipitates specifically with the survival of motor neuron protein (SMN). SMN is an assembly and recycling factor of the splicing machinery and locates to the cytoplasm, the nucleoplasm, and nuclear gems, where it co-localizes with 23-kDa FGF-2. Patients with spinal muscular atrophy suffer from fatal degeneration of motoneurons because of mutations and deletions of the gene for the SMN protein.	Hannover Med Sch, Dept Neuroanat, D-30625 Hannover, Germany; Hannover Med Sch, Dept Mol & Cell Physiol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Claus, P (corresponding author), Hannover Med Sch, Dept Neuroanat, OE 4140,Carl Neuberg Str 1, D-30625 Hannover, Germany.		Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445				AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; Choi JK, 2000, MOL VIS, V6, P222; CLAUS P, 1994, J BIOL CHEM, V269, P33042; CohenJonathan E, 1997, CANCER RES, V57, P1364; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; ESTIVAL A, 1993, CANCER RES, V53, P1182; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; Grothe C, 2000, NEUROSCIENCE, V100, P73, DOI 10.1016/S0306-4522(00)00247-5; Grothe C, 1998, MOL BRAIN RES, V57, P97, DOI 10.1016/S0169-328X(98)00076-X; Grothe C, 1996, INT J DEV BIOL, V40, P403; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hebert MD, 2000, MOL BIOL CELL, V11, P4159, DOI 10.1091/mbc.11.12.4159; Huber K, 1997, J COMP NEUROL, V382, P189; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Meisinger C, 1996, J BIOL CHEM, V271, P16520, DOI 10.1074/jbc.271.28.16520; MOROIANU J, 1994, BIOCHEMISTRY-US, V33, P12535, DOI 10.1021/bi00208a001; Muller-Ostermeyer F, 2001, GROWTH FACTORS, V19, P175; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Pasumarthi KBS, 1996, CIRC RES, V78, P126, DOI 10.1161/01.RES.78.1.126; PASUMARTHI KBS, 1994, J MOL CELL CARDIOL, V26, P1045, DOI 10.1006/jmcc.1994.1125; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Reimers K, 2001, MOL CELL BIOL, V21, P4996, DOI 10.1128/MCB.21.15.4996-5007.2001; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; Sun CP, 2001, J CELL PHYSIOL, V186, P457, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1044>3.0.CO;2-2; TENNEKOON GI, 1987, J CELL BIOL, V105, P2315, DOI 10.1083/jcb.105.5.2315; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	56	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					479	485		10.1074/jbc.M206056200	http://dx.doi.org/10.1074/jbc.M206056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12397076	hybrid			2022-12-25	WOS:000180255700063
J	Lee, YH; Li, Y; Uyeda, K; Hasemann, CA				Lee, YH; Li, Y; Uyeda, K; Hasemann, CA			Tissue-specific structure/function differentiation of the liver isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; RAT-LIVER; MYOCARDIAL FRUCTOSE-6-PHOSPHATE,2-KINASE; BIFUNCTIONAL ENZYME; DOMAIN; DEPHOSPHORYLATION; PHOSPHORYLATION; PURIFICATION	The crystal structures of the human liver 6-phospho-fructo-2-kinase/fructose-2,6-bisphosphatase in three different liganding states were determined and compared with those of the rat testis isozyme. A set of amino acid sequence heterogeneity from the two distinct genes encoding the two different tissue isozymes leads to both global and local conformational differences that may cause the differences in catalytic properties of the two isozymes. The sequence differences in a beta-hairpin loop in the kinase domain causes a translational shift of several hydrophobic interactions in the dimeric contact region, and its propagation to the domains interface results in a 5degrees twist of the entire bisphosphatase domain relative to the kinase domain. The bisphosphatase domain twist allows the dimeric interactions between the bisphosphatase domains, which are negligible in the testis enzyme, and as a result, the conformational. stability of the domain is increased. Sequence polymorphisms also confer small but significant structural dissimilarities in the substrate-binding loops, allowing the differentiated catalytic properties between the two different tissue-type isozymes. Whereas the polymorphic sequence at the bisphosphatase-active pocket suggests a more suitable substrate binding, a similar extent of sequence differences at the kinase-active pocket confers a different mechanism of substrates bindings to the kinase-active pocket. It includes the ATP-sensitive unwinding of the switch helix alpha5, which is a characteristic ATP-dependent conformational change in the testis form. The sequence-dependent structural difference disallows the liver kinase to follow the ATP-switch mechanism. Altogether these suggest that the liver isoform has structural features more appropriate for an elevated bisphosphatase activity, compared with that of the testis form. The structural predisposition for bisphosphatase activity in the liver isozyme is consistent with the liver-unique glucose metabolic pathway, gluconeogenesis.	Univ Missouri, Columbia, MO 65211 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Vet Affairs Med Ctr, Res Serv, Dallas, TX 75216 USA; Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA	University of Missouri System; University of Missouri Columbia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer	Lee, YH (corresponding author), Univ Missouri, 125 Chem Bldg, Columbia, MO 65211 USA.	leeyon@missouri.edu			NIDDK NIH HHS [DK52089, DK16194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEDOROV S, 1992, J BIOL CHEM, V267, P20826; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; KURLAND IJ, 1995, PROTEIN SCI, V4, P1023, DOI 10.1002/pro.5560040601; LANGE AJ, 1993, J BIOL CHEM, V268, P8078; Lee YH, 1997, NAT STRUCT BIOL, V4, P615, DOI 10.1038/nsb0897-615; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; LI L, 1992, J BIOL CHEM, V267, P21588; LI L, 1992, J BIOL CHEM, V267, P16669; Liu YQ, 1996, J BIOL CHEM, V271, P8824, DOI 10.1074/jbc.271.15.8824; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mizuguchi H, 1997, BIOCHEMISTRY-US, V36, P8775, DOI 10.1021/bi970639o; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RICHARDS CS, 1982, BIOCHEM BIOPH RES CO, V104, P1073, DOI 10.1016/0006-291X(82)91359-6; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SAKATA J, 1991, J BIOL CHEM, V266, P15764; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; UYEDA K, 1991, STUDY ENZYMES, V2, P445; VENTURA F, 1992, J BIOL CHEM, V267, P17939; Yuen MH, 1999, BIOCHEMISTRY-US, V38, P12333, DOI 10.1021/bi991268+; Yuen MH, 1999, J BIOL CHEM, V274, P2176, DOI 10.1074/jbc.274.4.2176	33	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					523	530		10.1074/jbc.M209105200	http://dx.doi.org/10.1074/jbc.M209105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12379646	hybrid, Green Published			2022-12-25	WOS:000180255700069
J	Mitsuhashi, S; Shima, H; Tanuma, N; Matsuura, N; Takehawa, M; Urano, T; Kataoka, T; Ubukata, M; Kikuchi, K				Mitsuhashi, S; Shima, H; Tanuma, N; Matsuura, N; Takehawa, M; Urano, T; Kataoka, T; Ubukata, M; Kikuchi, K			Usage of tautomycetin, a novel inhibitor of protein phosphatase 1 (PP1), reveals that PP1 is a positive regulator of Raf-1 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES HEPATOMA-CELLS; CATALYTIC SUBUNIT; SERINE/THREONINE PHOSPHATASES; MOLECULAR-CLONING; GENE-EXPRESSION; RAT HEPATOMAS; 1-ALPHA; TYPE-1; IDENTIFICATION; APOPTOSIS	Protein phosphatase type 1 (PP1), together with protein phosphatase 2A (PP2A), is a major eukaryotic serine/threonine protein phosphatase involved in regulation of numerous cell functions. Although the roles of PP2A have been studied extensively using okadaic acid, a well known inhibitor of PP2A, biological analysis of PP1 has remained restricted because of lack of a specific inhibitor. Recently we reported that tautomycetin (TC) is a highly specific inhibitor of PP1. To elucidate the biological effects of TC, we demonstrated in preliminary experiments that treatment of COS-7 cells with 5 mum TC for 5 h inhibits endogenous PP1 by more than 90% without affecting PP2A activity. Therefore, using TC as a specific PP1 inhibitor, the biological effect of PP1 on MAPK signaling was examined. First, we found that inhibition of PP1 in COS-7 cells by TC specifically suppresses activation of ERK, among three MAPK kinases (ERE, JNK, and p38). TC-mediated inhibition of PP1 also suppressed activation of Raf-1, resulting in the inactivation of the MEK-ERK pathway. To examine the role of PP1 in regulation of Raf-1, we overexpressed the PP1 catalytic subunit (PP1C) in COS-7 cells and found that PP1C enhanced activation of Raf-1 activity, whereas phosphatase-dead PP1C blocked Raf-1 activation. Furthermore, a physical interaction between PP1C and Raf-1 was also observed. These data strongly suggest that PP1 positively regulates Raf-1 in vivo.	Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Toyama Prefectural Univ, Lab Biofunct Chem, Biotechnol Res Ctr, Toyama 9390398, Japan; Univ Tokyo, Inst Med Sci, Div Mol Cell Signalling, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Kobe Univ, Grad Sch Med, Div Mol Biol, Dept Mol & Cellular Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Hokkaido University; Toyama Prefectural University; University of Tokyo; Japan Science & Technology Agency (JST); Nagoya University; Kobe University	Kikuchi, K (corresponding author), Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Kita-15,Nishi-7, Sapporo, Hokkaido 0600815, Japan.		Mitsuhashi, Shinya/A-4337-2012; 生方, 信/AAF-6870-2020; Ubukata, Makoto/B-8856-2012	Ubukata, Makoto/0000-0001-8911-2815; Takekawa, Mutsuhiro/0000-0002-8027-3847; Urano, Takeshi/0000-0003-3383-3554				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; CHENG XC, 1990, J ANTIBIOT, V43, P890, DOI 10.7164/antibiotics.43.890; CHENG XC, 1989, J ANTIBIOT, V42, P141; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FRIEDENAUER S, 1989, ANAL BIOCHEM, V178, P263, DOI 10.1016/0003-2697(89)90636-2; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kawamura T, 1998, BIOCHEM PHARMACOL, V55, P995, DOI 10.1016/S0006-2952(97)00539-X; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KIKUCHI K, 1984, JPN J CANCER RES, V75, P388; Kim SE, 2000, INT J ONCOL, V16, P751; KITAMURA K, 1991, J BIOCHEM-TOKYO, V109, P307; KITAMURA K, 1992, JPN J CANCER RES, V83, P66, DOI 10.1111/j.1349-7006.1992.tb02353.x; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuzawa S, 1999, BIOORGAN MED CHEM, V7, P381, DOI 10.1016/S0968-0896(98)00226-0; Mitsuhashi S, 1999, BIOORG MED CHEM LETT, V9, P2007, DOI 10.1016/S0960-894X(99)00309-1; Mitsuhashi S, 2001, BIOCHEM BIOPH RES CO, V287, P328, DOI 10.1006/bbrc.2001.5596; Mitsuhashi S, 2000, ANAL BIOCHEM, V278, P192, DOI 10.1006/abio.1999.4422; Nakamura K, 2002, J BIOCHEM, V132, P463, DOI 10.1093/oxfordjournals.jbchem.a003244; Nomoto K, 1998, INT J ONCOL, V13, P331; Nomoto K, 1996, BBA-GENE STRUCT EXPR, V1309, P221, DOI 10.1016/S0167-4781(96)00165-0; OIKAWA M, 1995, J ORG CHEM, V60, P5048, DOI 10.1021/jo00121a026; Okada T, 1999, MOL CELL BIOL, V19, P6057; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; SAADAT M, 1994, CANCER DETECT PREV, V18, P115; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHINEHA R, 1990, JPN J CANCER RES, V81, P161, DOI 10.1111/j.1349-7006.1990.tb02543.x; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TAKIZAWA N, 1994, J BIOCHEM-TOKYO, V116, P411, DOI 10.1093/oxfordjournals.jbchem.a124540; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	54	74	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					82	88		10.1074/jbc.M208888200	http://dx.doi.org/10.1074/jbc.M208888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12374792	hybrid			2022-12-25	WOS:000180255700011
J	Ochi, H; Ogino, H; Kageyama, Y; Yasuda, K				Ochi, H; Ogino, H; Kageyama, Y; Yasuda, K			The stability of the lens-specific maf protein is regulated by fibroblast growth factor (FGF)/ERK signaling in lens fiber differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TRANSGENIC MICE; CRYSTALLIN GENES; EPITHELIAL-CELLS; BETA-CRYSTALLIN; FGF FAMILY; C-MAF; EXPRESSION; ACTIVATION; RECEPTOR	Fibroblast growth factor (FGF) signaling is necessary for both proliferation and differentiation of lens cells. However, the molecular mechanisms by which FGFs exert their effects on the lens remain poorly understood. In this study, we show that FGF-2 repressed the expression of lens-specific genes at the proliferative phase in primary cultured lens cells. Using transfected cells, we also found that the activity of L-Maf, a lens differentiation factor, is repressed by FGF/ERK signaling. L-Maf is shown to be phosphorylated by ERK, and introduction of mutations into the ERK target sites on L-Maf promotes its stabilization. The stable L-Maf mutant protein promotes the differentiation of lens cells from neural retina cells. Taken together, these results indicate that FGF/ERK signaling negatively regulates the function of L-Maf in proliferative lens cells and that stabilization of the L-Maf protein is important for lens fiber differentiation.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan	Nara Institute of Science & Technology	Yasuda, K (corresponding author), Univ Virginia, Gilmer Hall,Rm 253, Charlottesville, VA 22903 USA.		Ogino, Hajime/G-5279-2019; Ochi, Haruki/AAR-7235-2020	Ogino, Hajime/0000-0003-2707-2330; Ochi, Haruki/0000-0002-0088-581X				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Chambers D, 2000, MOL CELL NEUROSCI, V15, P22, DOI 10.1006/mcne.1999.0801; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; deIongh RU, 1997, INVEST OPHTH VIS SCI, V38, P1688; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Govindarajan V, 2001, DEVELOPMENT, V128, P1617; Graw J, 1996, DEV GENET, V18, P181, DOI 10.1002/(SICI)1520-6408(1996)18:3<181::AID-DVG1>3.0.CO;2-5; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Le ACN, 2001, DEV BIOL, V233, P394, DOI 10.1006/dbio.2001.0194; Lengler J, 2001, NUCLEIC ACIDS RES, V29, P515, DOI 10.1093/nar/29.2.515; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Lovicu FJ, 2001, DEVELOPMENT, V128, P5075; Lovicu FJ, 1998, DEVELOPMENT, V125, P3365; Maegawa S, 1999, MECH DEVELOP, V81, P223, DOI 10.1016/S0925-4773(98)00242-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUO I, 1991, DEVELOPMENT, V113, P539; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MENKO AS, 1984, DEV BIOL, V103, P129, DOI 10.1016/0012-1606(84)90014-9; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; OKADA TS, 1971, DEV GROWTH DIFFER, V13, P323; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Reza HM, 2002, MECH DEVELOP, V116, P61, DOI 10.1016/S0925-4773(02)00137-5; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Ring BZ, 2000, DEVELOPMENT, V127, P307; Robinson ML, 1995, DEVELOPMENT, V121, P3959; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHULZ MW, 1993, DEVELOPMENT, V118, P117; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Wu M, 2000, GENE DEV, V14, P301; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	42	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					537	544		10.1074/jbc.M208380200	http://dx.doi.org/10.1074/jbc.M208380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12393904	hybrid			2022-12-25	WOS:000180255700071
J	Caudron, N; Arnal, I; Buhler, E; Job, D; Valiron, O				Caudron, N; Arnal, I; Buhler, E; Job, D; Valiron, O			Microtubule nucleation from stable tubulin oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-TUBULIN; DYNAMIC PROPERTIES; RING COMPLEX; IN-VITRO; ENDS; MICROSCOPY; MECHANISM; TEMPLATE; INVITRO; MINUS	Microtubule assembly from purified tubulin preparations involves both microtubule nucleation and elongation. Whereas elongation is well documented, microtubule nucleation remains poorly understood because of difficulties in isolating molecular intermediates between tubulin dimers and microtubules. Based on kinetic studies, we have previously proposed that the basic building blocks of microtubule nuclei are persistent tubulin oligomers, present at the onset of tubulin assembly. Here we have tested this model directly by isolating nucleation-competent cross-linked tubulin oligomers. We show that such oligomers are composed of 10-15 laterally associated tubulin dimers. In the presence of added free tubulin dimers, several oligomers combine to form microtubule nuclei competent for elongation. We provide evidence that these nuclei have heterogeneous structures, indicating unexpected flexibility in nucleation pathways. Our results suggest that microtubule nucleation in purified tubulin solution is mechanistically similar to that templated by gamma-tubulin ring complexes with the exception that in the absence of gamma-tubulin complexes the production of productive microtubule seeds from tubulin oligomers involves trial and error and a selection process.	Commiss Energie Atom Grenoble, Dept Reponse & Dynam Cellulaires Cytosquelette, INSERM, U366, F-38054 Grenoble 9, France; Univ Rennes 1, Equipe Struct & Dynam Cytosquelette, CNRS, UMR 6026, F-35042 Rennes, France; Ctr Rech Macromol Vegetales, CNRS, UPR 5301, F-38041 Grenoble 9, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Valiron, O (corresponding author), Commiss Energie Atom Grenoble, Dept Reponse & Dynam Cellulaires Cytosquelette, INSERM, U366, 17 Rue Martyrs, F-38054 Grenoble 9, France.	ovaliron@cea.fr	Arnal, Isabelle/X-6559-2019	Arnal, Isabelle/0000-0001-6149-8189; Buhler, Eric/0000-0003-3946-1982				Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Bayley Peter M., 1994, V13, P111; Buhler E, 1998, MACROMOLECULES, V31, P7347, DOI 10.1021/ma980442j; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; Caudron N, 2000, J MOL BIOL, V297, P211, DOI 10.1006/jmbi.2000.3554; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; Cummins H Z, 1974, PHOTON CORRELATION L; DUBOCHET J, 1985, TRENDS BIOCHEM SCI, V10, P143, DOI 10.1016/0968-0004(85)90150-1; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; Fanara P, 1999, EMBO J, V18, P565, DOI 10.1093/emboj/18.3.565; FYGENSON DK, 1994, PHYS REV E, V50, P1579, DOI 10.1103/PhysRevE.50.1579; FYGENSON DK, 1995, PHYS REV E, V51, P5058, DOI 10.1103/PhysRevE.51.5058; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; Keating TJ, 2000, NAT CELL BIOL, V2, P352, DOI 10.1038/35014045; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; Leguy R, 2000, J BIOL CHEM, V275, P21975, DOI 10.1074/jbc.M000688200; MANDELKOW E, 1989, CELL MOVEMENT, V2, P23; MANDELKOW EM, 1988, EMBO J, V7, P357, DOI 10.1002/j.1460-2075.1988.tb02821.x; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; Moritz M, 2000, NAT CELL BIOL, V2, P365, DOI 10.1038/35014058; Nogales E, 1999, CELL MOL LIFE SCI, V56, P133, DOI 10.1007/s000180050012; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SIMON JR, 1990, J CELL SCI, V96, P571; Symmons MF, 1996, J CELL SCI, V109, P2755; Valiron O, 2001, CELL MOL LIFE SCI, V58, P2069, DOI 10.1007/PL00000837; VOTER WA, 1984, J BIOL CHEM, V259, P430; WADE RH, 1990, J MOL BIOL, V212, P775, DOI 10.1016/0022-2836(90)90236-F; WADE RH, 1989, BIOL CELL, V65, P37, DOI 10.1016/0248-4900(89)90007-5; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; Wiese C, 2000, NAT CELL BIOL, V2, P358, DOI 10.1038/35014051	33	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50973	50979		10.1074/jbc.M209753200	http://dx.doi.org/10.1074/jbc.M209753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393880	hybrid			2022-12-25	WOS:000180177700101
J	da Costa, CA; Paitel, E; Vincent, B; Checler, F				da Costa, CA; Paitel, E; Vincent, B; Checler, F			alpha-Synuclein lowers p53-dependent apoptotic response of neuronal cells - Abolishment by 6-hydroxydopamine and implication for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODIES; TUMOR SUPPRESSION; WILD-TYPE; AGGREGATION; EXPRESSION; MUTATION; P53; RAT; PATHOGENESIS; DEMENTIA	We have examined the influence of alpha-synuclein on the responsiveness of TSM1 neuronal cells to apoptotic stimulus. We show that alpha-synuclein drastically lowers basal and staurosporine-stimulated caspase 3 immunoreactivity and activity. This is accompanied by lower DNA fragmentation and reduced number of terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) -positive neurons. Interestingly,, alpha-synuclein also diminishes both p53 expression and transcriptional activity. We demonstrate that the antiapoptotic phenotype displayed by alpha-synuclein can be fully reversed by the Parkinson's disease-associated dopamine derivative 6-hydroxydopamine. Thus, 6-hydroxydopamine fully abolishes the alpha-synuclein-mediated reduction of caspase 3 activity and reverses the associated decrease of p53 expression. 6-Hydroxydopamine triggers thioflavin T-positive deposits in alpha-synuclein, but not mock-transfected TSM1 neurons, and drastically increases alpha-synuclein immunoreactivity. Altogether, we suggest that alpha-synuclein lowers the p53-dependent caspase 3 activation of TSM1 in response to apoptotic stimuli and we propose that the natural toxin 6-hydroxydopamine abolishes this antiapoptotic phenotype by triggering alpha-synuclein aggregation, thereby likely contributing to Parkinson's disease neuropathology.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route Lucioles, F-06560 Valbonne, France.		Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X; Vincent, Bruno/0000-0003-3876-2118				Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1998, AM J PATHOL, V152, P879; Bogdanovic N., 2001, Journal of Cellular and Molecular Medicine, V5, P318, DOI 10.1111/j.1582-4934.2001.tb00166.x; Cass WA, 2002, BRAIN RES, V938, P29, DOI 10.1016/S0006-8993(02)02481-2; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; DACOSTA CA, 2002, IN PRESS CURR MOL ME; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirsch EC, 1999, MOVEMENT DISORD, V14, P383, DOI 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F; Irwin I, 1995, ETIOLOGY PARKINSONS, P153; Jellinger K, 1995, J NEURAL TRANSM-SUPP, P297; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kim KS, 2002, FREE RADICAL BIO MED, V32, P544, DOI 10.1016/S0891-5849(02)00741-4; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRZEDBORSKI S, 1995, NEUROSCIENCE, V67, P631, DOI 10.1016/0306-4522(95)00066-R; Riobo NA, 2002, FREE RADICAL BIO MED, V32, P115, DOI 10.1016/S0891-5849(01)00758-4; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Shastry BS, 2001, NEUROSCI RES, V41, P5, DOI 10.1016/S0168-0102(01)00254-1; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600	42	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50980	50984		10.1074/jbc.M207825200	http://dx.doi.org/10.1074/jbc.M207825200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397073	hybrid			2022-12-25	WOS:000180177700102
J	Ichida, M; Nemoto, S; Finkel, T				Ichida, M; Nemoto, S; Finkel, T			Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BIOGENESIS; HEPATIC GLUCONEOGENESIS; NUCLEAR RECEPTORS; PGC-1; TRANSCRIPTION; OXIDATION	The nuclear co-activator PGC-1alpha is a pivotal regulator of numerous pathways controlling both metabolism and overall energy homeostasis. Inappropriate increases in PGC-1alpha activity have been linked to a number of pathological conditions including heart failure and diabetes mellitus. Previous studies (Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O'Malley, B., and Spiegelman, B. M. (1999) Science 286, 1368-1371) have demonstrated an inhibitory domain within PGC-1a that limits transcriptional activity. Using this inhibitory domain in a yeast two-hybrid screen, we demonstrate that PGC-1alpha directly associates with the orphan nuclear receptor estrogen-related receptor-alpha (ERR-alpha). The binding of ERR-alpha to PGC-1alpha requires the C-terminal AF2 domain of ERR-alpha. PGC-1alpha and ERR-alpha have a similar pattern of expression in human tissues, with both being present predominantly in organs with high metabolic needs such as skeletal muscle and kidney. Similarly, we show that in mice physiological stimuli such as fasting coordinately induces PGC-1alpha and ERR-alpha transcription. We also demonstrate that under normal conditions PGC-1alpha is located within discrete nuclear speckles, whereas the expression of ERR-alpha results in PGC-1alpha redistributing uniformly throughout the nucleoplasm. Finally, we show that the expression of ERR-alpha can dramatically and specifically repress PGC-1alpha transcriptional activity. These results suggest a novel mechanism of transcriptional control wherein ERR-alpha can function as a specific molecular repressor of PGC-1alpha activity. In addition, our results suggest that other co-activators might also have specific repressors, thereby identifying another layer of combinatorial complexity in transcriptional regulation.	NHLBI, Mol Biol Lab, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Mol Biol Lab, Cardiovasc Branch, NIH, Bldg 10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005012, ZIAHL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; Glass CK, 2000, GENE DEV, V14, P121; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Oberkofler H, 2002, J BIOL CHEM, V277, P16750, DOI 10.1074/jbc.M200475200; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu D, 2002, BIOCHEM BIOPH RES CO, V294, P245, DOI 10.1016/S0006-291X(02)00464-3; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	26	119	122	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50991	50995		10.1074/jbc.M210262200	http://dx.doi.org/10.1074/jbc.M210262200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12397057	hybrid			2022-12-25	WOS:000180177700104
J	Kajava, AV; Zolov, SN; Pyatkov, KI; Kalinin, AE; Nesmeyanova, MA				Kajava, AV; Zolov, SN; Pyatkov, KI; Kalinin, AE; Nesmeyanova, MA			Processing of Escherichia coli alkaline phosphatase - Sequence requirements and possible conformations of the-6 to-4 region of the signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CYTOPLASMIC MEMBRANE; SITE-DIRECTED MUTAGENESIS; GRAM-NEGATIVE BACTERIA; PROTEIN TRANSLOCATION; BETA-LACTAMASE; CRYSTAL-STRUCTURE; LIPID BILAYER; IN-VIVO; CLEAVAGE; PHOSPHOLIPIDS	Analysis of the precursors of bacterial exported proteins revealed that those having bulky hydrophobic residues at position -5 have a high incidence of Pro residues at positions -6 and -4, Val at position -3, and Ser at positions -4 and -2. This led to a hypothesis that the previously observed inhibition of processing by bulky residues at position -5 can be suppressed by introduction of Pro, Ser, or Val in the corresponding nearby positions. Subsequent mutational analysis of Escherichia coli alkaline phosphatase showed that, as it was predicted, Pro on either side of bulky hydrophobic -5 Leu, Ile, or Tyr completely restores efficiency of the maturation. Introduction of Val at position -3 also partially suppresses the inhibition imposed by -5 Leu, while a Ser residue at position -4 or -2 does not restore processing. In addition, effective maturation of a mutant with Pro residues at positions from -6 throughout -4 proved that polyproline conformation of this region is permissive for processing. To understand the effects of the mutations, we modeled a peptide substrate into the active site of the signal peptidase using the known position of the beta-lactam inhibitor. The inhibitory effect of the -5 residue and its suppression by either Pro -6 or Pro -4 can be explained if we assume that Pro-containing -6 to -4 regions adopt a polyproline conformation whereas the region without Pro residues has a beta-conformation. These results permit us to specify sequence requirements at -6, -5, and -4 positions for efficient processing and to improve the prediction of yet unknown cleavage sites.	NIH, CIT, Ctr Mol Modeling, Bethesda, MD 20892 USA; Russian Acad Sci, Skryabin Inst Biochem & Physiol Microorganisms, Lab Prot Secret Bacteria, Pushchino 142290, Moscow Region, Russia; Inst Cellular Biophys, Pushchino 142290, Russia	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); Russian Academy of Sciences; Russian Academy of Sciences; Institute of Cell Biophysics RAS	Kajava, AV (corresponding author), CNRS, UPR 1086, CRBM, 1919 Route de Mende, F-34293 Montpellier 5, France.		Zolov, Sergey/C-4017-2008; Zolov, Sergey/D-9761-2011; Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886				BACHMANN BJ, 1987, ESCHERICHIA COLI SAL; BARKOCYGALLAGHER GA, 1994, J BIOL CHEM, V269, P13609; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; KADONAGA JT, 1985, J BIOL CHEM, V260, P6192; Kajava AV, 2000, J BACTERIOL, V182, P2163, DOI 10.1128/JB.182.8.2163-2169.2000; Kalinin AE, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1021; Karamyshev A L, 1994, Mol Biol (Mosk), V28, P362; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN A, 1994, EUR J BIOCHEM, V226, P891, DOI 10.1111/j.1432-1033.1994.00891.x; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LOJDA Z, 1979, ENZYME HISTOCHEMISTR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NESMEYANOVA MA, 1989, FEBS LETT, V257, P203, DOI 10.1016/0014-5793(89)81534-0; Nesmeyanova MA, 1997, FEBS LETT, V403, P203, DOI 10.1016/S0014-5793(97)00052-5; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PALZKILL T, 1994, J BACTERIOL, V176, P563, DOI 10.1128/jb.176.3.563-568.1994; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; TORRIANI A, 1966, PROCEDURES NUCLEIC A, P224; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; VENABLE RM, 1993, SCIENCE, V262, P223, DOI 10.1126/science.8211140; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZAITSEV EN, 1986, GENETIKA+, V22, P2721; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	54	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50396	50402		10.1074/jbc.M205781200	http://dx.doi.org/10.1074/jbc.M205781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393890	hybrid			2022-12-25	WOS:000180177700025
J	Sachon, E; Bolbach, G; Chassaing, G; Lavielle, S; Sagan, S				Sachon, E; Bolbach, G; Chassaing, G; Lavielle, S; Sagan, S			C gamma H2 of Met(174) side chain is the site of covalent attachment of a substance P analog photoactivable in position 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOAFFINITY CROSS-LINKING; LIGAND-BINDING SITE; DIRECT IDENTIFICATION; NEUROKININ-1 RECEPTOR; ANGIOTENSIN-II; NK-1 RECEPTOR; ANTAGONIST; METHIONINE; AGONIST; DOMAINS	Analogs of substance P (H-RPKPQQFFGLM-NH2) incorporating a photoreactive para-benzoyl-L-phenylalanine (p-Bzl)Phe at position 4,5,6,9, or 10 of the sequence have been synthesized and pharmacologically characterized previously as full NK-1 receptor agonists. In this study we show that all analogs, [BAPA(o), (p-Bzl)Phe(x), Met(O-2)(11)]SP also display high yields (40-70%) of NK-1 receptor photolabeling. To identify the site of photoinsertion in the receptor, covalent ligand/receptor complexes were digested with enzymes or chemically cleaved with cyanogen bromide and purified with streptavidin-coated magnetic beads before matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry analysis. Only the analog photoreactive at position 5 gave irreversible, reproducible, and unequivocal covalent linkage. Sequential digestions of the covalent complex, substance P analog photoreactive at position 5/NK-1 receptor, with trypsin, endo-GluC and carboxypeptidase Y, led to the identification of the tripeptide (TMP175)-T-173 in the second extracellular loop of the hNK-1 receptor as the site of photoinsertion. Reaction of cyanogen bromide on the pentapeptide TMPSR did not yield the expected cleavage on the carboxylic side of methionine. The high precision of mass spectrometry analysis on the mass measured led us to determine that CgammaH2 of Met(174) was the site of covalent linkage of the photoreactive substance P analog. Such an insertion (photolinked ligand) on its CgammaH2 renders methionine refractory to CNBr cleavage.	Univ Paris 06, CNRS, UMR 7613, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Sagan, S (corresponding author), Univ Paris 06, CNRS, UMR 7613, Case 182,4 Pl Jussieu, F-75252 Paris 05, France.	sagan@ccr.jussieu.fr	s, s/GYR-2278-2022; QI, DANDAN/GVR-9324-2022; S, SAGAN/I-8132-2013; s, s/GVS-3323-2022; s, s/HIK-1178-2022; SAGAN, Sandrine/AAA-8537-2022; Sachon, Emmanuelle/AAR-6792-2020; s, s/HHD-0404-2022	S, SAGAN/0000-0003-0083-4411; sachon, emmanuelle/0000-0002-2271-8924				Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; Breton C, 2001, J BIOL CHEM, V276, P26931, DOI 10.1074/jbc.M102073200; CHASSAING G, 1985, TETRAHEDRON LETT, V26, P623, DOI 10.1016/S0040-4039(00)89163-7; CHASSAING G, 1986, EUR J BIOCHEM, V154, P77, DOI 10.1111/j.1432-1033.1986.tb09361.x; Deseke E, 1998, EUR J ORG CHEM, V1998, P243, DOI 10.1002/(SICI)1099-0690(199802)1998:2<243::AID-EJOC243>3.0.CO;2-I; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dorman G, 2000, TRENDS BIOTECHNOL, V18, P64, DOI 10.1016/S0167-7799(99)01402-X; Egnaczyk GF, 2001, BIOCHEMISTRY-US, V40, P11706, DOI 10.1021/bi002852h; FONG TM, 1995, CAN J PHYSIOL PHARM, V73, P860, DOI 10.1139/y95-118; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; Girault S, 1996, ANAL CHEM, V68, P2122, DOI 10.1021/ac960043r; Gros E., 1967, METHOD ENZYMOL, V11, P238; Hayashi R, 1977, Methods Enzymol, V47, P84; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JONES MD, 1994, ANAL BIOCHEM, V216, P135, DOI 10.1006/abio.1994.1017; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KEILDLOUHA V, 1971, FEBS LETT, V16, P287, DOI 10.1016/0014-5793(71)80372-1; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578; Lequin O, 2002, J BIOL CHEM, V277, P22386, DOI 10.1074/jbc.M110614200; Li HZ, 2001, J BIOL CHEM, V276, P10589, DOI 10.1074/jbc.M007397200; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Macdonald D, 2001, BIOCHEMISTRY-US, V40, P2530, DOI 10.1021/bi001880x; Mills JS, 1998, J BIOL CHEM, V273, P10428, DOI 10.1074/jbc.273.17.10428; Mouledous L, 2000, J BIOL CHEM, V275, P29268, DOI 10.1074/jbc.M004971200; Quartara L, 1997, NEUROPEPTIDES, V31, P537, DOI 10.1016/S0143-4179(97)90001-9; Sachon E, 2002, TETRAHEDRON LETT, V43, P7485, DOI 10.1016/S0040-4039(02)01801-4; Sachon E, 2002, J PEPT RES, V59, P232, DOI 10.1034/j.1399-3011.2002.01977.x; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; STONE PG, 1981, J PHYS CHEM-US, V85, P1719, DOI 10.1021/j150612a026; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; Zoffmann S, 2002, MOL PHARMACOL, V62, P729, DOI 10.1124/mol.62.3.729	34	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50409	50414		10.1074/jbc.M207242200	http://dx.doi.org/10.1074/jbc.M207242200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393913	hybrid			2022-12-25	WOS:000180177700027
J	Somwar, R; Koterski, S; Sweeney, G; Sciotti, R; Djuric, S; Berg, C; Trevillyan, J; Scherer, PE; Rondinone, CM; Klip, A				Somwar, R; Koterski, S; Sweeney, G; Sciotti, R; Djuric, S; Berg, C; Trevillyan, J; Scherer, PE; Rondinone, CM; Klip, A			A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT SKELETAL-MUSCLE; ADIPOSE-CELLS; MAMMALIAN-CELLS; TRANSPORTER TRANSLOCATION; SIGNAL-TRANSDUCTION; POTENTIAL ROLE; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC ACTIVITY; PLASMA-MEMBRANES	Participation of p38 mitogen-activated protein kinase (p38) in insulin-induced glucose uptake was suggested using pyridinylimidazole p38 inhibitors (e.g. SB203580). However, the role of p38 in insulin action remains controversial. We further test p38 participation in glucose uptake using a dominant-negative p38 mutant and two novel pharmacological p38 inhibitors related to but different from SB203580. We present the structures and activities of the azaazulene pharmacophores A291077 and A304000. p38 kinase activity was inhibited in vitro by A291077 and A304000 (IC50 = 0.6 and 4.7 muM). At higher concentrations A291017 but not A304000 inhibited JNK2alpha (IC50 = 3.5 muM). Pretreatment of 3T3-L1 adipocytes and L6 myotubes expressing GLUT4myc (L6-GLUT4myc myotubes) with A291077, A304000, SB202190, or SB203580 reduced insulin-stimulated glucose uptake by 50-60%, whereas chemical analogues inert toward p38 were ineffective. Expression of an inducible, dominant-negative p38 mutant in 3T3-L1 adipocytes reduced insulin-stimulated glucose uptake. GLUT4 translocation to the cell surface, immunodetected on plasma membrane lawns of 3T3-L1 adipocytes or on intact L6-GLUT4myc myotubes, was not altered by chemical or molecular inhibition of p38. We propose that p38 contributes to enhancing GLUT4 activity, thereby increasing glucose uptake. In addition, the azaazulene class of inhibitors described will be useful to decipher cellular actions of p38 and JNK.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Abbott Labs, Div Pharmaceut Prod, Diabet Res, Abbott Pk, IL 60064 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Abbott Laboratories; Yeshiva University; Albert Einstein College of Medicine	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Sciotti, Richard/A-9069-2011; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Sciotti, Richard/0000-0002-3069-3122	NIDDK NIH HHS [1R01-DK55758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; BARROS LF, 1995, BIOCHEM J, V309, P731, DOI 10.1042/bj3090731; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; BROZINICK JTJ, 1994, AM J PHYSIOL, V367, pR236; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEEMS RO, 1994, DIABETOLOGIA, V37, P1097, DOI 10.1007/s001250050222; DEEMS RO, 1994, BIOCHEM BIOPH RES CO, V199, P662, DOI 10.1006/bbrc.1994.1279; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Ferrara CM, 1999, BIOCHEM J, V343, P571, DOI 10.1042/0264-6021:3430571; Fladeby C, 1999, BBA-MOL CELL RES, V1452, P313, DOI 10.1016/S0167-4889(99)00145-7; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Igarashi M, 2000, EUR J CLIN INVEST, V30, P668; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; KAHN BB, 1987, J BIOL CHEM, V262, P5118; KANAI F, 1993, J BIOL CHEM, V268, P14523; KARNIELI E, 1989, AM J PHYSIOL, V256, pE179, DOI 10.1152/ajpendo.1989.256.1.E179; KARNIELI E, 1993, ENDOCRINOLOGY, V133, P2943, DOI 10.1210/en.133.6.2943; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KLIP A, 1988, BIOCHEM J, V255, P1023, DOI 10.1042/bj2551023; Konrad D, 2002, DIABETES, V51, P2719, DOI 10.2337/diabetes.51.9.2719; Konrad D, 2001, DIABETES, V50, P1464, DOI 10.2337/diabetes.50.6.1464; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Malide D, 2000, J CELL SCI, V113, P4203; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; Niu WY, 2002, DIABETES, V51, pA310; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; SCIOTTI R, 2001, WORLD INTELLECTUAL P; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	81	99	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50386	50395		10.1074/jbc.M205277200	http://dx.doi.org/10.1074/jbc.M205277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12393894	hybrid			2022-12-25	WOS:000180177700024
J	Ma, YC; Greener, T; Pacold, ME; Kaushal, S; Greene, LE; Eisenberg, E				Ma, YC; Greener, T; Pacold, ME; Kaushal, S; Greene, LE; Eisenberg, E			Identification of domain required for catalytic activity of auxilin in supporting clathrin uncoating by Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; MOLECULAR CHAPERONE; MEDIATED ENDOCYTOSIS; ASSEMBLY PROTEIN; DNAJ HOMOLOGS; IN-VIVO; HSP70; DISSOCIATION; ATPASE; BINDING	During clathrin-mediated endocytosis Hsc70, supported by the J-domain protein auxilin, uncoats clathrin-coated vesicles. Auxilin contains both a clathrin-binding domain and a J-domain that binds Hsc70, and it has been suggested that these two domains are both necessary and sufficient for auxilin activity. To test this hypothesis, we created a chimeric protein consisting of the J-domain of auxilin linked to the clathrin-binding domain of the assembly protein AP180. This chimera supported uncoating, but unlike auxilin it acted stoichiometrically rather than catalytically because, like Hsc70, it remained associated with the uncoated clathrin. This observation supports our proposal that Hsc70 chaperones uncoated clathrin by inducing formation of a stable Hsc70-clathrin-AP complex. It also shows that Hsc70 acts by dissociating individual clathrin triskelions rather than cooperatively destabilizing clathrin-coated vesicles. Because the chimera lacks the C-terminal subdomain of the auxilin clathrin-binding domain, it seemed possible that this subdomain is required for auxilin to act catalytically, and indeed its deletion caused auxilin to act stoichiometrically. In contrast, deletion of the N-terminal subdomain weakened auxilinclathrin binding and prevented auxilin from polymerizing clathrin. Therefore the C-terminal subdomain of the clathrin-binding domain of auxilin is required for auxilin to act catalytically, whereas the N-terminal subdomain strengthens auxilin-clathrin binding.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Eisenberg, E (corresponding author), NHLBI, Cell Biol Lab, NIH, 50 South Dr,Rm 2537,MSC 8017, Bethesda, MD 20892 USA.							AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Gall WE, 2000, CURR BIOL, V10, P1349, DOI 10.1016/S0960-9822(00)00771-5; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Greener T, 2001, NAT CELL BIOL, V3, P215, DOI 10.1038/35055137; Haynie DT, 1996, PROTEIN SCI, V5, P2643, DOI 10.1002/pro.5560051227; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; Lemmon SK, 2001, CURR BIOL, V11, pR49, DOI 10.1016/S0960-9822(01)00010-0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pishvaee B, 2000, NAT CELL BIOL, V2, P958, DOI 10.1038/35046619; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Rajapandi T, 1998, BIOCHEMISTRY-US, V37, P7244, DOI 10.1021/bi972252r; Scheele U, 2001, J BIOL CHEM, V276, P36131, DOI 10.1074/jbc.M106511200; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Umeda A, 2000, EUR J CELL BIOL, V79, P336, DOI 10.1078/S0171-9335(04)70037-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	30	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49267	49274		10.1074/jbc.M203695200	http://dx.doi.org/10.1074/jbc.M203695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12377777	hybrid			2022-12-25	WOS:000180028900021
J	Sahara, T; Goda, T; Ohgiya, S				Sahara, T; Goda, T; Ohgiya, S			Comprehensive expression analysis of time-dependent genetic responses in yeast cells to low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; FATTY-ACID DESATURASE; COLD-SHOCK RESPONSE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ENVIRONMENTAL-CHANGES; MULTIDRUG-RESISTANCE; TREHALOSE SYNTHESIS; NSR1 PROTEIN; IN-VITRO	We performed genome-wide expression analysis to determine genetic responses in Saccharomyces cerevisiae to a low temperature environment using a cDNA microarray. Approximately 25% of the genes in the yeast genome were found to be involved in the response of yeast to low temperature. This finding of a large number of genes being involved in the response to low temperature enabled us to give a functional interpretation to the genetic responses to the stimulus. Functional and clustering analyses of temporal changes in gene expression revealed that global states of the expressions of up-regulated genes could be characterized as having three phases (the early, middle, and late phases). In each phase, genes related to rRNA synthesis, ribosomal proteins, or several stress responses are time-dependently up-regulated, respectively. Through these phases, yeast cells may improve reduced efficiency of translation and enhance cell protection mechanisms to survive under a low temperature condition. Furthermore, these time-dependent regulations of these genes would be controlled by the cAMP-protein kinase A pathway. The results of our study provide a global description of transcriptional response for adaptation to low temperature in yeast cells.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funt, Toyohira Ku, Sapporo, Hokkaido 0628517, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Ohgiya, S (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funt, Toyohira Ku, 2-17-2-1 Tsukisamu Higashi, Sapporo, Hokkaido 0628517, Japan.		Ohgiya, Satoru/V-3117-2018; Sahara, Takehiko/M-3309-2018	Ohgiya, Satoru/0000-0001-8257-8284; Sahara, Takehiko/0000-0002-8061-3856				Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; AIBA H, 1981, J BIOL CHEM, V256, P1905; Benaroudj N, 2001, J BIOL CHEM, V276, P24261, DOI 10.1074/jbc.M101487200; Browse J, 2001, CURR OPIN PLANT BIOL, V4, P241, DOI 10.1016/S1369-5266(00)00167-9; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Diniz-Mendes L, 1999, BIOTECHNOL BIOENG, V65, P572, DOI [10.1002/(SICI)1097-0290(19991205)65:5<572::AID-BIT10>3.0.CO;2-7, 10.1002/(SICI)1097-0290(19991205)65:5&lt;572::AID-BIT10&gt;3.0.CO;2-7]; Donzeau M, 1996, MOL MICROBIOL, V20, P449, DOI 10.1111/j.1365-2958.1996.tb02631.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holden CP, 1996, AM J PHYSIOL-REG I, V271, pR1205, DOI 10.1152/ajpregu.1996.271.5.R1205; Holden CP, 1998, ARCH BIOCHEM BIOPHYS, V358, P243, DOI 10.1006/abbi.1998.0810; Holden CP, 2000, CRYOBIOLOGY, V40, P323, DOI 10.1006/cryo.2000.2252; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; HOTTIGER T, 1994, EUR J BIOCHEM, V219, P187, DOI 10.1111/j.1432-1033.1994.tb19929.x; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Jiang WN, 1997, J BIOL CHEM, V272, P196; Jones PG, 1996, MOL MICROBIOL, V21, P1207, DOI 10.1111/j.1365-2958.1996.tb02582.x; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1991, J BIOL CHEM, V266, P17537; KONDO K, 1992, J BIOL CHEM, V267, P16252; KOPP M, 1993, J BIOL CHEM, V268, P4766; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Laoteng K, 1999, Mol Cell Biol Res Commun, V1, P36, DOI 10.1006/mcbr.1999.0107; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Lengeler KB, 2000, MICROBIOL MOL BIOL R, V64, P746, DOI 10.1128/MMBR.64.4.746-785.2000; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lorenz MC, 1998, GENETICS, V150, P1443; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; Nakagawa Y, 2002, BIOCHEM BIOPH RES CO, V291, P707, DOI 10.1006/bbrc.2002.6507; Nakagawa Y, 2001, J BACTERIOL, V183, P745, DOI 10.1128/JB.183.2.745-751.2001; Nakashima S, 1996, BIOCHEM J, V317, P29, DOI 10.1042/bj3170029; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; NWAKA S, 1995, J BIOL CHEM, V270, P10193, DOI 10.1074/jbc.270.17.10193; Panoff JM, 1998, CRYOBIOLOGY, V36, P75, DOI 10.1006/cryo.1997.2069; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Pfister TD, 2002, INSECT BIOCHEM MOLEC, V32, P505, DOI 10.1016/S0965-1748(01)00128-X; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Piper P, 1998, TRENDS MICROBIOL, V6, P43, DOI 10.1016/S0966-842X(97)01190-6; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; RIBEIRO MJS, 1994, BBA-GEN SUBJECTS, V1200, P139, DOI 10.1016/0304-4165(94)90128-7; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sakamoto T, 1997, MOL MICROBIOL, V23, P1281, DOI 10.1046/j.1365-2958.1997.3071676.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thieringer HA, 1998, BIOESSAYS, V20, P49; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Tiku PE, 1996, SCIENCE, V271, P815, DOI 10.1126/science.271.5250.815; VANDIJCK P, 1995, APPL ENVIRON MICROB, V61, P109, DOI 10.1128/AEM.61.1.109-115.1995; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Zhang SR, 1999, GENETICS, V151, P473	69	127	134	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50015	50021		10.1074/jbc.M209258200	http://dx.doi.org/10.1074/jbc.M209258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12379644	hybrid			2022-12-25	WOS:000180028900119
J	Saint-Georges, Y; Bonnefoy, N; di Rago, JP; Chiron, S; Dujardin, G				Saint-Georges, Y; Bonnefoy, N; di Rago, JP; Chiron, S; Dujardin, G			A pathogenic cytochrome b mutation reveals new interactions between subunits of the mitochondrial bc1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; CATALYTIC CENTER-N; SACCHAROMYCES-CEREVISIAE; BC(1) COMPLEX; C OXIDOREDUCTASE; MISSENSE MUTATION; HISTIOCYTOID CARDIOMYOPATHY; EXERCISE INTOLERANCE; HEART-MITOCHONDRIA; DEFICIENT MUTANTS	Energy transduction in mitochondria involves five oligomeric complexes embedded within the inner membrane. They are composed of catalytic and noncatalytic subunits, the role of these latter proteins often being difficult to assign. One of these complexes, the bc1 complex, is composed of three catalytic subunits including cytochrome b and seven or eight noncatalytic subunits. Recently, several mutations in the human cytochrome b gene have been linked to various diseases. We have studied in detail the effects of a cardiomyopathy generating mutation G252D in yeast. This mutation disturbs the biogenesis of the bc1 complex at 36 degreesC and decreases the steady-state level of the noncatalytic subunit Qcr9p. In addition, the G252D mutation and the deletion of QCR9 show synergetic defects that can be partially bypassed by suppressor mutations at position 252 and by a new cytochrome b mutation, P174T. Altogether, our results suggest that the supernumerary subunit Qcr9p enhances or stabilizes the interactions between the catalytic subunits, this role being essential at high temperature.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Dujardin, G (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91198 Gif Sur Yvette, France.	dujardin@cgm.cnrs-gif.fr	Bonnefoy, Nathalie/GYD-2949-2022; Saint-Georges-Chaumet, Yann/AAL-1204-2021	Saint-Georges-Chaumet, Yann/0000-0002-1123-254X; Bonnefoy, Nathalie/0000-0002-5068-8849				Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008; Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444; Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; BRASSEUR G, 1995, J BIOL CHEM, V270, P29356, DOI 10.1074/jbc.270.49.29356; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COPPEE JY, 1994, J BIOL CHEM, V269, P4221; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; Hamel P, 1998, GENETICS, V150, P601; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Lamantea E, 2002, NEUROMUSCULAR DISORD, V12, P49, DOI 10.1016/S0960-8966(01)00244-9; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; MULERO JJ, 1994, MOL GEN GENET, V242, P383, DOI 10.1007/BF00281787; PAPADIMITRIOU A, 1984, PEDIATR RES, V18, P1023, DOI 10.1203/00006450-198418100-00023; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; Saint-Georges Y, 2001, P NATL ACAD SCI USA, V98, P13814, DOI 10.1073/pnas.251503098; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzagoloff A, 1995, METHOD ENZYMOL, V260, P51, DOI 10.1016/0076-6879(95)60129-5; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG MJ, 1994, J BIOL CHEM, V269, P1270; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	39	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49397	49402		10.1074/jbc.M207219200	http://dx.doi.org/10.1074/jbc.M207219200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12384503	hybrid			2022-12-25	WOS:000180028900038
J	Strauss, E; Begley, TP				Strauss, E; Begley, TP			The antibiotic activity of N-pentylpantothenamide results from its conversion to ethyldethia-coenzyme A, a coenzyme A antimetabolite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; SYNTHETASE; ENZYME; GENE	Pantothenic acid (vitamin B-5) is the natural precursor of coenzyme A (CoA), an essential cofactor in all organisms. The pantothenic acid antimetabolite N-pentylpantothenamide inhibits the growth of Escherichia coli with a minimum inhibitory concentration of 2 muM. In this study, we examine the mechanism of this inhibition. Using the last five enzymes of the CoA biosynthetic pathway in E. coli we demonstrate that N-pentylpantothenamide does not inhibit the CoA biosynthetic enzymes but instead acts as an alternative substrate, forming the CoA analog ethyldethia-CoA. We show that N-pentylpantothenamide is converted to ethyldethia-CoA 10.5 times faster than CoA is biosynthesized from pantothenic acid, demonstrating that ethyldethia-CoA biosynthesis can effectively compete with CoA biosynthesis in the cell. We conclude that the mechanism of toxicity of N-pentylpantothenamide is most likely due to its biosynthetic conversion to the CoA analog ethyldethia-CoA, which may act as an inhibitor of CoA- and acetyl-CoA-utilizing enzymes.	Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14853 USA	Cornell University	Begley, TP (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Baker Lab, 120 Baker Lab, Ithaca, NY 14853 USA.		Strauss, Erick/G-1783-2010; Begley, Tadhg/B-5801-2015; Zhang, Ning/F-1387-2014	Strauss, Erick/0000-0002-9898-8226; 				CHASE JFA, 1966, BIOCHEM BIOPH RES CO, V23, P208, DOI 10.1016/0006-291X(66)90529-8; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Mishra PK, 2000, CHEM REV, V100, P3283, DOI 10.1021/cr990010m; MOFFATT JG, 1961, J AM CHEM SOC, V83, P663, DOI 10.1021/ja01464a036; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; Reddick JJ, 2001, BIOORG MED CHEM LETT, V11, P2245, DOI 10.1016/S0960-894X(01)00373-0; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1985, J BACTERIOL, V164, P136, DOI 10.1128/JB.164.1.136-142.1985	15	96	100	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48205	48209		10.1074/jbc.M204560200	http://dx.doi.org/10.1074/jbc.M204560200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372838	hybrid			2022-12-25	WOS:000179789600032
J	Godl, K; Johansson, MEV; Lidell, ME; Morgelin, M; Karlsson, H; Olson, FJ; Gum, JR; Kim, YS; Hansson, GC				Godl, K; Johansson, MEV; Lidell, ME; Morgelin, M; Karlsson, H; Olson, FJ; Gum, JR; Kim, YS; Hansson, GC			The N terminus of the MUC2 mucin forms trimers that are held together within a trypsin-resistant core fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; RAT SMALL-INTESTINE; VON-WILLEBRAND-FACTOR; ELECTRON-MICROSCOPY; INSOLUBLE MUCIN; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; D-DOMAINS; IDENTIFICATION; COMPLEX	The N terminus of the human MUC2 mucin (amino acids 1-1397) has been expressed as a recombinant tagged protein in Chinese hamster ovary cells. The intracellular form was found to be an endoglycosidase H-sensitive monomer, whereas the secreted form was an oligomer that gave monomers upon disulfide bond reduction. The secreted MUC2 N terminus contained a trypsin-resistant core fragment. Edman sequencing and mass spectrometry of the peptides obtained localized this core fragment to the C-terminal end of the recombinant protein. This core retained its oligomeric nature with an apparent mass of similar to240 kDa. Upon reduction, peptides of similar to85 kDa were found, suggesting that the N terminus forms trimers. This interpretation was also supported by gel electrophoresis and gel filtration of the intact MUC2 N terminus. Electron microscopy revealed three globular domains each linked via an extended and flexible region to a central part in a trefoil-like manner. Immunostaining with gold-labeled antibodies localized the N-terminal end to the three globular structures, and the antibodies directed against the Myc and green fluorescent protein tags attached at the C terminus localized these to the stalk side of the central trefoil. The N terminus of the MUC2 mucin is thus assembled into trimers that contain proteolytically stable parts, suggesting that MUC2 can only be partly degraded by intestinal proteases and thus is able to maintain a mucin network protecting the intestine.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden; Lund Univ, S-22184 Lund, Sweden; Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA	University of Gothenburg; Lund University; University of California System; University of California San Francisco	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Medicinaregatan 9A, S-41390 Gothenburg, Sweden.		Hansson, Gunnar C/A-1236-2009; Johansson, Malin E. V./HCH-7451-2022; Hansson, Gunnar C./AAF-7324-2019	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				Asker N, 1998, BIOCHEM J, V335, P381, DOI 10.1042/bj3350381; Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; Bell SL, 1998, EUR J BIOCHEM, V253, P123, DOI 10.1046/j.1432-1327.1998.2530123.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Forstner Janet F., 1994, P1255; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1994, J BIOL CHEM, V269, P2440; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147; Sheehan JK, 2000, METH MOL B, V125, P87; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	26	149	152	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47248	47256		10.1074/jbc.M208483200	http://dx.doi.org/10.1074/jbc.M208483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12374796	hybrid			2022-12-25	WOS:000179663700053
J	Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M				Coquelle, A; Rozier, L; Dutrillaux, B; Debatisse, M			Induction of multiple double-strand breaks within an hsr by meganuclease I-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements	ONCOGENE			English	Article						I-SceI meganuclease; mammalian gene amplification; double-strand break repair; fragile sites; hypoxia; chromosomal rearrangements	DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; TUMOR PROGRESSION; TRANSIENT HYPOXIA; SOLID TUMORS; CAD GENES; AMPLIFICATION; CANCER; TRANSLOCATIONS; INSTABILITY	Gene amplification is frequently associated with tumor progression, hence, understanding the underlying mechanisms is important. The study of in vitro model systems indicated that different initial mechanisms accumulate amplified copies within the chromosomes (hsr) or on extra-chromosomal elements (dmin). It has long been suggested that formation of dmin could also occur following hsr breakdown. In order to check this hypothesis, we developed an approach based on the properties of the I-SceI meganuclease, which induces targeted DNA double-strand breaks. A clone containing an I-SceI site, integrated by chance close to an endogenous dhfr gene locus, was used to select for methotrexate resistant mutants. We recovered clones in which the I-SceI site was passively co-amplified with the dhfr gene within the same hsr. We show that I-SceI-induced hsr breakdown leads to the formation of dmin and creates different types of chromosomal rearrangements, including inversions. This demonstrates, for the first time, a direct relationship between double-strand breaks and inversions. Finally, we show that activation of fragile sites by aphidicolin or hypoxia in hsr-containing cells also generates dmin and a variety of chromosomal rearrangements. This may constitute a valuable model to study the consequences of breaks induced in hsr of cancer cells in vivo.	Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Debatisse, M (corresponding author), Inst Curie, CNRS, UMR 147, Unit Cytogenet Mol & Oncol, 26 Rue Ulm, F-75248 Paris 05, France.		Coquelle, Arnaud/AAE-5425-2020					BALABANMALENBAU.G, 1981, CANCER GENET CYTOGEN, V2, P339; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brizel DM, 1996, CANCER RES, V56, P941; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; LEBEAU MM, 1986, BLOOD, V67, P849; LUK CK, 1990, J NATL CANCER I, V82, P684, DOI 10.1093/jnci/82.8.684; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; Nowell P, 1998, NAT MED, V4, P1107, DOI 10.1038/2598; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Smith DI, 1998, INT J ONCOL, V12, P187; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	39	49	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7671	7679		10.1038/sj.onc.1205880	http://dx.doi.org/10.1038/sj.onc.1205880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400009				2022-12-25	WOS:000178756200006
J	Behfar, A; Zingman, LV; Hodgson, DM; Rauzier, JM; Kane, GC; Terzic, A; Puceat, M				Behfar, A; Zingman, LV; Hodgson, DM; Rauzier, JM; Kane, GC; Terzic, A; Puceat, M			Stem cell differentiation requires a paracrine pathway in the heart	FASEB JOURNAL			English	Article						TGF-beta; ischemic heart disease; cardiomyocytes; cardioblasts	GROWTH-FACTOR-BETA; NEONATAL CARDIAC MYOCYTES; IN-VITRO; MYOCARDIAL-INFARCTION; TGF-BETA; CARDIOMYOCYTES; PROTEIN; RAT; EXPRESSION; FAILURE	Members of the transforming growth factor beta1 (TGF-beta) superfamily-namely, TGF-beta and BMP2-applied to undifferentiated murine embryonic stem cells up-regulated mRNA of mesodermal (Brachyury) and cardiac specific transcription factors (Nkx2.5, MEF2C). Embryoid bodies generated from stem cells primed with these growth factors demonstrated an increased potential for cardiac differentiation with a significant increase in beating areas and enhanced myofibrillogenesis. In an environment of postmitotic cardiomyocytes, stem cells engineered to express a fluorescent protein under the control of a cardiac promoter differentiated into fluorescent ventricular myocytes beating in synchrony with host cells, a process significantly enhanced by TGF-beta or BMP2. In vitro, disruption of the TGF-beta/BMP signaling pathways by latency-associated peptide and/or noggin prevented differentiation of stem cells. In fact, only host cells that secrete a TGF-beta family member induced a cardiac phenotype in stem cells. In vivo, transplantation of stem cells into heart also resulted in cardiac differentiation provided that TGF-beta/BMP2 signaling was intact. In infarcted myocardium, grafted stem cells differentiated into functional cardiomyocytes integrated with surrounding tissue, improving contractile performance. Thus, embryonic stem cells are directed to differentiate into cardiomyocytes by signaling mediated through TGF-beta/BMP2, a cardiac paracrine pathway required for therapeutic benefit of stem cell transplantation in diseased heart.	CRBM, CNRS, UPR 1086, F-34293 Montpellier, France; INSERM, U390, Lab Physiopathol Cardiovasc, Montpellier, France; Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Mayo Clinic; Mayo Clinic	Puceat, M (corresponding author), CRBM, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier, France.	puceat@crbm.cnrs-mop.fr	Zingman, Leonid V/GXG-0136-2022; PUCEAT, michel/R-6140-2017	Zingman, Leonid V/0000-0002-7566-4616; Behfar, Atta/0000-0003-3775-5784; PUCEAT, michel/0000-0001-9055-7563	NHLBI NIH HHS [HL-07111, HL-64822] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; AKHURST RJ, 1990, DEVELOPMENT, V108, P645; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BRAND T, 1993, J BIOL CHEM, V268, P11500; Braunwald E, 2000, CIRCULATION, V102, P14; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARROW BJ, 1995, CIRC RES, V76, P381, DOI 10.1161/01.RES.76.3.381; FLANDERS KC, 1995, J MOL CELL CARDIOL, V27, P805, DOI 10.1016/0022-2828(95)90087-X; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; FRANDRICH F, 2002, NAT MED, V8, P171; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Hao JM, 2000, AM J PHYSIOL-HEART C, V279, pH3020, DOI 10.1152/ajpheart.2000.279.6.H3020; Hao JM, 1999, J MOL CELL CARDIOL, V31, P667, DOI 10.1006/jmcc.1998.0902; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Izumi M, 2001, J BIOL CHEM, V276, P31133, DOI 10.1074/jbc.M101463200; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kessler PD, 1999, ANNU REV PHYSIOL, V61, P219, DOI 10.1146/annurev.physiol.61.1.219; KLUG MG, 1996, J CLIN INVEST, V98, P216; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Leor J, 1996, CIRCULATION, V94, P332; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291; Olson EN, 2001, SCIENCE, V291, P2327, DOI 10.1126/science.1060063; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Oyamada Y, 1996, EXP CELL RES, V229, P318, DOI 10.1006/excr.1996.0377; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; Roell W, 2002, CIRCULATION, V105, P2435, DOI 10.1161/01.CIR.0000016063.66513.BB; Ruwhof C, 2000, MOL CELL BIOCHEM, V208, P89, DOI 10.1023/A:1007046105745; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Scorsin M, 1996, CIRCULATION, V94, P337; Scorsin M, 2000, J THORAC CARDIOV SUR, V119, P1169, DOI 10.1067/mtc.2000.104865; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strom TB, 2001, TRANSPL P, V33, P3044, DOI 10.1016/S0041-1345(01)02303-X; SUN JZ, 1993, J MOL CELL CARDIOL, V25, P379, DOI 10.1006/jmcc.1993.1044; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	51	368	414	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1558	1566		10.1096/fj.02-0072com	http://dx.doi.org/10.1096/fj.02-0072com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374778				2022-12-25	WOS:000179167600037
J	Thore, S; Mayer, C; Sauter, C; Weeks, S; Suck, D				Thore, S; Mayer, C; Sauter, C; Weeks, S; Suck, D			Crystal structures of the Pyrococcus abyssi Sm core and its complex with RNA - Common features of RNA binding in Archaea and Eukarya	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; PROTEINS ASSEMBLE; DIFFRACTION DATA; U1 SNRNA; SITE; HFQ; HOMOLOG; U6; IDENTIFICATION; ASSOCIATION	The Sm proteins are conserved in all three domains of life and are always associated with U-rich RNA sequences. Their proposed function is to mediate RNA-RNA interactions. We present here the crystal structures of Pyrococcus abyssi Sm protein (PA-Sm1) and its complex with a uridine heptamer. The overall structure of the protein complex, a heptameric ring with a central cavity, is similar to that proposed for the eukaryotic Sm core complex and found for other archaeal Sm proteins. RNA molecules bind to the protein at two different sites. They interact specifically inside the ring with three highly conserved residues, defining the uridine-binding pocket. In addition, nucleotides also interact on the surface formed by the N-terminal alpha-helix as well as a conserved aromatic residue in beta-strand 2 of the PA-Sm1 protein. The mutation of this conserved aromatic residue shows the importance of this second site for the discrimination between RNA sequences. Given the high structural homology between archaeal and eukaryotic Sm proteins, the PA-Sm1-RNA complex provides a model for how the small nuclear RNA contacts the Sm proteins in the Sm core. In addition, it suggests how Sm proteins might exert their function as modulators of RNA-RNA interactions.	European Mol Biol Lab, Struct Biol Program, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Suck, D (corresponding author), European Mol Biol Lab, Struct Biol Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.	suck@embl-heidelberg.de	Weeks, Stephen/N-4813-2019; Weeks, Stephen D/G-6150-2017; Thore, Stephane/AAW-6482-2020; Thore, stéphane/M-7759-2014	Weeks, Stephen/0000-0002-1360-0852; Weeks, Stephen D/0000-0002-1360-0852; Thore, Stephane/0000-0001-7058-3887; Thore, stéphane/0000-0001-7058-3887				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; Bordonne R, 1996, GENE, V176, P111, DOI 10.1016/0378-1119(96)00230-2; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; GILMARTIN GM, 1988, MOL CELL BIOL, V8, P1076, DOI 10.1128/MCB.8.3.1076; Hajnsdorf E, 2000, P NATL ACAD SCI USA, V97, P1501, DOI 10.1073/pnas.040549897; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hartmuth K, 1999, J MOL BIOL, V285, P133, DOI 10.1006/jmbi.1998.2300; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; HEINRICHS V, 1992, J MOL BIOL, V227, P15, DOI 10.1016/0022-2836(92)90678-D; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; Kuhn JF, 2002, NUCLEIC ACIDS RES, V30, P931, DOI 10.1093/nar/30.4.931; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAGRUM LJ, 1978, J MOL EVOL, V11, P1, DOI 10.1007/BF01768019; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mattaj IW, 1998, CURR BIOL, V8, pR93, DOI 10.1016/S0960-9822(98)70055-7; Mayer C, 2001, TRENDS BIOCHEM SCI, V26, P143, DOI 10.1016/S0968-0004(00)01779-5; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADGETT RA, 1983, CELL, V35, P101, DOI 10.1016/0092-8674(83)90212-X; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; STRUB K, 1986, EMBO J, V5, P1675, DOI 10.1002/j.1460-2075.1986.tb04411.x; Toro I, 2002, J MOL BIOL, V320, P129, DOI 10.1016/S0022-2836(02)00406-0; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wassarman KM, 2001, GENE DEV, V15, P1637, DOI 10.1101/gad.901001; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; Zhang D, 2001, MOL CELL, V7, P319, DOI 10.1016/S1097-2765(01)00180-0	55	83	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1239	1247		10.1074/jbc.M207685200	http://dx.doi.org/10.1074/jbc.M207685200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12409299	hybrid			2022-12-25	WOS:000180321900071
J	Chandra, D; Liu, JW; Tang, DG				Chandra, D; Liu, JW; Tang, DG			Early mitochondrial activation and cytochrome c up-regulation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; SERINE-PROTEASE; CELL-DEATH; BCL-2 FAMILY; RELEASE; BAX; IDENTIFICATION; INDUCTION; PRECURSOR; REQUIRES	Apoptosis induced by many stimuli requires the mitochondrial respiratory chain (MRC) function. While studying the molecular mechanisms underlying this AIRC-dependent apoptotic pathway, we find that apoptosis in multiple cell types induced by a variety of stimuli is preceded by an early induction of MRC proteins such as cytochrome c (which is encoded by a nuclear gene) and cytochrome c oxidase subunit II (COX II) (which is encoded by the mitochondrial genome). Several non-MRC proteins localized in the mitochondria, e.g. Smac, Bim, Bak, and Bcl-2, are also rapidly up-regulated. The up-regulation of many of these proteins (e.g. cytochrome c, COX II, and Bim) results from transcriptional activation of the respective genes. The up-regulated cytosolic cytochrome c rapidly translocates to the mitochondria, resulting in an accumulation of holocytochrome c in the mitochondria accompanied by increasing holocytochrome c release into the cytosol. The increased cytochrome c transport from cytosol to the mitochondria does not depend on the mitochondrial protein synthesis or MRC per se. In contrast, cytochrome c release from the mitochondria involves dynamic changes in Bcl-2 family proteins (e.g. up-regulation of Bak, Bcl-2, and Bcl-x(L)), opening of permeability transition pore, and loss of mitochondrial membrane potential. Overexpression of cytochrome c enhances caspase activation and promotes cell death in response to apoptotic stimulation, but simple up-regulation of cytochrome c using an ecdysone-inducible system is, by itself, insufficient to induce apoptosis. Taken together, these results suggest that apoptosis induced by many stimuli involves an early mitochondrial activation, which may be responsible for the subsequent disruption of MRC functions, loss of Deltapsi(m), cytochrome c release, and ultimately cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [CA90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banki K, 1999, J IMMUNOL, V162, P1466; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Degterev A, 2001, J CELL BIOL, V155, P695, DOI 10.1083/jcb.200110147; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Eguchi Y, 1997, CANCER RES, V57, P1835; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hail N, 2001, CANCER RES, V61, P6698; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Jemmerson R, 2002, CELL DEATH DIFFER, V9, P538, DOI 10.1038/sj.cdd.4400981; Joshi B, 1999, CANCER RES, V59, P4343; Kataoka A, 1997, CANCER RES, V57, P5243; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu JW, 2002, CANCER RES, V62, P2976; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Oubrahim H, 2001, P NATL ACAD SCI USA, V98, P9505, DOI 10.1073/pnas.181319898; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Sanchez-Alcazar JA, 2001, CANCER RES, V61, P1038; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sestili P, 1999, FEBS LETT, V457, P139, DOI 10.1016/S0014-5793(99)01027-3; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Um HD, 1996, J IMMUNOL, V156, P3469; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang XD, 2001, GENE DEV, V15, P2922; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zarotti M., 1995, BIOCHIM BIOPHYS ACTA, V1241, P139	69	160	170	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50842	50854		10.1074/jbc.M207622200	http://dx.doi.org/10.1074/jbc.M207622200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12407106	hybrid			2022-12-25	WOS:000180177700085
J	Lan, ZJ; Chung, ACK; Xu, XP; DeMayo, FJ; Cooney, AJ				Lan, ZJ; Chung, ACK; Xu, XP; DeMayo, FJ; Cooney, AJ			The embryonic function of germ cell nuclear factor is dependent on the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN RECEPTOR GCNF; RESPONSE ELEMENT; EXPRESSION; GENE; CLONING; REPRESSOR; MUTANTS; XGCNF; OCT-4; MICE	Germ cell nuclear factor (GCNF), an orphan nuclear receptor, is essential for mouse embryogenesis. GCNF specifically binds to a DR0 response element via its DNA binding domain (DBD) in vitro and functions as a repressor of gene transcription. To further study the role of GCNF during embryogenesis, we have employed a Cre/ loxP strategy and generated a line of GCNF mutant mice (GCNF(lox/lox)) in which the 243-base pair DBD-encoding exon has been deleted in the germline. However, the ligand binding domain (LBD) of GCNF is still expressed at the mRNA and protein levels in the GCNF(lox/lox) mice. GCNF(lox/lox) mice die at 9.5-10.5 days postcoitum. The tailbuds of these mutant embryos protrude outside the yolk sac. Expression of Oct-4 in the somatic cells of GC-NFlox/lox embryos at 8.25 days postcoitum. was not silenced as in the GCNF(+/+) embryos. Therefore, GCNF(lox)/ lox mice phenocopy the GCNF(-/-) mice. Our results indicate that the DBD is essential for the function of GCNF during early mouse embryogenesis, and that the LBD does not mediate any function independent of the DBD at this stage of embryonic development. Our results also suggest that GCNF is indeed a transcriptional factor that represses gene transcription mediated via its DBD.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Cooney, AJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, BCMM-M733,1 Baylor Plaza, Houston, TX 77030 USA.	acooney@bcm.tmc.edu	Lan, Zi-Jian/F-2747-2012; DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Lan, Zi-Jian/0000-0002-5904-6834	NICHD NIH HHS [R01 HD-32878] Funding Source: Medline; NIDDK NIH HHS [T32 DK07763] Funding Source: Medline; ONDIEH CDC HHS [U54 ND 07495-28] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007763] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ONDIEH CDC HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achermann JC, 1999, NAT GENET, V22, P125, DOI 10.1038/9629; Agoulnik IY, 1998, FEBS LETT, V424, P73, DOI 10.1016/S0014-5793(98)00142-2; Auwerx J, 1999, CELL, V97, P161; Bauer UM, 1997, EUR J BIOCHEM, V249, P826, DOI 10.1111/j.1432-1033.1997.t01-1-00826.x; Bauer UM, 1998, FEBS LETT, V439, P208, DOI 10.1016/S0014-5793(98)01327-1; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; Braat AK, 1999, MOL REPROD DEV, V53, P369, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;369::AID-MRD1&gt;3.0.CO;2-U; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001; Cooney AJ, 1999, AM ZOOL, V39, P796; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; David R, 1998, MECH DEVELOP, V79, P137, DOI 10.1016/S0925-4773(98)00181-6; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Greschik H, 1998, J MOL MED-JMM, V76, P800, DOI 10.1007/s001090050284; Greschik H, 1999, MOL CELL BIOL, V19, P690; HIROSE T, 1995, GENE, V152, P247, DOI 10.1016/0378-1119(94)00656-D; Holzenberger M, 2000, ENDOCRINOLOGY, V141, P2557, DOI 10.1210/en.141.7.2557; Hummelke GC, 2001, FRONT BIOSCI, V6, pD1186, DOI 10.2741/Hummelke; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; Joos TO, 1996, MECH DEVELOP, V60, P45, DOI 10.1016/S0925-4773(96)00599-0; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; Lan Z. J., 2001, Recent Research Developments in Endocrinology, V2, P295; LAN ZJ, 2003, IN PRESS BIOL REPROD; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; Scacheri PC, 2001, GENESIS, V30, P259, DOI 10.1002/gene.1072; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; Seidl KJ, 1999, P NATL ACAD SCI USA, V96, P3000, DOI 10.1073/pnas.96.6.3000; Song K, 1999, DEV BIOL, V213, P170, DOI 10.1006/dbio.1999.9368; Susens U, 2001, GENOME BIOL, V2; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z	43	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50660	50667		10.1074/jbc.M209586200	http://dx.doi.org/10.1074/jbc.M209586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12381721	hybrid			2022-12-25	WOS:000180177700062
J	Xu, GR; Pan, LX; Li, H; Forman, BM; Erickson, SK; Shefer, S; Bollineni, J; Batta, AK; Christie, J; Wang, TH; Michel, J; Yang, S; Tsai, R; Lai, L; Shimada, K; Tint, GS; Salen, G				Xu, GR; Pan, LX; Li, H; Forman, BM; Erickson, SK; Shefer, S; Bollineni, J; Batta, AK; Christie, J; Wang, TH; Michel, J; Yang, S; Tsai, R; Lai, L; Shimada, K; Tint, GS; Salen, G			Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; ORPHAN NUCLEAR RECEPTOR; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; CELLS; RNA	We investigated the roles of hydrophobic deoxycholic acid (DCA) and hydrophilic ursocholic acid (UCA) in the regulation of the orphan nuclear farnesoid X receptor (FXR) in vivo. Rabbits with bile fistula drainage (removal of the endogenous bile acid pool), rabbits with bile fistula drainage and replacement with either DCA or UCA, and intact rabbits fed 0.5% cholic acid (CA) (enlarged endogenous bile acid pool) were studied. After bile fistula drainage, cholesterol 7alpha-hydroxylase (CY-P7A1) mRNA and activity levels increased, FXR-mediated transcription was decreased, and FXR mRNA and nuclear protein levels declined. Replacing the enterohepatic bile acid pool with DCA restored FAR mRNA and nuclear protein levels and activated FXR-mediated transcription as evidenced by the increased expression of its target genes, SHP and BSEP, and decreased CYP7A1 mRNA level and activity. Replacing the bile acid pool with UCA also restored FXR mRNA and nuclear protein levels but did not activate FXR-mediated transcription, because the SHP mRNA level and CYP7A1 mRNA level and activity were unchanged. Feeding CA to intact rabbits expanded the bile acid pool enriched with the FXR high affinity ligand, DCA. FXR-mediated transcription became activated as shown by increased SHP and BSEP mRNA levels and decreased CYP7A1 mRNA level and activity but did not change FXR mRNA or nuclear protein levels. Thus, both hydrophobic and hydrophilic bile acids are effective in maintaining FXR mRNA and nuclear protein levels. However, the activating ligand (DCA) in the enterohepatic flux is necessary for FXR-mediated transcriptional regulation, which leads to down-regulation of CYP7A1.	Vet Affairs Med Ctr, GI Lab 15A, Med Serv, E Orange, NJ 07018 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University New Brunswick; Rutgers State University Medical Center; City of Hope; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Xu, GR (corresponding author), Vet Affairs Med Ctr, GI Lab 15A, Med Serv, 385 Tremont Ave, E Orange, NJ 07018 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057636, R37DK026756, R01DK056830, R01DK026756] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18094] Funding Source: Medline; NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [DK26756, DK56830, DK57636] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SHEFER S, 1986, METHODS ASSAY, P43; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xu GR, 2002, J LIPID RES, V43, P45; Xu GR, 1999, J CLIN INVEST, V103, P89, DOI 10.1172/JCI4414	20	38	38	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50491	50496		10.1074/jbc.M209176200	http://dx.doi.org/10.1074/jbc.M209176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12401785	hybrid			2022-12-25	WOS:000180177700040
J	Mercatante, DR; Mohler, JL; Kole, R				Mercatante, DR; Mohler, JL; Kole, R			Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; RESISTANCE-ASSOCIATED PROTEIN; PROSTATE-CANCER CELLS; BREAST-CANCER; MULTIDRUG-RESISTANCE; P53-INDEPENDENT INDUCTION; BCL-X(S) ADENOVIRUS; ANTICANCER DRUGS; DOWN-REGULATION; MESSENGER-RNA	Overexpression of Bel-xL, an anti-apoptotic member of the Bcl-2 family, negatively correlates with the sensitivity of various cancers to chemotherapeutic agents. We show here that high levels of expression of Bcl-xL promoted apoptosis of cells treated with an antisense oligonucleotide (5'Bcl-x AS) that shifts the splicing pattern of Bcl-x pre-mRNA from the anti-apoptotic variant, Bel-xL, to the pro-apoptotic variant, Bcl-xS. This surprising finding illustrates the advantage of antisense-induced modulation of alternative splicing versus down-regulation of targeted genes. It also suggests a specificity of the oligonucleotide effects since non-cancerous cells with low levels of Bcl-xL should resist the treatment. 5'Bcl-x AS sensitized cells to several antineoplastic agents and radiation and was effective in promoting apoptosis of MCF-7/ADR cells, a breast cancer cell line resistant to doxorubicin via overexpression of the mdr1 gene. Efficacy of 5'Bcl-x AS combined with chemotherapeutic agents in the PC3 prostate cancer cell line may be translated to clinical prostate cancer since recurrent prostate cancer tissue samples expressed higher levels of Bcl-xL than benign prostate tissue. Treatment with 5'Bcl-x AS may enhance the efficacy of standard anti-cancer regimens and should be explored, especially in recurrent prostate cancer.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Div Urol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7295, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM059299] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 77739] Funding Source: Medline; NIGMS NIH HHS [P01 GM 59299-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundson SA, 2000, CANCER RES, V60, P6101; Benderra Z, 2000, EUR J CANCER, V36, P428, DOI 10.1016/S0959-8049(99)00288-9; Bennett C F, 1999, Expert Opin Investig Drugs, V8, P237, DOI 10.1517/13543784.8.3.237; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Cattaneo-Pangrazzi RMC, 2000, J CANCER RES CLIN, V126, P247, DOI 10.1007/s004320050339; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; DOLE MG, 1995, CANCER RES, V55, P2576; Dorr FA, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P269; Ealovega MW, 1996, CANCER RES, V56, P1965; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Fisher AA, 2002, J BIOL CHEM, V277, P22980, DOI 10.1074/jbc.M203347200; Fridman JS, 2001, J BIOL CHEM, V276, P4205, DOI 10.1074/jbc.M008171200; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Han JS, 1998, SPRINGER SEMIN IMMUN, V19, P279, DOI 10.1007/BF00787225; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kano Y, 1996, CANCER CHEMOTH PHARM, V37, P525, DOI 10.1007/s002800050424; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; KATZUNG BG, 1998, BASIC CLIN PHARM, P881; Kim R, 1999, INT J ONCOL, V15, P751; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lebedeva I, 2000, CANCER RES, V60, P6052; Lee JU, 1999, EUR J CANCER, V35, P1374, DOI 10.1016/S0959-8049(99)00134-3; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mercatante DR, 2002, BBA-MOL BASIS DIS, V1587, P126, DOI 10.1016/S0925-4439(02)00075-3; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Mesner P W Jr, 1997, Adv Pharmacol, V41, P461, DOI 10.1016/S1054-3589(08)61069-8; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Miyake H, 2001, INT J UROL, V8, P337, DOI 10.1046/j.1442-2042.2001.00311.x; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Nita ME, 2000, JPN J CANCER RES, V91, P825, DOI 10.1111/j.1349-7006.2000.tb01020.x; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ohi Y, 2000, INT J ONCOL, V16, P959; Olie RA, 2001, DRUG RESIST UPDATE, V4, P9, DOI 10.1054/drup.2001.0181; Olopade OI, 1997, CANCER J SCI AM, V3, P230; PARDO OE, 2002, J BIOL CHEM, V28, P28; Peters GJ, 2000, PHARMACOL THERAPEUT, V87, P227, DOI 10.1016/S0163-7258(00)00086-3; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rieber MS, 2001, CLIN CANCER RES, V7, P1446; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Sazani P, 2001, NUCLEIC ACIDS RES, V29, P3965, DOI 10.1093/nar/29.19.3965; SCHNEIDER E, 1994, CANCER RES, V54, P152; SCHNEIDER E, 1995, BRIT J CANCER, V71, P738, DOI 10.1038/bjc.1995.144; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Shao ZM, 2000, ANTICANCER RES, V20, P2409; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tsushima H, 1997, CELL GROWTH DIFFER, V8, P1317; Vilenchik M, 2002, CANCER RES, V62, P2175; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wei Q, 2002, MOL BIOL CELL, V13, P683, DOI 10.1091/mbc.01-07-0358; Xu ZW, 2001, INT J CANCER, V94, P268, DOI 10.1002/ijc.1447; Yang CC, 2000, CLIN CANCER RES, V6, P1024; Zhan QM, 1996, ONCOGENE, V13, P2287	66	133	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49374	49382		10.1074/jbc.M209236200	http://dx.doi.org/10.1074/jbc.M209236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12381725	hybrid, Green Published			2022-12-25	WOS:000180028900035
J	Schlaak, JF; Hilkens, CMU; Costa-Pereira, AP; Strobl, B; Aberger, F; Frischauf, AM; Kerr, IM				Schlaak, JF; Hilkens, CMU; Costa-Pereira, AP; Strobl, B; Aberger, F; Frischauf, AM; Kerr, IM			Cell-type and donor-specific transcriptional responses to interferon-alpha - Use of customized gene arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SERIAL ANALYSIS; EXPRESSION; GAMMA; BETA; POLYMORPHISMS; HYBRIDIZATION; ASSOCIATION; DISCOVERY; RIBAVIRIN	A sensitive, specific, reproducible, robust, and cost-effective customized cDNA array system based on established nylon membrane technology has been developed for convenient multisample expression profiling for several hundred genes of choice. The genes represented are easily adjusted (depending on the availability of corresponding cDNAs) and the method is accordingly readily applicable to a wide variety of systems. Here we have focused on the expression profiles for interferon-alpha2a, the most widely used interferon for the treatment of viral hepatitis and malignancies, in primary cells (peripheral blood mononuclear cells, T cells, and dendritic cells) and cell lines (Kit255, HT1080, HepG2, and HuH7). Of 150 genes studied, only six were consistently induced in all cell types and donors, whereas 74 genes were induced in at least one cell type. IRF-7 was identified as the only gene exclusively induced in the hematopoietic cells. No gene was exclusively induced in the nonhematopoietic cell lines. In T cells 12, and in dendritic cells, 25 genes were induced in all donors whereas 45 and 42 genes, respectively, were induced in at least one donor. The data suggest that signaling through IFN-alpha2 can be substantially modulated to yield significant cell-type and donor-specific qualitative and quantitative differences in gene expression in response to this cytokine under highly standardized conditions.	Canc Res UK, London Res Inst, London WC2A 3PX, England; Inst Anim Breeding & Genet, A-1210 Vienna, Austria; Salzburg Univ, Genet Inst, A-5020 Salzburg, Austria	Cancer Research UK; Salzburg University	Schlaak, JF (corresponding author), Univ Essen Gesamthsch, Dept Gastroenterol & Hepatol, Hufelandstr 55, D-45122 Essen, Germany.	joerg.schlaak@uni-essen.de	Aberger, Fritz/B-6357-2012; Costa-Pereira, Ana/AAE-8192-2020	Aberger, Fritz/0000-0003-2009-6305; Costa-Pereira, Ana/0000-0001-8265-8065; Strobl, Birgit/0000-0001-5716-3212; Hilkens, Catharien/0000-0003-2283-8886; Schlaak, Joerg/0000-0002-9499-1014				Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Bonifazi F, 2001, BLOOD, V98, P3074, DOI 10.1182/blood.V98.10.3074; Certa U, 2001, BRIT J CANCER, V85, P107, DOI 10.1054/bjoc.2001.1865; Cho SS, 1996, J IMMUNOL, V157, P4781; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Donn RP, 2001, ARTHRITIS RHEUM, V44, P802, DOI 10.1002/1529-0131(200104)44:4<802::AID-ANR136>3.3.CO;2-7; Fasler-Kan E, 1998, EUR J BIOCHEM, V254, P514, DOI 10.1046/j.1432-1327.1998.2540514.x; Fossa SD, 2000, SEMIN ONCOL, V27, P187; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heathcote J, 2000, SEMIN LIVER DIS, V20, P185, DOI 10.1055/s-2000-9941; HORI T, 1987, BLOOD, V70, P1069; Kjaergard LL, 2001, BMJ-BRIT MED J, V323, P1151, DOI 10.1136/bmj.323.7322.1151; Lens MB, 2002, J CLIN ONCOL, V20, P1818, DOI 10.1200/JCO.2002.07.070; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marrack P, 2000, CURR OPIN IMMUNOL, V12, P206, DOI 10.1016/S0952-7915(99)00075-8; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nacht M, 1999, CANCER RES, V59, P5464; Nakao F, 2001, J ALLERGY CLIN IMMUN, V107, P499, DOI 10.1067/mai.2001.113051; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Nishio Y, 2001, J HUM GENET, V46, P664, DOI 10.1007/s100380170018; Pietu G, 1996, GENOME RES, V6, P492, DOI 10.1101/gr.6.6.492; Rast JP, 2000, DEV BIOL, V228, P270, DOI 10.1006/dbio.2000.9941; Saito H, 2001, J CELL BIOCHEM, P191; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strobl B, 2001, EMBO J, V20, P5431, DOI 10.1093/emboj/20.19.5431; Sundstrom JB, 2001, J VIROL, V75, P6070, DOI 10.1128/JVI.75.13.6070-6085.2001; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Vasmatzis G, 1998, P NATL ACAD SCI USA, V95, P300, DOI 10.1073/pnas.95.1.300; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Whitney LW, 1999, ANN NEUROL, V46, P425; Yuen M F, 2001, Lancet Infect Dis, V1, P232, DOI 10.1016/S1473-3099(01)00118-9; Zackheim HZ, 1999, DERMATOLOGY, V199, P102, DOI 10.1159/000018214; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	55	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49428	49437		10.1074/jbc.M205571200	http://dx.doi.org/10.1074/jbc.M205571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386168	hybrid			2022-12-25	WOS:000180028900043
J	Wang, H; Brautigan, DL				Wang, H; Brautigan, DL			A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SMOOTH-MUSCLE; REGULATORY SUBUNITS; PHOSPHORYLATION; TYPE-1; EXPRESSION; SEQUENCE; IDENTIFICATION	Protein kinases and protein phosphatases exert coordinated control over many essential cellular processes. Here, we describe the cloning and characterization of a novel human transmembrane protein KPI-2 (Kinase/Phosphatase/Inhibitor-2) that was identified by yeast two-hybrid using protein phosphatase inhibitor-2 (Inh2) as bait. KPI-2 mRNA was predominantly expressed in skeletal muscle. KPI-2 is a 1503-residue protein with two predicted transmembrane helices at the N terminus, a kinase domain, followed by a C-terminal domain. The transmembrane helices were sufficient for targeting proteins to the membrane. KPI-2 kinase domain has about 60% identity with its closest relative, a tyrosine kinase. However, it only exhibited serine/threonine kinase activity in autophosphorylation reactions or with added substrates. KPI-2 kinase domain phosphorylated protein phosphatase-1 (PP1C) at Thr(320), which attenuated PPIC activity. KPI-2 C-terminal domain directly associated with PP1C, and this required a VTF motif. lnh2 associated with KPI-2 C-terminal domain with and without PPIC. Thus, KPI-2 is a kinase with sites to associate with PP1C and lnh2 to form a regulatory complex that is localized to membranes.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Baker SJ, 2001, ONCOGENE, V20, P1015, DOI 10.1038/sj.onc.1204209; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BRAUTIGAN DL, 1991, ADV PROTEIN PHOSPHAT, V6, P375; CANNON JF, 1994, GENETICS, V136, P485; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; Cohen PTW, 2002, J CELL SCI, V115, P241; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; FENG ZH, 1991, J BIOL CHEM, V266, P23796; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KURIHARA T, 1988, J NEUROSCI, V8, P508; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; PARK IK, 1994, J BIOL CHEM, V269, P944; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6; Ramaswamy NT, 1998, GENETICS, V149, P57; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; TANG PM, 1991, J BIOL CHEM, V266, P15782; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; Tomomura M, 2001, ONCOGENE, V20, P1022, DOI 10.1038/sj.onc.1204210; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TUNG HYL, 1984, EUR J BIOCHEM, V145, P57, DOI 10.1111/j.1432-1033.1984.tb08521.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; VANDENHEEDE JR, 1989, ADV PROT PHOSPHATASE, V5, P19; Williams DM, 2000, J BIOL CHEM, V275, P38127, DOI 10.1074/jbc.C000606200; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zhu L, 1997, Methods Mol Biol, V63, P173	48	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49605	49612		10.1074/jbc.M209335200	http://dx.doi.org/10.1074/jbc.M209335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393858	hybrid			2022-12-25	WOS:000180028900067
J	Davies, JK; Hagan, RM; Wilton, DC				Davies, JK; Hagan, RM; Wilton, DC			Effect of charge reversal mutations on the ligand- and membrane-binding properties of liver fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE LYSINE RESIDUES; RAT-LIVER; PHOSPHOLIPID-MEMBRANES; ESCHERICHIA-COLI; COLLISIONAL TRANSFER; INTERFACIAL BINDING; CRYSTAL-STRUCTURE; VESICLES; EXPRESSION; PEPTIDES	Liver fatty acid-binding protein (FABP) is able to bind to anionic phospholipid vesicles under conditions of low ionic strength. This binding results in the release of ligand, the fluorescent fatty acid analogue 11-dansylaminoundecanoic acid (DAUDA), with loss of fluorescence intensity (Davies, J. K., Thumser, A. E. A., and Wilton, D. C. (1999) Biochemistry 38,16932-16940). Using a strategy of charge reversal mutagenesis, the potential role of specific cationic residues in promoting interfacial binding of FABP to anionic phospholipid vesicles has been investigated. Cationic residues chosen included those within the a-helical region (Lys-20, Lys-31, and Lys-33) and those that make a significant contribution to the positive surface potential of the protein (Lys-31, Lys-36, Lys-47, Lys-57, and Arg-126). Only three cationic residues make a significant contribution to interfacial binding, and these residues (Lys-31, Lys-36, and Lys-57) are all located within the ligand portal region, where the protein may be predicted to exhibit maximum disorder. The binding of tryptophan mutants, F3W, F18W, and C69W, to dioleoylphosphatidylglycerol vesicles, containing 5 mol% of the fluorescent phospholipid dansyldihexadecanoylphosphatidylethanolamine, was monitored by fluorescence resonance energy transfer (FRET). All three mutants showed enhanced dansyl fluorescence due to FRET on addition of phospholipid to protein; however, this fluorescence was considerably greater with the F3W mutant, consistent with the N-terminal region of the protein coming in close proximity to the phospholipid interface. These results were confirmed by succinimide quenching studies. Overall, the results indicate that the portal region of liver FABP and specifically Lys-31, Lys-36, and Lys-57 are involved in the interaction with the interface of anionic vesicles and that the N-terminal region of the protein undergoes a conformational change, resulting in DAUDA release.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England	University of Southampton	Wilton, DC (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.			Thumser, Alfred/0000-0003-0256-8006				BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BORCHERS T, 1994, CURR TOP MEMBR, V40, P261, DOI 10.1016/S0070-2161(08)60984-3; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1483, P199, DOI 10.1016/S1388-1981(99)00188-2; Cajal Y, 2000, BIOCHEMISTRY-US, V39, P413, DOI 10.1021/bi991927i; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Davies JK, 1999, BIOCHEMISTRY-US, V38, P16932, DOI 10.1021/bi991926q; EFTINK MR, 1984, BIOCHEMISTRY-US, V23, P3891, DOI 10.1021/bi00312a016; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HEIMBURG T, 1995, BIOPHYS J, V68, P536, DOI 10.1016/S0006-3495(95)80215-8; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kennedy MW, 2000, BIOCHEM J, V349, P377, DOI 10.1042/0264-6021:3490377; Lehrer RI, 1996, ANN NY ACAD SCI, V797, P228, DOI 10.1111/j.1749-6632.1996.tb52963.x; Liou HL, 2001, BIOCHEMISTRY-US, V40, P6475, DOI 10.1021/bi0101042; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Sanghera N, 2000, PROTEIN SCI, V9, P1194, DOI 10.1110/ps.9.6.1194; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, MOL CELL BIOCHEM, V192, P9, DOI 10.1023/A:1006806616963; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THUMSER AEA, 1994, BIOCHEM J, V300, P827, DOI 10.1042/bj3000827; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; Watts A, 1997, BIOCHEM SOC T, V25, P1119, DOI 10.1042/bst0251119; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; WORRALL AF, 1991, BIOCHEM J, V278, P365, DOI 10.1042/bj2780365; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	40	16	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48395	48402		10.1074/jbc.M208141200	http://dx.doi.org/10.1074/jbc.M208141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379651	hybrid			2022-12-25	WOS:000179789600057
J	Li, XF; Kraev, AS; Lytton, J				Li, XF; Kraev, AS; Lytton, J			Molecular cloning of a fourth member of the potassium-dependent sodium-calcium exchanger gene family, NCKX4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; NA/CA-K EXCHANGER; NA+/CA2+ EXCHANGER; FUNCTIONAL EXPRESSION; NA+-CA2+ EXCHANGER; RETINAL CONE; INSECT CELLS; STOICHIOMETRY; NCX1; PROMOTERS	We report here the identification and characterization of a fourth member of the potassium-dependent sodium-calcium exchanger gene family, NCKX4 (gene SLC24A4), which mapped to the chromosomal region 14q32. Human NCKX4 encoded a protein of 605 amino acids that displayed a high level of sequence identity to previously described family members, rod NCKX1 (gene SLC24A1), cone/neuronal NCKX2 (gene SLC24A2), and ubiquitous NCKX3 (gene SLC24A3), in the hydrophobic regions surrounding the a-repeat sequences thought to form the ion-binding pocket used for transport. The protein product of the NCKX4 gene shared the highest level of amino acid identity, as well as an almost identical arrangement of exon boundaries, with NCKX3, indicating that these two genes have arisen from a recent duplication event. NCKX4 transcripts were abundantly expressed in all brain regions, aorta, lung, and thymus, as well as at a lower level in many other tissues. The NCKX4 protein demonstrated potassium-dependent sodium calcium exchanger activity when assayed in transfected HEK293 cells using digital imaging of fura-2 fluorescence. The discovery of NCKX4, as far as can be ascertained from the current version of the human genome sequence, completes the mammalian potassium-dependent sodium-calcium exchanger gene family.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Poon S, 2000, AM J PHYSIOL-CELL PH, V278, pC651, DOI 10.1152/ajpcell.2000.278.4.C651; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; Saaf A, 2001, J BIOL CHEM, V276, P18905, DOI 10.1074/jbc.M101716200; Sambrook J, 2001, MOL CLONING LAB MANU; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Szerencsei RT, 2001, BIOCHEMISTRY-US, V40, P6009, DOI 10.1021/bi0102353; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; [No title captured]	39	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48410	48417		10.1074/jbc.M210011200	http://dx.doi.org/10.1074/jbc.M210011200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379639	hybrid			2022-12-25	WOS:000179789600059
J	Rodrigues, CO; Ruiz, FA; Rohloff, P; Scott, DA; Moreno, SNJ				Rodrigues, CO; Ruiz, FA; Rohloff, P; Scott, DA; Moreno, SNJ			Characterization of isolated acidocalcisomes from Toxoplasma gondii tachyzoites reveals a novel pool of hydrolyzable polyphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-PYROPHOSPHATASE; PROTON-PUMPING PYROPHOSPHATASE; TRYPANOSOMA-CRUZI; INORGANIC POLYPHOSPHATE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BRUCEI; LOCALIZATION; COMPARTMENT; EXCHANGE	Toxoplasma gondii tachyzoites were fractionated by modification of an iodixanol density gradient method previously used for acidocalcisome isolation from Trypanosoma cruzi epimastigotes. Fractions were characterized using electron microscopy, x-ray microanalysis, and enzymatic markers, and it was demonstrated that the heaviest (pellet) fraction contains electron-dense vacuoles rich in phosphorus, calcium, and magnesium, as found before for acidocalcisomes. Staining with 4',6-diamidino-2-phenylindole (DAPI) indicated that polyphosphate (polyP) was preferentially localized in this fraction together with pyrophosphate (PPi). Using an enzyme-based method, millimolar levels (in terms of P-i residues) of polyP chains of less than 50 residues long and micromolar levels in polyP chains of about 700-800 residues long were found to be preferentially localized in this fraction. The fraction also contained the pyrophosphatase and polyphosphatase activities characteristic of acidocalcisomes. Western blot analysis using antibodies against proteins from micronemes, dense granules, rhoptries, and plasma membrane showed that the acidocalcisomal fraction was not contaminated by these other organelles. T. gondii polyP levels rapidly decreased upon exposure of the parasites to a calcium ionophore (ionomycin), to an inhibitor of the V-H+-ATPase (bafilomycin A,), or to the alkalinizing agent NH4Cl. These changes were in parallel to an increase in intracellular Ca2+ concentration, suggesting a close association between polyP hydrolysis and Ca2+ release from the acidocalcisome. These results provide a useful method for the isolation and characterization of acidocalcisomes, showing that they are distinct from other previously recognized organelles present in T. gondii, and provide evidence for the role of polyP metabolism in response to cellular stress.	Univ Illinois, Mol Parasitol Lab, Dept Pathobiol, Coll Vet Med, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Moreno, SNJ (corresponding author), Univ Illinois, Mol Parasitol Lab, Dept Pathobiol, Coll Vet Med, 2001 S Lincoln Ave, Urbana, IL 61802 USA.		Ruiz, Felix A./B-1032-2008; Rohloff, Peter/P-8722-2017	Ruiz, Felix A./0000-0003-0748-5015; Rohloff, Peter/0000-0001-7274-8315; Scott, David/0000-0002-8668-2449	NIAID NIH HHS [AI-43614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ault-Riche D, 1998, J BACTERIOL, V180, P1841; BARRETT AJ, 1977, LYSOSOMES LABORATORY, P36; BULOW R, 1991, J IMMUNOL, V147, P3496; CASTRO CD, 1995, APPL ENVIRON MICROB, V61, P4448, DOI 10.1128/AEM.61.12.4448-4453.1995; CHAMBERLAND S, 1991, ANTIMICROB AGENTS CH, V35, P903, DOI 10.1128/AAC.35.5.903; Chapman A G, 1977, Adv Microb Physiol, V15, P253, DOI 10.1016/S0065-2911(08)60318-5; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; CROOKE E, 1994, J BIOL CHEM, V269, P6290; DAMPER D, 1976, J PROTOZOOL, V23, P349, DOI 10.1111/j.1550-7408.1976.tb03787.x; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kulaev I S, 1999, Prog Mol Subcell Biol, V23, P27; Kuroda A, 1999, P NATL ACAD SCI USA, V96, P14264, DOI 10.1073/pnas.96.25.14264; Labruyere E, 1999, MOL BIOCHEM PARASIT, V102, P311, DOI 10.1016/S0166-6851(99)00092-4; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166-6851(91)90092-K; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; PENG ZY, 1992, MOL BIOCHEM PARASIT, V54, P223, DOI 10.1016/0166-6851(92)90114-Y; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SERAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775; TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Vieira MCF, 2000, MOL BIOCHEM PARASIT, V106, P157, DOI 10.1016/S0166-6851(99)00182-6; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	43	34	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48650	48656		10.1074/jbc.M208990200	http://dx.doi.org/10.1074/jbc.M208990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12379647	hybrid			2022-12-25	WOS:000179789600089
J	Wulf, GM; Liou, YC; Ryo, A; Lee, SW; Lu, KP				Wulf, GM; Liou, YC; Ryo, A; Lee, SW; Lu, KP			Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; BREAST-CANCER; PHOSPHORYLATION; ISOMERIZATION; INHIBITOR; APOPTOSIS	DNA damage leads to stabilization and accumulation of p53, which plays a pivotal role in transcriptional activation of p21 and cell cycle arrest. The increase in p53 stability depends critically on its phosphorylation on serine/threonine residues, including those preceding a proline (Ser(P)/Thr-Pro). The Ser(P)/Thr-Pro moiety exists in the two distinct cis and trans conformations and their conversion is catalyzed specifically by the prolyl isomerase Pin1. Pin1 regulates the conformation and function of certain phosphorylated proteins and plays an important role in cell cycle regulation, oncogenesis, and Alzheimer's disease. However, nothing is known about the role of Pin1 in DNA damage. Here we found that DNA damage enhanced the interaction between Pin1 and p53, which depended on the WW domain in Pin1 and Ser(33/46)-Pro motifs in p53. Furthermore, Pin1 regulates the stability of p53 and its transcriptional activity toward the p22 promoter. As a result, p53 and p21. barely increased after DNA damage in Pin1 knock-out embryonic fibroblasts or in neoplastic cells depleted of Pin1. Moreover, Pin1 null cells displayed significant defects in cell cycle checkpoints induced by DNA damage. These results demonstrate a new role of Pin1 in regulating p53 function during DNA damage.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lu, KP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Canc Biol Program, 330 Brookline Ave,HIM 1047, Boston, MA 02215 USA.	klu@caregroup.harvard.edu	Wulf, Gerburg/AAS-6713-2021		NCI NIH HHS [CA093655] Funding Source: Medline; NIGMS NIH HHS [GM58556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA093655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kishi S, 2002, J BIOL CHEM, V277, P7420, DOI 10.1074/jbc.M111365200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	28	186	194	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					47976	47979		10.1074/jbc.C200538200	http://dx.doi.org/10.1074/jbc.C200538200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12388558	hybrid			2022-12-25	WOS:000179789600003
J	Inui, S; Fukuzato, Y; Nakajima, T; Yoshikawa, K; Itami, S				Inui, S; Fukuzato, Y; Nakajima, T; Yoshikawa, K; Itami, S			Androgen-inducible TGF-beta 1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understanding paradoxical effects of androgen on human hair growth	FASEB JOURNAL			English	Article						androgenetic alopecia; androgen receptor; growth factor	IN-VITRO; RECEPTOR; 5-ALPHA-REDUCTASE; EXPRESSION; BETA; CONTAIN; BEARD; DIFFERENTIATION; KERATINOCYTES; TESTOSTERONE	We attempted establishing an in vitro coculture system by using human dermal papilla cells (DPCs) from androgenetic alopecia (AGA) and keratinocytes (KCs) to explore the role of androgens in hair growth regulation. Androgen showed no significant effect on the growth of KCs when they were cocultured with DPCs from AGA. Because the expressions of mRNA of androgen receptor (AR) decreased during subcultivation of DPCs in vitro, we transiently transfected the AR expression vector into the DPCs and cocultured them with KCs. In this modified coculture, androgen significantly suppressed the growth of KCs by similar to50%, indicating that overexpression of AR can restore the responsiveness of the DPCs to androgen in vivo. We found that androgen stimulated the expression of TGF-beta1 mRNA in the cocultured DPCs. ELISA assays demonstrated that androgen treatment increased the secretion of both total and active TGF-beta1 in the conditioned medium. Moreover, the neutralizing anti-TGF-beta1 antibody reversed the androgen-elicited growth inhibition of KCs in a dose-dependent manner. These findings suggest that androgen-inducible TGF-beta1 derived from DPCs of AGA is involved in epithelial cell growth suppression in our coculture system, providing the clue to understand the paradoxical effects of androgens for human hair growth.	Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University	Itami, S (corresponding author), Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	itami@derma.med.osaka-u.ac.jp						Ando Y, 1999, BRIT J DERMATOL, V141, P840, DOI 10.1046/j.1365-2133.1999.03156.x; Asada Y, 2001, J CLIN ENDOCR METAB, V86, P2875, DOI 10.1210/jc.86.6.2875; CHOUDHRY R, 1992, J ENDOCRINOL, V133, P467, DOI 10.1677/joe.0.1330467; EBILING FJG, 1986, J CLIN ENDOCR METAB, V15, P319; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HEINLEIN CA, 2002, ENDOCR REV, V23, P175, DOI DOI 10.1210/ER.23.2.175; Hibberts NA, 1998, J ENDOCRINOL, V156, P59, DOI 10.1677/joe.0.1560059; Inui S, 2000, J DERMATOL SCI, V23, P87, DOI 10.1016/S0923-1811(99)00091-2; ITAMI S, 1991, ANN NY ACAD SCI, V642, P385; ITAMI S, 1995, BRIT J DERMATOL, V132, P527; ITAMI S, 1995, BIOCHEM BIOPH RES CO, V212, P988, DOI 10.1006/bbrc.1995.2067; ITAMI S, 1990, J INVEST DERMATOL, V94, P150, DOI 10.1111/1523-1747.ep12874003; ITAMI S, 1991, J INVEST DERMATOL, V96, P57, DOI 10.1111/1523-1747.ep12514729; Kamimura J, 1997, J INVEST DERMATOL, V109, P534, DOI 10.1111/1523-1747.ep12336704; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; Obana N, 1997, ENDOCRINOLOGY, V138, P356, DOI 10.1210/en.138.1.356; Pan HJ, 1999, ENDOCRINE, V11, P321, DOI 10.1385/ENDO:11:3:321; Parrelli JM, 1998, INT J BIOCHEM CELL B, V30, P623, DOI 10.1016/S1357-2725(98)00005-3; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; Pentyala SN, 1998, CANCER LETT, V130, P121, DOI 10.1016/S0304-3835(98)00120-7; RANDALL VA, 1992, J ENDOCRINOL, V133, P141, DOI 10.1677/joe.0.1330141; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Soma T, 1998, J INVEST DERMATOL, V111, P948, DOI 10.1046/j.1523-1747.1998.00408.x; Sonoda Tadashige, 1993, Journal of Dermatological Science, V6, P214, DOI 10.1016/0923-1811(93)90041-M; UNO H, 1967, J INVEST DERMATOL, V49, P288, DOI 10.1038/jid.1967.138; Xing RHM, 1999, ENDOCRINOLOGY, V140, P4056, DOI 10.1210/en.140.9.4056; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	31	147	164	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1967	+		10.1096/fj.02-0043fje	http://dx.doi.org/10.1096/fj.02-0043fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397096				2022-12-25	WOS:000179167600010
J	Reiner, DS; Hetsko, ML; Meszaros, JG; Sun, CH; Morrison, HG; Brunton, LL; Gillin, FD				Reiner, DS; Hetsko, ML; Meszaros, JG; Sun, CH; Morrison, HG; Brunton, LL; Gillin, FD			Calcium signaling in excystation of the early diverging eukaryote, Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; GENE; CELL; KINASE; DIFFERENTIATION; IDENTIFICATION; TROPHOZOITES; FLUORESCENCE; EXPRESSION	Excystation of Giardia lamblia, which initiates infection, is a poorly understood but dramatic differentiation induced by physiological signals from the host. Our data implicate a central role for calcium homeostasis in excystation. Agents that alter cytosolic Ca2+ levels (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-tetra(acetyloxymethyl) ester, a Ca2+ channel blocker, Ca2+ ionophores, and thapsigargin) strongly inhibit excystation. Treatment of Giardia with thapsigargin raised intracellular Ca2+ levels, and peak Ca2+ responses increased with each stage of excystation, consistent with the kinetics of inhibition. Fluorescent thapsigargin localized to a likely Ca2+ storage compartment in cysts. The ability to sequester ions in membrane-bounded compartments is a hallmark of the eukaryotic cell. These studies support the existence of a giardial thapsigargin-sensitive Ca2+ storage compartment resembling the sarcoplasmic/endoplasmic reticulum calcium ATPase pump-leak system and suggest that it is important in regulation of differentiation and appeared early in the evolution of eukaryotic cells. Calmodulin antagonists also blocked excystation. The divergent giardial calmodulin localized to the eight flagellar basal bodies/centrosomes, like protein kinase A. Inhibitor kinetics suggest that protein kinase A signaling triggers excystation, whereas calcium signaling is mainly required later, for parasite activation and emergence. Thus, the basal bodies may be a cellular control center to coordinate the resumption of motility and cytokinesis in excystation.	Univ Calif San Diego, Dept Pathol, Sch Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Mol Genet, San Diego, CA 92103 USA; Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Marine Biological Laboratory - Woods Hole	Gillin, FD (corresponding author), Univ Calif San Diego, Dept Pathol, Sch Med, 214 Dickinson St, San Diego, CA 92103 USA.	fgillin@ucsd.edu	Shin, Jerry/AAO-2515-2021; Reiner, David S./F-6106-2012	Reiner, David S./0000-0002-8289-7311; SUN, CHIN-HUNG/0000-0002-8604-8085; Morrison, Hilary/0000-0003-0281-326X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043273, U01AI043273, R01AI051687, R01AI042488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061896] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43273, AI51687, AI42488] Funding Source: Medline; NIDDK NIH HHS [DK35108] Funding Source: Medline; NIGMS NIH HHS [GM61896] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel ES, 2001, J BIOL CHEM, V276, P10320, DOI 10.1074/jbc.M006589200; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ALBERTS B, 2002, MOL BIOL CELL, P854; Balakumaran A, 1996, TOXICOL APPL PHARM, V139, P122, DOI 10.1006/taap.1996.0150; Bernal RM, 1998, PARASITOL RES, V84, P687, DOI 10.1007/s004360050471; Bernander R, 2001, CELL MICROBIOL, V3, P55, DOI 10.1046/j.1462-5822.2001.00094.x; BINGHAM AK, 1979, NATURE, V277, P301, DOI 10.1038/277301a0; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; Despommier D.D., 1987, PARASITE LIFE CYCLES; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Edwards RA, 1998, BIOCHEM J, V331, P149, DOI 10.1042/bj3310149; Eichinger D, 2001, J EUKARYOT MICROBIOL, V48, P17, DOI 10.1111/j.1550-7408.2001.tb00411.x; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; FEELY DE, 1982, J PARASITOL, V68, P869, DOI 10.2307/3280996; Furuya T, 2001, J BIOL CHEM, V276, P32437, DOI 10.1074/jbc.M104000200; Gauthier ML, 2001, CELL SIGNAL, V13, P575, DOI 10.1016/S0898-6568(01)00187-5; Guerini D, 2002, FASEB J, V16, P519, DOI 10.1096/fj.01-0362com; Guerini D, 1999, CALCIUM AS A CELLULAR REGULATOR, P249; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hetsko ML, 1998, EXP PARASITOL, V88, P172, DOI 10.1006/expr.1998.4246; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; KACHINTORN U, 1992, AM J PHYSIOL, V262, pC15, DOI 10.1152/ajpcell.1992.262.1.C15; Klee C, 1999, CALCIUM AS A CELLULAR REGULATOR, P344; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; Leclerc P, 2000, BIOL REPROD, V62, P1875, DOI 10.1095/biolreprod62.6.1875; Lee HW, 2002, BBA-PROTEINS PROTEOM, V1598, P80, DOI 10.1016/S0167-4838(02)00338-2; Li CJ, 1999, J CELL SCI, V112, P1567; LORELL BH, 1990, CIRC RES, V67, P415, DOI 10.1161/01.RES.67.2.415; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; Marshall MM, 1997, CLIN MICROBIOL REV, V10, P67, DOI 10.1128/CMR.10.1.67; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P220, DOI 10.1006/expr.1994.1086; McCormack JG, 1999, CALCIUM AS A CELLULAR REGULATOR, P529; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Meng TC, 1996, MOL BIOCHEM PARASIT, V79, P103, DOI 10.1016/0166-6851(96)02636-9; Meszaros JG, 2000, AM J PHYSIOL-CELL PH, V278, pC154, DOI 10.1152/ajpcell.2000.278.1.C154; MIDDENDORF LR, 1992, ELECTROPHORESIS, V13, P487, DOI 10.1002/elps.11501301103; MUNOZ MD, 1987, EXP PARASITOL, V63, P42, DOI 10.1016/0014-4894(87)90076-2; Nelson MR, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P17; PAGET TA, 1989, J GEN MICROBIOL, V135, P145; RAVDIN JI, 1985, J INFECT DIS, V152, P542, DOI 10.1093/infdis/152.3.542; RICE EW, 1981, J CLIN MICROBIOL, V14, P709, DOI 10.1128/JCM.14.6.709-710.1981; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; ROBSON KJH, 1991, MOL BIOCHEM PARASIT, V46, P19, DOI 10.1016/0166-6851(91)90195-C; Sanchez LB, 1999, GENE, V233, P225, DOI 10.1016/S0378-1119(99)00134-1; Silva-Neto MAC, 2002, J BIOL CHEM, V277, P14085, DOI 10.1074/jbc.M107903200; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; Slupsky CM, 1999, CALCIUM AS A CELLULAR REGULATOR, P73; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 2000, MOL BIOCHEM PARASIT, V105, P51, DOI 10.1016/S0166-6851(99)00163-2; Tsien RY, 1999, CALCIUM AS A CELLULAR REGULATOR, P28; Van Eldik LJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P1; Wang JH, 1996, BBA-MOL CELL RES, V1313, P223, DOI 10.1016/0167-4889(96)00093-6; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; Weljie AM, 2000, PROTEIN ENG, V13, P59, DOI 10.1093/protein/13.1.59; WENTZELL B, 1978, FEBS LETT, V86, P255, DOI 10.1016/0014-5793(78)80574-2; Williams RJP, 1999, CALCIUM AS A CELLULAR REGULATOR, P3; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	67	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2533	2540		10.1074/jbc.M208033200	http://dx.doi.org/10.1074/jbc.M208033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12397071	hybrid			2022-12-25	WOS:000180562000062
J	Wen, YD; Cress, WD; Roy, AL; Seto, E				Wen, YD; Cress, WD; Roy, AL; Seto, E			Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-BETA PROMOTER; COREPRESSOR COMPLEX; NUCLEAR EXPORT; N-COR; REPRESSION; PROTEIN; HDAC3; ELEMENT; CLONING; SIGNAL	Histone deacetylase 3 (HDAC3) is one of four members of the human class I histone deacetylases that are implicated in transcriptional repression through deacetylation of acetyllysines in amino-terminal tails of core histones. In an immunoaffinity purification using anti-HDAC3, transcription factor TFII-I copurified with HDAC3. Specificity of the HDAC3-TFII-I interaction was confirmed by coimmunoprecipitation of epitope-tagged proteins, GST pull-down assays, and protein colocalization with indirect immunofluorescence. An anti-TFII-I immunoprecipitate contained histone deacetylase enzymatic activity. Mutational analyses revealed that the carboxyl-terminal of HDAC3 (residues 373-401) and residues 363-606 of TFII-I were required for the HDAC3-TFII-I interaction. Transcriptional activation by TFII-I was severely reduced by overexpression of HDAC3. These results suggest that HDAC3 modulates some of the functions of TFII-I and provides a link between histone deacetylase and a multifunctional transcriptional activator.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	State University System of Florida; University of South Florida; Tufts University	Seto, E (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Interdisciplinary Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	setoe@moffitt.usf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058486] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45150] Funding Source: Medline; NIGMS NIH HHS [GM58486] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laj A, 1999, MOL CELL BIOL, V19, P6632; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nicolas E, 2001, NUCLEIC ACIDS RES, V29, P3131, DOI 10.1093/nar/29.15.3131; Novina CD, 1997, METHODS, V12, P254, DOI 10.1006/meth.1997.0477; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	2003	278	3					1841	1847		10.1074/jbc.M206528200	http://dx.doi.org/10.1074/jbc.M206528200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	636NK	12393887	hybrid			2022-12-25	WOS:000180462200064
J	Rios-Doria, J; Day, KC; Kuefer, R; Rashid, MG; Chinnaiyan, AM; Rubin, MA; Day, ML				Rios-Doria, J; Day, KC; Kuefer, R; Rashid, MG; Chinnaiyan, AM; Rubin, MA; Day, ML			The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; ALPHA-CATENIN; SIGNAL-TRANSDUCTION; ADHESION COMPLEX; HUMAN BREAST; CANCER; EXPRESSION; APOPTOSIS; PROTEASE; BINDING	The E-cadherin protein mediates Ca2+-dependent interepithelial adhesion. Association of E-cadherin with the catenin family of proteins is critical for the maintenance of a functional adhesive complex. We have identified a novel truncated E-cadherin species of 100-kDa (E-cad(100)) in Prostate and mammary epithelial cells. E-cad(100) was generated by treatment of cells with ionomycin or TPA. Cell-permeable calpain inhibitors prevented E-cad(100) induction by ionomycin. Immunoblotting for spectrin and mu-calpain confirmed calpain activation in response to ionomycin treatment. Both the mu- and in isoforms of calpain efficiently generated E-cad(100) in vitro. The E-cad(100) fragment was unable to bind to beta-catenin, gamma-catenin, and p120, suggesting that this cleavage event would disrupt the E-cadherin adhesion complex. Mutational analysis localized the calpain cleavage site to the cytosolic domain upstream of the beta-and gamma-catenin binding motifs of E-cadherin. Because E-cadherin is inactivated in many adenocarcinomas we hypothesized that calpain may play a role in prostate tumorigenesis. A prostate cDNA microarray data base was analyzed for calpain expression in which it was found that m-calpain was up-regulated in localized prostate cancer, and to an even higher degree in metastatic prostate cancer compared with normal prostate tissue. Furthermore, we examined the cleavage of E-cadherin in prostate cancer specimens and found that E-cad(100) accumulated in both localized and metastatic prostate tumors, supporting the cDNA microarray data. These findings demonstrate a novel mechanism by which E-cadherin is functionally inactivated through calpain-mediated proteolysis and suggests that E-cadherin is targeted by calpain during the tumorigenic progression of prostate cancer.	Univ Ulm, Dept Urol, D-89075 Ulm, Germany; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Ulm University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Day, KC (corresponding author), Box 0944,Room 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.			Rios-Doria, Jonathan/0000-0002-9376-0679; Rubin, Mark/0000-0002-8321-9950	NIDDK NIH HHS [R01 DK56137] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bryden AAG, 1999, BJU INT, V84, P1032; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Cheng L, 1996, AM J PATHOL, V148, P1375; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Davies G, 1998, ONCOL REP, V5, P1567; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gofuku J, 1998, BRIT J CANCER, V78, P1095, DOI 10.1038/bjc.1998.634; GRAFF JR, 1995, CANCER RES, V55, P5195; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hajra KM, 2002, CANCER RES, V62, P1613; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nieman MT, 1999, J CELL SCI, V112, P1621; Nieset JE, 1997, J CELL SCI, V110, P1013; Noe V, 2001, J CELL SCI, V114, P111; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rashid MG, 2001, CANCER RES, V61, P489; Richmond PJM, 1997, CANCER RES, V57, P3189; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; STEINHUSEN U, 2000, J BIOL CHEM, V13, P13; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; UMBAS R, 1992, CANCER RES, V52, P5104; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	55	135	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1372	1379		10.1074/jbc.M208772200	http://dx.doi.org/10.1074/jbc.M208772200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12393869	hybrid			2022-12-25	WOS:000180321900087
J	Lehmann, U; Schmitz, J; Weissenbach, M; Sobota, RM; Hortner, M; Friederichs, K; Behrmann, I; Tsiaris, W; Sasaki, A; Schneider-Mergener, J; Yoshimura, A; Neel, BG; Heinrich, PC; Schaper, F				Lehmann, U; Schmitz, J; Weissenbach, M; Sobota, RM; Hortner, M; Friederichs, K; Behrmann, I; Tsiaris, W; Sasaki, A; Schneider-Mergener, J; Yoshimura, A; Neel, BG; Heinrich, PC; Schaper, F			SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LEUKEMIA-INHIBITORY FACTOR; TRANSDUCER GP130; ONCOSTATIN-M; SH2 DOMAIN; TRANSCRIPTION FACTOR; LEPTIN RECEPTOR; GROWTH-FACTOR; KINASE JAK1; BOX MOTIF	Interleukin-6 (IL-6) activates the Jak/STAT pathway as well as the mitogen-activated protein kinase cascade. Tyrosine 759 of the IL-6 signal-transducing receptor subunit gp130 has been identified as being involved in negative regulation of IL-6-induced gene induction and activation of the Jak/STAT pathway. Because this site is known to be a recruitment motif for the protein-tyrosine phosphatase SHP2, it has been suggested that SHP2 is the mediator of tyrosine 759-dependent signal attenuation. We recently observed that the suppressor of cytokine-signaling SOCS3 also acts through the tyrosine motif 759 of gp130. However, the relative contributions of SHP2 and SOCS3 to the repression of IL-6 signaling are not understood. Therefore, we designed experiments allowing the independent recruitment of each of these proteins to the IL-6-receptor complex. We show that receptor- and membrane-targeted SHP2 counteracts IL-6 signaling independent of SOCS3 binding to gp130. On the other hand, SOCS3 inhibits signaling in cells expressing a truncated SHP2 protein, which is not recruited to gp130. These data suggest, that there are two, largely distinct modes of negative regulation of gp130 activity, despite the fact that both SOCS3 and SHP2 are recruited to the same site within gp130.	Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany; Bayer Pharma Res Ctr, D-42096 Wuppertal, Germany; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02215 USA; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Univ Klinikum Charite, Dept Med Immunol, D-10117 Berlin, Germany	RWTH Aachen University; Bayer AG; Bayer Healthcare Pharmaceuticals; Harvard University; Beth Israel Deaconess Medical Center; Kyushu University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Heinrich, PC (corresponding author), Rhein Westfal TH Aachen, Dept Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Schaper, Fred/F-1403-2013; Yoshimura, Akihiko/K-5515-2013	Schaper, Fred/0000-0002-8899-5414; Sasaki, Atsuo/0000-0003-2963-4501; Behrmann, Iris/0000-0003-3688-3645; Tsiaras, William/0000-0002-4080-4762				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	185	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					661	671		10.1074/jbc.M210552200	http://dx.doi.org/10.1074/jbc.M210552200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403768	hybrid			2022-12-25	WOS:000180255700084
J	Reiken, S; Gaburjakova, M; Guatimosim, S; Gomez, AM; D'Armiento, J; Burkhoff, D; Wang, J; Vassort, G; Lederer, WJ; Marks, AR				Reiken, S; Gaburjakova, M; Guatimosim, S; Gomez, AM; D'Armiento, J; Burkhoff, D; Wang, J; Vassort, G; Lederer, WJ; Marks, AR			Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts - Role of phosphatases and response to isoproterenol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; DEPENDENT PHOSPHORYLATION; BINDING-PROTEIN; FAILURE; MUSCLE; CA2+; ACTIVATION; FKBP12; IMMUNOPHILINS; DYSFUNCTION	The cardiac ryanodine receptor/calcium release channel (RyR2) on the sarcoplasmic reticulum (SR) comprises a macromolecular complex that includes a kinase and two phosphatases that are bound to the channel via targeting proteins. We previously found that the RyR2 is protein kinase A (PKA)-hyperphosphorylated in end-stage human heart failure. Because heart failure is a progressive disease that often evolves from hypertrophy, we analyzed the RyR2 macromolecular complex in several animal models of cardiomyopathy that lead to heart failure, including hypertrophy, and at different stages of disease progression. We now show that RyR2 is PKA-hyperphosphorylated in diverse models of heart failure and that the degree of RyR2 PKA phosphorylation correlates with the degree of cardiac dysfunction. Interestingly, we show that RyR2 PKA hyperphosphorylation can be lost during perfusion of isolated hearts due to the activity of the endogenous phosphatases in the RyR2 macromolecular complex. Moreover, infusion of isoproterenol resulted in PKA phosphorylation of RyR2 in rat, indicating that systemic catecholamines can activate phosphorylation of RyR2 in vivo. These studies extend our previous analyses of the RyR2 macromolecular complex, show that both the kinase and phosphatase activities in the macromolecular complex are regulated physiologically in vivo, and suggest that RyR2 PKA hyperphosphorylation is likely a general feature of heart failure.	Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Circulatory Physiol Div, Dept Med, New York, NY 10032 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Dept Physiol,Sch Med, Baltimore, MD 21201 USA; INSERM, F-34295 Montpellier, France; Slovak Acad Sci, Inst Mol Physiol & Genet, Bratislava 83334, Slovakia	Columbia University; Columbia University; Columbia University; University System of Maryland; University of Maryland Baltimore; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Slovak Academy of Sciences	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, 630 W 168th St,Box 65,Rm 9-401, New York, NY 10032 USA.		Burkhoff, Daniel/D-7674-2011; Lederer, William/B-1285-2010; Guatimosim, Silvia/AAN-7441-2021; Gaburjakova, Marta/AAV-6066-2021; Gomez, Ana M./B-5376-2013	Guatimosim, Silvia/0000-0001-8386-3722; Gaburjakova, Marta/0000-0002-9300-0688; Gomez, Ana M./0000-0003-0009-2884				Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Alvarez JL, 2000, J MOL CELL CARDIOL, V32, P1169, DOI 10.1006/jmcc.2000.1155; Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROSTROM CO, 1977, J BIOL CHEM, V252, P5677; Chen L, 1999, J BIOL CHEM, V274, P32603, DOI 10.1074/jbc.274.46.32603; FOZZARD HA, 1992, BASIC RES CARDIOL, V87, P105; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Gyorke I, 1998, BIOPHYS J, V75, P2801, DOI 10.1016/S0006-3495(98)77723-9; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; Hasenfuss G, 1996, CIRCULATION, V94, P3155, DOI 10.1161/01.CIR.94.12.3155; Hobai IA, 2001, CIRCULATION, V103, P1577; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; Koch W J, 1998, Adv Pharmacol, V42, P502; LEDERER WJ, 1976, J PHYSIOL-LONDON, V263, P73, DOI 10.1113/jphysiol.1976.sp011622; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Litwin SE, 2000, CIRC RES, V87, P1040, DOI 10.1161/01.RES.87.11.1040; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Marks AR, 2002, CIRCULATION, V105, P272, DOI 10.1161/circ.105.3.272; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; NEWMAN WH, 1980, CARDIOVASC RES, V14, P530, DOI 10.1093/cvr/14.9.530; Pogwizd SM, 2001, CIRC RES, V88, P1159, DOI 10.1161/hh1101.091193; Reiken S, 2001, CIRCULATION, V104, P2843, DOI 10.1161/hc4701.099578; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Semsarian C, 2002, J CLIN INVEST, V109, P1013, DOI 10.1172/JCI200214677; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Sobie EA, 2002, BIOPHYS J, V83, P59, DOI 10.1016/S0006-3495(02)75149-7; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIT AL, 1983, AM HEART J, V106, P798, DOI 10.1016/0002-8703(83)90003-0; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; Yao A, 1998, AM J PHYSIOL-HEART C, V275, pH1441, DOI 10.1152/ajpheart.1998.275.4.H1441; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735	50	166	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					444	453		10.1074/jbc.M207028200	http://dx.doi.org/10.1074/jbc.M207028200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12401811	hybrid			2022-12-25	WOS:000180255700059
J	Uchida, Y				Uchida, Y			Overexpression of full-length but not N-terminal truncated isoform of microtubule-associated protein (MAP) 1B accelerates apoptosis of cultured cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; A-BETA DEPOSITION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; NEUROPATHOLOGICAL CHANGES; LEWY BODIES; BRAIN; COMPONENT; IMMUNOREACTIVITY	beta-amyloid (Abeta) is presumed to play a pathogenic role in Alzheimer's disease (AD). However, there is an imperfect correlation between Abeta deposition and neuronal loss or dementia. To clarify neuronal responses to Abeta, Abeta-induced gene expression in cultured cortical neurons was analyzed by differential display followed by Northern blotting. Here we report that nonaggregated or aggregated Abeta induced microtubule-associated protein 1B (MAP1B) mRNA, especially the alternative transcript containing exon 3U, before disruption of the cell membrane by Abeta. An alternative transcript containing exon 313 is translated into an N-terminal truncated shorter isoform of MAP1B. Transfection experiments reveal that overexpression of this isoform does not accelerate neurite outgrowth or apoptosis of cortical neurons. In contrast, overexpression of MAP1B fragments containing the N-terminal 126 amino acids promoted neurite outgrowth and neuronal apoptosis. These results suggest that Abeta does not induce deleterious full-length MAP1B directly, but overexpression of full-length MAP1B might act as an effector of cell death in neurodegenerative disorders related to cytoskeletal abnormalities.	Tokyo Metropolitan Inst Gerontol, Gene Express Res Grp, Div Neurosci & Brain Funct, Tokyo 1730015, Japan	Tokyo Metropolitan Institute of Gerontology	Uchida, Y (corresponding author), Tokyo Metropolitan Inst Gerontol, Gene Express Res Grp, Div Neurosci & Brain Funct, 35-2 Sakaecho, Tokyo 1730015, Japan.	uchiday@tmig.or.jp						Arendt T, 2001, NEUROSCIENCE, V102, P723, DOI 10.1016/S0306-4522(00)00516-9; ARMSTRONG RA, 1994, NEUROSCI LETT, V178, P59, DOI 10.1016/0304-3940(94)90289-5; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Ding JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055; Donahue JE, 1999, P NATL ACAD SCI USA, V96, P6468, DOI 10.1073/pnas.96.11.6468; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Estus S, 1997, J NEUROSCI, V17, P7736; Gai WP, 1996, ACTA NEUROPATHOL, V91, P78; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; GEDDES JW, 1991, J NEUROSCI RES, V30, P183, DOI 10.1002/jnr.490300119; GIANNAKOPOULOS P, 1994, ACTA NEUROPATHOL, V87, P456; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kutschera W, 1998, GENOMICS, V49, P430, DOI 10.1006/geno.1998.5294; Liu D, 1996, GENE, V171, P307, DOI 10.1016/0378-1119(95)00061-5; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Phinney AL, 1999, J NEUROSCI, V19, P8552; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; SNOW AD, 1988, AM J PATHOL, V133, P456; TAKAHASHI H, 1991, ACTA NEUROPATHOL, V81, P626, DOI 10.1007/BF00296372; ULLOA L, 1994, MOL BRAIN RES, V26, P113, DOI 10.1016/0169-328X(94)90081-7; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Yamaguchi H, 2001, J NEUROPATH EXP NEUR, V60, P731, DOI 10.1093/jnen/60.7.731; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037; ZAUNER W, 1992, EUR J CELL BIOL, V57, P66	37	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					366	371		10.1074/jbc.M210091200	http://dx.doi.org/10.1074/jbc.M210091200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12376528	hybrid			2022-12-25	WOS:000180255700049
J	Zhou, YL; Mehta, KR; Choi, AP; Scolavino, S; Zhang, X				Zhou, YL; Mehta, KR; Choi, AP; Scolavino, S; Zhang, X			DNA damage-induced inhibition of securin expression is mediated by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-TRANSFORMING GENE; SISTER-CHROMATID SEPARATION; DEPENDENT PROTEIN-KINASE; NF-Y; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL STABILITY; ANAPHASE INHIBITOR; HSP70 PROMOTER; FISSION YEAST	Tumor suppressor p53 induces the cellular response to DNA damage mainly by regulating expression of its downstream target genes. The human securin is an anaphase inhibitor, preventing premature chromosome separation through inhibition of separase activity. It is also known as the product of the human pituitary tumor-transforming gene, pttg, a proto-oncogene. Here we report that the expression of human securin is suppressed in cells treated with the DNA-damaging drugs doxorubicin and bleomycin. This suppression requires functional p53. Analysis of the human securin promoter reveals that DNA-binding sites for Sp1 and NF-Y are both required for activation of securin expression; however, only the NF-Y site is essential for the suppression by p53. Our study indicates that securin is a p53 target gene and may play a role in p53-mediated cellular response to DNA damage.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Zhang, X (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, 55 Fruit St,Bulfinch 457, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [F32CA088519] Funding Source: NIH RePORTER; NCI NIH HHS [5 F32 CA88519-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Facchinetti V, 2000, ONCOGENE, V19, P3931, DOI 10.1038/sj.onc.1203730; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Huet X, 1996, MOL CELL BIOL, V16, P3789; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; PERREM K, 1995, ONCOGENE, V11, P1299; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhao RB, 2000, GENE DEV, V14, P981; Zhong ZD, 2000, J BIOL CHEM, V275, P18602, DOI 10.1074/jbc.M001389200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	65	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					462	470		10.1074/jbc.M203793200	http://dx.doi.org/10.1074/jbc.M203793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12403781	hybrid			2022-12-25	WOS:000180255700061
J	Munshi, CB; Graeff, R; Lee, HC				Munshi, CB; Graeff, R; Lee, HC			Evidence for a causal role of CD38 expression in granulocytic differentiation of human HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; CALCIUM-CONCENTRATION; ENZYMATIC-SYNTHESIS; RNA INTERFERENCE; RETINOIC ACID; CYCLASE; INDUCTION; RELEASE; NAADP; IDENTIFICATION	Granulocytic differentiation of human HL-60 cells can be induced by retinoic acid and is accompanied by a massive expression of CD38, a multi-functional enzyme responsible for metabolizing cyclic ADP-ribose (cADPR), a Ca2+ messenger. Immunofluorescence staining showed that CD38 was expressed not only on the surface of intact HL-60 cells but also intracellularly, which was revealed after permeabilization with Triton. Concomitant with CD38 expression was the accumulation of cADPR, and both time courses preceded the onset of differentiation, suggesting a causal role for CD38. Consistently, treatment of HL-60 cells with a permeant inhibitor of CD38, nicotinamide, inhibited both the CD38 activity and differentiation. More specific blockage of CD38 expression was achieved by using morpholino antisense oligonucleotides targeting its mRNA, which produced a corresponding inhibition of differentiation as well. Similar inhibitory effects were observed when CD38 expression was reduced by the RNA interference technique targeting two separate regions of the coding sequence of CD38. Further support came from transfecting HL-60 cells with a Tet-On expression vector containing a full-length CD38. Subsequent treatments with doxycycline induced both CD38 expression and differentiation in the absence of retinoic acid. These results provide the first evidence that CD38 expression and the consequential accumulation of cADPR play a causal role in mediating cellular differentiation.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Lee, HC (corresponding author), Univ Minnesota, Dept Pharmacol, 321 church St,SE,4-145 Jackson Hall, Minneapolis, MN 55455 USA.	leehc@tc.umn.edu	Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011		NIGMS NIH HHS [GM 60333, GM 61568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061568, R01GM060333] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Bruzzone S, 2001, FASEB J, V15, P10; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fukushi Y, 2001, J BIOL CHEM, V276, P649, DOI 10.1074/jbc.M004469200; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; Iversen PL, 2001, CURR OPIN MOL THER, V3, P235; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Khoo KM, 2000, J BIOL CHEM, V275, P24807, DOI 10.1074/jbc.M908231199; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Kipshidze N, 2001, CURR OPIN MOL THER, V3, P265; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Lee HC, 1999, BIOL CHEM, V380, P785, DOI 10.1515/BC.1999.098; Lee HC, 2000, CHEM IMMUNOL, V75, P39; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 2000, J MEMBRANE BIOL, V173, P1, DOI 10.1007/s002320001001; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Munshi C, 1997, PROTEIN EXPRES PURIF, V11, P104, DOI 10.1006/prep.1997.0773; Ohguchi K, 1999, BBA-MOL CELL BIOL L, V1439, P215, DOI 10.1016/S1388-1981(99)00096-7; Okamoto H, 1999, MOL CELL BIOCHEM, V193, P115, DOI 10.1023/A:1006980630912; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Ullu E, 2002, PHILOS T ROY SOC B, V357, P65, DOI 10.1098/rstb.2001.0952; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yusufi ANK, 2001, BIOCHEM J, V353, P531, DOI 10.1042/0264-6021:3530531; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	40	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49453	49458		10.1074/jbc.M209313200	http://dx.doi.org/10.1074/jbc.M209313200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12386160	hybrid			2022-12-25	WOS:000180028900046
J	Pitson, SM; Moretti, PAB; Zebol, JR; Zareie, R; Derian, CK; Darrow, AL; Qi, J; D'Andrea, RJ; Bagley, CJ; Vadas, MA; Wattenberg, BW				Pitson, SM; Moretti, PAB; Zebol, JR; Zareie, R; Derian, CK; Darrow, AL; Qi, J; D'Andrea, RJ; Bagley, CJ; Vadas, MA; Wattenberg, BW			The nucleotide-binding site of human sphingosine kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATP-BINDING; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; DIACYLGLYCEROL KINASE; CATALYTIC DOMAIN; CELL-GROWTH; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION; LOCALIZATION	Sphingosine kinase catalyzes the formation of sphingosine 1-phosphate, a lipid second messenger that has been implicated in a number of agonist-driven cellular responses including mitogenesis, anti-apoptosis, and expression of inflammatory molecules. Despite the importance of sphingosine kinase, very little is known regarding its structure or mechanism of catalysis. Moreover, sphingosine kinase does not contain recognizable catalytic or substrate-binding sites, based on sequence motifs found in other kinases. Here we have elucidated the nucleotide-binding site of human sphingosine kinase 1 (hSK1) through a combination of site-directed mutagenesis and affinity labeling with the ATP analogue, FSBA. We have shown that Gly(82) of hSK1 is involved in ATP binding since mutation of this residue to alanine resulted in an enzyme with an similar to45-fold higher K-m(ATP). We have also shown that Lys(103) is important in catalysis since an alanine substitution of this residue ablates catalytic activity. Furthermore, we have shown that this residue is covalently modified by FSBA. Our data, combined with amino acid sequence comparison, suggest a. motif of SGDGX(17-21)K is involved in nucleotide binding in the sphingosine kinases. This motif differs in primary sequence from all previously identified nucleotide-binding sites. It does, however, share some sequence and likely structural similarity with the highly conserved glycine-rich loop, which is known to be involved in anchoring and positioning the nucleotide in the catalytic site of many protein kinases.	Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA 19477 USA	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; Johnson & Johnson; Johnson & Johnson USA	Pitson, SM (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Frome Rd, Adelaide, SA 5000, Australia.		Zareie, Reza/D-5799-2011; Pitson, Stuart/B-9342-2009; Vadas, Mathew/R-1378-2019	Pitson, Stuart/0000-0002-9527-2740; 				Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hartog AF, 1997, BBA-BIOENERGETICS, V1318, P107, DOI 10.1016/S0005-2728(96)00110-7; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; KOMATSU H, 1993, BIOCHEM J, V296, P53, DOI 10.1042/bj2960053; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olcott MC, 1998, J BIOL CHEM, V273, P24853, DOI 10.1074/jbc.273.38.24853; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2001, FEBS LETT, V509, P169; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	52	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49545	49553		10.1074/jbc.M206687200	http://dx.doi.org/10.1074/jbc.M206687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12393916	hybrid			2022-12-25	WOS:000180028900059
J	Meyers, JM; Prekeris, R				Meyers, JM; Prekeris, R			Formation of mutually exclusive Rab11 complexes with members of the family of Rab11-interacting proteins regulates Rab11 endocytic targeting and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE TRAFFICKING; VESICULAR TRANSPORT; CLASS-II; IDENTIFICATION; RECEPTOR; ARFOPHILIN; ENDOSOMES; PATHWAY	Several Rabs, including Rab11, regulate the traffic and sorting of proteins in the endosomal pathway. Recently, six novel Rab11 family interacting proteins (FIPs) were identified. Although they share little overall sequence homology, all FIPs contain a conserved Rab11-binding domain. Here we investigate the role of FIPs as Rab11-targeting proteins and show that the Rab11-binding domain assumes an a-helical structure, with the conserved residues forming a hydrophobic Rab11-binding patch. This hydrophobic patch mediates the formation of mutually exclusive complexes between Rab11 and various members of FIP protein family. Furthermore, the formation of Rab11/FIP complexes regulates Rab11 localization by recruiting it to distinct endocytic compartments. Thus, we propose that Rab11/FIP complexes serve as targeting patches, regulating Rab11 localization and recruitment of additional cellular factors to different endocytic compartments.	Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Prekeris, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, B111,4200 E 9th Ave, Denver, CO 80262 USA.	rytis.prekeris@uchsc.edu						BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Shin OH, 2001, BIOCHEMISTRY-US, V40, P10846, DOI 10.1021/bi0107391; Shin OH, 1999, J BIOL CHEM, V274, P36609, DOI 10.1074/jbc.274.51.36609; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	33	66	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49003	49010		10.1074/jbc.M205728200	http://dx.doi.org/10.1074/jbc.M205728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12376546	hybrid			2022-12-25	WOS:000179789600133
J	Takeuchi, Y; Watanabe, S; Ishii, G; Takeda, S; Nakayama, K; Fukumoto, S; Kaneta, Y; Inoue, D; Matsumoto, T; Harigaya, K; Fujita, T				Takeuchi, Y; Watanabe, S; Ishii, G; Takeda, S; Nakayama, K; Fukumoto, S; Kaneta, Y; Inoue, D; Matsumoto, T; Harigaya, K; Fujita, T			Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC PROTEIN; TRABECULAR BONE; CELL-FORMATION; MARROW; EXPRESSION; PATHOGENESIS; INDUCTION; CYTOKINES	Cytokines in interleukin (IL)-11 subfamily participate in the regulation of bone cell proliferation and differentiation. We report here positive effects of IL-11 on osteoblasts and bone formation. Overexpression of human IL-11 gene in transgenic mice resulted in the stimulation of bone formation to increase cortical thickness and strength of long bones, and in the prevention of cortical bone loss with advancing age. Bone resorption and osteoclastogenesis were not affected in IL-11 transgenic mice. In experiments in vitro, IL-11 stimulated transcription of the target gene for bone morphogenetic protein (BMP) via STAT3, leading to osteoblastic differentiation in the presence of BMP-2, but inhibited adipogenesis in bone marrow stromal cells. These results indicate that IL-11 is a stimulatory factor for osteoblastogenesis and bone formation to conserve cortical bone, possibly by enhancing BMP actions in bone. IL-11 may be a new therapeutic target for senile osteoporosis.	Univ Tokyo, Sch Med, Dept Med, Div Endocrinol & Nephrol, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Mol & Tumor Pathol, Chiba 2608670, Japan; Univ Tokyo, Sch Med, Dept Lab Med, Tokyo 1138655, Japan; Sankyo Co Ltd, Biomed Res Labs, Tokyo 140, Japan; Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 7708503, Japan	University of Tokyo; Chiba University; University of Tokyo; Daiichi Sankyo Company Limited; Tokushima University	Takeuchi, Y (corresponding author), Univ Tokyo, Sch Med, Dept Med, Div Endocrinol,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	takeuchi-tky@umin.ac.jp	takeda, shu/B-5195-2012; Ishii, Genichiro/E-2913-2012; Fukumoto, Seiji/B-7853-2015	Fukumoto, Seiji/0000-0003-3610-3469				Benes H, 2000, J BONE MINER RES, V15, P626, DOI 10.1359/jbmr.2000.15.4.626; BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756-3282(87)90015-9; Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008; DU XX, 1994, BLOOD, V83, P2023; EASTELL R, 1991, J BONE MINER RES, V6, P125; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; Kodama Y, 1998, J BONE MINER RES, V13, P1370, DOI 10.1359/jbmr.1998.13.9.1370; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kuliwaba JS, 2000, J BONE MINER RES, V15, P332, DOI 10.1359/jbmr.2000.15.2.332; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MATSUSHITA M, 1986, AM J PATHOL, V125, P276; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086-197110000-00021; NAKAMURA T, 1989, BONE, V10, P117, DOI 10.1016/8756-3282(89)90009-4; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; Okazaki R, 1999, ENDOCRINOLOGY, V140, P5060, DOI 10.1210/en.140.11.5060; ORWOLL ES, 1986, J CLIN ENDOCR METAB, V63, P1262, DOI 10.1210/jcem-63-6-1262; Pacifici R, 1996, J BONE MINER RES, V11, P1043; PARFITT AM, 1995, J BONE MINER RES, V10, P466; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Saha BK, 1996, J IMMUNOL METHODS, V194, P77, DOI 10.1016/0022-1759(96)00065-8; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Schwertschlag US, 1999, LEUKEMIA, V13, P1307, DOI 10.1038/sj.leu.2401514; SHERMAN SS, 1992, J BONE MINER RES, V7, P1123; Suga K, 2001, J INTERF CYTOK RES, V21, P695, DOI 10.1089/107999001753124435; Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takeuchi Y, 2000, BONE, V27, P769, DOI 10.1016/S8756-3282(00)00396-3; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772; Trepicchio WL, 1998, ANN NY ACAD SCI, V856, P12, DOI 10.1111/j.1749-6632.1998.tb08308.x; Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yanagisawa M, 2000, J NEUROCHEM, V74, P1498, DOI 10.1046/j.1471-4159.2000.0741498.x; Yanagisawa M, 2001, FEBS LETT, V489, P139, DOI 10.1016/S0014-5793(01)02095-6; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7	49	105	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49011	49018		10.1074/jbc.M207804200	http://dx.doi.org/10.1074/jbc.M207804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12384500	hybrid			2022-12-25	WOS:000179789600134
J	Kang, KW; Kim, YG; Cho, MK; Bae, SK; Kim, CW; Lee, MG; Kim, SG				Kang, KW; Kim, YG; Cho, MK; Bae, SK; Kim, CW; Lee, MG; Kim, SG			Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation	FASEB JOURNAL			English	Article						liver cirrhosis; C/EBP; TGF-beta 1	PRIMARY BILIARY-CIRRHOSIS; URSODEOXYCHOLIC-ACID THERAPY; HEPATOCYTE GROWTH-FACTOR; REPUBLIC-OF-CHINA; RAT-LIVER; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOL-3-THIONE OLTIPRAZ; TRANSFORMING GROWTH-FACTOR-BETA-1; HEPATIC-FIBROSIS; GENE-EXPRESSION; COLLAGEN GENE	Liver cirrhosis (LC) is a chronic disease with high mortality rate. In the United States and Western world as well as Asian countries, LC is the major leading cause of death by disease. Yet, no effective therapeutic agent is available for LC treatment. Laboratory cirrhotic rats produced by dimethylnitrosamine administrations simulate the clinical features of human LC such as mortality, ascites, hepatic parenchymal cell destruction, and formation of connective tissue and nodular regeneration, providing a preclinical model to evaluate therapeutic efficacy of drugs and the underlying mechanisms. Oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] has been used clinically and is of little toxicity. Comprehensive mechanistic and phase IIa clinical studies supported the notion that oltipraz exerts chemopreventive effects against chemical carcinogenesis. We report here that oltipraz within the clinical dose range regenerates cirrhotic liver in the established LC rats as a result of reduction of the intensities of cirrhotic nodules, elimination of accumulated extracellular matrix, and inactivation of stellate cells, thereby improving survival rate. We also reveal that activation of CCAAT/enhancer binding protein by oltipraz inhibits transforming growth factor beta1 gene expression in stellate cells, which provides a molecular target for pharmacological treatment of LC. Oltipraz is the first therapeutic agent that regenerates cirrhotic liver.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Seoul Natl Univ, Natl Res Lab, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Clin Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Sillim Dong,Kwanak Gu, Seoul 151742, South Korea.	sgk@snu.ac.kr						Albanis E, 2001, Clin Liver Dis, V5, P315, DOI 10.1016/S1089-3261(05)70168-9; ANSHER SS, 1983, HEPATOLOGY, V3, P932; Baroni GS, 1996, HEPATOLOGY, V23, P1189; BOLTON MG, 1993, CANCER RES, V53, P3499; Chi WJ, 1998, CARCINOGENESIS, V19, P2133, DOI 10.1093/carcin/19.12.2133; CLAPPER ML, 1995, CARCINOGENESIS, V16, P2159, DOI 10.1093/carcin/16.9.2159; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Corpechot C, 2000, HEPATOLOGY, V32, P1196, DOI 10.1053/jhep.2000.20240; Crowell JA, 1997, FUND APPL TOXICOL, V35, P9, DOI 10.1006/faat.1996.2256; DEBAKEY SF, 1996, 41 NAT I ALC AB ALC; ELTAYEB M, 1988, ANN TROP MED PARASIT, V82, P53; FREIDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; George J, 1996, BBA-PROTEIN STRUCT M, V1292, P215, DOI 10.1016/0167-4838(95)00202-2; Goulis J, 1999, LANCET, V354, P1053, DOI 10.1016/S0140-6736(98)11293-X; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; HENRIKSEN JH, 1980, SCAND J CLIN LAB INV, V40, P493, DOI 10.3109/00365518009091956; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Iraburu MJ, 2000, HEPATOLOGY, V31, P1086, DOI 10.1053/he.2000.5981; Jacobson LP, 1997, CANCER EPIDEM BIOMAR, V6, P257; KAKIZOE T, 1999, CANC STAT JAPAN 1999; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Kang KW, 2002, CHEM-BIOL INTERACT, V139, P61, DOI 10.1016/S0009-2797(01)00286-1; Kensler T W, 1995, J Cell Biochem Suppl, V22, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Kiiasov A P, 1998, Tsitologiia, V40, P876; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Kruse JJM, 1999, CYTOKINE, V11, P179, DOI 10.1006/cyto.1998.0413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; Luo JC, 1998, J GASTROEN HEPATOL, V13, P685, DOI 10.1111/j.1440-1746.1998.tb00714.x; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATSUZAKI Y, 1990, AM J GASTROENTEROL, V85, P15; Mizuno S, 2000, KIDNEY INT, V57, P937; Moragas A, 1998, ANAL QUANT CYTOL, V20, P169; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Neuberger J, 2000, HEPATOLOGY, V31, P1027; NOMURA F, 1990, J HEPATOL, V11, P65, DOI 10.1016/0168-8278(90)90273-T; Pares A, 1998, J HEPATOL, V28, P615, DOI 10.1016/S0168-8278(98)80285-7; Pares A, 2000, J HEPATOL, V32, P561, DOI 10.1016/S0168-8278(00)80216-0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; Pinzani M, 1998, LIVER, V18, P2; PROCHASKA HJ, 1995, MOL PHARMACOL, V48, P15; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; RAO CV, 1993, CANCER RES, V53, P2502; Skrtic S, 2001, HORM RES, V55, P1, DOI 10.1159/000063454; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; VYBERG M, 1987, ACTA PATH MICRO IM A, V95, P11; Wagner AH, 2000, MOL PHARMACOL, V58, P1333, DOI 10.1124/mol.58.6.1333; Wang JS, 1999, JNCI-J NATL CANCER I, V91, P347, DOI 10.1093/jnci/91.4.347; WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P979, DOI 10.1093/carcin/13.6.979; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; Yao FY, 2001, HEPATOLOGY, V34, P411, DOI 10.1053/jhep.2001.26512; YOON G, 2000, AF249327 GENB; YOON YH, 2001, 57 NAT I ALC AB ALC; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200	61	74	75	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1988	+		10.1096/fj.02-0406fje	http://dx.doi.org/10.1096/fj.02-0406fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397085				2022-12-25	WOS:000179167600009
